assay_id,confidence_score,src_assay_id,bao_format,curated_by,tissue_id,doc_id,description,assay_type,assay_test_type,assay_category,assay_organism,assay_tax_id,assay_strain
1,8,,BAO_0000019,Autocuration,,11087,The compound was tested for the in vitro inhibition of platelet 12-lipoxygenase at a concentration of 30 uM,B,,,,,
2,0,,BAO_0000219,Autocuration,,684,Compound was evaluated for its ability to mobilize calcium in 1321NI cells,F,,,,,
3,0,,BAO_0000019,Autocuration,,15453,,B,,,,,
4,4,,BAO_0000249,Autocuration,,17841,Binding affinity against A2 adenosine receptor in bovine striatal membranes using [3H]CGS-21680,B,,,Bos taurus,9913.0,
5,1,,BAO_0000219,Intermediate,,17430,In vitro cell cytotoxicity against 143-B cell lines (Human osteosarcoma cell line),F,,,Homo sapiens,9606.0,
6,1,,BAO_0000219,Intermediate,,17430,In vitro cell cytotoxicity against 143-B cell lines (Human osteosarcoma cell line),F,,,Homo sapiens,9606.0,
7,1,,BAO_0000219,Intermediate,,13799,Cytotoxic Activity was evaluated against 143B (TK-) tumor cells,F,,,Mus musculus,10090.0,
8,1,,BAO_0000219,Expert,,17774,In vitro cell cytotoxicity was determined against 143B cell line,F,,,Homo sapiens,9606.0,
9,1,,BAO_0000219,Intermediate,,3801,Inhibitory activity against tumor osteosarcoma cell line 143B after 72 hr continuous exposure to compound,F,,,Homo sapiens,9606.0,
10,1,,BAO_0000219,Intermediate,,17430,In vitro cell cytotoxicity against 143B-LTK cell lines expressed in HSV-1 TK,F,,,Homo sapiens,9606.0,
11,1,,BAO_0000219,Intermediate,,17430,In vitro cell cytotoxicity against 143B-LTK cell lines expressed in HSV-1 TK,F,,,Homo sapiens,9606.0,
12,1,,BAO_0000219,Expert,,17774,In vitro cell cytotoxicity was determined against 143B-LTK cell line,F,,,Homo sapiens,9606.0,
13,1,,BAO_0000218,Intermediate,,11324,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",F,,,Staphylococcus aureus,1280.0,
14,1,,BAO_0000218,Intermediate,,11324,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",F,,,Staphylococcus aureus,1280.0,
15,1,,BAO_0000218,Intermediate,,11324,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",F,,,Staphylococcus aureus,1280.0,
16,1,,BAO_0000218,Intermediate,,11324,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",F,,,Staphylococcus aureus,1280.0,
17,9,,BAO_0000357,Expert,,11347,Inhibition of cytochrome P450 progesterone 15-alpha hydroxylase,A,,,Rattus norvegicus,10116.0,
18,8,,BAO_0000357,Autocuration,,16474,Concentration that cause 50% activation of human reticulocyte 15-lipoxygenase (15-HLO),B,,,,,
19,8,,BAO_0000019,Autocuration,,10091,Inhibition of partially purified 15-lipoxygenase from human leukocytes,B,,,,,
20,8,,BAO_0000357,Autocuration,,16474,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO),B,,,,,
21,8,,BAO_0000357,Autocuration,,16474,Compound was evaluated for the percent increase in activation concentration of human reticulocyte 15-lipoxygenase (15-HLO),B,,,,,
22,8,,BAO_0000357,Autocuration,,16474,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO),B,,,,,
23,8,,BAO_0000357,Autocuration,,16474,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO); NI is no inhibition,B,,,,,
24,8,,BAO_0000357,Autocuration,,16474,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO); NI is no inhibition,B,,,,,
25,0,,BAO_0000219,Autocuration,,14352,"Inhibitory concentration against 15-lipoxygenase, by inhibiting 15-HETE production by human umbilical vein endothelial cells (HUVEC) stimulated by calcium ionophore A 23187 at concentration of 10e-5 M.",B,,,,,
26,8,,BAO_0000357,Autocuration,,5646,In vitro inhibitory activity of compound on rabbit reticulocyte 15-lipoxygenase,B,,,Oryctolagus cuniculus,9986.0,
27,8,,BAO_0000357,Autocuration,,5646,Inhibition of rabbit reticulocyte 15-lipoxygenase by compound (30 uM),B,,,Oryctolagus cuniculus,9986.0,
28,8,,BAO_0000219,Autocuration,,10997,Inhibitory activity against 15-lipoxygenase in rat polymorphonuclear leukocytes,B,,,,,
29,8,,BAO_0000357,Autocuration,,6309,Inhibitory activity against 15-lipoxygenase was determined obtained from soya bean,B,,,soya bean,3847.0,
30,8,,BAO_0000357,Autocuration,,167,Inhibitory activity against soybean 15-lipoxygenase was evaluated,B,,,Glycine max,3847.0,
31,8,,BAO_0000357,Autocuration,,167,Inhibitory activity against soybean 15-lipoxygenase was evaluated at 100 uM,B,,,Glycine max,3847.0,
32,8,,BAO_0000357,Autocuration,,11087,The compound was tested for the in vitro inhibition of 15-lipoxygenase of soybean at a concentration of 10 uM,B,,,Glycine max,3847.0,
33,8,,BAO_0000357,Autocuration,,11087,The compound was tested for the in vitro inhibition of 15-lipoxygenase of soybean at a concentration of 100 uM,B,,,Glycine max,3847.0,
34,8,,BAO_0000357,Autocuration,,13622,Compound was tested in vitro for inhibition of 15-lipoxygenase soybean,B,,,Glycine max,3847.0,
35,8,,BAO_0000357,Autocuration,,13622,Compound at 100 uM was tested in vitro for inhibition of 15-lipoxygenase soybean,B,,,Glycine max,3847.0,
36,0,,BAO_0000019,Autocuration,,11347,Inhibition of cytochrome P450 progesterone 16-alpha hydroxylase,A,,,Rattus norvegicus,10116.0,
37,0,,BAO_0000019,Autocuration,,5926,Binding affinity against bacterial 16S rRNA using mass spectrometry based assay,B,,,Escherichia coli,562.0,
38,0,,BAO_0000019,Autocuration,,4567,Dissociation constant with dimeric 16S rRNA RNA construct B,B,,,,,
39,3,,BAO_0000225,Intermediate,,3782,Dissociation constant towards 16S rRNA construct A,B,,,,,
40,3,,BAO_0000225,Intermediate,,3782,Dissociation constant towards 16S rRNA construct B,B,,,,,
41,3,,BAO_0000225,Expert,,4466,Binding affinity of aminoglycoside to 16S ribosomal RNA A-site in Escherichia coli,B,,,Escherichia coli,562.0,
42,3,,BAO_0000225,Expert,,6592,Binding affinity for the 16S ribosomal RNA A-site of Escherichia coli,B,,,Escherichia coli,562.0,
43,8,,BAO_0000019,Autocuration,,898,Inhibitory activity against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),B,,,,,
44,8,,BAO_0000019,Autocuration,,898,Inhibitory constant against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),B,,,,,
45,8,,BAO_0000019,Autocuration,,13163,The compound was tested at a concentration of 1 uM for inhibitory activity against 17 beta-hydroxysteroid dehydrogenase from human placental microsomes,B,,,Homo sapiens,9606.0,
46,8,,BAO_0000019,Autocuration,,13163,The compound was tested at a concentration of 1 uM for inhibitory activity against 17 beta-hydroxysteroid dehydrogenase from human placental microsomes,B,,,Homo sapiens,9606.0,
47,9,,BAO_0000019,Expert,,10691,"Inhibition of 17-alpha-hydroxylase/17,20 lyase from rat testes microsomal preparation",B,,,Rattus norvegicus,10116.0,
48,9,,BAO_0000019,Expert,,10691,"Inhibition of 17-alpha-hydroxylase/17,20 lyase from rat testes microsomal preparation",B,,,Rattus norvegicus,10116.0,
49,9,,BAO_0000019,Expert,,10691,"Percent inhibition of 17-alpha-hydroxylase/17,20 lyase of rat testes microsomes at 100 uM",B,,,Rattus norvegicus,10116.0,
50,9,,BAO_0000019,Expert,,10691,"Percent inhibition of Steroid 17-alpha-hydroxylase/17,20 lyase of rat testes microsomes at 100 uM",B,,,Rattus norvegicus,10116.0,
51,8,,BAO_0000019,Autocuration,,898,Inhibitory activity against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),B,,,,,
52,8,,BAO_0000357,Autocuration,,912,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1),B,,,,,
53,8,,BAO_0000357,Autocuration,,912,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1) at 1 uM concentration,B,,,,,
54,8,,BAO_0000357,Autocuration,,912,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1) at 10 uM concentration,B,,,,,
55,5,,BAO_0000249,Autocuration,,15103,Selectivity ratio of binding affinity towards mu to delta receptors of rat brain membranes,B,,,Rattus norvegicus,10116.0,
56,1,,BAO_0000219,Intermediate,,5116,Cytotoxicity against ovarian cancer cell line (1A-9) of humans was determined,F,,,Homo sapiens,9606.0,
57,7,,BAO_0000219,Autocuration,,14578,Functional antagonism by electrical assays in Xenopus oocytes expressing 1A/2A NMDA receptor subtype,F,,,Rattus norvegicus,10116.0,
58,7,,BAO_0000219,Autocuration,,14578,Functional antagonism by electrical assays in Xenopus oocytes expressing the 1A/2B NMDA receptor,F,,,Rattus norvegicus,10116.0,
59,7,,BAO_0000219,Autocuration,,14578,Functional antagonism by electrical assays in Xenopus oocytes expressing the 1A/2C NMDA receptor,F,,,Rattus norvegicus,10116.0,
60,1,,BAO_0000219,Expert,,4787,In vitro effective concentration required to reduce the number of human ovarian cancer (1A9) after 3-day incubation,F,,,Homo sapiens,9606.0,
61,1,,BAO_0000219,Intermediate,,4787,In vitro effective concentration required to reduce the number of human ovarian cancer cells (1A9) after 3-day incubation,F,,,Homo sapiens,9606.0,
62,1,,BAO_0000219,Intermediate,,3547,Cytotoxic activity against human ovarian cancer (1A9) cell line,F,,,Homo sapiens,9606.0,
63,1,,BAO_0000219,Intermediate,,3547,Cytotoxic activity against human ovarian cancer (1A9) cell line; ND=Not determined,F,,,Homo sapiens,9606.0,
64,1,,BAO_0000219,Intermediate,,6726,Effective dose of compound against replication of 1A9 cell line was evaluated,F,,,Homo sapiens,9606.0,
65,1,,BAO_0000219,Expert,,3455,In vitro cytotoxic activity was determined against ovarian cancer (1A9) cell line,F,,,Homo sapiens,9606.0,
66,1,,BAO_0000219,Intermediate,,5726,In vitro cytotoxicity evaluated against human ovarian cancer (1A9 cell line),F,,,Homo sapiens,9606.0,
67,1,,BAO_0000219,Intermediate,,5726,In vitro cytotoxicity evaluated against human ovarian cancer (1A9 cell line); NA is not active,F,,,Homo sapiens,9606.0,
68,1,,BAO_0000219,Intermediate,,5726,In vitro percent inhibition evaluated against human ovarian cancer (1A9 cell line) at >20 ug/mL,F,,,Homo sapiens,9606.0,
69,1,,BAO_0000219,Intermediate,,3395,Inhibitory activity against Taxol resistant 1A9 cell lines,F,,,Homo sapiens,9606.0,
70,1,,BAO_0000219,Expert,,3415,Cytotoxicity against human ovarian cancer (1A9) cell lines.,F,,,Homo sapiens,9606.0,
71,1,,BAO_0000219,Expert,,3415,Percentage inhibition of human ovarian cancer (1A9) cell lines.,F,,,Homo sapiens,9606.0,
72,1,,BAO_0000219,Expert,,17099,Effective dose required for inhibitory activity against 1A9 human tumor cell line.,F,,,Homo sapiens,9606.0,
73,1,,BAO_0000219,Intermediate,,17099,Percent inhibition against 1A9 human tumor cell line at 0.10 ug/mL,F,,,Homo sapiens,9606.0,
74,1,,BAO_0000219,Intermediate,,17099,Percent inhibition against 1A9 human tumor cell line at <0.00008 ug/mL,F,,,Homo sapiens,9606.0,
75,1,,BAO_0000219,Intermediate,,17099,Percent inhibition against 1A9 human tumor cell line at >10 ug/mL,F,,,Homo sapiens,9606.0,
76,1,,BAO_0000219,Intermediate,,17721,Inhibitory concentration against Jurkat cells,F,,,Homo sapiens,9606.0,
77,0,,BAO_0000019,Intermediate,,1229,In vitro anticancer activity against 2 NCI SCLC cell lines; inactive,F,,,,,
78,9,,BAO_0000357,Expert,,11347,Inhibition of cytochrome P450 progesterone 2-alpha-hydroxylase,A,,,Rattus norvegicus,10116.0,
79,8,,BAO_0000357,Expert,,17117,"In vitro inhibition of human 2,3-oxidosqualene cyclase.",B,,,,,
80,8,,BAO_0000357,Expert,,17117,"In vitro inhibition of human 2,3-oxidosqualene cyclase.",B,,,,,
81,8,,BAO_0000357,Expert,,17117,"In vitro inhibition of human 2,3-oxidosqualene cyclase at 100 nM.",B,,,,,
82,8,,BAO_0000251,Autocuration,,11375,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in Candida albicans microsomes",B,,,Candida albicans,5476.0,
83,8,,BAO_0000251,Autocuration,,11375,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in Candida albicans microsomes",B,,,Candida albicans,5476.0,
84,8,,BAO_0000251,Autocuration,,11375,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in Saccharomyces cerevisiae microsomes",B,,,Saccharomyces cerevisiae,4932.0,
85,8,,BAO_0000251,Autocuration,,11375,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in Saccharomyces cerevisiae microsomes",B,,,Saccharomyces cerevisiae,4932.0,
86,8,,BAO_0000251,Autocuration,2107.0,11375,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in pig liver microsomes",B,,,Sus scrofa,9823.0,
87,8,,BAO_0000019,Autocuration,,791,"Concentration required to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase",B,,,Rattus norvegicus,10116.0,
88,8,,BAO_0000019,Autocuration,,791,"Concentration required to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase (OSC)",B,,,Rattus norvegicus,10116.0,
89,8,,BAO_0000019,Autocuration,,791,"Evaluated for its activity to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase, activity expressed as Ki",B,,,Rattus norvegicus,10116.0,
90,9,,BAO_0000251,Autocuration,2107.0,11375,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in rat liver microsomes",B,,,Rattus norvegicus,10116.0,
91,9,,BAO_0000251,Autocuration,2107.0,11375,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in rat liver microsomes",B,,,Rattus norvegicus,10116.0,
92,9,,BAO_0000251,Autocuration,2107.0,153,"Compound was evaluated for inhibitory activity against 2,3-oxidosqualene-lanosterol cyclase in rat liver microsomes",B,,,Rattus norvegicus,10116.0,
93,8,,BAO_0000357,Expert,,8269,Molar concentration needed to give 50% prevention of 2-5A (Adenosine dependent endoribonuclease),B,,,,,
94,8,,BAO_0000357,Expert,,8269,Molar concentration required to displace 50% of the radiolabeled probe from 2-5A (Adenosine dependent endoribonuclease) in endonuclease-nitrocellulose complex,B,,,,,
95,1,,BAO_0000219,Expert,,17653,In vitro cytotoxic concentration required to inhibit hepatitisB virus (HBV) replication in 2.2.15 cell line,F,,,Homo sapiens,9606.0,
96,1,,BAO_0000219,Intermediate,,14277,50% Effective concentration of compound required for inhibiting intracellular viral replicative intermediate DNA in HBV-transfected 2.2.15 cell line.,F,,,Homo sapiens,9606.0,
97,1,,BAO_0000219,Intermediate,,1717,Antiviral activity against Hepatitis B virus in 2.2.15 cell line,F,,,Homo sapiens,9606.0,
98,1,,BAO_0000219,Intermediate,,14091,In vitro effective concentration against hepatitis B virus was determined in 2.2.15 cells,F,,,Homo sapiens,9606.0,
99,1,,BAO_0000219,Intermediate,,14091,In vitro effective concentration against hepatitis B virus was determined in 2.2.15 cells; Not determined,F,,,Homo sapiens,9606.0,
100,1,,BAO_0000218,Expert,,17653,In vitro effective concentration required to inhibit hepatitisB virus (HBV) replication in 2.2.15 cell line,F,,,Hepatitis B virus,10407.0,
101,1,,BAO_0000219,Intermediate,,13105,Ability to inhibit the episomal HBV-DNA in 2.2.15 cells.,F,,,Homo sapiens,9606.0,
102,1,,BAO_0000219,Intermediate,,1717,Concentration required to inhibit 50% of 2.2.15 cell line,F,,,Homo sapiens,9606.0,
103,1,,BAO_0000219,Intermediate,,13105,Anti viral activity against 2.2.15 cells (concentration required to reduce the log phase cell growth by 50%).,A,,,Homo sapiens,9606.0,
104,1,,BAO_0000218,Intermediate,,13600,Cytotoxic activity of compound against uninfected 2.2.15 cells.,F,,,Homo sapiens,9606.0,
105,1,,BAO_0000218,Intermediate,,13467,Anti hepatitis-B virus activity was evaluated in 2.2.15 cells.,F,,,Homo sapiens,9606.0,
106,1,,BAO_0000218,Expert,,17477,"Inhibition of the replication of HBV in 2.2.15 cells, by DNA hybridization assay",F,,,Hepatitis B virus,10407.0,
107,1,,BAO_0000218,Intermediate,,1593,In vitro anti-HBV activity in 2.2.15 cells,F,,,Homo sapiens,9606.0,
108,1,,BAO_0000218,Intermediate,,1593,In vitro anti-HBV activity in 2.2.15 cells; Not determined,F,,,Homo sapiens,9606.0,
109,1,,BAO_0000218,Intermediate,,15089,The compound was tested in vitro for the anti-HBV activity against 2.2.15 cells,F,,,Homo sapiens,9606.0,
110,1,,BAO_0000218,Intermediate,,15089,The compound was tested in vitro for the anti-HBV activity in 2.2.15 cells,F,,,Homo sapiens,9606.0,
111,1,,BAO_0000218,Intermediate,,1593,Cytotoxicity in 2.2.15 cells,F,,,Homo sapiens,9606.0,
112,1,,BAO_0000218,Intermediate,,1593,Cytotoxicity in 2.2.15 cells; Not determined,F,,,Homo sapiens,9606.0,
113,1,,BAO_0000218,Intermediate,,13600,Inhibitory activity of compound against hepatitis B virus (HBV) in growing cultures of 2.2.15 cells,F,,,Homo sapiens,9606.0,
114,1,,BAO_0000218,Intermediate,,13467,The growth inhibition activity for the compound was evaluated in 2.2.15 cells.,F,,,Homo sapiens,9606.0,
115,1,,BAO_0000218,Intermediate,,13467,Selectivity index was determined from the ratio of IC50 to the EC50 values evaluated in 2.2.15 cells.,F,,,Homo sapiens,9606.0,
116,1,,BAO_0000219,Intermediate,,14764,Antiviral activity against HBV was determined in 2.215 cell line,F,,,Homo sapiens,9606.0,
117,0,,BAO_0000251,Autocuration,,6531,Inhibition of 20-HETE synthesis in human renal microsomes,B,,,Homo sapiens,9606.0,
118,0,,BAO_0000019,Autocuration,,17322,Inhibitory activity against 20-HETE production from arachidonic acid using human renal microsome 20-HETE synthase.,B,,,,,
119,1,,BAO_0000219,Intermediate,,17072,Inhibitory concentration against 2008 (ovarian) cells,F,,,Homo sapiens,9606.0,
120,1,,BAO_0000219,Intermediate,,16936,50% Growth inhibitory concentration( GI 50 ) by using 2008 human ovarian carcinoma cell lines.,F,,,Homo sapiens,9606.0,
121,1,,BAO_0000219,Intermediate,,16936,Compound was tested for 50% growth inhibitory concentration by using human ovarian carcinoma cell lines (2008),F,,,Homo sapiens,9606.0,
122,1,,BAO_0000219,Intermediate,,17146,Direct cytotoxicity against the selected tumor cell line 2008 was determined especially on ovarian adenocarcinoma derived cells,F,,,Homo sapiens,9606.0,
123,1,,BAO_0000219,Intermediate,,17146,Direct cytotoxicity against the selected tumor cell line 2008 was determined especially on ovarian adenocarcinoma derived cells; not detected,F,,,Homo sapiens,9606.0,
124,1,,BAO_0000219,Intermediate,,10797,In vitro inhibition of 2008/R ovarian cancer cell line,F,,,Homo sapiens,9606.0,
125,1,,BAO_0000219,Intermediate,,10797,In vitro inhibition of 2008/R ovarian cancer cell line; NA= Not achievable,F,,,Homo sapiens,9606.0,
126,1,,BAO_0000219,Intermediate,,10797,In vitro inhibition of 2008/S ovarian cancer cell line,F,,,Homo sapiens,9606.0,
127,1,,BAO_0000219,Intermediate,,10797,In vitro inhibition of 2008/S ovarian cancer cell line; NA= Not achievable,F,,,Homo sapiens,9606.0,
128,2,,BAO_0000220,Expert,,4823,Tested in vitro for inhibition of chymotrypsin like activity of purified human 20S proteasome,B,,,Homo sapiens,9606.0,
129,2,,BAO_0000220,Intermediate,,12912,Compound was evaluated for inhibitory activity against 20S proteasome from human liver and brain,B,,,Homo sapiens,9606.0,
130,2,,BAO_0000220,Expert,,2957,Inhibition of chymotrypsin-like activity of 20S proteasome,B,,,,,
131,2,,BAO_0000220,Expert,,2957,Inhibition of chymotrypsin-like activity of 20S proteasome; value ranges from 10-20 uM,B,,,,,
132,2,,BAO_0000220,Intermediate,,3260,Inhibitory activity against 20S proteosome,B,,,,,
133,0,,BAO_0000019,Autocuration,,3451,Compound was tested for inhibitory activity against tryptase,B,,,Homo sapiens,9606.0,
134,1,,BAO_0000219,Intermediate,,13885,Concentration required to inhibit 50% of extracellular circular replication of HBV DNA using 2215 cell line,F,,,Homo sapiens,9606.0,
135,1,,BAO_0000219,Intermediate,,13885,Concentration required to inhibit 50% of intracellular circular replication of HBV DNA using 2215 cell line,F,,,Homo sapiens,9606.0,
136,0,,BAO_0000019,Autocuration,,3676,Compound was tested for the inhibition of Alpha-glucosidase,B,,,,,
137,8,,BAO_0000357,Autocuration,,6043,Inhibitory concentration against human neutrophil elastase (HNE),B,,,,,
138,0,,BAO_0000218,Autocuration,948.0,11140,Change in heart rate was expressed in percent at at a dose 0.002 mg/kg iv in anesthetized rat,F,,,Rattus norvegicus,10116.0,
139,8,,BAO_0000019,Autocuration,,10543,90% inhibition of the 20 Mycobacterium avium complex (MAC) clinical isolates,F,,,,,
140,8,,BAO_0000019,Expert,,10543,Minimum inhibitory concentration of compound against 20 Mycobacterium avium complex (MAC) clinical isolates,F,,,,,
141,8,,BAO_0000357,Autocuration,,10543,Minimum inhibitory concentration of compound against 20 Mycobacterium avium complex (MAC) clinical isolates,B,,,,,
142,8,,BAO_0000019,Expert,,10543,90% inhibition of the 20 Mycobacterium avium complex (MAC) clinical isolates,F,,,,,
143,1,,BAO_0000219,Intermediate,,11365,In Vitro evaluation for the growth inhibition of Subline (P388/AMSA) Leukemia cell lines,F,,,Mus musculus,10090.0,
144,1,,BAO_0000219,Intermediate,,11365,In Vitro evaluation for the growth inhibition of Subline (P388/CP) Leukemia cell lines,F,,,Mus musculus,10090.0,
145,1,,BAO_0000219,Intermediate,,11803,Compound was evaluated for the inhibition of cell replication human peripheral blood lymphocytes (PBL's).,F,,,Homo sapiens,9606.0,
146,0,,BAO_0000019,Autocuration,,11803,Compound was evaluated for the inhibition of cell replication sheep choroid plexus (SCP) cells,F,,,Ovis aries,9940.0,
147,0,,BAO_0000019,Autocuration,,11803,Compound was evaluated for the inhibition of cell replication sheep choroid plexus (SCP) cells.,F,,,Ovis aries,9940.0,
148,8,,BAO_0000357,Autocuration,,12278,Compound is evaluated in vitro for the inhibition single mutant of HIV-1 RT (Y181C),B,,,,,
149,0,,BAO_0000019,Autocuration,,8249,Compound was evaluated for its inhibitory effect on thymidine [3H]dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-5,F,,,Homo sapiens,9606.0,
150,0,,BAO_0000019,Autocuration,,8249,Compound was evaluated for its inhibitory effect on thymidine [3H]-dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-6,F,,,Homo sapiens,9606.0,
151,0,,BAO_0000219,Autocuration,,8249,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in at conc. 10e-7,F,,,Homo sapiens,9606.0,
152,0,,BAO_0000219,Autocuration,,8249,Compound was evaluated for its inhibitory effect on thymidine ([3H]-dThd) incorporation into DNA of CEM cells in culture at conc. 10e-4,F,,,Homo sapiens,9606.0,
153,0,,BAO_0000219,Autocuration,,8249,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in culture at conc. 10e-5,F,,,Homo sapiens,9606.0,
154,0,,BAO_0000219,Autocuration,,8249,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in culture at conc. 10e-6,F,,,Homo sapiens,9606.0,
155,0,,BAO_0000019,Autocuration,,8249,Compound was evaluated for its inhibitory effect on thymidine ([3H]-dThd) incorporation into DNA of CEM/MTX cells in at conc. 10e-7.,F,,,Homo sapiens,9606.0,
156,0,,BAO_0000019,Autocuration,,8249,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-4,F,,,Homo sapiens,9606.0,
157,6,,BAO_0000249,Autocuration,,16992,In vitro binding affinity towards (alpha-4)2(beta-2)3 neuronal nicotinic acetylcholine receptor in P2 membrane fractions of rat forebrain,B,,,,,
158,1,,BAO_0000218,Intermediate,,10543,Minimum inhibitory concentration of compound against Streptococcus pyogenus septicemia in the mouse,F,,,Streptococcus pyogenes,1314.0,
159,1,,BAO_0000218,Intermediate,,17833,Antiviral activity against 07/1 strain of thymidine kinase negative (TK-) Varicella-Zoster Virus (VZV),F,,,Human herpesvirus 3,10335.0,
160,1,,BAO_0000218,Expert,,17290,Antiviral activity against 07/1 strain of VZV in HEL (human erythroleukemia) cells.,F,,,vericilla zoster virus,10335.0,
161,1,,BAO_0000218,Intermediate,,17290,Antiviral activity against 07/1 strain of VZV; ND: No data,F,,,vericilla zoster virus,10335.0,
162,1,,BAO_0000218,Intermediate,,17290,Antiviral activity against 07/1 strain of VZV; ND=No data,F,,,vericilla zoster virus,10335.0,
163,1,,BAO_0000218,Intermediate,,10932,"Antibacterial activity was determined against gram negative organism, Enterobacter cloacae (MA2646)",F,,,escherichia cloac,561.0,
164,0,,BAO_0000019,Autocuration,,9707,Ratio of Ki at A2 to Ki at A1 receptors,B,,,,,
165,8,,BAO_0000249,Expert,,2346,"In vitro inhibition of 1,3-beta-glucan synthase in Candida albicans membrane assay.",B,,,Candida albicans,5476.0,
166,8,,BAO_0000357,Expert,,2205,"Inhibition of 1,3-beta-glucan synthase",B,,,Candida glabrata CBS 138,284593.0,
167,1,,BAO_0000219,Intermediate,,11900,Inhibition of growth of 1-87 human tumor cell line,F,,,Homo sapiens,9606.0,
168,9,,BAO_0000219,Expert,,14864,Inhibition of 1-lipoxygenase (LOX)in RBL cells,B,,,Rattus norvegicus,10116.0,
169,9,,BAO_0000357,Autocuration,,16474,Inhibitory activity against soybean 1-lipoxygenase (SLO),B,,,Glycine max,3847.0,
170,9,,BAO_0000357,Autocuration,,16474,Inhibitory activity against soybean 1-lipoxygenase (SLO); no effect,B,,,Glycine max,3847.0,
171,9,,BAO_0000357,Autocuration,,16474,% inhibition against soybean 1-lipoxygenase (SLO),B,,,Glycine max,3847.0,
172,9,,BAO_0000357,Autocuration,,16474,percent inhibition against soybean 1-lipoxygenase (SLO);NI is no inhibition,B,,,Glycine max,3847.0,
173,9,,BAO_0000357,Autocuration,,3094,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 10:90,B,,,Glycine max,3847.0,
174,9,,BAO_0000357,Autocuration,,3094,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 1:99,B,,,Glycine max,3847.0,
175,9,,BAO_0000357,Autocuration,,3094,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 25:75,B,,,Glycine max,3847.0,
176,9,,BAO_0000357,Autocuration,,3094,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 35:65,B,,,Glycine max,3847.0,
177,9,,BAO_0000357,Autocuration,,3094,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 50:50,B,,,Glycine max,3847.0,
178,9,,BAO_0000357,Autocuration,,3094,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 76:24,B,,,Glycine max,3847.0,
179,9,,BAO_0000357,Autocuration,,3094,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 87:13,B,,,Glycine max,3847.0,
180,9,,BAO_0000357,Autocuration,,3094,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 89:11,B,,,Glycine max,3847.0,
181,9,,BAO_0000357,Autocuration,,3094,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 95:5,B,,,Glycine max,3847.0,
182,9,,BAO_0000357,Autocuration,,3094,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 97:3,B,,,Glycine max,3847.0,
183,9,,BAO_0000357,Autocuration,,3094,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 99:1,B,,,Glycine max,3847.0,
184,0,,BAO_0000019,Autocuration,,10413,Evaluated for inhibitory activity on 10-formyltetrahydrofolate synthetase(L cell) at folate substrate concentration of 100 uM,B,,,Mus musculus,10090.0,
185,1,,BAO_0000219,Intermediate,,16929,Cells were harvested and were assayed for luciferase and -galactosidase activities (Transcriptional activity),F,,,Mus musculus,10090.0,
186,0,,BAO_0000019,Intermediate,,1229,In vitro anticancer activity against 11 NCI NSCLC cell lines; inactive,F,,,,,
187,8,,BAO_0000357,Autocuration,,16587,In vitro inhibitory activity against human 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA),B,,,,,
188,8,,BAO_0000357,Autocuration,,16587,In vitro inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA),B,,,,,
189,8,,BAO_0000357,Autocuration,,16587,In vitro inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA).,B,,,,,
190,8,,BAO_0000357,Autocuration,,16587,Ability to convert [3H]cortisol to the tritium labeled cortisone in the presence of human 11 beta hydroxysteroid dehydrogenase type 2,B,,,,,
191,8,,BAO_0000357,Autocuration,,16587,Inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 2 at a concentration of 0.2 mM; NI means no inhibition,B,,,,,
192,9,,BAO_0000019,Expert,,8058,Evaluated for inhibition of bovine adrenal cortical mitochondrial 11 beta-hydroxylase,F,,,Bos taurus,9913.0,
193,9,,BAO_0000357,Expert,,9065,Effect on adrenal 11-beta-hydroxylase activity at 10e-4 M; No significant effect,B,,,Rattus norvegicus,10116.0,
194,9,,BAO_0000357,Expert,2369.0,8865,Inhibition of 11 beta-hydroxylase from rat adrenal gland,B,,,Rattus norvegicus,10116.0,
195,9,,BAO_0000357,Expert,,9066,Inhibition of rat adrenal 11-beta-hydroxylase,B,,,Rattus norvegicus,10116.0,
196,9,,BAO_0000357,Expert,,8394,Inhibition of rat adrenal 11-beta-hydroxylase,B,,,Rattus norvegicus,10116.0,
197,9,,BAO_0000357,Expert,,8394,Inhibition of rat adrenal 11-beta-hydroxylase at 10e-5 M,B,,,Rattus norvegicus,10116.0,
198,8,,BAO_0000019,Autocuration,,6431,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 1 of wistar rat liver cytosol at 10 uM was determined using [3H]cortisone,B,,,,,
199,8,,BAO_0000357,Autocuration,,6431,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 2 of wistar rat kidney at 10 uM was determined using [3H]cortisol,B,,,,,
200,8,,BAO_0000357,Autocuration,,6431,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 2 of wistar rat kidney at 10 uM was determined using [3H]cortisol,B,,,,,
201,8,,BAO_0000019,Autocuration,,9295,Compound was tested for the percent of inhibition against 12-LO at 10 uM,F,,,,,
202,8,,BAO_0000019,Autocuration,,10193,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,B,,,,,
203,8,,BAO_0000019,Autocuration,,13622,Compound was tested in vitro for inhibition of 12-LO human platelet,B,,,,,
204,8,,BAO_0000019,Autocuration,,12079,Inhibitory concentration against human platelet 12-lipoxygenase,F,,,,,
205,8,,BAO_0000019,Autocuration,,13622,Compound at 100 uM was tested in vitro for inhibition of 12-LO human platelet,B,,,,,
206,9,,BAO_0000019,Autocuration,,12079,Inhibitory concentration against human platelet 12-lipoxygenase,F,,,Homo sapiens,9606.0,
207,8,,BAO_0000019,Expert,,13500,Tested for inhibition of 12-LO (12-lipoxygenase) as an inhibitor of 12(S)-HETE biosynthesis in mouse epidermal homogenates,B,,,,,
208,8,,BAO_0000357,Expert,,13723,Inhibitory activity against conversion of [1-14C]arachidonic acid to 12-HPETE and its reduction product 12-HETE by porcine leukocyte type 12-lipoxygenase,B,,,,,
209,8,,BAO_0000019,Autocuration,,16474,Inhibitory activity against human platelet 12-lipoxygenase (12-HLO),B,,,,,
210,8,,BAO_0000019,Autocuration,,1630,Inhibitory activity against human platelet 12-lipoxygenase,B,,,,,
211,8,,BAO_0000019,Autocuration,,167,Inhibitory activity against human platelet 12-lipoxygenase was evaluated,B,,,,,
212,8,,BAO_0000019,Autocuration,,16474,% inhibition against human platelet 12-lipoxygenase (12-HLO),B,,,,,
213,8,,BAO_0000019,Autocuration,,167,Inhibitory activity against human platelet 12-lipoxygenase was evaluated at 100 uM,B,,,,,
214,8,,BAO_0000019,Autocuration,,16474,percent inhibition against human platelet 12-lipoxygenase (12-HLO); NI is no inhibition,B,,,,,
215,8,,BAO_0000357,Autocuration,,10091,Inhibitory activity towards porcine 12-lipoxygenase,B,,,,,
216,8,,BAO_0000357,Autocuration,,11966,Tested for inhibition against porcine 12-LO,B,,,,,
217,8,,BAO_0000019,Autocuration,,951,Inhibition of 12-lipoxygenase was evaluated in rat platelets stimulated by thrombin up to a concentration of 10 uM; NE means No effect,B,,,,,
218,8,,BAO_0000019,Autocuration,,10997,Inhibitory activity against 12-lipoxygenase in rat platelet rich plasma,B,,,,,
219,8,,BAO_0000019,Expert,,10193,In vitro inhibition of rat platelet 12-lipoxygenase,B,,,,,
220,8,,BAO_0000019,Autocuration,,10193,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,B,,,,,
221,8,,BAO_0000019,Autocuration,,10193,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 100 uM,B,,,,,
222,8,,BAO_0000019,Autocuration,,10193,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 30 uM,B,,,,,
223,8,,BAO_0000019,Autocuration,,10193,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,B,,,,,
224,8,,BAO_0000019,Autocuration,,10193,In vitro inhibitory activity against rat platelet 12-lipoxygenase,B,,,,,
225,8,,BAO_0000019,Autocuration,,11087,The compound was tested for the in vitro inhibition of platelet 12-lipoxygenase at a concentration of 100 uM,B,,,,,
226,1,,BAO_0000219,Intermediate,,15569,Cytotoxic activity in a panel of Human ovarian tumor 41M cell line after 96h of drug exposure,F,,,Homo sapiens,9606.0,
227,1,,BAO_0000219,Expert,,12989,In vitro antitumor activity against 41M cell line.,F,,,Homo sapiens,9606.0,
228,1,,BAO_0000219,Intermediate,,16745,cytotoxicity against 41M cells incubated for 24 hr in MTT assay.,F,,,Homo sapiens,9606.0,
229,1,,BAO_0000219,Intermediate,,15569,Cytotoxic activity in a panel of Human ovarian tumor 41M/CDDP cell line after 96h of drug exposure,F,,,Homo sapiens,9606.0,
230,1,,BAO_0000219,Expert,,12989,In vitro antitumor activity against 41McisR cell line.,F,,,Homo sapiens,9606.0,
231,1,,BAO_0000219,Expert,,12989,Resistant factor was determined between IC50 of cisplatin-resistant human tumor cell lines to that of 41McisR cell line,F,,,Homo sapiens,9606.0,
232,1,,BAO_0000219,Intermediate,,16745,cytotoxicity against 41McisR cells incubated for 24 hr in MTT assay,F,,,Homo sapiens,9606.0,
233,9,,BAO_0000357,Expert,,6210,Inhibition of 5'-inosine monophosphate dehydrogenase type I (IMPDH I),B,,,Homo sapiens,9606.0,
234,9,,BAO_0000357,Expert,,6210,Inhibition of 5'-inosine monophosphate dehydrogenase type II (IMPDH II),B,,,Homo sapiens,9606.0,
235,8,,BAO_0000357,Expert,,6226,Inhibitory activity against inosine 5'-inosine monophosphate dehydrogenase type II (IMPDH II),B,,,,,
236,8,,BAO_0000357,Expert,,17855,Equilibrium dissociation constant towards human 5'-methylthioadenosine phosphorylase,B,,,,,
237,8,,BAO_0000357,Expert,,17855,Equilibrium dissociation constant towards human 5'-methylthioadenosine phosphorylase; nd = Not determined,B,,,,,
238,8,,BAO_0000357,Expert,,17855,Initial dissociation constant towards human 5'-methylthioadenosine phosphorylase,B,,,,,
239,8,,BAO_0000357,Autocuration,,10413,"Evaluated for inhibitory activity on 5,10-Methenyl Tetrahydrofolate Cyclohydrolase(L cell) at folate substrate concentration of 100 uM",B,,,,,
240,8,,BAO_0000357,Autocuration,,10413,"Inhibitory activity against 5,10-methylenetetrahydrofolate dehydrogenase from Escherichia coli at a concentration of 0.1 mM; NT=Not tested",B,,,Escherichia coli,562.0,
241,8,,BAO_0000357,Autocuration,,10413,"Inhibitory activity against 5,10-Methylene Tetrahydrofolate Cyclohydrolase from Escherichia coli at a concentration of 0.1 mM; NT=Not tested",B,,,Escherichia coli,562.0,
242,8,,BAO_0000357,Autocuration,,10413,"Inhibitory activity against 5,10-Methylene Tetrahydrofolate Cyclohydrolase from Escherichia coli at a concentration of 0.1 mM;NT=Not tested",B,,,Escherichia coli,562.0,
243,8,,BAO_0000357,Autocuration,,10413,"Evaluated for inhibitory activity on 5,10-Methylene Tetrahydrofolate Cyclohydrolase(L cell) at folate substrate concentration of 100 uM",B,,,,,
244,8,,BAO_0000357,Autocuration,,10413,"Evaluated for inhibitory activity on 5,10-methylenetetrahydrofolate dehydrogenase(L cell) at folate substrate concentration of 100 uM",B,,,,,
245,8,,BAO_0000357,Autocuration,,7587,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",B,,,Sus scrofa,9823.0,
246,8,,BAO_0000019,Autocuration,,7587,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (A,porcine liver) enzyme.",B,,,Sus scrofa,9823.0,
247,8,,BAO_0000357,Autocuration,,7587,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-4 M inhibitory concentration",B,,,Sus scrofa,9823.0,
248,8,,BAO_0000357,Autocuration,,7587,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-5 M inhibitory concentration",B,,,Sus scrofa,9823.0,
249,8,,BAO_0000357,Autocuration,,7587,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",B,,,Sus scrofa,9823.0,
250,8,,BAO_0000019,Autocuration,,7587,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-4 M inhibitory concentration",B,,,Sus scrofa,9823.0,
251,8,,BAO_0000019,Autocuration,,7587,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-5 M inhibitory concentration",B,,,Sus scrofa,9823.0,
252,8,,BAO_0000019,Autocuration,,7587,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-6 M inhibitory concentration",B,,,Sus scrofa,9823.0,
253,8,,BAO_0000019,Autocuration,,7587,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-7 M inhibitory concentration",B,,,Sus scrofa,9823.0,
254,8,,BAO_0000019,Autocuration,,7587,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme.",B,,,Sus scrofa,9823.0,
255,8,,BAO_0000357,Autocuration,,7587,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",B,,,Sus scrofa,9823.0,
256,8,,BAO_0000019,Autocuration,,7587,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-4 M inhibitory concentration",B,,,Sus scrofa,9823.0,
257,8,,BAO_0000357,Autocuration,,7323,"Compound was tested for in vitro inhibition of 5,10-Methylene Tetrahydrofolate Cyclohydrolase, competitive against (+)-L-5,10-methenyltetrahydrofolate",B,,,,,
258,0,,BAO_0000019,Autocuration,,7587,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Reductase (porcine kidney) enzyme at 10E-4 M inhibitory concentration",B,,,Sus scrofa,9823.0,
259,0,,BAO_0000019,Autocuration,,7587,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Reductase (porcine kidney) enzyme.",B,,,Sus scrofa,9823.0,
260,8,,BAO_0000357,Expert,,13750,Inhibition of 5-Desaturase involved in ergosterol biosynthesis,B,,,Saccharomyces cerevisiae,4932.0,
261,0,,BAO_0000019,Autocuration,,7662,Ability for reversible inhibition of Walker 256 5-Fluoro-2'-deoxyuridine Phosphorylase,B,,,Rattus norvegicus,10116.0,
262,0,,BAO_0000019,Autocuration,,7662,Ability for reversible inhibition of Walker 256 5-Fluoro-2'-deoxyuridine Phosphorylase,B,,,Rattus norvegicus,10116.0,
263,0,,BAO_0000019,Autocuration,,7662,"Irreversible inhibition of Walker 256 FUDR phosphorylase; expressed as Vo/Vi, velocity without inhibitor to that of velocity with inhibitor",B,,,Rattus norvegicus,10116.0,
264,6,,BAO_0000019,Autocuration,,12211,"Tested for 5-HT 3 receptor antagonist potency by ability to inhibit the reflex bradycardia, the Bezold-Jarisch reflex in the rat",F,,,,,
265,6,,BAO_0000019,Autocuration,,12211,"Compound was tested for its 5-HT 3 receptor antagonist potency by their ability to inhibit the reflex bradycardia, the Bezold-Jarisch reflex in the rat",F,,,,,
266,9,,BAO_0000221,Intermediate,2116.0,12211,Relative ability to increase cholinergically mediated contractions in isolated ileum of guinea pig,F,,,Cavia porcellus,10141.0,
267,8,,BAO_0000019,Expert,,12211,Stimulatory activity of intragastric pressure was tested in the rat,F,,,,,
268,8,,BAO_0000357,Autocuration,,15453,% Decrease of 5-HT carrier-receptor -bound radioactivity using paroxetine as a radioligand.,B,,,,,
269,0,,BAO_0000218,Autocuration,,11884,Dose to reduce neuronal firing against 5-HT cells in rats (iv),F,,,Rattus norvegicus,10116.0,
270,8,,BAO_0000019,Autocuration,,7185,Antagonistic activity of corresponding methoxy compound against serotonin 5-HT receptor,F,,,,,
271,9,,BAO_0000357,Expert,,6876,Binding affinity at 5-HT reuptake site labeled with [3H]paroxetine,B,,,Homo sapiens,9606.0,
272,9,,BAO_0000357,Expert,,6876,Binding affinity at 5-HT reuptake site labeled with [3H]paroxetine; No data,B,,,Homo sapiens,9606.0,
273,8,,BAO_0000019,Autocuration,,11863,Inhibition of high affinity 5-HT uptake at concentration of 1 uM,F,,,,,
274,8,,BAO_0000357,Autocuration,,11863,Inhibition constant of high-affinity 5-HT uptake,B,,,,,
275,8,,BAO_0000019,Autocuration,,11863,Michaelis-Menten constant was reported for high affinity transport of 5-HT,F,,,,,
276,8,,BAO_0000019,Autocuration,,11863,Maximum rate was determined for high affinity transport of 5-HT,F,,,,,
277,4,,BAO_0000019,Autocuration,,4639,Compound was tested for agonistic activity against 5-HT uptake,F,,,,,
278,8,,BAO_0000019,Expert,,15796,Inhibition affinity against 5-HT-1B receptor in rat frontal cortex using radio binding assay,B,,,,,
279,8,,BAO_0000357,Expert,,15796,Inhibition affinity against 5-HT-1D receptor in bovine caudate nucleus using radio binding assay,B,,,Bos taurus,9913.0,
280,5,,BAO_0000224,Autocuration,,12801,Binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand,B,,,Rattus norvegicus,10116.0,
281,4,,BAO_0000224,Autocuration,,12801,The compound was evaluated for the binding affinity towards 5-hydroxytryptamine 1 using [3H]5-HT as radioligand,B,,,,,
282,4,,BAO_0000249,Autocuration,,12120,Percent inhibition of binding of 3.0 nM [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat caudate membranes at 10 e -5 M,B,,,,,
283,4,,BAO_0000249,Autocuration,,12120,Percent inhibition of binding of 3.0 nM [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat caudate membranes at 10 e -5 M.,B,,,,,
284,4,,BAO_0000019,Autocuration,,11963,Displacement of binding of [3H]-5-HT to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,B,,,,,
285,8,,BAO_0000019,Autocuration,,11701,Dose required to reduce neuronal firing of 5-HT1A cells by 50%,F,,,,,
286,8,,BAO_0000221,Autocuration,10000000.0,9995,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,B,,,,,
287,8,,BAO_0000221,Autocuration,10000000.0,9995,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,B,,,,,
288,8,,BAO_0000221,Autocuration,10000000.0,9995,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,B,,,,,
289,8,,BAO_0000218,Autocuration,,16394,Antagonistic activity at postsynaptic 5-HT1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (.26-3.52),F,In vivo,,,,
290,9,,BAO_0000019,Intermediate,,11574,Effect on forskolin stimulated adenylate cyclase activity at 5-HT1D receptor of guinea pig substantia nigra.,F,,,Cavia porcellus,10141.0,
291,8,,BAO_0000219,Autocuration,,15779,Binding affinity towards 5-HT1F (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,B,,,,,
292,8,,BAO_0000357,Autocuration,,15363,Compound was tested for the displacement of [125I]DOI from clone human 5-hydroxytryptamine 2A receptor,B,,,,,
293,9,,BAO_0000019,Expert,,15363,Efficacy against 5-hydroxytryptamine 2A receptor,F,,,Rattus norvegicus,10116.0,
294,8,,BAO_0000019,Expert,,15329,Intrinsic activity towards 5-HT2A receptor of rat tail artery,F,,,,,
295,8,,BAO_0000019,Expert,,15329,Relative potency towards 5-HT2A receptor of rat tail artery,F,,,,,
296,8,,BAO_0000019,Expert,,15329,Blocking 5-HT2A receptor-mediated contractions of rat tail artery,F,,,,,
297,8,,BAO_0000019,Expert,,15329,Partial agonism at 5-HT2A receptor was evaluated in presence of ketanserin (3-10 nM) in isolated rat tail artery,F,,,,,
298,8,,BAO_0000019,Autocuration,,15329,Compound was tested for the intrinsic activity against 5-HT2A receptors of rat tail artery.,F,,,,,
299,8,,BAO_0000019,Expert,,15329,Effectiveness in blocking 5-HT2A receptor-mediated contractions of rat tail artery,F,,,,,
300,9,,BAO_0000221,Intermediate,2116.0,273,Evaluated for the agonistic activity against 5-HT4 receptor in non-electrically stimulated guinea-pig ileum.,F,,,Cavia porcellus,10141.0,
301,9,,BAO_0000221,Intermediate,2116.0,273,Agonistic activity against Serotonin 5-HT4 receptor in low frequency field stimulation of guinea-pig ileum (FSGPI),F,,,Cavia porcellus,10141.0,
302,9,,BAO_0000221,Intermediate,2116.0,273,Evaluated for the agonistic activity against Serotonin 5-HT4 receptor in non-electrically stimulated guinea-pig ileum.,F,,,Cavia porcellus,10141.0,
303,8,,BAO_0000357,Autocuration,,12092,The binding affinity was measured on 5-hydroxytryptamine 4 receptor using [3H]- GR-113808 as radioligand.,B,,,,,
304,9,,BAO_0000019,Expert,,1317,Antagonist activity against 5-HT4 receptor mediated relaxation of rat carbachol contracted esophageal muscularis mucosae,F,,,Rattus norvegicus,10116.0,
305,8,,BAO_0000357,Expert,,12409,Binding affinity against 5-hydroxytryptamine 4 receptor,B,,,,,
306,0,,BAO_0000019,Autocuration,,11126,Relative competitive index values for binding to 25-OH-D3-1-hydroxylase of chick intestine,B,,,Gallus gallus,9031.0,
307,0,,BAO_0000019,Autocuration,,11126,Inhibitory effect (10e-6 M) on the 25-OH-D3-1-hydroxylase activity,F,,,Homo sapiens,9606.0,
308,0,,BAO_0000019,Autocuration,,11126,25-OH-D3-1-hydroxylase activity (10e-6 M) was measured as %control,F,,,Homo sapiens,9606.0,
309,1,,BAO_0000219,Autocuration,,11126,Relative competitive index values for binding to 25-OH-D3-1-hydroxylase of human HL-60 cells,B,,,Homo sapiens,9606.0,
310,0,,BAO_0000019,Autocuration,,11126,Inhibitory effect (10e-6 M) on the 25-hydroxyvitamin D3-1-hydroxylase activity,B,,,Homo sapiens,9606.0,
311,0,,BAO_0000019,Autocuration,,11126,25-hydroxyvitamin D3-1-hydroxylase activity (10e-6 M) was measured as %control,B,,,Homo sapiens,9606.0,
312,7,,BAO_0000219,Autocuration,,17807,Displacement of [3H]-Ro- 15-1788 from human GABA-A alpha-1-beta-3-gamma-2 receptor subunits expressed in Xenopus oocytes,B,,,Homo sapiens,9606.0,
313,2,,BAO_0000220,Intermediate,,16575,Chymotryptic inhibitory activity against 26S proteasome,F,,,,,
314,2,,BAO_0000220,Intermediate,,15407,Inhibitory activity against 26S proteasome degradation of IkB,B,,,,,
315,1,,BAO_0000219,Intermediate,,10797,In vitro inhibition of 2780/DOX ovarian cancer cell line,F,,,Homo sapiens,9606.0,
316,1,,BAO_0000219,Intermediate,,10797,In vitro inhibition of 2780/S ovarian cancer cell line,F,,,Homo sapiens,9606.0,
317,0,,BAO_0000019,Autocuration,,3469,Relative activity on the cellular accumulation of vincristine in multidrug-resistant (MDR) human ovarian cancer 2780AD cells,F,,,Homo sapiens,9606.0,
318,3,,BAO_0000225,Intermediate,,16037,Association constant for binding to AATT 28-mer AATT hairpin,B,,,,,
319,3,,BAO_0000225,Intermediate,,16037,Kinetically Defined Association Constant for 28-mer AATT hairpin.,B,,,,,
320,3,,BAO_0000225,Intermediate,,16037,Reaction Rate Parameter for 28-mer AATT hairpin,B,,,,,
321,3,,BAO_0000225,Intermediate,,16037,Reaction Rate Parameter for 28-mer AATT hairpin,B,,,,,
322,0,,BAO_0000019,Autocuration,,16524,Antiviral activity against envelope deficient HIV-1 in a single cycle replication assay (experiment 1),F,,,Homo sapiens,9606.0,
323,0,,BAO_0000019,Autocuration,,16524,Antiviral activity against envelope deficient HIV-1 in a single cycle replication assay (experiment 2),F,,,Homo sapiens,9606.0,
324,0,,BAO_0000019,Autocuration,,16524,Inhibitory concentration by single cycle replication assay using envelope deficient HIV-1,F,,,Homo sapiens,9606.0,
325,0,,BAO_0000019,Autocuration,,16758,Cytotoxicity against cell line 2SC/20 determined by MTT test,F,,,Cricetulus griseus,10029.0,
326,0,,BAO_0000019,Autocuration,,16758,Cytotoxicity against cell line 2SC/20 of hamster determined by MTT test,F,,,Cricetulus griseus,10029.0,
327,0,,BAO_0000019,Autocuration,,16758,Inhibitory concentration against the growth of 2SC/20 cell line after 72 hr of drug exposure by MTT test,F,,,Cricetulus griseus,10029.0,
328,8,,BAO_0000357,Autocuration,,14360,Binding affinity on 3 beta-hydroxysteroid dehydrogenase,B,,,,,
329,9,,BAO_0000357,Expert,,14360,Binding affinity for 3-beta-hydroxysteroid dehydrogenase,B,,,Homo sapiens,9606.0,
330,0,,BAO_0000019,Autocuration,,9964,Selectivity ratio of ID50 in liver and heart,B,,,Rattus norvegicus,10116.0,
331,8,,BAO_0000019,Autocuration,,9964,"Selectivity, ratio of relative ID50 in liver and heart",B,,,,,
332,8,,BAO_0000019,Autocuration,,9964,Binding affinity to the receptor was determined in isolated nuclei of heart(In vitro) relative to T3,B,,,,,
333,8,,BAO_0000218,Autocuration,,9964,"Binding affinity to the receptor was determined in nuclei of heart In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",B,,,,,
334,8,,BAO_0000218,Autocuration,,9964,"Binding affinity to the receptor was determined in nuclei of liver In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",B,,,,,
335,8,,BAO_0000218,Autocuration,,9964,"Binding affinity to the receptor was determined in nuclei of liver in vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",B,In vivo,,,,
336,8,,BAO_0000218,Autocuration,,9964,"Binding affinity to the receptor was determined in nuclei of liver in vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",F,In vivo,,,,
337,0,,BAO_0000019,Autocuration,,9964,"Binding affinity to the thyroid hormone receptor was determined in vitro in isolated nuclei of rat liver relative to 3,5,3' triiodothyronine",B,,,,,
338,8,,BAO_0000019,Autocuration,,9964,Binding affinity to the receptor was determined in vitro in isolated nuclei of rat liver relative to T3,B,,,,,
339,0,,BAO_0000019,Autocuration,,9964,"Binding affinity to thyroid hormone receptor beta, relative to 3,5,3' triiodothyronine receptor, in isolated nuclei of heart",B,,,Homo sapiens,9606.0,
340,8,,BAO_0000019,Autocuration,,9964,In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to T3,B,,,,,
341,8,,BAO_0000019,Autocuration,,9964,In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to T3,F,,,,,
342,8,,BAO_0000019,Autocuration,,9964,"Binding affinity to the receptor was determined in isolated nuclei of heart(In vitro) relative to 3,5,3' triiodothyronine receptor",B,,,,,
343,0,,BAO_0000218,Autocuration,,9964,"In vivo binding affinity for 3,5,3'' triiodothyronine receptor of heart nuclei 1 hr after intravenous administration",B,,,Rattus norvegicus,10116.0,
344,8,,BAO_0000218,Autocuration,,9964,Binding affinity to the receptor was determined in nuclei of heart in vivo 1 hour after intravenous administration relative to T3,B,In vivo,,,,
345,8,,BAO_0000218,Autocuration,,9964,"Binding affinity to the receptor was determined in nuclei of liver In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",B,,,,,
346,0,,BAO_0000218,Autocuration,,9964,"In vivo binding affinity for 3,5,3' triiodothyronine receptor of liver nuclei 1 hour after intravenous administration",B,,,Rattus norvegicus,10116.0,
347,8,,BAO_0000019,Autocuration,,9964,"In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to 3,5,3' triiodothyronine receptor",B,,,,,
348,8,,BAO_0000019,Autocuration,,9964,"In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to 3,5,3' triiodothyronine receptor",F,,,,,
349,0,,BAO_0000019,Autocuration,,3796,"Inhibition of [125I]L-T3 binding to rat hepatic 3,5,3''-triiodo-L-thyronine receptor",B,,,Rattus norvegicus,10116.0,
350,8,,BAO_0000357,Autocuration,,4251,Inhibition constant for binding to Co2+ form of 3-dehydroquinate synthase (DHQ) purified from Escherichia coli,B,,,Escherichia coli,562.0,
351,8,,BAO_0000357,Autocuration,,4251,Inhibition constant for binding to Zn2+ form of 3-dehydroquinate synthase (DHQ) purified from Escherichia coli,B,,,Escherichia coli,562.0,
352,8,,BAO_0000357,Autocuration,,4251,Kinetics expressed as Michaelis-Menten constant against Co2+ form of 3-dehydroquinate synthase purified from Escherichia coli,B,,,Escherichia coli,562.0,
353,8,,BAO_0000357,Autocuration,,4251,Kinetics expressed as Michaelis-Menten constant against Zn2+ form of 3-dehydroquinate synthase purified from Escherichia coli,B,,,Escherichia coli,562.0,
354,8,,BAO_0000357,Autocuration,,166,Type of inhibition of 3-dehydroquinate synthase was determined; R - Slowly reversible,B,,,,,
355,8,,BAO_0000357,Autocuration,,17861,Compound was evaluated for its inhibitory constant against 3-dehydroquinate synthase,B,,,,,
356,8,,BAO_0000357,Autocuration,,166,Inhibition constant against 3-dehydroquinate synthase,B,,,,,
357,8,,BAO_0000357,Autocuration,,166,Association rate constant against 3-dehydroquinate synthase,B,,,,,
358,8,,BAO_0000357,Autocuration,,166,Rate constant against 3-dehydroquinate synthase,B,,,,,
359,0,,BAO_0000019,Autocuration,,3548,Inhibitory activity against fuc-TVII,B,,,,,
360,9,,BAO_0000251,Autocuration,2107.0,9877,Ability of compound (2.5 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,B,,,Rattus norvegicus,10116.0,
361,9,,BAO_0000251,Autocuration,2107.0,9877,Ability of compound (2500 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,B,,,Rattus norvegicus,10116.0,
362,9,,BAO_0000251,Autocuration,2107.0,9877,Ability of compound (250 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,B,,,Rattus norvegicus,10116.0,
363,9,,BAO_0000251,Autocuration,2107.0,9877,Ability of compound (25 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,B,,,Rattus norvegicus,10116.0,
364,9,,BAO_0000251,Autocuration,2107.0,9877,Ability of compound at 0 uM to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,B,,,Rattus norvegicus,10116.0,
365,9,,BAO_0000251,Autocuration,2107.0,9877,Ability of compound to inhibit the activity of 3-hydroxy-3-methylglutarylcoenzyme A(HMGR) reductase in rat liver microsomes,B,,,Rattus norvegicus,10116.0,
366,9,,BAO_0000251,Autocuration,2107.0,9877,Percentage inhibition of 3-hydroxy-3-methyl glutaryl coenzyme A reductase in rat liver microsomes at 250 uM,B,,,Rattus norvegicus,10116.0,
367,9,,BAO_0000251,Autocuration,2107.0,9877,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 0 uM,B,,,Rattus norvegicus,10116.0,
368,9,,BAO_0000251,Autocuration,2107.0,9877,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 2.5 uM,B,,,Rattus norvegicus,10116.0,
369,9,,BAO_0000251,Autocuration,2107.0,9877,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 2500 uM,B,,,Rattus norvegicus,10116.0,
370,9,,BAO_0000251,Autocuration,2107.0,9877,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 25 uM,B,,,Rattus norvegicus,10116.0,
371,4,,BAO_0000224,Autocuration,,3003,Inhibitory activity against 3-phosphoglycerate kinase.,B,,,,,
372,4,,BAO_0000224,Autocuration,,3003,Binding affinity was evaluated towards 3-phosphoglycerate kinase at 37 degrees Celsius in 0.1 m NaCl pH 7.1,B,,,,,
373,4,,BAO_0000224,Autocuration,,3003,"Michaelis-Menten constant with 1,3-bisphosphoglyceric acid (1,3-BPG) against 3-phosphoglycerate kinase",B,,,,,
374,9,,BAO_0000357,Expert,,17185,Inhibition of human 3-phosphoinositide-dependent protein kinase 1 at 10 uM,B,,,Homo sapiens,9606.0,
375,1,,BAO_0000219,Intermediate,,6072,Cytotoxicity on 3677 melanoma cells,F,,,Homo sapiens,9606.0,
376,1,,BAO_0000219,Intermediate,,6072,Cytotoxicity on 3677 melanoma cells in combination with L-49-sFv-bL,F,,,Homo sapiens,9606.0,
377,1,,BAO_0000219,Intermediate,,5018,Antitumor activity against Mouse colon 38 at 500 ug/disk in disk diffusion assay,F,,,Mus musculus,10090.0,
378,0,,BAO_0000019,Intermediate,,2852,Compound was evaluated for inhibition of tumor cell growth using sulforhodamine-B assay in 38 human cell lines,F,,,Homo sapiens,9606.0,
379,0,,BAO_0000218,Autocuration,,8663,In vivo antitumor activity against 3B131 intraperitoneally implanted B16 melanoma cells; NT= Not tested,F,,,,,
380,0,,BAO_0000218,Autocuration,,8663,In vivo antitumor activity against 3B131 intraperitoneally implanted B16 melanoma cells; reproducible significant activity.,F,,,,,
381,9,,BAO_0000019,Expert,,3245,Inhibitory activity against Human RhinoVirus serotype-14 3C Protease,F,,,Human rhinovirus 14,12131.0,
382,1,,BAO_0000218,Intermediate,,3245,Inhibitory activity against Human RhinoVirus serotype-14 3C Protease; NI means No inhibition to 50 uM,F,,,Human rhinovirus sp.,169066.0,
383,1,,BAO_0000218,Intermediate,,3877,Compound was evaluated for the inactivation of HRV 14 3C protease activity expressed as KI,F,,,human rhinovirus type 14,169066.0,
384,1,,BAO_0000218,Intermediate,,3877,Compound was evaluated for the inactivation of HRV 14 3C protease activity expressed as kinact,F,,,human rhinovirus type 14,169066.0,
385,9,,BAO_0000019,Expert,,5861,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,F,,,Human rhinovirus 14,12131.0,
386,9,,BAO_0000019,Expert,,5861,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,F,,,Human rhinovirus 14,12131.0,
387,9,,BAO_0000019,Expert,,5861,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,F,,,Human rhinovirus 14,12131.0,
388,9,,BAO_0000019,Expert,,5861,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay; inactive,F,,,Human rhinovirus 14,12131.0,
389,1,,BAO_0000218,Intermediate,,13748,Compound was tested for the inhibitory activity of compound towards human rhinovirus 3C protease,F,,,Enterovirus,12059.0,
390,1,,BAO_0000218,Intermediate,,13748,Compound was tested for the inhibitory activity of compound towards human rhinovirus-16 3C protease,F,,,Enterovirus,12059.0,
391,1,,BAO_0000218,Intermediate,,13748,Compound was tested for the inhibitory activity of compound towards human rhinovirus-2 3C protease,F,,,Enterovirus,12059.0,
392,1,,BAO_0000218,Intermediate,,13748,Compound was tested for the inhibitory activity of compound towards human rhinovirus-89 3C protease,F,,,Enterovirus,12059.0,
393,8,,BAO_0000357,Expert,,13748,Inhibition of human rhinovirus 3C protease,B,,,Human rhinovirus B,147712.0,
394,0,,BAO_0000019,Autocuration,,17699,Compound was tested for inhibition of a proteinase 3CL pro of human coronavirus; Inhibited,B,,,Homo sapiens,9606.0,
395,1,,BAO_0000218,Intermediate,,7145,Compound tested for activity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose of 100 mg/kg (Dose range 200-12.5),F,,,Mus musculus,10090.0,
396,1,,BAO_0000218,Intermediate,,7145,Compound tested for activity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose of 128 mg/kg (Dose range 256-16),F,,,Mus musculus,10090.0,
397,1,,BAO_0000218,Intermediate,,7145,Compound tested for toxicity against 3EM 37 Mouse Ependymoblastoma after single ip injection on day 1 at optimal dose (OD) of 100 mg/kg on the 5th day after the injection of the compound; (10/10),F,,,Mus musculus,10090.0,
398,1,,BAO_0000218,Intermediate,,7145,Compound tested for toxicity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose (OD) of 100 mg/kg on the 5th day after the injection of the compound; (6/6),F,,,Mus musculus,10090.0,
399,1,,BAO_0000218,Intermediate,,7145,Effect of compound on 3EM 37 mouse ependymoblastoma after single ip injection on day 1 recorded as animal weight difference of the treated and the control (T-C) at OD of 100 mg/kg,F,,,Mus musculus,10090.0,
400,1,,BAO_0000218,Intermediate,,7145,Effect of compound on 3EM 37 mouse ependymoblastoma after single ip injection on day 1 recorded as percentage of cured animals at OD of 100 mg/kg,F,,,Mus musculus,10090.0,
401,1,,BAO_0000218,Intermediate,,5325,In vivo anti-tumor and anti-metastatic activity was measured after oral dosing 15 mg/kg b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor,F,,,Mus musculus,10090.0,
402,1,,BAO_0000218,Intermediate,,5325,In vivo anti-tumor and anti-metastatic activity was measured after oral dosing b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor,F,,,Mus musculus,10090.0,
403,1,,BAO_0000218,Expert,,5325,In vivo anti-tumor and anti-metastatic activity following p.o. administration b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor; Not tested.,F,,,Mus musculus,10090.0,
404,1,,BAO_0000219,Intermediate,,16169,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 1 uM dose,F,,,Mus musculus,10090.0,
405,1,,BAO_0000219,Intermediate,,16169,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 10 uM dose,F,,,Mus musculus,10090.0,
406,1,,BAO_0000219,Intermediate,,16169,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 250 uM dose,F,,,Mus musculus,10090.0,
407,1,,BAO_0000219,Intermediate,,16169,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 50 uM dose,F,,,Mus musculus,10090.0,
408,1,,BAO_0000219,Intermediate,,16169,accumulation of compound in 3LL cells was measured with DFMO by ICP-AES at 50 uM dose,F,,,Mus musculus,10090.0,
409,1,,BAO_0000219,Intermediate,,16169,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 1 uM dose,F,,,Mus musculus,10090.0,
410,1,,BAO_0000219,Intermediate,,16169,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 10 uM dose,F,,,Mus musculus,10090.0,
411,1,,BAO_0000219,Intermediate,,16169,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 250 uM dose,F,,,Mus musculus,10090.0,
412,1,,BAO_0000219,Intermediate,,16169,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 50 uM dose,F,,,Mus musculus,10090.0,
413,1,,BAO_0000219,Intermediate,,16169,accumulation of compound in 3LL cells was measured without DFMO by ICP-AES at 50 uM dose,F,,,Mus musculus,10090.0,
414,1,,BAO_0000219,Intermediate,,16169,Effect on the growth of 3LL cells by DFMO pretreatment at 48 hr incubation,F,,,Mus musculus,10090.0,
415,1,,BAO_0000219,Intermediate,,16169,Effect on the growth of 3LL cells was evaluated using an MTT assay at 48 hour incubation,F,,,Mus musculus,10090.0,
416,1,,BAO_0000219,Intermediate,,16169,Effect on the growth of 3LL cells was evaluated using an MTT assay at 72 hour incubation,F,,,Mus musculus,10090.0,
417,1,,BAO_0000219,Intermediate,,16169,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 50 uM dose,F,,,Mus musculus,10090.0,
418,1,,BAO_0000219,Intermediate,,16169,putrescine levels in 3LL cells after the treatment of 1 uM of Compound,F,,,Mus musculus,10090.0,
419,1,,BAO_0000219,Intermediate,,16169,putrescine levels in 3LL cells after the treatment of 10 uM of Compound,F,,,Mus musculus,10090.0,
420,1,,BAO_0000219,Intermediate,,16169,putrescine levels in 3LL cells after the treatment of 250 uM of Compound,F,,,Mus musculus,10090.0,
421,1,,BAO_0000219,Intermediate,,16169,putrescine levels in 3LL cells after the treatment of 50 uM of Compound,F,,,Mus musculus,10090.0,
422,1,,BAO_0000219,Intermediate,,16169,spermidine levels in 3LL cells after the treatment of 1 uM of Compound,F,,,Mus musculus,10090.0,
423,1,,BAO_0000219,Intermediate,,16169,spermidine levels in 3LL cells after the treatment of 10 uM of Compound,F,,,Mus musculus,10090.0,
424,1,,BAO_0000219,Intermediate,,16169,spermidine levels in 3LL cells after the treatment of 250 uM of Compound,F,,,Mus musculus,10090.0,
425,1,,BAO_0000219,Intermediate,,16169,spermidine levels in 3LL cells after the treatment of 50 uM of Compound,F,,,Mus musculus,10090.0,
426,1,,BAO_0000219,Intermediate,,16169,spermine levels in 3LL cells after the treatment of 1 uM of Compound,F,,,Mus musculus,10090.0,
427,1,,BAO_0000219,Intermediate,,16169,spermine levels in 3LL cells after the treatment of 10 uM of Compound,F,,,Mus musculus,10090.0,
428,1,,BAO_0000219,Intermediate,,16169,spermine levels in 3LL cells after the treatment of 250 uM of Compound,F,,,Mus musculus,10090.0,
429,1,,BAO_0000219,Intermediate,,16169,spermine levels in 3LL cells after the treatment of 50 uM of Compound,F,,,Mus musculus,10090.0,
430,1,,BAO_0000219,Intermediate,,15547,Concentration required to inhibit the colony formation of lung carcinoma (3LLD122) cell lines by 50%,F,,,Homo sapiens,9606.0,
431,0,,BAO_0000218,Autocuration,,8663,In vivo antitumor activity against 3M531 is the sarcoma M5076; reproducible minimal activity,F,,,,,
432,0,,BAO_0000218,Autocuration,,8663,In vivo antitumor activity against 3M531 is the sarcoma M5076; reproducible significant activity.,F,,,,,
433,0,,BAO_0000218,Autocuration,,8663,In vivo antitumor activity against 3MBG5 subrenal capsule mammary carcinoma MX-1 xenograft; NT= Not tested,F,,,,,
434,0,,BAO_0000218,Autocuration,,8663,In vivo antitumor activity against 3MBG5 subrenal capsule mammary carcinoma MX-1 xenograft; reproducible significant activity.,F,,,,,
435,1,,BAO_0000219,Intermediate,,4504,Effective dose required against Trypanosoma cruzi amastigotes in 3T3 Fibroblasts,F,,,Mus musculus,10090.0,
436,1,,BAO_0000219,Intermediate,,4504,Effective dose required against Trypanosoma cruzi amastigotes in 3T3 Fibroblasts,F,,,Mus musculus,10090.0,
437,8,,BAO_0000219,Expert,,12695,Inhibition of 6 nM bombesin induced [3H]thymidine incorporation measured in swiss 3T3 cells using a mitogenicity assay,F,,,,,
438,1,,BAO_0000219,Intermediate,,12695,Ability of the peptide to inhibit 6 nM bombesin induced [3H]thymidine incorporation was measured in swiss 3T3 cells using mitogenicity assay; na=Not active,F,,,Mus musculus,10090.0,
439,1,,BAO_0000219,Intermediate,,12695,Ability of the peptide to inhibit 6 nM bombesin induced [3H]thymidine incorporation was measured in swiss 3T3 cells using mitogenicity assay; nt=Not tested,F,,,Mus musculus,10090.0,
440,1,,BAO_0000219,Expert,,17642,Effective dose against murine 3T3 fibroblasts cells,F,,,Mus musculus,10090.0,
441,1,,BAO_0000219,Expert,,17642,Dose required against murine 3T3 fibroblasts cells; 1-10 uM,F,,,Mus musculus,10090.0,
442,1,,BAO_0000219,Expert,,12340,Cytotoxic effect on 3T3 cells,F,,,Mus musculus,10090.0,
443,1,,BAO_0000219,Expert,,12340,Cytotoxic effect on 3T3 cells,F,,,Mus musculus,10090.0,
444,1,,BAO_0000219,Intermediate,,12716,Compound was tested for the concentration necessary to inhibit swiss 3T3 Mouse Fibroblast cell growth rate by 50%.,F,,,Mus musculus,10090.0,
445,1,,BAO_0000219,Intermediate,,6277,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration,F,,,Mus musculus,10090.0,
446,1,,BAO_0000219,Intermediate,,6277,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration; nd=No data,F,,,Mus musculus,10090.0,
447,1,,BAO_0000219,Expert,,6277,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration,F,,,Mus musculus,10090.0,
448,1,,BAO_0000219,Expert,,6277,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration; n.d.=no data,F,,,Mus musculus,10090.0,
449,1,,BAO_0000219,Intermediate,,6277,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration; n.t.=not tested,F,,,Mus musculus,10090.0,
450,1,,BAO_0000219,Expert,,6277,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration,F,,,Mus musculus,10090.0,
451,1,,BAO_0000219,Expert,,6277,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration; n.d.=no data,F,,,Mus musculus,10090.0,
452,1,,BAO_0000219,Intermediate,,6277,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration; n.t.=not tested,F,,,Mus musculus,10090.0,
453,1,,BAO_0000218,Expert,,17780,In vivo inhibition of H-ras-transformed 3T3 fibroblasts in nude mouse tumor models,F,,,Mus musculus,10090.0,
454,7,,BAO_0000219,Autocuration,,12751,Inhibition of PDGF-dependent autophosphorylation of PDGF-R in mouse BALB/c3T3 cells,F,,,Mus musculus,10090.0,
455,1,,BAO_0000219,Expert,,12380,Inhibition of Swiss 3T3 Mouse fibroblast proliferation,F,,,Mus musculus,10090.0,
456,1,,BAO_0000219,Intermediate,,14892,Inhibitory activity against 3T3 cell line,F,,,Mus musculus,10090.0,
457,1,,BAO_0000219,Intermediate,,12695,The ability of the peptide to inhibit the binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane was measured,F,,,Mus musculus,10090.0,
458,8,,BAO_0000019,Expert,,12695,Ability of peptide to inhibit binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane.,F,,,,,
459,1,,BAO_0000219,Intermediate,,12695,The ability of the peptide to inhibit the binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane was measured; nt=Not tested,F,,,Mus musculus,10090.0,
460,1,,BAO_0000219,Intermediate,,12695,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells was measured,F,,,Mus musculus,10090.0,
461,8,,BAO_0000019,Expert,,12695,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells,F,,,,,
462,8,,BAO_0000019,Expert,,12695,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells; nt=Not tested,F,,,,,
463,1,,BAO_0000219,Intermediate,,6277,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration,F,,,Mus musculus,10090.0,
464,1,,BAO_0000219,Expert,,6277,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line was determined using NR coloration; n.d.=no data,F,,,Mus musculus,10090.0,
465,9,,BAO_0000219,Expert,,4959,Inhibition of ligand-induced proliferation in human EGF-R Kinase expressing 3T3 cells,F,,,Homo sapiens,9606.0,
466,9,,BAO_0000219,Expert,,4959,Inhibition of ligand-induced proliferation in human EGF-R Kinase expressing 3T3 cells (Not tested),F,,,Homo sapiens,9606.0,
467,9,,BAO_0000219,Expert,,4959,Inhibition of ligand induced proliferation in human Her-2 (p185erbB) tyrosine kinase expressing 3T3 cells,F,,,Homo sapiens,9606.0,
468,9,,BAO_0000219,Expert,,4959,Inhibition of ligand-induced proliferation in human Her-2 (p185erbB) tyrosine kinase expressing 3T3 cells (Not tested),F,,,Homo sapiens,9606.0,
469,1,,BAO_0000219,Intermediate,,12082,Inhibitory concentration of compound rwas calculated on 3T3 cells by [3H]Thd incorporation,F,,,Mus musculus,10090.0,
470,1,,BAO_0000219,Intermediate,,12082,Inhibitory concentration of compound was calculated on 3T3 cells by [14C]Leu incorporation,F,,,Mus musculus,10090.0,
471,1,,BAO_0000219,Intermediate,,12082,Inhibitory concentration of compound was calculated on 3T3 cells by using clonal assay,F,,,Mus musculus,10090.0,
472,1,,BAO_0000219,Intermediate,,12082,Inhibitory concentration was calculated on 3T3 cells by using growth assay,F,,,Mus musculus,10090.0,
473,1,,BAO_0000219,Intermediate,,2643,In vitro cytotoxicity was evaluated in mouse embryo BALB/c 3T3 cells,F,,,Mus musculus,10090.0,
474,1,,BAO_0000219,Expert,,11926,Inhibition of Swiss 3T3 mouse fibroblast proliferation,F,,,Mus musculus,10090.0,
475,1,,BAO_0000219,Intermediate,,15204,The compound was tested for cytotoxicity against 3T3 fibroblast murine cell line.,A,,,Mus musculus,10090.0,
476,1,,BAO_0000219,Expert,,15992,Effective concentration required to inhibit the growth of murine 3T3 fibroblasts,F,,,Mus musculus,10090.0,
477,1,,BAO_0000219,Intermediate,,16279,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014); Not tested,F,,,Mus musculus,10090.0,
478,1,,BAO_0000219,Intermediate,,16279,Cytotoxicity against 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),F,,,Mus musculus,10090.0,
479,1,,BAO_0000219,Intermediate,,16279,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),F,,,Mus musculus,10090.0,
480,1,,BAO_0000219,Intermediate,,16279,cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),F,,,Mus musculus,10090.0,
481,1,,BAO_0000219,Intermediate,,16279,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),F,,,Mus musculus,10090.0,
482,1,,BAO_0000219,Intermediate,,16279,Cytotoxicity against 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),F,,,Mus musculus,10090.0,
483,1,,BAO_0000219,Expert,,12831,Inhibition of swiss 3T3 mouse fibroblast proliferation,F,,,Mus musculus,10090.0,
484,1,,BAO_0000219,Intermediate,,13497,Compound was tested for sublethal concentrations in 3T3 mouse fibroblast lysis.,F,,,Mus musculus,10090.0,
485,1,,BAO_0000218,Intermediate,,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,F,,,,,
486,1,,BAO_0000219,Intermediate,,13618,Concentration required to stimulate glucose uptake in 3T3-L1 adipocytes after 48 hr incubation,F,,,Mus musculus,10090.0,
487,1,,BAO_0000219,Intermediate,,11902,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 0.3 uM,F,,,Mus musculus,10090.0,
488,1,,BAO_0000219,Intermediate,,11902,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 3 uM,F,,,Mus musculus,10090.0,
489,1,,BAO_0000219,Intermediate,,11902,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 30 uM,F,,,Mus musculus,10090.0,
490,1,,BAO_0000218,Intermediate,,14840,"In vitro ability to stimulate glucose transport in 3T3-L1 adipocytes, given at 100 mg/kg in mouse, after 24 hr",F,,,Mus musculus,10090.0,
491,1,,BAO_0000218,Intermediate,,14840,"In vitro ability to stimulate glucose transport in 3T3-L1 adipocytes, given at 100 mg/kg in mouse, after 3 hr",F,,,Mus musculus,10090.0,
492,1,,BAO_0000219,Intermediate,,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes,F,,,,,
493,1,,BAO_0000219,Intermediate,,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 10 micro M,F,,,,,
494,1,,BAO_0000219,Intermediate,,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,F,,,,,
495,1,,BAO_0000219,Intermediate,,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 30 micro M,F,,,,,
496,1,,BAO_0000219,Intermediate,,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,F,,,,,
497,1,,BAO_0000218,Intermediate,,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 0.3 uM dose.,F,,,,,
498,1,,BAO_0000218,Intermediate,,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 0.5 uM dose.,F,,,,,
499,1,,BAO_0000218,Intermediate,,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 1 uM dose.,F,,,,,
500,1,,BAO_0000218,Intermediate,,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,F,,,,,
501,1,,BAO_0000218,Expert,,13715,In vitro measurements 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 100 uM dose.,F,,,,,
502,1,,BAO_0000218,Expert,,13715,Acute effects in vitro by measuring 2-deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,F,,,,,
503,1,,BAO_0000218,Intermediate,,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 1 uM dose.,F,,,,,
504,1,,BAO_0000218,Intermediate,,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,F,,,,,
505,1,,BAO_0000218,Intermediate,,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 300 uM dose.,F,,,,,
506,1,,BAO_0000218,Expert,,13715,Acute effects in vitro by measuring 2-deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,F,,,,,
507,1,,BAO_0000218,Expert,,13715,In vitro by measurements of 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,F,,,,,
508,1,,BAO_0000218,Expert,,13715,In vitro measurements of 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 60 uM dose.,F,,,,,
509,1,,BAO_0000219,Intermediate,,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 10 micro M,F,,,,,
510,1,,BAO_0000219,Intermediate,,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,F,,,,,
511,1,,BAO_0000219,Intermediate,,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 30 micro M,F,,,,,
512,1,,BAO_0000218,Intermediate,,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 100 uM dose.,F,,,,,
513,1,,BAO_0000218,Intermediate,,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,F,,,,,
514,1,,BAO_0000218,Intermediate,,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,F,,,,,
515,1,,BAO_0000218,Intermediate,,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,F,,,,,
516,1,,BAO_0000218,Intermediate,,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 60 uM dose.,F,,,,,
517,8,,BAO_0000219,Expert,,6411,Inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells,F,,,,,
518,1,,BAO_0000219,Intermediate,,6411,Evaluated for the inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells; ND = No data,F,,,Mus musculus,10090.0,
519,8,,BAO_0000219,Expert,,6411,Evaluated for the inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells; Na = Not active,F,,,,,
520,1,,BAO_0000219,Expert,,3966,Insulin-sensitizing activity; triglyceride accumulation from insulin regulated differentiation of 3T3-L1 cells at 1 uM expressed as percent activity of pioglitazone,F,,,Mus musculus,10090.0,
521,1,,BAO_0000219,Intermediate,,3966,Compound was tested for insulin-sensitizing activity by measuring triglyceride accumulation from insulin regulated differentiation of 3T3-L1 cells at 10 uM expressed as percent activity of pioglitazone,F,,,Mus musculus,10090.0,
522,1,,BAO_0000219,Expert,,15556,Stimulation of adipogenesis in 3T3-L1 cells is expressed as concentration equivalent to the [ 1-14C] uptake counts after treatment with 0.2 ug/mL troglitazone,F,,,Mus musculus,10090.0,
523,1,,BAO_0000219,Expert,,5845,Effective concentration for enhancement of insulin-induced triglyceride accumulation in 3T3-L1 cells,F,,,Mus musculus,10090.0,
524,1,,BAO_0000219,Expert,,14422,Effective concentration for 50% enhancement of insulin-induced triglyceride accumulation in 3T3-L1 cells,F,,,Mus musculus,10090.0,
525,1,,BAO_0000219,Expert,,5845,Percentage of rosiglitazone response for insulin-sensitizing activity at 1 uM concentration in 3T3-L1 cells,F,,,Mus musculus,10090.0,
526,1,,BAO_0000219,Expert,,14508,In vitro glucose transport activity in 3T3-LI adipocytes at 10 uM concentration.,F,,,Mus musculus,10090.0,
527,1,,BAO_0000219,Expert,,14508,In vitro glucose transport activity in 3T3-LI adipocytes at 3 uM concentration.,F,,,Mus musculus,10090.0,
528,1,,BAO_0000219,Expert,,14508,In vitro glucose transport activity in 3T3-LI adipocytes at 30 uM concentration.,F,,,Mus musculus,10090.0,
529,1,,BAO_0000219,Intermediate,,6349,Inhibitory activity against rat fibroblast (3Y1) cell line,F,,,Rattus norvegicus,10116.0,
530,1,,BAO_0000219,Expert,,15899,Mean concentration causing inhibition of cell growth in 3Y1 cells.,F,,,Rattus norvegicus,10116.0,
531,1,,BAO_0000219,Expert,,15899,Cytotoxicity in 3Y1 cells.,F,,,Rattus norvegicus,10116.0,
532,1,,BAO_0000219,Expert,,15899,Cytostatic effect in 3Y1 cells.,F,,,Rattus norvegicus,10116.0,
533,1,,BAO_0000219,Intermediate,,15899,"Mean averaged concentration for total growth inhibition, which signifies cytostatic effect",F,,,Rattus norvegicus,10116.0,
534,1,,BAO_0000219,Expert,,17038,Concentration to inhibit growth of normal rat fibroblast cells (3Y1-B cells) after 72 h exposure,F,,,Rattus norvegicus,10116.0,
535,0,,BAO_0000019,Autocuration,,12421,In vitro inhibitory activity against human adrenal 3-beta hydroxy-delta 5-teroid isomerase,B,,,,,
536,0,,BAO_0000019,Autocuration,,12947,Inhibition of recombinant human adrenal 3-beta-hydroxy-delta-5-steroid dehydrogenase,B,,,,,
537,0,,BAO_0000019,Autocuration,,12947,Inhibition of recombinant rat adrenal 3-beta-hydroxy-delta-5-steroid dehydrogenase,B,,,,,
538,9,,BAO_0000019,Expert,,4896,In vitro inhibition against of 4-Hydroxyphenylpyruvate dioxygenase (4-HPPD) from pig liver by the enol borate method,B,,,Sus scrofa,9823.0,
539,8,,BAO_0000019,Autocuration,,6148,In vitro inhibitory concentration required against 4-hydroxyphenylpyruvate dioxygenase (4-HPPD) taken from pig liver,B,,,,,
540,8,,BAO_0000019,Autocuration,,16432,Inhibition of pig liver 4-Hydroxyphenylpyruvate dioxygenase (4-HPPD) enzyme,B,,,,,
541,8,,BAO_0000019,Expert,,4978,Concentration required to achieve 50% inhibition against 4-Hydroxyphenylpyruvate dioxygenase (HPPD) from pig liver,B,,,,,
542,8,,BAO_0000019,Expert,,4978,Concentration required to achieve 50% inhibition against 4-Hydroxyphenylpyruvate dioxygenase (HPPD) from pig liver; (observed value),B,,,,,
543,8,,BAO_0000019,Autocuration,,3723,In vitro inhibitory activity against HPPD(4-hydroxyphenylpyruvate Dioxygenase) from pig liver using enol borate assay method,B,,,,,
544,8,,BAO_0000357,Autocuration,,3518,Compound was evaluated for complete competitive inhibition of 4-hydroxyphenylpyruvate dioxygenase (HPPD),B,,,,,
545,8,,BAO_0000019,Autocuration,,4164,In vitro inhibition of 4-hydroxyphenylpyruvate dioxygenase obtained from purified pig liver by enol-borate method,B,,,,,
546,8,,BAO_0000019,Autocuration,,3518,Inhibitory activity on pig liver 4-hydroxyphenylpyruvate dioxygenase (HPPD) was evaluated,B,,,,,
547,9,,BAO_0000019,Expert,,4164,Inhibition of 4-hydroxyphenylpyruvate dioxygenase of purified pig liver by enol-borate method,B,,,Sus scrofa,9823.0,
548,8,,BAO_0000019,Autocuration,,3518,The inhibitory activity on pig liver 4-hydroxyphenylpyruvate dioxygenase (HPPD) was evaluated.,B,,,,,
549,8,,BAO_0000357,Autocuration,,3518,Compound was evaluated for competitive inhibition of 4-hydroxyphenylpyruvate dioxygenase (HPPD) (complete inhibition was observed at a concentration of 0.5-1.0 mM),B,,,,,
550,8,,BAO_0000019,Autocuration,,4978,Concentration required to achieve 50% inhibition against 4-hydroxyphenylpyruvate dioxygenase from pig liver,B,,,,,
551,8,,BAO_0000019,Autocuration,,4978,Concentration required to achieve 50% inhibition against 4-hydroxyphenylpyruvate dioxygenase from pig liver; (observed value),B,,,,,
552,4,,BAO_0000224,Autocuration,,6455,Binding affinity against melatonin (MT1) receptor (pC1),B,,,,,
553,0,,BAO_0000019,Autocuration,,2222,Compound was tested for inhibitory activity against 5-hydroxytryptamine 1 receptor,B,,,,,
554,0,,BAO_0000019,Autocuration,,13020,Inhibition of [3H]- 5-HT binding to 5-hydroxytryptamine 1 receptor at 10e-5 M,B,,,,,
555,0,,BAO_0000019,Autocuration,,13021,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1 receptor of central nervous system,B,,,,,
556,8,,BAO_0000357,Autocuration,,14532,Inhibitory activity against 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand at 10e-5 M concentration,B,,,,,
557,8,,BAO_0000357,Autocuration,,14118,Binding affinity against 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand,B,,,,,
558,8,,BAO_0000221,Autocuration,10000000.0,11884,Binding affinity at 5-hydroxytryptamine 1A receptor in bovine hippocampal preparation using [3H]8-OH-DPAT,B,,,,,
559,8,,BAO_0000357,Expert,,13969,Binding affinity against 5-hydroxytryptamine 1A receptor was measured using [3H]8-OH-DPAT as radioligand,B,,,,,
560,8,,BAO_0000357,Expert,,13392,Binding affinity for 5-hydroxytryptamine 1A receptor,B,,,,,
561,8,,BAO_0000019,Expert,,14430,Affinity towards 5-hydroxytryptamine 1A receptor in membranes from bovine hippocampus using [3H]OH-DPAT,B,,,,,
562,8,,BAO_0000221,Autocuration,10000000.0,12248,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,B,,,,,
563,8,,BAO_0000221,Autocuration,10000000.0,12249,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,B,,,,,
564,8,,BAO_0000221,Autocuration,10000000.0,9995,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-HT1A receptor from bovine hippocampus,B,,,,,
565,8,,BAO_0000221,Autocuration,10000000.0,9995,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,B,,,,,
566,8,,BAO_0000221,Autocuration,10000000.0,9995,In vitro inhibition of azido-[125I]-IPAPP (0.25 nM) binding to 5-HT1A receptor from bovine hippocampus,B,,,,,
567,8,,BAO_0000221,Autocuration,10000000.0,9995,In vitro inhibition of [125I]IPAPP (0.25 nM) binding to 5-HT1A receptor from bovine hippocampus,B,,,,,
568,8,,BAO_0000221,Autocuration,10000000.0,9995,In vitro inhibition of [125I]IPAPP (2.5 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,B,,,,,
569,8,,BAO_0000221,Autocuration,10000000.0,12249,Inhibitory concentration against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,B,,,,,
570,8,,BAO_0000221,Autocuration,10000000.0,11799,"Compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor from bovine hippocampus, used [3H]8-OH-DPAT as radioligand",B,,,,,
571,9,,BAO_0000249,Expert,,14331,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampal membranes,B,,,Rattus norvegicus,10116.0,
572,8,,BAO_0000221,Expert,10000000.0,11884,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of bovine hippocampus.,B,,,Bos taurus,9913.0,
573,8,,BAO_0000221,Autocuration,10000000.0,14331,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT (0.5 nM) ligand in hippocampus + frontal bovine was determined,B,,,,,
574,8,,BAO_0000221,Autocuration,10000000.0,11701,Compound was evaluated for its ability to displace [3H]DPAT from 5-HT1A receptor in homogenates of bovine hippocampus,B,,,,,
575,8,,BAO_0000221,Expert,10000000.0,11701,Ability to displace [3H]-DPAT from 5-hydroxytryptamine 1A receptor in homogenates of bovine hippocampus.,B,,,,,
576,8,,BAO_0000221,Autocuration,10000000.0,12248,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor in bovine hippocampus,B,,,,,
577,8,,BAO_0000219,Autocuration,,12248,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in CHO cells,B,,,,,
578,8,,BAO_0000221,Expert,10000000.0,12248,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,B,,,,,
579,8,,BAO_0000221,Expert,10000000.0,12249,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,B,,,,,
580,8,,BAO_0000219,Autocuration,,12248,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,B,,,,,
581,8,,BAO_0000221,Expert,10000000.0,11799,"Binding affinity against 5-hydroxytryptamine 1A receptor from bovine hippocampus, used [3H]8-OH-DPAT as radioligand",B,,,,,
582,8,,BAO_0000357,Autocuration,,634,Compound was tested for its binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand,B,,,,,
583,8,,BAO_0000221,Autocuration,10000000.0,9995,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-HT1A receptor from bovine hippocampus,B,,,,,
584,8,,BAO_0000221,Autocuration,10000000.0,9995,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,B,,,,,
585,8,,BAO_0000221,Autocuration,10000000.0,9995,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,B,,,,,
586,8,,BAO_0000221,Autocuration,10000000.0,9995,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,B,,,,,
587,8,,BAO_0000221,Autocuration,10000000.0,9995,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,B,,,,,
588,8,,BAO_0000218,Expert,10000000.0,12210,In vivo binding affinity towards [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus.,B,,,,,
589,8,,BAO_0000221,Expert,10000000.0,13311,Tested for activity against 5-hydroxytryptamine 1A receptor from bovine hippocampus,B,,,,,
590,9,,BAO_0000219,Expert,,2331,"Tested in vitro for the inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor, expressed in cloned CHO cells.",B,,,Homo sapiens,9606.0,
591,8,,BAO_0000019,Autocuration,,1375,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor in guinea pig,F,,,Cavia porcellus,10141.0,
592,8,,BAO_0000019,Autocuration,,1375,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor in guinea pig; NT means not tested,F,,,Cavia porcellus,10141.0,
593,8,,BAO_0000221,Autocuration,10000000.0,11574,Effect on forskolin stimulated adenylate cyclase activity at 5-hydroxytryptamine 1A receptor of guinea pig hippocampus.,F,,,Cavia porcellus,10141.0,
594,8,,BAO_0000221,Autocuration,2116.0,12867,Ability to antagonize Acetylcholine induced contractile responses in Guinea pig ileum for 5-HT1A receptor.,B,,,Cavia porcellus,10141.0,
595,8,,BAO_0000221,Autocuration,2116.0,12867,Ability to antagonize Acetylcholine induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,B,,,Cavia porcellus,10141.0,
596,8,,BAO_0000221,Autocuration,2116.0,12867,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor.,B,,,Cavia porcellus,10141.0,
597,8,,BAO_0000221,Autocuration,2116.0,12867,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,B,,,Cavia porcellus,10141.0,
598,8,,BAO_0000221,Autocuration,2116.0,12867,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,B,,,Cavia porcellus,10141.0,
599,8,,BAO_0000221,Autocuration,2116.0,12867,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor; Inactive at dose level of 1.0 uM,B,,,Cavia porcellus,10141.0,
600,8,,BAO_0000357,Autocuration,,11574,Binding affinity against 5-hydroxytryptamine 1A receptor,B,,,Cavia porcellus,10141.0,
601,8,,BAO_0000357,Autocuration,,13114,Compound is evaluated for in vitro receptor binding affinity against 5-hydroxytryptamine 1A receptor,B,,,Cavia porcellus,10141.0,
602,8,,BAO_0000357,Autocuration,,13181,Binding affinity was determined against 5-hydroxytryptamine 1A receptor,B,,,Cavia porcellus,10141.0,
603,8,,BAO_0000221,Autocuration,10000000.0,10639,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1A receptor of guinea pig hippocampus,B,,,Cavia porcellus,10141.0,
604,8,,BAO_0000221,Autocuration,10000000.0,10639,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1A receptor of guinea pig hippocampus,F,,,Cavia porcellus,10141.0,
605,8,,BAO_0000218,Autocuration,,11883,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand in CHO cells (sc),B,,,Cricetulus griseus,10029.0,
606,8,,BAO_0000357,Autocuration,,17785,Fraction involved in salt bridge interactions with Asp3:11 part of the 5-hydroxytryptamine 1A receptor,B,,,,,
607,8,,BAO_0000219,Autocuration,,1558,Compound was tested for its ability to inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-HT 1A receptor in HeLa cells; value ranges from 85-370,F,,,,,
608,8,,BAO_0000219,Autocuration,,1558,Compound was tested for its ability to inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1A receptor in HeLa cells; value ranges from 95-320,F,,,,,
609,8,,BAO_0000019,Autocuration,,15740,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor,F,,,,,
610,8,,BAO_0000219,Autocuration,,17624,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor,F,,,,,
611,8,,BAO_0000219,Expert,,17624,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor,F,,,,,
612,8,,BAO_0000219,Autocuration,,17624,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor; nd=Not determined,F,,,,,
613,8,,BAO_0000219,Autocuration,,17624,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor; nd=not determined,F,,,,,
614,8,,BAO_0000219,Expert,,17624,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,B,,,,,
615,8,,BAO_0000219,Expert,,17624,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,B,,,,,
616,8,,BAO_0000219,Autocuration,,17624,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells; nd=not determined,B,,,,,
617,8,,BAO_0000219,Autocuration,,14256,In vitro potency at human 5-hydroxytryptamine 1A receptor in inhibiting forskolin-stimulated accumulation of intracellular cAMP,F,,,,,
618,9,,BAO_0000219,Expert,,3445,Stimulation of [35S]- GIPyS binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells,B,,,Homo sapiens,9606.0,
619,9,,BAO_0000219,Expert,,3445,Stimulation of [35S]- GIPyS binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells; Inverse,B,,,Homo sapiens,9606.0,
620,9,,BAO_0000219,Expert,,17200,Tested for functional response on CHO cells expressing cloned human 5-hydroxytryptamine 1A receptor,B,,,Homo sapiens,9606.0,
621,9,,BAO_0000219,Expert,,17200,Tested for functional response on CHO cells expressing cloned human 5-hydroxytryptamine 1A receptor; Not determined,B,,,Homo sapiens,9606.0,
622,8,,BAO_0000019,Autocuration,,15180,Eudisimic ratio(ER) is the antilog of the defference between the pKb and pD2 values against 5-hydroxytryptamine 1A receptor,F,,,,,
623,8,,BAO_0000019,Autocuration,,15180,Eudisimic ratio(ER) is the antilog of the difference between the pKb and pD2 values against 5-hydroxytryptamine 1A receptor,F,,,,,
624,8,,BAO_0000019,Autocuration,,16026,"Percent of maximum effect on binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",F,,,,,
625,8,,BAO_0000219,Autocuration,,2759,Agonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,F,,,,,
626,9,,BAO_0000219,Expert,,2759,Agonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 1),F,,,Homo sapiens,9606.0,
627,8,,BAO_0000219,Autocuration,,2759,Agonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 2),F,,,,,
628,9,,BAO_0000219,Expert,,2759,Agonistic efficacy in adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 2),F,,,Homo sapiens,9606.0,
629,8,,BAO_0000219,Autocuration,,2759,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,F,,,,,
630,8,,BAO_0000219,Autocuration,,2759,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 1),F,,,,,
631,9,,BAO_0000219,Expert,,2759,Antagonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 1),F,,,Homo sapiens,9606.0,
632,8,,BAO_0000219,Autocuration,,2759,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 2),F,,,,,
633,9,,BAO_0000219,Expert,,2759,Antagonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 2),F,,,Homo sapiens,9606.0,
634,9,,BAO_0000019,Expert,,3445,Percent efficacy against cloned human 5-hydroxytryptamine 1A receptor normalized to the maximal 5-HT response,F,,,Homo sapiens,9606.0,
635,9,,BAO_0000019,Expert,,5272,"Agonist activity at the 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",F,,,Homo sapiens,9606.0,
636,9,,BAO_0000019,Expert,,5272,"Agonist activity at the 5-hydroxytryptamine 1A receptor in vitro using a [35S]GTP-gamma-S, No data",F,,,Homo sapiens,9606.0,
637,9,,BAO_0000019,Expert,,5272,"Agonist activity at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S,",F,,,Homo sapiens,9606.0,
638,8,,BAO_0000219,Autocuration,,17624,Agonistic effect against 5-HT1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,F,,,,,
639,8,,BAO_0000219,Autocuration,,17624,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,F,,,,,
640,8,,BAO_0000219,Autocuration,,17624,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=Not determined,F,,,,,
641,8,,BAO_0000219,Expert,,17624,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,F,,,,,
642,8,,BAO_0000219,Autocuration,,17624,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=Not determined,F,,,,,
643,8,,BAO_0000219,Autocuration,,17624,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=not determined,F,,,,,
644,8,,BAO_0000219,Autocuration,,17624,Agonistic effect against 5-HT 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,F,,,,,
645,8,,BAO_0000219,Autocuration,,17624,Agonistic effect against 5-HT 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT; nd=Not determined,F,,,,,
646,8,,BAO_0000219,Expert,,17624,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,F,,,,,
647,8,,BAO_0000219,Autocuration,,17624,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT; nd=not determined,F,,,,,
648,8,,BAO_0000219,Autocuration,,17624,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,F,,,,,
649,8,,BAO_0000219,Autocuration,,17624,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35]GTPgammaS as radioligand in CHO cells relative to 5-HT; nd=Not determined,F,,,,,
650,8,,BAO_0000019,Autocuration,,6563,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",F,,,,,
651,8,,BAO_0000019,Autocuration,,6563,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",F,,,,,
652,8,,BAO_0000019,Autocuration,,6563,Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by forskolin stimulated cAMP assay,F,,,,,
653,8,,BAO_0000219,Autocuration,,17296,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,F,,,,,
654,9,,BAO_0000019,Expert,,6876,"Evaluated for stimulation at 1 uM concentration expressed as percent of the maximal [35S]GTP-gamma-S, binding induced by 5-hydroxytryptamine",F,,,Homo sapiens,9606.0,
655,8,,BAO_0000019,Expert,,6876,"Stimulation of percent maximal [35S]GTP-gamma-S, binding induced by 5-hydroxytryptamine at 1 uM; nd = not determined",F,,,,,
656,9,,BAO_0000019,Expert,,5272,In vitro agonist activity at the 5-hydroxytryptamine 1A receptor,F,,,Homo sapiens,9606.0,
657,9,,BAO_0000019,Expert,,5272,In vitro agonist activity at the 5-hydroxytryptamine 1A receptor; No data,F,,,Homo sapiens,9606.0,
658,8,,BAO_0000019,Autocuration,,5548,"Maximal response as a result of 5-HT1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",F,,,,,
659,8,,BAO_0000019,Expert,,5548,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding",F,,,,,
660,8,,BAO_0000019,Autocuration,,5548,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",F,,,,,
661,8,,BAO_0000019,Autocuration,,5548,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",F,,,,,
662,8,,BAO_0000019,Expert,,5929,"Maximal stimulation of expressed human 5-hydroxytryptamine 1A receptor assayed by [35S]GTP-gamma-S, binding",F,,,,,
663,9,,BAO_0000019,Expert,,5929,"Maximal response towards 5-hydroxytryptamine 1A receptor in human using [35S]GTP-gamma-S, as radioligand; ND means not determined",F,,,Homo sapiens,9606.0,
664,9,,BAO_0000019,Expert,,5929,"Maximal response towards 5-hydroxytryptamine 1A receptor in human using [35S]GTP-gamma-S, as radioligand; ND=Not determined",F,,,Homo sapiens,9606.0,
665,8,,BAO_0000019,Autocuration,,16245,"Maximal stimulation was expressed as percentage of the maximal 5-HT response in the [35S]GTP-gamma-S, binding assay on 5-hydroxytryptamine 1A receptor",F,,,,,
666,8,,BAO_0000019,Expert,,5640,"Inhibition of 5-HT induced [35S]GTP-gamma-S, binding at human cloned 5-HT 1A receptors.",F,,,,,
667,8,,BAO_0000019,Autocuration,,5640,"5-hydroxytryptamine 1A receptor antagonism was evaluated by the ability to inhibit [35S]GTP-gamma-S, binding that was induced by 5-HT; Emin (%): not determined",F,,,,,
668,8,,BAO_0000219,Autocuration,,14509,Antagonist activity was measured against CHO cells expressing the human 5-hydroxytryptamine 1A receptor in a forskolin stimulated adenylate cyclase (FSC) assay,F,,,,,
669,8,,BAO_0000219,Expert,,14509,Antagonist activity against CHO cells expressing the human 5-hydroxytryptamine 1A receptor in a forskolin stimulated adenylate cyclase (FSC) assay.,F,,,,,
670,8,,BAO_0000357,Autocuration,,15331,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,B,,,,,
671,8,,BAO_0000357,Autocuration,,15331,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,B,,,,,
672,8,,BAO_0000019,Autocuration,,6563,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",F,,,,,
673,8,,BAO_0000019,Autocuration,,6563,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay; NA indicates not available",F,,,,,
674,8,,BAO_0000019,Autocuration,,6563,Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by forskolin stimulated cAMP assay,F,,,,,
675,9,,BAO_0000019,Expert,,6563,Forskolin stimulated cAMP assessment of agonist activity for 5-hydroxytryptamine 1A receptor,F,,,Homo sapiens,9606.0,
676,8,,BAO_0000019,Autocuration,,6563,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",F,,,,,
677,9,,BAO_0000019,Expert,,5272,Antagonism of 5-hydroxytryptamine 1A receptor determined in vitro,F,,,Homo sapiens,9606.0,
678,9,,BAO_0000019,Expert,,5272,"Antagonism of 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",F,,,Homo sapiens,9606.0,
679,9,,BAO_0000019,Expert,,5272,"Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S, No data",F,,,Homo sapiens,9606.0,
680,9,,BAO_0000019,Expert,,5272,Antagonism at the 5-hydroxytryptamine 1A receptor was determined in vitro; No data,F,,,Homo sapiens,9606.0,
681,9,,BAO_0000019,Expert,,5272,Antagonism at the 5-hydroxytryptamine 1A receptor in vitro,F,,,Homo sapiens,9606.0,
682,9,,BAO_0000019,Expert,,5272,"Antagonism at the 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",F,,,Homo sapiens,9606.0,
683,9,,BAO_0000019,Expert,,5272,"Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S, No data",F,,,Homo sapiens,9606.0,
684,9,,BAO_0000019,Expert,,5272,Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro; No data,F,,,Homo sapiens,9606.0,
685,9,,BAO_0000357,Expert,,16146,Inhibition of human 5-hydroxytryptamine 1A receptor,B,,,Homo sapiens,9606.0,
686,8,,BAO_0000219,Autocuration,,17624,Binding affinity against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,B,,,,,
687,9,,BAO_0000219,Expert,,13706,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor alpha expressed in HEK 293 cells,B,,,,,
688,8,,BAO_0000219,Autocuration,,15250,Compound was tested for the displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1A receptor stably expressed in CHO cells,B,,,,,
689,8,,BAO_0000219,Autocuration,,17624,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,F,,,,,
690,8,,BAO_0000357,Expert,,6861,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in human CYP3A4 assay,B,,,,,
691,9,,BAO_0000357,Expert,,17200,In vitro inhibitory concentration required against [3H]8-OH-DPAT binding to cloned human 5-hydroxytryptamine 1A receptor,B,,,Homo sapiens,9606.0,
692,8,,BAO_0000219,Autocuration,,17624,Inhibition concentration against 5-HT 1A receptor using cAMP as radioligand in CHO cells,B,,,,,
693,8,,BAO_0000219,Autocuration,,17624,Inhibition concentration against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,B,,,,,
694,0,,BAO_0000218,Autocuration,,12058,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration,F,In vivo,,Rattus norvegicus,10116.0,
695,0,,BAO_0000218,Autocuration,,12058,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration; Inactive,F,In vivo,,Rattus norvegicus,10116.0,
696,0,,BAO_0000218,Autocuration,,12058,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration,F,In vivo,,Rattus norvegicus,10116.0,
697,0,,BAO_0000218,Autocuration,,12058,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Inactive,F,In vivo,,Rattus norvegicus,10116.0,
698,0,,BAO_0000218,Autocuration,,12058,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Partial response at the highest dose tested,F,In vivo,,Rattus norvegicus,10116.0,
699,0,,BAO_0000218,Autocuration,,12058,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Inactive,F,In vivo,,Rattus norvegicus,10116.0,
700,0,,BAO_0000218,Autocuration,,12058,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by po administration,F,In vivo,,Rattus norvegicus,10116.0,
701,0,,BAO_0000218,Autocuration,,12058,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by po administration; Inactive,F,In vivo,,Rattus norvegicus,10116.0,
702,0,,BAO_0000218,Autocuration,,12058,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration,F,In vivo,,Rattus norvegicus,10116.0,
703,0,,BAO_0000218,Autocuration,,12058,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration; Inactive,F,In vivo,,Rattus norvegicus,10116.0,
704,0,,BAO_0000218,Autocuration,,12058,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration; partial response at the highest dose tested,F,In vivo,,Rattus norvegicus,10116.0,
705,0,,BAO_0000218,Autocuration,,12058,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration,F,In vivo,,Rattus norvegicus,10116.0,
706,0,,BAO_0000218,Autocuration,,12058,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration; Inactive,F,In vivo,,Rattus norvegicus,10116.0,
707,0,,BAO_0000218,Autocuration,,12058,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration; Partial response at the highest dose tested,F,In vivo,,Rattus norvegicus,10116.0,
708,0,,BAO_0000218,Autocuration,,12058,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration,F,In vivo,,Rattus norvegicus,10116.0,
709,0,,BAO_0000218,Autocuration,,12058,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; Inactive,F,In vivo,,Rattus norvegicus,10116.0,
710,0,,BAO_0000218,Autocuration,,12058,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; Partial response at the highest dose tested,F,In vivo,,Rattus norvegicus,10116.0,
711,0,,BAO_0000218,Autocuration,,12058,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; partial response at the highest dose tested,F,In vivo,,Rattus norvegicus,10116.0,
712,0,,BAO_0000218,Autocuration,,12058,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration,F,In vivo,,Rattus norvegicus,10116.0,
713,4,,BAO_0000019,Autocuration,,11440,Affinity in displacing [125I](R)-DOI from rat cortical homogenate 5-HT2 receptor.,B,,,,,
714,8,,BAO_0000249,Autocuration,1898.0,6238,Binding affinity towards 5-HT 7 receptor in rat hypothalamus membranes using [3H]5-CT as radioligand,B,,,,,
715,8,,BAO_0000019,Autocuration,,10046,Inhibitory activity against 5-HT1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand; nd is No Data,B,,,,,
716,8,,BAO_0000019,Autocuration,,10046,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand; nd is No Data.,B,,,,,
717,8,,BAO_0000019,Expert,,10046,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand.,B,,,,,
718,8,,BAO_0000357,Autocuration,,167,"Inhibitory activity against human whole blood, LTB4 5-lipoxygenase was evaluated",B,,,,,
719,8,,BAO_0000357,Autocuration,,167,"Inhibitory activity against intact human PMNL, LTB4 5-lipoxygenase was evaluated",B,,,,,
720,8,,BAO_0000019,Autocuration,,11520,Compound was evaluated for the inhibition of 5-LO (lipoxygenase),F,,,,,
721,8,,BAO_0000019,Autocuration,,11520,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,F,,,,,
722,8,,BAO_0000019,Autocuration,,11520,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,F,,,,,
723,8,,BAO_0000019,Autocuration,,11520,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,F,,,,,
724,8,,BAO_0000019,Autocuration,,135,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-LO isolated from guinea pig PMN,F,,,Cavia porcellus,10141.0,
725,8,,BAO_0000019,Autocuration,,135,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-LO isolated from guinea pig PMN; not active at the highest concentration (3 ug/mL) tested; No activity,F,,,Cavia porcellus,10141.0,
726,8,,BAO_0000019,Autocuration,,11311,The compound was tested for inhibitory activity against 5-Lipoxygenase in guinea pig polymorphonuclear leukocytes,B,,,Cavia porcellus,10141.0,
727,8,,BAO_0000357,Autocuration,,10193,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant at 10 uM,B,,,Cavia porcellus,10141.0,
728,9,,BAO_0000357,Expert,,12281,Inhibitory concentration against 5-lipoxygenase from human whole blood,B,,,Homo sapiens,9606.0,
729,8,,BAO_0000219,Autocuration,,11311,The compound was tested for inhibitory activity against 5-Lipoxygenase in human polymorphonuclear leukocytes[PMNS],B,,,,,
730,8,,BAO_0000218,Autocuration,,12576,In vivo inhibition of 5-lipoxygenase (LTC4) in the mouse zymosan peritonitis assay at an oral dose of 30 mg/Kg,F,,,,,
731,8,,BAO_0000357,Autocuration,,12281,Inhibitory concentration against 5-lipoxygenase from mouse macrophage,B,,,,,
732,8,,BAO_0000218,Autocuration,,12576,In vivo inhibition of 5-lipoxygenase (LTC4) in the mouse zymosan peritonitis assay at an oral dose of 30 mg/Kg,F,,,,,
733,8,,BAO_0000019,Expert,,11089,Inhibition of arachidonate 5-lipoxygenase purified from porcine leukocytes.,B,,,Sus scrofa,9823.0,
734,8,,BAO_0000357,Expert,,11006,In vitro inhibition of rat 5-Lipoxygenase,B,,,,,
735,9,,BAO_0000357,Expert,,11481,Inhibitory activity against 5-Lipoxygenase,B,,,Rattus norvegicus,10116.0,
736,8,,BAO_0000219,Expert,,10864,Inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells,B,,,,,
737,8,,BAO_0000219,Autocuration,,3595,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),B,,,,,
738,8,,BAO_0000219,Autocuration,,11311,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat RBL-1,B,,,,,
739,8,,BAO_0000019,Autocuration,,11311,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat blood,B,,,,,
740,8,,BAO_0000219,Autocuration,,11311,The compound was tested for inhibitory activity against 5-Lipoxygenase receptor in rat polymorphonuclear leukocytes[PMNS],B,,,,,
741,8,,BAO_0000357,Autocuration,,11006,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM,B,,,,,
742,8,,BAO_0000219,Autocuration,,3595,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1)at 10 uM,B,,,,,
743,8,,BAO_0000357,Autocuration,,11311,The compound was tested for inhibition of isolated 5-Lipoxygenase,B,,,,,
744,0,,BAO_0000019,Autocuration,,11481,Ratio of IC50 against 5-LO and COX,B,,,Rattus norvegicus,10116.0,
745,8,,BAO_0000357,Autocuration,,11006,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM,B,,,,,
746,8,,BAO_0000357,Autocuration,,11006,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM; range is 20-35%,B,,,,,
747,8,,BAO_0000219,Autocuration,,11311,The compound was tested for inhibition against 5-Lipoxygenase in rat polymorphonuclear leukocytes at 10 uM concentration,B,,,,,
748,8,,BAO_0000019,Autocuration,,11006,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) ex vivo,F,,,,,
749,8,,BAO_0000357,Autocuration,2367.0,4288,Compound was tested for the inhibition of type 2 5-alpha-reductase of human prostates,B,,,,,
750,0,,BAO_0000019,Autocuration,,7587,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme at 10E-4 M inhibitory concentration,B,,,Columba livia,8932.0,
751,0,,BAO_0000019,Autocuration,,7587,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme at 10E-5 M inhibitory concentration,B,,,Columba livia,8932.0,
752,0,,BAO_0000019,Autocuration,,7587,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme.,B,,,Columba livia,8932.0,
753,8,,BAO_0000357,Autocuration,,11249,Compound was evaluated for the inhibition of 5-aminoimidazole-4-carboxamide ribonucleotide transformylase obtained from human at 100 uM,B,,,,,
754,9,,BAO_0000019,Expert,,8003,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT); NT = Not Tested,F,,,Rattus norvegicus,10116.0,
755,9,,BAO_0000019,Expert,,8003,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT),F,,,Rattus norvegicus,10116.0,
756,9,,BAO_0000019,Expert,,8003,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT),F,,,Rattus norvegicus,10116.0,
757,8,,BAO_0000221,Expert,10000000.0,12416,In vitro affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in hippocampus,B,,,,,
758,8,,BAO_0000357,Autocuration,,16293,Binding affinity towards human 5-hydroxytryptamine 1 receptor,B,,,,,
759,0,,BAO_0000019,Autocuration,,13047,Intrinsic activity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,B,,,Oryctolagus cuniculus,9986.0,
760,0,,BAO_0000019,Autocuration,,13047,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,B,,,Oryctolagus cuniculus,9986.0,
761,0,,BAO_0000019,Autocuration,,13047,Binding affinity against 5-hydroxytryptamine 1D receptor using rabbit saphenous vein assay.,B,,,Oryctolagus cuniculus,9986.0,
762,0,,BAO_0000019,Autocuration,,13047,Binding affinity against 5-hydroxytryptamine 4 receptor using rabbit saphenous vein assay.,B,,,Oryctolagus cuniculus,9986.0,
763,4,,BAO_0000221,Autocuration,10000000.0,10085,Ability to bind at 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,B,,,,,
764,4,,BAO_0000221,Autocuration,10000000.0,10085,Ability to bind at 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,B,,,,,
765,4,,BAO_0000221,Autocuration,10000000.0,10085,Ability to bind at serotonin 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,B,,,,,
766,4,,BAO_0000249,Autocuration,,9841,Ability to inhibit binding of titreated serotonin to the 5-hydroxytryptamine 1 receptor in rat brain frontal cortex membranes,B,,,,,
767,5,,BAO_0000249,Autocuration,,8822,Binding affinity towards 5-hydroxytryptamine 1 receptor in brain cortical membranes of rat,B,,,Rattus norvegicus,10116.0,
768,5,,BAO_0000019,Autocuration,,9806,Binding affinity towards 5-hydroxytryptamine 1 receptor in rat frontal cortex homogenates using [3H]5-HT as a radioligand,B,,,Rattus norvegicus,10116.0,
769,5,,BAO_0000019,Autocuration,,9806,Binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT as a radioligand from rat frontal cortex homogenates,B,,,Rattus norvegicus,10116.0,
770,4,,BAO_0000224,Autocuration,,8868,Binding affinity towards 5-hydroxytryptamine 1 receptor was measured using radioligand ([3H]5-HT) binding assay,B,,,,,
771,4,,BAO_0000221,Autocuration,10000000.0,9036,Binding affinity towards hippocampus 5-hydroxytryptamine 1 receptor was measured using radioligand [3H]5-HT,B,,,,,
772,4,,BAO_0000221,Autocuration,10000000.0,11374,Compound was evaluated for the inhibition of [3H]5-HT (concentration of 12 nM) specific binding to rat hippocampus,B,,,,,
773,4,,BAO_0000224,Autocuration,,10881,Inhibitory activity against 5-hydroxytryptamine 1 receptor by 3H ligand binding experiments.,B,,,,,
774,4,,BAO_0000019,Autocuration,,8822,Tested for its binding affinity towards 5-hydroxytryptamine 1 receptor in rat,B,,,,,
775,5,,BAO_0000249,Autocuration,,9806,Tested for its binding affinity towards 5-hydroxytryptamine 1 receptor in rat cortical membrane homogenates using radioligand ([3H]5-HT) binding assay.,B,,,Rattus norvegicus,10116.0,
776,4,,BAO_0000019,Autocuration,,15463,Compound at 1 uM was tested for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,B,,,,,
777,4,,BAO_0000019,Autocuration,,15463,Compound at 1 uM was tested for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,B,,,,,
778,4,,BAO_0000221,Autocuration,955.0,14542,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,B,,,,,
779,4,,BAO_0000221,Autocuration,955.0,14542,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,B,,,,,
780,4,,BAO_0000019,Autocuration,,8569,Percent inhibition of 5-hydroxytryptamine 1 receptor from rat cortex membrane using [3H]- serotonin as radioligand at 33 uM,B,,,,,
781,5,,BAO_0000224,Autocuration,,10062,Inhibition of [3H]5-HT radioligand binding against 5-hydroxytryptamine 1 receptor,B,,,Rattus norvegicus,10116.0,
782,4,,BAO_0000224,Autocuration,,4771,Ancillary Binding affinity towards rat 5-hydroxytryptamine 1 receptor,B,,,,,
783,4,,BAO_0000224,Autocuration,,10062,Binding affinity determined in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,B,,,,,
784,4,,BAO_0000224,Autocuration,,10062,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,B,,,,,
785,4,,BAO_0000224,Autocuration,,10062,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,B,,,,,
786,4,,BAO_0000019,Autocuration,,15463,Binding affinity towards 5-hydroxytryptamine 1 receptor was determined in rat cerebral cortex using [3H]5-HT as radioligand,B,,,,,
787,4,,BAO_0000019,Autocuration,,15463,Binding affinity towards central 5-hydroxytryptamine 1 receptor was determined in rat cerebral cortex using [3H]5-HT as radioligand,B,,,,,
788,4,,BAO_0000224,Autocuration,,9098,Binding affinity towards 5-hydroxytryptamine 1 receptor was determined,B,,,,,
789,0,,BAO_0000019,Autocuration,,3070,Affinity for 5-hydroxytryptamine 1 receptor,B,,,Rattus norvegicus,10116.0,
790,4,,BAO_0000221,Autocuration,955.0,14542,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex,B,,,,,
791,4,,BAO_0000221,Autocuration,955.0,14542,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,B,,,,,
792,4,,BAO_0000224,Autocuration,,6398,Compound was evaluated for 5-hydroxytryptamine 1 receptor binding,B,,,,,
793,4,,BAO_0000221,Autocuration,955.0,1344,Compound was evaluated for its binding affinity to 5-hydroxytryptamine 1 receptor in rat brain using [3H]HT radioligand assay,B,,,,,
794,4,,BAO_0000019,Autocuration,,11963,Displacement of binding of [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,B,,,,,
795,0,,BAO_0000019,Autocuration,,8908,Displacement of [3H]spiperone from 5-hydroxytryptamine 1 receptor of rat cortex,B,,,Rattus norvegicus,10116.0,
796,4,,BAO_0000019,Autocuration,,9098,Evaluated for binding affinity towards rat cortical membranes at 5-hydroxytryptamine 1 receptor binding site by using [3H]-5-HT as a radioligand.,B,,,,,
797,5,,BAO_0000019,Autocuration,,8841,Binding affinity for 5-hydroxytryptamine 1 receptor of rat prefrontal cortex,B,,,Rattus norvegicus,10116.0,
798,0,,BAO_0000019,Autocuration,,8814,Displacement of [3H]5-HT from 5-hydroxytryptamine 1 receptor of rat cortical membrane homogenates,B,,,Rattus norvegicus,10116.0,
799,4,,BAO_0000019,Autocuration,,11752,The ability to inhibit [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cortex,B,,,,,
800,4,,BAO_0000221,Autocuration,955.0,11642,The binding affinity was measured on serotonin 5-hydroxytryptamine 1 receptor in rat brain tissue,B,,,,,
801,4,,BAO_0000019,Autocuration,,11642,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1 receptor by displacing [3H]5-HT radioligand in rat cerebral cortex,B,,,,,
802,4,,BAO_0000220,Autocuration,955.0,9231,Tested for 5-hydroxytryptamine 1 receptor binding ability by displacement of [3H]5-HT from rat brain synaptosomes,B,,,,,
803,4,,BAO_0000221,Autocuration,955.0,11351,Inhibition constant (1 uM) was measured on 5-hydroxytryptamine 1 receptor/uptake using [3H]- serotonin as radioligand in rat brain cortex.,B,,,,,
804,0,,BAO_0000019,Autocuration,,4639,Compound was tested for binding affinity against 5-HT1 receptor,B,,,,,
805,0,,BAO_0000019,Autocuration,,1205,Inhibitory concentration against 5-hydroxytryptamine 1 receptor,B,,,,,
806,8,,BAO_0000357,Expert,,10025,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor at 1 uM,B,,,,,
807,8,,BAO_0000249,Autocuration,,13241,"Ability to inhibit 5-HT sensitive,forskolin-stimulated adenylyl cyclase(FSC) activity in rat hippocampal membranes mediated through 5-hydroxytryptamine 1A receptor",F,,,,,
808,8,,BAO_0000218,Autocuration,,16245,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while iv administration,F,In vivo,,,,
809,8,,BAO_0000218,Autocuration,,16245,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while subcutaneous administration,F,In vivo,,,,
810,8,,BAO_0000019,Autocuration,,12438,Inhibition of forskolin stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor,F,,,,,
811,8,,BAO_0000218,Autocuration,,16245,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while iv administration,F,In vivo,,,,
812,8,,BAO_0000218,Autocuration,,16245,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while subcutaneous administration,F,In vivo,,,,
813,8,,BAO_0000019,Autocuration,,15740,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats,F,,,,,
814,8,,BAO_0000219,Autocuration,,15535,Percent of maximum response by 5-HT when tested for inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation assessed in GH4ZD10 cells at 10 uM concentration,F,,,,,
815,8,,BAO_0000219,Expert,,15535,Percent inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation in GH4ZD10 cells expressing 5-HT1A receptor at 50 uM relative to 5-HT,F,,,,,
816,8,,BAO_0000219,Autocuration,,15535,Percent of maximum response by 5-HT when tested for inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation assessed in GH4ZD10 cells at 50 uM concentration; No effect,F,,,,,
817,8,,BAO_0000249,Expert,,9888,Binding affinity at [3H]8-OH-DPAT-Labeled 5-hydroxytryptamine 1A receptor sites in rat brain hippocampal membranes expressed as Hill values,B,,,,,
818,8,,BAO_0000221,Autocuration,10000000.0,10085,Ability to bind at 5-hydroxytryptamine 1A receptor of rat hippocampus by displacing [3H]8-OH-DPAT,B,,,,,
819,8,,BAO_0000221,Autocuration,10000000.0,10085,Ability to bind at serotonin 5-hydroxytryptamine 1A receptors of rat hippocampus by displacing [3H]8-OH-DPAT,B,,,,,
820,8,,BAO_0000249,Expert,,17331,Binding affinity against 5-hydroxytryptamine 1A receptor (5-HT1A) by displacement of [3H]8-OH-DPAT from rat hippocampus membranes,B,,,,,
821,9,,BAO_0000221,Expert,10000000.0,10845,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]8-OH-DPAT,B,,,Rattus norvegicus,10116.0,
822,9,,BAO_0000221,Expert,10000000.0,10845,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]5-HT,B,,,Rattus norvegicus,10116.0,
823,8,,BAO_0000221,Expert,10000000.0,10845,Binding affinity against 5-hydroxytryptamine 1A receptor using in rat hippocampal tissue using [3H]8-OH-DPAT as radioligand,B,,,,,
824,9,,BAO_0000221,Expert,10000000.0,10845,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor; IA-Inactive,B,,,Rattus norvegicus,10116.0,
825,9,,BAO_0000221,Expert,10000000.0,10845,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]5-HT,B,,,Rattus norvegicus,10116.0,
826,8,,BAO_0000357,Expert,,13730,Binding affinity towards rat 5-hydroxytryptamine 1A receptor was evaluated using [3H]8-OH-DPAT as radioligand,B,,,,,
827,8,,BAO_0000249,Expert,,13508,Binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampus membranes using [3H]8-OH-DPAT as radioligand,B,,,,,
828,8,,BAO_0000249,Expert,10000000.0,13508,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus membrane using [3H]8-OH-DPAT as radioligand,B,,,,,
829,8,,BAO_0000221,Expert,10000000.0,12073,Binding affinity by measuring displacement of [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,B,,,,,
830,8,,BAO_0000221,Autocuration,10000000.0,4671,Binding affinity to 5-hydroxytryptamine 1A receptor of rat hippocampus with [3H]8-OH-DPAT as radioligand,B,,,,,
831,8,,BAO_0000221,Expert,10000000.0,13631,Binding affinity towards serotonin 5-HT1A receptor was determined in rat hippocampus using [3H]8-OH-DPAT as ligand,B,,,,,
832,8,,BAO_0000357,Autocuration,,12438,Binding affinity was measured against serotonin 5-hydroxytryptamine 1A receptor,B,,,,,
833,8,,BAO_0000019,Autocuration,,10483,Binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]-8-OH- DPAT as radioligand,B,,,,,
834,8,,BAO_0000221,Autocuration,10000000.0,10483,Binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]-8-OH- DPAT as radioligand,B,,,,,
835,8,,BAO_0000249,Intermediate,,12352,Binding affinity against 5-hydroxytryptamine 1A (5-HT1A) receptor in rat hippocampus membranes,B,,,,,
836,8,,BAO_0000249,Autocuration,10000000.0,14732,Binding affinity was measured at the serotonin 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat hippocampal membrane.,B,,,,,
837,9,,BAO_0000019,Expert,,11049,Binding affinity to 5-hydroxytryptamine 1A receptor in the rat brain using [3H]8-hydroxy-2-(di-n-propylamine)tetralin as radioligand.,B,,,Rattus norvegicus,10116.0,
838,9,,BAO_0000019,Expert,,11049,Binding affinity to 5-hydroxytryptamine 1A receptor in the rat brain using [3H]8-hydroxy-2-(di-n-propylamine)tetralin as radioligand; ND-Not determined,B,,,Rattus norvegicus,10116.0,
839,8,,BAO_0000249,Expert,,13657,"Binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampus membranes,3H-8-OH-DPAT and buspirone for nonspecific binding (NSB)",B,,,,,
840,8,,BAO_0000019,Autocuration,,11473,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor in rat cortex using [3H]-8-OH-DPAT as radioligand,B,,,,,
841,8,,BAO_0000249,Autocuration,,2014,Compound was evaluated for its ability to displace [3H]8-OH-DPAT from serotonin 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes,B,,,,,
842,8,,BAO_0000221,Expert,10000000.0,3086,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,B,,,,,
843,8,,BAO_0000019,Expert,,15854,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,B,,,,,
844,8,,BAO_0000221,Expert,10000000.0,10922,Affinity for 5-hydroxytryptamine 1A receptor labeled with [3H]8-OH-DPAT radioligand in hippocampus tissue,B,,,,,
845,8,,BAO_0000221,Expert,10000000.0,13346,Inhibition of [3H]8-OH-DPAT binding at serotonin 5-hydroxytryptamine 1A receptor from rat hippocampus tissue.,B,,,,,
846,8,,BAO_0000357,Expert,,15311,In vitro inhibition of [3H]8-OH-DPAT binding to rat 5-HT 1a receptors.,B,,,,,
847,8,,BAO_0000221,Autocuration,10000000.0,10922,Compound was measured for affinity at 5-hydroxytryptamine 1A receptor labeled with [3H]8-OH-DPAT radioligand in hippocampus tissue,B,,,,,
848,8,,BAO_0000357,Autocuration,,10025,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor<br>at 1 uM,B,,,,,
849,8,,BAO_0000357,Expert,,10025,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor at 1 uM,B,,,,,
850,8,,BAO_0000019,Autocuration,,9742,In vitro Inhibitory activity tested at 5-hydroxytryptamine 1A receptor binding site in rat,B,,,,,
851,8,,BAO_0000019,Autocuration,,9742,In vitro Inhibitory activity tested at 5-hydroxytryptamine 1A receptor binding site in rat,F,,,,,
852,8,,BAO_0000019,Expert,,12304,In vitro ability to inhibit binding of radioligand [3H]8-OH-DPAT to 5-hydroxytryptamine 1A receptor in rat cerebral cortex,B,,,,,
853,8,,BAO_0000221,Autocuration,10000000.0,15789,In vitro affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT in rat hippocampus,B,,,,,
854,8,,BAO_0000019,Autocuration,,9912,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]-8-OH-DPAT as the radioligand",B,,,,,
855,8,,BAO_0000019,Autocuration,,9912,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]8-OH-DPAT as the radioligand.",B,,,,,
856,8,,BAO_0000019,Autocuration,,9912,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]8-OH-DPAT as the radioligand",B,,,,,
857,8,,BAO_0000019,Expert,,16693,In vitro binding affinity for serotonin 5-hydroxytryptamine 1A receptor fof rat cerebral cortex using [3H]8-OH-DPAT as radioligand,B,,,,,
858,8,,BAO_0000357,Expert,,13276,In vitro binding affinity measured on serotonin 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,B,,,,,
859,8,,BAO_0000221,Autocuration,10000000.0,12678,In vitro binding affinity to 5-hydroxytryptamine 1A receptor using [125I](R)-(+)-trans-8-OH-PIPAT as radioligand in rat hippocampal homogenate,B,,,,,
860,8,,BAO_0000357,Autocuration,,11825,In vitro binding affinity towards the 5-hydroxytryptamine 1A receptor was evaluated,B,,,,,
861,8,,BAO_0000357,Expert,,12443,In vitro binding affinity was measured on serotonergic 5-hydroxytryptamine 1A receptor by displacement of [3H]- tetralin,B,,,,,
862,8,,BAO_0000357,Expert,,13830,In vitro inhibitory activity against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,B,,,,,
863,8,,BAO_0000249,Expert,10000000.0,14286,In vitro inhibitory concentration against radioligand [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membrane.,B,,,,,
864,9,,BAO_0000221,Expert,10000000.0,14356,In vitro radioligand binding assay on 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,B,,,Rattus norvegicus,10116.0,
865,8,,BAO_0000357,Autocuration,,15306,Inhibition concentration against 5-hydroxytryptamine 1A receptor,B,,,,,
866,8,,BAO_0000357,Expert,,15306,Inhibitory concentration against 5-hydroxytryptamine 1A receptor (Inactive at >1000 nM concentration),B,,,,,
867,9,,BAO_0000249,Expert,,16616,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in hippocampal membranes",F,,,Rattus norvegicus,10116.0,
868,8,,BAO_0000221,Autocuration,10000000.0,3651,"Inhibition of [3H]8-hydroxy-2-dipropylamino-1,2,3,4-tetrahydronaphthalene binding to 5-hydroxytryptamine 1A receptor in hippocampus region of rat brain; Residual radioligand binding higher than 50%",B,,,,,
869,8,,BAO_0000221,Autocuration,10000000.0,14331,Inhibition of forskolin-activated adenylate cyclase (cAMP) activity at 5-hydroxytryptamine 1A receptor in rat hippocampus,F,,,,,
870,8,,BAO_0000221,Autocuration,10000000.0,14331,Inhibition of forskolin-activated adenylate cyclase (cAMP) activity at 5-hydroxytryptamine 1A receptor in rat hippocampus,F,,,,,
871,9,,BAO_0000357,Expert,,14178,Inhibition of radiolabeled [3H]-8-OH-DPAT ligand binding to 5-hydroxytryptamine 1A receptor,B,,,Rattus norvegicus,10116.0,
872,9,,BAO_0000019,Expert,,10639,Displacement of [3H]8-OH-DPAT from rat cortex 5-hydroxytryptamine 1A receptor,B,,,Rattus norvegicus,10116.0,
873,8,,BAO_0000221,Autocuration,10000000.0,12306,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,B,,,,,
874,9,,BAO_0000357,Expert,,1348,Inhibitory activity against 5-hydroxytryptamine 1A receptor subtype,B,,,Rattus norvegicus,10116.0,
875,8,,BAO_0000221,Autocuration,10000000.0,13605,Inhibitory activity against [3H]DPAT binding to 5-HT1A receptor in rat hippocampus,B,,,,,
876,8,,BAO_0000219,Autocuration,,17624,Inhibition concentration against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,B,,,,,
877,8,,BAO_0000219,Autocuration,,17624,Inhibition concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,F,,,,,
878,8,,BAO_0000219,Autocuration,,17624,Inhibition concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,F,,,,,
879,8,,BAO_0000357,Autocuration,,15267,Inhibition of [3H]- 8-OH-DAPT binding against human recombinant 5-hydroxytryptamine 1A receptor,B,,,,,
880,8,,BAO_0000357,Autocuration,,16532,The binding affinity at the 5-hydroxytryptamine 1A receptor determined using [3H]5-CT; Not tested,B,,,,,
881,8,,BAO_0000019,Autocuration,,6563,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",F,,,,,
882,8,,BAO_0000219,Autocuration,,4751,Ability to displace [3H]-8-OH-DPAT from CHO cells stably transfected with human 5-hydroxytryptamine 1A receptor at a concentration of 1 uM,B,,,,,
883,8,,BAO_0000357,Autocuration,,15463,Compound at 1 uM was tested for the inhibition of radioligand [3H]8-OH-DPAT binding to recombinant human 5-hydroxytryptamine 1A receptor,B,,,,,
884,8,,BAO_0000357,Autocuration,,3805,In vitro binding affinity against human 5-hydroxytryptamine 1A receptor at a concentration of 100 (nM),B,,,,,
885,8,,BAO_0000357,Autocuration,,5640,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,B,,,,,
886,8,,BAO_0000357,Autocuration,,6563,Inhibition of [3H]8-OH-DPAT binding to human 5-hydroxytryptamine 1A receptor at 1000 nM compound concentration,B,,,,,
887,8,,BAO_0000357,Autocuration,,5548,Inhibitory activity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand at 100 nM concentration,B,,,,,
888,8,,BAO_0000357,Autocuration,,6347,Percent binding affinity against 5-hydroxytryptamine 1A receptor,B,,,,,
889,8,,BAO_0000219,Autocuration,,17296,Intrinsic activity for human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,F,,,,,
890,8,,BAO_0000019,Autocuration,,13047,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit jugular vein assay in the absence of endothelium,B,,,,,
891,8,,BAO_0000357,Autocuration,,15740,Dissociation constant against human 5-hydroxytryptamine 1A receptor receptor,B,,,,,
892,8,,BAO_0000019,Expert,,5640,"Inhibition of 5-HT induced [35S]GTP-gamma-S, binding at human cloned 5-HT 1A receptors.",F,,,,,
893,8,,BAO_0000019,Autocuration,,5640,"5-hydroxytryptamine 1A receptor antagonism was evaluated by the ability to inhibit [35S]GTP-gamma-S, binding that was induced by 5-HT; Ki (nM): not determined",F,,,,,
894,8,,BAO_0000219,Expert,,17211,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor,B,,,,,
895,8,,BAO_0000219,Autocuration,,4751,Ability to displace [3H]8-OH-DPAT from CHO cells stably transfected with human 5-hydroxytryptamine 1A receptor,B,,,,,
896,9,,BAO_0000357,Expert,,6491,Affinity towards human 5-hydroxytryptamine 1A serotonin receptor,B,,,Homo sapiens,9606.0,
897,8,,BAO_0000357,Autocuration,,4707,Binding affinity towards human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT-as radioligand,B,,,,,
898,9,,BAO_0000357,Expert,,13910,Binding affinity against 5-hydroxytryptamine 1A receptor,B,,,Homo sapiens,9606.0,
899,8,,BAO_0000219,Autocuration,,16190,Binding affinity against 5-hydroxytryptamine 1A receptor in HeLa cells was determined using [3H]5-HT,B,,,,,
900,8,,BAO_0000357,Autocuration,,16633,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,B,,,,,
901,8,,BAO_0000219,Autocuration,,11898,Binding affinity against [3H]- -8-OH-DPAT -labeled 5-hydroxytryptamine 1A sites in cloned CHO cells,B,,,,,
902,8,,BAO_0000219,Autocuration,,11898,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,B,,,,,
903,8,,BAO_0000357,Autocuration,,14331,Binding affinity against human 5-hydroxytryptamine 1A receptor,B,,,,,
904,8,,BAO_0000219,Expert,,17624,Binding affinity against human 5-hydroxytryptamine 1A receptor in CHO cells labeled with [3H]8-OH-DPAT radioligand,B,,,,,
905,8,,BAO_0000219,Autocuration,,17624,Binding affinity against human 5-hydroxytryptamine 1A receptor in CHO cells labeled with [3H]8-OH-DPAT radioligand; nd=not determined,B,,,,,
906,8,,BAO_0000357,Autocuration,,3307,Binding affinity of compound to human 5-hydroxytryptamine 1A receptor,B,,,,,
907,9,,BAO_0000219,Expert,,6563,Displacement of [3H]8-OH-DPAT from human 5-hydroxytryptamine 1A receptor expressed in CHO cells,B,,,Homo sapiens,9606.0,
908,8,,BAO_0000019,Autocuration,,14165,Binding affinity for 5-hydroxytryptamine 1A receptor in HeLa transfected cell type using [3H]8-OH-DPAT as radioligand,B,,,,,
909,8,,BAO_0000357,Autocuration,,5732,Binding affinity towards cloned human 5-hydroxytryptamine 1A receptor was determined,B,,,,,
910,8,,BAO_0000357,Expert,,13366,In vitro affinity at human cloned 5-hydroxytryptamine 1A receptor by [3H]8-OH-DPAT displacement.,B,,,,,
911,8,,BAO_0000357,Autocuration,,17626,Binding affinity towards human 5-hydroxytryptamine 1A receptor,B,,,,,
912,8,,BAO_0000219,Expert,,6588,Binding affinity towards human 5-hydroxytryptamine 1A receptor by the displacement of [3H]5-HT radioligand from the cloned receptor expressed in HeLa cells,B,,,,,
913,8,,BAO_0000357,Autocuration,,16209,Binding affinity towards human 5-hydroxytryptamine 1A receptor was determined using [3H]-5-HT as radioligand,B,,,,,
914,8,,BAO_0000357,Autocuration,,15463,Binding affinity towards recombinant human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,B,,,,,
915,8,,BAO_0000357,Autocuration,,15463,Binding affinity towards recombinant human Compound at 1 uM was tested for the inhibition of radioligand [3H]8-OH-DPAT binding to recombinant human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,B,,,,,
916,8,,BAO_0000357,Autocuration,,14770,Binding affinity for recombinant human 5-hydroxytryptamine 1A receptor using [3H]5-HT as radioligand.,B,,,,,
917,8,,BAO_0000219,Autocuration,,16245,Binding affinity on human cloned 5-hydroxytryptamine 1A receptor transfected in human cell lines (He La),B,,,,,
918,8,,BAO_0000019,Autocuration,,16245,Binding affinity on human cloned 5-hydroxytryptamine 1A receptor transfected in human cell lines(He La),B,,,,,
919,8,,BAO_0000357,Autocuration,,5548,Binding affinity towards 5-HT1A receptor using [3H]8-OH-DPAT as radioligand,B,,,,,
920,8,,BAO_0000357,Expert,,5548,Binding affinity was determined towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,B,,,,,
921,8,,BAO_0000357,Autocuration,,5548,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,B,,,,,
922,8,,BAO_0000357,Expert,,6876,Binding affinity was evaluated at 5-hydroxytryptamine 1A receptor labeled with [3H]-8-OH-DPAT,B,,,,,
923,8,,BAO_0000357,Autocuration,,2598,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,B,,,,,
924,8,,BAO_0000357,Expert,,17785,Binding affinity to human 5-hydroxytryptamine 1A receptor was measured using [3H]-8-hydroxy-2-(di-n-propylamine) tetraline [3H]8-OH-DPAT) as radioligand,B,,,,,
925,8,,BAO_0000357,Autocuration,,6013,Binding affinity towards 5-hydroxytryptamine 1A receptor,B,,,,,
926,8,,BAO_0000357,Expert,,5929,Binding affinity towards 5-hydroxytryptamine 1A receptor in human using [3H]8-OH-DPAT as radioligand,B,,,,,
927,8,,BAO_0000357,Autocuration,,16633,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,B,,,,,
928,8,,BAO_0000357,Autocuration,,1558,Binding affinity towards cloned human 5-hydroxytryptamine 1A receptor was determined,B,,,,,
929,8,,BAO_0000357,Expert,,16026,Binding affinity towards human cloned 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,B,,,,,
930,8,,BAO_0000219,Autocuration,,12469,Binding affinity was measured on 5-hydroxytryptamine 1A receptor in AK cells transfected with human 5-HT1A gene labeled with [3H]-8-OH-DPAT,B,,,,,
931,9,,BAO_0000357,Expert,,15874,Binding affinity was measured on cloned Human 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,B,,,Homo sapiens,9606.0,
932,8,,BAO_0000357,Autocuration,,15874,Binding affinity was measured on cloned human 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,B,,,,,
933,8,,BAO_0000357,Autocuration,,3935,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1A receptor,B,,,,,
934,8,,BAO_0000357,Autocuration,,15818,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1A receptor,B,,,,,
935,8,,BAO_0000219,Autocuration,,13706,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells.,B,,,,,
936,8,,BAO_0000219,Expert,,13729,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1A receptor in CHO-K1 cells,F,,,,,
937,8,,BAO_0000019,Autocuration,,15413,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor,B,,,,,
938,8,,BAO_0000019,Autocuration,,15413,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor (Experiment 1),B,,,,,
939,8,,BAO_0000019,Autocuration,,15413,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor (Experiment 2),B,,,,,
940,8,,BAO_0000019,Autocuration,,15413,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor by Panlabs assay,B,,,,,
941,9,,BAO_0000219,Expert,,3445,Displacement of specific [3H]- 5-HT binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells,B,,,Homo sapiens,9606.0,
942,8,,BAO_0000357,Autocuration,,15740,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor,B,,,,,
943,8,,BAO_0000357,Autocuration,,15740,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor receptor,B,,,,,
944,8,,BAO_0000357,Autocuration,,17626,In vitro binding affinity tested on human 5-hydroxytryptamine 1A receptor,B,,,,,
945,9,,BAO_0000357,Expert,,4234,In vitro binding affinity to human 5-hydroxytryptamine 1A receptor,B,,,Homo sapiens,9606.0,
946,8,,BAO_0000357,Expert,,5640,In vitro binding affinity at 5-hydroxytryptamine 1A receptor by [3H]8-OH-DPAT displacement.,B,,,,,
947,8,,BAO_0000357,Expert,,5272,In vitro binding affinity towards Human 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT,B,,,Rattus norvegicus,10116.0,
948,8,,BAO_0000219,Autocuration,,4622,In vitro binding affinity towards cloned human 5-hydroxytryptamine 1A receptor expressed in Chinese hamster ovary (CHO) cells using [3H]8-OH-DPAT as radioligand,B,,,,,
949,8,,BAO_0000019,Expert,,17085,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1A receptor,B,,,,,
950,8,,BAO_0000357,Autocuration,,3025,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand,B,,,,,
951,8,,BAO_0000357,Expert,,15315,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1A receptor,B,,,,,
952,8,,BAO_0000357,Autocuration,,15267,Inhibition of [3H]- OH-DPAT binding against 5-hydroxytryptamine 1A receptor from human recombinant,B,,,,,
953,8,,BAO_0000219,Autocuration,,17158,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor serotonergic receptor in human HeLa cells,B,,,,,
954,9,,BAO_0000219,Expert,,14214,Receptor binding affinity for cloned human 5-hydroxytryptamine 1A receptor in HeLa cells,B,,,Homo sapiens,9606.0,
955,8,,BAO_0000357,Autocuration,,17133,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,B,,,,,
956,8,,BAO_0000357,Autocuration,,16532,The binding affinity at the 5-hydroxytryptamine 1A receptor determined using [3H]5-CT,B,,,,,
957,9,,BAO_0000357,Expert,,2391,Affinity for 5-hydroxytryptamine 1A receptor subtype,B,,,Homo sapiens,9606.0,
958,8,,BAO_0000019,Autocuration,,14447,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1A receptor from cloned Human membranes,B,,,,,
959,8,,BAO_0000019,Autocuration,,14447,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1A receptor from cloned Human membranes.,B,,,,,
960,8,,BAO_0000357,Autocuration,,15086,The compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor receptor,B,,,,,
961,9,,BAO_0000357,Expert,,13051,Binding affinity for cloned human 5-hydroxytryptamine 1A receptor,B,,,Homo sapiens,9606.0,
962,8,,BAO_0000019,Autocuration,,16026,"Ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor; Not active",F,,,,,
963,8,,BAO_0000019,Expert,,17085,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1A receptor; ND means not determined,B,,,,,
964,8,,BAO_0000357,Autocuration,,17133,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,B,,,,,
965,8,,BAO_0000357,Autocuration,,17133,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand; ND means Not determined,B,,,,,
966,8,,BAO_0000219,Autocuration,,17211,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,B,,,,,
967,8,,BAO_0000219,Autocuration,,17211,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT=not tested,B,,,,,
968,8,,BAO_0000219,Autocuration,,17211,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,B,,,,,
969,8,,BAO_0000219,Autocuration,,17211,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,B,,,,,
970,8,,BAO_0000019,Autocuration,,16394,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",F,,,,,
971,8,,BAO_0000019,Autocuration,,16394,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",F,,,,,
972,8,,BAO_0000019,Autocuration,,16394,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",F,,,,,
973,8,,BAO_0000218,Autocuration,,16394,Antagonist induction of hypothermia by 8-OH-DPAT in 5-hydroxytryptamine 1A receptor after subcutaneous administration; NT is not tested,F,In vivo,,,,
974,8,,BAO_0000019,Autocuration,,16394,Binding affinity at human 5-hydroxytryptamine 1A receptor by inhibition of [3H]-8-OH-DPAT binding in Chinese hamster ovary cell line; NT is not tested,B,,,,,
975,8,,BAO_0000019,Autocuration,,15740,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor receptor; Not tested,F,,,,,
976,8,,BAO_0000019,Autocuration,,15740,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor; Not tested,F,,,,,
977,8,,BAO_0000357,Autocuration,,15740,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor,B,,,,,
978,8,,BAO_0000219,Autocuration,,17296,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,F,,,,,
979,8,,BAO_0000019,Expert,,5640,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at 1 uM.",F,,,,,
980,8,,BAO_0000019,Autocuration,,5640,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; ND means Not determined",F,,,,,
981,8,,BAO_0000019,Autocuration,,5640,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; ND means not determined",F,,,,,
982,8,,BAO_0000019,Autocuration,,5640,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; Not determined",F,,,,,
983,8,,BAO_0000219,Autocuration,,2759,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,F,,,,,
984,8,,BAO_0000019,Autocuration,,16394,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT",F,,,,,
985,9,,BAO_0000019,Expert,,16394,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared to 5-HT",F,,,Homo sapiens,9606.0,
986,9,,BAO_0000019,Expert,,3445,Percent efficacy against human 5-hydroxytryptamine 1A receptor relative to maximal 5-HT response,F,,,Homo sapiens,9606.0,
987,8,,BAO_0000219,Expert,,4316,Binding affinity for 5-hydroxytryptamine 1A receptor was determined by incubating human 5-hydroxytryptamine 1A receptor transfected CHO cells with [3H]8-OH-DPAT,B,,,,,
988,8,,BAO_0000019,Expert,,4316,In vitro inhibition of [3H]8-OH-DPAT binding to human cloned 5-hydroxytryptamine 1A receptor on CHO cell membranes.,B,,,,,
989,9,,BAO_0000019,Expert,,15180,Agonist efficacy on 5-hydroxytryptamine 1A receptor subtype,F,,,Homo sapiens,9606.0,
990,9,,BAO_0000019,Expert,,15180,Agonist efficacy on 5-hydroxytryptamine 1A receptor subtype,F,,,Homo sapiens,9606.0,
991,8,,BAO_0000019,Autocuration,,15042,Maximum binding affinity was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,F,,,,,
992,8,,BAO_0000019,Autocuration,,15042,Maximum binding affinity was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,F,,,,,
993,8,,BAO_0000019,Autocuration,,15042,Maximum binding affinity was evaluated as ([35S]GTP binding on cloned human 5-hydroxytryptamine 1A receptor,F,,,,,
994,8,,BAO_0000019,Autocuration,,15042,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,F,,,,,
995,8,,BAO_0000019,Autocuration,,15042,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,F,,,,,
996,8,,BAO_0000019,Autocuration,,15042,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,F,,,,,
997,8,,BAO_0000019,Autocuration,,15042,Agonist efficacy was evaluated as [35S]GTP binding on cloned human 5-hydroxytryptamine 1A receptor,F,,,,,
998,9,,BAO_0000219,Expert,,15180,Concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,F,,,Homo sapiens,9606.0,
999,9,,BAO_0000219,Expert,,15180,Negative logarithm of concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,F,,,Homo sapiens,9606.0,
1000,9,,BAO_0000219,Expert,,15180,Negative logarithm of concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,F,,,Homo sapiens,9606.0,
1001,8,,BAO_0000019,Autocuration,,16245,"Potency (pD2) for the stimulation of [35S]GTP-gamma-S, binding on 5-hydroxytryptamine 1A receptor",F,,,,,
1002,8,,BAO_0000019,Autocuration,,16026,"Ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",F,,,,,
1003,8,,BAO_0000219,Autocuration,,17296,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,F,,,,,
1004,8,,BAO_0000219,Autocuration,,2759,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 2),F,,,,,
1005,8,,BAO_0000219,Autocuration,,2759,Compound was tested for its potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells,F,,,,,
1006,9,,BAO_0000219,Expert,,2759,Potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 1),F,,,Homo sapiens,9606.0,
1007,8,,BAO_0000219,Autocuration,,2759,Compound was tested for its potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 2),F,,,,,
1008,8,,BAO_0000219,Expert,,15419,In vitro effective concentration required to inhibit forskolin-stimulated cAMP levels in HA7 cells expressing human 5-HT1A receptor,F,,,,,
1009,8,,BAO_0000219,Autocuration,,15419,In vitro effective concentration required to inhibit forskolin-stimulated cAMP levels in HA7 cells expressing human 5-HT1A receptor; Not tested,F,,,,,
1010,8,,BAO_0000019,Autocuration,,16026,"ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",F,,,,,
1011,8,,BAO_0000219,Expert,,1414,Ability to bind to 5-hydroxytryptamine 1A receptor from cloned human expressed in Ha7 cells,B,In vitro,,,,
1012,8,,BAO_0000219,Expert,,1414,Ability to bind to 5-hydroxytryptamine 1A receptor subtype from cloned human expressed in Ha7 cells,B,In vitro,,,,
1013,8,,BAO_0000357,Autocuration,,12861,Binding activity radioligand.,B,,,,,
1014,8,,BAO_0000019,Autocuration,,12861,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,B,,,,,
1015,8,,BAO_0000357,Autocuration,,5104,Binding affinity for human cloned 5-hydroxytryptamine 1A receptor,B,,,,,
1016,8,,BAO_0000357,Autocuration,,5105,Binding affinity for human cloned 5-hydroxytryptamine 1A receptor,B,,,,,
1017,8,,BAO_0000357,Autocuration,,16312,binding affinity towards human recombinant 5-hydroxytryptamine 1A receptor,B,,,,,
1018,9,,BAO_0000357,Expert,,15180,Displacement of [3H]8-hydroxy-2-(di-n-propylamino)tetralin from human 5-hydroxytryptamine 1A receptor,B,,,Homo sapiens,9606.0,
1019,8,,BAO_0000357,Autocuration,,5033,Ability to displace the radioligand [3H]-8-OH-DPAT from human 5-hydroxytryptamine 1A receptor,B,,,,,
1020,9,,BAO_0000219,Expert,,16909,Affinity constant on CHO cells expressing Human recombinant 5-hydroxytryptamine receptor 1A,B,,,Homo sapiens,9606.0,
1021,8,,BAO_0000019,Autocuration,,2590,Antagonistic affinity against cloned human 5-hydroxytryptamine 1A receptor,F,,,,,
1022,8,,BAO_0000019,Autocuration,,2590,Antagonistic affinity against cloned human 5-hydroxytryptamine 1A receptor; Not determined,F,,,,,
1023,8,,BAO_0000019,Expert,,16394,Binding affinity at human 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding in Chinese hamster ovary cell line,B,,,,,
1024,9,,BAO_0000219,Expert,,4540,Binding affinity to human cloned 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]-8-OH- DPAT as radioligand,B,,,Homo sapiens,9606.0,
1025,8,,BAO_0000219,Autocuration,,17296,Binding affinity against 5-hydroxytryptamine 1A human cloned receptors in HEK293 cells,B,,,,,
1026,8,,BAO_0000219,Autocuration,,17296,Binding affinity against 5-hydroxytryptamine 1A human cloned receptors in HEK293 cells using [3H]8-OH-DPAT as radioligand,B,,,,,
1027,8,,BAO_0000219,Autocuration,,15779,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;,B,,,,,
1028,8,,BAO_0000219,Autocuration,,15779,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand; ND means no data,B,,,,,
1029,8,,BAO_0000219,Autocuration,,15779,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;ND means no data.,B,,,,,
1030,8,,BAO_0000357,Autocuration,,6166,Binding affinity towards 5-hydroxytryptamine 1A receptor in human using [3H]8-OH-DPAT as radioligand,B,,,,,
1031,8,,BAO_0000219,Autocuration,,15779,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;,B,,,,,
1032,8,,BAO_0000219,Autocuration,,4199,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]8-OH-DPAT as the radioligand,B,,,,,
1033,8,,BAO_0000219,Autocuration,,15316,Compound was evaluated for its ability to displace [3H]8-OH-DPAT binding from human 5-hydroxytryptamine 1A receptor in mammalian cells,B,,,,,
1034,8,,BAO_0000357,Autocuration,,14875,Compound was tested for binding affinity against human 5-hydroxytryptamine 1A receptor,B,,,,,
1035,8,,BAO_0000219,Expert,,14727,Binding affinity at human cloned 5-hydroxytryptamine 1A receptor expressed in HeLa cells by [3H]8-hydroxy-2-(di-n-propylamino)tetraline displacement.,B,,,,,
1036,8,,BAO_0000019,Expert,,14727,Binding affinity at native 5-hydroxytryptamine 1A receptor in rat by [3H]8-hydroxy-2-(di-n-propylamino)tetraline displacement.,B,,,,,
1037,8,,BAO_0000219,Autocuration,,15146,Compound was tested for its binding affinity against 5-hydroxytryptamine 1A receptor in human cloned receptors in HEK 293 cells using [3H]8-OH-DPAT,B,,,,,
1038,8,,BAO_0000219,Autocuration,,5213,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1A receptor in HEK 293 using [3H]5-CT as a radioligand,B,,,,,
1039,8,,BAO_0000219,Autocuration,,16429,In vitro binding affinity at human recombinant 5-hydroxytryptamine 1A receptor in mammalian cells using 3[H]8-OH-DPAT as the radioligand,B,,,,,
1040,9,,BAO_0000219,Expert,,15042,The binding affinity was evaluated on cloned human 5-hydroxytryptamine 1A receptor expressed in HeLa cells by using DPAT as radioligand.,B,,,Homo sapiens,9606.0,
1041,8,,BAO_0000219,Autocuration,,14818,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]8-OH-DPAT.,B,,,,,
1042,8,,BAO_0000219,Autocuration,,4829,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1A receptor in HEK293 cells, using [3H]8-OH-DPAT as radioligand",B,,,,,
1043,9,,BAO_0000357,Expert,,17200,In vitro inhibitory concentration required against [3H]8-OH-DPAT binding to cloned human 5-hydroxytryptamine 1A receptor,B,,,,,
1044,9,,BAO_0000357,Autocuration,,13051,The compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1A receptor,B,,,Homo sapiens,9606.0,
1045,8,,BAO_0000357,Autocuration,,5486,Binding affinity towards 5-HT1B receptor by the displacement of [3H]-5-CT] in human recombinant receptors in mammalian cell,B,,,,,
1046,8,,BAO_0000357,Autocuration,,5254,Binding affinity against 5-HT1D receptor,B,,,,,
1047,8,,BAO_0000357,Autocuration,,5254,Binding affinity against 5-hydroxytryptamine 1A receptor,B,,,,,
1048,8,,BAO_0000357,Autocuration,,15331,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,B,,,,,
1049,8,,BAO_0000357,Autocuration,,13506,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT binding assay,B,,,Homo sapiens,9606.0,
1050,8,,BAO_0000357,Autocuration,,15267,Inhibition of [3H]- 8-OH-DAPT binding against human recombinant 5-hydroxytryptamine 1A receptor,B,,,,,
1051,8,,BAO_0000218,Autocuration,,16616,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 15 min after administration of the compound,F,In vivo,,,,
1052,8,,BAO_0000218,Autocuration,,16616,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 30 min after administration of the compound,F,In vivo,,,,
1053,8,,BAO_0000218,Autocuration,,16616,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 60 min after administration of the compound,F,In vivo,,,,
1054,9,,BAO_0000218,Expert,,16616,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 15 min,F,,,Mus musculus,10090.0,
1055,9,,BAO_0000218,Expert,,16616,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 30 min,F,,,Mus musculus,10090.0,
1056,9,,BAO_0000218,Expert,,16616,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 60 min,F,,,Mus musculus,10090.0,
1057,9,,BAO_0000218,Expert,,16616,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 15 min,F,,,Mus musculus,10090.0,
1058,9,,BAO_0000218,Expert,,16616,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 30 min,F,,,Mus musculus,10090.0,
1059,9,,BAO_0000218,Expert,,16616,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 60 min,F,,,Mus musculus,10090.0,
1060,8,,BAO_0000221,Autocuration,10000000.0,10297,Hill number was determined for inhibition of of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in mouse hippocampus,B,,,,,
1061,8,,BAO_0000357,Expert,,13704,Inhibitory activity against serotonin 5-hydroxytryptamine 1A receptor from mice.,B,,,,,
1062,9,,BAO_0000221,Expert,10000000.0,10297,Inhibitory activity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus,B,,,Mus musculus,10090.0,
1063,8,,BAO_0000221,Autocuration,10000000.0,10297,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus; Not determined,B,,,,,
1064,9,,BAO_0000221,Expert,10000000.0,10297,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus,B,,,Mus musculus,10090.0,
1065,8,,BAO_0000221,Autocuration,10000000.0,10297,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus; Not determined,B,,,,,
1066,8,,BAO_0000357,Autocuration,,217,Compound was tested for binding affinity to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as a radioligand,B,,,,,
1067,9,,BAO_0000221,Expert,10000000.0,10297,Hill number was determined for inhibition of of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in mouse hippocampus,B,,,Mus musculus,10090.0,
1068,8,,BAO_0000357,Autocuration,,4921,Ability to displace [3H]8-OH-DPAT radioligand from porcine 5-hydroxytryptamine 1A receptor,B,,,Sus scrofa,9823.0,
1069,8,,BAO_0000357,Autocuration,,4921,Ability to displace [3H]8-OH-DPAT radioligand from porcine 5-hydroxytryptamine 1A receptor; ND denotes not determined,B,,,Sus scrofa,9823.0,
1070,8,,BAO_0000019,Autocuration,,4996,Binding affinity of compound measured for 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT-labeled porcine brain homogenates,B,,,Sus scrofa,9823.0,
1071,8,,BAO_0000357,Autocuration,,12918,Compound was evaluated for the binding affinity at 5- HT1A receptor,B,,,Sus scrofa,9823.0,
1072,8,,BAO_0000019,Autocuration,,5333,Compound was tested in vitro for its ability to compete with [3H]8-OH-DPAT at 5-hydroxytryptamine 1A receptor in porcine brain homogenate,B,,,Sus scrofa,9823.0,
1073,8,,BAO_0000019,Autocuration,,4437,In vitro for its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in porcine brain homogenate,B,,,Sus scrofa,9823.0,
1074,8,,BAO_0000019,Autocuration,,1742,Compound was tested for its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in pig cortex,B,,,Sus scrofa,9823.0,
1075,8,,BAO_0000357,Expert,,16688,Displacement of [3H]- 8-OH-DPAT from porcine 5-hydroxytryptamine 1A receptor,B,,,Sus scrofa,9823.0,
1076,8,,BAO_0000357,Autocuration,,12861,Binding activity radioligand.,B,,,Sus scrofa,9823.0,
1077,8,,BAO_0000019,Expert,,12861,Binding activity against 5-hydroxytryptamine 1A receptor from pig cortex membrane using [3H]8-OH-DPAT-HT as radioligand.,B,,,Sus scrofa,9823.0,
1078,8,,BAO_0000019,Autocuration,,12861,Binding activity against 5-hydroxytryptamine 1A receptor from pig cortex membrane using [3H]8-OH-DPAT-HT as radioligand.,B,,,Sus scrofa,9823.0,
1079,8,,BAO_0000019,Expert,,12490,Displacement of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor from pig cortex,B,,,,,
1080,8,,BAO_0000019,Expert,,11828,Displacement of [3H]8-OH-DPAT from pig cortex 5-hydroxytryptamine 1A receptor,B,,,Sus scrofa,9823.0,
1081,8,,BAO_0000221,Autocuration,10000000.0,11866,Binding affinity for 5-hydroxytryptamine 1A receptor in piglet hippocampus using [3H]8-OH-DPAT,B,,,Sus scrofa,9823.0,
1082,8,,BAO_0000249,Autocuration,,12827,Binding affinity towards 5-hydroxytryptamine 1A receptor in pig frontal cortex membranes using [8H]-OH-DPAT,B,,,Sus scrofa,9823.0,
1083,8,,BAO_0000019,Autocuration,,12918,Binding affinity was evaluated by 5-hydroxytryptamine 1A receptor agonism in the pig cortex by displacing 8-OH-DPAT,B,,,Sus scrofa,9823.0,
1084,8,,BAO_0000019,Expert,,12919,Agonistic activity against 5-hydroxytryptamine 1A receptor in pig cortex using [3H]8-OH-DPAT,F,,,Sus scrofa,9823.0,
1085,8,,BAO_0000019,Autocuration,,13047,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit jugular vein assay in the presence of endothelium,B,,,Oryctolagus cuniculus,9986.0,
1086,9,,BAO_0000249,Expert,,15796,Inhibition activity against 5-hydroxytryptamine 1A receptor in rat hippocampus membranes using radio binding assays,B,,,Rattus norvegicus,10116.0,
1087,9,,BAO_0000221,Expert,10000000.0,3651,"Inhibition of [3H]8-hydroxy-2-dipropylamino-1,2,3,4-tetrahydronaphthalene binding to 5-hydroxytryptamine 1A receptor in hippocampus region of rat brain; Less active",B,,,Rattus norvegicus,10116.0,
1088,8,,BAO_0000357,Autocuration,,188,Tested for the effect on binding at 5-hydroxytryptamine 1A receptor; No activity,B,,,,,
1089,9,,BAO_0000249,Expert,,16616,"Antagonist activity to stimulate binding of [35S]GTP-gamma-S, to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes",F,,,Rattus norvegicus,10116.0,
1090,9,,BAO_0000249,Expert,10000000.0,16616,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding in rat hippocampal membranes",F,,,Rattus norvegicus,10116.0,
1091,8,,BAO_0000221,Autocuration,10000000.0,12306,The binding of [125I]MPPI ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,B,,,,,
1092,9,,BAO_0000221,Expert,10000000.0,17167,Binding affinity for rat hippocampus 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding,B,,,Rattus norvegicus,10116.0,
1093,8,,BAO_0000019,Autocuration,,14776,Binding affinity measured at the 5-hydroxytryptamine 1A receptor by the inhibition of [3H]8-OH-DPAT binding to rat cortex using unlabeled buspirone for nonspecific binding.,B,,,,,
1094,8,,BAO_0000357,Expert,,12158,Binding affinity of 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand.,B,,,,,
1095,8,,BAO_0000357,Autocuration,,13481,Binding affinity of [3H]- -8-OH-DPAT labelled towards Rat Hippocampal 5-hydroxytryptamine 1A receptor using radioligand binding assay,B,,,,,
1096,8,,BAO_0000219,Autocuration,,13427,Binding affinity of [3H]-8-OH-DPAT towards 5-hydroxytryptamine 1A receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,B,In vitro,,,,
1097,8,,BAO_0000357,Autocuration,,10210,Binding affinity of compound against 5-hydroxytryptamine 1A receptor binding site using radioligand [3H]8-OH-DPAT,B,,,,,
1098,8,,BAO_0000249,Autocuration,,10205,Binding affinity of compound towards 5-HT 1A receptor by measuring ability to displace [3H]OH-DPAT from 5-hydroxytryptamine 1A receptor in rat striatal membranes,B,,,,,
1099,8,,BAO_0000249,Autocuration,,10205,Binding affinity of compound towards 5-HT 1A receptor by measuring ability to displace [3H]OH-DPAT from 5-hydroxytryptamine 1A receptor in rat striatal membranes,B,,,,,
1100,8,,BAO_0000249,Expert,,10205,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor in rat striatal membranes by [3H]OH-DPAT displacement.,B,,,,,
1101,9,,BAO_0000357,Expert,,12280,Binding affinity for 5-hydroxytryptamine 1A receptor with [3H]5-HT,B,,,Rattus norvegicus,10116.0,
1102,8,,BAO_0000357,Expert,,17386,Binding affinity to the rat 5-hydroxytryptamine 1A receptor,B,,,,,
1103,8,,BAO_0000357,Expert,,13654,Binding affinity was tested on 5-hydroxytryptamine 1A receptor using radioligand [3H]5-HT binding assay.,B,,,,,
1104,8,,BAO_0000221,Autocuration,10000000.0,14423,Binding affinity against 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as the radioligand.,B,,,,,
1105,8,,BAO_0000221,Autocuration,10000000.0,15412,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampus tissue.,B,,,,,
1106,8,,BAO_0000221,Autocuration,10000000.0,12073,Binding affinity by measuring displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,B,,,,,
1107,9,,BAO_0000357,Expert,,4101,Displacement of [3H]8-OH-DPAT from rat striata 5-hydroxytryptamine 1A receptor,B,,,Rattus norvegicus,10116.0,
1108,8,,BAO_0000357,Autocuration,,10062,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1A receptor,B,,,,,
1109,8,,BAO_0000249,Autocuration,,6238,Binding affinity towards 5-HT 1A receptor in rat cerebral cortex membranes using [3H]8-OH-DPAT as radioligand,B,,,,,
1110,8,,BAO_0000357,Autocuration,,16273,Binding affinity towards 5-hydroxytryptamine 1A receptor,B,,,,,
1111,8,,BAO_0000357,Autocuration,,11139,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in competitive binding assay,B,,,,,
1112,8,,BAO_0000019,Expert,,16796,Binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampal membranes,B,,,,,
1113,9,,BAO_0000221,Expert,955.0,9548,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,B,,,Rattus norvegicus,10116.0,
1114,8,,BAO_0000221,Autocuration,955.0,10381,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,B,,,,,
1115,8,,BAO_0000249,Autocuration,,13408,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hypocampus membrane using [3H]8-OH-DPAT as radioligand,B,,,,,
1116,9,,BAO_0000221,Expert,10000000.0,13825,Binding affinity towards 5-hydroxytryptamine 1A receptor in the rat brain (hippocampus) using [3H]8-OH-DPAT,B,,,Rattus norvegicus,10116.0,
1117,8,,BAO_0000221,Expert,10000000.0,11147,Binding affinity towards 5-hydroxytryptamine 1A receptor of rat hippocampus using [3H]-8-hydroxy-2-(di-n-propylamine) tetralin (8-OH-DPAT) as a radioligand,B,,,,,
1118,8,,BAO_0000249,Autocuration,,10552,Binding affinity towards 5-hydroxytryptamine 1A receptor sites in cortical membranes using [3H]8-OH-DPAT as radioligand,B,,,,,
1119,8,,BAO_0000249,Autocuration,2435.0,10552,"Binding affinity towards 5-hydroxytryptamine 1A receptor sites, in rat striatum membranes using [3H]- sandoz 205-501 as radioligand",B,,,,,
1120,9,,BAO_0000249,Expert,,17136,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat cortex membranes,B,,,Rattus norvegicus,10116.0,
1121,9,,BAO_0000249,Expert,,5778,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat cerebral cortex membranes,B,,,Rattus norvegicus,10116.0,
1122,8,,BAO_0000221,Autocuration,10000000.0,13481,Binding affinity towards rat hippocampal 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,B,,,,,
1123,8,,BAO_0000221,Autocuration,10000000.0,13481,Binding affinity towards rat hippocampal 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand; Not tested,B,,,,,
1124,8,,BAO_0000221,Intermediate,10000000.0,13630,Binding affinity against rat hippocampal 5-hydroxytryptamine 1A (5-HT1A) receptor determined using [3H]8-OH-DPAT as radioligand,B,,,,,
1125,8,,BAO_0000249,Expert,,16245,Binding was determined on 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,B,,,,,
1126,8,,BAO_0000221,Autocuration,10000000.0,14509,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand,B,,,,,
1127,8,,BAO_0000221,Expert,10000000.0,14509,Binding affinity against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand.,B,,,,,
1128,8,,BAO_0000221,Autocuration,10000000.0,14509,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand.; ND = Not determined,B,,,,,
1129,8,,BAO_0000221,Autocuration,10000000.0,14509,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand; ND = Not determined,B,,,,,
1130,8,,BAO_0000019,Expert,,14256,Binding affinity was evaluated by determining in vitro displacement of [3H]8-OH-DPAT from the central 5-hydroxytryptamine 1A receptor recognition site in rat frontal cortex homogenate.,B,,,,,
1131,8,,BAO_0000357,Autocuration,,11139,Binding affinity was evaluated by using [3H]8-OH-DPAT radioligand by using competitive binding assay on 5-hydroxytryptamine 1A receptor,B,,,,,
1132,9,,BAO_0000019,Expert,,11047,Binding affinity for 5-HT1A measured by displacing [3H]8-OH-DPAT from rat cortical membranes; Not determined,B,,,Rattus norvegicus,10116.0,
1133,9,,BAO_0000019,Expert,,11047,Binding affinity for 5-hydroxytryptamine 1A receptor measured by displacing [3H]8-OH-DPAT from rat cortical membranes,B,,,Rattus norvegicus,10116.0,
1134,9,,BAO_0000019,Expert,,11047,Binding affinity for 5-hydroxytryptamine 1A receptor measured by displacing [3H]8-OH-DPAT from rat cortical membranes;ND-Not determined,B,,,Rattus norvegicus,10116.0,
1135,9,,BAO_0000219,Expert,,2395,Binding affinity against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells,B,,,Rattus norvegicus,10116.0,
1136,8,,BAO_0000357,Autocuration,,9699,Binding affinity towards 5-hydroxytryptamine 1A receptor,B,,,,,
1137,9,,BAO_0000221,Expert,10000000.0,12028,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [125I]trans-8-OH-PIPAT in membrane homogenates of hippocampal tissue of rat brain,B,,,Rattus norvegicus,10116.0,
1138,8,,BAO_0000221,Autocuration,10000000.0,12028,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in membrane homogenates of hippocampal tissue of rat brain,B,,,,,
1139,8,,BAO_0000019,Autocuration,,5815,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex,B,,,,,
1140,8,,BAO_0000019,Expert,,16616,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenates,B,,,,,
1141,8,,BAO_0000019,Autocuration,,5815,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]-8-OH-DPAT,B,,,,,
1142,8,,BAO_0000221,Autocuration,10000000.0,2761,"Binding affinity towards 5-hydroxytryptamine 1A receptor using 0.1 nM [3H]-8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tet-ralin), from rat hippocampal homogenate",B,,,,,
1143,8,,BAO_0000357,Expert,,13133,Binding affinity was determined against 5-hydroxytryptamine 1A receptor using [3H]WB-4101,B,,,,,
1144,8,,BAO_0000019,Autocuration,,10444,Binding affinity was determined against 5-hydroxytryptamine 1A receptor was determined in male Sprague-Dawley rat brain.,B,,,,,
1145,9,,BAO_0000357,Expert,,13278,Binding affinity was measured against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT by lysergic acid amides,B,,,Rattus norvegicus,10116.0,
1146,8,,BAO_0000357,Autocuration,,15874,Binding affinity was measured on cloned rat 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,B,,,,,
1147,8,,BAO_0000249,Autocuration,2435.0,10552,"Binding affinity of the compound towards 5-hydroxytryptamine 1A receptor sites, in rat striatum membranes using [3H]- sandoz 205-501 as radioligand",B,,,,,
1148,8,,BAO_0000357,Autocuration,,11130,Binding constant against 5-hydroxytryptamine 1A receptor (in vitro),B,,,,,
1149,8,,BAO_0000218,Autocuration,,11130,Binding constant against 5-hydroxytryptamine 1A receptor (in vivo),B,In vivo,,,,
1150,8,,BAO_0000221,Autocuration,955.0,14542,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]-8-OH- -DPAT in rat brain cortex,B,,,,,
1151,9,,BAO_0000357,Expert,,13670,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,B,,,Rattus norvegicus,10116.0,
1152,8,,BAO_0000249,Expert,,9888,Binding affinity at [3H]8-OH-DPAT-Labeled 5-hydroxytryptamine 1A receptor sites in rat brain hippocampal membranes,B,,,,,
1153,9,,BAO_0000249,Expert,,3678,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus membranes,B,,,Rattus norvegicus,10116.0,
1154,8,,BAO_0000221,Autocuration,10000000.0,11332,Compound was evaluated for in vitro binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]8-OH-DPAT as radioligand,B,,,,,
1155,8,,BAO_0000221,Autocuration,10000000.0,11332,Compound was evaluated for in vitro binding affinity towards serotonin 5-hydroxytryptamine 1A receptor receptor in rat hippocampus using [3H]8-OH-DPAT as radioligand,B,,,,,
1156,8,,BAO_0000357,Expert,,1185,Ability to displace [3H]-8-OH-DPAT from serotonergic 5-hydroxytryptamine 1A receptor,B,,,,,
1157,8,,BAO_0000249,Expert,,2014,Binding affinity at 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes by [3H]8-OH-DPAT displacement.,B,,,,,
1158,8,,BAO_0000357,Autocuration,,1185,Compound was evaluated for its ability to displace [3H]8-OH-DPAT from serotonergic 5-hydroxytryptamine 1A receptor,B,,,,,
1159,8,,BAO_0000019,Expert,,14429,Compound was evaluated for its binding affinity against 5-hydroxytryptamine 1A receptor from rat cerebral cortex,B,,,,,
1160,8,,BAO_0000019,Expert,,16288,"Binding affinity to 5-hydroxytryptamine 1A receptor (5-HT 1A receptor, serotonin receptor) from rat cortex using [3H]8-OH-DPAT as radioligand",B,,,,,
1161,9,,BAO_0000019,Expert,,5432,Displacement of [3H]prazosin from rat cortex membrane 5-hydroxytryptamine 1A receptor,B,,,Rattus norvegicus,10116.0,
1162,8,,BAO_0000019,Autocuration,,14429,Compound was evaluated for its binding affinity with 5-hydroxytryptamine 1A receptor using membranes prepared from rat cerebral cortex,B,,,,,
1163,8,,BAO_0000357,Expert,,13672,Binding affinity towards rat 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand.,B,,,,,
1164,8,,BAO_0000221,Expert,10000000.0,11296,In vitro ability to displace [3H]8-hydroxy-2-(di-n-propylamino) tetralin binding from 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,B,,,,,
1165,8,,BAO_0000357,Autocuration,,11296,In vitro ability to displace [3H]8-hydroxy-2-(di-n-propylamino) tetralin binding from 5-hydroxytryptamine 1A receptor site.,B,,,,,
1166,8,,BAO_0000219,Expert,,14749,Binding affinity against rat 5-hydroxytryptamine 1A receptor in CHO cells.,B,,,,,
1167,8,,BAO_0000019,Expert,,15086,Binding affinity towards 5-hydroxytryptamine 1A receptor from rat brain using [3H]-8-OH-DPAT as radioligand,B,,,,,
1168,8,,BAO_0000221,Autocuration,10000000.0,13462,Compound was tested for the Binding affinity against rat hippocampal 5-hydroxytryptamine 1A receptor by Radio ligand [3H]8-OH-DPAT binding assay.,B,,,,,
1169,8,,BAO_0000019,Autocuration,,15363,Compound was tested for the displacement of [3H]-8-OH- DPAT from rat brain 5-hydroxytryptamine 1A receptor,B,,,,,
1170,8,,BAO_0000019,Autocuration,,15363,Compound was tested for the displacement of [3H]-8-OH- DPAT from rat brain 5-hydroxytryptamine 1A receptor,B,,,,,
1171,8,,BAO_0000357,Autocuration,,10796,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 1A receptor,B,,,,,
1172,8,,BAO_0000221,Expert,955.0,12816,Binding affinity for 5-hydroxytryptamine 1A receptor in rat brain tissue using [3H]8-OH-DPAT as radioligand,B,,,,,
1173,8,,BAO_0000221,Expert,10000000.0,13542,In vitro displacement of [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,B,,,,,
1174,8,,BAO_0000019,Expert,,13308,In vitro ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor sites of rat brain cortex.,B,,,,,
1175,8,,BAO_0000221,Expert,10000000.0,13541,In vitro affinity at 5-hydroxytryptamine 1A receptor of rat hippocampus by [3H]8-OH-DPAT displacement.,B,,,,,
1176,8,,BAO_0000221,Autocuration,10000000.0,10058,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-HT1A receptor of rat hippocampus and the value ranges from 9 - 12,B,,,,,
1177,8,,BAO_0000221,Autocuration,10000000.0,10058,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus,B,,,,,
1178,8,,BAO_0000221,Autocuration,10000000.0,10058,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus (94%CI) from 12 to 17,B,,,,,
1179,8,,BAO_0000221,Autocuration,10000000.0,10058,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus (94%CI) from 391-841,B,,,,,
1180,8,,BAO_0000221,Autocuration,10000000.0,10058,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 12 to 17.,B,,,,,
1181,8,,BAO_0000221,Autocuration,10000000.0,10058,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 12 to 20.,B,,,,,
1182,8,,BAO_0000221,Autocuration,10000000.0,10058,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 245 to 736,B,,,,,
1183,8,,BAO_0000221,Autocuration,10000000.0,10058,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 25 - 84,B,,,,,
1184,8,,BAO_0000221,Autocuration,10000000.0,10058,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 48 to 59,B,,,,,
1185,8,,BAO_0000221,Autocuration,10000000.0,10058,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 3 -5,B,,,,,
1186,8,,BAO_0000221,Autocuration,10000000.0,10058,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 15 - 31,B,,,,,
1187,8,,BAO_0000221,Autocuration,10000000.0,10058,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 27 - 42,B,,,,,
1188,8,,BAO_0000221,Autocuration,10000000.0,10058,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 6 - 13,B,,,,,
1189,9,,BAO_0000221,Expert,10000000.0,10058,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus,B,,,Rattus norvegicus,10116.0,
1190,8,,BAO_0000221,Autocuration,10000000.0,10058,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus.; ND is No Data.,B,,,,,
1191,8,,BAO_0000221,Autocuration,10000000.0,10058,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus. and the value ranges from 16 - 27,B,,,,,
1192,8,,BAO_0000019,Expert,,12879,Displacement of [3H]2-(di-N-propylamino)-8-hydroxytetralin from central 5-hydroxytryptamine 1A receptor recognition sites in rat frontal cortex homogenates.,B,,,,,
1193,8,,BAO_0000019,Expert,,11964,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate,B,,,,,
1194,8,,BAO_0000019,Autocuration,,11964,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate (experiment 1),B,,,,,
1195,8,,BAO_0000019,Autocuration,,11964,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate (experiment 2),B,,,,,
1196,8,,BAO_0000221,Expert,955.0,9548,Evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,B,,,,,
1197,8,,BAO_0000019,Expert,,9098,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand.,B,,,,,
1198,8,,BAO_0000019,Autocuration,,9098,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand; ND is no data.,B,,,,,
1199,8,,BAO_0000019,Autocuration,,9098,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand;ND means no data,B,,,,,
1200,8,,BAO_0000219,Expert,,13248,In vitro displacement of radioactively labeled ligand [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor site in CHO cells,B,,,,,
1201,8,,BAO_0000249,Expert,,3147,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat cortical membranes,B,,,,,
1202,8,,BAO_0000019,Expert,,13949,In vitro binding affinity against 5-hydroxytryptamine 1A receptor of rat cerebral cortex using [3H]8-OH-DPAT as radioligand.,B,,,,,
1203,8,,BAO_0000218,Autocuration,,11883,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand in CHO cells (sc),B,,,,,
1204,8,,BAO_0000218,Autocuration,,11883,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT (agonist) as radioligand (sc),B,,,,,
1205,9,,BAO_0000357,Expert,,11883,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT,B,,,Rattus norvegicus,10116.0,
1206,8,,BAO_0000249,Expert,,15535,In vitro binding affinity at 5-HT1A receptors assayed by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,B,,,,,
1207,8,,BAO_0000249,Autocuration,,15535,In vitro binding affinity at 5-HT1A receptor by measuring its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes + cortex,B,,,,,
1208,8,,BAO_0000249,Autocuration,,15535,In vitro binding affinity at 5-HT1A receptor by measuring its ability to displace [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes+cortex,B,,,,,
1209,9,,BAO_0000219,Expert,,16372,Displacement of [3H]8-OH-DPAT from human 5-hydroxytryptamine 1A receptor expressed in CHO cells,B,,,Homo sapiens,9606.0,
1210,8,,BAO_0000249,Expert,,14608,In vitro binding affinity for 5-hydroxytryptamine 1A receptor in rat hippocampal membranes by [125I]-labeled agonist displacement.,B,,,,,
1211,9,,BAO_0000221,Expert,10000000.0,4795,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus,B,,,Rattus norvegicus,10116.0,
1212,8,,BAO_0000357,Autocuration,,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,B,,,,,
1213,8,,BAO_0000357,Autocuration,,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=100-230,B,,,,,
1214,8,,BAO_0000357,Autocuration,,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=12-14,B,,,,,
1215,8,,BAO_0000357,Autocuration,,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=16-20,B,,,,,
1216,8,,BAO_0000357,Autocuration,,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=160-430,B,,,,,
1217,8,,BAO_0000357,Autocuration,,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=174-224,B,,,,,
1218,8,,BAO_0000357,Autocuration,,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=184-503,B,,,,,
1219,8,,BAO_0000357,Autocuration,,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=19-23,B,,,,,
1220,8,,BAO_0000357,Autocuration,,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=2.2-3.2,B,,,,,
1221,8,,BAO_0000357,Autocuration,,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=2.7-3.6,B,,,,,
1222,8,,BAO_0000357,Autocuration,,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=20-23,B,,,,,
1223,8,,BAO_0000357,Autocuration,,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=21-28,B,,,,,
1224,8,,BAO_0000357,Autocuration,,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=240-760,B,,,,,
1225,8,,BAO_0000357,Autocuration,,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=39-87,B,,,,,
1226,8,,BAO_0000357,Autocuration,,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=4.6-5.2,B,,,,,
1227,8,,BAO_0000019,Autocuration,,9742,Inhibitory activity tested in vitro at 5-hydroxytryptamine 1A receptor binding site in rat,B,,,,,
1228,8,,BAO_0000357,Autocuration,,12073,Inhibitory concentration against 5-hydroxytryptamine 1A receptor,B,,,,,
1229,8,,BAO_0000357,Autocuration,,4101,Inhibitory concentration against binding of 5-hydroxytryptamine 1A receptor from striata of male Wistar rats by displacement of [3H]8-OH-DPAT,B,,,,,
1230,8,,BAO_0000019,Autocuration,,15360,Inhibitory concentration against radioligand [3H]hydroxy-2-(di-n-propylamino)-tetralin binding to 5-hydroxytryptamine 1A receptor in rat,B,,,,,
1231,8,,BAO_0000221,Autocuration,10000000.0,11576,Inhibitory concentration against radioligand [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,B,,,,,
1232,8,,BAO_0000019,Expert,,5834,Inhibition of the 5-hydroxytryptamine 1A receptor in rat dorsal raphe,B,,,,,
1233,9,,BAO_0000219,Expert,,2395,Inhibitory concentration against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells,B,,,Rattus norvegicus,10116.0,
1234,8,,BAO_0000019,Autocuration,,1375,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]OH-DPAT radioligand,B,,,,,
1235,8,,BAO_0000019,Autocuration,,1375,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]OH-DPAT radioligand; NT means not tested,B,,,,,
1236,8,,BAO_0000357,Autocuration,,3967,The compound was evaluated for the ability to displace [3H]- 8-OH -DPAT from 5-hydroxytryptamine 1A receptor ( striata of male wistar rats),B,,,,,
1237,8,,BAO_0000357,Expert,,12884,Binding affinity towards 5-hydroxytryptamine 1A receptor binding site using [3H]8-OH-DPAT. ,B,,,,,
1238,8,,BAO_0000357,Expert,,2343,Binding affinity towards 5-hydroxytryptamine 1A receptor using receptor binding assay,B,,,,,
1239,8,,BAO_0000019,Autocuration,,11511,"The compound was tested in vitro for inhibitory activity against 5-HT1A receptor in rats, using [3H]8-OH-DPAT as radioligand",B,,,,,
1240,9,,BAO_0000019,Expert,,11511,"Inhibitory activity against 5-hydroxytryptamine 1A receptor in rats, using [3H]8-OH-DPAT as radioligand",B,,,Rattus norvegicus,10116.0,
1241,8,,BAO_0000218,Autocuration,,16394,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat,F,In vivo,,,,
1242,8,,BAO_0000218,Autocuration,,16394,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.10-6.20),F,In vivo,,,,
1243,8,,BAO_0000218,Autocuration,,16394,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.20-1.60),F,In vivo,,,,
1244,8,,BAO_0000218,Autocuration,,16394,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.20-1.80),F,In vivo,,,,
1245,8,,BAO_0000218,Autocuration,,16394,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.37-4.27),F,In vivo,,,,
1246,8,,BAO_0000218,Autocuration,,16394,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.40-2.70),F,In vivo,,,,
1247,8,,BAO_0000218,Autocuration,,16394,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.40-4),F,In vivo,,,,
1248,8,,BAO_0000218,Autocuration,,16394,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.45-4.51),F,In vivo,,,,
1249,8,,BAO_0000218,Autocuration,,16394,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.50-5.30),F,In vivo,,,,
1250,8,,BAO_0000218,Autocuration,,16394,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.60-1.60),F,In vivo,,,,
1251,8,,BAO_0000218,Autocuration,,16394,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.72-2.87),F,In vivo,,,,
1252,8,,BAO_0000218,Autocuration,,16394,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.80-5.80),F,In vivo,,,,
1253,8,,BAO_0000218,Autocuration,,16394,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (1.50-16.5),F,In vivo,,,,
1254,8,,BAO_0000218,Autocuration,,16394,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (2.20-30.5),F,In vivo,,,,
1255,8,,BAO_0000218,Autocuration,,16394,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges is not computable,F,In vivo,,,,
1256,9,,BAO_0000249,Expert,,16616,"Percent increase of R(+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes",F,,,Rattus norvegicus,10116.0,
1257,8,,BAO_0000019,Autocuration,,16796,% inhibition towards 5-HT1A receptor from rat hippocampal membranes,B,,,,,
1258,8,,BAO_0000019,Autocuration,,16796,% inhibition towards 5-hydroxytryptamine 1A receptor from rat hippocampal membranes,B,,,,,
1259,8,,BAO_0000357,Autocuration,,15629,Tested in vitro for % inhibition against (serotonin)5-HT 1A receptor.,B,,,,,
1260,8,,BAO_0000249,Autocuration,,13241,"Ability to inhibit 5-HT sensitive,forskolin-stimulated adenylyl cyclase(FSC) activity in rat hippocampal membranes mediated through 5-hydroxytryptamine 1A receptor",F,,,,,
1261,8,,BAO_0000221,Expert,10000000.0,12073,Measurement of binding affinity by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,B,,,,,
1262,8,,BAO_0000249,Autocuration,10000000.0,14286,Compound at 10E-5 M was tested in vitro for the inhibition of radioligand [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membrane,B,,,,,
1263,8,,BAO_0000221,Autocuration,955.0,14542,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]-8-OH- -DPAT in rat brain cortex at 10 uM,B,,,,,
1264,8,,BAO_0000019,Autocuration,,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 10 uM 5-HT.,F,,,,,
1265,8,,BAO_0000019,Autocuration,,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0+ 1 uM 5-HT.,F,,,,,
1266,8,,BAO_0000019,Autocuration,,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.01 uM+ 1 uM 5-HT.,F,,,,,
1267,8,,BAO_0000019,Autocuration,,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM,F,,,,,
1268,8,,BAO_0000019,Expert,,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM,F,,,,,
1269,8,,BAO_0000019,Autocuration,,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM+ 1 uM 5-HT.,F,,,,,
1270,9,,BAO_0000019,Expert,,13630,Effect against 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at 0.1 uM dose,F,,,Rattus norvegicus,10116.0,
1271,8,,BAO_0000019,Autocuration,,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 10 uM 5-HT.,F,,,,,
1272,8,,BAO_0000019,Expert,,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 1 uM 5-HT.,F,,,,,
1273,8,,BAO_0000019,Autocuration,,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 0.1 uM 5-HT.,F,,,,,
1274,8,,BAO_0000019,Expert,,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 10 uM,F,,,,,
1275,8,,BAO_0000019,Autocuration,,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 10 uM+ 10 uM 5-HT.,F,,,,,
1276,8,,BAO_0000019,Expert,,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM,F,,,,,
1277,8,,BAO_0000019,Autocuration,,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 0.1 uM 5-HT.,F,,,,,
1278,8,,BAO_0000019,Autocuration,,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 10 uM 5-HT.,F,,,,,
1279,8,,BAO_0000019,Autocuration,,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 1 uM 5-HT.,F,,,,,
1280,8,,BAO_0000019,Expert,,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 3 uM 5-HT.,F,,,,,
1281,8,,BAO_0000019,Expert,,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 50 uM 5-HT.,F,,,,,
1282,8,,BAO_0000019,Autocuration,,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 30 uM,F,,,,,
1283,8,,BAO_0000019,Expert,,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 50 uM,F,,,,,
1284,8,,BAO_0000019,Autocuration,,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 50 uM+ 50 uM 5-HT.,F,,,,,
1285,8,,BAO_0000019,Autocuration,,13630,Effect on 5-hydroxytryptamine 1A receptor-mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM,F,,,,,
1286,8,,BAO_0000019,Autocuration,,13630,Effect on 5-hydroxytryptamine 1A receptor-mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 10 uM 5-HT.,F,,,,,
1287,8,,BAO_0000019,Autocuration,,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM,F,,,,,
1288,8,,BAO_0000221,Autocuration,10000000.0,9783,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue,B,,,,,
1289,8,,BAO_0000221,Expert,10000000.0,9783,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue at 1 uM,B,,,,,
1290,9,,BAO_0000249,Expert,,14331,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membranes at 10e-7 M,B,,,Rattus norvegicus,10116.0,
1291,8,,BAO_0000221,Expert,10000000.0,15260,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue at 1 uM,B,,,,,
1292,8,,BAO_0000221,Autocuration,10000000.0,15260,Inhibitory activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor at 0.1 uM concentration,B,,,,,
1293,8,,BAO_0000221,Autocuration,10000000.0,15260,Inhibitory activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor at 1 uM concentration,B,,,,,
1294,9,,BAO_0000249,Expert,,16616,"Percent inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in hippocampal membranes",F,,,Rattus norvegicus,10116.0,
1295,8,,BAO_0000357,Autocuration,,15629,Tested in vitro for % inhibition against (serotonin)5-HT 1A receptor,B,,,,,
1296,8,,BAO_0000019,Autocuration,,15086,The compound was tested binding affinity against 5-hydroxytryptamine 1A receptor from rat brain using [3H]8-OH-DPAT as radioligand at 10e-6 M.,B,,,,,
1297,8,,BAO_0000019,Expert,,5717,Antagonistic activity against 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]8-OH-DPAT as radioligand.,F,,,,,
1298,8,,BAO_0000357,Autocuration,,12652,Binding affinity against the site labelled by the 5-hydroxytryptamine 1A receptor agonist [3H]- 8-OH-DPAT,B,,,,,
1299,8,,BAO_0000221,Autocuration,10000000.0,14608,In vitro binding affinity for 5-hydroxytryptamine 1A receptor was determined by measuring specific inhibition of [125I]-binding to rat hippocampal membrane preparations,B,,,,,
1300,8,,BAO_0000221,Autocuration,10000000.0,12306,Inhibition of binding of [125I]-8-OH-PIPAT ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,B,,,,,
1301,8,,BAO_0000221,Autocuration,10000000.0,12306,The binding of [125I]MPPI ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,B,,,,,
1302,9,,BAO_0000357,Expert,,15247,Ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,B,,,Rattus norvegicus,10116.0,
1303,8,,BAO_0000221,Expert,10000000.0,17529,Ability to bind to central serotonin 5-hydroxytryptamine 1A receptor in vitro in hippocampus of the rat brain using [3H]8-OH-DPAT radioligand,B,,,,,
1304,8,,BAO_0000221,Autocuration,10000000.0,14826,Ability to displace [3H]- -OH-DPAT bound to 5-hydroxytryptamine 1A receptor in rat hippocampus,B,,,,,
1305,8,,BAO_0000221,Autocuration,10000000.0,14826,Ability to displace [3H]- -(OH)-DPAT bound to 5-hydroxytryptamine 1A receptor in rat hippocampus,B,,,,,
1306,8,,BAO_0000221,Autocuration,10000000.0,13241,Ability to displace [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,B,,,,,
1307,8,,BAO_0000221,Autocuration,10000000.0,14093,Ability to displace [3H]-8-OH-DPAT from rat hippocampal homogenate 5-hydroxytryptamine 1A receptor,B,,,,,
1308,8,,BAO_0000221,Autocuration,10000000.0,14093,Ability to displace [3H]-8-OH-DPAT from rat hippocampal homogenate 5-hydroxytryptamine 1A receptor; Not tested,B,,,,,
1309,8,,BAO_0000221,Autocuration,955.0,14442,Affinity at [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor in rat brain homogenate was determined,B,,,,,
1310,8,,BAO_0000357,Autocuration,,9919,Affinity for 5-hydroxytryptamine 1A receptor site,B,,,,,
1311,8,,BAO_0000357,Autocuration,,9919,Affinity for 5-hydroxytryptamine 1A receptor site,B,,,,,
1312,8,,BAO_0000221,Autocuration,10000000.0,11440,Affinity in displacing [3H]8-OH-DPAT from rat hippocampal 5-HT1A receptor.,B,,,,,
1313,8,,BAO_0000357,Autocuration,,11257,Affinity on 5-hydroxytryptamine 1A receptor labeled by [3H]8-OH-DPAT,B,,,,,
1314,8,,BAO_0000357,Expert,,10330,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand,B,,,,,
1315,9,,BAO_0000221,Expert,10000000.0,17331,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus mambranes,B,,,Rattus norvegicus,10116.0,
1316,8,,BAO_0000249,Expert,,16567,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane,B,,,,,
1317,9,,BAO_0000019,Expert,,12058,"Binding affinity against 5-hydroxytryptamine 1A receptor in homogenated rat brain tissue, using by [3H]8-OH-DPAT as radioligand",B,,,Rattus norvegicus,10116.0,
1318,8,,BAO_0000221,Autocuration,10000000.0,9699,Binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal tissue,B,,,,,
1319,8,,BAO_0000357,Autocuration,,9547,Binding affinity against 5-hydroxytryptamine 1A receptor of rat was determined using [3H]8-OH-DPAT in binding assay,B,,,,,
1320,8,,BAO_0000357,Autocuration,,10330,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]DOB as radioligand,B,,,,,
1321,8,,BAO_0000357,Autocuration,,14331,Binding affinity against rat 5-hydroxytryptamine 1A receptor,B,,,,,
1322,9,,BAO_0000019,Expert,,14060,Binding affinity against rat brain 5-hydroxytryptamine 1A receptor,B,,,Rattus norvegicus,10116.0,
1323,8,,BAO_0000221,Autocuration,10000000.0,14744,Binding affinity against the 5-hydroxytryptamine 1A receptor labelled with [3H]8-OH-DPAT in rat hippocampal homogenates,B,,,,,
1324,8,,BAO_0000357,Autocuration,,13506,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT binding assay,B,,,,,
1325,8,,BAO_0000221,Expert,955.0,10862,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,B,,,,,
1326,8,,BAO_0000221,Expert,955.0,10862,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,B,,,,,
1327,8,,BAO_0000357,Expert,,10062,Binding affinity at rat 5-hydroxytryptamine 1A receptor by [3H]WB-4101 displacement.,B,,,,,
1328,8,,BAO_0000357,Autocuration,,12073,Binding affinity for 5-hydroxytryptamine 1A receptor by use of [3H]8-OH-DPAT in male rat,B,,,,,
1329,8,,BAO_0000357,Autocuration,,14875,GTPgammaS radioligand binding assay,B,,,,,
1330,8,,BAO_0000357,Autocuration,,2391,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Not determined,B,,,,,
1331,8,,BAO_0000019,Autocuration,,2391,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Partial agonist,F,,,,,
1332,8,,BAO_0000019,Autocuration,,2391,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Slient antagonist,F,,,,,
1333,8,,BAO_0000357,Autocuration,,2391,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor,B,,,,,
1334,8,,BAO_0000357,Autocuration,,2391,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Not determined,B,,,,,
1335,8,,BAO_0000019,Autocuration,,2391,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; silent antagonist,F,,,,,
1336,8,,BAO_0000219,Expert,,17211,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor,B,,,,,
1337,8,,BAO_0000219,Autocuration,,17211,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor receptor,B,,,,,
1338,9,,BAO_0000357,Expert,,6491,Affinity towards human 5-hydroxytryptamine 1B serotonin receptor,B,,,Homo sapiens,9606.0,
1339,8,,BAO_0000219,Autocuration,,16190,Binding affinity against 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as radioligand,B,,,,,
1340,8,,BAO_0000019,Autocuration,,14165,Binding affinity for 5-hydroxytryptamine 1B receptor in C6-glial transfected cell type using [3H]5-CT as radioligand,B,,,,,
1341,8,,BAO_0000019,Autocuration,,14165,Binding affinity for 5-hydroxytryptamine 1B receptor in C6-glial transfected cell type using [3H]GR-125743 as radioligand,B,,,,,
1342,9,,BAO_0000357,Expert,,4234,Binding affinity to cloned human 5-hydroxytryptamine 1B receptor,B,,,Homo sapiens,9606.0,
1343,8,,BAO_0000219,Expert,,6328,Binding affinity towards human 5-hydroxytryptamine 1B receptor in L-M(tk-) cells using [3H]GR-125743 as radioligand,B,,,,,
1344,8,,BAO_0000357,Autocuration,,14770,Binding affinity for recombinant human 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,B,,,,,
1345,8,,BAO_0000357,Autocuration,,2598,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1B receptor using [3H]5-CT as radioligand,B,,,,,
1346,8,,BAO_0000357,Expert,,6897,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1B receptor,B,,,,,
1347,8,,BAO_0000357,Autocuration,,6897,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1B receptor,B,,,,,
1348,8,,BAO_0000357,Autocuration,,6013,Binding affinity towards 5-hydroxytryptamine 1B receptor,B,,,,,
1349,8,,BAO_0000357,Expert,,5843,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor,B,,,,,
1350,8,,BAO_0000357,Expert,,14454,Binding affinity towards human 5-hydroxytryptamine 1B receptor using [3H]5-HT trifluoroacetate as radioligand,B,,,,,
1351,8,,BAO_0000357,Autocuration,,16209,Binding affinity towards human 5-hydroxytryptamine 1B receptor using [3H]5-HT radioligand,B,,,,,
1352,8,,BAO_0000357,Autocuration,,3935,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1B receptor,B,,,,,
1353,8,,BAO_0000219,Expert,,13729,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1B receptor in CHO-K1 cells,F,,,,,
1354,8,,BAO_0000019,Expert,,14251,Agonist activity to the human recombinant 5-hydroxytryptamine 1B receptor,F,,,,,
1355,8,,BAO_0000019,Expert,,17085,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1B receptor,B,,,,,
1356,8,,BAO_0000357,Autocuration,,3025,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1B receptor using [3H]5-CT radioligand,B,,,,,
1357,8,,BAO_0000357,Expert,,15315,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1B receptor,B,,,,,
1358,9,,BAO_0000219,Expert,,14214,Receptor binding affinity for cloned human 5-hydroxytryptamine 1B receptor in Cos-7 cells,B,,,Homo sapiens,9606.0,
1359,9,,BAO_0000357,Expert,,3804,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor,B,,,Homo sapiens,9606.0,
1360,9,,BAO_0000357,Expert,,2391,Affinity for 5-hydroxytryptamine 1B receptor subtype,B,,,Homo sapiens,9606.0,
1361,9,,BAO_0000357,Expert,,4175,Binding affinity for human 5-hydroxytryptamine 1B receptor,B,,,Homo sapiens,9606.0,
1362,8,,BAO_0000219,Autocuration,,17296,Binding affinity against cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-CT as radioligand; Not determined,B,,,,,
1363,8,,BAO_0000019,Expert,,17085,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1B receptor; ND means not determined,B,,,,,
1364,8,,BAO_0000219,Autocuration,,17211,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT denotes not tested,B,,,,,
1365,8,,BAO_0000219,Autocuration,,17211,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT=not tested,B,,,,,
1366,8,,BAO_0000219,Autocuration,,17211,Ability to displace [3H]-5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT denotes not tested,B,,,,,
1367,9,,BAO_0000357,Expert,,15926,Binding activity against human 5-hydroxytryptamine 1B receptor; NT means not tested,B,,,Homo sapiens,9606.0,
1368,8,,BAO_0000219,Autocuration,,16312,Binding affinity in CHO-K1 cells transfected with human recombinant 5-hydroxytryptamine 1B receptor; not tested,B,,,,,
1369,8,,BAO_0000357,Expert,,5843,Selectivity ratio against cloned human 5-HT1B receptor to that of h5-HT1D receptor,B,,,,,
1370,8,,BAO_0000357,Autocuration,,5843,Selectivity ratio against cloned human 5-hydroxytryptamine 1B receptor to that of human 5-hydroxytryptamine 1D receptor,B,,,,,
1371,8,,BAO_0000219,Expert,,16312,Binding affinity in CHO-K1 cells transfected with human recombinant 5-hydroxytryptamine 1B receptor,B,,,,,
1372,9,,BAO_0000357,Expert,,15926,Binding activity against human 5-hydroxytryptamine 1B receptor,B,,,Homo sapiens,9606.0,
1373,9,,BAO_0000357,Expert,,15926,Binding activity against human 5-hydroxytryptamine 1B receptor,B,,,Homo sapiens,9606.0,
1374,9,,BAO_0000219,Expert,,4540,Binding affinity to human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as radioligand,B,,,Homo sapiens,9606.0,
1375,8,,BAO_0000357,Autocuration,,6166,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor was determined,B,,,,,
1376,8,,BAO_0000219,Autocuration,,17296,Binding affinity against cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-CT as radioligand,B,,,,,
1377,8,,BAO_0000219,Autocuration,,17296,Binding affinity against human 5-hydroxytryptamine 1B receptor cloned receptors in CHO cells,B,,,,,
1378,8,,BAO_0000219,Autocuration,,17296,Binding affinity against human 5-hydroxytryptamine 1B receptor cloned receptors in CHO cells using [3H]5-CT as radioligand,B,,,,,
1379,8,,BAO_0000219,Autocuration,,15779,Binding affinity towards 5-hydroxytryptamine 1B (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,B,,,,,
1380,8,,BAO_0000219,Autocuration,,15779,Binding affinity towards 5-hydroxytryptamine 1B receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,B,,,,,
1381,8,,BAO_0000219,Autocuration,,15779,Binding affinity towards 5-hydroxytryptamine 1B receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand;ND means no data.,B,,,,,
1382,8,,BAO_0000219,Autocuration,,4199,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as the radioligand,B,,,,,
1383,9,,BAO_0000357,Expert,,14875,Binding affinity for human 5-hydroxytryptamine 1B receptor,B,,,Homo sapiens,9606.0,
1384,8,,BAO_0000219,Autocuration,,15146,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT,B,,,,,
1385,8,,BAO_0000357,Autocuration,,5213,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1B receptor in CHO using [3H]5-HT as a radioligand,B,,,,,
1386,8,,BAO_0000219,Autocuration,,14818,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT,B,,,,,
1387,8,,BAO_0000219,Autocuration,,4829,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1B receptor in CHO cells, using [3H]5-HT as radioligand",B,,,,,
1388,8,,BAO_0000019,Expert,,14454,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1B receptor at concentration 1 uM,F,,,,,
1389,8,,BAO_0000019,Expert,,14454,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1B receptor at concentration 10 uM,F,,,,,
1390,8,,BAO_0000219,Autocuration,,14875,"Effect of compound on [35S]GTP-gamma-S, radioligand binding CHO cells expressing human 5-hydroxytryptamine 1B receptor",F,,,,,
1391,8,,BAO_0000219,Autocuration,,14875,"Effect of compound on [35S]GTP-gamma-S, radioligand binding in CHO cells expressing human 5-hydroxytryptamine 1B receptor",F,,,,,
1392,8,,BAO_0000019,Autocuration,,15250,"Compound was tested for maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by 5-HT.",F,,,,,
1393,8,,BAO_0000219,Autocuration,,15250,Compound was tested for the displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1D receptor stably expressed in CHO cells.,B,,,,,
1394,8,,BAO_0000357,Autocuration,,15086,The compound was tested for binding affinity against 5-hydroxytryptamine 1B receptor,B,,,,,
1395,8,,BAO_0000019,Autocuration,,3025,5-hydroxytryptamine 1B receptor agonist potency determined in rabbit saphenous vein contraction model,F,,,Oryctolagus cuniculus,9986.0,
1396,8,,BAO_0000019,Autocuration,,14998,The vascular 5-hydroxytryptamine 1B receptor affinity was assessed using ring preparations of rabbit saphenous vein (RbSV).,B,,,Oryctolagus cuniculus,9986.0,
1397,8,,BAO_0000019,Intermediate,,14998,"Binding affinity against vascular 5-hydroxytryptamine 1B receptor, measured using ring preparations of rabbit saphenous vein (RbSV)",B,,,Oryctolagus cuniculus,9986.0,
1398,8,,BAO_0000019,Autocuration,,14998,The vascular 5-hydroxytryptamine 1B receptor affinity was assessed using ring preparations of rabbit saphenous vein(RbSV).,B,,,Oryctolagus cuniculus,9986.0,
1399,8,,BAO_0000357,Expert,,13969,Binding affinity towards 5-hydroxytryptamine 1B receptor was measured using [3H]5-HT as radioligand,B,,,,,
1400,9,,BAO_0000357,Intermediate,,13392,Binding affinity for 5-hydroxytryptamine 1B receptor,B,,,,,
1401,9,,BAO_0000019,Expert,2435.0,3651,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatum; Less active,B,,,Rattus norvegicus,10116.0,
1402,8,,BAO_0000357,Expert,,10025,Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol binding to 5-hydroxytryptamine 1B receptor at 1 uM,B,,,,,
1403,8,,BAO_0000357,Autocuration,,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=48-77,B,,,,,
1404,8,,BAO_0000357,Autocuration,,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=63-95,B,,,,,
1405,8,,BAO_0000357,Autocuration,,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=710-980,B,,,,,
1406,8,,BAO_0000357,Autocuration,,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=78-140,B,,,,,
1407,8,,BAO_0000357,Autocuration,,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=85-130,B,,,,,
1408,8,,BAO_0000357,Autocuration,,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=89-280,B,,,,,
1409,8,,BAO_0000249,Autocuration,10000000.0,4622,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat hippocampus membrane.,B,,,,,
1410,8,,BAO_0000019,Intermediate,,14911,Binding affinity at 5-hydroxytryptamine 1A (5-HT1A) receptor in rat cerebral cortex using [3H]8-OH-DPAT as radioligand,B,,,,,
1411,8,,BAO_0000221,Autocuration,10000000.0,12678,In vitro binding affinity to 5-hydroxytryptamine 1A receptor using [125I](R)-(+)-trans-8-OH-PIPAT as radioligand in rat hippocampal homogenate,B,,,,,
1412,8,,BAO_0000221,Expert,10000000.0,12678,In vitro binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampal homogenate by [125I](R)-(+)-trans-8-OH-PIPAT displacement.,B,,,,,
1413,8,,BAO_0000221,Expert,10000000.0,14235,In vitro binding affinity to rat hippocampal 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,B,,,,,
1414,8,,BAO_0000221,Expert,10000000.0,14949,In vitro binding affinity towards 5-hydroxytryptamine 1A r receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates,B,,,,,
1415,8,,BAO_0000221,Expert,10000000.0,14949,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates,B,,,,,
1416,8,,BAO_0000221,Expert,10000000.0,14949,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; ND=not determined,B,,,,,
1417,8,,BAO_0000221,Expert,10000000.0,14949,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; Not determined,B,,,,,
1418,8,,BAO_0000221,Expert,10000000.0,14949,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; not determined,B,,,,,
1419,8,,BAO_0000249,Expert,,16118,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes,B,,,,,
1420,8,,BAO_0000249,Autocuration,,3268,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membranes,B,,,,,
1421,8,,BAO_0000249,Autocuration,,3268,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membranes; Inactive,B,,,,,
1422,8,,BAO_0000357,Expert,,16117,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using radioligand [3H]-8-OH-DPAT,B,,,,,
1423,8,,BAO_0000221,Expert,10000000.0,9783,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue.,B,,,,,
1424,8,,BAO_0000221,Autocuration,10000000.0,9783,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue; NT=Not tested,B,,,,,
1425,9,,BAO_0000221,Expert,10000000.0,14356,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor,B,,,Rattus norvegicus,10116.0,
1426,8,,BAO_0000019,Autocuration,,15740,Inhibition constant of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor,F,,,,,
1427,8,,BAO_0000221,Autocuration,10000000.0,12306,Inhibition of binding of [125I]8-OH-PIPAT ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,B,,,,,
1428,9,,BAO_0000221,Expert,10000000.0,13348,Displacement of [3H]5-HT from rat hippocampal 5-hydroxytryptamine 1A receptor with 10e-6 M ketanserin,B,,,Rattus norvegicus,10116.0,
1429,8,,BAO_0000249,Autocuration,,10394,Inhibitory activity against 5-hydroxytryptamine 1A receptor in rat cortical membranes using [3H]8-OH-DPAT as a radioligand,B,,,,,
1430,8,,BAO_0000221,Autocuration,10000000.0,15260,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue,B,,,,,
1431,8,,BAO_0000221,Expert,10000000.0,10046,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,B,,,,,
1432,8,,BAO_0000221,Intermediate,10000000.0,15260,Antagonist activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor,F,,,,,
1433,8,,BAO_0000357,Autocuration,,12851,Inhibitory affinity constant against 5-hydroxytryptamine 1A receptor,B,,,,,
1434,9,,BAO_0000221,Expert,10000000.0,2148,Displacement of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat brain hippocampus,B,,,Rattus norvegicus,10116.0,
1435,8,,BAO_0000357,Expert,,13134,Affinity against the 5-hydroxytryptamine receptor 1A using [3H]WB-4101.,B,,,,,
1436,8,,BAO_0000019,Autocuration,,12462,Tested for affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in homogenized rat brain,B,,,,,
1437,8,,BAO_0000019,Expert,,12462,Tested for affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in homogenized rat brain tissue,B,,,,,
1438,8,,BAO_0000219,Autocuration,,12462,Tested for affinity against 5-hydroxytryptamine 1A receptors using [3H]8-OH-DPAT in homogenized rat cloned CHO cells,B,,,,,
1439,8,,BAO_0000357,Expert,,11933,Tested for binding affinity against 5-hydroxytryptamine 1A receptor from rat frontal cortical regions using [3H]8-OH-DPAT as radioligand,B,,,,,
1440,8,,BAO_0000357,Autocuration,,11933,Tested for binding affinity against 5-hydroxytryptamine 1A receptor from rat frontal cortical regions using [3H]8-OH-DPAT as radioligand; ND is Not Determined,B,,,,,
1441,9,,BAO_0000221,Expert,10000000.0,403,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor,B,,,Rattus norvegicus,10116.0,
1442,8,,BAO_0000221,Autocuration,10000000.0,15538,Tested for binding affinity by measuring displacement of [3H]8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus,B,,,,,
1443,8,,BAO_0000221,Autocuration,10000000.0,15538,Tested for binding affinity by measuring displacement of [3H]8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus; NA means Not Active,B,,,,,
1444,8,,BAO_0000221,Autocuration,10000000.0,15538,Tested for binding affinity by measuring displacement of [3H]-8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus; ND means Not Determined,B,,,,,
1445,8,,BAO_0000019,Intermediate,,12464,Binding affinity to displace [3H]2-(di-N-propylamino)-8-hydroxy-tetralin from 5-hydroxytryptamine 1A (5-HT1A) receptor in rat frontal cortex homogenates,B,,,,,
1446,8,,BAO_0000357,Expert,,1455,Binding affinity to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand assay.,B,,,,,
1447,8,,BAO_0000357,Autocuration,,12652,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 1A receptor agonist [3H]- 8-OH-DPAT,B,,,,,
1448,8,,BAO_0000221,Autocuration,10000000.0,12639,Tested for the inhibitory activity against 5-hydroxytryptamine 1A receptor in rat hippocampal,B,,,,,
1449,8,,BAO_0000249,Expert,,13949,Tested in vitro for binding affinity by measuring its ability to inhibit [3H]8-OH-DPAT binding at 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes.,B,,,,,
1450,9,,BAO_0000357,Expert,,12463,Tested in vitro for receptor binding affinity against 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT,B,,,Rattus norvegicus,10116.0,
1451,8,,BAO_0000221,Expert,10000000.0,14829,The binding affinity by measuring its ability to displace [3H]8-OH-DPAT radioligand in 5-hydroxytryptamine 1A receptor on rat hippocampal preparation,B,,,,,
1452,8,,BAO_0000221,Autocuration,10000000.0,14829,The binding affinity by measuring its ability to displace [3H]8-OH-DPAT radioligand in 5-hydroxytryptamine 1A receptor on rat hippocampal preparation; ND=not determined,B,,,,,
1453,8,,BAO_0000357,Autocuration,,12092,The binding affinity was measured on 5-hydroxytryptamine 1A receptor using [3H]- 8-OH-DPAT as radioligand.,B,,,,,
1454,8,,BAO_0000249,Autocuration,,403,The compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal membranes using [3H]8-OH-DPAT as radioligand in the presence of 1 mM of MnCl2,B,,,,,
1455,8,,BAO_0000249,Autocuration,,403,The compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal membranes using [3H]8-OH-DPAT as radioligand in the presence of 3*10e-5 M GTP gamma S,B,,,,,
1456,8,,BAO_0000357,Expert,,3967,Binding affinity at 5-hydroxytryptamine 1A receptor from striata of wistar rats by [3H]- 8-OH -DPAT displacement.,B,,,,,
1457,9,,BAO_0000019,Expert,,12771,Binding affinity towards 5-hydroxytryptamine 1A receptor of rat brain synaptosomal preparations,B,,,Rattus norvegicus,10116.0,
1458,8,,BAO_0000019,Autocuration,,15086,The compound was tested binding affinity against 5-hydroxytryptamine 1A receptor from rat brain using [3H]8-OH-DPAT as radioligand at 10e-6 M.,B,,,,,
1459,8,,BAO_0000221,Autocuration,10000000.0,14909,The compound was tested for binding affinity on [3H]8-OH-DPAT as specific ligand on 5-hydroxytryptamine 1A receptor in rat hippocampus,B,,,,,
1460,8,,BAO_0000221,Expert,10000000.0,14949,The compound was tested for binding affinity on [3H]8-OH-DPAT as specific ligand on 5-hydroxytryptamine 1A receptor in rat hippocampus,B,,,,,
1461,9,,BAO_0000221,Expert,10000000.0,2309,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampus using [3H]8-OH-DPAT,B,,,Rattus norvegicus,10116.0,
1462,8,,BAO_0000357,Expert,,4170,Binding affinity towards 5-hydroxytryptamine 1A receptor,B,,,,,
1463,9,,BAO_0000221,Expert,10000000.0,11642,Binding affinity towards 5-hydroxytryptamine 1A receptor by displacing [3H]WB-4101 from rat hippocampus,B,,,Rattus norvegicus,10116.0,
1464,8,,BAO_0000221,Autocuration,10000000.0,11642,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1A receptor by displacing [3H]WB-4101 radioligand in rat hippocampus,B,,,,,
1465,8,,BAO_0000221,Autocuration,10000000.0,12953,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]-8-OH-DPAT as radioligand,B,,,,,
1466,8,,BAO_0000221,Autocuration,10000000.0,12953,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as radioligand.,B,,,,,
1467,8,,BAO_0000221,Expert,10000000.0,12953,Binding affinity for 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as radioligand,B,,,,,
1468,8,,BAO_0000219,Expert,,12903,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1A receptor expressed in CHO cells, by using [3H]8-OH-DPAT as radioligand.",B,,,,,
1469,8,,BAO_0000357,Expert,,12536,Displacement of the radioligand [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,B,,,,,
1470,8,,BAO_0000357,Autocuration,,10058,The inhibition activity of 5-HT1A at 1 uM,B,,,,,
1471,8,,BAO_0000219,Expert,,12902,"Binding affinity against 5-hydroxytryptamine 1A receptor from CHO-K1 cells, using [3H]8-OH-DPAT as the radioligand.",B,,,,,
1472,8,,BAO_0000249,Expert,,14057,Binding affinities against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membrane,B,,,,,
1473,8,,BAO_0000357,Autocuration,,11296,Compound was evaluated for its ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-HT 1A receptor site.,B,,,,,
1474,8,,BAO_0000221,Autocuration,10000000.0,11296,Compound was evaluated for its ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,B,,,,,
1475,8,,BAO_0000221,Expert,10000000.0,11296,Ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,B,,,,,
1476,9,,BAO_0000249,Expert,,16616,Antagonist activity to stimulate binding of [35S]-GTP-gamma S binding to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes,F,,,Rattus norvegicus,10116.0,
1477,9,,BAO_0000249,Expert,10000000.0,16616,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding in rat hippocampal membranes",F,,,Rattus norvegicus,10116.0,
1478,8,,BAO_0000019,Autocuration,,16567,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not -determined.,B,,,,,
1479,8,,BAO_0000019,Autocuration,,16567,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not defined.,B,,,,,
1480,8,,BAO_0000019,Autocuration,,16567,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not determined.,B,,,,,
1481,8,,BAO_0000019,Autocuration,,16567,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND means not determined.,B,,,,,
1482,8,,BAO_0000249,Autocuration,,17136,Binding affinity towards 5-hydroxytryptamine 1A receptor was determined in rat cortex membranes using [3H]8-OH-DPAT as radioligand; No data,B,,,,,
1483,8,,BAO_0000249,Autocuration,,17136,Binding affinity towards 5-hydroxytryptamine 1A receptor was determined in rat cortex membranes using [3H]8-OH-DPAT as radioligand; Not determined,B,,,,,
1484,9,,BAO_0000019,Expert,,16616,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenates; ND means No data,B,,,Rattus norvegicus,10116.0,
1485,8,,BAO_0000221,Autocuration,10000000.0,17331,Binding affinity against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT from rat hippocampus mambranes,B,,,,,
1486,8,,BAO_0000221,Autocuration,10000000.0,17331,Binding affinity against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT from rat hippocampus mambranes; Not tested,B,,,,,
1487,9,,BAO_0000221,Expert,10000000.0,17167,Binding affinity for rat hippocampus 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding; Not tested,B,,,Rattus norvegicus,10116.0,
1488,8,,BAO_0000019,Autocuration,,15740,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; Not tested,F,,,,,
1489,8,,BAO_0000019,Autocuration,,15740,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; not tested,F,,,,,
1490,8,,BAO_0000357,Autocuration,,4671,Ratio of binding affinity to 5-HT 1A and D2 receptor,B,,,,,
1491,8,,BAO_0000221,Autocuration,10000000.0,10058,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus at 1 uM,B,,,,,
1492,8,,BAO_0000221,Autocuration,10000000.0,10058,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus at 1 uM,B,,,,,
1493,8,,BAO_0000221,Autocuration,10000000.0,10058,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus.,B,,,,,
1494,8,,BAO_0000357,Autocuration,,12073,Percentage inhibition against 5-hydroxytryptamine 1A receptor,B,,,,,
1495,8,,BAO_0000249,Autocuration,,2759,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 1),B,,,,,
1496,8,,BAO_0000249,Autocuration,,2759,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 1),F,,,,,
1497,8,,BAO_0000249,Autocuration,,2759,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 2),B,,,,,
1498,8,,BAO_0000249,Autocuration,,2759,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 2),F,,,,,
1499,8,,BAO_0000249,Autocuration,,2759,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes.,F,,,,,
1500,8,,BAO_0000249,Autocuration,955.0,9737,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,B,,,,,
1501,8,,BAO_0000019,Autocuration,,9737,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex using [3H]8-OH-DPAT as a radioligand,B,,,,,
1502,8,,BAO_0000019,Expert,,5717,Antagonistic activity against 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]-8-OH-DPAT as radioligand.,F,,,,,
1503,8,,BAO_0000221,Autocuration,10000000.0,12253,Binding affinity of 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,B,,,,,
1504,8,,BAO_0000019,Autocuration,,14025,Affinity pKi for 5-hydroxytryptamine 1A receptor was measured in rat cortex homogenates.,B,,,,,
1505,8,,BAO_0000249,Expert,,10425,Binding affinity against 5-hydroxytryptamine 1A receptor in rat cerebral cortical membrane using [3H]-8-OH-DPAT as radioligand.,B,,,,,
1506,8,,BAO_0000019,Autocuration,,14998,Binding affinity against 5-hydroxytryptamine 1A receptor in rat cortex homogenates.,B,,,,,
1507,8,,BAO_0000221,Autocuration,10000000.0,13694,Binding affinity against native 5-HT1A-receptors from rat hippocampus using radioligand ([3H]- 8-hydri\oxy-2-(di-n-propylamino)tetraline) binding assay,B,,,,,
1508,8,,BAO_0000221,Autocuration,10000000.0,13694,Binding affinity against native 5-HT1A-receptors from rat hippocampus using radioligand ([3H]8-hydroxy-2-(di-n-propylamino)-tetraline) binding assay,B,,,,,
1509,8,,BAO_0000357,Autocuration,,4342,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined,B,,,,,
1510,9,,BAO_0000357,Expert,,12936,Binding affinity against rat 5-hydroxytryptamine 1A receptor,B,,,Rattus norvegicus,10116.0,
1511,9,,BAO_0000019,Expert,,13144,Inhibition of [3H]2-(di-N-propylamino)-8-hydroxytetralin binding to 5-HT1A receptor of rat frontal cortex homogenates,B,,,Rattus norvegicus,10116.0,
1512,8,,BAO_0000019,Expert,,13343,Binding affinity of a compound to rat brain 5-hydroxytryptamine 1A (serotonin) receptor assayed by radiolabeled [3H]-8-OH-DPAT ligand displacement,B,,,,,
1513,8,,BAO_0000357,Expert,,12132,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,B,,,,,
1514,8,,BAO_0000019,Expert,,15419,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cortex using [3H]8-OH-DPAT as a radioligand,B,,,,,
1515,8,,BAO_0000221,Autocuration,10000000.0,1479,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,B,,,,,
1516,8,,BAO_0000019,Expert,,14287,In vitro by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor on rat cortical membrane,B,,,,,
1517,8,,BAO_0000357,Expert,,13116,Binding affinity at 5-hydroxytryptamine 1A receptor,B,,,,,
1518,9,,BAO_0000249,Expert,,2759,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat frontal cortex membranes,B,,,Rattus norvegicus,10116.0,
1519,8,,BAO_0000249,Autocuration,,2759,Compound was tested for inhibition constant against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes.,B,,,,,
1520,8,,BAO_0000019,Expert,,14748,"Binding affinity for rat cortex 5-hydroxytryptamine 1A receptor, by displacement of 0.2 nM [3H]8-OH-DPAT radioligand",B,,,,,
1521,8,,BAO_0000019,Autocuration,,12304,In vitro ability to inhibit binding of radioligand [3H]8-OH-DPAT to 5-hydroxytryptamine 1A receptor in rat cerebral cortex,B,,,,,
1522,9,,BAO_0000221,Expert,10000000.0,12409,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]8-OH-DPAT,B,,,Rattus norvegicus,10116.0,
1523,9,,BAO_0000221,Expert,10000000.0,12409,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus with [3H]8-OH-DPAT,B,,,Rattus norvegicus,10116.0,
1524,8,,BAO_0000221,Autocuration,10000000.0,13267,The binding affinity (pKi) was measured against 5-hydroxytryptamine 4 receptor of piglet hippocampus using [125I]-SB 207710 as radioligand,B,,,,,
1525,8,,BAO_0000357,Autocuration,,15194,The compound was tested for the binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,B,,,,,
1526,8,,BAO_0000357,Expert,,14256,pKi value against rat 5-hydroxytryptamine 1A receptor.,B,,,,,
1527,8,,BAO_0000019,Autocuration,,16567,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is define as non-determined.,B,,,,,
1528,8,,BAO_0000019,Autocuration,,15740,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; Not tested,F,,,,,
1529,9,,BAO_0000357,Expert,,13278,Binding affinity was measured against 5-hydroxytryptamine 2A receptor by displacement of [3H]- ketanserin by lysergic acid amides,B,,,Rattus norvegicus,10116.0,
1530,8,,BAO_0000249,Expert,,1970,Inhibition of specific [3H]OH-DPAT binding at 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,B,,,,,
1531,8,,BAO_0000221,Autocuration,955.0,10034,Concentration of compound required to inhibit cortical 5-hydroxytryptamine 1A receptor binding sites in rat brain was evaluated,B,,,,,
1532,8,,BAO_0000019,Autocuration,,13348,Inhibitory activity against 5-hydroxytryptamine 1A receptor isolated from rat hippocampus membranes membrane using [3H]5-HT as radioligand in the presence of 10e-6 M ketanserin as 5-HT2 blocker,B,,,Rattus norvegicus,10116.0,
1533,8,,BAO_0000019,Autocuration,,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 50 uM 5-HT.,F,,,,,
1534,8,,BAO_0000221,Autocuration,955.0,10862,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,B,,,,,
1535,8,,BAO_0000019,Autocuration,,12058,"Binding affinity against 5-hydroxytryptamine 1A receptor in homogenated rat brain tissue, using by [3H]8-OH-DPAT as radioligand",B,,,,,
1536,8,,BAO_0000357,Autocuration,,4639,Compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor,B,,,,,
1537,8,,BAO_0000357,Expert,,15453,Percent decrease in 5-hydroxytryptamine 1A receptor binding using 8-OH-DPAT,B,,,,,
1538,8,,BAO_0000357,Expert,,4820,Binding affinity towards 5-hydroxytryptamine 1A receptor,B,,,,,
1539,8,,BAO_0000357,Autocuration,,1089,Tested for binding affinity for 5-hydroxytryptamine 1A receptor,B,,,,,
1540,8,,BAO_0000249,Autocuration,,386,The compound was evaluated for its ability to displace [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in cellular brain membranes,B,,,,,
1541,8,,BAO_0000357,Autocuration,,6011,Inhibition of binding towards 5-hydroxytryptamine 1A receptor at 100 nM concentration,B,,,,,
1542,8,,BAO_0000357,Autocuration,,5014,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1A receptor,B,,,,,
1543,8,,BAO_0000357,Expert,,4402,Binding affinity for 5-hydroxytryptamine 1A receptor determined using [3H]8-OH-DPAT as radioligand,B,,,,,
1544,8,,BAO_0000357,Expert,,17066,Binding affinity towards 5-hydroxytryptamine 1A receptor,B,,,,,
1545,8,,BAO_0000357,Autocuration,,17515,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1A receptor; inactive at 10 uM,B,,,,,
1546,8,,BAO_0000357,Autocuration,,2474,Binding affinity against 5-hydroxytryptamine 1A receptor,B,,,,,
1547,8,,BAO_0000357,Autocuration,,4775,Binding affinity to 5-hydroxytryptamine 1A receptor was determined,B,,,,,
1548,9,,BAO_0000357,Expert,,14294,Binding affinity towards Serotonin 5-hydroxytryptamine 1A receptor by displacement of [3H]-(+)-8-OH-DPAT.,B,,,Homo sapiens,9606.0,
1549,9,,BAO_0000357,Expert,,14294,Binding affinity towards Serotonin 5-hydroxytryptamine 1A receptor by displacement of [3H](+)-8-OH-DPAT; inactive,B,,,Homo sapiens,9606.0,
1550,8,,BAO_0000219,Autocuration,,12249,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,B,,,,,
1551,8,,BAO_0000219,Expert,,11376,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor expressed in CHO cell membranes,B,,,,,
1552,8,,BAO_0000218,Autocuration,,2474,Compound was measured in vivo for its binding affinity at 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,B,In vivo,,,,
1553,8,,BAO_0000221,Autocuration,10000000.0,13311,Tested for activity against 5-hydroxytryptamine 1A receptor from bovine hippocampus,B,,,,,
1554,8,,BAO_0000357,Autocuration,,4373,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1A receptor was determined,B,,,,,
1555,8,,BAO_0000357,Expert,,1633,Binding affinity towards 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT.,B,,,,,
1556,8,,BAO_0000357,Autocuration,,11866,Binding affinity for 5-hydroxytryptamine 1A receptor was determined,B,,,,,
1557,8,,BAO_0000357,Autocuration,,4373,Binding affinity for 5-hydroxytryptamine 1A receptor was determined,B,,,,,
1558,8,,BAO_0000357,Autocuration,,4687,Evaluated for the binding affinity to 5-hydroxytryptamine 1A receptor,B,,,,,
1559,8,,BAO_0000357,Autocuration,,16946,Ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,B,,,,,
1560,8,,BAO_0000357,Autocuration,,13291,Binding affinity against 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT radioligand,B,,,,,
1561,8,,BAO_0000357,Autocuration,,14159,Compound was evaluated for the affinity at 5-hydroxytryptamine 1A receptor,B,,,,,
1562,8,,BAO_0000357,Autocuration,,10812,Compound was tested for the binding affinity against 5-hydroxytryptamine 1A receptor by using [3H]DPAT as radioligand,B,,,,,
1563,9,,BAO_0000219,Expert,,3032,In vitro binding affinity against 5-hydroxytryptamine 1A receptor in CHO cells,B,,,Mus musculus,10090.0,
1564,8,,BAO_0000357,Autocuration,,16655,Inhibition of 5-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,B,,,,,
1565,8,,BAO_0000357,Autocuration,,14532,Inhibitory activity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand at 10e-5 M concentration,B,,,,,
1566,8,,BAO_0000357,Autocuration,,13944,Binding affinity against 5-hydroxytryptamine 1A receptor,B,,,,,
1567,8,,BAO_0000357,Autocuration,,13033,Binding affinity against serotonergic 5-HT1a receptor,B,,,,,
1568,8,,BAO_0000357,Autocuration,,10321,Binding affinity for 5-hydroxytryptamine 1A receptor was determined by using [3H]8-OH-DPAT as radioligand,B,,,,,
1569,9,,BAO_0000357,Expert,,2968,Binding affinity for 5-hydroxytryptamine 1A receptor,B,,,Mus musculus,10090.0,
1570,8,,BAO_0000357,Autocuration,,13964,Binding affinity at 5-hydroxytryptamine 1A receptor,B,,,,,
1571,8,,BAO_0000357,Autocuration,,15527,"Binding affinity towards 5-hydroxytryptamine 1A receptor receptor, using [3H]5-HT as radioligand.",B,,,,,
1572,8,,BAO_0000219,Autocuration,,12248,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,B,,,,,
1573,8,,BAO_0000219,Autocuration,,12249,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,B,,,,,
1574,8,,BAO_0000357,Autocuration,,15120,Compound was tested for binding affinity using [3H]8-OH-DPAT against 5-hydroxytryptamine 1A receptor,B,,,,,
1575,8,,BAO_0000357,Autocuration,,13313,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by using [3H]-8-OH-DPAT as radioligand,B,,,,,
1576,8,,BAO_0000218,Autocuration,,2613,In vivo binding affinity was evaluated against 5-hydroxytryptamine 1A receptor,B,,,,,
1577,8,,BAO_0000357,Autocuration,,16700,The binding affinity towards 5-hydroxytryptamine 1A receptor; No affinity,B,,,,,
1578,8,,BAO_0000357,Autocuration,,2201,Ability to displace [125I]iodosulpiride from 5-hydroxytryptamine 1A receptor,B,,,,,
1579,9,,BAO_0000357,Expert,,1274,Binding affinity against 5-hydroxytryptamine 1A receptor,B,,,Mus musculus,10090.0,
1580,8,,BAO_0000357,Autocuration,,1317,Compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor using radioligand binding assay,B,,,,,
1581,8,,BAO_0000357,Autocuration,,12146,Tested against 5-hydroxytryptamine 1A receptor,B,,,,,
1582,8,,BAO_0000357,Autocuration,,14059,The compound's binding affinity against 5-hydroxytryptamine 1A receptor,B,,,,,
1583,8,,BAO_0000019,Expert,,14025,Dissociation equilibrium constant against the vascular 5-hydroxytryptamine 1B like receptor in the rabbit saphenous vein,B,,,Oryctolagus cuniculus,9986.0,
1584,8,,BAO_0000019,Autocuration,,14025,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 1B like receptor in the rabbit saphenous vein(RbSV); NS=non surmountable,B,,,Oryctolagus cuniculus,9986.0,
1585,9,,BAO_0000219,Intermediate,,14447,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1B receptor from cloned gorilla membranes expressed in cultured HEK 293 cells,B,,,Gorilla gorilla,9593.0,
1586,8,,BAO_0000218,Autocuration,,3025,5-HT1B agonist potency was evaluated as effective dose that induced hypothermia in the guinea-pig upon intraperitoneal administration,F,In vivo,,Cavia porcellus,10141.0,
1587,8,,BAO_0000218,Autocuration,,3025,5-hydroxytryptamine 1B receptor agonist potency was evaluated as effective dose that induced hypothermia in the guinea-pig upon intraperitoneal administration,F,In vivo,,Cavia porcellus,10141.0,
1588,8,,BAO_0000019,Autocuration,,15329,Affinity of compound towards 5-hydroxytryptamine 1B receptor in isolated guinea-pig iliac artery,F,,,Cavia porcellus,10141.0,
1589,8,,BAO_0000019,Autocuration,,15329,Affinity of compound towards 5-hydroxytryptamine 1B receptor in isolated guinea-pig iliac artery; n.d. indicates Not determined,F,,,Cavia porcellus,10141.0,
1590,8,,BAO_0000019,Autocuration,,15847,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 1B receptor of guinea pig,F,,,Cavia porcellus,10141.0,
1591,8,,BAO_0000019,Autocuration,,15847,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 1B receptor of guinea pig; ND means not done,F,,,Cavia porcellus,10141.0,
1592,8,,BAO_0000019,Autocuration,,14165,Intrinsic activity for Antagonism of 5-hydroxytryptamine 1B receptor-mediated stimulation of [35S]GTP gamma S binding,F,,,,,
1593,8,,BAO_0000019,Autocuration,,14214,Antagonism tested at 1 uM against the agonist-induced inhibitory effect of 10 nM 5-carbamoyltryptamine (5-CT),F,,,,,
1594,8,,BAO_0000019,Autocuration,,14214,Antagonism tested at 1 uM against the agonist-induced inhibitory effect of 10 nM 5-carbamoyltryptamine(5-CT),F,,,,,
1595,9,,BAO_0000019,Expert,,14214,Agonist activity at 5-hydroxytryptamine 1B receptor by measuring the inhibition of forskolin-stimulated cAMP formation,F,,,Homo sapiens,9606.0,
1596,9,,BAO_0000219,Expert,,13729,Inhibition of forskolin-stimulated c-AMP formation by human 5-hydroxytryptamine 1B receptor expressed in CHO-K1 cells,F,,,Homo sapiens,9606.0,
1597,8,,BAO_0000219,Autocuration,,3025,Effective concentration determined by measuring inhibition of forskolin-stimulated c-AMP formation at 5-hydroxytryptamine 1B receptor stably transfected in CHO cell lines,F,,,,,
1598,8,,BAO_0000357,Autocuration,,2391,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor,B,,,,,
1599,8,,BAO_0000019,Autocuration,,2391,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; full agonist,F,,,,,
1600,8,,BAO_0000219,Expert,,14956,"Agonist-induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with human 5-hydroxytryptamine 1B receptor",F,,,,,
1601,8,,BAO_0000219,Autocuration,,2598,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line,F,,,,,
1602,8,,BAO_0000219,Autocuration,,2598,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Antagonist,F,,,,,
1603,8,,BAO_0000219,Autocuration,,2598,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Full Agonist,F,,,,,
1604,8,,BAO_0000219,Autocuration,,2598,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Partial Agonist,F,,,,,
1605,8,,BAO_0000019,Expert,,14956,"Efficacy was evaluated relative to human 5-HT1B receptor using [35S]GTP-gamma-S, as radioligand",F,,,,,
1606,8,,BAO_0000019,Autocuration,,14956,"Efficacy of compound was evaluated relative to human 5-hydroxytryptamine 1B receptor using [35S]GTP-gamma-S, as radioligand",F,,,,,
1607,9,,BAO_0000357,Expert,,14214,Percentage Maximal inhibition obtained with 1 uM 5-HT against 5-hydroxytryptamine 1B receptor,B,,,Homo sapiens,9606.0,
1608,8,,BAO_0000219,Expert,,3463,Ability to displace [3H]5-HT from recombinant human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells determined in vitro,B,,,,,
1609,8,,BAO_0000357,Autocuration,,15331,Affinity of compound towards 5-hydroxytryptamine 1B receptor was evaluated using radioligand binding technique,B,,,,,
1610,9,,BAO_0000357,Expert,,16146,Binding affinity against 5-hydroxytryptamine 1B receptor,B,,,Homo sapiens,9606.0,
1611,9,,BAO_0000219,Expert,,14159,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1B receptor expressed in CHO cells,B,,,Homo sapiens,9606.0,
1612,8,,BAO_0000219,Expert,,14158,Binding affinity to human cloned 5-hydroxytryptamine 1B receptor in CHO cells by [3H]5-HT binding displacement.,B,,,,,
1613,8,,BAO_0000357,Autocuration,,14159,Compound was evaluated for the affinity at 5-hydroxytryptamine 1B receptor,B,,,,,
1614,8,,BAO_0000219,Expert,,15250,Displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1B receptor stably expressed in CHO cells,B,,,,,
1615,8,,BAO_0000219,Expert,,15250,Binding affinity at cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells by [3H]5-HT displacement.,B,,,,,
1616,8,,BAO_0000219,Expert,,15331,Displacement of [3H]5-HT binding from the cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells,B,,,,,
1617,8,,BAO_0000219,Expert,,15332,Displacement of [3H]5-HT binding from cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells.,B,,,,,
1618,8,,BAO_0000219,Expert,,14956,Displacement of specific [3H]5-HT binding to cloned human 5-hydroxytryptamine 1B receptor expressed in CHO cells,B,,,,,
1619,8,,BAO_0000357,Autocuration,,3805,In vitro binding affinity against human 5-hydroxytryptamine 1B receptor at a concentration of 100 (nM),B,,,,,
1620,8,,BAO_0000357,Autocuration,,14875,Intrinsic activity for each compound is calculated as a percentage of the 5-hydroxytryptamine 1B receptor response,B,,,,,
1621,8,,BAO_0000019,Autocuration,,14454,Compound was tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),F,,,Oryctolagus cuniculus,9986.0,
1622,8,,BAO_0000019,Expert,,14454,Tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),F,,,Oryctolagus cuniculus,9986.0,
1623,8,,BAO_0000357,Autocuration,,16288,Affinity at 5-hydroxytryptamine 1D receptor (For sumatriptan = Ki (nM)-12+/-1.9),B,,,,,
1624,8,,BAO_0000357,Autocuration,,16288,Affinity at 5-hydroxytryptamine 1D receptor from calf caudate using [3H]5-HT as radioligand (For sumatriptan = Ki(nM)-12+/-1.9),B,,,,,
1625,8,,BAO_0000357,Autocuration,,16312,Binding affinity against calf caudate 5-hydroxytryptamine 1D receptor,B,,,,,
1626,8,,BAO_0000357,Expert,,1348,Inhibitory activity against 5-hydroxytryptamine 1D receptor subtype,B,,,Bos taurus,9913.0,
1627,8,,BAO_0000357,Autocuration,,5834,Inhibitory concentration required against 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT,B,,,Bos taurus,9913.0,
1628,8,,BAO_0000019,Autocuration,2435.0,13366,Binding affinity towards 5-hydroxytryptamine 1D receptor was determined in calf striatum homogenate,B,,,Bos taurus,9913.0,
1629,8,,BAO_0000357,Expert,,1414,Ability to bind to 5-hydroxytryptamine 1D receptor of calf substantia nigra,B,,,Bos taurus,9913.0,
1630,8,,BAO_0000019,Autocuration,,14998,Binding affinity against 5-hydroxytryptamine 1D receptor in calf caudate homogenates.,B,,,Bos taurus,9913.0,
1631,8,,BAO_0000357,Autocuration,,11473,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]- serotonin as radioligand,B,,,Bos taurus,9913.0,
1632,8,,BAO_0000357,Autocuration,,11473,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]- serotonin as radioligand,B,,,Bos taurus,9913.0,
1633,8,,BAO_0000357,Autocuration,,10639,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 1D receptor of bovine caudate using [3H]5-HT as the radioligand,B,,,Bos taurus,9913.0,
1634,8,,BAO_0000357,Autocuration,,10639,Inhibitory activity against 5-hydroxytryptamine 1D receptor of bovine caudate using [3H]5-HT as the radioligand,B,,,Bos taurus,9913.0,
1635,8,,BAO_0000357,Autocuration,,1375,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT radioligand,B,,,Bos taurus,9913.0,
1636,8,,BAO_0000357,Autocuration,,1375,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT radioligand; NT means not tested,B,,,Bos taurus,9913.0,
1637,8,,BAO_0000357,Autocuration,,16532,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT; Not tested,B,,,Bos taurus,9913.0,
1638,8,,BAO_0000357,Autocuration,,11147,Binding affinity towards 5-hydroxytryptamine 1D receptor using [3H]5-HT as radioligand,B,,,Bos taurus,9913.0,
1639,8,,BAO_0000019,Autocuration,2435.0,13366,Binding affinity towards 5-hydroxytryptamine 1D receptor was determined in calf striatum homogenate,B,,,Bos taurus,9913.0,
1640,8,,BAO_0000019,Autocuration,,10444,Binding affinity was determined against 5-hydroxytryptamine 1D receptor in bovine caudate homogenate,B,,,Bos taurus,9913.0,
1641,8,,BAO_0000357,Autocuration,,16532,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT,B,,,Bos taurus,9913.0,
1642,8,,BAO_0000357,Autocuration,,16532,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT; Not tested,B,,,Bos taurus,9913.0,
1643,8,,BAO_0000249,Autocuration,,12827,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex membranes using [125]ICYP,B,,,Bos taurus,9913.0,
1644,8,,BAO_0000249,Autocuration,,12827,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex membranes using [125]ICYP; Not determined,B,,,Bos taurus,9913.0,
1645,8,,BAO_0000019,Expert,,12919,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,F,,,Bos taurus,9913.0,
1646,8,,BAO_0000019,Autocuration,,14025,Affinity pKi for 5-hydroxytryptamine 1D receptor was measured in calf caudate homogenate,B,,,Bos taurus,9913.0,
1647,8,,BAO_0000019,Expert,,12919,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,F,,,Bos taurus,9913.0,
1648,8,,BAO_0000019,Expert,,12919,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,F,,,Bos taurus,9913.0,
1649,8,,BAO_0000019,Expert,,12919,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,F,,,Bos taurus,9913.0,
1650,8,,BAO_0000219,Autocuration,,14447,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1D receptor from cloned gorilla membranes expressed in cultured HEK 293 cells,B,,,Gorilla gorilla,9593.0,
1651,9,,BAO_0000019,Intermediate,,1375,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor in guinea pig substantia nigra,B,,,Cavia porcellus,10141.0,
1652,9,,BAO_0000019,Intermediate,,1375,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor in guinea pig substantia nigra; NT means not tested,B,,,Cavia porcellus,10141.0,
1653,9,,BAO_0000019,Intermediate,,12409,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptor by the agonist GR-46611,F,,,Cavia porcellus,10141.0,
1654,9,,BAO_0000019,Intermediate,,12409,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,F,,,Cavia porcellus,10141.0,
1655,9,,BAO_0000019,Intermediate,,12409,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611; range is 2-9,F,,,Cavia porcellus,10141.0,
1656,9,,BAO_0000019,Intermediate,,12409,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611;range is 0.2-0.4,F,,,Cavia porcellus,10141.0,
1657,9,,BAO_0000019,Intermediate,,12409,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611;range is 0.2-1.2,F,,,Cavia porcellus,10141.0,
1658,9,,BAO_0000357,Intermediate,,11574,Binding affinity against 5-hydroxytryptamine 1D receptor,B,,,Cavia porcellus,10141.0,
1659,9,,BAO_0000357,Intermediate,,1558,Binding affinity towards guinea pig 5-hydroxytryptamine 1D receptor was determined,B,,,Cavia porcellus,10141.0,
1660,9,,BAO_0000218,Intermediate,,12409,Compound at 3 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,F,,,Cavia porcellus,10141.0,
1661,9,,BAO_0000218,Intermediate,,12409,Compound at 45 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,F,,,Cavia porcellus,10141.0,
1662,9,,BAO_0000218,Intermediate,,12409,Compound at 50 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,F,,,Cavia porcellus,10141.0,
1663,9,,BAO_0000218,Intermediate,,12409,Compound at oral dose of 45 mg/kg was tested for percent inhibition against 5-hydroxytryptamine 1D receptor causes hypothermia in guinea pig,F,,,Cavia porcellus,10141.0,
1664,9,,BAO_0000019,Intermediate,,12253,Binding affinity of 5-hydroxytryptamine 1D receptor using [3H]-8-HT in guinea pig cortex,B,,,Cavia porcellus,10141.0,
1665,9,,BAO_0000357,Intermediate,,12936,Binding affinity against guinea pig 5-hydroxytryptamine 1D receptor,B,,,Cavia porcellus,10141.0,
1666,8,,BAO_0000019,Autocuration,,13181,Binding affinity was determined against 5-hydroxytryptamine 4 receptor using [125I]SB 207710 as radioligand from piglet hippocampal membranes,B,,,Cavia porcellus,10141.0,
1667,9,,BAO_0000357,Intermediate,2435.0,12409,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor in guinea-pig striatum in presence of BMY-7378 and mesulergine,B,,,Cavia porcellus,10141.0,
1668,9,,BAO_0000357,Intermediate,,10639,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1D receptor of guinea pig substantia nigra,B,,,Cavia porcellus,10141.0,
1669,8,,BAO_0000357,Autocuration,,5254,Binding affinity against 5-hydroxytryptamine 1D receptor,B,,,,,
1670,8,,BAO_0000357,Autocuration,,13051,The compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor beta,B,,,,,
1671,8,,BAO_0000019,Expert,,3463,Maximum stimulation of [35S]GTP gamma-S binding expressed relative to the maximal effect produced by 5-hydroxytryptamine 1D receptor,F,,,,,
1672,8,,BAO_0000019,Autocuration,,15315,Ability to inhibit forskolin-stimulated adenylate cyclase in a cell line expressing human 5-hydroxytryptamine 1D receptor,F,,,,,
1673,8,,BAO_0000019,Autocuration,,6011,Ability to inhibit forskolin-stimulated adenylate cyclase activity in Chinese hamster ovary (CHO) stable cell lines expressing human 5-hydroxytryptamine 1D receptor,F,,,,,
1674,9,,BAO_0000219,Expert,,14159,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing 5-hydroxytryptamine 1D receptor",F,,,Homo sapiens,9606.0,
1675,8,,BAO_0000219,Autocuration,,14159,"Compound was evaluated for the stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor.",F,,,,,
1676,8,,BAO_0000219,Expert,,15250,Agonist-induced [35S]- GTPgammaS binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor,B,,,,,
1677,8,,BAO_0000219,Autocuration,,15250,Compound was tested for measuring agonist-induced [35S]- GTPgammaS binding in CHO cells stably transfected with human 5-hydroxytryptamine 1D receptor,B,,,,,
1678,8,,BAO_0000219,Expert,,15331,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor",F,,,,,
1679,9,,BAO_0000219,Expert,,15332,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor",F,,,Homo sapiens,9606.0,
1680,8,,BAO_0000219,Expert,,15332,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the human 5-hydroxytryptamine 1D receptor.",F,,,,,
1681,8,,BAO_0000219,Autocuration,,3294,"Measurement of agonist induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor",F,,,,,
1682,8,,BAO_0000219,Expert,,14158,"Measurement of agonist induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor.",F,,,,,
1683,8,,BAO_0000219,Expert,,14956,"Agonist-induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with human 5-hydroxytryptamine 1D receptor",F,,,,,
1684,8,,BAO_0000019,Autocuration,,12469,Compound was evaluated for its agonistic activity on 5-hydroxytryptamine 1D receptor,F,,,,,
1685,8,,BAO_0000219,Expert,,3463,Measurement of agonist-induced [35S]-GTP gamma-S binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor,F,,,,,
1686,9,,BAO_0000219,Expert,,15250,"Maximum stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing human 5-HT-1d relative to 5-HT",F,,,Homo sapiens,9606.0,
1687,9,,BAO_0000219,Expert,,15250,"Maximum stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing human 5-HT-1d relative to 5-HT",F,,,Homo sapiens,9606.0,
1688,8,,BAO_0000019,Expert,,14956,"Efficacy was evaluated relative to human 5-hydroxytryptamine 1D receptor using [35S]GTP-gamma-S, as radioligand",F,,,,,
1689,8,,BAO_0000019,Autocuration,,14159,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by 5-hydroxytryptamine 1D receptor.",F,,,,,
1690,9,,BAO_0000019,Expert,,14159,"Maximum stimulation of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1D receptor relative to 5-HT",F,,,Homo sapiens,9606.0,
1691,9,,BAO_0000219,Expert,,14499,Percent efficacy relative to 5-HT treatment of CHO cells expressing 5-HT 1d receptor,F,,,Homo sapiens,9606.0,
1692,8,,BAO_0000019,Autocuration,,15315,Intrinsic activity for 5-hydroxytryptamine 1D receptor,F,,,,,
1693,8,,BAO_0000219,Autocuration,,3294,Ability to displace [3H]- -5-HT binding to cloned 5-hydroxytryptamine 1D receptor stably expressed in chinese hamster cells (CHO cells),B,In vitro,,,,
1694,8,,BAO_0000219,Expert,,3463,Ability to displace [3H]-5-HT from recombinant human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells determined in vitro,B,,,,,
1695,8,,BAO_0000357,Autocuration,,15331,Affinity of compound towards 5-hydroxytryptamine 1D receptor was evaluated using radioligand binding technique,B,,,,,
1696,9,,BAO_0000219,Expert,,14159,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,B,,,Homo sapiens,9606.0,
1697,8,,BAO_0000219,Expert,,14158,Binding affinity by displacement to human cloned 5-hydroxytryptamine 1D receptor in CHO cells by [3H]5-HT displacement.,B,,,,,
1698,8,,BAO_0000357,Autocuration,,14159,Compound was evaluated for the affinity at 5-hydroxytryptamine 1D receptor,B,,,,,
1699,8,,BAO_0000219,Expert,,15250,Binding affinity at human cloned 5-hydroxytryptamine 1D receptor stably expressed in CHO cells by [3H]5-HT displacement.,B,,,,,
1700,8,,BAO_0000219,Expert,,15250,Displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,B,,,,,
1701,8,,BAO_0000219,Expert,,15331,Displacement of [3H]5-HT binding from the cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,B,,,,,
1702,9,,BAO_0000219,Expert,,15332,Displacement of [3H]5-HT binding from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,B,,,Homo sapiens,9606.0,
1703,9,,BAO_0000219,Expert,,14499,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,B,,,Homo sapiens,9606.0,
1704,8,,BAO_0000219,Expert,,15332,Displacement of [3H]5-HT binding to the cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,B,,,,,
1705,8,,BAO_0000219,Expert,,14956,Displacement of specific [3H]5-HT binding to cloned human 5-hydroxytryptamine 1D receptor expressed in CHO cells,B,,,,,
1706,8,,BAO_0000357,Autocuration,,3805,In vitro binding affinity against human 5-hydroxytryptamine 1D receptor at a concentration of 100 (nM),B,,,,,
1707,9,,BAO_0000219,Expert,,6011,Inhibition of [3H]5-HT binding to human 5-hydroxytryptamine 1D receptor expressed in CHO cells at 1 uM,B,,,Homo sapiens,9606.0,
1708,8,,BAO_0000219,Autocuration,,16190,Binding affinity against 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand,B,,,,,
1709,8,,BAO_0000019,Autocuration,,14165,Binding affinity for 5-hydroxytryptamine 1D receptor in Cos-7 transfected cell type using [3H]5-CT as radioligand,B,,,,,
1710,9,,BAO_0000357,Expert,,4234,Binding affinity to cloned human 5-hydroxytryptamine 1D receptor,B,,,Homo sapiens,9606.0,
1711,8,,BAO_0000357,Autocuration,,15527,"Binding affinity towards 5-HT1D receptor, using [3H]5-HT as radioligand.",B,,,,,
1712,8,,BAO_0000219,Expert,,6328,Binding affinity towards human 5-hydroxytryptamine 1D receptor in L-M(tk-) cells using [3H]GR-125743 as radioligand,B,,,,,
1713,8,,BAO_0000357,Autocuration,,16209,Binding affinity towards human 5-hydroxytryptamine 1D receptor was determined using [3H]5-HT as radioligand,B,,,,,
1714,8,,BAO_0000357,Autocuration,,14770,Binding affinity for recombinant human 5-hydroxytryptamine 1D receptor using [3H]5-HT as radioligand.,B,,,,,
1715,8,,BAO_0000357,Autocuration,,2598,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1D receptor using [3H]-5-CT as radioligand,B,,,,,
1716,8,,BAO_0000357,Expert,,6897,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1D receptor,B,,,,,
1717,8,,BAO_0000357,Autocuration,,6013,Binding affinity towards 5-hydroxytryptamine 1D receptor,B,,,,,
1718,8,,BAO_0000357,Expert,,5843,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor,B,,,,,
1719,8,,BAO_0000357,Expert,,14454,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand,B,,,,,
1720,8,,BAO_0000357,Autocuration,,14454,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand; Not determined,B,,,,,
1721,8,,BAO_0000357,Autocuration,,14454,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand; not determined,B,,,,,
1722,8,,BAO_0000357,Autocuration,,15818,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1D receptor,B,,,,,
1723,8,,BAO_0000219,Expert,,13729,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1D receptor in CHO-K1 cells,F,,,,,
1724,9,,BAO_0000219,Expert,,6011,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in Chinese hamster ovary cells (CHO cells),B,In vitro,,Homo sapiens,9606.0,
1725,9,,BAO_0000357,Expert,,4234,In vitro binding affinity to human 5-hydroxytryptamine 1D receptor,B,,,Homo sapiens,9606.0,
1726,8,,BAO_0000019,Expert,,17085,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor,B,,,,,
1727,8,,BAO_0000357,Autocuration,,3025,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1D receptor using [3H]5-CT radioligand,B,,,,,
1728,8,,BAO_0000357,Expert,,15315,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1D receptor,B,,,,,
1729,9,,BAO_0000219,Expert,,14214,Receptor binding affinity for cloned human 5-hydroxytryptamine 1D receptor in Cos-7 cells,B,,,Homo sapiens,9606.0,
1730,9,,BAO_0000357,Expert,,3804,Binding affinity for human 5-hydroxytryptamine 1D receptor,B,,,Homo sapiens,9606.0,
1731,8,,BAO_0000357,Autocuration,,16700,The binding affinity towards the 5-hydroxytryptamine 1D receptor; No affinity,B,,,,,
1732,9,,BAO_0000357,Expert,,2391,Affinity for 5-hydroxytryptamine 1D receptor subtype,B,,,Homo sapiens,9606.0,
1733,9,,BAO_0000357,Expert,,4175,Binding affinity for human 5-hydroxytryptamine 1D receptor,B,,,Homo sapiens,9606.0,
1734,8,,BAO_0000019,Autocuration,,17085,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor,B,,,,,
1735,8,,BAO_0000019,Expert,,17085,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor; ND means not determined,B,,,,,
1736,9,,BAO_0000357,Expert,,15926,Binding activity against human 5-hydroxytryptamine 1D receptor; NT means not tested,B,,,Homo sapiens,9606.0,
1737,8,,BAO_0000219,Autocuration,,16312,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor; Not tested,B,,,,,
1738,8,,BAO_0000219,Autocuration,,16312,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor; not tested,B,,,,,
1739,4,,BAO_0000219,Autocuration,,14956,Selectivity towards 5-HT1D and to that of 5-HT1B in CHO cells,B,,,,,
1740,8,,BAO_0000019,Autocuration,,3294,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by the 5-HT",F,,,,,
1741,8,,BAO_0000357,Autocuration,,12861,Binding activity radioligand.,B,,,,,
1742,8,,BAO_0000019,Autocuration,,12861,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,B,,,,,
1743,8,,BAO_0000219,Expert,,16312,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor,B,,,,,
1744,8,,BAO_0000357,Autocuration,,5104,Binding affinity for human cloned 5-hydroxytryptamine 1D receptor,B,,,,,
1745,8,,BAO_0000357,Autocuration,,5105,Binding affinity for human cloned 5-hydroxytryptamine 1D receptor,B,,,,,
1746,8,,BAO_0000357,Autocuration,,14499,Measured as -log Ka on 5-hydroxytryptamine 1D receptor,B,,,,,
1747,9,,BAO_0000357,Expert,,15926,Binding activity against human 5-hydroxytryptamine 1D receptor,B,,,Homo sapiens,9606.0,
1748,9,,BAO_0000219,Expert,,4540,Binding affinity to human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand,B,,,Homo sapiens,9606.0,
1749,8,,BAO_0000219,Autocuration,,15779,Binding affinity towards 5-hydroxytryptamine 1D (human cloned receptor) in CHO cells using [3H]-5-HT as radioligand.,B,,,,,
1750,8,,BAO_0000219,Autocuration,,15779,Binding affinity towards 5-hydroxytryptamine 1D (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,B,,,,,
1751,8,,BAO_0000357,Autocuration,,6166,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor,B,,,,,
1752,8,,BAO_0000219,Autocuration,,15779,Binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand.,B,,,,,
1753,8,,BAO_0000219,Autocuration,,15779,Binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]-5-HT as radioligand.;ND means no data.,B,,,,,
1754,8,,BAO_0000219,Autocuration,,17451,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand,B,,,,,
1755,8,,BAO_0000219,Autocuration,,17451,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand,B,,,,,
1756,8,,BAO_0000219,Autocuration,,17451,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand; Not determined,B,,,,,
1757,8,,BAO_0000219,Autocuration,,4199,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as the radioligand,B,,,,,
1758,9,,BAO_0000357,Expert,,14875,Binding affinity for human 5-hydroxytryptamine 1D receptor,B,,,Homo sapiens,9606.0,
1759,8,,BAO_0000219,Autocuration,,15146,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT,B,,,,,
1760,8,,BAO_0000357,Autocuration,,5213,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1D receptor in CHO using [3H]5-HT as a radioligand,B,,,,,
1761,8,,BAO_0000219,Autocuration,,14818,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT.,B,,,,,
1762,8,,BAO_0000219,Autocuration,,4829,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells, using [3H]5-HT as radioligand",B,,,,,
1763,8,,BAO_0000019,Expert,,14454,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1D receptor at concentration 1 uM,F,,,,,
1764,8,,BAO_0000019,Expert,,14454,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1D receptor at concentration 10 uM,F,,,,,
1765,8,,BAO_0000357,Autocuration,,5254,Binding affinity against 5-HT2C receptor,B,,,,,
1766,8,,BAO_0000357,Autocuration,,5254,Binding affinity against 5-hydroxytryptamine 1D receptor,B,,,,,
1767,8,,BAO_0000357,Autocuration,,10639,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1B receptor of rat substantia nigra,B,,,,,
1768,8,,BAO_0000019,Autocuration,,10639,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1B receptor of rat substantia nigra,F,,,,,
1769,8,,BAO_0000019,Expert,,12352,"Binding affinity for 5-hydroxytryptamine 1B receptor in rat cortex, striatum and globus pallidus",B,,,,,
1770,8,,BAO_0000357,Autocuration,,9098,Binding affinity towards 5-HT1B was determined,B,,,,,
1771,8,,BAO_0000019,Expert,,14430,Affinity towards 5-hydroxytryptamine 1B receptor in membranes from rat frontal cortex using [3H]5-HT,B,,,,,
1772,8,,BAO_0000019,Expert,,13657,"Binding affinity to 5-HT1B receptors using rat cortex+striatum + globus pallidus,[3H]-5-OH-tryptamine, and serotonin for NSB",B,,,,,
1773,8,,BAO_0000019,Autocuration,,13657,"Compound was evaluated for binding affinity on 5-HT1B receptors using rat cortex+striatum+ globus pallidus,[ 3H]-5-OH-tryptamine, and serotonin for NSB.",B,,,,,
1774,8,,BAO_0000019,Expert,,15854,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,B,,,,,
1775,9,,BAO_0000019,Expert,,10639,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat cortex using [3H]5-HT,B,,,Rattus norvegicus,10116.0,
1776,8,,BAO_0000357,Autocuration,,10025,Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol binding to 5-hydroxytryptamine 1B receptor at 1 uM,B,,,,,
1777,8,,BAO_0000357,Autocuration,,10025,"Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol, binds to 5-hydroxytryptamine 1B receptor at 1 uM",B,,,,,
1778,8,,BAO_0000249,Autocuration,,14286,In vitro inhibitory concentration against radioligand [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatal membrane,B,,,,,
1779,8,,BAO_0000019,Autocuration,2435.0,3651,Inhibition of [3H]-5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatum; Residual radioligand binding higher than 50%,B,,,,,
1780,9,,BAO_0000357,Expert,,14178,Inhibition of radiolabeled [3H]-5-HT ligand binding to 5-hydroxytryptamine 1B receptor,B,,,Rattus norvegicus,10116.0,
1781,8,,BAO_0000019,Autocuration,,10639,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat cortex using [3H]5-HT as the radioligand.,B,,,,,
1782,8,,BAO_0000019,Autocuration,2435.0,13605,Inhibitory activity against [3H]5-HT binding to 5-HT1B receptor in rat striatum,B,,,,,
1783,8,,BAO_0000019,Autocuration,2435.0,5834,Inhibitory concentration required against 5-hydroxytryptamine 1B receptor in rat striatum using [3H]5-HT,B,,,,,
1784,8,,BAO_0000357,Autocuration,2435.0,10922,compound was measured for affinity against 5-hydroxytryptamine 1B receptor labelled with [3H]5-HT radioligand in striatum tissue,B,,,,,
1785,8,,BAO_0000249,Autocuration,,14286,Compound at 10E-5 M was tested in vitro for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatal membrane,B,,,,,
1786,8,,BAO_0000357,Autocuration,,11825,In vitro binding affinity towards the 5-hydroxytryptamine 1B receptor at 10 e-6 M,B,,,,,
1787,8,,BAO_0000019,Autocuration,2435.0,14826,Ability to displace [3H]5-HT bound to 5-hydroxytryptamine 1B receptor in rat striatum,B,,,,,
1788,8,,BAO_0000019,Autocuration,2435.0,9699,Binding affinity against 5-HT1B serotonin receptor in rat striatum,B,,,,,
1789,8,,BAO_0000019,Autocuration,,14423,Binding affinity against 5-hydroxytryptamine 1B receptor in membranes of Rat cerebral cortex,B,,,,,
1790,8,,BAO_0000357,Expert,,10062,Binding affinity at rat 5-hydroxytryptamine 1B receptor by [3H]5-HT displacement.,B,,,,,
1791,8,,BAO_0000357,Autocuration,,10062,Binding affinity determined in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1B receptor,B,,,,,
1792,9,,BAO_0000357,Expert,,12280,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1B receptor,B,,,Rattus norvegicus,10116.0,
1793,8,,BAO_0000357,Autocuration,2435.0,15412,Binding affinity against 5-hydroxytryptamine 1B receptor of rat striatum,B,,,,,
1794,8,,BAO_0000357,Autocuration,2435.0,15412,Binding affinity against 5-hydroxytryptamine 1B receptor of rat striatum.,B,,,,,
1795,8,,BAO_0000357,Autocuration,,10062,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1B receptor,B,,,,,
1796,8,,BAO_0000357,Autocuration,,11147,Binding affinity towards 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand,B,,,,,
1797,8,,BAO_0000019,Autocuration,,9547,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat was determined using 50 uL of [125I]ICYP in binding assay,B,,,,,
1798,8,,BAO_0000019,Autocuration,,10444,Binding affinity was determined against 5-hydroxytryptamine 1B receptor was determined in male Sprague-Dawley rat brain.,B,,,,,
1799,8,,BAO_0000019,Autocuration,2435.0,12469,Binding affinity was measured on 5-hydroxytryptamine 1B receptor in rat striatum labeled with [3H]5-HT,B,,,,,
1800,8,,BAO_0000019,Expert,,9098,Binding affinity (Ki) to rat cortical membranes at 5-HT1B binding site by using [125 I] ICYP as a radioligand.,B,,,,,
1801,8,,BAO_0000019,Autocuration,,9098,Compound was evaluated for the binding affinity (Ki) to rat cortical membranes at 5-HT1B binding site by using [125 I] ICYP as a radioligand; ND is no data.,B,,,,,
1802,8,,BAO_0000357,Autocuration,,9699,Evaluated for binding affinity towards 5-hydroxytryptamine 1B receptor,B,,,,,
1803,8,,BAO_0000249,Autocuration,,10394,Inhibitory activity against 5-hydroxytryptamine 1B receptor in rat cortical membranes using [3H]5-HT as a radioligand,B,,,,,
1804,8,,BAO_0000357,Autocuration,,12092,The binding affinity was measured on 5-hydroxytryptamine 1B receptor using [3H]- serotonin as radioligand.,B,,,,,
1805,8,,BAO_0000357,Autocuration,,16700,The binding affinity towards the receptor rat 5-hydroxytryptamine 1B receptor; No affinity,B,,,,,
1806,9,,BAO_0000249,Expert,,403,Binding affinity against 5-hydroxytryptamine 1B receptor in rat striatal membranes using [3H]5-HT as radioligand,B,,,Rattus norvegicus,10116.0,
1807,9,,BAO_0000357,Expert,,12771,Binding affinity towards 5-hydroxytryptamine 1B receptor,B,,,Rattus norvegicus,10116.0,
1808,8,,BAO_0000019,Autocuration,,11642,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1B receptor by displacing [3H]serotonin radioligand in rat cerebral cortex,B,,,,,
1809,8,,BAO_0000357,Autocuration,,12953,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand,B,,,,,
1810,8,,BAO_0000357,Autocuration,,12953,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand.,B,,,,,
1811,8,,BAO_0000019,Expert,2435.0,12953,Binding affinity for 5-hydroxytryptamine 1B receptor in rat striatum using [3H]5-HT as radioligand,B,,,,,
1812,8,,BAO_0000357,Autocuration,,12953,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand; Nonactive at 10 uM,B,,,,,
1813,8,,BAO_0000249,Autocuration,955.0,9737,Binding affinity against 5-HT1B receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,B,,,,,
1814,8,,BAO_0000019,Autocuration,,9737,Binding affinity against 5-HT1B receptor in rat frontal cortex using [3H]-5-HT in presence of 0.1 uM [3H]-8-OH-DPAT as a radioligand,B,,,,,
1815,8,,BAO_0000249,Autocuration,955.0,9737,Binding affinity towards 5-HT1B receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,B,,,,,
1816,8,,BAO_0000357,Autocuration,,12827,Binding affinity towards 5-hydroxytryptamine 2C receptor of porcine choroid plexus using [3H]mesulergine,B,,,,,
1817,8,,BAO_0000357,Autocuration,,5033,Ability to displace the radioligand [125I](-)-iodocyanopindolol from rat striatal 5-hydroxytryptamine 1B receptor,B,,,,,
1818,9,,BAO_0000019,Expert,,9786,Displacement of [3H]5-HT from 5-HT1B receptor of rat frontal cortex homogenate,B,,,Rattus norvegicus,10116.0,
1819,8,,BAO_0000357,Expert,,13116,Binding affinity at 5-hydroxytryptamine 1B receptor,B,,,,,
1820,8,,BAO_0000019,Autocuration,,16429,In vitro binding affinity at 5-hydroxytryptamine 1B receptor in rat striatal muscles using [125I](-)-iodocyanopindolol as the radioligand,B,,,,,
1821,9,,BAO_0000249,Expert,,12409,In vitro binding affinity towards 5-hydroxytryptamine 1B receptor in rat striatal membrane with [125I]- iodocyanopindolol,B,,,Rattus norvegicus,10116.0,
1822,8,,BAO_0000357,Autocuration,,15194,The compound was tested for the binding affinity against 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand,B,,,,,
1823,8,,BAO_0000357,Autocuration,,15194,The compound was tested for the binding affinity against 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,B,,,,,
1824,4,,BAO_0000019,Autocuration,,5486,Binding affinity towards 5-HT2 receptor by the displacement of [3H]-ketanserin] in rat cerebral cortex,B,,,,,
1825,8,,BAO_0000357,Autocuration,,4639,Compound was tested for binding affinity against 5-hydroxytryptamine 1B receptor,B,,,,,
1826,8,,BAO_0000249,Autocuration,,386,The compound was evaluated for its ability to displace [3H]5-HT from 5-hydroxytryptamine 1B receptor in cellular brain membranes,B,,,,,
1827,8,,BAO_0000357,Autocuration,,2474,Compound was measured for its binding affinity at 5-hydroxytryptamine 1B receptor at a concentration of 100 nM using [125I]CYP as radioligand,B,,,,,
1828,8,,BAO_0000357,Autocuration,,6011,Inhibition of binding towards 5-hydroxytryptamine 1B receptor at 100 nM concentration,B,,,,,
1829,8,,BAO_0000357,Autocuration,,5014,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1B receptor,B,,,,,
1830,8,,BAO_0000357,Autocuration,,17515,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1B receptor; inactive at 10 uM,B,,,,,
1831,8,,BAO_0000357,Autocuration,,4373,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1B receptor was determined,B,,,,,
1832,8,,BAO_0000357,Expert,,1633,Binding affinity towards 5-hydroxytryptamine 1B receptor by displacement of [3H]5-HT.,B,,,,,
1833,8,,BAO_0000357,Autocuration,,1633,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 1B receptor by displacement of [3H]ketanserin.,B,,,,,
1834,8,,BAO_0000357,Autocuration,,4373,Binding affinity for 5-hydroxytryptamine 1B receptor was determined,B,,,,,
1835,8,,BAO_0000357,Autocuration,,4687,Evaluated for the binding affinity to 5-hydroxytryptamine 1B receptor,B,,,,,
1836,8,,BAO_0000357,Autocuration,,11574,Binding affinity against 5-hydroxytryptamine 1B receptor,B,,,,,
1837,8,,BAO_0000357,Autocuration,,10321,Binding affinity for 5-hydroxytryptamine 1B receptor was determined by using [3H]5-HT as radioligand,B,,,,,
1838,8,,BAO_0000357,Autocuration,,15527,Binding affinity towards 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,B,,,,,
1839,8,,BAO_0000357,Autocuration,,17200,Inhibitory constant against 5-hydroxytryptamine 1B receptor using with [125I]- cyanopindolol radioligand,B,,,,,
1840,4,,BAO_0000224,Autocuration,,14423,Binding affinity against 5-hydroxytryptamine 1B receptor - 5-hydroxytryptamine 1D receptor using [3H]5-HT as the radioligand.,B,,,,,
1841,8,,BAO_0000357,Autocuration,,5834,Inhibitory concentration required against 5-hydroxytryptamine 1C receptor in bovine choroid plexus using [3H]mesulergine,B,,,Bos taurus,9913.0,
1842,8,,BAO_0000357,Autocuration,,11473,Binding affinity towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand,B,,,Sus scrofa,9823.0,
1843,8,,BAO_0000357,Autocuration,,11473,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1C receptor in pig choroid plexus using [3H]mesulergine as radioligand,B,,,Sus scrofa,9823.0,
1844,8,,BAO_0000357,Autocuration,,10639,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 1C receptor of pig choroid plexus using [3H]mesulergine as the radioligand,B,,,Sus scrofa,9823.0,
1845,8,,BAO_0000357,Autocuration,,10639,inhibitory activity against 5-hydroxytryptamine 1C receptor of pig choroid plexus using [3H]mesulergine as the radioligand,B,,,Sus scrofa,9823.0,
1846,8,,BAO_0000357,Autocuration,,14331,Binding affinity of compound towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine (1.2 nM) ligand in choroid Plexus pig was determined,B,,,Sus scrofa,9823.0,
1847,8,,BAO_0000357,Autocuration,,10796,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 1C receptor,B,,,Sus scrofa,9823.0,
1848,8,,BAO_0000357,Expert,,9098,Evaluated for the binding affinity to porcine choroid plexus at 5-hydroxytryptamine 2C receptor binding site by using [3H]-MES as a radioligand.,B,,,Sus scrofa,9823.0,
1849,8,,BAO_0000357,Expert,,14331,Inhibition of [3H]mesulergine binding to 5-hydroxytryptamine 1C receptor of pig choroid Plexus,B,,,Sus scrofa,9823.0,
1850,8,,BAO_0000019,Expert,,11828,Displacement of [3H]mesulergine from pig cortex 5-hydroxytryptamine 1C receptor,B,,,Sus scrofa,9823.0,
1851,8,,BAO_0000357,Autocuration,,11866,Binding affinity for 5-hydroxytryptamine 1C receptor in piglet choroid plexus using [3H]5-HT,B,,,Sus scrofa,9823.0,
1852,8,,BAO_0000019,Autocuration,,13047,Binding affinity against 5-hydroxytryptamine 1D receptor alpha using rabbit saphenous vein assay.,B,,,Oryctolagus cuniculus,9986.0,
1853,9,,BAO_0000357,Autocuration,,188,Tested for the effect on binding at 5-hydroxytryptamine 1C receptor; No activity,B,,,Rattus norvegicus,10116.0,
1854,9,,BAO_0000357,Autocuration,,11825,In vitro binding affinity towards the 5-hydroxytryptamine 1C receptor at 10 e-6 M,B,,,Rattus norvegicus,10116.0,
1855,9,,BAO_0000357,Autocuration,,11825,In vitro binding affinity towards the 5-hydroxytryptamine 1C receptor at 10 e-6 M,B,,,Rattus norvegicus,10116.0,
1856,9,,BAO_0000019,Expert,,11624,Binding affinity against 5-hydroxytryptamine 1C receptor in rat using [3H]mesulergine as radioligand,B,,,Rattus norvegicus,10116.0,
1857,9,,BAO_0000357,Autocuration,,11139,Binding affinity towards 5-hydroxytryptamine 1C receptor using [125 I]-SCH23982 as radioligand in competitive binding assay,B,,,Rattus norvegicus,10116.0,
1858,9,,BAO_0000357,Autocuration,,11147,Binding affinity towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand,B,,,Rattus norvegicus,10116.0,
1859,9,,BAO_0000019,Autocuration,,10444,Binding affinity was determined against 5-hydroxytryptamine 1C receptor was determined in male Sprague-Dawley rat brain.,B,,,Rattus norvegicus,10116.0,
1860,9,,BAO_0000357,Expert,,11624,Binding affinity against 5-hydroxytryptamine 1C receptor,B,,,Rattus norvegicus,10116.0,
1861,9,,BAO_0000019,Autocuration,,11662,"Compound was tested for binding affinity towards 5-HT1C (5-HT1C) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",B,,,Rattus norvegicus,10116.0,
1862,9,,BAO_0000019,Autocuration,,11662,"Compound was tested for binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",B,,,Rattus norvegicus,10116.0,
1863,9,,BAO_0000019,Expert,,11662,"Binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",B,,,Rattus norvegicus,10116.0,
1864,9,,BAO_0000019,Autocuration,,11662,"Compound was tested for binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",B,,,Rattus norvegicus,10116.0,
1865,9,,BAO_0000357,Autocuration,,9098,Evaluated for the binding affinity to porcine choroid plexus at 5-hydroxytryptamine 1C receptor binding site by using [3H]- MES as a radioligand.,B,,,Rattus norvegicus,10116.0,
1866,9,,BAO_0000249,Autocuration,,10394,Inhibitory activity against 5-hydroxytryptamine 1C receptor in rat cortical membranes using [3H]mesulergine as a radioligand,B,,,Rattus norvegicus,10116.0,
1867,8,,BAO_0000357,Expert,,11933,Tested for binding affinity against 5-hydroxytryptamine 1C receptor from rat frontal cortical regions using [3H]mesulergine as radioligand,B,,,,,
1868,9,,BAO_0000357,Autocuration,,12092,The binding affinity was measured on 5-hydroxytryptamine 1C receptor using [3H]- serotonin as radioligand.,B,,,Rattus norvegicus,10116.0,
1869,9,,BAO_0000019,Autocuration,,12253,Binding affinity of 5-hydroxytryptamine 1C receptor using [3H]- ketanserin in rat frontal cortex,B,,,Rattus norvegicus,10116.0,
1870,9,,BAO_0000219,Autocuration,,12253,Binding affinity towards rat 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand expressed in 293 cells,B,,,Rattus norvegicus,10116.0,
1871,8,,BAO_0000357,Autocuration,,1558,Compound was tested for its affinity towards 5-hydroxytryptamine 1C receptor,B,,,,,
1872,8,,BAO_0000357,Autocuration,,2474,Compound was measured for its binding affinity at 5-hydroxytryptamine 1C receptor at a concentration of 100 nM using [3H]mesulergine as radioligand,B,,,,,
1873,8,,BAO_0000357,Autocuration,,2474,Compound was measured for its binding affinity at 5-hydroxytryptamine 1C receptor at a concentration of 100 nM using [3H]mesulergine as radioligand,B,,,,,
1874,8,,BAO_0000357,Autocuration,,11574,Binding affinity against 5-hydroxytryptamine 1C receptor,B,,,,,
1875,8,,BAO_0000357,Autocuration,,1558,Compound was tested for its affinity towards 5-hydroxytryptamine 1C receptor,B,,,,,
1876,8,,BAO_0000357,Autocuration,,13944,Binding affinity against 5-hydroxytryptamine 1C receptor,B,,,,,
1877,8,,BAO_0000357,Autocuration,,13033,Binding affinity against serotonergic 5-HT1c receptor,B,,,,,
1878,8,,BAO_0000357,Autocuration,,10321,Binding affinity for 5-hydroxytryptamine 1C receptor was determined by using [3H]- mesulergine as radioligand,B,,,,,
1879,8,,BAO_0000357,Autocuration,,11866,Binding affinity for 5-hydroxytryptamine 1C receptor was determined,B,,,,,
1880,8,,BAO_0000019,Autocuration,,14454,Compound was tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),B,,,Oryctolagus cuniculus,9986.0,
1881,4,,BAO_0000224,Autocuration,,11574,Binding affinity against 5-hydroxytryptamine 2 receptor using [125I]DOI as radioligand.,B,,,,,
1882,4,,BAO_0000224,Autocuration,,11574,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ket as radioligand.,B,,,,,
1883,4,,BAO_0000019,Autocuration,,13631,Binding affinity towards serotonin 5-HT2 receptor was determined in rat cortex using [3H]spiperone as ligand,B,,,,,
1884,5,,BAO_0000019,Autocuration,,9630,Binding affinity towards 5-hydroxytryptamine 2 receptor as antagonism of serotonin-induced contractions in rat jugular vein,B,,,Rattus norvegicus,10116.0,
1885,5,,BAO_0000249,Autocuration,,8822,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain cortical membranes,B,,,Rattus norvegicus,10116.0,
1886,5,,BAO_0000221,Autocuration,955.0,9064,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain using [3H]spiroperidol,B,,,Rattus norvegicus,10116.0,
1887,4,,BAO_0000224,Autocuration,,8868,Binding affinity towards 5-hydroxytryptamine 2 receptor measured using radioligand ([3H]spiperone) binding assay,B,,,,,
1888,4,,BAO_0000224,Autocuration,,9064,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- spiroperidol,B,,,,,
1889,4,,BAO_0000019,Autocuration,,9806,Binding affinity at 5-hydroxytryptamine 2 receptor from rat frontal cortex homogenates by [3H]-spiperone displacement.,B,,,,,
1890,4,,BAO_0000224,Autocuration,,9098,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,B,,,,,
1891,4,,BAO_0000224,Autocuration,,8868,Binding affinity towards 5-hydroxytryptamine 2 receptor was measured using radioligand ([3H]spiperone) binding assay,B,,,,,
1892,4,,BAO_0000224,Autocuration,,12765,Binding affinity at serotonin 5-hydroxytryptamine 2 receptor by [3H]ketanserin displacement.,B,,,,,
1893,4,,BAO_0000019,Autocuration,,11049,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,B,,,,,
1894,4,,BAO_0000019,Autocuration,,11049,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,B,,,,,
1895,4,,BAO_0000019,Autocuration,,11049,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]-Ketanserin as radioligand; not determined,B,,,,,
1896,4,,BAO_0000019,Autocuration,,11049,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand; ND-Not determined,B,,,,,
1897,4,,BAO_0000019,Autocuration,,11049,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,B,,,,,
1898,4,,BAO_0000019,Autocuration,,11473,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor in rat anterior cortex using [125I]DOI as radioligand,B,,,,,
1899,4,,BAO_0000019,Autocuration,,11473,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor in rat anterior cortex using [3H]ketanserin as radioligand,B,,,,,
1900,4,,BAO_0000019,Autocuration,,3086,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat pre frontal cortex,B,,,,,
1901,4,,BAO_0000019,Autocuration,,11049,Compound was evaluated for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,B,,,,,
1902,4,,BAO_0000019,Autocuration,,11049,Compound was evaluated for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,B,,,,,
1903,4,,BAO_0000019,Autocuration,,10639,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 2 receptor of rat anterior cortex using [3H]ketanserin as the radioligand,B,,,,,
1904,4,,BAO_0000019,Autocuration,,10922,Compound was measured for affinity at 5-hydroxytryptamine 2 receptor in rat cortical by [3H]spiroperidol displacement.,B,,,,,
1905,5,,BAO_0000221,Autocuration,955.0,9064,Binding affinity against serotonin-2 receptor in rat brain using [3H]spiroperidol,B,,,Rattus norvegicus,10116.0,
1906,4,,BAO_0000221,Autocuration,955.0,10748,Compound was tested for its inhibitory effect on the binding profile in 5-hydroxytryptamine 2 receptor using [3H]spiroperidol in rat brain.,B,,,,,
1907,4,,BAO_0000249,Autocuration,,11614,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor from rat cortical membranes.,B,,,,,
1908,4,,BAO_0000249,Autocuration,,11615,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat cortical membranes,B,,,,,
1909,4,,BAO_0000224,Autocuration,,11615,Compound was tested for the displacement of [3H]ketanserin from serotonin 5-hydroxytryptamine 2 receptor,B,,,,,
1910,4,,BAO_0000249,Autocuration,,11614,Compound was tested for the displacement of [3H]ketanserin from serotonin 5-hydroxytryptamine 2 receptor from rat cortical membranes.,B,,,,,
1911,4,,BAO_0000224,Autocuration,,11702,Inhibition of [3H]ketanserin binding to rat 5-hydroxytryptamine 2 receptors.,B,,,,,
1912,4,,BAO_0000224,Autocuration,,11702,Compound was tested for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor; NT=Not tested,B,,,,,
1913,5,,BAO_0000224,Autocuration,,11702,Inhibition of [3H]ketanserin binding to dopamine 5-hydroxytryptamine 2 receptor,B,,,Rattus norvegicus,10116.0,
1914,4,,BAO_0000224,Autocuration,,11702,Compound was tested for the inhibition of [3H]ketanserin binding to dopamine 5-hydroxytryptamine 2 receptor; NT=Not tested,B,,,,,
1915,4,,BAO_0000019,Autocuration,,13346,Inhibition of [3H]ketanserin binding at 5-hydroxytryptamine 2 receptor from rat frontal cortex.,B,,,,,
1916,4,,BAO_0000224,Autocuration,,10025,Concentration necessary to achieve half maximal inhibition of [3H]-ketanserin binding to 5-hydroxytryptamine 2 receptor,B,,,,,
1917,4,,BAO_0000224,Autocuration,,10025,Concentration necessary to achieve half maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 1 uM,B,,,,,
1918,4,,BAO_0000224,Autocuration,,10025,"Concentration necessary to achieve half maximal inhibition of [3H]ketanserin, binds to 5-hydroxytryptamine 2 receptor at 1 uM",B,,,,,
1919,4,,BAO_0000224,Autocuration,,9036,Evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using radioligand [3H]-spiperone,B,,,,,
1920,4,,BAO_0000224,Autocuration,,9036,Evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using radioligand [3H]spiperone; IA=Inactive,B,,,,,
1921,4,,BAO_0000019,Autocuration,,9161,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.,B,,,,,
1922,4,,BAO_0000019,Autocuration,,12304,Inhibition of binding of radioligand [3H]ketanserin to 5-hydroxytryptamine 2 receptor in rat cerebral cortex,B,,,,,
1923,4,,BAO_0000224,Autocuration,,13276,In vitro binding affinity measured on serotonin 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand.,B,,,,,
1924,4,,BAO_0000224,Autocuration,,11825,In vitro binding affinity towards the 5-hydroxytryptamine 2 receptor at 10 e-6 M,B,,,,,
1925,4,,BAO_0000224,Autocuration,,12443,In vitro binding affinity was measured on serotonergic 5-hydroxytryptamine 2 receptor by displacement of [3H]- ketanserin,B,,,,,
1926,4,,BAO_0000224,Autocuration,,13830,In vitro inhibitory activity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor,B,,,,,
1927,4,,BAO_0000249,Autocuration,,9592,Inhibition of [3H]spiperone binding to 5-hydroxytryptamine 2 receptor from rat cortical membranes,B,,,,,
1928,4,,BAO_0000249,Autocuration,,9592,Inhibition of [3H]spiperone binding to 5-hydroxytryptamine 2 receptor from rat cortical membranes; Not tested,B,,,,,
1929,4,,BAO_0000224,Autocuration,,10881,Inhibitory activity against 5-hydroxytryptamine 2 receptor by 3H ligand binding experiments.,B,,,,,
1930,4,,BAO_0000019,Autocuration,,13605,Inhibitory activity against [3H]spiroperidol binding to 5-HT2 receptor in rat cortex,B,,,,,
1931,5,,BAO_0000224,Autocuration,,11624,Inhibitory activity against 5-hydroxytryptamine 2 receptor,B,,,Rattus norvegicus,10116.0,
1932,4,,BAO_0000224,Autocuration,,4101,Inhibitory concentration against 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]-ketanserin,B,,,,,
1933,4,,BAO_0000224,Autocuration,,4101,Inhibitory concentration against binding of 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]-ketanserin,B,,,,,
1934,4,,BAO_0000019,Autocuration,,15360,Inhibitory concentration against radioligand [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat,B,,,,,
1935,4,,BAO_0000019,Autocuration,,11576,Inhibitory concentration against radioligand [3H]spiperone binding to 5-hydroxytryptamine 2 receptor in rat cortex,B,,,,,
1936,4,,BAO_0000019,Autocuration,,5834,Inhibitory concentration required against 5-hydroxytryptamine 2 receptor in rat cortex using [3H]spiperone,B,,,,,
1937,5,,BAO_0000219,Autocuration,,2395,Inhibitory concentration against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,B,,,Rattus norvegicus,10116.0,
1938,4,,BAO_0000249,Autocuration,,11965,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat cortical membranes,B,,,,,
1939,4,,BAO_0000224,Autocuration,,3967,The compound was evaluated for the ability to displace [3H]ketanserin from 5-hydroxytryptamine 2 receptor ( striata of male wistar rats),B,,,,,
1940,4,,BAO_0000249,Autocuration,,11130,The concentration required to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat brain membranes (in vitro),B,,,,,
1941,4,,BAO_0000219,Autocuration,,13427,Binding affinity of [3H]ketanserin towards 5-hydroxytryptamine 2 receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,B,In vitro,,,,
1942,4,,BAO_0000224,Autocuration,,9443,Binding affinity towards 5-hydroxytryptamine 2 receptor,B,,,,,
1943,4,,BAO_0000224,Autocuration,,9443,Binding affinity towards 5-hydroxytryptamine 2 receptor at 1.0 uM concentration,B,,,,,
1944,4,,BAO_0000224,Autocuration,,11825,In vitro binding affinity towards the 5-hydroxytryptamine 2 receptor at 10 e-6 M,B,,,,,
1945,4,,BAO_0000249,Autocuration,,12120,Percent inhibition of binding of 1.0 nM [3H]ketanserin to 5-hydroxytryptamine 2 receptor in rat cortical membranes at 10 e -5 M,B,,,,,
1946,4,,BAO_0000249,Autocuration,,12120,Percent inhibition of binding of 1.0 nM [3H]-ketanserin to 5-hydroxytryptamine 2 receptor in rat cortical membranes at 10 e-5 M.,B,,,,,
1947,4,,BAO_0000019,Autocuration,1515.0,11963,Tested for antagonistic activity against 5-hydroxytryptamine 2 receptor from rat thoracic aorta,F,,,,,
1948,4,,BAO_0000019,Autocuration,,9069,Binding affinity for membrane-bound 5-hydroxytryptamine 2 receptor,B,,,,,
1949,4,,BAO_0000224,Autocuration,,8868,Compound was tested for its effect on 5-hydroxytryptamine 2 receptor saturation analysis,B,,,,,
1950,8,,BAO_0000357,Autocuration,,17200,Inhibitory constant against human 5-hydroxytryptamine 1B receptor using [3H]5-CT radioligand,B,,,,,
1951,8,,BAO_0000357,Autocuration,,17200,Inhibitory constant against human 5-hydroxytryptamine 1D receptor using [3H]5-CT radioligand,B,,,,,
1952,8,,BAO_0000357,Expert,,13969,Binding affinity against 5-hydroxytryptamine 1D receptor was measured using [3H]5-HT as radioligand,B,,,,,
1953,9,,BAO_0000357,Expert,,13392,Binding affinity for 5-hydroxytryptamine 1D receptor,B,,,,,
1954,8,,BAO_0000249,Autocuration,,1742,Compound was tested for its ability to displace [125I]GTI binding to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,B,,,,,
1955,8,,BAO_0000249,Autocuration,,1742,Compound was tested for its ability to displace [3H]-5-HT binding to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,B,,,,,
1956,8,,BAO_0000357,Autocuration,2435.0,14331,Binding affinity against 5-hydroxytryptamine 1D receptor using [3H]5-HT in pig striatum + frontalCortex,B,,,,,
1957,8,,BAO_0000019,Autocuration,,12861,Relative agonist efficacy against 1 uM 5-hydroxytryptamine 1D receptor,F,,,,,
1958,8,,BAO_0000019,Expert,,12861,Binding activity against 5-hydroxytryptamine 1D receptor from pig caudate membrane using [3H]5-HT as radioligand,B,,,,,
1959,8,,BAO_0000357,Autocuration,,12861,Binding activity radioligand.,B,,,,,
1960,8,,BAO_0000019,Autocuration,,12861,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,B,,,,,
1961,8,,BAO_0000019,Expert,,12861,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,B,,,,,
1962,8,,BAO_0000019,Autocuration,,12861,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand; NA Not Available,B,,,,,
1963,8,,BAO_0000249,Autocuration,,675,Compound was tested for the displacement of [3H]-5-HT to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,B,,,,,
1964,8,,BAO_0000019,Expert,,12490,Displacement of [3H]5-HT binding to 5-hydroxytryptamine 1D receptor from pig caudate membrane,B,,,,,
1965,8,,BAO_0000249,Expert,,11828,Displacement of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1D receptor in pig caudate membrane,B,,,,,
1966,8,,BAO_0000357,Autocuration,,11866,Binding affinity for 5-hydroxytryptamine 1D receptor in piglet caudate using [3H]5-HT,B,,,,,
1967,8,,BAO_0000357,Autocuration,,773,In Vitro Binding affinity againist 5-hydroxytryptamine 1D receptor by displacing [125I]GTI from pig caudate,B,,,Sus scrofa,9823.0,
1968,8,,BAO_0000357,Expert,,13047,The compound was tested for intrinsic activity against 5-HT1D receptor,B,,,Oryctolagus cuniculus,9986.0,
1969,8,,BAO_0000019,Autocuration,,13047,Intrinsic activity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,B,,,Oryctolagus cuniculus,9986.0,
1970,8,,BAO_0000357,Expert,,13047,The compound was tested for binding affinity against 5-HT1D receptor,B,,,Oryctolagus cuniculus,9986.0,
1971,8,,BAO_0000357,Autocuration,,188,Tested for the effect on binding at 5-hydroxytryptamine 1D receptor; No activity,B,,,,,
1972,8,,BAO_0000019,Autocuration,,10639,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1D receptor of rat substantia nigra,F,,,,,
1973,8,,BAO_0000019,Autocuration,,12438,Inhibition of forskolin stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor,F,,,,,
1974,8,,BAO_0000357,Autocuration,,12438,Binding affinity was measured against serotonin 5-hydroxytryptamine 1D receptor,B,,,,,
1975,8,,BAO_0000019,Expert,,15854,Binding affinity towards 5-hydroxytryptamine 1D receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,B,,,,,
1976,8,,BAO_0000249,Autocuration,,10394,Inhibitory activity against 5-hydroxytryptamine 1D receptor in rat cortical membranes using [3H]5-HT as a radioligand,B,,,,,
1977,8,,BAO_0000357,Autocuration,,12092,The binding affinity was measured on 5-hydroxytryptamine 1D receptor using [3H]- serotonin as radioligand.,B,,,,,
1978,8,,BAO_0000019,Expert,,3389,Binding affinity to 5-hydroxytryptamine 1D receptor in the rat forebrain by [3H]- SB-204269 displacement.,B,,,,,
1979,8,,BAO_0000357,Autocuration,,6011,Inhibition of binding towards 5-hydroxytryptamine 1D receptor at 100 nM concentration,B,,,,,
1980,8,,BAO_0000357,Autocuration,,4639,Compound was tested for binding affinity against 5-hydroxytryptamine 1D receptor,B,,,,,
1981,8,,BAO_0000357,Autocuration,,2474,Compound was measured for its binding affinity at 5-hydroxytryptamine 1D receptor at a concentration of 10 uM using [3H]5-HT as radioligand,B,,,,,
1982,8,,BAO_0000357,Autocuration,,5014,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1D receptor,B,,,,,
1983,8,,BAO_0000357,Autocuration,,17515,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1D receptor; inactive at 10 uM,B,,,,,
1984,8,,BAO_0000357,Autocuration,,11866,Binding affinity for 5-hydroxytryptamine 1D receptor was determined,B,,,,,
1985,8,,BAO_0000357,Autocuration,,4687,Evaluated for the binding affinity against 5-hydroxytryptamine 1D receptor,B,,,,,
1986,8,,BAO_0000357,Autocuration,,12146,Tested against 5-hydroxytryptamine 1D receptor,B,,,,,
1987,8,,BAO_0000357,Autocuration,,10321,Binding affinity for 5-hydroxytryptamine 1D receptor was determined by using [3H]5-HT as radioligand,B,,,,,
1988,8,,BAO_0000219,Autocuration,,13267,Antagonistic binding affinity measured against 5-hydroxytryptamine 2A receptor (human clone expressed in 293 cells) using [3H]ketanserin as radioligand,B,,,,,
1989,9,,BAO_0000357,Expert,,1274,Binding affinity against 5-Hydroxytryptamine 1D receptor,B,,,Homo sapiens,9606.0,
1990,8,,BAO_0000357,Autocuration,,15250,,B,,,,,
1991,8,,BAO_0000219,Autocuration,,13706,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,B,,,,,
1992,8,,BAO_0000219,Autocuration,,13706,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,B,,,,,
1993,8,,BAO_0000219,Autocuration,,13706,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor alpha clones expressed in human embryonic kidney (HEK 293) cells line.,B,,,,,
1994,8,,BAO_0000219,Autocuration,,13706,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor alpha clones expressed in human embryonic kidney (HEK 293) cells line; NT= not tested,B,,,,,
1995,8,,BAO_0000019,Autocuration,,13047,Binding affinity against 5-hydroxytryptamine 1D receptor beta using rabbit saphenous vein assay.,B,,,,,
1996,8,,BAO_0000357,Autocuration,,13366,Binding affinity of compound against 5-HT1Dalpha Binding affinity of compound against 5-HT1D alpha receptors in human,B,,,,,
1997,8,,BAO_0000357,Expert,,13366,In vitro affinity human cloned 5-hydroxytryptamine 1D receptor alpha by [3H]5-HT displacement.,B,,,,,
1998,8,,BAO_0000357,Autocuration,,1558,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor alpha was determined,B,,,,,
1999,8,,BAO_0000219,Expert,,12902,"Binding affinity against 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells, using [3H]-5-HT as the radioligand.",B,,,,,
2000,8,,BAO_0000219,Autocuration,,13706,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,B,,,,,
2001,8,,BAO_0000019,Autocuration,,13706,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor alpha measured as the reduction of forskolin-stimulated cAMP.,F,,,,,
2002,8,,BAO_0000019,Autocuration,,13706,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,F,,,,,
2003,8,,BAO_0000019,Autocuration,,14251,Compound was tested for its agonist activity against human 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,F,,,,,
2004,8,,BAO_0000019,Autocuration,,14251,Compound was tested for its agonist activity against human recombinant 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,F,,,,,
2005,8,,BAO_0000019,Autocuration,,14251,Compound was tested for its agonist activity against human recombinant 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,F,,,,,
2006,8,,BAO_0000357,Autocuration,,13313,In vitro binding affinity towards 5-HT1D alpha receptor by using [3H]5-HT as radioligand,B,,,,,
2007,8,,BAO_0000357,Autocuration,,13313,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor alpha by using [3H]5-HT as radioligand,B,,,,,
2008,8,,BAO_0000357,Autocuration,,13366,Selectivity towards 5-hydroxytryptamine 1D receptor beta to that of 5-hydroxytryptamine 1D receptor alpha,B,,,,,
2009,8,,BAO_0000357,Expert,,13051,Binding affinity to recombinant human 5-hydroxytryptamine 1D receptor alpha,B,,,,,
2010,8,,BAO_0000219,Expert,,12903,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor alpha expressed in CHO cells, by using [3H]5-HT as radioligand",B,,,,,
2011,9,,BAO_0000219,Autocuration,,12469,Binding affinity was measured on 5-hydroxytryptamine 1D receptor alpha in COS cells transfected with human 5-HT1D alpha gene labeled with [3H]5-HT,B,,,Homo sapiens,9606.0,
2012,8,,BAO_0000357,Autocuration,,5619,Binding affinity (in vitro) against 5-hydroxytryptamine 1D receptor alpha using radio-ligand binding assay,B,,,,,
2013,8,,BAO_0000019,Autocuration,,13047,Binding affinity against 5-hydroxytryptamine 4 receptor using rabbit saphenous vein assay.,B,,,Oryctolagus cuniculus,9986.0,
2014,8,,BAO_0000357,Autocuration,,16633,Binding affinities against 5-hydroxytryptamine 1D receptor alpha,B,,,,,
2015,8,,BAO_0000357,Autocuration,,16633,Binding affinities towards 5-hydroxytryptamine 1D receptor alpha,B,,,,,
2016,8,,BAO_0000357,Autocuration,,16633,Binding affinities towards 5-hydroxytryptamine 1D receptor alpha,B,,,,,
2017,8,,BAO_0000357,Autocuration,,16633,Binding affinity towards 5-hydroxytryptamine 1D receptor alpha using [3H]8-OH-DPAT as radioligand,B,,,,,
2018,8,,BAO_0000357,Autocuration,,3269,Affinity against 5-hydroxytryptamine 1D receptor alpha,B,,,,,
2019,8,,BAO_0000357,Expert,,12409,Binding affinity against 5-hydroxytryptamine 1D receptor alpha,B,,,,,
2020,8,,BAO_0000019,Autocuration,,13706,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,F,,,,,
2021,8,,BAO_0000219,Autocuration,,13706,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor beta clones expressed in human embryonic kidney (HEK 293) cells line.,B,,,,,
2022,8,,BAO_0000219,Autocuration,,13706,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor beta clones expressed in human embryonic kidney (HEK 293) cells line; NT= not tested,B,,,,,
2023,8,,BAO_0000219,Autocuration,,12903,"The compound was tested in vitro for binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor beta expressed in CHO cells, by using [3H]5-HT as radioligand",B,,,,,
2024,8,,BAO_0000019,Autocuration,,13047,Binding affinity against 5-hydroxytryptamine 1D receptor beta using rabbit saphenous vein assay.,B,,,,,
2025,9,,BAO_0000357,Expert,,13366,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,B,,,,,
2026,9,,BAO_0000357,Expert,,13366,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,B,,,,,
2027,9,,BAO_0000357,Expert,,13366,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,B,,,,,
2028,8,,BAO_0000357,Autocuration,,13366,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor beta was determined using [3H]8-OH-DPAT as radioligand,B,,,,,
2029,8,,BAO_0000357,Autocuration,,13366,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor was determined using [3H]8-OH-DPAT as radioligand,B,,,,,
2030,8,,BAO_0000219,Autocuration,,12469,Binding affinity was measured on 5-hydroxytryptamine 1D receptor beta in CHO cells transfected with human 5-HT1D beta gene labeled with [3H]5-HT,B,,,,,
2031,8,,BAO_0000219,Autocuration,,13706,Compound was tested for binding affinity against cloned human 5-HT1D beta receptor expressed in CHO-K1 cells.,B,,,,,
2032,8,,BAO_0000219,Autocuration,,13706,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor beta expressed in CHO-K1 cells.,B,,,,,
2033,8,,BAO_0000019,Autocuration,,13706,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,F,,,,,
2034,8,,BAO_0000219,Expert,,12902,"Binding affinity against 5-hydroxytryptamine 1D receptor beta expressed in CHO-K1 cells, using [3H]5-HT as the radioligand.",B,,,,,
2035,8,,BAO_0000357,Expert,,13051,Binding affinity for cloned human 5-hydroxytryptamine 1D receptor beta,B,,,,,
2036,8,,BAO_0000219,Expert,,12903,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor beta expressed in CHO cells, by using [3H]5-HT as radioligand",B,,,,,
2037,8,,BAO_0000219,Autocuration,,1558,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 0.24-0.55,F,,,,,
2038,8,,BAO_0000219,Autocuration,,1558,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 0.6-2.0,F,,,,,
2039,8,,BAO_0000219,Autocuration,,1558,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 2.8-6.5,F,,,,,
2040,8,,BAO_0000219,Autocuration,,1558,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 30-70,F,,,,,
2041,8,,BAO_0000357,Autocuration,,1558,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor beta was determined,B,,,,,
2042,8,,BAO_0000019,Autocuration,,13047,Binding affinity against 5-hydroxytryptamine 3 receptor using rabbit saphenous vein assay.,B,,,Oryctolagus cuniculus,9986.0,
2043,8,,BAO_0000357,Autocuration,,13313,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor alpha by using [3H]-5-HT as radioligand,B,,,,,
2044,8,,BAO_0000357,Autocuration,,13313,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor beta by using [3H]5-HT as radioligand,B,,,,,
2045,8,,BAO_0000357,Expert,,12409,Binding affinity against 5-hydroxytryptamine 1D receptor beta,B,,,,,
2046,8,,BAO_0000219,Autocuration,,15250,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1E receptor stably expressed in CHO cells,B,,,,,
2047,9,,BAO_0000357,Expert,,1348,Inhibitory activity against 5-hydroxytryptamine 1E receptor subtype,B,,,Homo sapiens,9606.0,
2048,8,,BAO_0000357,Autocuration,,1348,Inhibitory activity against 5-hydroxytryptamine 1E receptor subtype; NA denotes data not available,B,,,,,
2049,9,,BAO_0000357,Expert,,4234,Binding affinity to cloned human 5-hydroxytryptamine 1E receptor,B,,,Homo sapiens,9606.0,
2050,8,,BAO_0000357,Autocuration,,16209,Binding affinity towards human 5-hydroxytryptamine 1E receptor was determined using [3H]5-HT as radioligand,B,,,,,
2051,8,,BAO_0000019,Autocuration,,10444,Binding affinity was determined against 5-hydroxytryptamine 1E receptor in human cortical homogenate,B,,,,,
2052,8,,BAO_0000357,Autocuration,,3935,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1E receptor,B,,,,,
2053,8,,BAO_0000357,Autocuration,,15818,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1E receptor,B,,,,,
2054,8,,BAO_0000019,Autocuration,,17085,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1E receptor,B,,,,,
2055,9,,BAO_0000219,Expert,,12936,Binding affinity against human 5-hydroxytryptamine 1E receptor expressed in CHO cells,B,,,Homo sapiens,9606.0,
2056,8,,BAO_0000357,Autocuration,,6166,Binding affinity towards cloned human 5-hydroxytryptamine 1E receptor was determined,B,,,,,
2057,8,,BAO_0000219,Autocuration,,15779,Binding affinity towards 5-hydroxytryptamine 1E receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,B,,,,,
2058,8,,BAO_0000219,Autocuration,,15779,Binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as radioligand.,B,,,,,
2059,8,,BAO_0000219,Autocuration,,15779,Binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as radioligand;ND means no data.,B,,,,,
2060,8,,BAO_0000357,Autocuration,,13181,Binding affinity was determined against 5-hydroxytryptamine 1D receptor,B,,,,,
2061,8,,BAO_0000219,Autocuration,,4199,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as the radioligand,B,,,,,
2062,8,,BAO_0000357,Autocuration,,14875,Compound was tested for binding affinity against human 5-hydroxytryptamine 1E receptor,B,,,,,
2063,8,,BAO_0000219,Autocuration,,15146,Compound was tested for its binding affinity against cloned human 5-hydroxytryptamine 1E receptor in CHO cells using [3H]-5-HT,B,,,,,
2064,8,,BAO_0000357,Autocuration,,5213,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1E receptor in CHO using [3H]5-HT as a radioligand,B,,,,,
2065,8,,BAO_0000357,Autocuration,,12146,Tested for binding affinity towards cloned human 5-hydroxytryptamine 1E receptor using [3H]5-HT as radioligand,B,,,,,
2066,8,,BAO_0000219,Autocuration,,13267,The binding affinity (pKi) measured against 5-hydroxytryptamine 1E receptor (cloned human receptors in CHO cells) using [3H]5-HT1E as radioligand,B,,,,,
2067,8,,BAO_0000219,Autocuration,,14818,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT.,B,,,,,
2068,8,,BAO_0000219,Autocuration,,4829,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells, using [3H]5-HT as radioligand",B,,,,,
2069,8,,BAO_0000357,Autocuration,,4373,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1E receptor was determined,B,,,,,
2070,8,,BAO_0000357,Autocuration,,4373,Binding affinity for 5-hydroxytryptamine 1E receptor was determined,B,,,,,
2071,8,,BAO_0000357,Autocuration,,14159,Compound was evaluated for the affinity at 5-hydroxytryptamine 1E receptor,B,,,,,
2072,8,,BAO_0000357,Autocuration,,16633,Binding affinity towards 5-hydroxytryptamine 1E receptor,B,,,,,
2073,8,,BAO_0000019,Autocuration,,17085,"In vitro effective concentration for stimulation of [35S]GTP-gamma-S, binding in mouse LM(tk-)cells expressing the human 5-HT1F receptor",F,,,,,
2074,8,,BAO_0000019,Expert,,17085,"In vitro effective concentration for stimulation of [35S]GTP-gamma-S, binding in mouse LM(tk-)cells expressing the human 5-hydroxytryptamine 1F receptor",F,,,,,
2075,8,,BAO_0000019,Autocuration,,16209,In vitro effective concentration for inhibition of skolin-stimulated adenylate cyclase in cell line expressing human 5-hydroxytryptamine 1F receptor,F,,,,,
2076,8,,BAO_0000019,Autocuration,,16209,In vitro agonist potency against human 5-hydroxytryptamine 1F receptor,F,,,,,
2077,8,,BAO_0000019,Expert,,17085,"Maximum stimulation of of [35S]GTP-gamma-S, binding expressed relative to the maximal effect of 5-hydroxytryptamine 1F receptor",F,,,,,
2078,8,,BAO_0000357,Autocuration,,14159,Compound was evaluated for the affinity at 5-hydroxytryptamine 1F receptor,B,,,,,
2079,8,,BAO_0000219,Autocuration,,15250,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1F receptor stably expressed in CHO cells,B,,,,,
2080,8,,BAO_0000357,Autocuration,,3805,In vitro binding affinity against human 5-hydroxytryptamine 1F receptor at a concentration of 100 (nM),B,,,,,
2081,8,,BAO_0000219,Autocuration,,16190,Binding affinity against 5-hydroxytryptamine 1F receptor in CHO cells using [3H]5-HT radioligand,B,,,,,
2082,8,,BAO_0000357,Autocuration,,16190,Binding affinity against 5-hydroxytryptamine 1F receptor in CHO using [3H]5-HT radioligand,B,,,,,
2083,8,,BAO_0000357,Autocuration,,16209,Binding affinity towards human 5-hydroxytryptamine 1F receptor,B,,,,,
2084,8,,BAO_0000357,Autocuration,,16209,Binding affinity towards human 5-hydroxytryptamine 1F receptor was determined,B,,,,,
2085,8,,BAO_0000357,Autocuration,,16209,Binding affinity towards human 5-hydroxytryptamine 1F receptor using [3H]-5-HT radioligand,B,,,,,
2086,8,,BAO_0000357,Autocuration,,6866,In vitro binding affinity for human 5-hydroxytryptamine 1F receptor,B,,,,,
2087,8,,BAO_0000019,Expert,,17085,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1F receptor,B,,,,,
2088,8,,BAO_0000357,Autocuration,,16312,Binding affinity towards human recombinant 5-hydroxytryptamine 1F receptor,B,,,,,
2089,8,,BAO_0000357,Autocuration,,6166,Binding affinity towards cloned human 5-hydroxytryptamine 1F receptor was determined,B,,,,,
2090,8,,BAO_0000219,Autocuration,,15779,Binding affinity towards 5-hydroxytryptamine 1F receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,B,,,,,
2091,8,,BAO_0000219,Autocuration,,4199,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1F receptor in CHO cells using [3H]-5-HT as the radioligand,B,,,,,
2092,8,,BAO_0000357,Autocuration,,14875,Compound was tested for binding affinity against human 5-hydroxytryptamine 1F receptor,B,,,,,
2093,8,,BAO_0000219,Autocuration,,15146,Compound was tested for its binding affinity against 5-hydroxytryptamine 1F receptor in human cloned receptors in CHO cells using [3H]5-HT,B,,,,,
2094,8,,BAO_0000357,Autocuration,,5213,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1F receptor in CHO using [3H]5-HT as a radioligand,B,,,,,
2095,8,,BAO_0000219,Autocuration,,14818,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1F receptor in CHO cells using [3H]5-HT.,B,,,,,
2096,8,,BAO_0000219,Autocuration,,4829,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1F receptor in CHO cells, using [3H]5-HT as radioligand",B,,,,,
2097,8,,BAO_0000219,Autocuration,,4829,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1F receptor in CHO cells, using [3H]5-HT as radioligand",B,,,,,
2098,8,,BAO_0000357,Autocuration,,4373,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1F receptor was determined,B,,,,,
2099,8,,BAO_0000357,Autocuration,,4373,Binding affinity for 5-hydroxytryptamine 1F receptor was determined,B,,,,,
2100,8,,BAO_0000357,Autocuration,,5014,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1F receptor,B,,,,,
2101,4,,BAO_0000019,Autocuration,,11662,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 (5-hydroxytryptamine-2) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]-ketanserin as radioligand",B,,,,,
2102,4,,BAO_0000019,Autocuration,,11662,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand",B,,,,,
2103,4,,BAO_0000019,Autocuration,,11662,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 (5-hydroxytryptamine-2) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",B,,,,,
2104,8,,BAO_0000019,Autocuration,,14093,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor,B,,,,,
2105,4,,BAO_0000218,Autocuration,,11200,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-HT2 receptor 1 hr after oral administration",F,In vivo,,,,
2106,4,,BAO_0000019,Autocuration,,11200,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,F,,,,,
2107,8,,BAO_0000019,Intermediate,,12352,Binding affinity towards 5-hydroxytryptamine 2 receptor in calf frontal cortex,B,,,,,
2108,0,,BAO_0000019,Autocuration,,13657,"Binding affinity to 5-hydroxytryptamine 2 receptor using calf frontal cortex, [3H]- ketanserin, and spiperone for NSB",B,,,Bos taurus,9913.0,
2109,0,,BAO_0000019,Autocuration,,14331,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of bovine frontal cortex at 10e-7 M,B,,,Bos taurus,9913.0,
2110,0,,BAO_0000019,Autocuration,,14331,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of bovine frontal cortex,B,,,Bos taurus,9913.0,
2111,0,,BAO_0000019,Autocuration,,14331,Binding affinity of compound towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin (0.8 nM) ligand in frontal cortex bovine was determined,B,,,,,
2112,4,,BAO_0000019,Autocuration,,12685,Binding affinity for serotonin 5-hydroxytryptamine 2 receptor using [3H]ketanserin in guinea pig frontal cortex,B,,,Cavia porcellus,10141.0,
2113,4,,BAO_0000019,Autocuration,,14389,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of guinea pig frontal cortex membranes,B,,,Cavia porcellus,10141.0,
2114,4,,BAO_0000019,Autocuration,,14386,Compound was tested for its binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin from guinea pig frontal cortex,B,,,Cavia porcellus,10141.0,
2115,4,,BAO_0000224,Autocuration,,5732,Binding affinity towards cloned human 5-hydroxytryptamine 2 receptor was determined,B,,,,,
2116,4,,BAO_0000224,Autocuration,,16293,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,B,,,,,
2117,4,,BAO_0000224,Autocuration,,2078,In vitro binding affinity of compound against neuronal 5-hydroxytryptamine 2 receptor,B,,,,,
2118,8,,BAO_0000357,Autocuration,,5486,Binding affinity towards 5-HT7 receptor by the displacement of [3H]-5-CT] in human recombinant receptors in mammalian cell,B,,,,,
2119,4,,BAO_0000218,Autocuration,,11820,Effective dose through peroral route for in vivo inhibition against 5-hydroxytryptamine 2 receptor in male CF-1 mice by using radioligand [3H]ketanserin,B,In vivo,,,,
2120,4,,BAO_0000019,Autocuration,,10297,Hill number was determined for inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in mouse cerebral cortex,B,,,,,
2121,4,,BAO_0000224,Autocuration,,13704,Inhibitory activity against serotonin 5-hydroxytryptamine 2 receptor from mice.,B,,,,,
2122,5,,BAO_0000019,Autocuration,,10297,Inhibitory activity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]ketanserin in mouse cerebral cortex,B,,,Mus musculus,10090.0,
2123,4,,BAO_0000218,Autocuration,,11820,Effective dose through peroral route for in vivo inhibition against 5-hydroxytryptamine 2 receptor in male CF-1 mice by using radioligand [3H]ketanserin,B,In vivo,,,,
2124,5,,BAO_0000019,Autocuration,,10297,Binding affinity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]-ketanserin in mouse cerebral cortex,B,,,Mus musculus,10090.0,
2125,4,,BAO_0000224,Autocuration,,11555,The compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2 receptor,B,,,,,
2126,4,,BAO_0000224,Autocuration,,11555,In vitro binding affinity for serotonin 5-hydroxytryptamine (5-HT) 2 receptors,B,,,,,
2127,4,,BAO_0000224,Autocuration,,11555,The compound was tested in vitro for its binding affinity towards serotonin 5-hydroxytryptamine 2 receptor; nd = no data,B,,,,,
2128,5,,BAO_0000019,Autocuration,,10297,Hill number was determined for inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in mouse cerebral cortex,B,,,Mus musculus,10090.0,
2129,4,,BAO_0000224,Autocuration,,16688,Binding affinity for porcine 5-hydroxytryptamine 2 receptor using [3H]- ketanserin,B,,,Sus scrofa,9823.0,
2130,4,,BAO_0000224,Autocuration,,16688,Binding affinity for porcine 5-hydroxytryptamine 2 receptor using [3H]- ketanserin with 10 uM prazosin,B,,,Sus scrofa,9823.0,
2131,0,,BAO_0000221,Autocuration,,5333,Compound was tested in vitro for its ability to compete with [3H]-ketanserin at 5-hydroxytryptamine 2 receptor in porcine brain homogenate,B,,,,,
2132,0,,BAO_0000221,Autocuration,,4437,In vitro for its ability to displace [3H]- ketanserin from 5-hydroxytryptamine 2 receptor in porcine brain homogenate,B,,,,,
2133,8,,BAO_0000357,Autocuration,,5033,Ability to displace the radioligand [3H]mesulergine from pig choroid plexus 5-hydroxytryptamine 2 receptor,B,,,Sus scrofa,9823.0,
2134,4,,BAO_0000019,Autocuration,,15267,Inhibition of [3H]- Ketanserin binding against rat brain 5-hydroxytryptamine 2 receptor,B,,,,,
2135,4,,BAO_0000019,Autocuration,,15267,Inhibition of [3H]- Ketanserin binding against rat brain 5-hydroxytryptamine 2 receptor,B,,,,,
2136,4,,BAO_0000019,Autocuration,,11820,Binding affinity against 5-hydroxytryptamine 2 receptor from rat cortical synaptosomal membrane using radioligand [3H]ketanserin.,B,,,,,
2137,4,,BAO_0000224,Autocuration,,9069,Evaluated for binding activity against [3H]ketanserin as radioligand for 5-hydroxytryptamine 2 receptor,B,,,,,
2138,5,,BAO_0000019,Autocuration,,9162,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein; ND means no data,B,,,Rattus norvegicus,10116.0,
2139,4,,BAO_0000019,Autocuration,,9162,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein.,B,,,,,
2140,4,,BAO_0000019,Autocuration,,9162,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein; no appreciable 5-HT2 receptor affinity,B,,,,,
2141,4,,BAO_0000019,Autocuration,,10428,Antagonistic activity against (5-hydroxytryptamine 2 receptor) serotonin-induced contractions in the rat jugular vein,F,,,,,
2142,4,,BAO_0000019,Autocuration,,9628,Binding affinity to the 5-hydroxytryptamine 2 receptor assayed by antagonism of serotonin-induced contractions in the rat jugular vein,B,,,,,
2143,4,,BAO_0000224,Autocuration,,12704,Binding affinity against serotonin 5-hydroxytryptamine 2 receptor,B,,,,,
2144,5,,BAO_0000224,Autocuration,,15453,Percent decrease in 5-hydroxytryptamine 2 receptor binding using ketanserin,B,,,Rattus norvegicus,10116.0,
2145,4,,BAO_0000224,Autocuration,,188,Tested for the effect on binding at 5-hydroxytryptamine 2 receptor; No activity,B,,,,,
2146,4,,BAO_0000224,Autocuration,,10349,Effect of 2 week administration of compound on 5-hydroxytryptamine 2 receptor binding by using 0.4 nM dose of [3H]- spiperone as a radioligand.,B,,,,,
2147,4,,BAO_0000224,Autocuration,,10349,Effect of 2 week administration of compound on 5-hydroxytryptamine 2 receptor binding by using 0.6 nM dose of [3H]- spiperone as a radioligand.,B,,,,,
2148,4,,BAO_0000224,Autocuration,,8868,Compound was tested for its effect on 5-hydroxytryptamine 2 receptor saturation analysis,B,,,,,
2149,4,,BAO_0000224,Autocuration,,10025,Concentration necessary to achieve half maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 1 uM,B,,,,,
2150,4,,BAO_0000224,Autocuration,,10025,"Concentration necessary to achieve half maximal inhibition of [3H]ketanserin, binds to 5-hydroxytryptamine 2 receptor at 1 uM",B,,,,,
2151,4,,BAO_0000224,Autocuration,,11702,Compound was tested for the inhibition of quipazine binding at 5-HT2 receptor,B,,,,,
2152,4,,BAO_0000224,Autocuration,,11702,Compound was tested for the inhibition of quipazine binding at 5-hydroxytryptamine 2 receptor,B,,,,,
2153,4,,BAO_0000224,Autocuration,,11702,Compound was tested for the inhibition of quipazine binding at 5-hydroxytryptamine 2 receptor; NT=Not tested,B,,,,,
2154,4,,BAO_0000019,Autocuration,,11702,Compound was tested for the inhibition of quipazine induced head twitches in rats,F,,,,,
2155,4,,BAO_0000019,Autocuration,,11702,Compound was tested for the inhibition of quipazine induced head twitches in rats; NT=Not tested,F,,,,,
2156,4,,BAO_0000221,Autocuration,10000000.0,10085,Ability to bind at 5-hydroxytryptamine 2 receptor of rat hippocampus by displacing [3H]spiperone,B,,,,,
2157,4,,BAO_0000221,Autocuration,10000000.0,10085,Ability to bind at serotonin 5-hydroxytryptamine 2 receptors of rat hippocampus by displacing [3H]spiperone,B,,,,,
2158,5,,BAO_0000221,Autocuration,955.0,9630,Displacement of [3H]spiroperidol from 5-hydroxytryptamine 2 receptor in rat brain,B,,,Rattus norvegicus,10116.0,
2159,4,,BAO_0000019,Autocuration,,11070,Ability to inhibit binding of [3H]KET to 5-hydroxytryptamine 2 receptor in rat cortex,B,,,,,
2160,4,,BAO_0000249,Autocuration,,9841,Ability to inhibit binding of titreated spiperone to 5-hydroxytryptamine 2 receptor in rat brain frontal cortex membranes,B,,,,,
2161,4,,BAO_0000249,Autocuration,,9841,Ability to inhibit binding of titreated spiperone to the 5-hydroxytryptamine 2 receptor in rat brain frontal cortex membranes,B,,,,,
2162,4,,BAO_0000019,Autocuration,,13291,Affinity for 5-hydroxytryptamine 2 receptor binding sites by its ability to displace [3H]spiperone from rat frontal cortex.,B,,,,,
2163,4,,BAO_0000019,Autocuration,,10590,Antagonistic activity against 5-hydroxytryptamine 2 receptor on rat frontal cortex membrane.,F,,,,,
2164,5,,BAO_0000221,Autocuration,955.0,9064,Binding affinity against serotonin-2 receptor in rat brain using [3H]spiroperidol,B,,,Rattus norvegicus,10116.0,
2165,5,,BAO_0000249,Autocuration,,12268,Binding affinity at 5-hydroxytryptamine 2 receptor by the inhibition of binding to [3H]ketanserin in rat cortical membranes,B,,,Rattus norvegicus,10116.0,
2166,4,,BAO_0000221,Autocuration,955.0,13508,Binding affinity against 5-hydroxytryptamine 2 receptor in rat brain using [3H]ketanserin as radioligand,B,,,,,
2167,4,,BAO_0000019,Autocuration,,11279,5-hydroxytryptamine 2 receptor antagonistic activity on the rat tail artery determined by Schild plot.,F,,,,,
2168,4,,BAO_0000019,Autocuration,,11200,In vitro antagonistic activity against the contraction induced by 5-HT through 5-HT2 receptor in rat thoracic aortic strips,F,,,,,
2169,4,,BAO_0000019,Autocuration,,11200,In vitro antagonistic activity tested against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,F,,,,,
2170,4,,BAO_0000019,Autocuration,,11200,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips; NC=non competitive antagonism,F,,,,,
2171,4,,BAO_0000019,Autocuration,,11200,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips; NC=non competitive antagonism,F,,,,,
2172,4,,BAO_0000019,Autocuration,,11200,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,F,,,,,
2173,4,,BAO_0000220,Autocuration,955.0,9231,Tested for 5-hydroxytryptamine 2 receptor binding ability by displacement of [3H]spiperone from rat brain frontal cortex synaptosomes,B,,,,,
2174,4,,BAO_0000019,Autocuration,,9737,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex using [3H]ketanserin as radioligand,B,,,,,
2175,4,,BAO_0000249,Autocuration,955.0,9737,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,B,,,,,
2176,4,,BAO_0000019,Autocuration,,9737,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex,B,,,,,
2177,4,,BAO_0000019,Autocuration,,9737,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex using [3H]ketanserin as radioligand,B,,,,,
2178,5,,BAO_0000019,Autocuration,,11828,isplacement of [3H]DOB from rat cortex homogenate 5-hydroxytryptamine 2 receptor,B,,,Rattus norvegicus,10116.0,
2179,4,,BAO_0000019,Autocuration,,12253,Binding affinity of 5-hydroxytryptamine 2 receptor using [3H]- ketanserin in rat frontal cortex,B,,,,,
2180,4,,BAO_0000019,Autocuration,,12253,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin in rat frontal cortex,B,,,,,
2181,4,,BAO_0000019,Autocuration,,11279,"5-hydroxytryptamine 2 receptor antagonistic activity at concentrations of<br>3,10 and 30 uM on the rat tail artery.",F,,,,,
2182,4,,BAO_0000019,Autocuration,,11866,Binding affinity for 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- ketanserin,B,,,,,
2183,5,,BAO_0000224,Autocuration,,14424,Binding affinity against 5-hydroxytryptamine 2 receptor in serotonin-induced contraction of the rat aorta,B,,,Rattus norvegicus,10116.0,
2184,5,,BAO_0000019,Autocuration,,15180,Displacement of [3H]ketanserin from rat brain 5-hydroxytryptamine 2 receptor,B,,,Rattus norvegicus,10116.0,
2185,5,,BAO_0000019,Autocuration,,15180,Displacement of [3H]ketanserin from rat brain 5-hydroxytryptamine 2 receptor,B,,,Rattus norvegicus,10116.0,
2186,5,,BAO_0000019,Autocuration,,9786,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat frontal cortex homogenate,B,,,Rattus norvegicus,10116.0,
2187,4,,BAO_0000224,Autocuration,,12132,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]-ketanserin as radioligand.,B,,,,,
2188,4,,BAO_0000249,Autocuration,,5486,Binding affinity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]ketanserin in rat cerebral cortex membrane,B,,,,,
2189,4,,BAO_0000019,Autocuration,,15316,Compound was evaluated for its ability to displace [3H]ketanserin binding from cloned rat cerebral cortex membranes 5-hydroxytryptamine 2 receptor,B,,,,,
2190,4,,BAO_0000019,Autocuration,,16429,In vitro binding affinity to 5-hydroxytryptamine 2 receptor of rat cerebral cortex membranes using [3H]ketanserin as the radioligand,B,,,,,
2191,4,,BAO_0000224,Autocuration,,14617,pKi value for 5-hydroxytryptamine 2 receptor binding site,B,,,,,
2192,4,,BAO_0000221,Autocuration,955.0,11351,Inhibitory constant (1 uM) was measured on 5-hydroxytryptamine 2 receptor/uptake using [3H]- ketanserin as radioligand in rat brain cortex.,B,,,,,
2193,4,,BAO_0000019,Autocuration,,11279,5-hydroxytryptamine 2 receptor antagonistic activity on the rat tail artery determined by Schild plot.,F,,,,,
2194,4,,BAO_0000019,Autocuration,,9523,Binding affinity at 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,B,,,,,
2195,4,,BAO_0000019,Autocuration,,9523,Binding affinity at 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,B,,,,,
2196,4,,BAO_0000019,Autocuration,,9523,Binding affinity at [3H]DOB labeled sites of 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,B,,,,,
2197,4,,BAO_0000019,Autocuration,,9523,Binding affinity at [3H]DOB labeled sites of 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,B,,,,,
2198,4,,BAO_0000019,Autocuration,,9523,Binding affinity at [3H]KET labeled sites of 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,B,,,,,
2199,4,,BAO_0000019,Autocuration,,9523,Binding affinity at [3H]KET labeled sites of 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,B,,,,,
2200,4,,BAO_0000224,Autocuration,,9523,Hill coefficient of compound was determined,B,,,,,
2201,0,,BAO_0000019,Autocuration,,4771,Ancillary Binding affinity towards rat 5-hydroxytryptamine 2 receptor,B,,,,,
2202,5,,BAO_0000019,Autocuration,,5033,Ability to displace the radioligand [3H]5-carboximidotryptamine ([3H]-ketanserin) from 5-hydroxytryptamine 2 receptor of rat cerebral cortex membrane,B,,,Rattus norvegicus,10116.0,
2203,8,,BAO_0000019,Expert,,10845,Binding affinity against rat 5-hydroxytryptamine 2 receptor in rat cerebral cortex tissue using [3H]spiperone as radioligand,B,,,,,
2204,8,,BAO_0000019,Expert,,10845,Binding affinity against rat 5-hydroxytryptamine 2 receptor in rat cerebral cortex tissue using [3H]spiperone as radioligand; IA-Inactive,B,,,,,
2205,8,,BAO_0000357,Autocuration,,16288,Affinity at 5-hydroxytryptamine 2 receptor (For ketanserin = Ki(nM)= 0.7+/-0.09),B,,,,,
2206,8,,BAO_0000019,Autocuration,,16288,Affinity at 5-hydroxytryptamine 2 receptor from rat frontal cortex using [3H]ketanserin as radioligand (For ketanserin = Ki(nM)=0.7+/-0.09),B,,,,,
2207,8,,BAO_0000019,Autocuration,,16190,Binding affinity for 5-hydroxytryptamine 2 receptor of rat cortical membrane using [3H]DOB radioligand,B,,,,,
2208,5,,BAO_0000224,Autocuration,,12463,Tested in vitro for receptor binding affinity against 5-hydroxytryptamine 2 receptor using radioligand [3H]ketanserin,B,,,Rattus norvegicus,10116.0,
2209,4,,BAO_0000224,Autocuration,,9699,"Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- 1-(4-bromo-2,5-dimethoxy-phenyl)-2-aminopropane (D) as radioligand",B,,,,,
2210,4,,BAO_0000224,Autocuration,,9699,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- ketanserin as radioligand,B,,,,,
2211,4,,BAO_0000019,Autocuration,,11662,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",B,,,,,
2212,4,,BAO_0000224,Autocuration,,1205,Inhibitory concentration against 5-hydroxytryptamine 2 receptor,B,,,,,
2213,0,,BAO_0000219,Autocuration,,11376,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2 receptor from mammalian clones expressed in CHO cell membranes using [3H]-ketanserin as radioligand,B,,,,,
2214,4,,BAO_0000219,Autocuration,,11376,"Binding affinity towards 5-hydroxytryptamine 2 receptor expressed in CHO cell membranes using [3H]ketanserin (60 Ci/mmol, 1 nM)",B,,,,,
2215,4,,BAO_0000224,Autocuration,,4639,Compound was tested for binding affinity against 5-hydroxytryptamine 2 receptor,B,,,,,
2216,4,,BAO_0000224,Autocuration,,2222,Compound was tested for inhibitory activity against 5-hydroxytryptamine 2 receptor,B,,,,,
2217,4,,BAO_0000224,Autocuration,,1558,Compound was tested for its affinity towards 5-hydroxytryptamine 2 receptor,B,,,,,
2218,4,,BAO_0000224,Autocuration,,1089,Tested for binding affinity for 5-hydroxytryptamine 2 receptor,B,,,,,
2219,4,,BAO_0000249,Autocuration,,386,The compound was evaluated for its ability to displace [3H]ketanserin from 5-hydroxytryptamine 2 receptor in cellular brain membranes,B,,,,,
2220,4,,BAO_0000224,Autocuration,,2474,Compound was measured for its binding affinity at 5-hydroxytryptamine 2 receptor at a concentration of 10 uM using [3H]ketanserin as radioligand,B,,,,,
2221,4,,BAO_0000224,Autocuration,,17066,Binding affinity towards 5-HT2 receptor,B,,,,,
2222,4,,BAO_0000224,Autocuration,,959,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor,B,,,,,
2223,4,,BAO_0000224,Autocuration,,6398,Compound was evaluated for 5-hydroxytryptamine 2 receptor binding,B,,,,,
2224,4,,BAO_0000224,Autocuration,,11889,In vitro binding affinity against rat 5-hydroxytryptamine 2 receptor.,B,,,,,
2225,4,,BAO_0000224,Autocuration,,4221,In vitro binding affinity for 5-hydroxytryptamine 2 receptor,B,,,,,
2226,4,,BAO_0000224,Autocuration,,11026,The compound was tested for binding affinity against 5-hydroxytryptamine 2 receptor using ketanserin as radioligand,B,,,,,
2227,4,,BAO_0000224,Autocuration,,11866,Binding affinity for 5-hydroxytryptamine 2 receptor was determined,B,,,,,
2228,4,,BAO_0000224,Autocuration,,4221,In vitro binding affinity for 5-hydroxytryptamine 2 receptor,B,,,,,
2229,0,,BAO_0000019,Autocuration,,13950,In Vitro binding affinity for 5-hydroxytryptamine 2 receptor,B,,,,,
2230,4,,BAO_0000224,Autocuration,,1263,5-hydroxytryptamine 2 receptor binding affinity,B,,,,,
2231,8,,BAO_0000357,Autocuration,,13291,Binding affinity against 5-hydroxytryptamine 2 receptor was determined using [ [3H]spiperone radioligand,B,,,,,
2232,8,,BAO_0000357,Autocuration,,10812,Compound was tested for the binding affinity against 5-hydroxytryptamine 2 receptor by using [3H]ketanserin as radioligand,B,,,,,
2233,4,,BAO_0000224,Autocuration,,13020,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 10e-5 M,B,,,,,
2234,4,,BAO_0000224,Autocuration,,13021,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of central nervous system,B,,,,,
2235,4,,BAO_0000224,Autocuration,,13020,Ketanserin binding to 5-hydroxytryptamine 2 receptor at 10e-5 M,B,,,,,
2236,8,,BAO_0000357,Autocuration,,14532,Inhibitory activity against 5-hydroxytryptamine 2 receptor using [3H]-ketanserin as radioligand at 10e-5 M concentration,B,,,,,
2237,8,,BAO_0000357,Autocuration,,13944,Binding affinity against 5-hydroxytryptamine 2 receptor,B,,,,,
2238,8,,BAO_0000357,Autocuration,,14331,Binding affinity against 5-hydroxytryptamine 2 receptor,B,,,,,
2239,8,,BAO_0000357,Autocuration,,14118,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand,B,,,,,
2240,8,,BAO_0000357,Autocuration,,13033,Binding affinity against serotonergic 5-HT2 receptor,B,,,,,
2241,8,,BAO_0000357,Autocuration,,10321,Binding affinity for 5-hydroxytryptamine 2 receptor was determined by using [3H]ketanserin as radioligand,B,,,,,
2242,8,,BAO_0000357,Autocuration,,12918,Compound was evaluated for the binding affinity at 5- HT2 receptor,B,,,,,
2243,8,,BAO_0000357,Autocuration,,15120,Compound was tested for binding affinity using [3H]ketanserin against 5-hydroxytryptamine 2 receptor,B,,,,,
2244,8,,BAO_0000218,Autocuration,,2613,In vivo binding affinity was evaluated against 5-hydroxytryptamine 2 receptor,B,,,,,
2245,5,,BAO_0000224,Autocuration,,13378,Inhibitory activity against cloned human 5-HT2 receptor,B,,,Homo sapiens,9606.0,
2246,5,,BAO_0000219,Autocuration,,2331,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells",B,,,Homo sapiens,9606.0,
2247,5,,BAO_0000219,Autocuration,,2331,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells.",B,,,Homo sapiens,9606.0,
2248,5,,BAO_0000219,Autocuration,,2331,"Tested in vitro for the inhibition of [3H]-ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells; Inactive",B,,,Homo sapiens,9606.0,
2249,5,,BAO_0000219,Autocuration,,2331,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells; not tested",B,,,Homo sapiens,9606.0,
2250,4,,BAO_0000224,Autocuration,,4170,Binding affinity towards 5-hydroxytryptamine 2 receptor,B,,,,,
2251,4,,BAO_0000224,Autocuration,,15453,Percent decrease in 5-hydroxytryptamine 2 receptor binding using ketanserin,B,,,,,
2252,8,,BAO_0000357,Autocuration,,1479,Binding affinity towards 5-hydroxytryptamine 2 receptor,B,,,,,
2253,4,,BAO_0000224,Autocuration,,11139,Binding affinity towards 5-hydroxytryptamine 2- receptor using [3H]ketanserin as radioligand in competitive binding assay,B,,,,,
2254,8,,BAO_0000357,Expert,,13969,Binding affinity against 5-hydroxytryptamine 2A receptor was measured using [3H]ketanserin as radioligand,B,,,,,
2255,8,,BAO_0000357,Expert,,13392,Binding affinity towards 5-hydroxytryptamine 2A receptor,B,,,,,
2256,8,,BAO_0000019,Expert,,14430,Affinity towards 5-hydroxytryptamine 2A receptor in membranes from bovine frontal cortex using [3H]ketanserin,B,,,,,
2257,8,,BAO_0000357,Autocuration,,13181,Binding affinity was determined against 5-hydroxytryptamine 2A receptor,B,,,Cavia porcellus,10141.0,
2258,8,,BAO_0000357,Autocuration,,17200,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,B,,,,,
2259,8,,BAO_0000357,Autocuration,,17200,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,B,,,,,
2260,8,,BAO_0000357,Autocuration,,17200,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,B,,,,,
2261,8,,BAO_0000357,Autocuration,,13463,Binding affinity analysed on 5-HT 2A human clone using [3H]ketanserin as radioligand,B,,,,,
2262,8,,BAO_0000219,Autocuration,,6347,Effective concentration against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand,B,,,,,
2263,9,,BAO_0000219,Expert,,6857,Functional activity against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader,F,,,Homo sapiens,9606.0,
2264,8,,BAO_0000219,Autocuration,,4176,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line,F,,,,,
2265,8,,BAO_0000219,Autocuration,,4176,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line; no data,F,,,,,
2266,8,,BAO_0000219,Autocuration,,4176,Functional antagonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line,F,,,,,
2267,8,,BAO_0000219,Autocuration,,6347,"Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand, expressed as Emax",B,,,,,
2268,8,,BAO_0000219,Autocuration,,6347,"Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells, expressed as Emax",B,,,,,
2269,8,,BAO_0000357,Autocuration,,15331,Affinity of compound towards human 5-hydroxytryptamine 2A receptor was evaluated using radioligand binding technique,B,,,,,
2270,9,,BAO_0000357,Expert,,16146,Inhibition of human 5-hydroxytryptamine 2A receptor,B,,,Homo sapiens,9606.0,
2271,8,,BAO_0000219,Autocuration,,15250,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,B,,,,,
2272,8,,BAO_0000219,Expert,,13631,Inhibitory concentration against human 5-HT2A receptor in BEK cells,B,,,,,
2273,8,,BAO_0000357,Autocuration,,3805,In vitro binding affinity against human 5-hydroxytryptamine 2A receptor at a concentration of 100 (nM),B,,,,,
2274,8,,BAO_0000219,Autocuration,,4011,Ability to displace [3H]ketanserin from CHO cells expressing human 5-hydroxytryptamine 2A receptor was determined,B,,,,,
2275,8,,BAO_0000219,Expert,,4012,Displacement of [3H]ketanserin from CHO cells expressing human 5-hydroxytryptamine 2A receptor.,B,,,,,
2276,8,,BAO_0000219,Expert,,6366,Ability to displace [125I]R91150 from human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells,B,,,,,
2277,8,,BAO_0000219,Expert,,15949,Ability to displace [3H]ketanserin binding to human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,B,,,,,
2278,8,,BAO_0000019,Autocuration,,14093,Agonist activity at cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI radioligand,F,,,,,
2279,8,,BAO_0000019,Autocuration,,13481,Agonistic activity at cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,F,,,,,
2280,8,,BAO_0000219,Autocuration,,6347,Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand,B,,,,,
2281,8,,BAO_0000219,Autocuration,,6347,Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand; Nd means not done,B,,,,,
2282,8,,BAO_0000019,Autocuration,,14093,Antagonist activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]-Ketanserin radioligand,F,,,,,
2283,8,,BAO_0000019,Autocuration,,14093,Antagonist activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin radioligand; Not tested,F,,,,,
2284,8,,BAO_0000019,Autocuration,,13481,Antagonistic activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,F,,,,,
2285,8,,BAO_0000357,Autocuration,,14442,Binding ability of compound at cloned human 5-hydroxytryptamine 2A receptor using [125 I]DOI as radioligand,B,,,,,
2286,8,,BAO_0000357,Autocuration,,14442,Binding ability of compound at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,B,,,,,
2287,8,,BAO_0000357,Autocuration,,14755,Binding activity against cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as the radioligand.,B,,,,,
2288,8,,BAO_0000357,Autocuration,,16441,Binding affinity against 5-hydroxytryptamine 2A receptor in humans,B,,,,,
2289,8,,BAO_0000357,Autocuration,,14744,Binding affinity against the cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as the radioligand,B,,,,,
2290,8,,BAO_0000219,Expert,,16659,Binding affinity for displacement of [3H]ketanserin to human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,B,,,,,
2291,8,,BAO_0000357,Autocuration,,3307,Binding affinity of compound to human 5-hydroxytryptamine 2A receptor,B,,,,,
2292,9,,BAO_0000019,Expert,,6857,Affinity for human 5-hydroxytryptamine 2A receptor expressed in mammalian cell line,B,,,Homo sapiens,9606.0,
2293,8,,BAO_0000357,Expert,,5635,Binding affinity against 5-hydroxytryptamine 2A receptor using [125I]DOI radioligand.,B,,,,,
2294,9,,BAO_0000357,Expert,,4234,Binding affinity to cloned human 5-hydroxytryptamine 2A receptor,B,,,Homo sapiens,9606.0,
2295,8,,BAO_0000357,Autocuration,,15527,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand.,B,,,,,
2296,8,,BAO_0000219,Expert,,6588,Binding affinity towards human 5-hydroxytryptamine 2A receptor by the displacement of [3H]ketanserin radioligand from the cloned receptor expressed in CHO cells,B,,,,,
2297,8,,BAO_0000219,Expert,,13631,Binding affinity towards human 5-HT2A receptor in BEK cells,B,,,,,
2298,8,,BAO_0000357,Autocuration,,17723,Binding affinity towards human serotonin 5-hydroxytryptamine 2A receptor,B,,,,,
2299,8,,BAO_0000357,Autocuration,,14770,Binding affinity for recombinant human 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand.,B,,,,,
2300,9,,BAO_0000357,Expert,,16293,Binding affinity for human 5-hydroxytryptamine 2A receptor,B,,,Homo sapiens,9606.0,
2301,8,,BAO_0000357,Autocuration,,16209,Binding affinity towards human 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,B,,,,,
2302,8,,BAO_0000219,Autocuration,,12469,Binding affinity was measured on 5-hydroxytryptamine 2A receptor in GF6 cells transfected with human 5-HT2A gene labeled with [3H]ketanserin,B,,,,,
2303,8,,BAO_0000357,Autocuration,,15363,Compound was tested for the displacement of [125I]-DOI from clone human 5-hydroxytryptamine 2A receptor,B,,,,,
2304,8,,BAO_0000357,Autocuration,,15363,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2A receptor,B,,,,,
2305,8,,BAO_0000019,Expert,,16441,"Tested on genetically transfected COS7 cell membranes selectively expressing human 5-hydroxytryptamine 2A receptor, using [3H]ketanserin as radioligand",B,,,,,
2306,8,,BAO_0000357,Autocuration,,8,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in human using [3H]ketanserin as radioligand,B,,,,,
2307,8,,BAO_0000219,Autocuration,,4176,In vitro binding affinity towards human 5-hydroxytryptamine 2A receptor expressed in HEK293 cells was determined using [3H]ketanserin as radioligand,B,,,,,
2308,8,,BAO_0000019,Autocuration,,17085,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2A receptor,B,,,,,
2309,8,,BAO_0000357,Autocuration,,17200,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,B,,,,,
2310,9,,BAO_0000357,Expert,,17200,Inhibitory constant determined against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,B,,,Homo sapiens,9606.0,
2311,9,,BAO_0000219,Expert,,4013,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor expressed in CHO cells,B,,,Homo sapiens,9606.0,
2312,8,,BAO_0000357,Autocuration,,5088,Tested for binding affinity towards 5-hydroxytryptamine 2A receptor,B,,,,,
2313,9,,BAO_0000357,Expert,,5088,Displacement of [3H]DOB from human 5-hydroxytryptamine 2A receptor,B,,,Homo sapiens,9606.0,
2314,8,,BAO_0000357,Autocuration,,5088,Tested for binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]DOB as labeled ligand; binding data not obtained,B,,,,,
2315,9,,BAO_0000357,Expert,,5088,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor,B,,,Homo sapiens,9606.0,
2316,8,,BAO_0000357,Autocuration,,5088,Tested for binding affinity towards human 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand,B,,,,,
2317,8,,BAO_0000357,Autocuration,,5088,Tested for binding affinity towards human 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,B,,,,,
2318,4,,BAO_0000019,Autocuration,,9786,Ability to displace 0.75 nM [3H]ketanserin in 5-hydroxytryptamine 2 receptor from rat frontal cortex homogenate,B,,,,,
2319,5,,BAO_0000019,Autocuration,,9205,Ability to inhibit [3H]spiperone binding to 5-hydroxytryptamine 2 receptor determined in rat,B,,,Rattus norvegicus,10116.0,
2320,4,,BAO_0000224,Autocuration,,11257,Affinity on 5-hydroxytryptamine 2 receptor labeled by [125I]DOI,B,,,,,
2321,4,,BAO_0000019,Autocuration,,9362,Affinity towards [3H]- DOB -labeled 5-hydroxytryptamine 2 receptor sites in rat cortical homogenates,B,,,,,
2322,4,,BAO_0000019,Autocuration,,9362,Affinity towards [3H]- ketanserin-labeled 5-hydroxytryptamine 2 receptor sites in rat cortical homogenates,B,,,,,
2323,4,,BAO_0000224,Autocuration,,10590,Inhibition of 5-hydroxytryptamine 2 induced vasoconstriction of rat caudal artery.,B,,,,,
2324,4,,BAO_0000019,Autocuration,,10468,Binding affinity against 5-hydroxytryptamine 2 receptor of rat frontal cortex using [3H]ketanserin radioligand,B,,,,,
2325,4,,BAO_0000019,Autocuration,,13050,Binding affinity against 5-hydroxytryptamine 2 receptor from rat frontal cortex using [125]-(R)-DOI as radioligand,B,,,,,
2326,4,,BAO_0000019,Autocuration,,11624,Binding affinity against 5-hydroxytryptamine 2 receptor in rat using [3H]ketanserin as radioligand,B,,,,,
2327,4,,BAO_0000019,Autocuration,,10468,Binding affinity against 5-hydroxytryptamine 2 receptor of rat frontal cortex using [3H]ketanserin radioligand,B,,,,,
2328,4,,BAO_0000224,Autocuration,,10330,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand,B,,,,,
2329,4,,BAO_0000224,Autocuration,,10062,Binding affinity at rat 5-hydroxytryptamine 2 receptor by [3H]ketanserin displacement.,B,,,,,
2330,4,,BAO_0000224,Autocuration,,11642,Binding affinity determined in radioreceptor binding assay by using [3H]ketanserin radioligand against 5-hydroxytryptamine 2 receptor,B,,,,,
2331,4,,BAO_0000224,Autocuration,,10062,Binding affinity determined in radioreceptor binding assay by using [3H]ketanserin radioligand against 5-hydroxytryptamine 2 receptor,B,,,,,
2332,4,,BAO_0000219,Autocuration,,13427,Binding affinity of [3H]ketanserin towards 5-hydroxytryptamine 2 receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,B,In vitro,,,,
2333,5,,BAO_0000224,Autocuration,,12280,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor,B,,,Rattus norvegicus,10116.0,
2334,5,,BAO_0000224,Autocuration,,4101,Binding affinity for 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]ketanserin,B,,,Rattus norvegicus,10116.0,
2335,4,,BAO_0000224,Autocuration,,10062,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 2 receptor,B,,,,,
2336,4,,BAO_0000224,Autocuration,,11147,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]DOB as,B,,,,,
2337,5,,BAO_0000219,Autocuration,,2395,Binding affinity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,B,,,Rattus norvegicus,10116.0,
2338,5,,BAO_0000219,Autocuration,,2395,Binding affinity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,B,,,Rattus norvegicus,10116.0,
2339,5,,BAO_0000019,Autocuration,,9098,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- DOB as a radioligand,B,,,Rattus norvegicus,10116.0,
2340,4,,BAO_0000019,Autocuration,,9098,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- DOB as a radioligand.,B,,,,,
2341,5,,BAO_0000019,Autocuration,,9098,Binding affinity to 5-hydroxytryptamine 2 receptor of rat cortical membranes using [3H]- DOB; ND means no data.,B,,,Rattus norvegicus,10116.0,
2342,4,,BAO_0000224,Autocuration,,9443,Binding affinity towards 5-hydroxytryptamine 2 receptor,B,,,,,
2343,4,,BAO_0000224,Autocuration,,9443,Binding affinity towards 5-hydroxytryptamine 2 receptor at 1.0 uM concentration,B,,,,,
2344,4,,BAO_0000019,Autocuration,,9699,"Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- 1-(4-bromo-2,5-dimethoxy-phenyl)-2-aminopropane (D) as radioligand in rat frontal cortex",B,,,,,
2345,4,,BAO_0000019,Autocuration,,9699,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- ketanserin as radioligand in rat frontal cortex,B,,,,,
2346,4,,BAO_0000224,Autocuration,,9098,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,B,,,,,
2347,5,,BAO_0000224,Autocuration,,3070,Affinity for 5-hydroxytryptamine 2 receptor,B,,,Rattus norvegicus,10116.0,
2348,4,,BAO_0000224,Autocuration,,9547,Binding affinity towards serotonin 5-hydroxytryptamine 2 receptor of rat determined using 0.5 nM of [3H]ketanserin in binding assay,B,,,,,
2349,4,,BAO_0000019,Autocuration,,10444,Binding affinity was determined against 5-hydroxytryptamine 2 receptor from male Sprague-Dawley rat brain.,B,,,,,
2350,4,,BAO_0000019,Autocuration,,14617,Binding affinity which represents concentration giving half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor from rat tissue homogenate,B,,,,,
2351,4,,BAO_0000019,Autocuration,,14617,Binding affinity which represents concentration giving half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor rat tissue homogenate,B,,,,,
2352,4,,BAO_0000224,Autocuration,,11130,Binding constant against 5-hydroxytryptamine 2 receptor (in vitro),B,,,,,
2353,4,,BAO_0000218,Autocuration,,11130,Binding constant against 5-hydroxytryptamine 2 receptor (in vivo),B,In vivo,,,,
2354,4,,BAO_0000221,Autocuration,955.0,14542,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin in rat brain,B,,,,,
2355,4,,BAO_0000224,Autocuration,,2797,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2 receptor from rat,B,,,,,
2356,4,,BAO_0000019,Autocuration,,11332,Compound was evaluated for in vitro binding affinity towards 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- spiperone as radioligand,B,,,,,
2357,4,,BAO_0000019,Autocuration,,11332,Compound was evaluated for in vitro binding affinity towards serotonin 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- spiperone as radioligand,B,,,,,
2358,4,,BAO_0000019,Autocuration,1870.0,10752,Compound was evaluated for its ability to displace 0.25 nM [125I](R)-DOI from binding sites in rat frontal cortex.,B,,,,,
2359,4,,BAO_0000224,Autocuration,,1185,Ability to displace [3H]ketanserin from serotonergic 5-hydroxytryptamine 2 receptor,B,,,,,
2360,4,,BAO_0000224,Autocuration,,1185,Compound was evaluated for its ability to displace [3H]ketanserin from serotonergic 5-hydroxytryptamine 2 receptor,B,,,,,
2361,5,,BAO_0000224,Autocuration,,11624,Binding affinity against 5-Hydroxy tryptamine 2 (5-hydroxytryptamine 2)receptor,B,,,Rattus norvegicus,10116.0,
2362,4,,BAO_0000019,Autocuration,,1344,Compound was evaluated for its binding affinity to 5-hydroxytryptamine 2 receptor in rat cortex using [3H]ketanserin radioligand assay,B,,,,,
2363,5,,BAO_0000019,Autocuration,2435.0,15453,Binding affinity against 5-hydroxytryptamine 2 receptor in rat striatum using [3H]-RP62203,B,,,Rattus norvegicus,10116.0,
2364,4,,BAO_0000019,Autocuration,,11662,"Binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand",B,,,,,
2365,4,,BAO_0000019,Autocuration,,11662,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",B,,,,,
2366,4,,BAO_0000224,Autocuration,,10796,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 2 receptor,B,,,,,
2367,4,,BAO_0000224,Autocuration,,9069,Evaluated for binding activity against [3H]ketanserin as radioligand for 5-hydroxytryptamine 2 receptor,B,,,,,
2368,5,,BAO_0000019,Autocuration,,8814,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat cortical membrane homogenates,B,,,Rattus norvegicus,10116.0,
2369,5,,BAO_0000019,Autocuration,,8908,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat cortex,B,,,Rattus norvegicus,10116.0,
2370,4,,BAO_0000019,Autocuration,,9098,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand; ND means no data.,B,,,,,
2371,4,,BAO_0000019,Autocuration,,9098,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 (5-HT2) receptor using [3H]KET as a radioligand,B,,,,,
2372,4,,BAO_0000019,Autocuration,,9098,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand; ND means no data.,B,,,,,
2373,4,,BAO_0000019,Autocuration,,9098,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand.,B,,,,,
2374,4,,BAO_0000249,Autocuration,,9098,Binding affinity to 5-hydroxytryptamine 2 receptor in rat frontal cortical membranes by [3H]- KET displacement.,B,,,,,
2375,4,,BAO_0000019,Autocuration,,9098,Evaluated for the binding affinity to rat frontal cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand.;ND is not determined,B,,,,,
2376,4,,BAO_0000019,Autocuration,,9098,Evaluated for the binding affinity to rat frontal cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand;ND means no data,B,,,,,
2377,4,,BAO_0000019,Autocuration,,9161,In vitro binding affinity at 5-hydroxytryptamine 2 receptor in rat cortical tissue by [3H]spiperone displacement; No data.,B,,,,,
2378,4,,BAO_0000019,Autocuration,,9161,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 165 to 263,B,,,,,
2379,4,,BAO_0000019,Autocuration,,9161,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 2.4 to 5.3,B,,,,,
2380,4,,BAO_0000019,Autocuration,,9161,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]-Spiperone as the radioligand in rat cortical tissue.,B,,,,,
2381,4,,BAO_0000019,Autocuration,,9161,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.; value may range from 140 to 980,B,,,,,
2382,4,,BAO_0000019,Autocuration,,9161,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.; value may range from 76 to 299,B,,,,,
2383,4,,BAO_0000019,Autocuration,,9161,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]-Spiperone as the radioligand in rat cortical tissue; value may range from 12 to 66,B,,,,,
2384,4,,BAO_0000019,Autocuration,,9161,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 136 to 220,B,,,,,
2385,4,,BAO_0000019,Autocuration,,9161,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 197 to 341,B,,,,,
2386,4,,BAO_0000019,Autocuration,,9161,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 23 to 187,B,,,,,
2387,4,,BAO_0000019,Autocuration,,9161,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 29 to 132,B,,,,,
2388,4,,BAO_0000019,Autocuration,,9161,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 6 to 75,B,,,,,
2389,4,,BAO_0000019,Autocuration,,12094,In vitro binding affinity on 5-hydroxytryptamine 2 receptor is inhibition of binding of [125I]- I-LSD to P11 cells,B,,,,,
2390,4,,BAO_0000249,Autocuration,,12018,In vitro binding affinity towards 5-hydroxytryptamine 2 receptor in rat striatal membranes by [3H]ketanserin displacement.,B,,,,,
2391,4,,BAO_0000249,Autocuration,,10394,Inhibitory activity against 5-hydroxytryptamine 2 receptor in rat cortical membranes using [3H]ketanserin as a radioligand,B,,,,,
2392,4,,BAO_0000224,Autocuration,,15260,Inhibitory activity against rat cortical 5-hydroxytryptamine 2 receptor,B,,,,,
2393,5,,BAO_0000224,Autocuration,,11624,Inhibitory constant against 5-hydroxytryptamine 2 receptor,B,,,Rattus norvegicus,10116.0,
2394,4,,BAO_0000224,Autocuration,,13654,Percentage specific displacement of radioligand [3H]-ketanserin from 5-hydroxytryptamine 2 receptor,B,,,,,
2395,4,,BAO_0000019,Autocuration,,9541,Potency to displace [3H]- Spiperone from 5-hydroxytryptamine 2 receptor in rat striatum,B,,,,,
2396,4,,BAO_0000224,Autocuration,,11933,Tested for binding affinity against 5-hydroxytryptamine 2 receptor from rat frontal cortical regions using [3H]ketanserin as radioligand,B,,,,,
2397,4,,BAO_0000019,Autocuration,,15538,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex,B,,,,,
2398,4,,BAO_0000019,Autocuration,,15538,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex; NA means Not Active,B,,,,,
2399,4,,BAO_0000019,Autocuration,,15538,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex; not determined,B,,,,,
2400,5,,BAO_0000019,Autocuration,,8841,Displacement of [3H]ketanserin from rat prefrontal cortex 5-hydroxytryptamine 2 receptor,B,,,,,
2401,4,,BAO_0000224,Autocuration,,1455,Binding affinity to 5-hydroxytryptamine 2 receptor using [3H]ketanserin radioligand assay.,B,,,,,
2402,4,,BAO_0000224,Autocuration,,1455,Tested for its binding affinity to Tested for its binding affinity to 5-hydroxytryptamine 2 receptor using [3H]-ketanserin radioligand assay using [3H]-ketanserin radioligand assay,B,,,,,
2403,4,,BAO_0000019,Autocuration,,11752,The ability to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat whole brain,B,,,,,
2404,4,,BAO_0000221,Autocuration,955.0,11642,The binding affinity was measured on 5-hydroxytryptamine 2 receptor in rat brain tissue,B,,,,,
2405,4,,BAO_0000224,Autocuration,,12092,The binding affinity was measured on 5-hydroxytryptamine 2 receptor using [3H]- spiperone as radioligand.,B,,,,,
2406,4,,BAO_0000224,Autocuration,,3967,Binding affinity at 5-hydroxytryptamine 2 receptor from striata wistar rats by [3H]ketanserin displacement.,B,,,,,
2407,5,,BAO_0000224,Autocuration,,12771,Binding affinity towards 5-hydroxytryptamine 2 receptor,B,,,Rattus norvegicus,10116.0,
2408,4,,BAO_0000019,Autocuration,,11642,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2 receptor by displacing [3H]ketanserin radioligand in rat cerebral cortex,B,,,,,
2409,4,,BAO_0000224,Autocuration,,11628,The compound was tested in vitro for binding affinity towards 5-hydroxytryptamine 2 receptor by displacing [125]I-LSD radioligand,B,,,,,
2410,4,,BAO_0000224,Autocuration,,13654,Percentage specific displacement of radioligand [3H]ketanserin from 5-hydroxytryptamine 2 receptor,B,,,,,
2411,4,,BAO_0000019,Autocuration,,11200,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,F,,,,,
2412,4,,BAO_0000019,Autocuration,,11200,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,F,,,,,
2413,4,,BAO_0000218,Autocuration,,11200,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 1 hr after oral administration",F,In vivo,,,,
2414,4,,BAO_0000218,Autocuration,,11200,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 3h after oral administration",F,In vivo,,,,
2415,4,,BAO_0000218,Autocuration,,11200,"In vivo inhibitory activity of 3 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 1 hr after oral administration",F,In vivo,,,,
2416,4,,BAO_0000218,Autocuration,,11200,"In vivo inhibitory activity of 3 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 3h after oral administration",F,In vivo,,,,
2417,8,,BAO_0000221,Expert,955.0,15436,Affinity for 5-hydroxytryptamine 2A receptor in rat brain cortex by ability to displace [3H]ketanserin,B,,,,,
2418,9,,BAO_0000019,Expert,,15436,Affinity at 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,B,,,Rattus norvegicus,10116.0,
2419,8,,BAO_0000019,Autocuration,,14025,Affinity pKi for 5-hydroxytryptamine 2A receptor was measured in rat cortex homogenates,B,,,,,
2420,8,,BAO_0000357,Autocuration,,4342,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2A receptor was determined,B,,,,,
2421,9,,BAO_0000019,Expert,,13735,Displacement of [3H]ketanserin from 5-HT2A receptor of rat frontal cortex,B,,,Rattus norvegicus,10116.0,
2422,9,,BAO_0000357,Expert,,5816,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin,B,,,Rattus norvegicus,10116.0,
2423,8,,BAO_0000019,Expert,,14287,Binding affinity was evaluated in vitro by displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor on rat cortical membrane,B,,,,,
2424,8,,BAO_0000357,Autocuration,,15738,In vitro affinity against serotonin ( 5-hydroxytryptamine 2A receptor ) receptor,B,,,,,
2425,9,,BAO_0000357,Expert,,15738,In vitro affinity against serotonin 5-hydroxytryptamine 2A receptor,B,,,Rattus norvegicus,10116.0,
2426,8,,BAO_0000019,Autocuration,,15026,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat frontal cortex using [3H]-ketanserin as radioligand,B,,,,,
2427,8,,BAO_0000019,Expert,,16647,Half-maximal inhibition of [3H]- Ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex homogenate,B,,,,,
2428,8,,BAO_0000019,Autocuration,,16647,Half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat tissue homogenate,B,,,,,
2429,9,,BAO_0000019,Expert,,13345,Displacement of [3H]-ketanserin from rat brain 5-hydroxytryptamine 2A receptor,B,,,Rattus norvegicus,10116.0,
2430,8,,BAO_0000249,Autocuration,,1543,Inhibition constant for in vitro inhibition of [3H]ketanserin binding to rat frontal cortex membranes 5-hydroxytryptamine 2A receptor,B,,,,,
2431,8,,BAO_0000019,Autocuration,,12444,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor rat frontal cortex membrane,B,,,,,
2432,8,,BAO_0000019,Expert,,16404,Inhibitory constant on 5-hydroxytryptamine 2A receptor of Rat frontal cortex,B,,,,,
2433,8,,BAO_0000219,Autocuration,,16404,Inhibitory constant on human 5-hydroxytryptamine 2A receptor transfected in to CHO cells,B,,,,,
2434,8,,BAO_0000357,Expert,,15577,Kinetic inhibition constant evaluated by measuring serotonergic activity,B,,,,,
2435,8,,BAO_0000357,Autocuration,,15577,Serotonergic activity of the compound.,B,,,,,
2436,8,,BAO_0000249,Autocuration,,2495,Tested in vitro for its ability to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat frontal cortex membranes,B,,,,,
2437,9,,BAO_0000019,Expert,,15042,The binding affinity was evaluated on 5-hydroxytryptamine 2A receptor expressed in rat cortex by using [3H]ketanserin as radioligand.,B,,,Rattus norvegicus,10116.0,
2438,8,,BAO_0000249,Expert,,15026,In vitro ability to displace [3H]ketanserin binding from 5-hydroxytryptamine 2A receptor in rat striatal membrane.,B,,,,,
2439,9,,BAO_0000019,Expert,,12919,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,F,,,Rattus norvegicus,10116.0,
2440,9,,BAO_0000019,Expert,,12919,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,F,,,Rattus norvegicus,10116.0,
2441,9,,BAO_0000019,Expert,,12919,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,F,,,Rattus norvegicus,10116.0,
2442,8,,BAO_0000357,Autocuration,,15194,The compound was tested for the binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,B,,,,,
2443,8,,BAO_0000357,Autocuration,,15194,The compound was tested for the binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand.,B,,,,,
2444,8,,BAO_0000357,Expert,,4820,Binding affinity towards 5-hydroxytryptamine 2A receptor,B,,,,,
2445,8,,BAO_0000357,Autocuration,,6736,Binding affinity against serotonin 5-hydroxytryptamine 2A receptor was determined using human [125I]-eotaxin,B,,,,,
2446,8,,BAO_0000357,Autocuration,,5163,Binding affinity towards 5-hydroxytryptamine 2A receptor was determined at a concentration of 0.000001 mol/L,B,,,,,
2447,8,,BAO_0000357,Autocuration,,5163,Binding affinity towards 5-hydroxytryptamine 2A receptor was determined at a concentration of 0.00001 mol/L,B,,,,,
2448,8,,BAO_0000357,Autocuration,,6011,Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration,B,,,,,
2449,9,,BAO_0000357,Expert,,14294,Percent inhibition against 5-hydroxytryptamine 2A receptor using [3H]ketanserin at 1 uM,B,,,Homo sapiens,9606.0,
2450,8,,BAO_0000357,Autocuration,,5014,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 2A receptor,B,,,,,
2451,8,,BAO_0000357,Expert,,17066,Binding affinity towards 5-hydroxytryptamine 2A receptor,B,,,,,
2452,8,,BAO_0000357,Autocuration,,17515,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2A receptor; inactive at 10 uM,B,,,,,
2453,8,,BAO_0000357,Expert,,6736,Inhibition of [125I]-eotaxin binding to serotonin 5-hydroxytryptamine 2A receptor,B,,,,,
2454,8,,BAO_0000357,Expert,,5163,Affinity for 5-hydroxytryptamine 2A receptor,B,,,,,
2455,8,,BAO_0000219,Expert,,16911,Binding affinity was performed using [3H]ketanserin as the radioligand and stably transfected NIH3T3 cells expressing the 5-hydroxytryptamine 2A receptor (GF-62 cells).,B,,,,,
2456,8,,BAO_0000357,Expert,,6841,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin,B,,,,,
2457,8,,BAO_0000357,Expert,,6119,Binding affinity towards 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand.,B,,,,,
2458,8,,BAO_0000357,Autocuration,,3962,Compound was evaluated for its binding against 5-hydroxytryptamine 2A receptor,B,,,,,
2459,8,,BAO_0000357,Autocuration,,4373,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2A receptor was determined,B,,,,,
2460,8,,BAO_0000357,Autocuration,,4373,Binding affinity relative to indolopiperidine (compound 1)for 5-hydroxytryptamine 2A receptor was determined,B,,,,,
2461,8,,BAO_0000019,Autocuration,,3962,Compound was evaluated for its inverse agonist activity against 5-hydroxytryptamine 2A receptor,F,,,,,
2462,8,,BAO_0000357,Expert,,1633,Binding affinity towards 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin,B,,,,,
2463,8,,BAO_0000357,Autocuration,,4373,Binding affinity for 5-hydroxytryptamine 2A receptor was determined,B,,,,,
2464,8,,BAO_0000357,Expert,,6576,Binding affinity towards serotonin 5-hydroxytryptamine 2A receptor,B,,,,,
2465,8,,BAO_0000357,Autocuration,,4687,Evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor,B,,,,,
2466,8,,BAO_0000357,Autocuration,,16946,Ability to displace [3H]-ketanserin from 5-hydroxytryptamine 2A receptor,B,,,,,
2467,8,,BAO_0000357,Autocuration,,14159,Compound was evaluated for the affinity at 5-hydroxytryptamine 2A receptor,B,,,,,
2468,8,,BAO_0000219,Expert,,3032,In vitro binding affinity against 5-hydroxytryptamine 2A receptor in CHO cells,B,,,Mus musculus,10090.0,
2469,8,,BAO_0000357,Autocuration,,16655,Inhibition of ketanserin binding to 5-hydroxytryptamine 2A receptor,B,,,,,
2470,8,,BAO_0000357,Autocuration,,13964,Binding affinity at 5-hydroxytryptamine 2A receptor,B,,,,,
2471,8,,BAO_0000357,Expert,,16989,Binding affinity towards Serotonin 5-hydroxytryptamine 2A receptor,B,,,,,
2472,8,,BAO_0000357,Autocuration,,16117,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor was determined,B,,,,,
2473,8,,BAO_0000357,Autocuration,,16700,The binding affinity towards 5-hydroxytryptamine 2A receptor; No affinity,B,,,,,
2474,8,,BAO_0000357,Autocuration,,3269,Affinity against 5-hydroxytryptamine 2A receptor,B,,,,,
2475,9,,BAO_0000357,Expert,,1274,Binding affinity against 5-Hydroxytryptamine 2A receptor,B,,,Homo sapiens,9606.0,
2476,8,,BAO_0000357,Autocuration,,1317,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using radioligand binding assay,B,,,,,
2477,8,,BAO_0000357,Autocuration,,12146,Tested against 5-hydroxytryptamine 2A receptor,B,,,,,
2478,4,,BAO_0000224,Autocuration,,12652,Binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H]- ketanserin,B,,,,,
2479,4,,BAO_0000224,Autocuration,,12652,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H] ketanserin,B,,,,,
2480,4,,BAO_0000224,Autocuration,,12652,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor agonist [125I]- - (+/-)DOI,B,,,,,
2481,4,,BAO_0000224,Autocuration,,12652,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H]- ketanserin,B,,,,,
2482,8,,BAO_0000357,Autocuration,,16647,Selectivity ratio towards 5-hydroxytryptamine 2A receptor to Dopamine receptor D2 (5-HT2A/D2 ),B,,,,,
2483,9,,BAO_0000219,Expert,,15851,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND means no data,B,,,Homo sapiens,9606.0,
2484,9,,BAO_0000219,Expert,,6857,Functional activity against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader,F,,,Homo sapiens,9606.0,
2485,8,,BAO_0000357,Autocuration,,3805,In vitro binding affinity against human 5-HT2B receptor at a concentration of 100 (nM),B,,,,,
2486,9,,BAO_0000357,Expert,,6491,Affinity towards human 5-hydroxytryptamine 2B serotonin receptor,B,,,Homo sapiens,9606.0,
2487,8,,BAO_0000019,Autocuration,,14093,Agonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT radioligand,F,,,,,
2488,8,,BAO_0000019,Autocuration,,13481,Agonistic activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]-5-HT as radioligand,F,,,,,
2489,8,,BAO_0000019,Autocuration,,14093,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine radioligand,F,,,,,
2490,8,,BAO_0000019,Autocuration,,14093,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine radioligand; Not tested,F,,,,,
2491,8,,BAO_0000019,Autocuration,,14093,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine radioligand,F,,,,,
2492,8,,BAO_0000019,Autocuration,,13481,Antagonistic activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand,F,,,,,
2493,8,,BAO_0000357,Autocuration,,14442,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine as radioligand,B,,,,,
2494,8,,BAO_0000357,Autocuration,,14442,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT 2B as radioligand,B,,,,,
2495,8,,BAO_0000357,Autocuration,,14442,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand,B,,,,,
2496,8,,BAO_0000357,Autocuration,,12369,The compound evaluated for its affinity against 5-hydroxytryptamine 2A receptor,B,,,,,
2497,8,,BAO_0000357,Expert,,12369,Affinity against 5-hydroxytryptamine 2A receptor (D) labeled with [125I]DOI.,B,,,,,
2498,8,,BAO_0000357,Expert,,12369,Affinity against 5-hydroxytryptamine 2A receptor (K) labeled with [3H]ketanserin.,B,,,,,
2499,8,,BAO_0000019,Autocuration,,14447,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 2A receptor from cloned Human membranes,B,,,,,
2500,8,,BAO_0000019,Autocuration,,14447,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 2A receptor from cloned Human membranes.,B,,,,,
2501,8,,BAO_0000219,Autocuration,,17451,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,B,,,,,
2502,8,,BAO_0000219,Autocuration,,6857,Relative efficacy against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,F,,,,,
2503,9,,BAO_0000219,Expert,,6857,Relative efficacy against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,F,,,Homo sapiens,9606.0,
2504,4,,BAO_0000224,Autocuration,,5635,Selectivity ratio of binding affinity of 5-hydroxytryptamine 2A receptor to that of 5-hydroxytryptamine 2C receptor.,B,,,,,
2505,8,,BAO_0000357,Autocuration,,12861,Binding activity radioligand.,B,,,,,
2506,8,,BAO_0000019,Autocuration,,12861,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,B,,,,,
2507,8,,BAO_0000219,Autocuration,,5105,Binding affinity for human cloned 5-HT2A receptor expressed in L929 cells using [125I]R91150 as radioligand,B,,,,,
2508,8,,BAO_0000219,Expert,,5104,Binding affinity for human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells using [125I]R91150 as radioligand,B,,,,,
2509,8,,BAO_0000219,Expert,,5105,Binding affinity at human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells by [125I]R91150 displacement.,B,,,,,
2510,8,,BAO_0000219,Autocuration,,5105,Binding affinity for human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells using [125I]R91150 as radioligand; Not tested,B,,,,,
2511,8,,BAO_0000357,Autocuration,,5254,Binding affinity against 5-HT2A receptor,B,,,,,
2512,8,,BAO_0000357,Autocuration,,5254,Binding affinity against 5-hydroxytryptamine 2A receptor,B,,,,,
2513,8,,BAO_0000219,Autocuration,,13267,Antagonistic binding affinity measured against 5-hydroxytryptamine 2A receptor (human clone expressed in 293 cells) using [3H]ketanserin as radioligand,B,,,,,
2514,8,,BAO_0000219,Autocuration,,13267,Antagonistic binding affinity measured against 5-hydroxytryptamine 2C receptor (human clone expressed in 293 cells) using [3H]mesulergine as radioligand,B,,,,,
2515,9,,BAO_0000219,Expert,,14157,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor expressed in HEK 293 cells,B,,,Homo sapiens,9606.0,
2516,9,,BAO_0000219,Expert,,12936,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,B,,,Homo sapiens,9606.0,
2517,8,,BAO_0000357,Expert,,14068,Binding affinity against human 5-hydroxytryptamine 2A receptor using displacement of [3H]5-HT,B,,,,,
2518,9,,BAO_0000219,Expert,,12936,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,B,,,Homo sapiens,9606.0,
2519,9,,BAO_0000219,Expert,,12936,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,B,,,Homo sapiens,9606.0,
2520,9,,BAO_0000219,Expert,,4540,Binding affinity to human cloned 5-hydroxytryptamine 2A receptor in HEK 293 cells using [3H]- ketanserin as radioligand,B,,,Homo sapiens,9606.0,
2521,8,,BAO_0000357,Expert,,6166,Binding affinity at human cloned 5-hydroxytryptamine 2A receptor.,B,,,,,
2522,8,,BAO_0000219,Autocuration,,17296,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptors in HEK 293 cells using [3H]ketanserin as radioligand,B,,,,,
2523,8,,BAO_0000219,Autocuration,,17296,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptors in HEK 293 cells using [3H]ketanserin as radioligand,B,,,,,
2524,8,,BAO_0000219,Autocuration,,17296,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptorswithouteffect in HEK 293 cells using [3H]ketanserin as radioligand,B,,,,,
2525,9,,BAO_0000219,Expert,,15779,Binding affinity towards 5-hydroxytryptamine 2A receptor (human cloned receptor) in HEK 293 cells using [3H]ketanserin as radioligand.,B,,,Homo sapiens,9606.0,
2526,8,,BAO_0000219,Expert,,14391,Binding affinity towards human 5-hydroxytryptamine 2A receptor expressed in HEK 293 cells using [3H]ketanserin as radioligand,B,,,,,
2527,8,,BAO_0000219,Expert,,15851,"Binding affinity towards human cloned 5-hydroxytryptamine receptor 2A in HEK293 cells, using [3H]ketanserin as radioligand.",B,,,,,
2528,9,,BAO_0000219,Expert,,15851,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor expressed in HEK293 cells; compound is insoluble,B,,,Homo sapiens,9606.0,
2529,8,,BAO_0000219,Expert,,3832,Binding affinity towards human cloned 5-hydroxytryptamine 2A receptor of HEK293 cells by displacement of [3H]ketanserin,B,,,,,
2530,8,,BAO_0000219,Expert,,3833,In vitro binding affinity at human cloned 5-hydroxytryptamine 2A receptor of HEK293 cells by [3H]ketanserin displacement.,B,,,,,
2531,9,,BAO_0000219,Expert,,12936,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,B,,,Homo sapiens,9606.0,
2532,8,,BAO_0000219,Autocuration,,17451,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand,B,,,,,
2533,8,,BAO_0000219,Autocuration,,17451,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,B,,,,,
2534,8,,BAO_0000219,Autocuration,,17451,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,B,,,,,
2535,8,,BAO_0000219,Autocuration,,4199,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 2A receptor in HEK 293 cells using [3H]ketanserin as the radioligand,B,,,,,
2536,8,,BAO_0000219,Autocuration,,1883,Compound was evaluated for displacement of [3H]ketanserin from human cloned 5-hydroxytryptamine 2A receptor in transfected CHO-K1 cells,B,,,,,
2537,8,,BAO_0000219,Expert,,1883,Displacement of [3H]-ketanserin from human cloned 5-hydroxytryptamine 2A receptor expressed in CHO-K1 cells.,B,,,,,
2538,9,,BAO_0000357,Expert,,14875,Binding affinity for human 5-hydroxytryptamine 2A receptor,B,,,Homo sapiens,9606.0,
2539,8,,BAO_0000219,Autocuration,,15146,Compound was tested for its binding affinity against 5-hydroxytryptamine 2A receptor in human cloned receptors in HEK 293 cells using [3H]ketanserin,B,,,,,
2540,8,,BAO_0000219,Autocuration,,5213,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2A receptor in HEK 293 using [3H]ketanserin as a radioligand,B,,,,,
2541,9,,BAO_0000219,Expert,,16404,Inhibitory constant for human 5-hydroxytryptamine 2A receptor transfected in to CHO cells,B,,,Homo sapiens,9606.0,
2542,8,,BAO_0000219,Autocuration,,14818,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2A receptor in HEK293 cells using [3H]-ketanserin.,B,,,,,
2543,8,,BAO_0000219,Autocuration,,4829,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2A receptor in HEK293 cells, using [3H]ketanserin as radioligand",B,,,,,
2544,8,,BAO_0000219,Autocuration,,12652,Percent of maximum stimulation of phosphatidylinositol turnover at cloned 5-hydroxytryptamine 2A receptor in 3T3 cells,F,,,,,
2545,8,,BAO_0000219,Expert,,4682,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor expressed NIH3T3 cells,B,,,,,
2546,8,,BAO_0000019,Autocuration,,12652,The maximum responses of [3H]- inositol monophosphate accumulation in cells expressing the 5-hydroxytryptamine 2A receptor,F,,,,,
2547,8,,BAO_0000357,Autocuration,,4921,Ability to displace [3H]-Ketanserin radioligand from porcine 5-hydroxytryptamine 2A receptor,B,,,,,
2548,8,,BAO_0000357,Autocuration,,4921,Ability to displace [3H]ketanserin radioligand from porcine 5-hydroxytryptamine 2A receptor; ND denotes not determined,B,,,,,
2549,8,,BAO_0000357,Autocuration,,16312,Binding affinity against rabbit aorta 5-HT2A receptor,B,,,Oryctolagus cuniculus,9986.0,
2550,8,,BAO_0000357,Expert,,14998,Binding affinity for 5-hydroxytryptamine 2A receptor of rabbit aorta ring preparations,B,,,Oryctolagus cuniculus,9986.0,
2551,8,,BAO_0000357,Expert,,14025,Dissociation equilibrium constant against the vascular 5-hydroxytryptamine 2A receptor in the rabbit saphenous aorta,B,,,Oryctolagus cuniculus,9986.0,
2552,8,,BAO_0000019,Autocuration,,13047,Binding affinity against 5-hydroxytryptamine 1D receptor alpha using rabbit saphenous vein assay.,B,,,Oryctolagus cuniculus,9986.0,
2553,8,,BAO_0000357,Expert,,13047,The compound was tested for binding affinity against 5-HT2A receptor,B,,,Oryctolagus cuniculus,9986.0,
2554,8,,BAO_0000219,Autocuration,,1883,Compound was evaluated for displacement of [3H]ketanserin from cloned rat 5-hydroxytryptamine 2A receptor in transfected CHO-K1 cells.,B,,,,,
2555,8,,BAO_0000019,Autocuration,,13463,Binding affinity analysed towards 5-HT 2A in rat jugular vein,B,,,,,
2556,8,,BAO_0000019,Autocuration,,13463,Binding affinity analysed towards 5-HT 2A in rat jugular vein.,B,,,,,
2557,8,,BAO_0000019,Autocuration,945.0,13463,Binding affinity analysed on 5-HT 2A in rat stomach fundus.,B,,,,,
2558,9,,BAO_0000019,Expert,945.0,13463,Binding affinity for 5-HT 2A in rat stomach fundus,B,,,Rattus norvegicus,10116.0,
2559,8,,BAO_0000019,Autocuration,,13463,Binding affinity analysed towards 5-HT 2A in rat jugular vein.,B,,,,,
2560,8,,BAO_0000219,Expert,,16326,Ability to stimulate phosphoinositide hydrolysis in NIH3T3 cells expressing the 5-hydroxytryptamine 2A receptor,B,,,,,
2561,8,,BAO_0000019,Autocuration,,14093,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast 5-hydroxytryptamine 2A receptor,F,,,,,
2562,8,,BAO_0000019,Autocuration,,14093,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast expressing 5-hydroxytryptamine 2A receptor,F,,,,,
2563,8,,BAO_0000357,Autocuration,,15740,Evaluated for the effective concentration at [125I]-DOI-labeled rat 5-hydroxytryptamine 2A receptor,B,,,,,
2564,8,,BAO_0000357,Autocuration,,16633,Functional potency at the rat 5-hydroxytryptamine 2A receptor as effective concentration EC50 for stimulating Phosphoinositide accumulation,B,,,,,
2565,9,,BAO_0000019,Expert,,17200,In vitro relative agonist activity against 5-hydroxytryptamine 2A using PI assay in rat vascular smooth muscle cells,F,,,Rattus norvegicus,10116.0,
2566,8,,BAO_0000357,Autocuration,,17133,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,B,,,,,
2567,8,,BAO_0000357,Autocuration,,17133,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,B,,,,,
2568,8,,BAO_0000357,Autocuration,,17133,Tested for its ability to activate phospholipase c by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,B,,,,,
2569,8,,BAO_0000219,Autocuration,,17200,The receptor (5-hydroxytryptamine 2A ) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,F,,,,,
2570,8,,BAO_0000019,Autocuration,,15363,Efficacy at 5-hydroxytryptamine 2A receptor,F,,,,,
2571,8,,BAO_0000357,Autocuration,,17200,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor was determined by using CA+ assay (Emax),B,,,,,
2572,9,,BAO_0000357,Expert,,17200,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor was determined by using CA+ assay (Emax),B,,,Rattus norvegicus,10116.0,
2573,9,,BAO_0000357,Expert,,17200,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor determined by using PI assay (Emax),B,,,Rattus norvegicus,10116.0,
2574,9,,BAO_0000219,Expert,,17200,The receptor (5-hydroxytryptamine 2A ) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,F,,,Rattus norvegicus,10116.0,
2575,8,,BAO_0000219,Autocuration,,17200,The receptor (5-hydroxytryptamine 2A) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,F,,,,,
2576,8,,BAO_0000019,Autocuration,,17211,Ability to displace [3H]ketanserin (0.5 nM) from cerebral cortex of rat 5-hydroxytryptamine 2A receptor,B,,,,,
2577,8,,BAO_0000019,Expert,,17331,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]-ketanserin from rat prefrontal cerebral cortex mambranes,B,,,,,
2578,8,,BAO_0000249,Expert,,13565,Binding affinity to serotonin 5-hydroxytryptamine 2A receptors using a radioligand [3H]ketanserin binding assay in rat cortical membranes,B,,,,,
2579,8,,BAO_0000357,Expert,,13730,Binding affinity towards rat 5-hydroxytryptamine 2A receptor was evaluated using [3H]- ketanserin as radioligand,B,,,,,
2580,8,,BAO_0000019,Expert,,12416,In vitro affinity towards 5-hydroxytryptamine 2A receptor using [3H]spiroperidol as radioligand in cortex,B,,,,,
2581,8,,BAO_0000357,Autocuration,,15295,Compound was tested for it's binding affinity towards 5-hydroxytryptamine 2A receptor,B,,,,,
2582,8,,BAO_0000019,Autocuration,,1742,Compound was tested for its ability to displace [3H]DOB from 5-hydroxytryptamine 2A receptor in rat cortex homogenates,B,,,,,
2583,8,,BAO_0000357,Autocuration,,15295,Compound was tested for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor,B,,,,,
2584,8,,BAO_0000019,Expert,,14970,Binding affinity towards 5-hydroxytryptamine 2A receptor from rat frontal cortex using [3H]ketanserin as radioligand,B,,,,,
2585,8,,BAO_0000019,Expert,,16693,In vitro binding affinity for serotonin 5-hydroxytryptamine 2A receptor of rat cerebral cortex using [3H]ketanserin as radioligand,B,,,,,
2586,9,,BAO_0000019,Expert,,14776,Inhibition of [3H]ketanserin binding to rat frontal cortex membrane 5-hydroxytryptamine 2A receptor,B,,,Rattus norvegicus,10116.0,
2587,8,,BAO_0000249,Autocuration,,14286,In vitro inhibitory concentration against radioligand [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cortical membrane,B,,,,,
2588,9,,BAO_0000019,Expert,,17200,In vitro inhibition of [125I]DOI binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex,B,,,Rattus norvegicus,10116.0,
2589,8,,BAO_0000357,Expert,,15306,Inhibitory concentration against 5-hydroxytryptamine 2A receptor (Inactive at >1000 nM concentration),B,,,,,
2590,9,,BAO_0000357,Expert,,14178,Inhibition of radiolabeled [3H]-Ketanserin ligand binding to 5-hydroxytryptamine 2A receptor,B,,,Rattus norvegicus,10116.0,
2591,9,,BAO_0000019,Expert,,14229,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor from rat brain,B,,,Rattus norvegicus,10116.0,
2592,8,,BAO_0000357,Expert,,12884,Binding affinity towards 5-hydroxytryptamine 2A receptor binding site using [3H]ketanserin. ,B,,,,,
2593,8,,BAO_0000357,Expert,,13149,"Binding affinity for 5-hydroxytryptamine 2A receptor, activity is expressed as IC50 values.",B,,,,,
2594,9,,BAO_0000019,Expert,,15295,Displacement of [3H]ketanserin from rat cortical membrane 5-hydroxytryptamine 2A receptor at 10e-7 M,B,,,Rattus norvegicus,10116.0,
2595,8,,BAO_0000357,Autocuration,,15740,Intrinsic activity was determined at 5-hydroxytryptamine 2A receptor which is percentage response given compared with the response produced by 10 uM serotonin.,B,,,,,
2596,8,,BAO_0000019,Autocuration,,15185,"Compound was tested for binding affinity at 5-hydroxytryptamine 2A receptor sites in rat cortical homogenate using [125I]-2,5-Dimethoxy -4-iodoamphetamine (DOI).",B,,,,,
2597,8,,BAO_0000019,Autocuration,,15185,"Compound was tested for binding affinity using [3H]MDL-100,907 at 5-hydroxytryptamine 2A receptor sites in rat cortical homogenate.",B,,,,,
2598,8,,BAO_0000019,Expert,,17529,Ability to bind to central serotonin 5-hydroxytryptamine 2A receptor in vitro in cortex of the rat brain using [3H]ketanserin radioligand,B,,,,,
2599,8,,BAO_0000019,Autocuration,,14826,Ability to displace [3H]- ketanserin bound to 5-hydroxytryptamine 2A receptor in rat pre-frontal cortex,B,,,,,
2600,8,,BAO_0000019,Expert,,17211,Displacement of [3H]ketanserin (0.5 nM) from rat cerebral cortex 5-hydroxytryptamine 2A receptors,B,,,,,
2601,8,,BAO_0000019,Autocuration,,14826,Ability to displace [3H]ketanserin bound to 5-hydroxytryptamine 2A receptor in rat pre-frontal cortex,B,,,,,
2602,8,,BAO_0000019,Autocuration,,14093,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor,B,,,,,
2603,8,,BAO_0000019,Autocuration,,14093,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor; Not tested,B,,,,,
2604,8,,BAO_0000219,Expert,,13246,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2A serotonin receptor in NIH3T3 cell line membranes,B,,,,,
2605,8,,BAO_0000357,Expert,,13246,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2A serotonin receptor.,B,,,,,
2606,9,,BAO_0000019,Expert,,15436,Affinity 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,B,,,Rattus norvegicus,10116.0,
2607,9,,BAO_0000019,Expert,,15436,Affinity at 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,B,,,Rattus norvegicus,10116.0,
2608,8,,BAO_0000221,Autocuration,955.0,14442,Affinity at [3H]ketanserin-labeled 5-hydroxytryptamine 2A receptor in rat brain homogenate was determined,B,,,,,
2609,8,,BAO_0000357,Expert,,12457,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 2A receptor,B,,,,,
2610,8,,BAO_0000219,Expert,,12457,Affinity was evaluated by inhibition of [125I]LSD binding to NIH 3T3 cells transfected with cloned rat 5-hydroxytryptamine 2A receptor,B,,,,,
2611,8,,BAO_0000221,Autocuration,,14755,"Antagonistic activity measured for 5-hydroxytryptamine 2A receptor using [3H]-MDL- 100,907 as radioligand in rat cortical homogenates.",F,,,,,
2612,8,,BAO_0000357,Autocuration,,4707,Binding affinity towards rat 5-hydroxytryptamine 2A receptor was determined using [125I]- DOI as radioligand,B,,,,,
2613,8,,BAO_0000357,Expert,,13297,Binding affinity against 5-hydroxytryptamine 2A receptor,B,,,,,
2614,8,,BAO_0000019,Expert,,17331,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin from rat prefrontal cerebral cortex mambranes,B,,,,,
2615,8,,BAO_0000019,Autocuration,,4664,Binding affinity against 5-hydroxytryptamine 2A receptor from rat forebrain using [3H]ketanserin as radioligand,B,,,,,
2616,8,,BAO_0000357,Autocuration,,16633,Binding affinity against 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,B,,,,,
2617,9,,BAO_0000219,Expert,,4664,Binding affinity against 5-hydroxytryptamine 2A receptor expressed NIH3T3 cells using [3H]ketanserin,B,,,Rattus norvegicus,10116.0,
2618,8,,BAO_0000357,Expert,,16133,Binding affinity against rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,B,,,,,
2619,8,,BAO_0000357,Expert,,16133,Binding affinity against rat 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,B,,,,,
2620,9,,BAO_0000019,Expert,,14060,Binding affinity against rat brain 5-hydroxytryptamine 2A receptor,B,,,Rattus norvegicus,10116.0,
2621,8,,BAO_0000357,Expert,,16326,Binding affinity at cloned rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,B,,,,,
2622,8,,BAO_0000219,Expert,,16659,Binding affinity for displacement of [3H]ketanserin to rat 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,B,,,,,
2623,8,,BAO_0000019,Autocuration,,14776,Binding affinity measured at the 5-hydroxytryptamine 2A receptor by the inhibition of [3H]ketanserin binding to rat cortex using unlabeled mianserin for nonspecific binding.,B,,,,,
2624,8,,BAO_0000357,Autocuration,,13481,Binding affinity of [3H]- ketanserin labelled towards Rat cortical 5-hydroxytryptamine 2A receptor using radioligand binding assay,B,,,,,
2625,8,,BAO_0000357,Autocuration,,17386,Binding affinity of compound was tested for 5-hydroxytryptamine 2A receptor,B,,,,,
2626,9,,BAO_0000357,Expert,,6611,Binding affinity for 5-hydroxytryptamine 2A receptor,B,,,Rattus norvegicus,10116.0,
2627,8,,BAO_0000019,Autocuration,,14423,Binding affinity against 5-hydroxytryptamine 2A receptor from rat cortex using [3H]ketanserin as the radioligand.,B,,,,,
2628,8,,BAO_0000019,Autocuration,,15412,Binding affinity against 5-hydroxytryptamine 2A receptor of rat pre-frontal cortex,B,,,,,
2629,8,,BAO_0000019,Autocuration,,15412,Binding affinity against 5-hydroxytryptamine 2A receptor of rat pre-frontal cortex.,B,,,,,
2630,8,,BAO_0000019,Autocuration,,6238,Binding affinity towards 5-HT 2A receptor in rat cerebral frontal cortex membranes using [3H]ketanserin as radioligand,B,,,,,
2631,8,,BAO_0000357,Expert,,6648,Binding affinity at 5-hydroxytryptamine 2A receptor of rat.,B,,,,,
2632,8,,BAO_0000357,Expert,,5667,Binding affinity towards 5-hydroxytryptamine 2A receptor sites by using [3H]ketanserin as radioligand,B,,,,,
2633,9,,BAO_0000357,Expert,,6611,Binding affinity for 5-hydroxytryptamine 2A serotonin receptor,B,,,Rattus norvegicus,10116.0,
2634,8,,BAO_0000357,Autocuration,,13481,Binding affinity towards rat cortical 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,B,,,,,
2635,8,,BAO_0000357,Autocuration,,13481,Binding affinity towards rat cortical 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand; Not tested,B,,,,,
2636,8,,BAO_0000219,Expert,,15558,Displacement of [3H]ketanserin from NIH3T3 cells stably expressing rat 5-hydroxytryptamine 2A receptor,B,,,,,
2637,8,,BAO_0000357,Autocuration,,6013,Binding affinity towards 5-hydroxytryptamine 2A receptor,B,,,,,
2638,8,,BAO_0000357,Autocuration,,16633,Binding affinity towards 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,B,,,,,
2639,8,,BAO_0000357,Autocuration,,6013,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor from fundus tissue was determined using [3H]mesulergine as radioligand,B,,,,,
2640,9,,BAO_0000357,Expert,,6013,Binding affinity for rat 5-hydroxytryptamine 2A receptor using [3H]DOB,B,,,Rattus norvegicus,10116.0,
2641,8,,BAO_0000357,Autocuration,,6013,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor was determined using [3H]DOB as radioligand; ND=No data,B,,,,,
2642,8,,BAO_0000357,Expert,,6013,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor by [3H]ketanserin displacement.,B,,,,,
2643,8,,BAO_0000357,Autocuration,,6013,Binding affinity towards cloned rat Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration was determined using [3H]DOB as radioligand,B,,,,,
2644,8,,BAO_0000357,Autocuration,,6013,Binding affinity towards cloned rat Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration was determined using [3H]ketanserin as radioligand,B,,,,,
2645,8,,BAO_0000357,Autocuration,,16293,Binding affinity towards rat 5-hydroxytryptamine 2A receptor,B,,,,,
2646,8,,BAO_0000219,Expert,,17175,Binding affinity towards rat 5-hydroxytryptamine 2A receptor expressed in NIH3T3 cells using [3H]ketanserin as radioligand,B,,,,,
2647,9,,BAO_0000357,Expert,,13278,Binding affinity was measured against 5-hydroxytryptamine 2A receptor by displacement of [3H]- ketanserin by lysergic acid amides,B,,,Rattus norvegicus,10116.0,
2648,8,,BAO_0000019,Autocuration,5383.0,3682,Compound was evaluated for affinity towards cerebral 5-hydroxytryptamine 2A receptor in homogenate of caudate putamen tissue from rat brain,B,,,,,
2649,8,,BAO_0000357,Autocuration,,2014,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as a radioligand,B,,,,,
2650,8,,BAO_0000357,Autocuration,,2014,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as a radioligand; Not determined,B,,,,,
2651,8,,BAO_0000357,Autocuration,,4932,Compound was evaluated for its ability to displace (+/-)[125I]-DOI from 5-hydroxytryptamine 2A receptor in cloned rat cell culture,B,,,,,
2652,8,,BAO_0000019,Autocuration,,4932,Compound was evaluated for its ability to displace [125I](R)-DOI from 5-hydroxytryptamine 2A receptor in cloned rat prefrontal cortex homogenate,B,,,,,
2653,8,,BAO_0000357,Autocuration,,3935,Compound was evaluated for its binding affinity for rat 5-hydroxytryptamine 2A receptor,B,,,,,
2654,9,,BAO_0000221,Expert,10000000.0,5432,Displacement of [3H]8-OH-DPAT from rat hippocampus membrane 5-hydroxytryptamine 2A receptor,B,,,Rattus norvegicus,10116.0,
2655,8,,BAO_0000357,Autocuration,,15818,Compound was evaluated for its binding affinity towards rat 5-hydroxytryptamine 2A receptor,B,,,,,
2656,8,,BAO_0000357,Autocuration,,13672,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin radioligand.,B,,,,,
2657,8,,BAO_0000357,Autocuration,,13672,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]-ketanserin radioligand.,B,,,,,
2658,8,,BAO_0000219,Expert,,14749,Binding affinity against rat 5-hydroxytryptamine 2A receptor in NIH3T3 cells.,B,,,,,
2659,8,,BAO_0000019,Autocuration,,13462,Compound was tested for the Binding affinity against rat frontal cortex 5-hydroxytryptamine 2A receptor by Radio ligand [3H]ketanserin binding assay.,B,,,,,
2660,8,,BAO_0000357,Autocuration,,15740,Evaluated for the binding constant at [125I]-DOI-labeled rat 5-hydroxytryptamine 2A receptor,B,,,,,
2661,8,,BAO_0000019,Expert,,16647,Half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex homogenate,B,,,,,
2662,8,,BAO_0000221,Autocuration,955.0,13345,In vitro ability to displace [3H]ketanserin from 5-hydroxytryptamine 2A receptor in rat brain.,B,,,,,
2663,8,,BAO_0000249,Autocuration,,16740,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,B,,,,,
2664,8,,BAO_0000249,Autocuration,,16740,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,B,,,,,
2665,9,,BAO_0000019,Expert,,15535,In vitro binding affinity at 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin from rat cortex,B,,,Rattus norvegicus,10116.0,
2666,8,,BAO_0000249,Expert,,16740,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,B,,,,,
2667,8,,BAO_0000249,Autocuration,,16740,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,B,,,,,
2668,8,,BAO_0000249,Autocuration,,16740,In vitro binding affinity at serotonin 5-hydroxytryptamine 2A receptor in rat cortical membrane,B,,,,,
2669,9,,BAO_0000019,Expert,,4795,Displacement of [3H]- Ketanserin from rat cortex 5-hydroxytryptamine 2A receptor,B,,,Rattus norvegicus,10116.0,
2670,8,,BAO_0000019,Expert,,8,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in rat tissue homogenate using [3H]ketanserin as radioligand,B,,,,,
2671,8,,BAO_0000019,Autocuration,,8,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in rat tissue homogenate using [3H]ketanserin as radioligand; Not active at 10-5 M,B,,,,,
2672,9,,BAO_0000019,Expert,,17200,In vitro inhibitory constant against [125I]DOI binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex,B,,,Rattus norvegicus,10116.0,
2673,9,,BAO_0000019,Expert,,2148,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor of rat brain cortex,B,,,Rattus norvegicus,10116.0,
2674,5,,BAO_0000224,Expert,,13345,"Relative binding affinity for D2 receptor and 5-hydroxytryptamine 2A receptor, ratio of Ki",B,,,Rattus norvegicus,10116.0,
2675,8,,BAO_0000357,Autocuration,,5088,Tested for binding affinity towards rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,B,,,,,
2676,8,,BAO_0000357,Autocuration,,5088,Tested for binding affinity towards rat 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,B,,,,,
2677,8,,BAO_0000357,Autocuration,,17133,Tested in vitro for its ability to bind to 5-hydroxytryptamine 2A receptor using [125 I]-DOI as radioligand,B,,,,,
2678,9,,BAO_0000357,Expert,,17133,In vitro binding to 5-hydroxytryptamine 2A receptor using [125 I]-DOI,B,,,Rattus norvegicus,10116.0,
2679,8,,BAO_0000357,Autocuration,,16532,The binding affinity at 5-hydroxytryptamine 2A receptor was determined using [3H]ketanserin,B,,,,,
2680,8,,BAO_0000357,Autocuration,,15086,The compound was tested for binding affinity against 5-hydroxytryptamine 2A receptor,B,,,,,
2681,9,,BAO_0000019,Expert,,2309,Binding affinity for 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,B,,,Rattus norvegicus,10116.0,
2682,8,,BAO_0000019,Expert,,12953,Binding affinity to 5-hydroxytryptamine 2A receptor from rat cortex assayed using [3H]ketanserin as radioligand.,B,,,,,
2683,8,,BAO_0000019,Autocuration,,12953,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat cortex using [3H]ketanserin as radioligand.; Nonactive at 10 uM,B,,,,,
2684,8,,BAO_0000019,Autocuration,,12953,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat cortex using [3H]-ketanserin as radioligand; Nonactive at 10 uM,B,,,,,
2685,8,,BAO_0000219,Autocuration,,16659,Binding affinity for displacement of [3H]ketanserin to rat 5-hydroxytryptamine 2A receptor stably expressed in CHO cells; ND is No Data,B,,,,,
2686,8,,BAO_0000019,Autocuration,,16740,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane; ND means no data,B,,,,,
2687,8,,BAO_0000019,Autocuration,,16740,In vitro binding affinity at serotonin 5-hydroxytryptamine 2A receptor in rat cortical membrane; ND means no data,B,,,,,
2688,8,,BAO_0000357,Autocuration,,17133,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor; Not determined,B,,,,,
2689,8,,BAO_0000019,Autocuration,,17211,Ability to displace [3H]ketanserin (0.5 nM) from cerebral cortex of rat 5-hydroxytryptamine 2A receptor; NT=not tested,B,,,,,
2690,8,,BAO_0000019,Autocuration,,17331,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]-ketanserin from rat prefrontal cerebral cortex mambranes; Not tested,B,,,,,
2691,8,,BAO_0000218,Autocuration,,16633,Compound was evaluated for effective dose measured in nmol/kg following a dose of 0.04 mg/kg and 0.093 uM/kg (95%CI); range 32-63,B,,,,,
2692,8,,BAO_0000218,Autocuration,,16633,Compound was evaluated for the percentage of rats disrupted following a dose of 0.04 mg/kg and 0.097 uM/kg,B,,,,,
2693,8,,BAO_0000218,Autocuration,,16633,Compound was evaluated for the percentage of rats disrupted following a dose of 0.08 mg/kg and 0.194 uM/kg,B,,,,,
2694,8,,BAO_0000357,Expert,,15026,Ratio of pKi of 5-HT2A to that of 5-HT2C receptor,B,,,,,
2695,8,,BAO_0000357,Expert,,15026,Ratio of pKi of 5-HT2A to that of D2 receptor,B,,,,,
2696,4,,BAO_0000224,Expert,,16404,Selectivity ratio towards KB of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2B receptor,B,,,,,
2697,4,,BAO_0000224,Expert,,16404,Selectivity ratio towards KB of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2B receptor,B,,,,,
2698,4,,BAO_0000224,Expert,,16404,Selectivity ratio towards Ki of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2C receptor,B,,,,,
2699,8,,BAO_0000357,Autocuration,,16404,Selectivity ratio towards Ki of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2C receptor; ND is no data,B,,,,,
2700,8,,BAO_0000357,Expert,,16326,Percent maximal 5-HT stimulation at cloned rat 5-hydroxytryptamine 2A receptor (phosphoinositide hydrolysis study) at a conc of 100 uM,B,,,,,
2701,8,,BAO_0000019,Autocuration,,15847,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 2A receptor of rat,F,,,,,
2702,8,,BAO_0000019,Autocuration,,15847,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 2A receptor of rat; ND means not done,F,,,,,
2703,8,,BAO_0000019,Autocuration,,15329,Effectiveness of compound in blocking 5-hydroxytryptamine 2A receptor-mediated contractions of rat tail artery,F,,,,,
2704,8,,BAO_0000019,Expert,1515.0,16404,Negative log concentration of antagonist on 5-hydroxytryptamine 2A receptor in rat thoracic aorta,F,,,,,
2705,8,,BAO_0000019,Expert,1515.0,16404,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2A receptor of Rat thoracic aorta,F,,,,,
2706,8,,BAO_0000019,Autocuration,1515.0,16404,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2A receptor of Rat thoracic aorta; ND is not determined.,F,,,,,
2707,8,,BAO_0000357,Autocuration,,12861,Binding activity radioligand.,B,,,,,
2708,8,,BAO_0000019,Expert,,12861,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,B,,,,,
2709,8,,BAO_0000019,Autocuration,,12861,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand; NA Not Available,B,,,,,
2710,8,,BAO_0000019,Expert,,12490,Displacement of [3H]DOB binding to 5-hydroxytryptamine 2A receptor from rat cortex homogenate,B,,,,,
2711,8,,BAO_0000219,Autocuration,,12827,Binding affinity towards 5-hydroxytryptamine 3 receptor in membranes of N1E-115 neuroblastoma cells using [3H]-ICS 205-930,B,,,,,
2712,8,,BAO_0000219,Autocuration,,12827,Binding affinity towards 5-hydroxytryptamine 3 receptor in membranes of N1E-115 neuroblastoma cells using [3H]-ICS 205-930; Not determined,B,,,,,
2713,8,,BAO_0000019,Autocuration,,12918,Binding affinity was evaluated by 5-hydroxytryptamine 2A receptor agonism in the rat cortex by displacing ketanserin,B,,,,,
2714,9,,BAO_0000019,Expert,,12919,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]-ketanserin,F,,,Rattus norvegicus,10116.0,
2715,8,,BAO_0000357,Autocuration,,17723,Binding affinity towards human serotonin 5-hydroxytryptamine 2C receptor,B,,,,,
2716,8,,BAO_0000357,Autocuration,,6013,Binding affinity towards 5-hydroxytryptamine 2C receptor,B,,,,,
2717,8,,BAO_0000357,Autocuration,,16293,Binding affinity towards human 5-hydroxytryptamine 2C receptor,B,,,,,
2718,8,,BAO_0000019,Expert,,3857,Binding affinity using [125I]DOI as radioligand with membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor,B,,,,,
2719,8,,BAO_0000019,Expert,,3857,Binding affinity using [125I]DOI as radioligand with membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor; Not determined,B,,,,,
2720,8,,BAO_0000019,Expert,,3857,Binding affinity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor,B,,,,,
2721,8,,BAO_0000357,Autocuration,,15363,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2C receptor,B,,,,,
2722,8,,BAO_0000357,Autocuration,,15363,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2C receptor,B,,,,,
2723,8,,BAO_0000019,Expert,,16441,Tested on transfected cell membranes selectively expressing human 5-hydroxytryptamine 2C receptor using [3H]mesulergine,B,,,,,
2724,8,,BAO_0000019,Expert,,16441,Tested on transfected cell membranes selectively expressing human 5-hydroxytryptamine 2C receptor using [3H]-mesulergine; ND is No Data.,B,,,,,
2725,8,,BAO_0000219,Autocuration,,4176,In vitro binding affinity towards human 5-hydroxytryptamine 2C receptor expressed in HEK293 cells was determined using [3H]mesulergine as radioligand,B,,,,,
2726,8,,BAO_0000019,Autocuration,,17085,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2C receptor,B,,,,,
2727,9,,BAO_0000357,Expert,,17200,Inhibitory constant against cloned human 5-hydroxytryptamine 2C receptor using with [125I]- DOI radioligand,B,,,Homo sapiens,9606.0,
2728,8,,BAO_0000357,Expert,,5088,Binding affinity towards human 5-hydroxytryptamine 2C receptor.,B,,,,,
2729,8,,BAO_0000357,Autocuration,,5088,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]DOB as radioligand,B,,,,,
2730,8,,BAO_0000357,Autocuration,,5088,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,B,,,,,
2731,8,,BAO_0000357,Autocuration,,5088,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]5-HT as radioligand,B,,,,,
2732,8,,BAO_0000219,Autocuration,,16659,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,B,,,,,
2733,8,,BAO_0000219,Autocuration,,16659,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells; ND is no data,B,,,,,
2734,8,,BAO_0000219,Autocuration,,17451,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2C receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,B,,,,,
2735,9,,BAO_0000219,Expert,,6857,Relative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,F,,,Homo sapiens,9606.0,
2736,8,,BAO_0000019,Expert,,3857,Inhibitory activity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor at a concentration of 1 uM,B,,,,,
2737,8,,BAO_0000357,Autocuration,,12861,Binding activity radioligand.,B,,,,,
2738,8,,BAO_0000019,Autocuration,,12861,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,B,,,,,
2739,8,,BAO_0000219,Expert,,5104,Binding affinity for human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells using [3H]mesulergine as radioligand,B,,,,,
2740,8,,BAO_0000219,Expert,,5105,Binding affinity at human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells by [3H]mesulergine displacement.,B,,,,,
2741,8,,BAO_0000219,Autocuration,,5105,Binding affinity for human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells using [3H]mesulergine as radioligand; NT means not tested,B,,,,,
2742,8,,BAO_0000357,Autocuration,,5254,Binding affinity against 5-HT2C receptor,B,,,,,
2743,8,,BAO_0000219,Autocuration,,13267,Antagonistic binding affinity measured against 5-hydroxytryptamine 2C receptor (human clone expressed in 293 cells) using [3H]mesulergine as radioligand,B,,,,,
2744,9,,BAO_0000219,Expert,,14157,Displacement of [3H]mesulergine from 5-hydroxytryptamine 2C receptor expressed in HEK 293 cells,B,,,Homo sapiens,9606.0,
2745,9,,BAO_0000219,Expert,,12936,Binding affinity against human 5-hydroxytryptamine 2C receptor expressed in 293 cells using [3H]mesulergine,B,,,Homo sapiens,9606.0,
2746,8,,BAO_0000357,Expert,,14068,Binding affinity against human 5-hydroxytryptamine 2C receptor using displacement of [3H]DOB,B,,,,,
2747,9,,BAO_0000219,Expert,,12936,Binding affinity against human 5-hydroxytryptamine 2C receptor expressed in 293 cells using [3H]mesulergine,B,,,Homo sapiens,9606.0,
2748,9,,BAO_0000219,Expert,,4540,Binding affinity to human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]- mesulergine as radioligand,B,,,Homo sapiens,9606.0,
2749,9,,BAO_0000219,Expert,,4540,Binding affinity to human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]- mesulergine as radioligand; Nd means not determined,B,,,Homo sapiens,9606.0,
2750,8,,BAO_0000357,Autocuration,,6166,Binding affinity towards cloned human 5-hydroxytryptamine 2C receptor was determined,B,,,,,
2751,8,,BAO_0000219,Autocuration,,17296,Binding affinity against 5-hydroxytryptamine 2C receptor human cloned receptors in HEK 293 cells using [3H]mesulergine as radioligand,B,,,,,
2752,8,,BAO_0000219,Autocuration,,17296,Binding affinity against 5-hydroxytryptamine 2C receptor human cloned receptorswithouteffect in HEK 293 cells using [3H]mesulergine as radioligand,B,,,,,
2753,8,,BAO_0000219,Autocuration,,15779,Binding affinity towards 5-HT2C (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,B,,,,,
2754,8,,BAO_0000219,Autocuration,,15779,Binding affinity towards 5-hydroxytryptamine 2C receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,B,,,,,
2755,8,,BAO_0000219,Expert,,14391,Binding affinity towards cloned human 5-hydroxytryptamine 2C receptor expressed in HEK 293 cells using [3H]mesulergine as radioligand,B,,,,,
2756,8,,BAO_0000219,Autocuration,,15779,"Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]mesulergine as radioligand",B,,,,,
2757,8,,BAO_0000219,Expert,,15851,"Binding affinity towards human cloned 5-hydroxytryptamine receptor 2C in HEK293 cells, using [3H]mesulergine as radioligand.",B,,,,,
2758,9,,BAO_0000219,Expert,,15851,Displacement of [3H]mesulergine from human 5-hydroxytryptamine 2C receptor expressed in HEK293 cells; compound insoluble,B,,,Homo sapiens,9606.0,
2759,8,,BAO_0000219,Autocuration,,15779,"Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]mesulergine as radioligand; no data",B,,,,,
2760,8,,BAO_0000219,Expert,,3832,Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor of HEK293 cells by displacement of [3H]mesulergine,B,,,,,
2761,8,,BAO_0000219,Expert,,3833,In vitro binding affinity at human cloned 5-hydroxytryptamine 2C receptor of HEK293 cells by [3H]mesulergine displacement.,B,,,,,
2762,8,,BAO_0000219,Autocuration,,17451,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2C receptor expressed in 3T3 cells using [3H]5-HT as radioligand,B,,,,,
2763,8,,BAO_0000219,Autocuration,,4199,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]mesulergine as the radioligand,B,,,,,
2764,8,,BAO_0000219,Expert,,1883,Displacement of [3H]mesulergine from human cloned 5-hydroxytryptamine 2C receptor expressed in CHO-K1 cells,B,,,,,
2765,9,,BAO_0000357,Expert,,4321,Binding affinity against 5-hydroxytryptamine 2C receptor,B,,,Homo sapiens,9606.0,
2766,8,,BAO_0000357,Autocuration,,14875,Compound was tested for binding affinity against human 5-hydroxytryptamine 2C receptor,B,,,,,
2767,8,,BAO_0000219,Autocuration,,15146,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]mesulergine,B,,,,,
2768,8,,BAO_0000219,Autocuration,,5213,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2C receptor in HEK 293 using [3H]mesulergine as a radioligand,B,,,,,
2769,8,,BAO_0000219,Autocuration,,16404,Inhibitory constant on human 5-hydroxytryptamine 2C receptor transfected in to HeLa cells,B,,,,,
2770,8,,BAO_0000019,Autocuration,,13267,Selectivity as the ratio of Ki value towards 5-hydroxytryptamine 2C receptor to that of pA2 value towards 5-hydroxytryptamine 2B receptor,F,,,,,
2771,8,,BAO_0000221,Autocuration,10000000.0,13267,The binding affinity (pKi) measured against 5-hydroxytryptamine 3 receptor of rat hippocampus and entorhinal cortex using [3H]granisetron as radioligand,F,,,,,
2772,8,,BAO_0000219,Autocuration,,14818,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2C receptor in HEK293 cells using [3H]mesulergine.,B,,,,,
2773,8,,BAO_0000219,Autocuration,,4829,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]5-mesulergine as radioligand",B,,,,,
2774,8,,BAO_0000357,Autocuration,,13463,Binding affinity analysed on 5-HT 2C in human clone using [3H]mesulergine as radioligand,B,,,,,
2775,8,,BAO_0000019,Autocuration,945.0,13463,Binding affinity analysed on 5-HT 2C in rat stomach fundus,B,,,,,
2776,8,,BAO_0000019,Autocuration,945.0,13463,Binding affinity analysed towards 5-HT 2C in rat stomach fundus,B,,,,,
2777,8,,BAO_0000219,Autocuration,,12652,Percent of maximum stimulation of phosphatidylinositol turnover at cloned 5-hydroxytryptamine 2C receptor in A9 cells,F,,,,,
2778,8,,BAO_0000219,Autocuration,,4682,Binding affinity to 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand in stably transfected NIH3T3 cells,B,,,,,
2779,8,,BAO_0000219,Autocuration,,4682,Binding affinity to 5-hydroxytryptamine 2C receptor measured using radioligand [3H]Mesulergine in stably transfected NIH3T3 cells,B,,,,,
2780,8,,BAO_0000219,Autocuration,,4682,Binding affinity to 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand in stably transfected NIH3T3 cells,B,,,,,
2781,8,,BAO_0000019,Autocuration,,12652,The maximum responses of [3H]- inositol monophosphate accumulation in cells expressing the 5-hydroxytryptamine 2C receptor,F,,,,,
2782,8,,BAO_0000019,Autocuration,945.0,13463,Binding affinity analysed on 5-HT 2C in rat stomach fundus.,B,,,Mus musculus,10090.0,
2783,9,,BAO_0000019,Expert,945.0,13463,Binding affinity towards 5-HT 2C receptor in rat stomach fundus,B,,,Rattus norvegicus,10116.0,
2784,8,,BAO_0000357,Expert,,13969,Binding affinity against 5-Hydroxytryptamine 2C Receptor was measured using [3H]N-methyl-mesulergine as radioligand,B,,,,,
2785,8,,BAO_0000357,Expert,,13392,Binding affinity for 5-hydroxytryptamine 2C receptor,B,,,Sus scrofa,9823.0,
2786,8,,BAO_0000357,Expert,,13392,Binding affinity towards 5-hydroxytryptamine 2C receptor,B,,,,,
2787,8,,BAO_0000019,Expert,,14430,Affinity towards 5-hydroxytryptamine 2C receptor in membranes from pig choroid plexus using [3H]N-methyl-mesulergine,B,,,,,
2788,8,,BAO_0000019,Autocuration,,1742,Compound was tested for its ability to displace [3H]mesulergine from 5-hydroxytryptamine 2C receptor in pig cortex,B,,,,,
2789,8,,BAO_0000249,Autocuration,,14286,In vitro inhibitory concentration against radioligand [3H]mesulergine binding to 5-hydroxytryptamine 2C receptor in pig cortical membrane,B,,,,,
2790,8,,BAO_0000357,Autocuration,,5619,Binding affinity towards pig 5-hydroxytryptamine 2C receptor,B,,,,,
2791,8,,BAO_0000357,Autocuration,,15086,The compound was tested for binding affinity against 5-hydroxytryptamine 2C receptor,B,,,,,
2792,8,,BAO_0000357,Autocuration,,12861,Binding activity radioligand.,B,,,,,
2793,8,,BAO_0000019,Expert,,12861,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,B,,,,,
2794,8,,BAO_0000019,Autocuration,,12861,Binding activity against 5-hydroxytryptamine 3 receptor from pig cortex membrane using [3H]mesulergine as radioligand; NA Not Available,B,,,,,
2795,8,,BAO_0000249,Autocuration,,12827,Binding affinity towards 5-hydroxytryptamine 1D receptor in calf caudate membranes using [3H]5-HT,B,,,,,
2796,8,,BAO_0000249,Autocuration,,12827,Binding affinity towards 5-hydroxytryptamine 1D receptor in calf caudate membranes using [3H]5-HT; Not determined,B,,,,,
2797,8,,BAO_0000019,Expert,,12919,Agonistic activity against 5-hydroxytryptamine 2C receptor in pig choroid plexus using [3H]mesulergine,F,,,Sus scrofa,9823.0,
2798,8,,BAO_0000019,Expert,,12919,Agonistic activity against 5-hydroxytryptamine 2C receptor in pig choroid plexus using [3H]mesulergine,F,,,Sus scrofa,9823.0,
2799,8,,BAO_0000357,Autocuration,,16429,In vitro binding affinity at 5-hydroxytryptamine 2C receptor in pig choroid plexus using 3[H]mesulergine as the radioligand,B,,,Sus scrofa,9823.0,
2800,8,,BAO_0000019,Autocuration,,773,In Vitro Binding affinity againist 5-hydroxytryptamine 2C receptor by displacing [3H]mesulergine from pig cortex,B,,,Sus scrofa,9823.0,
2801,8,,BAO_0000357,Autocuration,,5033,Ability to displace the radioligand [3H]mesulergine from pig choroid plexus 5-hydroxytryptamine 2C receptor,B,,,Sus scrofa,9823.0,
2802,8,,BAO_0000019,Autocuration,,12861,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,B,,,,,
2803,8,,BAO_0000019,Autocuration,,14093,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast 5-hydroxytryptamine 2C receptor,F,,,,,
2804,8,,BAO_0000357,Expert,,14970,Binding affinity towards 5-HT2C receptor from rat using [3H]mesulergine as radioligand,B,,,,,
2805,8,,BAO_0000357,Autocuration,,14970,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2C receptor from rat using [3H]mesulergine as radioligand,B,,,,,
2806,8,,BAO_0000357,Autocuration,,14970,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2C receptor from rat using [3H]mesulergine as radioligand; Not tested,B,,,,,
2807,9,,BAO_0000357,Expert,,14178,Inhibition of radiolabeled [3H]-Ketanserin ligand binding to 5-hydroxytryptamine 2C receptor,B,,,Rattus norvegicus,10116.0,
2808,9,,BAO_0000357,Expert,,14178,Inhibition of radiolabeled [3H]mesulergine ligand binding to 5-hydroxytryptamine 2C receptor,B,,,Rattus norvegicus,10116.0,
2809,9,,BAO_0000249,Expert,,14229,Inhibition of [3H]mesulergine binding to 5-hydroxytryptamine 2C receptor in rat brain membranes,B,,,Rattus norvegicus,10116.0,
2810,8,,BAO_0000357,Autocuration,,16532,The binding affinity at 5-hydroxytryptamine 2C receptor was determined using [3H]mesulergine; Not tested,B,,,,,
2811,8,,BAO_0000019,Autocuration,,14826,Ability to displace [3H]mesulergine bound to 5-hydroxytryptamine 2C receptor in rat cortex,B,,,,,
2812,8,,BAO_0000019,Autocuration,,17211,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-HT2C receptor,B,,,,,
2813,8,,BAO_0000219,Expert,,17211,Displacement of [3H]mesulergine (0.5 nM) from rat 5-hydroxytryptamine 2C receptor expressed in SR-3T3 cells,B,In vitro,,,,
2814,8,,BAO_0000219,Expert,,13246,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2C serotonin receptor in NIH3T3 cell line membranes,B,,,,,
2815,8,,BAO_0000357,Expert,,13246,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2C serotonin receptor.,B,,,,,
2816,8,,BAO_0000357,Expert,,12457,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 2C receptor,B,,,,,
2817,8,,BAO_0000219,Expert,,12457,Affinity was evaluated by inhibition of [125I]LSD binding to NIH 3T3 cells transfected with cloned rat 5-hydroxytryptamine 2C receptor,B,,,,,
2818,8,,BAO_0000357,Autocuration,,4707,Binding affinity towards rat 5-hydroxytryptamine 2C receptor was determined using [125I]- DOI as radioligand,B,,,,,
2819,8,,BAO_0000357,Expert,,13297,Binding affinity against 5-hydroxytryptamine 2C receptor,B,,,,,
2820,8,,BAO_0000357,Autocuration,,16633,Binding affinity against 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,B,,,,,
2821,8,,BAO_0000357,Expert,,16133,Binding affinity against rat 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,B,,,,,
2822,8,,BAO_0000357,Expert,,16326,Binding affinity at cloned rat 5-hydroxytryptamine 2C receptor using [3H]DOI as radioligand,B,,,,,
2823,8,,BAO_0000019,Autocuration,,14423,Binding affinity against 5-hydroxytryptamine 2C receptor from rat cortex using [3H]mesulergine as the radioligand.,B,,,,,
2824,8,,BAO_0000019,Autocuration,,15412,Binding affinity against 5-hydroxytryptamine 2C receptor of rat cortex,B,,,,,
2825,8,,BAO_0000019,Autocuration,,15412,Binding affinity against 5-hydroxytryptamine 2C receptor of rat cortex.,B,,,,,
2826,8,,BAO_0000219,Expert,,15558,Displacement of [3H]mesulergine from A9 cells stably expressing rat 5-hydroxytryptamine 2C receptor,B,,,,,
2827,8,,BAO_0000357,Autocuration,,16633,Binding affinity towards 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,B,,,,,
2828,8,,BAO_0000357,Expert,,6013,Binding affinity towards cloned rat 5-hydroxytryptamine 2C receptor from fundus tissue by [3H]mesulergine displacement.,B,,,,,
2829,8,,BAO_0000219,Expert,,17175,Binding affinity towards rat 5-hydroxytryptamine 2C receptor expressed in A-9 cells using [3H]mesulergine as radioligand,B,In vitro,,,,
2830,8,,BAO_0000219,Autocuration,,12469,Binding affinity was measured on 5-hydroxytryptamine 2C receptor in J1 cells transfected with rat 5-HT2C gene labeled with [3H]mesulergine,B,,,,,
2831,8,,BAO_0000019,Autocuration,5383.0,3682,Compound was evaluated for affinity towards cerebral 5-hydroxytryptamine 2C receptor in homogenate of caudate putamen tissue from rat brain,B,,,,,
2832,8,,BAO_0000357,Autocuration,,4932,Compound was evaluated for its ability to displace (+/-)[125I]-DOI from 5-hydroxytryptamine 2C receptor in cloned rat cell culture,B,,,,,
2833,8,,BAO_0000019,Autocuration,,4932,Compound was evaluated for its ability to displace [125I](R)-DOI from 5-hydroxytryptamine 2C receptor in cloned rat prefrontal cortex homogenate; ND denotes no data,B,,,,,
2834,8,,BAO_0000357,Autocuration,,3935,Compound was evaluated for its binding affinity for rat 5-hydroxytryptamine 2C receptor,B,,,,,
2835,8,,BAO_0000357,Autocuration,,15818,Compound was evaluated for its binding affinity towards rat 5-hydroxytryptamine 2C receptor,B,,,,,
2836,8,,BAO_0000357,Autocuration,,15818,Compound was evaluated for its binding affinity towards rat r5-hydroxytryptamine 2C receptor,B,,,,,
2837,8,,BAO_0000219,Expert,,14749,Binding affinity against rat 5-hydroxytryptamine 2C receptor in A-9 cells.,B,,,,,
2838,8,,BAO_0000357,Autocuration,,15740,Evaluated for the binding constant at [125I]-DOI-labeled rat 5-hydroxytryptamine 2C receptor,B,,,,,
2839,9,,BAO_0000357,Expert,,17133,In vitro binding to 5-hydroxytryptamine 2C receptor using [125 I]-DOI,B,,,Rattus norvegicus,10116.0,
2840,8,,BAO_0000357,Autocuration,,16532,The binding affinity at 5-hydroxytryptamine 2C receptor was determined using [3H]mesulergine,B,,,,,
2841,8,,BAO_0000357,Autocuration,,12369,The compound evaluated for its affinity against 5-hydroxytryptamine 2C receptor,B,,,,,
2842,8,,BAO_0000219,Expert,,12369,Affinity against 5-hydroxytryptamine 2C receptor in J1 cells transfected with the rat 5-HT2C gene labeled with [3H]mesulergine.,B,,,,,
2843,9,,BAO_0000019,Expert,,2309,Binding affinity against 5-hydroxytryptamine 2C receptor in rat choroid plexus using [3H]N-methyl-mesulergine,B,,,Rattus norvegicus,10116.0,
2844,8,,BAO_0000357,Autocuration,,12953,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor,B,,,,,
2845,8,,BAO_0000019,Autocuration,,12953,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor from rat cortex using [3H]-citalopram as radioligand; Nonactive at 10 uM,B,,,,,
2846,8,,BAO_0000357,Autocuration,,12953,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand; Nonactive at 10 uM,B,,,,,
2847,8,,BAO_0000357,Expert,,12953,Binding affinity for 5-hydroxytryptamine 2C receptor,B,,,,,
2848,8,,BAO_0000357,Autocuration,,17133,Tested in vitro for its ability to bind to 5-hydroxytryptamine 2C receptor using [125 I]-DOI as radioligand; Not determined,B,,,,,
2849,8,,BAO_0000019,Autocuration,,17211,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-hydroxytryptamine 2C receptor; NT denotes not tested,B,,,,,
2850,8,,BAO_0000019,Autocuration,,17211,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-hydroxytryptamine 2C receptor; NT=not tested,B,,,,,
2851,8,,BAO_0000019,Autocuration,,14025,Affinity pKi for 5-hydroxytryptamine 2C receptor was measured in rat cortex homogenates.,B,,,,,
2852,8,,BAO_0000019,Autocuration,,14998,Binding affinity against 5-hydroxytryptamine 2C receptor in rat cortex homogenates.,B,,,,,
2853,8,,BAO_0000357,Autocuration,,4342,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2C receptor was determined,B,,,,,
2854,9,,BAO_0000019,Expert,,13735,Displacement of [3H]mesulergine from rat 5-HT2C receptor expressed in HEK293,B,,,Rattus norvegicus,10116.0,
2855,8,,BAO_0000357,Autocuration,,13181,Binding affinity was determined against cloned human 5-hydroxytryptamine 2C receptor using [3H]5-HT as radioligand,B,,,,,
2856,8,,BAO_0000219,Autocuration,,1883,Compound was evaluated for displacement of [3H]mesulergine from cloned rat 5-hydroxytryptamine 2C receptor in transfected CHO-K1 cells.,B,,,,,
2857,8,,BAO_0000357,Autocuration,,15194,The compound was tested for the binding affinity against 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,B,,,,,
2858,8,,BAO_0000357,Autocuration,,15194,The compound was tested for the binding affinity against 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand.,B,,,,,
2859,8,,BAO_0000019,Autocuration,,14579,Compound tested for relative response using 0.1 uM 5-HT as agonist against 5-hydroxytryptamine 2C receptor,F,,,,,
2860,8,,BAO_0000357,Autocuration,,4639,Compound was tested for binding affinity against 5-hydroxytryptamine 2C receptor,B,,,,,
2861,8,,BAO_0000357,Expert,,4820,Binding affinity towards 5-hydroxytryptamine 2C receptor,B,,,,,
2862,8,,BAO_0000357,Autocuration,,14442,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand; Not Tested,B,,,,,
2863,8,,BAO_0000357,Autocuration,,14755,Binding activity against cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT as the radioligand.,B,,,,,
2864,8,,BAO_0000357,Autocuration,,14744,Binding affinity against the cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT as the radioligand,B,,,,,
2865,9,,BAO_0000019,Expert,,6857,Affinity for human 5-hydroxytryptamine 2B receptor expressed in mammalian cell line,B,,,Homo sapiens,9606.0,
2866,8,,BAO_0000357,Autocuration,,16209,Binding affinity towards human 5-hydroxytryptamine 2B receptor using [3H]5-HT as radioligand,B,,,,,
2867,8,,BAO_0000357,Autocuration,,15363,Compound was tested for the displacement of [3H]5-HT from clone human 5-hydroxytryptamine 2B receptor,B,,,,,
2868,8,,BAO_0000357,Autocuration,,15363,Compound was tested for the displacement of [3H]5-HT from clone human 5-hydroxytryptamine 2B receptor,B,,,,,
2869,8,,BAO_0000357,Autocuration,,15363,Compound was tested for the displacement of [3H]5-HT from cloned human 5-hydroxytryptamine 2B receptor,B,,,,,
2870,8,,BAO_0000019,Autocuration,,17085,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2B receptor,B,,,,,
2871,9,,BAO_0000357,Expert,,17200,Inhibitory constant against cloned human 5-hydroxytryptamine 2B receptor using with [125I]- DOI radioligand,B,,,Homo sapiens,9606.0,
2872,9,,BAO_0000219,Expert,,15851,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND = no data,B,,,Homo sapiens,9606.0,
2873,9,,BAO_0000219,Expert,,15851,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND = no data,B,,,Homo sapiens,9606.0,
2874,9,,BAO_0000219,Expert,,6857,Relative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,F,,,Homo sapiens,9606.0,
2875,9,,BAO_0000219,Expert,,6857,Rleative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,F,,,Homo sapiens,9606.0,
2876,8,,BAO_0000219,Autocuration,,15779,"Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",B,,,,,
2877,8,,BAO_0000219,Expert,,15851,Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells using [3H]5-HT as radioligand.,B,,,,,
2878,8,,BAO_0000219,Autocuration,,15779,"Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand; no data",B,,,,,
2879,9,,BAO_0000219,Expert,,14157,Displacement of [3H]5-HT from 5-hydroxytryptamine 2B receptor expressed in HEK 293 cells,B,,,Homo sapiens,9606.0,
2880,9,,BAO_0000219,Expert,,4540,Binding affinity to human cloned 5-HT2B receptor in HEK 293 cells using [3H]- -5-HT as radioligand,B,,,Homo sapiens,9606.0,
2881,8,,BAO_0000357,Autocuration,,6166,Binding affinity towards cloned human 5-hydroxytryptamine 2B receptor was determined,B,,,,,
2882,8,,BAO_0000219,Autocuration,,15779,Binding affinity towards 5-hydroxytryptamine 2B receptor (human cloned receptor) in HEK 293 cells using [3H]5-HT as radioligand.,B,,,,,
2883,8,,BAO_0000219,Expert,,14391,Binding affinity towards cloned human 5-hydroxytryptamine 2B receptor expressed in HEK 293 cells using [3H]5-HT as radioligand,B,,,,,
2884,8,,BAO_0000219,Expert,,3832,Binding affinity towards human cloned 5-HT2B receptor of HEK293 cells by displacement of [3H]5-HT,B,,,,,
2885,8,,BAO_0000219,Expert,,3833,In vitro binding affinity at human cloned 5-hydroxytryptamine 2B receptor of HEK293 cells by [3H]5-HT displacement.,B,,,,,
2886,9,,BAO_0000219,Expert,,15851,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells,B,,,Homo sapiens,9606.0,
2887,9,,BAO_0000219,Expert,,15851,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; compound is insoluble,B,,,Homo sapiens,9606.0,
2888,8,,BAO_0000219,Autocuration,,4199,Compound was evaluated for binding affinity against human cloned 5-HT2B receptor in HEK 293 cells using [3H]5-HT as the radioligand,B,,,,,
2889,8,,BAO_0000219,Expert,,1883,Displacement of [3H]-5-5HT from human cloned 5-hydroxytryptamine 2B receptor expressed in CHO-K1 cells,B,,,,,
2890,8,,BAO_0000357,Expert,,4321,Binding affinity against 5-hydroxytryptamine 2B receptor,B,,,,,
2891,8,,BAO_0000219,Autocuration,,15146,Compound was tested for its binding affinity against cloned human 5-hydroxytryptamine 2B receptor in HEK 293 cells using [3H]5-HT,B,,,,,
2892,8,,BAO_0000219,Autocuration,,5213,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2B receptor in HEK 293 using [3H]ketanserin as a radioligand,B,,,,,
2893,8,,BAO_0000219,Autocuration,,14818,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2B receptors in HEK293 cells using [3H]5-HT.,B,,,,,
2894,8,,BAO_0000219,Autocuration,,4829,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",B,,,,,
2895,8,,BAO_0000219,Autocuration,,4829,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",B,,,,,
2896,8,,BAO_0000019,Autocuration,,14025,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 2B receptor in the endothelium intact rabbit jugular vein.,B,,,Oryctolagus cuniculus,9986.0,
2897,8,,BAO_0000019,Expert,945.0,13463,Binding affinity analysed for 5-HT 2B receptor in rat stomach fundus,B,,,,,
2898,8,,BAO_0000357,Expert,945.0,7259,Affinity against 5-hydroxytryptamine 2B receptor in the isolated rat stomach fundus,B,,,,,
2899,8,,BAO_0000357,Autocuration,945.0,7259,Affinity against serotonergic receptor in the isolated rat stomach fundus,B,,,,,
2900,9,,BAO_0000019,Expert,945.0,7185,Antagonistic activity against 5-hydroxytryptamine 2B receptor obtained from rat stomach fundus preparation,F,,,Rattus norvegicus,10116.0,
2901,9,,BAO_0000019,Expert,,7185,Antagonistic against 5-hydroxytryptamine 2B receptor,F,,,Rattus norvegicus,10116.0,
2902,8,,BAO_0000019,Autocuration,945.0,13267,Antagonistic affinity measured as pA2 value on 5-hydroxytryptamine 2B receptor of the rat stomach fundus,F,,,,,
2903,9,,BAO_0000357,Expert,945.0,13735,Inhibition of 5-HT binding to 5-HT2B receptor of Rat stomach fundus,B,,,Rattus norvegicus,10116.0,
2904,8,,BAO_0000019,Autocuration,,15738,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B receptor ) receptor,F,,,,,
2905,8,,BAO_0000019,Autocuration,,15738,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B receptor ) receptor; No data,F,,,,,
2906,8,,BAO_0000019,Autocuration,,15738,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B) receptor,F,,,,,
2907,9,,BAO_0000357,Expert,945.0,12936,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,B,,,Rattus norvegicus,10116.0,
2908,9,,BAO_0000357,Expert,945.0,12936,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,B,,,Rattus norvegicus,10116.0,
2909,9,,BAO_0000357,Expert,945.0,12936,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,B,,,Rattus norvegicus,10116.0,
2910,9,,BAO_0000357,Expert,945.0,12936,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,B,,,Rattus norvegicus,10116.0,
2911,8,,BAO_0000019,Autocuration,945.0,16404,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,F,,,,,
2912,8,,BAO_0000019,Expert,945.0,16404,Negative log concentration of antagonist was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,F,,,,,
2913,8,,BAO_0000019,Autocuration,945.0,16404,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus; ND is No Data.,F,,,,,
2914,8,,BAO_0000019,Autocuration,945.0,16404,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus; ND is not determined.,F,,,,,
2915,9,,BAO_0000019,Expert,945.0,16404,Antagonistic activity on 5-hydroxytryptamine 2B receptor of Rat stomach fundus;ND is not determined,F,,,Rattus norvegicus,10116.0,
2916,8,,BAO_0000019,Autocuration,1515.0,16404,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat thoracic aorta; ND is not determined,F,,,,,
2917,8,,BAO_0000357,Autocuration,,7483,The binding affinity of compound to 5-HT receptor of rat fundus was expressed as pA2 value; Unable to determine valid PA2 value due to slope of Schild plot,B,,,,,
2918,8,,BAO_0000357,Expert,,7483,The binding affinity to 5-hydroxytryptamine 2B receptor of rat fundus,B,,,,,
2919,8,,BAO_0000357,Autocuration,,7483,The binding affinity of compound to 5-hydroxytryptamine 2B receptor of rat fundus was expressed as pA2 value; Unable to determine valid PA2 value due to slope of Schild plot,B,,,,,
2920,8,,BAO_0000357,Autocuration,,7483,The binding affinity of compound to 5-hydroxytryptamine 2B receptor of rat fundus; Unable to determine valid PA2 value due to slope of Schild plot,B,,,,,
2922,9,,BAO_0000019,Autocuration,945.0,16404,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,F,,,Rattus norvegicus,10116.0,
2923,8,,BAO_0000357,Autocuration,,6347,Binding affinity against 5-hydroxytryptamine 1A receptor,B,,,,,
2924,8,,BAO_0000357,Autocuration,,4373,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2B receptor was determined,B,,,,,
2925,8,,BAO_0000357,Autocuration,,4373,Binding affinity for 5-hydroxytryptamine 2B receptor was determined,B,,,,,
2926,8,,BAO_0000357,Autocuration,,4687,Evaluated for the binding affinity to 5-HT 2B receptor,B,,,,,
2927,8,,BAO_0000357,Autocuration,,16946,Ability to displace [3H]5-HT from 5-hydroxytryptamine 2B receptor,B,,,,,
2928,8,,BAO_0000357,Autocuration,,16633,Binding affinities against 5-hydroxytryptamine 2B receptor,B,,,,,
2929,8,,BAO_0000357,Autocuration,,16633,Binding affinities towards 5-hydroxytryptamine 2B receptor,B,,,,,
2930,8,,BAO_0000357,Autocuration,,16633,Binding affinity towards 5-hydroxytryptamine 2B receptor using [125I]DOI as radioligand,B,,,,,
2931,8,,BAO_0000357,Expert,,15026,In vitro ability to displace [3H]mesulergine binding from 5-hydroxytryptamine 2C receptor from bovine choroid plexus.,B,,,,,
2932,8,,BAO_0000357,Autocuration,,15738,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor,B,,,Bos taurus,9913.0,
2933,8,,BAO_0000357,Autocuration,,15738,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at a concentration of 10E-6 M,B,,,Bos taurus,9913.0,
2934,8,,BAO_0000357,Autocuration,,15738,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at a concentration of 10e-6 M,B,,,Bos taurus,9913.0,
2935,8,,BAO_0000357,Autocuration,,15738,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at concentration of 10e-6 M,B,,,Bos taurus,9913.0,
2936,8,,BAO_0000357,Expert,,16404,Inhibitory constant was determined on 5-hydroxytryptamine 2C receptor of Bovine choroid plexus,B,,,Bos taurus,9913.0,
2937,8,,BAO_0000357,Expert,,15026,In vitro ability to displace [3H]mesulergine binding from 5-hydroxytryptamine 2C receptor from bovine choroid plexus.,B,,,Bos taurus,9913.0,
2938,8,,BAO_0000357,Autocuration,,15738,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor,B,,,Bos taurus,9913.0,
2939,8,,BAO_0000019,Autocuration,,16312,Binding affinity against guinea pig cortex 5-HT2C receptor in the presence of [3H]mesulergine,B,,,Cavia porcellus,10141.0,
2940,9,,BAO_0000357,Intermediate,2435.0,5486,Binding affinity towards 5-HT4 receptor by the displacement of [3H]GR-113808 in guinea-pig striatum,B,,,Cavia porcellus,10141.0,
2941,8,,BAO_0000357,Autocuration,,5254,Binding affinity against 5-HT1A receptor,B,,,,,
2942,8,,BAO_0000219,Expert,,3857,Agonistic activity for 5-HT2c (5-HT2C) by measuring [3H]inositol monophosphate fromation in CHO cells in which the human 5-HT2C receptor subtype was stably expressed,F,,,,,
2943,9,,BAO_0000219,Expert,,6857,Functional activity against human 5-hydroxytryptamine 2C receptor expressed in CHO cells using fluorometric imaging plate reader,F,,,Homo sapiens,9606.0,
2944,8,,BAO_0000219,Autocuration,,4176,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2c receptor cell line,F,,,,,
2945,8,,BAO_0000219,Autocuration,,6347,Agonistic binding efficacy against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI radioligand,B,,,,,
2946,8,,BAO_0000219,Autocuration,,6347,"Agonistic binding affinity against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI radioligand, expressed as Emax",B,,,,,
2947,9,,BAO_0000357,Expert,,16146,Inhibition of human 5-hydroxytryptamine 2C receptor,B,,,Homo sapiens,9606.0,
2948,8,,BAO_0000357,Autocuration,,3805,In vitro binding affinity against human 5-hydroxytryptamine 2C receptor at a concentration of 100 (nM),B,,,,,
2949,8,,BAO_0000019,Autocuration,,3857,Inhibitory activity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor at a concentration of 1 uM,B,,,,,
2950,8,,BAO_0000357,Autocuration,,5635,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor,B,,,,,
2951,8,,BAO_0000357,Autocuration,,5635,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor Intrinsic efficacy against 5-hydroxytryptamine 2C receptor; Intrinsic efficacy (%) not determined,B,,,,,
2952,8,,BAO_0000357,Autocuration,,5635,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor; Intrinsic efficacy (%) not determined,B,,,,,
2953,8,,BAO_0000219,Expert,,4012,Displacement of [H]-mesulergine from CHO cells expressing human 5-hydroxytryptamine 2C receptor.,B,,,,,
2954,8,,BAO_0000219,Expert,,6366,Ability to displace [3H]- mesulergine from human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells,B,,,,,
2955,8,,BAO_0000219,Expert,,15949,Ability to displace [3H]mesulergine binding to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,B,,,,,
2956,8,,BAO_0000219,Autocuration,,17211,Ability to displace [3H]mesulergine (0.5 nM) from CHO cells of human 5-hydroxytryptamine 2C receptor,B,,,,,
2957,9,,BAO_0000357,Expert,,6491,Affinity towards human 5-hydroxytryptamine 2C serotonin receptor,B,,,Homo sapiens,9606.0,
2958,8,,BAO_0000019,Autocuration,,14093,Agonist activity at cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI radioligand,F,,,,,
2959,8,,BAO_0000019,Autocuration,,13481,Agonistic activity at cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,F,,,,,
2960,8,,BAO_0000219,Expert,,6347,Agonistic binding affinity against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI ,B,,,Rattus norvegicus,10116.0,
2961,8,,BAO_0000019,Autocuration,,14093,Antagonist activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine radioligand,F,,,,,
2962,8,,BAO_0000019,Autocuration,,14093,Antagonist activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine radioligand; Not tested,F,,,,,
2963,8,,BAO_0000019,Autocuration,,13481,Antagonistic activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,F,,,,,
2964,8,,BAO_0000357,Autocuration,,14442,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [125 I]DOI as radioligand,B,,,,,
2965,8,,BAO_0000357,Autocuration,,14442,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [3H]- mesulergine as radioligand,B,,,,,
2966,8,,BAO_0000357,Autocuration,,14442,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [3H]- mesulergine as radioligand;not tested,B,,,,,
2967,8,,BAO_0000357,Autocuration,,14755,Binding activity against cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as the radioligand.,B,,,,,
2968,8,,BAO_0000357,Autocuration,,14744,Binding affinity against the cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as the radioligand,B,,,,,
2969,8,,BAO_0000219,Expert,,16659,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,B,,,,,
2970,9,,BAO_0000019,Expert,,6857,Affinity for human 5-hydroxytryptamine 2C receptor expressed in mammalian cell line,B,,,Homo sapiens,9606.0,
2971,8,,BAO_0000357,Expert,,5635,Binding affinity against 5-hydroxytryptamine 2C receptor using [125I]DOI radioligand.,B,,,,,
2972,9,,BAO_0000357,Expert,,4234,Binding affinity to cloned human 5-hydroxytryptamine 2C receptor,B,,,Homo sapiens,9606.0,
2973,8,,BAO_0000357,Autocuration,,16209,Binding affinity towards human 5-HT2C receptor was determined using [125I]- DOI as radioligand,B,,,,,
2974,7,,BAO_0000249,Autocuration,,5778,Binding affinity for 5-HT3 receptor by displacement of [3H]-LY 278584 in rat cerebral cortex membranes,B,,,Rattus norvegicus,10116.0,
2975,6,,BAO_0000223,Autocuration,,5094,Binding affinity towards rat 5-hydroxytryptamine 3 receptor was evaluated,B,,,,,
2976,7,,BAO_0000019,Autocuration,,809,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 in rat posterior cortex,B,,,Rattus norvegicus,10116.0,
2977,6,,BAO_0000019,Autocuration,,1578,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 as radioligand in rat posterior cortex,B,,,,,
2978,6,,BAO_0000019,Autocuration,,809,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 as radioligand in rat posterior cortex; Not tested,B,,,,,
2979,6,,BAO_0000219,Autocuration,,12469,Binding affinity was measured on 5-hydroxytryptamine 3 receptor in NG-108 cells labeled with [3H]GR-65630,B,,,,,
2980,6,,BAO_0000019,Autocuration,,14290,Binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]-BRL 43694 as radioligand in rat posterior cortex,B,,,,,
2981,6,,BAO_0000019,Autocuration,,14290,Binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]-BRL 43694 as radioligand in rat posterior cortex.,B,,,,,
2982,6,,BAO_0000223,Autocuration,,10609,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]-5-HT,B,,,,,
2983,6,,BAO_0000223,Autocuration,,10609,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]GR-65630,B,,,,,
2984,6,,BAO_0000223,Autocuration,,10609,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]-ketanserin,B,,,,,
2985,6,,BAO_0000249,Autocuration,,15253,"Compound was evaluated for its in vitro affinity at serotonergic 5-hydroxytryptamine 3 receptor by radioligand binding assay, using [3H]-LY 278584 in rat cerebral cortex membranes.",B,,,,,
2986,6,,BAO_0000249,Autocuration,,15253,"In vitro affinity at serotonergic 5-hydroxytryptamine 3 receptor by radioligand binding assay, using [3H]-LY 278584 in rat cerebral cortex membranes.",B,,,,,
2987,6,,BAO_0000249,Autocuration,,11683,Displacement of the 5-hydroxytryptamine 3 receptor ligand [3H]GR-65630 from rat brain cortical membranes.,B,,,,,
2988,6,,BAO_0000223,Autocuration,,12092,Compound was evaluated for binding affinity against 5-hydroxytryptamine 3 receptor,B,,,,,
2989,6,,BAO_0000019,Autocuration,,1946,Binding affinity at 5-hydroxytryptamine 3 receptor in rat entorhinal cortex by [3H]BRL-43694 displacement.,B,,,,,
2990,6,,BAO_0000223,Autocuration,,11623,Ability to displace [3H]quipazine binding to 5-hydroxytryptamine 3 receptor sites in NG 108-15.,B,,,,,
2991,6,,BAO_0000223,Autocuration,,11623,Compound was evaluated for its ability to displace [3H]quipazine binding to 5-hydroxytryptamine 3 receptor sites in NG 108-15. ,B,,,,,
2992,6,,BAO_0000019,Autocuration,,14788,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement [3H]GR-65630 in rat cerebral cortex,B,,,,,
2993,7,,BAO_0000019,Autocuration,,5432,Displacement of [3H]ketanserin from rat cortex 5-HT3 receptor,B,,,Rattus norvegicus,10116.0,
2994,6,,BAO_0000249,Autocuration,,14826,Ability to displace [3H]granisetron specifically bound to 5-hydroxytryptamine 3 receptor in rat cortical membrane,B,,,,,
2995,6,,BAO_0000223,Autocuration,,2222,Compound was tested for its binding affinity for the 5-hydroxytryptamine 3 receptor,B,,,,,
2996,6,,BAO_0000019,Autocuration,,11963,Displacement of binding of [3H]-BRL 43694 to 5-hydroxytryptamine 3 receptor in rat cerebral cortex,B,,,,,
2997,6,,BAO_0000019,Autocuration,,14145,In vitro affinity for 5-hydroxytryptamine 3 (5-HT3) receptor by displacement of [3H]BRL-43694 from rat entorhinal cortex,B,,,,,
2998,6,,BAO_0000019,Autocuration,,17819,In vitro binding affinity at serotonin 5-hydroxytryptamine 3 receptor in rat cortex by [3H]granisetron displacement.,B,,,,,
2999,6,,BAO_0000249,Autocuration,,10394,Inhibitory activity against 5-hydroxytryptamine 3 receptor in rat cortical membranes using [3H]- 1-Methyl-1H-indazole-3-carboxylic acid (8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-amide as a radioligand,B,,,,,
3000,6,,BAO_0000249,Autocuration,,10394,Inhibitory activity against 5-hydroxytryptamine 3 receptor in rat cortical membranes using [3H]-1-Methyl-1H-indazole-3-carboxylic acid (8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-amide as a radioligand,B,,,,,
3001,6,,BAO_0000019,Autocuration,,15034,Inhibitory concentration against 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-LY 278584 as radioligand,B,,,,,
3002,6,,BAO_0000019,Autocuration,,691,Binding affinity at 5-hydroxytryptamine 3 receptor in rat entorhinal cortex by [3H]BRL-43694 displacement.,B,,,,,
3003,6,,BAO_0000249,Autocuration,,12092,Displacement of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor in rat brain cortical membranes,B,,,,,
3004,7,,BAO_0000223,Autocuration,,11752,Inhibition of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor,B,,,Rattus norvegicus,10116.0,
3005,6,,BAO_0000221,Autocuration,955.0,11752,The ability to inhibit [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor in rat brain cortices,B,,,,,
3006,6,,BAO_0000019,Autocuration,,301,Binding affinity at 5-hydroxytryptamine 3 receptor in rat posterior cortex by [3H]-BRL 43694 displacement.,B,,,,,
3007,6,,BAO_0000223,Autocuration,,16532,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584,B,,,,,
3008,6,,BAO_0000223,Autocuration,,16532,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584; Not tested,B,,,,,
3009,6,,BAO_0000223,Autocuration,,12092,The binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand.,B,,,,,
3010,6,,BAO_0000223,Autocuration,,11684,The compound was evaluated for the binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of radioligand [3H]GR-65630,B,,,,,
3011,6,,BAO_0000223,Autocuration,,11684,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of radioligand [3H]GR-65630.,B,,,,,
3012,6,,BAO_0000019,Autocuration,,12953,Binding affinity for 5-hydroxytryptamine 3 receptor from rat cortex using [3H]BRL-43694 as radioligand,B,,,,,
3013,6,,BAO_0000019,Autocuration,,12953,The compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor from rat cortex using [3H]BRL-43694 as radioligand; NA means Not active,B,,,,,
3014,6,,BAO_0000223,Autocuration,,12953,The compound was tested for their binding affinity towards 5-hydroxytryptamine 3 receptor; Nonactive at 10 uM,B,,,,,
3015,6,,BAO_0000019,Autocuration,,12861,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand; NA Not Available,B,,,,,
3016,6,,BAO_0000218,Autocuration,,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 0.5 hours in urethane-anesthetized rats,F,In vivo,,,,
3017,6,,BAO_0000218,Autocuration,,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 1 hour in urethane-anesthetized rats,F,In vivo,,,,
3018,6,,BAO_0000218,Autocuration,,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 3 hours in urethane-anesthetized rats,F,In vivo,,,,
3019,6,,BAO_0000218,Autocuration,,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 6 hours in urethane-anesthetized rats,F,In vivo,,,,
3020,6,,BAO_0000218,Autocuration,,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 0.5 hours in urethane-anesthetized rats,F,In vivo,,,,
3021,6,,BAO_0000218,Autocuration,,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 1 hour in urethane-anesthetized rats,F,In vivo,,,,
3022,6,,BAO_0000218,Autocuration,,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 16 hours in urethane-anesthetized rats,F,In vivo,,,,
3023,6,,BAO_0000218,Autocuration,,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 3 hours in urethane-anesthetized rats,F,In vivo,,,,
3024,6,,BAO_0000218,Autocuration,,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 6 hours in urethane-anesthetized rats,F,In vivo,,,,
3025,6,,BAO_0000218,Autocuration,,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 0.5 hours in urethane-anesthetized rats,F,In vivo,,,,
3026,6,,BAO_0000218,Autocuration,,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 1 hour in urethane-anesthetized rats,F,In vivo,,,,
3027,6,,BAO_0000218,Autocuration,,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 3 hours in urethane-anesthetized rats,F,In vivo,,,,
3028,6,,BAO_0000218,Autocuration,,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 6 hours in urethane-anesthetized rats,F,In vivo,,,,
3029,6,,BAO_0000218,Autocuration,,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 0.5 hours in urethane-anesthetized rats,F,In vivo,,,,
3030,6,,BAO_0000218,Autocuration,,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 3 hours in urethane-anesthetized rats,F,In vivo,,,,
3031,6,,BAO_0000218,Autocuration,,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 mg/kg at 1 hour in urethane-anesthetized rats,F,In vivo,,,,
3032,6,,BAO_0000218,Autocuration,,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 mg/kg at 3 hours in urethane-anesthetized rats,F,In vivo,,,,
3033,6,,BAO_0000218,Autocuration,,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 1 hour in urethane-anesthetized rats,F,In vivo,,,,
3034,6,,BAO_0000019,Autocuration,,10609,5-hydroxytryptamine 3 receptor antagonist activity was confirmed by its ability to antagonize 5-HT evoked tachycardia of rabbit isolated heart,F,,,,,
3035,6,,BAO_0000019,Autocuration,,12861,Binding activity against 5-hydroxytryptamine 2A receptor from rat cortex homogenates using [3H]DOB as radioligand.,B,,,,,
3036,7,,BAO_0000019,Autocuration,,12861,Inhibition of [3H]-Q-ICS 205-930 binding to rat cortex homogenate 5-hydroxytryptamine 3 receptor,B,,,Rattus norvegicus,10116.0,
3037,6,,BAO_0000223,Autocuration,,12861,Binding activity radioligand.,B,,,,,
3038,6,,BAO_0000249,Autocuration,,10728,Compound was evaluated for the displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor in rat brain membranes,B,,,,,
3039,6,,BAO_0000249,Autocuration,,10728,Displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor recognition sites in rat brain membranes.,B,,,,,
3040,8,,BAO_0000357,Autocuration,,5163,Binding affinity towards 5-hydroxytryptamine 2C receptor was determined at a concentration of 0.000001 mol/L,B,,,,,
3041,8,,BAO_0000357,Autocuration,,5163,Binding affinity towards 5-hydroxytryptamine 2C receptor was determined at a concentration of 0.00001 mol/L,B,,,,,
3042,8,,BAO_0000357,Autocuration,,6011,Inhibition of binding towards 5-hydroxytryptamine 2C receptor at 100 nM concentration,B,,,,,
3043,8,,BAO_0000357,Autocuration,,5014,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 2C receptor,B,,,,,
3044,8,,BAO_0000357,Autocuration,,5635,Binding affinity of compound towards 5-hydroxytryptamine 2C receptor,B,,,,,
3045,8,,BAO_0000357,Expert,,5163,Affinity for 5-hydroxytryptamine 2C receptor,B,,,,,
3046,8,,BAO_0000357,Autocuration,,6841,Binding affinity towards 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,B,,,,,
3047,8,,BAO_0000357,Expert,,6119,Binding affinity towards 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand.,B,,,,,
3048,8,,BAO_0000357,Autocuration,,4373,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2C receptor was determined,B,,,,,
3049,8,,BAO_0000357,Autocuration,,1633,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2C receptor by displacement of [3H]-Ketanserin,B,,,,,
3050,8,,BAO_0000357,Expert,,1633,Binding affinity towards 5-hydroxytryptamine 2C receptor by displacement of [3H]N-methyl-mesulergine,B,,,,,
3051,8,,BAO_0000357,Autocuration,,4373,Binding affinity for 5-hydroxytryptamine 2C receptor was determined,B,,,,,
3052,8,,BAO_0000357,Expert,,6576,Binding affinity towards serotonin 5-hydroxytryptamine 2C receptor,B,,,,,
3053,8,,BAO_0000357,Autocuration,,4687,Evaluated for the binding affinity to 5-hydroxytryptamine 2C receptor,B,,,,,
3054,8,,BAO_0000357,Autocuration,,12146,Tested agains t5-hydroxytryptamine 2C receptor in experiment 1,B,,,,,
3055,8,,BAO_0000357,Autocuration,,12146,Tested against 5-hydroxytryptamine 2C receptor in experiment 2,B,,,,,
3056,8,,BAO_0000357,Autocuration,,16946,Ability to displace [3H]mesulergine from 5-hydroxytryptamine 2C receptor,B,,,,,
3057,8,,BAO_0000357,Autocuration,,14159,Compound was evaluated for the affinity at 5-hydroxytryptamine 2C receptor,B,,,,,
3058,8,,BAO_0000357,Autocuration,,16700,The binding affinity towards 5-hydroxytryptamine 2C receptor; No affinity,B,,,,,
3059,8,,BAO_0000357,Autocuration,,3269,Affinity against 5-hydroxytryptamine 2C receptor,B,,,,,
3060,9,,BAO_0000357,Expert,,1274,Binding affinity against 5-hydroxytryptamine 2C receptor,B,,,Homo sapiens,9606.0,
3061,8,,BAO_0000357,Autocuration,,1317,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2C receptor using radioligand binding assay,B,,,,,
3062,8,,BAO_0000357,Autocuration,,5834,Inhibitory concentration required against 5-HT3 receptor in bovine area postrema using [3H]GR-65630,B,,,Bos taurus,9913.0,
3063,8,,BAO_0000357,Autocuration,,11147,Binding affinity towards 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand,B,,,Bos taurus,9913.0,
3064,4,,BAO_0000019,Expert,,14145,Antagonistic potency against serotonin 5-hydroxytryptamine 3 receptor in GPI assay,F,,,Cavia porcellus,10141.0,
3065,4,,BAO_0000221,Autocuration,2116.0,10561,Binding affinity to 5-hydroxytryptamine 3 receptor entirely in guinea pig ileum,B,,,Cavia porcellus,10141.0,
3066,4,,BAO_0000019,Autocuration,,15847,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 3 receptor of guinea pig,F,,,Cavia porcellus,10141.0,
3067,4,,BAO_0000019,Autocuration,,15847,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 3 receptor of guinea pig; ND means not done,F,,,Cavia porcellus,10141.0,
3068,4,,BAO_0000221,Autocuration,2116.0,10561,Potency to 5-hydroxytryptamine 3 receptor entirely in guinea pig ileum,B,,,Cavia porcellus,10141.0,
3069,4,,BAO_0000221,Autocuration,2116.0,11454,In vitro binding affinity was measured for 5-hydroxytryptamine 3 receptor in the guinea pig ileum.,B,,,Cavia porcellus,10141.0,
3070,4,,BAO_0000019,Autocuration,,4639,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea colon at a concentration 0.01 uM,F,,,Cavia porcellus,10141.0,
3071,4,,BAO_0000019,Autocuration,,4639,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 0.1 uM,F,,,Cavia porcellus,10141.0,
3072,4,,BAO_0000019,Autocuration,,4639,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 1 uM,F,,,Cavia porcellus,10141.0,
3073,4,,BAO_0000019,Autocuration,,4639,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 1 uM in the presence of 30 uM MDL 72222,F,,,Cavia porcellus,10141.0,
3074,4,,BAO_0000019,Autocuration,,4639,Percent of control response to 5-HT3 antagonistic activity on guinea colon at a concentration 0.01 uM,F,,,Cavia porcellus,10141.0,
3075,4,,BAO_0000019,Autocuration,,4639,Percent of control response to 5-HT3 antagonistic activity on guinea colon at a concentration 1 uM,F,,,Cavia porcellus,10141.0,
3076,4,,BAO_0000221,Autocuration,2116.0,15253,"Concentration required to produce 50% of maximal contraction induced by 5-HT through 5-HT3 receptors in the presence of the compound, in isolated guinea pig ileum",F,,,Cavia porcellus,10141.0,
3077,4,,BAO_0000221,Autocuration,2116.0,15253,"Concentration required to produce 50% of maximal contraction induced by 5-HT through 5-HT3 receptors in the presence of the compound, in isolated guinea pig ileum.",F,,,Cavia porcellus,10141.0,
3078,4,,BAO_0000221,Autocuration,2116.0,11963,Tested for the antagonistic activity against 5-hydroxytryptamine 3 receptor from guinea pig ileum,F,,,Cavia porcellus,10141.0,
3079,4,,BAO_0000221,Autocuration,2116.0,1946,In vitro 5-hydroxytryptamine 3 receptor activity in guinea pig ileum,B,,,Cavia porcellus,10141.0,
3080,4,,BAO_0000221,Autocuration,2116.0,1946,In vitro 5-hydroxytryptamine 3 receptor activity in guinea pig ileum; Not tested,B,,,Cavia porcellus,10141.0,
3081,4,,BAO_0000223,Autocuration,,12045,Binding affinity towards [3H]quipazine labeled 5-hydroxytryptamine 3 receptor sites in HG108-15,B,,,Cavia porcellus,10141.0,
3082,4,,BAO_0000221,Autocuration,2116.0,1559,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,B,,,Cavia porcellus,10141.0,
3083,4,,BAO_0000221,Autocuration,2116.0,273,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),F,,,Cavia porcellus,10141.0,
3084,4,,BAO_0000221,Autocuration,2116.0,273,Antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor of isolated guinea pig ileum (GPI),F,,,Cavia porcellus,10141.0,
3085,4,,BAO_0000221,Autocuration,2116.0,188,Tested for antagonistic activity on 5-hydroxytryptamine 3 receptor mediated effects of 5-HT in guinea pig isolated ileum,F,,,Cavia porcellus,10141.0,
3086,4,,BAO_0000221,Autocuration,2116.0,12919,Agonistic activity against 5-hydroxytryptamine 3 receptor in guinea pig ileum assay,F,,,Cavia porcellus,10141.0,
3087,4,,BAO_0000221,Autocuration,2116.0,12918,5-hydroxytryptamine 3 receptor agonism in the guinea pig ileum by functional 5-HT3 receptor assay,F,,,Cavia porcellus,10141.0,
3088,4,,BAO_0000221,Autocuration,2116.0,1559,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,B,,,Cavia porcellus,10141.0,
3089,4,,BAO_0000221,Autocuration,2116.0,273,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),F,,,Cavia porcellus,10141.0,
3090,4,,BAO_0000221,Autocuration,2116.0,1559,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,B,,,Cavia porcellus,10141.0,
3091,4,,BAO_0000221,Autocuration,2116.0,1559,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum; Not determined,B,,,Cavia porcellus,10141.0,
3092,4,,BAO_0000221,Autocuration,2116.0,1559,Binding affinity towards 5-hydroxytryptamine 3 receptor of guinea pig ileum; not determined,B,,,Cavia porcellus,10141.0,
3093,4,,BAO_0000221,Autocuration,2116.0,14424,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor in guinea pig ileum.,B,,,Cavia porcellus,10141.0,
3094,0,,BAO_0000019,Autocuration,,13181,Binding affinity was determined against 5-hydroxytryptamine 2A receptor,B,,,Cavia porcellus,10141.0,
3095,8,,BAO_0000357,Autocuration,,5486,Binding affinity towards 5-HT1A receptor by the displacement of [3H]-8-OH-DPAT] in human recombinant receptors in mammalian cell,B,,,,,
3096,5,,BAO_0000223,Expert,,6491,Affinity towards human 5-hydroxytryptamine 3 serotonin receptor,B,,,Homo sapiens,9606.0,
3097,4,,BAO_0000223,Autocuration,,6013,Binding affinity towards 5-HT3 receptor,B,,,,,
3098,4,,BAO_0000223,Autocuration,,12861,Binding activity radioligand.,B,,,,,
3099,4,,BAO_0000019,Autocuration,,12861,Binding activity against 5-hydroxytryptamine 1A receptor from human brain cortex using [3H]8-OH-DPAT-HT as radioligand.,B,,,,,
3100,4,,BAO_0000223,Autocuration,,5104,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor,B,,,,,
3101,4,,BAO_0000223,Autocuration,,5105,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor,B,,,,,
3102,4,,BAO_0000223,Autocuration,,5104,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor; NT means Not tested,B,,,,,
3103,0,,BAO_0000019,Autocuration,,3935,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 3 receptor,B,,,,,
3104,4,,BAO_0000219,Expert,,13657,Displacement of [3H]-BRC 36694 from 5-hydroxytryptamine 3 receptor in NG108-15 cells,B,,,,,
3105,4,,BAO_0000218,Autocuration,,10369,"Percent inhibition of [3H]5 binding to 5-hydroxytryptamine 3 receptor was evaluated by injection of compound (75 microCi/kg, 1.32 ug/kg) into the tail vein of mice (in vivo)",B,In vivo,,,,
3106,4,,BAO_0000019,Autocuration,,10369,The binding affinity was measured for 5-hydroxytryptamine 3 receptor on NG 108-15 cell line of mouse neuroblastoma-glioma cells in presence of [3H]5 radioligand (in vitro),B,,,,,
3107,4,,BAO_0000224,Autocuration,,12918,Compound was evaluated for the binding affinity at 5- HT3 receptor subtype,B,,,,,
3108,4,,BAO_0000224,Autocuration,,12918,Compound was evaluated for the binding affinity at 5- HT3 receptor,B,,,,,
3109,4,,BAO_0000019,Autocuration,,10369,The binding affinity was measured for 5-hydroxytryptamine 3 receptor on NG 108-15 cell line of mouse neuroblastoma-glioma cells in presence of [3H]5 radioligand (in vitro),B,,,,,
3110,4,,BAO_0000019,Autocuration,,773,In Vitro Binding affinity againist 5-hydroxytryptamine 3 receptor by displacing [3H]-Q-ICS 205-930 from rat cortex homogenates,B,,,,,
3111,4,,BAO_0000218,Autocuration,,12918,5-hydroxytryptamine 3 receptor agonism in mouse,F,,,,,
3112,4,,BAO_0000219,Autocuration,,10561,Binding affinity towards 5-hydroxytryptamine 3 receptor was determined by using [3H]-ICS 205-930 as radioligand in mouse N1E 115 cells,B,,,,,
3113,4,,BAO_0000019,Autocuration,,12827,Binding affinity towards 5-hydroxytryptamine 2A receptor in rat cortex preparations using [3H]ketanserin,B,,,,,
3114,4,,BAO_0000019,Autocuration,,12827,Binding affinity towards 5-hydroxytryptamine 2A receptor in rat cortex preparations using [3H]ketanserin,B,,,,,
3115,4,,BAO_0000224,Autocuration,,12918,Binding affinity was evaluated by 5-hydroxytryptamine 3 receptor agonism in the mouse NIE-115 by displacing tropisetron,B,,,,,
3116,4,,BAO_0000219,Autocuration,,273,Compound was evaluated for binding to 5-hydroxytryptamine 3 receptor in N1E cells using [3H]- -Tropisetron as radioligand,B,,,,,
3117,4,,BAO_0000219,Autocuration,,273,Compound was evaluated for binding to Serotonin 5-hydroxytryptamine 3 receptor in N1E cells using [3H]- -Tropisetron as radioligand,B,,,,,
3118,4,,BAO_0000224,Autocuration,,10561,Potency at neuronal 5-hydroxytryptamine 3 receptor in the rabbit heart,B,,,,,
3119,4,,BAO_0000219,Autocuration,,5033,Ability to displace the radioligand [3H]GR-65630 from 5-hydroxytryptamine 3 receptor expressed in NIE-115 cells,B,In vitro,,,,
3120,4,,BAO_0000219,Autocuration,,16429,In vitro binding affinity at 5-hydroxytryptamine 3 receptor in N1E-115 cells using 3[H]GR-65630 as the radioligand,B,,,,,
3121,8,,BAO_0000019,Autocuration,,10322,In vitro binding affinity for the 5-hydroxytryptamine 3 receptor was determined with NG-108-15 mouse neuroblastoma-glioma cells,B,,,,,
3122,8,,BAO_0000219,Autocuration,,14331,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor in NG cells 108-15,B,,,,,
3123,9,,BAO_0000357,Autocuration,,13462,Compound was tested for the Binding affinity against N1e-115 neuroblastoma 5-hydroxytryptamine 3 receptor by Radio ligand [3H]GR-65630 binding assay.,B,,,Mus musculus,10090.0,
3124,8,,BAO_0000019,Autocuration,,12861,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,B,,,,,
3125,8,,BAO_0000357,Autocuration,,15086,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor,B,,,Sus scrofa,9823.0,
3126,8,,BAO_0000357,Autocuration,,12861,Binding activity radioligand.,B,,,Sus scrofa,9823.0,
3127,4,,BAO_0000223,Autocuration,,10561,Binding affinity to 5-hydroxytryptamine 3 receptor of neuronal in the afferent rabbit vagus,B,,,Oryctolagus cuniculus,9986.0,
3128,4,,BAO_0000223,Autocuration,,10561,Potency at neuronal 5-hydroxytryptamine 3 receptor in the rabbit heart,B,,,Oryctolagus cuniculus,9986.0,
3129,4,,BAO_0000223,Autocuration,,10561,Potency at neuronal 5-hydroxytryptamine 3 receptors in the rabbit heart,B,,,Oryctolagus cuniculus,9986.0,
3130,4,,BAO_0000019,Autocuration,,10561,Potency to 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand in rat cortex,B,,,Oryctolagus cuniculus,9986.0,
3131,4,,BAO_0000019,Autocuration,,273,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),F,,,Oryctolagus cuniculus,9986.0,
3132,4,,BAO_0000019,Autocuration,,273,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),F,,,Oryctolagus cuniculus,9986.0,
3133,4,,BAO_0000221,Autocuration,2116.0,273,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),F,,,Oryctolagus cuniculus,9986.0,
3134,4,,BAO_0000019,Autocuration,,273,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),F,,,Oryctolagus cuniculus,9986.0,
3135,4,,BAO_0000019,Autocuration,,273,Antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),F,,,Oryctolagus cuniculus,9986.0,
3136,4,,BAO_0000019,Autocuration,,273,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),F,,,Oryctolagus cuniculus,9986.0,
3137,4,,BAO_0000019,Autocuration,,273,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),F,,,Oryctolagus cuniculus,9986.0,
3138,4,,BAO_0000219,Autocuration,,13047,Binding affinity against 5-hydroxytryptamine 3 receptor in CHO cells using [3H]5-HT as radioligand,B,,,Oryctolagus cuniculus,9986.0,
3139,7,,BAO_0000019,Autocuration,,1650,In vitro displacement of [3H]-LY 278584 from rat cerebral cortex 5-hydroxytryptamine 3 receptor,B,,,Rattus norvegicus,10116.0,
3140,8,,BAO_0000019,Autocuration,,16288,Affinity at 5-hydroxytryptamine 3 receptor from rat frontal cortex using [3H]granisetron as radioligand (For granisetron = Ki(nM)=0.3+/-0.01),B,,,,,
3141,8,,BAO_0000357,Autocuration,,16288,Affinity at 5-hydroxytryptamine 3 receptor (For granisetron = Ki (nM)=0.3+/-0.01),B,,,,,
3142,7,,BAO_0000019,Autocuration,,10254,In vitro displacement of [3H]ICS-205-930 from 5-hydroxytryptamine 3 receptor in cultured NG-108-15 rat glioma cells,B,,,Rattus norvegicus,10116.0,
3143,6,,BAO_0000019,Autocuration,,14532,"Binding affinity for 5-hydroxytryptamine 3 receptor in rat cerebral cortex, determined by displacement of [3H]GR-65630",B,,,,,
3144,6,,BAO_0000218,Autocuration,948.0,13392,"5-Hydroxy tryptamine 3 receptor showing agonist activity (in vivo) in Von Bezold-Jarisch Reflex in rats at 120 (ug/kg), evaluated as change in heart rate",F,In vivo,,,,
3145,6,,BAO_0000019,Autocuration,948.0,13392,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 100 (ug/kg), evaluated as change in heart rate",F,,,,,
3146,6,,BAO_0000019,Autocuration,948.0,13392,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 120 (ug/kg), evaluated as change in heart rate",F,,,,,
3147,6,,BAO_0000019,Autocuration,948.0,13392,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 60 (ug/kg), evaluated as change in heart rate",F,,,,,
3148,6,,BAO_0000019,Autocuration,948.0,13392,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptorr in Von Bezold-Jarisch Reflex in rats at 100 (ug/kg), evaluated as change in heart rate",F,,,,,
3149,6,,BAO_0000019,Autocuration,,13392,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 100(ug/kg), evaluated as percent inhibition of bradycardia",F,,,,,
3150,6,,BAO_0000019,Autocuration,,13392,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 60 (ug/kg), evaluated as percent inhibition of bradycardia",F,,,,,
3151,6,,BAO_0000019,Autocuration,,13392,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch reflex in rats at 60 (ug/kg), evaluated as percent inhibition of bradycardia",F,,,,,
3152,6,,BAO_0000019,Autocuration,,13392,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch reflex in rats at 60(ug/kg), evaluated as percent inhibition of bradycardia",F,,,,,
3153,7,,BAO_0000218,Autocuration,,1089,Antagonism of 5-HT-induced Von Bezold-Jarisch reflex in rat after intravenous administration of 30 ug/kg of HT (5-hydroxytryptamine 3 receptor antagonism),F,In vivo,,Rattus norvegicus,10116.0,
3154,6,,BAO_0000218,Autocuration,,1089,Ability to antagonise the 5-HT- induced Von Bezold-Jarisch reflex in the rat after intravenous administration of 30 ug/kg of HT (5-hydroxytryptamine 3 receptor),F,In vivo,,,,
3155,7,,BAO_0000218,Autocuration,,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1000 ug/kg dose in urethane-anesthetized rats,F,In vivo,,Rattus norvegicus,10116.0,
3156,7,,BAO_0000019,Autocuration,,11454,Inhibition of 5-HT-induced bradycardia by 5-hydroxytryptamine 3+,F,,,Rattus norvegicus,10116.0,
3157,7,,BAO_0000218,Autocuration,,12205,In vivo inhibitory concentration after 5 minutes against 5-hydroxytryptamine 3 receptor induced bradycardia [bezold-jarisch (B-J) reflex test] in rat by intravenous administration,F,In vivo,,Rattus norvegicus,10116.0,
3158,7,,BAO_0000019,Autocuration,,1089,Inhibition of 5-HT (1 ug/mL) induced depolarization in rat vagus nerve (5-hydroxytryptamine 3 receptor antagonism),F,,,Rattus norvegicus,10116.0,
3159,6,,BAO_0000019,Autocuration,,5094,Binding affinity towards 5-HT3 receptor in rat was evaluated,B,,,,,
3160,7,,BAO_0000019,Autocuration,,2622,Inhibition of [3H]GR-65630 binding to rat cortical membrane 5-hydroxytryptamine 3 receptor,B,,,Rattus norvegicus,10116.0,
3161,6,,BAO_0000223,Autocuration,,245,Binding affinity was evaluated in vitro by displacement of [3H]zacopride radioligand from 5-hydroxytryptamine 3 receptor,B,,,,,
3162,6,,BAO_0000019,Autocuration,,14788,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement [3H]GR-65630 in rat cerebral cortex.,B,,,,,
3163,6,,BAO_0000019,Autocuration,,14788,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement of [3H]granisetron from rat cerebral cortex,B,,,,,
3164,6,,BAO_0000249,Autocuration,,3020,Binding affinity against 5-hydroxytryptamine 3 receptor in rat cortical membrane using [3H]GR-65630 as radioligand,B,,,,,
3165,6,,BAO_0000019,Autocuration,,1742,Compound was tested for its ability to displace [3H]-Q-ICS 205-930 from 5-hydroxytryptamine 3 receptor in rat cortex homogenates,B,,,,,
3166,6,,BAO_0000249,Autocuration,955.0,17394,Concentration of compound required to inhibit the binding of radioligand [3H]GR-65630 to 5-hydroxytryptamine 3 receptor in rat brain cortical membrane,B,,,,,
3167,6,,BAO_0000221,Autocuration,955.0,17394,Concentration required to inhibit the binding of radioligand [3H]GR-65630 to serotonin 5-hydroxytryptamine-3 receptor (5-HT 3 receptor)in rat brain cortical membrane,B,,,,,
3168,6,,BAO_0000249,Autocuration,,17394,Concentration of compound required to inhibit the binding of radioligand [3H]GR-65630 to serotonin 5-hydroxytryptamine 3 receptor in rat cortical membrane,B,,,,,
3169,6,,BAO_0000249,Autocuration,,14286,In vitro inhibitory concentration against radioligand [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor in rat cortical membrane,B,,,,,
3170,6,,BAO_0000019,Autocuration,,14178,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate.,B,,,,,
3171,7,,BAO_0000019,Autocuration,,14178,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate; Not active at 10000 nm,B,,,Rattus norvegicus,10116.0,
3172,7,,BAO_0000019,Autocuration,,14178,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate; not active at 10000 nM,B,,,Rattus norvegicus,10116.0,
3173,7,,BAO_0000223,Autocuration,,14178,Inhibition of radiolabeled [3H]-Zacopride ligand binding to 5-hydroxytryptamine 3 receptor,B,,,Rattus norvegicus,10116.0,
3174,6,,BAO_0000019,Autocuration,,15034,Inhibitory concentration against 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-LY 278584 as radioligand,B,,,,,
3175,6,,BAO_0000249,Autocuration,,1089,"Tested for inhibition of binding of [3H]GR-65630 to rat cortical membranes, expressed as IC50",B,,,,,
3176,7,,BAO_0000019,Autocuration,,1089,Inhibition of [3H]GR-65630 binding to rat cortical membrane serotonin 3 receptor,B,,,Rattus norvegicus,10116.0,
3177,6,,BAO_0000223,Autocuration,,16532,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584; Not tested,B,,,,,
3178,7,,BAO_0000223,Autocuration,,12801,Inhibition of [3H]BRL-43694 binding to rat 5-hydroxytryptamine 3 receptor,B,,,Rattus norvegicus,10116.0,
3179,6,,BAO_0000219,Autocuration,,15194,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from NG108-15 cells (using [3H]zacopride as radioligand),B,,,,,
3180,6,,BAO_0000219,Autocuration,,15194,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from NG108-15 cells using [3H]zacopride as radioligand,B,,,,,
3181,6,,BAO_0000019,Autocuration,,15194,Binding affinity against 5-hydroxytryptamine 3 (5-HT3) receptor from rat cortical homogenate using [3H]zacopride as radioligand,B,,,,,
3182,6,,BAO_0000019,Autocuration,,15194,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; NA= Not active,B,,,,,
3183,6,,BAO_0000019,Autocuration,,15194,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; NA=Not active,B,,,,,
3184,6,,BAO_0000019,Autocuration,,15194,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; not active,B,,,,,
3185,6,,BAO_0000019,Autocuration,,10610,Antagonist potency to 5-hydroxytryptamine 3 receptor was assayed by antagonism of the 5-HT-evoked reflex bradycardia [Bezold-Jarisch(BJ) reflex] in rats,F,,,,,
3186,7,,BAO_0000019,Autocuration,,10355,Antagonistic activity against 5-hydroxytryptamine 3 receptor as inhibition of 5-HT-induced bradycardia (von Bezold-jarisch reflex) in anesthetized rat,F,,,Rattus norvegicus,10116.0,
3187,6,,BAO_0000019,Autocuration,,691,"Compound was tested as a 5-hydroxytryptamine 3 receptor antagonist in the rat by assessment of the inhibition of the Bezold-Jarisch effect, when administered intravenously",F,,,,,
3188,6,,BAO_0000218,Autocuration,,10611,In vivo 5-hydroxytryptamine 3 receptor (5-HT 3 receptor) antagonistic activity expressed as ability to inhibit Bezold-Jarich reflex evoked by 5-HT in rats,F,,,,,
3189,6,,BAO_0000218,Autocuration,,12801,Inhibition dose for 50 percent antagonism for 5-hydroxytryptamine 3 receptor in vivo in rats,F,In vivo,,,,
3190,6,,BAO_0000218,Autocuration,,10609,Inhibition of 5-HT evoked reflex bradycardia in rat.,F,,,,,
3191,6,,BAO_0000218,Autocuration,,11454,5-HT3 receptor antagonistic activity was measured by the inhibition of 5-HT-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,F,In vivo,,,,
3192,6,,BAO_0000218,Autocuration,,11454,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1 ug/kg dose in urethane-anesthetized rats,F,In vivo,,,,
3193,6,,BAO_0000218,Autocuration,,11454,5-hydroxytryptamine 3 receptor antagonistic activity measured by inhibition of 5-HT-induced bradycardia (iv administration 10 ug/kg dose in urethane-anesthetized rats),F,In vivo,,,,
3194,7,,BAO_0000218,Autocuration,,11454,5-hydroxytryptamine 3 receptor antagonistic activity as inhibition of 5-HT-induced bradycardia after iv administration of 100 ug/kg dose in urethane-anesthetized rats,F,In vivo,,Rattus norvegicus,10116.0,
3195,6,,BAO_0000218,Autocuration,,11454,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,F,In vivo,,,,
3196,6,,BAO_0000218,Autocuration,,11454,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1000 ug/kgetized rats,F,In vivo,,,,
3197,6,,BAO_0000218,Autocuration,,11454,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 3 ug/kg dose in urethane-anesthetized rats,F,In vivo,,,,
3198,6,,BAO_0000218,Autocuration,,11454,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 10 ug/kg dose in urethane-anesthetized rats,F,In vivo,,,,
3199,6,,BAO_0000218,Autocuration,,11454,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 100 ug/kg dose in urethane-anesthetized rats,F,In vivo,,,,
3200,6,,BAO_0000218,Autocuration,,11454,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 1000 ug/kg dose in urethane-anesthetized rats,F,In vivo,,,,
3201,6,,BAO_0000218,Autocuration,,11454,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 30 ug/kg dose in urethane-anesthetized rats,F,In vivo,,,,
3202,6,,BAO_0000218,Autocuration,,11454,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 300 ug/kg dose in urethane-anesthetized rats,F,In vivo,,,,
3203,6,,BAO_0000218,Autocuration,,11454,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 3ug/kg dose in urethane-anesthetized rats,F,In vivo,,,,
3204,6,,BAO_0000218,Autocuration,,11454,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5-HT-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,F,In vivo,,,,
3205,6,,BAO_0000218,Autocuration,,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 0.3 ug/kg dose in urethane-anesthetized rats,F,In vivo,,,,
3206,6,,BAO_0000218,Autocuration,,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 1 ug/kg dose in urethane-anesthetized rats,F,In vivo,,,,
3207,6,,BAO_0000218,Autocuration,,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 30 ug/kg dose in urethane-anesthetized rats,F,In vivo,,,,
3208,6,,BAO_0000218,Autocuration,,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 0.05 hour,F,In vivo,,,,
3209,6,,BAO_0000218,Autocuration,,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 1 hour,F,In vivo,,,,
3210,6,,BAO_0000218,Autocuration,,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 16 hour,F,In vivo,,,,
3211,6,,BAO_0000218,Autocuration,,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 3 hour,F,In vivo,,,,
3212,6,,BAO_0000218,Autocuration,,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 6 hour,F,In vivo,,,,
3213,6,,BAO_0000218,Autocuration,,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 ug/kg dose in urethane-anesthetized rats,F,In vivo,,,,
3214,6,,BAO_0000218,Autocuration,,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 100 ug/kg dose in urethane-anesthetized rats,F,In vivo,,,,
3215,6,,BAO_0000218,Autocuration,,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1000 ug/kg dose in urethane-anesthetized rats,F,In vivo,,,,
3216,6,,BAO_0000218,Autocuration,,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 ug/kg dose in urethane-anesthetized rats,F,In vivo,,,,
3217,6,,BAO_0000218,Autocuration,,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 3 ug/kg dose in urethane-anesthetized rats,F,In vivo,,,,
3218,6,,BAO_0000218,Autocuration,,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 30 ug/kg dose in urethane-anesthetized rats,F,In vivo,,,,
3219,6,,BAO_0000218,Autocuration,,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 300 ug/kg dose in urethane-anesthetized rats,F,In vivo,,,,
3220,6,,BAO_0000218,Autocuration,,670,"In vivo 5-hydroxytryptamine 3 receptor antagonist activity by antagonism of the von Bezold-Jarisch (B-J) reflex in anesthetized rats, (i.v.)",F,,,,,
3221,6,,BAO_0000218,Autocuration,,670,"In vivo 5-hydroxytryptamine 3 receptor antagonist activity by antagonism of the von Bezold-Jarisch (B-J) reflex in anesthetized rats, (i.v.); Not tested",F,,,,,
3222,6,,BAO_0000218,Autocuration,,10321,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 10 ug/Kg,F,In vivo,,,,
3223,6,,BAO_0000218,Autocuration,,10321,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 100 ug/Kg,F,In vivo,,,,
3224,6,,BAO_0000218,Autocuration,,10321,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 2 ug/Kg,F,In vivo,,,,
3225,6,,BAO_0000218,Autocuration,,10321,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 20 ug/Kg,F,In vivo,,,,
3226,6,,BAO_0000218,Autocuration,,10321,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 5 ug/Kg,F,In vivo,,,,
3227,6,,BAO_0000218,Autocuration,,10322,Tested for inhibition of Bezold-Jarisch (B-J) reflex mediated by 5-hydroxytryptamine 3 receptor in rats after intravenous administration (2.0 ug/kg),F,In vivo,,,,
3228,6,,BAO_0000019,Autocuration,,15412,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; A means pure agonist,F,,,,,
3229,6,,BAO_0000019,Autocuration,,15412,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; A means pure agonist,F,,,,,
3230,7,,BAO_0000223,Autocuration,,15412,Intrinsic efficacy for rat 5-hydroxytryptamine 3 receptor,B,,,Rattus norvegicus,10116.0,
3231,6,,BAO_0000019,Autocuration,,15412,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; PA means partial agonist,F,,,,,
3232,7,,BAO_0000221,Intermediate,10000000.0,15412,Inhibition of [3H]granisetron binding to 5-hydroxytryptamine 3 receptor (5-HT 3 receptor) of rat cortex and hippocampus tissue,B,,,,,
3233,7,,BAO_0000019,Autocuration,,15412,Inhibition of [3H]granisetron binding to 5-hydroxytryptamine 3 receptor of rat cortical membrane,B,,,Rattus norvegicus,10116.0,
3234,7,,BAO_0000019,Autocuration,,17394,Inhibition of [3H]GR-65630 binding to rat cortical membrane serotonin 5-hydroxytryptamine 3 receptor,B,,,Rattus norvegicus,10116.0,
3235,6,,BAO_0000223,Autocuration,,12457,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 3 receptor,B,,,,,
3236,6,,BAO_0000019,Autocuration,,12457,Affinity was evaluated by inhibition of [3H]GR-65630 binding to NG108-15 cell transfected with cloned rat 5-hydroxytryptamine 3 receptor,B,,,,,
3237,6,,BAO_0000019,Autocuration,,12205,Binding affinity against radioligand [3H]quipazine labeled 5-hydroxytryptamine 3 receptor sites in neuroblastoma-glioma (NG108-15) cells.,B,,,,,
3238,6,,BAO_0000019,Autocuration,,14532,Binding affinity for 5-hydroxytryptamine 3 receptor was determined by measuring displacement of [3H]GR-65630 from rat brain cortices,B,,,,,
3239,6,,BAO_0000019,Autocuration,,1122,Binding affinity to 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-BRL 43694 as radioligand,B,,,,,
3240,6,,BAO_0000019,Autocuration,,5094,Binding affinity towards 5-HT3 receptor in rat was evaluated,B,,,,,
3241,9,,BAO_0000221,Intermediate,2116.0,809,5-hydroxytryptamine 4 receptor agonist activity as increased response to electrical stimulation in guinea pig ileum,F,,,Cavia porcellus,10141.0,
3242,9,,BAO_0000221,Intermediate,2116.0,809,5-hydroxytryptamine 4 receptor agonist activity expressed as the concentration which gave a 50% increase in the response to the electrical stimulation in male guinea pig ileum; Not tested,F,,,Cavia porcellus,10141.0,
3243,9,,BAO_0000221,Intermediate,2116.0,14290,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum",F,,,Cavia porcellus,10141.0,
3244,9,,BAO_0000221,Intermediate,2116.0,14290,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Inactive up to 10E-5 M",F,,,Cavia porcellus,10141.0,
3245,9,,BAO_0000221,Intermediate,2116.0,14290,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Not tested",F,,,Cavia porcellus,10141.0,
3246,9,,BAO_0000221,Intermediate,2116.0,14290,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Not tested",F,,,Cavia porcellus,10141.0,
3247,9,,BAO_0000221,Intermediate,2116.0,14290,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not capable of evaluation",F,,,Cavia porcellus,10141.0,
3248,9,,BAO_0000221,Intermediate,2116.0,13961,concentration which gave a 50% increase in the response to electrical stimulation against 5-hydroxytryptamine 4 receptor in the guinea pig ileum.,F,,,Cavia porcellus,10141.0,
3249,9,,BAO_0000221,Intermediate,2116.0,13961,concentration which gave a 50% increase in the response to electrical stimulation against 5-hydroxytryptamine 4 receptor in the guinea pig ileum. Activity expressed as percent of the maximum 5-HT response given in brackets.,F,,,Cavia porcellus,10141.0,
3250,9,,BAO_0000221,Intermediate,2116.0,809,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum,F,,,Cavia porcellus,10141.0,
3251,9,,BAO_0000221,Intermediate,2116.0,809,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum; Not evaluable,F,,,Cavia porcellus,10141.0,
3252,9,,BAO_0000221,Intermediate,2116.0,809,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum; Not tested,F,,,Cavia porcellus,10141.0,
3253,9,,BAO_0000221,Intermediate,2116.0,14290,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum",F,,,Cavia porcellus,10141.0,
3254,9,,BAO_0000221,Intermediate,2116.0,14290,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Inactive up to 10-5 M",F,,,Cavia porcellus,10141.0,
3255,9,,BAO_0000221,Intermediate,2116.0,14290,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Inactive up to 10E-5 M",F,,,Cavia porcellus,10141.0,
3256,9,,BAO_0000221,Intermediate,2116.0,14290,5-hydroxytryptamine 4 receptor antagonist activity as inhibition of 5-HT-induced contractions in guinea pig ileum; Not capable of evaluation.,F,,,Cavia porcellus,10141.0,
3257,9,,BAO_0000221,Intermediate,2116.0,14290,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not tested",F,,,Cavia porcellus,10141.0,
3258,9,,BAO_0000221,Intermediate,2116.0,14290,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not tested",F,,,Cavia porcellus,10141.0,
3259,9,,BAO_0000357,Intermediate,,15034,Displacement of [3H]GR-113808 from 5-hydroxytryptamine 4 receptor in guinea pig striatum,B,,,Cavia porcellus,10141.0,
3260,9,,BAO_0000249,Intermediate,2435.0,5094,Binding affinity towards 5-HT4 receptor in striatum membranes of guinea-pig brain was evaluated,B,,,Cavia porcellus,10141.0,
3261,9,,BAO_0000249,Intermediate,2435.0,5094,Binding affinity towards 5-hydroxytryptamine 4 receptor in striatum membranes of guinea-pig brain was evaluated,B,,,Cavia porcellus,10141.0,
3262,9,,BAO_0000357,Intermediate,2435.0,5399,Inhibitory activity against 5-hydroxytryptamine 4 receptor of guinea pig striatum using [3H]GR-113808 as radioligand,B,,,Cavia porcellus,10141.0,
3263,9,,BAO_0000357,Intermediate,2435.0,17394,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to 5-hydroxytryptamine 4 receptor in guinea pig striatum,B,,,Cavia porcellus,10141.0,
3264,9,,BAO_0000357,Intermediate,2435.0,17394,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to 5-hydroxytryptamine 4 receptor in guinea-pig striatum,B,,,Cavia porcellus,10141.0,
3265,9,,BAO_0000357,Intermediate,2435.0,17394,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to serotonin 5-hydroxytryptamine 4 receptor in guinea-pig striatum,B,,,Cavia porcellus,10141.0,
3266,9,,BAO_0000221,Intermediate,2116.0,13961,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum.,F,,,Cavia porcellus,10141.0,
3267,9,,BAO_0000221,Intermediate,2116.0,13961,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum. 95% confidence limits are in brackets.,F,,,Cavia porcellus,10141.0,
3268,9,,BAO_0000221,Intermediate,2116.0,13961,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum;ne=not capable of evaluation.,F,,,Cavia porcellus,10141.0,
3269,9,,BAO_0000357,Intermediate,,16946,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor at concentration of 10e-6 M in guinea pig,B,,,Cavia porcellus,10141.0,
3270,9,,BAO_0000357,Intermediate,,16946,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor at concentration of 10e-8 M in guinea pig,B,,,Cavia porcellus,10141.0,
3271,9,,BAO_0000019,Intermediate,,15034,Agonistic activity against 5-hydroxytryptamine 4 receptor,F,,,Cavia porcellus,10141.0,
3272,9,,BAO_0000019,Intermediate,,15034,Agonistic activity against 5-hydroxytryptamine 4 receptor; not tested,F,,,Cavia porcellus,10141.0,
3273,9,,BAO_0000019,Intermediate,,12918,Compound was evaluated for the relative potency with respect to serotonin against 5-hydroxytryptamine 4 receptor,F,,,Cavia porcellus,10141.0,
3274,9,,BAO_0000357,Intermediate,,16946,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor,B,,,Cavia porcellus,10141.0,
3275,9,,BAO_0000357,Intermediate,2435.0,17394,Inhibition of [3H]GR-113808 binding to guinea pig striatum 5-hydroxytryptamine 4 receptor,B,,,Cavia porcellus,10141.0,
3276,9,,BAO_0000357,Intermediate,2435.0,15034,Binding affinity against 5-hydroxytryptamine 4 receptor in guinea pig striatum using [3H]GR-113808 as radioligand,B,,,Cavia porcellus,10141.0,
3277,9,,BAO_0000249,Intermediate,2435.0,5094,Binding affinity towards 5-HT4 receptor in striatum membranes of guinea-pig brain was evaluated,B,,,Cavia porcellus,10141.0,
3278,9,,BAO_0000249,Intermediate,2435.0,5094,Binding affinity towards 5-hydroxytryptamine 4 receptor in striatum membranes of guinea-pig brain was evaluated,B,,,Cavia porcellus,10141.0,
3279,9,,BAO_0000221,Intermediate,2116.0,17358,Tested for affinity against 5-hydroxytryptamine 4 receptor in the myenteric plexus of the guinea pig ileum.,B,,,Cavia porcellus,10141.0,
3280,9,,BAO_0000357,Expert,,12953,Displacement of [3H]-GR113808 from 5-HT4 receptor of guinea pig striatum,B,,,Cavia porcellus,10141.0,
3281,9,,BAO_0000357,Intermediate,,12953,The compound was tested for their binding affinity towards 5-HT4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand; Nonactive at 10 uM,B,,,Cavia porcellus,10141.0,
3282,9,,BAO_0000357,Intermediate,,12953,The compound was tested for their binding affinity towards 5-hydroxytryptamine 4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand.,B,,,Cavia porcellus,10141.0,
3283,9,,BAO_0000357,Intermediate,,12953,The compound was tested for their binding affinity towards 5-hydroxytryptamine 4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand; Nonactive at 10 uM,B,,,Cavia porcellus,10141.0,
3284,9,,BAO_0000221,Intermediate,2116.0,273,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in non-electrically stimulated guinea-pig ileum.,F,,,Cavia porcellus,10141.0,
3285,9,,BAO_0000221,Intermediate,2116.0,12918,5-hydroxytryptamine 4 receptor agonist activity in the guinea pig ileum assay,F,,,Cavia porcellus,10141.0,
3286,9,,BAO_0000221,Intermediate,2116.0,12919,5-hydroxytryptamine 4 receptor agonistic activity was measured by twitch response enhancing activity in electrically stimulated guinea pig ileum preparation,F,,,Cavia porcellus,10141.0,
3287,9,,BAO_0000221,Intermediate,2116.0,273,Agonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in low frequency field stimulation of guinea-pig ileum (FSGPI).,F,,,Cavia porcellus,10141.0,
3288,9,,BAO_0000221,Intermediate,2116.0,273,Agonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in non-electrically stimulated guinea-pig ileum.,F,,,Cavia porcellus,10141.0,
3289,9,,BAO_0000357,Intermediate,,13181,Ability to antagonize 5-HT-evoked contractions mediated through 5-hydroxytryptamine 4 receptor activation in the guinea pig distal colon LMMP,B,,,Cavia porcellus,10141.0,
3290,8,,BAO_0000357,Autocuration,,13181,Binding affinity was determined against 5-hydroxytryptamine 3 receptor,B,,,Cavia porcellus,10141.0,
3291,9,,BAO_0000019,Intermediate,,15034,Antagonistic activity against 5-hydroxytryptamine 4 receptor,F,,,Cavia porcellus,10141.0,
3292,9,,BAO_0000357,Intermediate,,5033,Ability to displace the radioligand [3H]GR-113808 from guinea pig striatum 5-hydroxytryptamine 4 receptor,B,,,Cavia porcellus,10141.0,
3293,9,,BAO_0000019,Intermediate,,1980,Binding affinity for 5-hydroxytryptamine 4 receptor by displacement of [3H]GR-113808 from guinea pig brain striatum.,B,,,Cavia porcellus,10141.0,
3294,8,,BAO_0000219,Autocuration,,13181,Binding affinity was determined against 5-hydroxytryptamine 2C receptor using cloned rat receptors expressed in 293 cells radiolabeled with [3H]mesulergine,B,,,Cavia porcellus,10141.0,
3295,9,,BAO_0000019,Intermediate,,14287,In vitro by displacement of [3H]GR-113808 from 5-hydroxytryptamine 4 receptor on guinea pig striatal membrane,B,,,Cavia porcellus,10141.0,
3296,9,,BAO_0000357,Intermediate,,1317,Compound was evaluated for binding affinity against 5-hydroxytryptamine 4 receptor using radioligand binding assay using [3H]GR as radioligand,B,,,Cavia porcellus,10141.0,
3297,9,,BAO_0000357,Intermediate,,15316,Compound was evaluated for its ability to displace [3H]GR-113808 binding from 5-hydroxytryptamine 4 receptor in guinea pig striatum.,B,,,Cavia porcellus,10141.0,
3298,9,,BAO_0000357,Intermediate,2435.0,16429,In vitro binding affinity at 5-hydroxytryptamine 4 receptor in guinea pig striatum using 3[H]GR-113808 as the radioligand,B,,,Cavia porcellus,10141.0,
3299,9,,BAO_0000221,Intermediate,10000000.0,14818,The compound was tested for its binding affinity towards 5-hydroxytryptamine 4 receptor in guinea pig hippocampus using [125I]SB-207710.,B,,,Cavia porcellus,10141.0,
3300,9,,BAO_0000357,Intermediate,,15194,The compound was tested for the binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand,B,,,Cavia porcellus,10141.0,
3301,9,,BAO_0000357,Intermediate,,15194,The compound was tested for the binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand.,B,,,Cavia porcellus,10141.0,
3302,9,,BAO_0000221,Intermediate,2116.0,13961,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum;ne=not capable of evaluation.,F,,,Cavia porcellus,10141.0,
3303,8,,BAO_0000357,Autocuration,,5486,Binding affinity towards 5-HT2C receptor by the displacement of [3H]mesulergine] in human recombinant receptors in mammalian cell,B,,,,,
3304,8,,BAO_0000357,Autocuration,,16209,Binding affinity towards human 5-hydroxytryptamine 4 receptor using [3H]5-HT as radioligand,B,,,,,
3305,8,,BAO_0000019,Autocuration,,17085,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 4 receptor,B,,,,,
3306,8,,BAO_0000219,Autocuration,,4199,Compound was evaluated for the binding affinity against human cloned 5-hydroxytryptamine 4 receptor in HeLa cells using [3H]-LSD as the radioligand,B,,,,,
3307,8,,BAO_0000357,Autocuration,,15146,Compound was tested for its binding affinity against 5-hydroxytryptamine 4 receptor,B,,,,,
3308,8,,BAO_0000357,Autocuration,,5213,Compound was tested for its binding affinity for 5-hydroxytryptamine 4 receptor,B,,,,,
3309,8,,BAO_0000219,Autocuration,,4829,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 4 receptor in HeLa cells, using [3H]LSD as radioligand",B,,,,,
3310,8,,BAO_0000357,Autocuration,,17358,Tested for ability to stimulate production of cAMP mediated by 5-hydroxytryptamine 4 receptor in mouse Coliculi neurons,B,,,,,
3311,8,,BAO_0000357,Autocuration,,17358,Tested for ability to stimulate production of cAMP mediated by 5-hydroxytryptamine 4 receptor in mouse Coliculi neurons; IA means inactive,B,,,,,
3312,8,,BAO_0000219,Autocuration,,16946,Ability to displace [3H]GR-113808 from mouse 5-hydroxytryptamine 4 receptor in COS7 cells,B,,,,,
3313,8,,BAO_0000357,Autocuration,,17358,Tested for ability to stimulate 5-hydroxytryptamine 4 receptors in mouse Coliculi neurons,B,,,,,
3314,8,,BAO_0000019,Autocuration,2081.0,268,Evaluated for the 5-hydroxytryptamine 4 receptor antagonistic activity in piglet atrium model,F,,,,,
3315,8,,BAO_0000019,Autocuration,2081.0,268,Evaluated for the 5-hydroxytryptamine 4 receptor antagonistic activity in piglet atrium model; compound found inactive at 1 uM,F,,,,,
3316,8,,BAO_0000357,Autocuration,,15086,The compound was tested for binding affinity against 5-hydroxytryptamine 4 receptor,B,,,,,
3317,8,,BAO_0000221,Autocuration,10000000.0,14875,Compound was tested for binding affinity against piglet hippocampus 5-hydroxytryptamine 4 receptor,B,,,,,
3318,8,,BAO_0000221,Autocuration,10000000.0,13267,The binding affinity (pKi) was measured against 5-hydroxytryptamine 4 receptor of piglet hippocampus using [125I]SB 207710 as radioligand,B,,,Sus scrofa,9823.0,
3319,8,,BAO_0000019,Autocuration,,13047,Binding affinity against 5-hydroxytryptamine 2A receptor using rabbit saphenous vein assay.,B,,,Oryctolagus cuniculus,9986.0,
3320,9,,BAO_0000357,Expert,,1650,Displacement of [3H]GR-113808 from rat striatum 5-hydroxytryptamine 4 receptor,B,,,Rattus norvegicus,10116.0,
3321,8,,BAO_0000019,Autocuration,,567,Tested for its agonist potency against the 5-hydroxytryptamine 4 receptor located in the rat esophageal tunica muscularis mucosae,F,,,,,
3322,8,,BAO_0000357,Autocuration,,17358,Tested for affinity towards 5-hydroxytryptamine 4 receptor in relaxation of rat oesophagus,B,,,,,
3323,8,,BAO_0000357,Autocuration,,188,Tested for the effect on binding at 5-hydroxytryptamine 4 receptor; No activity,B,,,,,
3324,8,,BAO_0000019,Autocuration,,670,lntrinsic activity relative to 5-HT receptor,F,,,,,
3325,8,,BAO_0000019,Autocuration,,204,Compound was evaluated for the agonistic activity towards 5-hydroxytryptamine 4 receptor using the rat tunica muscularis mucosae (TMM) esophagus strip assay,F,,,,,
3326,8,,BAO_0000019,Expert,,1946,In vitro relaxation of carbachol pre-contracted rat oesophageal TMM.,F,,,,,
3327,8,,BAO_0000019,Autocuration,,6398,Compound was tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay,F,,,,,
3328,8,,BAO_0000019,Autocuration,,6398,Compound was tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay; IN = Inactive,F,,,,,
3329,8,,BAO_0000019,Autocuration,,17358,Efficient 5-hydroxytryptamine 4 agonist in the rat tunica muscularis mucosae,F,,,,,
3330,8,,BAO_0000019,Autocuration,,6398,Tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay of racemate mixture,F,,,,,
3331,8,,BAO_0000357,Expert,,11752,Relaxation of carbachol induced contractions of rat tunica muscularis mucosae,B,,,,,
3332,8,,BAO_0000019,Autocuration,,809,5-hydroxytryptamine 4 receptor agonist activity was determined by the relaxation of the carbachol-contracted rat esophageal tunica muscularis mucosae,F,,,,,
3333,9,,BAO_0000357,Expert,,14178,Inhibition of radiolabeled [3H]GR-113808 ligand binding to 5-hydroxytryptamine 4 receptor,B,,,Rattus norvegicus,10116.0,
3334,8,,BAO_0000357,Autocuration,,567,Tested for its efficacy against the 5-hydroxytryptamine 4 receptor located in the rat esophageal tunica muscularis mucosae,B,,,,,
3335,8,,BAO_0000357,Autocuration,,1946,In vitro 5-hydroxytryptamine 4 receptor activity by using carbachol-precontracted esophageal tunica muscularis mucosae.,B,,,,,
3336,8,,BAO_0000357,Autocuration,,1946,In vitro 5-hydroxytryptamine 4 receptor activity by using carbachol-precontracted esophageal tunica muscularis mucosae; No activity up to 104M concentration,B,,,,,
3337,9,,BAO_0000019,Expert,,13961,Binding affinity (Ki+/-SEM) against 5-hydroxytryptamine 4 receptor from cheng Prusoff equation by using [3H]GR-113808 in rat striatum,B,,,Rattus norvegicus,10116.0,
3338,8,,BAO_0000249,Autocuration,2435.0,6238,Binding affinity towards 5-HT 4 receptor in rat striatum membranes using [3H]GR-113808 as radioligand,B,,,,,
3339,8,,BAO_0000249,Autocuration,,14290,Binding affinity towards 5-HT4 receptor was determined in rat striatal membranes using [3H]GR-113808 as radioligand; Not tested,B,,,,,
3340,8,,BAO_0000249,Expert,,14290,Binding affinity towards 5-hydroxytryptamine 4 receptor was determined in rat striatal membranes using [3H]GR-113808 as radioligand,B,,,,,
3341,9,,BAO_0000019,Expert,2435.0,809,Binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum,B,,,Rattus norvegicus,10116.0,
3342,8,,BAO_0000019,Autocuration,2435.0,1578,Binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum,B,,,,,
3343,8,,BAO_0000249,Expert,2435.0,16709,Binding affinity to 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum membrane,B,,,,,
3344,8,,BAO_0000019,Expert,2435.0,1946,Binding affinity at 5-hydroxytryptamine 4 receptor in rat striatum by [3H]GR-113808 displacement.,B,,,,,
3345,8,,BAO_0000249,Expert,2435.0,15253,In vitro affinity at serotonergic 5-hydroxytryptamine 4 receptor by radioligand binding assay using [3H]GR-113808 in rat striatum membranes.,B,,,,,
3346,8,,BAO_0000249,Expert,2435.0,4535,In vitro binding affinity to 5-hydroxytryptamine 4 receptor in rat striatum membrane,B,,,,,
3347,8,,BAO_0000249,Expert,,13961,Binding affinity at 5-hydroxytryptamine 4 receptor in rat striatal membranes by [3H]GR-113808 displacement.,B,,,,,
3348,8,,BAO_0000221,Autocuration,955.0,17358,Tested for potency against 5-hydroxytryptamine 4 receptor agonist in rat brain,F,,,,,
3349,8,,BAO_0000019,Autocuration,,15847,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 4 receptor of rat,F,,,,,
3350,8,,BAO_0000019,Autocuration,,15847,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 4 receptor of rat; ND means not done,F,,,,,
3351,8,,BAO_0000019,Autocuration,,670,5-hydroxytryptamine 4 receptor agonist activity in the rat esophageal muscularis mucosae,F,,,,,
3352,8,,BAO_0000019,Autocuration,,670,5-hydroxytryptamine 4 receptor agonist activity in the rat esophageal muscularis mucosae; Not tested,F,,,,,
3353,8,,BAO_0000019,Autocuration,,1317,Antagonist activity against 5-hydroxytryptamine 4 receptor mediated relaxation of rat carbachol contracted esophageal muscularis mucosae,F,,,,,
3354,9,,BAO_0000357,Expert,,12936,Binding affinity against rat 5-hydroxytryptamine 4 receptor,B,,,Rattus norvegicus,10116.0,
3355,8,,BAO_0000249,Expert,2435.0,4535,pKi against 5-hydroxytryptamine 4 receptor in rat striatum membrane,B,,,,,
3356,9,,BAO_0000019,Expert,,14424,Antagonistic activity evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-5 M.,F,,,Rattus norvegicus,10116.0,
3357,8,,BAO_0000019,Expert,,14424,Antagonistic activity by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-6 M.,F,,,,,
3358,8,,BAO_0000019,Expert,,14424,Antagonistic activity by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-7 M.,F,,,,,
3359,9,,BAO_0000019,Expert,,14424,Antagonistic activity evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-8 M.,F,,,Rattus norvegicus,10116.0,
3360,8,,BAO_0000019,Autocuration,,14424,Antagonistic activity of compound was evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 3*10e-7 M.,F,,,,,
3361,8,,BAO_0000019,Expert,,14424,Antagonistic activity evaluated by ability to block serotonin induced relaxation (via 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 3*10e-8 M.,F,,,,,
3362,8,,BAO_0000218,Expert,,14424,Antagonistic activity evaluated by ability to block serotonin induced relaxation via 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 0.1 mg/kg (p.o.),F,,,,,
3363,8,,BAO_0000019,Autocuration,,14424,Antagonistic activity of compound was evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-7 M.,F,,,,,
3364,8,,BAO_0000019,Autocuration,,1980,Estimate from relaxation of carbachol-contracted rat esophageal muscularis mucosae,F,,,Rattus norvegicus,10116.0,
3365,8,,BAO_0000019,Autocuration,,4639,Compound was tested for agonistic activity against 5-hydroxytryptamine 4 receptor on guinea colon at a concentration 0.1 uM,F,,,,,
3366,8,,BAO_0000357,Autocuration,,17358,Tested for affinity towards 5-hydroxytryptamine 4 receptor,B,,,,,
3367,8,,BAO_0000357,Autocuration,,17358,Tested for affinity towards 5-hydroxytryptamine 4 receptor.,B,,,,,
3368,8,,BAO_0000357,Autocuration,,17358,Compound was tested for 5-hydroxytryptamine 4 binding affinity,B,,,,,
3369,8,,BAO_0000357,Autocuration,,1558,Compound was tested for its affinity towards 5-hydroxytryptamine 4 receptor,B,,,,,
3370,8,,BAO_0000019,Autocuration,,17358,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,F,,,,,
3371,8,,BAO_0000357,Autocuration,,16117,In vitro binding affinity towards 5-HT4 receptor was determined,B,,,,,
3372,8,,BAO_0000019,Autocuration,,17358,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,F,,,,,
3373,8,,BAO_0000019,Autocuration,,17358,Tested for agonist activity against 5-hydroxytryptamine 4 receptor,F,,,,,
3374,8,,BAO_0000357,Autocuration,,17358,Tested for selectivity for 5-hydroxytryptamine 4 receptor,B,,,,,
3375,8,,BAO_0000357,Autocuration,,17358,Tested for 5-hydroxytryptamine 4 binding affinity against cisapride,B,,,,,
3376,8,,BAO_0000357,Autocuration,,17358,Tested for 5-hydroxytryptamine 4 binding affinity against renzapride,B,,,,,
3377,8,,BAO_0000357,Autocuration,,17358,Tested for 5-hydroxytryptamine 4 binding affinity against zacopride,B,,,,,
3378,8,,BAO_0000357,Expert,,1274,Binding affinity against 5-Hydroxytryptamine 4 receptor,B,,,,,
3379,6,,BAO_0000249,Autocuration,,10728,Compound was evaluated for the displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 recognition sites in rat brain membranes,B,,,,,
3380,6,,BAO_0000249,Autocuration,,11695,Compound was evaluated for the displacement of [3H]Q-ICS-205-930 from 5-HT3 recognition sites in rat brain membranes,B,,,,,
3381,6,,BAO_0000249,Autocuration,,11695,Displacement of [3H]Q-ICS-205-930 from 5-hydroxytryptamine 3 receptor recognition sites in rat brain membranes,B,,,,,
3382,6,,BAO_0000019,Autocuration,,12490,Displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor from rat cortex homogenate,B,,,,,
3383,7,,BAO_0000019,Autocuration,,11828,Displacement of [3H]-Q-ICS 205-930 from rat cortex homogenate 5-hydroxytryptamine 3 receptor,B,,,Rattus norvegicus,10116.0,
3384,6,,BAO_0000221,Autocuration,10000000.0,12253,Binding affinity of 5-hydroxytryptamine 3 receptor using [3H]granisetron in rat hippocampus and entorhinal cortex,B,,,,,
3385,6,,BAO_0000019,Autocuration,,10561,Binding affinity to 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand in rat cortex,B,,,,,
3386,6,,BAO_0000019,Autocuration,,10561,Binding affinity to 5-hydroxytryptamine 3 receptor using [3H]quipazine as radioligand in rat cortex,B,,,,,
3387,6,,BAO_0000019,Autocuration,,14432,Rat 5-hydroxytryptamine 3 receptor (5-HT3) antagonist,F,,,,,
3388,7,,BAO_0000223,Autocuration,,12936,Binding affinity against rat 5-hydroxytryptamine 3 receptor,B,,,Rattus norvegicus,10116.0,
3389,7,,BAO_0000223,Autocuration,,1274,Binding affinity against 5-Hydroxytryptamine 3 receptor,B,,,Rattus norvegicus,10116.0,
3390,6,,BAO_0000019,Autocuration,,1980,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of racemic [3H]zacopride from rat cortex,B,,,,,
3391,6,,BAO_0000249,Autocuration,,670,Binding affinity to 5-hydroxytryptamine 3 receptor was determined in rat cerebro cortical membranes using [3H]quipazine.,B,,,,,
3392,7,,BAO_0000019,Autocuration,,968,Displacement of [3H]granisetron from 5-hydroxytryptamine 3 receptor of rat cortex,B,,,Rattus norvegicus,10116.0,
3393,6,,BAO_0000019,Autocuration,,14287,In vitro by displacement of [3H]LY-278584 from 5-hydroxytryptamine 3 receptor on rat entorhinal cortex,B,,,,,
3394,6,,BAO_0000019,Autocuration,,567,Tested for its binding affinity by measuring its ability to displace [3H]granisetron from 5-hydroxytryptamine 3 receptor in rat cortex,B,,,,,
3395,6,,BAO_0000019,Autocuration,,13267,The binding affinity (pKi) measured against 5-hydroxytryptamine 1A receptor of rat cortex using [3H]8-OH-DPAT as radioligand,B,,,,,
3396,6,,BAO_0000249,Autocuration,,14826,Binding affinity at 5-hydroxytryptamine 3 receptor in rat cortical membrane by [3H]graniestron displacement.,B,,,,,
3397,6,,BAO_0000223,Autocuration,,15194,The compound was tested for the binding affinity against 5-hydroxytryptamine 3 receptor using [3H]zacopride as radioligand,B,,,,,
3398,6,,BAO_0000223,Autocuration,,15194,The compound was tested for the binding affinity against 5-hydroxytryptamine 3 receptor using [3H]zacopride as radioligand.,B,,,,,
3399,7,,BAO_0000223,Autocuration,,10394,pKi value for inhibition of [3H]LY-278584 binding to 5-hydroxytryptamine 3 receptor,B,,,Rattus norvegicus,10116.0,
3400,9,,BAO_0000249,Expert,,13657,"Compound was evaluated for binding affinity on 5-hydroxytryptamine 1A receptor in rat hippocampus membranes,3H-8-OH-DPAT and buspirone for nonspecific binding",B,,,,,
3401,8,,BAO_0000221,Autocuration,955.0,1879,Compound was tested for its antagonistic activity against 5-hydroxytryptamine 3 receptor in rat brain using [3H]zacopride as the radioligand.,F,,,,,
3402,8,,BAO_0000019,Autocuration,,1879,Compound was tested in vitro for its antagonistic activity against 5-hydroxytryptamine 3 receptor,F,,,,,
3403,8,,BAO_0000019,Autocuration,,1879,Compound was tested in vitro for its antagonistic activity against 5-hydroxytryptamine 3 receptor in rat CNS.,F,,,,,
3404,8,,BAO_0000218,Autocuration,,204,Compound was evaluated in vivo for the antagonistic activity towards 5-hydroxytryptamine 3 receptor,F,In vivo,,,,
3405,8,,BAO_0000019,Autocuration,,1879,Compound was tested for its binding affinity towards 5-HT-3 receptor in whole rat brain using (S)-[125I]-zacopride as the radioligand.,B,,,,,
3406,8,,BAO_0000357,Autocuration,,1879,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor,B,,,,,
3407,8,,BAO_0000019,Autocuration,,1879,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor in whole rat brain using (S)-[125I]-zacopride as the radioligand.,B,,,,,
3408,8,,BAO_0000019,Autocuration,,1879,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor in whole rat brain using [125I]DAIZAC as the radioligand.,B,,,,,
3409,6,,BAO_0000019,Autocuration,,10641,"Concentration that inhibits the binding of radioligand, [3H]-ICS 205930, to 5-hydroxytryptamine 3 receptor from rat cortex",B,,,,,
3410,8,,BAO_0000019,Autocuration,,773,In Vitro Binding affinity againist 5-hydroxytryptamine 3 receptor by displacing [3H]-Q-ICS 205-930 from rat cortex homogenates,B,,,,,
3411,6,,BAO_0000249,Autocuration,,11952,Binding affinity against 5-hydroxytryptamine 3 (5-HT3) receptor in rat brain cortical membranes using radioligand [3H]quipazine,B,,,,,
3412,9,,BAO_0000019,Autocuration,,14145,Antagonist activity (100 ug/kg) for the Bezold Jarisch reflex evoked by 30 (ug/Kg) of 5-hydroxytryptamine 3 receptor in ethylurethane anesthetized rats i.v.,F,,,Rattus norvegicus,10116.0,
3413,8,,BAO_0000357,Expert,,17066,Binding affinity towards 5-hydroxytryptamine 3 receptor,B,,,,,
3414,4,,BAO_0000223,Autocuration,,6398,Compound was evaluated for 5-hydroxytryptamine 3 receptor binding,B,,,,,
3415,0,,BAO_0000019,Autocuration,,10321,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of [3H]2 in Neuroblastoma-Glioma NG-108-15 cells,B,,,,,
3416,4,,BAO_0000019,Autocuration,,511,Tested for 5-hydroxytryptamine 3 receptor antagonist activity by inhibiting the 5-HT evoked Bezold-Jarisch reflex,F,,,,,
3417,4,,BAO_0000223,Autocuration,,4639,Compound was tested for binding affinity towards 5-hydroxytryptamine 3 receptor,B,,,,,
3418,4,,BAO_0000223,Autocuration,,4639,Binding affinity towards 5-hydroxytryptamine 3 receptor,B,,,,,
3419,4,,BAO_0000019,Autocuration,,4639,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 0.3 uM,F,,,Cavia porcellus,10141.0,
3420,4,,BAO_0000019,Autocuration,,4639,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 3 uM,F,,,Cavia porcellus,10141.0,
3421,4,,BAO_0000019,Autocuration,,4639,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 30 uM,F,,,Cavia porcellus,10141.0,
3422,4,,BAO_0000223,Autocuration,,1558,Compound was tested for its affinity towards 5-hydroxytryptamine 3 receptor,B,,,,,
3423,4,,BAO_0000019,Autocuration,,268,Evaluated for the 5-hydroxytryptamine 3 receptor antagonistic activity in Bezold-Jarisch model expressed as inhibition of the reflex bradycardia induced by an intravenous injection,F,,,,,
3424,4,,BAO_0000223,Autocuration,,2474,Compound was measured for its binding affinity at 5-hydroxytryptamine 3 receptor at a concentration of 10 uM using [3H]BRL-43694 as radioligand,B,,,,,
3425,4,,BAO_0000019,Autocuration,,5067,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); A: agonist,F,,,,,
3426,4,,BAO_0000019,Autocuration,,5067,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); ANT: agonist,F,,,,,
3427,4,,BAO_0000019,Autocuration,,5067,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); ANT: antagonist,F,,,,,
3428,4,,BAO_0000223,Autocuration,,5067,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); NA means data not available,B,,,,,
3429,4,,BAO_0000019,Autocuration,,5067,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); PA: Partial agonist,F,,,,,
3430,4,,BAO_0000019,Autocuration,,5067,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; A: agonist,F,,,,,
3431,4,,BAO_0000019,Autocuration,,5067,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; ANT: Antagonist,F,,,,,
3432,4,,BAO_0000223,Autocuration,,5067,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; NA: not active,B,,,,,
3433,4,,BAO_0000223,Autocuration,,5067,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; NA means data not available,B,,,,,
3434,4,,BAO_0000019,Autocuration,,5067,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; PA: Partial agonist,F,,,,,
3435,4,,BAO_0000223,Autocuration,,5067,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; na means data not available,B,,,,,
3436,4,,BAO_0000223,Autocuration,,5067,Binding affinity towards 5-hydroxytryptamine 3 receptor,B,,,,,
3437,4,,BAO_0000219,Autocuration,,14331,Binding affinity of compound towards 5-hydroxytryptamine 3 receptor using [3H]-BRL-43694 (1 nM) ligand in NG cells 108-15 was determined,B,,,,,
3438,4,,BAO_0000223,Autocuration,,5067,Binding affinity of compound towards 5-hydroxytryptamine 3 receptor; NA: not active,B,,,,,
3439,4,,BAO_0000219,Autocuration,,6179,Binding affinity for 5-HT3 receptor of NG108-15 cells using [3H]GR-65630,B,,,,,
3440,4,,BAO_0000019,Autocuration,,4265,Binding affinity to 5-HT3 serotonin receptor in NG 108-15 neuroblastoma glioma cells using [3H]GR-65630 radioligand.,B,,,,,
3441,4,,BAO_0000219,Autocuration,,4265,Binding affinity to 5-HT3 serotonin receptor in NG108-15 neuroblastoma glioma cells using [3H]GR-65630 radioligand,B,,,,,
3442,4,,BAO_0000223,Autocuration,,17358,Compound was tested for 5-hydroxytryptamine 3 receptor binding affinity,B,,,,,
3443,4,,BAO_0000223,Autocuration,,17358,Compound was tested for selectivity against 5-hydroxytryptamine 3 receptor binding affinity,B,,,,,
3444,4,,BAO_0000219,Autocuration,,13628,Compound was tested for the inhibition of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor expressed in NG 108-15 cells,B,In vitro,,,,
3445,4,,BAO_0000223,Autocuration,,4612,In vitro Binding affinity towards 5-hydroxytryptamine 3 receptor was determined,B,,,,,
3446,4,,BAO_0000019,Autocuration,,17358,Tested for 5-hydroxytryptamine 3 receptor antagonist activity,F,,,,,
3447,4,,BAO_0000019,Autocuration,,4639,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 1 uM,F,,,Cavia porcellus,10141.0,
3448,4,,BAO_0000019,Autocuration,,4639,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 10 uM,F,,,Cavia porcellus,10141.0,
3449,4,,BAO_0000019,Autocuration,,4639,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 10 uM in the presence of 30 uM MDL 72222,F,,,Cavia porcellus,10141.0,
3450,4,,BAO_0000019,Autocuration,,4639,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 3 uM,F,,,Cavia porcellus,10141.0,
3451,4,,BAO_0000223,Autocuration,,511,Binding affinity for the 5-hydroxytryptamine 3 receptor was evaluated in vitro by examining its ability to displace [3H]-BRL 43694.,B,,,,,
3452,4,,BAO_0000223,Autocuration,,1479,Binding affinity towards 5-hydroxytryptamine 3 receptor,B,,,,,
3453,4,,BAO_0000223,Autocuration,,1317,Compound was evaluated for binding affinity against 5-hydroxytryptamine 3 receptor using radioligand binding assay,B,,,,,
3454,4,,BAO_0000223,Autocuration,,12146,Tested against 5-hydroxytryptamine 3 receptor in experiment 1,B,,,,,
3455,4,,BAO_0000223,Autocuration,,12146,Tested against 5-hydroxytryptamine 3 receptor in experiment 2,B,,,,,
3456,4,,BAO_0000223,Autocuration,,13969,Binding affinity against 5-hydroxytryptamine 3 receptor was measured using [3H]granisetron as radioligand,B,,,,,
3457,8,,BAO_0000357,Expert,,13392,Binding affinity for 5-hydroxytryptamine 2C receptor,B,,,,,
3458,6,,BAO_0000223,Autocuration,,13392,Binding affinity towards 5-hydroxytryptamine 3 receptor,B,,,,,
3459,8,,BAO_0000357,Autocuration,,14159,Compound was evaluated for the affinity at 5-hydroxytryptamine 3 receptor,B,,,,,
3460,8,,BAO_0000357,Autocuration,,1558,Compound was tested for its affinity towards 5-hydroxytryptamine 3 receptor,B,,,,,
3461,8,,BAO_0000357,Autocuration,,16655,Inhibition of GR-65630 binding to 5-hydroxytryptamine 3 receptor,B,,,,,
3462,4,,BAO_0000223,Autocuration,,13020,Inhibition of [3H]- BRL 43 694 binding to 5-hydroxytryptamine 3 receptor at 10e-5 M,B,,,,,
3463,4,,BAO_0000223,Autocuration,,13021,Inhibition of [3H]-BRL 43 694 binding to 5-hydroxytryptamine 3 receptor of central nervous system,B,,,,,
3464,4,,BAO_0000223,Autocuration,,13020,Inhibition of [3H]- BRL 43 694 binding to 5-hydroxytryptamine 3 receptor at 10e-5 M,B,,,,,
3465,8,,BAO_0000019,Autocuration,,10321,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of [3H]2 in Neuroblastoma-Glioma NG-108-15 cells,B,,,,,
3466,8,,BAO_0000357,Autocuration,,15818,Compound was evaluated for its binding affinity towards 5-hydroxytryptamine 3 receptor,B,,,,,
3467,8,,BAO_0000357,Autocuration,,15818,Compound was evaluated for its binding affinity towards 5-hydroxytryptamine 3 receptor,B,,,,,
3468,8,,BAO_0000357,Autocuration,,17358,Compound was tested for 5-hydroxytryptamine 3 receptor binding affinity,B,,,,,
3469,8,,BAO_0000357,Autocuration,,2222,Compound was tested for its binding affinity for the 5-hydroxytryptamine 3 receptor,B,,,,,
3470,8,,BAO_0000019,Autocuration,,10322,In vitro binding affinity for the 5-hydroxytryptamine 3 receptor was determined with NG-108-15 mouse neuroblastoma-glioma cells,B,,,,,
3471,8,,BAO_0000357,Autocuration,,16117,In vitro binding affinity towards 5-hydroxytryptamine 3 receptor was determined,B,,,,,
3472,8,,BAO_0000357,Autocuration,,17200,Inhibitory constant against 5-hydroxytryptamine 3 receptor using [3H]GR-65630 radioligand,B,,,,,
3473,8,,BAO_0000019,Autocuration,,17358,Tested for 5-hydroxytryptamine 3 receptor agonist activity,F,,,,,
3474,8,,BAO_0000357,Autocuration,,16700,The binding affinity towards 5-hydroxytryptamine 3 receptor; No affinity,B,,,,,
3475,8,,BAO_0000019,Autocuration,,1980,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of [3H](R)-zacopride from ondansetron-treated NG-108-15 cell membranes,B,,,,,
3476,8,,BAO_0000019,Autocuration,,1980,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of [3H]-BRL 43694 from NG-108-15 cell membranes,B,,,,,
3477,4,,BAO_0000223,Autocuration,,12409,Binding affinity against the 5-hydroxytryptamine 3 receptor,B,,,,,
3478,8,,BAO_0000357,Autocuration,,4365,Binding affinity against human 5-hydroxytryptamine 3A receptor,B,,,,,
3479,8,,BAO_0000019,Autocuration,,4365,Percent efficacy against 5-hydroxytryptamine 3A receptor,F,,,,,
3480,8,,BAO_0000357,Autocuration,,4365,Binding affinity against human 5-hydroxytryptamine 3A receptor,B,,,,,
3481,9,,BAO_0000219,Expert,,6769,Response at rat 5-hydroxytryptamine 3a receptor expressed in xenopus oocytes,F,,,Rattus norvegicus,10116.0,
3482,9,,BAO_0000219,Expert,,6769,Ability to block serotonin (30 uM)-evoked responses at rat 5HT3-alpha receptor expressed in xenopus oocytes,F,,,Rattus norvegicus,10116.0,
3483,9,,BAO_0000219,Expert,,6769,Effect on rat 5-hydroxytryptamine 3a receptor expressed in xenopus oocytes at concentration up to 100 uM,F,,,Rattus norvegicus,10116.0,
3484,9,,BAO_0000221,Intermediate,2116.0,809,5-hydroxytryptamine 4 receptor agonist activity as percent maximum 5-HT effect in response to electrical stimulation in male guinea pig ileum,F,,,Cavia porcellus,10141.0,
3485,9,,BAO_0000221,Intermediate,2116.0,809,5-hydroxytryptamine 4 receptor agonist activity expressed as the concentration which gave a 50% increase in the response to the electrical stimulation in male guinea pig ileum,F,,,Cavia porcellus,10141.0,
3486,9,,BAO_0000019,Intermediate,,14290,5-hydroxytryptamine 4 receptor agonist activity is expressed as percent of the maximum 5-HT response,F,,,Cavia porcellus,10141.0,
3487,9,,BAO_0000221,Intermediate,2116.0,17358,Tested for affinity towards 5-hydroxytryptamine 4 receptor in electrically stimulated longitudinal muscle preparation of guinea pig ileum,B,,,Cavia porcellus,10141.0,
3488,9,,BAO_0000357,Intermediate,,17358,Tested for affinity towards 5-hydroxytryptamine 4 receptor in guinea pig distal colon preparation,B,,,Cavia porcellus,10141.0,
3489,9,,BAO_0000221,Intermediate,2116.0,17358,Tested for affinity towards 5-hydroxytryptamine 4 receptor in isolated guinea pig ileum longitudinal muscle preparation,B,,,Cavia porcellus,10141.0,
3490,8,,BAO_0000221,Autocuration,2116.0,17386,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor nondesensitization,B,,,,,
3491,8,,BAO_0000357,Autocuration,,3269,Affinity against 5-hydroxytryptamine 7 receptor,B,,,,,
3492,4,,BAO_0000224,Autocuration,,7721,Ability to displace [3H]5-HT binding from 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand,B,,,Cavia porcellus,10141.0,
3493,4,,BAO_0000224,Autocuration,,7721,Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand,B,,,Cavia porcellus,10141.0,
3494,4,,BAO_0000221,Autocuration,2116.0,9117,Evaluated for inhibition of 5-hydroxytryptamine receptor on guinea pig ileum at 10 uM; No effect,B,,,Cavia porcellus,10141.0,
3495,4,,BAO_0000224,Autocuration,,7721,"Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand, activity is expressed as Kd.",B,,,Cavia porcellus,10141.0,
3496,4,,BAO_0000224,Autocuration,,7721,"Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor using 1 uM LSD as masking ligand, activity is expressed as Kd.",B,,,Cavia porcellus,10141.0,
3497,4,,BAO_0000019,Autocuration,,15796,5-HT level in K+ induced 5-hydroxytryptamine release in guinea pig cortex.,F,,,Cavia porcellus,10141.0,
3498,4,,BAO_0000019,Autocuration,,15796,5-hydroxytryptamine level in K+ induced 5-hydroxytryptamine release in guinea pig cortex.,F,,,Cavia porcellus,10141.0,
3499,9,,BAO_0000219,Expert,2081.0,15650,Concentration required to produce half-maximal response against 5-hydroxytryptamine receptor in the presence of 10 nM compound in isolated human atrial myocytes,B,,,Homo sapiens,9606.0,
3500,9,,BAO_0000219,Expert,2081.0,15650,Concentration required to produce half-maximal response against 5-hydroxytryptamine receptor on the L-type calcium current (I Ca) in isolated human atrial myocytes,B,,,Homo sapiens,9606.0,
3501,5,,BAO_0000019,Autocuration,,6866,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect of 5-hydroxytryptamine",F,,,Homo sapiens,9606.0,
3502,9,,BAO_0000219,Expert,2081.0,15650,",Antagonism of stimulation of 5-hydroxytryptamine receptor on the L-type calcium current (I Ca) in isolated human atrial myocytes",F,,,Homo sapiens,9606.0,
3503,0,,BAO_0000019,Autocuration,,10063,Ability (10 ug/kg) to inhibit binding of [125I]iododexetimide to 5-hydroxytryptamine receptor in mice,B,,,Mus musculus,10090.0,
3504,0,,BAO_0000019,Autocuration,,12665,Percent inhibition of radioligand [3H]-LSD binding to 5-HT receptor at 10 uM concentration,B,,,Mus musculus,10090.0,
3505,4,,BAO_0000019,Autocuration,,7504,5-hydroxytryptamine receptor binding affinity was determined in rats,B,,,,,
3506,4,,BAO_0000224,Autocuration,,7504,Binding affinity at rat 5-hydroxytryptamine receptor.,B,,,,,
3507,4,,BAO_0000019,Autocuration,,7038,Affinity against 5-hydroxytryptamine receptors in rat fundus model,B,,,,,
3508,4,,BAO_0000224,Autocuration,,7626,Affinity for 5-hydroxytryptamine receptor was determined using male Dawley rat fundus preparation,B,,,,,
3509,4,,BAO_0000224,Autocuration,,7626,Affinity for 5-hydroxytryptamine receptor was determined using male Dawley rat fundus preparation; Not determined,B,,,,,
3510,4,,BAO_0000019,Autocuration,945.0,7185,Antagonistic activity against serotonin 5-HT receptor obtained from rat stomach fundus preparation,F,,,,,
3511,4,,BAO_0000019,Autocuration,945.0,7185,Antagonistic activity against serotonin 5-HT receptor obtained from rat stomach fundus preparation (resulted in discoloration in the oxygenated muscle bath to give varying results).,F,,,,,
3512,4,,BAO_0000019,Autocuration,,7185,Antagonistic activity of corresponding methoxy compound against serotonin 5-HT receptor,F,,,,,
3513,4,,BAO_0000224,Autocuration,,6960,Compound was evaluated for binding affinity towards 5-hydroxytryptamine receptor in isolated rat fundus preparation measured as pA2,B,,,,,
3514,4,,BAO_0000224,Autocuration,,6960,"Compound was evaluated for binding affinity towards 5-hydroxytryptamine receptor in isolated rat fundus preparation measured as pA2; Valid pA2, can not be determined because of slope of Schild plot.",B,,,,,
3515,8,,BAO_0000221,Autocuration,10000000.0,12416,In vitro affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in hippocampus,B,,,,,
3516,8,,BAO_0000357,Expert,,15753,Binding affinity for rat 5-hydroxytryptamine transporter.,B,,,,,
3517,4,,BAO_0000019,Autocuration,,8062,Evaluated for inhibition of specific [3H]5-HT receptor binding in rat cortex.,B,,,,,
3518,5,,BAO_0000019,Autocuration,,9036,Binding affinity at serotonin 5-HT1-type site receptor in rat cortex by displacing [3H]5-HT,B,,,Rattus norvegicus,10116.0,
3519,5,,BAO_0000224,Autocuration,,15067,Compound was tested for its inhibitory activity against 5-hydroxytryptamine receptor,B,,,Rattus norvegicus,10116.0,
3520,9,,BAO_0000019,Expert,955.0,15753,Inhibitory activity against [3H]- 5-hydroxytryptamine reuptake in whole rat brain minus cerebellum,F,,,Rattus norvegicus,10116.0,
3521,9,,BAO_0000221,Expert,2037.0,15753,Inhibition of [3H]5-HT reuptake in whole rat brain (minus cerebellum) homogenate.,F,,,Rattus norvegicus,10116.0,
3522,5,,BAO_0000019,Autocuration,,15295,Displacement of [3H]-citalopram from rat forebrain membrane 5-hydroxytryptamine receptor at 10e-7 M,B,,,Rattus norvegicus,10116.0,
3523,5,,BAO_0000224,Autocuration,,6347,Percent binding affinity against 5-hydroxytryptamine receptor,B,,,Rattus norvegicus,10116.0,
3524,0,,BAO_0000019,Autocuration,,6763,Ability to displace 0.4 nM [3H]paroxetine binding to 5-hydroxytryptamine receptor in rat frontal cortex,B,,,,,
3525,5,,BAO_0000224,Autocuration,,12092,The binding affinity was measured on 5-hydroxytryptamine receptor uptake receptor using [3H]- paroxetine as radioligand.,B,,,Rattus norvegicus,10116.0,
3526,5,,BAO_0000224,Autocuration,,1579,Affinity against 5-hydroxytryptamine receptor was determined,B,,,Rattus norvegicus,10116.0,
3527,5,,BAO_0000019,Autocuration,945.0,1579,Affinity against 5-hydroxytryptamine receptor was determined in rat stomach fundus strip,B,,,Rattus norvegicus,10116.0,
3528,9,,BAO_0000219,Expert,,5963,Inhibition of [3H]5-HT uptake in HEK cells expressing human SERT,B,In vitro,,Homo sapiens,9606.0,
3529,9,,BAO_0000219,Expert,,5963,Inhibition of [3H]5-HT uptake in HEK cells expressing human SERT,B,In vitro,,Homo sapiens,9606.0,
3530,8,,BAO_0000357,Autocuration,,5030,Ability to compete with radioactive ligands specific to the Serotonergic 5-HT receptor at 10 uM; NA means compound failed to compete,B,,,,,
3531,8,,BAO_0000357,Expert,,15796,Inhibition of 5-hydroxytryptamine reuptake,B,,,,,
3532,8,,BAO_0000019,Autocuration,,15413,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding",F,,,,,
3533,8,,BAO_0000019,Autocuration,,15413,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding (Experiment 1)",F,,,,,
3534,8,,BAO_0000019,Autocuration,,15413,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding (Experiment 2)",F,,,,,
3535,8,,BAO_0000019,Autocuration,,12409,Tested for 5-hydroxytryptamine receptor uptake,F,,,,,
3536,9,,BAO_0000219,Expert,,16909,Affinity constant on CHO cells expressing Human recombinant 5-hydroxytryptamine receptor 1A,B,,,Homo sapiens,9606.0,
3537,9,,BAO_0000019,Expert,,16909,Antagonistic affinity tested against isolated human cloned alpha-1d adrenoceptor subtype,F,,,Homo sapiens,9606.0,
3538,8,,BAO_0000249,Autocuration,,15629,In vitro binding affinity towards 5-hydroxytryptamine receptor 1A receptor by using [3H]8-OH-DPAT in rat hippocampal membranes.,B,,,Homo sapiens,9606.0,
3539,8,,BAO_0000357,Autocuration,,15629,Tested in vitro for % inhibition against 5-hydroxytryptamine receptor 1A,B,,,,,
3540,8,,BAO_0000249,Expert,,15629,In vitro binding affinity at 5-hydroxytryptamine receptor 1A receptor in rat hippocampal membranes by [3H]8-OH-DPAT displacement.,B,,,,,
3541,8,,BAO_0000019,Autocuration,2435.0,10034,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats corpus striatum at a dosage of 0.10 umol/kg,F,,,,,
3542,8,,BAO_0000019,Autocuration,2435.0,10034,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats corpus striatum at a dosage of 10 umol/kg,F,,,,,
3543,8,,BAO_0000019,Autocuration,2435.0,10034,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 0.32 umol/kg,F,,,,,
3544,8,,BAO_0000019,Autocuration,2435.0,10034,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 3.2 umol/kg,F,,,,,
3545,8,,BAO_0000019,Autocuration,2435.0,10034,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 32 umol/kg,F,,,,,
3546,8,,BAO_0000019,Autocuration,2435.0,10034,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 0.032 umol/kg,F,,,,,
3547,8,,BAO_0000019,Autocuration,2435.0,10034,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 1.0 umol/kg,F,,,,,
3548,8,,BAO_0000019,Autocuration,2435.0,10034,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 10 umol/kg,F,,,,,
3549,8,,BAO_0000019,Autocuration,2435.0,10034,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 100 umol/kg,F,,,,,
3550,8,,BAO_0000019,Autocuration,2435.0,10034,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 3.2 umol/kg,F,,,,,
3551,8,,BAO_0000019,Autocuration,2435.0,10034,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 32 umol/kg,F,,,,,
3552,8,,BAO_0000019,Autocuration,349.0,10034,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.032 umol/kg,F,,,,,
3553,8,,BAO_0000019,Autocuration,349.0,10034,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.10 umol/kg,F,,,,,
3554,8,,BAO_0000019,Autocuration,349.0,10034,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.32 umol/kg,F,,,,,
3555,8,,BAO_0000019,Autocuration,349.0,10034,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 1.0 umol/kg,F,,,,,
3556,8,,BAO_0000019,Autocuration,349.0,10034,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 10 umol/kg,F,,,,,
3557,8,,BAO_0000019,Autocuration,349.0,10034,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 100 umol/kg,F,,,,,
3558,8,,BAO_0000019,Autocuration,349.0,10034,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 3.2 umol/kg,F,,,,,
3559,8,,BAO_0000357,Expert,,1274,Binding affinity against 5-hydroxytryptamine 4 receptor,B,,,,,
3560,8,,BAO_0000019,Autocuration,,17358,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,F,,,,,
3561,8,,BAO_0000357,Autocuration,,14532,Inhibitory activity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand at 10e-5 M concentration,B,,,,,
3562,8,,BAO_0000357,Expert,,16989,Binding affinity towards Serotonin 5-hydroxytryptamine 4 receptor,B,,,,,
3563,8,,BAO_0000357,Autocuration,,17200,Inhibitory constant against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 radioligand,B,,,,,
3564,8,,BAO_0000357,Autocuration,,15779,Binding affinity towards 5-hydroxytryptamine 4 receptor,B,,,,,
3565,8,,BAO_0000357,Autocuration,,15779,Binding affinity towards 5-hydroxytryptamine 4 receptor; ND means no data.,B,,,,,
3566,8,,BAO_0000357,Autocuration,,15779,Binding affinity towards 5-hydroxytryptamine 4 receptor; ND means no data.,B,,,,,
3567,8,,BAO_0000219,Autocuration,,15650,Binding affinity was determined against cloned 5-hydroxytryptamine 4A receptor isoform expressed in COS-7 cells,B,,,,,
3568,8,,BAO_0000219,Autocuration,,15650,Binding affinity was determined against cloned 5-hydroxytryptamine 4B receptor isoform expressed in COS-7 cells,B,,,,,
3569,8,,BAO_0000219,Autocuration,,15650,Binding affinity was determined against cloned 5-hydroxytryptamine 4C receptor isoform expressed in COS-7 cells,B,,,,,
3570,8,,BAO_0000219,Autocuration,,15650,Binding affinity was determined against cloned 5-hydroxytryptamine 4D receptor isoform expressed in COS-7 cells,B,,,,,
3571,8,,BAO_0000219,Autocuration,,17046,Binding affinity of compound towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand,B,,,,,
3572,8,,BAO_0000219,Expert,,17046,Binding affinity towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand,B,,,,,
3573,8,,BAO_0000219,Expert,,15650,Binding affinity was determined against cloned 5-hydroxytryptamine 4E receptor isoform expressed in C6 glial cells incubated with 0.2 nM [3H]GR-113808,B,,,,,
3574,8,,BAO_0000219,Expert,,17046,Binding affinity towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand; Not determined,B,,,,,
3575,8,,BAO_0000357,Expert,,17066,Binding affinity towards 5-hydroxytryptamine 5 receptor,B,,,,,
3576,8,,BAO_0000357,Autocuration,,17200,Inhibitory constant against human 5-hydroxytryptamine 5A receptor using [3H]LSD radioligand,B,,,,,
3577,9,,BAO_0000357,Expert,,16146,Binding affinity against 5-hydroxytryptamine 5A receptor,B,,,Homo sapiens,9606.0,
3578,8,,BAO_0000219,Autocuration,,15250,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 5A receptor stably expressed in CHO cells,B,,,,,
3579,9,,BAO_0000357,Expert,,6491,Affinity towards human 5-hydroxytryptamine 5A serotonin receptor,B,,,Homo sapiens,9606.0,
3580,9,,BAO_0000357,Expert,,17066,Binding affinity towards human 5-hydroxytryptamine 5A receptor,B,,,Homo sapiens,9606.0,
3581,9,,BAO_0000357,Expert,,17066,Binding affinity towards human 5-hydroxytryptamine 5A receptor was evaluated using [3H]-5-CT as radioligand,B,,,Homo sapiens,9606.0,
3582,9,,BAO_0000357,Expert,,4234,Binding affinity to cloned human 5-hydroxytryptamine 5A receptor,B,,,Homo sapiens,9606.0,
3583,8,,BAO_0000357,Autocuration,,6013,Binding affinity towards 5-HT5A receptor,B,,,,,
3584,8,,BAO_0000357,Expert,,17175,Binding affinity towards human 5-hydroxytryptamine 5A receptor using LSD as radioligand,B,,,,,
3585,8,,BAO_0000357,Autocuration,,15818,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 5A receptor,B,,,,,
3586,8,,BAO_0000357,Autocuration,,6166,Binding affinity towards cloned human 5-HT5A receptor was determined,B,,,,,
3587,8,,BAO_0000219,Autocuration,,15779,Binding affinity towards 5-hydroxytryptamine 5A receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,B,,,,,
3588,8,,BAO_0000219,Autocuration,,15779,Binding affinity towards 5-hydroxytryptamine 5A receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand;ND means no data.,B,,,,,
3589,8,,BAO_0000219,Autocuration,,5213,Compound was tested for its binding affinity in 5-hydroxytryptamine 5A receptor (using human cloned receptors in HEK 293 and [3H]5-CTas a radioligand ),B,,,,,
3590,9,,BAO_0000357,Expert,,17066,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor,B,,,Mus musculus,10090.0,
3591,9,,BAO_0000357,Expert,,17066,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [125I]-2-iodo LSD as radioligand,B,,,Mus musculus,10090.0,
3592,9,,BAO_0000357,Expert,,17066,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [3H]- LSD as radioligand,B,,,Mus musculus,10090.0,
3593,9,,BAO_0000357,Expert,,17066,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [3H]LSD as radioligand,B,,,Mus musculus,10090.0,
3594,9,,BAO_0000357,Expert,,17066,Binding affinity towards murine 5-hydroxytryptamine 5A receptor,B,,,Mus musculus,10090.0,
3595,8,,BAO_0000357,Expert,,17175,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor using LSD as radioligand,B,,,,,
3596,8,,BAO_0000219,Autocuration,,16190,Binding affinity against 5-hydroxytryptamine 5A receptor in HEK 293 cells was determined using [3H]LSD as radioligand,B,,,,,
3597,8,,BAO_0000219,Autocuration,,16190,Binding affinity against 5-hydroxytryptamine 5A receptor in HEK 293 cells was determined using [3H]LSD as radioligand,B,,,,,
3598,8,,BAO_0000357,Expert,,4820,Binding affinity towards 5-HT5a receptor,B,,,,,
3599,9,,BAO_0000357,Expert,,17066,Binding affinity towards 5-hydroxytryptamine 5A receptor,B,,,Homo sapiens,9606.0,
3600,8,,BAO_0000357,Expert,,17066,Binding affinity for rodent 5-hydroxytryptamine 5A receptor,B,,,,,
3601,8,,BAO_0000357,Expert,,17175,Binding affinity towards 5-hydroxytryptamine 5A receptor using lysergic acid diethylamide (LSD) as radioligand,B,,,,,
3602,8,,BAO_0000357,Autocuration,,16633,Binding affinities against 5-hydroxytryptamine 5A receptor,B,,,,,
3603,8,,BAO_0000357,Autocuration,,16633,Binding affinities towards 5-hydroxytryptamine 5A receptor,B,,,,,
3604,8,,BAO_0000357,Autocuration,,16700,The binding affinity towards 5-hydroxytryptamine 5A receptor; No affinity,B,,,,,
3605,4,,BAO_0000019,Autocuration,,4639,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 0.01 uM,F,,,Cavia porcellus,10141.0,
3606,4,,BAO_0000223,Autocuration,,5486,Binding affinity towards 5-HT3 receptor by the displacement of [3H]GR-65630] in human recombinant receptors in mammalian cell,B,,,,,
3607,9,,BAO_0000357,Expert,,16146,Inhibition of human 5-hydroxytryptamine 6 receptor,B,,,Homo sapiens,9606.0,
3608,9,,BAO_0000357,Expert,,17273,Binding affinity towards 5-hydroxytryptamine 6 receptor using [3H]- LSD as radioligand,B,,,Homo sapiens,9606.0,
3609,8,,BAO_0000357,Autocuration,,17687,Inhibition against human 5-hydroxytryptamine 6 receptor,B,,,,,
3610,9,,BAO_0000357,Expert,,6491,Affinity towards human 5-hydroxytryptamine 6 serotonin receptor,B,,,Homo sapiens,9606.0,
3611,8,,BAO_0000219,Expert,,16190,Binding affinity as displacement of [3H]5-HT binding to 5-hydroxytryptamine 6 receptor in HeLa cells.,B,,,,,
3612,9,,BAO_0000357,Expert,,17066,Binding affinity towards [3H]LSD-labeled human 5-hydroxytryptamine 6 receptor,B,,,Homo sapiens,9606.0,
3613,9,,BAO_0000357,Expert,,17066,Binding affinity towards human 5-hydroxytryptamine 6 receptor,B,,,Homo sapiens,9606.0,
3614,9,,BAO_0000357,Expert,,17066,Binding affinity towards human 5-hydroxytryptamine 6 receptor was evaluated using [125I]-2-iodo LSD as radioligand,B,,,Homo sapiens,9606.0,
3615,9,,BAO_0000357,Expert,,17066,Binding affinity towards human 5-hydroxytryptamine 6 receptor was evaluated using [3H]-LSD as radioligand,B,,,Homo sapiens,9606.0,
3616,9,,BAO_0000357,Expert,,3555,Binding affinity against 5-hydroxytryptamine 6 receptor,B,,,Homo sapiens,9606.0,
3617,8,,BAO_0000357,Expert,,5808,Binding affinity towards human 5-hydroxytryptamine 6 receptor,B,,,,,
3618,8,,BAO_0000357,Autocuration,,6013,Binding affinity towards human 5-hydroxytryptamine 6 receptor,B,,,,,
3619,8,,BAO_0000219,Expert,,15818,"Binding affinity for human 5-hydroxytryptamine 6 receptor expressed in HEK 293 human embryonic kidney cells, [3H]-lysergic acid diethylamide as radioligand",B,,,,,
3620,8,,BAO_0000357,Autocuration,,16209,Binding affinity towards human 5-hydroxytryptamine 6 receptor using [3H]LSD as radioligand,B,,,,,
3621,8,,BAO_0000219,Expert,,3935,Binding affinity against human 5-hydroxytryptamine 6 receptor stably transfected to HEK 293 human embryonic kidney cells using [3H]-lysergic acid diethylamide as radioligand,B,,,,,
3622,8,,BAO_0000357,Autocuration,,15818,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 6 receptor,B,,,,,
3623,9,,BAO_0000219,Expert,,3805,Displacement of [3H]LSD from human 5-hydroxytryptamine 6 receptor expressed in HEK 293 cells,B,,,Homo sapiens,9606.0,
3624,8,,BAO_0000019,Expert,,16441,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 6 receptor incubated with 1 nM [3H]LSD,B,,,,,
3625,8,,BAO_0000019,Expert,,16441,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 6 receptor incubated with 1 nM [3H]LSD; ND is No Data.,B,,,,,
3626,8,,BAO_0000219,Expert,,6786,Ability to displace [3H]LSD from human 5-hydroxytryptamine 6 receptor transiently expressed in COS-7 cells,B,,,,,
3627,9,,BAO_0000357,Expert,,4234,In vitro binding affinity to human 5-hydroxytryptamine 6 receptor,B,,,Homo sapiens,9606.0,
3628,8,,BAO_0000019,Autocuration,,17085,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 6 receptor,B,,,,,
3629,8,,BAO_0000357,Autocuration,,17200,Inhibitory constant against human 5-hydroxytryptamine 6 receptor using [3H]LSD radioligand,B,,,,,
3630,8,,BAO_0000219,Autocuration,,17451,Antagonism assessed in a functional cAMP binding assay using 5-CT to stimulate human 5-hydroxytryptamine 6 receptor expressed in HEK 293 cells,B,,,,,
3631,8,,BAO_0000019,Autocuration,,3935,The compound was tested for antagonist activity by inhibition of human 5-HT6 stimulated adenylate cyclase,F,,,,,
3632,8,,BAO_0000357,Autocuration,,5033,Ability to displace the radioligand [3H]LSD from human 5-hydroxytryptamine 6 receptor,B,,,,,
3633,8,,BAO_0000357,Expert,,4540,Binding affinity against human 5-hydroxytryptamine 6 receptor,B,,,,,
3634,9,,BAO_0000219,Expert,,4540,Binding affinity to human cloned 5-HT6 receptor in HeLa cells using [3H]- LSD as radioligand,B,,,Homo sapiens,9606.0,
3635,9,,BAO_0000219,Expert,,4540,Binding affinity to human cloned 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]- LSD as radioligand,B,,,Homo sapiens,9606.0,
3636,8,,BAO_0000219,Autocuration,,17296,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells,B,,,,,
3637,8,,BAO_0000219,Autocuration,,17296,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells using [3H]LSD as radioligand,B,,,,,
3638,8,,BAO_0000219,Autocuration,,17296,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells using [3H]LSD as radioligand,B,,,,,
3639,8,,BAO_0000219,Autocuration,,15779,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,B,,,,,
3640,8,,BAO_0000219,Autocuration,,15779,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,B,,,,,
3641,8,,BAO_0000219,Autocuration,,15779,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand; ND means no data.,B,,,,,
3642,8,,BAO_0000219,Autocuration,,15779,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand;ND means no data.,B,,,,,
3643,8,,BAO_0000219,Autocuration,,15779,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HeLa cells using [3H]LSD as radioligand;ND means no data.,B,,,,,
3644,8,,BAO_0000357,Autocuration,,6166,Binding affinity towards human 5-hydroxytryptamine 6 receptor,B,,,,,
3645,8,,BAO_0000219,Autocuration,,17451,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 6 receptor expressed in HeLa cells using [3H]LSD as radioligand,B,,,,,
3646,8,,BAO_0000357,Autocuration,,15316,Compound was evaluated for its ability to displace [3H]LSD binding from human recombinant 5-hydroxytryptamine 6 receptor,B,,,,,
3647,8,,BAO_0000357,Expert,,4199,Binding affinity against human 5-hydroxytryptamine 6 receptor,B,,,,,
3648,8,,BAO_0000219,Expert,,15146,Binding affinity against human cloned 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]LSD,B,,,,,
3649,8,,BAO_0000357,Autocuration,,5213,Compound was tested for its binding affinity in 5-hydroxytryptamine 6 receptor (using human cloned receptors in HeLa and [3H]LSD as a radioligand ),B,,,,,
3650,8,,BAO_0000219,Autocuration,,16429,In vitro binding affinity at human recombinant 5-hydroxytryptamine 6 receptor in mammalian cells using 3[H]LSD as the radioligand,B,,,,,
3651,8,,BAO_0000219,Autocuration,,14818,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]5-LSD.,B,,,,,
3652,8,,BAO_0000219,Autocuration,,4829,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]5-LSD as radioligand; n=3",B,,,,,
3653,8,,BAO_0000219,Autocuration,,4829,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]5-LSD as radioligand; n=9",B,,,,,
3654,8,,BAO_0000219,Autocuration,,4829,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]LSD as radioligand; n=3",B,,,,,
3655,8,,BAO_0000219,Autocuration,,15250,Compound was tested for the displacement of [3H]5-HT binding to cloned rat 5-hydroxytryptamine 6 receptor stably expressed in CHO cells,B,,,,,
3656,8,,BAO_0000019,Autocuration,,14423,Binding affinity against 5-hydroxytryptamine 6 receptor from CHO cell membranes using [3H]5-HT as the radioligand.,B,,,,,
3657,8,,BAO_0000357,Autocuration,,15086,The compound was tested for binding affinity against 5-hydroxytryptamine 6 receptor,B,,,,,
3658,8,,BAO_0000357,Autocuration,,4342,Binding affinity of compound towards serotonin 5-hydroxytryptamine 6 receptor was determined,B,,,,,
3659,9,,BAO_0000219,Autocuration,,16190,Binding affinity as displacement of [3H]5-HT binding to 5-hydroxytryptamine 6 receptor in HeLa cells,B,,,Homo sapiens,9606.0,
3660,8,,BAO_0000357,Expert,,4820,Binding affinity towards human 5-hydroxytryptamine 6 receptor,B,,,,,
3661,8,,BAO_0000357,Autocuration,,4639,Percentage of displacement at 5-hydroxytryptamine 6 receptor at 10e-8 M,B,,,,,
3662,9,,BAO_0000019,Expert,,17066,Antagonistic activity towards 5-hydroxytryptamine 6 receptor was evaluated in cAMP assay,F,,,Homo sapiens,9606.0,
3663,8,,BAO_0000357,Autocuration,,6011,Inhibition of binding towards 5-hydroxytryptamine 6 receptor at 100 nM concentration,B,,,,,
3664,8,,BAO_0000357,Expert,,17066,Binding affinity towards human 5-hydroxytryptamine 6 receptor,B,,,,,
3665,8,,BAO_0000357,Autocuration,,17515,Binding affinity of compound towards serotonin 5-hydroxytryptamine 6 receptor; inactive at 10 uM,B,,,,,
3666,8,,BAO_0000357,Autocuration,,5014,Compound was tested for its binding affinity towards 5-hydroxytryptamine 6 receptor,B,,,,,
3667,8,,BAO_0000357,Autocuration,,4373,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 6 receptor was determined,B,,,,,
3668,8,,BAO_0000019,Expert,,17066,Antagonistic activity towards 5-hydroxytryptamine 6 receptor,F,,,,,
3669,8,,BAO_0000019,Expert,,17066,Antagonistic activity towards 5-hydroxytryptamine 6 receptor was evaluated in cAMP assay,F,,,,,
3670,8,,BAO_0000357,Autocuration,,4373,Binding affinity for 5-hydroxytryptamine 6 receptor was determined,B,,,,,
3671,8,,BAO_0000357,Autocuration,,4687,Evaluated for the binding affinity towards 5-hydroxytryptamine 6 receptor,B,,,,,
3672,8,,BAO_0000357,Autocuration,,16946,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 6 receptor at concentration of 10e-6 M,B,,,,,
3673,8,,BAO_0000357,Autocuration,,16946,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 6 receptor at concentration of 10e-8 M,B,,,,,
3674,8,,BAO_0000357,Autocuration,,16633,Binding affinities against 5-hydroxytryptamine 6 receptor,B,,,,,
3675,8,,BAO_0000357,Autocuration,,16633,Binding affinities towards 5-hydroxytryptamine 6 receptor,B,,,,,
3676,9,,BAO_0000357,Expert,,17066,Binding affinity towards 5-hydroxytryptamine 6 receptor,B,,,Homo sapiens,9606.0,
3677,8,,BAO_0000357,Autocuration,,16700,The binding affinity towards 5-hydroxytryptamine 6 receptor; No affinity,B,,,,,
3678,8,,BAO_0000357,Autocuration,,3269,Affinity against 5-hydroxytryptamine 6 receptor,B,,,,,
3679,8,,BAO_0000357,Autocuration,,5486,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor by the displacement of [3H]-5-CT],B,,,,,
3680,9,,BAO_0000357,Expert,,16146,Inhibition of human 5-hydroxytryptamine 7 receptor,B,,,Homo sapiens,9606.0,
3681,8,,BAO_0000219,Autocuration,,5014,Compound was tested for its binding affinity towards human 5-hydroxytryptamine 7 receptor from HEK293 cells using radioligand [3H]LSD,B,,,,,
3682,8,,BAO_0000357,Autocuration,,15463,Compound at 1 uM was tested for the inhibition of radioligand [3H]LSD binding to recombinant human 5-hydroxytryptamine 7 receptor,B,,,,,
3683,8,,BAO_0000357,Autocuration,,3805,In vitro binding affinity against human 5-hydroxytryptamine 7 receptor at a concentration of 100 (nM),B,,,,,
3684,8,,BAO_0000219,Expert,,5014,Inhibition (at 1 uM) of radioligand [3H]LSD binding to human 5-hydroxytryptamine 7 receptor on HEK293 cells,B,,,,,
3685,9,,BAO_0000357,Expert,,6491,Affinity towards human 5-hydroxytryptamine 7 serotonin receptor,B,,,Homo sapiens,9606.0,
3686,8,,BAO_0000219,Autocuration,,16190,Binding affinity for 5-hydroxytryptamine 7 receptor human cloned receptors in CHO cells using [3H]5-HT,B,,,,,
3687,9,,BAO_0000357,Expert,,17066,Binding affinity towards human 5-hydroxytryptamine 7 receptor,B,,,Homo sapiens,9606.0,
3688,9,,BAO_0000357,Expert,,17066,Displacement of [3H]5-HT from human 5-hydroxytryptamine 7 receptor,B,,,Homo sapiens,9606.0,
3689,9,,BAO_0000357,Expert,,3555,Binding affinity against 5-hydroxytryptamine 7 receptor,B,,,Homo sapiens,9606.0,
3690,8,,BAO_0000219,Expert,,6588,Binding affinity towards human 5-hydroxytryptamine 7 receptor by the displacement of [3H]-5-HT radioligand from the cloned receptor expressed in CHO cells,B,,,,,
3691,8,,BAO_0000357,Autocuration,,15463,Binding affinity towards recombinant human 5-hydroxytryptamine 7 receptor was determined using [3H]LSD as radioligand,B,,,,,
3692,8,,BAO_0000357,Autocuration,,6013,Binding affinity towards 5-hydroxytryptamine 7 receptor,B,,,,,
3693,8,,BAO_0000357,Autocuration,,16209,Binding affinity towards human 5-hydroxytryptamine 7 receptor using [3H]5-HT as radioligand,B,,,,,
3694,8,,BAO_0000357,Autocuration,,3935,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 7 receptor,B,,,,,
3695,8,,BAO_0000357,Autocuration,,15818,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 7 receptor,B,,,,,
3696,8,,BAO_0000219,Expert,,5014,Binding affinity towards human 5-hydroxytryptamine 7 receptor on HEK293 cells using radioligand [3H]LSD,B,,,,,
3697,8,,BAO_0000019,Expert,,16441,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 7 receptor incubated with 1 nM [3H]LSD,B,,,,,
3698,8,,BAO_0000019,Expert,,16441,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 7 receptor incubated with 1 nM [3H]LSD; ND is No Data.,B,,,,,
3699,9,,BAO_0000357,Expert,,4234,In vitro binding affinity to human 5-hydroxytryptamine 7 receptor,B,,,Homo sapiens,9606.0,
3700,8,,BAO_0000019,Autocuration,,17085,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 7 receptor,B,,,,,
3701,8,,BAO_0000357,Autocuration,,17200,Inhibitory constant against human 5-hydroxytryptamine 7 receptor using [3H]LSD radioligand,B,,,,,
3702,8,,BAO_0000219,Autocuration,,17451,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 7 receptor expressed in CHO cells using [3H]-LSD as radioligand; Not determined,B,,,,,
3703,8,,BAO_0000019,Autocuration,,17085,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 7 receptor; ND means not determined,B,,,,,
3704,8,,BAO_0000357,Autocuration,,5104,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor,B,,,,,
3705,8,,BAO_0000357,Autocuration,,5104,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor; Not tested,B,,,,,
3706,9,,BAO_0000219,Expert,,5033,Ability to displace the radioligand [3H]5-carboxyamidotryptamine ([3H]5-CT) from human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells,B,,,Homo sapiens,9606.0,
3707,8,,BAO_0000219,Autocuration,,5486,Ability to displace the radioligand [3H]5-carboximidotryptamine ([3H]-5-CT) from cloned human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells,B,,,,,
3708,9,,BAO_0000219,Expert,,4540,Binding affinity to human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]-5-CT as radioligand,B,,,Homo sapiens,9606.0,
3709,8,,BAO_0000357,Expert,,6166,Binding affinity at human cloned 5-hydroxytryptamine 7 receptor.,B,,,,,
3710,8,,BAO_0000219,Expert,,17342,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor was determined in HEK293 cells using [3H]5-CT as radioligand,B,,,,,
3711,8,,BAO_0000357,Expert,,17342,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor was determined using [3H]5-CT as radioligand,B,,,,,
3712,8,,BAO_0000357,Autocuration,,17296,Binding affinity against 5-hydroxytryptamine 7 human receptors,B,,,,,
3713,8,,BAO_0000219,Expert,,16429,Binding affinity to human recombinant 5-hydroxytryptamine 7 receptor in mammalian cells using [3H]5-CT as radioligand,B,,,,,
3714,8,,BAO_0000219,Autocuration,,15779,Binding affinity toward 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]-5-CT as radioligand.,B,,,,,
3715,8,,BAO_0000219,Autocuration,,15779,Binding affinity towards 5-hydroxytryptamine 7 receptor (a) (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,B,,,,,
3716,8,,BAO_0000219,Autocuration,,15779,Binding affinity towards 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,B,,,,,
3717,8,,BAO_0000219,Autocuration,,15779,Binding affinity towards 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,B,,,,,
3718,8,,BAO_0000219,Autocuration,,15779,Binding affinity towards 5-hydroxytryptamine 7 receptor 7(a) (human cloned receptor in HEK 293 cells using [3H]5-CT as radioligand.,B,,,,,
3719,8,,BAO_0000219,Autocuration,,17451,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 7 receptor expressed in CHO cells using [3H]LSD as radioligand,B,,,,,
3720,8,,BAO_0000219,Autocuration,,4199,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT as the radioligand (n=3),B,,,,,
3721,9,,BAO_0000219,Expert,,4199,Displacement of [3H]-5-CT from human 5-hydroxytryptamine 7 receptor expressed in HEK-293 cells,B,,,,,
3722,8,,BAO_0000219,Autocuration,,4199,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT as the radioligand(n=6),B,,,,,
3723,9,,BAO_0000219,Intermediate,,3680,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor in HEK 293 cells,B,,,,,
3724,9,,BAO_0000357,Intermediate,,3680,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor using [3H]5-CT as radioligand,B,,,,,
3725,8,,BAO_0000219,Autocuration,,15316,Compound was evaluated for its ability to displace [3H]5-CT binding from cloned human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells.,B,,,,,
3726,8,,BAO_0000219,Autocuration,,15146,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT,B,,,,,
3727,8,,BAO_0000219,Expert,,5213,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor in HEK 293 using [3H]5-CT as a radioligand,B,,,,,
3728,8,,BAO_0000219,Autocuration,,5213,Compound was tested for its binding affinity in 5-hydroxytryptamine 7 receptor (using human cloned receptors in HEK 293 and [3H]5-CT as a radioligand ),B,,,,,
3729,9,,BAO_0000219,Expert,,14818,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor expressed in HEK 293 cells using [3H]5-CT,B,,,Homo sapiens,9606.0,
3730,8,,BAO_0000219,Autocuration,,14818,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 7 receptor expressed in HEK 293 cells using [3H]5-CT. ,B,,,,,
3731,8,,BAO_0000219,Autocuration,,14818,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT.,B,,,,,
3732,8,,BAO_0000219,Autocuration,,4829,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 7 receptor in HEK293 cells, using [3H]5-CT as radioligand",B,,,,,
3733,9,,BAO_0000357,Autocuration,,17200,Inhibitory constant against human 5-hydroxytryptamine 7 receptor using [3H]-LSD radioligand; Not determined,B,,,Homo sapiens,9606.0,
3734,9,,BAO_0000357,Expert,,17066,Binding affinity towards mouse 5-hydroxytryptamine 7 receptor was evaluated using [3H]5-HT as radioligand,B,,,Mus musculus,10090.0,
3735,8,,BAO_0000019,Autocuration,,14025,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 7 receptor in the endothelium denuded rabbit jugular vein.,B,,,Oryctolagus cuniculus,9986.0,
3736,8,,BAO_0000219,Autocuration,,15250,Compound was tested for the displacement of [3H]5-HT binding to cloned rat 5-hydroxytryptamine 7 receptor stably expressed in CHO cells,B,,,,,
3737,8,,BAO_0000219,Autocuration,,16372,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 10000 nM,B,,,,,
3738,8,,BAO_0000219,Autocuration,,16372,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 100 nM,B,,,,,
3739,8,,BAO_0000219,Autocuration,,16372,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 1 nM,B,,,,,
3740,8,,BAO_0000219,Autocuration,,16372,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 10000 nM 5-HT.,B,,,,,
3741,8,,BAO_0000219,Autocuration,,16372,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 100 nM 5-HT.,B,,,,,
3742,8,,BAO_0000219,Autocuration,,16372,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 1 nM 5-HT,B,,,,,
3743,8,,BAO_0000219,Autocuration,,16372,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 10000 nM,B,,,,,
3744,8,,BAO_0000219,Autocuration,,16372,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 100 nM,B,,,,,
3745,8,,BAO_0000219,Autocuration,,16372,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 1 nM,B,,,,,
3746,8,,BAO_0000219,Autocuration,,16372,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 10000 nM 5-HT.,B,,,,,
3747,8,,BAO_0000219,Autocuration,,16372,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 100 nM 5-HT.,B,,,,,
3748,8,,BAO_0000219,Autocuration,,16372,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 1 nM 5-HT.,B,,,,,
3749,8,,BAO_0000357,Expert,,17066,Binding affinity towards rat 5-hydroxytryptamine 7 receptor,B,,,,,
3750,9,,BAO_0000357,Expert,,17066,Binding affinity towards rat 5-hydroxytryptamine 7 receptor was evaluated using [3H]5-HT as radioligand,B,,,Rattus norvegicus,10116.0,
3751,8,,BAO_0000357,Expert,,17386,Binding affinity to the rat 5-hydroxytryptamine 7 receptor,B,,,,,
3752,8,,BAO_0000019,Autocuration,,14423,Binding affinity against 5-hydroxytryptamine 7 receptor using from CHO cell membranes [3H]5-HT as the radioligand.,B,,,,,
3753,9,,BAO_0000357,Expert,,15874,Binding affinity against Rat 5-hydroxytryptamine 7 receptor using [3H]5-HT,B,,,Rattus norvegicus,10116.0,
3754,9,,BAO_0000357,Expert,,15874,Displacement of [3H]5-HT from over-expressed rat 5-hydroxytryptamine 7 receptor,B,,,Rattus norvegicus,10116.0,
3755,9,,BAO_0000219,Expert,,16372,Displacement of [3H]5-HT from rat 5-hydroxytryptamine 7 receptor expressed in CHO cells,B,,,Rattus norvegicus,10116.0,
3756,8,,BAO_0000357,Autocuration,,4622,In vitro binding affinity towards cloned rat 5-hydroxytryptamine 7 receptor using [3H]5-HT as radioligand,B,,,,,
3757,8,,BAO_0000357,Autocuration,,15086,The compound was tested for binding affinity against 5-hydroxytryptamine 7 receptor,B,,,,,
3758,8,,BAO_0000219,Autocuration,,16372,"Effect of compound on stimulation of cAMP production in CHO cells expressing rat 5-HT7 receptors at 1, 10, 100 1000 and 10000 nM conc; Not tested",B,,,,,
3759,8,,BAO_0000219,Autocuration,,16372,"Effect of compound on stimulation of cAMP production in CHO cells expressing rat 5-HT7 receptors at 1, 10, 100 1000 and 10000 nM conc; not tested",B,,,,,
3760,8,,BAO_0000219,Autocuration,,16372,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 1 nM; not tested,B,,,,,
3761,8,,BAO_0000219,Autocuration,,16372,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 1 nM 5-HT; Not tested,B,,,,,
3762,8,,BAO_0000221,Autocuration,2116.0,17386,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor desensitization,F,,,,,
3763,8,,BAO_0000221,Autocuration,2116.0,17386,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor nondesensitization,F,,,,,
3764,8,,BAO_0000221,Autocuration,2116.0,17386,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine receptor desensitization,F,,,,,
3765,9,,BAO_0000249,Expert,,5831,Inhibition of [3H]-5-CT binding to 5-hydroxytryptamine 7 receptor of rat cortical membranes,B,,,Rattus norvegicus,10116.0,
3766,8,,BAO_0000357,Autocuration,,4342,Binding affinity of compound towards serotonin 5-hydroxytryptamine 7 receptor was determined,B,,,,,
3767,8,,BAO_0000357,Expert,,17319,Binding affinity at rat 5-hydroxytryptamine 7 receptor.,B,,,,,
3768,8,,BAO_0000019,Expert,1898.0,17342,Binding affinity towards 5-hydroxytryptamine receptor 7 on rat hypothalamus membranes using [3H]5-CT as radioligand.,B,,,,,
3769,8,,BAO_0000357,Autocuration,,17342,Binding affinity towards cloned rat 5-hydroxytryptamine 7 receptor was determined using [3H]5-HT as radioligand,B,,,,,
3770,8,,BAO_0000249,Expert,1898.0,3680,Binding affinity against 5-hydroxytryptamine 7 receptor using [3H]-5-CT in rat hypothalamus membranes,B,,,,,
3771,8,,BAO_0000357,Expert,,3680,Binding affinity towards 5-hydroxytryptamine 7 receptor,B,,,,,
3772,9,,BAO_0000219,Expert,,17319,Agonistic activity against rat 5-HT7 adenyl cyclase expressed by HEK293 cells,F,,,Rattus norvegicus,10116.0,
3773,9,,BAO_0000219,Expert,,17319,Agonistic activity against rat 5-HT7 adenyl cyclase expressed in HEK293 cells; Active,F,,,Rattus norvegicus,10116.0,
3774,9,,BAO_0000219,Autocuration,,17319,Agonistic activity against rat 5-HT7-adenyl cyclase expressed by HEK293 cells; Active,F,,,Rattus norvegicus,10116.0,
3775,8,,BAO_0000357,Expert,,4820,Binding affinity towards 5-hydroxytryptamine 7 receptor,B,,,,,
3776,8,,BAO_0000357,Autocuration,,4639,Percentage of displacement at 5-hydroxytryptamine 7 receptor at 10e-8 M,B,,,,,
3777,8,,BAO_0000357,Autocuration,,6011,Inhibition of binding towards 5-hydroxytryptamine 7 receptor at 100 nM concentration,B,,,,,
3778,9,,BAO_0000357,Expert,,17066,Binding affinity towards human 5-hydroxytryptamine 7 receptor,B,,,Homo sapiens,9606.0,
3779,8,,BAO_0000357,Expert,,17066,Binding affinity of compound towards rodent 5-hydroxytryptamine 7 receptor,B,,,,,
3780,8,,BAO_0000357,Autocuration,,17515,Binding affinity of compound towards serotonin 5-hydroxytryptamine 7 receptor; inactive at 10 uM,B,,,,,
3781,8,,BAO_0000357,Autocuration,,4373,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 7 receptor was determined,B,,,,,
3782,8,,BAO_0000019,Expert,,17066,Antagonistic activity towards 5-hydroxytryptamine 7 receptor was evaluated by cAMP assay,F,,,,,
3783,8,,BAO_0000357,Autocuration,,4373,Binding affinity for 5-hydroxytryptamine 7 receptor was determined,B,,,,,
3784,8,,BAO_0000357,Autocuration,,4373,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 7 receptor was determined,B,,,,,
3785,8,,BAO_0000357,Autocuration,,4687,Evaluated for the binding affinity to 5-hydroxytryptamine 7 receptor,B,,,,,
3786,8,,BAO_0000357,Expert,,17342,Non-selective inhibitory activity was determined against 5-hydroxytryptamine 7 receptor,B,,,,,
3787,8,,BAO_0000357,Autocuration,,16946,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 7 receptor at concentration of 10e-6 M,B,,,,,
3788,8,,BAO_0000357,Autocuration,,16946,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 7 receptor at concentration of 10e-8 M,B,,,,,
3789,8,,BAO_0000357,Autocuration,,16633,Binding affinities against 5-hydroxytryptamine 7 receptor,B,,,,,
3790,8,,BAO_0000357,Autocuration,,16633,Binding affinities towards 5-hydroxytryptamine 7 receptor,B,,,,,
3791,8,,BAO_0000357,Expert,,17066,Binding affinity towards rodent 5-hydroxytryptamine 7 receptor,B,,,,,
3792,8,,BAO_0000357,Autocuration,,16700,The binding affinity towards 5-hydroxytryptamine 7 receptor; No affinity,B,,,,,
3793,8,,BAO_0000221,Autocuration,2116.0,17386,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor desensitization,B,,,,,
3794,8,,BAO_0000019,Autocuration,,14080,Compound was evaluated for the potency to inhibit oxidation of arachidonic acid by human recombinant 5-Lipoxygenase using a spectrophotometric assay,F,,,,,
3795,9,,BAO_0000019,Expert,,14080,Inhibition of oxidation of arachidonic acid by human 5-Lipoxygenase using spectrophotometric assay,F,,,Homo sapiens,9606.0,
3796,8,,BAO_0000357,Autocuration,,409,In vitro inhibition of human recombinant 5-lipoxygenase enzyme,B,,,,,
3797,8,,BAO_0000357,Autocuration,,409,In vitro inhibition of human recombinant lipoxygenase enzyme,B,,,,,
3798,8,,BAO_0000357,Autocuration,,409,In vitro inhibition of human recombinant lipoxygenase enzyme; No inhibition,B,,,,,
3799,8,,BAO_0000357,Expert,178.0,11090,Inhibition of 5-lipoxygenase in human whole blood.,B,,,,,
3800,8,,BAO_0000357,Expert,178.0,11090,Inhibition of 5-lipoxygenase in human whole blood.,B,,,,,
3801,8,,BAO_0000357,Autocuration,,948,Compound was tested for the inhibition of 5-lipoxygenase of human PMN stimulated by calcium ionophore A-23187 for the formation of 5-HETE,B,,,,,
3802,8,,BAO_0000357,Autocuration,,948,Compound was tested for the inhibition of 5-lipoxygenase of human PMN stimulated by calcium ionophore A-23187 for the formation of leukotriene B4 (LTB4),B,,,,,
3803,8,,BAO_0000219,Expert,,13622,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in human polymorphonuclear leukocytes.,F,,,,,
3804,8,,BAO_0000019,Autocuration,178.0,13622,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in human whole blood,F,,,,,
3805,8,,BAO_0000357,Autocuration,,9637,In vitro inhibition of 5-lipoxygenase from human polymorphs,B,,,,,
3806,8,,BAO_0000357,Autocuration,,11320,In vitro inhibition of leukotriene B4 synthesis in human whole blood by inhibiting 5-LPO (5-lipoxygenase),B,,,,,
3807,8,,BAO_0000357,Expert,,11320,In vitro inhibition of leukotriene B4 synthesis in human whole blood by inhibiting 5-lipoxygenase,B,,,,,
3808,8,,BAO_0000357,Autocuration,,6838,In vitro inhibitory activity against 5-lipoxygenase in a human whole blood assay,B,,,,,
3809,9,,BAO_0000357,Expert,178.0,17667,Inhibition of 5-Lipoxygenase (5-LO) of human whole blood (HWB),B,,,Homo sapiens,9606.0,
3810,8,,BAO_0000357,Autocuration,,12703,In vitro potency against human 5-Lipoxygenase,B,,,,,
3811,9,,BAO_0000019,Expert,,14312,Inhibitory activity against 5-lipoxygenase in Human whole blood (HWBL) stimulated with calcium ionophore (A23187) and LTB4 measured by enzyme immunoassay,F,,,Homo sapiens,9606.0,
3812,8,,BAO_0000019,Autocuration,178.0,14312,Inhibition activity against 5-lipoxygenase in Human whole blood (HWBL) stimulated with calcium ionophore (A23187) and LTB4 measured by enzyme immunoassay; No data,F,,,,,
3813,8,,BAO_0000019,Autocuration,,5364,Inhibition of 5-lipoxygenase activity of compound evaluated as determined by the inhibition of calcium ionophore-induced leukotriene B4 production in human blood.,F,,,,,
3814,8,,BAO_0000219,Autocuration,,951,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE,B,,,,,
3815,8,,BAO_0000219,Autocuration,,951,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE; NA means Not active,B,,,,,
3816,8,,BAO_0000219,Autocuration,,951,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4,B,,,,,
3817,8,,BAO_0000219,Autocuration,,951,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4; NA means Not active,B,,,,,
3818,8,,BAO_0000219,Autocuration,,12365,Inhibition of human 5-lipoxygenase in human cells,B,,,,,
3819,8,,BAO_0000357,Expert,,10603,Inhibition of human neutrophil 5-lipoxygenase,B,,,,,
3820,8,,BAO_0000019,Autocuration,,10501,Inhibitory activity against 5-lipoxygenase expressed from human polymorphonuclear cells,B,,,,,
3821,8,,BAO_0000357,Expert,178.0,12281,Inhibition of 5-lipoxygenase from human whole blood,B,,,,,
3822,8,,BAO_0000357,Autocuration,,2567,Inhibitory concentration required against 5-lipoxygenase activity in cytosolic fractions of human neutrophils,B,,,,,
3823,8,,BAO_0000219,Autocuration,,2567,Inhibitory concentration required against 5-lipoxygenase activity in intact cells of human neutrophils,B,,,,,
3824,8,,BAO_0000357,Expert,,10193,In vitro inhibition of polymorphonuclear leukocyte derived human 5-lipoxygenase,B,,,,,
3825,8,,BAO_0000357,Autocuration,,10193,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,B,,,,,
3826,8,,BAO_0000357,Expert,,13623,Potency to inhibit oxidation of arachidonic acid by recombinant human 5-lipoxygenase,B,,,,,
3827,8,,BAO_0000357,Autocuration,,12780,Tested against 5-lipoxygenase,B,,,,,
3828,8,,BAO_0000357,Autocuration,,12780,Tested for activity against 5-Lipoxygenase (5-LO),B,,,,,
3829,8,,BAO_0000357,Autocuration,,12780,Tested for activity against 5-lipoxygenase,B,,,,,
3830,8,,BAO_0000357,Autocuration,,11966,Tested for inhibition of 5-HPETE production by human 5-LO,B,,,,,
3831,8,,BAO_0000019,Autocuration,,5364,The 5-lipoxygenase activity by the inhibition of calcium ionophore-induced leukotriene B4 production in human blood.,F,,,,,
3832,8,,BAO_0000357,Expert,,13165,Inhibition of Human 5-lipoxygenase,B,,,,,
3833,8,,BAO_0000019,Autocuration,,5364,The compound was evaluated for its inhibitory activity against 5-lipoxygenase using granulocytes-type cells,B,,,,,
3834,8,,BAO_0000219,Autocuration,,11311,The compound was tested for inhibitory activity against 5-lipoxygenase in human polymorphonuclear leukocytes[PMNS],B,,,,,
3835,8,,BAO_0000219,Autocuration,,11311,The compound was tested for inhibitory activity against LT synthesis in human polymorphonuclear leukocytes[PMNS],B,,,,,
3836,8,,BAO_0000019,Autocuration,,14863,The compound was tested for the concentration (in uM) to inhibit 50% of 5-Lipoxygenase (5-LOX) and is expressed in IC50.,B,,,,,
3837,8,,BAO_0000019,Autocuration,,14863,The compound was tested for the concentration (in uM) to inhibit 50% of 5-Lipoxygenase (5-LOX) and is expressed in IC50; Not tested,B,,,,,
3838,8,,BAO_0000357,Autocuration,178.0,11087,The compound was tested for the inhibition of 5-lipoxygenase (5-lo) in human whole blood (HWBL),B,,,,,
3839,8,,BAO_0000357,Autocuration,,455,The compound was tested in vitro for inhibition against 5-lipoxygenase in intact human neutrophils,B,,,,,
3840,8,,BAO_0000357,Autocuration,,13183,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),B,,,,,
3841,8,,BAO_0000019,Expert,,10319,In vitro inhibitory activity against 5-lipoxygenase in human polymorphonuclear (PMN) cells,B,,,,,
3842,8,,BAO_0000357,Autocuration,,10193,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,B,,,,,
3843,8,,BAO_0000219,Autocuration,,951,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE at 10 uM,B,,,,,
3844,8,,BAO_0000219,Autocuration,,951,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE at 10 uM; NA means Inactive,B,,,,,
3845,8,,BAO_0000219,Autocuration,,951,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4 at 10 uM,B,,,,,
3846,8,,BAO_0000219,Autocuration,,951,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4 at 10 uM; NA means Inactive,B,,,,,
3847,8,,BAO_0000357,Expert,,9859,Inhibitory activity against 5-lipoxygenase at 10 uM concentration,B,,,,,
3848,8,,BAO_0000357,Expert,,9859,Inhibitory activity against 5-lipoxygenase at 1 uM concentration,B,,,,,
3849,8,,BAO_0000357,Autocuration,,9859,Inhibitory activity against lipoxygenase (LO) at 10 uM concentration,B,,,,,
3850,8,,BAO_0000357,Autocuration,,2567,Inhibitory concentration required against 5-lipoxygenase activity in cytosolic fractions of human neutrophils,B,,,,,
3851,8,,BAO_0000357,Autocuration,,10193,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 1 uM,B,,,,,
3852,8,,BAO_0000357,Autocuration,,10193,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,B,,,,,
3853,8,,BAO_0000019,Autocuration,,949,Tested for the inhibition of 5-lipoxygenase from human polymorphonuclear leukocytes(PMN) at 10 uM concentration of the compound; IA= Inactive,B,,,,,
3854,8,,BAO_0000019,Autocuration,,949,Tested for the inhibition of 5-lipoxygenase from human polymorphonuclear leukocytes(PMN) at 10 uM concentration of the compound; value ranges from 70-90,B,,,,,
3855,8,,BAO_0000357,Expert,,10603,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 0.1 uM,B,,,,,
3856,8,,BAO_0000357,Expert,,10603,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 1 uM,B,,,,,
3857,8,,BAO_0000019,Autocuration,,10603,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 1 uM,F,,,,,
3858,8,,BAO_0000357,Expert,,10603,Inhibition of lipoxygenase at the concentration of 0.1 uM,B,,,,,
3859,8,,BAO_0000357,Expert,,10603,Inhibition of lipoxygenase at the concentration of 1 uM,B,,,,,
3860,8,,BAO_0000357,Autocuration,,10193,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell,B,,,,,
3861,9,,BAO_0000357,Expert,,14580,Inhibition of 5-Lipoxygenase (5-LOX),B,,,Homo sapiens,9606.0,
3862,8,,BAO_0000357,Expert,,11090,Inhibition of 5-lipoxygenase in mouse macrophages.,B,,,,,
3863,8,,BAO_0000357,Expert,,11090,Inhibition of 5-lipoxygenase in mouse macrophages.,B,,,,,
3864,8,,BAO_0000357,Autocuration,,6339,Inhibitory activity against lipoxygenase-2 in mice,B,,,,,
3865,8,,BAO_0000357,Expert,,6339,Inhibitory activity against murine lipoxygenase-2.,B,,,,,
3866,9,,BAO_0000357,Expert,,12281,Inhibition of 5-lipoxygenase from mouse macrophage,B,,,Mus musculus,10090.0,
3867,8,,BAO_0000357,Autocuration,,11311,The compound was tested for inhibitory activity against 5-lipoxygenase in mouse macrophages,B,,,,,
3868,8,,BAO_0000019,Autocuration,,11089,The compound was tested for the inhibition of Arachidonate 5-lipoxygenase purified from porcine leukocytes.,B,,,Sus scrofa,9823.0,
3869,8,,BAO_0000019,Autocuration,,10091,Inhibition of 5-lipoxygenase reaction catalyzed by purified enzyme from porcine leukocytes,B,,,Sus scrofa,9823.0,
3870,8,,BAO_0000019,Autocuration,,14352,Inhibitory concentration against 5-lipoxygenase from isolated rabbit granulocytes,B,,,Oryctolagus cuniculus,9986.0,
3871,9,,BAO_0000019,Expert,,13329,5-lipoxygenase Inhibitory activity against rat polymorphonuclear leucocytes using 5-HETE,B,,,Rattus norvegicus,10116.0,
3872,8,,BAO_0000019,Autocuration,,13329,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE. ",B,,,,,
3873,8,,BAO_0000019,Autocuration,,13329,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE.",B,,,,,
3874,8,,BAO_0000019,Autocuration,,13329,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using LTB4.",B,,,,,
3875,8,,BAO_0000019,Expert,,13329,Inhibition of 5-lipoxygenase pathway in rat polymorphonuclear assay (inhibition of 5-HETE formation),B,,,,,
3876,8,,BAO_0000019,Expert,,13329,"Inhibition of 5-lipoxygenase pathway in rat polymorphonuclear assay, by ability to inhibit formation of LTB4 AT 10 uM",B,,,,,
3877,8,,BAO_0000019,Autocuration,,13329,Inhibition of 5-lipoxygenase pathway was evaluated in rat polymorphonuclear assay by compound (50 uM) ability to inhibit formation of 5-HETE,B,,,,,
3878,8,,BAO_0000019,Autocuration,,11311,The effective dose for inhibition of 5-lipoxygenase in rat blood leukocyte (ex vivo),B,,,,,
3879,8,,BAO_0000019,Autocuration,,11311,The effective dose for inhibition of 5-lipoxygenase in rat passive Arthus model after oral administration,B,,,,,
3880,8,,BAO_0000219,Autocuration,,105,"In vitro inhibition of 5-lipoxygenase HETE (5-hydroperoxyeicosatetraenoic acid) in RBL-1 macrophage, a cell-free enzyme assay",B,,,,,
3881,8,,BAO_0000219,Autocuration,,105,"In vitro inhibition of 5-lipoxygenase HETE (5-hydroperoxyeicosatetraenoic acid) in RBL-1 macrophage, a cell-free enzyme assay",B,,,,,
3882,8,,BAO_0000357,Autocuration,,9138,Inhibition of rat neutrophil 5- Lipoxygenase (5-LO),B,,,,,
3883,8,,BAO_0000357,Autocuration,,9138,"Inhibition of rat neutrophil 5- Lipoxygenase (5-LO),",B,,,,,
3884,8,,BAO_0000357,Autocuration,,9138,"Inhibition of rat neutrophil 5- Lipoxygenase (5-LO), (at a concentration of 0.2 nM ),",B,,,,,
3885,8,,BAO_0000357,Autocuration,,14427,5-LO inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography; Not determined,B,,,,,
3886,8,,BAO_0000019,Autocuration,,13329,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE.",B,,,,,
3887,8,,BAO_0000019,Autocuration,,13329,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using LTB4. ",B,,,,,
3888,9,,BAO_0000219,Expert,,14427,Inhibition of 5-lipoxygenase mediated conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cells,B,,,Rattus norvegicus,10116.0,
3889,8,,BAO_0000357,Autocuration,,14427,5-lipoxygenase inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography; Not determined,B,,,,,
3890,8,,BAO_0000357,Autocuration,,14427,5-lipoxygenase inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography.,B,,,,,
3891,8,,BAO_0000219,Expert,,10293,Ability to inhibit 5-lipoxygenase by using a crude preparation of the cytosolic enzyme from the rat basophilic leukemia (RBL-1) cell line,B,,,,,
3892,9,,BAO_0000219,Expert,,338,Inhibition of 5-Lipoxygenase of rat basophilic leukemia cells,B,,,Rattus norvegicus,10116.0,
3893,8,,BAO_0000357,Autocuration,,303,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase),B,,,,,
3894,8,,BAO_0000219,Autocuration,,303,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) in intact RBL-1 cell line assay,B,,,,,
3895,8,,BAO_0000219,Expert,,9247,Inhibition of rat basophilic leukemia-1 (RBL-1) 5-lipoxygenase,B,,,,,
3896,8,,BAO_0000219,Autocuration,,9247,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM; NS = no significant activity,B,,,,,
3897,8,,BAO_0000219,Autocuration,,137,Compound was evaluated in an intact RBL-1 cell line for inhibition of 5-lipoxygenase,B,,,,,
3898,8,,BAO_0000357,Expert,,11481,Evaluated in vitro for its inhibitory activity against 5-lipoxygenase,B,,,,,
3899,8,,BAO_0000357,Expert,,11481,"Evaluated in vitro for its inhibitory activity against 5-lipoxygenase; N=Inactive, <50% inhibition at 10 uM concentration",B,,,,,
3900,8,,BAO_0000357,Expert,,9029,Inhibition of rat polymorphonuclear leukocyte (PMN) 5-Lipoxygenase in vitro,B,,,,,
3901,8,,BAO_0000019,Autocuration,,1701,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells,B,,,,,
3902,8,,BAO_0000019,Autocuration,,1701,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells at concentration of 32 uM; Not active,B,,,,,
3903,8,,BAO_0000019,Autocuration,,1701,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells at concentration of 50 uM; Not active,B,,,,,
3904,8,,BAO_0000019,Autocuration,,1701,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells; No data,B,,,,,
3905,8,,BAO_0000219,Expert,,13358,Inhibition of 5-lipoxygenase by measuring 5-HETE levels in RBL-1 cell-free supernatant,F,,,,,
3906,8,,BAO_0000219,Expert,,1175,Inhibitory activity against 5-lipoxygenase enzyme from RBL-1 cells,B,,,,,
3907,8,,BAO_0000219,Expert,,8797,Ability to inhibit 5-lipoxygenase in rat basophilic leukemia cells.,B,,,,,
3908,8,,BAO_0000019,Autocuration,,8797,Compound was tested for its ability to inhibit 5-lipoxygenase in rat basophilic leukemia cells; No data,B,,,,,
3909,9,,BAO_0000357,Expert,,577,Inhibition of rat basophilic leukemia cell 5-lipoxygenase,B,,,Rattus norvegicus,10116.0,
3910,8,,BAO_0000219,Expert,,9295,In vitro inhibitory activity against RBL-1 5-LO,B,,,,,
3911,8,,BAO_0000219,Autocuration,,9295,Compound was tested for its in vitro inhibitory activity against RBL-1 5-LO (insoluble above 45 uM),B,,,,,
3912,8,,BAO_0000219,Autocuration,,9295,Compound was tested for its in vitro inhibitory activity against RBL-1 5-LO (time dependent),B,,,,,
3913,8,,BAO_0000218,Autocuration,,9295,Compound was tested for its inhibition activity against 5-LO of the whole cell in vitro in rat.,B,,,,,
3914,8,,BAO_0000357,Autocuration,,9295,Compound was tested for its inhibition activity against the 5-LO in isolated enzyme,B,,,,,
3915,8,,BAO_0000218,Autocuration,,216,Compound was tested for its inhibitory activity against 5-lipoxygenase in rat.,B,,,,,
3916,8,,BAO_0000219,Autocuration,,11090,Compound was tested for the inhibition of 5-lipoxygenase (5-LPO) in rat basophilic leukemia (RBL) cells.,B,,,,,
3917,8,,BAO_0000019,Autocuration,178.0,11090,Compound was tested for the inhibition of 5-lipoxygenase (5-Lpo) in rat whole blood.,B,,,,,
3918,8,,BAO_0000357,Expert,,10091,Concentration required for 50 % inhibition of arachidonic acid oxidation by rat 5-lipoxygenase,B,,,,,
3919,8,,BAO_0000019,Autocuration,,10274,Concentration that produces 50% inhibition of A-23187-stimulated radiolabeled 5-HETE and TXB2 synthesis by PMN 5-lipoxygenase.,F,,,,,
3920,8,,BAO_0000219,Autocuration,,13622,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in rat polymorphonuclear leukocytes,F,,,,,
3921,8,,BAO_0000219,Expert,,12118,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined,B,,,,,
3922,8,,BAO_0000357,Expert,,12576,In vitro inhibition of 5-lipoxygenase (5-HETE) derived from the 9000xg supernatant of RBL broken cell assay,B,,,,,
3923,8,,BAO_0000219,Expert,,9546,In vitro inhibition of 5-lipoxygenase from RBL-1 cells,B,,,,,
3924,8,,BAO_0000219,Autocuration,,9521,In vitro inhibition of 5-lipoxygenase in RBL-1 cells,B,,,,,
3925,8,,BAO_0000219,Expert,,10626,In vitro inhibition of 5-lipoxygenase pathway in rat basophilic leukemia (RBL-1) cells,B,,,,,
3926,8,,BAO_0000219,Autocuration,,9225,In vitro inhibition of RBL-1 5-lipoxygenase,B,,,,,
3927,8,,BAO_0000219,Autocuration,,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.18-0.31,B,,,,,
3928,8,,BAO_0000219,Autocuration,,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.3-1.6,B,,,,,
3929,8,,BAO_0000219,Autocuration,,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.4-2.2,B,,,,,
3930,8,,BAO_0000219,Autocuration,,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.72-1.07,B,,,,,
3931,8,,BAO_0000219,Autocuration,,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.9-4.0,B,,,,,
3932,8,,BAO_0000219,Autocuration,,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-1.5,B,,,,,
3933,8,,BAO_0000219,Autocuration,,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-1.7,B,,,,,
3934,8,,BAO_0000219,Autocuration,,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-2.4,B,,,,,
3935,8,,BAO_0000219,Autocuration,,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.07-5.54,B,,,,,
3936,8,,BAO_0000219,Autocuration,,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.1-1.6,B,,,,,
3937,8,,BAO_0000219,Autocuration,,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.3-2.8,B,,,,,
3938,8,,BAO_0000219,Autocuration,,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.4-3.2,B,,,,,
3939,8,,BAO_0000219,Autocuration,,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.7-2.6,B,,,,,
3940,8,,BAO_0000219,Autocuration,,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.8-2.8,B,,,,,
3941,8,,BAO_0000219,Autocuration,,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.8-5.7,B,,,,,
3942,8,,BAO_0000219,Autocuration,,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.9-2.4,B,,,,,
3943,8,,BAO_0000219,Autocuration,,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 2.3-.8,B,,,,,
3944,8,,BAO_0000219,Autocuration,,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 2.46-2.63,B,,,,,
3945,8,,BAO_0000219,Autocuration,,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 3.3-3.5,B,,,,,
3946,8,,BAO_0000219,Autocuration,,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 3.8-7.1,B,,,,,
3947,8,,BAO_0000219,Autocuration,,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 4.0-6.4,B,,,,,
3948,8,,BAO_0000219,Autocuration,,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 4.9-11.6,B,,,,,
3949,8,,BAO_0000219,Autocuration,,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 7.5-11.8,B,,,,,
3950,8,,BAO_0000019,Expert,,9401,In vitro inhibitory activity against 5-lipoxygenase from rat basophilic leukemia cells.,B,,,,,
3951,8,,BAO_0000019,Autocuration,,10325,In vitro inhibitory activity against 5-Lipoxygenase in rat by Peritoneal 5-lipoxygenase assay,B,,,,,
3952,8,,BAO_0000219,Expert,,1556,In vitro inhibition of 5-lipoxygenase in RBL-2H3 (Rat basophilic leukemia) cells.,F,,,,,
3953,8,,BAO_0000219,Expert,,1556,In vitro inhibition of 5-lipoxygenase in RBL-2H3 (Rat basophilic leukemia) cells; Not tested,F,,,,,
3954,9,,BAO_0000219,Expert,,961,Inhibition of 5-lipoxygenase from rat basophilic leukemia(RBL-1) cells,B,,,Rattus norvegicus,10116.0,
3955,8,,BAO_0000019,Autocuration,,6838,In vitro inhibitory activity against 5-lipoxygenase in an RBL-2H3 cell lysate,B,,,,,
3956,8,,BAO_0000019,Expert,,10325,In vitro inhibition of 5-lipoxygenase in rat (peritoneal assay),B,,,,,
3957,9,,BAO_0000219,Expert,,9209,In vitro inhibitory activity against 5-lipoxygenase in rat RBL-1 cells,B,,,Rattus norvegicus,10116.0,
3958,8,,BAO_0000219,Expert,,11520,inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cell line.,B,,,,,
3959,8,,BAO_0000357,Autocuration,,137,In vitro inhibitory activity against 5-lipoxygenase was determined,B,,,,,
3960,8,,BAO_0000219,Autocuration,,4717,In vitro inhibitory concentration against 5-lipoxygenase in RBL-1 cells,B,,,,,
3961,8,,BAO_0000219,Expert,,10636,Inhibition of 5-lipoxygenase in intact RBL-1 cell line,B,,,,,
3962,9,,BAO_0000019,Expert,,14312,Inhibitory activity against 5-lipoxygenase catalysis (5-LO) in sonicated rat basophilic leukemia cell lysate,F,,,Rattus norvegicus,10116.0,
3963,8,,BAO_0000219,Autocuration,,1203,Inhibition of 5-Lipoxygenase (5-LO) in rat basophilic leukemia cells,B,,,,,
3964,8,,BAO_0000019,Autocuration,,1203,Inhibition of 5-Lipoxygenase (5-LO) in rat basophilic leukemic cells,B,,,,,
3965,8,,BAO_0000219,Expert,,13622,Inhibition of 5-lipoxygenase catalysis in rat basophilic leukemia (RBL) cells by measuring 5-HETE product formation,B,,,,,
3966,8,,BAO_0000357,Autocuration,,9793,Inhibition of 5-lipoxygenase from rat peritoneal neutrophils after oral administration,B,,,,,
3967,9,,BAO_0000219,Expert,,1143,Inhibition of 5-lipoxygenase of rat basophilic leukemia (RBL) cell cytosolic enzymes,B,,,Rattus norvegicus,10116.0,
3968,9,,BAO_0000219,Expert,,11854,Inhibition 5-lipoxygenase mediated LTB4 formation in rat basophilic leukemia (RBL-1) cells,B,,,Rattus norvegicus,10116.0,
3969,8,,BAO_0000219,Autocuration,,3595,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),B,,,,,
3970,8,,BAO_0000219,Autocuration,,3595,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1),B,,,,,
3971,9,,BAO_0000219,Expert,,10501,Inhibition of 5-lipoxygenase in rat RBL-1 cells,B,,,Rattus norvegicus,10116.0,
3972,8,,BAO_0000219,Expert,,12526,Inhibition of 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,B,,,,,
3973,8,,BAO_0000019,Autocuration,349.0,10034,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 32 umol/kg,F,,,,,
3974,8,,BAO_0000019,Autocuration,349.0,10034,Compound was tested for its effects on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.10 umol/kg,F,,,,,
3975,8,,BAO_0000019,Autocuration,,10034,Approximate dose levels for a half maximal reduction of 5-HTP levels,F,,,,,
3976,8,,BAO_0000221,Autocuration,10000000.0,10046,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,B,,,,,
3977,8,,BAO_0000221,Autocuration,10000000.0,10046,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,B,,,,,
3978,8,,BAO_0000019,Autocuration,,10046,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand.,B,,,,,
3979,8,,BAO_0000019,Autocuration,178.0,12079,Inhibitory concentration against human platelet 5-lipoxygenase in dog whole blood,F,,,Canis lupus familiaris,9615.0,
3980,8,,BAO_0000019,Autocuration,178.0,12079,Inhibitory concentration against human platelet 5-lipoxygenase in human whole blood,F,,,,,
3981,8,,BAO_0000219,Autocuration,,11311,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat polymorphonuclear leukocytes[PMNS],B,,,,,
3982,8,,BAO_0000219,Expert,,12338,Inhibition of 5-lipoxygenase in bovine polymorphonuclear leukocytes,B,,,,,
3983,8,,BAO_0000219,Expert,,12143,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL).,B,,,,,
3984,8,,BAO_0000219,Autocuration,,12143,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL),B,,,,,
3985,8,,BAO_0000219,Expert,,12143,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL) at 30 uM,B,,,,,
3986,8,,BAO_0000219,Autocuration,,12143,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL) at 30 uM,B,,,,,
3987,8,,BAO_0000357,Expert,,12365,Inhibition of 5-lipoxygenase in bovine PMNL cell assay.,B,,,,,
3988,8,,BAO_0000357,Expert,,13500,Tested for inhibition of 5-lipoxygenase as inhibition of 5-HETE and LTB4 biosynthesis in bovine PMNL,B,,,,,
3989,8,,BAO_0000218,Autocuration,178.0,12832,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,
3990,8,,BAO_0000218,Autocuration,178.0,12832,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,
3991,8,,BAO_0000218,Autocuration,178.0,12832,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,
3992,8,,BAO_0000218,Autocuration,178.0,12832,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,
3993,8,,BAO_0000218,Autocuration,178.0,12832,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,
3994,8,,BAO_0000218,Autocuration,178.0,12832,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,
3995,8,,BAO_0000218,Autocuration,178.0,12832,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,
3996,8,,BAO_0000218,Autocuration,178.0,12832,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,
3997,8,,BAO_0000218,Autocuration,178.0,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,
3998,8,,BAO_0000218,Autocuration,178.0,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,
3999,8,,BAO_0000218,Autocuration,178.0,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 0.3 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,
4000,8,,BAO_0000218,Autocuration,178.0,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,
4001,8,,BAO_0000218,Autocuration,178.0,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 3.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,
4002,8,,BAO_0000218,Autocuration,178.0,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,
4003,8,,BAO_0000218,Autocuration,178.0,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 0.3 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,
4004,8,,BAO_0000218,Autocuration,178.0,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,
4005,8,,BAO_0000218,Autocuration,178.0,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 3.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,
4006,8,,BAO_0000218,Autocuration,178.0,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,
4007,8,,BAO_0000218,Autocuration,178.0,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 0.3 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,
4008,8,,BAO_0000218,Autocuration,178.0,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,
4009,8,,BAO_0000218,Autocuration,178.0,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 3.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,
4010,8,,BAO_0000218,Autocuration,178.0,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,
4011,8,,BAO_0000218,Autocuration,178.0,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 0.3 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,
4012,8,,BAO_0000218,Autocuration,178.0,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,
4013,8,,BAO_0000218,Autocuration,178.0,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 3.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,
4014,8,,BAO_0000218,Autocuration,178.0,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,
4015,8,,BAO_0000218,Autocuration,178.0,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 0.3 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,
4016,8,,BAO_0000218,Autocuration,178.0,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,
4017,8,,BAO_0000218,Autocuration,178.0,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 3.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,
4018,8,,BAO_0000218,Autocuration,178.0,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,
4019,8,,BAO_0000218,Autocuration,178.0,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 0.3 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,
4020,8,,BAO_0000218,Autocuration,178.0,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,
4021,8,,BAO_0000218,Autocuration,178.0,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 3.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,
4022,8,,BAO_0000218,Autocuration,178.0,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,
4023,8,,BAO_0000218,Autocuration,178.0,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 0.3 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,
4024,8,,BAO_0000218,Autocuration,178.0,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,
4025,8,,BAO_0000218,Autocuration,178.0,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 3.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,
4026,8,,BAO_0000218,Autocuration,178.0,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,
4027,8,,BAO_0000218,Autocuration,178.0,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,
4028,8,,BAO_0000218,Autocuration,178.0,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,
4029,8,,BAO_0000218,Autocuration,178.0,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,
4030,8,,BAO_0000218,Autocuration,178.0,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,
4031,8,,BAO_0000218,Autocuration,178.0,12832,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,
4032,8,,BAO_0000218,Autocuration,178.0,12832,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,
4033,8,,BAO_0000218,Autocuration,178.0,12832,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,
4034,8,,BAO_0000218,Autocuration,178.0,12832,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,
4035,8,,BAO_0000218,Autocuration,,3595,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 24 hr r,B,,,Canis lupus familiaris,9615.0,
4036,8,,BAO_0000218,Autocuration,,3595,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 24 hr r to canine,B,,,Canis lupus familiaris,9615.0,
4037,8,,BAO_0000218,Autocuration,,3595,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 2 hr,B,,,Canis lupus familiaris,9615.0,
4038,8,,BAO_0000218,Autocuration,,3595,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 2 hr to canine,B,,,Canis lupus familiaris,9615.0,
4039,8,,BAO_0000218,Autocuration,,3595,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 4 hr,B,,,Canis lupus familiaris,9615.0,
4040,8,,BAO_0000218,Autocuration,,3595,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 4 hr to canine,B,,,Canis lupus familiaris,9615.0,
4041,8,,BAO_0000218,Autocuration,,3595,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 8 hr,B,,,Canis lupus familiaris,9615.0,
4042,8,,BAO_0000218,Autocuration,,3595,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 8 hr to canine,B,,,Canis lupus familiaris,9615.0,
4043,8,,BAO_0000357,Autocuration,,9203,Ability to inhibit 5-lipoxygenase in guinea pig,B,,,Cavia porcellus,10141.0,
4044,8,,BAO_0000357,Expert,,82,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-lipoxygenase in vitro (guinea pig PMN),B,,,Cavia porcellus,10141.0,
4045,8,,BAO_0000357,Autocuration,,11090,Compound was tested for the inhibition of 5-lipoxygenase (5-Lpo) in guinea pig.,B,,,Cavia porcellus,10141.0,
4046,8,,BAO_0000218,Autocuration,178.0,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 12 h, following intravenous administration at the dose of 1.0 mg/kg",B,,,Cavia porcellus,10141.0,
4047,8,,BAO_0000357,Autocuration,,1065,In vitro 5-lipoxygenase inhibition in guinea pig PMNs was determined based on 5-hydroxyeicosapentaenoic acid (5-HETE) production,B,,,Cavia porcellus,10141.0,
4048,8,,BAO_0000357,Autocuration,,1065,In vitro 5-lipoxygenase inhibition in guinea pig PMNs was determined based on LTB4 production,B,,,Cavia porcellus,10141.0,
4049,8,,BAO_0000019,Expert,,12832,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]-AA to 5-HETE in guinea pig peritoneal polymorphonuclear leukocytes,B,,,Cavia porcellus,10141.0,
4050,8,,BAO_0000019,Expert,,12832,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]AA to LTB4 in guinea pig peritoneal polymorphonuclear leukocytes,B,,,Cavia porcellus,10141.0,
4051,8,,BAO_0000019,Autocuration,,12832,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]AA to LTB4 in guinea pig peritoneal polymorphonuclear leukocytes,B,,,Cavia porcellus,10141.0,
4052,8,,BAO_0000019,Autocuration,,10504,Inhibition against 5-lipoxygenase from guinea pig polymorphonuclear lymphocytes,B,,,Cavia porcellus,10141.0,
4053,8,,BAO_0000357,Autocuration,,7788,Inhibitory activity against 5-lipoxygenase,B,,,Cavia porcellus,10141.0,
4054,8,,BAO_0000357,Autocuration,,10001,Inhibitory activity against 5-lipoxygenase in guinea pig leukocyte,B,,,Cavia porcellus,10141.0,
4055,8,,BAO_0000357,Autocuration,,10193,Inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant,B,,,Cavia porcellus,10141.0,
4056,8,,BAO_0000357,Autocuration,,13243,Inhibitory activity against partially-purified Guinea pig PMN 5-lipoxygenase,B,,,Cavia porcellus,10141.0,
4057,8,,BAO_0000357,Autocuration,,13243,Inhibitory activity uM,B,,,Cavia porcellus,10141.0,
4058,8,,BAO_0000219,Autocuration,,969,Inhibitory activity against 5-lipoxygenase in guinea pig leukocytes was determined,B,,,Cavia porcellus,10141.0,
4059,8,,BAO_0000357,Autocuration,,10001,Inhibitory activity against 5-lipoxygenase at 10 uM,B,,,Cavia porcellus,10141.0,
4060,8,,BAO_0000357,Autocuration,,7788,Inhibitory activity against 5-lipoxygenase at a dose of 0.1 mM,B,,,Cavia porcellus,10141.0,
4061,8,,BAO_0000357,Autocuration,,10001,Inhibitory activity against 5-lipoxygenase in guinea pig leukocyte at 30 uM,B,,,Cavia porcellus,10141.0,
4062,8,,BAO_0000357,Autocuration,,10193,Inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant at 10 uM,B,,,Cavia porcellus,10141.0,
4063,8,,BAO_0000357,Autocuration,,13243,Inhibitory activity uM,B,,,Cavia porcellus,10141.0,
4064,8,,BAO_0000357,Autocuration,,13243,Inhibitory activity against partially-purified Guinea pig PMN 5-lipoxygenase at 10 uM,B,,,Cavia porcellus,10141.0,
4065,8,,BAO_0000357,Expert,,13243,Inhibitory activity uM,B,,,Cavia porcellus,10141.0,
4066,8,,BAO_0000019,Autocuration,,13243,Inhibitory activity uM,F,,,Cavia porcellus,10141.0,
4067,8,,BAO_0000019,Autocuration,,10504,Percent inhibition against 5-lipoxygenase from guinea pig polymorphonuclear lymphocytes,B,,,Cavia porcellus,10141.0,
4068,8,,BAO_0000357,Autocuration,,7788,Inhibitory activity against 5-lipoxygenase at a dose of 0.1 mM,B,,,Cavia porcellus,10141.0,
4069,8,,BAO_0000221,Expert,2116.0,10546,Evaluated for inhibition of the formation and release of 5-lipoxygenase in isolated guinea pig ileum,F,,,Cavia porcellus,10141.0,
4070,8,,BAO_0000357,Autocuration,,13183,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),B,,,,,
4071,8,,BAO_0000357,Autocuration,,13183,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),B,,,,,
4072,8,,BAO_0000357,Autocuration,,2578,Compound was evaluated for in vitro inhibition of recombinant human 5-lipoxygenase (5-LO),B,,,,,
4073,8,,BAO_0000357,Expert,,12780,In vitro inhibition of human 5-Lipoxygenase.,B,,,,,
4074,0,,BAO_0000251,Autocuration,2107.0,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 75 uM,B,,,Rattus norvegicus,10116.0,
4075,0,,BAO_0000251,Autocuration,2107.0,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1 uM,B,,,Rattus norvegicus,10116.0,
4076,0,,BAO_0000251,Autocuration,2107.0,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM,B,,,Rattus norvegicus,10116.0,
4077,0,,BAO_0000251,Autocuration,2107.0,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM exposed 100 uM,B,,,Rattus norvegicus,10116.0,
4078,0,,BAO_0000251,Autocuration,2107.0,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 100 uM,B,,,Rattus norvegicus,10116.0,
4079,0,,BAO_0000251,Autocuration,2107.0,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,B,,,Rattus norvegicus,10116.0,
4080,0,,BAO_0000251,Autocuration,2107.0,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,B,,,Rattus norvegicus,10116.0,
4081,0,,BAO_0000251,Autocuration,2107.0,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 150 uM,B,,,Rattus norvegicus,10116.0,
4082,0,,BAO_0000251,Autocuration,2107.0,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1500 uM,B,,,Rattus norvegicus,10116.0,
4083,0,,BAO_0000251,Autocuration,2107.0,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 2.5 uM,B,,,Rattus norvegicus,10116.0,
4084,0,,BAO_0000251,Autocuration,2107.0,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 200 uM,B,,,Rattus norvegicus,10116.0,
4085,0,,BAO_0000251,Autocuration,2107.0,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 27.5 uM,B,,,Rattus norvegicus,10116.0,
4086,0,,BAO_0000251,Autocuration,2107.0,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 5 uM,B,,,Rattus norvegicus,10116.0,
4087,0,,BAO_0000251,Autocuration,2107.0,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,B,,,Rattus norvegicus,10116.0,
4088,0,,BAO_0000251,Autocuration,2107.0,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 500 uM,B,,,Rattus norvegicus,10116.0,
4089,0,,BAO_0000251,Autocuration,2107.0,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to exposed to 3-methylcholanthrene at concentration of 200 uM,B,,,Rattus norvegicus,10116.0,
4090,0,,BAO_0000251,Autocuration,2107.0,7411,"Compound was evaluated for inhibition constant, in liver microsomes from 3-methylcholanthrene-exposed rats",B,,,Rattus norvegicus,10116.0,
4091,0,,BAO_0000251,Autocuration,2107.0,7411,"Compound was evaluated for inhibition constant, in liver microsomes from beta-naphthoflavone-exposed rats",B,,,Rattus norvegicus,10116.0,
4092,0,,BAO_0000251,Autocuration,2107.0,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 100 uM,B,,,Rattus norvegicus,10116.0,
4093,0,,BAO_0000251,Autocuration,2107.0,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 200 uM,B,,,Rattus norvegicus,10116.0,
4094,0,,BAO_0000251,Autocuration,2107.0,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 50 uM,B,,,Rattus norvegicus,10116.0,
4095,0,,BAO_0000251,Autocuration,2107.0,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at 5 uM,B,,,Rattus norvegicus,10116.0,
4096,0,,BAO_0000251,Autocuration,2107.0,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at 50 uM,B,,,Rattus norvegicus,10116.0,
4097,0,,BAO_0000251,Autocuration,2107.0,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 10 uM,B,,,Rattus norvegicus,10116.0,
4098,0,,BAO_0000251,Autocuration,2107.0,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 100 uM,B,,,Rattus norvegicus,10116.0,
4099,0,,BAO_0000251,Autocuration,2107.0,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 1 uM,B,,,Rattus norvegicus,10116.0,
4100,0,,BAO_0000251,Autocuration,2107.0,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 20 uM,B,,,Rattus norvegicus,10116.0,
4101,0,,BAO_0000251,Autocuration,2107.0,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 200 uM,B,,,Rattus norvegicus,10116.0,
4102,0,,BAO_0000251,Autocuration,2107.0,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 25 uM,B,,,Rattus norvegicus,10116.0,
4103,0,,BAO_0000251,Autocuration,2107.0,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 50 uM,B,,,Rattus norvegicus,10116.0,
4104,0,,BAO_0000251,Autocuration,2107.0,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 75 uM,B,,,Rattus norvegicus,10116.0,
4105,0,,BAO_0000251,Autocuration,2107.0,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1 uM,B,,,Rattus norvegicus,10116.0,
4106,0,,BAO_0000251,Autocuration,2107.0,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM,B,,,Rattus norvegicus,10116.0,
4107,0,,BAO_0000251,Autocuration,2107.0,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 100 uM,B,,,Rattus norvegicus,10116.0,
4108,0,,BAO_0000251,Autocuration,2107.0,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,B,,,Rattus norvegicus,10116.0,
4109,0,,BAO_0000251,Autocuration,2107.0,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 150 uM,B,,,Rattus norvegicus,10116.0,
4110,0,,BAO_0000251,Autocuration,2107.0,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1500 uM,B,,,Rattus norvegicus,10116.0,
4111,0,,BAO_0000251,Autocuration,2107.0,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 2.5 uM,B,,,Rattus norvegicus,10116.0,
4112,0,,BAO_0000251,Autocuration,2107.0,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 200 uM,B,,,Rattus norvegicus,10116.0,
4113,0,,BAO_0000251,Autocuration,2107.0,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 5 uM,B,,,Rattus norvegicus,10116.0,
4114,0,,BAO_0000251,Autocuration,2107.0,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,B,,,Rattus norvegicus,10116.0,
4115,0,,BAO_0000251,Autocuration,2107.0,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 500 uM,B,,,Rattus norvegicus,10116.0,
4116,0,,BAO_0000251,Autocuration,2107.0,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 1000 uM,B,,,Rattus norvegicus,10116.0,
4117,0,,BAO_0000251,Autocuration,2107.0,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 1500 uM,B,,,Rattus norvegicus,10116.0,
4118,0,,BAO_0000251,Autocuration,2107.0,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 27.5 uM,B,,,Rattus norvegicus,10116.0,
4119,0,,BAO_0000251,Autocuration,2107.0,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 500 uM,B,,,Rattus norvegicus,10116.0,
4120,0,,BAO_0000251,Autocuration,2107.0,7411,Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,B,,,Rattus norvegicus,10116.0,
4121,0,,BAO_0000251,Autocuration,,7411,Vmax determined by 7-ethoxycoumarin deethylation in the presence by liver microsomes from rats exposed to 3-methylcholanthrene at concentration of 10 uM,B,,,Rattus norvegicus,10116.0,
4122,0,,BAO_0000251,Autocuration,2107.0,7411,"Compound was evaluated for alpha -rate constant, in liver microsomes from 3-methylcholanthrene-exposed rats",B,,,Rattus norvegicus,10116.0,
4123,0,,BAO_0000251,Autocuration,2107.0,7411,"Compound was evaluated for alpha -rate constant, in liver microsomes from beta-naphthoflavone-exposed rats",B,,,Rattus norvegicus,10116.0,
4124,0,,BAO_0000251,Autocuration,2107.0,7411,"Compound was evaluated for alpha -rate constant, in liver microsomes from beta-naphthoflavone-exposed rats; competitive inhibition",B,,,Rattus norvegicus,10116.0,
4125,0,,BAO_0000251,Autocuration,2107.0,7411,"Compound was evaluated for alpha inhibition constant, in liver microsomes from 3-methylcholanthrene-exposed rats",B,,,Rattus norvegicus,10116.0,
4126,0,,BAO_0000251,Autocuration,2107.0,7411,"Compound was evaluated for alpha inhibition constant, in liver microsomes from beta-naphthoflavone-exposed rats",B,,,Rattus norvegicus,10116.0,
4127,1,,BAO_0000219,Intermediate,,10797,In vitro inhibition of 7226/S myeloma cancer cell line,F,,,Homo sapiens,9606.0,
4128,1,,BAO_0000219,Intermediate,,6881,In vitro antitumor activity of compound against 7404 cell line (human liver carcinoma cells),F,,,Homo sapiens,9606.0,
4129,1,,BAO_0000219,Intermediate,,3838,In vitro growth inhibition of compound was determined against 768-0 cell lines of Renal cancer,F,,,Homo sapiens,9606.0,
4130,1,,BAO_0000219,Intermediate,,3838,In vitro growth inhibition of compound was determined against 768-0 cell lines of Renal cancer,F,,,Homo sapiens,9606.0,
4131,1,,BAO_0000219,Expert,,12981,Net accumulation of the [99mTc]Isonitrile complex was measured in 77A cell lines in the presence of Verapamil.,F,,,Cricetulus griseus,10029.0,
4132,1,,BAO_0000219,Expert,,12981,Verapamil index represents the ratio of net uptake in the presense of verapamil over control in 77A cell lines.,F,,,Cricetulus griseus,10029.0,
4133,1,,BAO_0000219,Intermediate,,7653,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 10 ug/mL dose,F,,,Rattus norvegicus,10116.0,
4134,1,,BAO_0000219,Intermediate,,7653,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 2 ug/mL dose,F,,,Rattus norvegicus,10116.0,
4135,1,,BAO_0000219,Intermediate,,7653,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 20 ug/mL dose,F,,,Rattus norvegicus,10116.0,
4136,1,,BAO_0000219,Intermediate,,7653,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 5 ug/mL dose,F,,,Rattus norvegicus,10116.0,
4137,1,,BAO_0000219,Intermediate,,7653,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 50 ug/mL dose,F,,,Rattus norvegicus,10116.0,
4138,1,,BAO_0000219,Intermediate,,7653,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 75 ug/mL dose,F,,,Rattus norvegicus,10116.0,
4139,1,,BAO_0000219,Intermediate,,17229,In vitro antitumor activity against renal 786-0 tumor cell lines,F,,,Homo sapiens,9606.0,
4140,1,,BAO_0000219,Intermediate,,12858,Cytotoxic activity against 786-0 Renal cancer cell line,F,,,Homo sapiens,9606.0,
4141,1,,BAO_0000219,Intermediate,,16325,Growth inhibitory activity was determined against 786-0 cancer cell line of Renal cancer,F,,,Homo sapiens,9606.0,
4142,1,,BAO_0000219,Intermediate,,16325,Growth inhibitory activity was determined against 786-0 cancer cell line of renal cancer,F,,,Homo sapiens,9606.0,
4143,1,,BAO_0000219,Intermediate,,5858,In vitro antitumor activity against human renal 786-0 cell line,F,,,Homo sapiens,9606.0,
4144,1,,BAO_0000219,Intermediate,,16325,Inhibition of Renal cancer in 786-0 cancer cell lines,F,,,Homo sapiens,9606.0,
4145,1,,BAO_0000219,Intermediate,,14696,Inhibition of the growth of renal cancer(786-0) cell line. value in parentheses is percent inhibition at 0.01 uM,F,,,Homo sapiens,9606.0,
4146,1,,BAO_0000219,Intermediate,,3786,The compound was tested for its cytotoxic activity against the following renal cancer cell lines 786-0,F,,,Homo sapiens,9606.0,
4147,1,,BAO_0000219,Intermediate,,14696,inhibition of the growth of renal cancer(786-0) cell line,F,,,Homo sapiens,9606.0,
4148,1,,BAO_0000219,Intermediate,,14769,Compound was evaluated for in vitro activity against 786-0 kidney cell lines (Human tumor cells ),F,,,Homo sapiens,9606.0,
4149,1,,BAO_0000219,Intermediate,,15354,Compound was tested for the growth inhibition of 786-0 renal tumor cell line,F,,,Homo sapiens,9606.0,
4150,1,,BAO_0000219,Intermediate,,14255,The IC50 value was measured on 786-0 cell line in ovarian tumor,F,,,Homo sapiens,9606.0,
4151,1,,BAO_0000219,Intermediate,,14255,The IC50 value was measured on 786-0 cell line in ovarian tumor t,F,,,Homo sapiens,9606.0,
4152,1,,BAO_0000219,Intermediate,,14255,The IC50 value was measured on 786-0 cell line in renal tumor type.,F,,,Homo sapiens,9606.0,
4153,1,,BAO_0000219,Intermediate,,14696,Inhibition of the growth of renal cancer(786-0) cell line at 0.01 uM,F,,,Homo sapiens,9606.0,
4154,1,,BAO_0000219,Intermediate,,12016,Tested for cytotoxic activity against renal cancer 786-0 cell line,F,,,Homo sapiens,9606.0,
4155,1,,BAO_0000219,Intermediate,,2597,Compound was tested for growth inhibitory activity against 786-0 cell line,F,,,Homo sapiens,9606.0,
4156,8,,BAO_0000219,Autocuration,,12526,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187; Inactive(N)= <50% inhibition at 10 uM,B,,,,,
4157,8,,BAO_0000219,Autocuration,,12526,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187; N=Inactive,B,,,,,
4158,8,,BAO_0000019,Autocuration,,14799,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells,B,,,,,
4159,8,,BAO_0000219,Expert,,3595,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),B,,,,,
4160,8,,BAO_0000219,Expert,,3595,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1),B,,,,,
4161,8,,BAO_0000357,Autocuration,,12767,Inhibitory activity against rat basophilic leukemia 5-lipoxygenase,B,,,,,
4162,8,,BAO_0000219,Autocuration,,10997,Inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes,B,,,,,
4163,8,,BAO_0000219,Autocuration,,11388,Inhibitory activity against 5-lipoxygenase of RBL-1 cell line,B,,,,,
4164,8,,BAO_0000357,Autocuration,,167,Inhibitory activity against RBL broken cell-supematant 5-lipoxygenase was evaluated,B,,,,,
4165,8,,BAO_0000357,Autocuration,,167,"Inhibitory activity against intact rat PMNL, LTB4 5-lipoxygenase was evaluated",B,,,,,
4166,8,,BAO_0000357,Expert,,13744,Inhibitory activity against rat 5-lipoxygenase by using continuous oxygen consumption assay.,B,,,,,
4167,8,,BAO_0000357,Autocuration,,1630,Inhibitory activity against rat basophilic leukemia cell 5-lipoxygenase,B,,,,,
4168,8,,BAO_0000357,Autocuration,,1630,Inhibitory activity against rat basophilic leukemia cell 5-lipoxygenase (5-LO),B,,,,,
4169,9,,BAO_0000019,Expert,,969,"Inhibitory activity against 5-lipoxygenase in rat neutrophils as inhibition of A 23,187-induced LTB4 production",B,,,Rattus norvegicus,10116.0,
4170,8,,BAO_0000219,Autocuration,,13621,Inhibitory concentration against 5-lipoxygenase in rat RBL-1 cells,B,,,,,
4171,8,,BAO_0000357,Autocuration,,10089,Inhibitory concentration to inhibit 5-lipoxygenase in the rat,B,,,,,
4172,8,,BAO_0000357,Expert,,10193,In vitro inhibition of rat polymorphonuclear leukocyte 5-lipoxygenase,B,,,,,
4173,8,,BAO_0000357,Autocuration,,11966,Tested for inhibition of 5-HPETE production by rat 5-LO; value ranges from 16-36 nM,B,,,,,
4174,8,,BAO_0000019,Autocuration,,12251,Tested for inhibition of 5-LO by measuring the reduction of leukotriene B4 (LTB4) in intact basophilic rat leukemia cells,B,,,,,
4175,8,,BAO_0000219,Autocuration,,211,Tested for inhibition of 5-Lipoxygenase (ARBL) in calcium-stimulated rat basophilic leukemia cells(RBL-1),B,,,,,
4176,8,,BAO_0000019,Expert,,12251,Inhibition of 5-lipoxygenase measured by the reduction of leukotriene B4 (LTB4) in intact basophilic rat leukemia cells,F,,,,,
4177,8,,BAO_0000219,Autocuration,,12495,Tested for inhibitory activity against 5-lipoxygenase in microsome of RBL-1 cells,B,,,,,
4178,8,,BAO_0000357,Autocuration,,414,Tested for its inhibitory activity against 5-lipoxygenase,B,,,,,
4179,8,,BAO_0000357,Autocuration,,414,Tested for its inhibitory activity against 5-lipoxygenase; Not determined,B,,,,,
4180,8,,BAO_0000019,Expert,,10325,"Iin vitro inhibition of 5-lipoxygenase activity in rat basophil leukemia type 1(RBL1) cell homogenates, (reduction of [14C]-5-HETE formation)",B,,,,,
4181,8,,BAO_0000019,Expert,,11966,In vitro test for inhibition of 5-lipoxygenase in cell-free preparations from rat PMN leukocytes,B,,,,,
4182,8,,BAO_0000219,Expert,,165,In vitro inhibition of 5-lipoxygenase activity in RBL-1 cells.,B,,,,,
4183,8,,BAO_0000219,Autocuration,,165,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells; No significant inhibitory activity up to 30 uM,B,,,,,
4184,8,,BAO_0000219,Autocuration,,165,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells.,B,,,,,
4185,8,,BAO_0000219,Expert,,165,In vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells.,B,,,,,
4186,8,,BAO_0000218,Autocuration,,11311,The compound was tested for inhibitory activity against 5-lipoxygenase in mouse,B,,,,,
4187,8,,BAO_0000219,Autocuration,,11311,The compound was tested for inhibitory activity against 5-lipoxygenase in rat RBL-1,B,,,,,
4188,8,,BAO_0000219,Autocuration,,11311,The compound was tested for inhibitory activity against 5-lipoxygenase in rat RBL-1 cells,B,,,,,
4189,8,,BAO_0000219,Autocuration,,11311,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS],B,,,,,
4190,8,,BAO_0000219,Autocuration,,11311,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] (in vitro),B,,,,,
4191,8,,BAO_0000218,Autocuration,,11311,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] (in vivo),B,In vivo,,,,
4192,8,,BAO_0000219,Autocuration,,11311,The compound was tested for inhibitory activity against 5-lipoxygenase translocation inhibitor in RBL-2H3 cells,F,,,,,
4193,8,,BAO_0000219,Autocuration,,11311,The compound was tested for inhibitory activity against 5-lipoxygenase translocation inhibitor in rat RBL-2H3 cells,F,,,,,
4194,8,,BAO_0000019,Autocuration,,11311,The compound was tested for inhibitory activity against 5-lipoxygenase using rat polymorphonuclear leukocytes[PMNS],B,,,,,
4195,8,,BAO_0000019,Autocuration,,11732,The compound was tested for its inhibitory activity against arachidonic acid in rat 5-lipoxygenase,B,,,,,
4196,8,,BAO_0000019,Expert,,11732,Tested for its inhibitory activity against arachidonic acid in rat 5-lipoxygenase.,B,,,,,
4197,8,,BAO_0000019,Expert,,11087,In vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells,B,,,,,
4198,8,,BAO_0000019,Autocuration,,11087,The compound was tested for the in vitro inhibition of 5-lipoxygenase from the 20000 g supernatant of RBI-1 cells,B,,,,,
4199,8,,BAO_0000219,Autocuration,,11087,The compound was tested for the inhibition of 5-lipoxygenase (5-lo) in homogenized rat basophilic leukemia (RBL-1) cells,B,,,,,
4200,9,,BAO_0000357,Expert,,11087,Inhibition of 5-lipoxygenase (5-lo) in intact rat polymorphonuclear leukocyte RPMNL,B,,,Rattus norvegicus,10116.0,
4201,8,,BAO_0000219,Autocuration,,496,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells,B,,,,,
4202,8,,BAO_0000219,Expert,,13986,Inhibition of 5-lipoxygenase on rat basophil leukemia cell line lysate (RBL-1 2H3 subline) by measuring 5-HETE production,F,,,,,
4203,8,,BAO_0000357,Autocuration,,11520,Compound was evaluated for the inhibition of 5-lipoxygenase,B,,,,,
4204,8,,BAO_0000219,Autocuration,,10293,Ability to inhibit 5-lipoxygenase by using a crude preparation of the cytosolic enzyme from the rat basophilic leukemia (RBL-1) cell line at a concentration of 25 uM,B,,,,,
4205,8,,BAO_0000219,Autocuration,,303,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) at 10 uM concentration in intact RBL-1 cell line assay,B,,,,,
4206,8,,BAO_0000219,Autocuration,,303,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) at 10 uM concentration in intact RBL-1 cell line assay; Less than 5% inhibition at 10 uM reported as not active,B,,,,,
4207,8,,BAO_0000219,Autocuration,,9247,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 10 uM,B,,,,,
4208,9,,BAO_0000219,Expert,,9247,Inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM,B,,,Rattus norvegicus,10116.0,
4209,8,,BAO_0000219,Autocuration,,9247,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM; NS = no significant activity,B,,,,,
4210,8,,BAO_0000219,Autocuration,,9247,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 30 uM,B,,,,,
4211,8,,BAO_0000219,Autocuration,,9247,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 300 uM,B,,,,,
4212,8,,BAO_0000219,Autocuration,,9247,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 33 uM,B,,,,,
4213,8,,BAO_0000219,Autocuration,,9247,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 40 uM,B,,,,,
4214,8,,BAO_0000219,Autocuration,,9247,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 75 uM,B,,,,,
4215,9,,BAO_0000357,Expert,,11481,Inhibitory activity against 5-lipoxygenase at 10 uM,B,,,Rattus norvegicus,10116.0,
4216,8,,BAO_0000357,Autocuration,,105,In vitro inhibition of 5-lipoxygenase; NS means no significant inhibition,B,,,,,
4217,8,,BAO_0000357,Expert,,9029,In vitro inhibition of rat polymorphonuclear leukocyte (PMN) 5-Lipoxygenase at 10 uM,B,,,,,
4218,8,,BAO_0000219,Expert,,1175,Inhibitory activity against 5-lipoxygenase enzyme from RBL-1 cells at 20 uM,B,,,,,
4219,8,,BAO_0000219,Autocuration,,12118,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined at 100 uM,B,,,,,
4220,8,,BAO_0000219,Autocuration,,12118,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined at 10e-4 M,B,,,,,
4221,8,,BAO_0000219,Autocuration,,12118,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determinedb at 100 uM,B,,,,,
4222,8,,BAO_0000219,Autocuration,,9225,In vitro inhibition of RBL-1 5-lipoxygenase at 20 uM,B,,,,,
4223,8,,BAO_0000019,Autocuration,,9401,In vitro inhibitory activity against 5-Lipoxygenase from rat basophilic leukemia cells at 30 uM concentration,B,,,,,
4224,8,,BAO_0000357,Autocuration,,137,In vitro inhibitory activity against 5-lipoxygenase was determined at 16 uM,B,,,,,
4225,8,,BAO_0000357,Autocuration,,137,In vitro inhibitory activity against 5-lipoxygenase was determined at 16 uM,B,,,,,
4226,8,,BAO_0000219,Autocuration,,4717,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 10 uM concentration,B,,,,,
4227,8,,BAO_0000219,Autocuration,,3595,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1) at 10 uM,B,,,,,
4228,8,,BAO_0000219,Autocuration,,10501,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at 40 uM concentration,B,,,,,
4229,8,,BAO_0000219,Autocuration,,10501,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at a concentration 40 uM,B,,,,,
4230,8,,BAO_0000219,Autocuration,,10501,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at a concentration 40 uM.,B,,,,,
4231,8,,BAO_0000219,Autocuration,,12526,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,B,,,,,
4232,9,,BAO_0000219,Expert,,14799,Inhibition of 5-lipoxygenase of rat basophilic leukemia cells at 30 uM,B,,,Rattus norvegicus,10116.0,
4233,8,,BAO_0000019,Autocuration,,14799,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells at 30 uM concentration; NT=Not tested,B,,,,,
4234,8,,BAO_0000219,Autocuration,,3595,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1) at 10 uM,B,,,,,
4235,8,,BAO_0000219,Expert,,3595,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1)at 10 uM,B,,,,,
4236,8,,BAO_0000219,Autocuration,,12526,Inhibitory activity at 10 uM against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,B,,,,,
4237,8,,BAO_0000219,Autocuration,,12526,Inhibitory activity at 1 uM against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,B,,,,,
4238,8,,BAO_0000019,Autocuration,,10193,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 1 uM,B,,,,,
4239,8,,BAO_0000019,Autocuration,,10193,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 10 uM,B,,,,,
4240,8,,BAO_0000019,Autocuration,,10193,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 1 uM,B,,,,,
4241,8,,BAO_0000019,Autocuration,,10193,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 3 uM,B,,,,,
4242,8,,BAO_0000357,Expert,,9138,Percent inhibition of rat neutrophil 5-lipoxygenase (5-LO),B,,,,,
4243,8,,BAO_0000357,Autocuration,,9138,Percent inhibition of rat neutrophil 5- Lipoxygenase (5-LO) at 100 uM,B,,,,,
4244,8,,BAO_0000019,Autocuration,,11966,Tested in vitro for the inhibition of 5-lipoxygenase in cell-free preparations from rat PMN leukocytes,B,,,,,
4245,8,,BAO_0000219,Autocuration,,165,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 100 uM,B,,,,,
4246,8,,BAO_0000219,Autocuration,,165,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 30 uM,B,,,,,
4247,8,,BAO_0000219,Autocuration,,11311,The compound was tested for inhibition of 5-lipoxygenase in rat RBL-2H3 cells,B,,,,,
4248,8,,BAO_0000219,Autocuration,,11311,The compound was tested for inhibition of 5-lipoxygenase translocation in SAR in rat RBL-2H3 cells,B,,,,,
4249,8,,BAO_0000219,Autocuration,,11311,The compound was tested for inhibition of 5-lipoxygenase translocation in SAR in rat RBL-2H3 cells,F,,,,,
4250,8,,BAO_0000019,Autocuration,,11311,The compound was tested for inhibition of LTB4 synthesis on isolated 5-lipoxygenase,F,,,,,
4251,8,,BAO_0000357,Autocuration,,11311,The compound was tested for inhibition of isolated 5-lipoxygenase,B,,,,,
4252,8,,BAO_0000219,Autocuration,,11311,The compound was tested for inhibition of isolated 5-lipoxygenase translocation into rat RBL-2H3 cells,F,,,,,
4253,8,,BAO_0000019,Autocuration,,11087,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells at a concentration of 30 uM,B,,,,,
4254,8,,BAO_0000019,Autocuration,,11087,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells at a concentration of 32 uM,B,,,,,
4255,8,,BAO_0000019,Autocuration,,11087,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells measured at a concentration of 30 uM,B,,,,,
4256,8,,BAO_0000019,Autocuration,,11087,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells; NS indicates nonsignificant inhibition at 32 uM concentration,B,,,,,
4257,8,,BAO_0000019,Autocuration,,11087,The compound was tested for the in vitro inhibition of 5-lipoxygenase from the 20000 g supernatant of RBI-1 cells; NS indicates nonsignificant inhibition at 32 uM concentration,B,,,,,
4258,8,,BAO_0000219,Autocuration,,496,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells at 1.0 uM,B,,,,,
4259,8,,BAO_0000219,Autocuration,,496,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells at 10 uM,B,,,,,
4260,8,,BAO_0000219,Autocuration,,13986,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.1 uM,F,,,,,
4261,8,,BAO_0000219,Autocuration,,13986,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.195 uM,F,,,,,
4262,8,,BAO_0000219,Autocuration,,13986,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.2 at uM,F,,,,,
4263,8,,BAO_0000219,Autocuration,,13986,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.25 uM,F,,,,,
4264,8,,BAO_0000219,Autocuration,,13986,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.39,F,,,,,
4265,8,,BAO_0000219,Autocuration,,13986,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.39 uM,F,,,,,
4266,8,,BAO_0000219,Autocuration,,13986,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.195 uM,F,,,,,
4267,8,,BAO_0000219,Autocuration,,13986,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.2 uM,F,,,,,
4268,8,,BAO_0000219,Autocuration,,13986,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.39 uM,F,,,,,
4269,9,,BAO_0000019,Expert,,13986,Inhibition of 5-lipoxygenase on rat basophil leukemia cell (RBL-2H3) lysate as 5-HETE production at 32 uM,F,,,Rattus norvegicus,10116.0,
4270,8,,BAO_0000357,Autocuration,,10193,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase,B,,,,,
4271,8,,BAO_0000357,Autocuration,,9295,Compound was tested for the percent of inhibition against 5-LO at 10 uM,B,,,,,
4272,8,,BAO_0000219,Autocuration,,4717,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 1 uM concentration,B,,,,,
4273,8,,BAO_0000219,Autocuration,,4717,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 10 uM concentration,B,,,,,
4274,8,,BAO_0000219,Autocuration,,11854,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line,B,,,,,
4275,8,,BAO_0000219,Autocuration,,11854,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line at 10 uM,B,,,,,
4276,8,,BAO_0000219,Autocuration,,11854,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line at 16 uM,B,,,,,
4277,8,,BAO_0000019,Autocuration,,10193,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 10 uM,B,,,,,
4278,8,,BAO_0000219,Autocuration,,9295,Percent inhibition against RBL-1 5-LO in vitro at 10 uM,B,,,,,
4279,8,,BAO_0000219,Autocuration,,9295,Percent inhibition against RBL-1 5-LO in vitro at 100 uM,B,,,,,
4280,8,,BAO_0000219,Autocuration,,9295,Percent inhibition against RBL-1 5-LO in vitro at 30 uM,B,,,,,
4281,8,,BAO_0000219,Autocuration,,9295,Percent inhibition against RBL-1 5-LO in vitro at 300 uM,B,,,,,
4282,8,,BAO_0000219,Autocuration,,165,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 20 uM,B,,,,,
4283,8,,BAO_0000219,Autocuration,,11311,The compound was tested for inhibition against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] at 10 uM concentration,B,,,,,
4284,8,,BAO_0000219,Expert,,10489,In vitro inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells(RBL-1),B,,,Homo sapiens,9606.0,
4285,9,,BAO_0000219,Expert,,10489,In vitro inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells(RBL-1),B,,,Rattus norvegicus,10116.0,
4286,9,,BAO_0000219,Expert,,10489,Logarithmic value of inhibitory concentration against 5-lipoxygenase in rat basophilic leukemia cells (RBL-1),B,,,Rattus norvegicus,10116.0,
4287,9,,BAO_0000019,Autocuration,,14799,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells,B,,,Rattus norvegicus,10116.0,
4288,8,,BAO_0000357,Autocuration,,9295,Compound was tested for the percent of inhibition against soybean 15-LO (at 100 uM),B,,,Glycine max,3847.0,
4289,0,,BAO_0000019,Autocuration,,16811,"Inhibitory activity against 5-lipoxygenase, by using soybean lipoxygenase spectrophotometric assay",B,,,,,
4290,8,,BAO_0000357,Expert,,168,In vitro inhibition of 5-Lipoxygenase; Inactive.,B,,,,,
4291,8,,BAO_0000357,Autocuration,,6309,Inhibitory concentration against 5-lipoxygenase was determined; No inhibition,B,,,,,
4292,8,,BAO_0000357,Autocuration,,6309,Inhibitory concentration against 5-lipoxygenase; No inhibition,B,,,,,
4293,8,,BAO_0000219,Autocuration,,3092,Evaluated for inhibitory activity against RBL-1 cell 5-lipoxygenase in guinea pig,B,,,,,
4294,8,,BAO_0000357,Expert,,168,Inhibitory activity against 5-lipoxygenase.,B,,,,,
4295,8,,BAO_0000357,Autocuration,,168,Inhibitory Activity against 5-Lipoxygenase was determined; IA=Inactive,B,,,,,
4296,8,,BAO_0000357,Autocuration,,168,Inhibitory Activity against 5-Lipoxygenase was determined; IA=Inactive at concentrations less than 32 uM,B,,,,,
4297,8,,BAO_0000357,Autocuration,,168,Inhibitory Activity against 5-Lipoxygenase was determined; NA=No significant inhibitory activity up to 300 uM,B,,,,,
4298,8,,BAO_0000019,Expert,,12338,Inhibitory concentration against arachidonic acid 5-lipoxygenation,F,,,,,
4299,8,,BAO_0000357,Autocuration,,4501,Tested for the inhibitory activity against 5-lipoxygenase,B,,,,,
4300,8,,BAO_0000357,Autocuration,,1132,Compound was tested for its inhibitory activity against 5-lipoxygenase,B,,,,,
4301,8,,BAO_0000357,Autocuration,,2117,Compound was tested for inhibition of 5-lipoxygenase at 50 uM; NI means no inhibition was observed,B,,,,,
4302,8,,BAO_0000357,Autocuration,,168,Inhibitory Activity against 5-Lipoxygenase at 30 uM was determined; Weakly active,B,,,,,
4303,8,,BAO_0000357,Autocuration,,168,Inhibitory Activity against 5-Lipoxygenase at concentration 32 uM was determined,B,,,,,
4304,8,,BAO_0000219,Autocuration,,13575,Concentration required to inhibit RBL-1 supernatant 5-lipoxygenase,B,,,,,
4305,8,,BAO_0000357,Autocuration,,11089,,B,,,,,
4306,8,,BAO_0000357,Autocuration,,216,Compound was tested for its binding activity towards 5-lipoxygenase activating protein (FLAP),B,,,,,
4307,8,,BAO_0000019,Autocuration,,13165,Inhibition of 5-lipoxygenase activating protein using human leukocyte membrane preparations,B,,,,,
4308,8,,BAO_0000357,Autocuration,,3278,Measuring the affinity of leukotriene synthesis inhibitor for 5-Lipoxygenase activating protein (FLAP) by using [125I]L-691831 as radioligand.,B,,,,,
4309,8,,BAO_0000357,Expert,,3278,Measuring the affinity of leukotriene synthesis inhibitor for 5-lipoxygenase activating protein by using [125I]L-691831 as radioligand.,B,,,,,
4310,8,,BAO_0000357,Autocuration,,11966,Tested for inhibition of leukotriene biosynthesis by binding to 5-lipoxygenase activating protein,B,,,,,
4311,8,,BAO_0000357,Autocuration,,175,"The compound was tested for the inhibition of binding of [125I]- L- 691,831 binding to 5-lipoxygenase activating protein",B,,,,,
4312,8,,BAO_0000357,Autocuration,,175,"The compound was tested for the inhibition of binding of [125I]- L- 691,831 binding to 5-lipoxygenase activating protein (FLAP)",B,,,,,
4313,8,,BAO_0000357,Autocuration,,13449,Binding affinity of compound for 5-lipoxygenase activating protein protein by FLAP binding assay,B,,,,,
4314,8,,BAO_0000019,Autocuration,,12014,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane,B,,,,,
4315,8,,BAO_0000019,Autocuration,,12014,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane (R metabolically resistant),B,,,,,
4316,8,,BAO_0000019,Autocuration,,12014,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane (S substrate),B,,,,,
4317,2,,BAO_0000220,Intermediate,,99,Inhibition of protein biosynthesis at the level of the peptidyl transferase center of the 50 s ribosomal subunit,B,,,,,
4318,0,,BAO_0000019,Autocuration,,4349,The dark toxicity against 543 human galactophore carcinoma cells,F,,,Homo sapiens,9606.0,
4319,1,,BAO_0000219,Expert,,4071,Tested in vitro for cytotoxicity against 56 human tumor cell lines,F,,,Homo sapiens,9606.0,
4320,1,,BAO_0000219,Expert,,17589,Cytotoxic activity against human 5637 cell line at 20 uM expressed as percent growth value,F,,,Homo sapiens,9606.0,
4321,1,,BAO_0000219,Intermediate,,15002,Antitumor activity was evaluated against human bladder carcinoma cell line 5637.,F,,,Homo sapiens,9606.0,
4322,1,,BAO_0000219,Intermediate,,13958,"Compound was tested for antiproliferative activity against 5637, human bladder carcinoma cell line",F,,,Homo sapiens,9606.0,
4323,1,,BAO_0000219,Expert,,17589,Growth inhibition against human 5637 cell lines,F,,,Homo sapiens,9606.0,
4324,1,,BAO_0000219,Expert,,16748,Antitumor activity against human bladder carcinoma 5637 cells.,F,,,Homo sapiens,9606.0,
4325,1,,BAO_0000219,Intermediate,,16747,Antitumor activity against human bladder carcinoma 5637 cells,F,,,Homo sapiens,9606.0,
4326,1,,BAO_0000219,Intermediate,,16747,Antitumor activity against human bladder carcinoma 5637 cells,F,,,Homo sapiens,9606.0,
4327,9,,BAO_0000357,Expert,,15285,In vitro inhibition of bovine trypsin(Trp).,B,,,Bos taurus,9913.0,
4328,8,,BAO_0000219,Expert,,3726,Transcriptional activation in CV-1 cells expressing retinoic acid gamma receptor,B,,,Cercopithecidae,9527.0,
4329,8,,BAO_0000357,Autocuration,,5033,Ability to displace the radioligand [125I](-)-iodocyanopindolol from rat striatal 5-HT1B receptor,B,,,,,
4330,6,,BAO_0000019,Autocuration,,11756,In vitro antagonism of the 5-HT-3 receptor determined by inhibition of 5-HT-induced depolarization of the isolated rat vagus nerve.,F,,,,,
4331,0,,BAO_0000218,Autocuration,,11953,Concentration required to inhibit pressor response to serotonin after 15 min i.v. administration of compound mediated via activation of vascular 5-HT2 receptors in rat,F,In vivo,,,,
4332,9,,BAO_0000357,Intermediate,,5033,Ability to displace the radioligand [3H]GR-113808 from guinea pig striatum 5-HT4 receptor,B,,,Cavia porcellus,10141.0,
4333,8,,BAO_0000251,Expert,,11347,Inhibition of progesterone 6-beta-hydroxylase in rat hepatic microsomes,A,,,Rattus norvegicus,10116.0,
4334,8,,BAO_0000251,Expert,,11347,Inhibition of progesterone 6-beta-hydroxylase in rat hepatic microsomes,A,,,Rattus norvegicus,10116.0,
4335,0,,BAO_0000019,Intermediate,,1229,In vitro anticancer activity against 6 NCI ovarian cancer cell lines; inactive,F,,,,,
4336,0,,BAO_0000019,Intermediate,,1229,In vitro anticancer activity against 6 NCI ovarian cancer cell lines; inactive,F,,,,,
4337,8,,BAO_0000019,Expert,,17588,Inhibition constant against 6-phosphogluconate dehydrogenase of Trypanosoma brucei expressed in Escherichia coli,B,,,Trypanosoma brucei,5691.0,
4338,8,,BAO_0000019,Autocuration,,17588,Inhibition constant against 6-phosphogluconate dehydrogenase of Trypanosoma brucei expressed in Escherichia coli; NI denotes no inhibition,B,,,Trypanosoma brucei,5691.0,
4339,8,,BAO_0000019,Expert,,17588,Inhibition constant against 6-phosphogluconate dehydrogenase of sheep liver,B,,,Ovis aries,9940.0,
4340,8,,BAO_0000019,Autocuration,,17588,Inhibition constant against 6-phosphogluconate dehydrogenase of sheep liver; NI denotes no inhibition,B,,,Ovis aries,9940.0,
4341,8,,BAO_0000357,Autocuration,,16485,log Kd which is the binding affinity against 6-phosphogluconate dehydrogenase,B,,,,,
4342,0,,BAO_0000019,Intermediate,,4337,Average inhibitory concentration against 60 human cell lines was reported,F,,,Homo sapiens,9606.0,
4343,0,,BAO_0000019,Expert,,4112,Inhibition of proliferation in NCI panel of 60 human tumor cell lines,F,,,Homo sapiens,9606.0,
4344,1,,BAO_0000219,Intermediate,,16160,Cancer specificity was measured from the +/- value under average log LC50 60-cell line,F,,,Homo sapiens,9606.0,
4345,1,,BAO_0000219,Intermediate,,16160,Cancer specificity was measured from the +/- value under average log LC50 60-cell line. ,F,,,Homo sapiens,9606.0,
4346,1,,BAO_0000219,Expert,,17376,In vitro mean growth inhibitory activity against 60-cell panel,F,,,,,
4347,1,,BAO_0000219,Expert,,17376,In vitro mean growth lethal concentration against 60-cell panel,F,,,,,
4348,1,,BAO_0000219,Expert,,17376,In vitro mean growth lethal concentration in colon subpanel against 60-cell panel,F,,,,,
4349,1,,BAO_0000219,Expert,,17376,In vitro mean growth lethal concentration in renal subpanel against 60-cell panel,F,,,,,
4350,4,,BAO_0000019,Autocuration,,3241,Inhibition of CK-II-mediated 60S acidic ribosomal P protein activity at 10 uM,F,,,,,
4351,4,,BAO_0000019,Autocuration,,3241,Inhibition of CK-II-mediated 60S acidic ribosomal P protein activity at 10 uM,F,,,,,
4352,8,,BAO_0000357,Expert,,3725,Transcriptional activation in CV-1 expressing retinoid X receptor RXR alpha,B,,,,,
4353,1,,BAO_0000218,Expert,,10805,Inhibitory activity against Plasmodium falciparum 68 neutral proteinase,F,,,Plasmodium falciparum,5833.0,
4354,1,,BAO_0000218,Expert,,10805,In vitro inhibition of Plasmodium falciparum 68 neutral proteinase activity by reinvasion of red blood cells,F,,,Plasmodium falciparum,5833.0,
4355,1,,BAO_0000218,Expert,,10805,Inhibitory activity against Plasmodium falciparum 68 neutral proteinase.,F,,,Plasmodium falciparum,5833.0,
4356,1,,BAO_0000218,Expert,,10805,Substrate affinity for Plasmodium falciparum 68 neutral proteinase.,F,,,Plasmodium falciparum,5833.0,
4357,1,,BAO_0000218,Intermediate,,10805,Reaction velocity for Plasmodium falciparum 68 neutral proteinase.,F,,,Plasmodium falciparum,5833.0,
4358,1,,BAO_0000218,Intermediate,,10144,Percent inhibition against 6C3HED lymphosarcoma at dose 100 mg/kg in C3H mice,F,,,Mus musculus,10090.0,
4359,1,,BAO_0000218,Intermediate,,10144,Percent inhibition against 6C3HED lymphosarcoma at dose 12.5 mg/kg in C3H mice,F,,,Mus musculus,10090.0,
4360,1,,BAO_0000218,Intermediate,,10144,Percent inhibition against 6C3HED lymphosarcoma at dose 200 mg/kg in C3H mice,F,,,Mus musculus,10090.0,
4361,1,,BAO_0000218,Intermediate,,10144,Percent inhibition against 6C3HED lymphosarcoma at dose 25 mg/kg in C3H mice,F,,,Mus musculus,10090.0,
4362,1,,BAO_0000218,Intermediate,,10144,Percent inhibition against 6C3HED lymphosarcoma at dose 50 mg/kg in C3H mice,F,,,Mus musculus,10090.0,
4363,1,,BAO_0000218,Intermediate,,10144,Percent inhibition against 6C3HED lymphosarcoma at dose 6 mg/kg in C3H mice,F,,,Mus musculus,10090.0,
4364,0,,BAO_0000218,Autocuration,,10685,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 100 mg/kg,F,In vivo,,Mus musculus,10090.0,
4365,0,,BAO_0000218,Autocuration,,10685,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 150 mg/kg,F,In vivo,,Mus musculus,10090.0,
4366,0,,BAO_0000218,Autocuration,,10685,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 1600 mg/kg (intraperitoneal dosing for 8 days),F,In vivo,,Mus musculus,10090.0,
4367,0,,BAO_0000218,Autocuration,,10685,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 200 mg/kg,F,In vivo,,Mus musculus,10090.0,
4368,0,,BAO_0000218,Autocuration,,10685,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 225 mg/kg,F,In vivo,,Mus musculus,10090.0,
4369,0,,BAO_0000218,Autocuration,,10685,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 270 mg/kg,F,In vivo,,Mus musculus,10090.0,
4370,0,,BAO_0000218,Autocuration,,10685,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 275 mg/kg,F,In vivo,,Mus musculus,10090.0,
4371,0,,BAO_0000218,Autocuration,,10685,"Antitumor activity in vivo against the 6C3HED lymphosarcoma, dosed for 10 days at 300 mg/kg",F,In vivo,,Mus musculus,10090.0,
4372,0,,BAO_0000218,Autocuration,,10685,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 300 mg/kg (intraperitoneal dosing for 8 days),F,In vivo,,Mus musculus,10090.0,
4373,0,,BAO_0000218,Autocuration,,10685,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 300 mg/kg (ip dosing daily for 8 days),F,In vivo,,Mus musculus,10090.0,
4374,0,,BAO_0000218,Autocuration,,10685,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 600 mg/kg,F,In vivo,,Mus musculus,10090.0,
4375,0,,BAO_0000218,Autocuration,,10144,Percent inhibition against 6C3HED lymphosarcoma at dose 100 mg/kg in C3H mice,F,,,Mus musculus,10090.0,
4376,0,,BAO_0000218,Autocuration,,10144,Percent inhibition against 6C3HED lymphosarcoma at dose 12.5 mg/kg in C3H mice,F,,,Mus musculus,10090.0,
4377,0,,BAO_0000218,Autocuration,,10144,Percent inhibition against 6C3HED lymphosarcoma at dose 25 mg/kg in C3H mice,F,,,Mus musculus,10090.0,
4378,0,,BAO_0000218,Autocuration,,10144,Percent inhibition against 6C3HED lymphosarcoma at dose 50 mg/kg in C3H mice,F,,,Mus musculus,10090.0,
4379,0,,BAO_0000218,Autocuration,,10685,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 100 mg/kg dosage administered for 8 days intraperitoneally,F,,,Mus musculus,10090.0,
4380,0,,BAO_0000218,Autocuration,,10685,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 200 mg/kg dosage administered for 10 days intraperitoneally,F,,,Mus musculus,10090.0,
4381,0,,BAO_0000218,Autocuration,,10685,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 200 mg/kg dosage administered for 8 days intraperitoneally,F,,,Mus musculus,10090.0,
4382,0,,BAO_0000218,Autocuration,,10685,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 50 mg/kg dosage administered for 8 days intraperitoneally,F,,,Mus musculus,10090.0,
4383,0,,BAO_0000218,Autocuration,,10685,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 100 mg/kg dosage administered for 8 days intraperitoneally; 0/10,A,,,Mus musculus,10090.0,
4384,0,,BAO_0000218,Autocuration,,10685,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 200 mg/kg dosage administered for 8 days perorally; 1/10,A,,,Mus musculus,10090.0,
4385,0,,BAO_0000218,Autocuration,,10685,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 200 mg/kg dosage administered for 10 days intraperitoneally; 1/10,A,,,Mus musculus,10090.0,
4386,0,,BAO_0000218,Autocuration,,10685,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 50 mg/kg dosage administered for 8 days perorally; 3/10,A,,,Mus musculus,10090.0,
4387,1,,BAO_0000218,Intermediate,,8831,"Compound was evaluated for the antitumor activity against 6C3HED lymphosarcoma for ip administration and daily x 8 schedule; Number of toxic deaths over total number of mice per group (T/C), 0/10 at dose of 35 mg/kg",F,,,Mus musculus,10090.0,
4388,0,,BAO_0000218,Autocuration,,11704,In vivo antitumor activity against 6C3HED tumor type after intraperitoneal administration of 400 mg/kg,F,In vivo,,,,
4389,1,,BAO_0000218,Intermediate,,11704,In vivo antitumor activity against 6C3HED tumor type was expressed as toxic deaths/total treated mice at 400 mg/kg dose; 2/10,A,,,Mus musculus,10090.0,
4390,1,,BAO_0000218,Intermediate,,10685,Antitumor activity in vivo expressed as percent of inhibition in 6C3HED-lymphosarcoma tumor cell line,F,In vivo,,Mus musculus,10090.0,
4391,1,,BAO_0000218,Intermediate,,10685,Antitumor activity in vivo expressed as percent of inhibition in 6C3HED-lymphosarcoma tumor cell line; 95-100% inhibition,F,In vivo,,Mus musculus,10090.0,
4392,1,,BAO_0000218,Expert,,11368,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 150 mg/kg given orally(daily x 8),F,,,Mus musculus,10090.0,
4393,1,,BAO_0000218,Intermediate,,11368,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 200 mg/kg given orally(daily x 8),F,,,Mus musculus,10090.0,
4394,1,,BAO_0000218,Expert,,11368,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 300 mg/kg given orally (daily x 8),F,,,Mus musculus,10090.0,
4395,0,,BAO_0000019,Autocuration,,17763,"Inhibition of Staphylococcus aureus 7,8-dihydroneopterin aldolase",B,,,Staphylococcus aureus,1280.0,
4396,0,,BAO_0000251,Autocuration,2107.0,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at a concentration of 5 uM,B,,,Rattus norvegicus,10116.0,
4397,0,,BAO_0000251,Autocuration,2107.0,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 10 uM,B,,,Rattus norvegicus,10116.0,
4398,0,,BAO_0000251,Autocuration,2107.0,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 1 uM,B,,,Rattus norvegicus,10116.0,
4399,0,,BAO_0000251,Autocuration,2107.0,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 20 uM,B,,,Rattus norvegicus,10116.0,
4400,0,,BAO_0000251,Autocuration,2107.0,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 25 uM,B,,,Rattus norvegicus,10116.0,
4401,0,,BAO_0000251,Autocuration,2107.0,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 50 uM,B,,,Rattus norvegicus,10116.0,
4402,0,,BAO_0000251,Autocuration,2107.0,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 5 uM,B,,,Rattus norvegicus,10116.0,
4403,0,,BAO_0000251,Autocuration,2107.0,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 10 uM,B,,,Rattus norvegicus,10116.0,
4404,0,,BAO_0000251,Autocuration,2107.0,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 100 uM,B,,,Rattus norvegicus,10116.0,
4405,0,,BAO_0000251,Autocuration,2107.0,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 200 uM,B,,,Rattus norvegicus,10116.0,
4406,0,,BAO_0000251,Autocuration,2107.0,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 25 uM,B,,,Rattus norvegicus,10116.0,
4407,0,,BAO_0000251,Autocuration,2107.0,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 50 uM,B,,,Rattus norvegicus,10116.0,
4408,0,,BAO_0000218,Autocuration,1969.0,347,The apparent total plasma clearance in monkey,A,In vivo,,Cercopithecidae,9527.0,
4409,0,,BAO_0000218,Autocuration,,3341,Compound was evaluated for Hepatic clearance in monkey,A,In vivo,,Cercopithecidae,9527.0,
4410,0,,BAO_0000218,Autocuration,,17853,Lower clearance in monkey (i.v.) at 0.5 mpk,A,In vivo,,Cercopithecidae,9527.0,
4411,0,,BAO_0000218,Autocuration,,4514,Plasma clearance in rhesus monkey,A,In vivo,,Cercopithecidae,9527.0,
4412,0,,BAO_0000218,Autocuration,,6062,Plasma clearance for the compound was measured in monkey after an iv dose of 1 mg/kg,A,In vivo,,Cercopithecidae,9527.0,
4413,0,,BAO_0000218,Autocuration,,6821,Plasma clearance of compound was determined in monkey,A,In vivo,,Cercopithecidae,9527.0,
4414,0,,BAO_0000218,Autocuration,,6057,Plasma clearance was calculated in rhesus monkey,A,In vivo,,Cercopithecidae,9527.0,
4415,0,,BAO_0000218,Autocuration,,5145,Plasma clearance in rhesus monkey,A,In vivo,,Cercopithecidae,9527.0,
4416,0,,BAO_0000218,Autocuration,,6641,Plasma clearance in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),A,In vivo,,Cercopithecidae,9527.0,
4417,0,,BAO_0000218,Autocuration,,5472,Plasma clearance was evaluated in rhesus,A,In vivo,,Cercopithecidae,9527.0,
4418,0,,BAO_0000218,Autocuration,,4257,Plasma clearance value was determined in monkey after a 3 mg/kg of iv dose,A,In vivo,,Cercopithecidae,9527.0,
4419,0,,BAO_0000218,Autocuration,,5546,Plasma clearance was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,A,In vivo,,Cercopithecidae,9527.0,
4420,0,,BAO_0000218,Autocuration,,5334,Plasma clearance was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),A,In vivo,,Cercopithecidae,9527.0,
4421,0,,BAO_0000218,Autocuration,,5334,Plasma clearance was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),A,In vivo,,Cercopithecidae,9527.0,
4422,0,,BAO_0000218,Autocuration,,17509,Cmax 24 hr after 2 mg/kg oral administration in monkeys,A,In vivo,,Cercopithecidae,9527.0,
4423,0,,BAO_0000218,Autocuration,,6535,Cmax in monkey after administration of 1 mg/kg iv,A,In vivo,,Cercopithecidae,9527.0,
4424,0,,BAO_0000218,Autocuration,,5668,Cmax was determine after peroral administration at 10 mpk in Rhesus,A,In vivo,,Cercopithecidae,9527.0,
4425,0,,BAO_0000218,Autocuration,,5922,Cmax in cynomolgus monkey by iv administration,A,In vivo,,Cercopithecidae,9527.0,
4426,0,,BAO_0000218,Autocuration,,5922,Cmax in cynomolgus monkey by po administration,A,In vivo,,Cercopithecidae,9527.0,
4427,0,,BAO_0000218,Autocuration,,6078,Cmax value evaluated in monkey,A,In vivo,,Cercopithecidae,9527.0,
4428,0,,BAO_0000218,Autocuration,,2661,Compound was evaluated for maximum concentration after treatment with oral dose of 2 mgkg to female cynomolgus monkey,A,In vivo,,Cercopithecidae,9527.0,
4429,0,,BAO_0000218,Autocuration,1969.0,3249,Maximal concentration (Cmax) in rhesus monkey plasma at a dose of 5 mg/kg,A,In vivo,,Cercopithecidae,9527.0,
4430,0,,BAO_0000218,Autocuration,1969.0,3249,Maximal concentration (Cmax) in squirrel monkey plasma at a dose of 5 mg/kg,A,In vivo,,Cercopithecidae,9527.0,
4431,0,,BAO_0000218,Autocuration,1969.0,5553,Maximal plasma concentration in squirrel monkeys,A,In vivo,,Cercopithecidae,9527.0,
4432,0,,BAO_0000218,Autocuration,,1916,Maximum concentration was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,A,In vivo,,Cercopithecidae,9527.0,
4433,0,,BAO_0000218,Autocuration,1969.0,6227,Maximum plasma concentration (Cmax) in rhesus monkey(in vivo) at a dose of 5 mg/kg,A,In vivo,,Cercopithecidae,9527.0,
4434,0,,BAO_0000218,Autocuration,,4809,Pharmacokinetic parameter Cmax was determined in monkey after (po) administration of a dose of 50 (uM/kg),A,In vivo,,Cercopithecidae,9527.0,
4435,0,,BAO_0000218,Autocuration,,5355,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys; NA means Not applicable,A,In vivo,,Cercopithecidae,9527.0,
4436,0,,BAO_0000218,Autocuration,,5355,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys; NA means not applicable,A,In vivo,,Cercopithecidae,9527.0,
4437,0,,BAO_0000218,Autocuration,,5355,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys;NA means not applicable,A,In vivo,,Cercopithecidae,9527.0,
4438,0,,BAO_0000218,Autocuration,,5355,The peak concentration (Cmax) value after oral administration in cynomolgus monkeys,A,In vivo,,Cercopithecidae,9527.0,
4439,0,,BAO_0000218,Autocuration,1969.0,6221,The peak plasma concentration after 5 hr administration (2.5 mg/kg) in monkey was determined,A,In vivo,,Cercopithecidae,9527.0,
4440,0,,BAO_0000218,Autocuration,,167,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Monkey at maximum of 0.4 hours,A,,,Cercopithecidae,9527.0,
4441,0,,BAO_0000218,Autocuration,,167,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Monkey at maximum of 1.0 hours,A,,,Cercopithecidae,9527.0,
4442,0,,BAO_0000218,Autocuration,,4257,Absolute bioavailability was evaluated in monkey,A,In vivo,,monkey,9443.0,
4443,0,,BAO_0000218,Autocuration,,6221,Bioavailability after oral administration (2.5 mg/kg) in monkey was determined,A,In vivo,,monkey,9443.0,
4444,0,,BAO_0000218,Autocuration,,17667,Bioavailability of compound at 3 mg/kg in monkey after i.v. administration,A,In vivo,,monkey,9443.0,
4445,0,,BAO_0000218,Autocuration,,17267,Bioavailability of compound was determined in rhesus monkey,A,In vivo,,Macaca mulatta,9544.0,
4446,0,,BAO_0000218,Autocuration,,4256,Bioavailability determined after oral administration in marmoset,A,In vivo,,marmosets,38020.0,
4447,0,,BAO_0000218,Autocuration,,4256,Oral bioavailability in cynomolgus monkey,A,In vivo,,Macaca fascicularis,9541.0,
4448,0,,BAO_0000218,Autocuration,,17853,Bioavailability in monkey (p.o.) at 2.0 mpk,A,In vivo,,monkey,9443.0,
4449,0,,BAO_0000218,Autocuration,,16365,Bioavailability was evaluated after oral administration in monkey,A,In vivo,,monkey,9443.0,
4450,0,,BAO_0000218,Autocuration,,1916,Bioavailability was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,A,In vivo,,Macaca fascicularis,9541.0,
4451,0,,BAO_0000218,Autocuration,,5334,Bioavailability was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),A,In vivo,,Macaca mulatta,9544.0,
4452,0,,BAO_0000218,Autocuration,,5334,Bioavailability was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),A,In vivo,,Macaca mulatta,9544.0,
4453,0,,BAO_0000218,Autocuration,,17592,Bioavailability of the compound was determined in monkey,A,In vivo,,monkey,9443.0,
4454,0,,BAO_0000218,Autocuration,,1399,Bioavailability in squirrel monkey (dose 5 mg/kg),A,In vivo,,Saimiri sciureus,9521.0,
4455,0,,BAO_0000218,Autocuration,,4809,Bioavailability was determined in monkey after (po) administration of a dose of 50 (uM/kg),A,In vivo,,monkey,9443.0,
4456,0,,BAO_0000218,Autocuration,,3341,Oral bioavailability in monkey,A,In vivo,,monkey,9443.0,
4457,0,,BAO_0000218,Autocuration,,64,Compound was tested for bioavailability in squirrel monkey,A,In vivo,,Saimiri sciureus,9521.0,
4458,0,,BAO_0000218,Autocuration,,5005,Oral bioavailability in Rhesus monkey,A,In vivo,,Macaca mulatta,9544.0,
4459,0,,BAO_0000218,Autocuration,,5005,Oral bioavailability in Rhesus monkey (dose of 0.75 mg/kg i.v. and 1.5 mg/kg p.o.),A,In vivo,,Macaca mulatta,9544.0,
4460,0,,BAO_0000218,Autocuration,,5237,Oral bioavailability in cynomolgus monkeys for the compound was determined; Acceptable,A,In vivo,,Macaca fascicularis,9541.0,
4461,0,,BAO_0000218,Autocuration,,5237,Oral bioavailability in cynomolgus monkeys was determined; Acceptable,A,In vivo,,Macaca fascicularis,9541.0,
4462,0,,BAO_0000218,Autocuration,,5302,Oral bioavailability in monkey (dose 5 mg/kg),A,In vivo,,monkey,9443.0,
4463,0,,BAO_0000218,Autocuration,,17667,Oral bioavailability of compound at 5 mg/kg in monkey,A,In vivo,,monkey,9443.0,
4464,1,,BAO_0000218,Intermediate,,6161,Pharmacokinetic profile in terms of half life was determined at a dose of 0.5 mg/kg administered intravenously in dog,A,In vivo,,Canis lupus familiaris,9615.0,
4465,1,,BAO_0000218,Intermediate,,6161,Pharmacokinetic profile in terms of half life was determined at a dose of 5 mg/kg administered intravenously in dog,A,In vivo,,Canis lupus familiaris,9615.0,
4466,1,,BAO_0000218,Intermediate,1969.0,3854,Plasma half life determined,A,,,Canis lupus familiaris,9615.0,
4467,1,,BAO_0000218,Intermediate,1969.0,993,Plasma half life in dog,A,,,Canis lupus familiaris,9615.0,
4468,1,,BAO_0000218,Intermediate,1969.0,4514,Plasma half-life in Beagle dogs,A,,,Canis lupus familiaris,9615.0,
4469,1,,BAO_0000218,Intermediate,1969.0,5334,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),A,In vivo,,Canis lupus familiaris,9615.0,
4470,1,,BAO_0000218,Intermediate,1969.0,5334,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg respectively in Beagle dog (male),A,In vivo,,Canis lupus familiaris,9615.0,
4471,1,,BAO_0000218,Intermediate,,1466,Tested for t1/2 upon intravenous administration of 5.0 mg/Kg dose in dog,A,In vivo,,Canis lupus familiaris,9615.0,
4472,1,,BAO_0000218,Intermediate,,1466,Tested for t1/2 upon peroral administration of 10.0 mg/Kg dose in dog,A,In vivo,,Canis lupus familiaris,9615.0,
4473,1,,BAO_0000218,Intermediate,,5313,Tested for the half life period in dog,A,,,Canis lupus familiaris,9615.0,
4474,1,,BAO_0000218,Intermediate,,5313,Tested for the half life period in dog at dosage of 10 mpk,A,In vivo,,Canis lupus familiaris,9615.0,
4475,1,,BAO_0000218,Intermediate,,3880,The compound was tested for half life in dog,A,,,Canis lupus familiaris,9615.0,
4476,1,,BAO_0000218,Intermediate,1969.0,3639,"The compound was tested for time taken to decrease, half of its initial concentration in dog plasma.",A,,,Canis lupus familiaris,9615.0,
4477,1,,BAO_0000218,Intermediate,,3880,The half life was determined,A,,,Canis lupus familiaris,9615.0,
4478,1,,BAO_0000218,Intermediate,1969.0,3918,The plasma half-life in dogs,A,,,Canis lupus familiaris,9615.0,
4479,1,,BAO_0000218,Intermediate,1969.0,16452,suboptimal plasma half-life caused a10% prolongation of QTc interval in dogs at a plasma level of 2.5 M,A,,,Canis lupus familiaris,9615.0,
4480,1,,BAO_0000218,Intermediate,,17796,Half life in dog,A,,,Canis lupus familiaris,9615.0,
4481,1,,BAO_0000218,Intermediate,,5983,Pharmacokinetic property (t1/2beta) was measured in dog at the dose of 0.032 mg/kg i.v.,A,In vivo,,Canis lupus familiaris,9615.0,
4482,1,,BAO_0000218,Intermediate,,1466,tmax upon peroral administration of 10.0 mg/Kg dose in dog,A,In vivo,,Canis lupus familiaris,9615.0,
4483,1,,BAO_0000218,Intermediate,,16456,Volume of distribution in Beagle dogs after intravenous administration at a dose of 10 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,
4484,1,,BAO_0000218,Expert,,6113,Cmax in ferrets after 30 mg/kg oral dose,A,In vivo,,Mustela putorius furo,9669.0,
4485,1,,BAO_0000218,Expert,,6113,Emesis in ferrets at 30 mg/kg oral dose,F,In vivo,,Mustela putorius furo,9669.0,
4486,0,,BAO_0000218,Autocuration,,17796,Bioavailability in cynomolgus monkey,A,In vivo,,Macaca fascicularis,9541.0,
4487,1,,BAO_0000218,Intermediate,,17796,Volume of distribution in cynomolgus,A,In vivo,,Macaca fascicularis,9541.0,
4488,0,,BAO_0000218,Autocuration,1969.0,5308,AUC tested in guinea pig when 3 mg/kg dose was given perorally,A,,,Cavia porcellus,10141.0,
4489,0,,BAO_0000218,Autocuration,,4877,Tested for concentration as Area Under Curve against PDE4 in guinea pig lung eosinophilia orally at 5 mg/kg,A,,,Cavia porcellus,10141.0,
4490,0,,BAO_0000218,Autocuration,,4876,"Tested for the pharmacokinetic parameter in guinea pig, administered orally at 5 mg/kg",A,,,Cavia porcellus,10141.0,
4491,0,,BAO_0000218,Autocuration,1969.0,4878,AUC in guinea pig after 3mg/kg oral dose,A,In vivo,,Cavia porcellus,10141.0,
4492,0,,BAO_0000218,Autocuration,,5308,Bioavailability in guinea pig was tested,A,In vivo,,Cavia porcellus,10141.0,
4493,0,,BAO_0000218,Autocuration,,4877,Tested for oral bioavailability in guinea pig at 5 mg/kg,A,In vivo,,Cavia porcellus,10141.0,
4494,0,,BAO_0000218,Autocuration,,4876,Tested for the oral bioavailability of the compound,A,In vivo,,Cavia porcellus,10141.0,
4495,0,,BAO_0000218,Autocuration,,4876,Compound at a dose 5 mg/kg was administered orally to guinea pig and the pharmacokinetic parameter (Cmax) was reported,A,In vivo,,Cavia porcellus,10141.0,
4496,0,,BAO_0000218,Autocuration,,5308,Maximum plsma drug concentration in guinea pig when 3 mg/kg dose was given perorally,A,In vivo,,Cavia porcellus,10141.0,
4497,0,,BAO_0000218,Autocuration,2048.0,4877,Tested for maximum concentration against PDE4 in guinea pig lung eosinophilia orally at 5 mg/kg,A,In vivo,,Cavia porcellus,10141.0,
4498,0,,BAO_0000218,Autocuration,,4878,Cmax in guinea pig after 3mg/kg oral dose,A,In vivo,,Cavia porcellus,10141.0,
4499,0,,BAO_0000019,Autocuration,178.0,5689,Distribution in blood expressed as [18F]- organ uptake in % of injected activity/gram,A,,,Cavia porcellus,10141.0,
4500,0,,BAO_0000019,Autocuration,955.0,5689,Distribution in brain expressed as [18F]- organ uptake in % of injected activity/gram,A,,,Cavia porcellus,10141.0,
4501,0,,BAO_0000019,Autocuration,,5689,Distribution in heart expressed as [18F]- organ uptake in % of injected activity/gram,A,,,Cavia porcellus,10141.0,
4502,0,,BAO_0000019,Autocuration,160.0,5689,Distribution in intestine expressed as [18F]- organ uptake in % of injected activity/gram,A,,,Cavia porcellus,10141.0,
4503,0,,BAO_0000019,Autocuration,2113.0,5689,Distribution in kidney expressed as [18F]- organ uptake in % of injected activity/gram,A,,,Cavia porcellus,10141.0,
4504,0,,BAO_0000019,Autocuration,2107.0,5689,Distribution in liver expressed as [18F]- organ uptake in % of injected activity/gram,A,,,Cavia porcellus,10141.0,
4505,0,,BAO_0000019,Autocuration,,5689,Distribution in lung expressed as [18F]- organ uptake in % of injected activity/gram,A,,,Cavia porcellus,10141.0,
4506,0,,BAO_0000019,Autocuration,2106.0,5689,Distribution in spleen expressed as [18F]- organ uptake in % of injected activity/gram,A,,,Cavia porcellus,10141.0,
4507,0,,BAO_0000218,Autocuration,,14465,Elimination T1/2 in Guinea pig (PO dose),A,In vivo,,Cavia porcellus,10141.0,
4508,0,,BAO_0000019,Autocuration,,5689,Partition coefficient was measured as -log (counts per min ),A,,,Cavia porcellus,10141.0,
4509,0,,BAO_0000218,Autocuration,,611,Biological half life when administered at 0.1 umol/kg intravenously to guinea pig in GR-64349 antagonism,A,In vivo,,Cavia porcellus,10141.0,
4510,0,,BAO_0000218,Autocuration,,611,Biological half life when administered at 5 umol/kg intravenously to guinea pig in GR-64349 antagonism,A,In vivo,,Cavia porcellus,10141.0,
4511,0,,BAO_0000218,Autocuration,,14465,Elimination T1/2 in Guinea pig (PO dose),A,In vivo,,Cavia porcellus,10141.0,
4512,0,,BAO_0000218,Autocuration,,4876,"Tested for the half life period of the compound, intravenously",A,In vivo,,Cavia porcellus,10141.0,
4513,0,,BAO_0000019,Autocuration,,5689,Half-life was measured,A,,,Cavia porcellus,10141.0,
4514,0,,BAO_0000019,Autocuration,,7515,The time required for onset of inotropy after addition of a single dose of delta F75,A,,,Cavia porcellus,10141.0,
4515,0,,BAO_0000218,Autocuration,,17667,Bioavailability of compound at 10 mg/kg in guinea pig after i.v. administration,A,In vivo,,Cavia porcellus,10141.0,
4516,0,,BAO_0000218,Autocuration,,17667,Bioavailability of compound at 3 mg/kg in guinea pig after i.v. administration,A,In vivo,,Cavia porcellus,10141.0,
4517,0,,BAO_0000218,Autocuration,,4727,Plasma clearance was measured in hamster at the dose of 10 mg/kg by peroral administration,A,In vivo,,Cricetulus griseus,10029.0,
4518,1,,BAO_0000218,Intermediate,,10107,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,A,In vivo,,Mus musculus,10090.0,
4519,1,,BAO_0000218,Intermediate,,10107,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,A,In vivo,,Mus musculus,10090.0,
4520,1,,BAO_0000218,Intermediate,,10107,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,A,In vivo,,Mus musculus,10090.0,
4521,1,,BAO_0000218,Intermediate,,10107,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,A,In vivo,,Mus musculus,10090.0,
4522,1,,BAO_0000218,Intermediate,,10107,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hr,A,In vivo,,Mus musculus,10090.0,
4523,1,,BAO_0000218,Intermediate,,10107,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,A,In vivo,,Mus musculus,10090.0,
4524,1,,BAO_0000218,Intermediate,,10107,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,A,In vivo,,Mus musculus,10090.0,
4525,1,,BAO_0000218,Intermediate,178.0,3655,Biodistribution of the injected compound in blood of female BALB/C mice for 0.5 hours,A,In vivo,,Mus musculus,10090.0,
4526,1,,BAO_0000218,Intermediate,178.0,3655,Biodistribution of the injected compound in blood of female BALB/C mice for 2.5 hours,A,In vivo,,Mus musculus,10090.0,
4527,1,,BAO_0000218,Intermediate,178.0,3655,Biodistribution of the injected compound in blood of female BALB/C mice for 5 hours,A,In vivo,,Mus musculus,10090.0,
4528,1,,BAO_0000218,Intermediate,10000001.0,3655,Biodistribution of the injected compound in bone of female BALB/C mice for 0.5 hours,A,In vivo,,Mus musculus,10090.0,
4529,1,,BAO_0000218,Intermediate,10000001.0,3655,Biodistribution of the injected compound in bone of female BALB/C mice for 2.5 hours,A,In vivo,,Mus musculus,10090.0,
4530,1,,BAO_0000218,Intermediate,10000001.0,3655,Biodistribution of the injected compound in bone of female BALB/C mice for 5 hours,A,In vivo,,Mus musculus,10090.0,
4531,1,,BAO_0000218,Intermediate,955.0,3655,Biodistribution of the injected compound in brain of female BALB/C mice for 0.5 hours,A,In vivo,,Mus musculus,10090.0,
4532,1,,BAO_0000218,Intermediate,955.0,3655,Biodistribution of the injected compound in brain of female BALB/C mice for 2.5 hours,A,In vivo,,Mus musculus,10090.0,
4533,1,,BAO_0000218,Intermediate,955.0,3655,Biodistribution of the injected compound in brain of female BALB/C mice for 5 hours,A,In vivo,,Mus musculus,10090.0,
4534,1,,BAO_0000218,Intermediate,948.0,3655,Biodistribution of the injected compound in heart of female BALB/C mice for 0.5 hours,A,In vivo,,Mus musculus,10090.0,
4535,1,,BAO_0000218,Intermediate,948.0,3655,Biodistribution of the injected compound in heart of female BALB/C mice for 2.5 hours,A,In vivo,,Mus musculus,10090.0,
4536,1,,BAO_0000218,Intermediate,948.0,3655,Biodistribution of the injected compound in heart of female BALB/C mice for 5 hours,A,In vivo,,Mus musculus,10090.0,
4537,1,,BAO_0000218,Intermediate,160.0,3655,Biodistribution of the injected compound in intestines of female BALB/C mice for 0.5 hours,A,In vivo,,Mus musculus,10090.0,
4538,1,,BAO_0000218,Intermediate,160.0,3655,Biodistribution of the injected compound in intestines of female BALB/C mice for 2.5 hours,A,In vivo,,Mus musculus,10090.0,
4539,1,,BAO_0000218,Intermediate,160.0,3655,Biodistribution of the injected compound in intestines of female BALB/C mice for 5 hours,A,In vivo,,Mus musculus,10090.0,
4540,1,,BAO_0000218,Intermediate,2113.0,3655,Biodistribution of the injected compound in kidneys of female BALB/C mice for 0.5 hours,A,In vivo,,Mus musculus,10090.0,
4541,1,,BAO_0000218,Intermediate,2113.0,3655,Biodistribution of the injected compound in kidneys of female BALB/C mice for 2.5 hours,A,In vivo,,Mus musculus,10090.0,
4542,1,,BAO_0000218,Intermediate,2113.0,3655,Biodistribution of the injected compound in kidneys of female BALB/C mice for 5 hours,A,In vivo,,Mus musculus,10090.0,
4543,1,,BAO_0000218,Intermediate,2107.0,3655,Biodistribution of the injected compound in liver of female BALB/C mice for 0.5 hours,A,In vivo,,Mus musculus,10090.0,
4544,1,,BAO_0000218,Intermediate,2107.0,3655,Biodistribution of the injected compound in liver of female BALB/C mice for 2.5 hours,A,In vivo,,Mus musculus,10090.0,
4545,1,,BAO_0000218,Intermediate,2107.0,3655,Biodistribution of the injected compound in liver of female BALB/C mice for 5 hours,A,In vivo,,Mus musculus,10090.0,
4546,1,,BAO_0000218,Intermediate,2048.0,3655,Biodistribution of the injected compound in lung of female BALB/C mice for 0.5 hours,A,In vivo,,Mus musculus,10090.0,
4547,1,,BAO_0000218,Intermediate,2048.0,3655,Biodistribution of the injected compound in lung of female BALB/C mice for 2.5 hours,A,In vivo,,Mus musculus,10090.0,
4548,1,,BAO_0000218,Intermediate,2048.0,3655,Biodistribution of the injected compound in lung of female BALB/C mice for 5 hours,A,In vivo,,Mus musculus,10090.0,
4549,1,,BAO_0000218,Intermediate,2385.0,3655,Biodistribution of the injected compound in muscle of female BALB/C mice for 0.5 hours,A,In vivo,,Mus musculus,10090.0,
4550,1,,BAO_0000218,Intermediate,2385.0,3655,Biodistribution of the injected compound in muscle of female BALB/C mice for 2.5 hours,A,In vivo,,Mus musculus,10090.0,
4551,1,,BAO_0000218,Intermediate,2385.0,3655,Biodistribution of the injected compound in muscle of female BALB/C mice for 5 hours,A,In vivo,,Mus musculus,10090.0,
4552,1,,BAO_0000218,Intermediate,2106.0,3655,Biodistribution of the injected compound in spleen of female BALB/C mice for 0.5 hours,A,In vivo,,Mus musculus,10090.0,
4553,1,,BAO_0000218,Intermediate,2106.0,3655,Biodistribution of the injected compound in spleen of female BALB/C mice for 2.5 hours,A,In vivo,,Mus musculus,10090.0,
4554,1,,BAO_0000218,Intermediate,2106.0,3655,Biodistribution of the injected compound in spleen of female BALB/C mice for 5 hours,A,In vivo,,Mus musculus,10090.0,
4555,1,,BAO_0000218,Intermediate,945.0,3655,Biodistribution of the injected compound in stomach of female BALB/C mice for 0.5 hours,A,In vivo,,Mus musculus,10090.0,
4556,1,,BAO_0000218,Intermediate,945.0,3655,Biodistribution of the injected compound in stomach of female BALB/C mice for 2.5 hours,A,In vivo,,Mus musculus,10090.0,
4557,1,,BAO_0000218,Intermediate,945.0,3655,Biodistribution of the injected compound in stomach of female BALB/C mice for 5 hours,A,In vivo,,Mus musculus,10090.0,
4558,1,,BAO_0000218,Intermediate,,16597,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for MRT,A,In vivo,,Mus musculus,10090.0,
4559,1,,BAO_0000218,Intermediate,,16597,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for MRT,F,In vivo,,Mus musculus,10090.0,
4560,1,,BAO_0000218,Intermediate,,16597,MRT value at a dose of 10 mg/kg intravenous administration in mice.,A,In vivo,,Mus musculus,10090.0,
4561,1,,BAO_0000218,Intermediate,,16597,MRT value at a dose of 10 mg/kg peroral administration in mice.,A,In vivo,,Mus musculus,10090.0,
4562,1,,BAO_0000218,Intermediate,,17764,Mean-residence time of compound after intravenous administration in mice at 24 uM/kg,A,In vivo,,Mus musculus,10090.0,
4563,1,,BAO_0000218,Intermediate,,17764,Mean-residence time was determined for compound after intraperitoneal administration in mice at 18 uM/kg,F,In vivo,,Mus musculus,10090.0,
4564,1,,BAO_0000219,Intermediate,,3830,In vitro cytotoxicity of compound was determined against A2780 cell lines (cisplatin resistant) at 37 degree C after 96 hr,F,,,Homo sapiens,9606.0,
4565,1,,BAO_0000219,Intermediate,,3829,In vitro cytotoxicity of compound was determined against A2780 cell lines (cisplatin resistant) at 37 degree C for 96 hr,F,,,Homo sapiens,9606.0,
4566,1,,BAO_0000219,Intermediate,,2040,Compound was evaluated for cytotoxicity against A2780 cell lines.,F,,,Homo sapiens,9606.0,
4567,1,,BAO_0000219,Intermediate,,15684,Potentiation of growth inhibition of A2780 by compound alone in experiment 1,F,,,Homo sapiens,9606.0,
4568,1,,BAO_0000219,Intermediate,,15684,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 2,F,,,Homo sapiens,9606.0,
4569,1,,BAO_0000219,Intermediate,,15684,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 1,F,,,Homo sapiens,9606.0,
4570,1,,BAO_0000219,Intermediate,,15684,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 2,F,,,Homo sapiens,9606.0,
4571,1,,BAO_0000219,Intermediate,,15684,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 1,F,,,Homo sapiens,9606.0,
4572,1,,BAO_0000219,Intermediate,,15684,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 2,F,,,Homo sapiens,9606.0,
4573,1,,BAO_0000219,Intermediate,,2859,Compound was evaluated for cytotoxicity against A2780 cell line,F,,,Homo sapiens,9606.0,
4574,1,,BAO_0000219,Intermediate,,5618,In vitro inhibitory activity against human tumor cell line A2780,F,,,Homo sapiens,9606.0,
4575,1,,BAO_0000219,Intermediate,,15684,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 1,F,,,Homo sapiens,9606.0,
4576,1,,BAO_0000219,Intermediate,,15684,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 2,F,,,Homo sapiens,9606.0,
4577,1,,BAO_0000219,Intermediate,,15684,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 1,F,,,Homo sapiens,9606.0,
4578,1,,BAO_0000219,Intermediate,,15684,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 2,F,,,Homo sapiens,9606.0,
4579,1,,BAO_0000219,Intermediate,,2113,The compound was tested for cytotoxic potency against A2780 human tumor cell lines,F,,,Homo sapiens,9606.0,
4580,1,,BAO_0000219,Intermediate,,2113,The compound was tested for cytotoxic potency against A2780 human tumor cell lines.,F,,,Homo sapiens,9606.0,
4581,1,,BAO_0000219,Intermediate,,16745,cytotoxicity against A2780 cells incubated for 24 hr in MTT assay.,F,,,Homo sapiens,9606.0,
4582,1,,BAO_0000218,Expert,,16597,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,F,,,Homo sapiens,9606.0,
4583,1,,BAO_0000219,Intermediate,,15684,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 1,F,,,Homo sapiens,9606.0,
4584,1,,BAO_0000219,Intermediate,,15684,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 2,F,,,Homo sapiens,9606.0,
4585,1,,BAO_0000219,Intermediate,,2040,Compound was evaluated for cytotoxicity against A2780 cis cell lines.,F,,,Homo sapiens,9606.0,
4586,1,,BAO_0000219,Intermediate,,2040,Relative resistance factor in A2780 cisplatin-resistant line,F,,,Homo sapiens,9606.0,
4587,1,,BAO_0000219,Intermediate,,16165,Concentration required to inhibit 50% growth of A2780 human ovarian cancer cells,F,,,Homo sapiens,9606.0,
4588,1,,BAO_0000219,Intermediate,,16165,Concentration required to inhibit 50% growth of A2780 human ovarian cancer cells.,F,,,Homo sapiens,9606.0,
4589,1,,BAO_0000218,Expert,,16597,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,F,,,Homo sapiens,9606.0,
4590,1,,BAO_0000218,Expert,,16597,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,F,,,Homo sapiens,9606.0,
4591,1,,BAO_0000219,Intermediate,,3992,Cytotoxicity against A2780 ovarian carcinoma cells was evaluated using standard sulforhodamine 96h assay test,F,,,Homo sapiens,9606.0,
4592,1,,BAO_0000219,Intermediate,,10553,In vitro cytotoxicity was determined against A2780 human ovarian cell line using NCI screen,F,,,Homo sapiens,9606.0,
4593,1,,BAO_0000219,Intermediate,,15608,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin,F,,,Homo sapiens,9606.0,
4594,1,,BAO_0000219,Intermediate,,15608,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 1,F,,,Homo sapiens,9606.0,
4595,1,,BAO_0000219,Intermediate,,15608,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 2,F,,,Homo sapiens,9606.0,
4596,1,,BAO_0000219,Intermediate,,15608,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 3,F,,,Homo sapiens,9606.0,
4597,1,,BAO_0000219,Intermediate,,15608,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 5,F,,,Homo sapiens,9606.0,
4598,1,,BAO_0000219,Intermediate,,15608,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 8,F,,,Homo sapiens,9606.0,
4599,1,,BAO_0000219,Intermediate,,15569,Cytotoxic activity in a panel of Human ovarian tumor A2780/CDDP cell line after 96h of drug exposure,F,,,Homo sapiens,9606.0,
4600,1,,BAO_0000219,Intermediate,,17420,Antiproliferative effect of compound on A2780/DX cell line,F,,,Homo sapiens,9606.0,
4601,1,,BAO_0000219,Intermediate,,17420,Antiproliferative effect of compound on A2780/DX cell line; n.d. indicates not determined,F,,,Homo sapiens,9606.0,
4602,1,,BAO_0000219,Intermediate,,15099,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780/DX(RI),F,,,Homo sapiens,9606.0,
4603,1,,BAO_0000219,Intermediate,,15099,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780/Dx(RI),F,,,Homo sapiens,9606.0,
4604,1,,BAO_0000219,Intermediate,,17672,Cytotoxicity against ovarian carcinoma A2780/cis tumor cell lines,F,,,Homo sapiens,9606.0,
4605,1,,BAO_0000219,Intermediate,,17672,Cytotoxicity against ovarian carcinoma A2780/cis90 tumor cell lines,F,,,Homo sapiens,9606.0,
4606,1,,BAO_0000219,Intermediate,,17270,In vitro cytotoxicity against A2780ADR cell line,F,,,Homo sapiens,9606.0,
4607,1,,BAO_0000219,Intermediate,,17270,In vitro cytotoxicity against A2780CIS cell line,F,,,Homo sapiens,9606.0,
4608,1,,BAO_0000219,Intermediate,,5574,In vitro cytotoxic activity against human tumor cell line A2780CisR after incubation for 96 hours,F,,,Homo sapiens,9606.0,
4609,1,,BAO_0000219,Intermediate,,2113,The compound was tested for cytotoxic potency against A2780R human tumor cell lines.,F,,,Homo sapiens,9606.0,
4610,1,,BAO_0000219,Intermediate,,16913,"Inhibitory effect of Gold(III) complex, 2,2' bipy on growth of cisplatin-resistant A2780/R human tumor cell lines",F,,,Homo sapiens,9606.0,
4611,1,,BAO_0000219,Intermediate,,16913,"Inhibitory effect of Gold(III) complex, CDDP on growth of cisplatin-resistant A2780/R human tumor cell lines",F,,,Homo sapiens,9606.0,
4612,0,,BAO_0000218,Autocuration,,17839,Oral bioavailability of compound in rhesus macaques,A,In vivo,,Macaca mulatta,9544.0,
4613,0,,BAO_0000218,Autocuration,,6821,Oral bioavailability in monkey,A,In vivo,,monkey,9443.0,
4614,0,,BAO_0000218,Autocuration,,6078,Oral bioavailability evaluated in monkey,A,In vivo,,monkey,9443.0,
4615,0,,BAO_0000218,Autocuration,,6535,Oral bioavailability in monkey (dose 1 mg/kg p.o.),A,In vivo,,monkey,9443.0,
4616,0,,BAO_0000218,Autocuration,,4449,Oral bioavailability in Rhesus monkey,A,In vivo,,Macaca mulatta,9544.0,
4617,0,,BAO_0000218,Autocuration,,6057,Oral bioavailability was calculated in rhesus monkey,A,In vivo,,Macaca mulatta,9544.0,
4618,0,,BAO_0000218,Autocuration,,5922,Oral bioavailability in cynomolgus monkey,A,In vivo,,Macaca fascicularis,9541.0,
4619,0,,BAO_0000218,Autocuration,,5940,Oral bioavailability in monkey,A,In vivo,,monkey,9443.0,
4620,0,,BAO_0000218,Autocuration,,6265,Oral bioavailability in monkey,A,In vivo,,monkey,9443.0,
4621,0,,BAO_0000218,Autocuration,,6265,Oral bioavailability in monkey (dose 1 mg/kg),A,In vivo,,monkey,9443.0,
4622,0,,BAO_0000218,Autocuration,,6265,Oral bioavailability in monkey (dose 5 mg/kg),A,In vivo,,monkey,9443.0,
4623,0,,BAO_0000218,Autocuration,,5940,Oral bioavailability in monkey,A,In vivo,,monkey,9443.0,
4624,0,,BAO_0000218,Autocuration,,5940,Oral bioavailability in monkey,A,In vivo,,monkey,9443.0,
4625,0,,BAO_0000218,Autocuration,,4514,Oral bioavailability in rhesus monkey,A,In vivo,,Macaca mulatta,9544.0,
4626,0,,BAO_0000218,Autocuration,,5546,Oral bioavailability in rhesus monkey at a dose of 2 mg/kg by po administration,A,In vivo,,Macaca mulatta,9544.0,
4627,0,,BAO_0000218,Autocuration,,5553,Oral bioavailability in squirrel monkey at a dose of 10 mg/kg,A,In vivo,,Saimiri sciureus,9521.0,
4628,0,,BAO_0000218,Autocuration,,6641,Oral bioavailability in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),A,In vivo,,monkey,9443.0,
4629,0,,BAO_0000218,Autocuration,,5472,Oral bioavailability in Rhesus monkey,A,In vivo,,Macaca mulatta,9544.0,
4630,0,,BAO_0000218,Autocuration,,5668,Oral bioavailability in Rhesus monkey (dose 10 mg/kg p.o.),A,In vivo,,Macaca mulatta,9544.0,
4631,0,,BAO_0000218,Autocuration,,5711,Oral bioavailability in monkey at 10 mg/kg of the compound,A,In vivo,,monkey,9443.0,
4632,0,,BAO_0000218,Autocuration,,5145,Bioavailability in Rhesus monkey,A,In vivo,,Macaca mulatta,9544.0,
4633,0,,BAO_0000218,Autocuration,,3443,Glomerular Filtration Rate(GFR) evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,,,Cercopithecidae,9527.0,
4634,0,,BAO_0000218,Autocuration,,3443,Glomerular Filtration Rate(GFR)of the compound compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,,,Cercopithecidae,9527.0,
4635,0,,BAO_0000218,Autocuration,,3249,Half life by ''Cr'' assay in rhesus monkey at a dose of 5 mg/kg,A,In vivo,,Cercopithecidae,9527.0,
4636,0,,BAO_0000218,Autocuration,,3249,Half life the of compound was determined by ''Cr'' assay in squirrel monkey at a dose of 5 mg/kg,A,In vivo,,Cercopithecidae,9527.0,
4637,0,,BAO_0000218,Autocuration,,5355,Mean residence time was determined after intravenous administration in cynomolgus monkeys,A,In vivo,,Cercopithecidae,9527.0,
4638,0,,BAO_0000218,Autocuration,,5355,Mean residence time was determined after oral administration in cynomolgus monkeys; NA means Not applicable,A,In vivo,,Cercopithecidae,9527.0,
4639,0,,BAO_0000218,Autocuration,,5355,Mean residence time was determined after oral administration in cynomolgus monkeys; NA means not applicable,A,In vivo,,Cercopithecidae,9527.0,
4640,0,,BAO_0000218,Autocuration,,4809,Pharmacokinetic parameter MRT was determined in monkey after (iv) administration of a dose of 13 (uM/kg),A,In vivo,,Cercopithecidae,9527.0,
4641,0,,BAO_0000218,Autocuration,,4809,Pharmacokinetic parameter MRT was determined in monkey after (po) administration of a dose of 50 (uM/kg),A,In vivo,,Cercopithecidae,9527.0,
4642,0,,BAO_0000251,Autocuration,,14294,Metabolism of compound in monkey S9 microsomes ('+''indicates <20% largest observed peak),A,,,Cercopithecidae,9527.0,
4643,0,,BAO_0000251,Autocuration,,14294,Metabolism of compound in monkey S9 microsomes ('++''indicates 20-50% largest observed peak),A,,,Cercopithecidae,9527.0,
4644,0,,BAO_0000251,Autocuration,,14294,Metabolism of compound in monkey S9 microsomes ('+++'indicates 50-80% largest observed peak),A,,,Cercopithecidae,9527.0,
4645,0,,BAO_0000251,Autocuration,,14294,Metabolism of compound in monkey S9 microsomes ('++++' indicates largest observed peak),A,,,Cercopithecidae,9527.0,
4646,0,,BAO_0000218,Autocuration,,3443,Plasma clearance evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,In vivo,,Cercopithecidae,9527.0,
4647,0,,BAO_0000218,Autocuration,,3443,Plasma clearance compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,In vivo,,Cercopithecidae,9527.0,
4648,0,,BAO_0000019,Autocuration,,11271,Clearance from plasma(with matabolite-corrected plasma radioactivity-time integral) at 30 min after administration.,A,,,Cercopithecidae,9527.0,
4649,0,,BAO_0000218,Autocuration,,3443,Renal clearance evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,,,Cercopithecidae,9527.0,
4650,0,,BAO_0000218,Autocuration,,3443,Renal clearance compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,,,Cercopithecidae,9527.0,
4651,0,,BAO_0000019,Autocuration,,6821,Elimination Half-life of compound was determined in monkey,A,,,Cercopithecidae,9527.0,
4652,0,,BAO_0000019,Autocuration,,17267,Half life of compound was determined in rhesus monkey,A,,,Cercopithecidae,9527.0,
4653,0,,BAO_0000366,Autocuration,1969.0,5819,Half life in monkey plasma,A,,,Cercopithecidae,9527.0,
4654,0,,BAO_0000366,Autocuration,1969.0,5819,Half life in monkey plasma; Not detected,A,,,Cercopithecidae,9527.0,
4655,0,,BAO_0000218,Autocuration,,1916,Half life period was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,A,In vivo,,Cercopithecidae,9527.0,
4656,0,,BAO_0000218,Autocuration,,17509,Half-life 24 hr after 2 mg/kg iv administration in monkeys,A,In vivo,,Cercopithecidae,9527.0,
4657,0,,BAO_0000019,Autocuration,,1399,Terminal half life of the compound.,A,,,Cercopithecidae,9527.0,
4658,0,,BAO_0000218,Autocuration,,1916,Maximum time was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,A,In vivo,,Cercopithecidae,9527.0,
4659,0,,BAO_0000218,Autocuration,,4809,Pharmacokinetic parameter Tmax was determined in monkey after (po) administration of a dose of 50 (uM/kg),A,In vivo,,Cercopithecidae,9527.0,
4660,0,,BAO_0000218,Autocuration,,5546,Unbound plasma was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,A,,,Cercopithecidae,9527.0,
4661,0,,BAO_0000218,Autocuration,1088.0,3443,Urinary recovery evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,,,Cercopithecidae,9527.0,
4662,0,,BAO_0000218,Autocuration,1088.0,3443,Urinary recovery compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,,,Cercopithecidae,9527.0,
4663,0,,BAO_0000218,Autocuration,,4257,Volume of distribution was determined in monkey after a 3 mg/kg of iv dose,A,In vivo,,Cercopithecidae,9527.0,
4664,0,,BAO_0000218,Autocuration,,6221,Volume distribution after oral administration (2.5 mg/kg) in monkey was determined,A,In vivo,,Cercopithecidae,9527.0,
4665,0,,BAO_0000218,Autocuration,,5472,Volume of distribution was evaluated in rhesus,A,In vivo,,Cercopithecidae,9527.0,
4666,0,,BAO_0000218,Autocuration,,4727,Plasma clearance was measured in hamster at the dose of 10 mg/kg by peroral administration,A,In vivo,,Cricetulus griseus,10029.0,
4667,0,,BAO_0000218,Autocuration,,4727,Plasma clearance was measured in hamster at the dose of 3 mg/kg by intravenous administration,A,In vivo,,Cricetulus griseus,10029.0,
4668,0,,BAO_0000218,Autocuration,,4727,Bioavailability in hamster was determined,A,In vivo,,Cricetulus griseus,10029.0,
4669,0,,BAO_0000218,Autocuration,,4727,Bioavailability in hamster at a dose of 3 mg/kg by intravenous administration,A,In vivo,,Cricetulus griseus,10029.0,
4670,0,,BAO_0000218,Autocuration,,4727,Bioavailability in hamster at a dose of 3 mg/kg by oral administration,A,In vivo,,Cricetulus griseus,10029.0,
4671,0,,BAO_0000221,Autocuration,178.0,4727,Half life of compound was determined in hamster blood,A,,,Cricetulus griseus,10029.0,
4672,0,,BAO_0000019,Autocuration,,1452,Michaelis-Menten constant of the compound.,A,,,Sus scrofa,9823.0,
4673,0,,BAO_0000019,Autocuration,,1452,Vmax value was measured at 0 uM concentration of silyl ether.,A,,,Sus scrofa,9823.0,
4674,0,,BAO_0000019,Autocuration,,1452,Vmax value was measured at 10 uM concentration of silyl ether.,A,,,Sus scrofa,9823.0,
4675,0,,BAO_0000019,Autocuration,,1452,Vmax value was measured at 5 uM concentration of silyl ether.,A,,,Sus scrofa,9823.0,
4676,9,,BAO_0000357,Expert,,11706,Inactivation of human leukocyte (neutrophil) elastase(HLE)(HNE) as rate constant,B,,,Homo sapiens,9606.0,
4677,0,,BAO_0000218,Autocuration,,1916,Area under curve was evaluated against man at a dose of 10 mg/kg after po administration,A,,,Homo sapiens,9606.0,
4678,0,,BAO_0000019,Autocuration,,17791,Compound was evaluated for area under the curve expressed as (h*ug/ml),A,,,Homo sapiens,9606.0,
4679,0,,BAO_0000019,Autocuration,,7766,Active metabolite of ifosfamide determined in humans; A-Active,A,,,Homo sapiens,9606.0,
4680,0,,BAO_0000019,Autocuration,,6567,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis,A,,,Homo sapiens,9606.0,
4681,0,,BAO_0000019,Autocuration,,6567,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; -0.5 to 1,A,,,Homo sapiens,9606.0,
4682,0,,BAO_0000019,Autocuration,,6567,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; 1-2,A,,,Homo sapiens,9606.0,
4683,0,,BAO_0000019,Autocuration,,6567,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; trace,A,,,Homo sapiens,9606.0,
4684,0,,BAO_0000218,Autocuration,,17791,Compound was evaluated for oral bioavailability in human,A,,,Homo sapiens,9606.0,
4685,0,,BAO_0000019,Autocuration,1088.0,7766,Metabolite of ifosfamide determined in urine; NF-Not found,A,,,Homo sapiens,9606.0,
4686,0,,BAO_0000019,Autocuration,,6852,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection (Group A and B),A,,,Homo sapiens,9606.0,
4687,0,,BAO_0000019,Autocuration,,6852,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection after dosing with normal antibiotics,A,,,Homo sapiens,9606.0,
4688,0,,BAO_0000019,Autocuration,,6852,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection after dosing with normal antibiotics and lactose,A,,,Homo sapiens,9606.0,
4689,0,,BAO_0000019,Autocuration,,6852,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection before dosing with normal antibiotics,A,,,Homo sapiens,9606.0,
4690,0,,BAO_0000019,Autocuration,,6852,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection before dosing with normal antibiotics and lactose,A,,,Homo sapiens,9606.0,
4691,0,,BAO_0000019,Autocuration,,6852,Percent of compound in cirrhotic patients of sterile ascitic fluid (Group C),A,,,Homo sapiens,9606.0,
4692,0,,BAO_0000019,Autocuration,,6852,Percent of compound in healthy individuals (Group D),A,,,Homo sapiens,9606.0,
4693,0,,BAO_0000251,Autocuration,2107.0,4397,Percent of the parent compound remaining after 20 mins incubation with human liver microsomes,A,,,Homo sapiens,9606.0,
4694,0,,BAO_0000019,Autocuration,,17409,Binding towards human plasma protein at 10 uM,A,,,Homo sapiens,9606.0,
4695,0,,BAO_0000019,Autocuration,,17409,Binding towards human plasma protein at 100 uM,A,,,Homo sapiens,9606.0,
4696,0,,BAO_0000019,Autocuration,,17176,Human plasma protein binding activity was determined,A,,,Homo sapiens,9606.0,
4697,0,,BAO_0000019,Autocuration,,15444,The ability binding to plasma (Binding classified based on injection of compound at 80 concentration.),A,,,Homo sapiens,9606.0,
4698,0,,BAO_0000019,Autocuration,,17267,Percent binding of compound towards human plasma protein was determined,A,,,Homo sapiens,9606.0,
4699,0,,BAO_0000251,Autocuration,2107.0,5944,Plasma clearance in human liver microsomes,A,In vitro,,Homo sapiens,9606.0,
4700,0,,BAO_0000251,Autocuration,2107.0,5668,In vitro intrinsic clearance in human liver microsome,A,In vitro,,Homo sapiens,9606.0,
4701,0,,BAO_0000251,Autocuration,2107.0,5669,In vitro intrinsic clearance in human liver microsome,A,In vitro,,Homo sapiens,9606.0,
4702,0,,BAO_0000251,Autocuration,,5041,In vitro microsome metabolism clearance in human was determined,A,In vitro,,Homo sapiens,9606.0,
4703,0,,BAO_0000251,Autocuration,,5041,In vitro microsome metabolism clearance in human was determined; High,A,In vitro,,Homo sapiens,9606.0,
4704,0,,BAO_0000251,Autocuration,,5041,In vitro microsome metabolism clearance in human was determined; ND denotes no data,A,In vitro,,Homo sapiens,9606.0,
4705,0,,BAO_0000251,Autocuration,2107.0,5676,Pharmacokinetic property (clearance) in human liver microsome,A,In vitro,,Homo sapiens,9606.0,
4706,0,,BAO_0000251,Autocuration,2107.0,5944,Plasma clearance in human liver microsomes,A,In vitro,,Homo sapiens,9606.0,
4707,0,,BAO_0000251,Autocuration,2107.0,17538,In vitro clearance in human liver microsomes,A,In vitro,,Homo sapiens,9606.0,
4708,0,,BAO_0000251,Autocuration,2107.0,6331,Intrinsic clearance in human liver microsomes was determined,A,In vitro,,Homo sapiens,9606.0,
4709,0,,BAO_0000251,Autocuration,2107.0,5948,Intrinsic clearance in human liver microsomes was determined,A,In vitro,,Homo sapiens,9606.0,
4710,0,,BAO_0000218,Autocuration,,5965,Cmax (Tissue distribution) of compound was determined at a dose of 5 mg/kg in human,A,In vivo,,Homo sapiens,9606.0,
4711,0,,BAO_0000218,Autocuration,,1916,Maximum concentration was evaluated against man at a dose of 10 mg/kg after po administration,A,In vivo,,Homo sapiens,9606.0,
4712,0,,BAO_0000218,Autocuration,,5965,Cmin (Clearance) of compound was determined at a dose of 5 mg/kg in human,A,,,Homo sapiens,9606.0,
4713,0,,BAO_0000019,Autocuration,,1299,Stability in human plasma 2 hr after incubation expressed as percent concentration,A,,,Homo sapiens,9606.0,
4714,0,,BAO_0000019,Autocuration,,1299,Stability in human plasma 4 hr after incubation expressed as percent concentration,A,,,Homo sapiens,9606.0,
4715,0,,BAO_0000019,Autocuration,1088.0,7766,Portion of holoxan excreted in the form of the metabolite from 1200 mL of urine on day 3 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,A,,,Homo sapiens,9606.0,
4716,0,,BAO_0000019,Autocuration,1088.0,7766,Portion of holoxan excreted in the form of the metabolite from 1200 mL of urine on day 7 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,A,,,Homo sapiens,9606.0,
4717,0,,BAO_0000019,Autocuration,1088.0,7766,Portion of holoxan excreted in the form of the metabolite from 1300 mL of urine on day 6 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,A,,,Homo sapiens,9606.0,
4718,0,,BAO_0000019,Autocuration,1088.0,7766,Portion of holoxan excreted in the form of the metabolite from 1300 mL of urine on day 8 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,A,,,Homo sapiens,9606.0,
4719,1,,BAO_0000218,Intermediate,,17764,Mean-residence time was determined for compound after intraperitoneal administration in mice at 23 uM/kg,F,In vivo,,Mus musculus,10090.0,
4720,1,,BAO_0000218,Intermediate,,17764,Mean-residence time was determined for compound after intraperitoneal administration in mice at 25 uM/kg,F,In vivo,,Mus musculus,10090.0,
4721,1,,BAO_0000218,Intermediate,,17764,Mean-residence time was determined for compound after intraperitoneal administration in mice at 26 uM/kg,F,In vivo,,Mus musculus,10090.0,
4722,1,,BAO_0000218,Intermediate,,17764,Mean-residence time was determined for compound intravenous administration in mice at 23 uM/kg,F,In vivo,,Mus musculus,10090.0,
4723,1,,BAO_0000218,Intermediate,,14294,Metabolism of compound in Mouse S9 microsomes ('++++'indicates largest observed peak),A,,,Mus musculus,10090.0,
4724,1,,BAO_0000218,Intermediate,,14294,Metabolism of compound in mouse S9 microsomes ('+''indicates <20% largest observed peak),A,,,Mus musculus,10090.0,
4725,1,,BAO_0000218,Intermediate,,14294,Metabolism of compound in mouse S9 microsomes ('++++' indicates largest observed peak),A,,,Mus musculus,10090.0,
4726,1,,BAO_0000218,Intermediate,2107.0,6251,In vitro metabolic potential in mouse liver microsomes,A,,,Mus musculus,10090.0,
4727,1,,BAO_0000218,Intermediate,,17582,Ability of compound to bind to plasma protein was evaluated in HSA cells,A,,,Mus musculus,10090.0,
4728,1,,BAO_0000218,Intermediate,2369.0,17811,Compound was tested for radioactivity level in mice adrenal glands (Compound is radiolabeled),A,,,Mus musculus,10090.0,
4729,1,,BAO_0000218,Intermediate,955.0,17811,Compound was tested for radioactivity level in mice brain (Compound is radiolabeled); 2.2-4.9% ID/g,A,,,Mus musculus,10090.0,
4730,1,,BAO_0000218,Intermediate,955.0,17811,Compound was tested for radioactivity level in mice brain (Compound is radiolabeled); 2.6-4.4% ID/g,A,,,Mus musculus,10090.0,
4731,1,,BAO_0000218,Intermediate,,17811,Compound was tested for radioactivity level in mice heart (Compound is radiolabeled),A,,,Mus musculus,10090.0,
4732,1,,BAO_0000218,Intermediate,2113.0,17811,Compound was tested for radioactivity level in mice kidney (Compound is radiolabeled),A,,,Mus musculus,10090.0,
4733,1,,BAO_0000218,Intermediate,,17811,Compound was tested for radioactivity level in mice lungs (Compound is radiolabeled),A,,,Mus musculus,10090.0,
4734,1,,BAO_0000218,Intermediate,,5288,Tested for urinary recovery in mice after subcutaneous administration of 20 mg/Kg,A,,,Mus musculus,10090.0,
4735,1,,BAO_0000218,Intermediate,1977.0,2717,Compound was evaluated for its potency in CDF1 mice and the serum cholesterol levels were determined,A,,,Mus musculus,10090.0,
4736,1,,BAO_0000218,Intermediate,1977.0,2717,Compound was evaluated for its potency in CDF1 mice and the serum metabolite levels were determined,A,,,Mus musculus,10090.0,
4737,1,,BAO_0000218,Intermediate,1977.0,2717,Compound was evaluated for its potency in CDF1 mice and the serum triglyceride levels were determined,A,,,Mus musculus,10090.0,
4738,1,,BAO_0000218,Intermediate,1969.0,17753,Half life of compound was determined in plasma of mice at 24 mg/Kg,A,In vivo,,Mus musculus,10090.0,
4739,1,,BAO_0000218,Intermediate,1969.0,17753,Half life of compound was determined in plasma of mice at 40 mg/Kg,A,In vivo,,Mus musculus,10090.0,
4740,1,,BAO_0000218,Intermediate,1969.0,17753,Half life of compound was determined in plasma of mice at 5 mg/Kg,A,In vivo,,Mus musculus,10090.0,
4741,1,,BAO_0000218,Intermediate,,17764,Half life after intraperitoneal administration in mice at 18 uM/kg,F,In vivo,,Mus musculus,10090.0,
4742,1,,BAO_0000218,Intermediate,,17764,Half life after intraperitoneal administration in mice at 23 uM/kg,F,In vivo,,Mus musculus,10090.0,
4743,1,,BAO_0000218,Intermediate,,17764,Half life after intraperitoneal administration in mice at 25 uM/kg,F,In vivo,,Mus musculus,10090.0,
4744,1,,BAO_0000218,Intermediate,,17764,Half life after intraperitoneal administration in mice at 26 uM/kg,F,In vivo,,Mus musculus,10090.0,
4745,1,,BAO_0000218,Intermediate,,17764,Half life after intravenous administration in mice at 23 uM/kg,F,In vivo,,Mus musculus,10090.0,
4746,1,,BAO_0000218,Intermediate,,17764,Half life after intravenous administration in mice at 24 uM/kg,A,In vivo,,Mus musculus,10090.0,
4747,1,,BAO_0000218,Intermediate,,16597,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for T max,A,In vivo,,Mus musculus,10090.0,
4748,1,,BAO_0000218,Intermediate,,2675,Maximum time required to reach Cp max was evaluated in mice after intravenous administration; T max Not determined,A,In vivo,,Mus musculus,10090.0,
4749,1,,BAO_0000218,Intermediate,,2675,Maximum time required to reach Cp max was evaluated in mice after oral administration,A,In vivo,,Mus musculus,10090.0,
4750,1,,BAO_0000218,Intermediate,,16597,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for half life (T1/2),A,In vivo,,Mus musculus,10090.0,
4751,1,,BAO_0000218,Intermediate,,4890,"Compound was evaluated for the pharmacokinetic parameter, Terminal half life period",A,In vivo,,Mus musculus,10090.0,
4752,1,,BAO_0000218,Intermediate,,429,Evaluated for pharmacokinetic parameter half-life in mouse at the dose 20 mg/kg,A,In vivo,,Mus musculus,10090.0,
4753,1,,BAO_0000218,Intermediate,178.0,17837,Half life of compound in mouse blood following i.v. administration of 10 mg/kg,A,In vivo,,Mus musculus,10090.0,
4754,1,,BAO_0000218,Intermediate,,16597,Half life at a dose of 10 mg/kg intravenous administration in mice.,A,In vivo,,Mus musculus,10090.0,
4755,1,,BAO_0000218,Intermediate,,16597,Half life at a dose of 10 mg/kg peroral administration in mice.,A,In vivo,,Mus musculus,10090.0,
4756,1,,BAO_0000218,Intermediate,,6619,Half life in ob/ob mice,A,,,Mus musculus,10090.0,
4757,1,,BAO_0000218,Intermediate,,4066,Half-life at a single subcutaneous administration of 40 mg/kg in mice,A,In vivo,,Mus musculus,10090.0,
4758,1,,BAO_0000218,Intermediate,,4239,Half-life was measured in mouse,A,,,Mus musculus,10090.0,
4759,1,,BAO_0000218,Intermediate,,5969,In vivo half life period was determined in murine septicemia at dose of 50 mg/kg,A,In vivo,,Mus musculus,10090.0,
4760,1,,BAO_0000218,Intermediate,,8999,Time for esterases in unfractionated mouse serum to reduce the concentration due to thio ester deacylation,A,,,Mus musculus,10090.0,
4761,1,,BAO_0000218,Intermediate,,8999,Time for esterases in unfractionated mouse serum to reduce the concentration due to thio ester deacylation; 10 % hydrolysis at 60 mins,A,,,Mus musculus,10090.0,
4762,1,,BAO_0000218,Intermediate,955.0,17641,T2 in brain of mice at the oral dose of 50 mg/kg,A,,,Mus musculus,10090.0,
4763,1,,BAO_0000218,Intermediate,2113.0,17641,T2 in kidney of mice at the oral dose of 50 mg/kg,A,,,Mus musculus,10090.0,
4764,1,,BAO_0000218,Intermediate,2107.0,17641,T2 in liver of mice at the oral dose of 50 mg/kg,A,,,Mus musculus,10090.0,
4765,1,,BAO_0000218,Intermediate,2048.0,17641,T2 in lungs of mice at the oral dose of 50 mg/kg,A,,,Mus musculus,10090.0,
4766,1,,BAO_0000218,Intermediate,2106.0,17641,T2 in spleen of mice at the oral dose of 50 mg/kg,A,,,Mus musculus,10090.0,
4767,1,,BAO_0000218,Intermediate,,16597,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for T max,A,In vivo,,Mus musculus,10090.0,
4768,1,,BAO_0000218,Intermediate,,4890,"Compound was evaluated for the pharmacokinetic parameter, maximum time constant",A,In vivo,,Mus musculus,10090.0,
4769,1,,BAO_0000218,Intermediate,,429,Evaluated for pharmacokinetic parameter tmax in mouse at the dose 20 mg/kg,A,In vivo,,Mus musculus,10090.0,
4770,1,,BAO_0000218,Intermediate,,429,Evaluated for pharmacokinetic parameter tmax in mouse at the dose 20 mg/kg was determined,A,In vivo,,Mus musculus,10090.0,
4771,1,,BAO_0000218,Intermediate,,5969,In vivo Tmax was determined in murine septicemia at dose of 100 mg/kg,A,In vivo,,Mus musculus,10090.0,
4772,1,,BAO_0000219,Intermediate,,16913,"Inhibitory effect of Gold(III) complex, [Au(bipy)-(OH)2]-[PF6] on growth of cisplatin-resistant A2780/R human tumor cell lines",F,,,Homo sapiens,9606.0,
4773,1,,BAO_0000219,Intermediate,,16913,"Inhibitory effect of Gold(III) complex, [Au(bipy-H)(OH)]-[PF6] on growth of cisplatin-resistant A2780/R human tumor cell lines",F,,,Homo sapiens,9606.0,
4774,1,,BAO_0000219,Intermediate,,16913,"Inhibitory effect of Gold(III) complex, 2,2' bipy on growth of cisplatin-sensitive A2780/S human tumor cell lines",F,,,Homo sapiens,9606.0,
4775,1,,BAO_0000219,Intermediate,,16913,"Inhibitory effect of Gold(III) complex, CDDP on growth of cisplatin-sensitive A2780/S human tumor cell lines",F,,,Homo sapiens,9606.0,
4776,1,,BAO_0000219,Intermediate,,16913,"Inhibitory effect of Gold(III) complex, [Au(bipy)-(OH)2]-[PF6] on growth of cisplatin-sensitive A2780/S human tumor cell lines",F,,,Homo sapiens,9606.0,
4777,1,,BAO_0000219,Intermediate,,16913,"Inhibitory effect of Gold(III) complex, [Au(bipy-H)(OH)]-[PF6] on growth of cisplatin-sensitive A2780/S human tumor cell lines",F,,,Homo sapiens,9606.0,
4778,1,,BAO_0000219,Intermediate,,17270,In vitro cytotoxicity against A2780TAX cell line,F,,,Homo sapiens,9606.0,
4779,1,,BAO_0000219,Intermediate,,5618,In vitro inhibitory activity against human tumor cell line A2780cis,F,,,Homo sapiens,9606.0,
4780,1,,BAO_0000219,Expert,,17777,Growth inhibition against A2780 cisplatin resistant wild-type ovarian cell lines,F,,,Homo sapiens,9606.0,
4781,1,,BAO_0000219,Intermediate,,16112,Antitumor activity of compound for 96-h exposure in A2780cisR (acquired resistance to cisplatin) human ovarian cell line,F,,,Homo sapiens,9606.0,
4782,1,,BAO_0000219,Intermediate,,15748,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ),F,,,Homo sapiens,9606.0,
4783,1,,BAO_0000219,Intermediate,,6633,Concentration required to inhibit A2780cisR cell growth when compared with control after incubation for 96 h at 37 C,F,,,Homo sapiens,9606.0,
4784,1,,BAO_0000219,Intermediate,,16930,Compound was evaluated against human Ovarian carcinoma cell line A2780cisR,F,,,Homo sapiens,9606.0,
4785,1,,BAO_0000219,Intermediate,,17496,Cytotoxicity against human ovarian carcinoma A2780cisR cell line,F,,,Homo sapiens,9606.0,
4786,1,,BAO_0000219,Expert,,12989,In vitro antitumor activity against A2780cisR cell line.,F,,,Homo sapiens,9606.0,
4787,1,,BAO_0000219,Intermediate,,4840,Tested for the cytotoxicity in A2780cisR ovarian cell line (cisR denotes resistance to cisplatin),F,,,Homo sapiens,9606.0,
4788,1,,BAO_0000219,Expert,,12989,Resistant factor determined between IC50 of resistant line to that of A2780cisR cell line,F,,,Homo sapiens,9606.0,
4789,1,,BAO_0000219,Intermediate,,16745,cytotoxicity against A2780cisR cells incubated for 24 hr in MTT assay,F,,,Homo sapiens,9606.0,
4790,1,,BAO_0000219,Expert,,16597,Inhibition of A2780 / DDP-S human ovarian carcinoma cell proliferation,F,,,Homo sapiens,9606.0,
4791,9,,BAO_0000019,Expert,,16547,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes,B,,,Rattus norvegicus,10116.0,
4792,8,,BAO_0000019,Expert,,16547,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes (functional antagonist activity),F,,,,,
4793,9,,BAO_0000019,Expert,,16547,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes (functional antagonist activity),F,,,Rattus norvegicus,10116.0,
4794,9,,BAO_0000219,Expert,,15856,Antagonist activity against human A2B adenosine receptor expressed in HEK293 cells uisng [3H]ZM-241385 or [125I]-IABOPX,F,,,Homo sapiens,9606.0,
4795,9,,BAO_0000219,Expert,,15856,Antagonist activity against human A2B adenosine receptor expressed in HEK293 cells using [3H]ZM-241385 (or) [125 I]IABOPX at 10e-5 M,F,,,Homo sapiens,9606.0,
4796,9,,BAO_0000019,Expert,,16547,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes,B,,,Mus musculus,10090.0,
4797,8,,BAO_0000019,Expert,,16547,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes (functional antagonist activity),F,,,,,
4798,9,,BAO_0000019,Expert,,16547,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes (functional antagonist activity),F,,,Mus musculus,10090.0,
4799,8,,BAO_0000357,Expert,,17402,Ability to displace the binding of [3H]-MRE 3008-F20 to the ligand binding site of CHO:hA3 (human Adenosine receptor) at concentration of 10 uM,B,,,,,
4800,0,,BAO_0000219,Autocuration,,11746,Compound was tested in vitro for inhibition of cytopathogenicity of LAV(IIIB) in CD4+ T-cells (A3.01),F,,,Homo sapiens,9606.0,
4801,0,,BAO_0000219,Autocuration,,11746,Compound was tested in vitro for inhibition of cytopathogenicity of LAV(IIIB) in CD4+ T-cells (A3.01); Not active,F,,,Homo sapiens,9606.0,
4802,1,,BAO_0000219,Intermediate,,5455,Compound was evaluated for cytotoxic activity against human melanoma cell line A375,F,,,Homo sapiens,9606.0,
4803,1,,BAO_0000219,Intermediate,,2068,In vitro antitumor activity against A375 (melanoma) human tumor cell lines.,F,,,Homo sapiens,9606.0,
4804,1,,BAO_0000219,Intermediate,,2683,In vitro antitumor activity against A375cell line extracted form melanoma,F,,,Homo sapiens,9606.0,
4805,1,,BAO_0000219,Expert,,15313,Inhibition of cell growth in (A375) melan cell line,F,,,Homo sapiens,9606.0,
4806,1,,BAO_0000219,Intermediate,,13739,In vitro tumor cell growth inhibitory activity against Human melanoma cell lines A375,F,,,Homo sapiens,9606.0,
4807,1,,BAO_0000219,Intermediate,,13739,In vitro tumor cell growth inhibitory activity against Human melanoma cell lines. A375,F,,,Homo sapiens,9606.0,
4808,1,,BAO_0000219,Intermediate,,14750,Compound was tested in vitro for cytotoxicity against A375 cell lines from melanoma.,F,,,Homo sapiens,9606.0,
4809,1,,BAO_0000219,Intermediate,,14777,Antiproliferative activity measured against A427 human lung carcinoma,F,,,Homo sapiens,9606.0,
4810,1,,BAO_0000219,Intermediate,,14777,Antiproliferative activity measured against A427 human lung carcinoma,F,,,Homo sapiens,9606.0,
4811,1,,BAO_0000219,Intermediate,,17672,Cytotoxicity against lung carcinoma A427 tumor cell lines,F,,,Homo sapiens,9606.0,
4812,1,,BAO_0000219,Intermediate,,14368,Inhibition of large cell lung carcinoma (A427),F,,,Homo sapiens,9606.0,
4813,1,,BAO_0000219,Intermediate,,14368,Inhibition of large cell lung carcinoma (A427) after 48-h treatment,F,,,Homo sapiens,9606.0,
4814,1,,BAO_0000219,Intermediate,,13866,Inhibitory activity against A427 epithelial Cancer cell line at the concentration 0-30 uM for 48 hr,F,,,Homo sapiens,9606.0,
4815,1,,BAO_0000219,Intermediate,,2545,Inhibitory concentration in human lung carcinoma A427 cell line,F,,,Homo sapiens,9606.0,
4816,1,,BAO_0000219,Intermediate,,2545,Inhibitory concentration in human lung carcinoma A427/VCR cell line,F,,,Homo sapiens,9606.0,
4817,0,,BAO_0000218,Autocuration,,6062,Terminal phase volume of distribution was measured in monkey after an iv dose of 1 mg/kg,A,In vivo,,Cercopithecidae,9527.0,
4818,0,,BAO_0000218,Autocuration,,4578,Tested for volume of distribution upon iv administration to african green monkey,A,In vivo,,Cercopithecidae,9527.0,
4819,0,,BAO_0000218,Autocuration,,17592,Volume of distribution in monkey,A,In vivo,,Cercopithecidae,9527.0,
4820,0,,BAO_0000218,Autocuration,,5005,Compound was tested for its plasma volume distribution in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,A,In vivo,,Macaca mulatta,9544.0,
4821,0,,BAO_0000218,Autocuration,,5005,Compound was tested for its plasma volume distribution in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po; ND is not determined.,A,In vivo,,Macaca mulatta,9544.0,
4822,0,,BAO_0000218,Autocuration,,5922,Pharmacokinetic property(Vdss) in cynomolgus monkey,A,In vivo,,Cercopithecidae,9527.0,
4823,0,,BAO_0000218,Autocuration,,5355,The distribution volume after intravenous administration in cynomolgus monkeys,A,In vivo,,Cercopithecidae,9527.0,
4824,0,,BAO_0000218,Autocuration,,5355,The distribution volume after oral administration in cynomolgus monkeys; NA means Not applicable,A,In vivo,,Cercopithecidae,9527.0,
4825,0,,BAO_0000218,Autocuration,,5355,The distribution volume after oral administration in cynomolgus monkeys; NA means not applicable,A,In vivo,,Cercopithecidae,9527.0,
4826,0,,BAO_0000218,Autocuration,,6057,Volume displacement was calculated in rhesus monkey,A,In vivo,,Cercopithecidae,9527.0,
4827,0,,BAO_0000218,Autocuration,,5145,Volume of distribution in steady state was determined in rhesus monkey,A,In vivo,,Cercopithecidae,9527.0,
4828,0,,BAO_0000218,Autocuration,,6821,Volume of distribution of compound was determined in monkey,A,In vivo,,Cercopithecidae,9527.0,
4829,0,,BAO_0000218,Autocuration,,5334,Volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),A,In vivo,,Cercopithecidae,9527.0,
4830,0,,BAO_0000218,Autocuration,,5334,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),A,In vivo,,Cercopithecidae,9527.0,
4831,0,,BAO_0000218,Autocuration,,6641,Volumes of distribution in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),A,In vivo,,Cercopithecidae,9527.0,
4832,0,,BAO_0000218,Autocuration,,2661,Compound was evaluated for volume of distribution (steady state) after treatment with iv dose of 1 mgkg to female cynomolgus monkey,A,In vivo,,Cercopithecidae,9527.0,
4833,0,,BAO_0000218,Autocuration,,6535,Volume distribution in monkey after administration of 1 mg/kg iv,A,In vivo,,Cercopithecidae,9527.0,
4834,0,,BAO_0000218,Autocuration,,4809,Volume distribution was determined in monkey after (iv) administration of a dose of 13 (uM/kg),A,In vivo,,Cercopithecidae,9527.0,
4835,0,,BAO_0000218,Autocuration,,6062,Volume of distribution was measured in monkey after an iv dose of 1 mg/kg,A,In vivo,,Cercopithecidae,9527.0,
4836,0,,BAO_0000218,Autocuration,,3443,Half life evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,In vivo,,Cercopithecidae,9527.0,
4837,0,,BAO_0000218,Autocuration,,4578,Oral systemic bioavailability upon iv administration to african green monkey,A,In vivo,,Cercopithecidae,9527.0,
4838,0,,BAO_0000218,Autocuration,,4809,Plasma clearance was determined in monkey after (iv) administration of a dose of 13 (uM/kg),A,In vivo,,Cercopithecidae,9527.0,
4839,0,,BAO_0000019,Autocuration,,11271,Baboon plasma free fraction. ,A,,,Cercopithecidae,9527.0,
4840,0,,BAO_0000218,Autocuration,,6057,Area under the curve was calculated in rhesus monkey after iv administration,A,,,Cercopithecidae,9527.0,
4841,0,,BAO_0000019,Autocuration,,6057,Area under the curve was calculated in rhesus monkey after peroral administration,A,,,Cercopithecidae,9527.0,
4842,0,,BAO_0000019,Autocuration,,17853,Dose-normalized area under curve in monkey (p.o.) at 2.0 mpk,A,,,Cercopithecidae,9527.0,
4843,0,,BAO_0000218,Autocuration,,5302,Half life period in monkey after 5 mg/kg dose,A,In vivo,,Cercopithecidae,9527.0,
4844,0,,BAO_0000218,Autocuration,,4257,Half-life was determined in monkey after 3 mg/kg of i.v. dose,A,In vivo,,Cercopithecidae,9527.0,
4845,0,,BAO_0000218,Autocuration,,4257,Half-life was determined in monkey after 3 mg/kg of i.v. dose; Not determined,A,In vivo,,Cercopithecidae,9527.0,
4846,0,,BAO_0000218,Autocuration,1969.0,13501,Apparent Half life was determined from the linear portion of the log plasma concentration-time profile after oral administration of compound 18 at a dose of 1 mg/kg to rhesus monkey,A,In vivo,,Cercopithecidae,9527.0,
4847,0,,BAO_0000218,Autocuration,,5394,Compound at a dose 3 mg/kg was administered to monkey and was evaluated for half life after administration into monkey at 3 mg/kg,A,In vivo,,Cercopithecidae,9527.0,
4848,0,,BAO_0000218,Autocuration,,2661,Compound was evaluated for half-life after treatment with iv dose of 1 mgkg to female cynomolgus monkey,A,In vivo,,Cercopithecidae,9527.0,
4849,0,,BAO_0000019,Autocuration,,3341,Compound was evaluated for terminal half life in monkey,A,,,Cercopithecidae,9527.0,
4850,0,,BAO_0000218,Autocuration,,3045,Compound was evaluated for the half life period after iv administration in cynomolgus monkey,A,In vivo,,Cercopithecidae,9527.0,
4851,0,,BAO_0000218,Autocuration,1969.0,5005,Compound was tested for its plasma half life in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,A,In vivo,,Macaca mulatta,9544.0,
4852,0,,BAO_0000019,Autocuration,,4847,Half life of compound was determined in squirrel monkey,A,,,Cercopithecidae,9527.0,
4853,0,,BAO_0000218,Autocuration,,4256,Half life after iv administration in cynomolgus monkey,A,In vivo,,Macaca fascicularis,9541.0,
4854,0,,BAO_0000218,Autocuration,1969.0,6535,Half life in monkey plasma after administration of 1 mg/kg iv,A,In vivo,,Cercopithecidae,9527.0,
4855,0,,BAO_0000019,Autocuration,,6057,Half life was calculated in rhesus monkey,A,,,Cercopithecidae,9527.0,
4856,0,,BAO_0000019,Autocuration,,17592,Half life in monkey,A,,,Cercopithecidae,9527.0,
4857,0,,BAO_0000218,Autocuration,,6641,Half life in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),A,In vivo,,Cercopithecidae,9527.0,
4858,0,,BAO_0000019,Autocuration,,5472,Half life was evaluated in rhesus,A,,,Cercopithecidae,9527.0,
4859,0,,BAO_0000218,Autocuration,,6221,Half life period after oral administration (2.5 mg/kg) in monkey was determined,A,In vivo,,Cercopithecidae,9527.0,
4860,0,,BAO_0000218,Autocuration,,5668,Half life period was determine after peroral administration at 10 mpk in Rhesus,A,In vivo,,Cercopithecidae,9527.0,
4861,0,,BAO_0000218,Autocuration,,4809,Half life period was determined in monkey after (iv) administration of a dose of 13 (uM/kg),A,In vivo,,Cercopithecidae,9527.0,
4862,0,,BAO_0000218,Autocuration,,5546,Half life period was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,A,In vivo,,Cercopithecidae,9527.0,
4863,0,,BAO_0000218,Autocuration,,5553,Half life period was determined in squirrel monkey after iv administration at a dose of 5 mg/kg,A,In vivo,,Cercopithecidae,9527.0,
4864,0,,BAO_0000019,Autocuration,,6078,Half-life was calculated in monkey,A,,,Cercopithecidae,9527.0,
4865,0,,BAO_0000019,Autocuration,,5147,Half-life in Squirrel monkey,A,,,Cercopithecidae,9527.0,
4866,0,,BAO_0000019,Autocuration,,5145,Half-life in rhesus monkey,A,,,Cercopithecidae,9527.0,
4867,0,,BAO_0000218,Autocuration,,6062,Half-life was measured in monkey after an iv dose of 1 mg/kg,A,In vivo,,Cercopithecidae,9527.0,
4868,0,,BAO_0000218,Autocuration,,5355,Half-life period after intravenous administration in cynomolgus monkeys,A,In vivo,,Cercopithecidae,9527.0,
4869,0,,BAO_0000218,Autocuration,,5355,Half-life period after oral administration in cynomolgus monkeys,A,In vivo,,Cercopithecidae,9527.0,
4870,0,,BAO_0000218,Autocuration,,5355,Half-life period after oral administration in cynomolgus monkeys; ND meansn Not determined,A,In vivo,,Cercopithecidae,9527.0,
4871,0,,BAO_0000019,Autocuration,1088.0,7766,Portion of holoxan excreted in the form of the metabolite from 1500 mL of urine on day 9 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,A,,,Homo sapiens,9606.0,
4872,0,,BAO_0000019,Autocuration,1088.0,7766,Portion of holoxan excreted in the form of the metabolite from 1600 mL of urine on day 10 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,A,,,Homo sapiens,9606.0,
4873,0,,BAO_0000019,Autocuration,1088.0,7766,Portion of holoxan excreted in the form of the metabolite from 1700 mL of urine on day 5 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,A,,,Homo sapiens,9606.0,
4874,0,,BAO_0000019,Autocuration,1088.0,7766,Portion of holoxan excreted in the form of the metabolite from 2310 mL of urine on day 4 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,A,,,Homo sapiens,9606.0,
4875,0,,BAO_0000019,Autocuration,1088.0,7766,Percent ratio of the enantiomeric form (+)R extracted from the urine of alveolar rhabdomyosarcoma patients was determined,A,,,Homo sapiens,9606.0,
4876,0,,BAO_0000019,Autocuration,1088.0,7766,Percent ratio of the enantiomeric form (+)R extracted from the urine of embryonal rhabdomyosarcoma patients was determined,A,,,Homo sapiens,9606.0,
4877,0,,BAO_0000019,Autocuration,1088.0,7766,Percent ratio of the enantiomeric form (-)S extracted from the urine of alveolar rhabdomyosarcoma patients was determined,A,,,Homo sapiens,9606.0,
4878,0,,BAO_0000019,Autocuration,1088.0,7766,Percent ratio of the enantiomeric form (-)S extracted from the urine of embryonal rhabdomyosarcoma patients was determined,A,,,Homo sapiens,9606.0,
4879,0,,BAO_0000218,Autocuration,,1916,Bioavailability was evaluated in man at a dose of 10 mg/kg after po administration; not determined,A,In vivo,,Homo sapiens,9606.0,
4880,0,,BAO_0000218,Autocuration,,16643,Oral bioavailability in human,A,In vivo,,Homo sapiens,9606.0,
4881,0,,BAO_0000019,Autocuration,,17248,Compound was tested for human plasma protein binding,A,,,Homo sapiens,9606.0,
4882,0,,BAO_0000019,Autocuration,,17248,Compound was tested for human plasma protein binding; Not determined,A,,,Homo sapiens,9606.0,
4883,0,,BAO_0000019,Autocuration,,6241,Protein binding activity of compound in human plasma; % Free,A,,,Homo sapiens,9606.0,
4884,0,,BAO_0000019,Autocuration,,17716,Unbound fraction (plasma),A,,,Homo sapiens,9606.0,
4885,0,,BAO_0000366,Autocuration,1969.0,17605,Half life for the hydrolysis of compound in human blood serum,A,,,Homo sapiens,9606.0,
4886,0,,BAO_0000366,Autocuration,1969.0,17625,Half life period in human plasma using phosphate buffer (0.08 M),A,,,Homo sapiens,9606.0,
4887,0,,BAO_0000366,Autocuration,1969.0,17625,Half life period in human plasma using phosphate buffer (0.1 M),A,,,Homo sapiens,9606.0,
4888,0,,BAO_0000366,Autocuration,1969.0,17747,Half-life in human plasma was determined,A,,,Homo sapiens,9606.0,
4889,0,,BAO_0000019,Autocuration,,15613,Concentration required for 50% toxicity in metastatic lung carcinoma (MV522) cells.,A,,,Homo sapiens,9606.0,
4890,0,,BAO_0000019,Autocuration,,354,Effect of compound on gelation time of human serum induced by dithiothreitol (DTT),A,,,Homo sapiens,9606.0,
4891,0,,BAO_0000019,Autocuration,,3741,"Rate constant in chemical and enzymatic hydrolysis to form L-DOPA, in 80% human plasma",A,,,Homo sapiens,9606.0,
4892,0,,BAO_0000019,Autocuration,,3741,"Rate constant in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 1)",A,,,Homo sapiens,9606.0,
4893,0,,BAO_0000019,Autocuration,,3741,"Rate constant in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 2)",A,,,Homo sapiens,9606.0,
4894,0,,BAO_0000019,Autocuration,,17599,Partition coefficient (logP),A,,,Homo sapiens,9606.0,
4895,0,,BAO_0000019,Autocuration,,5486,In vitro metabolic stability in human was measured as pmol/min/mg/protein,A,,,Homo sapiens,9606.0,
4896,0,,BAO_0000251,Autocuration,,5600,In vitro metabolic stability determined after 30 min of incubation in human hepatic microsomes,A,,,Homo sapiens,9606.0,
4897,0,,BAO_0000019,Autocuration,,14294,Metabolism of compound in human liver slices (male) ('+''indicates <20% largest observed peak),A,,,Homo sapiens,9606.0,
4898,0,,BAO_0000019,Autocuration,,14294,Metabolism of compound in human liver slices (male) ('++''indicates 20-50% largest observed peak),A,,,Homo sapiens,9606.0,
4899,0,,BAO_0000019,Autocuration,,14294,Metabolism of compound in human liver slices (male) ('++++' indicates largest observed peak),A,,,Homo sapiens,9606.0,
4900,0,,BAO_0000251,Autocuration,,14294,Metabolism of compound in human microsomes ('+''indicates <20% largest observed peak),A,,,Homo sapiens,9606.0,
4901,0,,BAO_0000251,Autocuration,,14294,Metabolism of compound in human microsomes ('++++' indicates largest observed peak),A,,,Homo sapiens,9606.0,
4902,0,,BAO_0000251,Autocuration,,14294,Metabolism of compound in human microsomes; Trace,A,,,Homo sapiens,9606.0,
4903,0,,BAO_0000251,Autocuration,2107.0,6260,Percent of compound remaining after 120 min of Metabolization upon incubation with human liver microsomes,A,,,Homo sapiens,9606.0,
4904,0,,BAO_0000251,Autocuration,,6187,Percent metabolized in an in vitro human liver microsomal incubation assay after 60 min,A,,,Homo sapiens,9606.0,
4905,0,,BAO_0000251,Autocuration,2107.0,6251,In vitro metabolic potential in human liver microsomes,A,,,Homo sapiens,9606.0,
4906,0,,BAO_0000019,Autocuration,,3246,Metabolism by recombinant human NAD(P)H:quinone oxidoreductase (NQO1) was evaluated,A,,,Homo sapiens,9606.0,
4907,0,,BAO_0000019,Autocuration,,17313,Tested for human plasma protein binding of the compound; Not tested,A,,,Homo sapiens,9606.0,
4908,0,,BAO_0000019,Autocuration,,6227,Compound was tested for percent protein binding (PB) in human,A,,,Homo sapiens,9606.0,
4909,0,,BAO_0000019,Autocuration,1969.0,5530,Protein binding in human plasma,A,,,Homo sapiens,9606.0,
4910,0,,BAO_0000019,Autocuration,,6108,Permeability coefficient (B to A) in Caco-2 cell,A,,,Homo sapiens,9606.0,
4911,0,,BAO_0000019,Autocuration,,6108,Permeability directional ratio (PB-A/PA-B) in Caco-2 cell,A,,,Homo sapiens,9606.0,
4912,0,,BAO_0000019,Autocuration,,2774,Apparent permeability coefficient (Papp) was determined in human Caco-2 cell monolayer (n = 3),A,,,Homo sapiens,9606.0,
4913,0,,BAO_0000019,Autocuration,,16643,In vitro rate of absorption observed as Caco-2 permeability in humans,A,,,Homo sapiens,9606.0,
4914,0,,BAO_0000219,Autocuration,,17582,Cellular permeability of compound was determined in Caco-2 cells; High,A,,,Homo sapiens,9606.0,
4915,0,,BAO_0000219,Autocuration,,6838,Permeability in Caco-2 cells of compound,A,,,Homo sapiens,9606.0,
4916,0,,BAO_0000019,Autocuration,,6108,Permeability coefficient (A to B) in Caco-2 cell,A,,,Homo sapiens,9606.0,
4917,0,,BAO_0000019,Autocuration,,6108,Permeability coefficient (B to A) in Caco-2 cell,A,,,Homo sapiens,9606.0,
4918,0,,BAO_0000019,Autocuration,,6108,Permeability coefficient (Papp) (Caco-2 cell monolayer),A,,,Homo sapiens,9606.0,
4919,0,,BAO_0000019,Autocuration,,2146,Compound was measured for binding rate for human serum at a carbapenem concentration of 10 ug/mL,A,,,Homo sapiens,9606.0,
4920,0,,BAO_0000019,Autocuration,,4514,Compound was tested for protein binding in human plasma,A,,,Homo sapiens,9606.0,
4921,0,,BAO_0000019,Autocuration,,6108,Transcellular permeability of the [(PA-B+PB-A)/2)] compound was determined in Caco-2 cell,A,,,Homo sapiens,9606.0,
4922,0,,BAO_0000019,Autocuration,1088.0,7766,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1200 mL of urine tested on day 3,A,,,Homo sapiens,9606.0,
4923,1,,BAO_0000218,Intermediate,,5969,In vivo Tmax was determined in murine septicemia at dose of 50 mg/kg,A,In vivo,,Mus musculus,10090.0,
4924,1,,BAO_0000218,Intermediate,,3277,Maximum time was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),A,In vivo,,Mus musculus,10090.0,
4925,1,,BAO_0000218,Intermediate,,3802,Tested for Tmax value at the dose of 10 mg/kg when administered perorally in mouse,A,In vivo,,Mus musculus,10090.0,
4926,1,,BAO_0000218,Intermediate,1969.0,2862,Time taken to reach maximum concentration in plasma upon oral administration in mouse,A,In vivo,,Mus musculus,10090.0,
4927,1,,BAO_0000218,Intermediate,1969.0,6348,Time to reach maximum plasma concentration was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,A,In vivo,,Mus musculus,10090.0,
4928,1,,BAO_0000218,Intermediate,,17764,Tmax after intraperitoneal administration in mice at 23 uM/kg,F,In vivo,,Mus musculus,10090.0,
4929,1,,BAO_0000218,Intermediate,,5781,Tmax after oral administration at 30 mg/kg in ICR mouse,A,In vivo,,Mus musculus,10090.0,
4930,1,,BAO_0000218,Intermediate,,17764,Tmax after peroral administration in mice at 2.4 uM/kg,A,In vivo,,Mus musculus,10090.0,
4931,1,,BAO_0000218,Intermediate,,4066,Tmax at a single subcutaneous administration of 40 mg/kg in mice,A,In vivo,,Mus musculus,10090.0,
4932,1,,BAO_0000218,Intermediate,955.0,17641,Tmax in brain of mice at the oral dose of 50 mg/kg,A,In vivo,,Mus musculus,10090.0,
4933,1,,BAO_0000218,Intermediate,2113.0,17641,Tmax in kidney of mice at the oral dose of 50 mg/kg,A,In vivo,,Mus musculus,10090.0,
4934,1,,BAO_0000218,Intermediate,2107.0,17641,Tmax in liver of mice at the oral dose of 50 mg/kg,A,In vivo,,Mus musculus,10090.0,
4935,1,,BAO_0000218,Intermediate,2048.0,17641,Tmax in lungs of mice at the oral dose of 50 mg/kg,A,In vivo,,Mus musculus,10090.0,
4936,1,,BAO_0000218,Intermediate,,17764,Tmax in mice at 18 uM/kg i.p. administration,F,In vivo,,Mus musculus,10090.0,
4937,1,,BAO_0000218,Intermediate,,17764,Tmax in mice at 23 uM/kg i.v. administration,F,In vivo,,Mus musculus,10090.0,
4938,1,,BAO_0000218,Intermediate,,17764,Tmax in mice at 25 uM/kg i.p. administration,F,In vivo,,Mus musculus,10090.0,
4939,1,,BAO_0000218,Intermediate,,17764,Tmax in mice at 26 uM/kg i.p. administration,F,In vivo,,Mus musculus,10090.0,
4940,1,,BAO_0000218,Intermediate,2106.0,17641,Tmax in spleen of mice at the oral dose of 50 mg/kg,A,In vivo,,Mus musculus,10090.0,
4941,1,,BAO_0000218,Intermediate,,16597,Tmax value at a dose of 10 mg/kg intravenous administration in mice.,A,In vivo,,Mus musculus,10090.0,
4942,1,,BAO_0000218,Intermediate,,16597,Tmax value at a dose of 10 mg/kg peroral administration in mice.,A,In vivo,,Mus musculus,10090.0,
4943,1,,BAO_0000218,Intermediate,,5951,Tmax value in IRC mice,A,,,Mus musculus,10090.0,
4944,1,,BAO_0000218,Intermediate,,5506,Tmax value was determined at a dose of 100 mg/kg (i.p.) in Mice,A,In vivo,,Mus musculus,10090.0,
4945,1,,BAO_0000218,Intermediate,,5506,Tmax value was determined at a dose of 200 mg/kg (i.p.) in Mice,A,In vivo,,Mus musculus,10090.0,
4946,1,,BAO_0000218,Intermediate,1088.0,429,Evaluated for pharmacokinetic parameter urine recovery in mouse at the dose 20 mg/kg ( 0-24 hr ),A,,,Mus musculus,10090.0,
4947,1,,BAO_0000218,Intermediate,1088.0,429,Evaluated for pharmacokinetic parameter urine recovery in mouse at the dose 20 mg/kg (0-24 hr),A,,,Mus musculus,10090.0,
4948,1,,BAO_0000218,Intermediate,1088.0,4066,Urinary recovery by disk method using Streptococcus pyogenes (0-24 h),A,,,Mus musculus,10090.0,
4949,1,,BAO_0000218,Intermediate,,17734,The first compartment constitutes the majority of the volume of distribution after intraperitoneal administration of 100 mg/kg in mice,A,,,Mus musculus,10090.0,
4950,1,,BAO_0000218,Intermediate,,17734,The second majority of the volume of distribution after intraperitoneal administration of 100 mg/kg in mice,A,,,Mus musculus,10090.0,
4951,1,,BAO_0000218,Intermediate,,6062,Terminal phase volume of distribution was measured in mouse after an iv dose of 1 mg/kg,A,In vivo,,Mus musculus,10090.0,
4952,1,,BAO_0000218,Intermediate,,5969,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 100 mg/kg,A,In vivo,,Mus musculus,10090.0,
4953,1,,BAO_0000218,Intermediate,,5969,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 50 mg/kg,A,In vivo,,Mus musculus,10090.0,
4954,1,,BAO_0000218,Intermediate,,5969,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,A,In vivo,,Mus musculus,10090.0,
4955,1,,BAO_0000218,Intermediate,,5980,Vd in mice,A,In vivo,,Mus musculus,10090.0,
4956,1,,BAO_0000218,Intermediate,,17592,Volume of distribution in mouse,A,In vivo,,Mus musculus,10090.0,
4957,1,,BAO_0000218,Intermediate,,6348,Volume of distribution was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,A,In vivo,,Mus musculus,10090.0,
4958,1,,BAO_0000218,Intermediate,,17753,Volume of distribution of compound in plasma was determined at 24 mg/Kg,A,In vivo,,Mus musculus,10090.0,
4959,1,,BAO_0000218,Intermediate,,17753,Volume of distribution of compound in plasma was determined at 40 mg/Kg,A,In vivo,,Mus musculus,10090.0,
4960,1,,BAO_0000218,Intermediate,,17753,Volume of distribution of compound in plasma was determined at 5 mg/Kg,A,In vivo,,Mus musculus,10090.0,
4961,1,,BAO_0000218,Intermediate,,4239,Pharmacokinetic property (vdss) was measured in mouse,A,In vivo,,Mus musculus,10090.0,
4962,1,,BAO_0000218,Intermediate,,2862,Value distribution upon iv administration in mouse,A,In vivo,,Mus musculus,10090.0,
4963,1,,BAO_0000218,Intermediate,,17734,Volume of distribution after intraperitoneal administration of 100 mg/kg in mice,A,In vivo,,Mus musculus,10090.0,
4964,1,,BAO_0000218,Intermediate,,2675,Volume of distribution was evaluated in mice after intravenous administration,A,In vivo,,Mus musculus,10090.0,
4965,1,,BAO_0000218,Intermediate,,2675,Volume of distribution was evaluated in mice after oral administration,A,In vivo,,Mus musculus,10090.0,
4966,1,,BAO_0000218,Intermediate,,17837,Steady state volume of distribution of compound in mouse blood following i.v. administration of 10 mg/kg,A,In vivo,,Mus musculus,10090.0,
4967,1,,BAO_0000218,Intermediate,,5727,Steady state volume of distribution was determined in mice,A,In vivo,,Mus musculus,10090.0,
4968,1,,BAO_0000218,Intermediate,,17852,Volume distribution (steady state) of compound was determined in mouse,A,In vivo,,Mus musculus,10090.0,
4969,1,,BAO_0000218,Intermediate,,17764,Volume of solubility in solution after intravenous administration in mice at 24 uM/kg,A,In vivo,,Mus musculus,10090.0,
4970,1,,BAO_0000218,Intermediate,,16597,Vss value at a dose of 10 mg/kg intravenous administration in mice.,A,In vivo,,Mus musculus,10090.0,
4971,1,,BAO_0000218,Intermediate,,6062,Volume of distribution was measured in mouse after an iv dose of 1 mg/kg,A,In vivo,,Mus musculus,10090.0,
4972,1,,BAO_0000218,Intermediate,2113.0,16438,Biodistribution of compound (oxidized form) in in kidney tissue,A,In vivo,,Mus musculus,10090.0,
4973,1,,BAO_0000218,Intermediate,178.0,16438,Biodistribution in mice as total concentration of both oxidized and reduced forms in blood and animals were sacrificed 10 minutes after ip administration in DMSO solution,A,In vivo,,Mus musculus,10090.0,
4974,1,,BAO_0000218,Intermediate,178.0,16438,"Biodistribution in mice as total concentration of both oxidized and reduced forms in blood and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",A,In vivo,,Mus musculus,10090.0,
4975,1,,BAO_0000218,Intermediate,178.0,16438,"Biodistribution in mice as total concentration of both oxidized and reduced forms in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",A,In vivo,,Mus musculus,10090.0,
4976,1,,BAO_0000219,Intermediate,,10708,Evaluated for the inhibitory concentration required to cause growth inhibition of A427Mer- cell line of lung using the MTT Cytotoxicity Assay,F,,,Homo sapiens,9606.0,
4977,1,,BAO_0000219,Expert,,16597,Inhibition of A431 human squamous cell carcinoma cell proliferation,F,,,Homo sapiens,9606.0,
4978,1,,BAO_0000219,Expert,,16062,Inhibition of cell growth of human epidermoid carcinoma xenograft (A431) model using cell based assay,F,,,Homo sapiens,9606.0,
4979,1,,BAO_0000219,Expert,,16062,Inhibition of human epidermoid carcinoma xenograft (A431) tumor growth,F,,,Homo sapiens,9606.0,
4980,1,,BAO_0000219,Expert,,16958,Concentration required to inhibit growth of human carcinoma epidermoid (A431) cell line,F,,,Homo sapiens,9606.0,
4981,1,,BAO_0000219,Expert,,6700,Inhibition of A431 human carcinoma cell proliferation,F,,,Homo sapiens,9606.0,
4982,1,,BAO_0000219,Expert,,17226,In vitro inhibition of A431 (human carcinoma) cell basal growth.,F,,,Homo sapiens,9606.0,
4983,1,,BAO_0000219,Intermediate,,6828,Inhibitory concentration of compound against growth of human A431 cell line; Resistant,F,,,Homo sapiens,9606.0,
4984,1,,BAO_0000219,Intermediate,,12314,In vitro cytotoxicity against epidermoid carcinoma cell line,F,,,Homo sapiens,9606.0,
4985,9,,BAO_0000218,Expert,,13412,"In vivo efficacy following oral administration in nude mouse tumor model, xenograft A431 cells expressing EGF-R",F,,,Homo sapiens,9606.0,
4986,1,,BAO_0000219,Intermediate,,13299,Antiproliferative activity of compound was measured on human tumor cell line A431.,F,,,Homo sapiens,9606.0,
4987,1,,BAO_0000219,Intermediate,,17420,Antiproliferative effect of compound on A431 cell line expressing mutant p53,F,,,Homo sapiens,9606.0,
4988,1,,BAO_0000219,Intermediate,,13678,Compound was evaluated for cell growth inhibition against A 431 cell line by irradiation in the presence of examined compound,F,,,Homo sapiens,9606.0,
4989,8,,BAO_0000219,Expert,,14171,Inhibition of EGF-stimulated tyrosine phosphorylation in A431 cells.,F,,,,,
4990,1,,BAO_0000219,Expert,,6333,Tested for antiproliferative activity against human A431 cells,F,,,Homo sapiens,9606.0,
4991,9,,BAO_0000219,Expert,,2356,Inhibition of epidermal growth factor receptor (EGF-R) autophosphorylation in A431 cells,F,,,Homo sapiens,9606.0,
4992,1,,BAO_0000219,Expert,,15578,Concentration needed to inhibit 50% growth of the human A431 (epidermoid carcinoma) cell lines,F,,,Homo sapiens,9606.0,
4993,1,,BAO_0000219,Expert,,5126,Inhibition of A431 cell proliferation,F,,,Homo sapiens,9606.0,
4994,1,,BAO_0000219,Expert,,6844,Cytotoxic effect on A431 human epidermoid carcinoma cells,F,,,Homo sapiens,9606.0,
4995,1,,BAO_0000219,Expert,,6844,Cytotoxic effect on A431 human epidermoid carcinoma cells (No response to 1 mM),F,,,Homo sapiens,9606.0,
4996,1,,BAO_0000219,Intermediate,,4925,Cytotoxicity expressed as inhibitory concentration required to reduce the cell growth of A431 human epidermal carcinoma cell line,F,,,Homo sapiens,9606.0,
4997,1,,BAO_0000219,Intermediate,,4925,Cytotoxicity expressed as inhibitory concentration required to reduce the cell growth of A431 human epidermal carcinoma cell line; NT=Not tested,F,,,Homo sapiens,9606.0,
4998,1,,BAO_0000219,Intermediate,,13978,In vitro Growth Inhibitory activity against A431 Human vulva cancer cell line,F,,,Homo sapiens,9606.0,
4999,1,,BAO_0000219,Intermediate,,16786,In vitro cytotoxicity of compound against human A431 (epidermoid) cancer cell line after 72 hr of drug exposure,F,,,Homo sapiens,9606.0,
5000,8,,BAO_0000219,Expert,,13412,Inhibition of EGF-stimulated tyrosine phosphorylation in A431 cells expressing EGF-R,F,,,,,
5001,1,,BAO_0000218,Intermediate,,17824,In vivo antiproliferative activity against A431 cell line,F,,,Homo sapiens,9606.0,
5002,9,,BAO_0000219,Expert,,12751,Inhibition of EGF-dependent autophosphorylation of EGF-R in human A431 cells,F,,,Homo sapiens,9606.0,
5003,1,,BAO_0000219,Expert,,12380,Inhibition of A431 human epidermoid carcinoma cell proliferation,F,,,Homo sapiens,9606.0,
5004,9,,BAO_0000219,Expert,,4959,Inhibition of autophosphorylation of human epidermal growth factor-receptor (EGF-R) expressed in A431 cells,F,,,Homo sapiens,9606.0,
5005,1,,BAO_0000219,Intermediate,,6333,Inhibitory effect on nonphospho-Src after EGF (100 uM) stimulation of A431 cells (control=178),F,,,Homo sapiens,9606.0,
5006,1,,BAO_0000219,Intermediate,,6333,Inhibitory effect on phospho-Src (Tyr416) after EGF (100 uM) stimulation of A431 cells (38),F,,,Homo sapiens,9606.0,
5007,1,,BAO_0000219,Intermediate,,6333,Inhibitory effect on phospho-Src/nonphospho after EGF (100 uM) stimulation of A431 cells (21),F,,,Homo sapiens,9606.0,
5008,9,,BAO_0000019,Expert,,5296,Inhibition of EGFR overexpressing A431 cell proliferation,F,,,Homo sapiens,9606.0,
5009,1,,BAO_0000219,Expert,,12624,Inhibition of A431 cell proliferation,F,,,Homo sapiens,9606.0,
5010,9,,BAO_0000219,Expert,,14926,No inhibition of EGFR phosphorylation in A431 cells 8 hour after washing cells free of the inhibitor,F,,,Homo sapiens,9606.0,
5011,9,,BAO_0000219,Expert,,14926,"Partial inhibition of EGFR phosphorylation in A431 cells, 8 hour after washing cells free of the inhibitor",F,,,Homo sapiens,9606.0,
5012,8,,BAO_0000219,Expert,,14926,Irreversible inhibition of ATP binding site of EGFR (lack of phosphorylated EGFR) in A431 cells 8 hour after washing cells free of the inhibitor),F,,,,,
5013,1,,BAO_0000219,Intermediate,,15144,The compound was tested in vitro for antiproliferative activity against A431 tumor cell lines,F,,,Homo sapiens,9606.0,
5014,1,,BAO_0000219,Intermediate,,15144,The compound was tested in vitro for antiproliferative activity against A431 tumor cell lines,F,,,Homo sapiens,9606.0,
5015,1,,BAO_0000219,Intermediate,,5245,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration at 2 uM after 48 h; Did not affect the viability,F,,,Homo sapiens,9606.0,
5016,1,,BAO_0000219,Intermediate,,5245,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration in the range of 1-10 uM after 48 h; Did not affect the viability,F,,,Homo sapiens,9606.0,
5017,1,,BAO_0000219,Intermediate,,5245,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration up to 10 uM after 48 h; Did not affect the viability,F,,,Homo sapiens,9606.0,
5018,1,,BAO_0000219,Intermediate,,5245,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration 0.01 uM after 48 h; Cell death,F,,,Homo sapiens,9606.0,
5019,1,,BAO_0000219,Intermediate,,5245,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration 2 uM after 48 h; Cell death,F,,,Homo sapiens,9606.0,
5020,0,,BAO_0000019,Autocuration,,5922,Half-life period in cynomolgus monkey,A,,,Cercopithecidae,9527.0,
5021,0,,BAO_0000366,Autocuration,1969.0,1116,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in monkey plasma",A,In vitro,,Cercopithecidae,9527.0,
5022,0,,BAO_0000218,Autocuration,,17853,Longer half-life in monkey (i.v.) at 0.5 mpk,A,In vivo,,Cercopithecidae,9527.0,
5023,0,,BAO_0000366,Autocuration,1969.0,993,Plasma half life in monkey,A,,,Cercopithecidae,9527.0,
5024,0,,BAO_0000366,Autocuration,1969.0,4514,Plasma half-life in rhesus monkey,A,,,Cercopithecidae,9527.0,
5025,0,,BAO_0000218,Autocuration,1969.0,5334,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),A,In vivo,,Cercopithecidae,9527.0,
5026,0,,BAO_0000218,Autocuration,1969.0,5334,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),A,In vivo,,Cercopithecidae,9527.0,
5027,0,,BAO_0000218,Autocuration,,4578,Tested for half life upon iv administration to african green monkey,A,In vivo,,Cercopithecidae,9527.0,
5028,0,,BAO_0000218,Autocuration,,2661,Compound was evaluated for maximum time to reach Cmax after treatment with oral dose of 2 mgkg to female cynomolgus monkey,A,In vivo,,Cercopithecidae,9527.0,
5029,0,,BAO_0000218,Autocuration,,5355,The time for peak concentration value after intravenous administration in cynomolgus monkeys; NA means Not applicable,A,In vivo,,Cercopithecidae,9527.0,
5030,0,,BAO_0000218,Autocuration,,5355,The time for peak concentration value after intravenous administration in cynomolgus monkeys; NA means not applicable,A,In vivo,,Cercopithecidae,9527.0,
5031,0,,BAO_0000218,Autocuration,,5355,The time for peak concentration value after oral administration in cynomolgus monkeys,A,In vivo,,Cercopithecidae,9527.0,
5032,0,,BAO_0000019,Autocuration,,11271,Percentage of tracer or metabolite (CO2) in baboon plasma at 10 min after injection of the compound,A,,,Cercopithecidae,9527.0,
5033,0,,BAO_0000019,Autocuration,,11271,Percentage of tracer or metabolite (CO2) in baboon plasma at 1 min after injection of the compound,A,,,Cercopithecidae,9527.0,
5034,0,,BAO_0000019,Autocuration,,11271,Percentage of tracer or metabolite (CO2) in baboon plasma at 30 min after injection of the compound,A,,,Cercopithecidae,9527.0,
5035,0,,BAO_0000019,Autocuration,,11271,Percentage of tracer or metabolite (CO2) in baboon plasma at 5 min after injection of the compound,A,,,Cercopithecidae,9527.0,
5036,0,,BAO_0000019,Autocuration,,11271,Percentage of tracer or metabolite(EME) in baboon plasma at 10 min after injection of the compound,A,,,Cercopithecidae,9527.0,
5037,0,,BAO_0000019,Autocuration,,11271,Percentage of tracer or metabolite(EME) in baboon plasma at 1 min after injection of the compound,A,,,Cercopithecidae,9527.0,
5038,0,,BAO_0000019,Autocuration,,11271,Percentage of tracer or metabolite(EME) in baboon plasma at 30 min after injection of the compound,A,,,Cercopithecidae,9527.0,
5039,0,,BAO_0000019,Autocuration,,11271,Percentage of tracer or metabolite(EME) in baboon plasma at 5 min after injection of the compound,A,,,Cercopithecidae,9527.0,
5040,0,,BAO_0000019,Autocuration,,11271,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 10 min after injection of the compound,A,,,Cercopithecidae,9527.0,
5041,0,,BAO_0000019,Autocuration,,11271,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 1 min after injection of the compound,A,,,Cercopithecidae,9527.0,
5042,0,,BAO_0000019,Autocuration,,11271,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 30 min after injection of the compound,A,,,Cercopithecidae,9527.0,
5043,0,,BAO_0000019,Autocuration,,11271,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 5 min after injection of the compound,A,,,Cercopithecidae,9527.0,
5044,0,,BAO_0000019,Autocuration,,11271,Percentage of tracer or metabolite (unchanged) in baboon plasma at 10 min after injection of the compound,A,,,Cercopithecidae,9527.0,
5045,0,,BAO_0000019,Autocuration,,11271,Percentage of tracer or metabolite (unchanged) in baboon plasma at 1 min after injection of the compound,A,,,Cercopithecidae,9527.0,
5046,0,,BAO_0000019,Autocuration,,11271,Percentage of tracer or metabolite (unchanged) in baboon plasma at 30 min after injection of the compound,A,,,Cercopithecidae,9527.0,
5047,0,,BAO_0000019,Autocuration,,11271,Percentage of tracer or metabolite (unchanged) in baboon plasma at 5 min after injection of the compound,A,,,Cercopithecidae,9527.0,
5048,1,,BAO_0000218,Intermediate,,5809,Bioavailability in rat (cannulated) (dose 2 mg/kg),A,In vivo,,Rattus norvegicus,10116.0,
5049,1,,BAO_0000218,Intermediate,1969.0,17720,Half life at a dose of 4 mg/kg in Rat Plasma after iv administration,A,In vivo,,Rattus norvegicus,10116.0,
5050,1,,BAO_0000218,Intermediate,1969.0,3546,AUC value in rat after IV administration at a dose of 10 mg/kg,A,,,Rattus norvegicus,10116.0,
5051,1,,BAO_0000218,Intermediate,1969.0,3546,AUC value in rat after oral administration at a dose of 10 mg/kg,A,,,Rattus norvegicus,10116.0,
5052,1,,BAO_0000218,Intermediate,,3546,Cmax value in rat after oral administration at a dose of 10 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,
5053,1,,BAO_0000218,Intermediate,,3546,Bioavailability in rat after oral administration at a dose of 10 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,
5054,1,,BAO_0000218,Intermediate,,3546,Tmax value in rat after oral administration at a dose of 10 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,
5055,1,,BAO_0000218,Intermediate,,3546,Vc value in rat after IV administration at a dose of 10 mg/kg,A,,,Rattus norvegicus,10116.0,
5056,1,,BAO_0000218,Intermediate,,3546,Half life period in rat after IV administration at a dose of 10 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,
5057,0,,BAO_0000019,Autocuration,,10625,The absolute striatal uptake of the carbon-11 labeled compound at 60 min was determined in baboon,A,,,Papio hamadryas,9557.0,
5058,0,,BAO_0000019,Autocuration,,10625,Peak plasma radioactivity for the carbon-11 labeled compound was determined at 0.5 min after injection in baboon; (Range = 0.08-0.11),A,,,Papio hamadryas,9557.0,
5059,0,,BAO_0000019,Autocuration,,10625,Peak plasma radioactivity for the carbon-11 labeled compound was determined at 1.5 min after injection in baboon; (Range = 0.08-0.11),A,,,Papio hamadryas,9557.0,
5060,0,,BAO_0000019,Autocuration,,10625,The amount of unchanged tracer in baboon plasma was determined 1 min after injection of the carbon-11 labeled compound,A,,,Papio hamadryas,9557.0,
5061,0,,BAO_0000019,Autocuration,,10625,The amount of unchanged tracer in baboon plasma was determined 10 min after injection of the carbon-11 labeled compound,A,,,Papio hamadryas,9557.0,
5062,0,,BAO_0000019,Autocuration,,10625,The amount of unchanged tracer in baboon plasma was determined 30 min after injection of the carbon-11 labeled compound,A,,,Papio hamadryas,9557.0,
5063,0,,BAO_0000019,Autocuration,,10625,The amount of unchanged tracer in baboon plasma was determined 60 min after injection of the carbon-11 labeled compound,A,,,Papio hamadryas,9557.0,
5064,0,,BAO_0000019,Autocuration,,10625,The absolute striatal uptake of the carbon-11 labeled compound at 60 min was determined in baboon,A,,,Papio hamadryas,9557.0,
5065,0,,BAO_0000019,Autocuration,,3510,Area under curve after 1 mpk peroral administration to beagles,A,,,beagle,9615.0,
5066,0,,BAO_0000019,Autocuration,,3510,Area under curve after 2 mpk peroral administration to beagles,A,,,beagle,9615.0,
5067,0,,BAO_0000218,Autocuration,,3510,Cmax value after 1 mpk peroral administration to beagles,A,In vivo,,beagle,9615.0,
5068,0,,BAO_0000019,Autocuration,1088.0,7766,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1200 mL of urine tested on day 7,A,,,Homo sapiens,9606.0,
5069,0,,BAO_0000019,Autocuration,1088.0,7766,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1300 mL of urine tested on day 6,A,,,Homo sapiens,9606.0,
5070,0,,BAO_0000019,Autocuration,1088.0,7766,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1300 mL of urine tested on day 8,A,,,Homo sapiens,9606.0,
5071,0,,BAO_0000019,Autocuration,1088.0,7766,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1500 mL of urine tested on day 9,A,,,Homo sapiens,9606.0,
5072,0,,BAO_0000019,Autocuration,1088.0,7766,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1600 mL of urine tested on day 10,A,,,Homo sapiens,9606.0,
5073,0,,BAO_0000019,Autocuration,1088.0,7766,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1700 mL of urine tested on day 5,A,,,Homo sapiens,9606.0,
5074,0,,BAO_0000019,Autocuration,1088.0,7766,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 2310 mL of urine tested on day 4,A,,,Homo sapiens,9606.0,
5075,0,,BAO_0000251,Autocuration,2107.0,16643,Metabolic stability observed at 30 min after administration in human liver microsomes,A,,,Homo sapiens,9606.0,
5076,0,,BAO_0000019,Autocuration,,6852,Percent recovery of 100 ug/mL compound after administration in cirrhotic patients,A,,,Homo sapiens,9606.0,
5077,0,,BAO_0000019,Autocuration,,6852,Percent recovery of 10 ug/mL compound after administration in cirrhotic patients,A,,,Homo sapiens,9606.0,
5078,0,,BAO_0000019,Autocuration,,6852,Percent recovery of 500 ug/mL compound after administration in cirrhotic patients,A,,,Homo sapiens,9606.0,
5079,0,,BAO_0000251,Autocuration,2107.0,6567,"Compound remaining after incubation with 2 mg/mL of human liver microsomes at 37 degrees C for 30 min in a pH 7.4, 0.05 M phosphate buffer",A,,,Homo sapiens,9606.0,
5080,0,,BAO_0000019,Autocuration,,6570,Metabolic stability (% remaining at 30 mins) in human S9.,A,,,Homo sapiens,9606.0,
5081,0,,BAO_0000019,Autocuration,,6570,Metabolic stability determined as remaining percent after 30 min of incubation in human isolated liver S9 preparations; N/D= Not determined,A,,,Homo sapiens,9606.0,
5082,0,,BAO_0000251,Autocuration,2107.0,5237,Percent parent compound remaining after 20 min incubation with human liver microsomes,A,,,Homo sapiens,9606.0,
5083,0,,BAO_0000251,Autocuration,2107.0,5237,Percent parent compound remaining after 20 min incubation with human liver microsomes; ND=No data,A,,,Homo sapiens,9606.0,
5084,0,,BAO_0000251,Autocuration,2107.0,5237,Percent parent compound remaining after 20 min incubation with human liver microsomes; No data,A,,,Homo sapiens,9606.0,
5085,0,,BAO_0000218,Autocuration,,5202,First pass metabolism and metabolic bioavailability using human hepatic microsomes,A,,,Homo sapiens,9606.0,
5086,0,,BAO_0000019,Autocuration,,5481,Percent compound remaining in human plasma after incubation for 60 min at 37 C.,A,,,Homo sapiens,9606.0,
5087,0,,BAO_0000019,Autocuration,,5481,Percent remaining in human plasma after incubation for 60 min at 37 C.,A,,,Homo sapiens,9606.0,
5088,0,,BAO_0000019,Autocuration,,3956,The percent remaining in human plasma after 30 min was determined,A,,,Homo sapiens,9606.0,
5089,0,,BAO_0000366,Autocuration,1969.0,5074,Conversion rate of the prodrug in human plasma,A,,,Homo sapiens,9606.0,
5090,0,,BAO_0000366,Autocuration,1969.0,5074,Conversion rate of the prodrug in human plasma; ND means no data,A,,,Homo sapiens,9606.0,
5091,0,,BAO_0000221,Autocuration,178.0,4727,Half life of compound was determined in human blood,A,,,Homo sapiens,9606.0,
5092,0,,BAO_0000019,Autocuration,,5965,Half life of compound was determined in man with once daily dosing,A,,,Homo sapiens,9606.0,
5093,0,,BAO_0000251,Autocuration,,5732,Half life in human microsomes,A,In vitro,,Homo sapiens,9606.0,
5094,0,,BAO_0000366,Autocuration,1969.0,5819,Half life in human plasma,A,,,Homo sapiens,9606.0,
5095,0,,BAO_0000366,Autocuration,1969.0,5819,Half life in human plasma; Not detected,A,,,Homo sapiens,9606.0,
5096,0,,BAO_0000218,Autocuration,,1916,Half life period was evaluated against man at a dose of 10 mg/kg after po administration,A,In vivo,,Homo sapiens,9606.0,
5097,0,,BAO_0000251,Autocuration,2107.0,6597,Half-life for oxidative metabolic stability was determined using rat liver microsomes,A,In vitro,,Homo sapiens,9606.0,
5098,0,,BAO_0000366,Autocuration,1969.0,5229,Half-life in human plasma,A,,,Homo sapiens,9606.0,
5099,0,,BAO_0000366,Autocuration,1969.0,5229,Half-life of the parent prodrug in plasma,A,,,Homo sapiens,9606.0,
5100,0,,BAO_0000366,Autocuration,1969.0,2192,In vitro half life in human plasma was determined,A,In vitro,,Homo sapiens,9606.0,
5101,0,,BAO_0000251,Autocuration,2107.0,3032,The compound was tested In Vitro for half life in human liver microsomes.,A,In vitro,,Homo sapiens,9606.0,
5102,0,,BAO_0000218,Autocuration,,1916,Maximum time was evaluated against man at a dose of 10 mg/kg after po administration,A,In vivo,,Homo sapiens,9606.0,
5103,0,,BAO_0000218,Autocuration,,17716,Observed volume of distribution,A,In vivo,,Homo sapiens,9606.0,
5104,0,,BAO_0000218,Autocuration,,15778,Oral bioavailability in human,A,In vivo,,Homo sapiens,9606.0,
5105,0,,BAO_0000019,Autocuration,,17313,Tested for human plasma protein binding of the compound,A,,,Homo sapiens,9606.0,
5106,0,,BAO_0000019,Autocuration,,4231,"First order rate constant, k was determined in human plasma",A,,,Homo sapiens,9606.0,
5107,0,,BAO_0000019,Autocuration,,4755,Observed rate constant in 80% human plasma at 37 degree Centigrade,A,,,Homo sapiens,9606.0,
5108,0,,BAO_0000019,Autocuration,,4755,Observed rate constant in 80% human plasma at 37 degree Centigrade,A,,,Homo sapiens,9606.0,
5109,0,,BAO_0000251,Autocuration,2107.0,16907,Loss of compound (%metabolized) after 30 min exposure to human liver microsomes,A,,,Homo sapiens,9606.0,
5110,0,,BAO_0000019,Autocuration,,10839,The compound was tested for the plasma binding in human,A,,,Homo sapiens,9606.0,
5111,0,,BAO_0000019,Autocuration,,10839,Plasma protein binding (human),A,,,Homo sapiens,9606.0,
5112,0,,BAO_0000251,Autocuration,2107.0,3199,Compound was evaluated for half-life in human liver microsomes,A,In vitro,,Homo sapiens,9606.0,
5113,0,,BAO_0000221,Autocuration,178.0,1345,Half life measured in vitro for its stability in human blood,A,In vitro,,Homo sapiens,9606.0,
5114,0,,BAO_0000019,Autocuration,1977.0,4297,Half life in human serum,A,,,Homo sapiens,9606.0,
5115,0,,BAO_0000019,Autocuration,1977.0,4297,Half life in human serum; ND=not determined,A,,,Homo sapiens,9606.0,
5116,0,,BAO_0000019,Autocuration,,4297,Half life were determined in CEM-SS cell extract in decomposition step 1,A,,,Homo sapiens,9606.0,
5117,0,,BAO_0000019,Autocuration,,4297,Half life were determined in CEM-SS cell extract in decomposition step 2,A,,,Homo sapiens,9606.0,
5118,0,,BAO_0000366,Autocuration,1969.0,4231,Half life of the in human plasma,A,,,Homo sapiens,9606.0,
5119,0,,BAO_0000220,Autocuration,,5633,Half life period in human hepatic S9 fraction was determined,A,In vitro,,Homo sapiens,9606.0,
5120,0,,BAO_0000251,Autocuration,2107.0,5633,Half life period in human liver microsome was determined,A,In vitro,,Homo sapiens,9606.0,
5121,0,,BAO_0000019,Autocuration,,17791,Half life period was determined; 6-7,A,,,Homo sapiens,9606.0,
5122,0,,BAO_0000019,Autocuration,,17791,Half life period was evaluated in human,A,,,Homo sapiens,9606.0,
5123,0,,BAO_0000366,Autocuration,1969.0,3160,Half life time in human plasma,A,,,Homo sapiens,9606.0,
5124,1,,BAO_0000218,Intermediate,955.0,16438,"Biodistribution in mice as total concentration of both oxidized and reduced forms in brain tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",A,In vivo,,Mus musculus,10090.0,
5125,1,,BAO_0000218,Intermediate,948.0,16438,"Biodistribution in mice as total concentration of both oxidized and reduced forms in heart tissues, animals were sacrificed 10 minutes after dosing, in DMSO sol.",A,In vivo,,Mus musculus,10090.0,
5126,1,,BAO_0000218,Intermediate,948.0,16438,"Biodistribution in mice as total concentration of both oxidized and reduced forms in heart tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",A,In vivo,,Mus musculus,10090.0,
5127,1,,BAO_0000218,Intermediate,2113.0,16438,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney and animals were sacrificed 10 minutes after dosing, in DMSO sol.",A,In vivo,,Mus musculus,10090.0,
5128,1,,BAO_0000218,Intermediate,2113.0,16438,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",A,In vivo,,Mus musculus,10090.0,
5129,1,,BAO_0000218,Intermediate,2113.0,16438,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",A,In vivo,,Mus musculus,10090.0,
5130,1,,BAO_0000218,Intermediate,2107.0,16438,"Biodistribution in mice as total concentration of both oxidized and reduced forms in liver and animals were sacrificed 10 minutes after dosing, in DMSO sol.",A,In vivo,,Mus musculus,10090.0,
5131,1,,BAO_0000218,Intermediate,2107.0,16438,Biodistribution in mice as total concentration of both oxidized and reduced forms in liver and animals were sacrificed 10 minutes after ip administration in DMSO solution,A,In vivo,,Mus musculus,10090.0,
5132,1,,BAO_0000218,Intermediate,2107.0,16438,"Biodistribution in mice as total concentration of both oxidized and reduced forms in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",A,In vivo,,Mus musculus,10090.0,
5133,1,,BAO_0000218,Intermediate,2106.0,16438,Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen and animals were sacrificed 10 minutes after ip administration in DMSO solution,A,In vivo,,Mus musculus,10090.0,
5134,1,,BAO_0000218,Intermediate,2106.0,16438,"Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",A,In vivo,,Mus musculus,10090.0,
5135,1,,BAO_0000218,Intermediate,2106.0,16438,"Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",A,In vivo,,Mus musculus,10090.0,
5136,1,,BAO_0000218,Intermediate,955.0,16438,"Biodistribution in mice, total concentration of both oxidized and reduced forms in brain tissues, animals were sacrificed 60 minutes after dosing, in DMSO",A,In vivo,,Mus musculus,10090.0,
5137,1,,BAO_0000218,Intermediate,178.0,16438,Biodistribution of compound (oxidized form) in blood tissue,A,In vivo,,Mus musculus,10090.0,
5138,1,,BAO_0000218,Intermediate,178.0,16438,"Biodistribution of compound (oxidized form) in blood tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",A,In vivo,,Mus musculus,10090.0,
5139,1,,BAO_0000218,Intermediate,178.0,16438,"Biodistribution of compound (oxidized form) in blood tissue, animals were sacrificed 10 minutes after dosing, in DMSO solution",A,In vivo,,Mus musculus,10090.0,
5140,1,,BAO_0000218,Intermediate,178.0,16438,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO",A,In vivo,,Mus musculus,10090.0,
5141,1,,BAO_0000218,Intermediate,178.0,16438,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",A,In vivo,,Mus musculus,10090.0,
5142,1,,BAO_0000218,Intermediate,178.0,16438,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO solution",A,In vivo,,Mus musculus,10090.0,
5143,1,,BAO_0000218,Intermediate,955.0,16438,Biodistribution of compound (oxidized form) in brain tissue of mice,A,In vivo,,Mus musculus,10090.0,
5144,1,,BAO_0000218,Intermediate,955.0,16438,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",A,In vivo,,Mus musculus,10090.0,
5145,1,,BAO_0000218,Intermediate,955.0,16438,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO",A,In vivo,,Mus musculus,10090.0,
5146,1,,BAO_0000218,Intermediate,955.0,16438,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",A,In vivo,,Mus musculus,10090.0,
5147,1,,BAO_0000218,Intermediate,955.0,16438,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",A,In vivo,,Mus musculus,10090.0,
5148,1,,BAO_0000218,Intermediate,955.0,16438,"Biodistribution of compound (oxidized form) in brain tissues, animals were sacrificed 10 minutes after dosing, in DMSO solution",A,In vivo,,Mus musculus,10090.0,
5149,1,,BAO_0000218,Intermediate,948.0,16438,Biodistribution of compound (oxidized form) in heart tissue of mice,A,In vivo,,Mus musculus,10090.0,
5150,1,,BAO_0000218,Intermediate,948.0,16438,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",A,In vivo,,Mus musculus,10090.0,
5151,1,,BAO_0000218,Intermediate,948.0,16438,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",A,In vivo,,Mus musculus,10090.0,
5152,1,,BAO_0000218,Intermediate,948.0,16438,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO",A,In vivo,,Mus musculus,10090.0,
5153,1,,BAO_0000218,Intermediate,948.0,16438,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",A,In vivo,,Mus musculus,10090.0,
5154,1,,BAO_0000218,Intermediate,948.0,16438,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",A,In vivo,,Mus musculus,10090.0,
5155,1,,BAO_0000218,Intermediate,2113.0,16438,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",A,In vivo,,Mus musculus,10090.0,
5156,1,,BAO_0000218,Intermediate,2113.0,16438,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 10 minutes after dosing, in DMSO solution",A,In vivo,,Mus musculus,10090.0,
5157,1,,BAO_0000218,Intermediate,2113.0,16438,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO",A,In vivo,,Mus musculus,10090.0,
5158,1,,BAO_0000218,Intermediate,2113.0,16438,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",A,In vivo,,Mus musculus,10090.0,
5159,1,,BAO_0000218,Intermediate,2113.0,16438,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",A,In vivo,,Mus musculus,10090.0,
5160,1,,BAO_0000218,Intermediate,2107.0,16438,Biodistribution of compound (oxidized form) in liver tissue,A,In vivo,,Mus musculus,10090.0,
5161,1,,BAO_0000218,Intermediate,2107.0,16438,"Biodistribution of compound (oxidized form) in liver tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",A,In vivo,,Mus musculus,10090.0,
5162,1,,BAO_0000218,Intermediate,2107.0,16438,"Biodistribution of compound (oxidized form) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO",A,In vivo,,Mus musculus,10090.0,
5163,1,,BAO_0000219,Intermediate,,5245,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration in the range of 1-10 uM of the compound after 48 h; Cell death,F,,,Homo sapiens,9606.0,
5164,1,,BAO_0000219,Intermediate,,5245,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration up to 10 uM after 48 h; Did not affect the viability,F,,,Homo sapiens,9606.0,
5165,1,,BAO_0000218,Expert,,16289,"In vivo activity in A431 tumor bearing mice, maximum dose (schedule 10-24 days)",F,,,,,
5166,1,,BAO_0000218,Expert,,16289,"In vivo activity in A431 tumor bearing mice, maximum dose (schedule 12-26 days)",F,,,,,
5167,9,,BAO_0000219,Expert,,16093,Inhibition of EGF-induced Tyrosine phosphorylation in A431 cells expressing EGF-R,F,,,Homo sapiens,9606.0,
5168,1,,BAO_0000219,Intermediate,,16825,"Concentration required to inhibit the epidermoid A431 cell growth by 50%, P53 status of cell line used was wild-type. ",F,,,Homo sapiens,9606.0,
5169,1,,BAO_0000219,Intermediate,,4848,Inhibitory activity against proliferation of human epidermoid carcinoma (A431) cells,F,,,Homo sapiens,9606.0,
5170,9,,BAO_0000219,Expert,,14827,Inhibition of EGF-dependent autophosphorylation of EGF-R in A431 cells,F,,,Homo sapiens,9606.0,
5171,9,,BAO_0000219,Expert,,14827,Inhibition of autophosphorylation of epidermal growth factor receptor in A431 cells in culture,F,,,Homo sapiens,9606.0,
5172,1,,BAO_0000218,Expert,,16289,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 10-24 days)",F,,,,,
5173,1,,BAO_0000218,Expert,,16289,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 12-26 days)",F,,,,,
5174,1,,BAO_0000218,Expert,,16289,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 12-26 days)",F,,,,,
5175,1,,BAO_0000218,Expert,,16289,"In vivo activity in A431 tumor bearing mice, ratio of treated and control tumor mass day 24",F,,,,,
5176,1,,BAO_0000218,Expert,,16289,"In vivo activity in A431 tumor bearing mice, ratio of treated and control tumor mass day 26",F,,,,,
5177,9,,BAO_0000219,Expert,,16289,"Irreversible inhibition of EGF-R phosphorylation in A431 cells, 8 hr after washing cells free of compound",F,,,Homo sapiens,9606.0,
5178,8,,BAO_0000219,Expert,,16289,Irreversible inhibition of formation of phosphorylated EGFR in A431 cells 8 hr after washing cells free of compound,F,,,,,
5179,1,,BAO_0000218,Expert,,16289,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 10-24",F,,,,,
5180,1,,BAO_0000218,Expert,,16289,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 12-26",F,,,,,
5181,1,,BAO_0000218,Expert,,16289,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 12-26",F,,,,,
5182,1,,BAO_0000218,Expert,,14555,"Ratio of treated and control A431 cell tumor mass in mice at 5 mg/kg peroral dose, days 7-21 administration",F,,,Mus musculus,10090.0,
5183,1,,BAO_0000218,Expert,,14555,"Difference in days for treated (T) and control (C) A431 cell tumors to reach 750 mg in mice at 5 mg/kg peroral dose, days 7-21 administration",F,,,Mus musculus,10090.0,
5184,1,,BAO_0000218,Expert,,14555,"Net reduction in tumor burden between first and last treatments of A431 cell tumors in mice at 5 mg/kg peroral dose, days 7-21 administration",F,,,Mus musculus,10090.0,
5185,1,,BAO_0000218,Expert,,14555,"Weight change of A431 cell tumors in mice at 5 mg/kg peroral dose, days 7-21 administration",F,,,Mus musculus,10090.0,
5186,1,,BAO_0000219,Expert,,1937,In vitro antiproliferative effect against A431 human epidermoid carcinoma cells,F,,,Homo sapiens,9606.0,
5187,1,,BAO_0000219,Intermediate,,13739,In vitro tumor cell growth inhibitory activity against Human leiomyosarcoma A431 cell lines,F,,,Homo sapiens,9606.0,
5188,1,,BAO_0000219,Intermediate,,3558,Cytotoxicity against A437 cells is the dose giving 50% decrease in the formation of formazan dye,F,,,Homo sapiens,9606.0,
5189,1,,BAO_0000219,Intermediate,,3558,Dose giving a 50% decrease in the living cell number (A437 cells),F,,,Homo sapiens,9606.0,
5190,1,,BAO_0000219,Expert,,17686,In vitro inhibitory concentration against proliferation of A459 cell line.,F,,,Homo sapiens,9606.0,
5191,1,,BAO_0000219,Intermediate,,5305,Inhibitory concentration of compound for cytotoxicity against A459 human lung cells was determined,F,,,Homo sapiens,9606.0,
5192,1,,BAO_0000219,Intermediate,,3614,Inhibition of growth of human NSCL non small cell lung carcinoma cell line (A459) after 72 hr of drug exposure,F,,,Homo sapiens,9606.0,
5193,1,,BAO_0000219,Intermediate,,17229,In vitro antitumor activity against renal A498 tumor cell lines,F,,,Homo sapiens,9606.0,
5194,1,,BAO_0000219,Intermediate,,15935,"In vitro growth inhibition of human kidney carcinoma cell line, A498 with low levels of folate receptors",F,,,Homo sapiens,9606.0,
5195,1,,BAO_0000219,Intermediate,,15935,"In vitro growth inhibition of human kidney carcinoma cell line, A498 with low levels of folate receptors in folate deficient medium",F,,,Homo sapiens,9606.0,
5196,1,,BAO_0000219,Intermediate,,15560,Cytotoxicity against A498 Tumor cell line in SRB Cell viability test,F,,,Homo sapiens,9606.0,
5197,1,,BAO_0000219,Intermediate,,13891,Cytotoxicity concentration against human kidney carcinoma A-498 cell line,F,,,Homo sapiens,9606.0,
5198,1,,BAO_0000219,Intermediate,,13891,Cytotoxicity concentration against human kidney carcinoma A-498 cell line; NT =Not tested,F,,,Homo sapiens,9606.0,
5199,1,,BAO_0000219,Intermediate,,13788,Cytotoxicity on kidney carcinoma (A-498) cell line,F,,,Homo sapiens,9606.0,
5200,1,,BAO_0000219,Intermediate,,15403,Compound was evaluated against Human cell line renal A498,F,,,Homo sapiens,9606.0,
5201,1,,BAO_0000219,Intermediate,,1009,Compound was tested for inhibition of A498 human renal cancer cell line,F,,,Homo sapiens,9606.0,
5202,1,,BAO_0000219,Intermediate,,1043,Growth inhibitory activity against A498 human cancer cell line,F,,,Homo sapiens,9606.0,
5203,1,,BAO_0000219,Intermediate,,5858,In vitro antitumor activity against human renal A498 cell line,F,,,Homo sapiens,9606.0,
5204,1,,BAO_0000219,Intermediate,,5958,In vitro cytotoxic activity against renal (A498) cell line,F,,,Homo sapiens,9606.0,
5205,1,,BAO_0000219,Intermediate,,5506,In vitro cytotoxic activity against human renal cancer (A498) cell line,F,,,Homo sapiens,9606.0,
5206,1,,BAO_0000219,Intermediate,,12781,Tested for cytostatic activity against renal A498 cell line,F,,,Homo sapiens,9606.0,
5207,1,,BAO_0000219,Intermediate,,14399,The compound was tested for the concentration to inhibit 50% of renal A498 cell lines.,F,,,Homo sapiens,9606.0,
5208,1,,BAO_0000219,Expert,,5958,In vitro cytotoxic activity against renal (A498) cell line at a concentration of 10e-5 M,F,,,Homo sapiens,9606.0,
5209,0,,BAO_0000218,Autocuration,,3510,Cmax value after 2 mpk peroral administration to beagles,A,In vivo,,beagle,9615.0,
5210,0,,BAO_0000218,Autocuration,,3510,Bioavailability,A,In vivo,,Canis lupus familiaris,9615.0,beagle
5211,0,,BAO_0000218,Autocuration,,3510,Bioavailability after 1 mpk peroral administration to beagles,A,In vivo,,Canis lupus familiaris,9615.0,beagle
5212,0,,BAO_0000218,Autocuration,,3510,Bioavailability after 2 mpk peroral administration to beagles,A,In vivo,,Canis lupus familiaris,9615.0,beagle
5213,0,,BAO_0000019,Autocuration,,3085,Specificity constant of the BSA-catalyzed deprotonation of compound at pH 9,A,,,Bos taurus,9913.0,
5214,0,,BAO_0000019,Autocuration,,3085,Specificity constant of the bovine serum albumin catalyzed reaction expressed as (kcat/KM)/kuncat,A,,,Bos taurus,9913.0,
5215,0,,BAO_0000019,Autocuration,,3085,Michaelis-Menten kinetics of the bovine serum albumin catalyzed reaction of the compound,A,,,Bos taurus,9913.0,
5216,0,,BAO_0000019,Autocuration,,9372,Solubility against bovine alpha-chymotrypsin,A,,,Bos taurus,9913.0,
5217,0,,BAO_0000019,Autocuration,,3085,Rate constant of the bovine serum albumin catalyzed reaction of the compound,A,,,Bos taurus,9913.0,
5218,0,,BAO_0000019,Autocuration,,3085,Rate constant of the bovine serum albumin catalyzed reaction of the compound,A,,,Bos taurus,9913.0,
5219,0,,BAO_0000221,Autocuration,2106.0,1469,Half life (t) of enzymatic phosphodiester hydrolysis of compound towards calf spleen (CS-PDE) at a concentration of 20 microg,A,,,Bos taurus,9913.0,
5220,0,,BAO_0000019,Autocuration,,4297,Half life in culture medium containing 10% of heat inactivated foetal calf serum,A,,,Bos taurus,9913.0,
5221,0,,BAO_0000019,Autocuration,,4297,Half life in culture medium containing 10% of heat inactivated foetal calf serum; ND=not determined,A,,,Bos taurus,9913.0,
5222,0,,BAO_0000019,Autocuration,,17585,Ability to get deaminated by adenosine deaminase (ADA); Expressed as t1/2,A,,,Bos taurus,9913.0,
5223,0,,BAO_0000221,Autocuration,2106.0,1336,Enzymatic stability was assessed with bovine spleen phosphodiesterase (BS PDE) exonuclase,A,,,Bos taurus,9913.0,
5224,0,,BAO_0000019,Autocuration,,3085,Half life in presence of 2 mg/mL BSA at pH 8.8,A,,,Bos taurus,9913.0,
5225,0,,BAO_0000019,Autocuration,,2857,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 1,A,,,Bos taurus,9913.0,
5226,0,,BAO_0000019,Autocuration,,2857,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 2,A,,,Bos taurus,9913.0,
5227,0,,BAO_0000019,Autocuration,,2857,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 2; Not determined,A,,,Bos taurus,9913.0,
5228,0,,BAO_0000019,Autocuration,,1540,Half-life in the culture medium (RPMI 1640+10% fetal calf serum FCS),A,,,Bos taurus,9913.0,
5229,1,,BAO_0000218,Intermediate,1969.0,6316,AUC (Area Under Plasma concentration-time curve) was after oral administration at 5 mg/kg,A,,,Canis lupus familiaris,9615.0,
5230,1,,BAO_0000218,Intermediate,1969.0,17594,AUC after administration at 100 mg/kg/day in dogs,A,,,Canis lupus familiaris,9615.0,
5231,1,,BAO_0000218,Intermediate,1969.0,4953,AUC in dog at 0-24 hr by peroral administration at 3 mpk,A,,,Canis lupus familiaris,9615.0,
5232,1,,BAO_0000218,Intermediate,1969.0,16907,AUC value after 15 mg/kg iv dose in Dogs,A,,,Canis lupus familiaris,9615.0,
5233,1,,BAO_0000218,Intermediate,1969.0,16907,AUC value after 30 mg/kg po dose in Dogs,A,,,Canis lupus familiaris,9615.0,
5234,1,,BAO_0000218,Intermediate,1969.0,2959,AUC value after administration of 4 mg/Kg oral dose in dog,A,,,Canis lupus familiaris,9615.0,
5235,1,,BAO_0000218,Intermediate,1969.0,17594,AUC0-infinity after single intravenous bolus of 1 mg/kg in dogs,A,,,Canis lupus familiaris,9615.0,
5236,1,,BAO_0000218,Intermediate,,5356,Area Under Curve for the compound was determined in dogs at 1 mg/kg oral dosing; 25-50 ug min/mL,A,,,Canis lupus familiaris,9615.0,
5237,1,,BAO_0000218,Intermediate,,16807,Area under curve (AUC) value in dogs after an intravenous dose of 0.2 mg/Kg in 0.025 M aqueous methanesulfonic acid solution with 5% mannitol at a concentration of 0.2,A,,,Canis lupus familiaris,9615.0,
5238,1,,BAO_0000218,Intermediate,,4527,Area under curve by intravenous administration at a dose of 1 uM/kg in dog was determined,A,,,Canis lupus familiaris,9615.0,
5239,1,,BAO_0000218,Intermediate,,4527,Area under curve by oral administration at a dose of 10 uM/kg in dog was determined,A,,,Canis lupus familiaris,9615.0,
5240,1,,BAO_0000218,Intermediate,,15660,Area under curve determined in dogs after intravenous administration of 3 mg/kg,A,,,Canis lupus familiaris,9615.0,
5241,1,,BAO_0000218,Intermediate,,15660,Area under curve determined in dogs after oral administration of 10 mg/kg,A,,,Canis lupus familiaris,9615.0,
5242,1,,BAO_0000218,Intermediate,,5802,Area under curve of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,A,,,Canis lupus familiaris,9615.0,
5243,1,,BAO_0000218,Expert,,3598,Area under curve of compound determined in dog after iv administration at a dose of 10 mg/kg,A,,,Canis lupus familiaris,9615.0,
5244,1,,BAO_0000218,Expert,,3598,Area under curve of compound from zero time to infinity determined in dog after iv administration at a dose of 10 mg/kg,A,,,Canis lupus familiaris,9615.0,
5245,1,,BAO_0000218,Intermediate,,5944,Area under curve determined in dog at a dose of 0 mg/kg by oral administration along with indavir (10 mg/kg),A,,,Canis lupus familiaris,9615.0,
5246,1,,BAO_0000218,Intermediate,,5944,Area under curve determined in dog at a dose of 10 mg/kg by oral administration,A,,,Canis lupus familiaris,9615.0,
5247,1,,BAO_0000218,Intermediate,,5944,Area under curve determined in dog at a dose of 10 mg/kg by oral administration along with indavir (10 mg/kg),A,,,Canis lupus familiaris,9615.0,
5248,1,,BAO_0000218,Intermediate,,5944,Area under curve determined in dog at a dose of 5 mg/kg by oral administration,A,,,Canis lupus familiaris,9615.0,
5249,1,,BAO_0000218,Intermediate,,4186,Area under curve in dog after administration of 20 mg/kg dose through peroral route,A,,,Canis lupus familiaris,9615.0,
5250,1,,BAO_0000218,Intermediate,,5007,Area under curve in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),A,,,Canis lupus familiaris,9615.0,
5251,1,,BAO_0000218,Intermediate,,5668,Area under curve was determine after peroral administration at 10 mpk in dog,A,,,Canis lupus familiaris,9615.0,
5252,1,,BAO_0000218,Intermediate,,5668,Area under curve was determine after peroral administration at 5 mpk in dog,A,,,Canis lupus familiaris,9615.0,
5253,1,,BAO_0000218,Intermediate,,5006,Area under curve was determined,A,,,Canis lupus familiaris,9615.0,
5254,1,,BAO_0000218,Intermediate,,5006,Area under curve in dogs,A,,,Canis lupus familiaris,9615.0,
5255,1,,BAO_0000218,Intermediate,,3771,Area under curve in dogs at 10 mg/kg dose fo oral administration,A,,,Canis lupus familiaris,9615.0,
5256,1,,BAO_0000218,Intermediate,,3771,Area under curve in dogs at 10 mg/kg dose fo oral administration (Evokes hyperglycerolemia),A,,,Canis lupus familiaris,9615.0,
5257,1,,BAO_0000218,Intermediate,,3771,Area under curve in dogs at 3 mg/kg dose fo intravenous administration,A,,,Canis lupus familiaris,9615.0,
5258,1,,BAO_0000218,Intermediate,,1916,Area under curve was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,A,,,Canis lupus familiaris,9615.0,
5259,1,,BAO_0000218,Intermediate,,5302,Area under curve value in dog at a dose of 5 mg/kg,A,,,Canis lupus familiaris,9615.0,
5260,1,,BAO_0000218,Intermediate,,5600,Area under curve was determined after 0.1 mg/kg iv administration in dog,A,,,Canis lupus familiaris,9615.0,
5261,1,,BAO_0000218,Intermediate,,5600,Area under curve was determined after 0.3 mg/kg po administration in dog,A,,,Canis lupus familiaris,9615.0,
5262,1,,BAO_0000218,Intermediate,,17764,Area under curve was determined for compound after intravenous administration in dogs at 1.2 uM/kg,A,,,Canis lupus familiaris,9615.0,
5263,1,,BAO_0000218,Intermediate,,4368,Area under curve was determined for the compound by intravenous administration of 1.2 mg/kg in dog,A,,,Canis lupus familiaris,9615.0,
5264,0,,BAO_0000019,Autocuration,,5318,Tested for half life period at 37 degree Celsius in PBS buffer at 10.5 pH containing human serum esterase,A,,,Homo sapiens,9606.0,
5265,0,,BAO_0000019,Autocuration,,5318,Tested for half life period at 37 degree Centigrade in PBS buffer at 7.3 pH containing human serum esterase,A,,,Homo sapiens,9606.0,
5266,0,,BAO_0000019,Autocuration,,5318,Tested for half life period at 37 degree Celsius in PBS buffer at 8.0 pH containing human serum esterase,A,,,Homo sapiens,9606.0,
5267,0,,BAO_0000019,Autocuration,,5318,Tested for half life period at 37 degree Celsius in PBS buffer at 8.8 pH containing human serum esterase,A,,,Homo sapiens,9606.0,
5268,0,,BAO_0000221,Autocuration,178.0,14518,Time taken to reduce 50% of the concentration of compound in blood plasma,A,,,Homo sapiens,9606.0,
5269,0,,BAO_0000366,Autocuration,1969.0,2209,"Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I).",A,,,Homo sapiens,9606.0,
5270,0,,BAO_0000366,Autocuration,1969.0,6787,Half life in human plasma,A,,,Homo sapiens,9606.0,
5271,0,,BAO_0000366,Autocuration,1969.0,4898,Half life in human plasma was reported,A,,,Homo sapiens,9606.0,
5272,0,,BAO_0000019,Autocuration,1977.0,6072,Half life in human serum,A,,,Homo sapiens,9606.0,
5273,0,,BAO_0000366,Autocuration,1969.0,16907,Half life upon exposure to human plasma,A,,,Homo sapiens,9606.0,
5274,0,,BAO_0000251,Autocuration,,5656,t1/2 in human microsomes,A,In vitro,,Homo sapiens,9606.0,
5275,0,,BAO_0000366,Autocuration,1969.0,4755,Half life period in 80% human plasma at 37 degree Centigrade,A,,,Homo sapiens,9606.0,
5276,0,,BAO_0000221,Autocuration,14.0,17503,Half-life for rate of hydrolysis was determined in in human skin homogenate (pH 7.4),A,,,Homo sapiens,9606.0,
5277,0,,BAO_0000366,Autocuration,1969.0,12357,Half-life measured in in vitro Cathepsin B assay in human plasma,A,In vitro,,Homo sapiens,9606.0,
5278,0,,BAO_0000019,Autocuration,,3076,Half-life at initial concentration of 5*10e-5 M in CEM cell extract,A,,,Homo sapiens,9606.0,
5279,0,,BAO_0000251,Autocuration,2107.0,6410,Half-life determined by human liver microsome stability assay at a concentration of 5 uM,A,In vitro,,Homo sapiens,9606.0,
5280,0,,BAO_0000366,Autocuration,1969.0,3741,"Half-life in chemical and enzymatic hydrolysis to form L-DOPA, in 80% human plasma",A,,,Homo sapiens,9606.0,
5281,0,,BAO_0000366,Autocuration,1969.0,3741,"Half-life in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 1)",A,,,Homo sapiens,9606.0,
5282,0,,BAO_0000366,Autocuration,1969.0,3741,"Half-life in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 2)",A,,,Homo sapiens,9606.0,
5283,0,,BAO_0000019,Autocuration,,1540,Half-life in the CEM cell extracts,A,,,Homo sapiens,9606.0,
5284,0,,BAO_0000366,Autocuration,1969.0,2905,Half-life was calculated by Human plasma stability assay at 37 degree Centigrade,A,,,Homo sapiens,9606.0,
5285,0,,BAO_0000366,Autocuration,1969.0,2905,Half-life was calculated by Human plasma stability assay at 37 degree centigrade; Not hydrolyzed,A,,,Homo sapiens,9606.0,
5286,0,,BAO_0000019,Autocuration,,5523,Half-life was determined,A,,,Homo sapiens,9606.0,
5287,0,,BAO_0000221,Autocuration,178.0,1499,Half-life (human blood stability),A,,,Homo sapiens,9606.0,
5288,0,,BAO_0000221,Autocuration,178.0,1499,Half-life (human blood stability); no data,A,,,Homo sapiens,9606.0,
5289,0,,BAO_0000366,Autocuration,1969.0,17065,Half-life in human plasma,A,,,Homo sapiens,9606.0,
5290,0,,BAO_0000019,Autocuration,,6861,CYP3A4 metabolism half-life (t1/2),A,,,Homo sapiens,9606.0,
5291,0,,BAO_0000221,Autocuration,178.0,1499,Half-life was determined; 88% of parent remained after incubation for 120 min (human blood stability),A,,,Homo sapiens,9606.0,
5292,0,,BAO_0000366,Autocuration,1969.0,530,In vitro half life in human plasma,A,In vitro,,Homo sapiens,9606.0,
5293,0,,BAO_0000366,Autocuration,1969.0,1116,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in human plasma",A,In vitro,,Homo sapiens,9606.0,
5294,0,,BAO_0000366,Autocuration,1969.0,6695,In vitro hydrolysis in human plasma,A,In vitro,,Homo sapiens,9606.0,
5295,0,,BAO_0000366,Autocuration,1969.0,6695,In vitro hydrolysis in human plasma; no data,A,In vitro,,Homo sapiens,9606.0,
5296,0,,BAO_0000251,Autocuration,2107.0,10,In vitro metabolic stability at 5 uM was determined by incubating with human liver microsomes at 37 degree C,A,In vitro,,Homo sapiens,9606.0,
5297,0,,BAO_0000366,Autocuration,1969.0,993,Plasma half life in human,A,,,Homo sapiens,9606.0,
5298,0,,BAO_0000366,Autocuration,1969.0,15429,Stability after incubation with human plasma (at 37 degree C),A,,,Homo sapiens,9606.0,
5299,0,,BAO_0000366,Autocuration,1969.0,1675,T1/2 was evaluated in human plasma,A,,,Homo sapiens,9606.0,
5300,0,,BAO_0000366,Autocuration,1969.0,2209,"Tested for Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I).",A,,,Homo sapiens,9606.0,
5301,0,,BAO_0000366,Autocuration,1969.0,2209,"Tested for Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I); Not determined",A,,,Homo sapiens,9606.0,
5302,0,,BAO_0000019,Autocuration,,5318,Tested for half life period at 37 degree Centigrade in PBS buffer at 7.3 pH containing human serum esterase,A,,,Homo sapiens,9606.0,
5303,0,,BAO_0000019,Autocuration,,2412,Tested in vitro for the time for half reactivation against human lysosomal alpha-glucosidase,A,In vitro,,Homo sapiens,9606.0,
5304,0,,BAO_0000019,Autocuration,,2412,Tested in vitro for the time for half reactivation against human lysosomal alpha-glucosidase; ND=Not determined,A,In vitro,,Homo sapiens,9606.0,
5305,0,,BAO_0000366,Autocuration,1969.0,2906,The release rate of the free drug from the substrate in human plasma by human plasma stability assay,A,,,Homo sapiens,9606.0,
5306,0,,BAO_0000366,Autocuration,1969.0,2906,The release rate of the free drug from the substrate in human plasma by human plasma stability assay; Not hydrolyzed,A,,,Homo sapiens,9606.0,
5307,0,,BAO_0000019,Autocuration,,5495,Time taken for 50% to be consumed by serum PON1 was determined,A,,,Homo sapiens,9606.0,
5308,0,,BAO_0000019,Autocuration,,5495,Time taken for 50% to be consumed by serum PON1; NH is Not hydrolysed,A,,,Homo sapiens,9606.0,
5309,0,,BAO_0000251,Autocuration,2107.0,4397,Percent of the parent compound remaining after 20 mins incubation with human liver microsomes,A,,,Homo sapiens,9606.0,
5310,0,,BAO_0000218,Autocuration,,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice blood upon intraveneous administration at 2.6 gmol/mice after 1 hour,A,,,Mus sp.,10095.0,
5311,0,,BAO_0000218,Autocuration,,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice blood upon intraveneous administration at 2.6 gmol/mice after 3 hour,A,,,Mus sp.,10095.0,
5312,0,,BAO_0000218,Autocuration,,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice brain upon intraveneous administration at 2.6 gmol/mice after 1 hour,A,,,Mus sp.,10095.0,
5313,0,,BAO_0000218,Autocuration,,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice brain upon intraveneous administration at 2.6 gmol/mice after 3 hour,A,,,Mus sp.,10095.0,
5314,0,,BAO_0000218,Autocuration,,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 1 hour,A,,,Mus sp.,10095.0,
5315,0,,BAO_0000218,Autocuration,,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 24 hour,A,,,Mus sp.,10095.0,
5316,1,,BAO_0000219,Intermediate,,6058,Compound tested for growth inhibition of renal cancer cell line 786-0,F,,,Homo sapiens,9606.0,
5317,1,,BAO_0000219,Intermediate,,17708,Compound was tested for 50% growth inhibition against human renal cancer 786-0 cell line,F,,,Homo sapiens,9606.0,
5318,1,,BAO_0000219,Expert,,14017,Concentration which reduced cell growth to 50 % of level against 786-0 renal cancer line,F,,,Homo sapiens,9606.0,
5319,1,,BAO_0000219,Intermediate,,16818,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-4 concentration",F,,,Homo sapiens,9606.0,
5320,1,,BAO_0000219,Intermediate,,16818,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-6 concentration",F,,,Homo sapiens,9606.0,
5321,1,,BAO_0000219,Intermediate,,16818,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-8 concentration",F,,,Homo sapiens,9606.0,
5322,1,,BAO_0000219,Intermediate,,11970,Tested for cytotoxicity against 786-0 cell lines in renal cancer,F,,,Homo sapiens,9606.0,
5323,1,,BAO_0000219,Intermediate,,12400,Tested in vitro for cytotoxicity in 786-0 cell line of Renal cancer,F,,,Homo sapiens,9606.0,
5324,1,,BAO_0000219,Expert,,12888,Cytotoxic effect on renal cancer line 786-0,F,,,Homo sapiens,9606.0,
5325,1,,BAO_0000219,Intermediate,,15300,In vitro antitumor activity against Renal cancer 786-0 cell lines by 6-day assay,F,,,Homo sapiens,9606.0,
5326,1,,BAO_0000219,Intermediate,,14769,Compound was evaluated for in vitro activity against 786-0 kidney cell lines (Human tumor cells ),F,,,Homo sapiens,9606.0,
5327,1,,BAO_0000219,Intermediate,,15895,"Cytotoxicity against NCI tumor panel, 786-0 renal cancer cell line",F,,,Homo sapiens,9606.0,
5328,1,,BAO_0000219,Intermediate,,17376,Concentration of compound that cause 50% cytotoxicity of 786-0 renal cancer cell line,F,,,Homo sapiens,9606.0,
5329,1,,BAO_0000219,Intermediate,,14882,Compound was tested for antitumor activity against 786-0 renal cancer cell line(molar concentration that inhibits 50% net cell growth).,F,,,Homo sapiens,9606.0,
5330,1,,BAO_0000219,Intermediate,,14882,Compound was tested for antitumor activity against 786-0 renal cancer cell line(molar concentration leading to 50% net cell death),F,,,Homo sapiens,9606.0,
5331,1,,BAO_0000219,Intermediate,,15176,Growth inhibition of the 786-O Renal cancer cell line for 2-day in vitro assay.,F,,,Homo sapiens,9606.0,
5332,1,,BAO_0000219,Intermediate,,12696,In vitro anti tumor activity against human tumor Renal cancer cell lines was determined,F,,,Homo sapiens,9606.0,
5333,1,,BAO_0000219,Intermediate,,2496,The compound was tested in vitro for cytotoxic activity against 786-O cell line (human perirenal carcinoma),F,,,Homo sapiens,9606.0,
5334,1,,BAO_0000219,Intermediate,,11831,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression,F,,,Homo sapiens,9606.0,
5335,1,,BAO_0000219,Intermediate,,11831,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression (49% inhibition achieved at 100 micro g/mL),F,,,Homo sapiens,9606.0,
5336,1,,BAO_0000219,Intermediate,,11831,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression; <20% inhibition achieved,F,,,Homo sapiens,9606.0,
5337,1,,BAO_0000219,Intermediate,,11831,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H1: MSR-33),F,,,Homo sapiens,9606.0,
5338,1,,BAO_0000219,Intermediate,,11831,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H2: MSR-26),F,,,Homo sapiens,9606.0,
5339,1,,BAO_0000219,Intermediate,,11831,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H3: MSR-28); <20% inhibition achieved,F,,,Homo sapiens,9606.0,
5340,1,,BAO_0000219,Intermediate,,11831,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H1: MSR-33),F,,,Homo sapiens,9606.0,
5341,1,,BAO_0000219,Intermediate,,11831,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H2: MSR-26),F,,,Homo sapiens,9606.0,
5342,1,,BAO_0000219,Intermediate,,11831,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H2: MSR-26) (less than 20% inhibition achieved),F,,,Homo sapiens,9606.0,
5343,1,,BAO_0000219,Intermediate,,11831,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H3: MSR-28); <20% inhibition achieved,F,,,Homo sapiens,9606.0,
5344,1,,BAO_0000219,Intermediate,,12782,Growth inhibitory concentration against tumor cells in culture renal cancer 796-0 cell line,F,,,Homo sapiens,9606.0,
5345,0,,BAO_0000019,Intermediate,,1229,In vitro anticancer activity against 8 NCI CNS cancer cell lines; inactive,F,,,,,
5346,1,,BAO_0000219,Expert,,15313,Inhibition of cell growth in drug resistant 8226 myeloma cell line,F,,,Homo sapiens,9606.0,
5347,1,,BAO_0000219,Expert,,15313,Inhibition of cell growth in drug sensitive 8226 myeloma cell line,F,,,Homo sapiens,9606.0,
5348,1,,BAO_0000219,Intermediate,,11544,In vitro inhibition of tumor cell growth in the human myeloma 8226 system.,F,,,Homo sapiens,9606.0,
5349,1,,BAO_0000219,Intermediate,,9424,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,F,,,Homo sapiens,9606.0,
5350,1,,BAO_0000219,Intermediate,,9424,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,F,,,Homo sapiens,9606.0,
5351,1,,BAO_0000219,Intermediate,,9424,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),F,,,Homo sapiens,9606.0,
5352,1,,BAO_0000219,Intermediate,,9424,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),F,,,Homo sapiens,9606.0,
5353,1,,BAO_0000219,Intermediate,,9424,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),F,,,Homo sapiens,9606.0,
5354,1,,BAO_0000219,Intermediate,,9424,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),F,,,Homo sapiens,9606.0,
5355,1,,BAO_0000219,Intermediate,,9424,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),F,,,Homo sapiens,9606.0,
5356,1,,BAO_0000219,Intermediate,,9424,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),F,,,Homo sapiens,9606.0,
5357,1,,BAO_0000219,Intermediate,,9424,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),F,,,Homo sapiens,9606.0,
5358,1,,BAO_0000219,Intermediate,,14769,Compound was evaluated for in vitro activity against A498 kidney cell lines (Human tumor cells ),F,,,Homo sapiens,9606.0,
5359,1,,BAO_0000219,Intermediate,,15354,Compound was tested for the growth inhibition of A498 renal tumor cell line,F,,,Homo sapiens,9606.0,
5360,1,,BAO_0000219,Intermediate,,17445,In vitro cytotoxicity against human tumor A498 cell line (renal cancer),F,,,Homo sapiens,9606.0,
5361,1,,BAO_0000219,Intermediate,,4337,In vitro inhibitory concentration against renal cancer cell line A498,F,,,Homo sapiens,9606.0,
5362,1,,BAO_0000219,Intermediate,,15277,Cytotoxicity against A 498 tumor cell line,F,,,Homo sapiens,9606.0,
5363,1,,BAO_0000219,Intermediate,,4812,In vitro antitumor activity against A498 human cancer cell line,F,,,Homo sapiens,9606.0,
5364,1,,BAO_0000219,Intermediate,,4812,In vitro antitumor activity against A498 human cancer cell line (Data from NCI-screening),F,,,Homo sapiens,9606.0,
5365,1,,BAO_0000219,Intermediate,,4995,Inhibitory dose required against A498 human tumor cell lines,F,,,Homo sapiens,9606.0,
5366,1,,BAO_0000219,Intermediate,,5847,Anticancer activity against one renal cancer (A498 cell line),F,,,Homo sapiens,9606.0,
5367,1,,BAO_0000219,Intermediate,,6557,In vitro cytotoxicity against melanoma A498 cell line,F,,,Homo sapiens,9606.0,
5368,1,,BAO_0000219,Intermediate,,2597,Compound was tested for growth inhibitory activity against A498 cell line,F,,,Homo sapiens,9606.0,
5369,1,,BAO_0000219,Intermediate,,6058,Compound tested for growth inhibition of renal cancer cell line A498,F,,,Homo sapiens,9606.0,
5370,1,,BAO_0000219,Intermediate,,17708,Compound was tested for 50% growth inhibition against human renal cancer A498 cell line,F,,,Homo sapiens,9606.0,
5371,1,,BAO_0000219,Intermediate,,15176,Growth inhibition of the A498 Renal cancer cell line for 2-day in vitro assay.,F,,,Homo sapiens,9606.0,
5372,1,,BAO_0000219,Intermediate,,15300,In vitro antitumor activity against Renal cancer A498 cell lines by 6-day assay,F,,,Homo sapiens,9606.0,
5373,1,,BAO_0000219,Intermediate,,11970,Tested for cytotoxicity against A498 cell lines in renal cancer,F,,,Homo sapiens,9606.0,
5374,1,,BAO_0000219,Intermediate,,12400,Tested in vitro for cytotoxicity in A498 cell line of Renal cancer,F,,,Homo sapiens,9606.0,
5375,1,,BAO_0000219,Expert,,12888,Cytotoxic effect on renal cancer lines A498,F,,,Homo sapiens,9606.0,
5376,1,,BAO_0000219,Intermediate,,3030,Antitumor activity was evaluated for reduction of growth of renal cancer (A498) cells at a concentration of 100 uM,F,,,Homo sapiens,9606.0,
5377,1,,BAO_0000219,Intermediate,,14769,Compound was evaluated for in vitro activity against A498 kidney cell lines (Human tumor cells ),F,,,Homo sapiens,9606.0,
5378,1,,BAO_0000219,Intermediate,,17376,Concentration of compound that cause 50% cytotoxicity of A498 renal cancer cell line,F,,,Homo sapiens,9606.0,
5379,1,,BAO_0000219,Intermediate,,16558,Growth inhibitory activity against A498-2LM human solid tumor cell line using MTT assay,F,,,Homo sapiens,9606.0,
5380,1,,BAO_0000219,Intermediate,,5194,Cytotoxicity against human kidney carcinoma cell lines A4982LM,F,,,Homo sapiens,9606.0,
5381,1,,BAO_0000219,Intermediate,,10708,Evaluated for the inhibitory concentration required to cause growth inhibition of A498Rem- renal cell line using the MTT Cytotoxicity Assay,F,,,Homo sapiens,9606.0,
5382,1,,BAO_0000219,Expert,,16880,Antiproliferative activity in vitro against A549 (human non-small lung carcinoma) cell line.,F,,,Homo sapiens,9606.0,
5383,1,,BAO_0000219,Intermediate,,10196,Antitumor activity against A549 human lung carcinoma cell line,F,,,Homo sapiens,9606.0,
5384,1,,BAO_0000219,Intermediate,,10196,Antitumor activity against A549 human lung carcinoma cell line in experiment 1,F,,,Homo sapiens,9606.0,
5385,1,,BAO_0000219,Intermediate,,10196,Antitumor activity against A549 human lung carcinoma cell line in experiment 2,F,,,Homo sapiens,9606.0,
5386,1,,BAO_0000219,Intermediate,,12083,"Concentration required to inhibit tumor growth in A549, human lung carcinoma (NSCLC) cell line",F,,,Homo sapiens,9606.0,
5387,1,,BAO_0000219,Expert,,16464,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay,F,,,Homo sapiens,9606.0,
5388,1,,BAO_0000219,Intermediate,,16464,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,F,,,Homo sapiens,9606.0,
5389,1,,BAO_0000219,Expert,,16470,In vitro cytotoxic activity against human lung A549 cell line,F,,,Homo sapiens,9606.0,
5390,1,,BAO_0000219,Intermediate,,16470,In vitro cytotoxic activity against human lung A549 cell line ( standard deviation in parenthesis),F,,,Homo sapiens,9606.0,
5391,1,,BAO_0000219,Intermediate,,16470,In vitro cytotoxic activity against human lung A549 cell line),F,,,Homo sapiens,9606.0,
5392,1,,BAO_0000219,Intermediate,,16470,In vitro cytotoxic activity against human lung A549 cell line;NT is not tested,F,,,Homo sapiens,9606.0,
5393,1,,BAO_0000219,Expert,,16582,In vitro cytotoxicity against human non small-cell-lung cell line A549.,F,,,Homo sapiens,9606.0,
5394,1,,BAO_0000219,Intermediate,,15935,"In vitro growth inhibition of human lung carcinoma cell line, A549 with low levels of folate receptors",F,,,Homo sapiens,9606.0,
5395,1,,BAO_0000219,Intermediate,,15935,"In vitro growth inhibition of human lung carcinoma cell line, A549 with low levels of folate receptors in folate deficient medium",F,,,Homo sapiens,9606.0,
5396,1,,BAO_0000219,Expert,,16597,Inhibition of A549 human lung carcinoma cell proliferation,F,,,Homo sapiens,9606.0,
5397,1,,BAO_0000219,Intermediate,,17376,Inhibitory activity against A549 lung adenocarcinoma cell line,F,,,Homo sapiens,9606.0,
5398,1,,BAO_0000219,Intermediate,,16496,Inhibitory concentration required to reduce A549 tumor cell growth by 50% in MTT assay,F,,,Homo sapiens,9606.0,
5399,1,,BAO_0000219,Intermediate,,16152,in vitro anticancer activity against cultured A549 human tumor(lung) cell line,F,,,Homo sapiens,9606.0,
5400,1,,BAO_0000219,Intermediate,,16152,in vitro inhibition of tumor cell growth in cultured A549 human tumor cell line,F,,,Homo sapiens,9606.0,
5401,1,,BAO_0000219,Intermediate,,16464,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,F,,,Homo sapiens,9606.0,
5402,1,,BAO_0000219,Intermediate,,2288,Cytotoxicity was evaluated against A549 non-small cell lung carcinoma human cancer cell line,F,,,Homo sapiens,9606.0,
5403,1,,BAO_0000219,Intermediate,,17350,Compound was tested for antiproliferative activity against human A549 cancer cell lines using MTT assay,F,,,Homo sapiens,9606.0,
5404,1,,BAO_0000219,Expert,,4090,Inhibition of A549 cancer cell proliferation,F,,,Homo sapiens,9606.0,
5405,1,,BAO_0000219,Expert,,4090,Inhibition of A549 cancer cell proliferation (Not tested),F,,,Homo sapiens,9606.0,
5406,1,,BAO_0000219,Intermediate,,17350,Compound was tested for antiproliferative activity against human A549 cancer cell lines using MTT assay,F,,,Homo sapiens,9606.0,
5407,1,,BAO_0000219,Intermediate,,4197,In vitro inhibitory concentration required against human lung A549 carcinoma cells proliferation,F,,,Homo sapiens,9606.0,
5408,1,,BAO_0000219,Intermediate,,17072,Antiproliferative potency determined as inhibitory concentration against A549 cells,F,,,Homo sapiens,9606.0,
5409,1,,BAO_0000219,Intermediate,,17072,Percent assembly of bovine brain tubulin induced by compound at 10 uM versus that caused by 10 uM paclitaxel,F,,,Homo sapiens,9606.0,
5410,1,,BAO_0000219,Intermediate,,5194,Cytotoxicity against Renal cell lines A549 was determined,F,,,Homo sapiens,9606.0,
5411,1,,BAO_0000218,Intermediate,,4257,Area under curve was determined in dog after a 3 mg/kg of oral dose,A,,,Canis lupus familiaris,9615.0,
5412,1,,BAO_0000218,Intermediate,,6123,Area under curve was determined in dog after oral administration at 1 mg/kg,A,,,Canis lupus familiaris,9615.0,
5413,1,,BAO_0000218,Intermediate,,1337,Area under curve was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,A,,,Canis lupus familiaris,9615.0,
5414,1,,BAO_0000218,Intermediate,,1337,Area under curve was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,A,,,Canis lupus familiaris,9615.0,
5415,1,,BAO_0000218,Intermediate,,8833,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of ( 0-2 mins),A,,,Canis lupus familiaris,9615.0,
5416,1,,BAO_0000218,Intermediate,,8833,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of ( 0-5 mins),A,,,Canis lupus familiaris,9615.0,
5417,1,,BAO_0000218,Intermediate,,8833,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of (0-15 mins),A,,,Canis lupus familiaris,9615.0,
5418,1,,BAO_0000218,Intermediate,,8833,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of( 0-120 mins),A,,,Canis lupus familiaris,9615.0,
5419,1,,BAO_0000218,Intermediate,1969.0,17657,Area under plasma concentration time curve in dog upon oral administration,A,,,Canis lupus familiaris,9615.0,
5420,1,,BAO_0000218,Intermediate,1969.0,17650,Area under plasma concentration time curve was measured in dogs after an oral dose of 10 uM/kg,A,,,Canis lupus familiaris,9615.0,
5421,1,,BAO_0000218,Intermediate,,1977,Area under the curve for compound was evaluated in dog at a dose of 10 mg/kg.,A,,,Canis lupus familiaris,9615.0,
5422,1,,BAO_0000218,Intermediate,,1977,Area under the curve for compound was evaluated in dog at a dose of 20 mg/kg.,A,,,Canis lupus familiaris,9615.0,
5423,1,,BAO_0000218,Intermediate,,3132,Area under the curve for the compound was obtained when tested in dog,A,,,Canis lupus familiaris,9615.0,
5424,1,,BAO_0000218,Intermediate,,5473,Area under the curve at a dose of 1 mg/kg,A,,,Canis lupus familiaris,9615.0,
5425,1,,BAO_0000218,Intermediate,,5474,Area under the curve at a dose of 1 mg/kg (oral),A,,,Canis lupus familiaris,9615.0,
5426,1,,BAO_0000218,Intermediate,,5474,Area under the curve at i.v. dose of 0.2 mg/kg,A,,,Canis lupus familiaris,9615.0,
5427,1,,BAO_0000218,Intermediate,,6062,Area under the curve was measured in dog after an iv dose of 1 mg/kg,A,,,Canis lupus familiaris,9615.0,
5428,1,,BAO_0000218,Intermediate,,4709,Bioavailability from area under the curve at time 0 to infinity after intravenous administration of 1 mg/kg in dog,A,,,Canis lupus familiaris,9615.0,
5429,1,,BAO_0000218,Intermediate,,2652,Compound was evaluated for area under curve (total concentration) in dogs at a dose of 1 mpk perorally,A,,,Canis lupus familiaris,9615.0,
5430,1,,BAO_0000218,Intermediate,,2652,Compound was evaluated for area under curve (total concentration) in dogs at a dose of 5 mpk perorally,A,,,Canis lupus familiaris,9615.0,
5431,1,,BAO_0000218,Intermediate,,2877,Compound was evaluated for area under the curve in dog blood.,A,,,Canis lupus familiaris,9615.0,
5432,1,,BAO_0000218,Intermediate,,5444,In vivo area under curve was calculated by peroral administration at 1 mg/kg in fasted dog,A,,,Canis lupus familiaris,9615.0,
5433,1,,BAO_0000218,Intermediate,1969.0,5130,AUC in dog after oral dose (1 mg/kg),A,,,Canis lupus familiaris,9615.0,
5434,1,,BAO_0000218,Intermediate,,6265,Pharmacokinetic (PK) property (AUC) was determined in dog at the single oral dose of 1 mg/kg,A,,,Canis lupus familiaris,9615.0,
5435,1,,BAO_0000218,Intermediate,,4657,"Pharmacokinetic data in dogs at dose of 1 mg/kg perorally, and the area under curve (AUC) was reported.",A,,,Canis lupus familiaris,9615.0,
5436,1,,BAO_0000218,Intermediate,,16367,Pharmacokinetic parameter AUC after intravenous administration to dogs,A,,,Canis lupus familiaris,9615.0,
5437,1,,BAO_0000218,Intermediate,,16367,Pharmacokinetic parameter AUC after oral administration to dogs,A,,,Canis lupus familiaris,9615.0,
5438,1,,BAO_0000218,Intermediate,,9579,Pharmacokinetic parameter AUC was determined in dog after oral administration of 17b,A,,,Canis lupus familiaris,9615.0,
5439,1,,BAO_0000218,Intermediate,,9579,Pharmacokinetic parameter AUC was determined in dog after oral administration of 2b,A,,,Canis lupus familiaris,9615.0,
5440,1,,BAO_0000218,Intermediate,,5983,Pharmacokinetic property (AUC) was measured in dog at the dose of 0.032 mg/kg p.o.,A,,,Canis lupus familiaris,9615.0,
5441,1,,BAO_0000218,Intermediate,,6241,Pharmacokinetic property in dogs after oral administration at 1 mg/kg,A,,,Canis lupus familiaris,9615.0,
5442,1,,BAO_0000218,Intermediate,,5313,"Tested for the pharmacokinetic data, area under the curve of concentration versus time in dog",A,,,Canis lupus familiaris,9615.0,
5443,1,,BAO_0000218,Intermediate,,5313,"Tested for the pharmacokinetic data, area under the curve of concentration versus time in dog at dosage of 10 mpk",A,,,Canis lupus familiaris,9615.0,
5444,1,,BAO_0000218,Intermediate,,6642,Oral AUCN in dog ( (dosed as a mixture of five compounds at 0.5 mpk each via iv only),A,,,Canis lupus familiaris,9615.0,
5445,1,,BAO_0000218,Intermediate,,6642,Oral AUCN in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),A,,,Canis lupus familiaris,9615.0,
5446,1,,BAO_0000218,Intermediate,,6641,Oral AUCN in dog (dosed at 0.5 mpk iv ),A,,,Canis lupus familiaris,9615.0,
5447,1,,BAO_0000218,Intermediate,,6642,Oral AUCN in dog (dosed at 0.5 mpk iv ),A,,,Canis lupus familiaris,9615.0,
5448,1,,BAO_0000218,Intermediate,,17791,Compound was evaluated for oral bioavailability in dog; 90-100,A,,,Canis lupus familiaris,9615.0,
5449,1,,BAO_0000218,Intermediate,,17655,Compound was tested for its cell permeability in the Madin-Darby canine kidney cell monolayer transport assay,A,,,Canis lupus familiaris,9615.0,
5450,1,,BAO_0000218,Intermediate,,17655,Compound was tested for its cell permeability in the Madin-Darby canine kidney cell monolayer transport assay; Not determined,A,,,Canis lupus familiaris,9615.0,
5451,1,,BAO_0000218,Intermediate,,6596,PAPP (membrane permeability) in dog kidney cell monolayer assay,A,,,Canis lupus familiaris,9615.0,
5452,1,,BAO_0000218,Intermediate,,3880,Oral bioavailability in dog,A,,,Canis lupus familiaris,9615.0,
5453,1,,BAO_0000218,Intermediate,,16367,Bioavailability administered orally at a dose of 10 mg/kg to dogs,A,,,Canis lupus familiaris,9615.0,
5454,1,,BAO_0000218,Intermediate,1969.0,17409,Plasma protein binding towards dog plasma at 10 uM,A,,,Canis lupus familiaris,9615.0,
5455,1,,BAO_0000218,Intermediate,1969.0,17409,Plasma protein binding towards dog plasma at 100 uM,A,,,Canis lupus familiaris,9615.0,
5456,1,,BAO_0000218,Intermediate,,2959,Bioavailability in dog (dose 4 mg/kg p.o.),A,In vivo,,Canis lupus familiaris,9615.0,
5457,1,,BAO_0000218,Intermediate,,13501,Bioavailability was determined after oral administration of compound 18 at a dose of 2 mg/kg to dog,A,In vivo,,Canis lupus familiaris,9615.0,
5458,1,,BAO_0000218,Intermediate,,4527,Bioavailability by oral administration at a dose of 10 uM/kg in dog was determined,A,In vivo,,Canis lupus familiaris,9615.0,
5459,1,,BAO_0000218,Intermediate,,15145,Bioavailability in dogs,A,In vivo,,Canis lupus familiaris,9615.0,
5460,1,,BAO_0000218,Intermediate,,4219,Bioavailability,A,In vivo,,Canis lupus familiaris,9615.0,
5461,1,,BAO_0000218,Intermediate,,17538,Oral bioavailability in dog (dose 10 mg/kg),A,In vivo,,Canis lupus familiaris,9615.0,
5462,1,,BAO_0000218,Intermediate,,17538,Bioavailability in dog after po administration at a dose of 10 mg/kg; nd is not determined,A,In vivo,,Canis lupus familiaris,9615.0,
5463,1,,BAO_0000218,Intermediate,,1466,Bioavailability in dog (dose 10.0 mg/kg p.o.),A,In vivo,,Canis lupus familiaris,9615.0,
5464,1,,BAO_0000218,Intermediate,,17650,Bioavailability was measured in dogs after an oral dose of 10 uM/kg,A,In vivo,,Canis lupus familiaris,9615.0,
5465,1,,BAO_0000218,Intermediate,,3132,Bioavailability was obtained by the comparison of AUC of intravenous dosing and AUC of oral dosing in dog,A,In vivo,,Canis lupus familiaris,9615.0,
5466,0,,BAO_0000218,Autocuration,,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 3 hour,A,,,Mus sp.,10095.0,
5467,0,,BAO_0000218,Autocuration,2107.0,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 1 hour,A,,,Mus sp.,10095.0,
5468,0,,BAO_0000218,Autocuration,2107.0,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 24 hour,A,,,Mus sp.,10095.0,
5469,0,,BAO_0000218,Autocuration,2107.0,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 3 hour,A,,,Mus sp.,10095.0,
5470,0,,BAO_0000218,Autocuration,,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice lungs upon intraveneous administration at 2.6 gmol/mice after 1 hour,A,,,Mus sp.,10095.0,
5471,0,,BAO_0000218,Autocuration,,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice lungs upon intraveneous administration at 2.6 gmol/mice after 3 hour,A,,,Mus sp.,10095.0,
5472,0,,BAO_0000218,Autocuration,2385.0,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 1 hour,A,,,Mus sp.,10095.0,
5473,0,,BAO_0000218,Autocuration,2385.0,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 24 hour,A,,,Mus sp.,10095.0,
5474,0,,BAO_0000218,Autocuration,2385.0,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 3 hour,A,,,Mus sp.,10095.0,
5475,0,,BAO_0000218,Autocuration,2106.0,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice spleen upon intraveneous administration at 2.6 gmol/mice after 1 hour,A,,,Mus sp.,10095.0,
5476,0,,BAO_0000218,Autocuration,2106.0,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice spleen upon intraveneous administration at 2.6 gmol/mice after 3 hour,A,,,Mus sp.,10095.0,
5477,0,,BAO_0000218,Autocuration,,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 1 hour,A,,,Mus sp.,10095.0,
5478,0,,BAO_0000218,Autocuration,,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 24 hour,A,,,Mus sp.,10095.0,
5479,0,,BAO_0000218,Autocuration,,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 3 hour,A,,,Mus sp.,10095.0,
5480,0,,BAO_0000218,Autocuration,,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice uvea upon intraveneous administration at 2.6 gmol/mice after 24 hour,A,,,Mus sp.,10095.0,
5481,0,,BAO_0000218,Autocuration,,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice uvea upon intraveneous administration at 2.6 gmol/mice after 3 hour,A,,,Mus sp.,10095.0,
5482,0,,BAO_0000019,Autocuration,,17827,Compound (i.v.) was evaluated for elimination rate constants in brainstem of rhesus monkeys (Radiolabeled compound),A,,,Cercopithecidae,9527.0,
5483,0,,BAO_0000019,Autocuration,2037.0,17827,Compound (i.v.) was evaluated for elimination rate constants in cerebellum of rhesus monkeys (Radiolabeled compound),A,,,Cercopithecidae,9527.0,
5484,0,,BAO_0000019,Autocuration,1870.0,17827,Compound (i.v.) was evaluated for elimination rate constants in frontal cortex of rhesus monkey (Radiolabeled compound),A,,,Cercopithecidae,9527.0,
5485,0,,BAO_0000019,Autocuration,,17827,Compound (i.v.) was evaluated for elimination rate constants in jaw bone of rhesus monkeys; NA = not active (Radiolabeled compound),A,,,Cercopithecidae,9527.0,
5486,0,,BAO_0000019,Autocuration,2435.0,17827,Compound (i.v.) was evaluated for elimination rate constants in striatum of rhesus monkey (Radiolabeled compound),A,,,Cercopithecidae,9527.0,
5487,0,,BAO_0000019,Autocuration,,17827,Compound (i.v.) was evaluated for uptake rate constants in brainstem of rhesus monkeys (Radiolabeled compound),A,,,Cercopithecidae,9527.0,
5488,0,,BAO_0000019,Autocuration,2037.0,17827,Compound (i.v.) was evaluated for uptake rate constants in cerebellum of rhesus monkeys (Radiolabeled compound),A,,,Cercopithecidae,9527.0,
5489,0,,BAO_0000019,Autocuration,1870.0,17827,Compound (i.v.) was evaluated for uptake rate constants in frontal cortex of rhesus monkey (Radiolabeled compound),A,,,Cercopithecidae,9527.0,
5490,0,,BAO_0000019,Autocuration,,17827,Compound (i.v.) was evaluated for uptake rate constants in jaw bone of rhesus monkey (Radiolabeled compound),A,,,Cercopithecidae,9527.0,
5491,0,,BAO_0000019,Autocuration,2435.0,17827,Compound (i.v.) was evaluated for uptake rate constants in striatum of rhesus monkeys (Radiolabeled compound),A,,,Cercopithecidae,9527.0,
5492,0,,BAO_0000218,Autocuration,,17791,Compound was evaluated for oral bioavailability in rats,A,,,Cercopithecidae,9527.0,
5493,0,,BAO_0000218,Autocuration,1969.0,17667,Maximum concentration of compound found in plasma at 5 mg/kg after oral administration,A,In vivo,,Cercopithecidae,9527.0,
5494,0,,BAO_0000019,Autocuration,,17791,Half life period was evaluated in monkey,A,,,Cercopithecidae,9527.0,
5495,0,,BAO_0000218,Autocuration,,110,Half-life in rhesus monkeys by intravenous administration of dose,A,In vivo,,Cercopithecidae,9527.0,
5496,1,,BAO_0000218,Intermediate,1969.0,5781,AUC (0-6 hr) after oral administration at 30 mg/kg in ICR mouse,A,,,Mus musculus,10090.0,
5497,1,,BAO_0000218,Intermediate,1969.0,17734,AUC after intraperitoneal administration of 100 mg/kg in mice,A,,,Mus musculus,10090.0,
5498,1,,BAO_0000218,Intermediate,1969.0,17718,AUC value was determined after oral administration,A,,,Mus musculus,10090.0,
5499,1,,BAO_0000218,Intermediate,,4573,Area under curve (AUC) determined at a dose 10 mg/kg administered intraperitoneally to mice,A,,,Mus musculus,10090.0,
5500,1,,BAO_0000218,Intermediate,,3277,Area under curve (AUC) was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),A,,,Mus musculus,10090.0,
5501,1,,BAO_0000218,Intermediate,,2862,Area under curve by ioral administration in mouse,A,,,Mus musculus,10090.0,
5502,1,,BAO_0000218,Intermediate,,2862,Area under curve by iv administration in mouse,A,,,Mus musculus,10090.0,
5503,1,,BAO_0000218,Intermediate,,5951,Area under curve at 0-8 hr in IRC mice after peroral administration,A,,,Mus musculus,10090.0,
5504,1,,BAO_0000218,Intermediate,,17729,Area under curve when injected i.p. in mice at a dose of 50 mg/kg,A,,,Mus musculus,10090.0,
5505,1,,BAO_0000218,Intermediate,,17728,Area under curve when injected intraperitoneally in BALB/C mice at a dose of 20 mg/kg,A,,,Mus musculus,10090.0,
5506,1,,BAO_0000218,Intermediate,,17728,Area under curve when injected intravenously in BALB/C mice at a dose of 20 mg/kg,A,,,Mus musculus,10090.0,
5507,1,,BAO_0000218,Intermediate,,17729,Area under curve when injected intravenously in mice at a dose of 20 mg/kg,A,,,Mus musculus,10090.0,
5508,1,,BAO_0000219,Intermediate,,9424,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,F,,,Homo sapiens,9606.0,
5509,1,,BAO_0000219,Intermediate,,9424,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,F,,,Homo sapiens,9606.0,
5510,1,,BAO_0000219,Intermediate,,9424,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),F,,,Homo sapiens,9606.0,
5511,1,,BAO_0000219,Intermediate,,9424,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),F,,,Homo sapiens,9606.0,
5512,1,,BAO_0000219,Intermediate,,9424,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),F,,,Homo sapiens,9606.0,
5513,1,,BAO_0000219,Intermediate,,9424,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),F,,,Homo sapiens,9606.0,
5514,1,,BAO_0000219,Intermediate,,9424,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),F,,,Homo sapiens,9606.0,
5515,1,,BAO_0000219,Intermediate,,9424,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),F,,,Homo sapiens,9606.0,
5516,1,,BAO_0000219,Intermediate,,9424,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,F,,,Homo sapiens,9606.0,
5517,1,,BAO_0000219,Intermediate,,9424,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,F,,,Homo sapiens,9606.0,
5518,1,,BAO_0000219,Intermediate,,9424,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),F,,,Homo sapiens,9606.0,
5519,1,,BAO_0000219,Intermediate,,9424,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),F,,,Homo sapiens,9606.0,
5520,1,,BAO_0000219,Intermediate,,9424,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),F,,,Homo sapiens,9606.0,
5521,1,,BAO_0000219,Intermediate,,9424,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),F,,,Homo sapiens,9606.0,
5522,1,,BAO_0000219,Intermediate,,9424,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),F,,,Homo sapiens,9606.0,
5523,1,,BAO_0000219,Intermediate,,9424,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),F,,,Homo sapiens,9606.0,
5524,1,,BAO_0000219,Expert,,9424,In vitro inhibition of human 8226 myeloma tumor cell line growth.,F,,,Homo sapiens,9606.0,
5525,1,,BAO_0000219,Intermediate,,11544,In vitro inhibition of tumor cell growth in the human myeloma 8226/ADR system.,F,,,Homo sapiens,9606.0,
5526,1,,BAO_0000219,Intermediate,,17378,Cytotoxicity of compound against 8226/DOX1V cells,F,,,Homo sapiens,9606.0,
5527,1,,BAO_0000219,Intermediate,,17378,Cytotoxicity of compound against 8226/S cells,F,,,Homo sapiens,9606.0,
5528,1,,BAO_0000219,Intermediate,,17079,Inhibitory concentration against 8226 myeloma cancer cell line,F,,,Homo sapiens,9606.0,
5529,1,,BAO_0000219,Intermediate,,17079,Inhibitory concentration against 8226/Dox40 (Dox-Re) cancer cell line,F,,,Homo sapiens,9606.0,
5530,1,,BAO_0000219,Intermediate,,13466,Inhibition of cell growth was studied in human teratocarcinoma (833K).,F,,,Homo sapiens,9606.0,
5531,1,,BAO_0000219,Intermediate,,13466,Inhibition of cell growth was studied in human teratocarcinoma (833K); ND ='not determined',F,,,Homo sapiens,9606.0,
5532,1,,BAO_0000219,Expert,,2392,Tested in vitro for growth inhibitory activity against 833K (human teratorcarcinoma) cells,F,,,Homo sapiens,9606.0,
5533,1,,BAO_0000219,Intermediate,,2392,The compound was tested in vitro for growth inhibitory activity against 833K (human teratorcarcinoma) cells; No data,F,,,Homo sapiens,9606.0,
5534,0,,BAO_0000019,Autocuration,,6608,Inhibitory activity against caspase-1,B,,,,,
5535,8,,BAO_0000357,Autocuration,,10199,Percent inhibition of DAla-DAla Ligase at 10e -3 M of the compound,B,,,Enterococcus faecalis,1351.0,
5536,1,,BAO_0000219,Intermediate,,17749,In vitro antiproliferative activity against 8701-BC human breast cancer cells at a concentration of (0-100 uM) for 72 hr using MTT assay,F,,,Homo sapiens,9606.0,
5537,1,,BAO_0000219,Intermediate,,17749,In vitro antiproliferative activity against 8701-BC human breast cancer cells at a concentration of (0-100 uM,F,,,Homo sapiens,9606.0,
5538,0,,BAO_0000019,Intermediate,,1229,In vitro anticancer activity against 9 NCI colon cancer cell lines; inactive,F,,,,,
5539,0,,BAO_0000019,Intermediate,,1229,In vitro anticancer activity against 9 NCI melanoma cell lines; inactive,F,,,,,
5540,0,,BAO_0000019,Intermediate,,1229,In vitro anticancer activity against 9 NCI renal cancer cell lines; inactive,F,,,,,
5541,0,,BAO_0000019,Autocuration,,6390,Inhibitory activity was determined against 9-cis-epoxycarotenoid dioxygenase (NCED) expressed in Escherichia coli in presence of 9''-cis-neo-xanthin,B,,,,,
5542,0,,BAO_0000019,Autocuration,,16219,Minimum inhibitory concentration against Streptococcus pyogenes 930MLSB,F,,,Streptococcus pyogenes,1314.0,
5543,0,,BAO_0000019,Autocuration,,16219,Minimum inhibitory concentration against Streptococcus pyogenes 930MLSB,F,,,Streptococcus pyogenes,1314.0,
5544,8,,BAO_0000357,Autocuration,,17043,Percent inhibition against Cdc25C phosphatase at 50 uM of compound,B,,,,,
5545,1,,BAO_0000219,Intermediate,,6929,Tested for in vitro cytotoxic potency of compound in 9KB assay,F,,,Homo sapiens,9606.0,
5546,1,,BAO_0000219,Intermediate,,6929,Tested for in vitro cytotoxic potency of compound in 9KB assay,A,,,Homo sapiens,9606.0,
5547,0,,BAO_0000219,Autocuration,,7083,In vitro cytotoxicity of compound was tested against 9KB cells.,F,,,Homo sapiens,9606.0,
5548,1,,BAO_0000219,Intermediate,,12446,Cytotoxic concentration against 9L cells was determined on day 3,F,,,Rattus norvegicus,10116.0,
5549,1,,BAO_0000219,Expert,,15345,Tested in vitro for anticancer activity against 9L cells,F,,,Rattus norvegicus,10116.0,
5550,1,,BAO_0000219,Expert,,15345,Tested in vitro for anticancer activity against 9L cells; Not determined,F,,,Rattus norvegicus,10116.0,
5551,1,,BAO_0000219,Intermediate,,6301,In vitro inhibitory activity against human A549 non-small cell lung tumor; Active,F,,,Homo sapiens,9606.0,
5552,1,,BAO_0000219,Intermediate,,4833,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; No inhibition,F,,,Homo sapiens,9606.0,
5553,1,,BAO_0000219,Intermediate,,4833,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; Significant inhibition,F,,,Homo sapiens,9606.0,
5554,1,,BAO_0000219,Intermediate,,4833,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; Slight inhibition,F,,,Homo sapiens,9606.0,
5555,1,,BAO_0000219,Expert,,13330,Cytotoxicity against human lung carcinoma A549 cell line,F,,,Homo sapiens,9606.0,
5556,9,,BAO_0000219,Expert,,17517,Ability to induce human IL-6 assay in A549 lung carcinoma cell line.,F,,,Homo sapiens,9606.0,
5557,9,,BAO_0000219,Expert,,17517,"Ability to induce human IL-6 assay in A549 lung carcinoma cell line; n.r.: not reported, EC50 values not reported in cases were %dex e 35%.",F,,,Homo sapiens,9606.0,
5558,1,,BAO_0000219,Intermediate,,14425,"In vitro growth inhibition of A549, lung carcinoma",F,,,Homo sapiens,9606.0,
5559,1,,BAO_0000219,Intermediate,,14425,"In vitro growth inhibition of A549, lung carcinoma.",F,,,Homo sapiens,9606.0,
5560,1,,BAO_0000219,Expert,,5228,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,F,,,Homo sapiens,9606.0,
5561,1,,BAO_0000219,Intermediate,,5351,Cytotoxic activity against human lung cancer A549 cell line was determined,F,,,Homo sapiens,9606.0,
5562,1,,BAO_0000219,Expert,,12198,Cytotoxicity against human solid tumor lung carcinoma A549 cell line,F,,,Homo sapiens,9606.0,
5563,1,,BAO_0000219,Intermediate,,13891,Cytotoxicity concentration against human lung carcinoma A-549 cell line,F,,,Homo sapiens,9606.0,
5564,1,,BAO_0000219,Expert,,5677,Cytotoxicity in A549 (human carcinoma) cell line.,F,,,Homo sapiens,9606.0,
5565,1,,BAO_0000219,Intermediate,,13788,Cytotoxicity on lung carcinoma (A-549) cell line,F,,,Homo sapiens,9606.0,
5566,1,,BAO_0000219,Expert,,13384,Effective dose against 50% reduction in Human lung carcinoma (A-549) cell number after 3-day incubation.,F,,,Homo sapiens,9606.0,
5567,1,,BAO_0000219,Intermediate,,6726,Effective dose of compound against replication of A549 cell line was evaluated,F,,,Homo sapiens,9606.0,
5568,1,,BAO_0000219,Expert,,3455,In vitro cytotoxic activity was determined against lung carcinoma (A549) cell line,F,,,Homo sapiens,9606.0,
5569,1,,BAO_0000219,Intermediate,,5726,In vitro cytotoxicity evaluated against human lung cancer (A549 cell line),F,,,Homo sapiens,9606.0,
5570,1,,BAO_0000219,Intermediate,,5726,In vitro cytotoxicity evaluated against human lung cancer (A549 cell line); NA is not active,F,,,Homo sapiens,9606.0,
5571,1,,BAO_0000219,Intermediate,,3936,The compound was evaluated for antiproliferative activity against A549 cell line,F,,,Homo sapiens,9606.0,
5572,1,,BAO_0000219,Intermediate,,14991,The compound was tested for tumor cell growth inhibitory activity against human lung carcinoma (A549) cell line.,F,,,Homo sapiens,9606.0,
5573,1,,BAO_0000219,Intermediate,,5243,Concentration required for growth inhibition of human lung carcinoma cell line A549,F,,,Homo sapiens,9606.0,
5574,1,,BAO_0000219,Intermediate,,12858,Cytotoxic activity against A549/ATCC non-small cell-lung cancer cell line,F,,,Homo sapiens,9606.0,
5575,1,,BAO_0000219,Intermediate,,6776,Growth inhibition against A549 cell line was evaluated,F,,,Homo sapiens,9606.0,
5576,1,,BAO_0000219,Intermediate,,16558,Growth inhibitory activity against A549 human solid tumor cell line using MTT assay,F,,,Homo sapiens,9606.0,
5577,1,,BAO_0000219,Expert,,4583,Inhibition of anchorage independent growth of human tumor cell line A549 K-ras-transformed in soft agar,F,,,Homo sapiens,9606.0,
5578,1,,BAO_0000219,Intermediate,,13514,Inhibitor activity against A549 (Human lung carcinoma)cell line with varying concentration of the drug for 72 hrs,F,,,Homo sapiens,9606.0,
5579,1,,BAO_0000219,Expert,,15166,Chemosensitivity against DT-diaphorase rich A549 cell lines,F,,,Homo sapiens,9606.0,
5580,1,,BAO_0000219,Intermediate,,13873,Compound tested against A549 lung carcinoma in the sulforhodamine B assay.,F,,,Homo sapiens,9606.0,
5581,1,,BAO_0000219,Expert,,6447,In vitro cytotoxicity against human A549 (lung cancer) cell line.,F,,,Homo sapiens,9606.0,
5582,1,,BAO_0000219,Intermediate,,2068,In vitro antitumor activity against A549 (lung) human tumor cell lines.,F,,,Homo sapiens,9606.0,
5583,1,,BAO_0000219,Expert,,1863,In vitro cytotoxic activity against human lung carcinoma A549 cell line,F,,,Homo sapiens,9606.0,
5584,1,,BAO_0000219,Intermediate,,13873,Compound was tested against A549 lung cancer cell line in the sulforhodamine B assay.,F,,,Homo sapiens,9606.0,
5585,1,,BAO_0000219,Intermediate,,13873,Compound was tested against A549 lung carcinoma cell line in the sulforhodamine B assay.,F,,,Homo sapiens,9606.0,
5586,1,,BAO_0000219,Expert,,13873,Tested against A549 lung carcinoma in the sulforhodamine B assay.,F,,,Homo sapiens,9606.0,
5587,1,,BAO_0000219,Intermediate,,579,Compound was tested for cytotoxicity on A549 lung adenocarcinoma cell line using a proliferation assay (MTT reduction),F,,,Homo sapiens,9606.0,
5588,1,,BAO_0000219,Intermediate,,579,Compound was tested for cytotoxicity on A549 lung adenocarcinoma cell line using a proliferation assay (MTT reduction).,F,,,Homo sapiens,9606.0,
5589,1,,BAO_0000219,Intermediate,,4584,Compound was tested for inhibition of growth of human lung carcinoma cell line A549 up to a conc of 10 uM; NI means no inhibition,F,,,Homo sapiens,9606.0,
5590,1,,BAO_0000219,Expert,,5421,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line,F,,,Homo sapiens,9606.0,
5591,1,,BAO_0000219,Intermediate,,5421,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line,F,,,Homo sapiens,9606.0,
5592,1,,BAO_0000219,Intermediate,,5421,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line at 20 uM concentration,F,,,Homo sapiens,9606.0,
5593,1,,BAO_0000219,Intermediate,,5421,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line; NA=Not assayed,F,,,Homo sapiens,9606.0,
5594,1,,BAO_0000219,Intermediate,,14188,Compound was tested for potency against human lung A549 cells using sulforhodamine B assay.,F,,,Homo sapiens,9606.0,
5595,1,,BAO_0000219,Intermediate,,14188,Compound was tested for potency against human lung A549 cells using sulforhodamine B assay; UA=Potency was so low that the IC50 was unachievable.,F,,,Homo sapiens,9606.0,
5596,1,,BAO_0000219,Intermediate,,15354,Compound was tested for the growth inhibition of A549 lung tumor cell line,F,,,Homo sapiens,9606.0,
5597,1,,BAO_0000219,Expert,,14253,Growth inhibition of human non-small-lung carcinoma (A549) cell line,F,,,Homo sapiens,9606.0,
5598,1,,BAO_0000219,Intermediate,,13873,Compound was tested against A549 lung carcinoma cell line in the sulforhodamine B assay.,F,,,Homo sapiens,9606.0,
5599,1,,BAO_0000218,Intermediate,,3043,Oral bioavailability in dog (conscious),A,In vivo,,Canis lupus familiaris,9615.0,
5600,1,,BAO_0000218,Intermediate,,3045,Compound was evaluated for the oral bioavailability after oral administration in dog.,A,In vivo,,Canis lupus familiaris,9615.0,
5601,1,,BAO_0000218,Intermediate,,3022,Compound was tested for percent of oral bioavailability at 10 mg/ml dose in dogs,A,In vivo,,Canis lupus familiaris,9615.0,
5602,1,,BAO_0000218,Intermediate,,4453,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,
5603,1,,BAO_0000218,Intermediate,,1696,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,
5604,1,,BAO_0000218,Intermediate,,5045,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,
5605,1,,BAO_0000218,Intermediate,,5356,Oral bioavailability in dog (fasted),A,In vivo,,Canis lupus familiaris,9615.0,
5606,1,,BAO_0000218,Intermediate,,17764,Oral bioavailability after intravenous administration in dogs at 1.2 uM/kg,A,In vivo,,Canis lupus familiaris,9615.0,
5607,1,,BAO_0000218,Intermediate,,6448,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,
5608,1,,BAO_0000218,Intermediate,,1475,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,
5609,1,,BAO_0000218,Intermediate,,3788,Percent bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,
5610,1,,BAO_0000218,Intermediate,,3639,Percent oral bioavailability of intravenously administered compound (6 mg/kg) was tested in dog,A,In vivo,,Canis lupus familiaris,9615.0,
5611,1,,BAO_0000218,Intermediate,,13397,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,
5612,1,,BAO_0000218,Intermediate,,2137,The compound was evaluated for bioavailability in dogs; 34-44,A,In vivo,,Canis lupus familiaris,9615.0,
5613,1,,BAO_0000218,Intermediate,,2959,Bioavailability in dog (dose 4 mg/kg p.o.),A,In vivo,,Canis lupus familiaris,9615.0,
5614,1,,BAO_0000218,Intermediate,,6448,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,
5615,1,,BAO_0000218,Intermediate,,6084,8 hour trough Blood level in dog was measured after administration of compound,A,,,Canis lupus familiaris,9615.0,
5616,1,,BAO_0000218,Intermediate,1969.0,3639,The compound was tested for maximum concentration ( Cmax ) in dog plasma.,A,In vivo,,Canis lupus familiaris,9615.0,
5617,1,,BAO_0000218,Intermediate,,6316,C24 after oral administration at 5 mg/kg,A,,,Canis lupus familiaris,9615.0,
5618,1,,BAO_0000218,Intermediate,,5238,Clearance after oral and iv dosing in dogs,A,,,Canis lupus familiaris,9615.0,
5619,1,,BAO_0000218,Intermediate,1969.0,17796,Clearance of the drug was measured in the plasma of dog,A,,,Canis lupus familiaris,9615.0,
5620,1,,BAO_0000218,Intermediate,,2652,Compound was evaluated for Clearance in dogs at a dose of 1 mpk intravenously,A,,,Canis lupus familiaris,9615.0,
5621,1,,BAO_0000218,Intermediate,,5654,CL (clearance) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,
5622,1,,BAO_0000218,Intermediate,,6621,Clearance of compound was determined in dogs,A,In vivo,,Canis lupus familiaris,9615.0,
5623,1,,BAO_0000218,Intermediate,,6505,Clearance on i.v. administration of 2 mg/kg was measured in dog,A,In vivo,,Canis lupus familiaris,9615.0,
5624,1,,BAO_0000218,Intermediate,,5802,Clearance of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,A,In vivo,,Canis lupus familiaris,9615.0,
5625,1,,BAO_0000218,Intermediate,,17267,Plasma clearance in dog was determined,A,In vivo,,Canis lupus familiaris,9615.0,
5626,1,,BAO_0000218,Intermediate,,4521,Plasma clearance in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,A,In vivo,,Canis lupus familiaris,9615.0,
5627,1,,BAO_0000218,Intermediate,,6535,Plasma clearance in dog after administration of 0.25 mg/kg iv,A,In vivo,,Canis lupus familiaris,9615.0,
5628,1,,BAO_0000218,Intermediate,,6535,Plasma clearance in dog after administration of 1 mg/kg iv,A,In vivo,,Canis lupus familiaris,9615.0,
5629,1,,BAO_0000218,Intermediate,,6535,Plasma clearance in dogs,A,In vivo,,Canis lupus familiaris,9615.0,
5630,1,,BAO_0000218,Intermediate,,5542,Plasma clearance by iv administration in dog at a dose of 0.3 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,
5631,1,,BAO_0000218,Intermediate,,5199,Plasma clearance was determined in canine following intravenous (iv) administration of drug (1 mg/kg).,A,In vivo,,Canis lupus familiaris,9615.0,
5632,1,,BAO_0000218,Intermediate,,16907,Plasma clearance after 15 mg/kg iv dose in Dogs,A,In vivo,,Canis lupus familiaris,9615.0,
5633,1,,BAO_0000218,Intermediate,,16907,Plasma clearance after 30 mg/kg po dose in Dogs,A,In vivo,,Canis lupus familiaris,9615.0,
5634,1,,BAO_0000218,Intermediate,,16367,Plasma administration to dogs,A,In vivo,,Canis lupus familiaris,9615.0,
5635,1,,BAO_0000218,Intermediate,,5505,Plasma clearance was determined,A,In vivo,,Canis lupus familiaris,9615.0,
5636,1,,BAO_0000218,Intermediate,,6215,Systemic clearance after intravenous administration (0.5 mg/kg) was determined in dog,A,In vivo,,Canis lupus familiaris,9615.0,
5637,1,,BAO_0000218,Intermediate,,1466,Tested for systemic clearance upon intravenous administration of 5.0 mg/Kg dose in dog,A,In vivo,,Canis lupus familiaris,9615.0,
5638,2,,BAO_0000251,Intermediate,2107.0,5007,Intrinsic clearance in human liver microsomes,A,In vitro,,Homo sapiens,9606.0,
5639,2,,BAO_0000251,Intermediate,2107.0,5007,Intrinsic clearance in human liver microsomes,A,In vitro,,Homo sapiens,9606.0,
5640,1,,BAO_0000218,Intermediate,,16452,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,A,In vivo,,Canis lupus familiaris,9615.0,
5641,1,,BAO_0000218,Intermediate,,16452,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,A,In vivo,,Canis lupus familiaris,9615.0,
5642,1,,BAO_0000218,Intermediate,,16452,Clearance in dog (dose 1 mg/kg i.v.),A,In vivo,,Canis lupus familiaris,9615.0,
5643,1,,BAO_0000218,Intermediate,,6221,Plasma clearance after oral administration (2.5 mg/kg) in dog was determined,A,In vivo,,Canis lupus familiaris,9615.0,
5644,1,,BAO_0000218,Intermediate,,5007,Plasma clearance in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),A,In vivo,,Canis lupus familiaris,9615.0,
5645,1,,BAO_0000218,Intermediate,,5668,Plasma clearance after peroral administration at 10 mpk in dog,A,In vivo,,Canis lupus familiaris,9615.0,
5646,1,,BAO_0000218,Intermediate,,5668,Plasma clearance after peroral administration at 5 mpk in dog,A,In vivo,,Canis lupus familiaris,9615.0,
5647,1,,BAO_0000218,Intermediate,,5668,Plasma clearance after peroral administration at 5 mg/kg in dog,A,In vivo,,Canis lupus familiaris,9615.0,
5648,1,,BAO_0000218,Intermediate,,15660,Plasma clearance was measured in dog,A,In vivo,,Canis lupus familiaris,9615.0,
5649,1,,BAO_0000218,Intermediate,,15660,Plasma clearance was measured in dog,A,In vivo,,Canis lupus familiaris,9615.0,
5650,1,,BAO_0000218,Intermediate,,5983,Pharmacokinetic property (CLtot) was measured in dog at the dose of 0.032 mg/kg i.v.,A,In vivo,,Canis lupus familiaris,9615.0,
5651,1,,BAO_0000218,Intermediate,,5600,Total clearance was determined after 0.1 mg/kg iv administration in dog,A,In vivo,,Canis lupus familiaris,9615.0,
5652,1,,BAO_0000218,Intermediate,,17764,Clearance of compound after intravenous administration in dogs at 1.2 uM/kg,A,In vivo,,Canis lupus familiaris,9615.0,
5653,1,,BAO_0000218,Intermediate,,6039,Clearance after intravenous administration of 0.5 mg/kg in dog was determined,A,In vivo,,Canis lupus familiaris,9615.0,
5654,1,,BAO_0000218,Intermediate,,6039,Clearance after intravenous administration of 1.0 mg/kg in dog was determined,A,In vivo,,Canis lupus familiaris,9615.0,
5655,1,,BAO_0000218,Intermediate,,6039,Clearance after peroral administration of 0.2 mg/kg in dog was determined,A,In vivo,,Canis lupus familiaris,9615.0,
5656,1,,BAO_0000218,Intermediate,,4368,Clearance by intravenous administration of 1.2 mg/kg in dog,A,In vivo,,Canis lupus familiaris,9615.0,
5657,1,,BAO_0000218,Intermediate,,4305,Clearance by iv administration in dogs at a dose of 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,
5658,1,,BAO_0000218,Intermediate,1969.0,1918,Clearance value was evaluated in dog plasma,A,In vivo,,Canis lupus familiaris,9615.0,
5659,1,,BAO_0000218,Intermediate,,6005,Clearance was evaluated after i.v. administration in dog at a dose of 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,
5660,1,,BAO_0000218,Intermediate,1969.0,4839,Compound was tested for plasma clearance in dog,A,In vivo,,Canis lupus familiaris,9615.0,
5661,1,,BAO_0000218,Intermediate,,4239,Pharmacokinetic property (Plasma clearance) was measured in dog,A,In vivo,,Canis lupus familiaris,9615.0,
5662,1,,BAO_0000218,Intermediate,,17729,Area under curve when injected perorally in mice at a dose of 50 mg/kg,A,,,Mus musculus,10090.0,
5663,1,,BAO_0000218,Intermediate,,17728,Area under curve when injected perorally in BALB/C mice at a dose of 50 mg/kg,A,,,Mus musculus,10090.0,
5664,1,,BAO_0000218,Intermediate,,5302,Area under curve value in mouse at a dose of 10 mg/kg,A,,,Mus musculus,10090.0,
5665,1,,BAO_0000218,Intermediate,,5506,Area under curve was determined at a dose of 100 mg/kg (i.p.) in Mice,A,,,Mus musculus,10090.0,
5666,1,,BAO_0000218,Intermediate,,5506,Area under curve was determined at a dose of 200 mg/kg (i.p.) in Mice,A,,,Mus musculus,10090.0,
5667,1,,BAO_0000218,Intermediate,,17764,Area under curve was determined for compound after intraperitoneal administration in mice at 18 uM/kg,F,,,Mus musculus,10090.0,
5668,1,,BAO_0000218,Intermediate,,17764,Area under curve was determined for compound after intraperitoneal administration in mice at 23 uM/kg,F,,,Mus musculus,10090.0,
5669,1,,BAO_0000218,Intermediate,,17764,Area under curve was determined for compound after intraperitoneal administration in mice at 25 uM/kg,F,,,Mus musculus,10090.0,
5670,1,,BAO_0000218,Intermediate,,17764,Area under curve was determined for compound after intraperitoneal administration in mice at 26 uM/kg,F,,,Mus musculus,10090.0,
5671,1,,BAO_0000218,Intermediate,,17764,Area under curve was determined for compound after intravenous administration in mice at 24 uM/kg,A,,,Mus musculus,10090.0,
5672,1,,BAO_0000218,Intermediate,,17753,Area under curve was determined for the compound at 24 mg/Kg,A,,,Mus musculus,10090.0,
5673,1,,BAO_0000218,Intermediate,,17753,Area under curve was determined for the compound at 40 mg/Kg,A,,,Mus musculus,10090.0,
5674,1,,BAO_0000218,Intermediate,,17753,Area under curve was determined for the compound at 5 mg/Kg,A,,,Mus musculus,10090.0,
5675,1,,BAO_0000218,Intermediate,,3132,Area under the curve for the compound is obtained at dose 25 mg/kg,A,,,Mus musculus,10090.0,
5676,1,,BAO_0000218,Intermediate,,3132,Area under the curve for the compound was obtained when tested in mouse,A,,,Mus musculus,10090.0,
5677,1,,BAO_0000218,Intermediate,,17837,Area under the curve of compound in mouse blood following i.v. administration of 10 mg/kg,A,,,Mus musculus,10090.0,
5678,1,,BAO_0000218,Intermediate,,17837,Area under the curve of compound in mouse blood following p.o. administration of 30 mg/kg,A,,,Mus musculus,10090.0,
5679,1,,BAO_0000218,Intermediate,,6062,Area under the curve was measured in mouse after an iv dose of 1 mg/kg,A,,,Mus musculus,10090.0,
5680,1,,BAO_0000218,Intermediate,,4066,Area under the curve was determined for the compound at a single subcutaneous administration of 40 mg/kg in mice,A,,,Mus musculus,10090.0,
5681,1,,BAO_0000218,Intermediate,,16597,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for area under curve (AUCtot),A,,,Mus musculus,10090.0,
5682,1,,BAO_0000218,Intermediate,,14239,Compound was evaluated for the area under the concentration - time curve by administering intravenously at 25 mg/kg in mice,A,,,Mus musculus,10090.0,
5683,1,,BAO_0000218,Intermediate,,14239,Compound was evaluated for the area under the concentration - time curve by administering orally at 25 mg/kg in mice,A,,,Mus musculus,10090.0,
5684,1,,BAO_0000218,Intermediate,,4890,"Compound was evaluated for the pharmacokinetic parameter, area under curve",A,,,Mus musculus,10090.0,
5685,1,,BAO_0000218,Intermediate,,429,Evaluated for pharmacokinetic parameter area under curve in mouse at the dose 20 mg/kg (0-4 hr ),A,,,Mus musculus,10090.0,
5686,1,,BAO_0000218,Intermediate,,429,Evaluated for pharmacokinetic parameter area under curve in mouse at the dose 20 mg/kg (0-4 hr),A,,,Mus musculus,10090.0,
5687,1,,BAO_0000218,Intermediate,,5969,In vivo area under curve (AUC) was determined in murine septicemia at dose of 100 mg/kg,A,,,Mus musculus,10090.0,
5688,1,,BAO_0000218,Intermediate,,5969,In vivo area under curve (AUC) was determined in murine septicemia at dose of 50 mg/kg,A,,,Mus musculus,10090.0,
5689,1,,BAO_0000218,Intermediate,,5969,In vivo area under curve (AUC) was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,A,,,Mus musculus,10090.0,
5690,1,,BAO_0000218,Intermediate,,6091,Pharmacokinetic activity (AUC) in vivo after intravenous administration of 10 mg/kg in mouse,A,,,Mus musculus,10090.0,
5691,1,,BAO_0000218,Intermediate,,6091,Pharmacokinetic activity (AUC) in vivo after intravenous administration of 10 mg/kg in mouse;ND=Not determined,A,,,Mus musculus,10090.0,
5692,1,,BAO_0000218,Intermediate,,6091,Pharmacokinetic activity (AUC) in vivo after peroral administration of 10 mg/kg in mice,A,,,Mus musculus,10090.0,
5693,1,,BAO_0000218,Intermediate,,6091,Pharmacokinetic activity (AUC) in vivo after peroral administration of 10 mg/kg in mice;ND=Not determined,A,,,Mus musculus,10090.0,
5694,1,,BAO_0000218,Intermediate,,6178,Pharmacokinetic property (AUC) was determined after ip administration of 32 mg/kg in mice,A,,,Mus musculus,10090.0,
5695,1,,BAO_0000218,Intermediate,,6178,Pharmacokinetic property (AUC) was determined after po administration of 32 mg/kg in mice,A,,,Mus musculus,10090.0,
5696,1,,BAO_0000218,Intermediate,,6619,"Reduction in area under curve was determined in DIO mice by oral glucose tolerance test following a single i.p. dose (10 mg/kg, 30 min pre-treatment)",A,,,Mus musculus,10090.0,
5697,1,,BAO_0000218,Intermediate,,6619,"Reduction in area under curve was determined in ob/ob mice by oral glucose tolerance test following a single i.p. dose (10 mg/kg, 30 min pre-treatment)",A,,,Mus musculus,10090.0,
5698,1,,BAO_0000218,Intermediate,,3760,"The area under concentration-time curve(AUC) was determined at 5 mg/kg of compound dose, administered intravenously in mice",A,,,Mus musculus,10090.0,
5699,1,,BAO_0000218,Intermediate,,3760,"The area under concentration-time curve(AUC) was determined at 5 mg/kg of compound dose, administered perorally in mice",A,,,Mus musculus,10090.0,
5700,1,,BAO_0000218,Intermediate,,3760,"The area under concentration-time curve(AUC) was determined at 50 mg/kg of compound dose, administered intravenously in mice",A,,,Mus musculus,10090.0,
5701,1,,BAO_0000218,Intermediate,,3760,"The area under concentration-time curve(AUC) was determined at 50 mg/kg of compound dose, administered perorally in mice",A,,,Mus musculus,10090.0,
5702,1,,BAO_0000218,Intermediate,,3192,The area under curve in vivo in mouse blood level after oral administration at dose 50 mk/kg e-1,A,,,Mus musculus,10090.0,
5703,1,,BAO_0000218,Intermediate,,3192,The area under curve in vivo in mouse blood level after subcutaneous administration at dose 50 mk/kg e-1,A,,,Mus musculus,10090.0,
5704,1,,BAO_0000218,Intermediate,,2675,Area under the curve was evaluated in mice after intravenous administration,A,,,Mus musculus,10090.0,
5705,1,,BAO_0000218,Intermediate,,2675,Area under the curve was evaluated in mice after oral administration,A,,,Mus musculus,10090.0,
5706,1,,BAO_0000218,Intermediate,1969.0,16597,AUC total value at a dose of 10 mg/kg intravenous administration in mice.,A,,,Mus musculus,10090.0,
5707,1,,BAO_0000218,Intermediate,1969.0,16597,AUC total value at a dose of 10 mg/kg peroral administration in mice.,A,,,Mus musculus,10090.0,
5708,1,,BAO_0000218,Intermediate,,16597,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for area under curve (AUCtot),A,,,Mus musculus,10090.0,
5709,1,,BAO_0000218,Intermediate,,17734,AUMC after intraperitoneal administration of 100 mg/kg in mice,A,,,Mus musculus,10090.0,
5710,1,,BAO_0000218,Intermediate,178.0,7767,Biodistribution in blood was determined in mice after iv administration at 15 min Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,
5711,1,,BAO_0000219,Intermediate,,15345,The compound was tested in vitro for anticancer activity against 9L cells,F,,,,,
5712,0,,BAO_0000019,Autocuration,,2181,Anti proliferation activity determined; Weak effect,F,,,Rattus norvegicus,10116.0,
5713,0,,BAO_0000219,Autocuration,,2181,Inhibition of cell growth by compound at a concentration of 100 uM in 9Ltk+ cells; Completely stopped the process,F,,,Rattus norvegicus,10116.0,
5714,0,,BAO_0000219,Autocuration,,2181,Inhibition of cell growth by compound at a concentration of 10 uM in 9Ltk+ cells,F,,,Rattus norvegicus,10116.0,
5715,0,,BAO_0000219,Autocuration,,2181,Inhibition of cell growth by compound at a concentration of 10 uM in 9Ltk+ cells; Completely stopped the process,F,,,Rattus norvegicus,10116.0,
5716,0,,BAO_0000019,Autocuration,,10486,The cytotoxic activity was in vitro tested by 9PS assay method,F,,,Mus musculus,10090.0,
5717,0,,BAO_0000019,Autocuration,,10486,The cytotoxic activity was in vitro tested by 9PS assay method.,F,,,Mus musculus,10090.0,
5718,0,,BAO_0000019,Autocuration,,15508,Partition coefficient (logD6.5),A,,,,,
5719,1,,BAO_0000219,Expert,,5242,Inhibitory concentration in vitro for cytotoxic activity against A 2780 human ovarian carcinoma cells,F,,,Homo sapiens,9606.0,
5720,1,,BAO_0000219,Intermediate,,16167,Effective concentration against A 375 cell line growth (DFMO concentration is 5.0 mM),F,,,Homo sapiens,9606.0,
5721,1,,BAO_0000219,Expert,,4782,Inhibitory concentration required against A 431 human epidermoid carcinoma cell line,F,,,Homo sapiens,9606.0,
5722,9,,BAO_0000219,Expert,,16093,Inhibition of EGF-induced Tyrosine phosphorylation in A431 cells expressing EGF-R,F,,,Homo sapiens,9606.0,
5723,1,,BAO_0000219,Intermediate,,2596,Compound was evaluated for in vitro cytotoxicity against A 498 cancer cell line,F,,,Homo sapiens,9606.0,
5724,1,,BAO_0000219,Intermediate,,2596,in vitro cytotoxicity against A 498 cancer cell line,F,,,Homo sapiens,9606.0,
5725,1,,BAO_0000219,Intermediate,,3239,In vitro cytotoxic activity against renal (A 498) cancer cell line.,F,,,Homo sapiens,9606.0,
5726,1,,BAO_0000219,Intermediate,,1847,Cytotoxic activity against A 498 renal cancer cell lines.,F,,,Homo sapiens,9606.0,
5727,1,,BAO_0000219,Intermediate,,10553,In vitro cytotoxicity was determined against A 498 human renal tumor cell line using NCI screen,F,,,Homo sapiens,9606.0,
5728,0,,BAO_0000019,Autocuration,,16219,Minimum inhibitory concentration against Staphylococcus aureus A 5177 MLSB-i,F,,,Staphylococcus aureus,1280.0,
5729,0,,BAO_0000019,Autocuration,,16219,Minimum inhibitory concentration against Staphylococcus aureus A 5177 MLSB-i,F,,,Staphylococcus aureus,1280.0,
5730,0,,BAO_0000019,Autocuration,,16219,Minimum inhibitory concentration against Staphylococcus aureus A 5278 MLSB-c,F,,,Staphylococcus aureus,1280.0,
5731,0,,BAO_0000019,Autocuration,,16219,Minimum inhibitory concentration against Staphylococcus aureus A 5278 MLSB-c,F,,,Staphylococcus aureus,1280.0,
5732,1,,BAO_0000219,Intermediate,,4782,Inhibitory concentration required against A 549 lung cancer cell line,F,,,Homo sapiens,9606.0,
5733,1,,BAO_0000219,Intermediate,,11805,Growth inhibition of A 549 cell line by MTT reduction for 3 days of incubation time,F,,,Homo sapiens,9606.0,
5734,1,,BAO_0000219,Intermediate,,11805,Growth inhibition of A 549 cell line by MTT reduction for 7 days of incubation time,F,,,Homo sapiens,9606.0,
5735,1,,BAO_0000219,Intermediate,,2007,In vitro cytotoxicity against lung cancer A 549 cell lines,F,,,Homo sapiens,9606.0,
5736,1,,BAO_0000219,Intermediate,,4594,Compound was tested for its cytotoxicity against A 549 cell line,F,,,Homo sapiens,9606.0,
5737,1,,BAO_0000219,Expert,,6018,"Cytotoxic activity against A 549 human lung tumor cell line, using sulforhodamine B (SRB) assay.",F,,,Homo sapiens,9606.0,
5738,1,,BAO_0000219,Intermediate,,6018,"Cytotoxic activity against A 549 human lung tumor cell line, using sulforhodamine B (SRB) assay.; No data",F,,,Homo sapiens,9606.0,
5739,1,,BAO_0000219,Expert,,3599,In vitro cytotoxic activity against A 549 (non-small cell lung) using SRB (sulforhodamine B) assay,F,,,Homo sapiens,9606.0,
5740,1,,BAO_0000219,Intermediate,,2551,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay,F,,,Homo sapiens,9606.0,
5741,1,,BAO_0000219,Expert,,16132,In vitro inhibition of A549 (human lung cancer) cell growth.,F,,,Homo sapiens,9606.0,
5742,1,,BAO_0000219,Intermediate,,16132,Cytotoxic related antitumor activity against human cancer cell lines A 549; No data available,F,,,Homo sapiens,9606.0,
5743,1,,BAO_0000219,Expert,,2551,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay,F,,,Homo sapiens,9606.0,
5744,1,,BAO_0000219,Expert,,2551,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay; not active (> 100 uM),F,,,Homo sapiens,9606.0,
5745,0,,BAO_0000218,Autocuration,,11913,Tested against A II at (100 ng/kg iv) in Dawley rats (n=2). 24 h,F,,,,,
5746,4,,BAO_0000218,Autocuration,,12621,The duration of action for the % peak inhibition of A II pressor response for dose of 0.1 mg/kg intravenous administration in conscious dogs.,F,In vivo,,,,
5747,4,,BAO_0000218,Autocuration,,12621,The duration of action for the % peak inhibition of A II pressor response for dose of 1.0 mg/kg peroral administration in rhesus monkeys.,F,In vivo,,,,
5748,4,,BAO_0000218,Autocuration,,12621,The duration of action for the % peak inhibition of angiotensin II pressor response for dose of 0.1 mg/kg peroral administration in conscious rats.,F,In vivo,,,,
5749,4,,BAO_0000218,Autocuration,,12621,The compound was evaluated for the % peak inhibition of A II pressor response for dose of 0.3 mg/kg peroral administration in rhesus monkeys.,F,In vivo,,,,
5750,4,,BAO_0000218,Autocuration,,12621,The compound was evaluated for the percentage of inhibition of A II pressor response in rats for peroral administration.,F,In vivo,,,,
5751,1,,BAO_0000219,Expert,,3600,Inhibition of A-498 human Renal cell proliferation,F,,,Homo sapiens,9606.0,
5752,0,,BAO_0000019,Autocuration,,1796,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 0.1 uM",F,,,Rattus norvegicus,10116.0,
5753,0,,BAO_0000019,Autocuration,,1796,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 1 uM",F,,,Rattus norvegicus,10116.0,
5754,0,,BAO_0000019,Autocuration,,1796,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 10 uM",F,,,Rattus norvegicus,10116.0,
5755,1,,BAO_0000219,Expert,,16464,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay,F,,,Homo sapiens,9606.0,
5756,1,,BAO_0000219,Intermediate,,16464,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay; NE is no effect at 1x 10 E-5,F,,,Homo sapiens,9606.0,
5757,1,,BAO_0000219,Intermediate,,16464,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay; NE is no effect at 1x 10 E-5,F,,,Homo sapiens,9606.0,
5758,1,,BAO_0000219,Expert,,13617,Concentration required to inhibit growth of human tumor A549 (NSCL) cell line.,F,,,Homo sapiens,9606.0,
5759,1,,BAO_0000219,Intermediate,,4584,Concentration which produces 50% inhibition of growth of human lung carcinoma cell line A549,F,,,Homo sapiens,9606.0,
5760,1,,BAO_0000219,Expert,,13799,Cytotoxic activity evaluated against A549 tumor cells,F,,,Homo sapiens,9606.0,
5761,1,,BAO_0000219,Intermediate,,16726,Cytotoxic potentiation of Topotecan (TP) by the compound in human lung carcinoma A549 cell line,F,,,Homo sapiens,9606.0,
5762,1,,BAO_0000219,Intermediate,,16109,Cytotoxicity against A549 cells when the drug is exposed for a time of 1 hr,F,,,Homo sapiens,9606.0,
5763,1,,BAO_0000219,Intermediate,,16109,Cytotoxicity against A549 cells when the drug is exposed for a time of 96 hrs,F,,,Homo sapiens,9606.0,
5764,1,,BAO_0000219,Intermediate,,15474,Cytotoxicity against A549 tumor cell line determined by WST-1 assay,F,,,Homo sapiens,9606.0,
5765,1,,BAO_0000219,Intermediate,,6851,Cytotoxicity of compound against A549 cell line,F,,,Homo sapiens,9606.0,
5766,1,,BAO_0000219,Expert,,17534,Cytotoxicity against human lung cell carcinoma A549 cell line,F,,,Homo sapiens,9606.0,
5767,1,,BAO_0000219,Intermediate,,2621,Cytotoxicity against human lung carcinoma A549 cell line using MTT assay,F,,,Homo sapiens,9606.0,
5768,1,,BAO_0000219,Intermediate,,830,Cytotoxicity was evaluated in vitro against A549 (non-small cell lung carcinoma) human tumor cell lines,F,,,Homo sapiens,9606.0,
5769,1,,BAO_0000219,Intermediate,,14255,In vitro antitumor activity against A549 human non-small lung carcinoma cells containing 10% fetal bovine serum,F,,,Homo sapiens,9606.0,
5770,1,,BAO_0000219,Intermediate,,14255,In vitro antitumor activity against A549 human non-small lung carcinoma cells containing 10% fetal bovine serum; Not determined,F,,,Homo sapiens,9606.0,
5771,1,,BAO_0000219,Intermediate,,1590,In vitro antitumor activity against A549 human NSCLC lung carcinoma cells,F,,,Homo sapiens,9606.0,
5772,1,,BAO_0000219,Expert,,6146,In vitro concentration required to inhibit the TNF-alpha-induced RANTES production in A549 human lung epithelium cell line,F,,,Homo sapiens,9606.0,
5773,1,,BAO_0000219,Expert,,17427,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,F,,,Homo sapiens,9606.0,
5774,1,,BAO_0000219,Intermediate,,5280,In vitro cytotoxicity against parental and drug resistant lung human tumor cell line A549,F,,,Homo sapiens,9606.0,
5775,1,,BAO_0000219,Intermediate,,16786,In vitro cytotoxicity of compound against human A549 (non small cell lung) cancer cell line after 72 hr of drug exposure,F,,,Homo sapiens,9606.0,
5776,1,,BAO_0000219,Intermediate,,5895,In vitro cytotoxicity against A549 (human lung cancer),F,,,Homo sapiens,9606.0,
5777,1,,BAO_0000219,Expert,,14297,In vitro cytotoxicity against A-549 (human lung carcinoma) cell line.,F,,,Homo sapiens,9606.0,
5778,1,,BAO_0000218,Intermediate,,17824,In vivo antiproliferative activity against A549 cell line,F,,,Homo sapiens,9606.0,
5779,1,,BAO_0000219,Intermediate,,14368,Inhibition of non-small-cell lung adenocarcinoma (A549),F,,,Homo sapiens,9606.0,
5780,1,,BAO_0000219,Intermediate,,14368,Inhibition of non-small-cell lung adenocarcinoma (A549) after 48-h treatment,F,,,Homo sapiens,9606.0,
5781,1,,BAO_0000219,Intermediate,,14254,Inhibition of the growth against human non-small-lung carcinoma (A549) cell line after 72 hr exposure,F,,,Homo sapiens,9606.0,
5782,1,,BAO_0000219,Intermediate,,15897,Inhibitory activity against A549 cell line using MTT assay(Wild type p53),F,,,Homo sapiens,9606.0,
5783,1,,BAO_0000219,Intermediate,,13866,Inhibitory activity against A549 epithelial Cancer cell line at the concentration 0-30 uM for 48 hr,F,,,Homo sapiens,9606.0,
5784,1,,BAO_0000219,Intermediate,,13370,Inhibitory activity of compound against human A549 lung carcinoma cell line.,F,,,Homo sapiens,9606.0,
5785,1,,BAO_0000219,Intermediate,,4862,Inhibitory activity against A549 lung cancer cell line,F,,,Homo sapiens,9606.0,
5786,1,,BAO_0000219,Intermediate,,4862,Inhibitory activity against Taxol-resistant A549 lung cancer cell line,F,,,Homo sapiens,9606.0,
5787,1,,BAO_0000219,Intermediate,,4862,Inhibitory activity against Taxol-resistant A549 lung cancer cell line; not determined,F,,,Homo sapiens,9606.0,
5788,1,,BAO_0000219,Intermediate,,15970,Inhibitory concentration against A549 (lung cancer) cell line,F,,,Homo sapiens,9606.0,
5789,1,,BAO_0000219,Expert,,17713,In vitro cytotoxicity against A-549 (human lung carcinoma) cell line.,F,,,Homo sapiens,9606.0,
5790,1,,BAO_0000219,Intermediate,,4833,Tested in vitro for inhibitory effect on the growth of human A-549 cancer cell line,F,,,Homo sapiens,9606.0,
5791,1,,BAO_0000219,Expert,,13736,Activity against A549 cancer cell line.,F,,,Homo sapiens,9606.0,
5792,1,,BAO_0000219,Intermediate,,4312,The compound was evaluated for cytotoxicity against A549 cell line,F,,,Homo sapiens,9606.0,
5793,1,,BAO_0000219,Intermediate,,5421,The compound was examined for its ability to block tumor necrosis factor alpha (TNF alpha) induced IL-8 production in A549 human lung carcinoma cell line using an ELISA,F,,,Homo sapiens,9606.0,
5794,1,,BAO_0000219,Intermediate,,5421,The compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line,F,,,Homo sapiens,9606.0,
5795,1,,BAO_0000219,Intermediate,,14717,Growth inhibitory activity was measured for human A549 tumor cell line.,F,,,Homo sapiens,9606.0,
5796,1,,BAO_0000219,Intermediate,,4634,Inhibitory activity against A549 lung cancer cell line,F,,,Homo sapiens,9606.0,
5797,1,,BAO_0000219,Intermediate,,1149,Inhibitory activity against A549 cell line; inactive,F,,,Homo sapiens,9606.0,
5798,1,,BAO_0000219,Expert,,5421,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line at 20 uM,F,,,Homo sapiens,9606.0,
5799,1,,BAO_0000219,Expert,,5421,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line at 20 uM,F,,,Homo sapiens,9606.0,
5800,1,,BAO_0000219,Intermediate,,5421,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line at 20 uM concentration,F,,,Homo sapiens,9606.0,
5801,1,,BAO_0000219,Intermediate,,3320,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-4 (M/L),F,,,Homo sapiens,9606.0,
5802,1,,BAO_0000219,Intermediate,,3320,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-5 (M/L),F,,,Homo sapiens,9606.0,
5803,1,,BAO_0000219,Intermediate,,3320,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-6 (M/L),F,,,Homo sapiens,9606.0,
5804,1,,BAO_0000219,Intermediate,,3320,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-7 (M/L),F,,,Homo sapiens,9606.0,
5805,1,,BAO_0000219,Intermediate,,3320,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-8 (M/L),F,,,Homo sapiens,9606.0,
5806,1,,BAO_0000219,Intermediate,,5726,In vitro percent inhibition evaluated against human lung cancer (A549 cell line) at >20 ug/mL,F,,,Homo sapiens,9606.0,
5807,1,,BAO_0000218,Intermediate,,17800,Plasma clearance (in vivo) in mongrel dogs was determined,A,In vivo,,Canis lupus familiaris,9615.0,
5808,1,,BAO_0000218,Intermediate,,5985,Plasma clearance was measured in dog,A,In vivo,,Canis lupus familiaris,9615.0,
5809,1,,BAO_0000218,Intermediate,,5530,Plasma clearance in vivo in dog by intravenous administration at a dose of 0.2 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,
5810,1,,BAO_0000218,Intermediate,,5530,Plasma clearance in vivo in dog by intravenous administration at a dose of 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,
5811,1,,BAO_0000218,Intermediate,1969.0,4839,Tested for plasma clearance in dog,A,In vivo,,Canis lupus familiaris,9615.0,
5812,1,,BAO_0000218,Intermediate,,3639,The compound was tested for clearance in dog plasma.,A,In vivo,,Canis lupus familiaris,9615.0,
5813,1,,BAO_0000218,Intermediate,,4838,"The pharmacokinetic parameter, clearance was reported in dog after intravenous administration",A,In vivo,,Canis lupus familiaris,9615.0,
5814,1,,BAO_0000218,Intermediate,,4137,Clearance value of compound was determined after intravenous administration of 1 mg/kg/h in dog,A,In vivo,,Canis lupus familiaris,9615.0,
5815,1,,BAO_0000218,Intermediate,1969.0,5017,Compound was tested for its ability of plasma clearance when administered in dog perorally (1 mg/kg) and intravenously (0.2 mg/kg),A,In vivo,,Canis lupus familiaris,9615.0,
5816,1,,BAO_0000218,Intermediate,2107.0,17538,In vitro clearance in dog liver microsomes,A,In vitro,,Canis lupus familiaris,9615.0,
5817,1,,BAO_0000218,Intermediate,,6161,Pharmacokinetic profile in terms of clearance was determined at a dose of 0.5 mg/kg administered intravenously in dog,A,In vivo,,Canis lupus familiaris,9615.0,
5818,1,,BAO_0000218,Intermediate,,6161,Pharmacokinetic profile in terms of clearance was determined at a dose of 5 mg/kg administered intravenously in dog,A,In vivo,,Canis lupus familiaris,9615.0,
5819,1,,BAO_0000218,Intermediate,,1696,Plasma clearance in dog,A,In vivo,,Canis lupus familiaris,9615.0,
5820,1,,BAO_0000218,Intermediate,,6762,Clearance rate in dog,A,In vivo,,Canis lupus familiaris,9615.0,
5821,1,,BAO_0000218,Intermediate,1969.0,5932,Plasma concentration in dogs after 2 hr at 30mg/kg oral dose,A,In vivo,,Canis lupus familiaris,9615.0,
5822,1,,BAO_0000218,Intermediate,,6305,Clearance in dogs,A,In vivo,,Canis lupus familiaris,9615.0,
5823,1,,BAO_0000218,Intermediate,,4942,Plasma clearance in dogs,A,In vivo,,Canis lupus familiaris,9615.0,
5824,1,,BAO_0000218,Intermediate,,4219,Plasma clearance was determined,A,In vivo,,Canis lupus familiaris,9615.0,
5825,1,,BAO_0000218,Intermediate,,17853,Lower clearance in dog (i.v.) at 0.5 mpk,A,In vivo,,Canis lupus familiaris,9615.0,
5826,1,,BAO_0000218,Intermediate,,4514,Plasma clearance in Beagle dogs,A,In vivo,,Canis lupus familiaris,9615.0,
5827,1,,BAO_0000218,Intermediate,,6448,Plasma clearance (Clp) in dog,A,In vivo,,Canis lupus familiaris,9615.0,
5828,1,,BAO_0000218,Intermediate,,6227,Plasma clearance (pharmacokinetic parameter) in dog (in vivo) at a dose of 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,
5829,1,,BAO_0000218,Intermediate,,6227,Plasma clearance (pharmacokinetic parameter) in dog was determined,A,In vivo,,Canis lupus familiaris,9615.0,
5830,1,,BAO_0000218,Intermediate,,6062,Plasma clearance for the compound was measured in dog after an iv dose of 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,
5831,1,,BAO_0000218,Intermediate,,6821,Plasma clearance of compound was determined in dog,A,In vivo,,Canis lupus familiaris,9615.0,
5832,1,,BAO_0000218,Intermediate,,4709,Plasma clearance after intravenous administration of 1 mg/kg in dog,A,In vivo,,Canis lupus familiaris,9615.0,
5833,1,,BAO_0000218,Intermediate,,4521,Plasma clearance in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,A,In vivo,,Canis lupus familiaris,9615.0,
5834,1,,BAO_0000218,Intermediate,,5374,Plasma clearance in dog was determined,A,In vivo,,Canis lupus familiaris,9615.0,
5835,1,,BAO_0000218,Intermediate,,6057,Plasma clearance was calculated in dog,A,In vivo,,Canis lupus familiaris,9615.0,
5836,1,,BAO_0000218,Intermediate,,4727,Plasma clearance at the dose of 2 mg/kg in dog,A,In vivo,,Canis lupus familiaris,9615.0,
5837,1,,BAO_0000218,Intermediate,,5145,Plasma clearance in dog,A,In vivo,,Canis lupus familiaris,9615.0,
5838,1,,BAO_0000218,Intermediate,,17657,Plasma clearance in dog,A,In vivo,,Canis lupus familiaris,9615.0,
5839,1,,BAO_0000218,Intermediate,,17657,Plasma clearance in dog; Unable to calculate,A,In vivo,,Canis lupus familiaris,9615.0,
5840,1,,BAO_0000218,Intermediate,,5145,Plasma clearance in rhesus monkey,A,In vivo,,Canis lupus familiaris,9615.0,
5841,1,,BAO_0000218,Intermediate,,6642,Plasma clearance in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),A,In vivo,,Canis lupus familiaris,9615.0,
5842,1,,BAO_0000218,Intermediate,,6641,Plasma clearance in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),A,In vivo,,Canis lupus familiaris,9615.0,
5843,1,,BAO_0000218,Intermediate,,6642,Plasma clearance in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),A,In vivo,,Canis lupus familiaris,9615.0,
5844,1,,BAO_0000218,Intermediate,,5472,Plasma clearance was evaluated in dog,A,In vivo,,Canis lupus familiaris,9615.0,
5845,1,,BAO_0000218,Intermediate,,5472,Plasma clearance was evaluated in dog; Not tested,A,In vivo,,Canis lupus familiaris,9615.0,
5846,1,,BAO_0000218,Intermediate,,5472,Plasma clearance was evaluated in rhesus,A,In vivo,,Canis lupus familiaris,9615.0,
5847,1,,BAO_0000218,Intermediate,,5472,Plasma clearance was evaluated in rhesus; Not tested,A,In vivo,,Canis lupus familiaris,9615.0,
5848,1,,BAO_0000218,Intermediate,,4257,Plasma clearance value was determined in dog after a 3 mg/kg of iv dose,A,In vivo,,Canis lupus familiaris,9615.0,
5849,1,,BAO_0000218,Intermediate,,6679,Plasma clearance was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,A,In vivo,,Canis lupus familiaris,9615.0,
5850,1,,BAO_0000218,Intermediate,,5546,Plasma clearance was determined in Beagle dog at a dose of 1 mg/kg by iv administration,A,In vivo,,Canis lupus familiaris,9615.0,
5851,1,,BAO_0000218,Intermediate,,6348,Plasma clearance was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,A,In vivo,,Canis lupus familiaris,9615.0,
5852,1,,BAO_0000218,Intermediate,,5474,Clearance value at a dose of 0.2 mg/kg i.v.,A,In vivo,,Canis lupus familiaris,9615.0,
5853,1,,BAO_0000218,Intermediate,1969.0,6316,Cmax (Maximum (Peak) plasma drug concentration) was after oral administration at 5 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,
5854,1,,BAO_0000218,Intermediate,,17594,Cmax after oral dose of compound at 3 mg/kg in dogs,A,In vivo,,Canis lupus familiaris,9615.0,
5855,1,,BAO_0000218,Intermediate,,17594,Cmax after single intravenous bolus of 1 mg/kg in dogs,A,In vivo,,Canis lupus familiaris,9615.0,
5856,1,,BAO_0000218,Intermediate,,5802,Cmax of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,A,In vivo,,Canis lupus familiaris,9615.0,
5857,1,,BAO_0000218,Intermediate,,6535,Cmax in dog after administration of 0.25 mg/kg iv; ND = not determined,A,In vivo,,Canis lupus familiaris,9615.0,
5858,1,,BAO_0000218,Intermediate,,6535,Cmax in dog after administration of 1 mg/kg iv,A,In vivo,,Canis lupus familiaris,9615.0,
5859,1,,BAO_0000218,Intermediate,1969.0,1466,Cmax in plasma was determined upon peroral administration of 10.0 mg/Kg dose in dog,A,In vivo,,Canis lupus familiaris,9615.0,
5860,1,,BAO_0000218,Intermediate,,6505,Cmax on p.o. administration of 10 mg/kg was measured in dog,A,In vivo,,Canis lupus familiaris,9615.0,
5861,1,,BAO_0000218,Intermediate,,5668,Cmax was determine after peroral administration at 10 mpk in dog,A,In vivo,,Canis lupus familiaris,9615.0,
5862,1,,BAO_0000218,Intermediate,,5668,Cmax was determine after peroral administration at 5 mpk in dog,A,In vivo,,Canis lupus familiaris,9615.0,
5863,1,,BAO_0000218,Intermediate,,5668,Cmax was determine after peroral administration at 5 mg/kg in dog,A,In vivo,,Canis lupus familiaris,9615.0,
5864,1,,BAO_0000218,Intermediate,,5600,Cmax after 0.3 mg/kg po administration in dog,A,In vivo,,Canis lupus familiaris,9615.0,
5865,1,,BAO_0000218,Intermediate,,17764,Cmax after peroral administration in dogs at 2.4 uM/kg,A,In vivo,,Canis lupus familiaris,9615.0,
5866,1,,BAO_0000218,Intermediate,,6123,Cmax in dog after oral administration at 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,
5867,1,,BAO_0000218,Intermediate,,6123,Cmax in dog after oral administration at 1 mg/kg; Below the level of quantitation,A,In vivo,,Canis lupus familiaris,9615.0,
5868,1,,BAO_0000218,Intermediate,,6757,Cmax upon oral administration in male Beagle dog at 10 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,
5869,1,,BAO_0000218,Intermediate,,16907,Cmax value after 15 mg/kg iv dose in Dogs,A,In vivo,,Canis lupus familiaris,9615.0,
5870,1,,BAO_0000218,Intermediate,178.0,7767,Biodistribution in blood was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,
5871,1,,BAO_0000218,Intermediate,178.0,7767,Biodistribution in blood was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,
5872,1,,BAO_0000218,Intermediate,10000001.0,7767,Biodistribution in bone was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,
5873,1,,BAO_0000218,Intermediate,10000001.0,7767,Biodistribution in bone was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,
5874,1,,BAO_0000218,Intermediate,10000001.0,7767,Biodistribution in bone was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,
5875,1,,BAO_0000218,Intermediate,,7767,Biodistribution in fat and fur was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,
5876,1,,BAO_0000218,Intermediate,,7767,Biodistribution in fat and fur was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,
5877,1,,BAO_0000218,Intermediate,,7767,Biodistribution in fat and fur was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,
5878,1,,BAO_0000218,Intermediate,948.0,7767,Biodistribution in heart was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,
5879,1,,BAO_0000218,Intermediate,948.0,7767,Biodistribution in heart was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,
5880,1,,BAO_0000218,Intermediate,948.0,7767,Biodistribution in heart was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,
5881,1,,BAO_0000218,Intermediate,2113.0,7767,Biodistribution in kidney was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,
5882,1,,BAO_0000218,Intermediate,2113.0,7767,Biodistribution in kidney was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,
5883,1,,BAO_0000218,Intermediate,2113.0,7767,Biodistribution in kidney was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,
5884,1,,BAO_0000218,Intermediate,160.0,7767,Biodistribution in large intestine after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,
5885,1,,BAO_0000218,Intermediate,160.0,7767,Biodistribution in large intestine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,
5886,1,,BAO_0000218,Intermediate,160.0,7767,Biodistribution in large intestine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,
5887,1,,BAO_0000218,Intermediate,2107.0,7767,Biodistribution in liver was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,
5888,1,,BAO_0000218,Intermediate,2107.0,7767,Biodistribution in liver was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,
5889,1,,BAO_0000218,Intermediate,2107.0,7767,Biodistribution in liver was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,
5890,1,,BAO_0000218,Intermediate,2048.0,7767,Biodistribution in lung was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,
5891,1,,BAO_0000218,Intermediate,2048.0,7767,Biodistribution in lung was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,
5892,1,,BAO_0000218,Intermediate,2048.0,7767,Biodistribution in lung was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,
5893,1,,BAO_0000218,Intermediate,2385.0,7767,Biodistribution in muscle was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,
5894,1,,BAO_0000218,Intermediate,2385.0,7767,Biodistribution in muscle was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,
5895,1,,BAO_0000218,Intermediate,2385.0,7767,Biodistribution in muscle was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,
5896,1,,BAO_0000218,Intermediate,,7767,Biodistribution in pancreatic tissue was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,
5897,1,,BAO_0000218,Intermediate,,7767,Biodistribution in pancreatic tissue was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,
5898,1,,BAO_0000218,Intermediate,,7767,Biodistribution in pancreatic tissue was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,
5899,1,,BAO_0000218,Intermediate,160.0,7767,Biodistribution in small intestine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,
5900,1,,BAO_0000218,Intermediate,160.0,7767,Biodistribution in small intestine was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,
5901,1,,BAO_0000218,Intermediate,160.0,7767,Biodistribution in small intestine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,
5902,1,,BAO_0000218,Intermediate,2106.0,7767,Biodistribution in spleen was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,
5903,1,,BAO_0000218,Intermediate,2106.0,7767,Biodistribution in spleen was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,
5904,1,,BAO_0000218,Intermediate,2106.0,7767,Biodistribution in spleen was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,
5905,1,,BAO_0000218,Intermediate,945.0,7767,Biodistribution in stomach was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,
5906,1,,BAO_0000218,Intermediate,945.0,7767,Biodistribution in stomach was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,
5907,1,,BAO_0000219,Expert,,2036,Cytotoxicity against A-172 human tumor cell lines,F,,,Homo sapiens,9606.0,
5908,1,,BAO_0000219,Intermediate,,2357,Compound was evaluated for the in vitro cytotoxicity against A-172 human glioblastoma cell line,F,,,Homo sapiens,9606.0,
5909,1,,BAO_0000219,Intermediate,,1457,Antiproliferative activity of compound was tested against rhabdomyosarcoma (A-204) human tumor cells,F,,,Homo sapiens,9606.0,
5910,1,,BAO_0000219,Intermediate,,4379,Tested for antiproliferative activity against A-2780 tumoral cell line,F,,,Homo sapiens,9606.0,
5911,1,,BAO_0000219,Intermediate,,1093,Inhibitory concentration against melanoma A-375 cell line for cytotoxicity was determined,F,,,Homo sapiens,9606.0,
5912,1,,BAO_0000219,Intermediate,,12152,Tested in vitro against A-375 cell line human melanoma,F,,,Homo sapiens,9606.0,
5913,1,,BAO_0000219,Expert,,16464,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay,F,,,Homo sapiens,9606.0,
5914,1,,BAO_0000219,Intermediate,,16464,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,F,,,Homo sapiens,9606.0,
5915,1,,BAO_0000219,Expert,,16582,In vitro cytotoxicity against human non small-cell-lung cell line A-427.,F,,,Homo sapiens,9606.0,
5916,1,,BAO_0000219,Intermediate,,16464,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,F,,,Homo sapiens,9606.0,
5917,1,,BAO_0000219,Intermediate,,10413,Antitumor activity on A-427 lung carcinoma cell lines,F,,,Homo sapiens,9606.0,
5918,1,,BAO_0000219,Intermediate,,6418,Cytotoxic activity against human A-427 lung tumor cell line,F,,,Homo sapiens,9606.0,
5919,1,,BAO_0000219,Expert,,17134,In vitro antitumor effects against human A-427 cell lines.,F,,,Homo sapiens,9606.0,
5920,1,,BAO_0000219,Expert,,16132,In vitro inhibition of A-427 (human lung cancer) cell growth.,F,,,Homo sapiens,9606.0,
5921,1,,BAO_0000219,Intermediate,,16132,Cytotoxic related antitumor activity against human cancer cell lines A-427; No data available,F,,,Homo sapiens,9606.0,
5922,1,,BAO_0000219,Intermediate,,16780,Cytotoxic activity of compound against A-427 lung human tumor cell line,F,,,Homo sapiens,9606.0,
5923,1,,BAO_0000219,Expert,,4085,Cytotoxicity measured for the growth inhibition of A-431 Human epidermoid carcinoma cell line,F,,,Homo sapiens,9606.0,
5924,1,,BAO_0000219,Intermediate,,1276,Cytotoxic activity was tested against human A-498 (Kidney carcinoma) cell line,F,,,Homo sapiens,9606.0,
5925,1,,BAO_0000219,Expert,,3498,Cytotoxicity against A-498 cell line in the purdue cell culture screen was determined,F,,,Homo sapiens,9606.0,
5926,1,,BAO_0000219,Intermediate,,1169,Cytotoxicity against human kidney carcinoma A-498cell lines,F,,,Homo sapiens,9606.0,
5927,1,,BAO_0000219,Intermediate,,4450,In vitro cytotoxic activity against A-498 (human kidney carcinoma) cell line,F,,,Homo sapiens,9606.0,
5928,1,,BAO_0000219,Intermediate,,3311,In vitro cytotoxicity against Renal A-498 human tumors following a 6 day exposure.,F,,,Homo sapiens,9606.0,
5929,1,,BAO_0000219,Intermediate,,4461,Antitumor cytotoxic activity against A-498 cell line was determined,F,,,Homo sapiens,9606.0,
5930,1,,BAO_0000219,Intermediate,,3311,In vitro cytotoxicity against Renal A-498 human tumors following a 2 day exposure.,F,,,Homo sapiens,9606.0,
5931,1,,BAO_0000219,Intermediate,,3311,In vitro cytotoxicity against Renal A-498 human tumors following a 2 day exposure; ND is no data,F,,,Homo sapiens,9606.0,
5932,1,,BAO_0000219,Intermediate,,1457,Antiproliferative activity of compound was tested against renal cancer (A-498) human tumor cells,F,,,Homo sapiens,9606.0,
5933,1,,BAO_0000219,Intermediate,,3664,In vitro inhibitory activity against A-498 ovarian cancer cell lines,F,,,Homo sapiens,9606.0,
5934,1,,BAO_0000219,Intermediate,,15895,"Cytotoxicity against NCI tumor panel, A-498 renal cancer cell line",F,,,Homo sapiens,9606.0,
5935,1,,BAO_0000219,Intermediate,,11843,Inhibition of growth lung non-small cell carcinoma A-549 cell line,F,,,Homo sapiens,9606.0,
5936,1,,BAO_0000219,Intermediate,,11843,Inhibition of growth of lung non-small cell carcinoma A-549 cell line,F,,,Homo sapiens,9606.0,
5937,1,,BAO_0000219,Intermediate,,17705,In vitro antiproliferative activity against human A-549 NSCL cell line,F,,,Homo sapiens,9606.0,
5938,1,,BAO_0000219,Intermediate,,17705,In vitro antiproliferative activity against human A-549 NSCL cell line; NS = Not significant,F,,,Homo sapiens,9606.0,
5939,1,,BAO_0000219,Intermediate,,4369,Growth inhibition of A-549 human lung adenocarcinoma at 0.01 uM compound concentration in standard MTT assay,F,,,Homo sapiens,9606.0,
5940,1,,BAO_0000219,Intermediate,,4369,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-6 M compound concentration in standard MTT assay,F,,,Homo sapiens,9606.0,
5941,1,,BAO_0000219,Intermediate,,4369,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-6 M compound concentration in standard MTT assay; ND means No data,F,,,Homo sapiens,9606.0,
5942,1,,BAO_0000219,Intermediate,,4369,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-7 M compound concentration in standard MTT assay,F,,,Homo sapiens,9606.0,
5943,1,,BAO_0000219,Intermediate,,4369,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-7 M compound concentration in standard MTT assay; ND means No data,F,,,Homo sapiens,9606.0,
5944,1,,BAO_0000219,Intermediate,,4369,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-8 M compound concentration in standard MTT assay,F,,,Homo sapiens,9606.0,
5945,1,,BAO_0000219,Intermediate,,4369,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-8 M compound concentration in standard MTT assay; ND means No data,F,,,Homo sapiens,9606.0,
5946,1,,BAO_0000219,Expert,,4787,In vitro effective concentration required to reduce the number of human lung carcinoma (A-549) after 3-day incubation,F,,,Homo sapiens,9606.0,
5947,1,,BAO_0000219,Intermediate,,4787,In vitro effective concentration required to reduce the number of human lung carcinoma cells (A-549) after 3-day incubation,F,,,Homo sapiens,9606.0,
5948,1,,BAO_0000219,Intermediate,,6513,Cytotoxic activity against A-549 cell line,F,,,Homo sapiens,9606.0,
5949,1,,BAO_0000219,Intermediate,,6690,Antitumor cytotoxicity was determined against the A-549(human lung carcinoma) cell line; Range: 0.01 to 0.03,F,,,Homo sapiens,9606.0,
5950,1,,BAO_0000219,Intermediate,,6690,Antitumor cytotoxicity was determined against the A-549(human lung carcinoma) cell line; Range: 10.4 to 118.1,F,,,Homo sapiens,9606.0,
5951,1,,BAO_0000219,Expert,,12263,"Cytotoxicity in vitro expressed as 50% reduction in cell number after a 3-day incubation, in human lung carcinoma A-549 cell line",F,,,Homo sapiens,9606.0,
5952,1,,BAO_0000219,Intermediate,,1054,Compound was tested for cytotoxic activity against human lung carcinoma (A-549),F,,,Homo sapiens,9606.0,
5953,1,,BAO_0000219,Intermediate,,1359,Compound was tested for its cytotoxic activity in MTT assay against A-549 cell line (human lung carcinoma),F,,,Homo sapiens,9606.0,
5954,1,,BAO_0000219,Intermediate,,3547,Cytotoxic activity against human lung carcinoma (A-549) cell line,F,,,Homo sapiens,9606.0,
5955,1,,BAO_0000219,Expert,,5771,Cytotoxic activity towards A-549 cells,F,,,Homo sapiens,9606.0,
5956,1,,BAO_0000219,Intermediate,,14425,"In vitro percent inhibition of A549, lung carcinoma.",F,,,Homo sapiens,9606.0,
5957,1,,BAO_0000219,Intermediate,,14425,"In vitro percent inhibition of A549, lung carcinoma",F,,,Homo sapiens,9606.0,
5958,1,,BAO_0000219,Intermediate,,14425,"In vitro percent inhibition of A549, lung carcinoma.",F,,,Homo sapiens,9606.0,
5959,1,,BAO_0000219,Intermediate,,14425,"In vitro percent inhibition of A549, lung carcinoma.; Range 18-23",F,,,Homo sapiens,9606.0,
5960,1,,BAO_0000219,Intermediate,,5280,Percentage inhibition against parental and drug resistant lung human tumor cell line A549 at 10 uM,F,,,Homo sapiens,9606.0,
5961,1,,BAO_0000219,Intermediate,,15176,Growth inhibition of the A549/ATCC non-small cell lung cancer cell line for 2-day in vitro assay.,F,,,Homo sapiens,9606.0,
5962,1,,BAO_0000219,Intermediate,,15300,In vitro antitumor activity against Non-small cell lung cancer A549/ATCC cell lines by 6-day assay,F,,,Homo sapiens,9606.0,
5963,1,,BAO_0000218,Intermediate,,17824,"Antitumor activity against A549 non small cell carcinoma at dose range of 1.56-6.25 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",F,,,Homo sapiens,9606.0,
5964,1,,BAO_0000218,Intermediate,,17824,"Antitumor activity against A549 non small cell carcinoma at dose range of 25-100 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",F,,,Homo sapiens,9606.0,
5965,1,,BAO_0000218,Intermediate,,17824,"Antitumor activity against A549 non small cell carcinoma at dose range of 3.12-12.5 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",F,,,Homo sapiens,9606.0,
5966,1,,BAO_0000218,Intermediate,,17824,"Antitumor activity against A549 non small cell carcinoma at dose range of 6.25-25 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",F,,,Homo sapiens,9606.0,
5967,1,,BAO_0000218,Intermediate,,17824,"Antitumor activity against A549 non small cell carcinoma at dose range of 70-100 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",F,,,Homo sapiens,9606.0,
5968,1,,BAO_0000219,Intermediate,,17824,"Antitumor activity against A549 non small cell carcinoma on day 14, 21, 28; activity expressed as maximum tolerated dose; NT = Not tested",F,,,Homo sapiens,9606.0,
5969,1,,BAO_0000218,Intermediate,,17528,Optimal dose required to inhibit human non small cell lung A549 tumor growth after subcutaneous transplantation on athymic mice at 10 mg/kg (treatment schedule: q7dX3),F,,,Homo sapiens,9606.0,
5970,1,,BAO_0000219,Expert,,6870,Cytotoxic potentiation factor of temoxolomide in human A549 tumor cell line at 0.4 uM concentration,F,,,Homo sapiens,9606.0,
5971,1,,BAO_0000219,Intermediate,,6870,Compound was evaluated for cytotoxic potentiation factor of temoxolomide in human A549 tumor cell line at 0.4 uM concentration; ND - not determined,F,,,Homo sapiens,9606.0,
5972,1,,BAO_0000219,Intermediate,,6870,Compound was evaluated for cytotoxic potentiation factor of topotecan in human A549 tumor cell line at 0.4 uM concentration,F,,,Homo sapiens,9606.0,
5973,1,,BAO_0000219,Intermediate,,6870,Compound was evaluated for cytotoxic potentiation factor of topotecan in human A549 tumor cell line at 0.4 uM concentration; ND - not determined,F,,,Homo sapiens,9606.0,
5974,1,,BAO_0000219,Intermediate,,16726,Cytotoxicity potentiation of Topotecan in human lung carcinoma A549 cells by the compound as potentiation factor at 50% growth inhibition,F,,,Homo sapiens,9606.0,
5975,1,,BAO_0000219,Intermediate,,6170,"Concentration required for 50% inhibition of proliferation of lung cancer cell line, A549 with respect to paclitaxel was tested in vitro after 72 hr of incubation",F,,,Homo sapiens,9606.0,
5976,1,,BAO_0000219,Expert,,6583,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-4 mol/L,F,,,Homo sapiens,9606.0,
5977,1,,BAO_0000219,Expert,,6583,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-5 mol/L,F,,,Homo sapiens,9606.0,
5978,1,,BAO_0000219,Expert,,6583,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-6 mol/L,F,,,Homo sapiens,9606.0,
5979,1,,BAO_0000219,Expert,,6583,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-7 mol/L,F,,,Homo sapiens,9606.0,
5980,1,,BAO_0000219,Expert,,6583,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-8 mol/L,F,,,Homo sapiens,9606.0,
5981,1,,BAO_0000219,Intermediate,,17321,Tested for cytotoxicity against human lung adenocarcinoma A549 cell line,F,,,Homo sapiens,9606.0,
5982,1,,BAO_0000219,Expert,,17528,Percentage tumor growth inhibition was calculated in respect to controls one week after the end of the treatment,F,,,Homo sapiens,9606.0,
5983,1,,BAO_0000219,Expert,,12888,Cytotoxic effect on non-small-cell lung cancer cell line A549/ATCC,F,,,Homo sapiens,9606.0,
5984,1,,BAO_0000219,Intermediate,,4312,Cytotoxicity of compound in synergy in 94% BCNU (10 uM) against A549 cell line,F,,,Homo sapiens,9606.0,
5985,1,,BAO_0000219,Intermediate,,4312,Cytotoxicity of compound in synergy in BCNU (10 uM) against A549 cell line,F,,,Homo sapiens,9606.0,
5986,1,,BAO_0000219,Intermediate,,4312,Cytotoxicity of compound in synergy in BCNU (10 uM) against A549 cell line; No data,F,,,Homo sapiens,9606.0,
5987,1,,BAO_0000219,Intermediate,,17737,In vitro antiproliferative activity against A549 cell line,F,,,Mus musculus,10090.0,
5988,1,,BAO_0000219,Intermediate,,6630,Synergism with indomethacin in A549 cells,F,,,,,
5989,1,,BAO_0000219,Intermediate,,6630,Synergism with tolmetin in A549 cells,F,,,,,
5990,1,,BAO_0000219,Intermediate,,6630,Synergism with sulindac in A549 cells,F,,,,,
5991,1,,BAO_0000219,Intermediate,,6630,Antagonism of indomethacin in A549 cells,F,,,,,
5992,1,,BAO_0000219,Intermediate,,6630,Antagonism of sulindac in A549 cells,F,,,,,
5993,1,,BAO_0000219,Intermediate,,6630,Antagonism of tolmetin in A549 cells,F,,,,,
5994,1,,BAO_0000219,Intermediate,,6630,Synergism with indomethacin in A549 cells,F,,,,,
5995,1,,BAO_0000219,Intermediate,,6630,Synergism with sulindac in A549 cells,F,,,,,
5996,1,,BAO_0000219,Intermediate,,6630,Drug interaction towards A549 cell line was determined in terms of combination index in presence of Tolmetin; Not available,F,,,,,
5997,1,,BAO_0000218,Intermediate,,16907,Cmax value after 30 mg/kg po dose in Dogs,A,In vivo,,Canis lupus familiaris,9615.0,
5998,1,,BAO_0000218,Intermediate,,5944,Cmax value determined in dog at a dose of 0 mg/kg by oral administration along with indavir (10 mg/kg),A,In vivo,,Canis lupus familiaris,9615.0,
5999,1,,BAO_0000218,Intermediate,,5944,Cmax value determined in dog at a dose of 10 mg/kg by oral administration,A,In vivo,,Canis lupus familiaris,9615.0,
6000,1,,BAO_0000218,Intermediate,,5944,Cmax value determined in dog at a dose of 10 mg/kg by oral administration along with indavir (10 mg/kg),A,In vivo,,Canis lupus familiaris,9615.0,
6001,1,,BAO_0000218,Intermediate,,5944,Cmax value determined in dog at a dose of 5 mg/kg by oral administration,A,In vivo,,Canis lupus familiaris,9615.0,
6002,1,,BAO_0000218,Intermediate,,2959,Cmax value after administration of 4 mg/Kg oral dose in dog,A,In vivo,,Canis lupus familiaris,9615.0,
6003,1,,BAO_0000218,Intermediate,,6241,Cmax value in dog,A,In vivo,,Canis lupus familiaris,9615.0,
6004,1,,BAO_0000218,Intermediate,,6241,Cmax value in dogs after oral administration at 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,
6005,1,,BAO_0000218,Intermediate,,2652,Bioavailability as Cmax in dogs at 5 mg/kg oral dose,A,In vivo,,Canis lupus familiaris,9615.0,
6006,1,,BAO_0000218,Intermediate,1969.0,1806,Compound was evaluated for maximum observed plasma concentration at dose 27.5 mg/kg DMP323 equiv in dogs,A,In vivo,,Canis lupus familiaris,9615.0,
6007,1,,BAO_0000218,Intermediate,1969.0,1806,Compound was evaluated for maximum observed plasma concentration at dose 7.7 mg/kg DMP323 equiv in dogs,A,In vivo,,Canis lupus familiaris,9615.0,
6008,1,,BAO_0000218,Intermediate,,1021,Concentration maxima after oral dosing in dogs,A,In vivo,,Canis lupus familiaris,9615.0,
6009,1,,BAO_0000218,Intermediate,,1021,Concentration maxima after oral dosing in dogs; not available,A,In vivo,,Canis lupus familiaris,9615.0,
6010,1,,BAO_0000218,Intermediate,,1021,Concentration maxima after oral dosing in dogs; not available,A,In vivo,,Canis lupus familiaris,9615.0,
6011,1,,BAO_0000218,Intermediate,,5444,In vivo maximal concentration was calculated at 0.4 mg/kg in dog; Not absorbed,A,In vivo,,Canis lupus familiaris,9615.0,
6012,1,,BAO_0000218,Intermediate,,5444,In vivo maximal concentration was calculated at 0.6 mg/kg in dog; Not absorbed,A,In vivo,,Canis lupus familiaris,9615.0,
6013,1,,BAO_0000218,Intermediate,,5444,In vivo maximal concentration was calculated at 1 mg/kg in dog,A,In vivo,,Canis lupus familiaris,9615.0,
6014,1,,BAO_0000218,Intermediate,,5444,In vivo maximal concentration was calculated at 1 mg/kg in dog; Not absorbed,A,In vivo,,Canis lupus familiaris,9615.0,
6015,1,,BAO_0000218,Intermediate,,5444,In vivo maximal concentration was calculated at 1 mg/kg in dog; Poor absorption,A,In vivo,,Canis lupus familiaris,9615.0,
6016,1,,BAO_0000218,Intermediate,1969.0,5130,Cmax in dog plasma after oral dose (1 mg/kg),A,In vivo,,Canis lupus familiaris,9615.0,
6017,1,,BAO_0000218,Intermediate,1969.0,3249,Maximal concentration (Cmax) in dog plasma at a dose of 5 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,
6018,1,,BAO_0000218,Intermediate,1969.0,5473,Maximal plasma concentration at a dose of 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,
6019,1,,BAO_0000218,Intermediate,1969.0,5474,Maximal plasma concentration at a dose of 1 mg/kg (oral),A,In vivo,,Canis lupus familiaris,9615.0,
6020,1,,BAO_0000218,Intermediate,1969.0,4657,Maximal plasma concentration required for pharmacokinetic data in dogs at dose of 1 mg/kg perorally,A,In vivo,,Canis lupus familiaris,9615.0,
6021,1,,BAO_0000218,Intermediate,,3031,Maximum concentration of compound in dog was evaluated.,A,In vivo,,Canis lupus familiaris,9615.0,
6022,1,,BAO_0000218,Intermediate,,4527,Maximum concentration by oral administration at a dose of 10 uM/kg in dog was determined,A,In vivo,,Canis lupus familiaris,9615.0,
6023,1,,BAO_0000218,Intermediate,,4186,Maximum concentration in dog after administration of 20 mg/kg dose through peroral route,A,In vivo,,Canis lupus familiaris,9615.0,
6024,1,,BAO_0000218,Intermediate,,5007,Maximum concentration in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),A,In vivo,,Canis lupus familiaris,9615.0,
6025,1,,BAO_0000218,Intermediate,1969.0,3132,Maximum concentration obtained in dog plasma was determined,A,In vivo,,Canis lupus familiaris,9615.0,
6026,1,,BAO_0000218,Intermediate,,5006,Maximum concentration was determined,A,In vivo,,Canis lupus familiaris,9615.0,
6027,1,,BAO_0000218,Intermediate,,4727,Maximum concentration at the dose of 2 mg/kg in dog,A,In vivo,,Canis lupus familiaris,9615.0,
6028,1,,BAO_0000218,Intermediate,,1916,Maximum concentration was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,A,In vivo,,Canis lupus familiaris,9615.0,
6029,1,,BAO_0000218,Intermediate,1969.0,1918,Maximum concentration was evaluated in dog plasma,A,In vivo,,Canis lupus familiaris,9615.0,
6030,1,,BAO_0000218,Intermediate,,3045,Maximum concentration was evaluated after 75 min after administration in dog,A,In vivo,,Canis lupus familiaris,9615.0,
6031,1,,BAO_0000218,Intermediate,1969.0,9579,Maximum plasma concentration determined in dog after oral administration of 17b,A,In vivo,,Canis lupus familiaris,9615.0,
6032,1,,BAO_0000218,Intermediate,1969.0,9579,Maximum plasma concentration determined in dog after oral administration of 2b,A,In vivo,,Canis lupus familiaris,9615.0,
6033,1,,BAO_0000218,Intermediate,1969.0,933,Maximum plasma concentration in dog,A,In vivo,,Canis lupus familiaris,9615.0,
6034,1,,BAO_0000218,Intermediate,1969.0,17839,Maximum plasma concentration of compound in dog following p.o. administration of 0.5 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,
6035,1,,BAO_0000218,Intermediate,1969.0,17839,Maximum plasma concentration of compound in dog following p.o. administration of 0.9 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,
6036,1,,BAO_0000218,Intermediate,1969.0,17839,Maximum plasma concentration of compound in dog following p.o. administration of 0.95 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,
6037,1,,BAO_0000218,Intermediate,1969.0,17839,Maximum plasma concentration of compound in dog following p.o. administration of 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,
6038,1,,BAO_0000218,Intermediate,1969.0,6348,Maximum plasma concentration of compound was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,A,In vivo,,Canis lupus familiaris,9615.0,
6039,1,,BAO_0000218,Intermediate,1969.0,16367,Maximum plasma concentration after oral administration to dogs at a dose of 10 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,
6040,1,,BAO_0000218,Intermediate,1969.0,1337,Maximum plasma concentration in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,A,In vivo,,Canis lupus familiaris,9615.0,
6041,1,,BAO_0000218,Intermediate,1969.0,1337,Maximum plasma concentration in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,A,In vivo,,Canis lupus familiaris,9615.0,
6042,1,,BAO_0000218,Intermediate,1969.0,5199,Maximum plasma concentration at a 1 mg/kg oral dose in male and female Beagle dogs.,A,In vivo,,Canis lupus familiaris,9615.0,
6043,1,,BAO_0000218,Intermediate,1969.0,17650,Maximum plasma concentration was measured in dogs after an oral dose of 10 uM/kg,A,In vivo,,Canis lupus familiaris,9615.0,
6044,1,,BAO_0000218,Intermediate,1969.0,6679,Maximum plasma concentration reached by compound was determined after 2 mg/kg (p.o.) administration,A,In vivo,,Canis lupus familiaris,9615.0,
6045,1,,BAO_0000218,Intermediate,1969.0,5356,Maximum plasma concentration was determined as in dogs at 1 mg/kg oral dosing Cmax; 0.05-0.2 ug/mL,A,In vivo,,Canis lupus familiaris,9615.0,
6046,1,,BAO_0000218,Intermediate,1969.0,5356,Maximum plasma concentration was determined in dogs at 1 mg/kg oral dosing; 0.05-0.2 ug/mL,A,In vivo,,Canis lupus familiaris,9615.0,
6047,1,,BAO_0000218,Intermediate,1969.0,6227,Maximum plasma concentration (Cmax) in dog (in vivo) at a dose of 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,
6048,1,,BAO_0000218,Intermediate,1969.0,6227,Maximum plasma concentration (Cmax) in dog at a dose of 0.5 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,
6049,1,,BAO_0000218,Intermediate,1969.0,6227,Maximum plasma concentration (Cmax) in dog at a dose of 0.7 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,
6050,1,,BAO_0000218,Intermediate,1969.0,6227,Maximum plasma concentration (Cmax) in dog at a dose of 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,
6051,1,,BAO_0000218,Expert,1969.0,3598,Maximum plasma drug concentration of compound determined in dog after iv administration at a dose of 10 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,
6052,1,,BAO_0000218,Intermediate,,4368,Maximum concentration by intravenous administration of 1.2 mg/kg in dog,A,In vivo,,Canis lupus familiaris,9615.0,
6053,1,,BAO_0000218,Intermediate,,6265,Pharmacokinetic (PK) property (Cmax) was determined in dog at the single dose of 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,
6054,1,,BAO_0000218,Intermediate,945.0,7767,Biodistribution in stomach was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,
6055,1,,BAO_0000218,Intermediate,1088.0,7767,Biodistribution in urine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,
6056,1,,BAO_0000218,Intermediate,1088.0,7767,Biodistribution in urine was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram; ND- No data,A,In vivo,,Mus musculus,10090.0,
6057,1,,BAO_0000218,Intermediate,1088.0,7767,Biodistribution in urine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram; ND- No data,A,In vivo,,Mus musculus,10090.0,
6058,1,,BAO_0000218,Intermediate,,17811,Compound (0.09% dose/g) was tested for accumulation in mice bone (Compound is radiolabeled) after 120 min; No increase,A,,,Mus musculus,10090.0,
6059,1,,BAO_0000218,Intermediate,,17811,Compound (0.31% dose/g) was tested for accumulation in mice bone (Compound is radiolabeled) after 30 min; Low increase,A,,,Mus musculus,10090.0,
6060,1,,BAO_0000218,Intermediate,,17827,Compound (i.v.) was tested for maximum activity in mice (Radiolabeled compound),A,,,Mus musculus,10090.0,
6061,1,,BAO_0000218,Intermediate,178.0,17827,Compound was evaluated for elimination rate constants in vivo in whole blood of normal mice (Radiolabeled compound),A,,,Mus musculus,10090.0,
6062,1,,BAO_0000218,Intermediate,,17827,Compound was evaluated for rate of bone uptake after administration of radiolabeled in mice (Radiolabeled compound),A,,,Mus musculus,10090.0,
6063,1,,BAO_0000218,Intermediate,,17827,Compound was evaluated for rate of bone uptake in mice (Radiolabeled compound),A,,,Mus musculus,10090.0,
6064,1,,BAO_0000218,Intermediate,,17827,Compound was evaluated for rate of bone uptake in mice; NA - not active (Radiolabeled compound),A,,,Mus musculus,10090.0,
6065,1,,BAO_0000218,Intermediate,178.0,17827,Compound was evaluated for uptake rate constants in vivo in whole blood of normal mice (Radiolabeled compound),A,,,Mus musculus,10090.0,
6066,1,,BAO_0000218,Intermediate,178.0,17827,Compound was evaluated for uptake rate constants in vivo in whole blood of normal mice; NA = not active (Radiolabeled compound),A,,,Mus musculus,10090.0,
6067,1,,BAO_0000218,Intermediate,,17827,Compound was evaluated for washout rate in mice (Radiolabeled compound),A,,,Mus musculus,10090.0,
6068,1,,BAO_0000218,Intermediate,,17827,Compound was evaluated for washout rate in mice after radiolabeled ligand injected,A,,,Mus musculus,10090.0,
6069,1,,BAO_0000218,Intermediate,,17827,"Maximum activity (i.v.) after in mice, expressed as [(ID%-kg)/g] (Radiolabeled compound)",A,,,Mus musculus,10090.0,
6070,1,,BAO_0000218,Intermediate,,17827,"Maximum activity in mice, expressed as [(ID%-kg)/g] (Radiolabeled compound)",A,,,Mus musculus,10090.0,
6071,1,,BAO_0000218,Intermediate,,17827,"Residual activity in mice at 120 minutes, expressed as [(ID%-kg)/g] (Radiolabeled compound)",A,,,Mus musculus,10090.0,
6072,1,,BAO_0000218,Intermediate,,17257,Tested for plasma level after 90 min of 10 mg/kg dose administered in mice,A,,,Mus musculus,10090.0,
6073,1,,BAO_0000218,Intermediate,,17257,Tested for plasma level after 90 min of 10 mg/kg dose administered in mice; Not detected.,A,,,Mus musculus,10090.0,
6074,1,,BAO_0000218,Intermediate,,17257,Tested for plasma level after 90 min of 30 mg/kg dose administered in mice,A,,,Mus musculus,10090.0,
6075,1,,BAO_0000218,Intermediate,,17257,Tested for plasma level after 90 min of 30 mg/kg dose administered in mice; Not determined,A,,,Mus musculus,10090.0,
6076,1,,BAO_0000218,Intermediate,,17827,Time at maximum activity in mice (Radiolabeled compound),A,,,Mus musculus,10090.0,
6077,1,,BAO_0000218,Intermediate,,3760,Percent oral bioavailability was determined after administration of compound at 5 mg/kg perorally in mice,A,,,Mus musculus,10090.0,
6078,1,,BAO_0000218,Intermediate,,3760,Percent oral bioavailability was determined after administration of compound at 50 mg/kg perorally in mice,A,,,Mus musculus,10090.0,
6079,1,,BAO_0000218,Intermediate,,17409,Binding towards mouse plasma protein at 10 uM,A,,,Mus musculus,10090.0,
6080,1,,BAO_0000218,Intermediate,,17409,Binding towards mouse plasma protein at 100 uM,A,,,Mus musculus,10090.0,
6081,1,,BAO_0000218,Intermediate,,2675,Bioavailability was evaluated in mice after intravenous administration,A,In vivo,,Mus musculus,10090.0,
6082,1,,BAO_0000218,Intermediate,,2675,Bioavailability was evaluated in mice after oral administration,A,In vivo,,Mus musculus,10090.0,
6083,1,,BAO_0000218,Intermediate,,3132,Bioavailability was obtained by the comparison of AUC of subcutaneous dosing and AUC of oral dosing in mouse,A,In vivo,,Mus musculus,10090.0,
6084,1,,BAO_0000218,Intermediate,,3132,Bioavailability was obtained by the comparison of AUC of subcutaneous dosing and AUC of oral dosing in mouse at dose 25 mg/kg,A,In vivo,,Mus musculus,10090.0,
6085,1,,BAO_0000218,Intermediate,,16597,Bioavailability at a dose of 10 mg/kg peroral administration in mice.,A,In vivo,,Mus musculus,10090.0,
6086,1,,BAO_0000218,Intermediate,,2862,Oral bioavailability in mouse,A,In vivo,,Mus musculus,10090.0,
6087,1,,BAO_0000218,Intermediate,,17764,Oral bioavailability after intravenous administration in mice at 24 uM/kg,A,In vivo,,Mus musculus,10090.0,
6088,1,,BAO_0000218,Intermediate,955.0,846,Biodistribution of [123I]- labeled compound in mice brain was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,
6089,1,,BAO_0000218,Intermediate,955.0,846,Biodistribution of [123I]- labeled compound in mice brain was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,
6090,1,,BAO_0000218,Intermediate,955.0,846,Biodistribution of [123I]- labeled compound in mice brain was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,
6091,1,,BAO_0000218,Intermediate,955.0,846,Biodistribution of [123I]- labeled compound in mice brain was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,
6092,1,,BAO_0000218,Intermediate,955.0,846,Biodistribution of [123I]- labeled compound in mice brain was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,
6093,1,,BAO_0000218,Intermediate,955.0,846,Biodistribution of [123I]- labeled compound in mice brain was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,
6094,1,,BAO_0000218,Intermediate,948.0,846,Biodistribution of [123I]- labeled compound in mice heart was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,
6095,1,,BAO_0000218,Intermediate,948.0,846,Biodistribution of [123I]- labeled compound in mice heart was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,
6096,1,,BAO_0000218,Intermediate,948.0,846,Biodistribution of [123I]- labeled compound in mice heart was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,
6097,1,,BAO_0000218,Intermediate,948.0,846,Biodistribution of [123I]- labeled compound in mice heart was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,
6098,1,,BAO_0000219,Intermediate,,1276,Cytotoxic activity was tested against human prostate cell line A-549 (lung carcinoma),F,,,Homo sapiens,9606.0,
6099,1,,BAO_0000219,Expert,,3498,Cytotoxicity against A-549 cell line in the purdue cell culture screen was determined,F,,,Homo sapiens,9606.0,
6100,1,,BAO_0000219,Intermediate,,1169,Cytotoxicity against human lung carcinoma A-549 cell lines,F,,,Homo sapiens,9606.0,
6101,1,,BAO_0000219,Intermediate,,4450,In vitro cytotoxic activity against A-549 (human lung carcinoma) cell line,F,,,Homo sapiens,9606.0,
6102,1,,BAO_0000219,Intermediate,,358,In vitro cytotoxicity against human lung carcinoma cell line A-549,F,,,Homo sapiens,9606.0,
6103,1,,BAO_0000219,Intermediate,,358,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 3.6*10e-5 M,F,,,Homo sapiens,9606.0,
6104,1,,BAO_0000219,Intermediate,,358,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 4.2*10e-5M,F,,,Homo sapiens,9606.0,
6105,1,,BAO_0000219,Intermediate,,358,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 4.3*10e-5M,F,,,Homo sapiens,9606.0,
6106,1,,BAO_0000219,Intermediate,,358,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 5.0*10e-5M,F,,,Homo sapiens,9606.0,
6107,1,,BAO_0000219,Intermediate,,358,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 6.1*10e-5 M,F,,,Homo sapiens,9606.0,
6108,1,,BAO_0000219,Intermediate,,358,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 7.4*10e-5 M,F,,,Homo sapiens,9606.0,
6109,1,,BAO_0000219,Intermediate,,15167,In vitro cytotoxicity against A-549 human lung cancer cells,F,,,Homo sapiens,9606.0,
6110,1,,BAO_0000219,Intermediate,,4139,In vitro cytotoxicity against human lung carcinoma (A-549) cell line,F,,,Homo sapiens,9606.0,
6111,1,,BAO_0000219,Intermediate,,833,In vitro cytotoxicity in human tumor lung carcinoma A-549 cell lines,F,,,Homo sapiens,9606.0,
6112,1,,BAO_0000219,Expert,,15718,Tested in vitro for cytotoxic activity against lung carcinoma (A-549) cell line,F,,,Homo sapiens,9606.0,
6113,1,,BAO_0000219,Intermediate,,12373,Tested in vitro for cytotoxicity against A-549 lung cancer cells,F,,,Homo sapiens,9606.0,
6114,1,,BAO_0000219,Intermediate,,637,The compound was tested for cytotoxicity against A-549 cell in human lung carcinoma,F,,,Homo sapiens,9606.0,
6115,1,,BAO_0000219,Expert,,14867,Cytotoxicity against human lung carcinoma cells (A-549) using SRB assay.,F,,,Homo sapiens,9606.0,
6116,1,,BAO_0000219,Intermediate,,4461,Antitumor cytotoxic activity against A-549 cell line was determined,F,,,Homo sapiens,9606.0,
6117,1,,BAO_0000219,Intermediate,,5406,"Tested for the cytotoxicity against the Non-small cell lung cancer cell line A-549, growth inhibition by 50% is reported",F,,,Homo sapiens,9606.0,
6118,1,,BAO_0000219,Intermediate,,4457,Compound was tested for cytotoxicity against A-549 human solid tumor cell line,F,,,Homo sapiens,9606.0,
6119,1,,BAO_0000219,Expert,,1386,Antineoplastic activity against A-549 (human lung carcinoma) cell line.,F,,,Homo sapiens,9606.0,
6120,1,,BAO_0000219,Intermediate,,3265,Antitumoral activity was assayed against A-549 cell line,F,,,Homo sapiens,9606.0,
6121,1,,BAO_0000219,Intermediate,,2359,Compound was evaluated for the cytotoxicity against A-549 tumor cell line after 3 days of incubation,F,,,Homo sapiens,9606.0,
6122,1,,BAO_0000219,Intermediate,,4457,Compound was tested for cytotoxicity against A-549 human solid tumor cell line,F,,,Homo sapiens,9606.0,
6123,1,,BAO_0000219,Expert,,12454,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,F,,,Homo sapiens,9606.0,
6124,1,,BAO_0000219,Intermediate,,1481,Compound was tested for inhibition of cell growth of A-549 cells,F,,,Homo sapiens,9606.0,
6125,1,,BAO_0000219,Intermediate,,1750,Compound was tested for its inhibitory effect on the growth of A-549 tumor cell line from lung.,F,,,Homo sapiens,9606.0,
6126,1,,BAO_0000219,Intermediate,,5065,Concentration required for 50% inhibition of growth in human lung carcinoma cell line was determined,F,,,Homo sapiens,9606.0,
6127,1,,BAO_0000219,Expert,,808,In vitro cytotoxicity against A549-human lung carcinoma cells.,F,,,Homo sapiens,9606.0,
6128,1,,BAO_0000219,Expert,,16364,Cytotoxic activity against cultured cells of A-549 human lung carcinoma.,F,,,Homo sapiens,9606.0,
6129,1,,BAO_0000219,Intermediate,,1847,Cytotoxic activity against A-549 cell lines.,F,,,Homo sapiens,9606.0,
6130,1,,BAO_0000219,Expert,,1747,Cytotoxicity was measured against neoplastic cultured A-549 cells of human lung carcinoma.,F,,,Homo sapiens,9606.0,
6131,1,,BAO_0000219,Intermediate,,1003,Cytotoxicity against human A549 non small cell lung cell lines,F,,,Homo sapiens,9606.0,
6132,1,,BAO_0000219,Expert,,15313,Inhibition of cell growth in (A-549) lung cell line,F,,,Homo sapiens,9606.0,
6133,1,,BAO_0000219,Intermediate,,3122,Growth inhibitory effect of compound was measured on A-549 human lung adenocarcinoma cancer cell line,F,,,Homo sapiens,9606.0,
6134,1,,BAO_0000219,Intermediate,,16049,In vitro antitumor activity against A-549 tumor cells.,F,,,Homo sapiens,9606.0,
6135,1,,BAO_0000219,Expert,,17134,In vitro antitumor effects against human A-549 cell lines.,F,,,Homo sapiens,9606.0,
6136,1,,BAO_0000219,Intermediate,,6406,In vitro cytotoxic activity of compound against A-549 cell line,F,,,Homo sapiens,9606.0,
6137,1,,BAO_0000219,Intermediate,,627,In vitro cytotoxicity against human lung carcinoma A-549 cell line,F,,,Homo sapiens,9606.0,
6138,1,,BAO_0000219,Intermediate,,12307,In vitro cytotoxicity against human non-small cell lung carcinoma A549,F,,,Homo sapiens,9606.0,
6139,1,,BAO_0000219,Intermediate,,17861,In vitro cytotoxicity against human A-549 cancer cell line was evaluated,F,,,Homo sapiens,9606.0,
6140,1,,BAO_0000219,Expert,,6682,In vitro cytotoxicity against the A-549 (human lung carcinoma) neoplastic cell line,F,,,Homo sapiens,9606.0,
6141,1,,BAO_0000219,Intermediate,,6663,Inhibitory concentration of compound against A-549 cell line,F,,,Homo sapiens,9606.0,
6142,1,,BAO_0000219,Intermediate,,2454,Tested for the cytostatic activity as inhibitory concentration against A-549 human pulmonary adenocarcinoma cells,F,,,Homo sapiens,9606.0,
6143,1,,BAO_0000219,Intermediate,,14709,cytotoxic activity against leukemia (A-549) cancer cell line,F,,,Homo sapiens,9606.0,
6144,1,,BAO_0000219,Expert,,15718,Tested in vitro for cytotoxic activity against lung carcinoma (A-549) cell line,F,,,Homo sapiens,9606.0,
6145,1,,BAO_0000219,Intermediate,,15718,Percent inhibition for cytotoxic activity against lung carcinoma (A-549) cell line,F,,,Homo sapiens,9606.0,
6146,1,,BAO_0000219,Intermediate,,17130,Cytotoxic activity of compound against A-549 cell lines at concentration of 0.1(ug/ml),F,,,Homo sapiens,9606.0,
6147,1,,BAO_0000219,Intermediate,,17130,Cytotoxic activity of compound against A-549 cell lines at concentration of 0.4(ug/ml),F,,,Homo sapiens,9606.0,
6148,1,,BAO_0000219,Intermediate,,17130,Cytotoxic activity of compound against A-549 cell lines at concentration of 1.1 (ug/ml),F,,,Homo sapiens,9606.0,
6149,1,,BAO_0000219,Intermediate,,17130,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml),F,,,Homo sapiens,9606.0,
6150,1,,BAO_0000219,Intermediate,,6630,Drug interaction towards A549 cell line was determined in terms of combination index in presence of Tometin; Not available,F,,,,,
6151,1,,BAO_0000219,Intermediate,,16726,Influence of PARP-1 cellular activity in human lung carcinoma A549 cells on %ADP Polymer formation at a concentration of 25 uM of the compound,F,,,Homo sapiens,9606.0,
6152,1,,BAO_0000219,Intermediate,,17846,Cytotoxicity against A549 cells; No cytotoxicity,F,,,Homo sapiens,9606.0,
6153,1,,BAO_0000219,Expert,,3415,Cytotoxicity against human lung carcinoma (A549) cell lines,F,,,Homo sapiens,9606.0,
6154,1,,BAO_0000219,Expert,,3415,Cytotoxicity against human lung carcinoma (A549) cell lines; Not active,F,,,Homo sapiens,9606.0,
6155,1,,BAO_0000219,Intermediate,,5609,In vitro anticancer activity against human lung (A549) cell line,F,,,Homo sapiens,9606.0,
6156,1,,BAO_0000219,Intermediate,,17206,Percent growth inhibition at 200 uM PARP inhibitor in A549 cells,F,,,Homo sapiens,9606.0,
6157,1,,BAO_0000219,Intermediate,,17206,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..006 uM compound concentration in A549 cells,F,,,Homo sapiens,9606.0,
6158,1,,BAO_0000219,Intermediate,,17206,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..03 uM compound concentration in A549 cells,F,,,Homo sapiens,9606.0,
6159,1,,BAO_0000219,Intermediate,,17206,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..15 uM compound concentration in A549 cells,F,,,Homo sapiens,9606.0,
6160,1,,BAO_0000219,Intermediate,,17206,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..4 uM compound concentration in A549 cells,F,,,Homo sapiens,9606.0,
6161,1,,BAO_0000219,Intermediate,,17206,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 11 uM compound concentration in A549 cells,F,,,Homo sapiens,9606.0,
6162,1,,BAO_0000219,Expert,,16295,Inhibition of A549 human lung tumor cell proliferation,F,,,Homo sapiens,9606.0,
6163,1,,BAO_0000219,Intermediate,,16825,"Concentration required to inhibit the lung A549 cell growth by 50%,P53 status of cell line used was wild-type. ",F,,,Homo sapiens,9606.0,
6164,1,,BAO_0000219,Expert,,3439,In vitro cytotoxicity against human tumor cell line A549,F,,,Homo sapiens,9606.0,
6165,1,,BAO_0000219,Intermediate,,10870,In vitro growth inhibitory activity against A549 human nonsmall cell lung carcinoma cells. ,F,,,Homo sapiens,9606.0,
6166,1,,BAO_0000219,Intermediate,,4845,Inhibitory concentration of compound against proliferation of lung carcinoma A549 cell line,F,,,Homo sapiens,9606.0,
6167,1,,BAO_0000219,Intermediate,,5822,Inhibitory concentration (resynthesized pure material) against TNF-alpha induced apoptosis of A549 cells,F,,,Homo sapiens,9606.0,
6168,1,,BAO_0000219,Intermediate,,5822,Inhibitory concentration (solid phase) against TNF-alpha induced apoptosis of A549 cells,F,,,Homo sapiens,9606.0,
6169,1,,BAO_0000219,Intermediate,,5822,Inhibitory concentration (solid phase) against TNF-alpha induced apoptosis of A549 cells: Not tested,F,,,Homo sapiens,9606.0,
6170,1,,BAO_0000219,Intermediate,,16381,% inhibition against A549 cells (lung cancer) at 0.04 ug/mL,F,,,Homo sapiens,9606.0,
6171,1,,BAO_0000219,Intermediate,,16381,% inhibition against A549 cells (lung cancer) at 0.4 ug/mL,F,,,Homo sapiens,9606.0,
6172,1,,BAO_0000219,Intermediate,,16381,% inhibition against A549 cells (lung cancer) at 4 ug/mL,F,,,Homo sapiens,9606.0,
6173,1,,BAO_0000219,Intermediate,,5609,In vitro anticancer activity against human lung (A549) cell line,F,,,Homo sapiens,9606.0,
6174,1,,BAO_0000219,Intermediate,,4644,Inhibition of proliferation of A549 cells at concentration of 0.1 uM was determined,F,,,Homo sapiens,9606.0,
6175,1,,BAO_0000219,Intermediate,,4644,Inhibition of proliferation of A549 cells at concentration of 100 uM was determined,F,,,Homo sapiens,9606.0,
6176,1,,BAO_0000219,Intermediate,,4644,Inhibition of proliferation of A549 cells at concentration of 10 uM was determined,F,,,Homo sapiens,9606.0,
6177,1,,BAO_0000219,Intermediate,,4644,Inhibition of proliferation of A549 cells at concentration of 1 uM was determined,F,,,Homo sapiens,9606.0,
6178,1,,BAO_0000219,Intermediate,,5822,Inhibitory concentration (resynthesized pure material) against TNF-alpha induced apoptosis of A549 cells at 20 uM,F,,,Homo sapiens,9606.0,
6179,1,,BAO_0000219,Expert,,3415,Percentage inhibition of human lung carcinoma (A549) cell lines,F,,,Homo sapiens,9606.0,
6180,1,,BAO_0000219,Intermediate,,16726,Influence of PARP-1 cellular activity on NAD+ levels at a concentration of 25 uM of the compound,F,,,Homo sapiens,9606.0,
6181,1,,BAO_0000219,Intermediate,,17206,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TM); ND denotes not determined",F,,,Homo sapiens,9606.0,
6182,1,,BAO_0000219,Intermediate,,17206,Concentration that gives 50% growth inhibition (temozolomide alone/ (temozolomide + 0.4 uM of compound)) in A549 cells; ND denotes not determined,F,,,Homo sapiens,9606.0,
6183,1,,BAO_0000219,Intermediate,,17206,Concentration that gives 50% growth inhibition (topotecan alone/ (topotecan + 0.4 uM of compound)) in A549 cells; ND denotes not determined,F,,,Homo sapiens,9606.0,
6184,1,,BAO_0000219,Intermediate,,17206,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TM)",F,,,Homo sapiens,9606.0,
6185,1,,BAO_0000219,Intermediate,,17206,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.006 uM",F,,,Homo sapiens,9606.0,
6186,1,,BAO_0000219,Intermediate,,17206,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.03 uM",F,,,Homo sapiens,9606.0,
6187,1,,BAO_0000219,Intermediate,,17206,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.15 uM",F,,,Homo sapiens,9606.0,
6188,1,,BAO_0000219,Intermediate,,17206,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.4 uM",F,,,Homo sapiens,9606.0,
6189,1,,BAO_0000219,Intermediate,,17206,Concentration that gives 50% growth inhibition (temozolomide alone/ (temozolomide + 0.4 uM of compound)) in A549 cells,F,,,Homo sapiens,9606.0,
6190,1,,BAO_0000219,Intermediate,,17206,Concentration that gives 50% growth inhibition (topotecan alone/ (topotecan + 0.4 uM of compound)) in A549 cells,F,,,Homo sapiens,9606.0,
6191,1,,BAO_0000219,Intermediate,,16726,Cytotoxicity potentiation of Topotecan in human lung carcinoma A549 cells by the compound as potentiation factor at 50% growth inhibition,F,,,Homo sapiens,9606.0,
6192,1,,BAO_0000219,Intermediate,,17206,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.006 uM compound concentration in A549 cells,F,,,Homo sapiens,9606.0,
6193,1,,BAO_0000219,Intermediate,,17206,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.03 uM compound concentration in A549 cells,F,,,Homo sapiens,9606.0,
6194,1,,BAO_0000219,Intermediate,,17206,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.15 uM compound concentration in A549 cells,F,,,Homo sapiens,9606.0,
6195,1,,BAO_0000219,Intermediate,,17206,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.4 uM compound concentration in A549 cells,F,,,Homo sapiens,9606.0,
6196,1,,BAO_0000218,Intermediate,,6084,Pharmacokinetic activity (Cmax) (10 mg/kg) was determined in dog,A,In vivo,,Canis lupus familiaris,9615.0,
6197,1,,BAO_0000218,Intermediate,,6084,Pharmacokinetic activity (Cmax) in dog,A,In vivo,,Canis lupus familiaris,9615.0,
6198,1,,BAO_0000218,Intermediate,,4809,Pharmacokinetic parameter Cmax was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),A,In vivo,,Canis lupus familiaris,9615.0,
6199,1,,BAO_0000218,Intermediate,,5983,Pharmacokinetic property (Cmax) was measured in dog at the dose of 0.032 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,
6200,1,,BAO_0000218,Intermediate,,6251,Plasma clearance rate by iv administration in dog at a dose of 6 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,
6201,1,,BAO_0000218,Intermediate,1969.0,5932,Cmax in dog plasma after 30mg/kg oral dose,A,In vivo,,Canis lupus familiaris,9615.0,
6202,1,,BAO_0000218,Intermediate,178.0,4273,Tested for the peak blood level in dog,A,In vivo,,Canis lupus familiaris,9615.0,
6203,1,,BAO_0000218,Intermediate,,5313,"Tested for the pharmacokinetic data, maximum concentration (Cmax) in dog",A,In vivo,,Canis lupus familiaris,9615.0,
6204,1,,BAO_0000218,Intermediate,,5313,"Tested for the pharmacokinetic data, maximum concentration (Cmax) in dog at dosage of 10 mpk",A,In vivo,,Canis lupus familiaris,9615.0,
6205,1,,BAO_0000218,Intermediate,178.0,6221,The peak blood concentration after 5 hr administration (2.5 mg/kg) in dog was determined,A,In vivo,,Canis lupus familiaris,9615.0,
6206,1,,BAO_0000218,Intermediate,,4709,Concentration in the plasma after intravenous administration of 1 mg/kg in dog,A,,,Canis lupus familiaris,9615.0,
6207,1,,BAO_0000218,Intermediate,,167,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Dog at maximum of 0.3 hours,A,,,Canis lupus familiaris,9615.0,
6208,1,,BAO_0000218,Intermediate,1969.0,6241,Final plasma concentration in dogs after oral administration at 1 mg/kg,A,,,Canis lupus familiaris,9615.0,
6209,1,,BAO_0000218,Intermediate,,344,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 300 min,A,,,Canis lupus familiaris,9615.0,
6210,1,,BAO_0000218,Intermediate,,344,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 30 min,A,,,Canis lupus familiaris,9615.0,
6211,1,,BAO_0000218,Intermediate,,344,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 60 min,A,,,Canis lupus familiaris,9615.0,
6212,1,,BAO_0000218,Intermediate,,2189,Percent of radioactive dose in urine and faeces excreted in 0-24 hr by dogs,A,,,Canis lupus familiaris,9615.0,
6213,1,,BAO_0000218,Intermediate,1088.0,2189,Percent of radioactive dose in urine and feces excreted by 0-24 hr in dogs,A,,,Canis lupus familiaris,9615.0,
6214,1,,BAO_0000218,Intermediate,1088.0,2189,Percent of radioactive dose in urine and feces excreted by 0-24 hr in dogs; NA is <10% inhibition at 1 uM for binding data,A,,,Canis lupus familiaris,9615.0,
6215,1,,BAO_0000218,Intermediate,1088.0,2189,Percent of radioactive dose in urine and feces excreted in 0-24 hr by dogs; NA is <10% inhibition at 1 uM for binding data,A,,,Canis lupus familiaris,9615.0,
6216,1,,BAO_0000218,Intermediate,,4257,Absolute bioavailability was evaluated in dog,A,In vivo,,Canis lupus familiaris,9615.0,
6217,1,,BAO_0000218,Intermediate,,6221,Bioavailability after oral administration (2.5 mg/kg) in dog was determined,A,In vivo,,Canis lupus familiaris,9615.0,
6218,1,,BAO_0000218,Intermediate,,6215,Bioavailability after peroral administration (1 mg/kg) was determined in dog,A,In vivo,,Canis lupus familiaris,9615.0,
6219,1,,BAO_0000218,Intermediate,,17267,Bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,
6220,1,,BAO_0000218,Intermediate,,6621,Bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,
6221,1,,BAO_0000218,Intermediate,,3854,Bioavailability after intravenous administration in dogs,A,In vivo,,Canis lupus familiaris,9615.0,
6222,1,,BAO_0000218,Intermediate,,3854,Bioavailability after peroral administration in dogs,A,In vivo,,Canis lupus familiaris,9615.0,
6223,1,,BAO_0000218,Intermediate,,5007,Bioavailability in dog (dose 5 mg/kg p.o. and 2 mg/kg i.v.),A,In vivo,,Canis lupus familiaris,9615.0,
6224,1,,BAO_0000218,Intermediate,,4333,Bioavailability in dog (Beagle) (male) (dose 3 mg/kg i.v. and 10 mg/kg p.o.) measured from 1 to 24 hr,A,In vivo,,Canis lupus familiaris,9615.0,
6225,1,,BAO_0000218,Intermediate,1969.0,4333,Bioavailability in plasma of male Beagle dogs treated with 3 mg/kg (i.v.) and 10 mg/kg (p.o.) measured from 1 to 24 hr; ND indicates not determined,A,In vivo,,Canis lupus familiaris,9615.0,
6226,1,,BAO_0000218,Intermediate,,5006,Bioavailability,A,In vivo,,Canis lupus familiaris,9615.0,
6227,1,,BAO_0000218,Intermediate,,5199,Bioavailability,A,In vivo,,Canis lupus familiaris,9615.0,
6228,1,,BAO_0000218,Intermediate,,4368,Bioavailability by intravenous administration of 1.2 mg/kg in dog,A,In vivo,,Canis lupus familiaris,9615.0,
6229,1,,BAO_0000218,Intermediate,,3771,Bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,
6230,1,,BAO_0000218,Intermediate,,4953,Bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,
6231,1,,BAO_0000218,Intermediate,,5064,Bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,
6232,1,,BAO_0000218,Intermediate,,17657,Bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,
6233,1,,BAO_0000218,Intermediate,,17796,Bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,
6234,1,,BAO_0000218,Intermediate,,17853,Bioavailability in dog (p.o.) at 2.0 mpk,A,In vivo,,Canis lupus familiaris,9615.0,
6235,1,,BAO_0000218,Intermediate,,4521,Bioavailability in dog (dose 2 mg/kg p.o. and 0.5 mg/kg i.v.),A,In vivo,,Canis lupus familiaris,9615.0,
6236,1,,BAO_0000218,Intermediate,,4521,Bioavailability in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,A,In vivo,,Canis lupus familiaris,9615.0,
6237,1,,BAO_0000218,Intermediate,,5006,Bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,
6238,1,,BAO_0000218,Intermediate,,16365,Bioavailability was evaluated after oral administration in dog,A,In vivo,,Canis lupus familiaris,9615.0,
6239,1,,BAO_0000218,Intermediate,,1916,Bioavailability was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,A,In vivo,,Canis lupus familiaris,9615.0,
6240,1,,BAO_0000218,Intermediate,,1918,Bioavailability was evaluated in dog,A,In vivo,,Canis lupus familiaris,9615.0,
6241,1,,BAO_0000218,Intermediate,,4239,Bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,
6242,1,,BAO_0000218,Intermediate,,6505,Bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,
6243,1,,BAO_0000218,Intermediate,,5334,Bioavailability was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),A,In vivo,,Canis lupus familiaris,9615.0,
6244,1,,BAO_0000218,Intermediate,,5334,Bioavailability was reported after oral administration at a dose of 2 mg/kg in Beagle dog (male),A,In vivo,,Canis lupus familiaris,9615.0,
6245,1,,BAO_0000218,Intermediate,,4809,Bioavailability was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),A,In vivo,,Canis lupus familiaris,9615.0,
6246,1,,BAO_0000218,Intermediate,,6348,Bioavailability was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,A,In vivo,,Canis lupus familiaris,9615.0,
6247,1,,BAO_0000218,Intermediate,,6005,Bioavailability was evaluated in dog after peroral administration at a dose of 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,
6248,1,,BAO_0000218,Intermediate,,17804,Bioavailability of compound in dog was determined after peroral administration,A,In vivo,,Canis lupus familiaris,9615.0,
6249,1,,BAO_0000218,Intermediate,,3184,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,
6250,1,,BAO_0000218,Intermediate,,1806,Compound was evaluated for oral bioavailability at different dose 27.5 mg/kg DMP323 equiv in dogs,A,In vivo,,Canis lupus familiaris,9615.0,
6251,1,,BAO_0000218,Intermediate,,1806,Compound was evaluated for oral bioavailability at different dose 7.7 mg/kg DMP323 equiv in dogs,A,In vivo,,Canis lupus familiaris,9615.0,
6252,1,,BAO_0000218,Intermediate,,1806,Compound was evaluated for oral bioavailability in dogs; 37-38 %,A,In vivo,,Canis lupus familiaris,9615.0,
6253,1,,BAO_0000218,Intermediate,,4839,Bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,
6254,1,,BAO_0000218,Intermediate,,5017,Oral bioavailability in dog (1 mg/kg p.o. and 0.2 mg/kg i.v.),A,In vivo,,Canis lupus familiaris,9615.0,
6255,1,,BAO_0000218,Intermediate,948.0,846,Biodistribution of [123I]- labeled compound in mice heart was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,
6256,1,,BAO_0000218,Intermediate,948.0,846,Biodistribution of [123I]- labeled compound in mice heart was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,
6257,1,,BAO_0000218,Intermediate,2113.0,846,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,
6258,1,,BAO_0000218,Intermediate,2113.0,846,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,
6259,1,,BAO_0000218,Intermediate,2113.0,846,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,
6260,1,,BAO_0000218,Intermediate,2113.0,846,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,
6261,1,,BAO_0000218,Intermediate,2113.0,846,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,
6262,1,,BAO_0000218,Intermediate,2113.0,846,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,
6263,1,,BAO_0000218,Intermediate,2107.0,846,Biodistribution of [123I]- labeled compound in mice liver was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,
6264,1,,BAO_0000218,Intermediate,2107.0,846,Biodistribution of [123I]- labeled compound in mice liver was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,
6265,1,,BAO_0000218,Intermediate,2107.0,846,Biodistribution of [123I]- labeled compound in mice liver was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,
6266,1,,BAO_0000218,Intermediate,2107.0,846,Biodistribution of [123I]- labeled compound in mice liver was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,
6267,1,,BAO_0000218,Intermediate,2107.0,846,Biodistribution of [123I]- labeled compound in mice liver was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,
6268,1,,BAO_0000218,Intermediate,2107.0,846,Biodistribution of [123I]- labeled compound in mice liver was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,
6269,1,,BAO_0000218,Intermediate,2048.0,846,Biodistribution of [123I]- labeled compound in mice lungs was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,
6270,1,,BAO_0000218,Intermediate,2048.0,846,Biodistribution of [123I]- labeled compound in mice lungs was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,
6271,1,,BAO_0000218,Intermediate,2048.0,846,Biodistribution of [123I]- labeled compound in mice lungs was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,
6272,1,,BAO_0000218,Intermediate,2048.0,846,Biodistribution of [123I]- labeled compound in mice lungs was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,
6273,1,,BAO_0000218,Intermediate,2048.0,846,Biodistribution of [123I]- labeled compound in mice lungs was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,
6274,1,,BAO_0000218,Intermediate,2048.0,846,Biodistribution of [123I]- labeled compound in mice lungs was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,
6275,1,,BAO_0000218,Intermediate,,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 1 hour,A,,,Mus musculus,10090.0,
6276,1,,BAO_0000218,Intermediate,,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 2 hours,A,,,Mus musculus,10090.0,
6277,1,,BAO_0000218,Intermediate,,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 30 minutes,A,,,Mus musculus,10090.0,
6278,1,,BAO_0000218,Intermediate,,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 4 hours,A,,,Mus musculus,10090.0,
6279,1,,BAO_0000218,Intermediate,,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 8 hours,A,,,Mus musculus,10090.0,
6280,1,,BAO_0000218,Intermediate,955.0,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice brain bearing S180 tumor cell line for 1 hour,A,,,Mus musculus,10090.0,
6281,1,,BAO_0000218,Intermediate,955.0,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 2 hours,A,,,Mus musculus,10090.0,
6282,1,,BAO_0000218,Intermediate,955.0,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 30 minutes,A,,,Mus musculus,10090.0,
6283,1,,BAO_0000218,Intermediate,955.0,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 4 hours,A,,,Mus musculus,10090.0,
6284,1,,BAO_0000218,Intermediate,955.0,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 8 hours,A,,,Mus musculus,10090.0,
6285,1,,BAO_0000218,Intermediate,948.0,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice heart bearing S180 tumor cell line for 1 hour,A,,,Mus musculus,10090.0,
6286,1,,BAO_0000218,Intermediate,948.0,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 2 hours,A,,,Mus musculus,10090.0,
6287,1,,BAO_0000218,Intermediate,948.0,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice heart bearing S180 tumor cell line for 30 minutes,A,,,Mus musculus,10090.0,
6288,1,,BAO_0000218,Intermediate,948.0,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 4 hours,A,,,Mus musculus,10090.0,
6289,1,,BAO_0000218,Intermediate,948.0,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 8 hours,A,,,Mus musculus,10090.0,
6290,1,,BAO_0000218,Intermediate,2113.0,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice kidney bearing S180 tumor cell line for 1 hour,A,,,Mus musculus,10090.0,
6291,1,,BAO_0000218,Intermediate,2113.0,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice kidney bearing S180 tumor cell line for 2 hours,A,,,Mus musculus,10090.0,
6292,1,,BAO_0000218,Intermediate,2113.0,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 30 minutes,A,,,Mus musculus,10090.0,
6293,1,,BAO_0000219,Intermediate,,17130,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml) on,F,,,Homo sapiens,9606.0,
6294,1,,BAO_0000219,Intermediate,,17130,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml)on,F,,,Homo sapiens,9606.0,
6295,1,,BAO_0000219,Intermediate,,17130,Cytotoxic activity of compound against A-549 cell lines at concentration of 3.3 (ug/ml),F,,,Homo sapiens,9606.0,
6296,1,,BAO_0000219,Intermediate,,17130,Cytotoxic activity of compound against A-549 cell lines at concentration of 3.3 (ug/ml)),F,,,Homo sapiens,9606.0,
6297,1,,BAO_0000219,Expert,,3263,Antineoplastic activity against A-549 (human lung carcinoma) cell line.,F,,,Homo sapiens,9606.0,
6298,1,,BAO_0000219,Expert,,6663,In vitro rate of inhibition of A-549 tumor cell growth at 10E-4 mol/L,F,,,Homo sapiens,9606.0,
6299,1,,BAO_0000219,Expert,,6663,In vitro rate of inhibition of A-549 tumor cell growth at 10E-5 mol/L,F,,,Homo sapiens,9606.0,
6300,1,,BAO_0000219,Expert,,6663,In vitro rate of inhibition of A-549 tumor cell growth at 10E-6 mol/L,F,,,Homo sapiens,9606.0,
6301,1,,BAO_0000219,Expert,,6663,In vitro rate of inhibition of A-549 tumor cell growth at 10E-7 mol/L,F,,,Homo sapiens,9606.0,
6302,1,,BAO_0000219,Expert,,6663,In vitro rate of inhibition of A-549 tumor cell growth at 10E-8 mol/L,F,,,Homo sapiens,9606.0,
6303,1,,BAO_0000219,Intermediate,,6663,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.0625 uM,F,,,Homo sapiens,9606.0,
6304,1,,BAO_0000219,Intermediate,,6663,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.125 uM,F,,,Homo sapiens,9606.0,
6305,1,,BAO_0000219,Intermediate,,6663,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.25 uM,F,,,Homo sapiens,9606.0,
6306,1,,BAO_0000219,Intermediate,,6663,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.5 uM,F,,,Homo sapiens,9606.0,
6307,1,,BAO_0000219,Intermediate,,6663,Rate of inhibition of A-549 tumor cell growth at a concentration of 1 uM,F,,,Homo sapiens,9606.0,
6308,1,,BAO_0000219,Intermediate,,3983,The compound was evaluated for its cytotoxic potency against A-549 cell line,F,,,Homo sapiens,9606.0,
6309,1,,BAO_0000219,Expert,,11141,Cytotoxic concentration required to inhibit 50% cell growth in A-549 lung carcinoma cell lines,F,,,Homo sapiens,9606.0,
6310,1,,BAO_0000219,Intermediate,,5076,Cytotoxic activity of compound against A-549 tumor cell line.,F,,,Homo sapiens,9606.0,
6311,1,,BAO_0000219,Intermediate,,3311,In vitro cytotoxicity against Lung A-549 human tumors following a 6 day exposure.,F,,,Homo sapiens,9606.0,
6312,1,,BAO_0000219,Intermediate,,3311,In vitro cytotoxicity against Lung A-549 human tumors following a 2 day exposure.,F,,,Homo sapiens,9606.0,
6313,1,,BAO_0000219,Intermediate,,3311,In vitro cytotoxicity against Lung A-549 human tumors following a 2 day exposure; ND is no data,F,,,Homo sapiens,9606.0,
6314,1,,BAO_0000219,Intermediate,,5076,Cytotoxic activity of compound against A-549 tumor cell line at conc. of 20 ug/mL,F,,,Homo sapiens,9606.0,
6315,1,,BAO_0000219,Intermediate,,4150,Compound was tested for cytotoxic activity against A-549 human lung carcinoma (ATCC:CCL-185),F,,,Homo sapiens,9606.0,
6316,1,,BAO_0000219,Expert,,2150,In vitro inhibitory concentration against cell culture of A-549 human lung carcinoma,F,,,Homo sapiens,9606.0,
6317,1,,BAO_0000219,Intermediate,,4644,Concentration for in vitro cytotoxicity against A-549 human lung tumor cells,F,,,Homo sapiens,9606.0,
6318,1,,BAO_0000219,Intermediate,,263,Dose required for in vitro cytotoxic activity against A-549 lung carcinoma cells at concentration of 10 ug/ml; NA is no cytotoxicity,F,,,Homo sapiens,9606.0,
6319,1,,BAO_0000219,Intermediate,,11333,Cytotoxic concentration against A-549 tumor cells.,F,,,Homo sapiens,9606.0,
6320,1,,BAO_0000219,Intermediate,,11333,Cytotoxic concentration against A-549 tumor cells; Inactive at 10 ug/mL.,F,,,Homo sapiens,9606.0,
6321,1,,BAO_0000219,Intermediate,,15895,"Cytotoxicity against NCI tumor panel, A-549/ATCC non small-cell lung cancer cell line",F,,,Homo sapiens,9606.0,
6322,1,,BAO_0000218,Expert,,16677,Minimum inhibitory concentration (lowest peptide concentration) required to prevent visible bacterial growth after 18 hr of incubation at 37 C in Mueller-Hinton broth against Acinetobacter baumannii 118A,F,,,Acinetobacter baumannii,470.0,
6323,1,,BAO_0000218,Intermediate,,10624,Activity against Acinetobacter calcoaceticus (AC54),F,,,Acinetobacter calcoaceticus,471.0,
6324,1,,BAO_0000218,Expert,,16717,In vitro antifungal activity against Aspergillus flavus CM74,F,,,Aspergillus flavus,5059.0,
6325,1,,BAO_0000218,Expert,,16717,In vitro antifungal activity against Aspergillus flavus CM74,F,,,Aspergillus flavus,5059.0,
6326,1,,BAO_0000218,Intermediate,,5513,Inhibitory activity tested against Aspergillus fumigatus at 256 ug/mL concentration,F,,,Aspergillus fumigatus,746128.0,
6327,1,,BAO_0000218,Intermediate,,15962,In vitro minimum fungicidal concentration required to inhibit Aspergillus fumigatus(MFC),F,,,Aspergillus fumigatus,746128.0,
6328,1,,BAO_0000218,Intermediate,,15962,Antimicrobial activity against Aspergillus fumigatus (MIC),F,,,Aspergillus fumigatus,746128.0,
6329,1,,BAO_0000218,Intermediate,,15962,Antimicrobial activity against Aspergillus fumigatus (MIC),F,,,Aspergillus fumigatus,746128.0,
6330,1,,BAO_0000218,Intermediate,,15962,In vitro antimicrobial activity against Aspergillus fumigatus (MIC),F,,,Aspergillus fumigatus,746128.0,
6331,1,,BAO_0000218,Expert,,16717,In vitro antifungal activity against Aspergillus fumigatus 48238E,F,,,Aspergillus fumigatus,746128.0,
6332,1,,BAO_0000218,Expert,,16717,In vitro antifungal activity against Aspergillus fumigatus 48238E,F,,,Aspergillus fumigatus,746128.0,
6333,1,,BAO_0000218,Intermediate,,8117,Compound is evaluated for plaque-bactericidal index (PBI) against Actinomyces naeslundii 631,F,,,Actinomyces naeslundii,1655.0,
6334,1,,BAO_0000218,Intermediate,,8117,Compound is evaluated for plaque-bactericidal index (PBI) against Actinomyces viscosus M-100,F,,,Actinomyces viscosus,1656.0,
6335,1,,BAO_0000218,Intermediate,,15472,Tested in vivo for Acanthocheilonema viteae at 200 mg/kg X 5 days(perorally),F,,,Acanthocheilonema viteae,6277.0,
6336,1,,BAO_0000218,Intermediate,,15472,Tested in vivo for Acanthocheilonema viteae at 200 mg/kg X 5 days(perorally),F,,,Acanthocheilonema viteae,6277.0,
6337,1,,BAO_0000218,Intermediate,,16443,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527,F,,,Aggregatibacter actinomycetemcomitans,714.0,
6338,1,,BAO_0000218,Intermediate,,16443,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527; value ranges from 1-2,F,,,Aggregatibacter actinomycetemcomitans,714.0,
6339,1,,BAO_0000218,Intermediate,,16443,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527; value ranges from 1-2; ND is Not Determined,F,,,Aggregatibacter actinomycetemcomitans,714.0,
6340,1,,BAO_0000219,Intermediate,,17206,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 11 uM compound concentration in A549 cells,F,,,Homo sapiens,9606.0,
6341,1,,BAO_0000219,Intermediate,,17206,Percent ADP-ribose polymer formation at 25 uM compound concentration in A549 cells,F,,,Homo sapiens,9606.0,
6342,1,,BAO_0000219,Intermediate,,16381,% inhibition against A549 cells (lung cancer) at 0.04 ug/mL,F,,,Homo sapiens,9606.0,
6343,1,,BAO_0000219,Intermediate,,16381,% inhibition against A549 cells (lung cancer) at 0.4 ug/mL,F,,,Homo sapiens,9606.0,
6344,1,,BAO_0000219,Intermediate,,16381,% inhibition against A549 cells (lung cancer) at 4 ug/mL,F,,,Homo sapiens,9606.0,
6345,1,,BAO_0000219,Intermediate,,16381,GI values against A549 cells (lung cancer),F,,,Homo sapiens,9606.0,
6346,1,,BAO_0000219,Intermediate,,17206,Effect on NAD+ depletion (% remaining versus vehicle control) 25 uM compound concentration in A549 cells,F,,,Homo sapiens,9606.0,
6347,1,,BAO_0000219,Intermediate,,16325,Inhibitory activity against A549 human adenocarcinoma,F,,,Homo sapiens,9606.0,
6348,1,,BAO_0000218,Intermediate,,10708,Evaluated for the antineoplastic activity against A549 lung (nonsmall cell) tumor xenograft in nude mice after administering 3 injections (intra peritoneally) at a dose of 200 mg/kg,F,,,Homo sapiens,9606.0,
6349,1,,BAO_0000218,Intermediate,,10708,Evaluated for the antineoplastic activity against A549 lung (nonsmall cell) tumor xenograft in nude mice after administering 3 injections (intra peritoneally) at a dose of 100 mg/kg,F,,,Homo sapiens,9606.0,
6350,1,,BAO_0000219,Intermediate,,17376,Inhibitory activity against A549 lung adenocarcinoma cell line,F,,,Homo sapiens,9606.0,
6351,1,,BAO_0000219,Intermediate,,17376,Inhibitory activity against A549 lung adenocarcinoma cell line; not determined,F,,,Homo sapiens,9606.0,
6352,1,,BAO_0000219,Intermediate,,17488,Cytotoxicity against human A549 lung cells,F,,,Homo sapiens,9606.0,
6353,1,,BAO_0000218,Intermediate,,17404,In vivo percent inhibitory activity of intraperitoneally administered compound (50 mg/kg/day) against mice infected with A549 tumor,F,,,Homo sapiens,9606.0,
6354,1,,BAO_0000219,Expert,,10958,Growth inhibition of A549 (human lung carcinoma) cell line.,F,,,Homo sapiens,9606.0,
6355,1,,BAO_0000219,Expert,,17099,Effective dose required for inhibitory activity against A549 human tumor cell line.,F,,,Homo sapiens,9606.0,
6356,1,,BAO_0000219,Intermediate,,17099,Effective dose required for inhibitory activity against A549 human tumor cell line; Not active,F,,,Homo sapiens,9606.0,
6357,1,,BAO_0000219,Intermediate,,4096,Cytotoxicity was evaluated against A549 tumor cell lines; Inactive,F,,,Homo sapiens,9606.0,
6358,1,,BAO_0000219,Expert,,4096,Cytotoxicity evaluated against A549 tumor cell lines; significant activity,F,,,Homo sapiens,9606.0,
6359,1,,BAO_0000219,Intermediate,,4096,Cytotoxicity was evaluated against A549 tumor cell lines; Slightly active,F,,,Homo sapiens,9606.0,
6360,1,,BAO_0000219,Intermediate,,2525,In vitro inhibitory activity against A549 tumor cell culture,F,,,Homo sapiens,9606.0,
6361,1,,BAO_0000219,Intermediate,,2525,In vitro inhibitory activity against A549 tumor cell culture; IA= Inactive,F,,,Homo sapiens,9606.0,
6362,1,,BAO_0000219,Intermediate,,5302,Activity against human lung cancer with mutated beta-tubulin (A549-T2415),F,,,Homo sapiens,9606.0,
6363,1,,BAO_0000219,Intermediate,,16325,Growth inhibitory activity was determined against A549/ATCC cancer cell line of non-small cell lung cancer,F,,,Homo sapiens,9606.0,
6364,1,,BAO_0000219,Intermediate,,16939,Inhibition of growth of A549/ATCC nonsmall cell lung cancer cell line,F,,,Homo sapiens,9606.0,
6365,1,,BAO_0000219,Intermediate,,17229,In vitro antitumor activity against NSCL A549/ATCC tumor cell lines,F,,,Homo sapiens,9606.0,
6366,1,,BAO_0000219,Intermediate,,17380,Cytotoxicity evaluation against A549/ATCC non-small-cell lung cancer cells,F,,,Homo sapiens,9606.0,
6367,1,,BAO_0000219,Intermediate,,17380,Cytotoxicity evaluation against A549/ATCC non-small-cell lung cancer cells; No data,F,,,Homo sapiens,9606.0,
6368,1,,BAO_0000219,Intermediate,,1903,In vitro cytotoxicity against human Non-small cell lung cancer A549/ATCC cell line.,F,,,Homo sapiens,9606.0,
6369,1,,BAO_0000219,Intermediate,,3838,In vitro growth inhibition of compound was determined against A549/ATCC cell lines of non-small cell lung cancer,F,,,Homo sapiens,9606.0,
6370,1,,BAO_0000219,Intermediate,,14696,Inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line,F,,,Homo sapiens,9606.0,
6371,1,,BAO_0000219,Intermediate,,3838,In vitro growth inhibition of compound was determined against A549/ATCC cell lines of non-small cell lung cancer,F,,,Homo sapiens,9606.0,
6372,1,,BAO_0000219,Intermediate,,1522,Tested for in vitro cytotoxicity against non-small cell lung cancer cell line A549/ATCC,F,,,Homo sapiens,9606.0,
6373,1,,BAO_0000219,Intermediate,,12400,Tested in vitro for cytotoxicity in A549/ATCC cell lines,F,,,Homo sapiens,9606.0,
6374,1,,BAO_0000219,Intermediate,,14696,inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line,F,,,Homo sapiens,9606.0,
6375,1,,BAO_0000219,Intermediate,,14769,Compound was evaluated for in vitro activity against A549/ATCC lung cancer cell lines (Human tumor cells ),F,,,Homo sapiens,9606.0,
6376,1,,BAO_0000219,Intermediate,,14696,Inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line at 0.01 uM,F,,,Homo sapiens,9606.0,
6377,1,,BAO_0000219,Intermediate,,1888,Compound was evaluated for cytotoxic activity against non-small lung cancer A549/ATCC cell lines.,F,,,Homo sapiens,9606.0,
6378,1,,BAO_0000219,Intermediate,,12016,Tested for cytotoxic activity against non-small cell lung cancer A549/ATCC cell line,F,,,Homo sapiens,9606.0,
6379,1,,BAO_0000219,Intermediate,,6058,Compound tested for growth inhibition of non-small cell lung cancer cell line A549/ATCC,F,,,Homo sapiens,9606.0,
6380,1,,BAO_0000219,Intermediate,,17708,Compound was tested for 50% growth inhibition against human non-small cell lung cancer A549/ATCC cell line,F,,,Homo sapiens,9606.0,
6381,1,,BAO_0000219,Intermediate,,12301,Antitumor activity against A549/ATCC cell line,F,,,Homo sapiens,9606.0,
6382,1,,BAO_0000219,Intermediate,,11970,Tested for cytotoxicity against A549/ATCC cell lines in non-small-cell lung cancer,F,,,Homo sapiens,9606.0,
6383,1,,BAO_0000219,Expert,,11818,In vitro cytotoxicity against A549/ATCC cell line.,F,,,Homo sapiens,9606.0,
6384,1,,BAO_0000219,Intermediate,,12400,Tested in vitro for cytotoxicity in A549/ATCC cell line of Non-Small Cell Lung Cancer,F,,,Homo sapiens,9606.0,
6385,1,,BAO_0000219,Intermediate,,3381,In vitro inhibition of Non-Small Cell Lung Cancer A549/ATCC cell lines,F,,,Homo sapiens,9606.0,
6386,1,,BAO_0000219,Intermediate,,17376,Concentration of compound that cause 50% cytotoxicity of A549/ATCC non small cell lung cancer cell line,F,,,Homo sapiens,9606.0,
6387,1,,BAO_0000219,Intermediate,,10708,Evaluated for the inhibitory concentration required to cause growth inhibition of A549Rem- cell line of lung using the MTT Cytotoxicity Assay,F,,,Homo sapiens,9606.0,
6388,0,,BAO_0000219,Autocuration,,2964,Cytotoxicity was evaluated against A649 human mammary carcinoma cells,F,,,Homo sapiens,9606.0,
6389,0,,BAO_0000218,Intermediate,,5005,Compound was tested for oral bioavailability in dogs,A,In vivo,,Canis lupus familiaris,9615.0,
6390,1,,BAO_0000218,Intermediate,,6229,Compound was tested for orally bioavailable in dogs with a half life of 0.7 hr,A,In vivo,,Canis lupus familiaris,9615.0,
6391,1,,BAO_0000218,Intermediate,,6229,Compound was tested for orally bioavailable in dogs with a half life of 1.2h,A,In vivo,,Canis lupus familiaris,9615.0,
6392,1,,BAO_0000218,Intermediate,,5374,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,
6393,1,,BAO_0000218,Intermediate,,5374,Compound was tested for the oral bioavailability in dog; No availability,A,In vivo,,Canis lupus familiaris,9615.0,
6394,1,,BAO_0000218,Intermediate,,6265,Oral bioavailability in dog (dose 5 mg/kg),A,In vivo,,Canis lupus familiaris,9615.0,
6395,1,,BAO_0000218,Intermediate,,5654,Oral bioavailability (F%) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg; ND=not determined,A,In vivo,,Canis lupus familiaris,9615.0,
6396,1,,BAO_0000218,Intermediate,,5654,Oral bioavailability (F%) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg; ND=not determined,A,In vivo,,Canis lupus familiaris,9615.0,
6397,1,,BAO_0000218,Intermediate,,16456,Oral bioavailability in Beagle dogs after Per oral administration at dose of 50(mg/kg),A,In vivo,,Canis lupus familiaris,9615.0,
6398,1,,BAO_0000218,Intermediate,,5302,Oral bioavailability in dog (dose 5 mg/kg),A,In vivo,,Canis lupus familiaris,9615.0,
6399,1,,BAO_0000218,Intermediate,,3624,Oral bioavailability in dog (p.o. dosing of 0.05 M citric acid/0.05 M hydrochloric acid solution),A,In vivo,,Canis lupus familiaris,9615.0,
6400,1,,BAO_0000218,Intermediate,,16452,Oral bioavailability of active FTIs in dogs,A,In vivo,,Canis lupus familiaris,9615.0,
6401,1,,BAO_0000218,Intermediate,,5802,Oral bioavailability in dog (dose 5 mg/kg p.o. and 2 mg/kg i.v.),A,In vivo,,Canis lupus familiaris,9615.0,
6402,1,,BAO_0000218,Expert,,3598,Oral bioavailability of compound determined in dog after iv administration at a dose of 10 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,
6403,1,,BAO_0000218,Intermediate,,17839,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,
6404,1,,BAO_0000218,Intermediate,,6762,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,
6405,1,,BAO_0000218,Intermediate,,6821,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,
6406,1,,BAO_0000218,Intermediate,,6821,Oral bioavailability of compound was determined in dog; Not tested,A,In vivo,,Canis lupus familiaris,9615.0,
6407,1,,BAO_0000218,Intermediate,,5210,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,
6408,1,,BAO_0000218,Intermediate,,6227,Oral bioavailability (10 mg/kg) was determined in dog,A,In vivo,,Canis lupus familiaris,9615.0,
6409,1,,BAO_0000218,Intermediate,,761,Oral bioavailability,A,In vivo,,Canis lupus familiaris,9615.0,
6410,1,,BAO_0000218,Intermediate,,761,Oral bioavailability in dog (dosed as neat powder in hard gelatin capsule),A,In vivo,,Canis lupus familiaris,9615.0,
6411,1,,BAO_0000218,Intermediate,,761,Oral bioavailability administered in solution in rats,A,In vivo,,Canis lupus familiaris,9615.0,
6412,1,,BAO_0000218,Intermediate,,16907,Oral bioavailability after 30 mg/kg po dose in Dogs,A,In vivo,,Canis lupus familiaris,9615.0,
6413,1,,BAO_0000218,Intermediate,,5474,Oral bioavailability at a dose of 1 mg/kg in dogs,A,In vivo,,Canis lupus familiaris,9615.0,
6414,1,,BAO_0000218,Intermediate,,6535,Oral bioavailability in dog (dose 1 mg/kg p.o.),A,In vivo,,Canis lupus familiaris,9615.0,
6415,1,,BAO_0000218,Intermediate,,6535,Oral bioavailability in Dog; ND = not determined,A,In vivo,,Canis lupus familiaris,9615.0,
6416,1,,BAO_0000218,Intermediate,,3352,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,
6417,1,,BAO_0000218,Intermediate,,6168,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,
6418,1,,BAO_0000218,Intermediate,,5988,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,
6419,1,,BAO_0000218,Intermediate,,4942,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,
6420,1,,BAO_0000218,Intermediate,,4942,Oral bioavailability in dogs; No data,A,In vivo,,Canis lupus familiaris,9615.0,
6421,1,,BAO_0000218,Intermediate,,14541,Oral bioavailability measured in dogs,A,In vivo,,Canis lupus familiaris,9615.0,
6422,1,,BAO_0000218,Intermediate,,4449,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,
6423,1,,BAO_0000218,Intermediate,,6057,Oral bioavailability was calculated in dog,A,In vivo,,Canis lupus familiaris,9615.0,
6424,1,,BAO_0000218,Intermediate,,5600,Oral bioavailability after 0.3 mg/kg po administration in dog,A,In vivo,,Canis lupus familiaris,9615.0,
6425,1,,BAO_0000218,Intermediate,,5542,Oral bioavailability in dog (i.v. dosing),A,In vivo,,Canis lupus familiaris,9615.0,
6426,1,,BAO_0000218,Intermediate,,5542,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,
6427,1,,BAO_0000218,Intermediate,,5546,Oral bioavailability in Beagle dog at a dose of 2 mg/kg by po administration,A,In vivo,,Canis lupus familiaris,9615.0,
6428,1,,BAO_0000218,Intermediate,,4514,Oral bioavailability in Beagle dogs,A,In vivo,,Canis lupus familiaris,9615.0,
6429,1,,BAO_0000218,Intermediate,,3624,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,
6430,1,,BAO_0000218,Intermediate,,3854,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,
6431,1,,BAO_0000218,Intermediate,,5836,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,
6432,1,,BAO_0000218,Intermediate,,5940,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,
6433,1,,BAO_0000218,Intermediate,,6168,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,
6434,1,,BAO_0000218,Intermediate,,6227,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,
6435,1,,BAO_0000218,Intermediate,,6251,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,
6436,1,,BAO_0000218,Intermediate,,6448,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,
6437,1,,BAO_0000218,Intermediate,,6647,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,
6438,1,,BAO_0000218,Intermediate,,5940,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,
6439,1,,BAO_0000218,Intermediate,,933,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,
6440,1,,BAO_0000218,Intermediate,,5210,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,
6441,1,,BAO_0000218,Intermediate,,6642,Oral bioavailability in dog (dosed as a mixture of five compounds at 0.5 mg/kg each via i.v. only),A,In vivo,,Canis lupus familiaris,9615.0,
6442,1,,BAO_0000218,Intermediate,,6641,Oral bioavailability in dog (dose 0.5 mg/kg i.v. and 2.0 mg/kg p.o.),A,In vivo,,Canis lupus familiaris,9615.0,
6443,1,,BAO_0000218,Intermediate,,6642,Oral bioavailability in dog (dose 0.5 mg/kg i.v. and 2.0 mg/kg p.o.),A,In vivo,,Canis lupus familiaris,9615.0,
6444,1,,BAO_0000218,Intermediate,,5472,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,
6445,1,,BAO_0000218,Intermediate,,5985,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,
6446,1,,BAO_0000218,Intermediate,,15660,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,
6447,1,,BAO_0000218,Intermediate,,5530,Oral bioavailability in dog (dose 0.2 mg/kg i.v.),A,In vivo,,Canis lupus familiaris,9615.0,
6448,1,,BAO_0000218,Intermediate,,5530,Oral bioavailability in dog (dose 1 mg/kg i.v.),A,In vivo,,Canis lupus familiaris,9615.0,
6449,1,,BAO_0000218,Intermediate,,6305,Oral bioavailability (F) in dogs,A,In vivo,,Canis lupus familiaris,9615.0,
6450,1,,BAO_0000218,Intermediate,,5210,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,
6451,1,,BAO_0000218,Intermediate,,5238,Bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,
6452,1,,BAO_0000218,Intermediate,,5668,Oral bioavailability in dog (dose 10 mg/kg),A,In vivo,,Canis lupus familiaris,9615.0,
6453,1,,BAO_0000218,Intermediate,,5668,Oral bioavailability after peroral administration at 5 mpk in Dog,A,In vivo,,Canis lupus familiaris,9615.0,
6454,1,,BAO_0000218,Intermediate,,5668,Oral bioavailability in dog (dose 5 mg/kg),A,In vivo,,Canis lupus familiaris,9615.0,
6455,1,,BAO_0000218,Intermediate,,6084,Oral bioavailability in dog (dose 10 mg/kg),A,In vivo,,Canis lupus familiaris,9615.0,
6456,1,,BAO_0000218,Intermediate,2113.0,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 4 hours,A,,,Mus musculus,10090.0,
6457,1,,BAO_0000218,Intermediate,2113.0,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 8 hours,A,,,Mus musculus,10090.0,
6458,1,,BAO_0000218,Intermediate,2107.0,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 1 hour,A,,,Mus musculus,10090.0,
6459,1,,BAO_0000218,Intermediate,2107.0,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 2 hours,A,,,Mus musculus,10090.0,
6460,1,,BAO_0000218,Intermediate,2107.0,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice liver bearing S180 tumor cell line for 30 minutes,A,,,Mus musculus,10090.0,
6461,1,,BAO_0000218,Intermediate,2107.0,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice liver bearing S180 tumor cell line for 4 hours,A,,,Mus musculus,10090.0,
6462,1,,BAO_0000218,Intermediate,2107.0,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 8 hours,A,,,Mus musculus,10090.0,
6463,1,,BAO_0000218,Intermediate,2048.0,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 1 hour,A,,,Mus musculus,10090.0,
6464,1,,BAO_0000218,Intermediate,2048.0,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 2 hours,A,,,Mus musculus,10090.0,
6465,1,,BAO_0000218,Intermediate,2048.0,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice lung bearing S180 tumor cell line for 30 minutes,A,,,Mus musculus,10090.0,
6466,1,,BAO_0000218,Intermediate,2048.0,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 4 hours,A,,,Mus musculus,10090.0,
6467,1,,BAO_0000218,Intermediate,2048.0,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice lung bearing S180 tumor cell line for 8 hours,A,,,Mus musculus,10090.0,
6468,1,,BAO_0000218,Intermediate,,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 1 hour,A,,,Mus musculus,10090.0,
6469,1,,BAO_0000218,Intermediate,,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice muscle bearing S180 tumor cell line for 2 hours,A,,,Mus musculus,10090.0,
6470,1,,BAO_0000218,Intermediate,,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 30 minutes,A,,,Mus musculus,10090.0,
6471,1,,BAO_0000218,Intermediate,,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 4 hours,A,,,Mus musculus,10090.0,
6472,1,,BAO_0000218,Intermediate,,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 8 hours,A,,,Mus musculus,10090.0,
6473,1,,BAO_0000218,Intermediate,2106.0,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice spleen bearing S180 tumor cell line for 1 hour,A,,,Mus musculus,10090.0,
6474,1,,BAO_0000218,Intermediate,2106.0,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 2 hours,A,,,Mus musculus,10090.0,
6475,1,,BAO_0000218,Intermediate,2106.0,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 30 minutes,A,,,Mus musculus,10090.0,
6476,1,,BAO_0000218,Intermediate,2106.0,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 4 hours,A,,,Mus musculus,10090.0,
6477,1,,BAO_0000218,Intermediate,2106.0,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 8 hours,A,,,Mus musculus,10090.0,
6478,1,,BAO_0000218,Intermediate,,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 1 hour,A,,,Mus musculus,10090.0,
6479,1,,BAO_0000218,Intermediate,,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor bearing S180 tumor cell line for 2 hours,A,,,Mus musculus,10090.0,
6480,1,,BAO_0000218,Intermediate,,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 30 minutes,A,,,Mus musculus,10090.0,
6481,1,,BAO_0000218,Intermediate,,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 4 hours,A,,,Mus musculus,10090.0,
6482,1,,BAO_0000218,Intermediate,,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor bearing S180 tumor cell line for 8 hours,A,,,Mus musculus,10090.0,
6483,1,,BAO_0000218,Intermediate,,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 1 hour,A,,,Mus musculus,10090.0,
6484,1,,BAO_0000218,Intermediate,,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 2 hours,A,,,Mus musculus,10090.0,
6485,1,,BAO_0000218,Intermediate,,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 30 minutes,A,,,Mus musculus,10090.0,
6486,1,,BAO_0000218,Intermediate,,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 4 hours,A,,,Mus musculus,10090.0,
6487,1,,BAO_0000218,Intermediate,,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 8 hours,A,,,Mus musculus,10090.0,
6488,1,,BAO_0000218,Intermediate,948.0,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/heart bearing S180 tumor cell line for 1 hour,A,,,Mus musculus,10090.0,
6489,1,,BAO_0000218,Intermediate,948.0,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/heart bearing S180 tumor cell line for 2 hours,A,,,Mus musculus,10090.0,
6490,1,,BAO_0000218,Intermediate,948.0,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 30 minutes,A,,,Mus musculus,10090.0,
6491,1,,BAO_0000218,Intermediate,948.0,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 4 hours,A,,,Mus musculus,10090.0,
6492,1,,BAO_0000218,Intermediate,948.0,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 8 hours,A,,,Mus musculus,10090.0,
6493,1,,BAO_0000218,Intermediate,2107.0,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 1 hour,A,,,Mus musculus,10090.0,
6494,1,,BAO_0000218,Intermediate,2107.0,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/liver bearing S180 tumor cell line for 2 hours,A,,,Mus musculus,10090.0,
6495,1,,BAO_0000218,Intermediate,2107.0,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/liver bearing S180 tumor cell line for 30 minutes,A,,,Mus musculus,10090.0,
6496,1,,BAO_0000218,Intermediate,2107.0,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 4 hours,A,,,Mus musculus,10090.0,
6497,1,,BAO_0000218,Intermediate,2107.0,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 8 hours,A,,,Mus musculus,10090.0,
6498,1,,BAO_0000218,Intermediate,2048.0,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 1 hour,A,,,Mus musculus,10090.0,
6499,1,,BAO_0000218,Intermediate,2048.0,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/lung bearing S180 tumor cell line for 2 hours,A,,,Mus musculus,10090.0,
6500,1,,BAO_0000218,Intermediate,,12269,Compound tested for the antimicrobial activity against Acinetobacter anitratus,F,,,aeinetobacter anitrotap,107673.0,
6501,1,,BAO_0000218,Intermediate,,12269,Compound tested for the antimicrobial activity against Acinetobacter anitratus,F,,,Acinetobacter calcoaceticus subsp. anitratus,107673.0,
6502,1,,BAO_0000218,Intermediate,,12269,Compound tested for the antimicrobial activity against Acinetobacter anitratus,F,,,Acinetobacter calcoaceticus subsp. anitratus,107673.0,
6503,1,,BAO_0000218,Intermediate,,12269,Compound tested for the antimicrobial activity against Acinetobacter anitratus,F,,,aeinetobacter anitrotap,107673.0,
6504,1,,BAO_0000218,Intermediate,,10624,Activity against Acinetobacter calcoaceticus (AC54),F,,,Acinetobacter calcoaceticus,471.0,
6505,1,,BAO_0000218,Intermediate,,17216,Biological activity using the lizard skin (Anolis carolinensis) assay. The value indicates no prolonged biological activity,F,,,Anolis carolinensis,28377.0,
6506,1,,BAO_0000218,Intermediate,,17216,Biological activity using the lizard skin (Anolis carolinensis) assay. The value indicates prolonged biological activity,F,,,Anolis carolinensis,28377.0,
6507,1,,BAO_0000218,Intermediate,,9560,Chlorohexidine coefficient for Actinomyces naeslundii 631,F,,,Actinomyces naeslundii,1655.0,
6508,1,,BAO_0000218,Intermediate,,9560,Chlorohexidine coefficient for Actinomyces naeslundii B74,F,,,Actinomyces naeslundii,1655.0,
6509,1,,BAO_0000218,Intermediate,,9560,Chlorohexidine coefficient for Actinomyces naeslundii N/3,F,,,Actinomyces naeslundii,1655.0,
6510,1,,BAO_0000218,Intermediate,,9560,Chlorohexidine coefficient for Actinomyces naeslundii N/9,F,,,Actinomyces naeslundii,1655.0,
6511,1,,BAO_0000218,Intermediate,,9560,Plaque bactericidal index against Actinomyces naeslundii 631,F,,,Actinomyces naeslundii,1655.0,
6512,1,,BAO_0000218,Intermediate,,9560,Plaque bactericidal index against Actinomyces naeslundii N/9,F,,,Actinomyces naeslundii,1655.0,
6513,1,,BAO_0000218,Intermediate,,9560,Plaque bactericidal index against Actinomyces naeslundii B74,F,,,Actinomyces naeslundii,1655.0,
6514,1,,BAO_0000218,Intermediate,,9560,Plaque bactericidal index against Actinomyces naeslundii N/3,F,,,Actinomyces naeslundii,1655.0,
6515,1,,BAO_0000218,Intermediate,,114,Compound was tested for its inhibitory activity using brine shrimp (Artemia salina) immobilization assay,F,,,Artemia salina,85549.0,
6516,1,,BAO_0000218,Intermediate,,114,"Compound was tested for its inhibitory activity using brine shrimp (Artemia salina) immobilization assay; highest level tested, showed <100% activity",F,,,Artemia salina,85549.0,
6517,1,,BAO_0000218,Intermediate,,10841,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 0 uM,F,,,Ascaris suum,6253.0,
6518,1,,BAO_0000218,Intermediate,,10841,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 10 uM,F,,,Ascaris suum,6253.0,
6519,1,,BAO_0000218,Intermediate,,10841,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 200 uM,F,,,Ascaris suum,6253.0,
6520,1,,BAO_0000218,Intermediate,,10841,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 25 uM,F,,,Ascaris suum,6253.0,
6521,1,,BAO_0000218,Intermediate,,10841,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 3 uM,F,,,Ascaris suum,6253.0,
6522,1,,BAO_0000218,Intermediate,,10841,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 50 uM.,F,,,Ascaris suum,6253.0,
6523,1,,BAO_0000218,Intermediate,,10841,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 0 uM,F,,,Ascaris suum,6253.0,
6524,1,,BAO_0000218,Intermediate,,10841,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 10 uM,F,,,Ascaris suum,6253.0,
6525,1,,BAO_0000218,Intermediate,,10841,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 200 uM,F,,,Ascaris suum,6253.0,
6526,1,,BAO_0000218,Intermediate,,10841,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 25 uM,F,,,Ascaris suum,6253.0,
6527,1,,BAO_0000218,Intermediate,,10841,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 3 uM,F,,,Ascaris suum,6253.0,
6528,1,,BAO_0000218,Intermediate,,10841,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 50 uM,F,,,Ascaris suum,6253.0,
6529,1,,BAO_0000218,Intermediate,,8117,Compound is evaluated for minimal bactericidal concentration against plaque formation for Actinomyces viscosus,F,,,Actinomyces viscosus,1656.0,
6530,1,,BAO_0000218,Intermediate,,8117,Compound is evaluated for minimal bactericidal concentration against plaque formation for Actinomyces viscosus,F,,,Actinomyces viscosus,1656.0,
6531,1,,BAO_0000218,Intermediate,,9560,Chlorohexidine coefficient for Actinomyces viscosus 8A06,F,,,Actinomyces viscosus,1656.0,
6532,1,,BAO_0000218,Expert,,9560,Chlorohexidine coefficient for Actinomyces viscosus M-100,F,,,Actinomyces viscosus,1656.0,
6533,1,,BAO_0000218,Intermediate,,9560,Chlorohexidine coefficient for Actinomyces viscosus M-626,F,,,Actinomyces viscosus,1656.0,
6534,1,,BAO_0000218,Intermediate,,9560,Chlorohexidine coefficient for Actinomyces viscosus T14V,F,,,Actinomyces viscosus,1656.0,
6535,1,,BAO_0000218,Intermediate,,9560,Plaque bactericidal index against Actinomyces viscosus 8A06,F,,,Actinomyces viscosus,1656.0,
6536,1,,BAO_0000218,Intermediate,,9560,Plaque bactericidal index against Actinomyces viscosus M-100,F,,,Actinomyces viscosus,1656.0,
6537,1,,BAO_0000218,Expert,,9560,Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient,F,,,Actinomyces viscosus,1656.0,
6538,1,,BAO_0000218,Intermediate,,9560,"Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient; d=Not bactericidal at highest concentration tested (0.2% w/v, 2min, 5 days)",F,,,Actinomyces viscosus,1656.0,
6539,1,,BAO_0000218,Intermediate,,9560,"Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient; not bactericidal at highest concentration tested (0.2% w/v, 2min, 5 days)",F,,,Actinomyces viscosus,1656.0,
6540,1,,BAO_0000218,Intermediate,,9560,Plaque bactericidal index against Actinomyces viscosus 626,F,,,Actinomyces viscosus,1656.0,
6541,1,,BAO_0000218,Intermediate,,9560,Plaque bactericidal index against Actinomyces viscosus T14V,F,,,Actinomyces viscosus,1656.0,
6542,1,,BAO_0000218,Intermediate,,10986,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 1.56 mg/kg/day(5 days) dose,F,,,Acanthocheilonema viteae,6277.0,
6543,1,,BAO_0000218,Intermediate,,10986,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 100 mg/kg/day(5 days) dose,F,,,Acanthocheilonema viteae,6277.0,
6544,1,,BAO_0000218,Intermediate,,10986,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 12.5 mg/kg/day(5 days) dose,F,,,Acanthocheilonema viteae,6277.0,
6545,1,,BAO_0000218,Intermediate,,10986,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 200 mg/kg/day(5 days) dose,F,,,Acanthocheilonema viteae,6277.0,
6546,1,,BAO_0000218,Intermediate,,10986,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 25 mg/kg/day(5 days) dose,F,,,Acanthocheilonema viteae,6277.0,
6547,1,,BAO_0000219,Intermediate,,10708,Evaluated for the inhibitory concentration required to cause growth inhibition of A673Mer+ sarcoma cell line using the MTT Cytotoxicity Assay,F,,,Homo sapiens,9606.0,
6548,1,,BAO_0000219,Intermediate,,10708,Evaluated for the inhibitory concentration required to cause growth inhibition of A704Rem- renal cell line using the MTT Cytotoxicity Assay,F,,,Homo sapiens,9606.0,
6549,0,,BAO_0000219,Autocuration,,416,Tested for inhibition of ET-1 induced phosphoinositide (PI) turnover in A7r5 smooth muscle cells,F,,,Rattus norvegicus,10116.0,
6550,1,,BAO_0000219,Intermediate,,14354,Inhibition of Forskolin-Induced cAMP production in A9 L cells expressing m2 receptors,F,,,Mus musculus,10090.0,
6551,1,,BAO_0000219,Intermediate,,14354,Percent inhibition of Forskolin-Induced cAMP production in A9 L cells expressing m2 receptors,F,,,Mus musculus,10090.0,
6552,1,,BAO_0000219,Intermediate,,5116,Cytotoxicity against Beta- tubulin mutant expressing A9-PTX10 cell line of humans was tested,F,,,Homo sapiens,9606.0,
6553,1,,BAO_0000219,Intermediate,,5116,Percentage inhibition at higher concentration (100 nM) against Beta- tubulin mutant expressing A9-PTX10 cell line,F,,,Homo sapiens,9606.0,
6554,1,,BAO_0000219,Expert,,15694,Inhibition of human ovarian carcinoma (A90) FGF-R overexpressing cell proliferation,F,,,Homo sapiens,9606.0,
6555,1,,BAO_0000219,Expert,,13038,"Tested for stimulating PI (phosphoinositol) hydrolysis in A9L-m1 cells, activity expressed as EC50 mM.",F,,,Mus musculus,10090.0,
6556,1,,BAO_0000219,Expert,,13038,Stimulating PI (phosphoinositol) hydrolysis in A9L-m1 cells.,F,,,Mus musculus,10090.0,
6557,1,,BAO_0000219,Expert,,10923,Increase in phosphoinositide (PI) metabolism in A9L-m1 cells at 100 uM.,F,,,Mus musculus,10090.0,
6558,1,,BAO_0000219,Intermediate,,10923,The increase in phosphoinositide (PI) metabolism in A9L-m1 cells was measured at 100 uM; - = Not determined,F,,,Mus musculus,10090.0,
6559,1,,BAO_0000219,Intermediate,,10923,The increase in phosphoinositide (PI) metabolism in A9L-m1 cells was measured at 100 uM; i = inactive,F,,,Mus musculus,10090.0,
6560,8,,BAO_0000019,Expert,,10923,"Increase in phosphoinositide (PI) metabolism in A9L-cholinergic receptor, muscarinic 3 expressing cells was measured at 100 uMolar",F,,,,,
6561,1,,BAO_0000219,Intermediate,,10923,The increase in phosphoinositide (PI) metabolism in A9L-m3 cells was measured at 100 uM; - = Not determined,F,,,Mus musculus,10090.0,
6562,1,,BAO_0000219,Intermediate,,10923,The increase in phosphoinositide (PI) metabolism in A9L-m3 cells was measured at 100 uM; i = inactive,F,,,Mus musculus,10090.0,
6563,1,,BAO_0000219,Intermediate,,8158,Ability to inhibit growth of AA-6 cells (a mutant cell line resistant to 8-azaadenine and lacks adenine phosphoryltransferase) was determined,F,,,Cricetulus griseus,10029.0,
6564,0,,BAO_0000219,Autocuration,,15494,Intracellular phosphorylation (100 uM) in uninfected AA2 cells was studied after 5 hrs of Incubation.,F,,,Homo sapiens,9606.0,
6565,0,,BAO_0000219,Autocuration,,15494,"Intracellular phosphorylation (100 uM) in uninfected AA2 cells was studied, after 5 hrs of Incubation.",F,,,Homo sapiens,9606.0,
6566,1,,BAO_0000219,Intermediate,,12348,Anti -HIV activity was measured against AA5/HIV-1(IIIB),F,,,Homo sapiens,9606.0,
6567,1,,BAO_0000219,Intermediate,,12348,Cytotoxicity was measured against AA5/HIV-1(IIIB),F,,,Homo sapiens,9606.0,
6568,1,,BAO_0000219,Intermediate,,2726,Compound was evaluated for the anti-HIV activity against HIV strain IIIB in AA5 EBV-infected B-cell,F,,,Homo sapiens,9606.0,
6569,1,,BAO_0000219,Intermediate,,2726,Compound was evaluated for the anti-HIV activity against HIV strain IIIB in U937 monocytic cell,F,,,Homo sapiens,9606.0,
6570,1,,BAO_0000219,Intermediate,,10747,Hypersensitivity factor obtained from in vitro cytotoxicities against Chinese hamster ovary derived AA8 / UV4 cell lines,F,,,Cricetulus griseus,10029.0,
6571,1,,BAO_0000219,Expert,,11005,"Inhibition of cell growth in culture against Chinese hamster ovary derived cell line, AA8",F,,,Cricetulus griseus,10029.0,
6572,1,,BAO_0000219,Intermediate,,12687,Average intracellular compound concentration when the hypoxic SER=1.6,F,,,Cricetulus griseus,10029.0,
6573,1,,BAO_0000219,Intermediate,,12687,Average intracellular compound concentration when the hypoxic SER=1.6.,F,,,Cricetulus griseus,10029.0,
6574,1,,BAO_0000219,Intermediate,,12687,Average intracellular compound concentration where the hypoxia sensitizer enhancement ratio (SER)=1.6,F,,,Cricetulus griseus,10029.0,
6575,1,,BAO_0000219,Intermediate,,12687,Average intracellular compound concentration where the sensitizer enhancement ratio (SER)=1.6 under hypoxia,F,,,Cricetulus griseus,10029.0,
6576,1,,BAO_0000219,Intermediate,,12687,Compound concentration at which sensitizer enhancement ratio =1.6 under hypoxia.,F,,,Cricetulus griseus,10029.0,
6577,1,,BAO_0000219,Intermediate,,13436,"Compound was tested for the concentration required to reduce cell survival under hypoxic conditions, using the cell line AA8 in the clonogenic assay.",F,,,Cricetulus griseus,10029.0,
6578,1,,BAO_0000219,Intermediate,,13435,"Concentration needed to reduce cell survival to 10% of control values, using 1 hour exposure of plateau phase AA8 cells at 10e6 cells/ml",F,,,Cricetulus griseus,10029.0,
6579,1,,BAO_0000219,Intermediate,,13302,Activity to reduce the surviving fraction to 10% (CT10) was used as an inverse measure of cytotoxic potency in aerobic conditions,F,,,Cricetulus griseus,10029.0,
6580,1,,BAO_0000219,Intermediate,,12687,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition,F,,,Cricetulus griseus,10029.0,
6581,1,,BAO_0000219,Intermediate,,12687,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition,A,,,Cricetulus griseus,10029.0,
6582,1,,BAO_0000219,Intermediate,,12687,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition.,A,,,Cricetulus griseus,10029.0,
6583,1,,BAO_0000219,Expert,,12878,Concentration x time (uM h) to reduce cell survival to 10% of control values under hypoxic conditions by clonogenic assay,A,,,Cricetulus griseus,10029.0,
6584,1,,BAO_0000219,Intermediate,,12878,Concentration x time (uM h) to reduce cell survival to 10% of control values under hypoxic conditions by clonogenic assay. Inactive at the solubility limit,A,,,Cricetulus griseus,10029.0,
6585,1,,BAO_0000219,Expert,,14367,Cytotoxicity under aerobic conditions determined to reduce the AA8 cell survival to 10% controls in clonogenic assay,F,,,Cricetulus griseus,10029.0,
6586,1,,BAO_0000219,Intermediate,,14367,Cytotoxicity under aerobic conditions determined to reduce the AA8 cell survival to 10% of controls in clonogenic assay,F,,,Cricetulus griseus,10029.0,
6587,1,,BAO_0000219,Expert,,12398,Aerobic cytotoxicity was assessed in a growth inhibition assay using log phase cultures of the chinese hamster ovary fibroblast line AA8,F,,,hampster,36483.0,
6588,1,,BAO_0000219,Expert,,12878,Aerobic growth inhibition in Chinese hamster cell line AA8,F,,,Cricetulus griseus,10029.0,
6589,1,,BAO_0000219,Expert,,13820,Cytotoxicity against AA8 cell and IC50 values were determined as drug concentration required to inhibit cell protein to 50%.,F,,,Cricetulus griseus,10029.0,
6590,1,,BAO_0000219,Expert,,13436,Inhibition of growth under aerobic conditions in AA8 cells,F,,,Cricetulus griseus,10029.0,
6591,1,,BAO_0000218,Intermediate,,6084,Oral bioavailability in dog (dose 10 mg/kg),A,In vivo,,Canis lupus familiaris,9615.0,
6592,1,,BAO_0000218,Intermediate,,5711,Oral bioavailability in dog at 10 mg/kg of the compound,A,In vivo,,Canis lupus familiaris,9615.0,
6593,1,,BAO_0000218,Intermediate,,4353,Oral bioavailability in dog (dose 5 uM/kg),A,In vivo,,Canis lupus familiaris,9615.0,
6594,1,,BAO_0000218,Intermediate,,4353,Oral bioavailability in dog (dose 5 uM/kg),A,In vivo,,Canis lupus familiaris,9615.0,
6595,1,,BAO_0000218,Intermediate,,17800,Oral bioavailability in dog (mongrel),A,In vivo,,Canis lupus familiaris,9615.0,
6596,1,,BAO_0000218,Intermediate,,3994,Oral bioavailability in dog (dose 10 mg/kg),A,In vivo,,Canis lupus familiaris,9615.0,
6597,1,,BAO_0000218,Intermediate,,3994,Oral bioavailability in dog (dose 10 mg/kg),F,In vivo,,Canis lupus familiaris,9615.0,
6598,1,,BAO_0000218,Intermediate,,5145,Bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,
6599,1,,BAO_0000218,Intermediate,,16452,Bioavailability in dog (dose 1 mg/kg i.v.),A,In vivo,,Canis lupus familiaris,9615.0,
6600,1,,BAO_0000218,Intermediate,,16452,Pharmacokinetic data for dose given to dogs intravenously (oral PK study in parentheses),A,In vivo,,Canis lupus familiaris,9615.0,
6601,1,,BAO_0000218,Intermediate,,5983,Pharmacokinetic property (F) was measured in dog at the dose of 0.032 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,
6602,1,,BAO_0000218,Intermediate,,4273,Bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,
6603,1,,BAO_0000218,Intermediate,,12500,Bioavailability in dog (dose 3-10 mg/kg),A,In vivo,,Canis lupus familiaris,9615.0,
6604,1,,BAO_0000218,Intermediate,1969.0,12500,The compound was tested for bioavailability of compound in plasma of dog; Complete,A,In vivo,,Canis lupus familiaris,9615.0,
6605,1,,BAO_0000218,Intermediate,,3639,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,
6606,1,,BAO_0000218,Intermediate,,3880,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,
6607,1,,BAO_0000218,Intermediate,,4838,Bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,
6608,1,,BAO_0000218,Intermediate,,15600,oral bioavailability was measured in dogs,A,In vivo,,Canis lupus familiaris,9615.0,
6609,1,,BAO_0000218,Intermediate,,17248,Compound was tested for plasma protein binding in dog; Not determined,A,,,Canis lupus familiaris,9615.0,
6610,1,,BAO_0000218,Intermediate,,17248,Compound was tested for plasma protein binding of dog,A,,,Canis lupus familiaris,9615.0,
6611,1,,BAO_0000218,Intermediate,,17248,Compound was tested for plasma protein binding of dog; Not determined,A,,,Canis lupus familiaris,9615.0,
6612,1,,BAO_0000218,Intermediate,,17443,Concentration in dogs after oral administration at dose of 1 mg/kg after 180 min.,A,,,Canis lupus familiaris,9615.0,
6613,1,,BAO_0000218,Intermediate,,4186,Apparent terminal elimination half-life in dog after administration of 20 mg/kg dose through peroral route,A,In vivo,,Canis lupus familiaris,9615.0,
6614,1,,BAO_0000218,Intermediate,,3749,Half life was determined,A,,,Canis lupus familiaris,9615.0,
6615,1,,BAO_0000218,Intermediate,,3249,Half life by ''Cr'' assay in dog at a dose of 5 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,
6616,1,,BAO_0000218,Intermediate,,3022,Half life was evaluated in dog,A,,,Canis lupus familiaris,9615.0,
6617,1,,BAO_0000218,Intermediate,,3749,Half life was determined,A,,,Canis lupus familiaris,9615.0,
6618,1,,BAO_0000218,Intermediate,,2517,Biodistribution of compound was measured in bile at 2 hr post-injection in canine deep vein thrombosis model (DVT),A,In vivo,,Canis lupus familiaris,9615.0,
6619,1,,BAO_0000218,Intermediate,948.0,2517,Biodistribution of compound was measured in heart at 2 hr post-injection in canine deep vein thrombosis model (DVT),A,In vivo,,Canis lupus familiaris,9615.0,
6620,1,,BAO_0000218,Intermediate,2113.0,2517,Biodistribution of compound was measured in kidney at 2 hr post-injection in canine deep vein thrombosis model (DVT),A,In vivo,,Canis lupus familiaris,9615.0,
6621,1,,BAO_0000218,Intermediate,2107.0,2517,Biodistribution of compound was measured in liver at 2 hr post-injection in canine deep vein thrombosis model (DVT),A,In vivo,,Canis lupus familiaris,9615.0,
6622,1,,BAO_0000218,Intermediate,2048.0,2517,Biodistribution of compound was measured in lung at 2 hr post-injection in canine deep vein thrombosis model (DVT),A,In vivo,,Canis lupus familiaris,9615.0,
6623,1,,BAO_0000218,Intermediate,2106.0,2517,Biodistribution of compound was measured in spleen at 2 hr post-injection in canine deep vein thrombosis model (DVT),A,In vivo,,Canis lupus familiaris,9615.0,
6624,1,,BAO_0000218,Intermediate,,3639,LogP in dog,A,,,Canis lupus familiaris,9615.0,
6625,1,,BAO_0000218,Intermediate,,6227,Partition coefficient (logP),A,,,Canis lupus familiaris,9615.0,
6626,1,,BAO_0000218,Intermediate,,6227,Partition coefficient in dog,A,,,Canis lupus familiaris,9615.0,
6627,1,,BAO_0000218,Intermediate,,17764,Mean-residence time of compound after intravenous administration in dogs at 1.2 uM/kg,A,In vivo,,Canis lupus familiaris,9615.0,
6628,1,,BAO_0000218,Intermediate,,4809,Pharmacokinetic parameter MRT was determined in Beagle dogs after (po) administration of a dose of 28 (uM/kg),A,In vivo,,Canis lupus familiaris,9615.0,
6629,1,,BAO_0000218,Intermediate,,5600,In vitro metabolic stability determined after 30 min of incubation in dog hepatic microsomes,A,,,Canis lupus familiaris,9615.0,
6630,1,,BAO_0000218,Intermediate,,14294,Metabolism of compound in dog S9 microsomes ('++''indicates 20-50% largest observed peak),A,,,Canis lupus familiaris,9615.0,
6631,1,,BAO_0000218,Intermediate,,14294,Metabolism of compound in dog S9 microsomes ('++++' indicates largest observed peak),A,,,Canis lupus familiaris,9615.0,
6632,1,,BAO_0000218,Intermediate,,14294,Metabolism of compound in dog S9 microsomes; Trace,A,,,Canis lupus familiaris,9615.0,
6633,1,,BAO_0000218,Intermediate,2107.0,6251,In vitro metabolic potential in dog liver microsomes,A,,,Canis lupus familiaris,9615.0,
6634,1,,BAO_0000218,Intermediate,,3748,Oral bioavailability of perorally administered compound (10 mg/kg) was tested in dogs,A,In vivo,,Canis lupus familiaris,9615.0,
6635,1,,BAO_0000218,Intermediate,,2713,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,
6636,1,,BAO_0000218,Intermediate,,6512,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,
6637,1,,BAO_0000218,Intermediate,,6679,Oral bioavailability was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,A,In vivo,,Canis lupus familiaris,9615.0,
6638,1,,BAO_0000218,Intermediate,,3749,The compound was tested for bioavailability in dogs,A,In vivo,,Canis lupus familiaris,9615.0,
6639,1,,BAO_0000218,Intermediate,,3749,The compound was tested for oral bioavailability in dogs,A,In vivo,,Canis lupus familiaris,9615.0,
6640,1,,BAO_0000218,Intermediate,,6742,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,
6641,1,,BAO_0000218,Intermediate,,6227,Compound was tested for percent protein binding (PB) in dog,A,,,Canis lupus familiaris,9615.0,
6642,1,,BAO_0000218,Intermediate,,6874,Apparent permeability coefficient (Papp) for apical to basolateral flux was determined in MadinDarby Canine Kidney cells,A,,,Canis lupus familiaris,9615.0,
6643,1,,BAO_0000218,Intermediate,1969.0,2877,Compound was evaluated for plasma clearance.,A,In vivo,,Canis lupus familiaris,9615.0,
6644,1,,BAO_0000218,Intermediate,1969.0,12500,The compound was tested for plasma clearance in dog,A,In vivo,,Canis lupus familiaris,9615.0,
6645,1,,BAO_0000218,Intermediate,1969.0,12500,The compound was tested for plasma clearance in dog at dose of 3-10 mgkg,A,In vivo,,Canis lupus familiaris,9615.0,
6646,1,,BAO_0000218,Intermediate,,4709,Plasma protein binding was determined after intravenous administration of 1 mg/kg in dog,A,,,Canis lupus familiaris,9615.0,
6647,1,,BAO_0000218,Intermediate,2107.0,5542,In vitro relative rate of metabolism was determined in dog liver microsomes,A,,,Canis lupus familiaris,9615.0,
6648,1,,BAO_0000218,Intermediate,,17594,Relative bioavailability after oral dose of compound at 3 mg/kg in dogs,A,In vivo,,Canis lupus familiaris,9615.0,
6649,1,,BAO_0000218,Intermediate,,2652,Compound was evaluated for half-life period in dogs at a dose of 5 mpk perorally,A,In vivo,,Canis lupus familiaris,9615.0,
6650,1,,BAO_0000218,Intermediate,,17764,Half life after intravenous administration in dogs at 1.2 uM/kg,A,In vivo,,Canis lupus familiaris,9615.0,
6651,1,,BAO_0000218,Intermediate,2048.0,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 30 minutes,A,,,Mus musculus,10090.0,
6652,1,,BAO_0000218,Intermediate,2048.0,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 4 hours,A,,,Mus musculus,10090.0,
6653,1,,BAO_0000218,Intermediate,2048.0,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 8 hours,A,,,Mus musculus,10090.0,
6654,1,,BAO_0000218,Intermediate,,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 1 hour,A,,,Mus musculus,10090.0,
6655,1,,BAO_0000218,Intermediate,,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/muscle bearing S180 tumor cell line for 2 hours,A,,,Mus musculus,10090.0,
6656,1,,BAO_0000218,Intermediate,,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 30 minutes,A,,,Mus musculus,10090.0,
6657,1,,BAO_0000218,Intermediate,,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/muscle bearing S180 tumor cell line for 4 hours,A,,,Mus musculus,10090.0,
6658,1,,BAO_0000218,Intermediate,,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 8 hours,A,,,Mus musculus,10090.0,
6659,1,,BAO_0000218,Intermediate,955.0,17641,C2 in brain of mice at the oral dose of 50 mg/kg,A,,,Mus musculus,10090.0,
6660,1,,BAO_0000218,Intermediate,2113.0,17641,C2 in kidney of mice at the oral dose of 50 mg/kg,A,,,Mus musculus,10090.0,
6661,1,,BAO_0000218,Intermediate,2107.0,17641,C2 in liver of mice at the oral dose of 50 mg/kg,A,,,Mus musculus,10090.0,
6662,1,,BAO_0000218,Intermediate,2048.0,17641,C2 in lungs of mice at the oral dose of 50 mg/kg,A,,,Mus musculus,10090.0,
6663,1,,BAO_0000218,Intermediate,2106.0,17641,C2 in spleen of mice at the oral dose of 50 mg/kg,A,,,Mus musculus,10090.0,
6664,1,,BAO_0000218,Intermediate,,17852,Plasma clearance in mouse,A,In vivo,,Mus musculus,10090.0,
6665,1,,BAO_0000218,Intermediate,,17764,Clearance of compound after intravenous administration in mice at 24 uM/kg,A,In vivo,,Mus musculus,10090.0,
6666,1,,BAO_0000218,Intermediate,,17837,Clearance from mouse blood following i.v. administration of 10 mg/kg,A,In vivo,,Mus musculus,10090.0,
6667,1,,BAO_0000218,Intermediate,,2675,Clearance was evaluated in mice after intravenous administration,A,In vivo,,Mus musculus,10090.0,
6668,1,,BAO_0000218,Intermediate,,2675,Clearance was evaluated in mice after oral administration,A,In vivo,,Mus musculus,10090.0,
6669,1,,BAO_0000218,Intermediate,,4239,Pharmacokinetic property (Plasma clearance) was measured in mouse,A,In vivo,,Mus musculus,10090.0,
6670,1,,BAO_0000218,Intermediate,,17753,Plasma clearance of compound was determined at 40 mg/Kg,A,In vivo,,Mus musculus,10090.0,
6671,1,,BAO_0000218,Intermediate,,17753,Plasma clearance of at 24 mg/Kg,A,In vivo,,Mus musculus,10090.0,
6672,1,,BAO_0000218,Intermediate,,17753,Plasma clearance at 24 mg/Kg,A,In vivo,,Mus musculus,10090.0,
6673,1,,BAO_0000218,Intermediate,,17753,Plasma clearance at 5 mg/Kg,A,In vivo,,Mus musculus,10090.0,
6674,1,,BAO_0000218,Intermediate,,5727,Plasma clearance in mice,A,In vivo,,Mus musculus,10090.0,
6675,1,,BAO_0000218,Intermediate,,2862,Plasma clearance value upon iv administration in mouse,A,In vivo,,Mus musculus,10090.0,
6676,1,,BAO_0000218,Intermediate,1969.0,5980,Total plasma clearance in mice,A,In vivo,,Mus musculus,10090.0,
6677,1,,BAO_0000218,Intermediate,,17592,Clearance in mouse,A,In vivo,,Mus musculus,10090.0,
6678,1,,BAO_0000218,Intermediate,,17718,Clearance value was determined,A,In vivo,,Mus musculus,10090.0,
6679,1,,BAO_0000218,Intermediate,,16597,Plasma clearance at a dose of 10 mg/kg intravenous administration in mice.,A,In vivo,,Mus musculus,10090.0,
6680,0,,BAO_0000100,Intermediate,,17384,Calculated partition coefficient (clogP),P,,,,,
6681,1,,BAO_0000218,Intermediate,,6062,Plasma clearance for the compound was measured in mouse after an iv dose of 1 mg/kg,A,In vivo,,Mus musculus,10090.0,
6682,1,,BAO_0000218,Intermediate,,17734,Plasma clearance rate after intraperitoneal administration of 100 mg/kg in mice,A,In vivo,,Mus musculus,10090.0,
6683,1,,BAO_0000218,Intermediate,,6348,Plasma clearance was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,A,In vivo,,Mus musculus,10090.0,
6684,1,,BAO_0000218,Intermediate,,5969,In vivo total clearance was determined in murine septicemia at dose of 100 mg/kg,A,In vivo,,Mus musculus,10090.0,
6685,1,,BAO_0000218,Intermediate,,5969,In vivo total clearance was determined in murine septicemia at dose of 50 mg/kg,A,In vivo,,Mus musculus,10090.0,
6686,1,,BAO_0000218,Intermediate,,5969,In vivo total clearance was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,A,In vivo,,Mus musculus,10090.0,
6687,1,,BAO_0000218,Intermediate,,16597,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for Cmax,A,In vivo,,Mus musculus,10090.0,
6688,1,,BAO_0000218,Intermediate,,5781,Cmax after oral administration at 30 mg/kg in ICR mouse,A,In vivo,,Mus musculus,10090.0,
6689,1,,BAO_0000218,Intermediate,,17764,Cmax after peroral administration in mice at 2.4 uM/kg,A,In vivo,,Mus musculus,10090.0,
6690,1,,BAO_0000218,Intermediate,955.0,17641,Cmax in brain of mice at the oral dose of 50 mg/kg,A,In vivo,,Mus musculus,10090.0,
6691,1,,BAO_0000218,Intermediate,2113.0,17641,Cmax in kidney of mice at the oral dose of 50 mg/kg,A,In vivo,,Mus musculus,10090.0,
6692,1,,BAO_0000218,Intermediate,2107.0,17641,Cmax in liver of mice at the oral dose of 50 mg/kg,A,In vivo,,Mus musculus,10090.0,
6693,1,,BAO_0000218,Intermediate,2048.0,17641,Cmax in lungs of mice at the oral dose of 50 mg/kg,A,In vivo,,Mus musculus,10090.0,
6694,1,,BAO_0000218,Intermediate,,17764,Cmax in mice at 18 uM/kg i.p. administration,F,In vivo,,Mus musculus,10090.0,
6695,1,,BAO_0000218,Intermediate,,17764,Cmax in mice at 23 uM/kg i.v. administration,F,In vivo,,Mus musculus,10090.0,
6696,1,,BAO_0000218,Intermediate,,17764,Cmax in mice at 24 uM/kg i.p. administration,F,In vivo,,Mus musculus,10090.0,
6697,1,,BAO_0000218,Intermediate,,17764,Cmax in mice at 25 uM/kg i.p. administration,F,In vivo,,Mus musculus,10090.0,
6698,1,,BAO_0000218,Intermediate,,17764,Cmax in mice at 26 uM/kg i.p. administration,F,In vivo,,Mus musculus,10090.0,
6699,1,,BAO_0000218,Intermediate,2106.0,17641,Cmax in spleen of mice at the oral dose of 50 mg/kg,A,In vivo,,Mus musculus,10090.0,
6700,1,,BAO_0000218,Intermediate,,16597,Cmax value at a dose of 10 mg/kg intravenous administration in mice.,A,In vivo,,Mus musculus,10090.0,
6701,1,,BAO_0000218,Intermediate,,16597,Cmax value at a dose of 10 mg/kg peroral administration in mice.,A,In vivo,,Mus musculus,10090.0,
6702,1,,BAO_0000218,Intermediate,,5727,Cmax value was determined,A,In vivo,,Mus musculus,10090.0,
6703,1,,BAO_0000218,Intermediate,,5951,Cmax value in IRC mice,A,In vivo,,Mus musculus,10090.0,
6704,1,,BAO_0000218,Intermediate,,5506,Cmax value was determined at a dose of 100 mg/kg (i.p.) in Mice,A,In vivo,,Mus musculus,10090.0,
6705,1,,BAO_0000218,Intermediate,,5506,Cmax value was determined at a dose of 200 mg/kg (i.p.) in Mice,A,In vivo,,Mus musculus,10090.0,
6706,1,,BAO_0000218,Intermediate,1969.0,14239,Compound was evaluated for maximum plasma concentration by administering orally at 25 mg/kg in mice,A,In vivo,,Mus musculus,10090.0,
6707,1,,BAO_0000218,Intermediate,1969.0,4890,"Compound was evaluated for the pharmacokinetic parameter, maximum plasma concentration",A,In vivo,,Mus musculus,10090.0,
6708,1,,BAO_0000218,Intermediate,,429,Evaluated for pharmacokinetic parameter Cmax in mouse at the dose 20 mg/kg,A,In vivo,,Mus musculus,10090.0,
6709,1,,BAO_0000218,Intermediate,,10986,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 50 mg/kg/day(5 days) dose,F,,,Acanthocheilonema viteae,6277.0,
6710,1,,BAO_0000218,Intermediate,,10986,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 6.25 mg/kg/day(5 days) dose,F,,,Acanthocheilonema viteae,6277.0,
6711,1,,BAO_0000218,Intermediate,,10986,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 75 mg/kg/day(5 days) dose,F,,,Acanthocheilonema viteae,6277.0,
6712,1,,BAO_0000219,Intermediate,,13227,Inhibitory activity against human tumor cell line A0375 melanoma.,F,,,Homo sapiens,9606.0,
6713,9,,BAO_0000249,Expert,,4481,Displacement of [3H]N6-PIA binding from A1 receptor in whole rat brain membranes,B,,,Rattus norvegicus,10116.0,
6714,9,,BAO_0000019,Expert,,16931,Forskolin-induced cAMP production at human A1 adenosine receptor,F,,,Homo sapiens,9606.0,
6715,8,,BAO_0000219,Autocuration,,3850,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1; change of less than 5% of allosteric enhancement.,F,,,,,
6716,8,,BAO_0000219,Autocuration,,3850,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM; An increase of cAmp content of cells,F,,,,,
6717,8,,BAO_0000219,Expert,,3850,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM,F,,,,,
6718,8,,BAO_0000219,Expert,,3850,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration,F,,,,,
6719,8,,BAO_0000219,Autocuration,,3850,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; An increase of cAmp content of cells,F,,,,,
6720,8,,BAO_0000219,Autocuration,,3850,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; change of less than 5% of allosteric enhancement,F,,,,,
6721,8,,BAO_0000219,Autocuration,,3850,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; change of less than 5% of allosteric enhancement.,F,,,,,
6722,9,,BAO_0000219,Expert,,3850,Percent response to 10 uM PD-81723 on CHO cells expressing human A1-adenosine receptor at 0.1 uM; An increase of cAmp content of cells,F,,,Homo sapiens,9606.0,
6723,8,,BAO_0000219,Autocuration,,3850,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM,F,,,,,
6724,8,,BAO_0000219,Autocuration,,3850,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM; change of less than 5% of allosteric enhancement.,F,,,,,
6725,8,,BAO_0000219,Expert,,3850,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM concentration,F,,,,,
6726,8,,BAO_0000219,Autocuration,,3850,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM concentration; change of less than 5% of allosteric enhancement.,F,,,,,
6727,8,,BAO_0000219,Expert,,3850,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM; An increase of cAmp content of cells,F,,,,,
6728,8,,BAO_0000219,Autocuration,,3850,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM,F,,,,,
6729,8,,BAO_0000219,Autocuration,,3850,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; An increase of cAmp content of cells,F,,,,,
6730,8,,BAO_0000219,Autocuration,,3850,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; change of less than 5% of allosteric enhancement.,F,,,,,
6731,8,,BAO_0000219,Expert,,3850,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration,F,,,,,
6732,8,,BAO_0000219,Autocuration,,3850,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration; An increase of cAmp content of cells,F,,,,,
6733,8,,BAO_0000219,Autocuration,,3850,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration; change of less than 5% of allosteric enhancement.,F,,,,,
6734,8,,BAO_0000219,Expert,,3850,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; An increase of cAmp content of cells,F,,,,,
6735,1,,BAO_0000219,Intermediate,,12680,Ability to inhibit [125I]ET1 binding to vascular smooth muscle (vsm)- A10 cells,F,,,Oryctolagus cuniculus,9986.0,
6736,0,,BAO_0000219,Autocuration,,1313,In vitro potassium channel opening activity in A10 (smooth muscle) cells,F,,,Rattus norvegicus,10116.0,
6737,0,,BAO_0000219,Autocuration,,1313,In vitro potassium channel opening activity in A10 (smooth muscle) cells; Inactive,F,,,Rattus norvegicus,10116.0,
6738,1,,BAO_0000219,Intermediate,,17567,Effect on membrane potential of mitochondria in A10 smooth muscle cells from rats,F,,,Rattus norvegicus,10116.0,
6739,1,,BAO_0000219,Intermediate,,17567,Effect on membrane potential of mitochondria of A10 smooth muscle cells in rats,F,,,Rattus norvegicus,10116.0,
6740,1,,BAO_0000219,Intermediate,,11819,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.001 uM,F,,,Rattus norvegicus,10116.0,
6741,1,,BAO_0000219,Intermediate,,13436,Compound was tested for aerobic growth inhibition against AA8 cells after 4 hr of exposure,F,,,Cricetulus griseus,10029.0,
6742,1,,BAO_0000219,Intermediate,,12687,Concentration required to reduce AA8 cell numbers to 50% of controls in a growth inhibition microassay,F,,,Cricetulus griseus,10029.0,
6743,1,,BAO_0000219,Intermediate,,12651,Concentration of the drug to inhibit chinese hamster ovary derived cell (AA8) growth in culture,F,,,Cricetulus griseus,10029.0,
6744,1,,BAO_0000219,Intermediate,,13300,Cytotoxicity in a growth inhibition assay against aerobic cultures of AA8 cells was determined,F,,,Cricetulus griseus,10029.0,
6745,1,,BAO_0000219,Intermediate,,15296,Cytotoxicity on AA8 cell growth (reduce cell number by 50%).,F,,,Cricetulus griseus,10029.0,
6746,1,,BAO_0000219,Intermediate,,15328,"Cytotoxicity in chinese hamster ovary tumor cell line-AA8, by growth inhibition assay.",F,,,Cricetulus griseus,10029.0,
6747,1,,BAO_0000219,Intermediate,,13302,Growth inhibition activity was measured in repair proficient AA8 cells under aerobic conditions (4 hours drug exposure),F,,,Cricetulus griseus,10029.0,
6748,1,,BAO_0000219,Expert,,14367,"Growth inhibition of aerobic AA8 cells, after 18 hours exposure",F,,,Cricetulus griseus,10029.0,
6749,1,,BAO_0000219,Expert,,17002,In vitro cellular toxicity against chinese hamster AA8 cell line after 4 hr of compound exposure,F,,,Cricetulus griseus,10029.0,
6750,1,,BAO_0000219,Intermediate,,13436,Inhibitory activity against AA8 cell growth in aerobic condition after 4 hr of exposure,F,,,Cricetulus griseus,10029.0,
6751,1,,BAO_0000219,Intermediate,,13435,Inhibitory activity against aerobic growth of AA8 cells.,F,,,Cricetulus griseus,10029.0,
6752,1,,BAO_0000219,Intermediate,,10503,Tested for the in vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,A,,,Cricetulus griseus,10029.0,
6753,1,,BAO_0000219,Expert,,10503,In vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,F,,,Cricetulus griseus,10029.0,
6754,1,,BAO_0000219,Intermediate,,10503,Tested for the in vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,F,,,Cricetulus griseus,10029.0,
6755,1,,BAO_0000219,Expert,,15090,Tested for growth inhibition against AA8 tumor cell line(chinese hamster ovary).,F,,,Cricetulus griseus,10029.0,
6756,1,,BAO_0000219,Expert,,10368,Cytotoxicity against AA8 cell line,F,,,Cricetulus griseus,10029.0,
6757,1,,BAO_0000219,Intermediate,,12651,Hypersensitivity factor(HF) was determined as ratio of IC50(AA8) to IC50(UV4),F,,,Cricetulus griseus,10029.0,
6758,1,,BAO_0000219,Intermediate,,12687,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),A,,,Cricetulus griseus,10029.0,
6759,1,,BAO_0000219,Intermediate,,12687,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),F,,,Cricetulus griseus,10029.0,
6760,1,,BAO_0000219,Intermediate,,12687,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),A,,,Cricetulus griseus,10029.0,
6761,1,,BAO_0000219,Intermediate,,1890,Compound was evaluated for cytotoxicity against CHO AA8 cell lines for 4 hr at pH-7.4,F,,,Cricetulus griseus,10029.0,
6762,1,,BAO_0000219,Intermediate,,10747,Compound was evaluated for in vitro cytotoxicities against Chinese hamster ovary derived AA8 cell lines.,F,,,Cricetulus griseus,10029.0,
6763,1,,BAO_0000219,Intermediate,,10747,Compound was evaluated for in vitro cytotoxicities against Chinese hamster ovary derived AA8 cell lines.,F,,,Cricetulus griseus,10029.0,
6764,0,,BAO_0000218,Autocuration,,11616,Maximum tolerated dose (MTD) in C3H/HeN mice (single ip dose),F,,,Cricetulus griseus,10029.0,
6765,1,,BAO_0000219,Expert,,11616,Concentration required to increase radiation sensitivity by 1.3 when AA8 cells are exposed to drug for 30 min before and during irradiation under hypoxic condition.,F,,,Cricetulus griseus,10029.0,
6766,0,,BAO_0000219,Autocuration,,3471,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 1 hr under anoxic conditions,F,,,Cricetulus griseus,10029.0,
6767,0,,BAO_0000219,Autocuration,,3471,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 3h under anoxic conditions,F,,,Cricetulus griseus,10029.0,
6768,0,,BAO_0000219,Autocuration,,3471,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 4 hr under anoxic conditions,F,,,Cricetulus griseus,10029.0,
6769,0,,BAO_0000219,Autocuration,,3471,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 1 hr under aerobic conditions,F,,,Cricetulus griseus,10029.0,
6770,0,,BAO_0000219,Autocuration,,3471,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 3h under aerobic conditions,F,,,Cricetulus griseus,10029.0,
6771,0,,BAO_0000219,Autocuration,,3471,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 4 hr under aerobic conditions,F,,,Cricetulus griseus,10029.0,
6772,0,,BAO_0000219,Autocuration,,3471,Ratio of oxygen dependence of cytotoxicities of AA8 cells in aerobic condition to anoxic condition,F,,,Cricetulus griseus,10029.0,
6773,1,,BAO_0000219,Expert,,11616,Concentration required to reduce AA8 cell survival by 10%,F,,,Cricetulus griseus,10029.0,
6774,0,,BAO_0000219,Autocuration,,2656,"Concentration required to reduce cell survival to 10% of controls under hypoxic conditions, using the AA8 (chinese hamster) aerobic cells",F,,,Cricetulus griseus,10029.0,
6775,0,,BAO_0000219,Autocuration,,10518,Tested for the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay,F,,,Cricetulus griseus,10029.0,
6776,0,,BAO_0000219,Autocuration,,10518,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay,F,,,Cricetulus griseus,10029.0,
6777,0,,BAO_0000219,Autocuration,,10518,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay; range is 0.8-1.5,F,,,Cricetulus griseus,10029.0,
6778,0,,BAO_0000219,Autocuration,,10518,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay; range is 1-2,F,,,Cricetulus griseus,10029.0,
6779,0,,BAO_0000219,Autocuration,,16156,Ability to reduce cell density of AA8 cells to 50% after 4 hr of exposure to air,F,,,Cricetulus griseus,10029.0,
6780,0,,BAO_0000219,Autocuration,,2656,Aerobic cytotoxic activity was evaluated by the growth inhibition of AA8 (chinese hamster) aerobic cells,F,,,Cricetulus griseus,10029.0,
6781,0,,BAO_0000019,Autocuration,,11005,"Compound was evaluated for the inhibition of cell growth in culture against Chinese hamster ovary derived cell line, AA8",F,,,Cricetulus griseus,10029.0,
6782,0,,BAO_0000219,Autocuration,,11942,Concentration for 50% inhibition of AA8 cells growth under aerobic conditions after 18 hours exposure,F,,,Cricetulus griseus,10029.0,
6783,0,,BAO_0000219,Autocuration,,2128,Concentration required for 50% inhibition of growth of AA8 cells following 4 hr drug exposure,F,,,Cricetulus griseus,10029.0,
6784,1,,BAO_0000218,Intermediate,,16907,Half life period after 15 mg/kg iv dose in Dogs,A,In vivo,,Canis lupus familiaris,9615.0,
6785,1,,BAO_0000218,Intermediate,,16907,Half life period after 30 mg/kg po dose in Dogs,A,In vivo,,Canis lupus familiaris,9615.0,
6786,1,,BAO_0000218,Intermediate,,9579,Half life was measured after oral 2b administration (tested in 6 dogs),A,In vivo,,Canis lupus familiaris,9615.0,
6787,1,,BAO_0000218,Intermediate,,9579,Half life was measured in dog after oral 17b administration,A,In vivo,,Canis lupus familiaris,9615.0,
6788,1,,BAO_0000218,Intermediate,,9579,Pharmacokinetic parameter T max determined in dog after oral administration of 17b,A,In vivo,,Canis lupus familiaris,9615.0,
6789,1,,BAO_0000218,Intermediate,,9579,Pharmacokinetic parameter T max determined in dog after oral administration of 2b,A,In vivo,,Canis lupus familiaris,9615.0,
6790,1,,BAO_0000218,Intermediate,,16907,Tmax value after 15 mg/kg iv dose in Dogs,A,In vivo,,Canis lupus familiaris,9615.0,
6791,1,,BAO_0000218,Intermediate,,16907,Tmax value after 30 mg/kg po dose in Dogs,A,In vivo,,Canis lupus familiaris,9615.0,
6792,1,,BAO_0000218,Intermediate,,3184,Compound was evaluated for its half life when administered intravenously in dog,A,In vivo,,Canis lupus familiaris,9615.0,
6793,1,,BAO_0000218,Intermediate,1969.0,5017,Compound was tested for plasma half life when administered in dog perorally (1 mg/kg) and intravenously (0.2 mg/kg),A,In vivo,,Canis lupus familiaris,9615.0,
6794,1,,BAO_0000218,Intermediate,,6821,Elimination Half-life of compound was determined in dog,A,,,Canis lupus familiaris,9615.0,
6795,1,,BAO_0000218,Intermediate,,17839,Half life of compound in dog following oral administration,A,In vivo,,Canis lupus familiaris,9615.0,
6796,1,,BAO_0000218,Intermediate,,17267,Half life of compound was determined in dog,A,,,Canis lupus familiaris,9615.0,
6797,1,,BAO_0000218,Intermediate,178.0,4727,Half life of compound was determined in dog blood,A,,,Canis lupus familiaris,9615.0,
6798,1,,BAO_0000218,Intermediate,,5238,Half life after oral and iv dosing in dogs,A,In vivo,,Canis lupus familiaris,9615.0,
6799,1,,BAO_0000218,Intermediate,,4942,Half life in dogs in hours,A,,,Canis lupus familiaris,9615.0,
6800,1,,BAO_0000218,Intermediate,,6505,Half life on i.v. administration of 2 mg/kg was measured in dog,A,In vivo,,Canis lupus familiaris,9615.0,
6801,1,,BAO_0000218,Intermediate,,5130,t1/2 in dog after oral dose (1 mg/kg),A,In vivo,,Canis lupus familiaris,9615.0,
6802,1,,BAO_0000218,Intermediate,,1475,Half life was evaluated in dog,A,,,Canis lupus familiaris,9615.0,
6803,1,,BAO_0000218,Intermediate,,17804,Half life period of compound was determined after intravenous administration at 2 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,
6804,1,,BAO_0000218,Intermediate,,17804,Half life period of compound was determined after peroral administration at 2 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,
6805,1,,BAO_0000218,Intermediate,,6084,Half life period (10 mg/kg) was determined in dog,A,In vivo,,Canis lupus familiaris,9615.0,
6806,1,,BAO_0000218,Intermediate,,6084,Half life period (10 mg/kg) was determined in dog,A,In vivo,,Canis lupus familiaris,9615.0,
6807,1,,BAO_0000218,Intermediate,,5542,Half life period by iv administration in dog at a dose of 0.3 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,
6808,1,,BAO_0000218,Intermediate,,5542,Half life period by po administration in dog at a dose of 0.3 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,
6809,1,,BAO_0000218,Intermediate,,6084,Half life period in dog,A,,,Canis lupus familiaris,9615.0,
6810,1,,BAO_0000218,Intermediate,,6241,Half life period in dogs after oral administration at 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,
6811,1,,BAO_0000218,Intermediate,,1916,Half life period was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,A,In vivo,,Canis lupus familiaris,9615.0,
6812,1,,BAO_0000218,Intermediate,,6621,Half-life of compound was determined in dogs,A,,,Canis lupus familiaris,9615.0,
6813,1,,BAO_0000218,Intermediate,1969.0,1696,Half-life in dog plasma,A,,,Canis lupus familiaris,9615.0,
6814,1,,BAO_0000218,Intermediate,,17800,Half-life in mongrel dogs was determined,A,,,Canis lupus familiaris,9615.0,
6815,1,,BAO_0000218,Intermediate,,17657,Half-life in dog upon oral administration,A,In vivo,,Canis lupus familiaris,9615.0,
6816,1,,BAO_0000218,Intermediate,,17657,Half-life in dog upon oral administration; Unable to calculate,A,In vivo,,Canis lupus familiaris,9615.0,
6817,1,,BAO_0000218,Intermediate,,4239,Half-life was measured in dog,A,,,Canis lupus familiaris,9615.0,
6818,1,,BAO_0000218,Intermediate,,5985,Half-life was measured in dog,A,,,Canis lupus familiaris,9615.0,
6819,1,,BAO_0000218,Intermediate,,9932,Half-recovery time (T1/2) of the vascular resistance decrease at ED30 in anesthetized dogs,A,,,Canis lupus familiaris,9615.0,
6820,1,,BAO_0000218,Intermediate,,5199,Oral half life was determined,A,In vivo,,Canis lupus familiaris,9615.0,
6821,1,,BAO_0000218,Intermediate,1969.0,5199,Plasma elimination half-life (08 h) was determined in canine following intravenous (iv) administration (1 mg/kg).,A,In vivo,,Canis lupus familiaris,9615.0,
6822,1,,BAO_0000218,Intermediate,1969.0,1475,Plasma half life was evaluated,A,,,Canis lupus familiaris,9615.0,
6823,1,,BAO_0000218,Intermediate,1969.0,1475,Plasma half life was evaluated in Dog,A,,,Canis lupus familiaris,9615.0,
6824,1,,BAO_0000218,Intermediate,1969.0,1475,Plasma half life was evaluated in dog,A,,,Canis lupus familiaris,9615.0,
6825,1,,BAO_0000218,Intermediate,,6316,T1/2 (Half-life) was after oral administration at 5 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,
6826,1,,BAO_0000218,Intermediate,,4883,Tested for the half life value in dog,A,,,Canis lupus familiaris,9615.0,
6827,1,,BAO_0000218,Intermediate,,4727,Maximum time at the dose of 2 mg/kg in dog,A,In vivo,,Canis lupus familiaris,9615.0,
6828,1,,BAO_0000218,Intermediate,,1916,Maximum time was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,A,In vivo,,Canis lupus familiaris,9615.0,
6829,1,,BAO_0000218,Intermediate,178.0,1337,Maximum time taken to reach maximum blood concentration was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,A,In vivo,,Canis lupus familiaris,9615.0,
6830,1,,BAO_0000218,Intermediate,178.0,1337,Maximum time taken to reach maximum blood concentration was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,A,In vivo,,Canis lupus familiaris,9615.0,
6831,1,,BAO_0000218,Intermediate,,6265,Pharmacokinetic (PK) property (Tmax) was determined in dog at the single dose of 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,
6832,1,,BAO_0000218,Intermediate,,4809,Pharmacokinetic parameter Tmax was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),A,In vivo,,Canis lupus familiaris,9615.0,
6833,1,,BAO_0000218,Intermediate,,5983,Pharmacokinetic property (Tmax) was measured in dog at the dose of 0.032 mg/kg p.o.,A,In vivo,,Canis lupus familiaris,9615.0,
6834,1,,BAO_0000218,Intermediate,,5313,"Tested for the pharmacokinetic data, time required to reach Cmax (Tmax) in dog",A,,,Canis lupus familiaris,9615.0,
6835,1,,BAO_0000218,Intermediate,,5313,"Tested for the pharmacokinetic data, time required to reach Cmax (Tmax) in dog at dosage of 10 mpk",A,In vivo,,Canis lupus familiaris,9615.0,
6836,1,,BAO_0000218,Intermediate,1969.0,17650,Time for maximum plasma concentration was measured in dogs after an oral dose of 10 uM/kg,A,In vivo,,Canis lupus familiaris,9615.0,
6837,1,,BAO_0000218,Intermediate,1969.0,5199,Time taken by the compound to achieve maximum plasma concentration at a 1 mg/kg oral dose in male and female Beagle dogs.,A,In vivo,,Canis lupus familiaris,9615.0,
6838,1,,BAO_0000218,Intermediate,1969.0,933,Time taken for maximum plasma concentration in dog,A,,,Canis lupus familiaris,9615.0,
6839,1,,BAO_0000218,Intermediate,,16367,Time to reach Cmax after oral administration to dogs,A,In vivo,,Canis lupus familiaris,9615.0,
6840,1,,BAO_0000218,Intermediate,1969.0,6348,Time to reach maximum plasma concentration was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,A,In vivo,,Canis lupus familiaris,9615.0,
6841,1,,BAO_0000218,Intermediate,,6316,Tmax (time to reach maximum concentration) was after oral administration at 5 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,
6842,1,,BAO_0000218,Intermediate,,6215,Tmax after peroral administration (1 mg/kg) was determined in dog,A,In vivo,,Canis lupus familiaris,9615.0,
6843,1,,BAO_0000218,Expert,,3598,Tmax of compound determined in dog after iv administration at a dose of 10 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,
6844,1,,BAO_0000218,Intermediate,,4527,Tmax by oral administration at a dose of 10 uM/kg in dog was determined,A,In vivo,,Canis lupus familiaris,9615.0,
6845,1,,BAO_0000218,Intermediate,,17764,Tmax after peroral administration in dogs at 2.4 uM/kg,A,In vivo,,Canis lupus familiaris,9615.0,
6846,1,,BAO_0000218,Intermediate,,5969,In vivo Cmax in mice at dose of 100 mg/kg,A,In vivo,,Mus musculus,10090.0,
6847,1,,BAO_0000218,Intermediate,,5969,In vivo Cmax in mice at dose of 50 mg/kg,A,In vivo,,Mus musculus,10090.0,
6848,1,,BAO_0000218,Intermediate,,4573,Maximal concentration determined at a dose 10 mg/kg administered intraperitoneally to mice,A,In vivo,,Mus musculus,10090.0,
6849,1,,BAO_0000218,Intermediate,1969.0,3277,Maximum plasma concentration was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),A,In vivo,,Mus musculus,10090.0,
6850,1,,BAO_0000218,Intermediate,1969.0,17734,Maximum concentration in plasma was determined after intraperitoneal administration of 100 mg/kg in mice,A,In vivo,,Mus musculus,10090.0,
6851,1,,BAO_0000218,Intermediate,1969.0,3132,Maximum concentration obtained in mouse plasma was determined,A,In vivo,,Mus musculus,10090.0,
6852,1,,BAO_0000218,Intermediate,1969.0,3132,Maximum concentration obtained in mouse plasma was determined at dose 25 mg/kg,A,In vivo,,Mus musculus,10090.0,
6853,1,,BAO_0000218,Intermediate,1969.0,6348,Maximum plasma concentration of compound was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,A,In vivo,,Mus musculus,10090.0,
6854,1,,BAO_0000218,Intermediate,1969.0,17729,Maximum plasma concentration when injected i.p. in mice at a dose of 50 mg/kg,A,In vivo,,Mus musculus,10090.0,
6855,1,,BAO_0000218,Intermediate,1969.0,17729,Maximum plasma concentration when injected intravenously in mice at a dose of 20 mg/kg,A,In vivo,,Mus musculus,10090.0,
6856,1,,BAO_0000218,Intermediate,1969.0,17729,Maximum plasma concentration when injected perorally in mice at a dose of 50 mg/kg,A,In vivo,,Mus musculus,10090.0,
6857,1,,BAO_0000218,Intermediate,1969.0,17728,Maximal plasma concentration in BALB/C mice after 20 mg/kg intraperitoneal dose,A,In vivo,,Mus musculus,10090.0,
6858,1,,BAO_0000218,Intermediate,1969.0,17728,Maximal plasma concentration in BALB/C mice after 20 mg/kg intravenous dose,A,In vivo,,Mus musculus,10090.0,
6859,1,,BAO_0000218,Intermediate,1969.0,17728,Maximal plasma concentration in BALB/C mice after 50 mg/kg oral dose,A,In vivo,,Mus musculus,10090.0,
6860,1,,BAO_0000218,Intermediate,,4066,Peak concentration at a single subcutaneous administration of 40 mg/kg in mice,A,In vivo,,Mus musculus,10090.0,
6861,1,,BAO_0000218,Intermediate,,6178,Pharmacokinetic property (C(max)) was determined after ip administration of 32 mg/kg in mice,A,In vivo,,Mus musculus,10090.0,
6862,1,,BAO_0000218,Intermediate,,6178,Pharmacokinetic property (C(max)) was determined after po administration of 32 mg/kg in mice,A,In vivo,,Mus musculus,10090.0,
6863,1,,BAO_0000218,Intermediate,,3760,Pharmacokinetic studies were carried out in vivo after administration of compound at 5 mg/kg intravenously in mice,A,In vivo,,Mus musculus,10090.0,
6864,1,,BAO_0000218,Intermediate,,3760,Pharmacokinetic studies were carried out in vivo after administration of compound at 5 mg/kg perorally in mice,A,In vivo,,Mus musculus,10090.0,
6865,1,,BAO_0000218,Intermediate,,3760,Pharmacokinetic studies were carried out in vivo after administration of compound at 50 mg/kg intravenously in mice,A,In vivo,,Mus musculus,10090.0,
6866,1,,BAO_0000218,Intermediate,,3760,Pharmacokinetic studies were carried out in vivo after administration of compound at 50 mg/kg perorally in mice,A,In vivo,,Mus musculus,10090.0,
6868,1,,BAO_0000218,Intermediate,,5961,Cmax in male mice after 2 mg/kg oral dose,A,In vivo,,Mus musculus,10090.0,
6869,1,,BAO_0000218,Intermediate,,6137,Plasma concentration of 5-FU in HT-3 (human cervical cancer) xenograft mice at 1.38 mg/kg oral dose co-administered with 135 mg/kg Capecitabine,A,In vivo,,Mus musculus,10090.0,
6870,1,,BAO_0000218,Intermediate,,3802,Tested for Cmax value at the dose of 10 mg/kg when administered perorally in mouse,A,In vivo,,Mus musculus,10090.0,
6871,1,,BAO_0000218,Intermediate,,3535,Concentration in plasma (systemic) following oral dose in mouse at 0.25 hr,A,,,Mus musculus,10090.0,
6872,1,,BAO_0000218,Intermediate,,3535,Concentration in plasma (systemic) following oral dose in mouse at 1 hr,A,,,Mus musculus,10090.0,
6873,1,,BAO_0000218,Intermediate,,3535,Concentration in plasma (systemic) following oral dose in mouse at 24 hr,A,,,Mus musculus,10090.0,
6874,1,,BAO_0000218,Intermediate,,3535,Concentration in plasma (systemic) following oral dose in mouse at 2 hr,A,,,Mus musculus,10090.0,
6875,1,,BAO_0000218,Intermediate,,3535,Concentration in plasma (systemic) following oral dose in mouse at 4 hr,A,,,Mus musculus,10090.0,
6876,1,,BAO_0000218,Intermediate,,3535,Concentration in plasma (systemic) following oral dose in mouse at 6 hr,A,,,Mus musculus,10090.0,
6877,1,,BAO_0000218,Intermediate,1969.0,2862,Maximum concentration in plasma upon oral administration in mouse,A,,,Mus musculus,10090.0,
6878,1,,BAO_0000218,Intermediate,1969.0,2675,Maximum plasma concentration was evaluated in mice after oral administration,A,,,Mus musculus,10090.0,
6879,1,,BAO_0000218,Intermediate,1969.0,2675,Maximum plasma concentration was evaluated in mice after intravenous administration; Cp max Not determined,A,In vivo,,Mus musculus,10090.0,
6880,1,,BAO_0000218,Intermediate,,5399,Dose at which the compound induced fecal excretion in mice,A,,,Mus musculus,10090.0,
6893,1,,BAO_0000219,Expert,,11819,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.01 uM,F,,,Rattus norvegicus,10116.0,
6894,1,,BAO_0000219,Expert,,11819,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.1 uM,F,,,Rattus norvegicus,10116.0,
6895,1,,BAO_0000219,Expert,,11819,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 1.0 uM,F,,,Rattus norvegicus,10116.0,
6896,1,,BAO_0000219,Expert,,11819,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 10.0 uM,F,,,Rattus norvegicus,10116.0,
6897,1,,BAO_0000219,Intermediate,,16361,In vitro [14C]- creatine uptake (1 mM) was determined in rat A10 smooth muscle cells at a concentration of (1 mM),F,,,Rattus norvegicus,10116.0,
6898,1,,BAO_0000219,Intermediate,,2288,Cytotoxicity was evaluated against A121 ovarian carcinoma human cancer cell line,F,,,Homo sapiens,9606.0,
6899,1,,BAO_0000219,Intermediate,,10404,Anticancer activity against human ovarian carcinoma A121 cells,F,,,Homo sapiens,9606.0,
6900,1,,BAO_0000219,Intermediate,,14790,Cytotoxic effect (tumor cell growth inhibition) on the human cell line A121 ovarian carcinoma at the dose of of 16.6 mM,F,,,Homo sapiens,9606.0,
6901,1,,BAO_0000219,Intermediate,,14790,Cytotoxic effect (tumor cell growth inhibition) on the human cell line A121 ovarian carcinoma at the dose of of 83 mM,F,,,Homo sapiens,9606.0,
6902,1,,BAO_0000219,Expert,,14253,Growth inhibition of human ovarian carcinoma (A121) cell line,F,,,Homo sapiens,9606.0,
6903,1,,BAO_0000219,Expert,,13617,Concentration required to inhibit growth of human tumor A121 (ovarian) cell line.,F,,,Homo sapiens,9606.0,
6904,1,,BAO_0000219,Intermediate,,1003,Cytotoxicity against human A121 ovarian cells,F,,,Homo sapiens,9606.0,
6905,1,,BAO_0000219,Intermediate,,830,Cytotoxicity was evaluated in vitro against A121 (ovarian carcinoma) human tumor cell lines,F,,,Homo sapiens,9606.0,
6906,1,,BAO_0000219,Intermediate,,12307,In vitro cytotoxicity against human ovarian carcinoma A21,F,,,Homo sapiens,9606.0,
6907,1,,BAO_0000219,Intermediate,,14254,Inhibition of the growth against human Ovarian Carcinoma (A121) cell line after 72 hr exposure,F,,,Homo sapiens,9606.0,
6908,1,,BAO_0000219,Intermediate,,13370,Inhibitory activity of compound against human A121 ovarian cell line.,F,,,Homo sapiens,9606.0,
6909,1,,BAO_0000219,Intermediate,,14790,Dose at which compound exhibits cytotoxicity in the A121 ovarian carcinoma cell line.,F,,,Homo sapiens,9606.0,
6910,1,,BAO_0000219,Intermediate,,3614,Inhibition of growth of human ovarian tumor cell line (A121) after 72 hr of drug exposure,F,,,Homo sapiens,9606.0,
6911,1,,BAO_0000219,Intermediate,,2664,Compound was evaluated for in vitro antiproliferative activity against A172 human CNS cancer cell line,F,,,Homo sapiens,9606.0,
6912,1,,BAO_0000219,Expert,,2037,In vitro cytotoxicity against A172 human tumor cell lines.,F,,,Homo sapiens,9606.0,
6913,1,,BAO_0000219,Intermediate,,14539,Growth inhibition time for A172 Human Glioma cell growth at concentration 5 uM,F,,,Homo sapiens,9606.0,
6914,1,,BAO_0000219,Intermediate,,2836,Compound was evaluated for cytotoxicity against human glioblastoma (A172) cell line,F,,,Homo sapiens,9606.0,
6915,1,,BAO_0000219,Intermediate,,10708,Evaluated for the inhibitory concentration required to cause growth inhibition of A172Mer- cell line of central nervous system (CNS) using the MTT Cytotoxicity Assay,F,,,Homo sapiens,9606.0,
6916,4,,BAO_0000224,Autocuration,,8975,Association constant against A2 adenosine receptor,B,,,Canis lupus familiaris,9615.0,
6917,1,,BAO_0000219,Intermediate,,7645,In vitro effective dose that causes 50% inhibition of growth of A2 cell line - amelanotic melanoma,F,,,fish,,
6918,5,,BAO_0000224,Autocuration,,11377,Ratio of Ki for adenosine A2 and A1 receptor binding,B,,,Rattus norvegicus,10116.0,
6919,1,,BAO_0000219,Expert,,13528,In vitro cytotoxicity against A204 human rhabdomyosarcoma cancer cell line,F,,,Homo sapiens,9606.0,
6920,1,,BAO_0000219,Expert,,10160,In vitro antitumor activity against A204 rhabdomyosarcoma tumor cell line was determined,F,,,Homo sapiens,9606.0,
6921,1,,BAO_0000219,Intermediate,,15144,The compound was tested in vitro for antiproliferative activity against A2058 tumor cell lines,F,,,Homo sapiens,9606.0,
6922,1,,BAO_0000219,Intermediate,,13160,Growth inhibition against Human squamous cell line(A 253),F,,,Homo sapiens,9606.0,
6923,1,,BAO_0000219,Intermediate,,12898,Growth inhibition of human squamous carcinoma cell lines following continuous (120 hours) exposure to MTX and compound A253 cell line,F,,,Homo sapiens,9606.0,
6924,1,,BAO_0000219,Intermediate,,13069,The compound was tested for Growth inhibition of the human squamous cell carcinoma A253 cells,F,,,Homo sapiens,9606.0,
6925,1,,BAO_0000219,Intermediate,,15984,Growth inhibition of A253 cell lines.,F,,,Homo sapiens,9606.0,
6926,1,,BAO_0000219,Intermediate,,15564,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h),F,,,Homo sapiens,9606.0,
6927,1,,BAO_0000219,Intermediate,,15564,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h); ND means not determined,F,,,Homo sapiens,9606.0,
6928,1,,BAO_0000219,Intermediate,,15564,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h); ND means not determined,F,,,Homo sapiens,9606.0,
6929,1,,BAO_0000219,Intermediate,,4720,In vitro cytotoxicity causing 50% growth inhibition was determined against A270 (human ovarian cancer)cell line,F,,,Homo sapiens,9606.0,
6930,1,,BAO_0000219,Intermediate,,16112,Antitumor activity of compound for 96-h exposure in A2780 human ovarian cell line,F,,,Homo sapiens,9606.0,
6931,1,,BAO_0000219,Expert,,16597,Cytotoxic activity against A2780 human ovarian carcinoma cell line,F,,,Homo sapiens,9606.0,
6932,1,,BAO_0000219,Intermediate,,16378,Cytotoxicity against human cancer cell lines A2780 (ovarian),F,,,Homo sapiens,9606.0,
6933,1,,BAO_0000219,Expert,,16085,Growth and colony formation inhibition of A2780 ovarian cancer cell lines,F,,,Homo sapiens,9606.0,
6934,1,,BAO_0000219,Intermediate,,16317,Inhibition of cell growth in human ovarian carcinoma cell line (A2780) using the 96 hour continuous exposure sulforhodamine B (SRB) growth delay assay,F,,,Homo sapiens,9606.0,
6935,1,,BAO_0000219,Intermediate,,15748,The compound was tested for cytotoxic activity against A2780 cell line(human ovarian carcinoma ),F,,,Homo sapiens,9606.0,
6936,1,,BAO_0000219,Expert,,16597,Inhibition of A2780 / DDP-R human ovarian carcinoma cell proliferation,F,,,Homo sapiens,9606.0,
6937,1,,BAO_0000219,Expert,,16597,Inhibition of A2780 / TAX-R human ovarian carcinoma cell proliferation,F,,,Homo sapiens,9606.0,
6938,1,,BAO_0000219,Expert,,16597,Inhibition of A2780 / TAX-S human ovarian carcinoma cell proliferation,F,,,Homo sapiens,9606.0,
6939,1,,BAO_0000219,Intermediate,,15608,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 2,F,,,Homo sapiens,9606.0,
6940,1,,BAO_0000219,Intermediate,,15608,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 3,F,,,Homo sapiens,9606.0,
6941,1,,BAO_0000219,Intermediate,,15608,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 5,F,,,Homo sapiens,9606.0,
6942,0,,BAO_0000019,Autocuration,,15296,Cytotoxicity on AA8 cell growth (reduce cell number by 50%).,F,,,Cricetulus griseus,10029.0,
6943,0,,BAO_0000219,Autocuration,,10251,Evaluated for cytotoxicity under aerobic conditions against AA8 cells using microassay,A,,,Cricetulus griseus,10029.0,
6944,0,,BAO_0000219,Autocuration,,10251,Evaluated for growth inhibition of AA8 cells under aerobic conditions,F,,,Cricetulus griseus,10029.0,
6945,0,,BAO_0000219,Autocuration,,10251,Evaluated for growth inhibition of AA8 cells under aerobic or hypoxic conditions,F,,,Cricetulus griseus,10029.0,
6946,0,,BAO_0000219,Autocuration,,10251,Evaluated for growth inhibition of AA8 cells under aerobic or hypoxic conditions (air/N2),F,,,Cricetulus griseus,10029.0,
6947,0,,BAO_0000019,Autocuration,,11858,Growth inhibition against CHO-derived cell line AA8,F,,,Cricetulus griseus,10029.0,
6948,0,,BAO_0000219,Autocuration,,11858,Growth inhibition against CHO-derived cell line AA8 (Non toxic at solubility limit) [RB6145 used as positive control],F,,,Cricetulus griseus,10029.0,
6949,1,,BAO_0000219,Expert,,11616,Growth inhibition in CHO subline AA8 cells exposed for 18 hr under aerobic(air) conditions,F,,,hampster,36483.0,
6950,1,,BAO_0000219,Expert,,11616,Growth inhibitory activity against CHO subline AA8 cells exposed for 18 hr under aerobic conditions,F,,,Cricetulus griseus,10029.0,
6951,0,,BAO_0000219,Autocuration,,10518,Tested for the concentration of the drug to reduce cell numbers to 50 percent of controls against AA8 cells in the microassay,F,,,Cricetulus griseus,10029.0,
6952,0,,BAO_0000219,Autocuration,,11396,Growth inhibition of aerobic chinese hamster ovary fibroblast AA8 cell line using an exposure time of 18 hours,F,,,Cricetulus griseus,10029.0,
6953,0,,BAO_0000219,Autocuration,,10518,IC50 (air/N2) ratio of the drug to reduce cell numbers to 50 percent of controls using AA8 cells in the microassay,F,,,Cricetulus griseus,10029.0,
6954,1,,BAO_0000219,Expert,,11616,In vitro therapeutic index as ratio of CT10 and C1.3 calculated for AA8 cells.,F,,,Cricetulus griseus,10029.0,
6955,8,,BAO_0000019,Autocuration,,14837,compound was evaluated for association constant (Ka) of isolated serum protein AAG,F,,,,,
6956,8,,BAO_0000019,Autocuration,,14837,Number of binding sites (n) of isolated serum protein AAG,F,,,,,
6957,3,,BAO_0000225,Intermediate,,16037,Association constant for binding to AATT duplex,B,,,,,
6958,1,,BAO_0000219,Expert,,16597,Inhibition of ABAE human fibroblast cell proliferation,F,,,Homo sapiens,9606.0,
6959,1,,BAO_0000218,Intermediate,,8831,"Compound was evaluated for the antitumor activity against AC755 breast carcinoma for ip administration and daily x 10 schedule; Number of toxic deaths over total number of mice per group (T/C), 1/7 at dose of 25 mg/kg",F,,,Mus musculus,10090.0,
6960,9,,BAO_0000218,Expert,,13419,Percent change in total cholesterol(TC) versus (T0)- at which drug intervention begins at a dose of 25 mg/kg in the chronic cholesterol-fed rabbit model,F,,,Oryctolagus cuniculus,9986.0,
6961,9,,BAO_0000218,Expert,,13419,Oral bioactivity expressed as %inhibition after 4 hours of drug administration (dose 25 mg/kg) in rabbit bioassay,F,In vivo,,Oryctolagus cuniculus,9986.0,
6962,8,,BAO_0000357,Autocuration,,15778,Inhibitory activity against angiotensin-converting enzyme (ACE).,B,,,,,
6963,8,,BAO_0000357,Autocuration,,15778,oral activity against angiotensin -converting enzyme ( ACE) and neutral endopeptidase in mouse.,B,,,,,
6964,1,,BAO_0000219,Intermediate,,12988,Effect against HIV-1 chronically infected promonocytic cell line ACH-2 cells,F,,,Homo sapiens,9606.0,
6965,1,,BAO_0000219,Intermediate,,12988,Effect against HIV-1 chronically infected promonocytic cell line ACH-2 cells in the presence of PMA(phorbol 12-myristate 13-acetate),F,,,Homo sapiens,9606.0,
6966,0,,BAO_0000219,Autocuration,,12988,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2,F,,,Human immunodeficiency virus 1,11676.0,
6967,0,,BAO_0000219,Autocuration,,12988,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2 in the presence of PMA(phorbol 12-myristate 13-acetate),F,,,Human immunodeficiency virus 1,11676.0,
6968,0,,BAO_0000219,Autocuration,,12988,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2i n the presence of PMA(phorbol 12-myristate 13-acetate),F,,,Human immunodeficiency virus 1,11676.0,
6969,1,,BAO_0000219,Intermediate,,11843,Inhibition of growth of renal cancer ACHN cell line,F,,,Homo sapiens,9606.0,
6970,1,,BAO_0000219,Intermediate,,16939,Inhibition of growth of ACHN renal cancer cell line,F,,,Homo sapiens,9606.0,
6971,1,,BAO_0000219,Intermediate,,4782,Inhibitory concentration required against ACHN renal cancer cell line,F,,,Homo sapiens,9606.0,
6972,1,,BAO_0000219,Expert,,6310,Concentration required to inhibit growth of human renal (ACHN) cell line,F,,,Homo sapiens,9606.0,
6973,1,,BAO_0000219,Intermediate,,6310,Concentration required to inhibit growth of human renal (ACHN) cell line; nt = not tested,F,,,Homo sapiens,9606.0,
6974,1,,BAO_0000219,Intermediate,,12858,Cytotoxic activity against ACHN Renal cancer cell line,F,,,Homo sapiens,9606.0,
6975,1,,BAO_0000219,Intermediate,,17380,Cytotoxicity evaluation against ACHN renal cancer cells,F,,,Homo sapiens,9606.0,
6976,1,,BAO_0000219,Intermediate,,5858,In vitro antitumor activity against human renal ACHN cell line,F,,,Homo sapiens,9606.0,
6977,1,,BAO_0000219,Intermediate,,3838,In vitro growth inhibition of compound was determined against ACHN cell lines of Renal cancer,F,,,Homo sapiens,9606.0,
6978,1,,BAO_0000219,Intermediate,,3838,In vitro growth inhibition of compound was determined against ACHN cell lines of Renal cancer,F,,,Homo sapiens,9606.0,
6979,1,,BAO_0000219,Intermediate,,5406,"Tested for the cytotoxicity against the Renal cancer cell line ACHN, growth inhibition by 50% is reported",F,,,Homo sapiens,9606.0,
6980,1,,BAO_0000219,Intermediate,,4071,The compound was tested in vitro for cytotoxicity against human tumor cell line ACHN (renal).,F,,,Homo sapiens,9606.0,
6981,1,,BAO_0000219,Expert,,4071,Tested in vitro for cytotoxicity against human tumor cell line ACHN (renal).,F,,,Homo sapiens,9606.0,
6982,1,,BAO_0000219,Intermediate,,4071,The compound was tested in vitro for cytotoxicity against human tumor cell line ACHN (renal); Not determined,F,,,Homo sapiens,9606.0,
6983,1,,BAO_0000219,Intermediate,,15002,Antitumor activity was evaluated against human renal adenocarcinoma cell line ACHN.,F,,,Homo sapiens,9606.0,
6984,1,,BAO_0000219,Intermediate,,14769,Compound was evaluated for in vitro activity against ACHN kidney cell lines (Human tumor cells ),F,,,Homo sapiens,9606.0,
6985,1,,BAO_0000219,Intermediate,,13958,"Compound was tested for antiproliferative activity against ACHN, human renal adenocarcinoma",F,,,Homo sapiens,9606.0,
6986,1,,BAO_0000219,Intermediate,,1665,Compound was tested for its effect on the proliferation of ACHN human kidney adenocarcinoma,F,,,Homo sapiens,9606.0,
6987,1,,BAO_0000219,Intermediate,,15354,Compound was tested for the growth inhibition of ACHN renal tumor cell line,F,,,Homo sapiens,9606.0,
6988,1,,BAO_0000219,Intermediate,,15354,Compound was tested for the growth inhibition of ACHN renal tumor cell line; ND=Not determined,F,,,Homo sapiens,9606.0,
6989,1,,BAO_0000219,Intermediate,,13978,In vitro Growth Inhibitory activity against ACHN Human kidney cancer cell line,F,,,Homo sapiens,9606.0,
6990,1,,BAO_0000219,Intermediate,,6798,In vitro cytotoxicity against human renal adenocarcinoma (ACHN) tumor cell line,F,,,Homo sapiens,9606.0,
6991,1,,BAO_0000218,Intermediate,,2959,Tmax value after administration of 4 mg/Kg oral dose in dog,A,In vivo,,Canis lupus familiaris,9615.0,
6992,1,,BAO_0000218,Intermediate,,9932,"Time to peak response on lowering of vascular resistance, in dogs when administered intravenously",A,,,Canis lupus familiaris,9615.0,
6993,1,,BAO_0000218,Intermediate,,5546,Unbound plasma was determined in Beagle dog at a dose of 1 mg/kg by iv administration,A,,,Canis lupus familiaris,9615.0,
6994,1,,BAO_0000218,Intermediate,,16907,Volume distribution after 15 mg/kg iv dose in Dogs,A,In vivo,,Canis lupus familiaris,9615.0,
6995,1,,BAO_0000218,Intermediate,,16907,Volume distribution after 30 mg/kg po dose in Dogs,A,In vivo,,Canis lupus familiaris,9615.0,
6996,1,,BAO_0000218,Intermediate,,4257,Volume of distribution was determined in dog after a 3 mg/kg of iv dose,A,In vivo,,Canis lupus familiaris,9615.0,
6997,1,,BAO_0000218,Intermediate,,4305,Volume of distribution was determined by iv administration in dogs at a dose of 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,
6998,1,,BAO_0000218,Intermediate,,5472,Volume of distribution was evaluated in dog,A,In vivo,,Canis lupus familiaris,9615.0,
6999,1,,BAO_0000218,Intermediate,,6062,Terminal phase volume of distribution was measured in dog after an iv dose of 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,
7000,1,,BAO_0000218,Expert,,3598,Apparent volume of the central plasma compartment (Vc) of compound determined in dog after iv administration at a dose of 10 mg/kg,A,,,Canis lupus familiaris,9615.0,
7001,1,,BAO_0000218,Intermediate,,12500,The compound was tested for volume of distribution in dog,A,In vivo,,Canis lupus familiaris,9615.0,
7002,1,,BAO_0000218,Intermediate,,12500,The compound was tested for volume of distribution in dog at dose of 3-10 mgkg,A,In vivo,,Canis lupus familiaris,9615.0,
7003,1,,BAO_0000218,Intermediate,,6227,Vd (1 mg/kg) was determined in dog (in vivo),A,In vivo,,Canis lupus familiaris,9615.0,
7004,1,,BAO_0000218,Intermediate,,6227,Vd in dog,A,In vivo,,Canis lupus familiaris,9615.0,
7005,1,,BAO_0000218,Intermediate,,4219,Volume distribution was determined,A,In vivo,,Canis lupus familiaris,9615.0,
7006,1,,BAO_0000218,Intermediate,,1696,Volume of distribution in dog,A,In vivo,,Canis lupus familiaris,9615.0,
7007,1,,BAO_0000218,Intermediate,,5542,Volume of distribution by as 4 fold increase by iv administration in dogs,A,In vivo,,Canis lupus familiaris,9615.0,
7008,1,,BAO_0000218,Intermediate,,5199,Volume of distribution was determined in canine following intravenous (iv) administration of drug (1 mg/kg).,A,In vivo,,Canis lupus familiaris,9615.0,
7009,1,,BAO_0000218,Intermediate,,6348,Volume of distribution was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,A,In vivo,,Canis lupus familiaris,9615.0,
7010,1,,BAO_0000218,Intermediate,,4727,Volume distribution at the dose of 2 mg/kg in dog,A,In vivo,,Canis lupus familiaris,9615.0,
7011,1,,BAO_0000218,Intermediate,,16367,Steady state volume of distribution was determined,A,In vivo,,Canis lupus familiaris,9615.0,
7012,1,,BAO_0000218,Intermediate,,2652,Bioavailability as Vdss in dogs at 1 mg/kg intravenous dose,A,In vivo,,Canis lupus familiaris,9615.0,
7013,1,,BAO_0000218,Intermediate,,16452,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,A,In vivo,,Canis lupus familiaris,9615.0,
7014,1,,BAO_0000218,Intermediate,,16452,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,A,In vivo,,Canis lupus familiaris,9615.0,
7015,1,,BAO_0000218,Intermediate,,16452,Bioavailability in dog (dose 1 mg/kg i.v.),A,In vivo,,Canis lupus familiaris,9615.0,
7016,1,,BAO_0000218,Intermediate,,5334,Pharmacokinetic parameter volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),A,In vivo,,Canis lupus familiaris,9615.0,
7017,1,,BAO_0000218,Intermediate,,4239,Pharmacokinetic property (vdss) was measured in dog,A,In vivo,,Canis lupus familiaris,9615.0,
7018,1,,BAO_0000218,Intermediate,,4709,Steady state volume of distribution for the compound after intravenous administration of 1 mg/kg in dog,A,In vivo,,Canis lupus familiaris,9615.0,
7019,1,,BAO_0000218,Intermediate,,5600,Vdss was determined after iv 0.1 mg/kg administration in dog,A,In vivo,,Canis lupus familiaris,9615.0,
7020,1,,BAO_0000218,Intermediate,,6057,Volume displacement was calculated in dog,A,In vivo,,Canis lupus familiaris,9615.0,
7021,1,,BAO_0000218,Intermediate,,5654,Volume distribution (Vdss) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,
7022,1,,BAO_0000218,Intermediate,,5505,Volume distribution constant was determined,A,In vivo,,Canis lupus familiaris,9615.0,
7023,1,,BAO_0000218,Intermediate,,4527,Volume distribution at a dose of 1 uM/kg in dog was determined,A,In vivo,,Canis lupus familiaris,9615.0,
7024,1,,BAO_0000218,Intermediate,,4521,Volume distribution in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,A,In vivo,,Canis lupus familiaris,9615.0,
7025,1,,BAO_0000218,Intermediate,,4521,Volume distribution in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,A,In vivo,,Canis lupus familiaris,9615.0,
7026,1,,BAO_0000218,Intermediate,,15660,Volume distribution (Vdss) was measured in dog,A,In vivo,,Canis lupus familiaris,9615.0,
7027,1,,BAO_0000218,Intermediate,,15660,Volume distribution (Vdss) was measured in dog,A,In vivo,,Canis lupus familiaris,9615.0,
7028,1,,BAO_0000218,Intermediate,,6679,Volume of distribution at steady state was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,A,In vivo,,Canis lupus familiaris,9615.0,
7029,1,,BAO_0000218,Intermediate,,5145,Volume of distribution in steady state was determined in dog,A,In vivo,,Canis lupus familiaris,9615.0,
7030,1,,BAO_0000218,Intermediate,,6821,Volume of distribution of compound was determined in dog,A,In vivo,,Canis lupus familiaris,9615.0,
7031,1,,BAO_0000218,Intermediate,,4137,Volume of distribution after intravenous administration of 1 mg/kg/h in dog,A,In vivo,,Canis lupus familiaris,9615.0,
7032,1,,BAO_0000218,Intermediate,,5334,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Beagle dog (male),A,In vivo,,Canis lupus familiaris,9615.0,
7033,1,,BAO_0000218,Intermediate,,15660,Volume of distribution (Vdss) was measured in dog,A,In vivo,,Canis lupus familiaris,9615.0,
7034,1,,BAO_0000218,Intermediate,,6642,Volumes of distribution in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),A,In vivo,,Canis lupus familiaris,9615.0,
7035,1,,BAO_0000218,Intermediate,,6641,Volumes of distribution in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),A,In vivo,,Canis lupus familiaris,9615.0,
7036,1,,BAO_0000218,Intermediate,,6642,Volumes of distribution in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),A,In vivo,,Canis lupus familiaris,9615.0,
7037,1,,BAO_0000218,Intermediate,,11659,Maximum rate of depolarization of the upstroke of the action potential,A,,,Canis lupus familiaris,9615.0,
7038,1,,BAO_0000218,Intermediate,,6448,Steady state volume distribution in dog,A,In vivo,,Canis lupus familiaris,9615.0,
7039,1,,BAO_0000218,Intermediate,,5474,Steady state volume of distribution at a dose of 0.2 mg/kg i.v.,A,In vivo,,Canis lupus familiaris,9615.0,
7040,1,,BAO_0000218,Intermediate,,1466,Tested for volume of distribution at steady state upon intravenous administration of 5.0 mg/Kg dose in dog,A,In vivo,,Canis lupus familiaris,9615.0,
7041,1,,BAO_0000218,Intermediate,,6535,Volume distribution in dog after administration of 0.25 mg/kg iv; ND = not determined,A,In vivo,,Canis lupus familiaris,9615.0,
7042,1,,BAO_0000218,Intermediate,,6535,Volume distribution in dog after administration of 1 mg/kg iv,A,In vivo,,Canis lupus familiaris,9615.0,
7043,1,,BAO_0000218,Intermediate,,17764,Volume of solubility in solution after intravenous administration in dogs at 1.2 uM/kg,A,In vivo,,Canis lupus familiaris,9615.0,
7044,1,,BAO_0000218,Intermediate,,6215,Vss after intravenous administration (0.5 mg/kg) was determined in dog,A,In vivo,,Canis lupus familiaris,9615.0,
7045,1,,BAO_0000218,Intermediate,,6505,Vss on i.v. administration of 2 mg/kg was measured in dog,A,In vivo,,Canis lupus familiaris,9615.0,
7046,1,,BAO_0000218,Intermediate,,3639,Vss was determined,A,,,Canis lupus familiaris,9615.0,
7047,1,,BAO_0000218,Intermediate,,3639,Vss in dog,A,,,Canis lupus familiaris,9615.0,
7048,1,,BAO_0000218,Intermediate,,6062,Volume of distribution was measured in dog after an iv dose of 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,
7049,1,,BAO_0000218,Intermediate,,4942,Volume distribution in dogs,A,In vivo,,Canis lupus familiaris,9615.0,
7050,1,,BAO_0000218,Intermediate,,17796,Volume of distribution in dog,A,In vivo,,Canis lupus familiaris,9615.0,
7051,1,,BAO_0000218,Intermediate,,4883,Tested for the oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,
7060,1,,BAO_0000218,Intermediate,,17837,Bioavailability of compound in mouse blood following p.o. administration of 30 mg/kg,A,In vivo,,Mus musculus,10090.0,
7061,1,,BAO_0000218,Intermediate,,17729,Bioavailability after i.p. administration of 50 mg/kg of dose in mice,A,In vivo,,Mus musculus,10090.0,
7062,1,,BAO_0000218,Intermediate,,17729,Bioavailability after peroral administration of 50 mg/kg of dose in mice,A,In vivo,,Mus musculus,10090.0,
7063,1,,BAO_0000218,Intermediate,,4239,Bioavailability was measured in mouse,A,In vivo,,Mus musculus,10090.0,
7064,1,,BAO_0000218,Intermediate,,17592,Bioavailability in mouse,A,In vivo,,Mus musculus,10090.0,
7065,1,,BAO_0000218,Intermediate,,6348,Bioavailability was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,A,In vivo,,Mus musculus,10090.0,
7066,1,,BAO_0000218,Intermediate,,2801,Bioavailability in mouse,A,In vivo,,Mus musculus,10090.0,
7067,1,,BAO_0000218,Intermediate,,2801,Compound was evaluated for its bioavailability in mice at a dose of 1 mg/kg,A,In vivo,,Mus musculus,10090.0,
7068,1,,BAO_0000218,Intermediate,,17718,Oral bioavailability in mouse,A,In vivo,,Mus musculus,10090.0,
7069,1,,BAO_0000218,Intermediate,,5727,Oral availability at 50 mg/kg po in male mice,A,In vivo,,Mus musculus,10090.0,
7070,1,,BAO_0000218,Intermediate,,5302,Oral bioavailability in mouse (dose 10 mg/kg),A,In vivo,,Mus musculus,10090.0,
7071,1,,BAO_0000218,Expert,,3598,Oral bioavailability of compound determined in mouse after iv administration at a dose of 10 mg/kg,A,In vivo,,Mus musculus,10090.0,
7072,1,,BAO_0000218,Intermediate,,5961,"Bioavailability in male mice, 2mg/kg oral and 1 mg/kg intravenous dose",A,In vivo,,Mus musculus,10090.0,
7074,1,,BAO_0000218,Intermediate,,6091,Oral bioavailability in mouse,A,In vivo,,Mus musculus,10090.0,
7075,1,,BAO_0000218,Intermediate,,6091,Oral bioavailability in vivo in mice;ND=Not determined,A,In vivo,,Mus musculus,10090.0,
7076,1,,BAO_0000218,Intermediate,,5711,Oral bioavailability in mouse at 10 mg/kg of the compound,A,In vivo,,Mus musculus,10090.0,
7077,1,,BAO_0000218,Intermediate,,17728,Bioavailability in mouse (BALB/C) (dose 50 mg/kg i.p.),A,In vivo,,Mus musculus,10090.0,
7078,1,,BAO_0000218,Intermediate,,17728,Bioavailability in mouse (BALB/C) (dose 20 mg/kg i.v.),A,In vivo,,Mus musculus,10090.0,
7079,1,,BAO_0000218,Intermediate,,3802,Tested for bioavailability of the compound,A,In vivo,,Mus musculus,10090.0,
7080,1,,BAO_0000218,Intermediate,,3802,Tested for half life at the dose of 10 mg/kg when administered intravenously,A,In vivo,,Mus musculus,10090.0,
7081,1,,BAO_0000218,Intermediate,1969.0,14029,The plasma half life of compound was determined on EDTA prepared by mouse plasma. ,A,,,Mus musculus,10090.0,
7082,1,,BAO_0000218,Intermediate,1969.0,14029,The plasma half life of compound was determined on heparin prepared by human plasma. ,A,,,Mus musculus,10090.0,
7083,1,,BAO_0000218,Intermediate,1969.0,14029,The plasma half life of compound was determined on heparin prepared by human plasma; Not degraded,A,,,Mus musculus,10090.0,
7084,1,,BAO_0000218,Intermediate,1969.0,14029,The plasma half life of compound was determined on heparin prepared by mouse plasma. ,A,,,Mus musculus,10090.0,
7085,1,,BAO_0000218,Intermediate,1969.0,14029,The plasma half life of compound was determined on heparin prepared by mouse plasma; Not degraded,A,,,Mus musculus,10090.0,
7086,1,,BAO_0000218,Intermediate,,17753,Inhibitory concentration of compound was determined after intravenous administration in mice after 6 hours of exposure at 40 mg/Kg,F,,,Mus musculus,10090.0,
7087,1,,BAO_0000218,Intermediate,,17753,Inhibitory concentration of compound was determined after intravenous administration in mice after 8 hours of exposure at 24 mg/Kg,A,,,Mus musculus,10090.0,
7088,1,,BAO_0000218,Intermediate,,17753,Inhibitory concentration of compound was determined after intravenous administration in mice after 8 hours of exposure at 5 mg/Kg,A,,,Mus musculus,10090.0,
7089,1,,BAO_0000218,Intermediate,178.0,10107,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,A,In vivo,,Mus musculus,10090.0,
7090,1,,BAO_0000218,Intermediate,178.0,10107,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,A,In vivo,,Mus musculus,10090.0,
7091,1,,BAO_0000218,Intermediate,178.0,10107,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,A,In vivo,,Mus musculus,10090.0,
7092,1,,BAO_0000218,Intermediate,178.0,10107,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,A,In vivo,,Mus musculus,10090.0,
7093,1,,BAO_0000218,Intermediate,178.0,10107,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,A,In vivo,,Mus musculus,10090.0,
7094,1,,BAO_0000218,Intermediate,178.0,10107,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,A,In vivo,,Mus musculus,10090.0,
7095,1,,BAO_0000218,Intermediate,178.0,10107,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,A,In vivo,,Mus musculus,10090.0,
7096,1,,BAO_0000218,Intermediate,10000001.0,10107,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,A,In vivo,,Mus musculus,10090.0,
7097,1,,BAO_0000218,Intermediate,10000001.0,10107,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,A,In vivo,,Mus musculus,10090.0,
7098,1,,BAO_0000219,Intermediate,,15608,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 8,F,,,Homo sapiens,9606.0,
7099,1,,BAO_0000219,Expert,,3290,In vitro cytotoxicity against human ovarian carcinoma cell line A2780 using sulforhodamine B (SRB) assay,F,,,Homo sapiens,9606.0,
7100,1,,BAO_0000219,Intermediate,,2859,Compound was evaluated for cytotoxicity against A2780 cell line,F,,,Homo sapiens,9606.0,
7101,1,,BAO_0000219,Expert,,15688,Inhibition of A2780 cell clonogenic assay,F,,,Homo sapiens,9606.0,
7102,1,,BAO_0000219,Expert,,5642,Cytotoxic effect on ovarian cancer cell line (A2780),F,,,Homo sapiens,9606.0,
7103,1,,BAO_0000219,Intermediate,,6633,Concentration required to inhibit A2780 cell growth when compared with control after incubation for 96 hr at 37 C,F,,,Homo sapiens,9606.0,
7104,1,,BAO_0000219,Intermediate,,3906,"MDR-reversing activity was measured by vincristine accumulation in the multidrug resistant 2780AD, a subline of A2780 ovarian carcinoma cells at 10 mg/mL",F,,,Homo sapiens,9606.0,
7105,1,,BAO_0000219,Expert,,6788,50% growth inhibition of A2780 (Human ovarian carcinoma) cell line compared with untreated control cells,F,,,Homo sapiens,9606.0,
7106,1,,BAO_0000219,Expert,,17582,Antiproliferative activity against human A2780 cells,F,,,Homo sapiens,9606.0,
7107,1,,BAO_0000219,Expert,,17764,Inhibition of human A2780 cell proliferation,F,,,Homo sapiens,9606.0,
7108,1,,BAO_0000219,Expert,,17764,Antiproliferative effect against human A2780 cell line was determined in a whole cell 72 hr cytotoxicity assay,F,,,Homo sapiens,9606.0,
7109,1,,BAO_0000219,Expert,,17764,Inhibition of human A2780 cell proliferation (No data),F,,,Homo sapiens,9606.0,
7110,1,,BAO_0000219,Intermediate,,2815,Cell cytotoxicity was determined against human ovarian cancer (A2780) cell line,F,,,Homo sapiens,9606.0,
7111,1,,BAO_0000219,Intermediate,,16930,Compound was evaluated against human Ovarian carcinoma cell line A2780,F,,,Homo sapiens,9606.0,
7112,1,,BAO_0000219,Expert,,17777,Growth inhibition against A2780 wild-type ovarian cell lines,F,,,Homo sapiens,9606.0,
7113,1,,BAO_0000219,Intermediate,,17777,Compound was evaluated for growth inhibition against A2780 wild-type ovarian cell lines; No data,F,,,Homo sapiens,9606.0,
7114,5,,BAO_0000019,Autocuration,,16936,Inhibition of tubulin polymerization in human ovarian cancer cell lines,F,,,Homo sapiens,9606.0,
7115,1,,BAO_0000219,Intermediate,,13759,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780,F,,,Homo sapiens,9606.0,
7116,1,,BAO_0000219,Intermediate,,13759,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780-R,F,,,Homo sapiens,9606.0,
7117,1,,BAO_0000219,Intermediate,,13759,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780,F,,,Homo sapiens,9606.0,
7118,1,,BAO_0000219,Intermediate,,13759,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780-R,F,,,Homo sapiens,9606.0,
7119,1,,BAO_0000219,Intermediate,,15292,Compound was tested for inhibitory activity against A2780 human ovarian carcinoma cell line; activity expressed in Mean IC50 values,F,,,Homo sapiens,9606.0,
7120,1,,BAO_0000219,Intermediate,,15292,Compound was tested for inhibitory activity against A2780cisR human ovarian carcinoma cell line; activity expressed in Mean IC50 values,F,,,Homo sapiens,9606.0,
7121,1,,BAO_0000219,Expert,,15069,In vitro inhibition of human ovarian cell line A2780,F,,,Homo sapiens,9606.0,
7122,1,,BAO_0000219,Expert,,15069,"In vitro inhibition of human ovarian cell line, resistant to cisplatin (A2780cisR).",F,,,Homo sapiens,9606.0,
7123,1,,BAO_0000219,Intermediate,,14073,Concentration of compound to inhibit the growth of human A2780 ovarian carcinoma cells(in vitro),F,,,Homo sapiens,9606.0,
7124,1,,BAO_0000219,Expert,,14553,Concentration required to inhibit A2780-cell growth by 50%,F,,,Homo sapiens,9606.0,
7125,1,,BAO_0000219,Expert,,13040,Concentration required to inhibit the cell growth by 50 % after 96 hr A2780 leukemic cells.,F,,,Homo sapiens,9606.0,
7126,1,,BAO_0000219,Expert,,6891,Cytotoxic effect on human ovarian (A2780) cancer cell line,F,,,Homo sapiens,9606.0,
7127,1,,BAO_0000219,Intermediate,,15569,Cytotoxic activity in a panel of Human ovarian tumor A2780 cell line after 96h of drug exposure,F,,,Homo sapiens,9606.0,
7128,1,,BAO_0000219,Expert,,14190,Cytotoxic potency required to inhibit A2780 cell growth by 50% after cell drug contact for 96 hrs,F,,,Homo sapiens,9606.0,
7129,1,,BAO_0000219,Expert,,15014,Cytotoxicity measured in human ovarian cell line A2780 using sulforhodamine B (SRB) assay,F,,,Homo sapiens,9606.0,
7130,1,,BAO_0000219,Intermediate,,15014,Cytotoxicity activity of the compound was measured in human ovarian cell line A2780 using sulforhodamine B (SRB) assay,F,,,Homo sapiens,9606.0,
7131,1,,BAO_0000219,Intermediate,,17496,Cytotoxicity against human ovarian carcinoma A2780 cell line,F,,,Homo sapiens,9606.0,
7132,1,,BAO_0000219,Intermediate,,13617,"Cytotoxicity against A2780-C25, oxaliplatin-resistant Ovarian carcinoma cell line",F,,,Homo sapiens,9606.0,
7133,1,,BAO_0000219,Intermediate,,13617,"Cytotoxicity against A2780-CP3, cisplatin-resistant Ovarian carcinoma cell line",F,,,Homo sapiens,9606.0,
7134,1,,BAO_0000219,Intermediate,,13617,"Cytotoxicity against A2780-DX5, Doxorubicin-resistant Ovarian carcinoma cell line",F,,,Homo sapiens,9606.0,
7135,1,,BAO_0000219,Intermediate,,13617,"Cytotoxicity against A2780-WT, human ovarian carcinoma cell line",F,,,Homo sapiens,9606.0,
7136,1,,BAO_0000219,Intermediate,,17672,Cytotoxicity against ovarian carcinoma A2780 tumor cell lines,F,,,Homo sapiens,9606.0,
7137,1,,BAO_0000219,Intermediate,,4544,Dose of required to inhibit growth of cisplatin resistant human ovarian carcinoma (A2780 cisR) cell line with compound free controls as measured by the sulforhodamine B growth delay assay,F,,,Homo sapiens,9606.0,
7138,1,,BAO_0000219,Intermediate,,4544,Dose of required to inhibit growth of human ovarian carcinoma (A2780) cell line with compound free controls as measured by the sulforhodamine B growth delay assay,F,,,Homo sapiens,9606.0,
7139,1,,BAO_0000219,Intermediate,,16317,"Growth inhibition in human ovarian carcinoma cell line (A2780cisR,cisplatin-resistant) using the 96 hour exposure sulforhodamine B (SRB) growth delay assay",F,,,Homo sapiens,9606.0,
7140,1,,BAO_0000219,Intermediate,,15099,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780,F,,,Homo sapiens,9606.0,
7141,1,,BAO_0000219,Intermediate,,13978,In vitro Growth Inhibitory activity against A2780 Human ovarian cancer cell line,F,,,Homo sapiens,9606.0,
7142,1,,BAO_0000219,Expert,,12989,In vitro antitumor activity against A2780 cell line.,F,,,Homo sapiens,9606.0,
7143,1,,BAO_0000219,Intermediate,,5574,In vitro cytotoxic activity against human tumor cell line A2780 after incubation for 96 hours,F,,,Homo sapiens,9606.0,
7144,1,,BAO_0000219,Expert,,13528,In vitro cytotoxicity against A2780 human ovarian cancer cell line,F,,,Homo sapiens,9606.0,
7145,1,,BAO_0000219,Intermediate,,12782,Inhibitory activity against kidney A-CHN tumor cell growth in culture,F,,,Homo sapiens,9606.0,
7146,1,,BAO_0000219,Intermediate,,14255,The IC50 value was measured on ACHN cell line in renal tumor type.,F,,,Homo sapiens,9606.0,
7147,1,,BAO_0000219,Intermediate,,16364,Concentration required for killing 50% of cells of renal ACHN cell lines was determined in vitro,F,,,Homo sapiens,9606.0,
7148,1,,BAO_0000219,Expert,,17376,In vitro lethal concentration against most sensitive ACHN cell line,F,,,Homo sapiens,9606.0,
7149,1,,BAO_0000219,Intermediate,,12016,Tested for cytotoxic activity against renal cancer ACHN cell line,F,,,Homo sapiens,9606.0,
7150,1,,BAO_0000219,Intermediate,,6058,Compound tested for growth inhibition of renal cancer cell line ACHN,F,,,Homo sapiens,9606.0,
7151,1,,BAO_0000219,Intermediate,,17708,Compound was tested for 50% growth inhibition against human renal cancer ACHN cell line,F,,,Homo sapiens,9606.0,
7152,1,,BAO_0000219,Intermediate,,15176,Growth inhibition of the ACHN Renal cancer cell line for 2-day in vitro assay.,F,,,Homo sapiens,9606.0,
7153,1,,BAO_0000219,Intermediate,,2806,In vitro anticancer activity against ACHN renal cancer cell line,F,,,Homo sapiens,9606.0,
7154,1,,BAO_0000219,Intermediate,,15300,In vitro antitumor activity against Renal cancer ACHN cell lines by 6-day assay,F,,,Homo sapiens,9606.0,
7155,1,,BAO_0000219,Intermediate,,16364,Percent selectivity was evaluated in renal ACHN cell lines,F,,,Homo sapiens,9606.0,
7156,1,,BAO_0000219,Intermediate,,13859,In vitro inhibitory activity against renal ACHN cancer cell line,F,,,Homo sapiens,9606.0,
7157,1,,BAO_0000219,Intermediate,,11970,Tested for cytotoxicity against ACHN cell lines in renal cancer,F,,,Homo sapiens,9606.0,
7158,1,,BAO_0000219,Intermediate,,2450,Tested for the in vitro cytotoxicity against ACHN renal cancer cell line,F,,,Homo sapiens,9606.0,
7159,1,,BAO_0000219,Intermediate,,12696,In vitro anti tumor activity against human tumor Renal cancer cell lines was determined,F,,,Homo sapiens,9606.0,
7160,1,,BAO_0000219,Intermediate,,12400,Tested in vitro for cytotoxicity in ACHN cell line of Renal cancer,F,,,Homo sapiens,9606.0,
7161,1,,BAO_0000219,Expert,,12888,Cytotoxic effect on renal cancer line ACHN,F,,,Homo sapiens,9606.0,
7162,1,,BAO_0000219,Intermediate,,3156,In vitro anti-cancer activity against ACHN(Renal) human tumor cell line,F,,,Homo sapiens,9606.0,
7163,1,,BAO_0000219,Intermediate,,3381,In vitro inhibition of Renal Cancer ACHN cell lines,F,,,Homo sapiens,9606.0,
7164,1,,BAO_0000219,Intermediate,,16747,Antitumor activity against human renal adenocarcinoma ACHN cells,F,,,Homo sapiens,9606.0,
7165,1,,BAO_0000219,Expert,,16748,Antitumor activity against human renal adenocarcinoma ACHN cells.,F,,,Homo sapiens,9606.0,
7166,1,,BAO_0000219,Intermediate,,12062,Inhibitory concentration required to decrease cell viability in cell growth culture against kidney cells ACHN,F,,,Homo sapiens,9606.0,
7167,1,,BAO_0000219,Intermediate,,14769,Compound was evaluated for in vitro activity against ACHN kidney cell lines (Human tumor cells ),F,,,Homo sapiens,9606.0,
7168,1,,BAO_0000219,Intermediate,,15895,"Cytotoxicity against NCI tumor panel, ACHN renal cancer cell line",F,,,Homo sapiens,9606.0,
7169,1,,BAO_0000219,Intermediate,,17376,Concentration of compound that cause 50% cytotoxicity of ACHN renal cancer cell line,F,,,Homo sapiens,9606.0,
7170,1,,BAO_0000219,Intermediate,,14882,Compound was tested for antitumor activity against ACHN renal cancer cell line(molar concentration that inhibits 50% net cell growth).,F,,,Homo sapiens,9606.0,
7171,1,,BAO_0000219,Intermediate,,14882,Compound was tested for antitumor activity against ACHN renal cancer cell line(molar concentration leading to 50% net cell death).,F,,,Homo sapiens,9606.0,
7172,1,,BAO_0000219,Intermediate,,15661,Cytotoxicity was tested against renal cancer ACHN tumor cell lines.,F,,,Homo sapiens,9606.0,
7173,0,,BAO_0000019,Autocuration,,9680,Keff is the effective biomolecular rate constant on paraxon for reactivation at pH 7.8 at 25 degree Centigrade,A,,,,,
7174,8,,BAO_0000019,Autocuration,,14579,Compound tested for relative response using 1 uM ACh as agonist against AChM1 receptor.,F,,,,,
7175,1,,BAO_0000218,Expert,,17290,Antiviral activity against AD169 strain of cytomegalovirus (CMV) in HEL (human erythroleukemia) cells.,F,,,Cytomegalovirus,10358.0,
7176,1,,BAO_0000218,Intermediate,,17290,Antiviral activity against AD169 strain of cytomegalovirus (CMV); ND=No data,F,,,Cytomegalovirus,10358.0,
7177,8,,BAO_0000357,Autocuration,,15891,Compound was evaluated for its inhibitory activity against calf intestinal Adenosine deaminase (ADA),B,,,,,
7178,8,,BAO_0000357,Autocuration,,15890,Evaluated for the inhibition of calf intestinal Adenosine deaminase (ADA),B,,,,,
7179,1,,BAO_0000219,Intermediate,,3801,Inhibitory activity against ovarian tumor cell line ADDP after 72 hr continuous exposure to compound,F,,,Bos taurus,9913.0,
7180,1,,BAO_0000219,Intermediate,,9222,Tumor growth inhibition activity after subcutaneous transplanted tumor in ADJ-PC6 plasmacytoma cells,F,,,Mus musculus,10090.0,
7181,1,,BAO_0000219,Intermediate,,9222,Tumor growth inhibition activity after subcutaneously transplanted tumor in ADJ-PC6 plasmacytoma cells,F,,,Mus musculus,10090.0,
7182,1,,BAO_0000219,Intermediate,,7257,"Compound was tested for dose producing 90% reduction in tumor weight, in ADJ/PC6 mouse plasma cell tumor",F,,,Mus musculus,10090.0,
7183,1,,BAO_0000219,Intermediate,,7257,Compound was tested for inhibition against ADJ/PC6 mouse plasma cell tumor at the dose of 320 mg/Kg,F,,,Mus musculus,10090.0,
7184,1,,BAO_0000219,Intermediate,,7257,Compound was tested for dose required to kill 50 % of ADJ/PC6 mouse plasma cell tumor in a group,A,,,Mus musculus,10090.0,
7185,1,,BAO_0000219,Intermediate,,8084,In vitro incorporation of the [3H]thymidine into the ADJ/PC6 Plasmacytoma cells,F,,,Mus musculus,10090.0,
7186,0,,BAO_0000019,Autocuration,,14943,Tested for cytotoxicity against ADJ/PC6 mouse plasmacytoma,F,,,Mus musculus,10090.0,
7187,0,,BAO_0000019,Autocuration,,14943,The compound was tested for cytotoxicity against ADJ/PC6 mouse plasmacytoma; Not determined,F,,,Mus musculus,10090.0,
7188,0,,BAO_0000019,Autocuration,,14943,Tested for cytotoxicity against ADJ/PC6 plasmacytoma,F,,,Mus musculus,10090.0,
7189,0,,BAO_0000218,Autocuration,,10524,Maximum concentration determined against Bacillus subtilis ATCC 6633 after oral administration in dog(25 mg/kg),A,In vivo,,Bacillus subtilis,1423.0,
7190,1,,BAO_0000218,Intermediate,1969.0,3546,AUC value in dog after IV administration at a dose of 5 mg/kg,A,,,Canis lupus familiaris,9615.0,
7191,1,,BAO_0000218,Intermediate,1969.0,3546,AUC value in dog after oral administration at a dose of 5 mg/kg,A,,,Canis lupus familiaris,9615.0,
7192,1,,BAO_0000218,Intermediate,,3546,Cmax value in dog after oral administration at a dose of 5 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,
7193,1,,BAO_0000218,Intermediate,,3546,Bioavailability in dog after oral administration at a dose of 5 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,
7194,1,,BAO_0000218,Intermediate,,3546,Tmax value in dog after oral administration at a dose of 5 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,
7195,1,,BAO_0000218,Intermediate,,3184,Compound was evaluated for its clearance when administered intravenously in dog,A,In vivo,,Canis lupus familiaris,9615.0,
7196,1,,BAO_0000218,Intermediate,,16456,Plasma clearance in Beagle dogs after intravenous administration at a dose of 10 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,
7197,1,,BAO_0000218,Intermediate,,4809,Plasma clearance was determined in Beagle dogs after (iv) administration of a dose of 12 (uM/kg),A,In vivo,,Canis lupus familiaris,9615.0,
7198,0,,BAO_0000100,Intermediate,,4219,Calculated partition coefficient (clogP),P,,,,,
7199,1,,BAO_0000218,Intermediate,,3748,Half life in dog,A,,,Canis lupus familiaris,9615.0,
7200,1,,BAO_0000218,Intermediate,,3132,Time taken for EC90 was determined when tested in dog,A,,,Canis lupus familiaris,9615.0,
7201,1,,BAO_0000218,Intermediate,,4219,Half life (iv) was determined,A,,,Canis lupus familiaris,9615.0,
7202,1,,BAO_0000218,Intermediate,2107.0,16907,Loss of compound (%metabolized) after 30 min exposure to human liver microsomes,A,,,Canis lupus familiaris,9615.0,
7203,1,,BAO_0000218,Intermediate,,6057,Area under the curve was calculated in dog after iv administration,A,,,Canis lupus familiaris,9615.0,
7204,1,,BAO_0000218,Intermediate,,6057,Area under the curve was calculated in dog after peroral administration,A,,,Canis lupus familiaris,9615.0,
7205,1,,BAO_0000218,Intermediate,,17853,Dose-normalized area under curve in dog (p.o.) at 2.0 mpk,A,,,Canis lupus familiaris,9615.0,
7206,1,,BAO_0000218,Intermediate,,3639,pKa was evaluated in dog,A,,,Canis lupus familiaris,9615.0,
7207,1,,BAO_0000218,Intermediate,,14541,Compound was evaluated for pronounced GH response at 100 mg (n=6)(area under concentration curve was determined from 0-8 hr following morning and evening dosing with 25 mg of the compound,A,,,Canis lupus familiaris,9615.0,
7208,1,,BAO_0000218,Intermediate,,16456,Alpha-elimination half-life in Beagle dogs after intravenous administration at a dose of 10 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,
7209,1,,BAO_0000218,Intermediate,,16456,Beta-elimination half-life in Beagle dogs after intravenous administration at a dose of 10 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,
7210,1,,BAO_0000218,Intermediate,,2652,Compound was evaluated for half-life period in dogs at a dose of 5 mpk perorally,A,In vivo,,Canis lupus familiaris,9615.0,
7211,1,,BAO_0000218,Intermediate,,3624,Compound was evaluated for the half-life (t 1/2) in hours,A,,,Canis lupus familiaris,9615.0,
7212,1,,BAO_0000218,Intermediate,178.0,1337,Half life to reach the blood concentration was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,A,In vivo,,Canis lupus familiaris,9615.0,
7213,1,,BAO_0000218,Intermediate,178.0,1337,Half life to reach the blood concentration was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,A,In vivo,,Canis lupus familiaris,9615.0,
7214,1,,BAO_0000218,Intermediate,,4709,Half life after intravenous administration of 1 mg/kg in dog,A,In vivo,,Canis lupus familiaris,9615.0,
7215,1,,BAO_0000218,Intermediate,,15660,Half life was measured in dog,A,,,Canis lupus familiaris,9615.0,
7216,1,,BAO_0000218,Intermediate,,5302,Half life period in dog after 5 mg/kg dose,A,In vivo,,Canis lupus familiaris,9615.0,
7217,1,,BAO_0000218,Intermediate,,17791,Half life period was evaluated in dog; 4-4.8,A,,,Canis lupus familiaris,9615.0,
7218,1,,BAO_0000218,Intermediate,,6348,Half life was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,A,In vivo,,Canis lupus familiaris,9615.0,
7219,1,,BAO_0000218,Intermediate,,4257,Half-life was determined in dog after a3 mg/kg of iv dose,A,In vivo,,Canis lupus familiaris,9615.0,
7220,1,,BAO_0000218,Intermediate,,3771,Half-life was determined,A,,,Canis lupus familiaris,9615.0,
7221,1,,BAO_0000218,Intermediate,,6305,Half life in dogs,A,,,Canis lupus familiaris,9615.0,
7222,1,,BAO_0000218,Intermediate,1969.0,13501,Apparent Half life was determined from the linear portion of the log plasma concentration-time profile after oral administration of compound 18 at a dose of 2 mg/kg tp dog,A,In vivo,,Canis lupus familiaris,9615.0,
7223,1,,BAO_0000218,Intermediate,,17594,Apparent half-life after single intravenous bolus of 1 mg/kg in dogs,A,In vivo,,Canis lupus familiaris,9615.0,
7224,1,,BAO_0000218,Intermediate,,3045,Compound was evaluated for the half life period after iv administration in Beagle dog.,A,In vivo,,Canis lupus familiaris,9615.0,
7225,1,,BAO_0000218,Intermediate,,3043,Compound was evaluated for the half life period after oral administration in conscious dog.,A,In vivo,,Canis lupus familiaris,9615.0,
7226,1,,BAO_0000218,Intermediate,,4839,Compound was tested for half life in dog,A,,,Canis lupus familiaris,9615.0,
7227,1,,BAO_0000218,Intermediate,,4839,Compound was tested for its half life in dog,A,,,Canis lupus familiaris,9615.0,
7228,1,,BAO_0000218,Intermediate,,5802,Half life of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,A,In vivo,,Canis lupus familiaris,9615.0,
7229,1,,BAO_0000218,Intermediate,,17839,Half life of compound in dog was determined,A,,,Canis lupus familiaris,9615.0,
7230,1,,BAO_0000218,Intermediate,,4219,Half life (iv) was determined,A,In vivo,,Canis lupus familiaris,9615.0,
7231,1,,BAO_0000218,Intermediate,178.0,13966,Half life following administration of 70 nM in canine whole blood (dose exceeding platelet binding capacity),A,,,Canis lupus familiaris,9615.0,
7232,1,,BAO_0000218,Intermediate,1969.0,3994,Half life in Dog plasma at a dosage 5 mg/kg after intravenous administration,A,In vivo,,Canis lupus familiaris,9615.0,
7233,1,,BAO_0000218,Intermediate,1969.0,3994,Half life in Dog plasma at a dosage 5 mg/kg after intravenous administration,F,In vivo,,Canis lupus familiaris,9615.0,
7234,1,,BAO_0000218,Intermediate,,4453,Half life in dog,A,,,Canis lupus familiaris,9615.0,
7235,1,,BAO_0000218,Intermediate,1969.0,6535,Half life in dog plasma,A,,,Canis lupus familiaris,9615.0,
7236,1,,BAO_0000218,Intermediate,1969.0,6535,Half life in dog plasma after administration of 0.25 mg/kg iv,A,In vivo,,Canis lupus familiaris,9615.0,
7237,1,,BAO_0000218,Intermediate,1969.0,6535,Half life in dog plasma after administration of 1 mg/kg iv,A,In vivo,,Canis lupus familiaris,9615.0,
7238,1,,BAO_0000218,Intermediate,1969.0,3132,Half life in dog plasma was determined at dose 10 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,
7239,1,,BAO_0000218,Intermediate,,5374,Half life in dog was determined,A,,,Canis lupus familiaris,9615.0,
7240,1,,BAO_0000218,Intermediate,,5007,Half life in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),A,In vivo,,Canis lupus familiaris,9615.0,
7241,1,,BAO_0000218,Intermediate,1969.0,16907,Half life upon exposure to human plasma,A,,,Canis lupus familiaris,9615.0,
7242,1,,BAO_0000218,Intermediate,,6057,Half life was calculated in dog,A,,,Canis lupus familiaris,9615.0,
7243,1,,BAO_0000218,Intermediate,,5006,Half life was determined,A,,,Canis lupus familiaris,9615.0,
7244,1,,BAO_0000218,Intermediate,,5473,Half life was determined,A,,,Canis lupus familiaris,9615.0,
7245,1,,BAO_0000218,Intermediate,,4368,Half life by intravenous administration of 1.2 mg/kg in dog,A,In vivo,,Canis lupus familiaris,9615.0,
7246,1,,BAO_0000218,Intermediate,,6448,Half life in dog,A,,,Canis lupus familiaris,9615.0,
7247,1,,BAO_0000218,Intermediate,,4353,Half life in dog after intra venous administration of the compound,A,,,Canis lupus familiaris,9615.0,
7248,1,,BAO_0000218,Intermediate,,4353,Half life in dog after intra venous administration of the compound; ND means Not determined,A,,,Canis lupus familiaris,9615.0,
7249,1,,BAO_0000218,Intermediate,,4353,Half life in dog after po administration of the compound,A,In vivo,,Canis lupus familiaris,9615.0,
7250,1,,BAO_0000218,Intermediate,,4353,Half life in dog after po administration of the compound; ND means Not determined,A,In vivo,,Canis lupus familiaris,9615.0,
7251,1,,BAO_0000218,Intermediate,,6265,Half life in dog at the single oral dose of 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,
7252,1,,BAO_0000218,Intermediate,,5006,Half life in dogs,A,,,Canis lupus familiaris,9615.0,
7253,1,,BAO_0000218,Intermediate,,5356,Half life in dogs at 1 mg/kg oral dosing; 35-100 min,A,In vivo,,Canis lupus familiaris,9615.0,
7254,1,,BAO_0000218,Intermediate,,405,Half life in rat,A,,,Canis lupus familiaris,9615.0,
7255,1,,BAO_0000218,Intermediate,,6642,Half life in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),A,In vivo,,Canis lupus familiaris,9615.0,
7256,1,,BAO_0000218,Intermediate,10000001.0,10107,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,A,In vivo,,Mus musculus,10090.0,
7257,1,,BAO_0000218,Intermediate,10000001.0,10107,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,A,In vivo,,Mus musculus,10090.0,
7258,1,,BAO_0000218,Intermediate,10000001.0,10107,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,A,In vivo,,Mus musculus,10090.0,
7259,1,,BAO_0000218,Intermediate,10000001.0,10107,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,A,In vivo,,Mus musculus,10090.0,
7260,1,,BAO_0000218,Intermediate,10000001.0,10107,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,A,In vivo,,Mus musculus,10090.0,
7261,1,,BAO_0000218,Intermediate,10000004.0,10107,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,A,In vivo,,Mus musculus,10090.0,
7262,1,,BAO_0000218,Intermediate,10000004.0,10107,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,A,In vivo,,Mus musculus,10090.0,
7263,1,,BAO_0000218,Intermediate,10000004.0,10107,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,A,In vivo,,Mus musculus,10090.0,
7264,1,,BAO_0000218,Intermediate,10000004.0,10107,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,A,In vivo,,Mus musculus,10090.0,
7265,1,,BAO_0000218,Intermediate,10000004.0,10107,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,A,In vivo,,Mus musculus,10090.0,
7266,1,,BAO_0000218,Intermediate,10000004.0,10107,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,A,In vivo,,Mus musculus,10090.0,
7267,1,,BAO_0000218,Intermediate,10000004.0,10107,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,A,In vivo,,Mus musculus,10090.0,
7268,1,,BAO_0000218,Intermediate,948.0,10107,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,A,In vivo,,Mus musculus,10090.0,
7269,1,,BAO_0000218,Intermediate,948.0,10107,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,A,In vivo,,Mus musculus,10090.0,
7270,1,,BAO_0000218,Intermediate,948.0,10107,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,A,In vivo,,Mus musculus,10090.0,
7271,1,,BAO_0000218,Intermediate,948.0,10107,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,A,In vivo,,Mus musculus,10090.0,
7272,1,,BAO_0000218,Intermediate,948.0,10107,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,A,In vivo,,Mus musculus,10090.0,
7273,1,,BAO_0000218,Intermediate,948.0,10107,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,A,In vivo,,Mus musculus,10090.0,
7274,1,,BAO_0000218,Intermediate,948.0,10107,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,A,In vivo,,Mus musculus,10090.0,
7275,1,,BAO_0000218,Intermediate,2113.0,10107,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,A,In vivo,,Mus musculus,10090.0,
7276,1,,BAO_0000218,Intermediate,2113.0,10107,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,A,In vivo,,Mus musculus,10090.0,
7277,1,,BAO_0000218,Intermediate,2113.0,10107,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,A,In vivo,,Mus musculus,10090.0,
7278,1,,BAO_0000218,Intermediate,2113.0,10107,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,A,In vivo,,Mus musculus,10090.0,
7279,1,,BAO_0000218,Intermediate,2113.0,10107,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,A,In vivo,,Mus musculus,10090.0,
7280,1,,BAO_0000218,Intermediate,2113.0,10107,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,A,In vivo,,Mus musculus,10090.0,
7281,1,,BAO_0000218,Intermediate,2113.0,10107,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,A,In vivo,,Mus musculus,10090.0,
7282,1,,BAO_0000218,Intermediate,2107.0,10107,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,A,In vivo,,Mus musculus,10090.0,
7283,1,,BAO_0000218,Intermediate,2107.0,10107,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,A,In vivo,,Mus musculus,10090.0,
7284,1,,BAO_0000218,Intermediate,2107.0,10107,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,A,In vivo,,Mus musculus,10090.0,
7285,1,,BAO_0000218,Intermediate,2107.0,10107,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,A,In vivo,,Mus musculus,10090.0,
7286,1,,BAO_0000218,Intermediate,2107.0,10107,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,A,In vivo,,Mus musculus,10090.0,
7287,1,,BAO_0000218,Intermediate,2107.0,10107,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,A,In vivo,,Mus musculus,10090.0,
7288,1,,BAO_0000218,Intermediate,2107.0,10107,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,A,In vivo,,Mus musculus,10090.0,
7289,1,,BAO_0000218,Intermediate,2048.0,10107,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,A,In vivo,,Mus musculus,10090.0,
7290,1,,BAO_0000219,Intermediate,,5895,In vitro cytotoxicity against A2780 (human ovarian cancer),F,,,Homo sapiens,9606.0,
7291,1,,BAO_0000219,Intermediate,,6338,In vitro cytotoxicity against the paclitaxel sensitive human breast carcinoma cell line A2780,F,,,Homo sapiens,9606.0,
7292,1,,BAO_0000219,Intermediate,,15163,In vitro cytotoxicity against. ovarian carcinoma cell line A2780.,F,,,Homo sapiens,9606.0,
7293,1,,BAO_0000219,Intermediate,,15163,In vitro cytotoxicity against. ovarian carcinoma cell line A2780cisR (cisplatin resistant counter part of A2780).,F,,,Homo sapiens,9606.0,
7294,1,,BAO_0000219,Expert,,15000,In vitro cytotoxicity was tested against human Ovarian carcinoma A2780 cell line,F,,,Homo sapiens,9606.0,
7295,1,,BAO_0000219,Expert,,15000,In vitro cytotoxicity was tested against human Ovarian carcinoma A2780 cisplatin resistant cell line,F,,,Homo sapiens,9606.0,
7296,1,,BAO_0000219,Expert,,14729,In vitro cytotoxicity against A2780 ovarian cells using the sulforhodamine B(SRB) assay.,F,,,Homo sapiens,9606.0,
7297,1,,BAO_0000219,Intermediate,,17270,In vitro cytotoxicity against A2780 cell line,F,,,Homo sapiens,9606.0,
7298,1,,BAO_0000219,Intermediate,,5685,In vitro growth inhibitory activity against A2780 human ovarium carcinoma cell line was determined,F,,,Homo sapiens,9606.0,
7299,1,,BAO_0000219,Intermediate,,3563,In vitro inhibitory activity against human ovarian cancer A2780 cell line,F,,,Homo sapiens,9606.0,
7300,1,,BAO_0000218,Intermediate,,17753,In vivo cytotoxic concentration of compound against A2780 cell line after 72 hr exposure,F,,,Homo sapiens,9606.0,
7301,1,,BAO_0000219,Intermediate,,16317,"Inhibition of cell growth in human ovarian carcinoma cell line (A2780cisR,cisplatin-resistant)using the 96 hour continuous exposure sulforhodamine B (SRB) growth delay assay",F,,,Homo sapiens,9606.0,
7302,1,,BAO_0000219,Intermediate,,16936,Inhibition of tubulin polymerization in analogy of ca.,F,,,Homo sapiens,9606.0,
7303,1,,BAO_0000219,Intermediate,,3801,Inhibitory activity against ovarian tumor cell line A2780 after 72 hr continuous exposure to compound,F,,,Homo sapiens,9606.0,
7304,1,,BAO_0000219,Expert,,6181,Cytotoxic effect in ovarian cancer cell line (A2780),F,,,Homo sapiens,9606.0,
7305,1,,BAO_0000219,Intermediate,,5318,Tested for cytotoxicity against Ovarian carcinoma parental type A2780 cell line expressing MDR-1 (-) gene,F,,,Homo sapiens,9606.0,
7306,1,,BAO_0000219,Intermediate,,4840,Tested for the cytotoxicity in A2780 ovarian cell line,F,,,Homo sapiens,9606.0,
7307,1,,BAO_0000219,Intermediate,,15748,The compound was tested for cytotoxic activity against A2780 cell line(human ovarian carcinoma ),F,,,Homo sapiens,9606.0,
7308,1,,BAO_0000219,Intermediate,,15748,The compound was tested for cytotoxic activity against A2780/Cs cell line(human ovarian carcinoma,F,,,Homo sapiens,9606.0,
7309,1,,BAO_0000219,Intermediate,,15748,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma,F,,,,,
7310,1,,BAO_0000219,Intermediate,,15748,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ),F,,,,,
7311,1,,BAO_0000219,Intermediate,,15748,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ); ND means no data,F,,,,,
7312,1,,BAO_0000219,Intermediate,,15748,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma),F,,,,,
7313,1,,BAO_0000218,Intermediate,,17753,In vivo log of cells killed after administration of compound in A2780 cell line,F,,,Homo sapiens,9606.0,
7314,1,,BAO_0000218,Intermediate,,17753,Compound was tested in vivo for maximum tolerated dose after i.v. administration twice a day for 5 days in A2780 cell line,F,In vivo,,Homo sapiens,9606.0,
7315,1,,BAO_0000219,Intermediate,,16936,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines.;NA means not active,F,,,Homo sapiens,9606.0,
7316,1,,BAO_0000219,Intermediate,,16936,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell lines (at 5 uM );NA means not active,F,,,Homo sapiens,9606.0,
7317,1,,BAO_0000219,Intermediate,,16936,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines; ND means no data,F,,,Homo sapiens,9606.0,
7318,1,,BAO_0000219,Intermediate,,16936,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell lines. (at 5 uM ); ND means no data,F,,,Homo sapiens,9606.0,
7319,1,,BAO_0000218,Intermediate,,17528,Optimal dose required to inhibit human ovarian A2780 tumor growth after subcutaneous transplantation on athymic mice at 10 mg/kg (treatment schedule: q4dX2),F,,,Homo sapiens,9606.0,
7320,1,,BAO_0000219,Intermediate,,6633,Resistance factor was determined as IC50 cisplatin-resistant/parent for human A2780 ovarian cell line,F,,,Homo sapiens,9606.0,
7321,1,,BAO_0000219,Expert,,15000,Resistance index is IC50 ratio of A2780 cell line and A2780cisR cell line,F,,,Homo sapiens,9606.0,
7322,1,,BAO_0000219,Expert,,17528,Percentage tumor growth inhibition was calculated in respect to controls one week after the end of the treatment,F,,,Homo sapiens,9606.0,
7323,1,,BAO_0000219,Intermediate,,16936,Compound was tested for Tubulin polymerization inhibition by using human ovarian cancer cell lines.,F,,,Homo sapiens,9606.0,
7324,1,,BAO_0000219,Intermediate,,16936,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines.,F,,,Homo sapiens,9606.0,
7325,1,,BAO_0000219,Intermediate,,16936,Percent of Tubulin polymerization inhibition by using human ovarian cancer cell lines at a concentration of 5 uM,F,,,Homo sapiens,9606.0,
7326,1,,BAO_0000219,Intermediate,,16936,"Colchicine Binding Inhibition ( CBI ) by using human ovarian cancer cell lines at 5 uM, (values are mean of 9 over 4 concentrations +/- SD)",F,,,Homo sapiens,9606.0,
7327,1,,BAO_0000219,Intermediate,,16936,Compound tested for colchicine Binding Inhibition by using human ovarian cancer cell line (at 5 uM ),F,,,Homo sapiens,9606.0,
7328,1,,BAO_0000219,Expert,,16936,"Tested for colchicine binding inhibition, using human ovarian cancer cell lines (at 5 uM )",F,,,Homo sapiens,9606.0,
7329,1,,BAO_0000219,Intermediate,,16936,Compound tested for colchicine Binding Inhibition by using human ovarian carcinoma cell line (at 5 uM ),F,,,Homo sapiens,9606.0,
7330,1,,BAO_0000219,Intermediate,,16936,Compound was tested for colchicine Binding Inhibition by using human ovarian carcinoma cell line (at 5 uM ),F,,,Homo sapiens,9606.0,
7331,1,,BAO_0000219,Intermediate,,16936,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell line (at 5 uM ),F,,,Homo sapiens,9606.0,
7332,1,,BAO_0000219,Intermediate,,17737,In vitro antiproliferative activity against A2780 cell line,F,,,Mus musculus,10090.0,
7333,1,,BAO_0000219,Expert,,17764,Maximum tolerated dose in A2780 tumor in mice after intraperitoneal administration daily for 8 days,F,,,Mus musculus,10090.0,
7334,1,,BAO_0000219,Intermediate,,3830,In vitro cytotoxicity of compound was determined against A2780 cell lines at 37 degree C after 96 hr,F,,,Homo sapiens,9606.0,
7335,1,,BAO_0000219,Intermediate,,3829,In vitro cytotoxicity of compound was determined against A2780 cell lines at 37 degree C for 96 hr,F,,,Homo sapiens,9606.0,
7336,1,,BAO_0000218,Intermediate,,3546,Vc value in dog after IV administration at a dose of 5 mg/kg,A,,,Canis lupus familiaris,9615.0,
7337,1,,BAO_0000218,Intermediate,,3546,Half life period in dog after IV administration at a dose of 5 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,
7338,0,,BAO_0000019,Autocuration,,5668,Area under curve was determine after peroral administration at 10 mpk in Rhesus,A,,,Cercopithecidae,9527.0,
7339,0,,BAO_0000218,Autocuration,1969.0,3443,AUC (area under curve) evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,,,Cercopithecidae,9527.0,
7340,0,,BAO_0000218,Autocuration,1969.0,3443,AUC (area under curve) compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,,,Cercopithecidae,9527.0,
7341,0,,BAO_0000218,Autocuration,,4256,Area under curve determined after intravenous administration at a dose of 3 mg/kg in cynomolgus monkey,A,In vivo,,Macaca fascicularis,9541.0,
7342,0,,BAO_0000218,Autocuration,,4256,Area under curve determined after peroral administration at a dose of 10 mg/kg in cynomolgus monkey,A,In vivo,,Macaca fascicularis,9541.0,
7343,0,,BAO_0000218,Autocuration,,4256,Area under curve determined after peroral administration at a dose of 3 mg/kg in cynomolgus monkey,A,In vivo,,Macaca fascicularis,9541.0,
7344,0,,BAO_0000218,Autocuration,,4256,Oral Bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,
7345,0,,BAO_0000218,Autocuration,,1916,Area under curve was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,A,,,Cercopithecidae,9527.0,
7346,0,,BAO_0000218,Autocuration,,5302,Area under curve value in monkey at a dose of 5 mg/kg,A,,,Cercopithecidae,9527.0,
7347,0,,BAO_0000218,Autocuration,,4257,Area under curve was determined in monkey after a 3 mg/kg of oral dose,A,,,Cercopithecidae,9527.0,
7348,0,,BAO_0000019,Autocuration,,5355,Area under curve was determined using trapezoidal rule after intravenous administration in cynomolgus monkeys,A,,,Cercopithecidae,9527.0,
7349,0,,BAO_0000019,Autocuration,,5355,Area under curve was determined using trapezoidal rule after oral administration in cynomolgus monkeys,A,,,Cercopithecidae,9527.0,
7350,0,,BAO_0000019,Autocuration,,5355,Area under curve was determined using trapezoidal rule after oral administration in cynomolgus monkeys; ND means Not determined,A,,,Cercopithecidae,9527.0,
7351,0,,BAO_0000218,Autocuration,,6078,Area under the curve for the compound calculated from 0-24 hr after intravenous administration at a dose of 10 mg/kg in monkey,A,,,Cercopithecidae,9527.0,
7352,0,,BAO_0000218,Autocuration,,6078,Area under the curve for the compound calculated from 0-24 hr after oral administration at a dose of 10 mg/kg in monkey,A,,,Cercopithecidae,9527.0,
7353,0,,BAO_0000218,Autocuration,,6062,Area under the curve was measured in monkey after an iv dose of 1 mg/kg,A,,,Cercopithecidae,9527.0,
7354,0,,BAO_0000218,Autocuration,,2661,Compound was evaluated for AUC after treatment with iv dose of 1 mgkg to female cynomolgus monkey,A,,,Cercopithecidae,9527.0,
7355,0,,BAO_0000019,Autocuration,,2661,Compound was evaluated for AUC after treatment with oral dose of 2 mgkg to female cynomolgus monkey,A,,,Cercopithecidae,9527.0,
7356,0,,BAO_0000218,Autocuration,,5394,Pharmacokinetic parameter Cmax was measured after administration into monkey at 3 mg/kg,A,,,Cercopithecidae,9527.0,
7357,0,,BAO_0000218,Autocuration,,4397,Pharmacokinetic property at the dose of 10 mg/kg (20% HPbetaCD) concentration in cynomolgus monkeys (0 to 24 hr) p.o.,A,,,Cercopithecidae,9527.0,
7358,0,,BAO_0000218,Autocuration,,17509,Area under curve value 24 hr after 2 mg/kg iv administration in monkeys,A,,,Cercopithecidae,9527.0,
7359,0,,BAO_0000218,Autocuration,,17509,Area under curve value 24 hr after 2 mg/kg oral administration in monkeys,A,,,Cercopithecidae,9527.0,
7360,0,,BAO_0000218,Autocuration,,6641,Oral AUCN in monkey (dosed at 0.5 mpk iv ),A,In vivo,,Cercopithecidae,9527.0,
7361,0,,BAO_0000218,Autocuration,,5355,Bioavailability was reported in cynomolgus monkeys (ratio of AUC in oral administration to that of intravenous administration),A,,,Cercopithecidae,9527.0,
7362,0,,BAO_0000218,Autocuration,,3443,Half life compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,In vivo,,Cercopithecidae,9527.0,
7363,0,,BAO_0000218,Autocuration,,3443,Half life evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,In vivo,,Cercopithecidae,9527.0,
7364,0,,BAO_0000019,Autocuration,,17409,Binding towards monkey plasma protein at 10 uM,A,,,Cercopithecidae,9527.0,
7365,0,,BAO_0000019,Autocuration,,17409,Binding towards monkey plasma protein at 100 uM,A,,,Cercopithecidae,9527.0,
7366,0,,BAO_0000218,Autocuration,,1052,Apparent bioavailability in squirrel monkey was determined,A,In vivo,,Cercopithecidae,9527.0,
7367,0,,BAO_0000218,Autocuration,,13501,Bioavailability was determined after oral administration of compound 18 at a dose of 1 mg/kg to rhesus monkey,A,In vivo,,Cercopithecidae,9527.0,
7368,0,,BAO_0000218,Autocuration,,17509,Bioavailability in monkey (dose 2 mg/kg),A,In vivo,,monkey,9443.0,
7369,0,,BAO_0000218,Autocuration,,5394,Compound at a dose 3 mg/kg was administered to monkey and was evaluated for bioavailability after administration into monkey at 3 mg/kg,A,In vivo,,Cercopithecidae,9527.0,
7370,0,,BAO_0000218,Autocuration,,2661,Compound was evaluated for bioavailability after treatment with oral dose of 2 mgkg to female cynomolgus monkey,A,In vivo,,Cercopithecidae,9527.0,
7371,0,,BAO_0000218,Autocuration,,11219,Bioavailability in monkey (i.d. dosing),A,In vivo,,monkey,9443.0,
7372,0,,BAO_0000218,Autocuration,,3045,Oral bioavailability after 5 mg/kg in cynomolgus monkey was determined,A,In vivo,,Cercopithecidae,9527.0,
7373,0,,BAO_0000019,Autocuration,,17796,Clearance of the drug was measured in cynomolgus,A,,,Cercopithecidae,9527.0,
7374,0,,BAO_0000218,Autocuration,,1399,Clearance was estimated in two squirrel monkeys after iv administration at 5 mg/kg,A,In vivo,,Cercopithecidae,9527.0,
7375,0,,BAO_0000218,Autocuration,,2661,Compound was evaluated for clearance after treatment with iv dose of 1 mgkg to female cynomolgus monkey,A,In vivo,,Cercopithecidae,9527.0,
7376,0,,BAO_0000218,Autocuration,1969.0,5005,Compound was tested for its plasma clearance rate in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,A,In vivo,,Macaca mulatta,9544.0,
7377,0,,BAO_0000218,Autocuration,,17267,Plasma clearance in rhesus monkey was determined,A,In vivo,,Cercopithecidae,9527.0,
7378,0,,BAO_0000218,Autocuration,,6535,Plasma clearance in monkey after administration of 1 mg/kg iv,A,In vivo,,Cercopithecidae,9527.0,
7379,0,,BAO_0000218,Autocuration,,5922,Plasma clearance in cynomolgus monkey,A,In vivo,,Cercopithecidae,9527.0,
7380,0,,BAO_0000218,Autocuration,,6221,Plasma clearance after oral administration (2.5 mg/kg) in monkey was determined,A,In vivo,,Cercopithecidae,9527.0,
7381,0,,BAO_0000218,Autocuration,,5668,Plasma clearance after peroral administration at 10 mpk in Rhesus,A,In vivo,,Cercopithecidae,9527.0,
7382,0,,BAO_0000218,Autocuration,,5355,The total clearance was determined after intravenous administration in cynomolgus monkeys,A,In vivo,,Cercopithecidae,9527.0,
7383,0,,BAO_0000218,Autocuration,,5355,The total clearance was determined after oral administration in cynomolgus monkeys; NA means Not applicable,A,In vivo,,Cercopithecidae,9527.0,
7384,0,,BAO_0000218,Autocuration,,5355,The total clearance was determined after oral administration in cynomolgus monkeys; NA means not applicable,A,In vivo,,Cercopithecidae,9527.0,
7385,0,,BAO_0000218,Autocuration,,4578,Tested for Clearance upon iv administration to african green monkey,A,In vivo,,Cercopithecidae,9527.0,
7386,0,,BAO_0000218,Autocuration,,17592,Clearance in monkey,A,In vivo,,Cercopithecidae,9527.0,
7387,1,,BAO_0000218,Intermediate,,6641,Half life in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),A,In vivo,,Canis lupus familiaris,9615.0,
7388,1,,BAO_0000218,Intermediate,,6642,Half life in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),A,In vivo,,Canis lupus familiaris,9615.0,
7389,1,,BAO_0000218,Intermediate,,16367,Half life was evaluated after intravenous administration to dogs,A,In vivo,,Canis lupus familiaris,9615.0,
7390,1,,BAO_0000218,Intermediate,,5472,Half life was evaluated in dog,A,,,Canis lupus familiaris,9615.0,
7391,1,,BAO_0000218,Intermediate,,5474,Half life was evaluated in dog,A,,,Canis lupus familiaris,9615.0,
7392,1,,BAO_0000218,Intermediate,,5654,Half life period (t1/2) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,
7393,1,,BAO_0000218,Intermediate,,6227,Half life period after intravenous administration (1 mg/kg) was determined in dog (in vivo),A,In vivo,,Canis lupus familiaris,9615.0,
7394,1,,BAO_0000218,Intermediate,,6227,Half life period after intravenous administration in dog,A,In vivo,,Canis lupus familiaris,9615.0,
7395,1,,BAO_0000218,Intermediate,,6221,Half life period after oral administration (2.5 mg/kg) in dog was determined,A,In vivo,,Canis lupus familiaris,9615.0,
7396,1,,BAO_0000218,Intermediate,,4527,Half life period at a dose of 1 uM/kg in dog was determined,A,,,Canis lupus familiaris,9615.0,
7397,1,,BAO_0000218,Intermediate,,5668,Half life period was determine after peroral administration at 10 mpk in dog,A,In vivo,,Canis lupus familiaris,9615.0,
7398,1,,BAO_0000218,Intermediate,,5668,Half life period was determine after peroral administration at 5 mpk in dog,A,In vivo,,Canis lupus familiaris,9615.0,
7399,1,,BAO_0000218,Intermediate,,3854,Half life period was determined,A,,,Canis lupus familiaris,9615.0,
7400,1,,BAO_0000218,Intermediate,,5505,Half life period was determined,A,,,Canis lupus familiaris,9615.0,
7401,1,,BAO_0000218,Intermediate,,6251,Half life period by iv administration in dog at a dose of 6 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,
7402,1,,BAO_0000218,Intermediate,,1918,Half life period was evaluated in dog,A,,,Canis lupus familiaris,9615.0,
7403,1,,BAO_0000218,Intermediate,,5546,Half life period was determined in Beagle dog at a dose of 1 mg/kg by iv administration,A,In vivo,,Canis lupus familiaris,9615.0,
7404,1,,BAO_0000218,Intermediate,,4809,Half life period was determined in Beagle dogs after (iv) administration of a dose of 12 (uM/kg),A,In vivo,,Canis lupus familiaris,9615.0,
7405,1,,BAO_0000218,Intermediate,,6215,Half life time after intravenous administration (0.5 mg/kg) was determined in dog,A,In vivo,,Canis lupus familiaris,9615.0,
7406,1,,BAO_0000218,Intermediate,,4527,Half-life period by oral administration at a dose of 10 uM/kg in dog was determined,A,In vivo,,Canis lupus familiaris,9615.0,
7407,1,,BAO_0000218,Intermediate,,17594,Half-life after oral dose of compound at 3 mg/kg in dogs,A,In vivo,,Canis lupus familiaris,9615.0,
7408,1,,BAO_0000218,Intermediate,,17839,Half-life of compound in dog following p.o. administration of 0.5 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,
7409,1,,BAO_0000218,Intermediate,,17839,Half-life of compound in dog following p.o. administration of 0.9 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,
7410,1,,BAO_0000218,Intermediate,,17839,Half-life of compound in dog following p.o. administration of 0.95 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,
7411,1,,BAO_0000218,Intermediate,,17839,Half-life of compound in dog following p.o. administration of 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,
7412,1,,BAO_0000218,Intermediate,1969.0,5210,Half-life of compound in plasma of dog was determined,A,,,Canis lupus familiaris,9615.0,
7413,1,,BAO_0000218,Intermediate,,5210,Half-life of compound was determined in dogs,A,,,Canis lupus familiaris,9615.0,
7414,1,,BAO_0000218,Intermediate,,2959,Half-life after administration of 4 mg/Kg oral dose in dog,A,In vivo,,Canis lupus familiaris,9615.0,
7415,1,,BAO_0000218,Intermediate,,4137,Half-life after intravenous administration of 1 mg/kg/h in dog,A,In vivo,,Canis lupus familiaris,9615.0,
7416,1,,BAO_0000218,Intermediate,,5064,Half-life in Dog,A,,,Canis lupus familiaris,9615.0,
7417,1,,BAO_0000218,Intermediate,,5147,Half-life in Dog,A,,,Canis lupus familiaris,9615.0,
7418,1,,BAO_0000218,Intermediate,,5145,Half-life in dog,A,,,Canis lupus familiaris,9615.0,
7419,1,,BAO_0000218,Intermediate,,6123,Half-life in dog after oral administration at 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,
7420,1,,BAO_0000218,Intermediate,,6123,Half-life in dog after oral administration at 1 mg/kg; nd is not determined,A,In vivo,,Canis lupus familiaris,9615.0,
7421,1,,BAO_0000218,Intermediate,,4333,Half-life in dogs,A,,,Canis lupus familiaris,9615.0,
7422,1,,BAO_0000218,Intermediate,,4333,Half-life in dogs; ND indicates not determined,A,,,Canis lupus familiaris,9615.0,
7423,1,,BAO_0000218,Intermediate,1969.0,12500,Half-life in plasma of dog,A,,,Canis lupus familiaris,9615.0,
7424,1,,BAO_0000218,Intermediate,1969.0,12500,Half-life in plasma of dog at dose of 3-10 mgkg,A,,,Canis lupus familiaris,9615.0,
7425,1,,BAO_0000218,Intermediate,,6005,Half-life was evaluated after i.v. administration in dog at a dose of 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,
7426,1,,BAO_0000218,Intermediate,,6062,Half-life was measured in dog after an iv dose of 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,
7427,1,,BAO_0000218,Intermediate,,17650,Half-life was measured in dogs after an oral dose of 10 uM/kg,A,In vivo,,Canis lupus familiaris,9615.0,
7428,1,,BAO_0000218,Intermediate,,5530,Half-life in vivo in dog by intravenous administration at a dose of 0.2 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,
7429,1,,BAO_0000218,Intermediate,,5530,Half-life in vivo in dog by intravenous administration at a dose of 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,
7430,1,,BAO_0000218,Intermediate,,5600,Half-life of the compound after 0.3 mg/kg po administration in dog,A,In vivo,,Canis lupus familiaris,9615.0,
7431,1,,BAO_0000218,Intermediate,,6039,Half-life period after intravenous administration of 0.5 mg/kg in dog was determined,A,In vivo,,Canis lupus familiaris,9615.0,
7432,1,,BAO_0000218,Intermediate,,6039,Half-life period after intravenous administration of 1.0 mg/kg in dog was determined,A,In vivo,,Canis lupus familiaris,9615.0,
7433,1,,BAO_0000218,Intermediate,,6039,Half-life period after peroral administration of 0.2 mg/kg in dog was determined,A,In vivo,,Canis lupus familiaris,9615.0,
7434,1,,BAO_0000218,Intermediate,,6227,t1/2 in dog,A,,,Canis lupus familiaris,9615.0,
7435,1,,BAO_0000218,Intermediate,,14541,Half-life period measured in dogs,A,,,Canis lupus familiaris,9615.0,
7436,1,,BAO_0000218,Intermediate,,4521,Half-life period in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,A,In vivo,,Canis lupus familiaris,9615.0,
7437,1,,BAO_0000218,Intermediate,,4521,Half-life period in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,A,In vivo,,Canis lupus familiaris,9615.0,
7438,1,,BAO_0000218,Intermediate,,6679,Half-life period was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,A,In vivo,,Canis lupus familiaris,9615.0,
7439,1,,BAO_0000218,Intermediate,1969.0,1116,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in dog plasma",A,In vitro,,Canis lupus familiaris,9615.0,
7440,1,,BAO_0000218,Intermediate,,5444,In vivo half life period was calculated at 1 mg/kg in dog,A,In vivo,,Canis lupus familiaris,9615.0,
7441,1,,BAO_0000218,Intermediate,,5444,In vivo half life period was calculated at 1 mg/kg in dog; ND=Not determined,A,In vivo,,Canis lupus familiaris,9615.0,
7442,1,,BAO_0000218,Intermediate,,17853,Longer half-life in dog (i.v.) at 0.5 mpk,A,In vivo,,Canis lupus familiaris,9615.0,
7443,1,,BAO_0000218,Intermediate,,4353,Oral bioavailability in dog (dose 5 uM/kg),A,In vivo,,Canis lupus familiaris,9615.0,
7444,1,,BAO_0000218,Intermediate,,16452,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,A,In vivo,,Canis lupus familiaris,9615.0,
7445,1,,BAO_0000218,Intermediate,,16452,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,A,In vivo,,Canis lupus familiaris,9615.0,
7446,1,,BAO_0000218,Intermediate,,16452,Bioavailability in dog (dose 1 mg/kg i.v.),A,In vivo,,Canis lupus familiaris,9615.0,
7447,1,,BAO_0000218,Intermediate,2048.0,10107,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,A,In vivo,,Mus musculus,10090.0,
7448,1,,BAO_0000218,Intermediate,2048.0,10107,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,A,In vivo,,Mus musculus,10090.0,
7449,1,,BAO_0000218,Intermediate,2048.0,10107,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,A,In vivo,,Mus musculus,10090.0,
7450,1,,BAO_0000218,Intermediate,2048.0,10107,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,A,In vivo,,Mus musculus,10090.0,
7451,1,,BAO_0000218,Intermediate,2048.0,10107,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,A,In vivo,,Mus musculus,10090.0,
7452,1,,BAO_0000218,Intermediate,2048.0,10107,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,A,In vivo,,Mus musculus,10090.0,
7453,1,,BAO_0000218,Intermediate,2385.0,10107,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,A,In vivo,,Mus musculus,10090.0,
7454,1,,BAO_0000218,Intermediate,2385.0,10107,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,A,In vivo,,Mus musculus,10090.0,
7455,1,,BAO_0000218,Intermediate,2385.0,10107,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,A,In vivo,,Mus musculus,10090.0,
7456,1,,BAO_0000218,Intermediate,2385.0,10107,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,A,In vivo,,Mus musculus,10090.0,
7457,1,,BAO_0000218,Intermediate,2385.0,10107,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,A,In vivo,,Mus musculus,10090.0,
7458,1,,BAO_0000218,Intermediate,2385.0,10107,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,A,In vivo,,Mus musculus,10090.0,
7459,1,,BAO_0000218,Intermediate,2385.0,10107,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,A,In vivo,,Mus musculus,10090.0,
7460,1,,BAO_0000218,Intermediate,14.0,10107,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,A,In vivo,,Mus musculus,10090.0,
7461,1,,BAO_0000218,Intermediate,14.0,10107,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,A,In vivo,,Mus musculus,10090.0,
7462,1,,BAO_0000218,Intermediate,14.0,10107,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,A,In vivo,,Mus musculus,10090.0,
7463,1,,BAO_0000218,Intermediate,14.0,10107,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,A,In vivo,,Mus musculus,10090.0,
7464,1,,BAO_0000218,Intermediate,14.0,10107,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,A,In vivo,,Mus musculus,10090.0,
7465,1,,BAO_0000218,Intermediate,14.0,10107,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,A,In vivo,,Mus musculus,10090.0,
7466,1,,BAO_0000218,Intermediate,14.0,10107,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,A,In vivo,,Mus musculus,10090.0,
7467,1,,BAO_0000218,Intermediate,2106.0,10107,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,A,In vivo,,Mus musculus,10090.0,
7468,1,,BAO_0000218,Intermediate,2106.0,10107,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,A,In vivo,,Mus musculus,10090.0,
7469,1,,BAO_0000218,Intermediate,2106.0,10107,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,A,In vivo,,Mus musculus,10090.0,
7470,1,,BAO_0000218,Intermediate,2106.0,10107,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,A,In vivo,,Mus musculus,10090.0,
7471,1,,BAO_0000218,Intermediate,2106.0,10107,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,A,In vivo,,Mus musculus,10090.0,
7472,1,,BAO_0000218,Intermediate,2106.0,10107,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,A,In vivo,,Mus musculus,10090.0,
7473,1,,BAO_0000218,Intermediate,2106.0,10107,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,A,In vivo,,Mus musculus,10090.0,
7474,1,,BAO_0000218,Intermediate,945.0,10107,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,A,In vivo,,Mus musculus,10090.0,
7475,1,,BAO_0000218,Intermediate,945.0,10107,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,A,In vivo,,Mus musculus,10090.0,
7476,1,,BAO_0000218,Intermediate,945.0,10107,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,A,In vivo,,Mus musculus,10090.0,
7477,1,,BAO_0000218,Intermediate,945.0,10107,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,A,In vivo,,Mus musculus,10090.0,
7478,1,,BAO_0000218,Intermediate,945.0,10107,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,A,In vivo,,Mus musculus,10090.0,
7479,1,,BAO_0000218,Intermediate,945.0,10107,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,A,In vivo,,Mus musculus,10090.0,
7480,1,,BAO_0000218,Intermediate,945.0,10107,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,A,In vivo,,Mus musculus,10090.0,
7481,1,,BAO_0000218,Intermediate,,4689,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,
7482,1,,BAO_0000218,Intermediate,,4950,Tested for the bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,
7483,1,,BAO_0000218,Intermediate,,5328,Bioavailability in rat (dose 1 mg/kg i.v. and 2 mg/kg p.o.),A,In vivo,,Rattus norvegicus,10116.0,
7484,1,,BAO_0000218,Intermediate,,406,Bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,
7485,1,,BAO_0000218,Intermediate,,12500,Bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,
7486,1,,BAO_0000218,Intermediate,,12500,Bioavailability in rat (dose 3-10 mg/kg),A,In vivo,,Rattus norvegicus,10116.0,
7487,1,,BAO_0000218,Intermediate,,5247,Bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,
7488,1,,BAO_0000218,Intermediate,1969.0,4186,Apparent terminal elimination half-life in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,A,In vivo,,Rattus norvegicus,10116.0,
7489,1,,BAO_0000218,Intermediate,1969.0,4186,Apparent terminal elimination half-life in rat plasma after administration of 50 mg/kg dose through subcutaneous route,A,In vivo,,Rattus norvegicus,10116.0,
7490,1,,BAO_0000218,Intermediate,,6647,Half life after oral administration was determined in rats at 6 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,
7491,1,,BAO_0000218,Intermediate,,6484,Half life was determined,A,,,Rattus norvegicus,10116.0,
7492,1,,BAO_0000218,Intermediate,,3249,Half life the of compound was determined by ''Cr'' assay in rat at a dose of 10 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,
7493,1,,BAO_0000218,Intermediate,1969.0,6281,Plasma half life in rat at oral dose 2.8 mg/mk body weight,A,In vivo,,Rattus norvegicus,10116.0,
7494,1,,BAO_0000218,Intermediate,,3307,Half life in rats,A,,,Rattus norvegicus,10116.0,
7495,1,,BAO_0000218,Intermediate,178.0,12058,Half-lives were estimated from the elimination phase of the blood conc-time curve after oral administration,A,In vivo,,Rattus norvegicus,10116.0,
7496,1,,BAO_0000218,Intermediate,,8833,Hill coefficient of the compound,A,,,Rattus norvegicus,10116.0,
7497,1,,BAO_0000218,Intermediate,178.0,3193,Compound was tested for percent hydrolysis in whole blood after a time interval of 0.5 min,A,,,Rattus norvegicus,10116.0,
7498,1,,BAO_0000218,Intermediate,178.0,3193,Compound was tested for percent hydrolysis in whole blood after a time interval of 180.0 min,A,,,Rattus norvegicus,10116.0,
7499,1,,BAO_0000218,Intermediate,178.0,3193,Compound was tested for percent hydrolysis in whole blood after a time interval of 2.0 min,A,,,Rattus norvegicus,10116.0,
7500,1,,BAO_0000218,Intermediate,178.0,3193,Compound was tested for percent hydrolysis in whole blood after a time interval of 5.0 min,A,,,Rattus norvegicus,10116.0,
7501,1,,BAO_0000218,Intermediate,178.0,3193,Compound was tested for percent hydrolysis in whole blood after a time interval of 60.0 min,A,,,Rattus norvegicus,10116.0,
7502,1,,BAO_0000218,Intermediate,178.0,3193,Compound was tested for percent hydrolysis in whole blood after a time interval of 7.0 min,A,,,Rattus norvegicus,10116.0,
7503,1,,BAO_0000218,Intermediate,178.0,3193,"Compound was tested for percent hydrolysis in whole blood, after a time interval of 15.0 min",A,,,Rattus norvegicus,10116.0,
7504,1,,BAO_0000218,Intermediate,,5960,Plasma concentration at 4 hr after 30 mg/kg post dosing in rat using HPLC/MS,A,,,Rattus norvegicus,10116.0,
7505,1,,BAO_0000218,Intermediate,955.0,13950,Biodistribution of [123I]-label in rat brain was reported at 0.33 hr post injection. Value shown is %ID/organ,A,In vivo,,Rattus norvegicus,10116.0,
7506,1,,BAO_0000218,Intermediate,955.0,13950,Biodistribution of [123I]-label in rat brain was reported at 1 hr post injection. Value shown is %ID/organ,A,In vivo,,Rattus norvegicus,10116.0,
7507,1,,BAO_0000218,Intermediate,955.0,13950,Biodistribution of [123I]-label in rat brain was reported at 2 hr post injection. Value shown is %ID/organ,A,In vivo,,Rattus norvegicus,10116.0,
7508,1,,BAO_0000218,Intermediate,955.0,13950,Biodistribution of [123I]-label in rat brain was reported at 24 hr post injection. Value shown is %ID/organ,A,In vivo,,Rattus norvegicus,10116.0,
7509,1,,BAO_0000218,Intermediate,955.0,13950,Biodistribution of [123I]-label in rat brain was reported at 4 hr post injection. Value shown is %ID/organ,A,In vivo,,Rattus norvegicus,10116.0,
7510,1,,BAO_0000218,Intermediate,2046.0,13950,Biodistribution of [123I]-label in rat thyroid was reported at 0.33 hr post injection. Value shown is %ID/organ,A,In vivo,,Rattus norvegicus,10116.0,
7511,1,,BAO_0000218,Intermediate,2046.0,13950,Biodistribution of [123I]-label in rat thyroid was reported at 1 hr post injection. Value shown is %ID/organ,A,In vivo,,Rattus norvegicus,10116.0,
7512,1,,BAO_0000218,Intermediate,2046.0,13950,Biodistribution of [123I]-label in rat thyroid was reported at 2 hr post injection. Value shown is %ID/organ,A,In vivo,,Rattus norvegicus,10116.0,
7513,1,,BAO_0000218,Intermediate,2046.0,13950,Biodistribution of [123I]-label in rat thyroid was reported at 24 hr post injection. Value shown is %ID/organ,A,In vivo,,Rattus norvegicus,10116.0,
7514,1,,BAO_0000218,Intermediate,2046.0,13950,Biodistribution of [123I]-label in rat thyroid was reported at 4 hr post injection. Value shown is %ID/organ,A,In vivo,,Rattus norvegicus,10116.0,
7515,1,,BAO_0000218,Intermediate,178.0,9866,Biodistribution in normal rat blood in the presence of 0.005 M Gd/0.01 M lig at 2 hr,A,In vivo,,Rattus norvegicus,10116.0,
7516,1,,BAO_0000218,Intermediate,178.0,9866,Biodistribution in normal rat blood in the presence of 0.01 M Gd/0.05 M lig,A,In vivo,,Rattus norvegicus,10116.0,
7517,1,,BAO_0000218,Intermediate,178.0,9866,Biodistribution in normal rat blood in the presence of NAC Gd 0.01 M lig at 2 hr,A,In vivo,,Rattus norvegicus,10116.0,
7518,1,,BAO_0000218,Intermediate,10000001.0,9866,Biodistribution in normal rat bone in the presence of 0.005 M Gd/0.01 M lig at 2 hr,A,In vivo,,Rattus norvegicus,10116.0,
7519,1,,BAO_0000218,Intermediate,10000001.0,9866,Biodistribution in normal rat bone in the presence of 0.01 M Gd/0.05 M lig,A,In vivo,,Rattus norvegicus,10116.0,
7520,1,,BAO_0000218,Intermediate,10000001.0,9866,Biodistribution in normal rat bone in the presence of NAC Gd 0.01 M lig at 2 hr,A,In vivo,,Rattus norvegicus,10116.0,
7521,1,,BAO_0000218,Intermediate,948.0,9866,Biodistribution in normal rat heart in the presence of 0.005 M Gd/0.01 M lig at 2 hr,A,In vivo,,Rattus norvegicus,10116.0,
7522,1,,BAO_0000218,Intermediate,948.0,9866,Biodistribution in normal rat heart in the presence of 0.01 M Gd/0.05 M lig,A,In vivo,,Rattus norvegicus,10116.0,
7523,1,,BAO_0000218,Intermediate,948.0,9866,Biodistribution in normal rat heart in the presence of NAC Gd 0.01 M lig at 2 hr,A,In vivo,,Rattus norvegicus,10116.0,
7524,1,,BAO_0000218,Intermediate,2113.0,9866,Biodistribution in normal rat kidney in the presence of 0.005 M Gd/0.01 M lig at 2 hr,A,In vivo,,Rattus norvegicus,10116.0,
7525,1,,BAO_0000218,Intermediate,2113.0,9866,Biodistribution in normal rat kidney in the presence of 0.01 M Gd/0.05 M lig,A,In vivo,,Rattus norvegicus,10116.0,
7526,1,,BAO_0000218,Intermediate,2113.0,9866,Biodistribution in normal rat kidney in the presence of NAC Gd 0.01 M lig at 2 hr,A,In vivo,,Rattus norvegicus,10116.0,
7527,1,,BAO_0000218,Intermediate,2107.0,9866,Biodistribution in normal rat liver in the presence of 0.005 M Gd/0.01 M lig at 2 hr,A,In vivo,,Rattus norvegicus,10116.0,
7528,1,,BAO_0000218,Intermediate,2107.0,9866,Biodistribution in normal rat liver in the presence of 0.01 M Gd/0.05 M lig,A,In vivo,,Rattus norvegicus,10116.0,
7529,1,,BAO_0000218,Intermediate,2107.0,9866,Biodistribution in normal rat liver in the presence of NAC Gd 0.01 M lig at 2 hr,A,In vivo,,Rattus norvegicus,10116.0,
7530,1,,BAO_0000218,Intermediate,2048.0,9866,Biodistribution in normal rat lung in the presence of 0.005 M Gd/0.01 M lig at 2 hr,A,In vivo,,Rattus norvegicus,10116.0,
7531,1,,BAO_0000218,Intermediate,2048.0,9866,Biodistribution in normal rat lung in the presence of 0.01 M Gd/0.05 M lig,A,In vivo,,Rattus norvegicus,10116.0,
7532,1,,BAO_0000218,Intermediate,2048.0,9866,Biodistribution in normal rat lung in the presence of NAC Gd 0.01 M lig at 2 hr,A,In vivo,,Rattus norvegicus,10116.0,
7533,1,,BAO_0000218,Intermediate,,6351,Recovery rate from urine and bile was determined after iv administration at 20 mg/kg in rats; Not tested,A,,,Rattus norvegicus,10116.0,
7534,1,,BAO_0000218,Intermediate,,1465,Compound was tested for solubility in water,A,,,Rattus norvegicus,10116.0,
7535,0,,BAO_0000100,Intermediate,,5182,Solubility in phosphate buffered saline (1% DMSO) at pH 6.5 (24 hr equilibration),P,,,,,
7536,1,,BAO_0000218,Intermediate,,17847,Solubility was determined,A,,,Rattus norvegicus,10116.0,
7537,1,,BAO_0000218,Intermediate,,15339,solubility in water (ug/mL) at 37 degree C.,A,,,Rattus norvegicus,10116.0,
7538,1,,BAO_0000218,Intermediate,,5202,First pass metabolism and metabolic bioavailability using rat hepatic microsomes,A,,,Rattus norvegicus,10116.0,
7539,1,,BAO_0000218,Intermediate,,1088,In vitro stability relative to (+)-AJ76 in rat hepatocyte assay,A,,,Rattus norvegicus,10116.0,
7540,1,,BAO_0000218,Intermediate,,3169,Half life in rats,A,,,Rattus norvegicus,10116.0,
7541,1,,BAO_0000218,Intermediate,,5353,Half life in Dawley rat,A,,,Rattus norvegicus,10116.0,
7542,1,,BAO_0000218,Intermediate,,2864,Half life period after 3 mg/kg iv administration,A,In vivo,,Rattus norvegicus,10116.0,
7543,1,,BAO_0000218,Intermediate,,2864,Half life period after 3 mg/kg iv administration in rat,A,In vivo,,Rattus norvegicus,10116.0,
7544,1,,BAO_0000218,Intermediate,,2864,Half life period after 3 mg/kg iv administration in the rat,A,In vivo,,Rattus norvegicus,10116.0,
7545,1,,BAO_0000218,Intermediate,,6362,Half life period in female Sprague-Dawley rats,A,,,Rattus norvegicus,10116.0,
7546,1,,BAO_0000218,Intermediate,,6249,Half life period in rat,A,,,Rattus norvegicus,10116.0,
7547,1,,BAO_0000218,Intermediate,,3169,Half-life in rats was determined,A,,,Rattus norvegicus,10116.0,
7548,1,,BAO_0000218,Intermediate,,3169,Half-life in rats with metabolic oxidation,A,,,Rattus norvegicus,10116.0,
7549,1,,BAO_0000218,Intermediate,,3169,Half-life in rats,A,,,Rattus norvegicus,10116.0,
7550,1,,BAO_0000218,Intermediate,,17260,T 1/2 at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,A,In vivo,,Rattus norvegicus,10116.0,
7551,1,,BAO_0000218,Intermediate,,17260,T 1/2 at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,A,In vivo,,Rattus norvegicus,10116.0,
7552,1,,BAO_0000218,Intermediate,,17260,T max at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,A,In vivo,,Rattus norvegicus,10116.0,
7553,1,,BAO_0000218,Intermediate,,17260,T max at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,A,In vivo,,Rattus norvegicus,10116.0,
7554,1,,BAO_0000218,Intermediate,1969.0,2879,Biological half-life measured in plasma of rat,A,,,Rattus norvegicus,10116.0,
7555,1,,BAO_0000218,Intermediate,1969.0,2879,Biological half-life measured in plasma of rat; 22-25,A,,,Rattus norvegicus,10116.0,
7556,1,,BAO_0000218,Intermediate,1969.0,2879,Biological half-life measured in plasma of rat; 9-16,A,,,Rattus norvegicus,10116.0,
7557,1,,BAO_0000218,Intermediate,,3184,Compound was evaluated for its half life when administered intravenously in rat,A,In vivo,,Rattus norvegicus,10116.0,
7558,1,,BAO_0000218,Intermediate,,4891,Compound was evaluated for pharmacokinetic parameter percent bioavailability at 8 h,A,In vivo,,Rattus norvegicus,10116.0,
7559,1,,BAO_0000218,Intermediate,,429,Evaluated for pharmacokinetic parameter half-life in rat at the dose 50 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,
7560,1,,BAO_0000218,Intermediate,,5656,Half life (T1/2) after oral administration in rat,A,In vivo,,Rattus norvegicus,10116.0,
7561,1,,BAO_0000218,Intermediate,,4413,Half life of compound after iv administration of 20 mg/kg dose in rat,A,In vivo,,Rattus norvegicus,10116.0,
7562,1,,BAO_0000218,Expert,,3598,Half life of compound determined in rat after iv administration at a dose of 10 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,
7563,1,,BAO_0000218,Intermediate,,17267,Half life of compound was determined in rat,A,,,Rattus norvegicus,10116.0,
7564,1,,BAO_0000218,Intermediate,178.0,4727,Half life of compound was determined in rat blood,A,,,Rattus norvegicus,10116.0,
7565,1,,BAO_0000218,Intermediate,,17651,Half life at 1 mg/kg was determined in rat,A,In vivo,,Rattus norvegicus,10116.0,
7566,1,,BAO_0000218,Intermediate,,17651,Half life at 10 mg/kg was determined in rat,A,In vivo,,Rattus norvegicus,10116.0,
7567,1,,BAO_0000218,Intermediate,,401,Half life in rats,A,,,Rattus norvegicus,10116.0,
7568,1,,BAO_0000218,Intermediate,,4942,Half life in rats in hours,A,,,Rattus norvegicus,10116.0,
7569,1,,BAO_0000218,Intermediate,,17735,Half life following 10 mg/kg intravenous or 50 mg/kg oral dosing in rats was determined,A,In vivo,,Rattus norvegicus,10116.0,
7570,1,,BAO_0000218,Intermediate,,6056,Half life was calculated at a single intravenous administration of 20 mg/kg in rat,A,In vivo,,Rattus norvegicus,10116.0,
7571,1,,BAO_0000218,Intermediate,,5213,Half life was determined,A,,,Rattus norvegicus,10116.0,
7572,1,,BAO_0000218,Intermediate,,6616,Half life after i.v. administration,A,In vivo,,Rattus norvegicus,10116.0,
7573,1,,BAO_0000218,Intermediate,,5937,Half life in rat after intravenous administration at a concentration 0.5 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,
7574,1,,BAO_0000218,Intermediate,1969.0,5819,Half life in rat plasma,A,,,Rattus norvegicus,10116.0,
7575,1,,BAO_0000218,Intermediate,1969.0,5819,Half life in rat plasma; Not detected,A,,,Rattus norvegicus,10116.0,
7576,1,,BAO_0000218,Intermediate,,6803,Half life in rats,A,,,Rattus norvegicus,10116.0,
7577,1,,BAO_0000218,Intermediate,,17804,Half life period of compound was determined after peroral administration,A,In vivo,,Rattus norvegicus,10116.0,
7578,1,,BAO_0000218,Intermediate,,17804,Half life period of compound was determined at a dose of 3 mg/kg by intravenous administration,A,In vivo,,Rattus norvegicus,10116.0,
7579,1,,BAO_0000218,Intermediate,,5948,Half life period in rat,A,,,Rattus norvegicus,10116.0,
7580,1,,BAO_0000218,Intermediate,,1916,Half life period was evaluated against Sprague-Dawley rats at a dose of 15 mg/kg after iv administration,A,In vivo,,Rattus norvegicus,10116.0,
7581,1,,BAO_0000218,Intermediate,,1916,Half life period was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after po administration,A,In vivo,,Rattus norvegicus,10116.0,
7582,1,,BAO_0000218,Intermediate,,1916,Half life period was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after po administration; Not available,A,In vivo,,Rattus norvegicus,10116.0,
7583,1,,BAO_0000218,Intermediate,,4890,Half life period was determined after intravenous administration at a dose 5 mg/kg to male Sprague-Dawley rats,A,In vivo,,Rattus norvegicus,10116.0,
7584,1,,BAO_0000218,Intermediate,,17764,Half life period was determined for compound after intravenous administration in rats at 24 uM/kg,A,In vivo,,Rattus norvegicus,10116.0,
7585,1,,BAO_0000218,Intermediate,,4727,Half life time in rat the dose of 2 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,
7586,1,,BAO_0000218,Intermediate,,17509,Half-life 24 hr after 10 mg/kg iv administration in rats,A,In vivo,,Rattus norvegicus,10116.0,
7587,1,,BAO_0000218,Intermediate,,17509,Half-life 24 hr after 2 mg/kg iv administration in rats,A,In vivo,,Rattus norvegicus,10116.0,
7588,1,,BAO_0000218,Intermediate,,6597,Half-life consistent with the observed metabolic steady state in rats,A,,,Rattus norvegicus,10116.0,
7589,1,,BAO_0000218,Intermediate,,17735,Half-life following 10 mg/kg intravenous or 50 mg/kg oral dosing in rats was determined,A,In vivo,,Rattus norvegicus,10116.0,
7590,1,,BAO_0000218,Intermediate,,6597,Half-life for oxidative metabolic stability was determined using male human,A,,,Rattus norvegicus,10116.0,
7591,1,,BAO_0000218,Intermediate,,17670,"Half-life in fischer rats at 5 mg/kg dose, administered intravenously",A,In vivo,,Rattus norvegicus,10116.0,
7592,1,,BAO_0000218,Intermediate,1969.0,1696,Half-life in rat plasma,A,,,Rattus norvegicus,10116.0,
7593,1,,BAO_0000218,Intermediate,1969.0,1742,Half-life in rat plasma was determined,A,,,Rattus norvegicus,10116.0,
7594,1,,BAO_0000218,Intermediate,,17800,Half-life in rats was determined,A,,,Rattus norvegicus,10116.0,
7595,0,,BAO_0000218,Autocuration,,12923,Area under curve of acid 2a was determined by HPLC at a dosage of 54.5 mg/kg administered intragastrically by gavage method in dog,A,,,,,
7596,0,,BAO_0000019,Autocuration,,11954,Area under curve after oral dose of 0.1 mg//kg,A,,,,,
7597,0,,BAO_0000218,Autocuration,,11954,Area under curve after oral dose of 0.3 mg/kg,A,,,,,
7598,0,,BAO_0000218,Autocuration,,11954,Area under curve after oral dose of 1 mg/kg,A,,,,,
7599,0,,BAO_0000218,Autocuration,,11954,Area under curve after oral dose of 10 mg/kg,A,,,,,
7600,0,,BAO_0000218,Autocuration,,11954,Area under curve after oral dose of 23.4 mg/kg,A,,,,,
7601,0,,BAO_0000218,Autocuration,,11954,Area under curve after oral dose of 3 mg/kg,A,,,,,
7602,0,,BAO_0000218,Autocuration,,11954,Area under curve after oral dose of 3.87 mg/kg,A,,,,,
7603,0,,BAO_0000019,Autocuration,,5237,Area under curve was determined,A,,,,,
7604,0,,BAO_0000218,Autocuration,,4026,Area under curve at a dose of 10 mg/kg,A,,,,,
7605,1,,BAO_0000218,Intermediate,,5237,Area under curve was determined; ND=No data,A,,,Rattus norvegicus,10116.0,
7606,1,,BAO_0000218,Intermediate,,14793,Area under curve was evaluated in rat brain when administered intraperitoneally at a dose of 10 mg/kg for 4 or 6 hours,A,,,Rattus norvegicus,10116.0,
7607,1,,BAO_0000218,Intermediate,,14793,Area under curve was evaluated in rat brain when administered intraperitoneally at a dose of 10 mg/kg for infinite hours,A,,,Rattus norvegicus,10116.0,
7608,1,,BAO_0000218,Intermediate,,14793,Area under curve was evaluated in rat brain when administered intravenously at a dose of 10 mg/kg for 4 or 6 hours,A,,,Rattus norvegicus,10116.0,
7609,1,,BAO_0000218,Intermediate,,14793,Area under curve was evaluated in rat brain when administered intravenously at a dose of 10 mg/kg for infinite hours,A,,,Rattus norvegicus,10116.0,
7610,1,,BAO_0000218,Intermediate,,14793,Area under curve was evaluated in rat brain when administered perorally at a dose of 100 mg/kg for 4 or 6 hours,A,,,Rattus norvegicus,10116.0,
7611,1,,BAO_0000218,Intermediate,,14793,Area under curve was evaluated in rat brain when administered perorally at a dose of 100 mg/kg for infinite hours; Not calculated,A,,,Rattus norvegicus,10116.0,
7612,1,,BAO_0000218,Intermediate,,14793,Area under curve was evaluated in rat brain when administered perorally at a dose of 10 mg/kg for 4 or 6 hours,A,,,Rattus norvegicus,10116.0,
7613,1,,BAO_0000218,Intermediate,,14793,Area under curve was evaluated in rat brain when administered perorally at a dose of 10 mg/kg for infinite hours; Not calculated,A,,,Rattus norvegicus,10116.0,
7614,1,,BAO_0000218,Intermediate,1969.0,14793,Area under curve was evaluated in rat plasma when administered intraperitoneally at a dose of 10 mg/kg for 4 or 6 hours,A,,,Rattus norvegicus,10116.0,
7615,1,,BAO_0000218,Intermediate,1969.0,14793,Area under curve was evaluated in rat plasma when administered intraperitoneally at a dose of 10 mg/kg for infinite hours,A,,,Rattus norvegicus,10116.0,
7616,1,,BAO_0000218,Intermediate,1969.0,14793,Area under curve was evaluated in rat plasma when administered intravenously at a dose of 10 mg/kg for 4 or 6 hours,A,,,Rattus norvegicus,10116.0,
7617,1,,BAO_0000218,Intermediate,1969.0,14793,Area under curve was evaluated in rat plasma when administered intravenously at a dose of 10 mg/kg for infinite hours,A,,,Rattus norvegicus,10116.0,
7618,1,,BAO_0000218,Intermediate,1969.0,14793,Area under curve was evaluated in rat plasma when administered perorally at a dose of 100 mg/kg for 4 or 6 hours,A,,,Rattus norvegicus,10116.0,
7619,1,,BAO_0000218,Intermediate,1969.0,14793,Area under curve was evaluated in rat plasma when administered perorally at a dose of 100 mg/kg for infinite hours,A,,,Rattus norvegicus,10116.0,
7620,1,,BAO_0000218,Intermediate,1969.0,14793,Area under curve was evaluated in rat plasma when administered perorally at a dose of 10 mg/kg for 4 or 6 hours,A,,,Rattus norvegicus,10116.0,
7621,1,,BAO_0000218,Intermediate,1969.0,14793,Area under curve was evaluated in rat plasma when administered perorally at a dose of 10 mg/kg for infinite hours,A,,,Rattus norvegicus,10116.0,
7622,1,,BAO_0000218,Intermediate,1969.0,11637,AUC in mice,A,,,Mus musculus,10090.0,
7623,0,,BAO_0000019,Autocuration,,11149,Area under curve was measured from the graph obtained from concentration Vs time,A,,,,,
7624,0,,BAO_0000019,Autocuration,,10016,Area under curve value of compound per hour after oral administration,A,,,,,
7625,1,,BAO_0000218,Intermediate,,17796,Area under curve was determined after oral administration in rats,A,,,Rattus norvegicus,10116.0,
7626,1,,BAO_0000218,Intermediate,,17796,Area under curve was determined after oral administration in rats; No data,A,,,Rattus norvegicus,10116.0,
7627,1,,BAO_0000218,Intermediate,,17796,Area under curve was determined after oral administration in rats;No data,A,,,Rattus norvegicus,10116.0,
7628,1,,BAO_0000218,Intermediate,,12923,Area under curve was determined by HPLC at a dosage of 2.27 mg/kg administered intravenously by bolus method in dog,A,,,Canis lupus familiaris,9615.0,
7629,1,,BAO_0000218,Intermediate,,15372,Area under curve was determined for the compound after iv dose of 4.74 mg/kg in rats,A,,,Rattus norvegicus,10116.0,
7630,1,,BAO_0000218,Intermediate,,15372,Area under curve was determined for the compound after iv dose of 5.06 in rats,A,,,Rattus norvegicus,10116.0,
7631,1,,BAO_0000218,Intermediate,,15372,Area under curve was determined for the compound after iv dose of 5.10 mg/kg in rats,A,,,Rattus norvegicus,10116.0,
7632,1,,BAO_0000218,Intermediate,,15372,Area under curve was determined for the compound after po dose of 5.01 mg/kg in rats,A,,,Rattus norvegicus,10116.0,
7633,1,,BAO_0000218,Intermediate,,15372,Area under curve was determined for the compound after po dose of 5.03 mg/kg in rats,A,,,Rattus norvegicus,10116.0,
7634,1,,BAO_0000218,Intermediate,,15372,Area under curve was determined for the compound after po dose of 5.22 mg/kg in rats,A,,,Rattus norvegicus,10116.0,
7635,1,,BAO_0000218,Intermediate,,15372,Area under curve was determined for the compound after po dose of 5.46 mg/kg in rats,A,,,Rattus norvegicus,10116.0,
7636,1,,BAO_0000218,Intermediate,,14169,Area under curve was determined in Dogs after peroral administration,A,,,Canis lupus familiaris,9615.0,
7637,1,,BAO_0000218,Intermediate,,14169,Area under curve was determined in Rats after peroral administration,A,,,Rattus norvegicus,10116.0,
7638,1,,BAO_0000218,Intermediate,,14258,Area under curve was determined in carotid blood of rat when administered intradermally,A,,,Rattus norvegicus,10116.0,
7639,1,,BAO_0000218,Intermediate,,14258,Area under curve was determined in portal blood of rat when administered intradermally,A,,,Rattus norvegicus,10116.0,
7640,1,,BAO_0000218,Intermediate,,15011,Area under curve was determined using 0.4% Methyl cellulose (MC) as vehicle. Compound was administered intravenously to nude mice at a dose of 25 mg/kg,A,,,Mus musculus,10090.0,
7641,1,,BAO_0000218,Intermediate,,15011,Area under curve was determined using 0.4% Methyl cellulose (MC) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg,A,,,Mus musculus,10090.0,
7642,1,,BAO_0000218,Intermediate,,15011,Area under curve was determined using 0.4% Methyl cellulose (MC) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg (micronized sample),A,,,Mus musculus,10090.0,
7643,1,,BAO_0000218,Intermediate,,15011,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered intravenously to nude mice at a dose of 25 mg/kg,A,,,Mus musculus,10090.0,
7644,1,,BAO_0000218,Intermediate,,15011,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered intravenously to nude mice at a dose of 25 mg/kg (run time 7 hr),A,,,Mus musculus,10090.0,
7645,1,,BAO_0000218,Intermediate,,15011,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg,A,,,Mus musculus,10090.0,
7646,1,,BAO_0000218,Intermediate,,15011,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg (Run time = 7 hr),A,,,Mus musculus,10090.0,
7647,1,,BAO_0000218,Intermediate,2106.0,11195,Biodistribution of the radiolabeled compound (2-5 uCi) in rat spleen 65 mins after i.v. administration,A,In vivo,,Rattus norvegicus,10116.0,
7648,1,,BAO_0000218,Intermediate,178.0,10130,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in blood; Expressed as percent dose/organ,A,,,Rattus norvegicus,10116.0,
7649,1,,BAO_0000218,Intermediate,955.0,10130,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in brain; Expressed as percent dose/organ,A,,,Rattus norvegicus,10116.0,
7650,1,,BAO_0000218,Intermediate,948.0,10130,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in heart; Expressed as percent dose/organ,A,,,Rattus norvegicus,10116.0,
7651,1,,BAO_0000218,Intermediate,2107.0,10130,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in liver; Expressed as percent dose/organ,A,,,Rattus norvegicus,10116.0,
7652,1,,BAO_0000218,Intermediate,2048.0,10130,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in lung; Expressed as percent dose/organ,A,,,Rattus norvegicus,10116.0,
7653,1,,BAO_0000218,Intermediate,2385.0,10130,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in muscle; Expressed as percent dose/organ,A,,,Rattus norvegicus,10116.0,
7654,1,,BAO_0000218,Intermediate,,10130,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in skin; Expressed as percent dose/organ,A,,,Rattus norvegicus,10116.0,
7655,1,,BAO_0000218,Intermediate,2106.0,10130,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in spleen; Expressed as percent dose/organ,A,,,Rattus norvegicus,10116.0,
7656,1,,BAO_0000218,Intermediate,2046.0,10130,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in thyroid; Expressed as percent dose/organ,A,,,Rattus norvegicus,10116.0,
7657,1,,BAO_0000218,Intermediate,2113.0,10130,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in kidney; Expressed as percent dose/organ,A,,,Rattus norvegicus,10116.0,
7658,1,,BAO_0000218,Intermediate,178.0,10130,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in blood; Expressed as percent dose/organ,A,,,Rattus norvegicus,10116.0,
7659,1,,BAO_0000218,Intermediate,955.0,10130,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in brain; Expressed as percent dose/organ,A,,,Rattus norvegicus,10116.0,
7660,1,,BAO_0000218,Intermediate,948.0,10130,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in heart; Expressed as percent dose/organ,A,,,Rattus norvegicus,10116.0,
7661,1,,BAO_0000218,Intermediate,2113.0,10130,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in kidney; Expressed as percent dose/organ,A,,,Rattus norvegicus,10116.0,
7662,1,,BAO_0000218,Intermediate,2107.0,10130,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in liver; Expressed as percent dose/organ,A,,,Rattus norvegicus,10116.0,
7663,1,,BAO_0000218,Intermediate,2048.0,10130,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in lung; Expressed as percent dose/organ,A,,,Rattus norvegicus,10116.0,
7664,1,,BAO_0000218,Intermediate,2385.0,10130,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in muscle; Expressed as percent dose/organ,A,,,Rattus norvegicus,10116.0,
7665,1,,BAO_0000218,Intermediate,,10130,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in skin; Expressed as percent dose/organ,A,,,Rattus norvegicus,10116.0,
7666,1,,BAO_0000218,Intermediate,2106.0,10130,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in spleen; Expressed as percent dose/organ,A,,,Rattus norvegicus,10116.0,
7667,1,,BAO_0000218,Intermediate,2046.0,10130,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in thyroid; Expressed as percent dose/organ,A,,,Rattus norvegicus,10116.0,
7668,1,,BAO_0000218,Intermediate,178.0,10130,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in blood; Expressed as percent dose/organ,A,,,Rattus norvegicus,10116.0,
7669,1,,BAO_0000218,Intermediate,948.0,10130,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in heart; Expressed as percent dose/organ,A,,,Rattus norvegicus,10116.0,
7670,1,,BAO_0000218,Intermediate,2113.0,10130,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in kidney; Expressed as percent dose/organ,A,,,Rattus norvegicus,10116.0,
7671,1,,BAO_0000218,Intermediate,2107.0,10130,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in liver; Expressed as percent dose/organ,A,,,Rattus norvegicus,10116.0,
7672,1,,BAO_0000218,Intermediate,2385.0,10130,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in muscle; Expressed as percent dose/organ,A,,,Rattus norvegicus,10116.0,
7673,1,,BAO_0000218,Intermediate,2106.0,10130,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in spleen; Expressed as percent dose/organ,A,,,Rattus norvegicus,10116.0,
7674,1,,BAO_0000218,Intermediate,2046.0,10130,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in thyroid; Expressed as percent dose/organ,A,,,Rattus norvegicus,10116.0,
7675,1,,BAO_0000218,Intermediate,955.0,10130,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in brain; Expressed as percent dose/organ,A,,,Rattus norvegicus,10116.0,
7676,1,,BAO_0000218,Intermediate,2048.0,10130,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in lung; Expressed as percent dose/organ,A,,,Rattus norvegicus,10116.0,
7677,1,,BAO_0000218,Intermediate,,10130,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in skin; Expressed as percent dose/organ,A,,,Rattus norvegicus,10116.0,
7678,1,,BAO_0000218,Intermediate,,6295,In vivo concentration in rat liver exposure 8 hour after oral administration 50 mg/kg,A,,,Rattus norvegicus,10116.0,
7679,1,,BAO_0000218,Intermediate,,6296,In vivo concentration in rat liver exposure 8 hour after oral administration 50 mg/kg,A,,,Rattus norvegicus,10116.0,
7680,1,,BAO_0000218,Intermediate,,6296,In vivo concentration in rat liver exposure 8 hour after oral administration 50 mg/kg; Below detection limit,A,,,Rattus norvegicus,10116.0,
7681,1,,BAO_0000218,Intermediate,,6295,In vivo concentration in rat plasma exposure at 8 hour after oral administration 50 mg/kg,A,,,Rattus norvegicus,10116.0,
7682,1,,BAO_0000218,Intermediate,,6296,In vivo concentration in rat plasma exposure at 8 hour after oral administration 50 mg/kg,A,,,Rattus norvegicus,10116.0,
7683,1,,BAO_0000218,Intermediate,,17260,C max at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,A,In vivo,,Rattus norvegicus,10116.0,
7684,1,,BAO_0000218,Intermediate,,17260,C max at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,A,In vivo,,Rattus norvegicus,10116.0,
7685,1,,BAO_0000218,Intermediate,,17686,C24h in rat p.o. at 20 mg/kg concentration,A,,,Rattus norvegicus,10116.0,
7686,1,,BAO_0000218,Intermediate,2385.0,9866,Biodistribution in normal rat muscle in the presence of 0.005 M Gd/0.01 M lig at 2 hr,A,In vivo,,Rattus norvegicus,10116.0,
7687,1,,BAO_0000218,Intermediate,2385.0,9866,Biodistribution in normal rat muscle in the presence of 0.01 M Gd/0.05 M lig,A,In vivo,,Rattus norvegicus,10116.0,
7688,1,,BAO_0000218,Intermediate,2385.0,9866,Biodistribution in normal rat muscle in the presence of NAC Gd 0.01 M lig at 2 hr,A,In vivo,,Rattus norvegicus,10116.0,
7689,1,,BAO_0000218,Intermediate,2106.0,9866,Biodistribution in normal rat spleen in the presence of 0.005 M Gd/0.01 M lig at 2 hr,A,In vivo,,Rattus norvegicus,10116.0,
7690,1,,BAO_0000218,Intermediate,2106.0,9866,Biodistribution in normal rat spleen in the presence of 0.01 M Gd/0.05 M lig,A,In vivo,,Rattus norvegicus,10116.0,
7691,1,,BAO_0000218,Intermediate,2106.0,9866,Biodistribution in normal rat spleen in the presence of NAC Gd 0.01 M lig at 2 hr,A,In vivo,,Rattus norvegicus,10116.0,
7692,1,,BAO_0000218,Intermediate,178.0,9866,Biodistribution in rat blood in the presence of 0.001 M/0.008 M GdDTPA-AEP,A,In vivo,,Rattus norvegicus,10116.0,
7693,1,,BAO_0000218,Intermediate,178.0,9866,Biodistribution in rat blood in the presence of 0.01 M GdDTPA-BDP,A,In vivo,,Rattus norvegicus,10116.0,
7694,1,,BAO_0000218,Intermediate,178.0,9866,Biodistribution in rat blood in the presence of 0.01 M/0.01 M GdDTPA-AEP,A,In vivo,,Rattus norvegicus,10116.0,
7695,1,,BAO_0000218,Intermediate,178.0,9866,Biodistribution in rat blood in the presence of 0.05 M Gd/0.15 M lig,A,In vivo,,Rattus norvegicus,10116.0,
7696,1,,BAO_0000218,Intermediate,178.0,9866,Biodistribution in rat blood in the presence of 0.05 M GdDTPA-BDP,A,In vivo,,Rattus norvegicus,10116.0,
7697,1,,BAO_0000218,Intermediate,178.0,9866,Biodistribution in rat blood in the presence of 0.05 M/0.05 M GdDTPA-AEP,A,In vivo,,Rattus norvegicus,10116.0,
7698,1,,BAO_0000218,Intermediate,178.0,9866,Biodistribution in rat blood in the presence of 0.05 M/0.08 M GdDTPA-HPDP,A,In vivo,,Rattus norvegicus,10116.0,
7699,1,,BAO_0000218,Intermediate,178.0,9866,Biodistribution in rat blood in the presence of 0.10 M GdDTPA-BDP,A,In vivo,,Rattus norvegicus,10116.0,
7700,1,,BAO_0000218,Intermediate,178.0,9866,Biodistribution in rat blood in the presence of 0.10 M/0.11 M GdDTPA-AEP,A,In vivo,,Rattus norvegicus,10116.0,
7701,1,,BAO_0000218,Intermediate,178.0,9866,Biodistribution in rat blood in the presence of 50 Gd/kg at 15 min,A,In vivo,,Rattus norvegicus,10116.0,
7702,1,,BAO_0000218,Intermediate,178.0,9866,Biodistribution in rat blood in the presence of 50 Gd/kg at 2 hr,A,In vivo,,Rattus norvegicus,10116.0,
7703,1,,BAO_0000218,Intermediate,178.0,9866,Biodistribution in rat blood in the presence of 50 Gd/kg at 6 hr,A,In vivo,,Rattus norvegicus,10116.0,
7704,1,,BAO_0000218,Intermediate,178.0,9866,Biodistribution in rat blood in the presence of GdDTPA at 15 min,A,In vivo,,Rattus norvegicus,10116.0,
7705,1,,BAO_0000218,Intermediate,178.0,9866,Biodistribution in rat blood in the presence of GdDTPA at 1 hr,A,In vivo,,Rattus norvegicus,10116.0,
7706,1,,BAO_0000218,Intermediate,178.0,9866,Biodistribution in rat blood in the presence of GdDTPA at 30 min,A,In vivo,,Rattus norvegicus,10116.0,
7707,1,,BAO_0000218,Intermediate,178.0,9866,Biodistribution in rat blood in the presence of GdDTPA at 4 hr,A,In vivo,,Rattus norvegicus,10116.0,
7708,1,,BAO_0000218,Intermediate,178.0,9866,Biodistribution in rat blood in the presence of GdDTPA-BDP at 15 min,A,In vivo,,Rattus norvegicus,10116.0,
7709,1,,BAO_0000218,Intermediate,178.0,9866,Biodistribution in rat blood in the presence of GdDTPA-BDP at 30 min,A,In vivo,,Rattus norvegicus,10116.0,
7710,1,,BAO_0000218,Intermediate,178.0,9866,Biodistribution in rat blood in the presence of GdDTPA-BDP at 4 hr,A,In vivo,,Rattus norvegicus,10116.0,
7711,1,,BAO_0000218,Intermediate,178.0,9866,Biodistribution in rat blood in the presence of GdDTPA-BDPat 1 hr,A,In vivo,,Rattus norvegicus,10116.0,
7712,1,,BAO_0000218,Intermediate,178.0,9866,Biodistribution in rat blood in the presence of GdDTPA-HPDP at 15 min,A,In vivo,,Rattus norvegicus,10116.0,
7713,1,,BAO_0000218,Intermediate,178.0,9866,Biodistribution in rat blood in the presence of GdDTPA-HPDP at 30 min,A,In vivo,,Rattus norvegicus,10116.0,
7714,1,,BAO_0000218,Intermediate,178.0,9866,Biodistribution in rat blood in the presence of GdDTPA-HPDP at 4 hr,A,In vivo,,Rattus norvegicus,10116.0,
7715,1,,BAO_0000218,Intermediate,178.0,9866,Biodistribution in rat blood in the presence of GdDTPA-HPDPat 1 hr,A,In vivo,,Rattus norvegicus,10116.0,
7716,1,,BAO_0000218,Intermediate,178.0,9866,Biodistribution in rat blood in the presence of NAC Gd/0.01 M GdDTPA-HPDP,A,In vivo,,Rattus norvegicus,10116.0,
7717,1,,BAO_0000218,Intermediate,178.0,9866,Biodistribution in rat blood in the presence of NCA Gd/0.01 M lip,A,In vivo,,Rattus norvegicus,10116.0,
7718,1,,BAO_0000218,Intermediate,178.0,9866,Biodistribution in rat blood in the presence of NCAGd/0.01 M lig,A,In vivo,,Rattus norvegicus,10116.0,
7719,1,,BAO_0000218,Intermediate,10000001.0,9866,Biodistribution in rat bone in the presence of 0.01 M GdDTPA-BDP,A,In vivo,,Rattus norvegicus,10116.0,
7720,1,,BAO_0000218,Intermediate,10000001.0,9866,Biodistribution in rat bone in the presence of 0.01 M/0.01 M GdDTPA-AEP,A,In vivo,,Rattus norvegicus,10116.0,
7721,1,,BAO_0000218,Intermediate,10000001.0,9866,Biodistribution in rat bone in the presence of 0.01 M/0.08 M GdDTPA-AEP,A,In vivo,,Rattus norvegicus,10116.0,
7722,1,,BAO_0000218,Intermediate,10000001.0,9866,Biodistribution in rat bone in the presence of 0.05 M Gd/0.15 M lig,A,In vivo,,Rattus norvegicus,10116.0,
7723,1,,BAO_0000218,Intermediate,10000001.0,9866,Biodistribution in rat bone in the presence of 0.05 M GdDTPA-BDP,A,In vivo,,Rattus norvegicus,10116.0,
7724,1,,BAO_0000218,Intermediate,10000001.0,9866,Biodistribution in rat bone in the presence of 0.05 M/0.05 M GdDTPA-AEP,A,In vivo,,Rattus norvegicus,10116.0,
7725,1,,BAO_0000218,Intermediate,10000001.0,9866,Biodistribution in rat bone in the presence of 0.05 M/0.08 M GdDTPA-HPDP,A,In vivo,,Rattus norvegicus,10116.0,
7726,1,,BAO_0000218,Intermediate,10000001.0,9866,Biodistribution in rat bone in the presence of 0.10 M GdDTPA-BDP,A,In vivo,,Rattus norvegicus,10116.0,
7727,1,,BAO_0000218,Intermediate,10000001.0,9866,Biodistribution in rat bone in the presence of 0.10 M/0.11 M GdDTPA-AEP,A,In vivo,,Rattus norvegicus,10116.0,
7728,1,,BAO_0000218,Intermediate,10000001.0,9866,Biodistribution in rat bone in the presence of GdDTPA at 15 min,A,In vivo,,Rattus norvegicus,10116.0,
7729,1,,BAO_0000218,Intermediate,10000001.0,9866,Biodistribution in rat bone in the presence of GdDTPA at 1 hr,A,In vivo,,Rattus norvegicus,10116.0,
7730,1,,BAO_0000218,Intermediate,10000001.0,9866,Biodistribution in rat bone in the presence of GdDTPA at 30 min,A,In vivo,,Rattus norvegicus,10116.0,
7731,1,,BAO_0000218,Intermediate,10000001.0,9866,Biodistribution in rat bone in the presence of GdDTPA at 4 hr,A,In vivo,,Rattus norvegicus,10116.0,
7732,1,,BAO_0000218,Intermediate,10000001.0,9866,Biodistribution in rat bone in the presence of GdDTPA-BDP at 15 min,A,In vivo,,Rattus norvegicus,10116.0,
7733,1,,BAO_0000218,Intermediate,10000001.0,9866,Biodistribution in rat bone in the presence of GdDTPA-BDP at 1 hr,A,In vivo,,Rattus norvegicus,10116.0,
7734,1,,BAO_0000218,Intermediate,10000001.0,9866,Biodistribution in rat bone in the presence of GdDTPA-BDP at 30 min,A,In vivo,,Rattus norvegicus,10116.0,
7735,1,,BAO_0000218,Intermediate,10000001.0,9866,Biodistribution in rat bone in the presence of GdDTPA-BDP at 4 hr,A,In vivo,,Rattus norvegicus,10116.0,
7736,1,,BAO_0000218,Intermediate,10000001.0,9866,Biodistribution in rat bone in the presence of GdDTPA-HPDP at 15 min,A,In vivo,,Rattus norvegicus,10116.0,
7737,1,,BAO_0000218,Intermediate,10000001.0,9866,Biodistribution in rat bone in the presence of GdDTPA-HPDP at 1 hr,A,In vivo,,Rattus norvegicus,10116.0,
7738,1,,BAO_0000218,Intermediate,10000001.0,9866,Biodistribution in rat bone in the presence of GdDTPA-HPDP at 30 min,A,In vivo,,Rattus norvegicus,10116.0,
7739,1,,BAO_0000218,Intermediate,10000001.0,9866,Biodistribution in rat bone in the presence of GdDTPA-HPDP at 4 hr,A,In vivo,,Rattus norvegicus,10116.0,
7740,1,,BAO_0000218,Intermediate,10000001.0,9866,Biodistribution in rat bone in the presence of NAC Gd/0.01 M GdDTPA-HPDP,A,In vivo,,Rattus norvegicus,10116.0,
7741,1,,BAO_0000218,Intermediate,10000001.0,9866,Biodistribution in rat bone in the presence of NCA Gd/0.01 M lip,A,In vivo,,Rattus norvegicus,10116.0,
7742,1,,BAO_0000218,Intermediate,10000001.0,9866,Biodistribution in rat bone in the presence of NCAGd/0.01 M lig,A,In vivo,,Rattus norvegicus,10116.0,
7743,1,,BAO_0000218,Intermediate,1969.0,17752,Half-life from rat plasma at a single oral dose of 25 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,
7744,1,,BAO_0000218,Intermediate,,5610,Half-life in male rat,A,,,Rattus norvegicus,10116.0,
7745,1,,BAO_0000218,Intermediate,,5939,Half-life in rat after peroral administration at 10 mg/kg concentration,A,In vivo,,Rattus norvegicus,10116.0,
7746,1,,BAO_0000218,Intermediate,,5939,Half-life in rat after peroral administration at 5 mg/kg concentration,A,In vivo,,Rattus norvegicus,10116.0,
7747,1,,BAO_0000218,Intermediate,,17771,Half-life in rat at a dose of 3 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,
7748,1,,BAO_0000218,Intermediate,,1974,Half-life was evaluated in rats,A,,,Rattus norvegicus,10116.0,
7749,1,,BAO_0000218,Intermediate,,4239,Half-life was measured in rat,A,,,Rattus norvegicus,10116.0,
7750,1,,BAO_0000218,Intermediate,,6681,Half-life period for the compound was determined in rats at 50 mg/kg dose,A,In vivo,,Rattus norvegicus,10116.0,
7751,1,,BAO_0000218,Intermediate,,17752,Half-life period in rats after intravenous administration at 5 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,
7752,1,,BAO_0000218,Intermediate,,6046,Half-life period in rat at 10 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,
7753,1,,BAO_0000218,Intermediate,,6685,"Half-life period was determined in rats at 10 mg/kg, p.o. dose",A,In vivo,,Rattus norvegicus,10116.0,
7754,1,,BAO_0000218,Intermediate,,6685,"Half-life period was determined in rats at 20 mg/kg, i.p. dose",A,In vivo,,Rattus norvegicus,10116.0,
7755,1,,BAO_0000218,Intermediate,,6685,"Half-life period was determined in rats at 2 mg/kg, i.v. dose",A,In vivo,,Rattus norvegicus,10116.0,
7756,1,,BAO_0000218,Intermediate,,4727,Half-life time in rat the dose of 2 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,
7757,1,,BAO_0000218,Intermediate,,1088,Half-life was estimated from the elimination phase of the oral [C] vs time curves in 4 rats,A,In vivo,,Rattus norvegicus,10116.0,
7758,1,,BAO_0000218,Intermediate,,5610,In vivo activity against Staphylococcus aureus when administered orally for 1 hr in rat at a dose of 15 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,
7759,1,,BAO_0000218,Intermediate,1969.0,3032,"In vivo half life of compound in rat plasma after a oral dose of 10 mg/kg (in water, N=4)",A,In vivo,,Rattus norvegicus,10116.0,
7760,1,,BAO_0000218,Intermediate,,5199,Oral half life was determined,A,In vivo,,Rattus norvegicus,10116.0,
7761,1,,BAO_0000218,Intermediate,,14941,"Pharmacokinetic Parameter, half life period measured in Female Wistar Rats at 100 mg/kg by po administration",A,In vivo,,Rattus norvegicus,10116.0,
7762,1,,BAO_0000218,Intermediate,,4408,Pharmacokinetic property (t1/2) in rat,A,In vivo,,Rattus norvegicus,10116.0,
7763,1,,BAO_0000218,Intermediate,1969.0,2552,Plasma elimination half-life was determined,A,,,Rattus norvegicus,10116.0,
7764,1,,BAO_0000218,Intermediate,1969.0,5199,Plasma elimination half-life was determined in female Sprague-Dawley rats following intravenous (iv) administration of drug (1 mg/kg).,A,In vivo,,Rattus norvegicus,10116.0,
7765,1,,BAO_0000218,Intermediate,1969.0,15662,Plasma half life was observed after intravenous administration in rat,A,In vivo,,Rattus norvegicus,10116.0,
7766,1,,BAO_0000218,Intermediate,1969.0,1465,Plasma half-life was determined,A,,,Rattus norvegicus,10116.0,
7767,1,,BAO_0000218,Intermediate,1969.0,1446,Plasma half-life following oral administration in Fisher rats,A,In vivo,,Rattus norvegicus,10116.0,
7768,1,,BAO_0000218,Intermediate,1969.0,6824,Plasma half-life in rat,A,,,Rattus norvegicus,10116.0,
7769,1,,BAO_0000218,Intermediate,1969.0,17533,Plasmatic Half-life after intravenous administration to rat,A,In vivo,,Rattus norvegicus,10116.0,
7770,1,,BAO_0000218,Intermediate,,5979,T1/2 (half life) of compound after 2 hr iv infusion of 8.4 mg/kg in three rat,A,In vivo,,Rattus norvegicus,10116.0,
7771,1,,BAO_0000218,Intermediate,,4689,Terminal half life after intravenous administration (1 mg/kg) in rat,A,In vivo,,Rattus norvegicus,10116.0,
7772,1,,BAO_0000218,Intermediate,,4689,Terminal half life in Rat at a oral dose of 5 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,
7773,1,,BAO_0000218,Intermediate,,2463,Terminal phase half-life was evaluated in vivo in rat at a dose of 5 mg/kg by intra venous administration,A,In vivo,,Rattus norvegicus,10116.0,
7774,1,,BAO_0000218,Intermediate,,4883,Tested for half life value after intravenous administration at dose of 0.2 mg/kg in rat,A,In vivo,,Rattus norvegicus,10116.0,
7775,1,,BAO_0000218,Intermediate,,4883,Tested for half life value after oral administration at dosage of 4 mg/kg in rat,A,In vivo,,Rattus norvegicus,10116.0,
7776,1,,BAO_0000218,Intermediate,1969.0,15662,plasma half life was observed after intravenous administration in rat,A,In vivo,,Rattus norvegicus,10116.0,
7777,1,,BAO_0000218,Expert,,3598,Half life of compound determined in rat after iv administration at a dose of 10 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,
7778,1,,BAO_0000218,Intermediate,,4576,Half life of compound determined in rat,A,,,Rattus norvegicus,10116.0,
7779,1,,BAO_0000218,Intermediate,,4576,Mean residence time determined in rat,A,,,Rattus norvegicus,10116.0,
7780,1,,BAO_0000218,Intermediate,,4576,Plasma half life determined in rat,A,,,Rattus norvegicus,10116.0,
7781,1,,BAO_0000218,Intermediate,955.0,4910,Compound was evaluated for Tmax in brain after intravenous administration in male rats,A,In vivo,,Rattus norvegicus,10116.0,
7782,1,,BAO_0000218,Intermediate,,4891,Compound was evaluated for pharmacokinetic parameter maximum time period,A,In vivo,,Rattus norvegicus,10116.0,
7783,1,,BAO_0000218,Intermediate,,429,Evaluated for pharmacokinetic parameter tmax in rat at the dose 50 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,
7784,1,,BAO_0000218,Intermediate,,5974,In vivo Tmax was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0,
7785,1,,BAO_0000218,Intermediate,,5974,In vivo Tmax was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0,
7786,1,,BAO_0000218,Intermediate,,5974,In vivo Tmax was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0,
7787,1,,BAO_0000218,Intermediate,,5974,In vivo Tmax was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0,
7788,1,,BAO_0000218,Intermediate,,17582,In vivo maximum time required for clearance of compound after oral (po) administration at a dose of 10 mg/kg was measured in rats,A,In vivo,,Rattus norvegicus,10116.0,
7789,1,,BAO_0000218,Intermediate,,4026,Maximum time (Tmax) required to reach Cmax in rats,A,,,Rattus norvegicus,10116.0,
7790,1,,BAO_0000218,Intermediate,,4890,Maximum time constant was determined after oral administration at a dose 10 mg/kg to male Sprague-Dawley rats,A,In vivo,,Rattus norvegicus,10116.0,
7791,1,,BAO_0000218,Intermediate,,6571,Maximum time of clearance of compound in rats after peroral administration,A,In vivo,,Rattus norvegicus,10116.0,
7792,1,,BAO_0000218,Intermediate,,4727,Maximum time at the dose of 2 mg/kg in rat,A,,,Rattus norvegicus,10116.0,
7793,1,,BAO_0000218,Intermediate,1969.0,17651,Maximum time to achieve peak plasma concentration was determined in rat at 1 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,
7794,1,,BAO_0000218,Intermediate,1969.0,17651,Maximum time to achieve peak plasma concentration was determined in rat at 10 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,
7795,1,,BAO_0000218,Intermediate,,14465,Tmax in Guinea pig (PO dose),A,In vivo,,Rattus norvegicus,10116.0,
7796,1,,BAO_0000218,Intermediate,,14941,"Pharmacokinetic Parameter, Tmax is the time at which maximum concentration (Cmax) is reached in Female Wistar Rats at 100 mg/kg by po administration",A,In vivo,,Rattus norvegicus,10116.0,
7797,1,,BAO_0000218,Intermediate,,5960,Pharmacokinetic parameter (Tmax) in rat,A,In vivo,,Rattus norvegicus,10116.0,
7798,1,,BAO_0000218,Intermediate,,5022,Pharmacokinetic parameter (Tmax) was estimated,A,In vivo,,Rattus norvegicus,10116.0,
7799,1,,BAO_0000218,Intermediate,,4408,Pharmacokinetic property (Tmax) in rat,A,In vivo,,Rattus norvegicus,10116.0,
7800,1,,BAO_0000218,Intermediate,,5983,Pharmacokinetic property (Tmax) was measured in rat at the dose of 0.32 mg/kg p.o.,A,In vivo,,Rattus norvegicus,10116.0,
7801,1,,BAO_0000218,Intermediate,,4689,T max in Rat at a oral dose of 5 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,
7802,1,,BAO_0000218,Intermediate,,2792,T max was determined at 10 mg/kg po dose in rats,A,In vivo,,Rattus norvegicus,10116.0,
7803,1,,BAO_0000218,Intermediate,,15011,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg (run time 7 hr),A,,,Mus musculus,10090.0,
7804,1,,BAO_0000218,Intermediate,,14180,Area under curve was evaluated after intravenous injection of 1 mg/kg of compound in dogs,A,,,Canis lupus familiaris,9615.0,
7805,1,,BAO_0000218,Intermediate,,14180,Area under curve was evaluated after intravenous injection of 1 mg/kg of compound in rats,A,,,Rattus norvegicus,10116.0,
7806,1,,BAO_0000218,Intermediate,,14599,Area under curve was measured after i.v. administration into Beagle dog.,A,,,Canis lupus familiaris,9615.0,
7807,1,,BAO_0000218,Intermediate,,14599,Area under curve was measured after iv administration into Beagle dog,A,,,Canis lupus familiaris,9615.0,
7808,1,,BAO_0000218,Intermediate,,14599,Area under curve was measured after po administration into Beagle dog,A,,,Canis lupus familiaris,9615.0,
7809,1,,BAO_0000218,Intermediate,,14599,Area under curve was measured after po administration into Beagle dog.,A,,,Canis lupus familiaris,9615.0,
7810,0,,BAO_0000218,Autocuration,,15675,Area under curve was measured at peroral dose of 3 mg/kg,A,,,,,
7811,0,,BAO_0000019,Autocuration,,12706,Area under curve was measured by using concentration Vs time,A,,,,,
7812,0,,BAO_0000019,Autocuration,,12706,Area under curve was measured by using concentration Vs time; not tested,A,,,,,
7813,1,,BAO_0000218,Intermediate,,9750,Area under curve(AUC) was measured in mice after oral administration (50 mg/kg),A,,,Mus musculus,10090.0,
7814,1,,BAO_0000218,Intermediate,,9750,Area under curve(AUC) was measured in mice after oral administration.,A,,,Mus musculus,10090.0,
7815,0,,BAO_0000019,Autocuration,,14691,Area under curve(AUC) value of the compound,A,,,,,
7816,0,,BAO_0000218,Autocuration,,14691,Area under curve(AUC) value of the compound in dogs at 0.5 mg/kg dose upon oral administration,A,,,,,
7817,1,,BAO_0000218,Intermediate,,14691,Area under curve(AUC) value of the compound in dogs at 1 mg/kg dose upon oral administration,A,,,Canis lupus familiaris,9615.0,
7818,0,,BAO_0000019,Autocuration,178.0,2939,Area under curve(carotid artery) was determined by the availability in blood,A,,,,,
7819,0,,BAO_0000019,Autocuration,178.0,2939,Area under curve(carotid artery) was determined by the availability in blood; ND means no data,A,,,,,
7820,0,,BAO_0000019,Autocuration,178.0,2939,Area under curve(carotid artery) was determined by the availability in blood; No data,A,,,,,
7821,0,,BAO_0000019,Autocuration,178.0,2939,Area under curve(portal vein) was determined by the availability in blood,A,,,,,
7822,0,,BAO_0000019,Autocuration,178.0,2939,Area under curve(portal vein) was determined by the availability in blood; ND means no data,A,,,,,
7823,0,,BAO_0000019,Autocuration,178.0,2939,Area under curve(portal vein) was determined by the availability in blood; No data,A,,,,,
7824,1,,BAO_0000218,Intermediate,1969.0,9552,"Area under plasma concentration vs time curve observed in Rhesus monkeys after, iv administration of single 30 mg/kg dose",A,,,Macaca mulatta,9544.0,
7825,1,,BAO_0000218,Intermediate,1969.0,9552,"Area under plasma concentration vs time curve observed in Rhesus monkeys after, iv administration of single 30 mg/kg dose",A,,,Macaca mulatta,9544.0,
7826,1,,BAO_0000218,Intermediate,1969.0,9552,Area under plasma concentration vs time curve observed in Rhesus monkeys after oral administration of single 30 mg/kg dose,A,,,Macaca mulatta,9544.0,
7827,1,,BAO_0000218,Intermediate,1969.0,9552,"Area under plasma concentration vs time curve observed in female mongrel dogs after, iv administration of single 15 mg/kg dose",A,,,Canis lupus familiaris,9615.0,
7828,1,,BAO_0000218,Intermediate,1969.0,9552,"Area under plasma concentration vs time curve observed in female mongrel dogs after, oral administration of single 15 mg/kg dose",A,,,Canis lupus familiaris,9615.0,
7829,0,,BAO_0000019,Autocuration,1969.0,9552,Area under plasma concentration vs time curve observed in rats for 0-3 h,A,,,,,
7830,1,,BAO_0000218,Intermediate,1969.0,11911,Area under plasma time curve determined in male rat,A,,,Rattus norvegicus,10116.0,
7831,0,,BAO_0000019,Autocuration,,16618,Area under the MAP curve measured over 5 min.,A,,,,,
7832,1,,BAO_0000218,Intermediate,,14387,Area under the concentration time curve (AUC) taken for 0-24 hr was measured when administered through iv route in mice,A,,,Mus musculus,10090.0,
7833,1,,BAO_0000218,Intermediate,,14387,Area under the concentration time curve (AUC) taken for 0-24 hr was measured when administered through oral route in mice,A,,,Mus musculus,10090.0,
7834,1,,BAO_0000218,Intermediate,,12836,Area under the concentration vs time curve in dog at 10 mg/kg oral dose,A,,,Canis lupus familiaris,9615.0,
7835,1,,BAO_0000218,Intermediate,,12836,Area under the concentration vs time curve in hamster at 10 mg/kg oral dose,A,,,Cricetinae,10026.0,
7836,1,,BAO_0000218,Intermediate,,12836,Area under the concentration vs time curve in rat at 10 mg/kg oral dose,A,,,Rattus norvegicus,10116.0,
7837,1,,BAO_0000218,Intermediate,,14339,Area under the concentration-time curve from time zero to infinity after intravenous administration of 2.5 mg/kg in dogs,A,,,Canis lupus familiaris,9615.0,
7838,1,,BAO_0000218,Intermediate,,14339,Area under the concentration-time curve from time zero to infinity in oral (5 mg/kg) fasted dogs,A,,,Canis lupus familiaris,9615.0,
7839,1,,BAO_0000218,Intermediate,,14339,Area under the concentration-time curve from time zero to infinity in oral (5 mg/kg) fed dogs,A,,,Canis lupus familiaris,9615.0,
7840,1,,BAO_0000218,Intermediate,,10524,Area under the concentration/ time determined against Bacillus subtilis ATCC 6633 after oral administration in dog(25 mg/kg),A,,,Canis lupus familiaris,9615.0,
7841,1,,BAO_0000218,Intermediate,,9994,Area under the concentration/ time in plasma after oral administration in dog (25 mg/kg),A,,,Canis lupus familiaris,9615.0,
7842,1,,BAO_0000218,Intermediate,,11325,Serum AUC in marmosets (IV dose),A,,,Canis lupus familiaris,9615.0,
7843,0,,BAO_0000019,Autocuration,,12536,Area under the curve after intravenous administration at a dose of 10 umol/kg,A,,,,,
7844,0,,BAO_0000019,Autocuration,,12536,Area under the curve after intravenous administration at a dose of 2 umol/kg,A,,,,,
7845,0,,BAO_0000019,Autocuration,,12536,Area under the curve after intravenous administration at a dose of 4 umol/kg,A,,,,,
7846,0,,BAO_0000019,Autocuration,,12536,Area under the curve after intravenous administration at a dose of 40 umol/kg,A,,,,,
7847,0,,BAO_0000019,Autocuration,,12536,Area under the curve after intravenous administration at a dose of 5 umol/kg,A,,,,,
7848,1,,BAO_0000218,Intermediate,,15556,Area under the curve for fumarate salt was evaluated in F344 Rats.,A,,,Rattus norvegicus,10116.0,
7849,0,,BAO_0000019,Autocuration,,2809,Area under the curve for the compound was calculated.,A,,,,,
7850,0,,BAO_0000019,Autocuration,,9511,Area under the curve in concentration/ time,A,,,,,
7851,1,,BAO_0000218,Intermediate,,12818,Area under the curve administered intraintestinal in rats.,A,,,Rattus norvegicus,10116.0,
7852,1,,BAO_0000218,Intermediate,,12818,Area under the curve administered intravenously in rats.,A,,,Rattus norvegicus,10116.0,
7853,0,,BAO_0000019,Autocuration,,15118,Area under the curve during intravenous administration,A,,,,,
7854,0,,BAO_0000019,Autocuration,,15118,Area under the curve during intravenous administration; Not determined,A,,,,,
7855,0,,BAO_0000019,Autocuration,,15118,Area under the curve during systemic administration,A,,,,,
7856,0,,BAO_0000019,Autocuration,,15118,Area under the curve during systemic administration; Not determined,A,,,,,
7857,0,,BAO_0000019,Autocuration,,2632,Area under the curve was calculated for the compound.,A,,,,,
7858,1,,BAO_0000218,Intermediate,,14346,Area under the curve was determined after intravenous administration of 1.8 mg/kg in male Beagle dogs,A,,,Canis lupus familiaris,9615.0,
7859,1,,BAO_0000218,Intermediate,,14346,Area under the curve was determined after intravenous administration of 10 mg/kg in male Beagle dogs,A,,,Canis lupus familiaris,9615.0,
7860,1,,BAO_0000218,Intermediate,,14346,Area under the curve was determined after intravenous administration of 2.5 mg/kg in male Dawley rats,A,,,Rattus norvegicus,10116.0,
7861,1,,BAO_0000218,Intermediate,,14346,Area under the curve was determined after intravenous administration of 2.6 mg/kg in male Dawley rats,A,,,Rattus norvegicus,10116.0,
7862,1,,BAO_0000218,Intermediate,,11149,C6h was measured as concentration obtained after 6 hr of oral administration in air pouch exudate after oral administration to male F344 rats,A,,,Rattus norvegicus,10116.0,
7863,1,,BAO_0000218,Intermediate,1969.0,17796,Clearance of the drug was measured in the plasma of rat; No data,A,,,Rattus norvegicus,10116.0,
7864,1,,BAO_0000218,Intermediate,1969.0,5247,The pharmacokinetic parameter plasma clearance in vivo in rats,A,,,Rattus norvegicus,10116.0,
7865,1,,BAO_0000218,Intermediate,,4727,Plasma clearance at the dose of 2 mg/kg in rat,A,,,Rattus norvegicus,10116.0,
7866,1,,BAO_0000218,Intermediate,,5654,CL (clearance) of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 16 mg/kg peroral administration,A,In vivo,,Rattus norvegicus,10116.0,
7867,1,,BAO_0000218,Intermediate,,5654,CL (clearance) of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 20 mg/kg peroral administration,A,In vivo,,Rattus norvegicus,10116.0,
7868,1,,BAO_0000218,Intermediate,,17260,CL at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,A,In vivo,,Rattus norvegicus,10116.0,
7869,1,,BAO_0000218,Intermediate,,17065,Clearance measured after intravenous bolus administration of 50 mg/kg of compound to rats,A,In vivo,,Rattus norvegicus,10116.0,
7870,1,,BAO_0000218,Intermediate,,17671,Clearance in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,
7871,1,,BAO_0000218,Intermediate,,6672,Clearance rate in rat,A,In vivo,,Rattus norvegicus,10116.0,
7872,1,,BAO_0000218,Intermediate,,6673,Clearance rate in rat,A,In vivo,,Rattus norvegicus,10116.0,
7873,1,,BAO_0000218,Intermediate,,5978,Clearance (Cl) of compound (10 mg/kg) after iv administration was determined in Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0,
7874,1,,BAO_0000218,Intermediate,,5978,Clearance (Cl) of compound (9.83 mg/kg) after iv administration was determined in Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0,
7875,1,,BAO_0000218,Intermediate,,5978,Clearance (Cl) of compound (9.84 mg/kg) after iv administration was determined in Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0,
7876,1,,BAO_0000218,Intermediate,,5978,Clearance (Cl) of compound (9.92 mg/kg) after iv administration was determined in Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0,
7877,1,,BAO_0000218,Intermediate,,4413,Clearance of compound after iv administration of 20 mg/kg dose in rat,A,In vivo,,Rattus norvegicus,10116.0,
7878,1,,BAO_0000218,Intermediate,,2661,Compound was evaluated for clearance after treatment with iv dose of 1 mgkg to female wistar rats,A,In vivo,,Rattus norvegicus,10116.0,
7879,1,,BAO_0000218,Intermediate,,2661,Compound was evaluated for clearance after treatment with iv dose of 1 mgkg to male wistar rats,A,In vivo,,Rattus norvegicus,10116.0,
7880,0,,BAO_0000218,Intermediate,1969.0,5005,Compound was tested for its plasma clearance rate in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,A,In vivo,,Macaca mulatta,9544.0,
7881,0,,BAO_0000218,Intermediate,1969.0,5005,Compound was tested for its plasma clearance rate in Sprague Dawley rats,A,In vivo,,Rattus norvegicus,10116.0,
7882,1,,BAO_0000218,Intermediate,,15765,Mean (%CV) PK parameters for CL(mL/min/kg).,A,In vivo,,Rattus norvegicus,10116.0,
7883,1,,BAO_0000218,Intermediate,,3747,Pharmacokinetic studies were carried out to determine the clearance after administration at 20 mg/kg intravenously in rat,A,In vivo,,Rattus norvegicus,10116.0,
7884,1,,BAO_0000218,Intermediate,1969.0,16366,Pharmacokinetic parameter plasma clearance was determined at when a dose of 1 mg/kg is administered,A,In vivo,,Rattus norvegicus,10116.0,
7885,1,,BAO_0000218,Intermediate,,4199,Plasma Clearance measured at steady-state following iv infusion at 0.6 mg/kg/h in rats,A,In vivo,,Rattus norvegicus,10116.0,
7886,1,,BAO_0000218,Intermediate,,17267,Plasma clearance in rat was determined,A,In vivo,,Rattus norvegicus,10116.0,
7887,1,,BAO_0000218,Intermediate,,6535,Plasma clearance in rat after administration of 2 mg/kg iv,A,In vivo,,Rattus norvegicus,10116.0,
7888,1,,BAO_0000218,Intermediate,,6535,Plasma clearance in rat after administration of 2 mg/kg iv,A,In vivo,,Rattus norvegicus,10116.0,
7889,1,,BAO_0000218,Intermediate,,5041,Plasma clearance was determined,A,In vivo,,Rattus norvegicus,10116.0,
7890,1,,BAO_0000218,Intermediate,,5960,Plasma clearance in rat,A,In vivo,,Rattus norvegicus,10116.0,
7891,1,,BAO_0000218,Intermediate,,5937,Plasma clearance in rat after intravenous administration at a concentration 0.5 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,
7892,1,,BAO_0000218,Intermediate,,5871,Plasma clearance in rat by iv administration,A,In vivo,,Rattus norvegicus,10116.0,
7893,1,,BAO_0000218,Intermediate,,5874,Plasma clearance in rat by iv administration at a dose of 3 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,
7894,1,,BAO_0000218,Intermediate,,6504,Plasma clearance in rat p.o.,A,In vivo,,Rattus norvegicus,10116.0,
7895,1,,BAO_0000218,Intermediate,,6803,Plasma clearance in rats,A,In vivo,,Rattus norvegicus,10116.0,
7896,1,,BAO_0000218,Intermediate,,5041,Plasma clearance was determined; ND denotes no data,A,In vivo,,Rattus norvegicus,10116.0,
7897,1,,BAO_0000218,Intermediate,,5041,Plasma clearance was determined; ND denotes not determined,A,In vivo,,Rattus norvegicus,10116.0,
7898,1,,BAO_0000218,Intermediate,,1916,Plasma clearance was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after iv administration,A,In vivo,,Rattus norvegicus,10116.0,
7899,1,,BAO_0000218,Intermediate,,5199,Plasma clearance was determined in female Sprague-Dawley rats following intravenous (iv) administration of drug (1 mg/kg).,A,In vivo,,Rattus norvegicus,10116.0,
7900,1,,BAO_0000218,Intermediate,,16367,Plasma administration to rats,A,In vivo,,Rattus norvegicus,10116.0,
7901,1,,BAO_0000218,Intermediate,,6362,Plasma clearance of the compound in female Sprague-Dawley rats,A,In vivo,,Rattus norvegicus,10116.0,
7902,1,,BAO_0000218,Intermediate,,15662,Plasma clearance was observed after intravenous administration in rat,A,In vivo,,Rattus norvegicus,10116.0,
7903,1,,BAO_0000218,Intermediate,,6215,Systemic clearance after intravenous administration (5.0 mg/kg) was determined in rat,A,In vivo,,Rattus norvegicus,10116.0,
7904,1,,BAO_0000218,Intermediate,,1466,Tested for systemic clearance upon intravenous administration of 5.0 mg/Kg dose in rat,A,In vivo,,Rattus norvegicus,10116.0,
7905,1,,BAO_0000218,Intermediate,1969.0,15662,plasma clearance was observed after intravenous administration in rat,A,In vivo,,Rattus norvegicus,10116.0,
7906,1,,BAO_0000218,Intermediate,,4723,In vivo CL/F determined,A,In vivo,,Rattus norvegicus,10116.0,
7907,1,,BAO_0000218,Intermediate,1969.0,2792,Pharmacokinetic parameter plasma clearance was determined at 2 mg/kg i.v. dose in rats,A,In vivo,,Rattus norvegicus,10116.0,
7908,1,,BAO_0000218,Intermediate,1969.0,2792,Pharmacokinetic parameter plasma clearance was determined at 5 mg/kg i.v. dose in rats,A,In vivo,,Rattus norvegicus,10116.0,
7909,1,,BAO_0000218,Intermediate,,5213,Compound was tested for the lower blood clearance in rat,A,In vivo,,Rattus norvegicus,10116.0,
7910,1,,BAO_0000218,Intermediate,,4687,Evaluated for the low clearance in rat (in vivo),A,In vivo,,Rattus norvegicus,10116.0,
7911,1,,BAO_0000218,Intermediate,,3371,Pharmacokinetic property (CLb)of the compound was determined in rat,A,In vivo,,Rattus norvegicus,10116.0,
7912,1,,BAO_0000218,Intermediate,,4690,Rapid clearance after intravenous administration in rat was determined,A,In vivo,,Rattus norvegicus,10116.0,
7913,1,,BAO_0000218,Intermediate,,5702,Clearance measured in rat,A,In vivo,,Rattus norvegicus,10116.0,
7914,1,,BAO_0000218,Intermediate,1969.0,740,Compound was evaluated for plasma clearance in rat,A,In vivo,,Rattus norvegicus,10116.0,
7915,1,,BAO_0000218,Intermediate,1969.0,4853,Low plasma clearance was calculated in rat,A,In vivo,,Rattus norvegicus,10116.0,
7916,1,,BAO_0000218,Intermediate,,5789,Pharmacokinetic property (Clp) in rat,A,In vivo,,Rattus norvegicus,10116.0,
7917,1,,BAO_0000218,Intermediate,,4527,Plasma clearance in dog at a dose of 1 uM/kg in rat was determined,A,In vivo,,Rattus norvegicus,10116.0,
7918,1,,BAO_0000218,Intermediate,,4527,Plasma clearance in rat at a dose of 10 uM/kg in rat was determined,A,In vivo,,Rattus norvegicus,10116.0,
7919,1,,BAO_0000218,Intermediate,,6518,Plasma clearance after IV dosing at 0.5 mg/kg in rat,A,In vivo,,Rattus norvegicus,10116.0,
7920,1,,BAO_0000218,Intermediate,,6518,Plasma clearance after IV dosing at 1 mg/kg in rat,A,In vivo,,Rattus norvegicus,10116.0,
7921,1,,BAO_0000218,Intermediate,948.0,9866,Biodistribution in rat heart in the presence of 0.01 M Gd/0.01 M GdDTPA-AEP,A,In vivo,,Rattus norvegicus,10116.0,
7922,1,,BAO_0000218,Intermediate,948.0,9866,Biodistribution in rat heart in the presence of 0.01 M GdDTPA-BDP,A,In vivo,,Rattus norvegicus,10116.0,
7923,1,,BAO_0000218,Intermediate,948.0,9866,Biodistribution in rat heart in the presence of 0.01 M/0.08 M GdDTPA-AEP,A,In vivo,,Rattus norvegicus,10116.0,
7924,1,,BAO_0000218,Intermediate,948.0,9866,Biodistribution in rat heart in the presence of 0.05 M /0.05 M GdDTPA-AEP,A,In vivo,,Rattus norvegicus,10116.0,
7925,1,,BAO_0000218,Intermediate,948.0,9866,Biodistribution in rat heart in the presence of 0.05 M Gd/0.15 M lig,A,In vivo,,Rattus norvegicus,10116.0,
7926,1,,BAO_0000218,Intermediate,948.0,9866,Biodistribution in rat heart in the presence of 0.05 M GdDTPA-BDP,A,In vivo,,Rattus norvegicus,10116.0,
7927,1,,BAO_0000218,Intermediate,948.0,9866,Biodistribution in rat heart in the presence of 0.05 M/0.08 M GdDTPA-HPDP,A,In vivo,,Rattus norvegicus,10116.0,
7928,1,,BAO_0000218,Intermediate,948.0,9866,Biodistribution in rat heart in the presence of 0.10 M GdDTPA-BDP,A,In vivo,,Rattus norvegicus,10116.0,
7929,1,,BAO_0000218,Intermediate,948.0,9866,Biodistribution in rat heart in the presence of 0.10 M/0.11 M GdDTPA-AEP,A,In vivo,,Rattus norvegicus,10116.0,
7930,1,,BAO_0000218,Intermediate,948.0,9866,Biodistribution in rat heart in the presence of GdDTPA at 15 min,A,In vivo,,Rattus norvegicus,10116.0,
7931,1,,BAO_0000218,Intermediate,948.0,9866,Biodistribution in rat heart in the presence of GdDTPA at 1 hr,A,In vivo,,Rattus norvegicus,10116.0,
7932,1,,BAO_0000218,Intermediate,948.0,9866,Biodistribution in rat heart in the presence of GdDTPA at 30 min,A,In vivo,,Rattus norvegicus,10116.0,
7933,1,,BAO_0000218,Intermediate,948.0,9866,Biodistribution in rat heart in the presence of GdDTPA at 4 hr,A,In vivo,,Rattus norvegicus,10116.0,
7934,1,,BAO_0000218,Intermediate,948.0,9866,Biodistribution in rat heart in the presence of GdDTPA-BDP at 1 hr,A,In vivo,,Rattus norvegicus,10116.0,
7935,1,,BAO_0000218,Intermediate,948.0,9866,Biodistribution in rat heart in the presence of GdDTPA-BDP at 30 min,A,In vivo,,Rattus norvegicus,10116.0,
7936,1,,BAO_0000218,Intermediate,948.0,9866,Biodistribution in rat heart in the presence of GdDTPA-BDP at 4 hr,A,In vivo,,Rattus norvegicus,10116.0,
7937,1,,BAO_0000218,Intermediate,948.0,9866,Biodistribution in rat heart in the presence of GdDTPA-BDPat 15 min,A,In vivo,,Rattus norvegicus,10116.0,
7938,1,,BAO_0000218,Intermediate,948.0,9866,Biodistribution in rat heart in the presence of GdDTPA-HPDP at 1 hr,A,In vivo,,Rattus norvegicus,10116.0,
7939,1,,BAO_0000218,Intermediate,948.0,9866,Biodistribution in rat heart in the presence of GdDTPA-HPDP at 30 min,A,In vivo,,Rattus norvegicus,10116.0,
7940,1,,BAO_0000218,Intermediate,948.0,9866,Biodistribution in rat heart in the presence of GdDTPA-HPDP at 4 hr,A,In vivo,,Rattus norvegicus,10116.0,
7941,1,,BAO_0000218,Intermediate,948.0,9866,Biodistribution in rat heart in the presence of GdDTPA-HPDPat 15 min,A,In vivo,,Rattus norvegicus,10116.0,
7942,1,,BAO_0000218,Intermediate,948.0,9866,Biodistribution in rat heart in the presence of NAC Gd/0.01 M GdDTPA-HPDP,A,In vivo,,Rattus norvegicus,10116.0,
7943,1,,BAO_0000218,Intermediate,948.0,9866,Biodistribution in rat heart in the presence of NCA Gd/0.01 M lip,A,In vivo,,Rattus norvegicus,10116.0,
7944,1,,BAO_0000218,Intermediate,948.0,9866,Biodistribution in rat heart in the presence of NCAGd/0.01 M lig,A,In vivo,,Rattus norvegicus,10116.0,
7945,1,,BAO_0000218,Intermediate,2113.0,9866,Biodistribution in rat kidney in the presence of 0.01 M GdDTPA-BDP,A,In vivo,,Rattus norvegicus,10116.0,
7946,1,,BAO_0000218,Intermediate,2113.0,9866,Biodistribution in rat kidney in the presence of 0.01 M/0.01 M GdDTPA-AEP,A,In vivo,,Rattus norvegicus,10116.0,
7947,1,,BAO_0000218,Intermediate,2113.0,9866,Biodistribution in rat kidney in the presence of 0.01 M/0.08 M GdDTPA-AEP,A,In vivo,,Rattus norvegicus,10116.0,
7948,1,,BAO_0000218,Intermediate,2113.0,9866,Biodistribution in rat kidney in the presence of 0.05 M Gd/0.15 M lig,A,In vivo,,Rattus norvegicus,10116.0,
7949,1,,BAO_0000218,Intermediate,2113.0,9866,Biodistribution in rat kidney in the presence of 0.05 M GdDTPA-BDP; ND=No data,A,In vivo,,Rattus norvegicus,10116.0,
7950,1,,BAO_0000218,Intermediate,2113.0,9866,Biodistribution in rat kidney in the presence of 0.05 M/0.05 M GdDTPA-AEP,A,In vivo,,Rattus norvegicus,10116.0,
7951,1,,BAO_0000218,Intermediate,2113.0,9866,Biodistribution in rat kidney in the presence of 0.05 M/0.08 M GdDTPA-HPDP,A,In vivo,,Rattus norvegicus,10116.0,
7952,1,,BAO_0000218,Intermediate,2113.0,9866,Biodistribution in rat kidney in the presence of 0.10 M GdDTPA-BDP,A,In vivo,,Rattus norvegicus,10116.0,
7953,1,,BAO_0000218,Intermediate,2113.0,9866,Biodistribution in rat kidney in the presence of 0.10 M/0.11 M GdDTPA-AEP; ND=No data,A,In vivo,,Rattus norvegicus,10116.0,
7954,1,,BAO_0000218,Intermediate,2113.0,9866,Biodistribution in rat kidney in the presence of NAC Gd/0.01 M GdDTPA-HPDP,A,In vivo,,Rattus norvegicus,10116.0,
7955,1,,BAO_0000218,Intermediate,2113.0,9866,Biodistribution in rat kidney in the presence of NCA Gd/0.01 M lip,A,In vivo,,Rattus norvegicus,10116.0,
7956,1,,BAO_0000218,Intermediate,2113.0,9866,Biodistribution in rat kidney in the presence of NCAGd/0.01 M lig,A,In vivo,,Rattus norvegicus,10116.0,
7957,1,,BAO_0000218,Intermediate,160.0,9866,Biodistribution in rat l. intestine in the presence of 0.01 M carrier at 1 hr,A,In vivo,,Rattus norvegicus,10116.0,
7958,1,,BAO_0000218,Intermediate,160.0,9866,Biodistribution in rat l. intestine in the presence of 50 Gd/kg at 2 hr,A,In vivo,,Rattus norvegicus,10116.0,
7959,1,,BAO_0000218,Intermediate,160.0,9866,Biodistribution in rat l. intestine in the presence of 50 Gd/kg at 6 hr,A,In vivo,,Rattus norvegicus,10116.0,
7960,1,,BAO_0000218,Intermediate,2107.0,9866,Biodistribution in rat liver by in the presence 50 Gd/kg at 15 min,A,In vivo,,Rattus norvegicus,10116.0,
7961,1,,BAO_0000218,Intermediate,2107.0,9866,Biodistribution in rat liver by in the presence of 0.05 M Gd/0.15 M lig,A,In vivo,,Rattus norvegicus,10116.0,
7962,1,,BAO_0000218,Intermediate,2107.0,9866,Biodistribution in rat liver by in the presence of NCAGd/0.01 M lig,A,In vivo,,Rattus norvegicus,10116.0,
7963,1,,BAO_0000218,Intermediate,2107.0,9866,Biodistribution in rat liver in the presence of 0.001 M/0.008 M GdDTPA-AEP,A,In vivo,,Rattus norvegicus,10116.0,
7964,1,,BAO_0000218,Intermediate,2107.0,9866,Biodistribution in rat liver in the presence of 0.01 M GdDTPA-BDP,A,In vivo,,Rattus norvegicus,10116.0,
7965,1,,BAO_0000218,Intermediate,2107.0,9866,Biodistribution in rat liver in the presence of 0.01 M/0.01 M GdDTPA-AEP,A,In vivo,,Rattus norvegicus,10116.0,
7966,1,,BAO_0000218,Intermediate,2107.0,9866,Biodistribution in rat liver in the presence of 0.05 M GdDTPA-BDP,A,In vivo,,Rattus norvegicus,10116.0,
7967,1,,BAO_0000218,Intermediate,2107.0,9866,Biodistribution in rat liver in the presence of 0.05 M/0.05 M GdDTPA-AEP,A,In vivo,,Rattus norvegicus,10116.0,
7968,1,,BAO_0000218,Intermediate,2107.0,9866,Biodistribution in rat liver in the presence of 0.05 M/0.08 M GdDTPA-HPDP,A,In vivo,,Rattus norvegicus,10116.0,
7969,1,,BAO_0000218,Intermediate,2107.0,9866,Biodistribution in rat liver in the presence of 0.10 M GdDTPA-BDP,A,In vivo,,Rattus norvegicus,10116.0,
7970,1,,BAO_0000218,Intermediate,2107.0,9866,Biodistribution in rat liver in the presence of 0.10 M/0.11 M GdDTPA-AEP; ND=No data,A,In vivo,,Rattus norvegicus,10116.0,
7971,1,,BAO_0000218,Intermediate,2107.0,9866,Biodistribution in rat liver in the presence of 50 Gd/kg at 2 hr,A,In vivo,,Rattus norvegicus,10116.0,
7972,1,,BAO_0000218,Intermediate,2107.0,9866,Biodistribution in rat liver in the presence of 50 Gd/kg at at 6 hr,A,In vivo,,Rattus norvegicus,10116.0,
7973,1,,BAO_0000218,Intermediate,2107.0,9866,Biodistribution in rat liver in the presence of GdDTPA at 15 min,A,In vivo,,Rattus norvegicus,10116.0,
7974,1,,BAO_0000218,Intermediate,2107.0,9866,Biodistribution in rat liver in the presence of GdDTPA at 1 hr,A,In vivo,,Rattus norvegicus,10116.0,
7975,1,,BAO_0000218,Intermediate,2107.0,9866,Biodistribution in rat liver in the presence of GdDTPA at 30 min,A,In vivo,,Rattus norvegicus,10116.0,
7976,1,,BAO_0000218,Intermediate,2107.0,9866,Biodistribution in rat liver in the presence of GdDTPA at 4 hr,A,In vivo,,Rattus norvegicus,10116.0,
7977,1,,BAO_0000218,Intermediate,2107.0,9866,Biodistribution in rat liver in the presence of GdDTPA-BDP at 15 min,A,In vivo,,Rattus norvegicus,10116.0,
7978,1,,BAO_0000218,Intermediate,,2792,T max was determined at 3 mg/kg po dose in rats,A,In vivo,,Rattus norvegicus,10116.0,
7979,1,,BAO_0000218,Intermediate,,15078,"The Tmax value in female wistar rat at 100 mg/kg, p.o. dose",A,In vivo,,Rattus norvegicus,10116.0,
7980,1,,BAO_0000218,Intermediate,,15078,"The Tmax value in male wistar rat at 100 mg/kg, p.o. dose",A,In vivo,,Rattus norvegicus,10116.0,
7981,1,,BAO_0000218,Intermediate,,15022,The time to reach maximum concentration of compound was measured at the dose of 100 umol/kg,A,,,Rattus norvegicus,10116.0,
7982,1,,BAO_0000218,Intermediate,,15022,The time to reach maximum concentration of compound was measured at the dose of 300 umol/kg,A,,,Rattus norvegicus,10116.0,
7983,1,,BAO_0000218,Intermediate,,15022,The time to reach maximum concentration of compound was measured at the dose of 30 umol/kg,A,,,Rattus norvegicus,10116.0,
7984,1,,BAO_0000218,Intermediate,1969.0,4576,Time for maximum plasma concentration determined in rat,A,,,Rattus norvegicus,10116.0,
7985,1,,BAO_0000218,Intermediate,1969.0,6681,Time for maximum plasma concentration reached by compound was determined in rats at 50 mg/kg dose,A,In vivo,,Rattus norvegicus,10116.0,
7986,1,,BAO_0000218,Intermediate,,16365,Time of maximum concentration of the drug when administered orally a dose of 10 mg/kg to a fasting rat,A,In vivo,,Rattus norvegicus,10116.0,
7987,1,,BAO_0000218,Intermediate,,16365,Time of maximum concentration of the drug when administered orally a dose of 1 mg/kg to a fasting rat,A,In vivo,,Rattus norvegicus,10116.0,
7988,1,,BAO_0000218,Intermediate,,16365,Time of maximum concentration of the drug when administered orally a dose of 30 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,
7989,1,,BAO_0000218,Intermediate,,16365,Time of maximum concentration of the drug when administered orally a dose of 3 mg/kg to a fasting rat,A,In vivo,,Rattus norvegicus,10116.0,
7990,1,,BAO_0000218,Intermediate,,16365,Time of maximum concentration of the drug when administered orally at dose of 3 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,
7991,1,,BAO_0000218,Intermediate,1969.0,6824,Time of maximum plasma concentration in rat,A,,,Rattus norvegicus,10116.0,
7992,1,,BAO_0000218,Intermediate,1969.0,6685,"Time required by compound for reaching maximum plasma concentration was determined in rats at 10 mg/kg, p.o. dose",A,,,Rattus norvegicus,10116.0,
7993,1,,BAO_0000218,Intermediate,1969.0,6685,"Time required by compound for reaching maximum plasma concentration was determined in rats at 20 mg/kg, i.p. dose",A,,,Rattus norvegicus,10116.0,
7994,1,,BAO_0000218,Intermediate,1969.0,6685,"Time required by compound for reaching maximum plasma concentration was determined in rats at 2 mg/kg, i.v. dose; n/a: not applicable",A,,,Rattus norvegicus,10116.0,
7995,1,,BAO_0000218,Intermediate,,15662,Time required to reach maximum concentration (Cmax) after oral administration in rat,A,In vivo,,Rattus norvegicus,10116.0,
7996,1,,BAO_0000218,Intermediate,1969.0,1742,Time required to reach maximum concentration in rat plasma,A,,,Rattus norvegicus,10116.0,
7997,1,,BAO_0000218,Intermediate,1969.0,2774,Time taken by the compound to achieve maximum concentration in rat plasma at 30 mg/Kg upon oral administration.,A,In vivo,,Rattus norvegicus,10116.0,
7998,1,,BAO_0000218,Intermediate,1969.0,5199,Time taken by the compound to achieve maximum plasma concentration at a 1 mg/kg oral dose in female Sprague-Dawley rats,A,In vivo,,Rattus norvegicus,10116.0,
7999,1,,BAO_0000218,Intermediate,1969.0,12873,Time taken for maximum plasma concentration for the compound in solution form (formulation) was determined in rats at peroral dose of 5 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,
8000,1,,BAO_0000218,Intermediate,1969.0,12873,Time taken for maximum plasma concentration for the compound in suspension form (formulation) was determined in rats at peroral dose of 5 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,
8001,1,,BAO_0000218,Intermediate,1969.0,1916,Time taken to reach maximum concentration in plasma was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after po administration,A,In vivo,,Rattus norvegicus,10116.0,
8002,1,,BAO_0000218,Intermediate,,16367,Time to reach Cmax after oral administration to rats,A,In vivo,,Rattus norvegicus,10116.0,
8003,1,,BAO_0000218,Intermediate,,16366,Time to reach Cmax when a dose of 1 mg/kg is administered orally,A,In vivo,,Rattus norvegicus,10116.0,
8004,1,,BAO_0000218,Intermediate,,216,Time to reach maximum concentration following oral administration of 200 mg/kg in rat; value ranges from 2-4,A,,,Rattus norvegicus,10116.0,
8005,1,,BAO_0000218,Intermediate,1969.0,6410,Time to reach maximum plasma concentration was evaluated at an intravenous dose of 3 mg/kg; Not applicable,A,In vivo,,Rattus norvegicus,10116.0,
8006,1,,BAO_0000218,Intermediate,1969.0,6410,Time to reach maximum plasma concentration was evaluated at an oral dose of 30 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,
8007,1,,BAO_0000218,Intermediate,,6215,Tmax after peroral administration (10 mg/kg) was determined in rat,A,In vivo,,Rattus norvegicus,10116.0,
8008,1,,BAO_0000218,Expert,,3598,Tmax of compound determined in rat after iv administration at a dose of 10 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,
8009,1,,BAO_0000218,Intermediate,,4527,Tmax by oral administration at a dose of 100 uM/kg in rat was determined,A,In vivo,,Rattus norvegicus,10116.0,
8010,1,,BAO_0000218,Intermediate,,17670,"Tmax in fischer rats at 5 mg/kg dose, administered intravenously",A,In vivo,,Rattus norvegicus,10116.0,
8011,1,,BAO_0000218,Intermediate,,1465,Tmax was determined,A,,,Rattus norvegicus,10116.0,
8012,1,,BAO_0000218,Intermediate,,2552,Tmax was determined,A,,,Rattus norvegicus,10116.0,
8013,1,,BAO_0000218,Intermediate,,5656,Tmax after oral administration in rat,A,In vivo,,Rattus norvegicus,10116.0,
8014,1,,BAO_0000218,Intermediate,,17764,Tmax after peroral administration in rats at 2.4 uM/kg,A,In vivo,,Rattus norvegicus,10116.0,
8015,1,,BAO_0000218,Intermediate,,5610,Tmax in male rat,A,,,Rattus norvegicus,10116.0,
8016,1,,BAO_0000218,Intermediate,,6046,Tmax in rat at 10 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,
8017,1,,BAO_0000218,Intermediate,,5874,Tmax in rat by po administration at a dose of 40 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,
8018,1,,BAO_0000218,Intermediate,,17596,Tmax in rats,A,,,Rattus norvegicus,10116.0,
8019,1,,BAO_0000218,Intermediate,,17804,Tmax was measured in rats after peroral administration at 5 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,
8020,1,,BAO_0000218,Intermediate,,1908,Tmax value after oral dose at a dose of 10 mg/kg in rats.,A,In vivo,,Rattus norvegicus,10116.0,
8021,1,,BAO_0000218,Intermediate,,2959,Tmax value after administration of 20 mg/Kg oral dose in rat,A,In vivo,,Rattus norvegicus,10116.0,
8022,1,,BAO_0000218,Intermediate,,6757,Tmax value at a dose of 10 mg/kg in male SD rats,A,In vivo,,Rattus norvegicus,10116.0,
8023,1,,BAO_0000218,Intermediate,,6757,Tmax value at a dose of 100 mg/kg in male SD rats,A,In vivo,,Rattus norvegicus,10116.0,
8024,1,,BAO_0000218,Intermediate,,6757,Tmax value at a dose of 50 mg/kg in male SD rats,A,In vivo,,Rattus norvegicus,10116.0,
8025,1,,BAO_0000218,Intermediate,1969.0,4186,Total concentration in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,A,In vivo,,Rattus norvegicus,10116.0,
8026,1,,BAO_0000218,Intermediate,,15662,time required to reach maximum concentration (Cmax) after oral administration in rat,A,In vivo,,Rattus norvegicus,10116.0,
8027,1,,BAO_0000218,Intermediate,1088.0,429,Evaluated for pharmacokinetic parameter urine recovery in rat at the dose 50 mg/kg ( 0-24 hr ),A,,,Rattus norvegicus,10116.0,
8028,1,,BAO_0000218,Intermediate,1088.0,429,Evaluated for pharmacokinetic parameter urine recovery in rat at the dose 50 mg/kg (0-24 hr),A,,,Rattus norvegicus,10116.0,
8029,1,,BAO_0000218,Intermediate,,5546,Unbound plasma was determined in Sprague-Dawley rats at a dose of 1 mg/kg by iv administration,A,,,Rattus norvegicus,10116.0,
8030,1,,BAO_0000218,Intermediate,1088.0,3173,Amount of urine output was measured in rat at a dose of 1 mg/kg/po,A,,,Rattus norvegicus,10116.0,
8031,1,,BAO_0000218,Intermediate,1088.0,3173,Amount of urine output was measured in rat at a dose of 10 mg/kg/po,A,,,Rattus norvegicus,10116.0,
8032,1,,BAO_0000218,Intermediate,1088.0,3173,Amount of urine output was measured in rat at a dose of 10 mg/kg/po; NT-Not tested,A,,,Rattus norvegicus,10116.0,
8033,1,,BAO_0000218,Intermediate,,4257,Volume of distribution was determined in rat after a 3 mg/kg of iv dose,A,In vivo,,Rattus norvegicus,10116.0,
8034,1,,BAO_0000218,Intermediate,,6011,Compound distribution in rat tissues was determined,A,In vivo,,Rattus norvegicus,10116.0,
8035,1,,BAO_0000218,Intermediate,,5472,Volume of distribution was evaluated in rat,A,In vivo,,Rattus norvegicus,10116.0,
8036,1,,BAO_0000218,Intermediate,,14346,Area under the curve was determined after intravenous administration of 2.7 mg/kg in male Dawley rats,A,,,Rattus norvegicus,10116.0,
8037,1,,BAO_0000218,Intermediate,,14346,Area under the curve was determined after intravenous administration of 2.8 mg/kg in male Dawley rats,A,,,Rattus norvegicus,10116.0,
8038,1,,BAO_0000218,Intermediate,,14346,Area under the curve was determined after intravenous administration of 4.9 mg/kg in male Beagle dogs,A,,,Canis lupus familiaris,9615.0,
8039,1,,BAO_0000218,Intermediate,,14346,Area under the curve was determined after intravenous administration of 5.1 mg/kg in male Dawley rats,A,,,Rattus norvegicus,10116.0,
8040,0,,BAO_0000019,Autocuration,,15469,Area under the curve was determined after oral administration (300 uM/Kg),A,,,,,
8041,1,,BAO_0000218,Intermediate,,14346,Area under the curve was determined after peroral administration of 5.0 mg/kg in male Dawley rats,A,,,Rattus norvegicus,10116.0,
8042,1,,BAO_0000218,Intermediate,,14346,Area under the curve was determined after peroral administration of 5.1 mg/kg in mal Dawley rats,A,,,Rattus norvegicus,10116.0,
8043,1,,BAO_0000218,Intermediate,,14346,Area under the curve was determined after peroral administration of 5.1 mg/kg in male Dawley rats,A,,,Rattus norvegicus,10116.0,
8044,1,,BAO_0000218,Intermediate,,14346,Area under the curve was determined after peroral administration of 5.2 mg/kg in mal Dawley rats,A,,,Rattus norvegicus,10116.0,
8045,1,,BAO_0000218,Intermediate,,14346,Area under the curve was determined after peroral administration of 5.2 mg/kg in male Dawley rats,A,,,Rattus norvegicus,10116.0,
8046,1,,BAO_0000218,Intermediate,,15372,Area under the curve was determined for the compound after iv dose of 4.97 mg/kg in rats,A,,,Rattus norvegicus,10116.0,
8047,1,,BAO_0000218,Intermediate,1969.0,12935,Area under the plasma concentration was determined in fasted Beagle dogs after peroral administration of 100 mg/kg,A,,,Canis lupus familiaris,9615.0,
8048,1,,BAO_0000218,Intermediate,1969.0,12935,Area under the plasma concentration was determined in fasted Beagle dogs after peroral administration of 20 mg/kg,A,,,Canis lupus familiaris,9615.0,
8049,0,,BAO_0000218,Autocuration,,14813,Plasma drug AUC in rat (PO dose),A,,,,,
8050,1,,BAO_0000218,Intermediate,,15792,Area under the tumor growth curve (AUC) in the B-6 Melanoma Model in C57/b1 mice at the dose of 1 mg/kg.,A,,,Mus musculus,10090.0,
8051,0,,BAO_0000218,Autocuration,,3579,Area under was determined at a dose of 30 mg/kg,A,,,,,
8052,1,,BAO_0000218,Intermediate,,12487,Average area under curve for compound at 1 mg/kg dose intravenous administration to Ferret,A,,,Mustela putorius furo,9669.0,
8053,1,,BAO_0000218,Intermediate,,12487,Average area under curve for the compound at 10 mg/kg dose after intraduodenal administration to rat,A,,,Rattus norvegicus,10116.0,
8054,1,,BAO_0000218,Intermediate,,12487,Average area under curve for the compound at 1 mg/kg dose after intravenous administration to rat,A,,,Rattus norvegicus,10116.0,
8055,1,,BAO_0000218,Intermediate,,12487,Average area under curve at 10 mg/kg dose after intraduodenal administration to Ferret,A,,,Mustela putorius furo,9669.0,
8056,1,,BAO_0000218,Intermediate,,12487,Average area under curve at 10 mg/kg intraduodenal administration to salt depleted dog,A,,,Canis lupus familiaris,9615.0,
8057,1,,BAO_0000218,Intermediate,,12487,Average area under curve at 1 mg/kg intravenous administration to salt depleted dog,A,,,Canis lupus familiaris,9615.0,
8058,1,,BAO_0000218,Intermediate,,12902,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 1.0(pmol/g/h)",A,,,Rattus norvegicus,10116.0,
8059,1,,BAO_0000218,Intermediate,,12902,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 2.0(pmol/g/h)",A,,,Rattus norvegicus,10116.0,
8060,1,,BAO_0000218,Intermediate,,12902,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 4.0(pmol/g/h)",A,,,Rattus norvegicus,10116.0,
8061,1,,BAO_0000218,Intermediate,,12902,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 5.0(pmol/g/h)",A,,,Rattus norvegicus,10116.0,
8062,1,,BAO_0000218,Intermediate,,12902,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 54.0(pmol/g/h)",A,,,Rattus norvegicus,10116.0,
8063,1,,BAO_0000218,Intermediate,,12902,"Bioavailability in male Sprague-Dawley rats, after the po administration at a dose of 10.0(pmol/g/h)",A,,,Rattus norvegicus,10116.0,
8064,1,,BAO_0000218,Intermediate,,12902,"Bioavailability in male Sprague-Dawley rats, after the po administration at a dose of 20.0(pmol/g/h)",A,,,Rattus norvegicus,10116.0,
8065,1,,BAO_0000218,Intermediate,,12902,"Bioavailability in male Sprague-Dawley rats, after the po administration at a dose of 40.0(pmol/g/h)",A,,,Rattus norvegicus,10116.0,
8066,1,,BAO_0000218,Intermediate,,12745,Bioavailability in mouse brain after intravenous administration of 105.1 mg/kg of dose,A,,,Mus musculus,10090.0,
8067,1,,BAO_0000218,Intermediate,,12745,Bioavailability in mouse brain after intravenous administration of equimolar doses of ( 2'F-ara-ddI + 2'F-ara-ddP),A,,,Mus musculus,10090.0,
8068,1,,BAO_0000218,Intermediate,,12745,Bioavailability in mouse brain after oral administration of 100 mg/kg of dose,A,,,Mus musculus,10090.0,
8069,1,,BAO_0000218,Intermediate,,12745,Bioavailability in mouse brain after oral administration of equimolar doses of ( 2'F-ara-ddI + 2'F-ara-ddP),A,,,Mus musculus,10090.0,
8070,1,,BAO_0000218,Intermediate,,12745,Bioavailability in mouse serum after intravenous administration of 105.1 mg/kg of dose,A,,,Mus musculus,10090.0,
8071,1,,BAO_0000218,Intermediate,,12745,Bioavailability in mouse serum after intravenous administration of equimolar doses of ( 2'F-ara-ddI + 2'F-ara-ddP),A,,,Mus musculus,10090.0,
8072,1,,BAO_0000218,Intermediate,,12745,Bioavailability in mouse serum after oral administration of 100 mg/kg of dose,A,,,Mus musculus,10090.0,
8073,1,,BAO_0000218,Intermediate,,12745,Bioavailability in mouse serum after oral administration of equimolar doses of ( 2'F-ara-ddI + 2'F-ara-ddP),A,,,Mus musculus,10090.0,
8074,0,,BAO_0000218,Autocuration,1969.0,13298,AUC in mice after oral dose (50 mg/kg),A,,,,,
8075,1,,BAO_0000218,Intermediate,1977.0,12226,Blood level after oral administration in mice (50 mg/kg) was determined by bioassay procedure and represent total activity present in the serum,A,,,Mus musculus,10090.0,
8076,0,,BAO_0000019,Autocuration,1969.0,12634,AUC (0-4 hr) ug/ml/h,A,,,,,
8077,1,,BAO_0000218,Intermediate,,14810,Compound at a dose of 10 mg/kg was orally administered to rats and Area under curve was reported,A,,,Rattus norvegicus,10116.0,
8078,0,,BAO_0000218,Autocuration,,13889,Compound evaluated for AUC = Area under the nucleoside serum or brain concentration versus time curve after iv administration,A,,,,,
8079,1,,BAO_0000218,Intermediate,,10018,Compound was evaluated for Area under curve in mice,A,,,Mus musculus,10090.0,
8080,1,,BAO_0000218,Intermediate,,8758,Compound was evaluated for area under curve doses in rat at 100 mg/kg po,A,,,Rattus norvegicus,10116.0,
8081,0,,BAO_0000218,Autocuration,,8758,Compound was evaluated for area under curve doses in rat at 100 mg/kg po,F,,,,,
8082,1,,BAO_0000218,Intermediate,,8758,Compound was evaluated for area under curve doses in rat at 50 mg/kg po,A,,,Rattus norvegicus,10116.0,
8083,0,,BAO_0000019,Autocuration,,2249,Compound was evaluated for area under curve of growth hormone release after chronic oral dosing at 0.5 mpk on day 1,A,,,,,
8084,0,,BAO_0000019,Autocuration,,2249,Compound was evaluated for area under curve of growth hormone release after chronic oral dosing at 0.5 mpk on day 4,A,,,,,
8085,0,,BAO_0000019,Autocuration,,2249,Compound was evaluated for area under curve of growth hormone release after chronic oral dosing at 1.0 mpk on day 1,A,,,,,
8086,0,,BAO_0000019,Autocuration,,2249,Compound was evaluated for area under curve of growth hormone release after chronic oral dosing at 1.0 mpk on day 4,A,,,,,
8087,1,,BAO_0000218,Intermediate,,15115,Compound was evaluated for area under curve when administered through oral route in mouse,A,,,Mus musculus,10090.0,
8088,1,,BAO_0000218,Intermediate,,6518,Plasma clearance after oral administration at a dose of 2 mg/kg in rat; no data,A,In vivo,,Rattus norvegicus,10116.0,
8089,1,,BAO_0000218,Intermediate,,6518,Plasma clearance after oral administration at a dose of 4 mg/kg in rat; no data,A,In vivo,,Rattus norvegicus,10116.0,
8090,1,,BAO_0000218,Intermediate,,6249,Plasma clearance in rat,A,In vivo,,Rattus norvegicus,10116.0,
8091,1,,BAO_0000218,Intermediate,,2463,Plasma clearance was evaluated in vivo in rat at a dose of 5 mg/kg by intra venous administration,A,In vivo,,Rattus norvegicus,10116.0,
8092,1,,BAO_0000218,Intermediate,,4969,Plasma clearance rate in Sprague-Dawley rats,A,In vivo,,Rattus norvegicus,10116.0,
8093,1,,BAO_0000218,Intermediate,,17720,CLtot at a dose of 4 mg/kg in Rat Plasma after iv administration,F,In vivo,,Rattus norvegicus,10116.0,
8094,1,,BAO_0000218,Intermediate,,3457,Pharmacokinetic property (total body clearance) in rat,A,In vivo,,Rattus norvegicus,10116.0,
8095,1,,BAO_0000218,Intermediate,,5983,Pharmacokinetic property (CLtot)of the compound was measured in rat at the dose of 0.32 mg/kg i.v.,A,In vivo,,Rattus norvegicus,10116.0,
8096,1,,BAO_0000218,Intermediate,,6295,In vivo concentration in rat liver exposure 0-8 hour after oral administration 50 mg/kg,A,,,Rattus norvegicus,10116.0,
8097,1,,BAO_0000218,Intermediate,,6296,In vivo concentration in rat liver exposure 0-8 hour after oral administration 50 mg/kg,A,,,Rattus norvegicus,10116.0,
8098,1,,BAO_0000218,Intermediate,,17686,Cl in rat i.v. at 2 mg/kg concentration,A,In vivo,,Rattus norvegicus,10116.0,
8099,1,,BAO_0000218,Intermediate,,17764,Clearance of compound after intravenous administration in rats at 24 uM/kg,A,In vivo,,Rattus norvegicus,10116.0,
8100,1,,BAO_0000218,Intermediate,,5503,Clearance was determined,A,In vivo,,Rattus norvegicus,10116.0,
8101,1,,BAO_0000218,Intermediate,,4368,Clearance by intravenous administration of 3.4 mg/kg in rat,A,In vivo,,Rattus norvegicus,10116.0,
8102,1,,BAO_0000218,Intermediate,,6005,Clearance was evaluated after i.v. administration in rat at a dose of 1 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,
8103,1,,BAO_0000218,Intermediate,,5031,Clearance rate after i.v. administration in rats,A,In vivo,,Rattus norvegicus,10116.0,
8104,1,,BAO_0000218,Intermediate,,4890,Clearance was determined after intravenous administration at a dose 5 mg/kg to male Sprague-Dawley rats,A,In vivo,,Rattus norvegicus,10116.0,
8105,1,,BAO_0000218,Intermediate,,5182,Clearance was determined by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat,A,In vivo,,Rattus norvegicus,10116.0,
8106,1,,BAO_0000218,Intermediate,,5979,Clearance (Cl) of compound after 2 h iv infusion of 8.4 mg/kg in three rat,A,In vivo,,Rattus norvegicus,10116.0,
8107,1,,BAO_0000218,Intermediate,,5656,Clearance (Cl) after oral administration in rat,A,In vivo,,Rattus norvegicus,10116.0,
8108,1,,BAO_0000218,Intermediate,,17804,Compound clearance in rats was measured after intravenous administration at 3 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,
8109,1,,BAO_0000218,Intermediate,1969.0,4839,Compound was tested for plasma clearance in rat,A,In vivo,,Rattus norvegicus,10116.0,
8110,1,,BAO_0000218,Intermediate,,5041,In vitro microsome metabolism clearance in rat was determined,A,In vitro,,Rattus norvegicus,10116.0,
8111,1,,BAO_0000218,Intermediate,,5041,In vitro microsome metabolism clearance in rat was determined; ND denotes no data,A,In vitro,,Rattus norvegicus,10116.0,
8112,1,,BAO_0000218,Intermediate,,5974,In vivo Clearance (Cl) was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0,
8113,1,,BAO_0000218,Intermediate,1969.0,5496,In vivo plasma clearance was determined,A,In vivo,,Rattus norvegicus,10116.0,
8114,1,,BAO_0000218,Intermediate,,5739,Pharmacokinetic property (Clearance) for the compound (5 mg/kg iv) was determined in rats,A,In vivo,,Rattus norvegicus,10116.0,
8115,1,,BAO_0000218,Intermediate,2107.0,5676,Pharmacokinetic property (Clearance) in rat hepatocyte i.v.,A,In vivo,,Rattus norvegicus,10116.0,
8116,1,,BAO_0000218,Intermediate,,4239,Pharmacokinetic property (Plasma clearance) was measured in rat,A,In vivo,,Rattus norvegicus,10116.0,
8117,1,,BAO_0000218,Intermediate,,5676,Pharmacokinetic property (clearance) in rat i.v.,A,In vivo,,Rattus norvegicus,10116.0,
8118,1,,BAO_0000218,Intermediate,,1918,"Plasma Clearance was evaluated in rats, iv",A,In vivo,,Rattus norvegicus,10116.0,
8119,1,,BAO_0000218,Intermediate,,17800,Plasma clearance (in vivo) in rats was determined,A,In vivo,,Rattus norvegicus,10116.0,
8120,1,,BAO_0000218,Intermediate,,6056,Plasma clearance for the compound was calculated at a single intravenous administration of 20 mg/kg in rat,A,In vivo,,Rattus norvegicus,10116.0,
8121,1,,BAO_0000218,Intermediate,,5496,Plasma clearance was determined,A,In vivo,,Rattus norvegicus,10116.0,
8122,1,,BAO_0000218,Intermediate,,5939,Plasma clearance in rat after peroral administration at 10 mg/kg concentration,A,In vivo,,Rattus norvegicus,10116.0,
8123,1,,BAO_0000218,Intermediate,,5939,Plasma clearance in rat after peroral administration at 5 mg/kg concentration,A,In vivo,,Rattus norvegicus,10116.0,
8124,1,,BAO_0000218,Intermediate,,17752,Plasma clearance in rats,A,In vivo,,Rattus norvegicus,10116.0,
8125,1,,BAO_0000218,Intermediate,,4576,Plasma clearance rate determined in rat,A,In vivo,,Rattus norvegicus,10116.0,
8126,1,,BAO_0000218,Intermediate,,6011,Plasma clearance was determined in rat,A,In vivo,,Rattus norvegicus,10116.0,
8127,1,,BAO_0000218,Intermediate,,5510,Plasma clearance was determined,A,In vivo,,Rattus norvegicus,10116.0,
8128,1,,BAO_0000218,Intermediate,,5948,Plasma clearance value in rat,A,In vivo,,Rattus norvegicus,10116.0,
8129,1,,BAO_0000218,Intermediate,2107.0,6125,Clearance rate constant using isolated perfused rat liver (IPRL) assay,A,Ex vivo,,Rattus norvegicus,10116.0,
8130,1,,BAO_0000218,Intermediate,,4839,Clearance in rat,A,In vivo,,Rattus norvegicus,10116.0,
8131,1,,BAO_0000218,Intermediate,,17686,Total body clearance in rat i.v. at 2 mg/kg concentration,A,In vivo,,Rattus norvegicus,10116.0,
8132,1,,BAO_0000218,Intermediate,,6571,Clearance of compound in rats after intravenous administration,A,In vivo,,Rattus norvegicus,10116.0,
8133,1,,BAO_0000218,Intermediate,,3364,Clearance after iv administration to rats,A,In vivo,,Rattus norvegicus,10116.0,
8134,1,,BAO_0000218,Intermediate,,13569,Clearance at an iv dose of 12 mg/Kg and po dose of 23 mg/Kg,A,In vivo,,Rattus norvegicus,10116.0,
8135,1,,BAO_0000218,Intermediate,,13569,Clearance at an iv dose of 14 mg/Kg and po dose of 15 mg/Kg,A,In vivo,,Rattus norvegicus,10116.0,
8136,1,,BAO_0000218,Intermediate,,13569,Clearance at an iv dose of 15 mg/Kg and po dose of 30 mg/Kg,A,In vivo,,Rattus norvegicus,10116.0,
8137,1,,BAO_0000218,Intermediate,,13569,Clearance at an iv dose of 15 mg/Kg and po dose of 30.2 mg/Kg,A,In vivo,,Rattus norvegicus,10116.0,
8138,1,,BAO_0000218,Intermediate,,13569,Clearance at an iv dose of 15.6 mg/Kg and po dose of 31.2 mg/Kg,A,In vivo,,Rattus norvegicus,10116.0,
8139,1,,BAO_0000218,Intermediate,,13569,Clearance at an iv dose of 15.7 mg/Kg and po dose of 31.4 mg/Kg,A,In vivo,,Rattus norvegicus,10116.0,
8140,1,,BAO_0000218,Intermediate,,13569,Clearance at an iv dose of 16 mg/Kg and po dose of 35 mg/Kg,A,In vivo,,Rattus norvegicus,10116.0,
8141,1,,BAO_0000218,Intermediate,,17670,"Clearance in fischer rats at 5 mg/kg dose, administered intravenously",A,In vivo,,Rattus norvegicus,10116.0,
8142,1,,BAO_0000218,Intermediate,,5970,Clearance in rat,A,In vivo,,Rattus norvegicus,10116.0,
8143,1,,BAO_0000218,Intermediate,,6495,Clearance in rat after oral administration at 10 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,
8144,1,,BAO_0000218,Intermediate,,4590,Clearance in rat.,A,In vivo,,Rattus norvegicus,10116.0,
8145,1,,BAO_0000218,Intermediate,,6193,Clearance rate following an oral dose of 20 mg/kg in rats,A,In vivo,,Rattus norvegicus,10116.0,
8146,1,,BAO_0000218,Intermediate,,2832,Compound was evaluated for the rate of clearance in rat upon intravenous administration.,A,In vivo,,Rattus norvegicus,10116.0,
8147,1,,BAO_0000218,Intermediate,1969.0,1052,Compound was tested for plasma clearance in rats after 5 mg/kg of intravenous dosing,A,In vivo,,Rattus norvegicus,10116.0,
8148,1,,BAO_0000218,Intermediate,2107.0,9866,Biodistribution in rat liver in the presence of GdDTPA-BDP at 1 hr,A,In vivo,,Rattus norvegicus,10116.0,
8149,1,,BAO_0000218,Intermediate,2107.0,9866,Biodistribution in rat liver in the presence of GdDTPA-BDP at 30 min,A,In vivo,,Rattus norvegicus,10116.0,
8150,1,,BAO_0000218,Intermediate,2107.0,9866,Biodistribution in rat liver in the presence of GdDTPA-BDP at 4 hr,A,In vivo,,Rattus norvegicus,10116.0,
8151,1,,BAO_0000218,Intermediate,2107.0,9866,Biodistribution in rat liver in the presence of GdDTPA-HPDP at 15 min,A,In vivo,,Rattus norvegicus,10116.0,
8152,1,,BAO_0000218,Intermediate,2107.0,9866,Biodistribution in rat liver in the presence of GdDTPA-HPDP at 1 hr,A,In vivo,,Rattus norvegicus,10116.0,
8153,1,,BAO_0000218,Intermediate,2107.0,9866,Biodistribution in rat liver in the presence of GdDTPA-HPDP at 30 min,A,In vivo,,Rattus norvegicus,10116.0,
8154,1,,BAO_0000218,Intermediate,2107.0,9866,Biodistribution in rat liver in the presence of GdDTPA-HPDP at 4 hr,A,In vivo,,Rattus norvegicus,10116.0,
8155,1,,BAO_0000218,Intermediate,2107.0,9866,Biodistribution in rat liver in the presence of NAC Gd/0.01 M GdDTPA-HPDP,A,In vivo,,Rattus norvegicus,10116.0,
8156,1,,BAO_0000218,Intermediate,2107.0,9866,Biodistribution in rat liver in the presence of NCA Gd/0.01 M lip,A,In vivo,,Rattus norvegicus,10116.0,
8157,1,,BAO_0000218,Intermediate,2385.0,9866,Biodistribution in rat muscle in the presence of 0.01 M GdDTPA-BDP,A,In vivo,,Rattus norvegicus,10116.0,
8158,1,,BAO_0000218,Intermediate,2385.0,9866,Biodistribution in rat muscle in the presence of 0.05 M Gd/0.15 M lig,A,In vivo,,Rattus norvegicus,10116.0,
8159,1,,BAO_0000218,Intermediate,2385.0,9866,Biodistribution in rat muscle in the presence of 0.05 M GdDTPA-BDP,A,In vivo,,Rattus norvegicus,10116.0,
8160,1,,BAO_0000218,Intermediate,2385.0,9866,Biodistribution in rat muscle in the presence of 0.10 M GdDTPA-BDP,A,In vivo,,Rattus norvegicus,10116.0,
8161,1,,BAO_0000218,Intermediate,2385.0,9866,Biodistribution in rat muscle in the presence of GdDTPA-BDP at 1 hr,A,In vivo,,Rattus norvegicus,10116.0,
8162,1,,BAO_0000218,Intermediate,2385.0,9866,Biodistribution in rat muscle in the presence of GdDTPA-BDP at 4 hr,A,In vivo,,Rattus norvegicus,10116.0,
8163,1,,BAO_0000218,Intermediate,2385.0,9866,Biodistribution in rat muscle in the presence of GdDTPA-BDPat 15 min,A,In vivo,,Rattus norvegicus,10116.0,
8164,1,,BAO_0000218,Intermediate,2385.0,9866,Biodistribution in rat muscle in the presence of GdDTPA-BDPat 30 min,A,In vivo,,Rattus norvegicus,10116.0,
8165,1,,BAO_0000218,Intermediate,2385.0,9866,Biodistribution in rat muscle in the presence of GdDTPA-HPDP at 1 hr,A,In vivo,,Rattus norvegicus,10116.0,
8166,1,,BAO_0000218,Intermediate,2385.0,9866,Biodistribution in rat muscle in the presence of GdDTPA-HPDP at 4 hr,A,In vivo,,Rattus norvegicus,10116.0,
8167,1,,BAO_0000218,Intermediate,2385.0,9866,Biodistribution in rat muscle in the presence of GdDTPA-HPDPat 15 min,A,In vivo,,Rattus norvegicus,10116.0,
8168,1,,BAO_0000218,Intermediate,2385.0,9866,Biodistribution in rat muscle in the presence of GdDTPA-HPDPat 30 min,A,In vivo,,Rattus norvegicus,10116.0,
8169,1,,BAO_0000218,Intermediate,2385.0,9866,Biodistribution in rat muscle in the presence of NCA Gd/0.01 M lip,A,In vivo,,Rattus norvegicus,10116.0,
8170,1,,BAO_0000218,Intermediate,2385.0,9866,Biodistribution in rat muscle in the presence of NCAGd/0.01 M lig,A,In vivo,,Rattus norvegicus,10116.0,
8171,1,,BAO_0000218,Intermediate,160.0,9866,Biodistribution in rat s. intestine in the presence of 50 Gd/kg at 2 hr,A,In vivo,,Rattus norvegicus,10116.0,
8172,1,,BAO_0000218,Intermediate,160.0,9866,Biodistribution in rat s. intestine in the presence of 50 Gd/kg at 6 hr,A,In vivo,,Rattus norvegicus,10116.0,
8173,1,,BAO_0000218,Intermediate,160.0,9866,Biodistribution in rat s. intestine in the presence of NCA (No carrier added),A,In vivo,,Rattus norvegicus,10116.0,
8174,1,,BAO_0000218,Intermediate,2106.0,9866,Biodistribution in rat spleen in the presence of 0.01 M GdDTPA-BDP,A,In vivo,,Rattus norvegicus,10116.0,
8175,1,,BAO_0000218,Intermediate,2106.0,9866,Biodistribution in rat spleen in the presence of 0.05 M Gd/0.15 M lig; ND=No data,A,In vivo,,Rattus norvegicus,10116.0,
8176,1,,BAO_0000218,Intermediate,2106.0,9866,Biodistribution in rat spleen in the presence of 0.05 M GdDTPA-BDP; ND=No data,A,In vivo,,Rattus norvegicus,10116.0,
8177,1,,BAO_0000218,Intermediate,2106.0,9866,Biodistribution in rat spleen in the presence of 0.10 M GdDTPA-BDP,A,In vivo,,Rattus norvegicus,10116.0,
8178,1,,BAO_0000218,Intermediate,2106.0,9866,Biodistribution in rat spleen in the presence of 50 Gd/kg at 15 min,A,In vivo,,Rattus norvegicus,10116.0,
8179,1,,BAO_0000218,Intermediate,2106.0,9866,Biodistribution in rat spleen in the presence of 50 Gd/kg at 2 hr,A,In vivo,,Rattus norvegicus,10116.0,
8180,1,,BAO_0000218,Intermediate,2106.0,9866,Biodistribution in rat spleen in the presence of 50 Gd/kg at 6 hr,A,In vivo,,Rattus norvegicus,10116.0,
8181,1,,BAO_0000218,Intermediate,2106.0,9866,Biodistribution in rat spleen in the presence of NCA Gd/0.01 M lip,A,In vivo,,Rattus norvegicus,10116.0,
8182,1,,BAO_0000218,Intermediate,2106.0,9866,Biodistribution in rat spleen in the presence of NCAGd/0.01 M lig,A,In vivo,,Rattus norvegicus,10116.0,
8183,1,,BAO_0000218,Intermediate,945.0,9866,Biodistribution in rat stomach in the presence of 50 Gd/kg at 15 min,A,In vivo,,Rattus norvegicus,10116.0,
8184,1,,BAO_0000218,Intermediate,945.0,9866,Biodistribution in rat stomach in the presence of 50 Gd/kg at 2 hr,A,In vivo,,Rattus norvegicus,10116.0,
8185,1,,BAO_0000218,Intermediate,945.0,9866,Biodistribution in rat stomach in the presence of 50 Gd/kg at 6 h; ND=No data,A,In vivo,,Rattus norvegicus,10116.0,
8186,1,,BAO_0000218,Intermediate,178.0,13950,Biodistribution of [123I]-label in rat blood was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Rattus norvegicus,10116.0,
8187,1,,BAO_0000218,Intermediate,178.0,13950,Biodistribution of [123I]-label in rat blood was reported at 1 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Rattus norvegicus,10116.0,
8188,1,,BAO_0000218,Intermediate,178.0,13950,Biodistribution of [123I]-label in rat blood was reported at 2 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Rattus norvegicus,10116.0,
8189,1,,BAO_0000218,Intermediate,178.0,13950,Biodistribution of [123I]-label in rat blood was reported at 24 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Rattus norvegicus,10116.0,
8190,1,,BAO_0000218,Intermediate,178.0,13950,Biodistribution of [123I]-label in rat blood was reported at 4 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Rattus norvegicus,10116.0,
8191,1,,BAO_0000218,Intermediate,955.0,13950,Biodistribution of [123I]-label in rat brain was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Rattus norvegicus,10116.0,
8192,1,,BAO_0000218,Intermediate,955.0,13950,Biodistribution of [123I]-label in rat brain was reported at 1 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Rattus norvegicus,10116.0,
8193,1,,BAO_0000218,Intermediate,955.0,13950,Biodistribution of [123I]-label in rat brain was reported at 2 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Rattus norvegicus,10116.0,
8194,1,,BAO_0000218,Intermediate,955.0,13950,Biodistribution of [123I]-label in rat brain was reported at 24 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Rattus norvegicus,10116.0,
8195,1,,BAO_0000218,Intermediate,955.0,13950,Biodistribution of [123I]-label in rat brain was reported at 4 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Rattus norvegicus,10116.0,
8196,1,,BAO_0000218,Intermediate,948.0,13950,Biodistribution of [123I]-label in rat heart was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Rattus norvegicus,10116.0,
8197,1,,BAO_0000218,Intermediate,948.0,13950,Biodistribution of [123I]-label in rat heart was reported at 1 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Rattus norvegicus,10116.0,
8198,1,,BAO_0000218,Intermediate,948.0,13950,Biodistribution of [123I]-label in rat heart was reported at 2 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Rattus norvegicus,10116.0,
8199,1,,BAO_0000218,Intermediate,,6062,Terminal phase volume of distribution was measured in rat after an iv dose of 1 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,
8200,1,,BAO_0000218,Expert,,3598,Apparent volume of the central plasma compartment (Vc) of compound determined in rat after iv administration at a dose of 10 mg/kg,A,,,Rattus norvegicus,10116.0,
8201,1,,BAO_0000218,Intermediate,,1908,Vc value after IV dose at a dose of 5 mg/kg in rats.,A,In vivo,,Rattus norvegicus,10116.0,
8202,1,,BAO_0000218,Intermediate,,17596,Apparent volume of distribution at 10 mg/kg in rat upon intravenous administration,A,In vivo,,Rattus norvegicus,10116.0,
8203,1,,BAO_0000218,Intermediate,,4891,Compound was evaluated for pharmacokinetic parameter volume of distribution,A,In vivo,,Rattus norvegicus,10116.0,
8204,1,,BAO_0000218,Intermediate,,740,Compound was evaluated for volume of distribution in rat,A,In vivo,,Rattus norvegicus,10116.0,
8205,1,,BAO_0000218,Intermediate,,16366,Steady state volume distribution was determined; steady state(ss),A,In vivo,,Rattus norvegicus,10116.0,
8206,1,,BAO_0000218,Intermediate,,3364,Steady state volume of distribution after iv administration to rats,A,In vivo,,Rattus norvegicus,10116.0,
8207,1,,BAO_0000218,Intermediate,,2552,Steady state volume of distribution dosing at 3 mg/kg iv,A,In vivo,,Rattus norvegicus,10116.0,
8208,1,,BAO_0000218,Intermediate,,406,The compound was evaluated for volume of distribution in rat,A,In vivo,,Rattus norvegicus,10116.0,
8209,1,,BAO_0000218,Intermediate,,12500,The compound was tested for volume of distribution in rat,A,In vivo,,Rattus norvegicus,10116.0,
8210,1,,BAO_0000218,Intermediate,,12500,The compound was tested for volume of distribution in rat at dose of 3-10 mgkg,A,In vivo,,Rattus norvegicus,10116.0,
8211,1,,BAO_0000218,Intermediate,,5656,Volume distribution (VD) after oral administration in rat,A,In vivo,,Rattus norvegicus,10116.0,
8212,1,,BAO_0000218,Intermediate,,17671,Volume distribution of compound in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,
8213,1,,BAO_0000218,Intermediate,,1094,Volume distribution in rat,A,In vivo,,Rattus norvegicus,10116.0,
8214,1,,BAO_0000218,Intermediate,,5833,Volume distribution in rat,A,In vivo,,Rattus norvegicus,10116.0,
8215,1,,BAO_0000218,Intermediate,,5939,Volume distribution in rat after peroral administration at 10 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,
8216,1,,BAO_0000218,Intermediate,,5939,Volume distribution in rat after peroral administration at 5 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,
8217,1,,BAO_0000218,Intermediate,,6005,Volume distribution was evaluated after i.v. administration in rat at a dose of 1 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,
8218,1,,BAO_0000218,Intermediate,,1696,Volume of distribution in rat.,A,In vivo,,Rattus norvegicus,10116.0,
8219,1,,BAO_0000218,Intermediate,,6672,Volume of distribution in rat,A,In vivo,,Rattus norvegicus,10116.0,
8220,1,,BAO_0000218,Intermediate,,6673,Volume of distribution in rat,A,In vivo,,Rattus norvegicus,10116.0,
8221,1,,BAO_0000218,Intermediate,,5871,Volume of distribution in rat by iv administration,A,In vivo,,Rattus norvegicus,10116.0,
8222,1,,BAO_0000218,Intermediate,,6803,Volume of distribution in rats,A,In vivo,,Rattus norvegicus,10116.0,
8223,1,,BAO_0000218,Intermediate,,5199,Volume of distribution was determined in female Sprague-Dawley rats following intravenous (iv) administration of drug (1 mg/kg).,A,In vivo,,Rattus norvegicus,10116.0,
8224,1,,BAO_0000218,Intermediate,,4727,Volume distribution at the dose of 2 mg/kg in rat,A,,,Rattus norvegicus,10116.0,
8225,1,,BAO_0000218,Intermediate,,16367,Steady state volume of distribution was determined,A,In vivo,,Rattus norvegicus,10116.0,
8226,0,,BAO_0000218,Intermediate,,5005,Compound was tested for its plasma volume distribution in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,A,In vivo,,Macaca mulatta,9544.0,
8227,0,,BAO_0000218,Intermediate,,5005,Compound was tested for its plasma volume distribution in Sprague Dawley rats,A,In vivo,,Rattus norvegicus,10116.0,
8228,0,,BAO_0000218,Intermediate,,5005,Compound was tested for its plasma volume distribution in Sprague Dawley rats; ND is not determined,A,In vivo,,Rattus norvegicus,10116.0,
8229,1,,BAO_0000218,Intermediate,,15765,Mean (%CV) PK parameters for Vdss(mL/kg).,A,In vivo,,Rattus norvegicus,10116.0,
8230,1,,BAO_0000218,Intermediate,,2792,Pharmacokinetic parameter Vdss was determined at 2 mg/kg i.v. dose in rats,A,In vivo,,Rattus norvegicus,10116.0,
8231,1,,BAO_0000218,Intermediate,,2792,Pharmacokinetic parameter Vdss was determined at 5 mg/kg i.v. dose in rats,A,In vivo,,Rattus norvegicus,10116.0,
8232,1,,BAO_0000218,Intermediate,,5334,Pharmacokinetic parameter volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0,
8233,1,,BAO_0000218,Intermediate,,5334,Pharmacokinetic parameter volume of distribution was reported in Sprague-Dawley rat; ND=Not determined,A,In vivo,,Rattus norvegicus,10116.0,
8234,1,,BAO_0000218,Intermediate,,5739,Pharmacokinetic property (Vdss) for the compound (5 mg/kg iv) was determined in rats,A,In vivo,,Rattus norvegicus,10116.0,
8235,1,,BAO_0000218,Intermediate,,5789,Pharmacokinetic property (Vdss) in rat,A,In vivo,,Rattus norvegicus,10116.0,
8236,1,,BAO_0000218,Intermediate,,4239,Pharmacokinetic property (vdss) was measured in rat,A,In vivo,,Rattus norvegicus,10116.0,
8237,1,,BAO_0000218,Intermediate,,4709,Steady state volume of distribution for the compound after intravenous administration of 1 mg/kg in rat,A,In vivo,,Rattus norvegicus,10116.0,
8238,1,,BAO_0000218,Intermediate,,6642,Volume of distribution in rat,A,In vivo,,Rattus norvegicus,10116.0,
8239,1,,BAO_0000218,Intermediate,,5247,The pharmacokinetic parameter volume of distribution in vivo in rats,A,In vivo,,Rattus norvegicus,10116.0,
8240,1,,BAO_0000218,Intermediate,,17720,Vdss at a dose of 4 mg/kg in Rat Plasma after iv administration,F,In vivo,,Rattus norvegicus,10116.0,
8241,1,,BAO_0000218,Intermediate,,17686,Vdss in rat i.v. at 2 mg/kg concentration,A,In vivo,,Rattus norvegicus,10116.0,
8242,1,,BAO_0000218,Intermediate,,4689,Volume distribution after intravenous administration (1 mg/kg) in rat,A,In vivo,,Rattus norvegicus,10116.0,
8243,1,,BAO_0000218,Intermediate,,5654,Volume distribution of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 16 mg/kg peroral administration,A,In vivo,,Rattus norvegicus,10116.0,
8244,1,,BAO_0000218,Intermediate,,5654,Volume distribution of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 20 mg/kg peroral administration,A,In vivo,,Rattus norvegicus,10116.0,
8245,1,,BAO_0000218,Intermediate,,4527,Volume distribution at a dose of 10 uM/kg in rat was determined,A,In vivo,,Rattus norvegicus,10116.0,
8246,1,,BAO_0000218,Intermediate,,4521,Volume distribution in rat after 5 mg/kg by oral and 1 mg/kg by intravenous administration,A,In vivo,,Rattus norvegicus,10116.0,
8247,1,,BAO_0000218,Intermediate,,6057,Volume distribution was calculated in rat,A,In vivo,,Rattus norvegicus,10116.0,
8248,1,,BAO_0000218,Intermediate,,5510,Volume distribution was determined,A,In vivo,,Rattus norvegicus,10116.0,
8249,1,,BAO_0000218,Intermediate,,2938,Volume of distribution after intravenous administration was evaluated in rat,A,In vivo,,Rattus norvegicus,10116.0,
8250,1,,BAO_0000218,Intermediate,,6679,Volume of distribution at steady state was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,A,In vivo,,Rattus norvegicus,10116.0,
8251,1,,BAO_0000218,Intermediate,,6685,"Volume of distribution at steady state was determined in rats at 10 mg/kg, p.o. dose; n/a: not applicable",A,In vivo,,Rattus norvegicus,10116.0,
8252,1,,BAO_0000218,Intermediate,,6685,"Volume of distribution at steady state was determined in rats at 20 mg/kg, i.p. dose; n/a: not applicable",A,In vivo,,Rattus norvegicus,10116.0,
8253,1,,BAO_0000218,Intermediate,,6685,"Volume of distribution at steady state was determined in rats at 2 mg/kg, i.v. dose",A,In vivo,,Rattus norvegicus,10116.0,
8254,1,,BAO_0000218,Intermediate,,5145,Volume of distribution in steady state was determined in rat,A,In vivo,,Rattus norvegicus,10116.0,
8255,1,,BAO_0000218,Intermediate,,6467,Volume of distribution in steady state was determined in rats at the dose of 1.0 mpk by i.v. administration,A,In vivo,,Rattus norvegicus,10116.0,
8256,1,,BAO_0000218,Intermediate,,6467,Volume of distribution in steady state was determined in rats at the dose of 1.0 mpk by i.v. administration; ND= not determined,A,In vivo,,Rattus norvegicus,10116.0,
8257,1,,BAO_0000218,Intermediate,,15115,Compound was evaluated for area under curve when administered through oral route to mouse,A,,,Mus musculus,10090.0,
8258,1,,BAO_0000218,Intermediate,,8758,Compound was evaluated for area under curve doses in rat at 100 mg/kg po,A,,,Rattus norvegicus,10116.0,
8259,1,,BAO_0000218,Intermediate,,8758,Compound was evaluated for area under curve doses in rat at 50 mg/kg po,A,,,Rattus norvegicus,10116.0,
8260,0,,BAO_0000218,Autocuration,,8267,Compound was evaluated for its bioavailability after oral administration (100 mg) to Beagle dogs,F,In vivo,,,,
8261,1,,BAO_0000218,Intermediate,,8267,Compound was evaluated for its bioavailability after oral administration (200 mg) to Beagle dogs,A,,,Canis lupus familiaris,9615.0,
8262,1,,BAO_0000218,Intermediate,,14239,Compound was evaluated for the area under the concentration - time curve by administering intravenously at 25 mg/kg in mice,A,,,Mus musculus,10090.0,
8263,1,,BAO_0000218,Intermediate,,14239,Compound was evaluated for the area under the concentration - time curve by administering orally at 25 mg/kg in mice,A,,,Mus musculus,10090.0,
8264,1,,BAO_0000218,Intermediate,178.0,10754,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration using Area under the time-concentration curve after 40 mg/kg intramuscular administration to mice,A,,,Mus musculus,10090.0,
8265,1,,BAO_0000218,Intermediate,178.0,10754,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration using Area under the time-concentration curve after 40 mg/kg peroral administration to mice,A,,,Mus musculus,10090.0,
8266,1,,BAO_0000218,Intermediate,,10754,Compound was evaluated in vivo in for its concentration using Area under the time-concentration curve after 40 mg/kg peroral administration to dogs.,A,,,Canis lupus familiaris,9615.0,
8267,1,,BAO_0000218,Intermediate,,14681,Compound was tested for area under concentration -time curve from time 0 to time infinity in three male Wistar rats at a single 5 mg/kg oral gavage dose,A,,,Rattus norvegicus,10116.0,
8268,1,,BAO_0000218,Intermediate,,14681,Compound was tested for area under concentration -time curve from time 0 to time infinity in three male Wistar rats at a single 5 mg/kg oral gavage dose. ,A,,,Rattus norvegicus,10116.0,
8269,1,,BAO_0000218,Intermediate,,14681,Compound was tested for area under concentration -time curve from time 0 to time of last detectable concentration in three male Wistar rats at a single 5 mg/kg oral gavage dose,A,,,Rattus norvegicus,10116.0,
8270,0,,BAO_0000019,Autocuration,,13118,Concentration of compound in Central nervous system,A,,,,,
8271,0,,BAO_0000019,Autocuration,,13118,Concentration of compound in Central nervous system; Not detectable,A,,,,,
8272,1,,BAO_0000218,Intermediate,,13318,"Concentration of diester in the blood, following oral administration in mice",A,,,Mus musculus,10090.0,
8273,1,,BAO_0000218,Intermediate,,13318,"Concentration of monoester in the blood, following oral administration in mice",A,,,Mus musculus,10090.0,
8274,1,,BAO_0000218,Intermediate,,13318,Concentration of the 9-[2-(Phosphonomethoxy)ethoxy]adenine in the blood following oral administration in mice,A,,,Mus musculus,10090.0,
8275,0,,BAO_0000019,Autocuration,,15692,Evaluated for Pharmacokinetic property: Area under the curve,A,,,,,
8276,1,,BAO_0000218,Intermediate,,14839,In vivo antitumor efficacy expressed as plasma area under the curve 0.4 hr after a peroral dose of 25 mg/kg in nude mice,A,,,Mus musculus,10090.0,
8277,1,,BAO_0000218,Intermediate,,14839,In vivo antitumor efficacy expressed as plasma area under the curve 0.4 hr after iv dose of 25 mg/kg in nude mice,A,,,Macaca fascicularis,9541.0,
8278,1,,BAO_0000218,Intermediate,,14839,In vivo antitumor efficacy in cynomolgus monkeys 0-48 hr after iv dose of 5 mg/kg expressed as Area under the curve,A,,,Macaca fascicularis,9541.0,
8279,1,,BAO_0000218,Intermediate,,14839,In vivo antitumor efficacy in cynomolgus monkeys 0-48 hr after peroral dose of 10 mg/kg expressed as Area under the curve,A,,,Macaca fascicularis,9541.0,
8280,1,,BAO_0000218,Intermediate,,14839,In vivo antitumor efficacy in cynomolgus monkeys 0-48 hr after peroral dose of 5 mg/kg expressed as Area under the curve,A,,,Macaca fascicularis,9541.0,
8281,1,,BAO_0000218,Intermediate,,14839,In vivo antitumor efficacy in cynomolgus monkeys 0-8 hours after peroral dose of 25 mg/kg expressed as Area under the curve,A,,,Macaca fascicularis,9541.0,
8282,1,,BAO_0000218,Intermediate,,14839,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 10 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-8 hr)",A,,,Macaca fascicularis,9541.0,
8283,1,,BAO_0000218,Intermediate,,14839,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as HCl salt in saline solution, iv and the total drug exposure was determined. (0-8 hr)",A,,,Macaca fascicularis,9541.0,
8284,1,,BAO_0000218,Intermediate,,14839,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-8 hr)",A,,,Macaca fascicularis,9541.0,
8285,1,,BAO_0000218,Intermediate,,14839,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as the micronised free base in corn oil, iv and the total drug exposure was determined. (0-8 hr)",A,,,Macaca fascicularis,9541.0,
8286,1,,BAO_0000218,Intermediate,,14839,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as the micronised free base in corn oil, perorally and the total drug exposure was determined (0-8 hr)",A,,,Macaca fascicularis,9541.0,
8287,1,,BAO_0000218,Intermediate,,14839,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 5 mg/kg, as HCl salt in saline solution, intravenously and the total drug exposure was determined (0-8 hr)",A,,,Macaca fascicularis,9541.0,
8288,1,,BAO_0000218,Intermediate,,14839,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 5 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-8 hr)",A,,,Macaca fascicularis,9541.0,
8289,1,,BAO_0000218,Intermediate,,14839,In vivo antitumor efficacy in nude mice 0-24 hr after intravenous dose of 25 mg/kg expressed as Area under the curve,A,,,Mus musculus,10090.0,
8290,1,,BAO_0000218,Intermediate,,14839,In vivo antitumor efficacy in nude mice 0-24 hr after iperoral dose of 25 mg/kg expressed as Area under the curve,A,,,Mus musculus,10090.0,
8291,1,,BAO_0000218,Intermediate,,14839,In vivo antitumor efficacy in nude mice 0-24 hr after iv dose of 25 mg/kg expressed as Area under the curve,A,,,Mus musculus,10090.0,
8292,1,,BAO_0000218,Intermediate,,14839,In vivo antitumor efficacy in nude mice 0-24 hr after peroral dose of 25 mg/kg expressed as Area under the curve,A,,,Mus musculus,10090.0,
8293,1,,BAO_0000218,Intermediate,,14839,In vivo antitumor efficacy in nude mice after peroral dose of 10 mg/kg expressed as Area under the curve,A,,,Mus musculus,10090.0,
8294,1,,BAO_0000218,Intermediate,,14839,In vivo antitumor efficacy in nude mice after peroral dose of 25 mg/kg expressed as Area under the curve,A,,,Mus musculus,10090.0,
8295,1,,BAO_0000218,Intermediate,,14839,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, iv and the total drug exposure was determined.",A,,,Mus musculus,10090.0,
8296,1,,BAO_0000218,Intermediate,,14839,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, iv and the total drug exposure was determined. (0-24hr)",A,,,Mus musculus,10090.0,
8297,1,,BAO_0000218,Intermediate,,14839,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, iv and the total drug exposure was determined. (0-4 hr)",A,,,Mus musculus,10090.0,
8298,1,,BAO_0000218,Intermediate,,14839,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined",A,,,Mus musculus,10090.0,
8299,1,,BAO_0000218,Intermediate,,14839,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-24hr)",A,,,Mus musculus,10090.0,
8300,1,,BAO_0000218,Intermediate,,14839,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-4 hr)",A,,,Mus musculus,10090.0,
8301,1,,BAO_0000218,Intermediate,1969.0,5408,Evaluated for plasma clearance after iv administration of 5 mg/kg to male Sprague-Dawley rats,A,In vivo,,Rattus norvegicus,10116.0,
8302,1,,BAO_0000218,Intermediate,,6827,High i.v. clearance in Dawley rats,A,In vivo,,Rattus norvegicus,10116.0,
8303,1,,BAO_0000218,Intermediate,2107.0,17538,In vitro clearance in rat liver microsomes,A,In vitro,,Rattus norvegicus,10116.0,
8304,1,,BAO_0000218,Intermediate,2107.0,6331,Intrinsic clearance in rat liver microsomes was determined,A,In vitro,,Rattus norvegicus,10116.0,
8305,1,,BAO_0000218,Intermediate,2107.0,5948,Intrinsic clearance in rat hepatocytes was determined,A,In vitro,,Rattus norvegicus,10116.0,
8306,1,,BAO_0000218,Intermediate,,4026,Plasma Clearance was determined,A,In vivo,,Rattus norvegicus,10116.0,
8307,1,,BAO_0000218,Intermediate,,6647,Plasma clearance after intravenous administration of 0.4 mg/kg of dose in rats was determined,A,In vivo,,Rattus norvegicus,10116.0,
8308,1,,BAO_0000218,Intermediate,,1696,Plasma clearance in rat.,A,In vivo,,Rattus norvegicus,10116.0,
8309,1,,BAO_0000218,Intermediate,,6597,Plasma clearance in rats,A,In vivo,,Rattus norvegicus,10116.0,
8310,1,,BAO_0000218,Intermediate,,347,Plasma clearance was estimated from the AUC after 5 mg/kg intravenous dosing in rats,A,In vivo,,Rattus norvegicus,10116.0,
8311,1,,BAO_0000218,Intermediate,,16423,Plasma clearance was evaluated after 10 uM/kg of intra arterial administration,A,In vivo,,Rattus norvegicus,10116.0,
8312,1,,BAO_0000218,Intermediate,,2879,Plasma clearance was measured in rat,A,In vivo,,Rattus norvegicus,10116.0,
8313,1,,BAO_0000218,Intermediate,,4883,Clearance after iv administration to Sprague-Dawley rat at dosage of 0.2 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,
8314,1,,BAO_0000218,Intermediate,1969.0,5328,"Tested for the plasma clearance in Dawley rat at a dose of 1 mg/kg intravenous, 2 mg/kg orally",A,In vivo,,Rattus norvegicus,10116.0,
8315,1,,BAO_0000218,Intermediate,,5160,The clearance rate in mature male rat at a intravenous dose of 3 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,
8316,1,,BAO_0000218,Intermediate,,17582,Total body clearance was evaluated for the compound after i.v. administration at a dose of 5 mg/kg was measured in rats,A,In vivo,,Rattus norvegicus,10116.0,
8317,1,,BAO_0000218,Intermediate,,17651,Total clearance at 1 mg/kg was determined in rat,A,In vivo,,Rattus norvegicus,10116.0,
8318,1,,BAO_0000218,Intermediate,,17651,Total clearance at 10 mg/kg was determined in rat,A,In vivo,,Rattus norvegicus,10116.0,
8319,1,,BAO_0000218,Intermediate,,6596,Clearance in rat,A,In vivo,,Rattus norvegicus,10116.0,
8320,1,,BAO_0000218,Intermediate,,4796,Plasma clearance rate determined in rats,A,In vivo,,Rattus norvegicus,10116.0,
8321,1,,BAO_0000218,Intermediate,,6850,Clearance of compound in rat was evaluated,A,In vivo,,Rattus norvegicus,10116.0,
8322,1,,BAO_0000218,Intermediate,1969.0,5932,Plasma concentration in rats after 7 hr at 30mg/kg oral dose,A,In vivo,,Rattus norvegicus,10116.0,
8323,1,,BAO_0000218,Intermediate,,3371,Pharmacokinetic property (blood clearance) in rat,A,In vivo,,Rattus norvegicus,10116.0,
8324,1,,BAO_0000218,Intermediate,,2083,Plasma clearance in rat,A,In vivo,,Rattus norvegicus,10116.0,
8325,1,,BAO_0000218,Intermediate,,4942,Plasma clearance in rats,A,In vivo,,Rattus norvegicus,10116.0,
8326,1,,BAO_0000218,Intermediate,2107.0,6838,Intrinsic clearance of compound against NADPH-fortified rat liver microsomes,A,In vitro,,Rattus norvegicus,10116.0,
8327,1,,BAO_0000218,Intermediate,,5353,Clearance in Dawley rat,A,In vivo,,Rattus norvegicus,10116.0,
8328,1,,BAO_0000218,Intermediate,,6641,Clearance rat,A,In vivo,,Rattus norvegicus,10116.0,
8329,1,,BAO_0000218,Intermediate,,6641,Clearance rat (dosed at 0.5 mpk IV and 2.0 mpk po.),A,In vivo,,Rattus norvegicus,10116.0,
8330,1,,BAO_0000218,Intermediate,,6641,Clearance rat; Not determined,A,In vivo,,Rattus norvegicus,10116.0,
8331,1,,BAO_0000218,Intermediate,,6444,Clearance rate was determined in rat at a dose of 1 mpk i.v.,A,In vivo,,Rattus norvegicus,10116.0,
8332,1,,BAO_0000218,Intermediate,,6444,Clearance rate was determined in rat at a dose of 1 mpk i.v.; ND means not determined,A,In vivo,,Rattus norvegicus,10116.0,
8333,1,,BAO_0000218,Intermediate,,6444,Clearance rate was determined in rat at a dose of 1 mpk i.v.; ND=not determined,A,In vivo,,Rattus norvegicus,10116.0,
8334,1,,BAO_0000218,Intermediate,,6211,Clearance was determined by iv administration (1.5 mg/kg) in fasted male Sprague-Dawley rats,A,In vivo,,Rattus norvegicus,10116.0,
8335,1,,BAO_0000218,Intermediate,1969.0,12873,"Clearance in plasma calculated from Time-Course plasma concentrations in rats at a dose of 2.5 mg/kg, iv",A,In vivo,,Rattus norvegicus,10116.0,
8336,1,,BAO_0000218,Intermediate,,6570,Clearance of compound in rat after 1 mg/kg i.v. administration,A,In vivo,,Rattus norvegicus,10116.0,
8337,1,,BAO_0000218,Intermediate,,3341,Compound was evaluated for Hepatic clearance in rat,A,In vivo,,Rattus norvegicus,10116.0,
8338,1,,BAO_0000218,Intermediate,,4891,In vivo clearance after 5 mg/kg dose,A,In vivo,,Rattus norvegicus,10116.0,
8339,1,,BAO_0000218,Intermediate,1969.0,1094,Compound was tested for plasma clearance in rats,A,In vivo,,Rattus norvegicus,10116.0,
8340,1,,BAO_0000218,Intermediate,,2938,Hepatic clearance after intravenous administration was evaluated in rat,A,In vivo,,Rattus norvegicus,10116.0,
8341,1,,BAO_0000218,Intermediate,,17853,Lower clearance in rat (i.v.) at 0.5 mpk,A,In vivo,,Rattus norvegicus,10116.0,
8342,1,,BAO_0000218,Intermediate,1969.0,6049,Pharmacokinetic parameter expressed as plasma clearance in rat,A,In vivo,,Rattus norvegicus,10116.0,
8343,1,,BAO_0000218,Intermediate,,5789,Pharmacokinetic property (Clp) in rat,A,In vivo,,Rattus norvegicus,10116.0,
8344,1,,BAO_0000218,Intermediate,,4514,Plasma clearance in Sprague-Dawley rats,A,In vivo,,Rattus norvegicus,10116.0,
8345,1,,BAO_0000218,Intermediate,,6448,Plasma clearance (Clp) in rat,A,In vivo,,Rattus norvegicus,10116.0,
8346,1,,BAO_0000218,Intermediate,,6062,Plasma clearance for the compound was measured in rat after an iv dose of 1 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,
8347,1,,BAO_0000218,Intermediate,,5710,Plasma clearance in fasted male Sprague dawely rats on administration of 0.5 mg/Kg i.v. of the compound,A,In vivo,,Rattus norvegicus,10116.0,
8348,1,,BAO_0000218,Intermediate,,4709,Plasma clearance after intravenous administration of 1 mg/kg in rat,A,In vivo,,Rattus norvegicus,10116.0,
8349,1,,BAO_0000218,Intermediate,,4521,Plasma clearance in rat after 5 mg/kg by oral and 1 mg/kg by intravenous administration,A,In vivo,,Rattus norvegicus,10116.0,
8350,1,,BAO_0000218,Intermediate,,1742,Plasma clearance in rat was determined,A,In vivo,,Rattus norvegicus,10116.0,
8351,1,,BAO_0000218,Intermediate,,6057,Plasma clearance measured in rat,A,In vivo,,Rattus norvegicus,10116.0,
8352,1,,BAO_0000218,Intermediate,,6057,Plasma clearance was calculated in rat,A,In vivo,,Rattus norvegicus,10116.0,
8353,1,,BAO_0000218,Intermediate,,5145,Plasma clearance in rat,A,In vivo,,Rattus norvegicus,10116.0,
8354,1,,BAO_0000218,Intermediate,,5833,Plasma clearance in rat,A,In vivo,,Rattus norvegicus,10116.0,
8355,1,,BAO_0000218,Intermediate,,6453,Plasma clearance in rat,A,In vivo,,Rattus norvegicus,10116.0,
8356,1,,BAO_0000218,Intermediate,,6640,Plasma clearance in rat,A,In vivo,,Rattus norvegicus,10116.0,
8357,1,,BAO_0000218,Intermediate,,6305,Plasma clearance in rats,A,In vivo,,Rattus norvegicus,10116.0,
8358,1,,BAO_0000218,Intermediate,,6642,Plasma clearance in rat,A,In vivo,,Rattus norvegicus,10116.0,
8359,1,,BAO_0000218,Intermediate,,5472,Plasma clearance was evaluated in rat,A,In vivo,,Rattus norvegicus,10116.0,
8360,1,,BAO_0000218,Intermediate,,5472,Plasma clearance was evaluated in rat; Not tested,A,In vivo,,Rattus norvegicus,10116.0,
8361,1,,BAO_0000218,Intermediate,,5144,Plasma clearance rate was determined for the compound in rat,A,In vivo,,Rattus norvegicus,10116.0,
8362,1,,BAO_0000218,Intermediate,,6685,"Plasma clearance rate was determined in rats at 10mg/kg, p.o. dose; n/a: not applicable",A,In vivo,,Rattus norvegicus,10116.0,
8363,1,,BAO_0000218,Intermediate,,6685,"Plasma clearance rate was determined in rats at 20 mg/kg, i.p. dose; n/a: not applicable",A,In vivo,,Rattus norvegicus,10116.0,
8364,1,,BAO_0000218,Intermediate,,6685,"Plasma clearance rate was determined in rats at 2 mg/kg, i.v. dose",A,In vivo,,Rattus norvegicus,10116.0,
8365,1,,BAO_0000218,Intermediate,948.0,13950,Biodistribution of [123I]-label in rat heart was reported at 24 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Rattus norvegicus,10116.0,
8366,1,,BAO_0000218,Intermediate,948.0,13950,Biodistribution of [123I]-label in rat heart was reported at 4 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Rattus norvegicus,10116.0,
8367,1,,BAO_0000218,Intermediate,160.0,13950,Biodistribution of [123I]-label in rat intestine was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Rattus norvegicus,10116.0,
8368,1,,BAO_0000218,Intermediate,160.0,13950,Biodistribution of [123I]-label in rat intestine was reported at 1 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Rattus norvegicus,10116.0,
8369,1,,BAO_0000218,Intermediate,160.0,13950,Biodistribution of [123I]-label in rat intestine was reported at 2 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Rattus norvegicus,10116.0,
8370,1,,BAO_0000218,Intermediate,160.0,13950,Biodistribution of [123I]-label in rat intestine was reported at 24 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Rattus norvegicus,10116.0,
8371,1,,BAO_0000218,Intermediate,160.0,13950,Biodistribution of [123I]-label in rat intestine was reported at 4 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Rattus norvegicus,10116.0,
8372,1,,BAO_0000218,Intermediate,2113.0,13950,Biodistribution of [123I]-label in rat kidneys was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Rattus norvegicus,10116.0,
8373,1,,BAO_0000218,Intermediate,2113.0,13950,Biodistribution of [123I]-label in rat kidneys was reported at 1 h post injection. Value shown is %ID/g of tissue,A,In vivo,,Rattus norvegicus,10116.0,
8374,1,,BAO_0000218,Intermediate,2113.0,13950,Biodistribution of [123I]-label in rat kidneys was reported at 2 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Rattus norvegicus,10116.0,
8375,1,,BAO_0000218,Intermediate,2113.0,13950,Biodistribution of [123I]-label in rat kidneys was reported at 24 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Rattus norvegicus,10116.0,
8376,1,,BAO_0000218,Intermediate,2113.0,13950,Biodistribution of [123I]-label in rat kidneys was reported at 4 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Rattus norvegicus,10116.0,
8377,1,,BAO_0000218,Intermediate,2107.0,13950,Biodistribution of [123I]-label in rat liver was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Rattus norvegicus,10116.0,
8378,1,,BAO_0000218,Intermediate,2107.0,13950,Biodistribution of [123I]-label in rat liver was reported at 1 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Rattus norvegicus,10116.0,
8379,1,,BAO_0000218,Intermediate,2107.0,13950,Biodistribution of [123I]-label in rat liver was reported at 2 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Rattus norvegicus,10116.0,
8380,1,,BAO_0000218,Intermediate,2107.0,13950,Biodistribution of [123I]-label in rat liver was reported at 24 h post injection. Value shown is %ID/g of tissue,A,In vivo,,Rattus norvegicus,10116.0,
8381,1,,BAO_0000218,Intermediate,2107.0,13950,Biodistribution of [123I]-label in rat liver was reported at 4 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Rattus norvegicus,10116.0,
8382,1,,BAO_0000218,Intermediate,2048.0,13950,Biodistribution of [123I]-label in rat lung was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Rattus norvegicus,10116.0,
8383,1,,BAO_0000218,Intermediate,2048.0,13950,Biodistribution of [123I]-label in rat lung was reported at 1 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Rattus norvegicus,10116.0,
8384,1,,BAO_0000218,Intermediate,2048.0,13950,Biodistribution of [123I]-label in rat lung was reported at 2 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Rattus norvegicus,10116.0,
8385,1,,BAO_0000218,Intermediate,2048.0,13950,Biodistribution of [123I]-label in rat lung was reported at 24 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Rattus norvegicus,10116.0,
8386,1,,BAO_0000218,Intermediate,2048.0,13950,Biodistribution of [123I]-label in rat lung was reported at 4 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Rattus norvegicus,10116.0,
8387,1,,BAO_0000218,Intermediate,2385.0,13950,Biodistribution of [123I]-label in rat muscle was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Rattus norvegicus,10116.0,
8388,1,,BAO_0000218,Intermediate,2385.0,13950,Biodistribution of [123I]-label in rat muscle was reported at 1 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Rattus norvegicus,10116.0,
8389,1,,BAO_0000218,Intermediate,2385.0,13950,Biodistribution of [123I]-label in rat muscle was reported at 2 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Rattus norvegicus,10116.0,
8390,1,,BAO_0000218,Intermediate,2385.0,13950,Biodistribution of [123I]-label in rat muscle was reported at 24 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Rattus norvegicus,10116.0,
8391,1,,BAO_0000218,Intermediate,2385.0,13950,Biodistribution of [123I]-label in rat muscle was reported at 4 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Rattus norvegicus,10116.0,
8392,1,,BAO_0000218,Intermediate,2106.0,13950,Biodistribution of [123I]-label in rat spleen was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Rattus norvegicus,10116.0,
8393,1,,BAO_0000218,Intermediate,2106.0,13950,Biodistribution of [123I]-label in rat spleen was reported at 1 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Rattus norvegicus,10116.0,
8394,1,,BAO_0000218,Intermediate,2106.0,13950,Biodistribution of [123I]-label in rat spleen was reported at 2 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Rattus norvegicus,10116.0,
8395,1,,BAO_0000218,Intermediate,2106.0,13950,Biodistribution of [123I]-label in rat spleen was reported at 24 h post injection. Value shown is %ID/g of tissue,A,In vivo,,Rattus norvegicus,10116.0,
8396,1,,BAO_0000218,Intermediate,2106.0,13950,Biodistribution of [123I]-label in rat spleen was reported at 4 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Rattus norvegicus,10116.0,
8397,1,,BAO_0000218,Intermediate,945.0,13950,Biodistribution of [123I]-label in rat stomach was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Rattus norvegicus,10116.0,
8398,1,,BAO_0000218,Intermediate,945.0,13950,Biodistribution of [123I]-label in rat stomach was reported at 1 h post injection. Value shown is %ID/g of tissue,A,In vivo,,Rattus norvegicus,10116.0,
8399,1,,BAO_0000218,Intermediate,945.0,13950,Biodistribution of [123I]-label in rat stomach was reported at 2 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Rattus norvegicus,10116.0,
8400,1,,BAO_0000218,Intermediate,945.0,13950,Biodistribution of [123I]-label in rat stomach was reported at 24 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Rattus norvegicus,10116.0,
8401,1,,BAO_0000218,Intermediate,945.0,13950,Biodistribution of [123I]-label in rat stomach was reported at 4 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Rattus norvegicus,10116.0,
8402,1,,BAO_0000218,Intermediate,2037.0,13950,Distribution of [123I]-label in rat brain (cerebellum) was reported at 20 min post injection. Value shown is %ID/g of tissue,A,,,Rattus norvegicus,10116.0,
8403,1,,BAO_0000218,Intermediate,2037.0,13950,Distribution of [123I]-label in rat brain (cerebellum) was reported at 60 min post injection. Value shown is %ID/g of tissue,A,,,Rattus norvegicus,10116.0,
8404,1,,BAO_0000218,Intermediate,,13950,Distribution of [123I]-label in rat brain (diencephalon) was reported at 20 min post injection. Value shown is %ID/g of tissue,A,,,Rattus norvegicus,10116.0,
8405,1,,BAO_0000218,Intermediate,,6570,Volume of distribution of compound in rat after 1 mg/kg i.v. administration,A,In vivo,,Rattus norvegicus,10116.0,
8406,1,,BAO_0000218,Intermediate,,6571,Volume of distribution of compound in rats after intravenous administration,A,In vivo,,Rattus norvegicus,10116.0,
8407,1,,BAO_0000218,Intermediate,,6453,Volume of distribution in rat,A,In vivo,,Rattus norvegicus,10116.0,
8408,1,,BAO_0000218,Intermediate,,6444,Volume of distribution was determined in rat at a dose of 1 mpk i.v.,A,In vivo,,Rattus norvegicus,10116.0,
8409,1,,BAO_0000218,Intermediate,,6444,Volume of distribution was determined in rat at a dose of 1 mpk i.v.; ND means not determined,A,In vivo,,Rattus norvegicus,10116.0,
8410,1,,BAO_0000218,Intermediate,,6444,Volume of distribution was determined in rat at a dose of 1 mpk i.v.; ND=not determined,A,In vivo,,Rattus norvegicus,10116.0,
8411,1,,BAO_0000218,Intermediate,,5353,Volume of distribution was determined in Dawley rat,A,In vivo,,Rattus norvegicus,10116.0,
8412,1,,BAO_0000218,Intermediate,,5334,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0,
8413,1,,BAO_0000218,Intermediate,,5334,Volume of distribution was reported in Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0,
8414,1,,BAO_0000218,Intermediate,,6641,Volumes of distribution in rat after peroral administration,A,In vivo,,Rattus norvegicus,10116.0,
8415,1,,BAO_0000218,Intermediate,,6641,Volumes of distribution in rat after po administration,A,In vivo,,Rattus norvegicus,10116.0,
8416,1,,BAO_0000218,Intermediate,,6641,Volumes of distribution in rat after po administration; Not determined,A,In vivo,,Rattus norvegicus,10116.0,
8417,1,,BAO_0000218,Intermediate,,5676,Pharmacokinetic property (Volume) in rat i.v.,A,In vivo,,Rattus norvegicus,10116.0,
8418,1,,BAO_0000218,Intermediate,,6410,Apparent volume of distribution when 3 mg/Kg dose was administered intravenously,A,In vivo,,Rattus norvegicus,10116.0,
8419,1,,BAO_0000218,Intermediate,,17670,"Volume distribution in fischer rats at 5 mg/kg dose, administered intravenously",A,In vivo,,Rattus norvegicus,10116.0,
8420,1,,BAO_0000218,Intermediate,,6495,Volume distribution in rat after oral administration at 10 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,
8421,1,,BAO_0000218,Intermediate,,5408,Evaluated for Volume of distribution after iv administration of 5 mg/kg to male Sprague-Dawley rats,A,In vivo,,Rattus norvegicus,10116.0,
8422,1,,BAO_0000218,Intermediate,,4883,Tested for volume of distribution after intravenous administration to Sprague-Dawley rat at dosage of 0.2 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,
8423,1,,BAO_0000218,Intermediate,,6647,Volume of distribution after oral administration of 6 mg/kg of dose in rats was determined,A,In vivo,,Rattus norvegicus,10116.0,
8424,1,,BAO_0000218,Intermediate,,6495,Volume of distribution in rats,A,In vivo,,Rattus norvegicus,10116.0,
8425,1,,BAO_0000218,Intermediate,,2661,Compound was evaluated for volume of distribution (steady state) after treatment with iv dose of 1 mgkg to female wistar rats,A,In vivo,,Rattus norvegicus,10116.0,
8426,1,,BAO_0000218,Intermediate,,2661,Compound was evaluated for volume of distribution (steady state) after treatment with iv dose of 1 mgkg to male wistar rats,A,In vivo,,Rattus norvegicus,10116.0,
8427,1,,BAO_0000218,Intermediate,,5974,In vivo Volume distribution (Vss) was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0,
8428,1,,BAO_0000218,Intermediate,,5974,In vivo Volume distribution (Vss) was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0,
8429,1,,BAO_0000218,Intermediate,,5974,In vivo Volume distribution (Vss) was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat;no value,A,In vivo,,Rattus norvegicus,10116.0,
8430,1,,BAO_0000218,Intermediate,,5974,In vivo Volume distribution (Vss) was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0,
8431,1,,BAO_0000218,Intermediate,,5960,Pharmacokinetic parameter (Vss) in rat,A,In vivo,,Rattus norvegicus,10116.0,
8432,1,,BAO_0000218,Intermediate,,5676,Pharmacokinetic property (Volume) in rat i.v.,A,In vivo,,Rattus norvegicus,10116.0,
8433,1,,BAO_0000218,Intermediate,,5948,Pharmacokinetic property (Vss) in rat,A,,,Rattus norvegicus,10116.0,
8434,1,,BAO_0000218,Intermediate,,5979,Steady state volume distribution (Vss) of compound after 2 hr iv infusion of 8.4 mg/kg in three rat,A,In vivo,,Rattus norvegicus,10116.0,
8435,1,,BAO_0000218,Intermediate,,5978,Steady state volume distribution (Vss) of compound after iv administration was determined in Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0,
8436,1,,BAO_0000218,Intermediate,,5978,Steady state volume distribution (Vss) of compound (10 mg/kg) after iv administration was determined in Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0,
8437,1,,BAO_0000218,Intermediate,,5978,Steady state volume distribution (Vss) of compound(9.83 mg/kg) after iv administration was determined in Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0,
8438,1,,BAO_0000218,Intermediate,,5978,Steady state volume distribution (Vss) of compound(9.84 mg/kg) after iv administration was determined in Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0,
8439,1,,BAO_0000218,Intermediate,,6448,Steady state volume distribution in rat,A,In vivo,,Rattus norvegicus,10116.0,
8440,1,,BAO_0000218,Intermediate,1969.0,12873,"Steady state volume of distribution calculated from Time-Course plasma concentrations in rats at a dose of 2.5 mg/kg, iv.",A,In vivo,,Rattus norvegicus,10116.0,
8441,1,,BAO_0000218,Intermediate,,4576,Steady state volume of distribution determined in rat,A,In vivo,,Rattus norvegicus,10116.0,
8442,1,,BAO_0000218,Intermediate,,17582,Steady-state volume of distribution was evaluated for the compound after i.v. administration at a dose of 5 mg/kg was measured in rats,A,In vivo,,Rattus norvegicus,10116.0,
8443,1,,BAO_0000218,Intermediate,,1466,Tested for volume of distribution at steady state upon intravenous administration of 5.0 mg/Kg dose in rat,A,In vivo,,Rattus norvegicus,10116.0,
8444,1,,BAO_0000218,Intermediate,,5182,Volume at steady state distribution by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat was determined,A,,,Rattus norvegicus,10116.0,
8445,1,,BAO_0000218,Intermediate,,5182,Volume at steady state distribution by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat was determined; NC means not calculated,A,,,Rattus norvegicus,10116.0,
8446,1,,BAO_0000218,Intermediate,,6535,Volume distribution in rat after administration of 2 mg/kg iv,A,In vivo,,Rattus norvegicus,10116.0,
8447,1,,BAO_0000218,Intermediate,,6535,Volume distribution in rat after administration of 2 mg/kg iv,A,In vivo,,Rattus norvegicus,10116.0,
8448,1,,BAO_0000218,Intermediate,,5041,Volume in steady state distribution value was determined,A,In vivo,,Rattus norvegicus,10116.0,
8449,1,,BAO_0000218,Intermediate,,5041,Volume in steady state distribution value was determined; ND denotes no data,A,In vivo,,Rattus norvegicus,10116.0,
8450,1,,BAO_0000218,Intermediate,,5041,Volume in steady state distribution value was determined; ND denotes not determined,A,In vivo,,Rattus norvegicus,10116.0,
8451,1,,BAO_0000218,Intermediate,,17065,Volume of distribution at a steady state measured after intravenous bolus administration of 50 mg/kg of compound to rats,A,In vivo,,Rattus norvegicus,10116.0,
8452,1,,BAO_0000218,Intermediate,,6597,Volume of distribution at steady state was evaluated in rats,A,In vivo,,Rattus norvegicus,10116.0,
8453,1,,BAO_0000218,Intermediate,,15662,Volume of distribution at steady state was observed after intravenous administration in rat,A,In vivo,,Rattus norvegicus,10116.0,
8454,1,,BAO_0000218,Intermediate,,6485,Volume of distribution in steady state was determined in rat,A,In vivo,,Rattus norvegicus,10116.0,
8455,1,,BAO_0000218,Intermediate,,17655,Volume of distribution in steady state was determined in rat,A,In vivo,,Rattus norvegicus,10116.0,
8456,1,,BAO_0000218,Intermediate,,6616,Volume of distribution after i.v. administration,A,In vivo,,Rattus norvegicus,10116.0,
8457,1,,BAO_0000218,Intermediate,,1916,Volume of distribution was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after iv administration,A,In vivo,,Rattus norvegicus,10116.0,
8458,1,,BAO_0000218,Intermediate,2107.0,16438,"Biodistribution of compound (oxidized form) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO solution",A,In vivo,,Mus musculus,10090.0,
8459,1,,BAO_0000218,Intermediate,2107.0,16438,"Biodistribution of compound (oxidized form) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",A,In vivo,,Mus musculus,10090.0,
8460,1,,BAO_0000218,Intermediate,2106.0,16438,Biodistribution of compound (oxidized form) in spleen tissue,A,In vivo,,Mus musculus,10090.0,
8461,1,,BAO_0000218,Intermediate,2106.0,16438,"Biodistribution of compound (oxidized form) in spleen tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",A,In vivo,,Mus musculus,10090.0,
8462,1,,BAO_0000218,Intermediate,2106.0,16438,"Biodistribution of compound (oxidized form) in spleen tissue, animals were sacrificed 10 minutes after dosing, in DMSO solution",A,In vivo,,Mus musculus,10090.0,
8463,1,,BAO_0000218,Intermediate,2106.0,16438,"Biodistribution of compound (oxidized form) in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO",A,In vivo,,Mus musculus,10090.0,
8464,1,,BAO_0000218,Intermediate,2106.0,16438,"Biodistribution of compound (oxidized form) in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",A,In vivo,,Mus musculus,10090.0,
8465,1,,BAO_0000218,Intermediate,2106.0,16438,"Biodistribution of compound (oxidized form) in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO solution",A,In vivo,,Mus musculus,10090.0,
8466,1,,BAO_0000218,Intermediate,178.0,16438,Biodistribution of compound (total concentration of both oxidized and reduced forms) in blood,A,In vivo,,Mus musculus,10090.0,
8467,1,,BAO_0000218,Intermediate,178.0,16438,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO",A,In vivo,,Mus musculus,10090.0,
8468,1,,BAO_0000218,Intermediate,955.0,16438,Biodistribution of compound (total concentration of both oxidized and reduced forms) in brain tissues,A,In vivo,,Mus musculus,10090.0,
8469,1,,BAO_0000218,Intermediate,955.0,16438,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in brain tissues, animals were sacrificed 10 minutes after dosing, in DMSO",A,In vivo,,Mus musculus,10090.0,
8470,1,,BAO_0000218,Intermediate,955.0,16438,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in brain tissues, animals were sacrificed 60 minutes after dosing, in DMSO",A,In vivo,,Mus musculus,10090.0,
8471,1,,BAO_0000218,Intermediate,948.0,16438,Biodistribution of compound (total concentration of both oxidized and reduced forms) in heart tissues,A,In vivo,,Mus musculus,10090.0,
8472,1,,BAO_0000218,Intermediate,948.0,16438,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in heart tissues, animals were sacrificed 10 minutes after dosing, in DMSO",A,In vivo,,Mus musculus,10090.0,
8473,1,,BAO_0000218,Intermediate,948.0,16438,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in heart tissues, animals were sacrificed 60 minutes after dosing, in DMSO",A,In vivo,,Mus musculus,10090.0,
8474,1,,BAO_0000218,Intermediate,2113.0,16438,Biodistribution of compound (total concentration of both oxidized and reduced forms) in kidney,A,In vivo,,Mus musculus,10090.0,
8475,1,,BAO_0000218,Intermediate,2113.0,16438,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in kidney tissues, animals were sacrificed 60 minutes after dosing in DMSO",A,In vivo,,Mus musculus,10090.0,
8476,1,,BAO_0000218,Intermediate,2113.0,16438,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in kidney tissues, animals were sacrificed 60 minutes after dosing, in DMSO",A,In vivo,,Mus musculus,10090.0,
8477,1,,BAO_0000218,Intermediate,2107.0,16438,Biodistribution of compound (total concentration of both oxidized and reduced forms) in liver,A,In vivo,,Mus musculus,10090.0,
8478,1,,BAO_0000218,Intermediate,2107.0,16438,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO",A,In vivo,,Mus musculus,10090.0,
8479,1,,BAO_0000218,Intermediate,2106.0,16438,Biodistribution of compound (total concentration of both oxidized and reduced forms) in spleen,A,In vivo,,Mus musculus,10090.0,
8480,1,,BAO_0000218,Intermediate,2106.0,16438,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in spleen tissues, animals were sacrificed 60 minutes after dosing in DMSO",A,In vivo,,Mus musculus,10090.0,
8481,1,,BAO_0000218,Intermediate,2106.0,16438,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO",A,In vivo,,Mus musculus,10090.0,
8482,1,,BAO_0000218,Intermediate,,12467,Cellular uptake kinetics of Porphycenes saturation cell level (cs) in SSK2 murine fibrosarcoma cells,A,,,Mus musculus,10090.0,
8483,1,,BAO_0000218,Intermediate,955.0,17208,Biodistribution of radioactivity in normal mice (ICR) brain after 1 hour of intravenous injection of [125I]-16(IMPY),A,In vivo,,Mus musculus,10090.0,
8484,1,,BAO_0000218,Intermediate,955.0,17208,Biodistribution of radioactivity in normal mice (ICR) brain after 2 hours of intravenous injection of [125I]-16(IMPY),A,In vivo,,Mus musculus,10090.0,
8485,1,,BAO_0000218,Intermediate,955.0,17208,Biodistribution of radioactivity in normal mice (ICR) brain after 2 minutes of intravenous injection of [125I]-16(IMPY),A,In vivo,,Mus musculus,10090.0,
8486,1,,BAO_0000218,Intermediate,955.0,17208,Biodistribution of radioactivity in normal mice (ICR) brain after 24 hours of intravenous injection of [125I]-16(IMPY),A,In vivo,,Mus musculus,10090.0,
8487,1,,BAO_0000218,Intermediate,955.0,17208,Biodistribution of radioactivity in normal mice (ICR) brain after 30 minutes of intravenous injection of [125I]-16(IMPY),A,In vivo,,Mus musculus,10090.0,
8488,1,,BAO_0000218,Intermediate,955.0,17208,Biodistribution of radioactivity in normal mice (ICR) brain after 6 hours of intravenous injection of [125I]-16(IMPY),A,In vivo,,Mus musculus,10090.0,
8489,1,,BAO_0000218,Intermediate,948.0,17208,Biodistribution of radioactivity in normal mice (ICR) heart after 1 hour of intravenous injection of [125I]-16(IMPY),A,In vivo,,Mus musculus,10090.0,
8490,1,,BAO_0000218,Intermediate,948.0,17208,Biodistribution of radioactivity in normal mice (ICR) heart after 2 hours of intravenous injection of [125I]-16(IMPY),A,In vivo,,Mus musculus,10090.0,
8491,1,,BAO_0000218,Intermediate,948.0,17208,Biodistribution of radioactivity in normal mice (ICR) heart after 2 minutes of intravenous injection of [125I]-16(IMPY),A,In vivo,,Mus musculus,10090.0,
8492,1,,BAO_0000218,Intermediate,948.0,17208,Biodistribution of radioactivity in normal mice (ICR) heart after 24 hours of intravenous injection of [125I]-16(IMPY),A,In vivo,,Mus musculus,10090.0,
8493,1,,BAO_0000218,Intermediate,948.0,17208,Biodistribution of radioactivity in normal mice (ICR) heart after 30 minutes of intravenous injection of [125I]-16(IMPY),A,In vivo,,Mus musculus,10090.0,
8494,1,,BAO_0000218,Intermediate,948.0,17208,Biodistribution of radioactivity in normal mice (ICR) heart after 6 hours of intravenous injection of [125I]-16(IMPY),A,In vivo,,Mus musculus,10090.0,
8495,1,,BAO_0000218,Intermediate,2113.0,17208,Biodistribution of radioactivity in normal mice (ICR) kidney after 1 hour of intravenous injection of [125I]-16(IMPY),A,In vivo,,Mus musculus,10090.0,
8496,1,,BAO_0000218,Intermediate,2113.0,17208,Biodistribution of radioactivity in normal mice (ICR) kidney after 2 hours of intravenous injection of [125I]-16(IMPY),A,In vivo,,Mus musculus,10090.0,
8497,1,,BAO_0000218,Intermediate,2113.0,17208,Biodistribution of radioactivity in normal mice (ICR) kidney after 2 minutes of intravenous injection of [125I]-16(IMPY),A,In vivo,,Mus musculus,10090.0,
8498,1,,BAO_0000218,Intermediate,2113.0,17208,Biodistribution of radioactivity in normal mice (ICR) kidney after 24 hours of intravenous injection of [125I]-16(IMPY),A,In vivo,,Mus musculus,10090.0,
8499,1,,BAO_0000218,Intermediate,,5089,Plasma clearance value at intravenous dose of 1 mg/kg (2 mg/kg po (cassette dosing) in Dawley rat,A,In vivo,,Rattus norvegicus,10116.0,
8500,1,,BAO_0000218,Intermediate,,5089,Plasma clearance value at intravenous dose of 1 mg/kg (2 mg/kg po (cassette dosing)) in Dawley rat,A,In vivo,,Rattus norvegicus,10116.0,
8501,1,,BAO_0000218,Intermediate,,4257,Plasma clearance value was determined in rat after a 3 mg/kg of iv dose,A,In vivo,,Rattus norvegicus,10116.0,
8502,1,,BAO_0000218,Intermediate,,6679,Plasma clearance was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,A,In vivo,,Rattus norvegicus,10116.0,
8503,1,,BAO_0000218,Intermediate,,5546,Plasma clearance was determined in Sprague-Dawley rats at a dose of 1 mg/kg by iv administration,A,In vivo,,Rattus norvegicus,10116.0,
8504,1,,BAO_0000218,Intermediate,,6141,Plasma clearance was evaluated at 1 mg/kg of iv administration in Sprague-Dawley rats,A,In vivo,,Rattus norvegicus,10116.0,
8505,1,,BAO_0000218,Intermediate,,5334,Plasma clearance was reported after intravenous administration at a dose of 1 mg/kg in Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0,
8506,1,,BAO_0000218,Intermediate,,5334,Plasma clearance was reported after oral administration at a dose of 2 mg/kg in Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0,
8507,1,,BAO_0000218,Intermediate,,5334,Plasma clearance was reported in Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0,
8508,1,,BAO_0000218,Intermediate,,4689,Plasma clearance after intravenous administration (1 mg/kg) in rat,A,In vivo,,Rattus norvegicus,10116.0,
8509,1,,BAO_0000218,Intermediate,,6848,Plasma clearance of compound in rats was evaluated,A,In vivo,,Rattus norvegicus,10116.0,
8510,1,,BAO_0000218,Intermediate,,6848,Plasma clearance of compound in rats was evaluated; ND indicates not determined,A,In vivo,,Rattus norvegicus,10116.0,
8511,1,,BAO_0000218,Intermediate,,6467,Plasma clearance in rats at the dose of 1.0 mpk by i.v. administration,A,In vivo,,Rattus norvegicus,10116.0,
8512,1,,BAO_0000218,Intermediate,,6467,Plasma clearance in rats at the dose of 1.0 mpk by i.v. administration; ND= not determined,A,In vivo,,Rattus norvegicus,10116.0,
8513,1,,BAO_0000218,Intermediate,,4956,Plasma clearance rate in Sprague-Dawley rats,A,In vivo,,Rattus norvegicus,10116.0,
8514,1,,BAO_0000218,Intermediate,,5529,Plasma clearance was determined in rat after intravenous administration (0.5 mg/kg),A,In vivo,,Rattus norvegicus,10116.0,
8515,1,,BAO_0000218,Intermediate,1969.0,406,The compound was evaluated for plasma clearance in rat,A,In vivo,,Rattus norvegicus,10116.0,
8516,1,,BAO_0000218,Intermediate,1969.0,17655,Total plasma clearance in rat,A,In vivo,,Rattus norvegicus,10116.0,
8517,1,,BAO_0000218,Intermediate,178.0,3293,Absorption behavior was judged by the peak blood concentration determined after oral dose of 30 mg/kg in rats.,A,In vivo,,Rattus norvegicus,10116.0,
8518,1,,BAO_0000218,Intermediate,178.0,4075,Blood level after a 10 mg/kg oral dose in rat expressed as Cmax was determined,A,In vivo,,Rattus norvegicus,10116.0,
8519,1,,BAO_0000218,Intermediate,,2792,C max was determined at 10 mg/kg po dose in rats,A,In vivo,,Rattus norvegicus,10116.0,
8520,1,,BAO_0000218,Intermediate,,2792,C max was determined at 3 mg/kg po dose in rats,A,In vivo,,Rattus norvegicus,10116.0,
8521,1,,BAO_0000218,Intermediate,,17594,Cmax after repeated oral dose of compound at 1 mg/kg in rats,A,In vivo,,Rattus norvegicus,10116.0,
8522,1,,BAO_0000218,Intermediate,,17594,Cmax after single intravenous bolus of 1 mg/kg in rats,A,In vivo,,Rattus norvegicus,10116.0,
8523,1,,BAO_0000218,Intermediate,,4762,Cmax of compound at 5 mg/kg after po administration was determined in rat,A,In vivo,,Rattus norvegicus,10116.0,
8524,1,,BAO_0000218,Intermediate,,17509,Cmax 24 hr after 10 mg/kg oral administration in rats,A,In vivo,,Rattus norvegicus,10116.0,
8525,1,,BAO_0000218,Intermediate,,17509,Cmax 24 hr after 2 mg/kg oral administration in rats,A,In vivo,,Rattus norvegicus,10116.0,
8526,1,,BAO_0000218,Intermediate,1969.0,1466,Cmax in plasma was determined upon peroral administration of 10.0 mg/Kg dose in rat,A,In vivo,,Rattus norvegicus,10116.0,
8527,1,,BAO_0000218,Intermediate,,6535,Cmax in rat after administration of 2 mg/kg iv,A,In vivo,,Rattus norvegicus,10116.0,
8528,1,,BAO_0000218,Intermediate,,6535,Cmax in rat after administration of 2 mg/kg iv,A,In vivo,,Rattus norvegicus,10116.0,
8529,1,,BAO_0000218,Intermediate,,3169,Cmax in rats determined 6 hours after oral dosing of 20 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,
8530,1,,BAO_0000218,Intermediate,1969.0,6515,Cmax wa determined in rat plasma at 30 mg/kg after po administration,A,In vivo,,Rattus norvegicus,10116.0,
8531,1,,BAO_0000218,Intermediate,178.0,11149,Cmax was calculated as maximum concentration reached in the blood after oral administration to male F344 rats,A,In vivo,,Rattus norvegicus,10116.0,
8532,1,,BAO_0000218,Intermediate,178.0,11149,Cmax was calculated as maximum concentration reached in the blood in air pouch exudate after oral administration to male F344 rats,A,In vivo,,Rattus norvegicus,10116.0,
8533,1,,BAO_0000218,Intermediate,,17858,Cmax after 10 mg/kg oral administration in rat,A,In vivo,,Rattus norvegicus,10116.0,
8534,1,,BAO_0000218,Intermediate,,6518,Cmax after IV dosing at 0.5 mg/kg in rat; no data,A,In vivo,,Rattus norvegicus,10116.0,
8535,1,,BAO_0000218,Intermediate,,6518,Cmax after IV dosing at 1 mg/kg in rat; no data,A,In vivo,,Rattus norvegicus,10116.0,
8536,1,,BAO_0000218,Intermediate,,4426,Cmax after oral administration at 20 mpk in rats,A,In vivo,,Rattus norvegicus,10116.0,
8537,1,,BAO_0000218,Intermediate,,4426,Cmax after oral administration at 20 mpk in rats; Not performed.,A,In vivo,,Rattus norvegicus,10116.0,
8538,1,,BAO_0000218,Intermediate,,4426,Cmax after oral administration at 20 mpk in rats d; Not performed.,A,In vivo,,Rattus norvegicus,10116.0,
8539,1,,BAO_0000218,Intermediate,,5656,Cmax after oral administration in rat,A,In vivo,,Rattus norvegicus,10116.0,
8540,1,,BAO_0000218,Intermediate,,6518,Cmax after oral administration at a dose of 2 mg/kg in rat,A,In vivo,,Rattus norvegicus,10116.0,
8541,1,,BAO_0000218,Intermediate,,6518,Cmax after oral administration at a dose of 4 mg/kg in rat,A,In vivo,,Rattus norvegicus,10116.0,
8542,1,,BAO_0000218,Intermediate,,6113,Cmax in rats after 20 mg/kg oral dose,A,In vivo,,Rattus norvegicus,10116.0,
8543,1,,BAO_0000218,Intermediate,,17764,Cmax after peroral administration in rats at 2.4 uM/kg,A,In vivo,,Rattus norvegicus,10116.0,
8544,1,,BAO_0000218,Intermediate,,4756,Cmax at the dose of 2 mg/Kg administered perorally in rats,A,In vivo,,Rattus norvegicus,10116.0,
8545,1,,BAO_0000218,Intermediate,,4756,Cmax at the dose of 5 mg/Kg administered perorally in rats,A,In vivo,,Rattus norvegicus,10116.0,
8546,1,,BAO_0000218,Intermediate,,6402,Cmax by administering at 20 mg/kg p.o. in rats,A,In vivo,,Rattus norvegicus,10116.0,
8547,1,,BAO_0000218,Intermediate,,5610,Cmax in male rat,A,In vivo,,Rattus norvegicus,10116.0,
8548,1,,BAO_0000218,Intermediate,,5207,Cmax in rat,A,In vivo,,Rattus norvegicus,10116.0,
8549,1,,BAO_0000218,Intermediate,,6011,Cmax in rat,A,In vivo,,Rattus norvegicus,10116.0,
8550,1,,BAO_0000218,Intermediate,,6504,Cmax in rat,A,In vivo,,Rattus norvegicus,10116.0,
8551,1,,BAO_0000218,Intermediate,,6046,Cmax in rat at 10 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,
8552,1,,BAO_0000218,Intermediate,,6504,Cmax in rat at the dose of 1 mg/kg i.v.,A,In vivo,,Rattus norvegicus,10116.0,
8553,1,,BAO_0000218,Intermediate,,5874,Cmax in rat by po administration at a dose of 40 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,
8554,1,,BAO_0000218,Intermediate,,17686,Cmax in rat p.o. at 20 mg/kg concentration,A,In vivo,,Rattus norvegicus,10116.0,
8555,1,,BAO_0000218,Intermediate,,5836,Cmax in rats,A,In vivo,,Rattus norvegicus,10116.0,
8556,1,,BAO_0000218,Intermediate,,17596,Cmax in rats,A,In vivo,,Rattus norvegicus,10116.0,
8557,1,,BAO_0000218,Intermediate,,16423,Cmax was evaluated after 20 uM/kg of peroral administration,A,In vivo,,Rattus norvegicus,10116.0,
8558,1,,BAO_0000218,Intermediate,,17804,Cmax was measured in rats after peroral administration at 3 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,
8559,1,,BAO_0000218,Intermediate,,1908,Cmax value after oral dose at a dose of 10 mg/kg in rats.,A,In vivo,,Rattus norvegicus,10116.0,
8560,1,,BAO_0000218,Intermediate,,13950,Distribution of [123I]-label in rat brain (diencephalon) was reported at 60 min post injection. Value shown is %ID/g of tissue,A,,,Rattus norvegicus,10116.0,
8561,1,,BAO_0000218,Intermediate,1870.0,13950,Distribution of [123I]-label in rat brain (frontal cortex) was reported at 20 min post injection. Value shown is %ID/g of tissue,A,,,Rattus norvegicus,10116.0,
8562,1,,BAO_0000218,Intermediate,1870.0,13950,Distribution of [123I]-label in rat brain (frontal cortex) was reported at 60 min post injection. Value shown is %ID/g of tissue,A,,,Rattus norvegicus,10116.0,
8563,1,,BAO_0000218,Intermediate,10000000.0,13950,Distribution of [123I]-label in rat brain (hippocampus) was reported at 20 min post injection. Value shown is %ID/g of tissue,A,,,Rattus norvegicus,10116.0,
8564,1,,BAO_0000218,Intermediate,10000000.0,13950,Distribution of [123I]-label in rat brain (hippocampus) was reported at 60 min post injection. Value shown is %ID/g of tissue,A,,,Rattus norvegicus,10116.0,
8565,1,,BAO_0000218,Intermediate,,13950,Distribution of [123I]-label in rat brain (medulla pons) was reported at 20 min post injection. Value shown is %ID/g of tissue,A,,,Rattus norvegicus,10116.0,
8566,1,,BAO_0000218,Intermediate,,13950,Distribution of [123I]-label in rat brain (medulla pons) was reported at 60 min post injection. Value shown is %ID/g of tissue,A,,,Rattus norvegicus,10116.0,
8567,1,,BAO_0000218,Intermediate,1891.0,13950,Distribution of [123I]-label in rat brain (midbrain) was reported at 20 min post injection. Value shown is %ID/g of tissue,A,,,Rattus norvegicus,10116.0,
8568,1,,BAO_0000218,Intermediate,1891.0,13950,Distribution of [123I]-label in rat brain (midbrain) was reported at 60 min post injection. Value shown is %ID/g of tissue,A,,,Rattus norvegicus,10116.0,
8569,1,,BAO_0000218,Intermediate,,13950,Distribution of [123I]-label in rat brain (posterior cortex) was reported at 20 min post injection. Value shown is %ID/g of tissue,A,,,Rattus norvegicus,10116.0,
8570,1,,BAO_0000218,Intermediate,,13950,Distribution of [123I]-label in rat brain (posterior cortex) was reported at 60 min post injection. Value shown is %ID/g of tissue,A,,,Rattus norvegicus,10116.0,
8571,1,,BAO_0000218,Intermediate,2435.0,13950,Distribution of [123I]-label in rat brain (striatum) was reported at 20 min post injection. Value shown is %ID/g of tissue,A,,,Rattus norvegicus,10116.0,
8572,1,,BAO_0000218,Intermediate,2435.0,13950,Distribution of [123I]-label in rat brain (striatum) was reported at 60 min post injection. Value shown is %ID/g of tissue,A,,,Rattus norvegicus,10116.0,
8573,1,,BAO_0000218,Intermediate,178.0,16434,Radioactivity distribution in blood of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,A,,,Rattus norvegicus,10116.0,
8574,1,,BAO_0000218,Intermediate,178.0,16434,Radioactivity distribution in blood of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,A,,,Rattus norvegicus,10116.0,
8575,1,,BAO_0000218,Intermediate,178.0,16434,Radioactivity distribution in blood of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,A,,,Rattus norvegicus,10116.0,
8576,1,,BAO_0000218,Intermediate,178.0,16434,Radioactivity distribution in blood of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,A,,,Rattus norvegicus,10116.0,
8577,1,,BAO_0000218,Intermediate,178.0,16434,Radioactivity distribution in blood of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,A,,,Rattus norvegicus,10116.0,
8578,1,,BAO_0000218,Intermediate,178.0,16434,Radioactivity distribution in blood of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,A,,,Rattus norvegicus,10116.0,
8579,1,,BAO_0000218,Intermediate,178.0,16434,Radioactivity distribution in blood of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,A,,,Rattus norvegicus,10116.0,
8580,1,,BAO_0000218,Intermediate,178.0,16434,Radioactivity distribution in blood of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,A,,,Rattus norvegicus,10116.0,
8581,1,,BAO_0000218,Intermediate,178.0,16435,Radioactivity distribution in blood of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,A,,,Rattus norvegicus,10116.0,
8582,1,,BAO_0000218,Intermediate,178.0,16435,Radioactivity distribution in blood of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,A,,,Rattus norvegicus,10116.0,
8583,1,,BAO_0000218,Intermediate,178.0,16435,Radioactivity distribution in blood of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,A,,,Rattus norvegicus,10116.0,
8584,1,,BAO_0000218,Intermediate,178.0,16435,Radioactivity distribution in blood of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,A,,,Rattus norvegicus,10116.0,
8585,1,,BAO_0000218,Intermediate,178.0,16435,Radioactivity distribution in blood of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,A,,,Rattus norvegicus,10116.0,
8586,1,,BAO_0000218,Intermediate,178.0,16435,Radioactivity distribution in blood of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,A,,,Rattus norvegicus,10116.0,
8587,1,,BAO_0000218,Intermediate,178.0,16435,Radioactivity distribution in blood of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,A,,,Rattus norvegicus,10116.0,
8588,1,,BAO_0000218,Intermediate,178.0,16435,Radioactivity distribution in blood of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,A,,,Rattus norvegicus,10116.0,
8589,1,,BAO_0000218,Intermediate,178.0,16434,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,A,,,Rattus norvegicus,10116.0,
8590,1,,BAO_0000218,Intermediate,178.0,16434,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,A,,,Rattus norvegicus,10116.0,
8591,1,,BAO_0000218,Intermediate,178.0,16434,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,A,,,Rattus norvegicus,10116.0,
8592,1,,BAO_0000218,Intermediate,178.0,16435,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,A,,,Rattus norvegicus,10116.0,
8593,1,,BAO_0000218,Intermediate,178.0,16435,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,A,,,Rattus norvegicus,10116.0,
8594,1,,BAO_0000218,Intermediate,178.0,16435,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,A,,,Rattus norvegicus,10116.0,
8595,1,,BAO_0000218,Intermediate,178.0,16435,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,A,,,Rattus norvegicus,10116.0,
8596,1,,BAO_0000218,Intermediate,178.0,16435,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,A,,,Rattus norvegicus,10116.0,
8597,1,,BAO_0000218,Intermediate,178.0,16435,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,A,,,Rattus norvegicus,10116.0,
8598,1,,BAO_0000218,Intermediate,,16434,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,A,,,Rattus norvegicus,10116.0,
8599,1,,BAO_0000218,Intermediate,,16434,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,A,,,Rattus norvegicus,10116.0,
8600,1,,BAO_0000218,Intermediate,,16434,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,A,,,Rattus norvegicus,10116.0,
8601,1,,BAO_0000218,Intermediate,,16434,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,A,,,Rattus norvegicus,10116.0,
8602,1,,BAO_0000218,Intermediate,,17764,Volume of solubility in solution after intravenous administration in rats at 24 uM/kg,A,In vivo,,Rattus norvegicus,10116.0,
8603,1,,BAO_0000218,Intermediate,,5031,Volume of steady state distribution after i.v. administration in rats,A,In vivo,,Rattus norvegicus,10116.0,
8604,1,,BAO_0000218,Intermediate,,6215,Vss after intravenous administration (5.0 mg/kg) was determined in rat,A,In vivo,,Rattus norvegicus,10116.0,
8605,1,,BAO_0000218,Intermediate,,17671,Vss in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,
8606,1,,BAO_0000218,Intermediate,,17752,Vss was determined,A,In vivo,,Rattus norvegicus,10116.0,
8607,1,,BAO_0000218,Intermediate,,6596,Vss in rat,A,In vivo,,Rattus norvegicus,10116.0,
8608,1,,BAO_0000218,Intermediate,,16423,Vss was evaluated after 10 uM/kg of intra arterial administration,A,In vivo,,Rattus norvegicus,10116.0,
8609,1,,BAO_0000218,Intermediate,,15662,volume of distribution at steady state was observed after intravenous administration in rat,A,In vivo,,Rattus norvegicus,10116.0,
8610,1,,BAO_0000218,Intermediate,,6062,Volume of distribution was measured in rat after an iv dose of 1 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,
8611,1,,BAO_0000218,Intermediate,,5874,Pharmacokinetic (PK) parameter Vz in rat,A,In vivo,,Rattus norvegicus,10116.0,
8612,1,,BAO_0000218,Intermediate,,4942,Volume distribution in rats,A,In vivo,,Rattus norvegicus,10116.0,
8613,1,,BAO_0000218,Intermediate,,17796,Volume of distribution in rat; No data,A,In vivo,,Rattus norvegicus,10116.0,
8614,1,,BAO_0000218,Intermediate,,4890,Volume of distribution was determined after intravenous administration at a dose 5 mg/kg to male Sprague-Dawley rats,A,In vivo,,Rattus norvegicus,10116.0,
8615,1,,BAO_0000218,Intermediate,2116.0,15765,% absorption predicted from in vitro rat ileum transport studies,A,,,Rattus norvegicus,10116.0,
8616,1,,BAO_0000218,Intermediate,,13569,Bioavailability at an iv dose of 12 mg/Kg and po dose of 23 mg/Kg,A,In vivo,,Rattus norvegicus,10116.0,
8617,1,,BAO_0000218,Intermediate,,13569,Bioavailability at an iv dose of 14 mg/Kg and po dose of 15 mg/Kg,A,In vivo,,Rattus norvegicus,10116.0,
8618,1,,BAO_0000218,Intermediate,,13569,Bioavailability at an iv dose of 14 mg/Kg and po dose of 28 mg/Kg,A,In vivo,,Rattus norvegicus,10116.0,
8619,1,,BAO_0000218,Intermediate,,13569,Bioavailability (dose 15 mg/kg i.v. and 30 mg/kg p.o.),A,In vivo,,Rattus norvegicus,10116.0,
8620,1,,BAO_0000218,Intermediate,,13569,Bioavailability at an iv dose of 15 mg/Kg and po dose of 30.2 mg/Kg,A,In vivo,,Rattus norvegicus,10116.0,
8621,1,,BAO_0000218,Intermediate,,13569,Bioavailability at an iv dose of 15.6 mg/Kg and po dose of 31.2 mg/Kg,A,In vivo,,Rattus norvegicus,10116.0,
8622,1,,BAO_0000218,Intermediate,,13569,Bioavailability at an iv dose of 15.7 mg/Kg and po dose of 31.4 mg/Kg,A,In vivo,,Rattus norvegicus,10116.0,
8623,1,,BAO_0000218,Intermediate,,13569,Bioavailability at an iv dose of 16 mg/Kg and po dose of 35 mg/Kg,A,In vivo,,Rattus norvegicus,10116.0,
8624,1,,BAO_0000218,Intermediate,,4576,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,
8625,1,,BAO_0000218,Intermediate,1969.0,750,Oral bioavailability estimated by measurement of the circulating plasma levels of BMS-183920 after intravenous and oral dosing to rats for 4 determinations,A,In vivo,,Rattus norvegicus,10116.0,
8626,1,,BAO_0000218,Intermediate,,750,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,
8627,1,,BAO_0000218,Intermediate,,4590,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,
8628,1,,BAO_0000218,Intermediate,,1716,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,
8629,1,,BAO_0000218,Intermediate,,1974,Bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,
8630,1,,BAO_0000218,Intermediate,,4502,Oral bioavailability in rat (dose 30 mg/kg),A,In vivo,,Rattus norvegicus,10116.0,
8631,1,,BAO_0000218,Intermediate,,3371,Pharmacokinetic property (cLogP) in rat,A,,,Rattus norvegicus,10116.0,
8632,1,,BAO_0000218,Intermediate,178.0,9099,Hyperglycemic activity and change in blood glucose concentration was reported 2 hours after administration of 100 mg/Kg perorally,F,,,Rattus norvegicus,10116.0,
8633,1,,BAO_0000218,Intermediate,178.0,9099,Hyperglycemic activity and change in blood glucose concentration was reported 4 hours after administration of 100 mg/Kg perorally,F,,,Rattus norvegicus,10116.0,
8634,1,,BAO_0000218,Intermediate,,4590,Clearance in rat.,A,In vivo,,Rattus norvegicus,10116.0,
8635,1,,BAO_0000218,Intermediate,,3184,Compound was evaluated for its clearance when administered intravenously in rat,A,In vivo,,Rattus norvegicus,10116.0,
8636,1,,BAO_0000218,Intermediate,,16456,Plasma clearance in Male Sprague-Dawley rats after intravenous administration at a dose of 10 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,
8637,1,,BAO_0000218,Intermediate,,4199,Blood: Brain distribution ratio is determined in rat,A,,,Rattus norvegicus,10116.0,
8638,1,,BAO_0000218,Intermediate,,4199,Blood: Brain distribution ratio is determined in rat; NQ: non quantifable,A,,,Rattus norvegicus,10116.0,
8639,1,,BAO_0000218,Intermediate,,4199,Blood: Brain distribution ratio is determined in rat; NQ:non quantifable,A,,,Rattus norvegicus,10116.0,
8640,1,,BAO_0000218,Intermediate,2113.0,8677,"Biodistribution in Sprague-Dawley rat kidneys(2) 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",A,In vivo,,Rattus norvegicus,10116.0,
8641,1,,BAO_0000218,Intermediate,,7449,Percent dose excreted in 0-48 hours administered ip to male rat,F,,,Rattus norvegicus,10116.0,
8642,1,,BAO_0000218,Intermediate,2037.0,11977,Uptake of radioligand [125I]FIDA1 by cerebellum in rat after 120 minutes after an intravenous injection is given (average of 3 rats),A,,,Rattus norvegicus,10116.0,
8643,1,,BAO_0000218,Intermediate,2037.0,11977,Uptake of radioligand [125I]FIDA1 by cerebellum in rat after 2 minutes after an intravenous injection is given (average of 3 rats),A,,,Rattus norvegicus,10116.0,
8644,1,,BAO_0000218,Intermediate,2037.0,11977,Uptake of radioligand [125I]-FIDA1 by cerebellum in rat after 30 minutes after an intravenous injection is given (average of 2 rats),A,,,Rattus norvegicus,10116.0,
8645,1,,BAO_0000218,Intermediate,2037.0,11977,Uptake of radioligand [125I]FIDA1 by cerebellum in rat after 30 minutes after an intravenous injection is given (average of 3 rats),A,,,Rattus norvegicus,10116.0,
8646,1,,BAO_0000218,Intermediate,2037.0,11977,Uptake of radioligand [125I]FIDA1 by cerebellum in rat after 60 minutes after an intravenous injection is given (average of 3 rats),A,,,Rattus norvegicus,10116.0,
8647,1,,BAO_0000218,Intermediate,,11977,Uptake of radioligand [125I]-FIDA1 by cortex in rat after 120 minutes after an intravenous injection is given (average of 3 rats),A,,,Rattus norvegicus,10116.0,
8648,1,,BAO_0000218,Intermediate,,11977,Uptake of radioligand [125I]FIDA1 by cortex in rat after 2 minutes after an intravenous injection is given (average of 3 rats),A,,,Rattus norvegicus,10116.0,
8649,1,,BAO_0000218,Intermediate,,11977,Uptake of radioligand [125I]FIDA1 by cortex in rat after 30 minutes after an intravenous injection is given (average of 2 rats),A,,,Rattus norvegicus,10116.0,
8650,1,,BAO_0000218,Intermediate,,11977,Uptake of radioligand [125I]-FIDA1 by cortex in rat after 30 minutes after an intravenous injection is given (average of 3 rats),A,,,Rattus norvegicus,10116.0,
8651,1,,BAO_0000218,Intermediate,,11977,Uptake of radioligand [125I]FIDA1 by cortex in rat after 60 minutes after an intravenous injection is given (average of 3 rats),A,,,Rattus norvegicus,10116.0,
8652,1,,BAO_0000218,Intermediate,,11977,Uptake of radioligand [125I]FIDA1 by hippo-campus in rat after 120 minutes after an intravenous injection is given (average of 3 rats),A,,,Rattus norvegicus,10116.0,
8653,1,,BAO_0000218,Intermediate,,11977,Uptake of radioligand [125I]FIDA1 by hippo-campus in rat after 2 minutes after an intravenous injection is given (average of 3 rats),A,,,Rattus norvegicus,10116.0,
8654,1,,BAO_0000218,Intermediate,2113.0,17208,Biodistribution of radioactivity in normal mice (ICR) kidney after 30 minutes of intravenous injection of [125I]-16(IMPY),A,In vivo,,Mus musculus,10090.0,
8655,1,,BAO_0000218,Intermediate,2113.0,17208,Biodistribution of radioactivity in normal mice (ICR) kidney after 6 hours of intravenous injection of [125I]-16(IMPY),A,In vivo,,Mus musculus,10090.0,
8656,1,,BAO_0000218,Intermediate,2107.0,17208,Biodistribution of radioactivity in normal mice (ICR) liver after 1 hour of intravenous injection of [125I]-16(IMPY),A,In vivo,,Mus musculus,10090.0,
8657,1,,BAO_0000218,Intermediate,2107.0,17208,Biodistribution of radioactivity in normal mice (ICR) liver after 2 hours of intravenous injection of [125I]-16(IMPY),A,In vivo,,Mus musculus,10090.0,
8658,1,,BAO_0000218,Intermediate,2107.0,17208,Biodistribution of radioactivity in normal mice (ICR) liver after 2 minutes of intravenous injection of [125I]-16(IMPY),A,In vivo,,Mus musculus,10090.0,
8659,1,,BAO_0000218,Intermediate,2107.0,17208,Biodistribution of radioactivity in normal mice (ICR) liver after 24 hours of intravenous injection of [125I]-16(IMPY),A,In vivo,,Mus musculus,10090.0,
8660,1,,BAO_0000218,Intermediate,2107.0,17208,Biodistribution of radioactivity in normal mice (ICR) liver after 30 minutes of intravenous injection of [125I]-16(IMPY),A,In vivo,,Mus musculus,10090.0,
8661,1,,BAO_0000218,Intermediate,2107.0,17208,Biodistribution of radioactivity in normal mice (ICR) liver after 6 hours of intravenous injection of [125I]-16(IMPY),A,In vivo,,Mus musculus,10090.0,
8662,1,,BAO_0000218,Intermediate,2048.0,17208,Biodistribution of radioactivity in normal mice (ICR) lung after 1 hour of intravenous injection of [125I]-16(IMPY),A,In vivo,,Mus musculus,10090.0,
8663,1,,BAO_0000218,Intermediate,2048.0,17208,Biodistribution of radioactivity in normal mice (ICR) lung after 2 hours of intravenous injection of [125I]-16(IMPY),A,In vivo,,Mus musculus,10090.0,
8664,1,,BAO_0000218,Intermediate,2048.0,17208,Biodistribution of radioactivity in normal mice (ICR) lung after 2 minutes of intravenous injection of [125I]-16(IMPY),A,In vivo,,Mus musculus,10090.0,
8665,1,,BAO_0000218,Intermediate,2048.0,17208,Biodistribution of radioactivity in normal mice (ICR) lung after 24 hours of intravenous injection of [125I]-16(IMPY),A,In vivo,,Mus musculus,10090.0,
8666,1,,BAO_0000218,Intermediate,2048.0,17208,Biodistribution of radioactivity in normal mice (ICR) lung after 30 minutes of intravenous injection of [125I]-16(IMPY),A,In vivo,,Mus musculus,10090.0,
8667,1,,BAO_0000218,Intermediate,2048.0,17208,Biodistribution of radioactivity in normal mice (ICR) lung after 6 hours of intravenous injection of [125I]-16(IMPY),A,In vivo,,Mus musculus,10090.0,
8668,1,,BAO_0000218,Intermediate,2385.0,17208,Biodistribution of radioactivity in normal mice (ICR) muscle after 1 hr of intravenous injection of [125I]-16(IMPY),A,In vivo,,Mus musculus,10090.0,
8669,1,,BAO_0000218,Intermediate,2385.0,17208,Biodistribution of radioactivity in normal mice (ICR) muscle after 2 hours of intravenous injection of [125I]-16(IMPY),A,In vivo,,Mus musculus,10090.0,
8670,1,,BAO_0000218,Intermediate,2385.0,17208,Biodistribution of radioactivity in normal mice (ICR) muscle after 2 minutes of intravenous injection of [125I]-16(IMPY),A,In vivo,,Mus musculus,10090.0,
8671,1,,BAO_0000218,Intermediate,2385.0,17208,Biodistribution of radioactivity in normal mice (ICR) muscle after 24 hours of intravenous injection of [125I]-16(IMPY),A,In vivo,,Mus musculus,10090.0,
8672,1,,BAO_0000218,Intermediate,2385.0,17208,Biodistribution of radioactivity in normal mice (ICR) muscle after 30 minutes of intravenous injection of [125I]-16(IMPY),A,In vivo,,Mus musculus,10090.0,
8673,1,,BAO_0000218,Intermediate,2385.0,17208,Biodistribution of radioactivity in normal mice (ICR) muscle after 6 hours of intravenous injection of [125I]-16(IMPY),A,In vivo,,Mus musculus,10090.0,
8674,1,,BAO_0000218,Intermediate,14.0,17208,Biodistribution of radioactivity in normal mice (ICR) skin after 1 hour of intravenous injection of [125I]-16(IMPY),A,In vivo,,Mus musculus,10090.0,
8675,1,,BAO_0000218,Intermediate,14.0,17208,Biodistribution of radioactivity in normal mice (ICR) skin after 2 hours of intravenous injection of [125I]-16(IMPY),A,In vivo,,Mus musculus,10090.0,
8676,1,,BAO_0000218,Intermediate,14.0,17208,Biodistribution of radioactivity in normal mice (ICR) skin after 2 minutes of intravenous injection of [125I]-16(IMPY),A,In vivo,,Mus musculus,10090.0,
8677,1,,BAO_0000218,Intermediate,14.0,17208,Biodistribution of radioactivity in normal mice (ICR) skin after 24 hours of intravenous injection of [125I]-16(IMPY),A,In vivo,,Mus musculus,10090.0,
8678,1,,BAO_0000218,Intermediate,14.0,17208,Biodistribution of radioactivity in normal mice (ICR) skin after 30 minutes of intravenous injection of [125I]-16(IMPY),A,In vivo,,Mus musculus,10090.0,
8679,1,,BAO_0000218,Intermediate,14.0,17208,Biodistribution of radioactivity in normal mice (ICR) skin after 6 hours of intravenous injection of [125I]-16(IMPY),A,In vivo,,Mus musculus,10090.0,
8680,1,,BAO_0000218,Intermediate,2106.0,17208,Biodistribution of radioactivity in normal mice (ICR) spleen after 1 hour of intravenous injection of [125I]-16(IMPY),A,In vivo,,Mus musculus,10090.0,
8681,1,,BAO_0000218,Intermediate,2106.0,17208,Biodistribution of radioactivity in normal mice (ICR) spleen after 2 hours of intravenous injection of [125I]-16(IMPY),A,In vivo,,Mus musculus,10090.0,
8682,1,,BAO_0000218,Intermediate,2106.0,17208,Biodistribution of radioactivity in normal mice (ICR) spleen after 2 minutes of intravenous injection of [125I]-16(IMPY),A,In vivo,,Mus musculus,10090.0,
8683,1,,BAO_0000218,Intermediate,2106.0,17208,Biodistribution of radioactivity in normal mice (ICR) spleen after 24 hours of intravenous injection of [125I]-16(IMPY),A,In vivo,,Mus musculus,10090.0,
8684,1,,BAO_0000218,Intermediate,2106.0,17208,Biodistribution of radioactivity in normal mice (ICR) spleen after 30 minutes of intravenous injection of [125I]-16(IMPY),A,In vivo,,Mus musculus,10090.0,
8685,1,,BAO_0000218,Intermediate,2106.0,17208,Biodistribution of radioactivity in normal mice (ICR) spleen after 6 hours of intravenous injection of [125I]-16(IMPY),A,In vivo,,Mus musculus,10090.0,
8686,1,,BAO_0000218,Intermediate,178.0,17208,Biodistribution of radioactivity in normal mice blood after 1 hour of intravenous injection of [125I]-16(IMPY),A,In vivo,,Mus musculus,10090.0,
8687,1,,BAO_0000218,Intermediate,178.0,17208,Biodistribution of radioactivity in normal mice blood after 2 hours of intravenous injection of [125I]-16(IMPY),A,In vivo,,Mus musculus,10090.0,
8688,1,,BAO_0000218,Intermediate,178.0,17208,Biodistribution of radioactivity in normal mice blood after 2 minutes of intravenous injection of [125I]-16(IMPY),A,In vivo,,Mus musculus,10090.0,
8689,1,,BAO_0000218,Intermediate,178.0,17208,Biodistribution of radioactivity in normal mice blood after 24 hours of intravenous injection of [125I]-16(IMPY),A,In vivo,,Mus musculus,10090.0,
8690,1,,BAO_0000218,Intermediate,178.0,17208,Biodistribution of radioactivity in normal mice blood after 30 minutes of intravenous injection of [125I]-16(IMPY),A,In vivo,,Mus musculus,10090.0,
8691,1,,BAO_0000218,Intermediate,178.0,17208,Biodistribution of radioactivity in normal mice blood after 6 hours of intravenous injection of [125I]-16(IMPY),A,In vivo,,Mus musculus,10090.0,
8692,1,,BAO_0000218,Intermediate,,3132,Time taken for EC90 was determined when tested in mouse,A,,,Mus musculus,10090.0,
8693,1,,BAO_0000218,Intermediate,,3132,Time taken for EC90 was determined when tested in mouse at dose 25 mg/kg,A,,,Mus musculus,10090.0,
8694,1,,BAO_0000218,Intermediate,,16597,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for half life (T1/2),A,In vivo,,Mus musculus,10090.0,
8695,1,,BAO_0000218,Intermediate,,5727,Half life in mice,A,,,Mus musculus,10090.0,
8696,1,,BAO_0000218,Intermediate,,5302,Half life period in mouse after 10 mg/Kg dose,A,In vivo,,Mus musculus,10090.0,
8697,1,,BAO_0000218,Intermediate,,5302,Half life period in mouse after 10 mg/kg dose,A,In vivo,,Mus musculus,10090.0,
8698,1,,BAO_0000218,Intermediate,,6348,Half life was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,A,In vivo,,Mus musculus,10090.0,
8699,1,,BAO_0000218,Intermediate,,5964,Cmax value at 5 mg/kg po was determined in rat,A,In vivo,,Rattus norvegicus,10116.0,
8700,1,,BAO_0000218,Intermediate,,6078,Cmax value evaluated in rat,A,In vivo,,Rattus norvegicus,10116.0,
8701,1,,BAO_0000218,Intermediate,955.0,5206,Cmax value was calculated by applying at a dose of 10 mg/Kg ip in rat brain,A,In vivo,,Rattus norvegicus,10116.0,
8702,1,,BAO_0000218,Intermediate,,2959,Cmax value after administration of 20 mg/Kg oral dose in rat,A,In vivo,,Rattus norvegicus,10116.0,
8703,1,,BAO_0000218,Intermediate,,5964,Cmax value at 1 mg/kg po in rat,A,In vivo,,Rattus norvegicus,10116.0,
8704,1,,BAO_0000218,Intermediate,,5964,Cmax value at 5 mg/kg po in rat,A,In vivo,,Rattus norvegicus,10116.0,
8705,1,,BAO_0000218,Intermediate,,6757,Cmax value at a dose of 10 mg/kg in male SD rats,A,In vivo,,Rattus norvegicus,10116.0,
8706,1,,BAO_0000218,Intermediate,,6757,Cmax value at a dose of 100 mg/kg in male SD rats,A,In vivo,,Rattus norvegicus,10116.0,
8707,1,,BAO_0000218,Intermediate,,6757,Cmax value at a dose of 50 mg/kg in male SD rats,A,In vivo,,Rattus norvegicus,10116.0,
8708,1,,BAO_0000218,Intermediate,,17617,Cmax value in rats at 10 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,
8709,1,,BAO_0000218,Intermediate,,1445,Cmax value was evaluated in rats at a dose of 20 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,
8710,1,,BAO_0000218,Intermediate,,6082,Cmax value was determined after peroral administration of 20 mg/kg in rat,A,In vivo,,Rattus norvegicus,10116.0,
8711,1,,BAO_0000218,Intermediate,,1446,Cmax value was determined between 15 and 30 minutes post administration in fisher rats; value ranges from 200-500,A,In vivo,,Rattus norvegicus,10116.0,
8712,1,,BAO_0000218,Intermediate,1969.0,5407,Compound was evaluated for its pharmacokinetic parameter maximum plasma concentration (Cmax) after oral administration to rats,A,In vivo,,Rattus norvegicus,10116.0,
8713,1,,BAO_0000218,Intermediate,1969.0,2690,Compound was evaluated for maximal plasma concentration in rat upon 5 mg/kg upon oral administration,A,In vivo,,Rattus norvegicus,10116.0,
8714,1,,BAO_0000218,Intermediate,,2661,Compound was evaluated for maximum concentration after treatment with oral dose of 2 mgkg to female wistar rats,A,In vivo,,Rattus norvegicus,10116.0,
8715,1,,BAO_0000218,Intermediate,,2661,Compound was evaluated for maximum concentration after treatment with oral dose of 2 mgkg to male wistar rats,A,In vivo,,Rattus norvegicus,10116.0,
8716,1,,BAO_0000218,Intermediate,1969.0,4891,Compound was evaluated for pharmacokinetic parameter maximum plasma concentration,A,In vivo,,Rattus norvegicus,10116.0,
8717,1,,BAO_0000218,Intermediate,1969.0,2807,Compound was evaluated for plasma concentration in rats when administered at 20 mg/kg in methocel at 0.5 hr,A,In vivo,,Rattus norvegicus,10116.0,
8718,1,,BAO_0000218,Intermediate,1969.0,2807,Compound was evaluated for plasma concentration in rats when administered at 20 mg/kg in methocel at 1 hr,A,In vivo,,Rattus norvegicus,10116.0,
8719,1,,BAO_0000218,Intermediate,1969.0,2807,Compound was evaluated for plasma concentration in rats when administered at 20 mg/kg in methocel at 2 hr,A,In vivo,,Rattus norvegicus,10116.0,
8720,1,,BAO_0000218,Intermediate,,3634,Compound was evaluated for the pharmacokinetic property in rats after an oral dose of 10 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,
8721,1,,BAO_0000218,Intermediate,1969.0,1881,Compound was tested for plasma concentration in rats when administered at 20 mg/kg in 1% methocel at 1 hr,A,In vivo,,Rattus norvegicus,10116.0,
8722,1,,BAO_0000218,Intermediate,1969.0,1881,Compound was tested for plasma concentration in rats when administered at 20 mg/kg in 1% methocel at 2 hr,A,In vivo,,Rattus norvegicus,10116.0,
8723,1,,BAO_0000218,Intermediate,,429,Evaluated for pharmacokinetic parameter Cmax in rat at the dose 50 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,
8724,1,,BAO_0000218,Intermediate,,5974,In vivo Cmax was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0,
8725,1,,BAO_0000218,Intermediate,,5974,In vivo Cmax was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0,
8726,1,,BAO_0000218,Intermediate,,5974,In vivo Cmax was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0,
8727,1,,BAO_0000218,Intermediate,,5974,In vivo Cmax was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0,
8728,1,,BAO_0000218,Intermediate,,17582,Maximal concentration in male Sprague-Dawley rats after 5 mg/kg intravenous dose,A,In vivo,,Rattus norvegicus,10116.0,
8729,1,,BAO_0000218,Intermediate,,17582,Maximal concentration in male Sprague-Dawley rats after 10 mg/kg oral dose,A,In vivo,,Rattus norvegicus,10116.0,
8730,1,,BAO_0000218,Intermediate,1969.0,3032,"In vivo maximum concentration of compound in rat plasma after a oral dose of 10 mg/kg (in water, N=4)",A,In vivo,,Rattus norvegicus,10116.0,
8731,1,,BAO_0000218,Intermediate,1969.0,6295,In vivo maximum concentration in rat plasma exposure after oral administration 50 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,
8732,1,,BAO_0000218,Intermediate,,6619,Maximal concentration in rat was determined,A,In vivo,,Rattus norvegicus,10116.0,
8733,1,,BAO_0000218,Intermediate,,6616,Maximal concentration after i.v. administration,A,In vivo,,Rattus norvegicus,10116.0,
8734,1,,BAO_0000218,Intermediate,1969.0,3249,Maximal concentration (Cmax) in the rat plasma at a dose of 10 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,
8735,1,,BAO_0000218,Intermediate,1969.0,17791,Maximal plasma concentration in rat after oral administration at 50 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,
8736,1,,BAO_0000218,Intermediate,1969.0,17791,Cmax in rat plasma after oral dose (50 mg/Kg),A,In vivo,,Rattus norvegicus,10116.0,
8737,1,,BAO_0000218,Intermediate,1969.0,1360,Maximal plasma concentration was determined.,A,In vivo,,Rattus norvegicus,10116.0,
8738,1,,BAO_0000218,Intermediate,1969.0,2552,Maximal plasma drug concentration was determined,A,In vivo,,Rattus norvegicus,10116.0,
8739,1,,BAO_0000218,Intermediate,,6571,Maximal concentration in rats after peroral administration,A,In vivo,,Rattus norvegicus,10116.0,
8740,1,,BAO_0000218,Intermediate,,6570,Maximum concentration in rat after 2 mg/kg peroral administration,A,In vivo,,Rattus norvegicus,10116.0,
8741,1,,BAO_0000218,Intermediate,1969.0,6567,Maximum concentration in rat plasma after 5 mg/kg oral gavage,A,In vivo,,Rattus norvegicus,10116.0,
8742,1,,BAO_0000218,Intermediate,,3031,Maximum concentration of compound in rat was evaluated.,A,In vivo,,Rattus norvegicus,10116.0,
8743,1,,BAO_0000218,Intermediate,,3436,Maximum concentration at 0.5 hr by peroral administration at a dose of 20 mg/kg in rats,A,In vivo,,Rattus norvegicus,10116.0,
8744,1,,BAO_0000218,Intermediate,,3436,Maximum concentration at 2 hr by peroral administration at a dose of 20 mg/kg in rats,A,In vivo,,Rattus norvegicus,10116.0,
8745,1,,BAO_0000218,Intermediate,,2083,Maximum concentration at 4 hr after administration of 5 mg/kg dose peroral in rat,A,In vivo,,Rattus norvegicus,10116.0,
8746,1,,BAO_0000218,Intermediate,,3436,Maximum concentration at 4 hr by peroral administration at a dose of 20 mg/kg in rats,A,In vivo,,Rattus norvegicus,10116.0,
8747,1,,BAO_0000218,Intermediate,,4527,Maximum concentration by oral administration at a dose of 100 uM/kg in rat was determined,A,In vivo,,Rattus norvegicus,10116.0,
8748,1,,BAO_0000218,Intermediate,,1974,Maximum concentration was evaluated in rats,A,In vivo,,Rattus norvegicus,10116.0,
8749,1,,BAO_0000218,Intermediate,1359.0,3307,Maximum concentration in CSF at 30 min following 24 mg/kg subcutaneous dose in rats,A,In vivo,,Rattus norvegicus,10116.0,
8750,1,,BAO_0000218,Intermediate,1969.0,3307,Maximum concentration in plasma at 30 min following 24 mg/kg subcutaneous dose in rats,A,In vivo,,Rattus norvegicus,10116.0,
8751,1,,BAO_0000218,Intermediate,1969.0,1916,Maximum concentration in plasma was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after po administration,A,In vivo,,Rattus norvegicus,10116.0,
8752,1,,BAO_0000218,Intermediate,,1500,Maximum concentration in portal vein was determined at a concentration of 10 mg/kg in rats,A,In vivo,,Rattus norvegicus,10116.0,
8753,1,,BAO_0000218,Intermediate,,1500,Maximum concentration in portal vein was determined at a concentration of 20 mg/kg in rats,A,In vivo,,Rattus norvegicus,10116.0,
8754,1,,BAO_0000218,Intermediate,1969.0,4186,Maximum concentration in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,A,In vivo,,Rattus norvegicus,10116.0,
8755,1,,BAO_0000218,Intermediate,,16434,Radioactivity distribution in bone of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,A,,,Rattus norvegicus,10116.0,
8756,1,,BAO_0000218,Intermediate,,16434,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 30 min.,A,,,Rattus norvegicus,10116.0,
8757,1,,BAO_0000218,Intermediate,,16434,Radioactivity distribution in bone of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,A,,,Rattus norvegicus,10116.0,
8758,1,,BAO_0000218,Intermediate,,16434,Radioactivity distribution in bone of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,A,,,Rattus norvegicus,10116.0,
8759,1,,BAO_0000218,Intermediate,,16435,Radioactivity distribution in bone of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,A,,,Rattus norvegicus,10116.0,
8760,1,,BAO_0000218,Intermediate,,16435,Radioactivity distribution in bone of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,A,,,Rattus norvegicus,10116.0,
8761,1,,BAO_0000218,Intermediate,,16435,Radioactivity distribution in bone of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,A,,,Rattus norvegicus,10116.0,
8762,1,,BAO_0000218,Intermediate,,16435,Radioactivity distribution in bone of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,A,,,Rattus norvegicus,10116.0,
8763,1,,BAO_0000218,Intermediate,,16435,Radioactivity distribution in bone of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,A,,,Rattus norvegicus,10116.0,
8764,1,,BAO_0000218,Intermediate,,16435,Radioactivity distribution in bone of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,A,,,Rattus norvegicus,10116.0,
8765,1,,BAO_0000218,Intermediate,,16435,Radioactivity distribution in bone of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,A,,,Rattus norvegicus,10116.0,
8766,1,,BAO_0000218,Intermediate,,16435,Radioactivity distribution in bone of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,A,,,Rattus norvegicus,10116.0,
8767,1,,BAO_0000218,Intermediate,,16434,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,A,,,Rattus norvegicus,10116.0,
8768,1,,BAO_0000218,Intermediate,,16434,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,A,,,Rattus norvegicus,10116.0,
8769,1,,BAO_0000218,Intermediate,,16434,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,A,,,Rattus norvegicus,10116.0,
8770,1,,BAO_0000218,Intermediate,,16435,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,A,,,Rattus norvegicus,10116.0,
8771,1,,BAO_0000218,Intermediate,,16435,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,A,,,Rattus norvegicus,10116.0,
8772,1,,BAO_0000218,Intermediate,,16435,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,A,,,Rattus norvegicus,10116.0,
8773,1,,BAO_0000218,Intermediate,,16435,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,A,,,Rattus norvegicus,10116.0,
8774,1,,BAO_0000218,Intermediate,,16435,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,A,,,Rattus norvegicus,10116.0,
8775,1,,BAO_0000218,Intermediate,,16435,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,A,,,Rattus norvegicus,10116.0,
8776,1,,BAO_0000218,Intermediate,955.0,16434,Radioactivity distribution in brain of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,A,,,Rattus norvegicus,10116.0,
8777,1,,BAO_0000218,Intermediate,955.0,16434,Radioactivity distribution in brain of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,A,,,Rattus norvegicus,10116.0,
8778,1,,BAO_0000218,Intermediate,955.0,16434,Radioactivity distribution in brain of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,A,,,Rattus norvegicus,10116.0,
8779,1,,BAO_0000218,Intermediate,955.0,16434,Radioactivity distribution in brain of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,A,,,Rattus norvegicus,10116.0,
8780,1,,BAO_0000218,Intermediate,955.0,16434,Radioactivity distribution in brain of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,A,,,Rattus norvegicus,10116.0,
8781,1,,BAO_0000218,Intermediate,955.0,16434,Radioactivity distribution in brain of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,A,,,Rattus norvegicus,10116.0,
8782,1,,BAO_0000218,Intermediate,955.0,16434,Radioactivity distribution in brain of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,A,,,Rattus norvegicus,10116.0,
8783,1,,BAO_0000218,Intermediate,955.0,16434,Radioactivity distribution in brain of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,A,,,Rattus norvegicus,10116.0,
8784,1,,BAO_0000218,Intermediate,955.0,16435,Radioactivity distribution in brain of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,A,,,Rattus norvegicus,10116.0,
8785,1,,BAO_0000218,Intermediate,955.0,16435,Radioactivity distribution in brain of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,A,,,Rattus norvegicus,10116.0,
8786,1,,BAO_0000218,Intermediate,955.0,16435,Radioactivity distribution in brain of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,A,,,Rattus norvegicus,10116.0,
8787,1,,BAO_0000218,Intermediate,955.0,16435,Radioactivity distribution in brain of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,A,,,Rattus norvegicus,10116.0,
8788,1,,BAO_0000218,Intermediate,955.0,16435,Radioactivity distribution in brain of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,A,,,Rattus norvegicus,10116.0,
8789,1,,BAO_0000218,Intermediate,955.0,16435,Radioactivity distribution in brain of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,A,,,Rattus norvegicus,10116.0,
8790,1,,BAO_0000218,Intermediate,955.0,16435,Radioactivity distribution in brain of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,A,,,Rattus norvegicus,10116.0,
8791,1,,BAO_0000218,Intermediate,955.0,16435,Radioactivity distribution in brain of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,A,,,Rattus norvegicus,10116.0,
8792,1,,BAO_0000218,Intermediate,955.0,16434,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,A,,,Rattus norvegicus,10116.0,
8793,1,,BAO_0000218,Intermediate,955.0,16434,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,A,,,Rattus norvegicus,10116.0,
8794,1,,BAO_0000218,Intermediate,955.0,16434,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,A,,,Rattus norvegicus,10116.0,
8795,1,,BAO_0000218,Intermediate,955.0,16435,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,A,,,Rattus norvegicus,10116.0,
8796,1,,BAO_0000218,Intermediate,955.0,16435,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,A,,,Rattus norvegicus,10116.0,
8797,1,,BAO_0000218,Intermediate,955.0,16435,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,A,,,Rattus norvegicus,10116.0,
8798,1,,BAO_0000218,Intermediate,955.0,16435,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,A,,,Rattus norvegicus,10116.0,
8799,1,,BAO_0000218,Intermediate,955.0,16435,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,A,,,Rattus norvegicus,10116.0,
8800,1,,BAO_0000218,Intermediate,955.0,16435,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,A,,,Rattus norvegicus,10116.0,
8801,1,,BAO_0000218,Intermediate,,11977,Uptake of radioligand [125I]FIDA1 by hippo-campus in rat after 30 minutes after an intravenous injection is given (average of 2 rats),A,,,Rattus norvegicus,10116.0,
8802,1,,BAO_0000218,Intermediate,,11977,Uptake of radioligand [125I]-FIDA1 by hippo-campus in rat after 60 minutes after an intravenous injection is given (average of 3 rats),A,,,Rattus norvegicus,10116.0,
8803,1,,BAO_0000218,Intermediate,10000000.0,11977,Uptake of radioligand [125I]FIDA1 by hippocampus in rat after 120 minutes after an intravenous injection is given (average of 3 rats),A,,,Rattus norvegicus,10116.0,
8804,1,,BAO_0000218,Intermediate,10000000.0,11977,Uptake of radioligand [125I]FIDA1 by hippocampus in rat after 2 minutes after an intravenous injection is given (average of 3 rats),A,,,Rattus norvegicus,10116.0,
8805,1,,BAO_0000218,Intermediate,10000000.0,11977,Uptake of radioligand [125I]-FIDA1 by hippocampus in rat after 30 minutes after an intravenous injection is given (average of 3 rats),A,,,Rattus norvegicus,10116.0,
8806,1,,BAO_0000218,Intermediate,10000000.0,11977,Uptake of radioligand [125I]FIDA1 by hippocampus in rat after 60 minutes after an intravenous injection is given (average of 3 rats),A,,,Rattus norvegicus,10116.0,
8807,1,,BAO_0000218,Intermediate,2435.0,11977,Uptake of radioligand [125I]FIDA1 by striatum in rat after 120 minutes after an intravenous injection is given (average of 3 rats),A,,,Rattus norvegicus,10116.0,
8808,1,,BAO_0000218,Intermediate,2435.0,11977,Uptake of radioligand [125I]FIDA1 by striatum in rat after 2 minutes after an intravenous injection is given (average of 3 rats),A,,,Rattus norvegicus,10116.0,
8809,1,,BAO_0000218,Intermediate,2435.0,11977,Uptake of radioligand [125I]FIDA1 by striatum in rat after 30 minutes after an intravenous injection is given (average of 2 rats),A,,,Rattus norvegicus,10116.0,
8810,1,,BAO_0000218,Intermediate,2435.0,11977,Uptake of radioligand [125I]FIDA1 by striatum in rat after 30 minutes after an intravenous injection is given (average of 3 rats),A,,,Rattus norvegicus,10116.0,
8811,1,,BAO_0000218,Intermediate,2435.0,11977,Uptake of radioligand [125I]FIDA1 by striatum in rat after 60 minutes after an intravenous injection is given (average of 3 rats),A,,,Rattus norvegicus,10116.0,
8812,1,,BAO_0000218,Intermediate,178.0,11977,Biodistribution of radioligand [125I]FIDA1 in blood of rat after 120 minutes after an intravenous injection is given (average of 3 rats),A,In vivo,,Rattus norvegicus,10116.0,
8813,1,,BAO_0000218,Intermediate,178.0,11977,Biodistribution of radioligand [125I]FIDA1 in blood of rat after 2 minutes after an intravenous injection is given (average of 3 rats),A,In vivo,,Rattus norvegicus,10116.0,
8814,1,,BAO_0000218,Intermediate,178.0,11977,Biodistribution of radioligand [125I]FIDA1 in blood of rat after 30 minutes after an intravenous injection is given (average of 3 rats),A,In vivo,,Rattus norvegicus,10116.0,
8815,1,,BAO_0000218,Intermediate,178.0,11977,Biodistribution of radioligand [125I]FIDA1 in blood of rat after 60 minutes after an intravenous injection is given (average of 3 rats),A,In vivo,,Rattus norvegicus,10116.0,
8816,1,,BAO_0000218,Intermediate,955.0,11977,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 120 minutes after an intravenous injection is given (average of 3 rats),A,In vivo,,Rattus norvegicus,10116.0,
8817,1,,BAO_0000218,Intermediate,955.0,11977,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 2 minutes after an intravenous injection is given (average of 3 rats),A,In vivo,,Rattus norvegicus,10116.0,
8818,1,,BAO_0000218,Intermediate,955.0,11977,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 30 minutes after an intravenous injection is given (average of 2 rats),A,In vivo,,Rattus norvegicus,10116.0,
8819,1,,BAO_0000218,Intermediate,955.0,11977,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 30 minutes after an intravenous injection is given (average of 3 rats),A,In vivo,,Rattus norvegicus,10116.0,
8820,1,,BAO_0000218,Intermediate,955.0,11977,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 60 minutes after an intravenous injection is given (average of 3 rats),A,In vivo,,Rattus norvegicus,10116.0,
8821,1,,BAO_0000218,Intermediate,948.0,11977,Biodistribution of radioligand [125I]-FIDA1 in heart of rat after 120 minutes after an intravenous injection is given (average of 3 rats),A,In vivo,,Rattus norvegicus,10116.0,
8822,1,,BAO_0000218,Intermediate,948.0,11977,Biodistribution of radioligand [125I]FIDA1 in heart of rat after 2 minutes after an intravenous injection is given (average of 3 rats),A,In vivo,,Rattus norvegicus,10116.0,
8823,1,,BAO_0000218,Intermediate,948.0,11977,Biodistribution of radioligand [125I]FIDA1 in heart of rat after 30 minutes after an intravenous injection is given (average of 2 rats),A,In vivo,,Rattus norvegicus,10116.0,
8824,1,,BAO_0000218,Intermediate,948.0,11977,Biodistribution of radioligand [125I]FIDA1 in heart of rat after 30 minutes after an intravenous injection is given (average of 3 rats),A,In vivo,,Rattus norvegicus,10116.0,
8825,1,,BAO_0000218,Intermediate,948.0,11977,Biodistribution of radioligand [125I]FIDA1 in heart of rat after 60 minutes after an intravenous injection is given (average of 3 rats),A,In vivo,,Rattus norvegicus,10116.0,
8826,1,,BAO_0000218,Intermediate,2113.0,11977,Biodistribution of radioligand [125I]FIDA1 in kidney of rat after 120 minutes after an intravenous injection is given (average of 3 rats),A,In vivo,,Rattus norvegicus,10116.0,
8827,1,,BAO_0000218,Intermediate,2113.0,11977,Biodistribution of radioligand [125I]-FIDA1 in kidney of rat after 2 minutes after an intravenous injection is given (average of 3 rats),A,In vivo,,Rattus norvegicus,10116.0,
8828,1,,BAO_0000218,Intermediate,2113.0,11977,Biodistribution of radioligand [125I]FIDA1 in kidney of rat after 30 minutes after an intravenous injection is given (average of 3 rats),A,In vivo,,Rattus norvegicus,10116.0,
8829,1,,BAO_0000218,Intermediate,2113.0,11977,Biodistribution of radioligand [125I]FIDA1 in kidney of rat after 60 minutes after an intravenous injection is given (average of 3 rats),A,In vivo,,Rattus norvegicus,10116.0,
8830,1,,BAO_0000218,Intermediate,2107.0,11977,Biodistribution of radioligand [125I]FIDA1 in liver of rat after 120 minutes after an intravenous injection is given (average of 3 rats),A,In vivo,,Rattus norvegicus,10116.0,
8831,1,,BAO_0000218,Intermediate,2107.0,11977,Biodistribution of radioligand [125I]-FIDA1 in liver of rat after 2 minutes after an intravenous injection is given (average of 3 rats),A,In vivo,,Rattus norvegicus,10116.0,
8832,1,,BAO_0000218,Intermediate,2107.0,11977,Biodistribution of radioligand [125I]FIDA1 in liver of rat after 30 minutes after an intravenous injection is given (average of 2 rats),A,In vivo,,Rattus norvegicus,10116.0,
8833,1,,BAO_0000218,Intermediate,2107.0,11977,Biodistribution of radioligand [125I]FIDA1 in liver of rat after 30 minutes after an intravenous injection is given (average of 3 rats),A,In vivo,,Rattus norvegicus,10116.0,
8834,1,,BAO_0000218,Intermediate,2107.0,11977,Biodistribution of radioligand [125I]FIDA1 in liver of rat after 60 minutes after an intravenous injection is given (average of 3 rats),A,In vivo,,Rattus norvegicus,10116.0,
8835,1,,BAO_0000218,Intermediate,2048.0,11977,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 120 minutes after an intravenous injection is given (average of 3 rats),A,In vivo,,Rattus norvegicus,10116.0,
8836,1,,BAO_0000218,Intermediate,2048.0,11977,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 2 minutes after an intravenous injection is given (average of 3 rats),A,In vivo,,Rattus norvegicus,10116.0,
8837,1,,BAO_0000218,Intermediate,2048.0,11977,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 30 minutes after an intravenous injection is given (average of 2 rats),A,In vivo,,Rattus norvegicus,10116.0,
8838,1,,BAO_0000218,Intermediate,2048.0,11977,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 30 minutes after an intravenous injection is given (average of 3 rats),A,In vivo,,Rattus norvegicus,10116.0,
8839,1,,BAO_0000218,Intermediate,2048.0,11977,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 60 minutes after an intravenous injection is given (average of 3 rats),A,In vivo,,Rattus norvegicus,10116.0,
8840,1,,BAO_0000218,Intermediate,2385.0,11977,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 120 minutes after an intravenous injection is given (average of 2 rats),A,In vivo,,Rattus norvegicus,10116.0,
8841,1,,BAO_0000218,Intermediate,,4573,Half life (t1/2) determined at a dose 10 mg/kg administered intraperitoneally to mice,A,In vivo,,Mus musculus,10090.0,
8842,1,,BAO_0000218,Intermediate,1969.0,3132,Half life in mouse plasma was determined at dose 25 mg/kg,A,In vivo,,Mus musculus,10090.0,
8843,1,,BAO_0000218,Intermediate,,17718,Half life was determined,A,,,Mus musculus,10090.0,
8844,1,,BAO_0000218,Intermediate,,17728,Half life in BALB/C mice at the dose of 20 mg/kg by i.v. administration,A,In vivo,,Mus musculus,10090.0,
8845,1,,BAO_0000218,Intermediate,,5961,Half-life in male mice after 1 mg/kg intravenous dose,A,In vivo,,Mus musculus,10090.0,
8847,1,,BAO_0000218,Intermediate,1969.0,17731,Half life in mice plasma,A,,,Mus musculus,10090.0,
8848,1,,BAO_0000218,Intermediate,,17592,Half life in mouse,A,,,Mus musculus,10090.0,
8849,1,,BAO_0000218,Intermediate,1969.0,3132,Half life in mouse plasma at dose 25 mg/kg,A,In vivo,,Mus musculus,10090.0,
8850,1,,BAO_0000218,Intermediate,,17729,Half life when injected i.p. in mice at a dose of 50 mg/kg was determined,A,In vivo,,Mus musculus,10090.0,
8851,1,,BAO_0000218,Intermediate,,17729,Half life when injected intravenously in mice at a dose of 20 mg/kg was determined,A,In vivo,,Mus musculus,10090.0,
8852,1,,BAO_0000218,Intermediate,,17729,Half life when injected perorally in mice at a dose of 50 mg/kg was determined,A,In vivo,,Mus musculus,10090.0,
8853,1,,BAO_0000218,Intermediate,,3277,Half life was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),A,In vivo,,Mus musculus,10090.0,
8854,1,,BAO_0000218,Intermediate,,3760,"Half life was evaluated at 5 mg/kg of compound dose, administered perorally in mice",A,In vivo,,Mus musculus,10090.0,
8855,1,,BAO_0000218,Intermediate,,3760,"Half life was evaluated at 50 mg/kg of compound dose, administered perorally in mice",A,In vivo,,Mus musculus,10090.0,
8856,1,,BAO_0000218,Intermediate,,2862,Half-life by iv administration in mouse,A,In vivo,,Mus musculus,10090.0,
8857,1,,BAO_0000218,Intermediate,,2862,Half-life by oral administration in mouse,A,In vivo,,Mus musculus,10090.0,
8858,1,,BAO_0000218,Intermediate,,5980,Half-life in mice,A,,,Mus musculus,10090.0,
8859,1,,BAO_0000218,Intermediate,955.0,6159,Half-life using mouse brain homogenate,A,,,Mus musculus,10090.0,
8860,1,,BAO_0000218,Intermediate,,6254,Half-life was measured in mice,A,,,Mus musculus,10090.0,
8861,1,,BAO_0000218,Intermediate,,6062,Half-life was measured in mouse after an iv dose of 1 mg/kg,A,In vivo,,Mus musculus,10090.0,
8862,1,,BAO_0000218,Intermediate,178.0,1574,Half-life period was determined in mouse blood,A,,,Mus musculus,10090.0,
8863,1,,BAO_0000218,Intermediate,955.0,56,"Half-times of inhibition of PEP in in an ex vivo enzyme studies, using mice brain",A,,,Mus musculus,10090.0,
8864,1,,BAO_0000218,Intermediate,1969.0,993,Plasma half life in mouse,A,,,Mus musculus,10090.0,
8865,1,,BAO_0000218,Intermediate,,6652,Stability of the peptide in the presence of mouse serum,A,,,Mus musculus,10090.0,
8866,1,,BAO_0000218,Intermediate,,17852,Terminal half life of compound was determined in mouse,A,,,Mus musculus,10090.0,
8867,1,,BAO_0000218,Intermediate,,2675,Terminal half life was evaluated in mice after intravenous administration,A,In vivo,,Mus musculus,10090.0,
8868,1,,BAO_0000218,Intermediate,,2675,Terminal half life was evaluated in mice after oral administration,A,In vivo,,Mus musculus,10090.0,
8869,1,,BAO_0000218,Intermediate,,499,The compound was evaluated for half life (release of DOX) in mice at 37 degree Celsius at the pH 5.,A,,,Mus musculus,10090.0,
8870,1,,BAO_0000218,Intermediate,,499,The compound was evaluated for half life (release of DOX) in mice at 37 degree Celsius at the pH 7.,A,,,Mus musculus,10090.0,
8871,1,,BAO_0000218,Intermediate,,499,The compound was evaluated for half life (release of DOX) in mice at 37 degree Celsius at the pH 7; ND means no data,A,,,Mus musculus,10090.0,
8872,1,,BAO_0000218,Intermediate,,14239,half life period is evaluated by administering intravenously at 25 mg/kg in mice,A,In vivo,,Mus musculus,10090.0,
8873,1,,BAO_0000218,Intermediate,,5506,"Half life beta(2,4,6,8h) value was determined at a dose of 200 mg/kg (i.p.) in Mice",A,In vivo,,Mus musculus,10090.0,
8874,1,,BAO_0000218,Intermediate,,5506,"Half life beta(2,4,6,8h) value was determined at a dose of 200 mg/kg (i.p.) in Mice; NC: not calculable",A,In vivo,,Mus musculus,10090.0,
8875,1,,BAO_0000218,Intermediate,,17734,Half life after intraperitoneal administration of 100 mg/kg in mice,A,,,Mus musculus,10090.0,
8876,1,,BAO_0000218,Intermediate,,17728,Half life in BALB/C mice at the dose of 20 mg/kg by i.p. administration,A,In vivo,,Mus musculus,10090.0,
8877,1,,BAO_0000218,Intermediate,,17728,Half life in BALB/C mice at the dose of 20 mg/kg by i.v. administration,A,In vivo,,Mus musculus,10090.0,
8878,1,,BAO_0000218,Intermediate,,17728,Half life in BALB/C mice at the dose of 20 mg/kg by p.o. administration,A,In vivo,,Mus musculus,10090.0,
8879,1,,BAO_0000218,Intermediate,,17728,Half life in BALB/C mice at the dose of 50 mg/kg by i.p. administration,A,In vivo,,Mus musculus,10090.0,
8880,1,,BAO_0000218,Intermediate,,17728,Half life in BALB/C mice at the dose of 50 mg/kg by p.o. administration,A,In vivo,,Mus musculus,10090.0,
8881,0,,BAO_0000251,Autocuration,,14294,Metabolism of compound in mini pig S9 microsomes ('+''indicates <20% largest observed peak),A,,,Sus scrofa,9823.0,
8882,0,,BAO_0000251,Autocuration,,14294,Metabolism of compound in mini pig S9 microsomes ('++++' indicates largest observed peak),A,,,Sus scrofa,9823.0,
8883,0,,BAO_0000019,Autocuration,,6056,Stability to porcine renal DHP-I,A,,,Sus scrofa,9823.0,
8884,0,,BAO_0000218,Autocuration,,1317,Compound was tested for its half-life period at an intravenous dose of 30 ug/kg,A,In vivo,,Sus scrofa,9823.0,
8885,0,,BAO_0000218,Autocuration,,1317,Compound was tested for its half-life period at an intravenous dose of 3 ug/kg,A,In vivo,,Sus scrofa,9823.0,
8886,0,,BAO_0000019,Autocuration,,5229,Half-life of the parent prodrug in porcine esterase solution,A,,,Sus scrofa,9823.0,
8887,0,,BAO_0000019,Autocuration,,4231,"First order rate constant, k was determined in in pig liver Esterase",A,,,Sus scrofa,9823.0,
8888,0,,BAO_0000221,Autocuration,2107.0,4231,Half life of the in pig liver Esterase,A,,,Sus scrofa,9823.0,
8889,0,,BAO_0000221,Autocuration,2107.0,5318,Tested for half life period at 37 degree Celsius in PBS buffer at 11.8 pH containing porcine liver esterase,A,,,Sus scrofa,9823.0,
8890,0,,BAO_0000221,Autocuration,2107.0,5318,Tested for half life period at 37 degree Celsius in PBS buffer at 7.3 pH containing porcine liver esterase,A,,,Sus scrofa,9823.0,
8891,0,,BAO_0000221,Autocuration,2107.0,5318,Tested for half life period at 37 degree Celsius in PBS buffer at 7.3 pH in containing porcine liver esterase,A,,,Sus scrofa,9823.0,
8892,0,,BAO_0000221,Autocuration,2107.0,3305,Compound was evaluated for esterase half-life (t 1/2) period using Pig Liver Esterase (PLE) assay,A,,,Sus scrofa,9823.0,
8893,0,,BAO_0000221,Autocuration,2107.0,3305,Compound was evaluated for esterase half-life (t 1/2) period using Pig Liver Esterase (PLE) assay; ND is not determined,A,,,Sus scrofa,9823.0,
8894,0,,BAO_0000221,Autocuration,2107.0,2842,Half-life in the presence of pig liver esterase(PLE) was evaluated.,A,,,Sus scrofa,9823.0,
8895,0,,BAO_0000221,Autocuration,2107.0,2842,Half-life in the presence of pig liver esterase(PLE) was evaluated; Stable,A,,,Sus scrofa,9823.0,
8896,0,,BAO_0000221,Autocuration,2107.0,889,Half-life in vitro in pig liver,A,In vitro,,Sus scrofa,9823.0,
8897,0,,BAO_0000221,Autocuration,2107.0,1904,Half-life time was determined for esterase-catalyzed hydrolysis of the phenol ester bond in porcine liver esterase,A,,,Sus scrofa,9823.0,
8898,1,,BAO_0000218,Intermediate,1969.0,4186,Maximum concentration in rat plasma after administration of 50 mg/kg dose through subcutaneous route,A,In vivo,,Rattus norvegicus,10116.0,
8899,1,,BAO_0000218,Intermediate,1969.0,2774,Maximum concentration in rat plasma at 30 mg/Kg upon oral administration.,A,In vivo,,Rattus norvegicus,10116.0,
8900,1,,BAO_0000218,Intermediate,1969.0,1742,Maximum concentration in rat plasma was determined,A,In vivo,,Rattus norvegicus,10116.0,
8901,1,,BAO_0000218,Intermediate,,3169,Maximum concentration in rats,A,In vivo,,Rattus norvegicus,10116.0,
8902,1,,BAO_0000218,Intermediate,,3169,Maximum concentration in rats at 1-2 hours,A,In vivo,,Rattus norvegicus,10116.0,
8903,1,,BAO_0000218,Intermediate,,2081,Maximum concentration in rats at 1 hr was determined when dosed at 20 mg/Kg perorally,A,In vivo,,Rattus norvegicus,10116.0,
8904,1,,BAO_0000218,Intermediate,955.0,3307,Maximum concentration in whole brain at 30 min following 24 mg/kg subcutaneous dose in rats,A,In vivo,,Rattus norvegicus,10116.0,
8905,1,,BAO_0000218,Intermediate,,4727,Maximum concentration at the dose of 2 mg/kg in rat,A,In vivo,,Rattus norvegicus,10116.0,
8906,1,,BAO_0000218,Intermediate,,6597,Maximum concentration was evaluated in rats,A,In vivo,,Rattus norvegicus,10116.0,
8907,1,,BAO_0000218,Intermediate,1969.0,16365,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 10 mg/kg to a fasting rat,A,In vivo,,Rattus norvegicus,10116.0,
8908,1,,BAO_0000218,Intermediate,1969.0,16365,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 1 mg/kg to a fasting rat,A,In vivo,,Rattus norvegicus,10116.0,
8909,1,,BAO_0000218,Intermediate,1969.0,16365,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 30 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,
8910,1,,BAO_0000218,Intermediate,1969.0,16365,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 3 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,
8911,1,,BAO_0000218,Intermediate,1969.0,16365,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 3 mg/kg to a fasting rat,A,In vivo,,Rattus norvegicus,10116.0,
8912,1,,BAO_0000218,Intermediate,178.0,2591,Maximum concentration value was evaluated for high sustained blood levels in rat after 1 hr of administration,A,In vivo,,Rattus norvegicus,10116.0,
8913,1,,BAO_0000218,Intermediate,178.0,2591,Maximum concentration value was evaluated for high sustained blood levels in rat after 2 hr of administration,A,In vivo,,Rattus norvegicus,10116.0,
8914,1,,BAO_0000218,Intermediate,178.0,2591,Maximum concentration value was evaluated for high sustained blood levels in rat after 30 min of administration,A,In vivo,,Rattus norvegicus,10116.0,
8915,1,,BAO_0000218,Intermediate,1969.0,5978,Maximum plasma concentration (Cmax) of compound (19.2 mg/kg) after po administration was determined Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0,
8916,1,,BAO_0000218,Intermediate,1969.0,5978,Maximum plasma concentration (Cmax) of compound (19.76 mg/kg) after po administration was determined Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0,
8917,1,,BAO_0000218,Intermediate,1969.0,5978,Maximum plasma concentration (Cmax) of compound (20.73 mg/kg) after po administration was determined Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0,
8918,1,,BAO_0000218,Intermediate,1969.0,5978,Maximum plasma concentration (Cmax) of compound (25 mg/kg) after po administration was determined Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0,
8919,1,,BAO_0000218,Intermediate,1969.0,5978,Maximum plasma concentration (Cmax) of compound (9.83 mg/kg) after iv administration was determined Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0,
8920,1,,BAO_0000218,Intermediate,1969.0,5978,Maximum plasma concentration (Cmax) of compound (9.84 mg/kg) after iv administration was determined Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0,
8921,1,,BAO_0000218,Intermediate,1969.0,5978,Maximum plasma concentration (Cmax) of compound (9.92 mg/kg) after iv administration was determined Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0,
8922,1,,BAO_0000218,Intermediate,,14465,Cmax in rat (PO dose),A,In vivo,,Rattus norvegicus,10116.0,
8923,1,,BAO_0000218,Intermediate,1969.0,4723,Maximum plasma concentration determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,A,In vivo,,Rattus norvegicus,10116.0,
8924,1,,BAO_0000218,Intermediate,1969.0,4723,Maximum plasma concentration determined after 3 mg/kg oral administration in potassium oxonate treated rats,A,In vivo,,Rattus norvegicus,10116.0,
8925,1,,BAO_0000218,Intermediate,1969.0,4576,Maximum plasma concentration determined in rat,A,In vivo,,Rattus norvegicus,10116.0,
8926,1,,BAO_0000218,Intermediate,1969.0,12873,Maximum plasma concentration for the compound in solution form (formulation) was determined in rats at peroral dose of 5 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,
8927,1,,BAO_0000218,Intermediate,1969.0,12873,Maximum plasma concentration for the compound in suspension form (formulation) was determined in rats at peroral dose of 5 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,
8928,1,,BAO_0000218,Intermediate,1969.0,6824,Maximum plasma concentration in rat,A,In vivo,,Rattus norvegicus,10116.0,
8929,1,,BAO_0000218,Intermediate,1969.0,17065,Maximum plasma concentration measured after intravenous bolus administration of 50 mg/kg of compound to rats,A,In vivo,,Rattus norvegicus,10116.0,
8930,1,,BAO_0000218,Intermediate,1969.0,2932,Maximum plasma concentration of compound present in rats at the dose of 37 mg/kg in 15 min,A,In vivo,,Rattus norvegicus,10116.0,
8931,1,,BAO_0000218,Intermediate,1969.0,2932,Maximum plasma concentration of compound present in rats at the dose of 38 mg/kg in 15 min,A,In vivo,,Rattus norvegicus,10116.0,
8932,1,,BAO_0000218,Intermediate,1969.0,2879,Maximum plasma concentration of compound was measured in rat,A,In vivo,,Rattus norvegicus,10116.0,
8933,1,,BAO_0000218,Intermediate,1969.0,2864,Maximum plasma concentration after 20 mg/kg oral administration in rat,A,In vivo,,Rattus norvegicus,10116.0,
8934,1,,BAO_0000218,Intermediate,1969.0,16367,Maximum plasma concentration after oral administration to rats,A,In vivo,,Rattus norvegicus,10116.0,
8935,1,,BAO_0000218,Intermediate,1969.0,17717,Maximum plasma concentration at a concentration of 15 mg/kg perorally in rats along with 100 mg/kg of compound 11,A,In vivo,,Rattus norvegicus,10116.0,
8936,1,,BAO_0000218,Intermediate,1969.0,17717,"Maximum plasma concentration at a concentration of 3 mg/kg in rats, intravenously",A,In vivo,,Rattus norvegicus,10116.0,
8937,1,,BAO_0000218,Intermediate,1969.0,17717,Maximum plasma concentration at a concentration of 60 mg/kg perorally in rats along with 100 mg/kg of compound 11,A,In vivo,,Rattus norvegicus,10116.0,
8938,1,,BAO_0000218,Intermediate,1969.0,17717,Maximum plasma concentration at a concentration of 60 mg/kg perorally in rats along with control,A,In vivo,,Rattus norvegicus,10116.0,
8939,1,,BAO_0000218,Intermediate,1969.0,17720,Maximum plasma concentration at a dose of 100 mg/kg in Rat Plasma after iv administration,F,In vivo,,Rattus norvegicus,10116.0,
8940,1,,BAO_0000218,Intermediate,1969.0,17720,Maximum plasma concentration at a dose of 4 mg/kg in Rat Plasma after iv administration,F,In vivo,,Rattus norvegicus,10116.0,
8941,1,,BAO_0000218,Intermediate,1969.0,17720,Maximum plasma concentration at a dose of 50 mg/kg in Rat Plasma after iv administration,F,In vivo,,Rattus norvegicus,10116.0,
8942,1,,BAO_0000218,Intermediate,1969.0,4516,Maximum plasma concentration dosed orally in rats,A,In vivo,,Rattus norvegicus,10116.0,
8943,1,,BAO_0000218,Intermediate,1969.0,4516,Maximum plasma concentration dosed orally in rats after 6 hours,A,In vivo,,Rattus norvegicus,10116.0,
8944,1,,BAO_0000218,Intermediate,1969.0,4516,Maximum plasma concentration dosed orally in rats after 6 hours; ND is not detected,A,In vivo,,Rattus norvegicus,10116.0,
8945,1,,BAO_0000218,Intermediate,1969.0,5199,Maximum plasma concentration at a 1 mg/kg oral dose in female Sprague-Dawley rats,A,In vivo,,Rattus norvegicus,10116.0,
8946,1,,BAO_0000218,Intermediate,1969.0,17538,Maximum plasma concentration in rat after po administration,A,In vivo,,Rattus norvegicus,10116.0,
8947,1,,BAO_0000218,Intermediate,1969.0,6685,"Maximum plasma concentration in rats at 10 mg/kg, p.o. dose",A,In vivo,,Rattus norvegicus,10116.0,
8948,1,,BAO_0000218,Intermediate,1969.0,6685,"Maximum plasma concentration in rats at 20mg/kg, i.p. dose",A,In vivo,,Rattus norvegicus,10116.0,
8949,1,,BAO_0000218,Intermediate,948.0,16434,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,A,,,Rattus norvegicus,10116.0,
8950,1,,BAO_0000218,Intermediate,948.0,16434,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,A,,,Rattus norvegicus,10116.0,
8951,1,,BAO_0000218,Intermediate,948.0,16434,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,A,,,Rattus norvegicus,10116.0,
8952,1,,BAO_0000218,Intermediate,948.0,16434,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,A,,,Rattus norvegicus,10116.0,
8953,1,,BAO_0000218,Intermediate,948.0,16434,Radioactivity distribution in heart of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,A,,,Rattus norvegicus,10116.0,
8954,1,,BAO_0000218,Intermediate,948.0,16434,Radioactivity distribution in heart of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,A,,,Rattus norvegicus,10116.0,
8955,1,,BAO_0000218,Intermediate,948.0,16434,Radioactivity distribution in heart of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,A,,,Rattus norvegicus,10116.0,
8956,1,,BAO_0000218,Intermediate,948.0,16434,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 60 min.,A,,,Rattus norvegicus,10116.0,
8957,1,,BAO_0000218,Intermediate,948.0,16435,Radioactivity distribution in heart of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,A,,,Rattus norvegicus,10116.0,
8958,1,,BAO_0000218,Intermediate,948.0,16435,Radioactivity distribution in heart of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,A,,,Rattus norvegicus,10116.0,
8959,1,,BAO_0000218,Intermediate,948.0,16435,Radioactivity distribution in heart of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,A,,,Rattus norvegicus,10116.0,
8960,1,,BAO_0000218,Intermediate,948.0,16435,Radioactivity distribution in heart of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,A,,,Rattus norvegicus,10116.0,
8961,1,,BAO_0000218,Intermediate,948.0,16434,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,A,,,Rattus norvegicus,10116.0,
8962,1,,BAO_0000218,Intermediate,948.0,16434,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,A,,,Rattus norvegicus,10116.0,
8963,1,,BAO_0000218,Intermediate,948.0,16434,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,A,,,Rattus norvegicus,10116.0,
8964,1,,BAO_0000218,Intermediate,948.0,16435,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,A,,,Rattus norvegicus,10116.0,
8965,1,,BAO_0000218,Intermediate,948.0,16435,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,A,,,Rattus norvegicus,10116.0,
8966,1,,BAO_0000218,Intermediate,948.0,16435,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,A,,,Rattus norvegicus,10116.0,
8967,1,,BAO_0000218,Intermediate,948.0,16435,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,A,,,Rattus norvegicus,10116.0,
8968,1,,BAO_0000218,Intermediate,948.0,16435,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,A,,,Rattus norvegicus,10116.0,
8969,1,,BAO_0000218,Intermediate,948.0,16435,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,A,,,Rattus norvegicus,10116.0,
8970,1,,BAO_0000218,Intermediate,948.0,16435,Radioactivity distribution in heart of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,A,,,Rattus norvegicus,10116.0,
8971,1,,BAO_0000218,Intermediate,948.0,16435,Radioactivity distribution in heart of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,A,,,Rattus norvegicus,10116.0,
8972,1,,BAO_0000218,Intermediate,948.0,16435,Radioactivity distribution in heart of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,A,,,Rattus norvegicus,10116.0,
8973,1,,BAO_0000218,Intermediate,948.0,16435,Radioactivity distribution in heart of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,A,,,Rattus norvegicus,10116.0,
8974,1,,BAO_0000218,Intermediate,2113.0,16434,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,A,,,Rattus norvegicus,10116.0,
8975,1,,BAO_0000218,Intermediate,2113.0,16434,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,A,,,Rattus norvegicus,10116.0,
8976,1,,BAO_0000218,Intermediate,2113.0,16434,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,A,,,Rattus norvegicus,10116.0,
8977,1,,BAO_0000218,Intermediate,2113.0,16434,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,A,,,Rattus norvegicus,10116.0,
8978,1,,BAO_0000218,Intermediate,2113.0,16434,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,A,,,Rattus norvegicus,10116.0,
8979,1,,BAO_0000218,Intermediate,2113.0,16434,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,A,,,Rattus norvegicus,10116.0,
8980,1,,BAO_0000218,Intermediate,2113.0,16434,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,A,,,Rattus norvegicus,10116.0,
8981,1,,BAO_0000218,Intermediate,2113.0,16434,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,A,,,Rattus norvegicus,10116.0,
8982,1,,BAO_0000218,Intermediate,2113.0,16435,Radioactivity distribution in kidney of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,A,,,Rattus norvegicus,10116.0,
8983,1,,BAO_0000218,Intermediate,2113.0,16435,Radioactivity distribution in kidney of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,A,,,Rattus norvegicus,10116.0,
8984,1,,BAO_0000218,Intermediate,2113.0,16435,Radioactivity distribution in kidney of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,A,,,Rattus norvegicus,10116.0,
8985,1,,BAO_0000218,Intermediate,2113.0,16435,Radioactivity distribution in kidney of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,A,,,Rattus norvegicus,10116.0,
8986,1,,BAO_0000218,Intermediate,2113.0,16435,Radioactivity distribution in kidney of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,A,,,Rattus norvegicus,10116.0,
8987,1,,BAO_0000218,Intermediate,2113.0,16435,Radioactivity distribution in kidney of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,A,,,Rattus norvegicus,10116.0,
8988,1,,BAO_0000218,Intermediate,2113.0,16435,Radioactivity distribution in kidney of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,A,,,Rattus norvegicus,10116.0,
8989,1,,BAO_0000218,Intermediate,2113.0,16435,Radioactivity distribution in kidney of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,A,,,Rattus norvegicus,10116.0,
8990,1,,BAO_0000218,Intermediate,2113.0,16434,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,A,,,Rattus norvegicus,10116.0,
8991,1,,BAO_0000218,Intermediate,2113.0,16434,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,A,,,Rattus norvegicus,10116.0,
8992,1,,BAO_0000218,Intermediate,2113.0,16434,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,A,,,Rattus norvegicus,10116.0,
8993,1,,BAO_0000218,Intermediate,2113.0,16435,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,A,,,Rattus norvegicus,10116.0,
8994,1,,BAO_0000218,Intermediate,2385.0,11977,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 120 minutes after an intravenous injection is given (average of 3 rats),A,In vivo,,Rattus norvegicus,10116.0,
8995,1,,BAO_0000218,Intermediate,2385.0,11977,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 2 minutes after an intravenous injection is given (average of 3 rats),A,In vivo,,Rattus norvegicus,10116.0,
8996,1,,BAO_0000218,Intermediate,2385.0,11977,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 30 minutes after an intravenous injection is given (average of 2 rats),A,In vivo,,Rattus norvegicus,10116.0,
8997,1,,BAO_0000218,Intermediate,2385.0,11977,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 30 minutes after an intravenous injection is given (average of 3 rats),A,In vivo,,Rattus norvegicus,10116.0,
8998,1,,BAO_0000218,Intermediate,2385.0,11977,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 60 minutes after an intravenous injection is given (average of 3 rats),A,In vivo,,Rattus norvegicus,10116.0,
8999,1,,BAO_0000218,Intermediate,14.0,11977,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 120 minutes after an intravenous injection is given (average of 3 rats),A,In vivo,,Rattus norvegicus,10116.0,
9000,1,,BAO_0000218,Intermediate,14.0,11977,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 2 minutes after an intravenous injection is given (average of 3 rats),A,In vivo,,Rattus norvegicus,10116.0,
9001,1,,BAO_0000218,Intermediate,14.0,11977,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 30 minutes after an intravenous injection is given (average of 2 rats),A,In vivo,,Rattus norvegicus,10116.0,
9002,1,,BAO_0000218,Intermediate,14.0,11977,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 30 minutes after an intravenous injection is given (average of 3 rats),A,In vivo,,Rattus norvegicus,10116.0,
9003,1,,BAO_0000218,Intermediate,14.0,11977,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 60 minutes after an intravenous injection is given (average of 3 rats),A,In vivo,,Rattus norvegicus,10116.0,
9004,1,,BAO_0000218,Intermediate,2106.0,11977,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 120 minutes after an intravenous injection is given (average of 3 rats),A,In vivo,,Rattus norvegicus,10116.0,
9005,1,,BAO_0000218,Intermediate,2106.0,11977,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 2 minutes after an intravenous injection is given (average of 3 rats),A,In vivo,,Rattus norvegicus,10116.0,
9006,1,,BAO_0000218,Intermediate,2106.0,11977,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 30 minutes after an intravenous injection is given (average of 2 rats),A,In vivo,,Rattus norvegicus,10116.0,
9007,1,,BAO_0000218,Intermediate,2106.0,11977,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 30 minutes after an intravenous injection is given (average of 3 rats),A,In vivo,,Rattus norvegicus,10116.0,
9008,1,,BAO_0000218,Intermediate,2106.0,11977,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 60 minutes after an intravenous injection is given (average of 3 rats),A,In vivo,,Rattus norvegicus,10116.0,
9009,1,,BAO_0000218,Intermediate,2046.0,11977,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 120 minutes after an intravenous injection is given (average of 3 rats),A,In vivo,,Rattus norvegicus,10116.0,
9010,1,,BAO_0000218,Intermediate,2046.0,11977,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 2 minutes after an intravenous injection is given (average of 3 rats),A,In vivo,,Rattus norvegicus,10116.0,
9011,1,,BAO_0000218,Intermediate,2046.0,11977,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 30 minutes after an intravenous injection is given (average of 2 rats),A,In vivo,,Rattus norvegicus,10116.0,
9012,1,,BAO_0000218,Intermediate,2046.0,11977,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 30 minutes after an intravenous injection is given (average of 3 rats),A,In vivo,,Rattus norvegicus,10116.0,
9013,1,,BAO_0000218,Intermediate,2046.0,11977,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 60 minutes after an intravenous injection is given (average of 3 rats),A,In vivo,,Rattus norvegicus,10116.0,
9014,1,,BAO_0000218,Intermediate,2107.0,11977,Biodistribution of radioligand [125I]-FIDA1 in liver of rat after 2 minutes after an intravenous injection is given (average of 3 rats),A,In vivo,,Rattus norvegicus,10116.0,
9015,1,,BAO_0000218,Intermediate,,3748,Half life in rats,A,,,Rattus norvegicus,10116.0,
9016,1,,BAO_0000218,Intermediate,,15765,Mean percent inhibition of joint damage reduction in fasted rats at 35 mg/kg administered orally twice daily,A,,,Rattus norvegicus,10116.0,
9017,1,,BAO_0000218,Intermediate,,4871,Compound was evaluated for rate of clearance by using IPRL (Isolated Perfused Rat Liver),A,,,Rattus norvegicus,10116.0,
9018,1,,BAO_0000218,Intermediate,,4871,Compound was evaluated for rate of clearance by using IPRL (Isolated Perfused Rat Liver); ND=Not determined,A,,,Rattus norvegicus,10116.0,
9019,1,,BAO_0000218,Intermediate,,4872,Compound was evaluated for rate of clearance in IPRL (Isolated Perfused Rat Liver),A,,,Rattus norvegicus,10116.0,
9020,1,,BAO_0000218,Intermediate,,4872,Compound was evaluated for rate of clearance in IPRL (Isolated Perfused Rat Liver); ND=Not determined,A,,,Rattus norvegicus,10116.0,
9021,1,,BAO_0000218,Intermediate,,5413,Rate constant (k) of clearance from isolated perfused rat liver (IPRL),A,,,Rattus norvegicus,10116.0,
9022,1,,BAO_0000218,Intermediate,,5413,Tested for rate of clearance from isolated perfused rat liver (IPRL) and expressed in terms of rate constant (k); not determined,A,,,Rattus norvegicus,10116.0,
9023,1,,BAO_0000218,Intermediate,178.0,15272,Maximal blood concentration after oral administration of a 30 uM/kg dose of compound,A,In vivo,,Rattus norvegicus,10116.0,
9024,1,,BAO_0000218,Intermediate,2107.0,4689,Stability (%) in rat liver microsomes,A,,,Rattus norvegicus,10116.0,
9025,1,,BAO_0000218,Intermediate,,6057,Area under curve was calculated after intravenous administration,A,,,Rattus norvegicus,10116.0,
9026,1,,BAO_0000218,Intermediate,,6057,Area under the curve was calculated after iv administration in rat,A,,,Rattus norvegicus,10116.0,
9027,1,,BAO_0000218,Intermediate,,6057,Area under the curve was calculated in rat after peroral administration,A,,,Rattus norvegicus,10116.0,
9028,1,,BAO_0000218,Intermediate,,6211,Dose-normalized AUC was determined by po administration (10 mg/kg) in fasted male Sprague-Dawley rats,A,,,Rattus norvegicus,10116.0,
9029,1,,BAO_0000218,Intermediate,,5710,Dose-normalized AUC measured in fasted male Sprague dawely rats when the compound was administered at a peroral dose of 2 mg/Kg,A,,,Rattus norvegicus,10116.0,
9030,1,,BAO_0000218,Intermediate,,5710,Dose-normalized AUC measured in fasted male Sprague dawely rats when the compound was administered at a peroral of 2 mg/Kg,A,,,Rattus norvegicus,10116.0,
9031,1,,BAO_0000218,Intermediate,,17853,Dose-normalized area under curve in rat (i.v.) at 0.5 mpk,A,,,Rattus norvegicus,10116.0,
9032,1,,BAO_0000218,Intermediate,,17853,Dose-normalized area under curve in rat (p.o.) at 2.0 mpk,A,,,Rattus norvegicus,10116.0,
9033,1,,BAO_0000218,Intermediate,,15765,p value of the compound,A,,,Rattus norvegicus,10116.0,
9034,1,,BAO_0000218,Intermediate,,15765,p value of the compound,F,,,Rattus norvegicus,10116.0,
9035,1,,BAO_0000218,Intermediate,,15765,p value of the compound,A,,,Rattus norvegicus,10116.0,
9036,1,,BAO_0000218,Intermediate,945.0,6175,pH of the gastric juice (Control value = 1.42+/-0.02) of stomach content of pylorus ligated rats was measured (10 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),A,,,Rattus norvegicus,10116.0,
9037,1,,BAO_0000218,Intermediate,945.0,6175,pH of the gastric juice (Control value = 1.42+/-0.02) of stomach content of pylorus ligated rats was measured (20 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),A,,,Rattus norvegicus,10116.0,
9038,1,,BAO_0000218,Intermediate,945.0,6175,pH of the gastric juice (Control value = 1.42+/-0.02) of stomach content of pylorus ligated rats was measured (5 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),A,,,Rattus norvegicus,10116.0,
9039,0,,BAO_0000019,Autocuration,,7991,Negative log of minimum effective dose (moles per kilogram) in rabbits (hypnotic),F,,,Oryctolagus cuniculus,9986.0,
9040,0,,BAO_0000218,Autocuration,,429,Evaluated for pharmacokinetic parameter area under curve in rabbit at the dose 20 mg/kg ( 0-4 hr ),A,,,Oryctolagus cuniculus,9986.0,
9041,0,,BAO_0000218,Autocuration,,429,Evaluated for pharmacokinetic parameter area under curve in rabbit at the dose 20 mg/kg (0-4 hr ),A,,,Oryctolagus cuniculus,9986.0,
9042,0,,BAO_0000218,Autocuration,,6253,Clearance was measured at the concentration of 1.11 mg/kg in rabbit blood sample,A,In vivo,,Oryctolagus cuniculus,9986.0,
9043,0,,BAO_0000218,Autocuration,,6253,Clearance was measured at the concentration of 2.0 mg/kg in rabbit blood sample,A,In vivo,,Oryctolagus cuniculus,9986.0,
9044,0,,BAO_0000218,Autocuration,,3615,Clearance rate in rabbits,A,In vivo,,Oryctolagus cuniculus,9986.0,
9045,0,,BAO_0000218,Autocuration,,4059,Plasma clearance was determined in rabbit at a dose of 5 mg/kg/h administered i.v.,A,In vivo,,Oryctolagus cuniculus,9986.0,
9046,0,,BAO_0000218,Autocuration,,5124,Clearance in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 4.9 mg/kg,A,In vivo,,Oryctolagus cuniculus,9986.0,
9047,0,,BAO_0000218,Autocuration,,5124,Clearance in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 5 mg/kg,A,In vivo,,Oryctolagus cuniculus,9986.0,
9048,0,,BAO_0000218,Autocuration,,5124,Clearance in male New Zealand white rabbits after i.v. administration at 2.0 mg/kg,A,In vivo,,Oryctolagus cuniculus,9986.0,
9049,0,,BAO_0000218,Autocuration,,429,Evaluated for pharmacokinetic parameter Cmax in rabbit at the dose 20 mg/kg,A,In vivo,,Oryctolagus cuniculus,9986.0,
9050,0,,BAO_0000218,Autocuration,1969.0,4059,Maximum plasma concentration was determined in rabbit at a dose of 5 mg/kg/h administered i.v.,A,In vivo,,Oryctolagus cuniculus,9986.0,
9051,0,,BAO_0000251,Autocuration,2107.0,9659,Oxidation by dutch rabbit liver microsomes in presence of NADPH/O2,A,,,Oryctolagus cuniculus,9986.0,
9052,0,,BAO_0000251,Autocuration,2107.0,9659,Oxidation by dutch rabbit liver microsomes in presence of cumene hydroperoxide,A,,,Oryctolagus cuniculus,9986.0,
9053,0,,BAO_0000218,Autocuration,,3639,Dose at which bioavailability of intravenously administered compound was tested in rabbit,A,,,Oryctolagus cuniculus,9986.0,
9054,0,,BAO_0000218,Autocuration,,3639,Dose at which bioavailability of perorally administered compound was tested in rabbit,A,,,Oryctolagus cuniculus,9986.0,
9055,0,,BAO_0000218,Autocuration,,3639,The compound was tested for its bioavailability in rabbit (by oral dosage).,A,In vivo,,Oryctolagus cuniculus,9986.0,
9056,0,,BAO_0000218,Autocuration,,5124,Mean retention time in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 4.9 mg/kg,A,In vivo,,Oryctolagus cuniculus,9986.0,
9057,0,,BAO_0000218,Autocuration,,5124,Mean retention time in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 5 mg/kg,A,In vivo,,Oryctolagus cuniculus,9986.0,
9058,0,,BAO_0000218,Autocuration,,5124,Mean retention time in male New Zealand white rabbits after i.v. administration at 2.0 mg/kg,A,In vivo,,Oryctolagus cuniculus,9986.0,
9059,0,,BAO_0000251,Autocuration,,14294,Metabolism of compound in rabbit S9 microsomes ('+''indicates <20% largest observed peak),A,,,Oryctolagus cuniculus,9986.0,
9060,0,,BAO_0000251,Autocuration,,14294,Metabolism of compound in rabbit S9 microsomes ('++++' indicates largest observed peak),A,,,Oryctolagus cuniculus,9986.0,
9061,0,,BAO_0000218,Autocuration,,429,Evaluated for pharmacokinetic parameter half-life in rabbit at the dose 20 mg/kg,A,In vivo,,Oryctolagus cuniculus,9986.0,
9062,0,,BAO_0000218,Autocuration,1969.0,5124,Plasma half-life in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 4.9 mg/kg,A,In vivo,,Oryctolagus cuniculus,9986.0,
9063,0,,BAO_0000218,Autocuration,1969.0,5124,Plasma half-life in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 5 mg/kg,A,In vivo,,Oryctolagus cuniculus,9986.0,
9064,0,,BAO_0000218,Autocuration,1969.0,5124,Plasma half-life in male New Zealand white rabbits after i.v. administration at 2.0 mg/kg,A,In vivo,,Oryctolagus cuniculus,9986.0,
9065,0,,BAO_0000218,Autocuration,,429,Evaluated for pharmacokinetic parameter tmax in rabbit at the dose 20 mg/kg,A,In vivo,,Oryctolagus cuniculus,9986.0,
9066,0,,BAO_0000218,Autocuration,1088.0,429,Evaluated for pharmacokinetic parameter urine recovery in rabbit at the dose 20 mg/kg ( 0-24 hr ),A,,,Oryctolagus cuniculus,9986.0,
9067,0,,BAO_0000218,Autocuration,1088.0,429,Evaluated for pharmacokinetic parameter urine recovery in rabbit at the dose 20 mg/kg (0-24 hr),A,,,Oryctolagus cuniculus,9986.0,
9068,0,,BAO_0000218,Autocuration,,4059,The compound was evaluated for volume of distribution in rabbit at a dose of 5 mg/kg/h administered i.v.,A,In vivo,,Oryctolagus cuniculus,9986.0,
9069,0,,BAO_0000218,Autocuration,,4137,Volume of distribution after intravenous administration of 1 mg/kg/h in dog,A,In vivo,,Oryctolagus cuniculus,9986.0,
9070,0,,BAO_0000221,Autocuration,,11672,In vitro Biological half-life in crude homogenate of rabbit renal cortex,A,In vitro,,Oryctolagus cuniculus,9986.0,
9071,0,,BAO_0000019,Autocuration,,12886,Time within which only 10% of the drug was degraded,A,,,Oryctolagus cuniculus,9986.0,
9072,0,,BAO_0000221,Autocuration,2107.0,3853,Half life period in rabbit liver homogenate,A,,,Oryctolagus cuniculus,9986.0,
9073,0,,BAO_0000019,Autocuration,,3615,Half life value in rabbits,A,,,Oryctolagus cuniculus,9986.0,
9074,0,,BAO_0000218,Autocuration,178.0,6253,Half-life was measured at the concentration of 1.11 mg/kg in rabbit blood sample,A,In vivo,,Oryctolagus cuniculus,9986.0,
9075,0,,BAO_0000218,Autocuration,178.0,6253,Half-life was measured at the concentration of 2.0 mg/kg in rabbit blood sample,A,In vivo,,Oryctolagus cuniculus,9986.0,
9076,0,,BAO_0000218,Autocuration,,6077,Half-life period in rabbits following intravenous administration at 2 mg/kg,A,In vivo,,Oryctolagus cuniculus,9986.0,
9077,1,,BAO_0000218,Intermediate,1969.0,17617,AUC 0-8 hr value in rats at 10 mg/kg,A,,,Rattus norvegicus,10116.0,
9078,1,,BAO_0000218,Intermediate,1969.0,17594,AUC after administration at 2000 mg/kg/day in rats,A,,,Rattus norvegicus,10116.0,
9079,1,,BAO_0000218,Intermediate,1969.0,6149,AUC of compound for a 2 mpk po dose of the sodium salt in rats.,A,,,Rattus norvegicus,10116.0,
9080,1,,BAO_0000218,Intermediate,1969.0,17260,AUC at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,A,,,Rattus norvegicus,10116.0,
9081,1,,BAO_0000218,Intermediate,1969.0,17260,AUC at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,A,,,Rattus norvegicus,10116.0,
9082,1,,BAO_0000218,Intermediate,1969.0,6644,AUC in rat after oral administration at 10.5 mg/kg dose,A,,,Rattus norvegicus,10116.0,
9083,1,,BAO_0000218,Intermediate,1969.0,6644,AUC in rat after oral administration at 11.2 mg/kg dose,A,,,Rattus norvegicus,10116.0,
9084,1,,BAO_0000218,Intermediate,1969.0,6644,AUC in rat after oral administration at 9.7 mg/kg dose,A,,,Rattus norvegicus,10116.0,
9085,1,,BAO_0000218,Intermediate,955.0,6495,AUC in rat brain after oral administration at 10 mg/kg,A,,,Rattus norvegicus,10116.0,
9086,1,,BAO_0000218,Intermediate,1969.0,6504,AUC in rat p.o.,A,,,Rattus norvegicus,10116.0,
9087,1,,BAO_0000218,Intermediate,1969.0,17686,AUC in rat p.o. at 20 mg/kg concentration,A,,,Rattus norvegicus,10116.0,
9088,1,,BAO_0000218,Intermediate,1969.0,6495,AUC in rat plasma after oral administration at 10 mg/kg,A,,,Rattus norvegicus,10116.0,
9089,1,,BAO_0000218,Intermediate,1969.0,216,AUC in rats,A,,,Rattus norvegicus,10116.0,
9090,1,,BAO_0000218,Intermediate,1969.0,1908,AUC value after IV dose at a dose of 5 mg/kg in rats.,A,,,Rattus norvegicus,10116.0,
9091,1,,BAO_0000218,Intermediate,1969.0,1908,AUC value after oral dose at a dose of 10 mg/kg in rats.,A,,,Rattus norvegicus,10116.0,
9092,1,,BAO_0000218,Intermediate,1969.0,6685,"Maximum plasma concentration in rats at 2 mg/kg, i.v. dose; n/a: not applicable",A,In vivo,,Rattus norvegicus,10116.0,
9093,1,,BAO_0000218,Intermediate,1969.0,216,Maximum plasma concentration in rats when a oral dose of 200 mg/kg was given,A,In vivo,,Rattus norvegicus,10116.0,
9094,1,,BAO_0000218,Intermediate,1969.0,6049,Maximum plasma concentration was evaluated in rat,A,In vivo,,Rattus norvegicus,10116.0,
9095,1,,BAO_0000218,Intermediate,1969.0,2463,Maximum plasma concentration was evaluated in vivo in rat at a dose of 5 mg/kg by oral administration,A,In vivo,,Rattus norvegicus,10116.0,
9096,1,,BAO_0000218,Intermediate,1969.0,6679,Maximum plasma concentration reached by compound was determined after 2 mg/kg (p.o.) administration,A,In vivo,,Rattus norvegicus,10116.0,
9097,1,,BAO_0000218,Intermediate,1969.0,6681,Maximum plasma concentration reached by compound was determined in rats at 50 mg/kg dose,A,In vivo,,Rattus norvegicus,10116.0,
9098,1,,BAO_0000218,Intermediate,1969.0,4890,Maximum plasma concentration was determined after oral administration at a dose 10 mg/kg to male Sprague-Dawley rats,A,In vivo,,Rattus norvegicus,10116.0,
9099,1,,BAO_0000218,Intermediate,1969.0,6410,Maximum plasma concentration was evaluated in rats at an intravenous dose of 3 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,
9100,1,,BAO_0000218,Intermediate,1969.0,6410,Maximum plasma concentration was evaluated in rats at an oral dose of 30 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,
9101,1,,BAO_0000218,Intermediate,1969.0,16366,Maximum plasma concentration was measured when a dose of 1 mg/kg is administered orally,A,In vivo,,Rattus norvegicus,10116.0,
9102,1,,BAO_0000218,Intermediate,1969.0,6227,Maximum plasma concentration (Cmax) in rat (in vivo) at a dose of 10 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,
9103,1,,BAO_0000218,Expert,1969.0,3598,Maximum plasma drug concentration of compound determined in rat after iv administration at a dose of 10 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,
9104,1,,BAO_0000218,Intermediate,1969.0,1465,Maximum plasma drug concentration was determined,A,In vivo,,Rattus norvegicus,10116.0,
9105,1,,BAO_0000218,Intermediate,,4368,Maximum concentration by intravenous administration of 3.4 mg/kg in rat,A,In vivo,,Rattus norvegicus,10116.0,
9106,1,,BAO_0000218,Intermediate,1969.0,15662,Mean peak plasma concentration was observed after intravenous administration in rat,A,In vivo,,Rattus norvegicus,10116.0,
9107,1,,BAO_0000218,Intermediate,1969.0,15662,Mean peak plasma concentration was observed after oral administration in rat,A,In vivo,,Rattus norvegicus,10116.0,
9108,1,,BAO_0000218,Intermediate,,5355,Peak concentration (Cmax) at a dose of 10 mg/kg in rats,A,In vivo,,Rattus norvegicus,10116.0,
9109,1,,BAO_0000218,Intermediate,,5355,Peak concentration (Cmax) at a dose of 20 mg/kg in rats,A,In vivo,,Rattus norvegicus,10116.0,
9110,1,,BAO_0000218,Intermediate,1969.0,1567,Peak oral plasma concentration was determined in rats by oral administration,A,In vivo,,Rattus norvegicus,10116.0,
9111,1,,BAO_0000218,Intermediate,1969.0,4026,Peak plasma concentration (Cmax) was determined,A,In vivo,,Rattus norvegicus,10116.0,
9112,1,,BAO_0000218,Intermediate,1969.0,6193,Peak plasma concentration (Cmax) following an oral dose of 20 mg/kg in rats,A,In vivo,,Rattus norvegicus,10116.0,
9113,1,,BAO_0000218,Intermediate,1969.0,4026,Peak plasma concentration (Cmax) in rats,A,In vivo,,Rattus norvegicus,10116.0,
9114,1,,BAO_0000218,Intermediate,1969.0,6485,Peak plasma concentration at 1 mg/kg peroral administration,A,In vivo,,Rattus norvegicus,10116.0,
9115,1,,BAO_0000218,Intermediate,1969.0,17655,Peak plasma concentration in rat,A,In vivo,,Rattus norvegicus,10116.0,
9116,1,,BAO_0000218,Intermediate,1969.0,14941,"Pharmacokinetic Parameter, Cmax is observed maximum plasma concentration in Female Wistar Rats at 100 mg/kg by po administration",A,In vivo,,Rattus norvegicus,10116.0,
9117,1,,BAO_0000218,Intermediate,,5394,Pharmacokinetic parameter Cmax was measured after administration into rat at 10 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,
9118,1,,BAO_0000218,Intermediate,,4408,Pharmacokinetic property (Cmax) in rat,A,In vivo,,Rattus norvegicus,10116.0,
9119,1,,BAO_0000218,Intermediate,,5983,Pharmacokinetic property (Cmax) was measured in rat at the dose of 0.32 mg/kg p.o.,A,In vivo,,Rattus norvegicus,10116.0,
9120,1,,BAO_0000218,Intermediate,,4878,Cmax in rat after 3mg/kg oral dose,A,In vivo,,Rattus norvegicus,10116.0,
9121,1,,BAO_0000218,Intermediate,,5862,Clearance in Sprague-Dawley rats after 2mg/kg oral dose,A,In vivo,,Rattus norvegicus,10116.0,Sprague-Dawley
9122,1,,BAO_0000218,Intermediate,,4517,Cmax in rats after 20 mg/kg oral dose,A,In vivo,,Rattus norvegicus,10116.0,
9123,1,,BAO_0000218,Intermediate,1969.0,5932,Cmax in rat plasma after 30mg/kg oral dose,A,In vivo,,Rattus norvegicus,10116.0,
9124,1,,BAO_0000218,Intermediate,1969.0,5436,Plasma concentration after oral administration of 100 mg/kg to rats,A,In vivo,,Rattus norvegicus,10116.0,
9125,1,,BAO_0000218,Intermediate,955.0,4910,Tested for concentration in brain after intravenous administration (4.7 mg/kg) to male rats,A,In vivo,,Rattus norvegicus,10116.0,
9126,1,,BAO_0000218,Intermediate,,4950,Tested for the Cmax in rat at 10 mg/kg per orally,A,In vivo,,Rattus norvegicus,10116.0,
9127,1,,BAO_0000218,Intermediate,,15078,"The Cmax value in female wistar rat at 100 mg/kg, p.o. dose",A,In vivo,,Rattus norvegicus,10116.0,
9128,1,,BAO_0000218,Intermediate,,15078,"The Cmax value in male wistar rat at 100 mg/kg, p.o. dose",A,In vivo,,Rattus norvegicus,10116.0,
9129,1,,BAO_0000218,Intermediate,,3360,Bioavailability as oral Cmax in rats at 30 mins,A,In vivo,,Rattus norvegicus,10116.0,
9130,1,,BAO_0000218,Intermediate,,3360,Bioavailability as oral Cmax in rats at 6hr,A,In vivo,,Rattus norvegicus,10116.0,
9131,1,,BAO_0000218,Intermediate,,15022,The maximum concentration of compound was measured at the dose of 100 umol/kg,A,In vivo,,Rattus norvegicus,10116.0,
9132,1,,BAO_0000218,Intermediate,,15022,The maximum concentration of compound was measured at the dose of 300 umol/kg,A,In vivo,,Rattus norvegicus,10116.0,
9133,1,,BAO_0000218,Intermediate,,15022,The maximum concentration of compound was measured at the dose of 30 umol/kg,A,In vivo,,Rattus norvegicus,10116.0,
9134,1,,BAO_0000218,Intermediate,1969.0,5160,The maximum plasma levels for the compounds were determined by LC-MS.,A,In vivo,,Rattus norvegicus,10116.0,
9135,1,,BAO_0000218,Intermediate,1969.0,15662,mean peak plasma concentration was observed after intravenous administration in rat,A,In vivo,,Rattus norvegicus,10116.0,
9136,1,,BAO_0000218,Intermediate,1969.0,15662,mean peak plasma concentration was observed after oral administration in rat,A,In vivo,,Rattus norvegicus,10116.0,
9137,1,,BAO_0000218,Intermediate,,4709,Concentration in the plasma after intravenous administration of 1 mg/kg in rat,A,,,Rattus norvegicus,10116.0,
9138,1,,BAO_0000218,Intermediate,,3535,Concentration in plasma (portal) following oral dose in rats at 0.25 hr,A,,,Rattus norvegicus,10116.0,
9139,1,,BAO_0000218,Intermediate,,3535,Concentration in plasma (portal) following oral dose in rats at 1 hr,A,,,Rattus norvegicus,10116.0,
9140,1,,BAO_0000218,Intermediate,,3535,Concentration in plasma (portal) following oral dose in rats at 2 hr,A,,,Rattus norvegicus,10116.0,
9141,1,,BAO_0000218,Intermediate,,3535,Concentration in plasma (systemic) following oral dose in rats at 0.25 hr,A,,,Rattus norvegicus,10116.0,
9142,1,,BAO_0000218,Intermediate,,3535,Concentration in plasma (systemic) following oral dose in rats at 1 hr,A,,,Rattus norvegicus,10116.0,
9143,1,,BAO_0000218,Intermediate,,3535,Concentration in plasma (systemic) following oral dose in rats at 2 hr,A,,,Rattus norvegicus,10116.0,
9144,0,,BAO_0000218,Intermediate,1969.0,5005,Compound was evaluated for the plasma concentration in rats versus time curves (AUC) in vivo,A,In vivo,,Rattus norvegicus,10116.0,
9145,1,,BAO_0000218,Intermediate,1898.0,6326,"Concentration (30 mg/kg, p.o.) in rat hypothalamus after 2 hours",A,,,Rattus norvegicus,10116.0,
9146,1,,BAO_0000218,Intermediate,1898.0,6326,"Concentration (30 mg/kg, p.o.) in rat hypothalamus after 6 hours",A,,,Rattus norvegicus,10116.0,
9147,1,,BAO_0000218,Intermediate,,6326,"Concentration (30 mg/kg, p.o.) in rat plasma after 2 hours",A,,,Rattus norvegicus,10116.0,
9148,1,,BAO_0000218,Intermediate,,6326,"Concentration (30 mg/kg, p.o.) in rat plasma after 6 hours",A,,,Rattus norvegicus,10116.0,
9149,1,,BAO_0000218,Intermediate,,17411,Kidney concentration was determined after 5 min. of intravenous administration to rats (n=4) at dose of 20 mg/kg,A,,,Rattus norvegicus,10116.0,
9150,1,,BAO_0000218,Intermediate,2113.0,16435,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,A,,,Rattus norvegicus,10116.0,
9151,1,,BAO_0000218,Intermediate,2113.0,16435,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,A,,,Rattus norvegicus,10116.0,
9152,1,,BAO_0000218,Intermediate,2113.0,16435,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,A,,,Rattus norvegicus,10116.0,
9153,1,,BAO_0000218,Intermediate,2113.0,16435,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,A,,,Rattus norvegicus,10116.0,
9154,1,,BAO_0000218,Intermediate,2113.0,16435,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,A,,,Rattus norvegicus,10116.0,
9155,1,,BAO_0000218,Intermediate,2107.0,16434,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,A,,,Rattus norvegicus,10116.0,
9156,1,,BAO_0000218,Intermediate,2107.0,16434,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,A,,,Rattus norvegicus,10116.0,
9157,1,,BAO_0000218,Intermediate,2107.0,16434,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,A,,,Rattus norvegicus,10116.0,
9158,1,,BAO_0000218,Intermediate,2107.0,16434,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,A,,,Rattus norvegicus,10116.0,
9159,1,,BAO_0000218,Intermediate,2107.0,16434,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 120 min.,A,,,Rattus norvegicus,10116.0,
9160,1,,BAO_0000218,Intermediate,2107.0,16434,Radioactivity distribution in liver of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,A,,,Rattus norvegicus,10116.0,
9161,1,,BAO_0000218,Intermediate,2107.0,16434,Radioactivity distribution in liver of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,A,,,Rattus norvegicus,10116.0,
9162,1,,BAO_0000218,Intermediate,2107.0,16434,Radioactivity distribution in liver of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,A,,,Rattus norvegicus,10116.0,
9163,1,,BAO_0000218,Intermediate,2107.0,16435,Radioactivity distribution in liver of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,A,,,Rattus norvegicus,10116.0,
9164,1,,BAO_0000218,Intermediate,2107.0,16435,Radioactivity distribution in liver of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,A,,,Rattus norvegicus,10116.0,
9165,1,,BAO_0000218,Intermediate,2107.0,16435,Radioactivity distribution in liver of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,A,,,Rattus norvegicus,10116.0,
9166,1,,BAO_0000218,Intermediate,2107.0,16435,Radioactivity distribution in liver of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,A,,,Rattus norvegicus,10116.0,
9167,1,,BAO_0000218,Intermediate,2107.0,16435,Radioactivity distribution in liver of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,A,,,Rattus norvegicus,10116.0,
9168,1,,BAO_0000218,Intermediate,2107.0,16435,Radioactivity distribution in liver of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,A,,,Rattus norvegicus,10116.0,
9169,1,,BAO_0000218,Intermediate,2107.0,16435,Radioactivity distribution in liver of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,A,,,Rattus norvegicus,10116.0,
9170,1,,BAO_0000218,Intermediate,2107.0,16435,Radioactivity distribution in liver of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,A,,,Rattus norvegicus,10116.0,
9171,1,,BAO_0000218,Intermediate,2107.0,16434,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,A,,,Rattus norvegicus,10116.0,
9172,1,,BAO_0000218,Intermediate,2107.0,16434,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,A,,,Rattus norvegicus,10116.0,
9173,1,,BAO_0000218,Intermediate,2107.0,16434,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,A,,,Rattus norvegicus,10116.0,
9174,1,,BAO_0000218,Intermediate,2107.0,16435,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,A,,,Rattus norvegicus,10116.0,
9175,1,,BAO_0000218,Intermediate,2107.0,16435,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,A,,,Rattus norvegicus,10116.0,
9176,1,,BAO_0000218,Intermediate,2107.0,16435,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,A,,,Rattus norvegicus,10116.0,
9177,1,,BAO_0000218,Intermediate,2107.0,16435,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,A,,,Rattus norvegicus,10116.0,
9178,1,,BAO_0000218,Intermediate,2107.0,16435,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,A,,,Rattus norvegicus,10116.0,
9179,1,,BAO_0000218,Intermediate,2107.0,16435,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,A,,,Rattus norvegicus,10116.0,
9180,1,,BAO_0000218,Intermediate,2048.0,16434,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,A,,,Rattus norvegicus,10116.0,
9181,1,,BAO_0000218,Intermediate,2048.0,16434,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,A,,,Rattus norvegicus,10116.0,
9182,1,,BAO_0000218,Intermediate,2048.0,16434,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,A,,,Rattus norvegicus,10116.0,
9183,1,,BAO_0000218,Intermediate,2048.0,16434,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,A,,,Rattus norvegicus,10116.0,
9184,1,,BAO_0000218,Intermediate,2048.0,16434,Radioactivity distribution in lung of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,A,,,Rattus norvegicus,10116.0,
9185,1,,BAO_0000218,Intermediate,2048.0,16434,Radioactivity distribution in lung of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,A,,,Rattus norvegicus,10116.0,
9186,1,,BAO_0000218,Intermediate,2048.0,16434,Radioactivity distribution in lung of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,A,,,Rattus norvegicus,10116.0,
9187,1,,BAO_0000218,Intermediate,2048.0,16434,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 60 min.,A,,,Rattus norvegicus,10116.0,
9188,1,,BAO_0000218,Intermediate,2048.0,16435,Radioactivity distribution in lung of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,A,,,Rattus norvegicus,10116.0,
9189,1,,BAO_0000218,Intermediate,2048.0,16435,Radioactivity distribution in lung of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,A,,,Rattus norvegicus,10116.0,
9190,1,,BAO_0000218,Intermediate,2048.0,16435,Radioactivity distribution in lung of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,A,,,Rattus norvegicus,10116.0,
9191,1,,BAO_0000218,Intermediate,2048.0,16435,Radioactivity distribution in lung of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,A,,,Rattus norvegicus,10116.0,
9192,1,,BAO_0000218,Intermediate,2048.0,16435,Radioactivity distribution in lung of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,A,,,Rattus norvegicus,10116.0,
9193,1,,BAO_0000218,Intermediate,2048.0,16435,Radioactivity distribution in lung of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,A,,,Rattus norvegicus,10116.0,
9194,1,,BAO_0000218,Intermediate,2048.0,16434,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 120 min,A,,,Rattus norvegicus,10116.0,
9195,1,,BAO_0000218,Intermediate,945.0,6175,pH of the gastric juice (Control value = 1.44+/-0.01) of stomach content of pylorus ligated rats was measured ( 5 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),A,,,Rattus norvegicus,10116.0,
9196,1,,BAO_0000218,Intermediate,945.0,6175,pH of the gastric juice (Control value = 1.44+/-0.01) of stomach content of pylorus ligated rats was measured (10 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),A,,,Rattus norvegicus,10116.0,
9197,1,,BAO_0000218,Intermediate,945.0,6175,pH of the gastric juice (control value = 1.39+/-0.02) of stomach content of pylorus ligated rats was measured (2.5 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),A,,,Rattus norvegicus,10116.0,
9198,1,,BAO_0000218,Intermediate,945.0,6175,pH of the gastric juice (control value = 1.39+/-0.02) of stomach content of pylorus ligated rats was measured (5 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),A,,,Rattus norvegicus,10116.0,
9199,1,,BAO_0000218,Intermediate,,10839,The compound was tested for the plasma binding in rat,A,,,Rattus norvegicus,10116.0,
9200,1,,BAO_0000218,Intermediate,,16459,"Plasma concentration after intravenous aministration at 1hr, (1 mg/kg, n=3)",A,,,Rattus norvegicus,10116.0,
9201,1,,BAO_0000218,Intermediate,,16459,"Plasma concentration after intravenous aministration at 30 min. (1 mg/kg, n=3)",A,,,Rattus norvegicus,10116.0,
9202,1,,BAO_0000218,Intermediate,,16459,"Plasma concentration after intravenous aministration at 60 min. (1 mg/kg, n=3)",A,,,Rattus norvegicus,10116.0,
9203,1,,BAO_0000218,Intermediate,,16459,Plasma concentration after oral aministration at 1 hr. (10 mg/kg),A,,,Rattus norvegicus,10116.0,
9204,1,,BAO_0000218,Intermediate,,16459,Plasma concentration after oral aministration at 2 hr. (10 mg/kg),A,,,Rattus norvegicus,10116.0,
9205,1,,BAO_0000218,Intermediate,,16459,Plasma concentration after oral aministration at 4 hr. (10 mg/kg),A,,,Rattus norvegicus,10116.0,
9206,1,,BAO_0000218,Intermediate,,3278,Plasma level at 2 hr after administration of the compound,A,,,Rattus norvegicus,10116.0,
9207,1,,BAO_0000218,Intermediate,,3278,plasma level at 2 hr after administration of the compound,A,,,Rattus norvegicus,10116.0,
9208,1,,BAO_0000218,Intermediate,1977.0,4684,Stability in rat serum measured as % recovery at 1 min,A,,,Rattus norvegicus,10116.0,
9209,1,,BAO_0000218,Intermediate,1977.0,4684,Stability in rat serum measured as % recovery at 10 min,A,,,Rattus norvegicus,10116.0,
9210,1,,BAO_0000218,Intermediate,1977.0,4684,Stability in rat serum measured as % recovery at 10 mins,A,,,Rattus norvegicus,10116.0,
9211,1,,BAO_0000218,Intermediate,1977.0,4684,Stability in rat serum measured as % recovery at 2 hr,A,,,Rattus norvegicus,10116.0,
9212,1,,BAO_0000218,Intermediate,1977.0,4684,Stability in rat serum measured as % recovery at 3 min,A,,,Rattus norvegicus,10116.0,
9213,1,,BAO_0000218,Intermediate,1977.0,4684,Stability in rat serum measured as % recovery at 3 mins,A,,,Rattus norvegicus,10116.0,
9214,1,,BAO_0000218,Intermediate,1977.0,4684,Stability in rat serum measured as % recovery at 5 min,A,,,Rattus norvegicus,10116.0,
9215,1,,BAO_0000218,Intermediate,1977.0,4684,Stability in rat serum measured as % recovery at 5 mins,A,,,Rattus norvegicus,10116.0,
9216,1,,BAO_0000218,Intermediate,,16456,Alpha-elimination half-life in Male Sprague-Dawley rats after intravenous administration at a dose of 10 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,
9217,1,,BAO_0000218,Intermediate,,16456,Beta-elimination half-life in Male Sprague-Dawley rats after intravenous administration at a dose of 10 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,
9218,1,,BAO_0000218,Intermediate,1969.0,723,Half life in plasma was determined against ovariectomized rats; t 1/2 (h) is short in plasma,A,,,Rattus norvegicus,10116.0,
9219,1,,BAO_0000218,Intermediate,1969.0,723,Half life in plasma was determined against ovariectomized rats; t1/2 is longer in plasma.,A,,,Rattus norvegicus,10116.0,
9220,1,,BAO_0000218,Intermediate,,5160,Half life tested in mature male rat at a dose of 30 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,
9221,1,,BAO_0000218,Intermediate,,4709,Half life after intravenous administration of 1 mg/kg in rat,A,In vivo,,Rattus norvegicus,10116.0,
9222,1,,BAO_0000218,Intermediate,,5633,Half life period after administration (30 mg/kg) in rat,A,In vivo,,Rattus norvegicus,10116.0,
9223,1,,BAO_0000218,Intermediate,,5302,Half life period in rat after 5 mg/Kg dose,A,In vivo,,Rattus norvegicus,10116.0,
9224,1,,BAO_0000218,Intermediate,,5302,Half life period in rat after 5 mg/kg dose,A,In vivo,,Rattus norvegicus,10116.0,
9225,1,,BAO_0000218,Intermediate,,17791,Half life period was determined,A,,,Rattus norvegicus,10116.0,
9226,1,,BAO_0000218,Intermediate,,17791,Half life period was evaluated in rat,A,,,Rattus norvegicus,10116.0,
9227,1,,BAO_0000218,Intermediate,,17791,Half life period was evaluated in rat; 0.5-1.0,A,,,Rattus norvegicus,10116.0,
9228,1,,BAO_0000218,Intermediate,,17791,Half life period was evaluated in rat; 5.9-7.5,A,,,Rattus norvegicus,10116.0,
9229,1,,BAO_0000218,Intermediate,1969.0,14512,Half-life in rat plasma,A,,,Rattus norvegicus,10116.0,
9230,1,,BAO_0000218,Intermediate,,6230,Half-life time in rat was determined,A,,,Rattus norvegicus,10116.0,
9231,1,,BAO_0000218,Intermediate,,3364,Terminal half-life after iv administration to rats,A,In vivo,,Rattus norvegicus,10116.0,
9232,1,,BAO_0000218,Intermediate,,6874,Tested for iv terminal half-life dosed as a solution in male Han Wistar rats,A,In vivo,,Rattus norvegicus,10116.0,
9233,1,,BAO_0000218,Intermediate,,857,Time required to return to 50% inhibition of pressor response after AI-challenge in normotensive rats at 0.5 umol/kg,A,,,Rattus norvegicus,10116.0,
9234,1,,BAO_0000218,Intermediate,,858,Time required to return to 50% inhibition of pressor response after AI-challenge in normotensive rats at 0.5 umol/kg (iv),A,In vivo,,Rattus norvegicus,10116.0,
9235,1,,BAO_0000218,Intermediate,,858,Time required to return to 50% inhibition of pressor response after AI-challenge in normotensive rats at 5 umol/kg (iv),A,In vivo,,Rattus norvegicus,10116.0,
9236,1,,BAO_0000218,Intermediate,,5355,Time for peak concentration (tmax) at a dose of 10 mg/kg in rats,A,In vivo,,Rattus norvegicus,10116.0,
9237,1,,BAO_0000218,Intermediate,,5355,Time for peak concentration (tmax) at a dose of 20 mg/kg in rats,A,In vivo,,Rattus norvegicus,10116.0,
9238,1,,BAO_0000218,Intermediate,,6305,Half life in rats,A,,,Rattus norvegicus,10116.0,
9239,1,,BAO_0000218,Intermediate,1969.0,13501,Apparent Half life was determined from the linear portion of the log plasma concentration-time profile after oral administration of compound 18 at a dose of 4 mg/kg to rat,A,In vivo,,Rattus norvegicus,10116.0,
9240,1,,BAO_0000218,Intermediate,,17594,Apparent half-life after single intravenous bolus of 1 mg/kg in rats,A,In vivo,,Rattus norvegicus,10116.0,
9241,1,,BAO_0000218,Intermediate,1969.0,4186,Apparent terminal elimination half-life in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,A,In vivo,,Rattus norvegicus,10116.0,
9242,1,,BAO_0000218,Intermediate,1969.0,2932,Biological half-life was measured in plasma of rats,A,,,Rattus norvegicus,10116.0,
9243,1,,BAO_0000218,Intermediate,,17065,Circulatory half life measured after intravenous bolus administration of 50 mg/kg of compound to rats,A,In vivo,,Rattus norvegicus,10116.0,
9244,1,,BAO_0000218,Intermediate,,15765,Compound demonstarted an oral bioavailability of 6% with the half-life time as given in rats.,A,In vivo,,Rattus norvegicus,10116.0,
9245,1,,BAO_0000218,Intermediate,,2713,Compound was evaluated for half life (t1/2) upon intravenous administration of 1 mg/Kg in rats,A,In vivo,,Rattus norvegicus,10116.0,
9246,1,,BAO_0000218,Intermediate,,2661,Compound was evaluated for half life after treatment with iv dose of 1 mgkg to female wistar rats,A,In vivo,,Rattus norvegicus,10116.0,
9247,1,,BAO_0000218,Intermediate,,2661,Compound was evaluated for half life after treatment with iv dose of 1 mgkg to male wistar rats,A,In vivo,,Rattus norvegicus,10116.0,
9248,1,,BAO_0000218,Intermediate,1969.0,740,Compound was evaluated for plasma half life in rat,A,,,Rattus norvegicus,10116.0,
9249,1,,BAO_0000218,Intermediate,1969.0,6597,AUC value at a dose of 5 mg/kg (p.o.) in rats,A,,,Rattus norvegicus,10116.0,
9250,1,,BAO_0000218,Intermediate,1969.0,2959,AUC value after administration of 20 mg/Kg oral dose in rat,A,,,Rattus norvegicus,10116.0,
9251,1,,BAO_0000218,Intermediate,1969.0,17594,AUC0-24 after repeated oral dose of compound at 1 mg/kg in rats,A,,,Rattus norvegicus,10116.0,
9252,1,,BAO_0000218,Intermediate,1969.0,17596,AUC0-96 after administration at 50 mg/kg,A,,,Rattus norvegicus,10116.0,
9253,1,,BAO_0000218,Intermediate,1969.0,17594,AUC0-infinity after single intravenous bolus of 1 mg/kg in rats,A,,,Rattus norvegicus,10116.0,
9254,1,,BAO_0000218,Intermediate,,3293,"Absorption behavior was judged by the area under the curve, determined after oral dose of 30 mg/kg in rats.",A,,,Rattus norvegicus,10116.0,
9255,1,,BAO_0000218,Intermediate,,6757,Area under curve (0-24 hr) at a dose of 10 mg/kg in male SD rats,A,,,Rattus norvegicus,10116.0,
9256,1,,BAO_0000218,Intermediate,,6757,Area under curve (0-24 hr) at a dose of 100 mg/kg in male SD rats,A,,,Rattus norvegicus,10116.0,
9257,1,,BAO_0000218,Intermediate,,6757,Area under curve (0-24 hr) at a dose of 50 mg/kg in male SD rats,A,,,Rattus norvegicus,10116.0,
9258,1,,BAO_0000218,Intermediate,2113.0,5979,Area under curve (AUC) at a dose 1 mg/kg was determined in rat kidney,A,,,Rattus norvegicus,10116.0,
9259,1,,BAO_0000218,Intermediate,,5979,Area under curve (AUC) at a dose 1 mg/kg was determined in rat liver,A,,,Rattus norvegicus,10116.0,
9260,1,,BAO_0000218,Intermediate,,5979,Area under curve (AUC) at a dose 1 mg/kg was determined in rat lung,A,,,Rattus norvegicus,10116.0,
9261,1,,BAO_0000218,Intermediate,,4026,Area under curve (AUC) at a dose of 30 mg/kg in rats,A,,,Rattus norvegicus,10116.0,
9262,1,,BAO_0000218,Intermediate,,5355,Area under curve (AUC) was calculated using trapezoidal rule at a dose of 20 mg/kg in rats,A,,,Rattus norvegicus,10116.0,
9263,1,,BAO_0000218,Intermediate,,5355,Area under curve (AUC) was calculated using trapezoidal rule. at a dose of 10 mg/kg in rats,A,,,Rattus norvegicus,10116.0,
9264,1,,BAO_0000218,Intermediate,,5355,Area under curve (AUC) was calculated using trapezoidal rule at a dose of 20 mg/kg in rats,A,,,Rattus norvegicus,10116.0,
9265,1,,BAO_0000218,Intermediate,,5633,Area under curve (AUC0-24 h) after administration (30 mg/kg) in rat,A,,,Rattus norvegicus,10116.0,
9266,1,,BAO_0000218,Intermediate,,1716,Area under curve (Pharmacokinetic property) was determined,A,,,Rattus norvegicus,10116.0,
9267,1,,BAO_0000218,Intermediate,,1716,Area under curve (Pharmacokinetic property) of the compound; Not determined,A,,,Rattus norvegicus,10116.0,
9268,1,,BAO_0000218,Intermediate,,4689,Area under curve after intravenous administration (1 mg/kg) in rat,A,,,Rattus norvegicus,10116.0,
9269,1,,BAO_0000218,Intermediate,,4527,Area under curve by intravenous administration at a dose of 10 uM/kg in rat was determined,A,,,Rattus norvegicus,10116.0,
9270,1,,BAO_0000218,Intermediate,,4527,Area under curve by oral administration at a dose of 100 uM/kg in rat was determined,A,,,Rattus norvegicus,10116.0,
9271,1,,BAO_0000218,Intermediate,,15662,Area under curve in male SD rats was observed after oral administration in rat,A,,,Rattus norvegicus,10116.0,
9272,1,,BAO_0000218,Intermediate,,4413,Area under curve of compound after iv administration of 20 mg/kg dose in rat,A,,,Rattus norvegicus,10116.0,
9273,1,,BAO_0000218,Expert,,3598,Area under curve of compound determined in rat after iv administration at a dose of 10 mg/kg,A,,,Rattus norvegicus,10116.0,
9274,1,,BAO_0000218,Expert,,3598,Area under curve of compound from zero time to infinity determined in rat after iv administration at a dose of 10 mg/kg,A,,,Rattus norvegicus,10116.0,
9275,1,,BAO_0000218,Intermediate,,5964,Area under curve at 5 mg/kg po was determined in rat,A,,,Rattus norvegicus,10116.0,
9276,1,,BAO_0000218,Intermediate,,4689,Area under curve in Rat at a oral dose of 5 mg/kg,A,,,Rattus norvegicus,10116.0,
9277,1,,BAO_0000218,Intermediate,,4186,Area under curve in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,A,,,Rattus norvegicus,10116.0,
9278,1,,BAO_0000218,Intermediate,,5510,Area under curve was determined,A,,,Rattus norvegicus,10116.0,
9279,1,,BAO_0000218,Intermediate,,17858,Area under curve after 10 mg/kg oral administration in rat at 0-24 hr,A,,,Rattus norvegicus,10116.0,
9280,1,,BAO_0000218,Intermediate,,17804,Area under curve after intravenous administration at 3 mg/kg,A,,,Rattus norvegicus,10116.0,
9281,1,,BAO_0000218,Intermediate,,6106,Area under curve after peroral administration at 10 mg/kg in rat for 0-6 h,A,,,Rattus norvegicus,10116.0,
9282,1,,BAO_0000218,Intermediate,,5964,Area under curve at 4 hr in rat,A,,,Rattus norvegicus,10116.0,
9283,1,,BAO_0000218,Intermediate,,4026,Area under curve at a dose of 30 mg/kg,A,,,Rattus norvegicus,10116.0,
9284,1,,BAO_0000218,Intermediate,,4756,Area under curve at the dose of 2 mg/Kg administered perorally in rats,A,,,Rattus norvegicus,10116.0,
9285,1,,BAO_0000218,Intermediate,,4756,Area under curve at the dose of 5 mg/Kg administered perorally in rats,A,,,Rattus norvegicus,10116.0,
9286,1,,BAO_0000218,Intermediate,,5862,Area under curve for a 2-mpk po dose in SD rats,A,,,Rattus norvegicus,10116.0,
9287,1,,BAO_0000218,Intermediate,,5862,Area under curve in SD rats,A,,,Rattus norvegicus,10116.0,
9288,1,,BAO_0000218,Intermediate,,6644,Area under curve in rat after oral administration at 13 mg/kg dose,A,,,Rattus norvegicus,10116.0,
9289,1,,BAO_0000218,Intermediate,,5871,Area under curve in rat by po administration at 0-24 hr,A,,,Rattus norvegicus,10116.0,
9290,1,,BAO_0000218,Intermediate,1969.0,5919,Area under curve in rat plasma,A,,,Rattus norvegicus,10116.0,
9291,1,,BAO_0000218,Intermediate,,5939,Area under curve in rat plasma for 0-4 hr after peroral administration at 10 mg/kg,A,,,Rattus norvegicus,10116.0,
9292,1,,BAO_0000218,Intermediate,,5939,Area under curve in rat plasma for 0-4 hr after peroral administration at 5 mg/kg,A,,,Rattus norvegicus,10116.0,
9293,1,,BAO_0000218,Intermediate,,10,Area under curve was evaluated in rat at 3 mg/kg dose administered intravenously,A,,,Rattus norvegicus,10116.0,
9294,1,,BAO_0000218,Intermediate,,11149,Area under curve was measured from the graph obtained from concentration Vs time after oral administration to male F344 rats,A,,,Rattus norvegicus,10116.0,
9295,1,,BAO_0000218,Intermediate,,5302,Area under curve value in rat at a dose of 5 mg/kg,A,,,Rattus norvegicus,10116.0,
9296,1,,BAO_0000218,Intermediate,,17796,Area under curve was determined after oral administration in rats,A,,,Rattus norvegicus,10116.0,
9297,1,,BAO_0000218,Intermediate,,4890,Area under curve was determined after oral administration at a dose 10 mg/kg to male Sprague-Dawley rats,A,,,Rattus norvegicus,10116.0,
9298,1,,BAO_0000218,Intermediate,,6011,Area under curve was determined after peroral administration in rat,A,,,Rattus norvegicus,10116.0,
9299,1,,BAO_0000218,Intermediate,,5375,Area under curve was determined at a dose 30 mpk administered orally.,A,,,Rattus norvegicus,10116.0,
9300,1,,BAO_0000218,Intermediate,,17764,Area under curve was determined for compound after intravenous administration in rats at 24 uM/kg,A,,,Rattus norvegicus,10116.0,
9301,1,,BAO_0000218,Intermediate,,4368,Area under curve was determined for the compound by intravenous administration of 3.4 mg/kg in rat,A,,,Rattus norvegicus,10116.0,
9302,1,,BAO_0000218,Intermediate,,5610,Area under curve was determined in male rat,A,,,Rattus norvegicus,10116.0,
9303,1,,BAO_0000218,Intermediate,,5833,Area under curve was determined in rat after PO administration,A,,,Rattus norvegicus,10116.0,
9304,1,,BAO_0000218,Intermediate,,4257,Area under curve was determined in rat after a 3 mg/kg of oral dose,A,,,Rattus norvegicus,10116.0,
9305,1,,BAO_0000218,Intermediate,,5937,Area under curve was determined in rat after oral administration at a concentration 1 mg/kg,A,,,Rattus norvegicus,10116.0,
9306,1,,BAO_0000218,Intermediate,,5932,Area under curve was determined in rat after oral administration at a concentration 30 mg/kg,A,,,Rattus norvegicus,10116.0,
9307,1,,BAO_0000218,Intermediate,,5932,Area under curve was determined in rat after oral administration at a concentration 30 mg/kg; NA= Not active,A,,,Rattus norvegicus,10116.0,
9308,1,,BAO_0000218,Intermediate,,17411,Liver concentration was determined after 5 min. of intravenous administration to rats (n=4) at dose of 20 mg/kg,A,,,Rattus norvegicus,10116.0,
9309,1,,BAO_0000218,Intermediate,,17411,Lung concentration was determined after 5 min. of intravenous administration to rats (n=4) at dose of 20 mg/kg,A,,,Rattus norvegicus,10116.0,
9310,1,,BAO_0000218,Intermediate,1969.0,17771,Peak plasma concentration in rat at a dose of 3 mg/kg,A,,,Rattus norvegicus,10116.0,
9311,1,,BAO_0000218,Intermediate,,1628,Plasma concentration at 2 hr in rats was evaluated.,A,,,Rattus norvegicus,10116.0,
9312,1,,BAO_0000218,Intermediate,,1628,Plasma concentration at 2 hr in rats was evaluated; Not available,A,,,Rattus norvegicus,10116.0,
9313,1,,BAO_0000218,Intermediate,,17411,Serum concentration was determined after 5 min. of intravenous administration to rats (n=4) at dose of 20 mg/kg,A,,,Rattus norvegicus,10116.0,
9314,1,,BAO_0000218,Intermediate,,4910,Tested for concentration in brain after 0.25 hrs of intravenous administration (5 mg/kg) to male rats,A,,,Rattus norvegicus,10116.0,
9315,1,,BAO_0000218,Intermediate,,4910,Tested for concentration in brain after 2 hrs of intravenous administration (5 mg/kg) to male rats,A,,,Rattus norvegicus,10116.0,
9316,1,,BAO_0000218,Intermediate,1969.0,4910,Tested for plasma concentration after 0.25 hrs of intravenous administration (5 mg/kg) to male rats,A,,,Rattus norvegicus,10116.0,
9317,1,,BAO_0000218,Intermediate,1969.0,4910,Tested for plasma concentration after 2 hrs of intravenous administration (5 mg/kg) to male rats,A,,,Rattus norvegicus,10116.0,
9318,1,,BAO_0000218,Intermediate,1969.0,4910,Tested for plasma concentration in the after 0.25 hrs of intravenous administration (5 mg/kg) to male rats,A,,,Rattus norvegicus,10116.0,
9319,1,,BAO_0000218,Intermediate,1969.0,4910,Tested for plasma concentration in the after 2 hrs of intravenous administration (5 mg/kg) to male rats,A,,,Rattus norvegicus,10116.0,
9320,1,,BAO_0000218,Intermediate,,5510,Percentage converted to BMS-191011 after 30 min incubation in rat plasma at 37 degree C,A,,,Rattus norvegicus,10116.0,
9321,1,,BAO_0000218,Intermediate,,5510,Percentage converted to BMS-191011 after 30 min incubation in rat plasma at 37 degree C; Converted to an unknown compound,A,,,Rattus norvegicus,10116.0,
9322,1,,BAO_0000218,Intermediate,,5510,Percentage converted to BMS-191011 after 30 min incubation in rat plasma at 37 degree C; Not determined,A,,,Rattus norvegicus,10116.0,
9323,1,,BAO_0000218,Intermediate,,5510,Percentage converted to BMS-191011 after 30 min incubation in rat plasma at 37 degree C; Not tested,A,,,Rattus norvegicus,10116.0,
9324,1,,BAO_0000218,Intermediate,,16427,PK study was carried to determine the relative absorption ranking in rat.,A,,,Rattus norvegicus,10116.0,
9325,1,,BAO_0000218,Intermediate,1969.0,4689,Maximum plasma concentration in Rat at a oral dose of 5 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,
9326,1,,BAO_0000218,Intermediate,178.0,11450,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.57-0.75 % dose/g",A,,,Rattus norvegicus,10116.0,
9327,1,,BAO_0000218,Intermediate,178.0,11450,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.06-0.63 % dose/g",A,,,Rattus norvegicus,10116.0,
9328,1,,BAO_0000218,Intermediate,178.0,11450,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.40-0.55 % dose/g",A,,,Rattus norvegicus,10116.0,
9329,1,,BAO_0000218,Intermediate,178.0,11450,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.28-0.37% dose/g",A,,,Rattus norvegicus,10116.0,
9330,1,,BAO_0000218,Intermediate,178.0,11450,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.56-0.74 % dose/g",A,,,Rattus norvegicus,10116.0,
9331,1,,BAO_0000218,Intermediate,178.0,11450,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from % dose/g",A,,,Rattus norvegicus,10116.0,
9332,1,,BAO_0000218,Intermediate,955.0,11450,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 2.20-2.85 % dose/g",A,,,Rattus norvegicus,10116.0,
9333,1,,BAO_0000218,Intermediate,955.0,11450,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.16-1.76 % dose/g",A,,,Rattus norvegicus,10116.0,
9334,1,,BAO_0000218,Intermediate,955.0,11450,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.96-3.72 % dose/g",A,,,Rattus norvegicus,10116.0,
9335,1,,BAO_0000218,Intermediate,955.0,11450,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 2.57-3.59 % dose/g",A,,,Rattus norvegicus,10116.0,
9336,1,,BAO_0000218,Intermediate,955.0,11450,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.36-1.53 % dose/g",A,,,Rattus norvegicus,10116.0,
9337,1,,BAO_0000218,Intermediate,955.0,11450,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.81-1.08 % dose/g",A,,,Rattus norvegicus,10116.0,
9338,1,,BAO_0000218,Intermediate,948.0,11450,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.84-0.98 % dose/g",A,,,Rattus norvegicus,10116.0,
9339,1,,BAO_0000218,Intermediate,948.0,11450,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.06-0.53 % dose/g",A,,,Rattus norvegicus,10116.0,
9340,1,,BAO_0000218,Intermediate,948.0,11450,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.22-1.48 % dose/g",A,,,Rattus norvegicus,10116.0,
9341,1,,BAO_0000218,Intermediate,948.0,11450,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.85-1.13 % dose/g",A,,,Rattus norvegicus,10116.0,
9342,1,,BAO_0000218,Intermediate,948.0,11450,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.55-0.63 % dose/g",A,,,Rattus norvegicus,10116.0,
9343,1,,BAO_0000218,Intermediate,948.0,11450,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.33-0.42 % dose/g",A,,,Rattus norvegicus,10116.0,
9344,1,,BAO_0000218,Intermediate,2048.0,16434,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 5 min,A,,,Rattus norvegicus,10116.0,
9345,1,,BAO_0000218,Intermediate,2048.0,16434,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,A,,,Rattus norvegicus,10116.0,
9346,1,,BAO_0000218,Intermediate,2048.0,16435,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,A,,,Rattus norvegicus,10116.0,
9347,1,,BAO_0000218,Intermediate,2048.0,16435,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,A,,,Rattus norvegicus,10116.0,
9348,1,,BAO_0000218,Intermediate,2048.0,16435,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,A,,,Rattus norvegicus,10116.0,
9349,1,,BAO_0000218,Intermediate,2048.0,16435,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,A,,,Rattus norvegicus,10116.0,
9350,1,,BAO_0000218,Intermediate,2048.0,16435,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,A,,,Rattus norvegicus,10116.0,
9351,1,,BAO_0000218,Intermediate,2048.0,16435,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,A,,,Rattus norvegicus,10116.0,
9352,1,,BAO_0000218,Intermediate,2048.0,16435,Radioactivity distribution in lungs of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,A,,,Rattus norvegicus,10116.0,
9353,1,,BAO_0000218,Intermediate,2048.0,16435,Radioactivity distribution in lungs of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,A,,,Rattus norvegicus,10116.0,
9354,1,,BAO_0000218,Intermediate,2385.0,16434,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,A,,,Rattus norvegicus,10116.0,
9355,1,,BAO_0000218,Intermediate,2385.0,16434,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,A,,,Rattus norvegicus,10116.0,
9356,1,,BAO_0000218,Intermediate,2385.0,16434,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,A,,,Rattus norvegicus,10116.0,
9357,1,,BAO_0000218,Intermediate,2385.0,16434,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,A,,,Rattus norvegicus,10116.0,
9358,1,,BAO_0000218,Intermediate,2385.0,16434,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,A,,,Rattus norvegicus,10116.0,
9359,1,,BAO_0000218,Intermediate,2385.0,16434,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,A,,,Rattus norvegicus,10116.0,
9360,1,,BAO_0000218,Intermediate,2385.0,16434,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 5 min.,A,,,Rattus norvegicus,10116.0,
9361,1,,BAO_0000218,Intermediate,2385.0,16434,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 60 min.,A,,,Rattus norvegicus,10116.0,
9362,1,,BAO_0000218,Intermediate,2385.0,16435,Radioactivity distribution in muscle of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,A,,,Rattus norvegicus,10116.0,
9363,1,,BAO_0000218,Intermediate,2385.0,16435,Radioactivity distribution in muscle of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,A,,,Rattus norvegicus,10116.0,
9364,1,,BAO_0000218,Intermediate,2385.0,16435,Radioactivity distribution in muscle of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,A,,,Rattus norvegicus,10116.0,
9365,1,,BAO_0000218,Intermediate,2385.0,16435,Radioactivity distribution in muscle of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,A,,,Rattus norvegicus,10116.0,
9366,1,,BAO_0000218,Intermediate,2385.0,16435,Radioactivity distribution in muscle of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,A,,,Rattus norvegicus,10116.0,
9367,1,,BAO_0000218,Intermediate,2385.0,16435,Radioactivity distribution in muscle of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,A,,,Rattus norvegicus,10116.0,
9368,1,,BAO_0000218,Intermediate,2385.0,16435,Radioactivity distribution in muscle of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,A,,,Rattus norvegicus,10116.0,
9369,1,,BAO_0000218,Intermediate,2385.0,16435,Radioactivity distribution in muscle of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,A,,,Rattus norvegicus,10116.0,
9370,1,,BAO_0000218,Intermediate,2385.0,16434,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,A,,,Rattus norvegicus,10116.0,
9371,1,,BAO_0000218,Intermediate,2385.0,16434,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 5 min,A,,,Rattus norvegicus,10116.0,
9372,1,,BAO_0000218,Intermediate,2385.0,16434,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,A,,,Rattus norvegicus,10116.0,
9373,1,,BAO_0000218,Intermediate,2385.0,16435,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,A,,,Rattus norvegicus,10116.0,
9374,1,,BAO_0000218,Intermediate,2385.0,16435,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,A,,,Rattus norvegicus,10116.0,
9375,1,,BAO_0000218,Intermediate,2385.0,16435,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,A,,,Rattus norvegicus,10116.0,
9376,1,,BAO_0000218,Intermediate,2385.0,16435,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,A,,,Rattus norvegicus,10116.0,
9377,1,,BAO_0000218,Intermediate,2385.0,16435,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,A,,,Rattus norvegicus,10116.0,
9378,1,,BAO_0000218,Intermediate,2385.0,16435,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,A,,,Rattus norvegicus,10116.0,
9379,1,,BAO_0000218,Intermediate,,16434,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,A,,,Rattus norvegicus,10116.0,
9380,1,,BAO_0000218,Intermediate,,16434,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,A,,,Rattus norvegicus,10116.0,
9381,1,,BAO_0000218,Intermediate,,16434,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,A,,,Rattus norvegicus,10116.0,
9382,1,,BAO_0000218,Intermediate,,16434,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,A,,,Rattus norvegicus,10116.0,
9383,1,,BAO_0000218,Intermediate,,16434,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,A,,,Rattus norvegicus,10116.0,
9384,1,,BAO_0000218,Intermediate,,16434,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,A,,,Rattus norvegicus,10116.0,
9385,1,,BAO_0000218,Intermediate,,16434,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,A,,,Rattus norvegicus,10116.0,
9386,1,,BAO_0000218,Intermediate,,16434,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,A,,,Rattus norvegicus,10116.0,
9387,1,,BAO_0000218,Intermediate,,16435,Radioactivity distribution in pancreas of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,A,,,Rattus norvegicus,10116.0,
9388,1,,BAO_0000218,Intermediate,,16435,Radioactivity distribution in pancreas of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,A,,,Rattus norvegicus,10116.0,
9389,1,,BAO_0000218,Intermediate,,3341,Compound was evaluated for terminal half life in rat,A,,,Rattus norvegicus,10116.0,
9390,1,,BAO_0000218,Intermediate,1969.0,3634,Compound was evaluated in vivo in rat for the plasma half-life at a iv dose of 3 mg/kg and oral dose of 10 mg/kg and experiment by using concentration vs time curve,A,In vivo,,Rattus norvegicus,10116.0,
9391,1,,BAO_0000218,Intermediate,1969.0,3634,Compound was evaluated in vivo in rat for the plasma half-life at a oral dose of 20 mg/kg experiment by using concentration vs time curve,A,In vivo,,Rattus norvegicus,10116.0,
9392,1,,BAO_0000218,Intermediate,,4839,Compound was tested for its half life in rat,A,,,Rattus norvegicus,10116.0,
9393,0,,BAO_0000218,Intermediate,1969.0,5005,Compound was tested for its plasma half life in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po; ND is not determined.,A,In vivo,,Macaca mulatta,9544.0,
9394,0,,BAO_0000366,Intermediate,1969.0,5005,Compound was tested for its plasma half life in Sprague Dawley rats,A,,,Rattus norvegicus,10116.0,
9395,0,,BAO_0000366,Intermediate,1969.0,5005,Compound was tested for its plasma half life in Sprague Dawley rats; ND is not determined,A,,,Rattus norvegicus,10116.0,
9396,1,,BAO_0000218,Intermediate,1969.0,1094,Compound was tested for plasma half-life period in rat,A,,,Rattus norvegicus,10116.0,
9397,1,,BAO_0000218,Intermediate,,5031,Elimination half life after i.v. administration of compound in rats,A,In vivo,,Rattus norvegicus,10116.0,
9398,1,,BAO_0000218,Intermediate,,6518,Elimination half-life after IV dosing at 0.5 mg/kg in rat,A,In vivo,,Rattus norvegicus,10116.0,
9399,1,,BAO_0000218,Intermediate,,6518,Elimination half-life after IV dosing at 1 mg/kg in rat,A,In vivo,,Rattus norvegicus,10116.0,
9400,1,,BAO_0000218,Intermediate,,6518,Elimination half-life after oral administration at a dose of 2 mg/kg in rat,A,In vivo,,Rattus norvegicus,10116.0,
9401,1,,BAO_0000218,Intermediate,,6518,Elimination half-life after oral administration at a dose of 4 mg/kg in rat,A,In vivo,,Rattus norvegicus,10116.0,
9402,1,,BAO_0000218,Intermediate,955.0,5408,Evaluated for half-life after iv administration of 1 mg/kg to male Sprague-Dawley rats in brain; not determined,A,In vivo,,Rattus norvegicus,10116.0,
9403,1,,BAO_0000218,Intermediate,1969.0,5408,Evaluated for half-life after iv administration of 1 mg/kg to male Sprague-Dawley rats in plasma,A,In vivo,,Rattus norvegicus,10116.0,
9404,1,,BAO_0000218,Intermediate,955.0,5408,Evaluated for half-life after iv administration of 5 mg/kg to male Sprague-Dawley rats in brain,A,In vivo,,Rattus norvegicus,10116.0,
9405,1,,BAO_0000218,Intermediate,1969.0,5408,Evaluated for half-life after iv administration of 5 mg/kg to male Sprague-Dawley rats in plasma,A,In vivo,,Rattus norvegicus,10116.0,
9406,1,,BAO_0000218,Intermediate,,4687,Evaluated for the half life in rat (in vivo),A,In vivo,,Rattus norvegicus,10116.0,
9407,1,,BAO_0000218,Intermediate,,6640,Hafl life in rat,A,,,Rattus norvegicus,10116.0,
9408,1,,BAO_0000218,Intermediate,,6640,Hafl life rat,A,,,Rattus norvegicus,10116.0,
9409,1,,BAO_0000218,Intermediate,,6641,Hafl life rat,A,,,Rattus norvegicus,10116.0,
9410,1,,BAO_0000218,Intermediate,,6640,Hafl life rat; Not determined,A,,,Rattus norvegicus,10116.0,
9411,1,,BAO_0000218,Intermediate,,6641,Hafl life rat; Not determined,A,,,Rattus norvegicus,10116.0,
9412,1,,BAO_0000218,Intermediate,2113.0,17411,Half life in kidney was determined after intravenous administration to rats (n=4) at dose of 20 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,
9413,1,,BAO_0000218,Intermediate,2107.0,17411,Half life in liver was determined after intravenous administration to rats (n=4) at dose of 20 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,
9414,1,,BAO_0000218,Intermediate,2048.0,17411,Half life in lung was determined after intravenous administration to rats (n=4) at dose of 20 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,
9415,1,,BAO_0000218,Intermediate,,6570,Half life in rat after 1 mg/kg i.v. administration,A,In vivo,,Rattus norvegicus,10116.0,
9416,1,,BAO_0000218,Intermediate,,6570,Half life in rat after 2 mg/kg peroral administration,A,In vivo,,Rattus norvegicus,10116.0,
9417,1,,BAO_0000218,Intermediate,,17411,Half life in serum was determined after intravenous administration to rats (n=4) at dose of 20 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,
9418,1,,BAO_0000218,Intermediate,,4722,Half life of 10 mg/kg oral dose determined in rats,A,In vivo,,Rattus norvegicus,10116.0,
9419,1,,BAO_0000218,Intermediate,,5978,Half life of compound (10 mg/kg) after iv administration was determined in Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0,
9420,1,,BAO_0000218,Intermediate,,5978,Half life of compound (19.2 mg/kg) after po administration was determined in Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0,
9421,1,,BAO_0000218,Intermediate,,5978,Half life of compound (20.73 mg/kg) after po administration was determined in Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0,
9422,1,,BAO_0000218,Intermediate,,5978,Half life of compound (25 mg/kg) after po administration was determined in Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0,
9423,1,,BAO_0000218,Intermediate,,5978,Half life of compound (9.83 mg/kg) after iv administration was determined in Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0,
9424,1,,BAO_0000218,Intermediate,,5978,Half life of compound (9.84 mg/kg) after iv administration was determined in Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0,
9425,1,,BAO_0000218,Intermediate,,5978,Half life of compound (9.84 mg/kg) after po administration was determined in Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0,
9426,1,,BAO_0000218,Intermediate,,5978,Half life of compound (9.92 mg/kg) after iv administration was determined in Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0,
9427,1,,BAO_0000218,Intermediate,,4762,Half life of compound at 5 mg/kg after po administration was determined in rat,A,In vivo,,Rattus norvegicus,10116.0,
9428,1,,BAO_0000218,Intermediate,,5327,Half life of compound determined after intravenous administration to rat,A,In vivo,,Rattus norvegicus,10116.0,
9429,1,,BAO_0000218,Intermediate,,4847,Half life of compound was determined in rat,A,,,Rattus norvegicus,10116.0,
9430,1,,BAO_0000218,Intermediate,1969.0,17720,Half life at a dose of 4 mg/kg in Rat Plasma after iv administration,A,In vivo,,Rattus norvegicus,10116.0,
9431,1,,BAO_0000218,Intermediate,,4723,Half life determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,A,In vivo,,Rattus norvegicus,10116.0,
9432,1,,BAO_0000218,Intermediate,,4723,Half life determined after 3 mg/kg oral administration in potassium oxonate treated rats,A,In vivo,,Rattus norvegicus,10116.0,
9433,0,,BAO_0000218,Intermediate,,4256,Half life determined after intravenous administration at a dose of 3 mg/kg in cynomolgus monkey,A,In vivo,,Macaca fascicularis,9541.0,
9434,0,,BAO_0000218,Intermediate,,4256,Half life determined in rat by intravenous administration,A,In vivo,,Rattus norvegicus,10116.0,
9435,1,,BAO_0000218,Intermediate,,4722,Half life determined in rats after iv administration,A,In vivo,,Rattus norvegicus,10116.0,
9436,1,,BAO_0000218,Intermediate,1969.0,6535,Half life in rat plasma after administration of 2 mg/kg iv,A,In vivo,,Rattus norvegicus,10116.0,
9437,1,,BAO_0000218,Intermediate,1969.0,6535,Half life in rat plasma after administration of 2 mg/kg iv,A,In vivo,,Rattus norvegicus,10116.0,
9438,1,,BAO_0000218,Intermediate,1969.0,1435,Half life in rat plasma was determined,A,,,Rattus norvegicus,10116.0,
9439,1,,BAO_0000218,Intermediate,1969.0,1435,Half life in rat plasma was determined; NA means not applicable,A,,,Rattus norvegicus,10116.0,
9440,1,,BAO_0000218,Intermediate,,5206,Half life in rat was tested,A,,,Rattus norvegicus,10116.0,
9441,1,,BAO_0000218,Intermediate,1969.0,6080,Half life measured in rat plasma,A,,,Rattus norvegicus,10116.0,
9442,1,,BAO_0000218,Intermediate,,4449,Half life recorded in rats,A,,,Rattus norvegicus,10116.0,
9443,1,,BAO_0000218,Intermediate,,6057,Half life was calculated,A,,,Rattus norvegicus,10116.0,
9444,1,,BAO_0000218,Intermediate,,6057,Half life was calculated in rat,A,,,Rattus norvegicus,10116.0,
9445,1,,BAO_0000218,Intermediate,,3747,Half life was determined,A,,,Rattus norvegicus,10116.0,
9446,1,,BAO_0000218,Intermediate,,17858,Half life after 10 mg/kg oral administration in rat,A,In vivo,,Rattus norvegicus,10116.0,
9447,1,,BAO_0000218,Intermediate,,16365,Half life after administering orally a dose of 10 mg/kg to a fasting rat,A,In vivo,,Rattus norvegicus,10116.0,
9448,1,,BAO_0000218,Intermediate,,16365,Half life after administering orally a dose of 30 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,
9449,1,,BAO_0000218,Intermediate,,5031,Area under the curve (Concentration) was determined for the compound as AUC with limits 0-8 after i.v. administration in rats,A,,,Rattus norvegicus,10116.0,
9450,1,,BAO_0000218,Intermediate,,4722,Area under the curve determined under pharmacokinetic behavior of the 10 mg/kg oral dose of compound for 0-6 hours,A,,,Rattus norvegicus,10116.0,
9451,1,,BAO_0000218,Intermediate,,6078,Area under the curve for the compound calculated from 0-24 hr after intravenous administration at a dose of 10 mg/kg in rat,A,,,Rattus norvegicus,10116.0,
9452,1,,BAO_0000218,Intermediate,,6078,Area under the curve for the compound calculated from 0-24 hr after oral administration at a dose of 10 mg/kg in rat,A,,,Rattus norvegicus,10116.0,
9453,1,,BAO_0000218,Intermediate,,6078,Area under the curve for the compound calculated from 0-6 hr after oral administration at a dose of 10 mg/kg,A,,,Rattus norvegicus,10116.0,
9454,1,,BAO_0000218,Intermediate,,6078,Area under the curve for the compound calculated from 0-6 hr after oral administration at a dose of 10 mg/kg; activity was not determined,A,,,Rattus norvegicus,10116.0,
9455,1,,BAO_0000218,Intermediate,,17065,Area under the curve measured after intravenous bolus administration of 50 mg/kg of compound to rats,A,,,Rattus norvegicus,10116.0,
9456,1,,BAO_0000218,Intermediate,,1353,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats,A,,,Rattus norvegicus,10116.0,
9457,1,,BAO_0000218,Intermediate,,1353,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats(0-1),A,,,Rattus norvegicus,10116.0,
9458,1,,BAO_0000218,Intermediate,,1353,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats(0-2),A,,,Rattus norvegicus,10116.0,
9459,1,,BAO_0000218,Intermediate,,1353,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats(0-5),A,,,Rattus norvegicus,10116.0,
9460,1,,BAO_0000218,Intermediate,,1353,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats(5-10),A,,,Rattus norvegicus,10116.0,
9461,1,,BAO_0000218,Intermediate,,16423,Area under the curve was evaluated after 10 uM/kg of intra arterial administration,A,,,Rattus norvegicus,10116.0,
9462,1,,BAO_0000218,Intermediate,,16423,Area under the curve was evaluated after 20 uM/kg of peroral administration,A,,,Rattus norvegicus,10116.0,
9463,1,,BAO_0000218,Intermediate,,6062,Area under the curve was measured in rat after an iv dose of 1 mg/kg,A,,,Rattus norvegicus,10116.0,
9464,1,,BAO_0000218,Intermediate,,6056,Area under the curve was calculated for the compound at a single intravenous administration of 20 mg/kg in rat,A,,,Rattus norvegicus,10116.0,
9465,1,,BAO_0000218,Intermediate,,5182,Area under the curve was determined by administering the compound at a dose of 1 mg/kg intravenously in male wistar rat,A,,,Rattus norvegicus,10116.0,
9466,1,,BAO_0000218,Intermediate,,6410,Area under the curve was evaluated at an intravenous dose of 3 mg/kg,A,,,Rattus norvegicus,10116.0,
9467,1,,BAO_0000218,Intermediate,,6410,Area under the curve was evaluated at an oral dose of 30 mg/kg,A,,,Rattus norvegicus,10116.0,
9468,1,,BAO_0000218,Intermediate,,4723,Area under the effect time curves from time 0-24 hr determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,A,,,Rattus norvegicus,10116.0,
9469,1,,BAO_0000218,Intermediate,,4723,Area under the effect time curves from time 0-24 hr determined after 3 mg/kg oral administration in potassium oxonate treated rats,A,,,Rattus norvegicus,10116.0,
9470,1,,BAO_0000218,Intermediate,,4723,Area under the effect time curves from time 0-6 hr determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,A,,,Rattus norvegicus,10116.0,
9471,1,,BAO_0000218,Intermediate,,4723,Area under the effect time curves from time 0-6 hr determined after 3 mg/kg oral administration in potassium oxonate treated rats,A,,,Rattus norvegicus,10116.0,
9472,1,,BAO_0000218,Intermediate,,4723,Area under the effect time curves from time 0-infinity hr determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,A,,,Rattus norvegicus,10116.0,
9473,1,,BAO_0000218,Intermediate,,4723,Area under the effect time curves from time 0-infinity hr determined after 3 mg/kg oral administration in potassium oxonate treated rats,A,,,Rattus norvegicus,10116.0,
9474,1,,BAO_0000218,Intermediate,1969.0,2463,Area under the plasma concentration curve was evaluated in vivo in rat at a dose of 5 mg/kg by oral administration,A,,,Rattus norvegicus,10116.0,
9475,1,,BAO_0000218,Intermediate,,4709,Bioavailability from area under the curve at time 0 to infinity after intravenous administration of 1 mg/kg in rat,A,,,Rattus norvegicus,10116.0,
9476,1,,BAO_0000218,Intermediate,,4075,Blood level after a 10 mg/kg oral dose in rat expressed as AUC was determined,A,,,Rattus norvegicus,10116.0,
9477,1,,BAO_0000218,Intermediate,,5394,Compound at a dose 10 mg/kg was administered orally to rat and the pharmacokinetic parameter area under curve (AUC) was measured,A,,,Rattus norvegicus,10116.0,
9478,1,,BAO_0000218,Intermediate,,2661,Compound was evaluated for AUC after treatment with iv dose of 1 mgkg to female wistar rats,A,,,Rattus norvegicus,10116.0,
9479,1,,BAO_0000218,Intermediate,,2661,Compound was evaluated for AUC after treatment with iv dose of 1 mgkg to male wistar rats,A,,,Rattus norvegicus,10116.0,
9480,1,,BAO_0000218,Intermediate,,2661,Compound was evaluated for AUC after treatment with oral dose of 2 mgkg to female wistar rats,A,,,Rattus norvegicus,10116.0,
9481,1,,BAO_0000218,Intermediate,,2661,Compound was evaluated for AUC after treatment with oral dose of 2 mgkg to male wistar rats,A,,,Rattus norvegicus,10116.0,
9482,1,,BAO_0000218,Intermediate,,17791,Compound was evaluated for area under the curve expressed as (h*ug/ml),A,,,Rattus norvegicus,10116.0,
9483,1,,BAO_0000218,Intermediate,,2591,Compound was tested for area under curve in rat,A,,,Rattus norvegicus,10116.0,
9484,1,,BAO_0000218,Intermediate,,6567,Concentration in rat plasma after 5 mg/kg oral gavage for 8 hours,A,,,Rattus norvegicus,10116.0,
9485,1,,BAO_0000218,Intermediate,,6211,Dose-normalized AUC was determined by po administration (10 mg/kg) in fasted male Sprague-Dawley rats,A,,,Rattus norvegicus,10116.0,
9486,1,,BAO_0000218,Intermediate,,5529,Dose-normalized AUC was determined in rat after peroral administration (2 mg/kg),A,,,Rattus norvegicus,10116.0,
9487,1,,BAO_0000218,Intermediate,,5408,Evaluated for AUC after iv administration of 1 mg/kg to male Sprague-Dawley rats in brain; not determined,A,,,Rattus norvegicus,10116.0,
9488,1,,BAO_0000218,Intermediate,,5408,Evaluated for AUC after iv administration of 1 mg/kg to male Sprague-Dawley rats in plasma,A,,,Rattus norvegicus,10116.0,
9489,1,,BAO_0000218,Intermediate,,5408,Evaluated for AUC after iv administration of 5 mg/kg to male Sprague-Dawley rats in brain,A,,,Rattus norvegicus,10116.0,
9490,1,,BAO_0000218,Intermediate,,5408,Evaluated for AUC after iv administration of 5 mg/kg to male Sprague-Dawley rats in plasma,A,,,Rattus norvegicus,10116.0,
9491,1,,BAO_0000218,Intermediate,,429,Evaluated for pharmacokinetic parameter area under curve in rat at the dose 50 mg/kg ( 0-8 hr ),A,,,Rattus norvegicus,10116.0,
9492,1,,BAO_0000218,Intermediate,,429,Evaluated for pharmacokinetic parameter area under curve in rat at the dose 50 mg/kg (0-8 hr ),A,,,Rattus norvegicus,10116.0,
9493,1,,BAO_0000218,Intermediate,,429,Evaluated for pharmacokinetic parameter area under curve in rat at the dose 50 mg/kg (0-8 hr),A,,,Rattus norvegicus,10116.0,
9494,1,,BAO_0000218,Intermediate,,4796,Hepatic portal AUC was determined by pharmacokinetic study conducted in portal vein cannulated rats,A,,,Rattus norvegicus,10116.0,
9495,1,,BAO_0000218,Intermediate,,5974,In vivo Area under curve (AUC) was determined after intravenous administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,A,,,Rattus norvegicus,10116.0,
9496,1,,BAO_0000218,Intermediate,,5974,In vivo Area under curve (AUC) was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,A,,,Rattus norvegicus,10116.0,
9497,1,,BAO_0000218,Intermediate,,5974,In vivo Area under curve (AUC) was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,A,,,Rattus norvegicus,10116.0,
9498,1,,BAO_0000218,Intermediate,2113.0,11450,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.98-2.56 % dose/g",A,,,Rattus norvegicus,10116.0,
9499,1,,BAO_0000218,Intermediate,2113.0,11450,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.15-1.43 % dose/g",A,,,Rattus norvegicus,10116.0,
9500,1,,BAO_0000218,Intermediate,2113.0,11450,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 3.43-4.52 % dose/g",A,,,Rattus norvegicus,10116.0,
9501,1,,BAO_0000218,Intermediate,2113.0,11450,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 2.12-3.14 % dose/g",A,,,Rattus norvegicus,10116.0,
9502,1,,BAO_0000218,Intermediate,2113.0,11450,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.40-1.60 % dose/g",A,,,Rattus norvegicus,10116.0,
9503,1,,BAO_0000218,Intermediate,2113.0,11450,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.74-0.85 % dose/g",A,,,Rattus norvegicus,10116.0,
9504,1,,BAO_0000218,Intermediate,2107.0,11450,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.31-1.45 % dose/g",A,,,Rattus norvegicus,10116.0,
9505,1,,BAO_0000218,Intermediate,2107.0,11450,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.08-0.90 % dose/g",A,,,Rattus norvegicus,10116.0,
9506,1,,BAO_0000218,Intermediate,2107.0,11450,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 2.02-2.78 % dose/g",A,,,Rattus norvegicus,10116.0,
9507,1,,BAO_0000218,Intermediate,2107.0,11450,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 1.64-2.38 % dose/g",A,,,Rattus norvegicus,10116.0,
9508,1,,BAO_0000218,Intermediate,2107.0,11450,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.95-1.07 % dose/g",A,,,Rattus norvegicus,10116.0,
9509,1,,BAO_0000218,Intermediate,2107.0,11450,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.61-0.81 % dose/g",A,,,Rattus norvegicus,10116.0,
9510,1,,BAO_0000218,Intermediate,2048.0,11450,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 5.01-7.13 % dose/g",A,,,Rattus norvegicus,10116.0,
9511,1,,BAO_0000218,Intermediate,2048.0,11450,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.51-3.71 % dose/g",A,,,Rattus norvegicus,10116.0,
9512,1,,BAO_0000218,Intermediate,2048.0,11450,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 10.84-13.77 % dose/g",A,,,Rattus norvegicus,10116.0,
9513,1,,BAO_0000218,Intermediate,2048.0,11450,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 5.92-8.51% dose/g",A,,,Rattus norvegicus,10116.0,
9514,1,,BAO_0000218,Intermediate,2048.0,11450,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 3.37-3.94 % dose/g",A,,,Rattus norvegicus,10116.0,
9515,1,,BAO_0000218,Intermediate,2048.0,11450,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 1.87-2.12 % dose/g",A,,,Rattus norvegicus,10116.0,
9516,1,,BAO_0000218,Intermediate,2046.0,11450,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 37.97-75.23 % dose/g",A,,,Rattus norvegicus,10116.0,
9517,1,,BAO_0000218,Intermediate,2046.0,11450,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 5.03-36.88 % dose/g",A,,,Rattus norvegicus,10116.0,
9518,1,,BAO_0000218,Intermediate,2046.0,11450,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 13.20-17.31 % dose/g",A,,,Rattus norvegicus,10116.0,
9519,1,,BAO_0000218,Intermediate,2046.0,11450,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 7.87-16.51 % dose/g",A,,,Rattus norvegicus,10116.0,
9520,1,,BAO_0000218,Intermediate,2046.0,11450,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 81.37-166.09 % dose/g",A,,,Rattus norvegicus,10116.0,
9521,1,,BAO_0000218,Intermediate,2046.0,11450,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 31.90-39.98 % dose/g",A,,,Rattus norvegicus,10116.0,
9522,1,,BAO_0000218,Intermediate,2046.0,11450,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.41-0.83 % dose/g",A,,,Rattus norvegicus,10116.0,
9523,1,,BAO_0000218,Intermediate,2046.0,11450,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.05-0.38 % dose/g",A,,,Rattus norvegicus,10116.0,
9524,1,,BAO_0000218,Intermediate,2046.0,11450,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.16-0.20 % dose/g",A,,,Rattus norvegicus,10116.0,
9525,1,,BAO_0000218,Intermediate,2046.0,11450,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.08-0.17 % dose/g",A,,,Rattus norvegicus,10116.0,
9526,1,,BAO_0000218,Intermediate,,16435,Radioactivity distribution in pancreas of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,A,,,Rattus norvegicus,10116.0,
9527,1,,BAO_0000218,Intermediate,,16435,Radioactivity distribution in pancreas of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,A,,,Rattus norvegicus,10116.0,
9528,1,,BAO_0000218,Intermediate,,16435,Radioactivity distribution in pancreas of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,A,,,Rattus norvegicus,10116.0,
9529,1,,BAO_0000218,Intermediate,,16435,Radioactivity distribution in pancreas of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,A,,,Rattus norvegicus,10116.0,
9530,1,,BAO_0000218,Intermediate,,16435,Radioactivity distribution in pancreas of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,A,,,Rattus norvegicus,10116.0,
9531,1,,BAO_0000218,Intermediate,,16435,Radioactivity distribution in pancreas of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,A,,,Rattus norvegicus,10116.0,
9532,1,,BAO_0000218,Intermediate,,16434,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,A,,,Rattus norvegicus,10116.0,
9533,1,,BAO_0000218,Intermediate,,16434,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 5 min,A,,,Rattus norvegicus,10116.0,
9534,1,,BAO_0000218,Intermediate,,16434,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 60 min,A,,,Rattus norvegicus,10116.0,
9535,1,,BAO_0000218,Intermediate,,16435,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,A,,,Rattus norvegicus,10116.0,
9536,1,,BAO_0000218,Intermediate,,16435,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,A,,,Rattus norvegicus,10116.0,
9537,1,,BAO_0000218,Intermediate,,16435,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,A,,,Rattus norvegicus,10116.0,
9538,1,,BAO_0000218,Intermediate,,16435,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,A,,,Rattus norvegicus,10116.0,
9539,1,,BAO_0000218,Intermediate,,16435,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,A,,,Rattus norvegicus,10116.0,
9540,1,,BAO_0000218,Intermediate,,16435,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,A,,,Rattus norvegicus,10116.0,
9541,1,,BAO_0000218,Intermediate,2106.0,16434,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,A,,,Rattus norvegicus,10116.0,
9542,1,,BAO_0000218,Intermediate,2106.0,16434,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,A,,,Rattus norvegicus,10116.0,
9543,1,,BAO_0000218,Intermediate,2106.0,16434,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,A,,,Rattus norvegicus,10116.0,
9544,1,,BAO_0000218,Intermediate,2106.0,16434,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,A,,,Rattus norvegicus,10116.0,
9545,1,,BAO_0000218,Intermediate,2106.0,16434,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,A,,,Rattus norvegicus,10116.0,
9546,1,,BAO_0000218,Intermediate,2106.0,16434,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,A,,,Rattus norvegicus,10116.0,
9547,1,,BAO_0000218,Intermediate,2106.0,16434,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,A,,,Rattus norvegicus,10116.0,
9548,1,,BAO_0000218,Intermediate,2106.0,16434,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,A,,,Rattus norvegicus,10116.0,
9549,1,,BAO_0000218,Intermediate,2106.0,16435,Radioactivity distribution in spleen of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,A,,,Rattus norvegicus,10116.0,
9550,1,,BAO_0000218,Intermediate,2106.0,16435,Radioactivity distribution in spleen of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,A,,,Rattus norvegicus,10116.0,
9551,1,,BAO_0000218,Intermediate,2106.0,16435,Radioactivity distribution in spleen of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,A,,,Rattus norvegicus,10116.0,
9552,1,,BAO_0000218,Intermediate,2106.0,16435,Radioactivity distribution in spleen of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,A,,,Rattus norvegicus,10116.0,
9553,1,,BAO_0000218,Intermediate,2106.0,16435,Radioactivity distribution in spleen of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,A,,,Rattus norvegicus,10116.0,
9554,1,,BAO_0000218,Intermediate,2106.0,16435,Radioactivity distribution in spleen of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,A,,,Rattus norvegicus,10116.0,
9555,1,,BAO_0000218,Intermediate,2106.0,16435,Radioactivity distribution in spleen of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,A,,,Rattus norvegicus,10116.0,
9556,1,,BAO_0000218,Intermediate,2106.0,16435,Radioactivity distribution in spleen of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,A,,,Rattus norvegicus,10116.0,
9557,1,,BAO_0000218,Intermediate,2106.0,16434,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,A,,,Rattus norvegicus,10116.0,
9558,1,,BAO_0000218,Intermediate,2106.0,16434,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,A,,,Rattus norvegicus,10116.0,
9559,1,,BAO_0000218,Intermediate,2106.0,16434,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,A,,,Rattus norvegicus,10116.0,
9560,1,,BAO_0000218,Intermediate,2106.0,16435,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,A,,,Rattus norvegicus,10116.0,
9561,1,,BAO_0000218,Intermediate,2106.0,16435,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,A,,,Rattus norvegicus,10116.0,
9562,1,,BAO_0000218,Intermediate,2106.0,16435,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,A,,,Rattus norvegicus,10116.0,
9563,1,,BAO_0000218,Intermediate,2106.0,16435,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,A,,,Rattus norvegicus,10116.0,
9564,1,,BAO_0000218,Intermediate,2106.0,16435,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,A,,,Rattus norvegicus,10116.0,
9565,1,,BAO_0000218,Intermediate,2106.0,16435,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,A,,,Rattus norvegicus,10116.0,
9566,1,,BAO_0000218,Intermediate,,16434,Radioactivity distribution in testis of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,A,,,Rattus norvegicus,10116.0,
9567,1,,BAO_0000218,Intermediate,,16434,Radioactivity distribution in testis of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,A,,,Rattus norvegicus,10116.0,
9568,1,,BAO_0000218,Intermediate,,16434,Radioactivity distribution in testis of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,A,,,Rattus norvegicus,10116.0,
9569,1,,BAO_0000218,Intermediate,,16434,Radioactivity distribution in testis of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,A,,,Rattus norvegicus,10116.0,
9570,1,,BAO_0000218,Intermediate,,16434,Radioactivity distribution in testis of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,A,,,Rattus norvegicus,10116.0,
9571,1,,BAO_0000218,Intermediate,,16365,Half life after administering orally a dose of 3 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,
9572,1,,BAO_0000218,Intermediate,,16365,Half life after administering orally a dose of 3 mg/kg to a fasting rat,A,In vivo,,Rattus norvegicus,10116.0,
9573,1,,BAO_0000218,Intermediate,,16365,Half life after administering intravenously a dose of 1 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,
9574,1,,BAO_0000218,Intermediate,,526,Half life after oral dosing in rats,A,In vivo,,Rattus norvegicus,10116.0,
9575,1,,BAO_0000218,Intermediate,,16365,Half life after the administered orally a dose of 1 mg/kg to a fasting rat,A,In vivo,,Rattus norvegicus,10116.0,
9576,1,,BAO_0000218,Intermediate,,4368,Half life by intravenous administration of 3.4 mg/kg in rat,A,In vivo,,Rattus norvegicus,10116.0,
9577,1,,BAO_0000218,Intermediate,,3371,Half life in rat,A,,,Rattus norvegicus,10116.0,
9578,1,,BAO_0000218,Intermediate,,6448,Half life in rat,A,,,Rattus norvegicus,10116.0,
9579,1,,BAO_0000218,Intermediate,,6453,Half life in rat,A,,,Rattus norvegicus,10116.0,
9580,1,,BAO_0000218,Intermediate,,4353,Half life in rat after intravenous administration of the compound,A,In vivo,,Rattus norvegicus,10116.0,
9581,1,,BAO_0000218,Intermediate,1969.0,4353,Half life in rat after intravenous administration of the compound; nf:unable to estimate plasma elimination half life,A,In vivo,,Rattus norvegicus,10116.0,
9582,1,,BAO_0000218,Intermediate,,4353,Half life in rat after po administration of the compound,A,In vivo,,Rattus norvegicus,10116.0,
9583,1,,BAO_0000218,Intermediate,,4353,Half life in rat after po administration of the compound; ND means Not determined,A,In vivo,,Rattus norvegicus,10116.0,
9584,1,,BAO_0000218,Intermediate,1969.0,4353,Half life in rat after po administration of the compound; nf: unable to estimate plasma elimination half life,A,In vivo,,Rattus norvegicus,10116.0,
9585,1,,BAO_0000218,Intermediate,1969.0,4353,Half life in rat after po administration of the compound; nf:unable to estimate plasma elimination half life,A,In vivo,,Rattus norvegicus,10116.0,
9586,1,,BAO_0000218,Intermediate,,5789,Half life in rat i.v.,A,In vivo,,Rattus norvegicus,10116.0,
9587,1,,BAO_0000218,Intermediate,,17686,Half life in rat i.v. at 2 mg/kg concentration,A,In vivo,,Rattus norvegicus,10116.0,
9588,1,,BAO_0000218,Intermediate,,6495,Half life in rats,A,,,Rattus norvegicus,10116.0,
9589,1,,BAO_0000218,Intermediate,,484,Half life in rats after intravenous administration,A,In vivo,,Rattus norvegicus,10116.0,
9590,1,,BAO_0000218,Intermediate,,6467,Half life in rats at the dose of 1.0 mpk by i.v. administration,A,In vivo,,Rattus norvegicus,10116.0,
9591,1,,BAO_0000218,Expert,,6642,Half life in rat,A,,,Rattus norvegicus,10116.0,
9592,1,,BAO_0000218,Intermediate,,16367,Half life was evaluated after intravenous administration to rats,A,In vivo,,Rattus norvegicus,10116.0,
9593,1,,BAO_0000218,Intermediate,,1369,Half life was evaluated by addition of 2 mM of 2-mercaptoethanol for inactivation of semicarbazide-sensitive amine oxidase (SSAO),A,,,Rattus norvegicus,10116.0,
9594,1,,BAO_0000218,Intermediate,,5472,Half life was evaluated in rat,A,,,Rattus norvegicus,10116.0,
9595,1,,BAO_0000218,Intermediate,,6049,Half life was evaluated in rat,A,,,Rattus norvegicus,10116.0,
9596,1,,BAO_0000218,Intermediate,,5472,Half life was evaluated in rat; Not tested,A,,,Rattus norvegicus,10116.0,
9597,1,,BAO_0000218,Intermediate,,16366,Half life was evaluated when a dose of 1 mg/kg was administered intravenously to rats,A,In vivo,,Rattus norvegicus,10116.0,
9598,1,,BAO_0000218,Intermediate,,11149,Half life was measured as time taken to reach the half of the initial dose in air pouch exudate after oral administration to male F344 rats,A,In vivo,,Rattus norvegicus,10116.0,
9599,1,,BAO_0000218,Intermediate,178.0,11149,Half life was measured as time taken to reach the half of the initial dose in the blood after oral administration to male F344 rats,A,In vivo,,Rattus norvegicus,10116.0,
9600,0,,BAO_0000218,Intermediate,,2891,Half life was measured in monkey at dose of 10 mg/kg by po administration,A,In vivo,,Primates,9443.0,
9601,0,,BAO_0000218,Intermediate,,2891,Half life was measured in monkey at dose of 10 mg/kg by po administration,A,In vivo,,Primates,9443.0,
9602,0,,BAO_0000218,Intermediate,,2891,Half life was measured in rat at dose of 30 mg/kg by iv administration,A,In vivo,,Rattus norvegicus,10116.0,
9603,0,,BAO_0000218,Intermediate,,2891,Half life was measured in rat at dose of 30 mg/kg by po administration,A,In vivo,,Rattus norvegicus,10116.0,
9604,1,,BAO_0000218,Intermediate,,4026,Half life (t1/2) was determined,A,,,Rattus norvegicus,10116.0,
9605,1,,BAO_0000218,Intermediate,,4527,Half life period at a dose of 10 uM/kg in rat was determined,A,,,Rattus norvegicus,10116.0,
9606,1,,BAO_0000218,Intermediate,,4527,Half life period by oral administration at a dose of 100 uM/kg in rat was determined; ND is not determined,A,In vivo,,Rattus norvegicus,10116.0,
9607,1,,BAO_0000218,Intermediate,,5503,Half life period was determined,A,,,Rattus norvegicus,10116.0,
9608,1,,BAO_0000218,Intermediate,,4426,Half life period after intravenous administration at 20 mpk in rats,A,In vivo,,Rattus norvegicus,10116.0,
9609,1,,BAO_0000218,Intermediate,,4426,Half life period after intravenous administration at 20 mpk in rats; Not performed.,A,In vivo,,Rattus norvegicus,10116.0,
9610,1,,BAO_0000218,Intermediate,,6109,Half life period after intravenous administration in rat,A,In vivo,,Rattus norvegicus,10116.0,
9611,1,,BAO_0000218,Intermediate,,5654,Half life period as average of four rats at each dose of 5 mg/kg intravenous and 16 mg/kg peroral administration,A,In vivo,,Rattus norvegicus,10116.0,
9612,1,,BAO_0000218,Intermediate,,5654,Half life period as average of four rats at each dose of 5 mg/kg intravenous and 20 mg/kg peroral administration,A,In vivo,,Rattus norvegicus,10116.0,
9613,1,,BAO_0000218,Intermediate,1969.0,4755,Half life period in 80% rat plasma at 37 degree Centigrade,A,,,Rattus norvegicus,10116.0,
9614,1,,BAO_0000218,Intermediate,,5862,Half life period in SD rats,A,,,Rattus norvegicus,10116.0,
9615,1,,BAO_0000218,Intermediate,1969.0,1515,Half life period in human plasma at 25 degree Celsius temperature (pH 7.4),A,,,Rattus norvegicus,10116.0,
9616,1,,BAO_0000218,Intermediate,1969.0,1515,Half life period in human plasma at 37 degree Celsius temperature (pH 7.4),A,,,Rattus norvegicus,10116.0,
9617,1,,BAO_0000218,Intermediate,1969.0,1515,Half life period in human plasma at 37 degree Celsius temperature (pH 7.4); ND means no data,A,,,Rattus norvegicus,10116.0,
9618,1,,BAO_0000218,Intermediate,1969.0,1515,Half life period in human plasma at 37 degree Celsius temperature (pH 7.4); ND means no data,A,,,Rattus norvegicus,10116.0,
9619,1,,BAO_0000218,Intermediate,,5960,Half life period in rat,A,,,Rattus norvegicus,10116.0,
9620,1,,BAO_0000218,Intermediate,,6103,Half life period in rat,A,,,Rattus norvegicus,10116.0,
9621,1,,BAO_0000218,Intermediate,,6317,Half life period in rat,A,,,Rattus norvegicus,10116.0,
9622,1,,BAO_0000218,Intermediate,,6644,Half life period in rat after oral administration at 10.5 mg/kg dose,A,In vivo,,Rattus norvegicus,10116.0,
9623,1,,BAO_0000218,Intermediate,,6644,Half life period in rat after oral administration at 11.2 mg/kg dose,A,In vivo,,Rattus norvegicus,10116.0,
9624,1,,BAO_0000218,Intermediate,,6644,Half life period in rat after oral administration at 13 mg/kg dose,A,In vivo,,Rattus norvegicus,10116.0,
9625,1,,BAO_0000218,Intermediate,,6644,Half life period in rat after oral administration at 9.7 mg/kg dose,A,In vivo,,Rattus norvegicus,10116.0,
9626,1,,BAO_0000218,Intermediate,,5974,In vivo Area under curve (AUC) was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,A,,,Rattus norvegicus,10116.0,
9627,1,,BAO_0000218,Intermediate,,6295,In vivo area under curve in rat plasma exposure after oral administration 50 mg/kg,A,,,Rattus norvegicus,10116.0,
9628,1,,BAO_0000218,Intermediate,,6296,In vivo area under curve in rat plasma exposure after oral administration 50 mg/kg,A,,,Rattus norvegicus,10116.0,
9629,1,,BAO_0000218,Intermediate,,16427,PK study was carried to determine AUC (area under curve) value in rat,A,,,Rattus norvegicus,10116.0,
9630,1,,BAO_0000218,Intermediate,,16367,Pharmacokinetic parameter AUC after intravenous administration to rats,A,,,Rattus norvegicus,10116.0,
9631,1,,BAO_0000218,Intermediate,,16367,Pharmacokinetic parameter AUC after oral administration to rats,A,,,Rattus norvegicus,10116.0,
9632,1,,BAO_0000218,Intermediate,,16365,Pharmacokinetic parameter AUC was evaluated intravenous administration of 3 mg/kg,A,,,Rattus norvegicus,10116.0,
9633,1,,BAO_0000218,Intermediate,,16365,Pharmacokinetic parameter AUC was evaluated when a dose of 10 mg/kg is administered orally to a fasting rat,A,,,Rattus norvegicus,10116.0,
9634,1,,BAO_0000218,Intermediate,,16365,Pharmacokinetic parameter AUC was evaluated when a dose of 1 mg/kg is administered orally to a fasting rat,A,,,Rattus norvegicus,10116.0,
9635,1,,BAO_0000218,Intermediate,,16365,Pharmacokinetic parameter AUC was evaluated when a dose of 30 mg/kg is administered orally,A,,,Rattus norvegicus,10116.0,
9636,1,,BAO_0000218,Intermediate,,16365,Pharmacokinetic parameter AUC was evaluated when a dose of 3 mg/kg is administered orally,A,,,Rattus norvegicus,10116.0,
9637,1,,BAO_0000218,Intermediate,,16365,Pharmacokinetic parameter AUC was evaluated when a dose of 3 mg/kg is administered orally to a fasting rat,A,,,Rattus norvegicus,10116.0,
9638,1,,BAO_0000218,Intermediate,,5394,Pharmacokinetic parameter area under curve (AUC) was measured after administration into monkey at 3 mg/kg,A,,,Rattus norvegicus,10116.0,
9639,1,,BAO_0000218,Intermediate,,5394,Pharmacokinetic parameter area under curve (AUC) was measured after administration into rat at 10 mg/kg,A,,,Rattus norvegicus,10116.0,
9640,1,,BAO_0000218,Intermediate,,2792,Pharmacokinetic parameter area under curve was determined at 10 mg/kg po dose in rats,A,,,Rattus norvegicus,10116.0,
9641,1,,BAO_0000218,Intermediate,,2792,Pharmacokinetic parameter area under curve was determined at 2 mg/kg i.v. dose in rats,A,,,Rattus norvegicus,10116.0,
9642,1,,BAO_0000218,Intermediate,,2792,Pharmacokinetic parameter area under curve was determined at 3 mg/kg po dose in rats,A,,,Rattus norvegicus,10116.0,
9643,1,,BAO_0000218,Intermediate,,2792,Pharmacokinetic parameter area under curve was determined at 5 mg/kg i.v. dose in rats,A,,,Rattus norvegicus,10116.0,
9644,1,,BAO_0000218,Intermediate,,5334,Pharmacokinetic parameter area under curve was reported,A,,,Rattus norvegicus,10116.0,
9645,1,,BAO_0000218,Intermediate,,4408,Pharmacokinetic property (AUC) in rat,A,,,Rattus norvegicus,10116.0,
9646,1,,BAO_0000218,Intermediate,,5983,Pharmacokinetic property (AUC) was measured in rat at the dose of 0.32 mg/kg p.o.,A,,,Rattus norvegicus,10116.0,
9647,1,,BAO_0000218,Intermediate,,4397,Pharmacokinetic property at the dose of 10 mg/kg (20% HPbetaCD) concentration in rat (0 to 6 hr) p.o.,A,,,Rattus norvegicus,10116.0,
9648,1,,BAO_0000218,Intermediate,,4397,Pharmacokinetic property at the dose of 10 mg/kg (20% HPbetaCD) concentration in rat (0 to 6 hr) p.o.; Not tested,A,,,Rattus norvegicus,10116.0,
9649,1,,BAO_0000218,Intermediate,,5491,Pharmacokinetic property was determined,A,,,Rattus norvegicus,10116.0,
9650,1,,BAO_0000218,Intermediate,,5491,Pharmacokinetic property when administered intravenously in rat at 2 mg/kg,A,,,Rattus norvegicus,10116.0,
9651,1,,BAO_0000218,Intermediate,,5491,Pharmacokinetic property when administered intravenously in rat at 2 mg/kg; Not tested,A,,,Rattus norvegicus,10116.0,
9652,1,,BAO_0000218,Intermediate,1969.0,4199,Pharmacokinetic property( plasma concentration) was determined upon 10 mg/kg in 1% methylcellulose peroral administration in rats,A,,,Rattus norvegicus,10116.0,
9653,1,,BAO_0000218,Intermediate,1969.0,4199,Pharmacokinetic property( plasma concentration) was determined upon 2 mg/kg in 1% methylcellulose peroral administration in rats,A,,,Rattus norvegicus,10116.0,
9654,1,,BAO_0000218,Intermediate,1969.0,4199,Pharmacokinetic property( plasma concentration) was determined upon 3 mg/kg in 1% methylcellulose peroral administration in rats,A,,,Rattus norvegicus,10116.0,
9655,1,,BAO_0000218,Intermediate,,5173,"Pharmacokinetic property, AUC determined by rapid rat PK assay observed at 0.25 h",A,,,Rattus norvegicus,10116.0,
9656,1,,BAO_0000218,Intermediate,,5173,"Pharmacokinetic property, AUC determined by rapid rat PK assay observed at 0.5 h",A,,,Rattus norvegicus,10116.0,
9657,1,,BAO_0000218,Intermediate,,5173,"Pharmacokinetic property, AUC determined by rapid rat PK assay observed at 1 h",A,,,Rattus norvegicus,10116.0,
9658,1,,BAO_0000218,Intermediate,,5173,"Pharmacokinetic property, AUC determined by rapid rat PK assay observed at 2 h",A,,,Rattus norvegicus,10116.0,
9659,1,,BAO_0000218,Intermediate,,16366,Pharmacokinetic parameter AUC was determined when a dose of 1 mg/kg was administered intravenously,A,,,Rattus norvegicus,10116.0,
9660,1,,BAO_0000218,Intermediate,,16366,Pharmacokinetic parameter AUC was determined when a dose of 1 mg/kg was administered orally,A,,,Rattus norvegicus,10116.0,
9661,1,,BAO_0000218,Intermediate,,5327,Plasma concentration expressed as area under curve after intravenous administration was determined in rat,A,,,Rattus norvegicus,10116.0,
9662,1,,BAO_0000218,Intermediate,,6681,Plasma concentration for the compound was determined in rats at 50 mg/kg dose,A,,,Rattus norvegicus,10116.0,
9663,1,,BAO_0000218,Intermediate,,12873,Plasma concentration was calculated in rats at a peroral dose of 5 mg/kg of solution (formulation of compound),A,,,Rattus norvegicus,10116.0,
9664,1,,BAO_0000218,Intermediate,,12873,Plasma concentration was calculated in rats at a peroral dose of 5 mg/kg of suspension (formulation of compound),A,,,Rattus norvegicus,10116.0,
9665,1,,BAO_0000218,Intermediate,,6685,"Plasma concentration was determined in rats at 10 mg/kg, p.o. dose",A,,,Rattus norvegicus,10116.0,
9666,1,,BAO_0000218,Intermediate,,6685,"Plasma concentration was determined in rats at 20 mg/kg, i.p. dose",A,,,Rattus norvegicus,10116.0,
9667,1,,BAO_0000218,Intermediate,,6685,"Plasma concentration was determined in rats at 2 mg/kg, i.v. dose",A,,,Rattus norvegicus,10116.0,
9668,1,,BAO_0000218,Intermediate,,6619,"Reduction in area under curve was determined in fa/fa Zucker rats by oral glucose tolerance test following a single i.p. dose (20 mg/kg, 30 min pre-treatment)",A,,,Rattus norvegicus,10116.0,
9669,1,,BAO_0000218,Intermediate,,6619,"Reduction in area under curve was determined in fa/fa Zucker rats by oral glucose tolerance test following a single i.p. dose (30 mg/kg, 30 min pre-treatment)",A,,,Rattus norvegicus,10116.0,
9670,1,,BAO_0000218,Intermediate,,10363,Suppressor cell activity was measured as area under curve(AUC) in normal rats by a splenic cell coculture assay at a dose of 30 mg/kg; Not significant,A,,,Rattus norvegicus,10116.0,
9671,1,,BAO_0000218,Intermediate,,4796,Systemic AUC was determined by pharmacokinetic study conducted in portal vein cannulated rats,A,,,Rattus norvegicus,10116.0,
9672,1,,BAO_0000218,Intermediate,,4910,Tested for concentration in brain after intravenous administration (4.7 mg/kg) to male rats,A,,,Rattus norvegicus,10116.0,
9673,1,,BAO_0000218,Intermediate,1969.0,4910,Tested for plasma concentration after intravenous administration (4.7 mg/kg) to male rats,A,,,Rattus norvegicus,10116.0,
9674,1,,BAO_0000218,Intermediate,,4839,Tested for the pharmacokinetic parameter in rat and expressed as area under curve,A,,,Rattus norvegicus,10116.0,
9675,1,,BAO_0000218,Intermediate,,15078,"The AUC(0-infinitive) value in female wistar rat at 100 mg/kg, p.o. dose",A,,,Rattus norvegicus,10116.0,
9676,1,,BAO_0000218,Intermediate,,15078,"The AUC(0-infinitive) value in male wistar rat at 100 mg/kg, p.o. dose",A,,,Rattus norvegicus,10116.0,
9677,1,,BAO_0000218,Intermediate,,15078,"The AUC(0-t)value in female wistar rat at 100 mg/kg, p.o. dose",A,,,Rattus norvegicus,10116.0,
9678,1,,BAO_0000218,Intermediate,,15078,"The AUC(0-t)value in male wistar rat at 100 mg/kg, p.o. dose",A,,,Rattus norvegicus,10116.0,
9679,1,,BAO_0000218,Intermediate,2046.0,11450,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 2.16-2.39% dose/g",A,,,Rattus norvegicus,10116.0,
9680,1,,BAO_0000218,Intermediate,2046.0,11450,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.99-1.40 % dose/g",A,,,Rattus norvegicus,10116.0,
9681,1,,BAO_0000218,Intermediate,,8151,Antidiuretic activity expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg.,A,,,Rattus norvegicus,10116.0,
9682,1,,BAO_0000218,Intermediate,,8151,Antidiuretic activity expressed as Na+(sodium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg,A,,,Rattus norvegicus,10116.0,
9683,1,,BAO_0000218,Intermediate,1088.0,8151,Antidiuretic activity was determined expressed as volume of urine excreted in mL was reported at a dose of 100 mg/Kg,A,,,Rattus norvegicus,10116.0,
9684,1,,BAO_0000218,Intermediate,178.0,8677,"Biodistribution in Sprague-Dawley rat blood 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",A,In vivo,,Rattus norvegicus,10116.0,
9685,1,,BAO_0000218,Intermediate,178.0,8677,"Biodistribution in Sprague-Dawley rat blood 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",A,In vivo,,Rattus norvegicus,10116.0,
9686,1,,BAO_0000218,Intermediate,178.0,8677,"Biodistribution in Sprague-Dawley rat blood 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",A,In vivo,,Rattus norvegicus,10116.0,
9687,1,,BAO_0000218,Intermediate,178.0,8677,"Biodistribution in Sprague-Dawley rat blood 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",A,In vivo,,Rattus norvegicus,10116.0,
9688,1,,BAO_0000218,Intermediate,955.0,8677,"Biodistribution in Sprague-Dawley rat brain 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",A,In vivo,,Rattus norvegicus,10116.0,
9689,1,,BAO_0000218,Intermediate,955.0,8677,"Biodistribution in Sprague-Dawley rat brain 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",A,In vivo,,Rattus norvegicus,10116.0,
9690,1,,BAO_0000218,Intermediate,955.0,8677,"Biodistribution in Sprague-Dawley rat brain 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",A,In vivo,,Rattus norvegicus,10116.0,
9691,1,,BAO_0000218,Intermediate,955.0,8677,"Biodistribution in Sprague-Dawley rat brain 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",A,In vivo,,Rattus norvegicus,10116.0,
9692,1,,BAO_0000218,Intermediate,955.0,8677,Biodistribution in Sprague-Dawley rat brain 2 minutes after intravenous administration.,A,In vivo,,Rattus norvegicus,10116.0,
9693,1,,BAO_0000218,Intermediate,948.0,8677,"Biodistribution in Sprague-Dawley rat heart 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",A,In vivo,,Rattus norvegicus,10116.0,
9694,1,,BAO_0000218,Intermediate,948.0,8677,"Biodistribution in Sprague-Dawley rat heart 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",A,In vivo,,Rattus norvegicus,10116.0,
9695,1,,BAO_0000218,Intermediate,948.0,8677,"Biodistribution in Sprague-Dawley rat heart 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",A,In vivo,,Rattus norvegicus,10116.0,
9696,1,,BAO_0000218,Intermediate,2113.0,8677,"Biodistribution in Sprague-Dawley rat kidneys(2) 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",A,In vivo,,Rattus norvegicus,10116.0,
9697,1,,BAO_0000218,Intermediate,2113.0,8677,"Biodistribution in Sprague-Dawley rat kidneys(2) 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",A,In vivo,,Rattus norvegicus,10116.0,
9698,1,,BAO_0000218,Intermediate,2113.0,8677,"Biodistribution in Sprague-Dawley rat kidneys(2) 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",A,In vivo,,Rattus norvegicus,10116.0,
9699,1,,BAO_0000218,Intermediate,2113.0,8677,"Biodistribution in Sprague-Dawley rat kidneys(2) 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",A,In vivo,,Rattus norvegicus,10116.0,
9700,1,,BAO_0000218,Intermediate,2107.0,8677,"Biodistribution in Sprague-Dawley rat liver 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",A,In vivo,,Rattus norvegicus,10116.0,
9701,1,,BAO_0000218,Intermediate,2107.0,8677,"Biodistribution in Sprague-Dawley rat liver 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",A,In vivo,,Rattus norvegicus,10116.0,
9702,1,,BAO_0000218,Intermediate,2107.0,8677,"Biodistribution in Sprague-Dawley rat liver 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",A,In vivo,,Rattus norvegicus,10116.0,
9703,1,,BAO_0000218,Intermediate,2107.0,8677,"Biodistribution in Sprague-Dawley rat liver 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",A,In vivo,,Rattus norvegicus,10116.0,
9704,1,,BAO_0000218,Intermediate,2048.0,8677,"Biodistribution in Sprague-Dawley rat lungs(2) 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",A,In vivo,,Rattus norvegicus,10116.0,
9705,1,,BAO_0000218,Intermediate,2048.0,8677,"Biodistribution in Sprague-Dawley rat lungs(2) 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",A,In vivo,,Rattus norvegicus,10116.0,
9706,1,,BAO_0000218,Intermediate,2048.0,8677,"Biodistribution in Sprague-Dawley rat lungs(2) 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",A,In vivo,,Rattus norvegicus,10116.0,
9707,1,,BAO_0000218,Intermediate,2048.0,8677,"Biodistribution in Sprague-Dawley rat lungs(2) 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",A,In vivo,,Rattus norvegicus,10116.0,
9708,1,,BAO_0000218,Intermediate,2385.0,8677,"Biodistribution in Sprague-Dawley rat muscle 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",A,In vivo,,Rattus norvegicus,10116.0,
9709,1,,BAO_0000218,Intermediate,2385.0,8677,"Biodistribution in Sprague-Dawley rat muscle 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",A,In vivo,,Rattus norvegicus,10116.0,
9710,1,,BAO_0000218,Intermediate,2385.0,8677,"Biodistribution in Sprague-Dawley rat muscle 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",A,In vivo,,Rattus norvegicus,10116.0,
9711,1,,BAO_0000218,Intermediate,2385.0,8677,"Biodistribution in Sprague-Dawley rat muscle 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",A,In vivo,,Rattus norvegicus,10116.0,
9712,1,,BAO_0000218,Intermediate,14.0,8677,"Biodistribution in Sprague-Dawley rat skin 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",A,In vivo,,Rattus norvegicus,10116.0,
9713,1,,BAO_0000218,Intermediate,14.0,8677,"Biodistribution in Sprague-Dawley rat skin 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",A,In vivo,,Rattus norvegicus,10116.0,
9714,1,,BAO_0000218,Intermediate,14.0,8677,"Biodistribution in Sprague-Dawley rat skin 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",A,In vivo,,Rattus norvegicus,10116.0,
9715,1,,BAO_0000218,Intermediate,14.0,8677,"Biodistribution in Sprague-Dawley rat skin 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",A,In vivo,,Rattus norvegicus,10116.0,
9716,1,,BAO_0000218,Intermediate,160.0,8677,"Biodistribution in Sprague-Dawley rat small intestine 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",A,In vivo,,Rattus norvegicus,10116.0,
9717,1,,BAO_0000218,Intermediate,160.0,8677,"Biodistribution in Sprague-Dawley rat small intestine 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",A,In vivo,,Rattus norvegicus,10116.0,
9718,1,,BAO_0000218,Intermediate,160.0,8677,"Biodistribution in Sprague-Dawley rat small intestine 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",A,In vivo,,Rattus norvegicus,10116.0,
9719,1,,BAO_0000218,Intermediate,160.0,8677,"Biodistribution in Sprague-Dawley rat small intestine 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",A,In vivo,,Rattus norvegicus,10116.0,
9720,1,,BAO_0000218,Intermediate,2106.0,8677,"Biodistribution in Sprague-Dawley rat spleen 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",A,In vivo,,Rattus norvegicus,10116.0,
9721,1,,BAO_0000218,Intermediate,2106.0,8677,"Biodistribution in Sprague-Dawley rat spleen 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",A,In vivo,,Rattus norvegicus,10116.0,
9722,1,,BAO_0000218,Intermediate,2106.0,8677,"Biodistribution in Sprague-Dawley rat spleen 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",A,In vivo,,Rattus norvegicus,10116.0,
9723,1,,BAO_0000218,Intermediate,2106.0,8677,"Biodistribution in Sprague-Dawley rat spleen 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",A,In vivo,,Rattus norvegicus,10116.0,
9724,1,,BAO_0000218,Intermediate,,16434,Radioactivity distribution in testis of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,A,,,Rattus norvegicus,10116.0,
9725,1,,BAO_0000218,Intermediate,,16434,Radioactivity distribution in testis of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,A,,,Rattus norvegicus,10116.0,
9726,1,,BAO_0000218,Intermediate,,16434,Radioactivity distribution in testis of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,A,,,Rattus norvegicus,10116.0,
9727,1,,BAO_0000218,Intermediate,,16435,Radioactivity distribution in testis of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,A,,,Rattus norvegicus,10116.0,
9728,1,,BAO_0000218,Intermediate,,16435,Radioactivity distribution in testis of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,A,,,Rattus norvegicus,10116.0,
9729,1,,BAO_0000218,Intermediate,,16435,Radioactivity distribution in testis of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,A,,,Rattus norvegicus,10116.0,
9730,1,,BAO_0000218,Intermediate,,16435,Radioactivity distribution in testis of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,A,,,Rattus norvegicus,10116.0,
9731,1,,BAO_0000218,Intermediate,,16435,Radioactivity distribution in testis of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,A,,,Rattus norvegicus,10116.0,
9732,1,,BAO_0000218,Intermediate,,16435,Radioactivity distribution in testis of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,A,,,Rattus norvegicus,10116.0,
9733,1,,BAO_0000218,Intermediate,,16435,Radioactivity distribution in testis of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,A,,,Rattus norvegicus,10116.0,
9734,1,,BAO_0000218,Intermediate,,16435,Radioactivity distribution in testis of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,A,,,Rattus norvegicus,10116.0,
9735,1,,BAO_0000218,Intermediate,,16434,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,A,,,Rattus norvegicus,10116.0,
9736,1,,BAO_0000218,Intermediate,,16434,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,A,,,Rattus norvegicus,10116.0,
9737,1,,BAO_0000218,Intermediate,,16434,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,A,,,Rattus norvegicus,10116.0,
9738,1,,BAO_0000218,Intermediate,,16435,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,A,,,Rattus norvegicus,10116.0,
9739,1,,BAO_0000218,Intermediate,,16435,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,A,,,Rattus norvegicus,10116.0,
9740,1,,BAO_0000218,Intermediate,,16435,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,A,,,Rattus norvegicus,10116.0,
9741,1,,BAO_0000218,Intermediate,,16435,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,A,,,Rattus norvegicus,10116.0,
9742,1,,BAO_0000218,Intermediate,,16435,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,A,,,Rattus norvegicus,10116.0,
9743,1,,BAO_0000218,Intermediate,,16435,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,A,,,Rattus norvegicus,10116.0,
9744,1,,BAO_0000218,Intermediate,,16434,Radioactivity distribution in tumor of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,A,,,Rattus norvegicus,10116.0,
9745,1,,BAO_0000218,Intermediate,,16434,Radioactivity distribution in tumor of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,A,,,Rattus norvegicus,10116.0,
9746,1,,BAO_0000218,Intermediate,,16434,Radioactivity distribution in tumor of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,A,,,Rattus norvegicus,10116.0,
9747,1,,BAO_0000218,Intermediate,,16434,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,A,,,Rattus norvegicus,10116.0,
9748,1,,BAO_0000218,Intermediate,,16434,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,A,,,Rattus norvegicus,10116.0,
9749,1,,BAO_0000218,Intermediate,,16434,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,A,,,Rattus norvegicus,10116.0,
9750,1,,BAO_0000218,Intermediate,,16435,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,F,,,Rattus norvegicus,10116.0,
9751,1,,BAO_0000218,Intermediate,,16435,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,A,,,Rattus norvegicus,10116.0,
9752,1,,BAO_0000218,Intermediate,,16435,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,A,,,Rattus norvegicus,10116.0,
9753,1,,BAO_0000218,Intermediate,,16435,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,F,,,Rattus norvegicus,10116.0,
9754,1,,BAO_0000218,Intermediate,,16435,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,A,,,Rattus norvegicus,10116.0,
9755,1,,BAO_0000218,Intermediate,,16435,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,A,,,Rattus norvegicus,10116.0,
9756,1,,BAO_0000218,Intermediate,,13091,Tissue biodistribution into estrogen-primed immature female rat blood at 1 hr blocked time interval,A,,,Rattus norvegicus,10116.0,
9757,1,,BAO_0000218,Intermediate,,13091,Tissue biodistribution into estrogen-primed immature female rat blood at 1 hr low time interval,A,,,Rattus norvegicus,10116.0,
9758,1,,BAO_0000218,Intermediate,,13091,Tissue biodistribution into estrogen-primed immature female rat blood at 1 hr time interval,A,,,Rattus norvegicus,10116.0,
9759,1,,BAO_0000218,Intermediate,,13091,Tissue biodistribution into estrogen-primed immature female rat blood at 3 hr time interval,A,,,Rattus norvegicus,10116.0,
9760,1,,BAO_0000218,Intermediate,,13091,Tissue biodistribution into estrogen-primed immature female rat bone at 1 hr blocked time interval,A,,,Rattus norvegicus,10116.0,
9761,1,,BAO_0000218,Intermediate,,13091,Tissue biodistribution into estrogen-primed immature female rat bone at 1 hr low time interval,A,,,Rattus norvegicus,10116.0,
9762,1,,BAO_0000218,Intermediate,,13091,Tissue biodistribution into estrogen-primed immature female rat bone at 1 hr time interval,A,,,Rattus norvegicus,10116.0,
9763,1,,BAO_0000218,Intermediate,,13091,Tissue biodistribution into estrogen-primed immature female rat bone at 3 hr time interval,A,,,Rattus norvegicus,10116.0,
9764,1,,BAO_0000218,Intermediate,,13091,Tissue biodistribution into estrogen-primed immature female rat brain at 1 hr blocked time interval,A,,,Rattus norvegicus,10116.0,
9765,1,,BAO_0000218,Intermediate,,13091,Tissue biodistribution into estrogen-primed immature female rat brain at 1 hr low time interval,A,,,Rattus norvegicus,10116.0,
9766,1,,BAO_0000218,Intermediate,,13091,Tissue biodistribution into estrogen-primed immature female rat brain at 1 hr time interval,A,,,Rattus norvegicus,10116.0,
9767,1,,BAO_0000218,Intermediate,,13091,Tissue biodistribution into estrogen-primed immature female rat brain at 3 hr time interval,A,,,Rattus norvegicus,10116.0,
9768,1,,BAO_0000218,Intermediate,,13091,Tissue biodistribution into estrogen-primed immature female rat fat at 1 hr blocked time interval,A,,,Rattus norvegicus,10116.0,
9769,1,,BAO_0000218,Intermediate,,5874,Half life period in rat by iv administration at a dose of 3 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,
9770,1,,BAO_0000218,Intermediate,1969.0,1515,Half life period in rat plasma at 25 degree Centigrade temperature (pH 7.4),A,,,Rattus norvegicus,10116.0,
9771,1,,BAO_0000218,Intermediate,1969.0,1515,Half life period in rat plasma at 37 degree Celsius temperature (pH 7.4),A,,,Rattus norvegicus,10116.0,
9772,1,,BAO_0000218,Intermediate,1969.0,1515,Half life period in rat plasma at 37 degree Celsius temperature (pH 7.4); ND means no data,A,,,Rattus norvegicus,10116.0,
9773,1,,BAO_0000218,Intermediate,1969.0,1515,Half life period in rat plasma at 37 degree Celsius temperature (pH 7.4); ND means no data,A,,,Rattus norvegicus,10116.0,
9774,1,,BAO_0000218,Intermediate,1969.0,5491,Half life period was evaluated in rat plasma,A,,,Rattus norvegicus,10116.0,
9775,1,,BAO_0000218,Intermediate,1969.0,5491,Half life period was evaluated in rat plasma; Not tested,A,,,Rattus norvegicus,10116.0,
9776,1,,BAO_0000218,Intermediate,,1918,Half life period was evaluated in rats,A,,,Rattus norvegicus,10116.0,
9777,1,,BAO_0000218,Intermediate,,1918,"Half life period was evaluated in rats, iv",A,In vivo,,Rattus norvegicus,10116.0,
9778,1,,BAO_0000218,Intermediate,,6113,Half life period after intravenous administration at 5 mg/kg in rat,A,In vivo,,Rattus norvegicus,10116.0,
9779,1,,BAO_0000218,Intermediate,,5546,Half life period was determined in Sprague-Dawley rats at a dose of 1 mg/kg by iv administration,A,In vivo,,Rattus norvegicus,10116.0,
9780,1,,BAO_0000218,Intermediate,,5553,Half life period was determined in rat after iv administration at a dose of 5 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,
9781,1,,BAO_0000218,Intermediate,1969.0,4188,Half life stability of compound was evaluated in rat plasma,A,,,Rattus norvegicus,10116.0,
9782,1,,BAO_0000218,Intermediate,,6215,Half life time after intravenous administration (5.0 mg/kg) was determined in rat,A,In vivo,,Rattus norvegicus,10116.0,
9783,1,,BAO_0000218,Intermediate,,6141,Half life time was evaluated at 1 mg/kg of iv administration in Sprague-Dawley rats,A,In vivo,,Rattus norvegicus,10116.0,
9784,1,,BAO_0000218,Intermediate,,5182,Half life was determined by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat,A,In vivo,,Rattus norvegicus,10116.0,
9785,1,,BAO_0000218,Intermediate,,5182,Half life was determined by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat; NC means not calculated,A,In vivo,,Rattus norvegicus,10116.0,
9786,1,,BAO_0000218,Intermediate,,5710,Half life was measured in fasted male administration of compound 0.5 mg/Kg i.v.,A,In vivo,,Rattus norvegicus,10116.0,
9787,1,,BAO_0000218,Intermediate,,5789,Half in rat i.v.,A,In vivo,,Rattus norvegicus,10116.0,
9788,1,,BAO_0000218,Intermediate,,6011,Half period in rat after intravenous administration,A,In vivo,,Rattus norvegicus,10116.0,
9789,1,,BAO_0000218,Intermediate,,17594,Half-life after repeated oral dose of compound at 1 mg/kg in rats,A,In vivo,,Rattus norvegicus,10116.0,
9790,1,,BAO_0000218,Intermediate,2107.0,12357,Half-life measured in in vitro Cathepsin B assay in rat liver,A,In vitro,,Rattus norvegicus,10116.0,
9791,1,,BAO_0000218,Intermediate,,5210,Half-life of compound was determined in rats,A,,,Rattus norvegicus,10116.0,
9792,1,,BAO_0000218,Intermediate,,17596,Half-life at 10 mg/kg in rat upon intravenous administration,A,In vivo,,Rattus norvegicus,10116.0,
9793,1,,BAO_0000218,Intermediate,,6672,Half-life determined in rat,A,,,Rattus norvegicus,10116.0,
9794,1,,BAO_0000218,Intermediate,,6673,Half-life determined in rat,A,,,Rattus norvegicus,10116.0,
9795,1,,BAO_0000218,Intermediate,955.0,4910,Half-life in brain after intravenous administration (4.7 mg/kg) to male rats,A,In vivo,,Rattus norvegicus,10116.0,
9796,1,,BAO_0000218,Intermediate,1969.0,3741,"Half-life in chemical and enzymatic hydrolysis, in 80% rat plasma",A,,,Rattus norvegicus,10116.0,
9797,1,,BAO_0000218,Intermediate,,17671,Half-life in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,
9798,1,,BAO_0000218,Intermediate,1969.0,4910,Half-life in plasma after intravenous administration (4.7 mg/kg) to male rats,A,In vivo,,Rattus norvegicus,10116.0,
9799,1,,BAO_0000218,Intermediate,1969.0,17537,Half-life in rat plasma,A,,,Rattus norvegicus,10116.0,
9800,1,,BAO_0000218,Intermediate,1969.0,4965,Half-life in rat plasma was determined,A,,,Rattus norvegicus,10116.0,
9801,1,,BAO_0000218,Intermediate,1969.0,17537,Half-life in rat plasma; Not tested,A,,,Rattus norvegicus,10116.0,
9802,1,,BAO_0000218,Intermediate,1977.0,6124,Half-life in rat serum,A,,,Rattus norvegicus,10116.0,
9803,1,,BAO_0000218,Intermediate,1977.0,6124,Half-life in rat serum; na is not available,A,,,Rattus norvegicus,10116.0,
9804,1,,BAO_0000218,Intermediate,,6078,Half-life was calculated in rat,A,,,Rattus norvegicus,10116.0,
9805,1,,BAO_0000218,Intermediate,1969.0,17668,Half-life was calculated in rat plasma,A,,,Rattus norvegicus,10116.0,
9806,1,,BAO_0000218,Intermediate,,3185,Half-life was determined,A,,,Rattus norvegicus,10116.0,
9807,1,,BAO_0000218,Intermediate,,4883,Half-life was determined,A,,,Rattus norvegicus,10116.0,
9808,1,,BAO_0000218,Intermediate,,2959,Half-life after administration of 20 mg/Kg oral dose in rat,A,In vivo,,Rattus norvegicus,10116.0,
9809,1,,BAO_0000218,Intermediate,,4029,Half-life after administration of 3.2 mg/kg intravenously in male rat,A,In vivo,,Rattus norvegicus,10116.0,
9810,1,,BAO_0000218,Intermediate,,4029,Half-life after intravenous administration in female rat,A,In vivo,,Rattus norvegicus,10116.0,
9811,1,,BAO_0000218,Intermediate,,4029,Half-life after intravenous administration in male rat,A,In vivo,,Rattus norvegicus,10116.0,
9812,1,,BAO_0000218,Intermediate,,6180,Half-life after intravenous dose in rat,A,In vivo,,Rattus norvegicus,10116.0,
9813,1,,BAO_0000218,Intermediate,2107.0,1557,Half-life in a rat liver homogenate preparation,A,,,Rattus norvegicus,10116.0,
9814,1,,BAO_0000218,Intermediate,1969.0,12500,Half-life in plasma of rat,A,,,Rattus norvegicus,10116.0,
9815,1,,BAO_0000218,Intermediate,1969.0,12500,Half-life in plasma of rat at dose of 3-10 mgkg,A,,,Rattus norvegicus,10116.0,
9816,1,,BAO_0000218,Intermediate,,5064,Half-life in rat,A,,,Rattus norvegicus,10116.0,
9817,1,,BAO_0000218,Intermediate,,5145,Half-life in rat,A,,,Rattus norvegicus,10116.0,
9818,1,,BAO_0000218,Intermediate,,5147,Half-life in rat,A,,,Rattus norvegicus,10116.0,
9819,1,,BAO_0000218,Intermediate,,5833,Half-life in rat,A,,,Rattus norvegicus,10116.0,
9820,1,,BAO_0000218,Intermediate,,6596,Half-life in rat,A,,,Rattus norvegicus,10116.0,
9821,1,,BAO_0000218,Intermediate,,17655,Half-life in rat,A,,,Rattus norvegicus,10116.0,
9822,1,,BAO_0000218,Intermediate,,6495,Half-life in rat after oral administration at 10 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,
9823,1,,BAO_0000218,Intermediate,,17538,Half-life in rat after po administration at a dose of 10 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,
9824,1,,BAO_0000218,Intermediate,,17538,Half-life in rat after po administration at a dose of 10 mg/kg; nd is not determined,A,In vivo,,Rattus norvegicus,10116.0,
9825,1,,BAO_0000218,Intermediate,,10,Half-life in rat at 3 mg/kg dose administered intravenously,A,In vivo,,Rattus norvegicus,10116.0,
9826,1,,BAO_0000218,Intermediate,955.0,17669,Half-life in rat brain homogenate,A,,,Rattus norvegicus,10116.0,
9827,1,,BAO_0000218,Intermediate,1969.0,17065,Half-life in rat plasma,A,,,Rattus norvegicus,10116.0,
9828,1,,BAO_0000218,Intermediate,,4333,Half-life in rats,A,,,Rattus norvegicus,10116.0,
9829,1,,BAO_0000218,Intermediate,,6827,Half-life in Dawley rats,A,,,Rattus norvegicus,10116.0,
9830,1,,BAO_0000218,Intermediate,1969.0,889,Half-life in vitro in rat plasma,A,In vitro,,Rattus norvegicus,10116.0,
9831,1,,BAO_0000218,Intermediate,1969.0,889,Half-life in vitro in rat plasma; No detectable degradation over 2 hr; no detectable degradation over 2 hours,A,In vitro,,Rattus norvegicus,10116.0,
9832,1,,BAO_0000218,Intermediate,,3747,"The area under concentration-time curve(AUC) was determined at 20 mg/kg of compound dose, administered intravenously in rat",A,,,Rattus norvegicus,10116.0,
9833,1,,BAO_0000218,Intermediate,,15022,The area under the curve of compound was measured at the dose of 100 umol/kg,A,,,Rattus norvegicus,10116.0,
9834,1,,BAO_0000218,Intermediate,,15022,The area under the curve of compound was measured at the dose of 300 umol/kg,A,,,Rattus norvegicus,10116.0,
9835,1,,BAO_0000218,Intermediate,,15022,The area under the curve of compound was measured at the dose of 30 umol/kg,A,,,Rattus norvegicus,10116.0,
9836,1,,BAO_0000218,Intermediate,,3360,Bioavailability as oral AUC in rats,A,In vivo,,Rattus norvegicus,10116.0,
9837,1,,BAO_0000218,Intermediate,1969.0,5334,The plasma concentration versus time curve (AUC) was determined,A,,,Rattus norvegicus,10116.0,
9838,1,,BAO_0000218,Intermediate,,17411,Total concentration in kidney was determined after 6 hr of intravenous administration to rats (n=4) at dose of 20 mg/kg,A,,,Rattus norvegicus,10116.0,
9839,1,,BAO_0000218,Intermediate,,17411,Total concentration in liver was determined after 6 hr of intravenous administration to rats (n=4) at dose of 20 mg/kg,A,,,Rattus norvegicus,10116.0,
9840,1,,BAO_0000218,Intermediate,,17411,Total concentration in lung was determined after 6 hr of intravenous administration to rats (n=4) at dose of 20 mg/kg,A,,,Rattus norvegicus,10116.0,
9841,1,,BAO_0000218,Intermediate,,6570,Total concentration in rat after 1 mg/kg i.v. administration in 24 hours,A,,,Rattus norvegicus,10116.0,
9842,1,,BAO_0000218,Intermediate,,6570,Total concentration in rat after 2 mg/kg peroral administration in 24 hours,A,,,Rattus norvegicus,10116.0,
9843,1,,BAO_0000218,Intermediate,,17411,Total concentration in serum was determined after 6 hr of intravenous administration to rats (n=4) at dose of 20 mg/kg,A,,,Rattus norvegicus,10116.0,
9844,1,,BAO_0000218,Intermediate,1969.0,14941,"Pharmacokinetic Parameter, AUC (0-infinity) is the area under the plasma concentration versus time curve extrapolated to infinity in Female Wistar Rats at 100 mg/kg by po administration",A,,,Rattus norvegicus,10116.0,
9845,1,,BAO_0000218,Intermediate,1969.0,14941,"Pharmacokinetic Parameter, AUC (0-t) is the area under the plasma concentration versus time curve in Female Wistar Rats at 100 mg/kg by po administration",A,,,Rattus norvegicus,10116.0,
9846,1,,BAO_0000218,Intermediate,1969.0,17538,AUC in rat after po administration at a dose of 10 mg/kg,A,,,Rattus norvegicus,10116.0,
9847,1,,BAO_0000218,Intermediate,1969.0,17752,Area under the plasma concentration-time curve in rats after oral administration at 25 mg/kg,A,,,Rattus norvegicus,10116.0,
9848,1,,BAO_0000218,Intermediate,,17509,Area under curve value 24 hr after 10 mg/kg iv administration in rats,A,,,Rattus norvegicus,10116.0,
9849,1,,BAO_0000218,Intermediate,,17509,Area under curve value 24 hr after 10 mg/kg oral administration in rats,A,,,Rattus norvegicus,10116.0,
9850,1,,BAO_0000218,Intermediate,,17509,Area under curve value 24 hr after 2 mg/kg iv administration in rats,A,,,Rattus norvegicus,10116.0,
9851,1,,BAO_0000218,Intermediate,,17509,Area under curve value 24 hr after 2 mg/kg oral administration in rats,A,,,Rattus norvegicus,10116.0,
9852,1,,BAO_0000218,Intermediate,,17509,Area under curve value 6 hr after po administration in rat,A,,,Rattus norvegicus,10116.0,
9853,1,,BAO_0000218,Intermediate,,17717,Area under the curve at a concentration of 15 mg/kg perorally in rats along with 100 mg/kg of compound 11,A,,,Rattus norvegicus,10116.0,
9854,1,,BAO_0000218,Intermediate,,17717,"Area under the curve at a concentration of 3 mg/kg in rats, intravenously",A,,,Rattus norvegicus,10116.0,
9855,1,,BAO_0000218,Intermediate,,17717,Area under the curve at a concentration of 60 mg/kg perorally in rats along with 100 mg/kg of compound 11,A,,,Rattus norvegicus,10116.0,
9856,1,,BAO_0000218,Intermediate,,17717,Area under the curve at a concentration of 60 mg/kg perorally in rats along with control,A,,,Rattus norvegicus,10116.0,
9857,1,,BAO_0000218,Intermediate,1969.0,6642,AUC normalized for dose (AUCN) in rat,A,,,Rattus norvegicus,10116.0,
9858,1,,BAO_0000218,Intermediate,,6640,Area under curve in rat after p.o. administration,A,,,Rattus norvegicus,10116.0,
9859,1,,BAO_0000218,Intermediate,,6641,Area under curve in rat after p.o. administration,A,,,Rattus norvegicus,10116.0,
9860,1,,BAO_0000218,Intermediate,,6641,Area under curve in rat after p.o. administration; Not determined,A,,,Rattus norvegicus,10116.0,
9861,1,,BAO_0000218,Intermediate,,6641,Area under curve in rat after peroral administration,A,,,Rattus norvegicus,10116.0,
9862,1,,BAO_0000218,Intermediate,,3603,Area under curve (carotid artery) value of the compound,A,,,Rattus norvegicus,10116.0,
9863,1,,BAO_0000218,Intermediate,,3550,Bioavailability expressed as the area under curve of rat carotid artery,A,,,Rattus norvegicus,10116.0,
9864,1,,BAO_0000218,Intermediate,,15662,Area under curve in male SD rats was observed after intravenous administration in rat,A,,,Rattus norvegicus,10116.0,
9865,1,,BAO_0000218,Intermediate,,17720,Area under curve of the compound was determined,A,,,Rattus norvegicus,10116.0,
9866,1,,BAO_0000218,Intermediate,,5407,Compound was evaluated for its pharmacokinetic parameter maximum area under curve AUCmax,A,,,Rattus norvegicus,10116.0,
9867,1,,BAO_0000218,Intermediate,1969.0,17752,Area under the plasma concentration-time curve in rats after oral administration at 20 mg/kg,A,,,Rattus norvegicus,10116.0,
9868,1,,BAO_0000218,Intermediate,1969.0,17752,Area under the plasma concentration-time curve in rats following oral administration at 20 mg/kg,A,,,Rattus norvegicus,10116.0,
9869,1,,BAO_0000218,Intermediate,,3603,Area under curve (portal vein) value of the compound,A,,,Rattus norvegicus,10116.0,
9870,1,,BAO_0000218,Intermediate,,3550,Bioavailability expressed as the area under curve of rat portal vein,A,,,Rattus norvegicus,10116.0,
9871,1,,BAO_0000218,Intermediate,1969.0,17655,Area Under plasma concentration time curve in rat upon peroral administration,A,,,Rattus norvegicus,10116.0,
9872,1,,BAO_0000218,Intermediate,,17582,In vivo area under curve was determined for the compound after i.v. administration at a dose of 5 mg/kg in rats,A,,,Rattus norvegicus,10116.0,
9873,1,,BAO_0000218,Intermediate,,17582,In vivo area under curve was determined for the compound after oral (po) administration at a dose of 10 mg/kg in rats,A,,,Rattus norvegicus,10116.0,
9874,1,,BAO_0000218,Intermediate,,17791,Compound was evaluated for oral bioavailability in rats,A,,,Rattus norvegicus,10116.0,
9875,1,,BAO_0000218,Intermediate,,17791,Compound was evaluated for oral bioavailability in rats after iv administration,A,,,Rattus norvegicus,10116.0,
9876,1,,BAO_0000218,Intermediate,,17791,Compound was evaluated for oral bioavailability in rats; 30-80,A,,,Rattus norvegicus,10116.0,
9877,1,,BAO_0000218,Intermediate,,17791,Compound was evaluated for oral bioavailability in rats; 50-60,A,,,Rattus norvegicus,10116.0,
9878,1,,BAO_0000218,Intermediate,,17791,Compound was evaluated for oral bioavailability in rats; no data,A,,,Rattus norvegicus,10116.0,
9879,1,,BAO_0000218,Intermediate,,17791,Compound was evaluated for oral bioavailability in rats; peptide,A,,,Rattus norvegicus,10116.0,
9880,1,,BAO_0000218,Intermediate,178.0,7768,"Distribution of radioactivity in blood of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.03-0.03",A,,,Rattus norvegicus,10116.0,
9881,1,,BAO_0000218,Intermediate,178.0,7768,"Distribution of radioactivity in blood of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range-0.9-1.03",A,,,Rattus norvegicus,10116.0,
9882,1,,BAO_0000218,Intermediate,178.0,7768,"Distribution of radioactivity in blood of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range = 0.88-1.15",A,,,Rattus norvegicus,10116.0,
9883,1,,BAO_0000218,Intermediate,178.0,7768,"Distribution of radioactivity in blood of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range = 0.71-0.87",A,,,Rattus norvegicus,10116.0,
9884,1,,BAO_0000218,Intermediate,945.0,8677,"Biodistribution in Sprague-Dawley rat stomach 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",A,In vivo,,Rattus norvegicus,10116.0,
9885,1,,BAO_0000218,Intermediate,945.0,8677,"Biodistribution in Sprague-Dawley rat stomach 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",A,In vivo,,Rattus norvegicus,10116.0,
9886,1,,BAO_0000218,Intermediate,945.0,8677,"Biodistribution in Sprague-Dawley rat stomach 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",A,In vivo,,Rattus norvegicus,10116.0,
9887,1,,BAO_0000218,Intermediate,945.0,8677,"Biodistribution in Sprague-Dawley rat stomach 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",A,In vivo,,Rattus norvegicus,10116.0,
9888,1,,BAO_0000218,Intermediate,2046.0,8677,"Biodistribution in Sprague-Dawley rat thyroid 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",A,In vivo,,Rattus norvegicus,10116.0,
9889,1,,BAO_0000218,Intermediate,2046.0,8677,"Biodistribution in Sprague-Dawley rat thyroid 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",A,In vivo,,Rattus norvegicus,10116.0,
9890,1,,BAO_0000218,Intermediate,2046.0,8677,"Biodistribution in Sprague-Dawley rat thyroid 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",A,In vivo,,Rattus norvegicus,10116.0,
9891,1,,BAO_0000218,Intermediate,2046.0,8677,"Biodistribution in Sprague-Dawley rat thyroid 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",A,In vivo,,Rattus norvegicus,10116.0,
9892,1,,BAO_0000218,Intermediate,948.0,8677,"Biodistribution in Sprague-Dawley rats heart 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",A,In vivo,,Rattus norvegicus,10116.0,
9893,1,,BAO_0000218,Intermediate,1088.0,6899,Compound was evaluated for percent dimer tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine,A,,,Rattus norvegicus,10116.0,
9894,1,,BAO_0000218,Intermediate,1088.0,6899,Compound was evaluated for percent dimer tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine; na - not available,A,,,Rattus norvegicus,10116.0,
9895,1,,BAO_0000218,Intermediate,2107.0,6899,Compound was evaluated for percent dose tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in liver,A,,,Rattus norvegicus,10116.0,
9896,1,,BAO_0000218,Intermediate,1088.0,6899,Compound was evaluated for percent thiol tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine,A,,,Rattus norvegicus,10116.0,
9897,1,,BAO_0000218,Intermediate,1088.0,6899,Compound was evaluated for percent thiol tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine; na - not available,A,,,Rattus norvegicus,10116.0,
9898,1,,BAO_0000218,Intermediate,2385.0,8677,"Compound was evaluated for the biodistribution in Sprague-Dawley rats in muscle 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",A,,,Rattus norvegicus,10116.0,
9899,1,,BAO_0000218,Intermediate,,6899,Compound was evaluated for tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in rat kidney,A,,,Rattus norvegicus,10116.0,
9900,1,,BAO_0000218,Intermediate,1088.0,6899,Compound was evaluated for tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine,A,,,Rattus norvegicus,10116.0,
9901,1,,BAO_0000218,Intermediate,,2189,Percent of radioactive dose in urine and faeces excreted in 0-24 hr by rats,A,,,Rattus norvegicus,10116.0,
9902,1,,BAO_0000218,Intermediate,1088.0,2189,Percent of radioactive dose in urine and feces excreted in 0-24 hr by rats,A,,,Rattus norvegicus,10116.0,
9903,1,,BAO_0000218,Intermediate,1088.0,2189,Percent of radioactive dose in urine and feces excreted in 0-24 hr by rats; NA is <10% inhibition at 1 uM for binding data,A,,,Rattus norvegicus,10116.0,
9904,1,,BAO_0000218,Intermediate,178.0,10839,Biodistribution of compound in rat blood after 5 min of administration,A,In vivo,,Rattus norvegicus,10116.0,
9905,1,,BAO_0000218,Intermediate,178.0,10839,Biodistribution of compound in rat blood after 5 min of administration.,A,In vivo,,Rattus norvegicus,10116.0,
9906,1,,BAO_0000218,Intermediate,955.0,10839,Biodistribution of compound in rat brain after 5 min of administration,A,In vivo,,Rattus norvegicus,10116.0,
9907,1,,BAO_0000218,Intermediate,948.0,10839,Biodistribution of compound in rat heart after 5 min of administration,A,In vivo,,Rattus norvegicus,10116.0,
9908,1,,BAO_0000218,Intermediate,948.0,10839,Biodistribution of compound in rat heart after 5 min of administration.,A,In vivo,,Rattus norvegicus,10116.0,
9909,1,,BAO_0000218,Intermediate,2113.0,10839,Biodistribution of compound in rat kidney after 5 min of administration,A,In vivo,,Rattus norvegicus,10116.0,
9910,1,,BAO_0000218,Intermediate,2113.0,10839,Biodistribution of compound in rat kidney after 5 min of administration.,A,In vivo,,Rattus norvegicus,10116.0,
9911,1,,BAO_0000218,Intermediate,2107.0,10839,Biodistribution of compound in rat liver after 5 min of administration,A,In vivo,,Rattus norvegicus,10116.0,
9912,1,,BAO_0000218,Intermediate,2107.0,10839,Biodistribution of compound in rat liver after 5 min of administration.,A,In vivo,,Rattus norvegicus,10116.0,
9913,1,,BAO_0000218,Intermediate,2048.0,10839,Biodistribution of compound in rat lung after 5 min of administration,A,In vivo,,Rattus norvegicus,10116.0,
9914,1,,BAO_0000218,Intermediate,2048.0,10839,Biodistribution of compound in rat lung after 5 min of administration.,A,In vivo,,Rattus norvegicus,10116.0,
9915,1,,BAO_0000218,Intermediate,2385.0,10839,Biodistribution of compound in rat muscle after 5 min of administration,A,In vivo,,Rattus norvegicus,10116.0,
9916,1,,BAO_0000218,Intermediate,2385.0,10839,Biodistribution of compound in rat muscle after 5 min of administration.,A,In vivo,,Rattus norvegicus,10116.0,
9917,1,,BAO_0000218,Intermediate,948.0,4043,In vivo heart distribution of free doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,A,,,Rattus norvegicus,10116.0,
9918,1,,BAO_0000218,Intermediate,948.0,4043,In vivo heart distribution of total doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,A,,,Rattus norvegicus,10116.0,
9919,1,,BAO_0000218,Intermediate,2107.0,4043,In vivo liver distribution of free doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,A,,,Rattus norvegicus,10116.0,
9920,1,,BAO_0000218,Intermediate,2107.0,4043,In vivo liver distribution of total doxorubicin after 6 h intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,A,,,Rattus norvegicus,10116.0,
9921,1,,BAO_0000218,Intermediate,,4043,In vivo plasma distribution of free doxorubicin after 6 h intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,A,,,Rattus norvegicus,10116.0,
9922,1,,BAO_0000218,Intermediate,,4043,In vivo plasma distribution of total doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,A,,,Rattus norvegicus,10116.0,
9923,1,,BAO_0000218,Intermediate,2106.0,4043,In vivo spleen distribution of free doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,A,,,Rattus norvegicus,10116.0,
9924,1,,BAO_0000218,Intermediate,2106.0,4043,In vivo spleen distribution of total doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,A,,,Rattus norvegicus,10116.0,
9925,1,,BAO_0000218,Intermediate,,4043,In vivo tumor distribution of free doxorubicin after 6 h intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,A,,,Rattus norvegicus,10116.0,
9926,1,,BAO_0000218,Intermediate,,4043,In vivo tumor distribution of total doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,A,,,Rattus norvegicus,10116.0,
9927,1,,BAO_0000218,Intermediate,,1446,Compound was tested for the duration that the plasma drug concentrations remained above the IC95,A,,,Rattus norvegicus,10116.0,
9928,1,,BAO_0000218,Intermediate,1088.0,9971,Dose required to lower urine osmolality to 300 mOsm/kg in rat,A,,,Rattus norvegicus,10116.0,
9929,1,,BAO_0000218,Intermediate,1088.0,9971,Dose required to lower urine osmolality to 300 mOsm/kg in rat; NT=Not tested,A,,,Rattus norvegicus,10116.0,
9930,1,,BAO_0000218,Intermediate,,5765,% Bioavailability after 1 day of the drug administration in rats,A,In vivo,,Rattus norvegicus,10116.0,
9931,1,,BAO_0000218,Intermediate,,5765,% Bioavailability after 4 day of the drug administration in rats,A,In vivo,,Rattus norvegicus,10116.0,
9932,1,,BAO_0000218,Intermediate,,4257,Absolute bioavailability was evaluated in rat,A,In vivo,,Rattus norvegicus,10116.0,
9933,1,,BAO_0000218,Intermediate,,13091,Tissue biodistribution into estrogen-primed immature female rat fat at 1 hr low time interval,A,,,Rattus norvegicus,10116.0,
9934,1,,BAO_0000218,Intermediate,,13091,Tissue biodistribution into estrogen-primed immature female rat fat at 1 hr time interval,A,,,Rattus norvegicus,10116.0,
9935,1,,BAO_0000218,Intermediate,,13091,Tissue biodistribution into estrogen-primed immature female rat fat at 3 hr time interval,A,,,Rattus norvegicus,10116.0,
9936,1,,BAO_0000218,Intermediate,2113.0,13091,Tissue biodistribution into estrogen-primed immature female rat kidney at 1 hr blocked time interval,A,,,Rattus norvegicus,10116.0,
9937,1,,BAO_0000218,Intermediate,2113.0,13091,Tissue biodistribution into estrogen-primed immature female rat kidney at 1 hr low time interval,A,,,Rattus norvegicus,10116.0,
9938,1,,BAO_0000218,Intermediate,2113.0,13091,Tissue biodistribution into estrogen-primed immature female rat kidney at 1 hr time interval,A,,,Rattus norvegicus,10116.0,
9939,1,,BAO_0000218,Intermediate,2113.0,13091,Tissue biodistribution into estrogen-primed immature female rat kidney at 3 hr time interval,A,,,Rattus norvegicus,10116.0,
9940,1,,BAO_0000218,Intermediate,2107.0,13091,Tissue biodistribution into estrogen-primed immature female rat liver at 1 hr blocked time interval,A,,,Rattus norvegicus,10116.0,
9941,1,,BAO_0000218,Intermediate,2107.0,13091,Tissue biodistribution into estrogen-primed immature female rat liver at 1 hr low time interval,A,,,Rattus norvegicus,10116.0,
9942,1,,BAO_0000218,Intermediate,2107.0,13091,Tissue biodistribution into estrogen-primed immature female rat liver at 1 hr time interval,A,,,Rattus norvegicus,10116.0,
9943,1,,BAO_0000218,Intermediate,2107.0,13091,Tissue biodistribution into estrogen-primed immature female rat liver at 3 hr time interval,A,,,Rattus norvegicus,10116.0,
9944,1,,BAO_0000218,Intermediate,,13091,Tissue biodistribution into estrogen-primed immature female rat lung at 1 hr blocked time interval,A,,,Rattus norvegicus,10116.0,
9945,1,,BAO_0000218,Intermediate,,13091,Tissue biodistribution into estrogen-primed immature female rat lung at 1 hr low time interval,A,,,Rattus norvegicus,10116.0,
9946,1,,BAO_0000218,Intermediate,,13091,Tissue biodistribution into estrogen-primed immature female rat lung at 1 hr time interval,A,,,Rattus norvegicus,10116.0,
9947,1,,BAO_0000218,Intermediate,,13091,Tissue biodistribution into estrogen-primed immature female rat lung at 3 hr time interval,A,,,Rattus norvegicus,10116.0,
9948,1,,BAO_0000218,Intermediate,2385.0,13091,Tissue biodistribution into estrogen-primed immature female rat muscle at 1 hr blocked time interval,A,,,Rattus norvegicus,10116.0,
9949,1,,BAO_0000218,Intermediate,2385.0,13091,Tissue biodistribution into estrogen-primed immature female rat muscle at 1 hr low time interval,A,,,Rattus norvegicus,10116.0,
9950,1,,BAO_0000218,Intermediate,2385.0,13091,Tissue biodistribution into estrogen-primed immature female rat muscle at 1 hr time interval,A,,,Rattus norvegicus,10116.0,
9951,1,,BAO_0000218,Intermediate,2385.0,13091,Tissue biodistribution into estrogen-primed immature female rat muscle at 3 hr time interval,A,,,Rattus norvegicus,10116.0,
9952,1,,BAO_0000218,Intermediate,,13091,Tissue biodistribution into estrogen-primed immature female rat ovaries at 1 hr blocked time interval,A,,,Rattus norvegicus,10116.0,
9953,1,,BAO_0000218,Intermediate,992.0,13091,Tissue biodistribution into estrogen-primed immature female rat ovaries at 1 hr low time interval,A,,,Rattus norvegicus,10116.0,
9954,1,,BAO_0000218,Intermediate,992.0,13091,Tissue biodistribution into estrogen-primed immature female rat ovaries at 1 hr time interval,A,,,Rattus norvegicus,10116.0,
9955,1,,BAO_0000218,Intermediate,992.0,13091,Tissue biodistribution into estrogen-primed immature female rat ovaries at 3 hr time interval,A,,,Rattus norvegicus,10116.0,
9956,1,,BAO_0000218,Intermediate,995.0,13091,Tissue biodistribution into estrogen-primed immature female rat uterus at 1 hr blocked time interval,A,,,Rattus norvegicus,10116.0,
9957,1,,BAO_0000218,Intermediate,995.0,13091,Tissue biodistribution into estrogen-primed immature female rat uterus at 1 hr low time interval,A,,,Rattus norvegicus,10116.0,
9958,1,,BAO_0000218,Intermediate,995.0,13091,Tissue biodistribution into estrogen-primed immature female rat uterus at 1 hr time interval,A,,,Rattus norvegicus,10116.0,
9959,1,,BAO_0000218,Intermediate,995.0,13091,Tissue biodistribution into estrogen-primed immature female rat uterus at 3 hr time interval,A,,,Rattus norvegicus,10116.0,
9960,1,,BAO_0000218,Intermediate,,13091,Tissue biodistribution into estrogen-primed immature female rat uterus/blood at 1 hr blocked time interval,A,,,Rattus norvegicus,10116.0,
9961,1,,BAO_0000218,Intermediate,,13091,Tissue biodistribution into estrogen-primed immature female rat uterus/blood at 1 hr low time interval,A,,,Rattus norvegicus,10116.0,
9962,1,,BAO_0000218,Intermediate,,13091,Tissue biodistribution into estrogen-primed immature female rat uterus/blood at 1 hr time interval,A,,,Rattus norvegicus,10116.0,
9963,1,,BAO_0000218,Intermediate,,13091,Tissue biodistribution into estrogen-primed immature female rat uterus/blood at 3 hr time interval,A,,,Rattus norvegicus,10116.0,
9964,1,,BAO_0000218,Intermediate,2385.0,13091,Tissue biodistribution into estrogen-primed immature female rat uterus/muscle at 1 hr blocked time interval,A,,,Rattus norvegicus,10116.0,
9965,1,,BAO_0000218,Intermediate,2385.0,13091,Tissue biodistribution into estrogen-primed immature female rat uterus/muscle at 1 hr low time interval,A,,,Rattus norvegicus,10116.0,
9966,1,,BAO_0000218,Intermediate,2385.0,13091,Tissue biodistribution into estrogen-primed immature female rat uterus/muscle at 1 hr time interval,A,,,Rattus norvegicus,10116.0,
9967,1,,BAO_0000218,Intermediate,2385.0,13091,Tissue biodistribution into estrogen-primed immature female rat uterus/muscle at 3 hr time interval,A,,,Rattus norvegicus,10116.0,
9968,1,,BAO_0000218,Intermediate,,11977,Dissociation constant was determined,A,,,Rattus norvegicus,10116.0,
9969,1,,BAO_0000218,Intermediate,,14941,"Pharmacokinetic Parameter, Kel is elimination rate constant in Female Wistar Rats at 100 mg/kg by po administration",A,,,Rattus norvegicus,10116.0,
9970,1,,BAO_0000218,Intermediate,,15078,"The Kel value in female wistar rat at 100 mg/kg, p.o. dose",A,,,Rattus norvegicus,10116.0,
9971,1,,BAO_0000218,Intermediate,,15078,"The Kel value in male wistar rat at 100 mg/kg, p.o. dose",A,,,Rattus norvegicus,10116.0,
9972,1,,BAO_0000218,Intermediate,,4755,Observed rate constant in 80% rat plasma at 37 degree Centigrade,A,,,Rattus norvegicus,10116.0,
9973,1,,BAO_0000218,Intermediate,,589,LogP value was evaluated in the in situ rat gut perfusion assay,A,,,Rattus norvegicus,10116.0,
9974,1,,BAO_0000218,Intermediate,,17582,In vivo retention time was evaluated for the compound after i.v. administration at a dose of 5 mg/kg was measured in rats,A,In vivo,,Rattus norvegicus,10116.0,
9975,1,,BAO_0000218,Intermediate,,5031,Mean residence time (Pharmacokinetic property) after i.v. administration in rats,A,In vivo,,Rattus norvegicus,10116.0,
9976,1,,BAO_0000218,Intermediate,,17764,Mean-residence time of compound after intravenous administration in rats at 24 uM/kg,A,In vivo,,Rattus norvegicus,10116.0,
9977,1,,BAO_0000218,Intermediate,,17720,Mean residence time at a dose of 4 mg/kg in Rat Plasma after iv administration,A,,,Rattus norvegicus,10116.0,
9978,1,,BAO_0000218,Expert,,2862,Streptococcal cell wall-washed arthritis model in rats at 10.0 mg/kg peroral dose,F,,,Rattus norvegicus,10116.0,
9979,1,,BAO_0000218,Intermediate,,16423,Half-life was evaluated after 10 uM/kg of intra arterial administration,A,,,Rattus norvegicus,10116.0,
9980,1,,BAO_0000218,Intermediate,,16423,Half-life was evaluated after 20 uM/kg of peroral administration,A,In vivo,,Rattus norvegicus,10116.0,
9981,1,,BAO_0000218,Intermediate,,6005,Half-life was evaluated after i.v. administration in rat at a dose of 1 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,
9982,1,,BAO_0000218,Intermediate,1969.0,2938,Half-life was evaluated in plasma of rat,A,,,Rattus norvegicus,10116.0,
9983,1,,BAO_0000218,Intermediate,,6410,Half-life was evaluated in rats at an intravenous dose of 3 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,
9984,1,,BAO_0000218,Intermediate,,6410,Half-life was evaluated in rats at an oral dose of 30 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,
9985,1,,BAO_0000218,Intermediate,,6062,Half-life was measured in rat after an iv dose of 1 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,
9986,1,,BAO_0000218,Intermediate,,6571,Half-life period of compound in rats after peroral administration,A,In vivo,,Rattus norvegicus,10116.0,
9987,1,,BAO_0000218,Intermediate,1969.0,3136,Half-life period of compound was measured in rat plasma.,A,,,Rattus norvegicus,10116.0,
9988,1,,BAO_0000218,Intermediate,1969.0,3136,Half-life period of compound was measured in rat plasma; ND is not determined,A,,,Rattus norvegicus,10116.0,
9989,1,,BAO_0000218,Intermediate,1969.0,3136,Half-life period of compound was measured in rat plasma; not determined,A,,,Rattus norvegicus,10116.0,
9990,1,,BAO_0000218,Intermediate,,4521,Half-life period in rat after 5 mg/kg by oral and 1 mg/kg by intravenous administration,A,In vivo,,Rattus norvegicus,10116.0,
9991,1,,BAO_0000218,Intermediate,,5871,Half-life period in rat by iv administration,A,In vivo,,Rattus norvegicus,10116.0,
9992,1,,BAO_0000218,Intermediate,,6077,Half-life period in rats following intravenous administration at 2 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,
9993,1,,BAO_0000218,Intermediate,,6679,Half-life period was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,A,In vivo,,Rattus norvegicus,10116.0,
9994,1,,BAO_0000218,Intermediate,,5144,Half-life period was determined for the compound in rat,A,,,Rattus norvegicus,10116.0,
9995,1,,BAO_0000218,Intermediate,,4498,"Half-life period was evaluated in rat, after administering 1 mg/kg intravenously",A,In vivo,,Rattus norvegicus,10116.0,
9996,1,,BAO_0000218,Intermediate,,4498,"Half-life period was evaluated in rat, after administering 10 mg/kg orally",A,In vivo,,Rattus norvegicus,10116.0,
9997,1,,BAO_0000218,Intermediate,,1908,Half-life value after IV dose at a dose of 5 mg/kg in rats.,A,In vivo,,Rattus norvegicus,10116.0,
9998,1,,BAO_0000218,Intermediate,,6211,Half-life was determined by iv administration (1.5 mg/kg) in fasted male Sprague-Dawley rats,A,In vivo,,Rattus norvegicus,10116.0,
9999,1,,BAO_0000218,Intermediate,,5529,Half-life was determined in rat after intravenous administration (0.5 mg/kg),A,In vivo,,Rattus norvegicus,10116.0,
10000,1,,BAO_0000218,Intermediate,,6444,Half-life was determined in rat at a dose of 1 mpk i.v.,A,In vivo,,Rattus norvegicus,10116.0,
10001,1,,BAO_0000218,Intermediate,,6444,Half-life was determined in rat at a dose of 1 mpk i.v.; ND means not determined,A,In vivo,,Rattus norvegicus,10116.0,
10002,1,,BAO_0000218,Intermediate,,6444,Half-life was determined in rat at a dose of 1 mpk i.v.; ND=not determined,A,In vivo,,Rattus norvegicus,10116.0,
10003,1,,BAO_0000218,Intermediate,,5207,Half-life in rat,A,,,Rattus norvegicus,10116.0,
10004,1,,BAO_0000218,Intermediate,1969.0,530,In vitro half life in rat plasma,A,In vitro,,Rattus norvegicus,10116.0,
10005,1,,BAO_0000218,Intermediate,1969.0,1116,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in rat plasma",A,In vitro,,Rattus norvegicus,10116.0,
10006,1,,BAO_0000218,Intermediate,,3219,In vitro half life in rat,A,In vitro,,Rattus norvegicus,10116.0,
10007,1,,BAO_0000218,Intermediate,,6109,In vivo half life period after intravenous administration in rat,A,In vivo,,Rattus norvegicus,10116.0,
10008,1,,BAO_0000218,Intermediate,,17582,In vivo half-life period for compound after i.v. administration at a dose of 5 mg/kg was measured in rats,A,In vivo,,Rattus norvegicus,10116.0,
10009,1,,BAO_0000218,Intermediate,,17582,In vivo half-life period for compound after oral (po) administration at a dose of 10 mg/kg was measured in rats,A,In vivo,,Rattus norvegicus,10116.0,
10010,1,,BAO_0000218,Intermediate,,5974,In vivo t1/2 was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0,
10011,1,,BAO_0000218,Intermediate,,5974,In vivo t1/2 was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0,
10012,1,,BAO_0000218,Intermediate,,5974,In vivo t1/2 was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0,
10013,1,,BAO_0000218,Intermediate,,5974,In vivo t1/2 was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0,
10014,1,,BAO_0000218,Intermediate,,17853,Longer half-life in rat (i.v.) at 0.5 mpk,A,In vivo,,Rattus norvegicus,10116.0,
10015,1,,BAO_0000218,Intermediate,,17853,Longer half-life in rat (p.o.) at 2.0 mpk,A,In vivo,,Rattus norvegicus,10116.0,
10016,1,,BAO_0000218,Intermediate,,3457,Pharmacokinetic property (half life) in rat,A,,,Rattus norvegicus,10116.0,
10017,1,,BAO_0000218,Intermediate,,2792,Pharmacokinetic parameter half-life was determined at 10 mg/kg po dose in rats,A,In vivo,,Rattus norvegicus,10116.0,
10018,1,,BAO_0000218,Intermediate,,2792,Pharmacokinetic parameter half-life was determined at 2 mg/kg i.v. dose in rats,A,In vivo,,Rattus norvegicus,10116.0,
10019,1,,BAO_0000218,Intermediate,,2792,Pharmacokinetic parameter half-life was determined at 3 mg/kg po dose in rats,A,In vivo,,Rattus norvegicus,10116.0,
10020,1,,BAO_0000218,Intermediate,,2792,Pharmacokinetic parameter half-life was determined at 5 mg/kg i.v. dose in rats,A,In vivo,,Rattus norvegicus,10116.0,
10021,1,,BAO_0000218,Intermediate,,5739,Pharmacokinetic property (t1/2) for the compound (5 mg/kg iv) was determined in rats,A,In vivo,,Rattus norvegicus,10116.0,
10022,1,,BAO_0000218,Intermediate,,15765,Pharmacokinetic half time was determined intravenously in rats.,A,In vivo,,Rattus norvegicus,10116.0,
10023,1,,BAO_0000218,Intermediate,1969.0,6567,Plasma half life in rat after 5 mg/kg oral gavage; 6-8 hours,A,In vivo,,Rattus norvegicus,10116.0,
10024,1,,BAO_0000218,Intermediate,1969.0,2448,Plasma half life of hydrolysis of the compound,A,,,Rattus norvegicus,10116.0,
10025,1,,BAO_0000218,Intermediate,1969.0,5423,Plasma half life was reported after a intravenous dose of 1 mg/kg in Dawley rat,A,In vivo,,Rattus norvegicus,10116.0,
10026,1,,BAO_0000218,Intermediate,1969.0,4853,Plasma half life period was calculated in rat,A,,,Rattus norvegicus,10116.0,
10027,1,,BAO_0000218,Intermediate,1969.0,4514,Plasma half-life in Sprague-Dawley rats,A,,,Rattus norvegicus,10116.0,
10028,1,,BAO_0000218,Intermediate,1969.0,4514,Plasma half-life in Sprague-Dawley rats; Not determined,A,,,Rattus norvegicus,10116.0,
10029,1,,BAO_0000218,Intermediate,1969.0,1500,Plasma half-life in rats,A,,,Rattus norvegicus,10116.0,
10030,1,,BAO_0000218,Intermediate,1969.0,1500,Plasma half-life in rats; <MQL,A,,,Rattus norvegicus,10116.0,
10031,1,,BAO_0000218,Intermediate,1969.0,5334,Plasma half-life period (0-8 h) was determined,A,,,Rattus norvegicus,10116.0,
10032,1,,BAO_0000218,Intermediate,1969.0,5334,Plasma half-life period (0-8 h) was determined in Sprague-Dawley rat,A,,,Rattus norvegicus,10116.0,
10033,1,,BAO_0000218,Intermediate,1969.0,5334,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0,
10034,1,,BAO_0000218,Intermediate,1969.0,5334,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg in Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0,
10035,1,,BAO_0000218,Intermediate,1969.0,4956,Plasma half-life was determined in Sprague-Dawley rats after 0-8 h administration of the compound,A,,,Rattus norvegicus,10116.0,
10036,1,,BAO_0000218,Intermediate,1969.0,4956,Plasma half-life was determined in Sprague-Dawley rats after 0-8 hr administration of the compound; Not determined,A,,,Rattus norvegicus,10116.0,
10037,1,,BAO_0000218,Intermediate,178.0,7768,"Distribution of radioactivity in blood of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range = 0.68-1.03",A,,,Rattus norvegicus,10116.0,
10038,1,,BAO_0000218,Intermediate,178.0,7768,"Distribution of radioactivity in blood of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.45-0.48",A,,,Rattus norvegicus,10116.0,
10039,1,,BAO_0000218,Intermediate,178.0,7768,"Distribution of radioactivity in blood of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range-0.81-1",A,,,Rattus norvegicus,10116.0,
10040,1,,BAO_0000218,Intermediate,,7768,"Distribution of radioactivity in brain tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.007-0.008",A,,,Rattus norvegicus,10116.0,
10041,1,,BAO_0000218,Intermediate,,7768,"Distribution of radioactivity in brain tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.18-0.22",A,,,Rattus norvegicus,10116.0,
10042,1,,BAO_0000218,Intermediate,,7768,"Distribution of radioactivity in brain tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.77-0.97",A,,,Rattus norvegicus,10116.0,
10043,1,,BAO_0000218,Intermediate,,7768,"Distribution of radioactivity in brain tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.08-0.13",A,,,Rattus norvegicus,10116.0,
10044,1,,BAO_0000218,Intermediate,,7768,"Distribution of radioactivity in brain tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.25-0.37",A,,,Rattus norvegicus,10116.0,
10045,1,,BAO_0000218,Intermediate,,7768,"Distribution of radioactivity in brain tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.03-0.04",A,,,Rattus norvegicus,10116.0,
10046,1,,BAO_0000218,Intermediate,,7768,"Distribution of radioactivity in brain tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.74-0.94",A,,,Rattus norvegicus,10116.0,
10047,1,,BAO_0000218,Intermediate,948.0,7768,"Distribution of radioactivity in heart tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.02-0.02",A,,,Rattus norvegicus,10116.0,
10048,1,,BAO_0000218,Intermediate,948.0,7768,"Distribution of radioactivity in heart tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.5-0.63",A,,,Rattus norvegicus,10116.0,
10049,1,,BAO_0000218,Intermediate,948.0,7768,"Distribution of radioactivity in heart tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 1.35-1.55",A,,,Rattus norvegicus,10116.0,
10050,1,,BAO_0000218,Intermediate,948.0,7768,"Distribution of radioactivity in heart tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.24-0.38",A,,,Rattus norvegicus,10116.0,
10051,1,,BAO_0000218,Intermediate,948.0,7768,"Distribution of radioactivity in heart tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.55-0.82",A,,,Rattus norvegicus,10116.0,
10052,1,,BAO_0000218,Intermediate,948.0,7768,"Distribution of radioactivity in heart tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.16-0.2",A,,,Rattus norvegicus,10116.0,
10053,1,,BAO_0000218,Intermediate,948.0,7768,"Distribution of radioactivity in heart tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 1.13-1.29",A,,,Rattus norvegicus,10116.0,
10054,1,,BAO_0000218,Intermediate,2107.0,7768,"Distribution of radioactivity in liver tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.02-0.02",A,,,Rattus norvegicus,10116.0,
10055,1,,BAO_0000218,Intermediate,2107.0,7768,"Distribution of radioactivity in liver tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.71-0.93",A,,,Rattus norvegicus,10116.0,
10056,1,,BAO_0000218,Intermediate,2107.0,7768,"Distribution of radioactivity in liver tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 2.91-3.53",A,,,Rattus norvegicus,10116.0,
10057,1,,BAO_0000218,Intermediate,2107.0,7768,"Distribution of radioactivity in liver tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.42-0.62",A,,,Rattus norvegicus,10116.0,
10058,1,,BAO_0000218,Intermediate,2107.0,7768,"Distribution of radioactivity in liver tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.97-1.41",A,,,Rattus norvegicus,10116.0,
10059,1,,BAO_0000218,Intermediate,2107.0,7768,"Distribution of radioactivity in liver tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.19-0.23",A,,,Rattus norvegicus,10116.0,
10060,1,,BAO_0000218,Intermediate,2107.0,7768,"Distribution of radioactivity in liver tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 2.49-2.82",A,,,Rattus norvegicus,10116.0,
10061,1,,BAO_0000218,Intermediate,2048.0,7768,"Distribution of radioactivity in lung tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.02-0.03",A,,,Rattus norvegicus,10116.0,
10062,1,,BAO_0000218,Intermediate,2048.0,7768,"Distribution of radioactivity in lung tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.66-0.77",A,,,Rattus norvegicus,10116.0,
10063,1,,BAO_0000218,Intermediate,2048.0,7768,"Distribution of radioactivity in lung tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 1.17-1.42",A,,,Rattus norvegicus,10116.0,
10064,1,,BAO_0000218,Intermediate,2048.0,7768,"Distribution of radioactivity in lung tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.47-0.58",A,,,Rattus norvegicus,10116.0,
10065,1,,BAO_0000218,Intermediate,2048.0,7768,"Distribution of radioactivity in lung tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.65-0.87",A,,,Rattus norvegicus,10116.0,
10066,1,,BAO_0000218,Intermediate,2048.0,7768,"Distribution of radioactivity in lung tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.28-0.31",A,,,Rattus norvegicus,10116.0,
10067,1,,BAO_0000218,Intermediate,2048.0,7768,"Distribution of radioactivity in lung tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.98-1.22",A,,,Rattus norvegicus,10116.0,
10068,1,,BAO_0000218,Intermediate,2046.0,7768,"Distribution of radioactivity in thyroid tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 406-499",A,,,Rattus norvegicus,10116.0,
10069,1,,BAO_0000218,Intermediate,2046.0,7768,"Distribution of radioactivity in thyroid tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 53.0-96",A,,,Rattus norvegicus,10116.0,
10070,1,,BAO_0000218,Intermediate,2046.0,7768,"Distribution of radioactivity in thyroid tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 6.65-8.0.8",A,,,Rattus norvegicus,10116.0,
10071,1,,BAO_0000218,Intermediate,2046.0,7768,"Distribution of radioactivity in thyroid tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 92-159",A,,,Rattus norvegicus,10116.0,
10072,1,,BAO_0000218,Intermediate,2046.0,7768,"Distribution of radioactivity in thyroid tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 18.74-30.84",A,,,Rattus norvegicus,10116.0,
10073,1,,BAO_0000218,Intermediate,2046.0,7768,"Distribution of radioactivity in thyroid tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 156-207",A,,,Rattus norvegicus,10116.0,
10074,1,,BAO_0000218,Intermediate,,4498,"Bioavailability (F) was evaluated in rat, after administering 1 mg/kg intravenously",A,In vivo,,Rattus norvegicus,10116.0,
10075,1,,BAO_0000218,Intermediate,,4498,"Bioavailability (F) was evaluated in rat, after administering 10 mg/kg orally",A,In vivo,,Rattus norvegicus,10116.0,
10076,1,,BAO_0000218,Intermediate,,3603,Bioavailability after a dose of 10 mg/kg p.o.,A,In vivo,,Rattus norvegicus,10116.0,
10077,1,,BAO_0000218,Intermediate,,6215,Bioavailability after peroral administration (10 mg/kg) was determined in rat,A,In vivo,,Rattus norvegicus,10116.0,
10078,1,,BAO_0000218,Intermediate,,5710,Bioavailability in fasted male administration of 2 mg/Kg of compound p.o.,A,In vivo,,Rattus norvegicus,10116.0,
10079,1,,BAO_0000218,Intermediate,,5710,Oral bioavailability in rat (Sprague-Dawley) (fasted male) (dose 2 mg/kg),A,In vivo,,Rattus norvegicus,10116.0,
10080,1,,BAO_0000218,Intermediate,,5676,Bioavailability in rat po was determined,A,In vivo,,Rattus norvegicus,10116.0,
10081,1,,BAO_0000218,Intermediate,,17667,Bioavailability of compound at 10 mg/kg in rat after oral administration,A,In vivo,,Rattus norvegicus,10116.0,
10082,1,,BAO_0000218,Intermediate,,17667,Bioavailability of compound at 3 mg/kg in rat after i.v. administration,A,In vivo,,Rattus norvegicus,10116.0,
10083,1,,BAO_0000218,Intermediate,,6848,Bioavailability in rat (dose 1 mg/kg i.v. and 2 mg/kg p.o.),A,In vivo,,Rattus norvegicus,10116.0,
10084,1,,BAO_0000218,Intermediate,,6848,Bioavailability in rat (dose 1 mg/kg i.v. and 2 mg/kg p.o.),A,In vivo,,Rattus norvegicus,10116.0,
10085,1,,BAO_0000218,Intermediate,,17267,Bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,
10086,1,,BAO_0000218,Intermediate,,6362,Bioavailability in rat (Sprague-Dawley) (female),A,In vivo,,Rattus norvegicus,10116.0,
10087,1,,BAO_0000218,Intermediate,,17671,Bioavailability in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,
10088,1,,BAO_0000218,Intermediate,,17671,Bioavailability in rat (Sprague-Dawley) (male) (dose 10-20 mg/kg),A,In vivo,,Rattus norvegicus,10116.0,
10089,1,,BAO_0000218,Intermediate,,4333,Bioavailability in rat (Sprague-Dawley) (male) (dose 1 mg/kg i.v. and 3 mg/kg p.o.) measured from 0.3 to 6 hr,A,In vivo,,Rattus norvegicus,10116.0,
10090,1,,BAO_0000218,Intermediate,,6077,Bioavailability in rat at an oral dose of 2 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,
10091,1,,BAO_0000218,Intermediate,,3278,Bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,
10092,1,,BAO_0000218,Intermediate,,5964,Bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,
10093,1,,BAO_0000218,Intermediate,,4884,Bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,
10094,1,,BAO_0000218,Intermediate,,4905,Bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,
10095,1,,BAO_0000218,Intermediate,,4884,Bioavailability in rat was reported at the dose of 6 mg/kg in 25% PEG-300,A,In vivo,,Rattus norvegicus,10116.0,
10096,1,,BAO_0000218,Intermediate,,6850,Bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,
10097,1,,BAO_0000218,Intermediate,,2864,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,
10098,1,,BAO_0000218,Intermediate,,5780,Bioavailability was determined in rat,A,In vivo,,Rattus norvegicus,10116.0,
10099,1,,BAO_0000218,Intermediate,,1465,Bioavailability,A,In vivo,,Rattus norvegicus,10116.0,
10100,1,,BAO_0000218,Intermediate,,5199,Bioavailability,A,In vivo,,Rattus norvegicus,10116.0,
10101,1,,BAO_0000218,Intermediate,,5765,Bioavailability in rat after 1 day dosing,A,In vivo,,Rattus norvegicus,10116.0,
10102,1,,BAO_0000218,Intermediate,,5765,Bioavailability in rat after 4 day dosing,A,In vivo,,Rattus norvegicus,10116.0,
10103,1,,BAO_0000218,Intermediate,,6518,Bioavailability after IV dosing at 0.5 mg/kg in rat; no data,A,In vivo,,Rattus norvegicus,10116.0,
10104,1,,BAO_0000218,Intermediate,,6518,Bioavailability after IV dosing at 1 mg/kg in rat; no data,A,In vivo,,Rattus norvegicus,10116.0,
10105,1,,BAO_0000218,Intermediate,,6518,Bioavailability after oral administration at a dose of 2 mg/kg in rat,A,In vivo,,Rattus norvegicus,10116.0,
10106,1,,BAO_0000218,Intermediate,,6518,Bioavailability after oral administration at a dose of 4 mg/kg in rat,A,In vivo,,Rattus norvegicus,10116.0,
10107,1,,BAO_0000218,Intermediate,,2083,Bioavailability at 4 hr after administration of 5 mg/kg dose peroral in rat,A,In vivo,,Rattus norvegicus,10116.0,
10108,1,,BAO_0000218,Intermediate,,17260,Bioavailability at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,A,In vivo,,Rattus norvegicus,10116.0,
10109,1,,BAO_0000218,Intermediate,,4956,Bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v. and 2 mg/kg p.o.),A,In vivo,,Rattus norvegicus,10116.0,
10110,1,,BAO_0000218,Intermediate,,4368,Bioavailability by intravenous administration of 3.4 mg/kg in rat,A,In vivo,,Rattus norvegicus,10116.0,
10111,1,,BAO_0000218,Intermediate,1969.0,17752,Bioavailability from rat plasma at a single oral dose of 25 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,
10112,1,,BAO_0000218,Intermediate,,1446,Bioavailability in rat (Fisher) (fasted),A,In vivo,,Rattus norvegicus,10116.0,
10113,0,,BAO_0000218,Intermediate,,2891,Bioavailability in monkey after po administration of 10 mg/kg dose,A,In vivo,,Primates,9443.0,
10114,0,,BAO_0000218,Intermediate,,2891,Oral bioavailability in monkey (dose 10 mg/kg),A,In vivo,,Primates,9443.0,
10115,1,,BAO_0000218,Intermediate,,6672,Bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,
10116,1,,BAO_0000218,Intermediate,,6673,Bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,
10117,1,,BAO_0000218,Intermediate,,17655,Bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,
10118,1,,BAO_0000218,Intermediate,,17796,Bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,
10119,1,,BAO_0000218,Intermediate,,17853,Bioavailability in rat (dose 2.0 mg/kg p.o.),A,In vivo,,Rattus norvegicus,10116.0,
10120,1,,BAO_0000218,Intermediate,,4521,Bioavailability in rat (dose 5 mg/kg p.o. and 1 mg/kg i.v.),A,In vivo,,Rattus norvegicus,10116.0,
10121,1,,BAO_0000218,Intermediate,,4940,Oral bioavailability in rat (dose 5 mg/kg p.o.),A,In vivo,,Rattus norvegicus,10116.0,
10122,0,,BAO_0000218,Intermediate,,2891,Bioavailability in rat after po administration of 30 mg/kg dose,A,In vivo,,Rattus norvegicus,10116.0,
10123,0,,BAO_0000218,Intermediate,,2891,Bioavailability in rat after po administration of 30 mg/kg dose,A,In vivo,,Rattus norvegicus,10116.0,
10124,1,,BAO_0000218,Intermediate,,4521,Bioavailability in rat after 5 mg/kg by oral and 1 mg/kg by intravenous administration,A,In vivo,,Rattus norvegicus,10116.0,
10125,1,,BAO_0000218,Intermediate,,17686,Bioavailability in rat (dose 2 mg/kg i.v.),A,In vivo,,Rattus norvegicus,10116.0,
10126,1,,BAO_0000218,Intermediate,,17796,Bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,
10127,1,,BAO_0000218,Intermediate,1969.0,17796,Bioavailability in rat; Only traces detected in rat plasma,A,In vivo,,Rattus norvegicus,10116.0,
10128,1,,BAO_0000218,Intermediate,,5064,Bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,
10129,1,,BAO_0000218,Intermediate,,5147,Bioavailability upon oral administration of compound,A,In vivo,,Rattus norvegicus,10116.0,
10130,1,,BAO_0000218,Intermediate,,1916,Oral bioavailability in rat (Sprague-Dawley) (dose 15 mg/kg),A,In vivo,,Rattus norvegicus,10116.0,
10131,1,,BAO_0000218,Intermediate,,6049,Bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,
10132,1,,BAO_0000218,Intermediate,,1445,"Bioavailability was evaluated in rats at a dose of 20 mg/kg, under fasting state",A,In vivo,,Rattus norvegicus,10116.0,
10133,1,,BAO_0000218,Intermediate,,1445,"Bioavailability was evaluated in rats at a dose of 20 mg/kg, under fed state",A,In vivo,,Rattus norvegicus,10116.0,
10134,1,,BAO_0000218,Expert,,2862,Streptococcal cell wall-washed arthritis model in rats at 3.0 mg/kg peroral dose,F,,,Rattus norvegicus,10116.0,
10135,1,,BAO_0000218,Expert,,2862,Streptococcal cell wall-washed arthritis model in rats at 30.0 mg/kg peroral dose,F,,,Rattus norvegicus,10116.0,
10136,1,,BAO_0000218,Intermediate,,4194,In vitro and metabolic stability was determined,A,,,Rattus norvegicus,10116.0,
10137,1,,BAO_0000218,Intermediate,,4194,In vitro metabolic stability in rat hepatocytes,A,,,Rattus norvegicus,10116.0,
10138,1,,BAO_0000218,Intermediate,,5486,In vitro metabolic stability in rat was measured as pmol/min/mg/protein,A,,,Rattus norvegicus,10116.0,
10139,1,,BAO_0000218,Intermediate,2107.0,17582,Metabolic rate for compound was observed in rat hepatocytes,A,In vitro,,Rattus norvegicus,10116.0,
10140,1,,BAO_0000218,Intermediate,,5600,In vitro metabolic stability determined after 30 min of incubation in rat hepatic microsomes,A,,,Rattus norvegicus,10116.0,
10141,1,,BAO_0000218,Intermediate,,14294,Metabolism of compound in rat S9 microsomes ('+''indicates <20% largest observed peak),A,,,Rattus norvegicus,10116.0,
10142,1,,BAO_0000218,Intermediate,,14294,Metabolism of compound in rat S9 microsomes ('++++' indicates largest observed peak),A,,,Rattus norvegicus,10116.0,
10143,1,,BAO_0000218,Intermediate,,14294,Metabolism of compound in rat S9 microsomes; Trace,A,,,Rattus norvegicus,10116.0,
10144,1,,BAO_0000218,Intermediate,,17847,Metabolism was measured as percent loss at 4 hr in rat hepatocytes,A,,,Rattus norvegicus,10116.0,
10145,1,,BAO_0000218,Intermediate,,11020,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex 5-HIAA,A,,,Rattus norvegicus,10116.0,
10146,1,,BAO_0000218,Intermediate,,11020,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex 5-HT,A,,,Rattus norvegicus,10116.0,
10147,1,,BAO_0000218,Intermediate,,11020,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex DA,A,,,Rattus norvegicus,10116.0,
10148,1,,BAO_0000218,Intermediate,,11020,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex DOPAC,A,,,Rattus norvegicus,10116.0,
10149,1,,BAO_0000218,Intermediate,,11020,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex HVA,A,,,Rattus norvegicus,10116.0,
10150,1,,BAO_0000218,Intermediate,,11020,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex NE,A,,,Rattus norvegicus,10116.0,
10151,1,,BAO_0000218,Intermediate,,11020,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Hippocampus 5-HIAA,A,,,Rattus norvegicus,10116.0,
10152,1,,BAO_0000218,Intermediate,,11020,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus 5-HT,A,,,Rattus norvegicus,10116.0,
10153,1,,BAO_0000218,Intermediate,,11020,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus DA; below level of detection,A,,,Rattus norvegicus,10116.0,
10154,1,,BAO_0000218,Intermediate,,11020,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus DA; below the levels of detection,A,,,Rattus norvegicus,10116.0,
10155,1,,BAO_0000218,Intermediate,,11020,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus DOPAC; below level of detection,A,,,Rattus norvegicus,10116.0,
10156,1,,BAO_0000218,Intermediate,,11020,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus DOPAC; below the levels of detection,A,,,Rattus norvegicus,10116.0,
10157,1,,BAO_0000218,Intermediate,,11020,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus HVA; below level of detection,A,,,Rattus norvegicus,10116.0,
10158,1,,BAO_0000218,Intermediate,,11020,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus HVA; below the levels of detection,A,,,Rattus norvegicus,10116.0,
10159,1,,BAO_0000218,Intermediate,,11020,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus NE,A,,,Rattus norvegicus,10116.0,
10160,1,,BAO_0000218,Intermediate,,11020,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex 5-HIAA,A,,,Rattus norvegicus,10116.0,
10161,1,,BAO_0000218,Intermediate,,11020,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex 5-HT,A,,,Rattus norvegicus,10116.0,
10162,1,,BAO_0000218,Intermediate,,11020,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex DA,A,,,Rattus norvegicus,10116.0,
10163,1,,BAO_0000218,Intermediate,,11020,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex DOPAC,A,,,Rattus norvegicus,10116.0,
10164,1,,BAO_0000218,Intermediate,,11020,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex HVA,A,,,Rattus norvegicus,10116.0,
10165,1,,BAO_0000218,Intermediate,,11020,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex NE,A,,,Rattus norvegicus,10116.0,
10166,1,,BAO_0000218,Intermediate,,11020,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex DA,A,,,Rattus norvegicus,10116.0,
10167,1,,BAO_0000218,Intermediate,,11020,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus 5-HIAA,A,,,Rattus norvegicus,10116.0,
10168,1,,BAO_0000218,Intermediate,,11020,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus 5-HT,A,,,Rattus norvegicus,10116.0,
10169,1,,BAO_0000218,Intermediate,,11020,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus DA; below level of detection,A,,,Rattus norvegicus,10116.0,
10170,1,,BAO_0000218,Intermediate,,11020,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus DA; below the levels of detection,A,,,Rattus norvegicus,10116.0,
10171,1,,BAO_0000218,Intermediate,,11020,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus DOPAC; below level of detection,A,,,Rattus norvegicus,10116.0,
10172,1,,BAO_0000218,Intermediate,,11020,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus DOPAC; below the levels of detection,A,,,Rattus norvegicus,10116.0,
10173,1,,BAO_0000218,Intermediate,,11020,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus HVA; below level of detection,A,,,Rattus norvegicus,10116.0,
10174,1,,BAO_0000218,Intermediate,1969.0,4969,Plasma half-life was determined in Sprague-Dawley rats after 0-8 hr of administration,A,,,Rattus norvegicus,10116.0,
10175,1,,BAO_0000218,Intermediate,1969.0,6737,Stability in rat plasma was determined,A,,,Rattus norvegicus,10116.0,
10176,1,,BAO_0000218,Intermediate,1969.0,6737,Stability in rat plasma was determined; ND= no data,A,,,Rattus norvegicus,10116.0,
10177,1,,BAO_0000218,Intermediate,1969.0,5089,Tested for plasma half life period in rat (0-8 hr),A,,,Rattus norvegicus,10116.0,
10178,1,,BAO_0000218,Intermediate,1969.0,5089,Tested for plasma half life period in rat (0-8 hr); Not determined,A,,,Rattus norvegicus,10116.0,
10179,1,,BAO_0000218,Intermediate,,1466,Tested for t1/2 upon intravenous administration of 5.0 mg/Kg dose in rat,A,In vivo,,Rattus norvegicus,10116.0,
10180,1,,BAO_0000218,Intermediate,,1466,Tested for t1/2 upon peroral administration of 10.0 mg/Kg dose in rat,A,In vivo,,Rattus norvegicus,10116.0,
10181,1,,BAO_0000218,Intermediate,,4950,Tested for the half life in rat,A,,,Rattus norvegicus,10116.0,
10182,1,,BAO_0000218,Intermediate,,2412,Tested in vitro for the time for half reactivation against rat small intestinal glucoamylase,A,In vitro,,Rattus norvegicus,10116.0,
10183,1,,BAO_0000218,Intermediate,,2412,Tested in vitro for the time for half reactivation against rat small intestinal glucoamylase; ND=Not determined,A,In vitro,,Rattus norvegicus,10116.0,
10184,1,,BAO_0000218,Intermediate,,2412,Tested in vitro for the time for half reactivation against rat small intestinal isomaltase,A,In vitro,,Rattus norvegicus,10116.0,
10185,1,,BAO_0000218,Intermediate,,2412,Tested in vitro for the time for half reactivation against rat small intestinal isomaltase; ND=Not determined,A,In vitro,,Rattus norvegicus,10116.0,
10186,1,,BAO_0000218,Intermediate,,2412,Tested in vitro for the time for half reactivation against rat small intestinal sucrase,A,In vitro,,Rattus norvegicus,10116.0,
10187,1,,BAO_0000218,Intermediate,,15022,The biological half life the compound was measured at the dose of 100 umol/kg,A,,,Rattus norvegicus,10116.0,
10188,1,,BAO_0000218,Intermediate,,15022,The biological half life the compound was measured at the dose of 30 umol/kg,A,,,Rattus norvegicus,10116.0,
10189,1,,BAO_0000218,Intermediate,1969.0,406,The compound was evaluated for plasma half life period in rat,A,,,Rattus norvegicus,10116.0,
10190,1,,BAO_0000218,Intermediate,,15078,"The half life value in female wistar rat at 100 mg/kg, p.o. dose",A,In vivo,,Rattus norvegicus,10116.0,
10191,1,,BAO_0000218,Intermediate,,15078,"The half life value in male wistar rat at 100 mg/kg, p.o. dose",A,In vivo,,Rattus norvegicus,10116.0,
10192,1,,BAO_0000218,Intermediate,,5247,The pharmacokinetic parameter half-life period in vivo in rats,A,In vivo,,Rattus norvegicus,10116.0,
10193,1,,BAO_0000218,Intermediate,,5041,"The pharmacokinetic property, Half-life was determined",A,In vivo,,Rattus norvegicus,10116.0,
10194,1,,BAO_0000218,Intermediate,,5041,"The pharmacokinetic property, Half-life in rat in vivo",A,In vivo,,Rattus norvegicus,10116.0,
10195,1,,BAO_0000218,Intermediate,,5041,"The pharmacokinetic property, Half-life was determined; ND denotes no data",A,In vivo,,Rattus norvegicus,10116.0,
10196,1,,BAO_0000218,Intermediate,,5041,"The pharmacokinetic property, Half-life was determined; ND denotes not determined",A,In vivo,,Rattus norvegicus,10116.0,
10197,1,,BAO_0000218,Intermediate,1969.0,3918,The plasma half life period in rats,A,,,Rattus norvegicus,10116.0,
10198,1,,BAO_0000218,Intermediate,2107.0,2906,The release rate of the free drug from the substrate in rat liver lysosomal preparation by rat liver lysosomal assay,A,,,Rattus norvegicus,10116.0,
10199,1,,BAO_0000218,Intermediate,,6467,half life in rats at the dose of 1.0 mpk by i.v. administration; ND= not determined,A,In vivo,,Rattus norvegicus,10116.0,
10200,1,,BAO_0000218,Intermediate,,5510,t1/2 (apparent elimination)of the compound was determined,A,,,Rattus norvegicus,10116.0,
10201,1,,BAO_0000218,Intermediate,,3788,t1/2 value in rat,A,,,Rattus norvegicus,10116.0,
10202,1,,BAO_0000218,Intermediate,,17796,Half life in rat,A,,,Rattus norvegicus,10116.0,
10203,1,,BAO_0000218,Intermediate,1969.0,12873,"Half life period calculated from Time-Course plasma concentrations in rats at a dose of 2.5 mg/kg, iv",A,In vivo,,Rattus norvegicus,10116.0,
10204,1,,BAO_0000218,Intermediate,,5983,Pharmacokinetic property (t1/2beta) was measured in rat at the dose of 0.32 mg/kg i.v.,A,In vivo,,Rattus norvegicus,10116.0,
10205,1,,BAO_0000218,Intermediate,,15765,Half-life period in fasted rats,A,,,Rattus norvegicus,10116.0,
10206,1,,BAO_0000218,Intermediate,,2661,Compound was evaluated for maximum time to reach Cmax after treatment with oral dose of 2 mgkg to female wistar rats,A,In vivo,,Rattus norvegicus,10116.0,
10207,1,,BAO_0000218,Intermediate,,2661,Compound was evaluated for maximum time to reach Cmax after treatment with oral dose of 2 mgkg to male wistar rats,A,In vivo,,Rattus norvegicus,10116.0,
10208,1,,BAO_0000218,Intermediate,,429,Evaluated for pharmacokinetic parameter tmax in rat at the dose 50 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,
10209,1,,BAO_0000218,Intermediate,,17655,Maximum time required to achieve Cmax was determined in rat,A,,,Rattus norvegicus,10116.0,
10210,1,,BAO_0000218,Intermediate,,17717,Time calculated to reach Cmax at a concentration of 15 mg/kg perorally in rats along with 100 mg/kg of compound 11,A,In vivo,,Rattus norvegicus,10116.0,
10211,1,,BAO_0000218,Intermediate,,17717,Time calculated to reach Cmax at a concentration of 60 mg/kg perorally in rats along with 100 mg/kg of compound 11,A,In vivo,,Rattus norvegicus,10116.0,
10212,1,,BAO_0000218,Intermediate,,17717,Time calculated to reach Cmax at a concentration of 60 mg/kg perorally in rats along with control,A,In vivo,,Rattus norvegicus,10116.0,
10213,1,,BAO_0000218,Intermediate,,6570,Time to reach maximum concentration in rat after 2 mg/kg peroral administration,A,In vivo,,Rattus norvegicus,10116.0,
10214,1,,BAO_0000218,Intermediate,,6570,Time to reach maximum concentration in rat after 2 mg/kg peroral administration; 4-6,A,In vivo,,Rattus norvegicus,10116.0,
10215,1,,BAO_0000218,Intermediate,,5978,Tmax of compound (19.2 mg/kg) after po administration was determined in Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0,
10216,1,,BAO_0000218,Intermediate,,5978,Tmax of compound (19.76 mg/kg) after po administration was determined in Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0,
10217,1,,BAO_0000218,Intermediate,,5978,Tmax of compound (20.73 mg/kg) after po administration was determined in Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0,
10218,1,,BAO_0000218,Intermediate,,5978,Tmax of compound (25 mg/kg) after po administration was determined in Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0,
10219,1,,BAO_0000218,Intermediate,1969.0,17720,Tmax at a dose of 4 mg/kg in Rat Plasma after iv administration,A,In vivo,,Rattus norvegicus,10116.0,
10220,1,,BAO_0000218,Intermediate,,4723,Tmax determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,A,In vivo,,Rattus norvegicus,10116.0,
10221,1,,BAO_0000218,Intermediate,,4723,Tmax determined after 3 mg/kg oral administration in potassium oxonate treated rats,A,In vivo,,Rattus norvegicus,10116.0,
10222,1,,BAO_0000218,Intermediate,,4756,Tmax at the dose of 2 mg/Kg administered perorally in rats,A,In vivo,,Rattus norvegicus,10116.0,
10223,1,,BAO_0000218,Intermediate,,4756,Tmax at the dose of 5 mg/Kg administered perorally in rats,A,In vivo,,Rattus norvegicus,10116.0,
10224,1,,BAO_0000218,Intermediate,1969.0,17720,tmax at a dose of 100 mg/kg in Rat Plasma after iv administration,A,In vivo,,Rattus norvegicus,10116.0,
10225,1,,BAO_0000218,Intermediate,1969.0,17720,tmax at a dose of 50 mg/kg in Rat Plasma after iv administration,A,In vivo,,Rattus norvegicus,10116.0,
10226,1,,BAO_0000218,Intermediate,,1466,tmax upon peroral administration of 10.0 mg/Kg dose in rat,A,In vivo,,Rattus norvegicus,10116.0,
10227,1,,BAO_0000218,Intermediate,,7449,Percent total excretion of 3-(thiomethyl)acetaminophen glucuronide,F,,,Rattus norvegicus,10116.0,
10228,1,,BAO_0000218,Intermediate,,7449,Percent total excretion of 3-(thiomethyl)acetaminophen sulfate,F,,,Rattus norvegicus,10116.0,
10229,1,,BAO_0000218,Intermediate,,7449,Percent total excretion of 3-methoxyacetaminophen glucuronide,F,,,Rattus norvegicus,10116.0,
10230,1,,BAO_0000218,Intermediate,,7449,Percent total excretion of N-methoxyacetaminophen glucuronide,F,,,Rattus norvegicus,10116.0,
10231,1,,BAO_0000218,Intermediate,,7449,Percent total excretion of N-methoxyacetaminophen sulfate,F,,,Rattus norvegicus,10116.0,
10232,1,,BAO_0000218,Intermediate,,7449,Percent total excretion of acetaminophen,F,,,Rattus norvegicus,10116.0,
10233,1,,BAO_0000218,Intermediate,2046.0,7768,"Distribution of radioactivity in thyroid tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 6.19-7.22",A,,,Rattus norvegicus,10116.0,
10234,1,,BAO_0000218,Intermediate,,17655,"Percent instability was measured by Rat S9 liver slice metabolism assay, in vitro",A,,,Rattus norvegicus,10116.0,
10235,1,,BAO_0000218,Intermediate,,17735,Plasma clearance following 10 mg/kg intravenous or 50 mg/kg oral dosing in rats,A,,,Rattus norvegicus,10116.0,
10236,1,,BAO_0000218,Intermediate,,5960,Plasma concentration at 4 hr after 30 mg/kg post dosing in rat using HPLC/MS,A,,,Rattus norvegicus,10116.0,
10237,1,,BAO_0000218,Intermediate,,17735,Volume of distribution following 10 mg/kg intravenous or 50 mg/kg oral dosing in rats was determined,A,,,Rattus norvegicus,10116.0,
10238,1,,BAO_0000218,Intermediate,,7116,Compound was tested for antidiuretic activity in rats,A,,,Rattus norvegicus,10116.0,
10239,1,,BAO_0000218,Intermediate,1969.0,4878,AUC in rat after 3mg/kg oral dose,A,In vivo,,Rattus norvegicus,10116.0,
10240,1,,BAO_0000218,Intermediate,,5939,Ratio in brain to that of rat plasma for 2 hr after peroral administration at 10 mg/kg,A,,,Rattus norvegicus,10116.0,
10241,1,,BAO_0000218,Intermediate,,5939,Ratio in brain to that of rat plasma for 2 hr after peroral administration at 5 mg/kg,A,,,Rattus norvegicus,10116.0,
10242,1,,BAO_0000218,Intermediate,,16367,Bioavailability administered orally at a dose of 10 mg/kg to rats,A,,,Rattus norvegicus,10116.0,
10243,1,,BAO_0000218,Intermediate,,16366,Oral Bioavailability was determined,A,,,Rattus norvegicus,10116.0,
10244,1,,BAO_0000218,Intermediate,,4426,Oral bioavailability in rat,A,,,Rattus norvegicus,10116.0,
10245,1,,BAO_0000218,Intermediate,,4426,Oral bioavailability in rat; Not performed.,A,,,Rattus norvegicus,10116.0,
10246,1,,BAO_0000218,Intermediate,,5041,Bioavailability,A,,,Rattus norvegicus,10116.0,
10247,1,,BAO_0000218,Intermediate,,5041,Bioavailability was determined; ND denotes no data,A,,,Rattus norvegicus,10116.0,
10248,1,,BAO_0000218,Intermediate,,1500,Biliary excretion when administered intravenously at a dose of 2.5 mg/kg in rats,A,,,Rattus norvegicus,10116.0,
10249,1,,BAO_0000218,Intermediate,,1500,Biliary excretion when administered intravenously at a dose of 5 mg/kg in rats,A,,,Rattus norvegicus,10116.0,
10250,1,,BAO_0000218,Intermediate,,17409,Binding towards rat plasma protein at 10 uM,A,,,Rattus norvegicus,10116.0,
10251,1,,BAO_0000218,Intermediate,,17409,Binding towards rat plasma protein at 100 uM,A,,,Rattus norvegicus,10116.0,
10252,1,,BAO_0000218,Intermediate,,2959,Bioavailability in rat (dose 20 mg/kg p.o.),A,In vivo,,Rattus norvegicus,10116.0,
10253,1,,BAO_0000218,Intermediate,,13501,Bioavailability was determined after oral administration of compound 18 at a dose of 4 mg/kg to rat,A,In vivo,,Rattus norvegicus,10116.0,
10254,1,,BAO_0000218,Intermediate,,6567,Bioavailability in rat after 5 mg/kg oral gavage,A,In vivo,,Rattus norvegicus,10116.0,
10255,1,,BAO_0000218,Intermediate,,6571,Bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,
10256,1,,BAO_0000218,Intermediate,,6715,Bioavailability in rat (dose 1 mg/kg i.v.),A,In vivo,,Rattus norvegicus,10116.0,
10257,1,,BAO_0000218,Intermediate,,6715,Bioavailability in rat (dose 3 mg/kg p.o.),A,In vivo,,Rattus norvegicus,10116.0,
10258,1,,BAO_0000218,Intermediate,,2932,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,
10259,1,,BAO_0000218,Intermediate,,4171,Bioavailability of the compound in rats after administration of 30 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,
10260,1,,BAO_0000218,Intermediate,,17509,Bioavailability after administration of 10 mg/kg in rats,A,In vivo,,Rattus norvegicus,10116.0,
10261,1,,BAO_0000218,Intermediate,,17509,Bioavailability after administration of 2 mg/kg in rats,A,In vivo,,Rattus norvegicus,10116.0,
10262,1,,BAO_0000218,Intermediate,,4527,Bioavailability by oral administration at a dose of 100 uM/kg in rat was determined,A,In vivo,,Rattus norvegicus,10116.0,
10263,1,,BAO_0000218,Intermediate,,4026,Bioavailability in dogs was determined; high,A,In vivo,,Rattus norvegicus,10116.0,
10264,1,,BAO_0000218,Intermediate,,6659,Bioavailability in monkey after intravenous administration at 1 mpk,A,In vivo,,Rattus norvegicus,10116.0,
10265,1,,BAO_0000218,Intermediate,,6659,Bioavailability in monkey after peroral administration at 10 mpk,A,In vivo,,Rattus norvegicus,10116.0,
10266,1,,BAO_0000218,Intermediate,,6659,Bioavailability in rat after intravenous administration at 1 mpk,A,In vivo,,Rattus norvegicus,10116.0,
10267,1,,BAO_0000218,Intermediate,,6659,Bioavailability in rat after intravenous administration at 2 mpk,F,In vivo,,Rattus norvegicus,10116.0,
10268,1,,BAO_0000218,Intermediate,,6659,Bioavailability in rat after peroral administration at 30 mpk,A,In vivo,,Rattus norvegicus,10116.0,
10269,1,,BAO_0000218,Intermediate,,6659,Bioavailability in rat after peroral administration at at 100 mpk,F,In vivo,,Rattus norvegicus,10116.0,
10270,1,,BAO_0000218,Intermediate,,6597,Bioavailability in rats was evaluated,A,In vivo,,Rattus norvegicus,10116.0,
10271,1,,BAO_0000218,Intermediate,,1202,Bioavailability was calculated after an intravenous dose of 0.3 mg/Kg in rats after 6 hr,A,In vivo,,Rattus norvegicus,10116.0,
10272,1,,BAO_0000218,Intermediate,,1202,Bioavailability was calculated after an intravenous dose of 1 mg/Kg in rats after 6 hr,A,In vivo,,Rattus norvegicus,10116.0,
10273,1,,BAO_0000218,Intermediate,,1202,Bioavailability was calculated after peroral dose of 3.0 mg/Kg in rats after 4 hr,A,In vivo,,Rattus norvegicus,10116.0,
10274,1,,BAO_0000218,Intermediate,,1202,Bioavailability was calculated after peroral dose of 3.0 mg/Kg in rats after 6 hr,A,In vivo,,Rattus norvegicus,10116.0,
10275,1,,BAO_0000218,Intermediate,,5207,Bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,
10276,1,,BAO_0000218,Intermediate,,5970,Bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,
10277,1,,BAO_0000218,Intermediate,,17538,Oral bioavailability in rat (dose 10 mg/kg),A,In vivo,,Rattus norvegicus,10116.0,
10278,1,,BAO_0000218,Intermediate,,17538,Bioavailability in rat after po administration at a dose of 10 mg/kg; nd is not determined,A,In vivo,,Rattus norvegicus,10116.0,
10279,1,,BAO_0000218,Intermediate,,1466,Bioavailability upon peroral administration of 10.0 mg/Kg dose in rat,A,In vivo,,Rattus norvegicus,10116.0,
10280,1,,BAO_0000218,Intermediate,,2879,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,
10281,1,,BAO_0000218,Intermediate,,2879,Bioavailability was measured in rat after oral administration; 2-4,A,In vivo,,Rattus norvegicus,10116.0,
10282,1,,BAO_0000218,Intermediate,,2879,Bioavailability was measured in rat after oral administration; 3-7,A,In vivo,,Rattus norvegicus,10116.0,
10283,1,,BAO_0000218,Intermediate,,3777,Bioavailability in rat (intraduodenal administration),A,In vivo,,Rattus norvegicus,10116.0,
10284,1,,BAO_0000218,Intermediate,,3777,Bioavailability in rat (intraduodenal administration),A,In vivo,,Rattus norvegicus,10116.0,
10285,1,,BAO_0000218,Intermediate,,3777,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,
10286,1,,BAO_0000218,Intermediate,,3777,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,
10287,1,,BAO_0000218,Intermediate,,5423,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg p.o.),A,In vivo,,Rattus norvegicus,10116.0,
10288,1,,BAO_0000218,Intermediate,,16365,Bioavailability was evaluated when a dose of 3 mg/kg was administered orally,A,In vivo,,Rattus norvegicus,10116.0,
10289,1,,BAO_0000218,Intermediate,,16365,Bioavailability was evaluated when a dose of 3 mg/kg was administered orally to a fasting rat,A,In vivo,,Rattus norvegicus,10116.0,
10290,1,,BAO_0000218,Intermediate,,4239,Bioavailability was measured in rat,A,In vivo,,Rattus norvegicus,10116.0,
10291,1,,BAO_0000218,Intermediate,,5438,Bioavailability was reported,A,In vivo,,Rattus norvegicus,10116.0,
10292,1,,BAO_0000218,Intermediate,,5334,Bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),A,In vivo,,Rattus norvegicus,10116.0,
10293,1,,BAO_0000218,Intermediate,,5334,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg),A,In vivo,,Rattus norvegicus,10116.0,
10294,1,,BAO_0000218,Intermediate,,4199,Bioavailability was determined upon 10 mg/kg in 1% methylcellulose peroral administration in rats,A,In vivo,,Rattus norvegicus,10116.0,
10295,1,,BAO_0000218,Intermediate,,4199,Bioavailability in rat (dose 2 mg/kg in 1% methylcellulose p.o.),A,In vivo,,Rattus norvegicus,10116.0,
10296,1,,BAO_0000218,Intermediate,,4199,Bioavailability in rat (dose 3 mg/kg in 1% methylcellulose ),A,In vivo,,Rattus norvegicus,10116.0,
10297,1,,BAO_0000218,Intermediate,,4890,Bioavailability was determined after intravenous administration at a dose 5 mg/kg to male Sprague-Dawley rats,A,In vivo,,Rattus norvegicus,10116.0,
10298,1,,BAO_0000218,Intermediate,,2792,Bioavailability was determined at 3 mg/kg po dose in rats,A,In vivo,,Rattus norvegicus,10116.0,
10299,1,,BAO_0000218,Intermediate,,5529,Oral bioavailability in rat (dose 2 mg/kg),A,In vivo,,Rattus norvegicus,10116.0,
10300,1,,BAO_0000218,Intermediate,,6685,"Bioavailability was determined in rats at 10 mg/kg, p.o. dose",A,In vivo,,Rattus norvegicus,10116.0,
10301,1,,BAO_0000218,Intermediate,,6685,"Bioavailability was determined in rats at 20 mg/kg, i.p. dose; n/a: not applicable",A,In vivo,,Rattus norvegicus,10116.0,
10302,1,,BAO_0000218,Intermediate,,6685,"Bioavailability was determined in rats at 2 mg/kg, i.v. dose; n/a: not applicable",A,In vivo,,Rattus norvegicus,10116.0,
10303,1,,BAO_0000218,Intermediate,,6005,Bioavailability was evaluated in rat after peroral administration at a dose of 1 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,
10304,1,,BAO_0000218,Intermediate,,6410,Bioavailability was evaluated in rats at an intravenous dose of 3 mg/kg; Not applicable,A,In vivo,,Rattus norvegicus,10116.0,
10305,1,,BAO_0000218,Intermediate,,6410,Bioavailability was evaluated in rats at an oral dose of 30 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,
10306,1,,BAO_0000218,Intermediate,,6103,Bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,
10307,1,,BAO_0000218,Intermediate,,6410,Bioavailability was evaluated in rats at an intravenous dose of 3 mg/kg; Not applicable,A,In vivo,,Rattus norvegicus,10116.0,
10308,1,,BAO_0000218,Intermediate,,6410,Bioavailability was evaluated in rats at an oral dose of 30 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,
10309,1,,BAO_0000218,Intermediate,,5353,Bioavailability in rat (Sprague-Dawley),A,In vivo,,Rattus norvegicus,10116.0,
10310,1,,BAO_0000218,Intermediate,,4727,Bioavailability in rat at the dose of 2 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,
10311,1,,BAO_0000218,Intermediate,,17804,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,
10312,1,,BAO_0000218,Intermediate,,5809,Bioavailability in rat (cannulated) (dose 2 mg/kg),A,In vivo,,Rattus norvegicus,10116.0,
10313,1,,BAO_0000218,Intermediate,,17804,Bioavailability value of compound in rats was determined after peroral administration,A,In vivo,,Rattus norvegicus,10116.0,
10314,1,,BAO_0000218,Intermediate,,3634,Oral bioavailability in rat (dose 20 mg/kg),A,In vivo,,Rattus norvegicus,10116.0,
10315,1,,BAO_0000218,Intermediate,,3341,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,
10316,1,,BAO_0000218,Intermediate,,2690,Oral bioavailability in rat (dose 5 mg/kg),A,In vivo,,Rattus norvegicus,10116.0,
10317,1,,BAO_0000218,Intermediate,,3184,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,
10318,1,,BAO_0000218,Intermediate,,740,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,
10319,1,,BAO_0000218,Intermediate,,1806,Compound was evaluated for oral bioavailability in rats; 15-27 %,A,In vivo,,Rattus norvegicus,10116.0,
10320,1,,BAO_0000218,Intermediate,,4891,Compound was evaluated for pharmacokinetic parameter percent bioavailability at 18 h,A,In vivo,,Rattus norvegicus,10116.0,
10321,1,,BAO_0000218,Intermediate,,3634,Compound was evaluated for pharmacokinetic property in rats after an oral dose of 10 mg/kg and the value was reported as oral bioavailability (F),A,In vivo,,Rattus norvegicus,10116.0,
10322,1,,BAO_0000218,Intermediate,,64,Compound was tested for bioavailability in rats,A,In vivo,,Rattus norvegicus,10116.0,
10323,1,,BAO_0000218,Intermediate,,4839,Bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,
10324,1,,BAO_0000218,Intermediate,,1094,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,
10325,0,,BAO_0000218,Intermediate,,5005,Compound was tested for oral bioavailability in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po.,A,In vivo,,Macaca mulatta,9544.0,
10326,0,,BAO_0000218,Intermediate,,5005,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v. and 2 mg/kg p.o.),A,In vivo,,Rattus norvegicus,10116.0,
10327,1,,BAO_0000218,Intermediate,,4687,Evaluated for the bioavailability in rat (in vivo),A,In vivo,,Rattus norvegicus,10116.0,
10328,1,,BAO_0000218,Intermediate,,17804,F value of compound in rats was determined after peroral administration,A,In vivo,,Rattus norvegicus,10116.0,
10329,1,,BAO_0000218,Intermediate,,5974,In vivo Oral bioavailability (F)was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0,
10330,1,,BAO_0000218,Intermediate,,5974,In vivo Oral bioavailability (F)was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0,
10331,1,,BAO_0000218,Intermediate,,5974,In vivo Oral bioavailability (F)was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0,
10332,1,,BAO_0000218,Intermediate,,5974,In vivo Oral bioavailability (F)was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0,
10333,1,,BAO_0000218,Intermediate,,1088,"In vivo percent of absolute bioavailability obtained from blood plasma levels analyzed by means of GC/MS (dose 5 uM/kg i.v. and 40 uM/kg, p.o.)",A,In vivo,,Rattus norvegicus,10116.0,
10334,1,,BAO_0000218,Intermediate,,1742,Maximum fall in carotid flow in rat,A,In vivo,,Rattus norvegicus,10116.0,
10335,1,,BAO_0000218,Intermediate,,4689,Oral Bioavailability after intravenous administration (1 mg/kg) in rat,A,In vivo,,Rattus norvegicus,10116.0,
10336,1,,BAO_0000218,Intermediate,,2463,Oral bioavailability in rat (dose 5 mg/kg),A,In vivo,,Rattus norvegicus,10116.0,
10337,1,,BAO_0000218,Intermediate,,5654,Oral bioavailability (F%) of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 16 mg/kg peroral administration,A,In vivo,,Rattus norvegicus,10116.0,
10338,1,,BAO_0000218,Intermediate,,5654,Oral bioavailability (F%) of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 20 mg/kg peroral administration,A,In vivo,,Rattus norvegicus,10116.0,
10339,1,,BAO_0000218,Intermediate,,6874,Oral bioavailability in rat (male Wistar),A,In vivo,,Rattus norvegicus,10116.0,
10340,1,,BAO_0000218,Intermediate,,5633,Oral bioavailability after administration (30 mg/kg) in rat; good,A,In vivo,,Rattus norvegicus,10116.0,
10341,1,,BAO_0000218,Intermediate,,5496,Oral bioavailability at the dose of 2 mg/kg in rat,A,In vivo,,Rattus norvegicus,10116.0,
10342,1,,BAO_0000218,Intermediate,,2358,Oral bioavailability determined in rats,A,In vivo,,Rattus norvegicus,10116.0,
10343,1,,BAO_0000218,Intermediate,,16456,Oral bioavailability in rat (Sprague-Dawley) (male) (dose 50 mg/kg p.o.),A,In vivo,,Rattus norvegicus,10116.0,
10344,1,,BAO_0000218,Intermediate,,5302,Oral bioavailability in rat (dose single 10 mg/kg),A,In vivo,,Rattus norvegicus,10116.0,
10345,1,,BAO_0000218,Intermediate,,5302,Oral bioavailability in rat (dose single 10 mg/kg),A,In vivo,,Rattus norvegicus,10116.0,
10346,1,,BAO_0000218,Intermediate,,5302,Oral bioavailability in rat (dose 5 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,
10347,1,,BAO_0000218,Intermediate,,11020,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus HVA; below the levels of detection,A,,,Rattus norvegicus,10116.0,
10348,1,,BAO_0000218,Intermediate,,11020,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus NE,A,,,Rattus norvegicus,10116.0,
10349,1,,BAO_0000218,Intermediate,,11020,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex 5-HIAA,A,,,Rattus norvegicus,10116.0,
10350,1,,BAO_0000218,Intermediate,,11020,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex 5-HT,A,,,Rattus norvegicus,10116.0,
10351,1,,BAO_0000218,Intermediate,,11020,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex DA,A,,,Rattus norvegicus,10116.0,
10352,1,,BAO_0000218,Intermediate,,11020,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex DOPAC,A,,,Rattus norvegicus,10116.0,
10353,1,,BAO_0000218,Intermediate,,11020,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex HVA,A,,,Rattus norvegicus,10116.0,
10354,1,,BAO_0000218,Intermediate,,11020,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex NE,A,,,Rattus norvegicus,10116.0,
10355,1,,BAO_0000218,Intermediate,,11020,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus 5-HIAA,A,,,Rattus norvegicus,10116.0,
10356,1,,BAO_0000218,Intermediate,,11020,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus 5-HT,A,,,Rattus norvegicus,10116.0,
10357,1,,BAO_0000218,Intermediate,,11020,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus DA; below level of detection,A,,,Rattus norvegicus,10116.0,
10358,1,,BAO_0000218,Intermediate,,11020,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus DA; below the levels of detection,A,,,Rattus norvegicus,10116.0,
10359,1,,BAO_0000218,Intermediate,,11020,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus DOPAC; below level of detection,A,,,Rattus norvegicus,10116.0,
10360,1,,BAO_0000218,Intermediate,,11020,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus DOPAC; below the levels of detection,A,,,Rattus norvegicus,10116.0,
10361,1,,BAO_0000218,Intermediate,,11020,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus HVA; below level of detection,A,,,Rattus norvegicus,10116.0,
10362,1,,BAO_0000218,Intermediate,,11020,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus HVA; below the levels of detection,A,,,Rattus norvegicus,10116.0,
10363,1,,BAO_0000218,Intermediate,,11020,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus NE,A,,,Rattus norvegicus,10116.0,
10364,1,,BAO_0000218,Intermediate,,11020,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex 5-HIAA",A,,,Rattus norvegicus,10116.0,
10365,1,,BAO_0000218,Intermediate,,11020,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex 5-HT",A,,,Rattus norvegicus,10116.0,
10366,1,,BAO_0000218,Intermediate,,11020,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex DA",A,,,Rattus norvegicus,10116.0,
10367,1,,BAO_0000218,Intermediate,,11020,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex DOPAC",A,,,Rattus norvegicus,10116.0,
10368,1,,BAO_0000218,Intermediate,,11020,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex HVA",A,,,Rattus norvegicus,10116.0,
10369,1,,BAO_0000218,Intermediate,,11020,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex NE",A,,,Rattus norvegicus,10116.0,
10370,1,,BAO_0000218,Intermediate,,11020,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus 5-HIAA",A,,,Rattus norvegicus,10116.0,
10371,1,,BAO_0000218,Intermediate,,11020,"Momoamine and metabolic levels observed at 3 h postdrug against, at a dose of 20 mg/kg Hippocampus 5-HT",A,,,Rattus norvegicus,10116.0,
10372,1,,BAO_0000218,Intermediate,,11020,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus DA; below the levels of detection",A,,,Rattus norvegicus,10116.0,
10373,1,,BAO_0000218,Intermediate,,11020,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus DOPAC; below the levels of detection",A,,,Rattus norvegicus,10116.0,
10374,1,,BAO_0000218,Intermediate,,11020,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus HVA; below the levels of detection",A,,,Rattus norvegicus,10116.0,
10375,1,,BAO_0000218,Intermediate,,11020,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus NE",A,,,Rattus norvegicus,10116.0,
10376,1,,BAO_0000218,Intermediate,,11020,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex 5-HIAA,A,,,Rattus norvegicus,10116.0,
10377,1,,BAO_0000218,Intermediate,,11020,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex 5-HT,A,,,Rattus norvegicus,10116.0,
10378,1,,BAO_0000218,Intermediate,,11020,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex DA,A,,,Rattus norvegicus,10116.0,
10379,1,,BAO_0000218,Intermediate,,11020,Momoamine and metabolic levels observed at 3 h postdrug against at a dose of 20 mg/kg Frontal cortex DOPAC,A,,,Rattus norvegicus,10116.0,
10380,1,,BAO_0000218,Intermediate,,11020,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex HVA,A,,,Rattus norvegicus,10116.0,
10381,1,,BAO_0000218,Intermediate,,11020,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex NE,A,,,Rattus norvegicus,10116.0,
10382,1,,BAO_0000218,Intermediate,,11020,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus 5-HIAA,A,,,Rattus norvegicus,10116.0,
10383,1,,BAO_0000218,Intermediate,,11020,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus 5-HT; below level of detection,A,,,Rattus norvegicus,10116.0,
10384,1,,BAO_0000218,Intermediate,,11020,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus DA; below level of detection,A,,,Rattus norvegicus,10116.0,
10385,1,,BAO_0000218,Intermediate,,11020,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus DOPAC; below level of detection,A,,,Rattus norvegicus,10116.0,
10386,1,,BAO_0000218,Intermediate,,11020,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus HVA; below level of detection,A,,,Rattus norvegicus,10116.0,
10387,1,,BAO_0000218,Intermediate,,7449,Percent total excretion of acetaminophen cysteine conjugate,F,,,Rattus norvegicus,10116.0,
10388,1,,BAO_0000218,Intermediate,,7449,Percent total excretion of acetaminophen glucuronide,F,,,Rattus norvegicus,10116.0,
10389,1,,BAO_0000218,Intermediate,,7449,Percent total excretion of acetaminophen sulfate,F,,,Rattus norvegicus,10116.0,
10390,1,,BAO_0000218,Intermediate,,7449,Percent total excretion of acetaminophen-mercapturic acid,F,,,Rattus norvegicus,10116.0,
10391,1,,BAO_0000218,Intermediate,1088.0,3172,Amount of urine output was measured in rat at a dose of 10 mg/kg administered orally,A,,,Rattus norvegicus,10116.0,
10392,1,,BAO_0000218,Intermediate,,16456,Volume of distribution in Male Sprague-Dawley rats after intravenous administration at a dose of 10 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,
10393,0,,BAO_0000218,Autocuration,2385.0,10839,Biodistribution of compound in rat muscle after 5 min of administration,A,In vivo,,ratrat,8656.0,
10394,0,,BAO_0000218,Autocuration,2385.0,10839,Biodistribution of compound in rat muscle after 5 min of administration.,A,In vivo,,ratrat,8656.0,
10395,0,,BAO_0000218,Autocuration,,5334,Plasma clearance was reported after intravenous administration at a dose of 1 mg/kg in Abraham sheep (female),A,In vivo,,Ovis aries,9940.0,
10396,0,,BAO_0000218,Autocuration,,5334,Plasma clearance was reported after oral administration at a dose of 2 mg/kg in Abraham sheep (female),A,In vivo,,Ovis aries,9940.0,
10397,0,,BAO_0000218,Autocuration,,5334,Bioavailability was reported after intravenous administration at a dose of 1 mg/kg in Abraham sheep (female),A,In vivo,,Ovis aries,9940.0,
10398,0,,BAO_0000218,Autocuration,,5334,Bioavailability was reported after oral administration at a dose of 2 mg/kg in Abraham sheep (female),A,In vivo,,Ovis aries,9940.0,
10399,0,,BAO_0000218,Autocuration,,5334,Volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Abraham sheep (female),A,In vivo,,Ovis aries,9940.0,
10400,0,,BAO_0000218,Autocuration,,5334,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Abraham sheep (female),A,In vivo,,Ovis aries,9940.0,
10401,0,,BAO_0000218,Autocuration,1969.0,5334,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Abraham sheep (female),A,In vivo,,Ovis aries,9940.0,
10402,0,,BAO_0000218,Autocuration,1969.0,5334,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg in Abraham sheep (female),A,In vivo,,Ovis aries,9940.0,
10403,1,,BAO_0000218,Intermediate,,1735,Biological half life period of compound was measured against snake venom phosphodiesterase (SVPDE),A,,,Serpentes,8570.0,
10404,1,,BAO_0000218,Intermediate,,1469,Half life (t) of enzymatic phosphodiester hydrolysis of compound towards snake venom (SV-PDE) at a concentration of 4 microg,A,,,Serpentes,8570.0,
10405,1,,BAO_0000218,Intermediate,,1336,Enzymatic stability was assessed with snake venom phosphodiesterase (SV PDE) exonuclase,A,,,Serpentes,8570.0,
10406,0,,BAO_0000366,Autocuration,1969.0,12403,The human biological plasma half life of the compound,A,,,Homo sapiens,9606.0,
10407,1,,BAO_0000218,Intermediate,1088.0,8151,Antidiuretic activity was determined expressed as volume of urine excreted in mL was reported at a dose of 100 mg/Kg,A,,,Rattus norvegicus,10116.0,
10408,1,,BAO_0000218,Intermediate,,8004,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 120 min after iv administration compound,A,,,Rattus norvegicus,10116.0,
10409,1,,BAO_0000218,Intermediate,,8004,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 15 after iv administration of compound,A,,,Rattus norvegicus,10116.0,
10410,1,,BAO_0000218,Intermediate,,8004,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 240 min after iv administration compound,A,,,Rattus norvegicus,10116.0,
10411,1,,BAO_0000218,Intermediate,,8004,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 30 min after iv administration of compound,A,,,Rattus norvegicus,10116.0,
10412,1,,BAO_0000218,Intermediate,,8004,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 5 min after iv administration of compound,A,,,Rattus norvegicus,10116.0,
10413,1,,BAO_0000218,Intermediate,,8004,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 60 min after iv administration of compound,A,,,Rattus norvegicus,10116.0,
10414,1,,BAO_0000218,Intermediate,,8004,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 120 min after iv administration compound,A,,,Rattus norvegicus,10116.0,
10415,1,,BAO_0000218,Intermediate,,8004,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 15 min after iv administration of compound,A,,,Rattus norvegicus,10116.0,
10416,1,,BAO_0000218,Intermediate,,8004,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 240 min after iv administration compound,A,,,Rattus norvegicus,10116.0,
10417,1,,BAO_0000218,Intermediate,,8004,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 30 min after iv administration of compound,A,,,Rattus norvegicus,10116.0,
10418,1,,BAO_0000218,Intermediate,,8004,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 5 min after iv administration of compound,A,,,Rattus norvegicus,10116.0,
10419,1,,BAO_0000218,Intermediate,,8004,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 60 min after iv administration of compound,A,,,Rattus norvegicus,10116.0,
10420,1,,BAO_0000218,Intermediate,,8004,Distribution of Se-75 activity in Liver of female Sprague-Dawley Rat 5 min after iv administration of compound,A,,,Rattus norvegicus,10116.0,
10421,1,,BAO_0000218,Intermediate,178.0,8004,Distribution of Se-75 activity in blood of female Sprague-Dawley Rat 120 min after iv administration of compound,A,,,Rattus norvegicus,10116.0,
10422,1,,BAO_0000218,Intermediate,178.0,8004,Distribution of Se-75 activity in blood of female Sprague-Dawley Rat 240 min after iv administration of compound,A,,,Rattus norvegicus,10116.0,
10423,9,,BAO_0000357,Expert,,15917,Dissociation constant against binding to human cyclophilin A,B,,,Homo sapiens,9606.0,
10424,8,,BAO_0000019,Expert,,12396,Michaelis-Menten constant for inhibitory activity against bovine liver glyoxalase II,B,,,Bos taurus,9913.0,
10425,0,,BAO_0000019,Autocuration,,7065,-Log C was determined by performing the electroshock minimum test,A,,,,,
10426,0,,BAO_0000019,Autocuration,,7065,-Log C was determined by performing the foot shock test,A,,,,,
10427,0,,BAO_0000019,Autocuration,,7065,-Log C was determined by performing the incl screen test,A,,,,,
10428,0,,BAO_0000019,Autocuration,,7065,-Log C was determined by performing the maximum electroshock test,A,,,,,
10429,0,,BAO_0000019,Autocuration,,7065,-Log C was determined by performing the pentylenetetrazole test,A,,,,,
10430,0,,BAO_0000019,Autocuration,,12415,Tested for experimental arotinoid inhibitory dose,A,,,,,
10431,0,,BAO_0000019,Autocuration,,10256,Negative log transformed activity,A,,,,,
10432,0,,BAO_0000019,Autocuration,,7991,"Negative log of Langmuir's alpha constant (-log alpha), which is inversely proportional to the effective binding constant (protein binding)",A,,,,,
10433,1,,BAO_0000218,Intermediate,,14342,Dissociation constant was evaluated on guinea pig bladder at M3 muscarinic receptor,A,,,Cavia porcellus,10141.0,
10434,1,,BAO_0000218,Intermediate,,14342,Dissociation constant was evaluated on guinea pig heart (force) at M2 muscarinic receptor,A,,,Cavia porcellus,10141.0,
10435,1,,BAO_0000218,Intermediate,,14342,Dissociation constant was evaluated on guinea pig heart (rate) at M2 muscarinic receptor,A,,,Cavia porcellus,10141.0,
10436,1,,BAO_0000218,Intermediate,2116.0,14342,Dissociation constant was evaluated on guinea pig ileum at M3 muscarinic receptor,A,,,Cavia porcellus,10141.0,
10437,0,,BAO_0000100,Autocuration,,6047,Solubility in water was determined; values expressed as -log,P,,,,,
10438,0,,BAO_0000019,Autocuration,,17269,Ratio of Kcat to that of Km was determined,A,,,,,
10439,0,,BAO_0000019,Autocuration,,10026,Observed first order rate constant,A,,,,,
10440,0,,BAO_0000019,Autocuration,,14583,Fraction of 88Y (%) released from chelate after incubation in serum for 15 hours,A,,,,,
10441,1,,BAO_0000218,Intermediate,,2661,Compound was evaluated for bioavailability after treatment with oral dose of 2 mgkg to female wistar rats,A,In vivo,,Rattus norvegicus,10116.0,
10442,1,,BAO_0000218,Intermediate,,2661,Compound was evaluated for bioavailability after treatment with oral dose of 2 mgkg to male wistar rats,A,In vivo,,Rattus norvegicus,10116.0,
10443,1,,BAO_0000218,Intermediate,,4029,Oral Bioavailability after administration of 10 mg/kg in male rat,A,In vivo,,Rattus norvegicus,10116.0,
10444,1,,BAO_0000218,Intermediate,,17735,Oral bioavailability in rat (dose 10 mg/kg i.v. and 50 mg/kg p.o.),A,In vivo,,Rattus norvegicus,10116.0,
10445,1,,BAO_0000218,Intermediate,,4576,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,
10446,1,,BAO_0000218,Intermediate,,17582,Oral bioavailability after oral (po) administration at a dose of 10 mg/kg was measured in rats,A,In vivo,,Rattus norvegicus,10116.0,
10447,1,,BAO_0000218,Intermediate,,17651,Oral bioavailability at 1 mg/kg was determined in rat,A,In vivo,,Rattus norvegicus,10116.0,
10448,1,,BAO_0000218,Intermediate,,17651,Oral bioavailability at 10 mg/kg was determined in rat,A,In vivo,,Rattus norvegicus,10116.0,
10449,1,,BAO_0000218,Intermediate,,17670,"Oral bioavailability in fischer rats at 30 mg/kg dose, administered perorally",A,In vivo,,Rattus norvegicus,10116.0,
10450,1,,BAO_0000218,Intermediate,,5045,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,
10451,1,,BAO_0000218,Intermediate,,1696,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,
10452,1,,BAO_0000218,Intermediate,,17764,Oral bioavailability after intravenous administration in rats at 24 uM/kg,A,In vivo,,Rattus norvegicus,10116.0,
10453,1,,BAO_0000218,Intermediate,,6448,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,
10454,1,,BAO_0000218,Intermediate,,6596,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,
10455,1,,BAO_0000218,Intermediate,,17547,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,
10456,1,,BAO_0000218,Intermediate,,17771,Oral bioavailability in rat at a dose of 3 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,
10457,1,,BAO_0000218,Intermediate,,6495,Oral bioavailability in rat after oral administration at 10 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,
10458,1,,BAO_0000218,Intermediate,,4558,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,
10459,1,,BAO_0000218,Intermediate,,17596,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,
10460,1,,BAO_0000218,Intermediate,,6827,Oral bioavailability in Dawley rats,A,In vivo,,Rattus norvegicus,10116.0,
10461,1,,BAO_0000218,Intermediate,,4026,Oral bioavailability,A,In vivo,,Rattus norvegicus,10116.0,
10462,1,,BAO_0000218,Intermediate,,10,Oral bioavailability in rat (dose 30 mg/kg),A,In vivo,,Rattus norvegicus,10116.0,
10463,1,,BAO_0000218,Intermediate,,17717,Bioavailability in rat at a concentration of 15 mg/kg perorally in rat along with 100 mg/kg 11,A,In vivo,,Rattus norvegicus,10116.0,
10464,1,,BAO_0000218,Intermediate,,17717,Bioavailability in rat (dose 3 mg/kg i.v.),A,In vivo,,Rattus norvegicus,10116.0,
10465,1,,BAO_0000218,Intermediate,,17717,Bioavailability in rat at a concentration of 60 mg/kg perorally in rat along with 100 mg/kg 11,A,In vivo,,Rattus norvegicus,10116.0,
10466,1,,BAO_0000218,Intermediate,,17717,Oral bioavailability in rat (dose 60 mg/kg p.o.),A,In vivo,,Rattus norvegicus,10116.0,
10467,1,,BAO_0000218,Intermediate,,4796,Percent oral bioavailability determined in rats,A,In vivo,,Rattus norvegicus,10116.0,
10468,1,,BAO_0000218,Intermediate,,4883,Tested for percent bioavailability after oral administration to Sprague-Dawley rat at dosage of 0.2 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,
10469,1,,BAO_0000218,Intermediate,,2137,The compound was evaluated for bioavailability in rats; 32-51,A,In vivo,,Rattus norvegicus,10116.0,
10470,1,,BAO_0000218,Intermediate,,2959,Bioavailability in rat (dose 20 mg/kg p.o.),A,In vivo,,Rattus norvegicus,10116.0,
10471,1,,BAO_0000218,Intermediate,,1361,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,
10472,1,,BAO_0000218,Intermediate,,4727,Bioavailability percent in rat at the dose of 2 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,
10473,1,,BAO_0000218,Intermediate,,16423,Bioavailability was evaluated after 20 uM/kg of peroral administration,A,In vivo,,Rattus norvegicus,10116.0,
10474,1,,BAO_0000218,Intermediate,,5206,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,
10475,1,,BAO_0000218,Intermediate,,6448,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,
10476,1,,BAO_0000218,Intermediate,,17723,Bioavailability in rats,A,In vivo,,Rattus norvegicus,10116.0,
10477,1,,BAO_0000218,Intermediate,178.0,17738,Biodistribution of radiolabeled compound in rat blood after 24 hr postinjection activity expressed as %ID/Organ,A,In vivo,,Rattus norvegicus,10116.0,
10478,1,,BAO_0000218,Intermediate,178.0,17738,Biodistribution of radiolabeled compound in rat blood after 24 hr activity expressed as %ID/Organ,A,In vivo,,Rattus norvegicus,10116.0,
10479,1,,BAO_0000218,Intermediate,178.0,17738,Biodistribution of radiolabeled compound in rat blood after 2 hr activity expressed as %ID/Organ,A,In vivo,,Rattus norvegicus,10116.0,
10480,1,,BAO_0000218,Intermediate,178.0,17738,Biodistribution of radiolabeled compound in rat blood after 30 min activity expressed as %ID/Organ,A,In vivo,,Rattus norvegicus,10116.0,
10481,1,,BAO_0000218,Intermediate,178.0,17738,Biodistribution of radiolabeled compound in rat blood after 5 min activity expressed as %ID/Organ,A,In vivo,,Rattus norvegicus,10116.0,
10482,1,,BAO_0000218,Intermediate,10000001.0,17738,Biodistribution of radiolabeled compound in rat bone after 24 hr activity expressed as %ID/Organ,A,In vivo,,Rattus norvegicus,10116.0,
10483,1,,BAO_0000218,Intermediate,10000001.0,17738,Biodistribution of radiolabeled compound in rat bone after 2 hr activity expressed as %ID/Organ,A,In vivo,,Rattus norvegicus,10116.0,
10484,1,,BAO_0000218,Intermediate,10000001.0,17738,Biodistribution of radiolabeled compound in rat bone after 30 min activity expressed as %ID/Organ,A,In vivo,,Rattus norvegicus,10116.0,
10485,1,,BAO_0000218,Intermediate,10000001.0,17738,Biodistribution of radiolabeled compound in rat bone after 5 min activity expressed as %ID/Organ,A,In vivo,,Rattus norvegicus,10116.0,
10486,1,,BAO_0000218,Intermediate,955.0,17738,Biodistribution of radiolabeled compound in rat brain after 24 hr activity expressed as %ID/Organ,A,In vivo,,Rattus norvegicus,10116.0,
10487,1,,BAO_0000218,Intermediate,955.0,17738,Biodistribution of radiolabeled compound in rat brain after 2 hr activity expressed as %ID/Organ,A,In vivo,,Rattus norvegicus,10116.0,
10488,1,,BAO_0000218,Intermediate,955.0,17738,Biodistribution of radiolabeled compound in rat brain after 30 min activity expressed as %ID/Organ,A,In vivo,,Rattus norvegicus,10116.0,
10489,1,,BAO_0000218,Intermediate,955.0,17738,Biodistribution of radiolabeled compound in rat brain after 5 min activity expressed as %ID/Organ,A,In vivo,,Rattus norvegicus,10116.0,
10490,1,,BAO_0000218,Intermediate,,17738,Biodistribution of radiolabeled compound in rat fat after 24 hr activity expressed as %ID/Organ,A,In vivo,,Rattus norvegicus,10116.0,
10491,1,,BAO_0000218,Intermediate,,17738,Biodistribution of radiolabeled compound in rat fat after 2 hr activity expressed as %ID/Organ,A,In vivo,,Rattus norvegicus,10116.0,
10492,1,,BAO_0000218,Intermediate,,17738,Biodistribution of radiolabeled compound in rat fat after 30 min activity expressed as %ID/Organ,A,In vivo,,Rattus norvegicus,10116.0,
10493,1,,BAO_0000218,Intermediate,,17738,Biodistribution of radiolabeled compound in rat fat after 5 min activity expressed as %ID/Organ,A,In vivo,,Rattus norvegicus,10116.0,
10494,1,,BAO_0000218,Intermediate,,5237,Oral bioavailability in rats was determined; High,A,In vivo,,Rattus norvegicus,10116.0,
10495,1,,BAO_0000218,Intermediate,,5503,Oral bioavailability in the rat was determined,A,In vivo,,Rattus norvegicus,10116.0,
10496,1,,BAO_0000218,Intermediate,,15765,Oral bioavailability measured by the ratio of intravenous to oral area under concentration.,A,In vivo,,Rattus norvegicus,10116.0,
10497,1,,BAO_0000218,Intermediate,,15660,Oral bioavailability in rat (dose 10 mg/kg p.o. and 3 mg/kg i.v.),A,In vivo,,Rattus norvegicus,10116.0,
10498,1,,BAO_0000218,Intermediate,,5978,Oral bioavailability of compound (19.2 mg/kg) after po administration was determined in Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0,
10499,1,,BAO_0000218,Intermediate,,5978,Oral bioavailability of compound (19.76 mg/kg) after po administration was determined in Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0,
10500,1,,BAO_0000218,Intermediate,,5978,Oral bioavailability of compound (20.73 mg/kg) after po administration was determined in Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0,
10501,1,,BAO_0000218,Intermediate,,5978,Oral bioavailability of compound (25 mg/kg) after po administration was determined in Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0,
10502,1,,BAO_0000218,Intermediate,,5656,Oral bioavailability of compound at a dose of 20 mg/kg was determined after oral administration in rat,A,In vivo,,Rattus norvegicus,10116.0,
10503,1,,BAO_0000218,Expert,,3598,Oral bioavailability of compound determined in rat after iv administration at a dose of 10 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,
10504,1,,BAO_0000218,Intermediate,,4216,Oral bioavailability of compound in Sprague Dawley rats,A,In vivo,,Rattus norvegicus,10116.0,
10505,1,,BAO_0000218,Intermediate,,17839,Oral bioavailability of compound in rat,A,In vivo,,Rattus norvegicus,10116.0,
10506,1,,BAO_0000218,Intermediate,,6570,Oral bioavailability in rat (dose 2 mg/kg),A,In vivo,,Rattus norvegicus,10116.0,
10507,1,,BAO_0000218,Intermediate,,5334,Oral bioavailability of compound in rat was determined,A,In vivo,,Rattus norvegicus,10116.0,
10508,1,,BAO_0000218,Intermediate,,6886,Oral bioavailability of compound in rats,A,In vivo,,Rattus norvegicus,10116.0,
10509,1,,BAO_0000218,Intermediate,,5210,Oral bioavailability of compound was determined in rats,A,In vivo,,Rattus norvegicus,10116.0,
10510,1,,BAO_0000218,Intermediate,,4170,Oral bioavailability at a dose of 30 mg/kg in rats,A,In vivo,,Rattus norvegicus,10116.0,
10511,1,,BAO_0000218,Intermediate,,6028,Oral bioavailability in rat (dose 10 mg/kg),A,In vivo,,Rattus norvegicus,10116.0,
10512,1,,BAO_0000218,Intermediate,,6028,Oral bioavailability in rat (dose 10 mg/kg),A,In vivo,,Rattus norvegicus,10116.0,
10513,1,,BAO_0000218,Intermediate,,6078,Oral bioavailability evaluated in rat,A,In vivo,,Rattus norvegicus,10116.0,
10514,1,,BAO_0000218,Intermediate,,6168,Oral bioavailability in fasted rat,A,In vivo,,Rattus norvegicus,10116.0,
10515,1,,BAO_0000218,Intermediate,,6168,Oral bioavailability in fed rat,A,In vivo,,Rattus norvegicus,10116.0,
10516,1,,BAO_0000218,Intermediate,,5160,Oral bioavailability in rat (mature male) (dose 30 mg/kg),A,In vivo,,Rattus norvegicus,10116.0,
10517,1,,BAO_0000218,Intermediate,,6057,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,
10518,1,,BAO_0000218,Intermediate,,6535,Oral bioavailability in rat (dose 10 mg/kg p.o.),A,In vivo,,Rattus norvegicus,10116.0,
10519,1,,BAO_0000218,Intermediate,,6535,Oral bioavailability in rat after administration of 10 mg/kg po,A,In vivo,,Rattus norvegicus,10116.0,
10520,1,,BAO_0000218,Intermediate,,4194,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,
10521,1,,BAO_0000218,Intermediate,,6230,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,
10522,1,,BAO_0000218,Intermediate,,6619,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,
10523,1,,BAO_0000218,Intermediate,,17607,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,
10524,1,,BAO_0000218,Intermediate,,4942,Oral bioavailability in ratrs,A,In vivo,,Rattus norvegicus,10116.0,
10525,1,,BAO_0000218,Intermediate,,4942,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,
10526,1,,BAO_0000218,Intermediate,,6646,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,
10527,1,,BAO_0000218,Intermediate,,5237,Oral bioavailability in rats was determined; High,A,In vivo,,Rattus norvegicus,10116.0,
10528,1,,BAO_0000218,Intermediate,,6646,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,
10529,1,,BAO_0000218,Intermediate,,4449,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,
10530,1,,BAO_0000218,Intermediate,,6057,Oral bioavailability was calculated in rat,A,In vivo,,Rattus norvegicus,10116.0,
10531,1,,BAO_0000218,Intermediate,,2552,Oral bioavailability,A,In vivo,,Rattus norvegicus,10116.0,
10532,1,,BAO_0000218,Intermediate,,5496,Oral bioavailability,A,In vivo,,Rattus norvegicus,10116.0,
10533,1,,BAO_0000218,Intermediate,,6484,Oral bioavailability,A,In vivo,,Rattus norvegicus,10116.0,
10534,1,,BAO_0000218,Intermediate,,6485,Oral bioavailability,A,In vivo,,Rattus norvegicus,10116.0,
10535,1,,BAO_0000218,Intermediate,,6616,Oral bioavailability after i.v. administration,A,In vivo,,Rattus norvegicus,10116.0,
10536,1,,BAO_0000218,Intermediate,,4969,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),A,In vivo,,Rattus norvegicus,10116.0,
10537,1,,BAO_0000218,Intermediate,,5862,Oral bioavailability in rat (Sprague-Dawley),A,In vivo,,Rattus norvegicus,10116.0,
10538,1,,BAO_0000218,Intermediate,,4514,Oral bioavailability in Sprague-Dawley rats,A,In vivo,,Rattus norvegicus,10116.0,
10539,1,,BAO_0000218,Intermediate,,4514,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),A,In vivo,,Rattus norvegicus,10116.0,
10540,1,,BAO_0000218,Intermediate,,4514,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg),A,In vivo,,Rattus norvegicus,10116.0,
10541,1,,BAO_0000218,Intermediate,,5546,Oral bioavailability in Sprague-Dawley rats at a dose of 2 mg/kg by po administration,A,In vivo,,Rattus norvegicus,10116.0,
10542,1,,BAO_0000218,Intermediate,,6168,Oral bioavailability in fasted rat,A,In vivo,,Rattus norvegicus,10116.0,
10543,1,,BAO_0000218,Intermediate,,6168,Oral bioavailability in fed rat,A,In vivo,,Rattus norvegicus,10116.0,
10544,1,,BAO_0000218,Intermediate,,3624,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,
10545,1,,BAO_0000218,Intermediate,,5213,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,
10546,1,,BAO_0000218,Intermediate,,5496,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,
10547,1,,BAO_0000218,Intermediate,,5553,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,
10548,1,,BAO_0000218,Intermediate,,5833,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,
10549,1,,BAO_0000218,Intermediate,,5836,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,
10550,1,,BAO_0000218,Intermediate,,5865,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,
10551,1,,BAO_0000218,Intermediate,,5960,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,
10552,1,,BAO_0000218,Intermediate,,6249,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,
10553,1,,BAO_0000218,Intermediate,,6448,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,
10554,1,,BAO_0000218,Intermediate,,6453,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,
10555,1,,BAO_0000218,Intermediate,,6640,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,
10556,1,,BAO_0000218,Intermediate,,17607,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,
10557,1,,BAO_0000218,Intermediate,,5939,Oral bioavailability in rat after peroral administration at 10 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,
10558,1,,BAO_0000218,Intermediate,,5939,Oral bioavailability in rat after peroral administration at 5 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,
10559,1,,BAO_0000218,Intermediate,,6281,Oral bioavailability in rat (dose 2.8 mg/kg p.o.),A,In vivo,,Rattus norvegicus,10116.0,
10560,1,,BAO_0000218,Intermediate,,5874,Oral bioavailability in rat by po administration at a dose of 40 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,
10561,1,,BAO_0000218,Intermediate,,5213,Oral bioavailability in rat; Not measured,A,In vivo,,Rattus norvegicus,10116.0,
10562,1,,BAO_0000218,Intermediate,,4964,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,
10563,1,,BAO_0000218,Intermediate,,11020,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus NE,A,,,Rattus norvegicus,10116.0,
10564,1,,BAO_0000218,Intermediate,2107.0,6251,In vitro metabolic potential in rat liver microsomes,A,,,Rattus norvegicus,10116.0,
10565,1,,BAO_0000218,Intermediate,,1568,"Oral availability was tested for plasma levels at a dose of 40 mg/kg, after 6 hr of in fed fisher rats.",A,In vivo,,Rattus norvegicus,10116.0,
10566,1,,BAO_0000218,Intermediate,,3032,"In vivo percentage mean absolute bioavailability of compound in rat after an oral dose of 10 mg/kg (in water, N=4)",A,In vivo,,Rattus norvegicus,10116.0,
10567,1,,BAO_0000218,Intermediate,,3748,Oral bioavailability of intravenously administered compound (3 mg/kg) was tested in rats,A,In vivo,,Rattus norvegicus,10116.0,
10568,1,,BAO_0000218,Intermediate,,401,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,
10569,1,,BAO_0000218,Intermediate,,6512,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,
10570,1,,BAO_0000218,Intermediate,,17617,Oral bioavailability in rats at 10 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,
10571,1,,BAO_0000218,Intermediate,,6679,Oral bioavailability was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,A,In vivo,,Rattus norvegicus,10116.0,
10572,1,,BAO_0000218,Intermediate,,6742,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,
10573,1,,BAO_0000218,Intermediate,,589,Tested for effective permeability across the rat intestinal membrane using mass balance analysis,A,,,Rattus norvegicus,10116.0,
10574,1,,BAO_0000218,Intermediate,,589,Tested for effective permeability across the rat intestinal membrane using mass balance analysis at 0.01 mM concentration,A,,,Rattus norvegicus,10116.0,
10575,1,,BAO_0000218,Intermediate,,3185,Plasma clearance of the compound,A,In vivo,,Rattus norvegicus,10116.0,
10576,1,,BAO_0000218,Intermediate,,17596,Plasma clearance at 10 mg/kg in rat upon intravenous administration,A,In vivo,,Rattus norvegicus,10116.0,
10577,1,,BAO_0000218,Intermediate,,2713,Plasma clearance upon intravenous administration of 1 mg/Kg in rats,A,In vivo,,Rattus norvegicus,10116.0,
10578,1,,BAO_0000218,Intermediate,1969.0,12500,The compound was tested for plasma clearance in rat,A,In vivo,,Rattus norvegicus,10116.0,
10579,1,,BAO_0000218,Intermediate,1969.0,12500,The compound was tested for plasma clearance in rat at dose of 3-10 mgkg,A,In vivo,,Rattus norvegicus,10116.0,
10580,1,,BAO_0000218,Intermediate,,2713,Plasma concentration upon oral administration of 1 mg/Kg in rats,A,,,Rattus norvegicus,10116.0,
10581,1,,BAO_0000218,Intermediate,,1446,Peak plasma level between 0.5 and 1.0 hour in Dawley rats; value ranges from 1021-2551,A,,,Rattus norvegicus,10116.0,
10582,1,,BAO_0000218,Intermediate,,6227,Plasma level after intravenous administration in rat model of FeCl3-induced carotid thrombosis,A,,,Rattus norvegicus,10116.0,
10583,1,,BAO_0000218,Intermediate,,4709,Plasma protein binding was determined after intravenous administration of 1 mg/kg in rat,A,,,Rattus norvegicus,10116.0,
10584,1,,BAO_0000218,Intermediate,,5510,"Rat plasma cleavage data expressed as percentage of compound remains at 24 hr in PEG400/Water, 1:1",A,,,Rattus norvegicus,10116.0,
10585,1,,BAO_0000218,Intermediate,,5510,"Rat plasma cleavage data expressed as percentage of compound remains at 24 hr in PEG400/Water, 1:1; Not determined",A,,,Rattus norvegicus,10116.0,
10586,1,,BAO_0000218,Intermediate,,5510,"Rat plasma cleavage data expressed as percentage of compound remains at 24 hr in PEG400/Water, 1:1; Not determined",A,,,Rattus norvegicus,10116.0,
10587,1,,BAO_0000218,Intermediate,,5510,"Rat plasma cleavage data expressed as percentage of compound remains at 24 hr in PEG400/Water, 1:1; Not stable",A,,,Rattus norvegicus,10116.0,
10588,1,,BAO_0000218,Intermediate,,4514,Compound was tested for protein binding in rat plasma,A,,,Rattus norvegicus,10116.0,
10589,1,,BAO_0000218,Intermediate,,2713,Compound was evaluated for absorption of radioligand following oral administration to bile duct cannulated rat. ,A,,,Rattus norvegicus,10116.0,
10590,1,,BAO_0000218,Intermediate,,2713,Compound was evaluated for absorption of radioligand upon oral administration to bile duct cannulated rats,A,,,Rattus norvegicus,10116.0,
10591,1,,BAO_0000218,Intermediate,2107.0,5340,In vitro metabolism in rat liver microsomes was evaluated to determine diminishing of glucuronidation rate,A,,,Rattus norvegicus,10116.0,
10592,1,,BAO_0000218,Intermediate,,12058,Area under curve ratio was determined (po/iv) in rat,A,,,Rattus norvegicus,10116.0,
10593,1,,BAO_0000218,Intermediate,,11195,Blood by brain ratio of the radiolabeled compound (2-5 uCi) in rat 15 mins after i.v. administration,A,,,Rattus norvegicus,10116.0,
10594,1,,BAO_0000218,Intermediate,,11195,Blood by brain ratio of the radiolabeled compound (2-5 uCi) in rat 2 mins after i.v. administration,A,,,Rattus norvegicus,10116.0,
10595,1,,BAO_0000218,Intermediate,,11195,Blood by brain ratio of the radiolabeled compound (2-5 uCi) in rat 65 mins after i.v. administration,A,,,Rattus norvegicus,10116.0,
10596,1,,BAO_0000218,Intermediate,,6495,Compound was tested for brain/plasma ratio after oral administration at 10 mg/kg,A,,,Rattus norvegicus,10116.0,
10597,1,,BAO_0000218,Intermediate,,6078,Ratio of AUCbrain to AUCplasma,A,,,Rattus norvegicus,10116.0,
10598,1,,BAO_0000218,Intermediate,,5656,Ratio of brain to plasma,A,,,Rattus norvegicus,10116.0,
10599,1,,BAO_0000218,Intermediate,,4910,Ratio of the AUC values of brain and plasma after intravenous administration (4.7 mg/kg) to male rats was evaluated,A,,,Rattus norvegicus,10116.0,
10600,1,,BAO_0000218,Intermediate,,4910,Ratio in brain and plasma after 0.25 hrs of intravenous administration (5 mg/kg) to male rats was evaluated,A,,,Rattus norvegicus,10116.0,
10601,1,,BAO_0000218,Intermediate,,4910,Ratio in brain and plasma after 2 hrs of intravenous administration (5 mg/kg) to male rats was evaluated,A,,,Rattus norvegicus,10116.0,
10602,1,,BAO_0000218,Intermediate,,10130,Selectivity ratio for biodistribution in brain and blood of rats after 15 minutes; Expressed as percent dose/gram ratio,A,,,Rattus norvegicus,10116.0,
10603,1,,BAO_0000218,Intermediate,,10130,Selectivity ratio for biodistribution in brain and blood of rats after 2 minutes; Expressed as percent dose/gram ratio,A,,,Rattus norvegicus,10116.0,
10604,1,,BAO_0000218,Intermediate,,10130,Selectivity ratio for biodistribution in brain and blood of rats after 60 minutes; Expressed as percent dose/gram ratio,A,,,Rattus norvegicus,10116.0,
10605,1,,BAO_0000218,Intermediate,,5213,Steady state brain :blood ratio was determined,A,,,Rattus norvegicus,10116.0,
10606,1,,BAO_0000218,Intermediate,,4910,Tested for ratio in brain and plasma after 0.25 hrs of intravenous administration (5 mg/kg) to male rats,A,,,Rattus norvegicus,10116.0,
10607,1,,BAO_0000218,Intermediate,,4910,Tested for ratio in brain and plasma after 0.25 hrs of intravenous administration (5 mg/kg) to male rats; ND = not determined,A,,,Rattus norvegicus,10116.0,
10608,1,,BAO_0000218,Intermediate,,4910,Tested for ratio in brain and plasma after 2 hrs of intravenous administration (5 mg/kg) to male rats,A,,,Rattus norvegicus,10116.0,
10609,1,,BAO_0000218,Intermediate,,4910,Tested for ratio in brain and plasma after 2 hrs of intravenous administration (5 mg/kg) to male rats; ND = not determined,A,,,Rattus norvegicus,10116.0,
10610,1,,BAO_0000218,Intermediate,,2083,Percentage recovery after 3h incubation with rat hapatocytes was determined,A,,,Rattus norvegicus,10116.0,
10611,1,,BAO_0000218,Intermediate,,2082,Percentage recovery in rat hepatic microsomal fractions under oxidative conditions after 1 hour,A,,,Rattus norvegicus,10116.0,
10612,1,,BAO_0000218,Intermediate,,2082,Percentage recovery in rhesus monkey hepatic microsomal fractions under oxidative conditions after 1 hour,A,,,Rattus norvegicus,10116.0,
10613,1,,BAO_0000218,Intermediate,,6351,Recovery rate from urine and bile was determined after iv administration at 20 mg/kg in rats,A,,,Rattus norvegicus,10116.0,
10614,0,,BAO_0000019,Autocuration,,14583,"Fraction of 88Y (%) released from chelate after incubation in serum for 15 hours; not measured, No site available for protein conjugation.",A,,,,,
10615,0,,BAO_0000019,Autocuration,,14583,Fraction of 88Y (%) released from chelate after incubation in serum for 15 hours; not measured.,A,,,,,
10616,1,,BAO_0000218,Intermediate,,4608,In vivo absorption in Caco-2 cell line monolayers was determined,A,,,Homo sapiens,9606.0,
10617,0,,BAO_0000100,Autocuration,,13668,Calculated partition coefficient (clogP),P,,,,,
10618,1,,BAO_0000218,Intermediate,,5669,Area under curve was determine after peroral administration at 10 mpk in Rat,A,,,Rattus norvegicus,10116.0,
10619,1,,BAO_0000218,Intermediate,,5669,Area under curve was determine after peroral administration at 10 mpk in Rhesus,A,,,Macaca mulatta,9544.0,
10620,1,,BAO_0000218,Intermediate,,5669,Area under curve was determine after peroral administration at 160 mpk in Rat,A,,,Rattus norvegicus,10116.0,
10621,1,,BAO_0000218,Intermediate,,5669,Area under curve was determine after peroral administration at 20 mpk in Rat,A,,,Rattus norvegicus,10116.0,
10622,1,,BAO_0000218,Intermediate,,5669,Area under curve was determine after peroral administration at 50 mpk in Rat,A,,,Rattus norvegicus,10116.0,
10623,0,,BAO_0000100,Autocuration,,6472,Calculated partition coefficient (clogP) (AlogP),P,,,,,
10624,0,,BAO_0000019,Autocuration,,15106,Activated partial thromboplastin time measured,A,,,,,
10625,0,,BAO_0000100,Autocuration,,15207,Compound was evaluated for the aqueous solubility (AS) in mg/mL (Measured in 0.2 M phosphate buffer of pH 7.4),P,,,,,
10626,0,,BAO_0000100,Autocuration,,15207,Compound was evaluated for the aqueous solubility (AS) in mg/mL (Measured in 0.2 M phosphate buffer of pH 7.4); ND=Not determined (AS mg/mL),P,,,,,
10627,1,,BAO_0000218,Intermediate,1969.0,13941,AUC (Area under curve) was determined after intravenous administration at a dose 1 mg/kg in dog,A,,,Canis lupus familiaris,9615.0,
10628,1,,BAO_0000218,Intermediate,1969.0,13941,AUC (Area under curve) was determined after intravenous administration at a dose 2 mg/kg in rat.,A,,,Rattus norvegicus,10116.0,
10629,1,,BAO_0000218,Intermediate,1969.0,13941,AUC (Area under curve) was determined after peroral administration at a dose 10 mg/kg in rat.,A,,,Rattus norvegicus,10116.0,
10630,1,,BAO_0000218,Intermediate,1969.0,13941,AUC (Area under curve) was determined after peroral administration at a dose 5 mg/kg in dog,A,,,Canis lupus familiaris,9615.0,
10631,1,,BAO_0000218,Intermediate,1969.0,15240,AUC (ng h/mL) value after oral administration of 10 mg/kg in guinea pig.,A,,,Cavia porcellus,10141.0,
10632,0,,BAO_0000019,Autocuration,955.0,10655,AUC in brain,A,,,,,
10633,0,,BAO_0000019,Autocuration,1977.0,10655,AUC in serum,A,,,,,
10634,0,,BAO_0000019,Autocuration,1969.0,6504,AUC was determined,A,,,,,
10635,0,,BAO_0000019,Autocuration,1969.0,10615,AUC of the compound.,A,,,,,
10636,0,,BAO_0000019,Autocuration,1969.0,10353,AUC value (0-4 hr),A,,,,,
10637,0,,BAO_0000019,Autocuration,1969.0,14907,"AUC was measured from the graph plotted against blood plasma concentration and time at the dose of 150 uMol/kg,",A,,,,,
10638,0,,BAO_0000019,Autocuration,1969.0,14907,AUC was measured from the graph plotted against blood plasma concentration and time at the dose of 300 uMol/kg,A,,,,,
10639,0,,BAO_0000019,Autocuration,1969.0,14907,"AUC was measured from the graph plotted against blood plasma concentration and time at the dose of 300 uMol/kg,",A,,,,,
10640,0,,BAO_0000019,Autocuration,1969.0,14907,"AUC was measured from the graph plotted against blood plasma concentration and time at the dose of 700 uMol/kg,",A,,,,,
10641,1,,BAO_0000218,Intermediate,1969.0,16359,AUC(area under curve) was determined after intravenous administration in rats,A,,,Rattus norvegicus,10116.0,
10642,1,,BAO_0000218,Intermediate,1969.0,16359,AUC(area under curve) was determined after oral administration in rats,A,,,Rattus norvegicus,10116.0,
10643,1,,BAO_0000218,Intermediate,1969.0,15240,AUC(ng h/mL)values after oral administration of 10 mg/kg in guinea pig.,A,,,Cavia porcellus,10141.0,
10644,1,,BAO_0000218,Intermediate,1969.0,15240,AUC(ng h/mL)values after oral administration of 10 mg/kg in rat.,A,,,Rattus norvegicus,10116.0,
10645,0,,BAO_0000019,Autocuration,,15469,Area Under Curve after oral dosing of 100 uM/Kg,A,,,,,
10646,0,,BAO_0000019,Autocuration,,15469,Area Under Curve after oral dosing of 30 uM/Kg,A,,,,,
10647,0,,BAO_0000019,Autocuration,,13520,Area Under Curve was measured by ploting the graph between concentration verses time,A,,,,,
10648,1,,BAO_0000218,Intermediate,,17025,Area under concentration-time curve of compound was determined in dog at 25 mg/kg orally,A,,,Canis lupus familiaris,9615.0,
10649,0,,BAO_0000218,Autocuration,,17025,Area under concentration-time curve of compound was determined in monkey at 25 mg/kg orally,A,,,Simiiformes,314293.0,
10650,1,,BAO_0000218,Intermediate,,17025,Area under concentration-time curve of compound was determined in rabbit at 25 mg/kg orally,A,,,Oryctolagus cuniculus,9986.0,
10651,1,,BAO_0000218,Intermediate,,17025,Area under concentration-time curve of compound was determined in rat at 25 mg/kg orally,A,,,Rattus norvegicus,10116.0,
10652,1,,BAO_0000218,Intermediate,178.0,12032,Area under curve (AUC) is the drug concentrations in blood samples of rats with arterial catheters at 5 min and 12 hr plotted against time,A,,,Rattus norvegicus,10116.0,
10653,0,,BAO_0000019,Autocuration,,10291,Area under curve (AUC) was determined,A,,,,,
10654,0,,BAO_0000218,Autocuration,,5767,Area under curve (AUC) following ip administration at 1 mg/kg,A,,,,,
10655,0,,BAO_0000019,Autocuration,,1434,Area under curve (AUC) was determined; ND is Not determined,A,,,,,
10656,1,,BAO_0000218,Intermediate,,14925,Area under curve (AUC) was determined in dogs fed after intravenous administration of 25 mg/kg of the compound,A,,,Canis lupus familiaris,9615.0,
10657,1,,BAO_0000218,Intermediate,,14925,Area under curve (AUC) was determined in dogs fed after oral administration of 25 mg/kg of the compound,A,,,Canis lupus familiaris,9615.0,
10658,1,,BAO_0000218,Intermediate,,14925,Area under curve (AUC) was determined in fasted dogs after oral administration of 25 mg/kg of the compound,A,,,Canis lupus familiaris,9615.0,
10659,0,,BAO_0000019,Autocuration,,1434,Area under curve (AUR) was determined,A,,,,,
10660,0,,BAO_0000019,Autocuration,,11883,Area under curve at 1 uM/dg administered intravenously,A,,,,,
10661,0,,BAO_0000019,Autocuration,,11883,Area under curve at 10 uM/dg administered perorally,A,,,,,
10662,0,,BAO_0000019,Autocuration,,11883,Area under curve at 2 uM/dg administered intravenously,A,,,,,
10663,0,,BAO_0000019,Autocuration,,11883,Area under curve at 20 uM/dg administered perorally,A,,,,,
10664,1,,BAO_0000218,Intermediate,,15233,Area under curve at a peroral dose of 3 mg/kg in dog,A,,,Canis lupus familiaris,9615.0,
10665,1,,BAO_0000218,Intermediate,,15233,Area under curve at a peroral dose of 3 mg/kg in rat,A,,,Rattus norvegicus,10116.0,
10666,1,,BAO_0000218,Intermediate,,15233,Area under curve at an iv dose of 1 mg/kg in dog,A,,,Canis lupus familiaris,9615.0,
10667,1,,BAO_0000218,Intermediate,,15233,Area under curve at an iv dose of 1 mg/kg in rat,A,,,Rattus norvegicus,10116.0,
10668,0,,BAO_0000019,Autocuration,,12978,Area under curve gives the effective duration for the angiotensin II antagonist effect of the compound.,A,,,,,
10669,0,,BAO_0000019,Autocuration,,12978,Area under curve gives the effective duration for the angiotensin II antagonist effect.,A,,,,,
10670,1,,BAO_0000218,Intermediate,,11355,Area under curve measured as conc vs time after intravenous administration to mice.,A,,,Mus musculus,10090.0,
10671,1,,BAO_0000218,Intermediate,,11355,Area under curve measured as conc vs time after peroral administration to mice.,A,,,Mus musculus,10090.0,
10672,1,,BAO_0000218,Intermediate,,12923,Area under curve of acid 2a was determined by HPLC at a dosage of 2.27 mg/kg administered intravenously by bolus method in dog,A,,,Canis lupus familiaris,9615.0,
10673,1,,BAO_0000218,Intermediate,,12923,Area under curve of acid 2a was determined by HPLC at a dosage of 5.45 mg/kg administered intragastrically by capsule method in dog,A,,,Canis lupus familiaris,9615.0,
10674,1,,BAO_0000218,Intermediate,,12923,Area under curve of acid 2a was determined by HPLC at a dosage of 5.45 mg/kg administered intragastrically by gavage method in dog,A,,,Canis lupus familiaris,9615.0,
10675,1,,BAO_0000218,Intermediate,,12923,Area under curve of acid 2a was determined by HPLC at a dosage of 54.5 mg/kg administered intragastrically by capsule method in dog,A,,,Canis lupus familiaris,9615.0,
10676,1,,BAO_0000218,Intermediate,948.0,17738,Biodistribution of radiolabeled compound in rat heart after 24 hr activity expressed as %ID/Organ,A,In vivo,,Rattus norvegicus,10116.0,
10677,1,,BAO_0000218,Intermediate,948.0,17738,Biodistribution of radiolabeled compound in rat heart after 2 hr activity expressed as %ID/Organ,A,In vivo,,Rattus norvegicus,10116.0,
10678,1,,BAO_0000218,Intermediate,948.0,17738,Biodistribution of radiolabeled compound in rat heart after 30 min activity expressed as %ID/Organ,A,In vivo,,Rattus norvegicus,10116.0,
10679,1,,BAO_0000218,Intermediate,948.0,17738,Biodistribution of radiolabeled compound in rat heart after 5 min activity expressed as %ID/Organ,A,In vivo,,Rattus norvegicus,10116.0,
10680,1,,BAO_0000218,Intermediate,2113.0,17738,Biodistribution of radiolabeled compound in rat kidney after 24 hr postinjection activity expressed as %ID/Organ,A,In vivo,,Rattus norvegicus,10116.0,
10681,1,,BAO_0000218,Intermediate,2113.0,17738,Biodistribution of radiolabeled compound in rat kidney after 24 hr activity expressed as %ID/Organ,A,In vivo,,Rattus norvegicus,10116.0,
10682,1,,BAO_0000218,Intermediate,2113.0,17738,Biodistribution of radiolabeled compound in rat kidney after 2 hr activity expressed as %ID/Organ,A,In vivo,,Rattus norvegicus,10116.0,
10683,1,,BAO_0000218,Intermediate,2113.0,17738,Biodistribution of radiolabeled compound in rat kidney after 30 min activity expressed as %ID/Organ,A,In vivo,,Rattus norvegicus,10116.0,
10684,1,,BAO_0000218,Intermediate,2113.0,17738,Biodistribution of radiolabeled compound in rat kidney after 5 min activity expressed as %ID/Organ,A,In vivo,,Rattus norvegicus,10116.0,
10685,1,,BAO_0000218,Intermediate,2107.0,17738,Biodistribution of radiolabeled compound in rat liver after 24 hr postinjection activity expressed as %ID/Organ,A,In vivo,,Rattus norvegicus,10116.0,
10686,1,,BAO_0000218,Intermediate,2107.0,17738,Biodistribution of radiolabeled compound in rat liver after 24 hr activity expressed as %ID/Organ,A,In vivo,,Rattus norvegicus,10116.0,
10687,1,,BAO_0000218,Intermediate,2107.0,17738,Biodistribution of radiolabeled compound in rat liver after 2 hr activity expressed as %ID/Organ,A,In vivo,,Rattus norvegicus,10116.0,
10688,1,,BAO_0000218,Intermediate,2107.0,17738,Biodistribution of radiolabeled compound in rat liver after 30 min activity expressed as %ID/Organ,A,In vivo,,Rattus norvegicus,10116.0,
10689,1,,BAO_0000218,Intermediate,2107.0,17738,Biodistribution of radiolabeled compound in rat liver after 5 min activity expressed as %ID/Organ,A,In vivo,,Rattus norvegicus,10116.0,
10690,1,,BAO_0000218,Intermediate,2048.0,17738,Biodistribution of radiolabeled compound in rat lung after 24 hr activity expressed as %ID/Organ,A,In vivo,,Rattus norvegicus,10116.0,
10691,1,,BAO_0000218,Intermediate,2048.0,17738,Biodistribution of radiolabeled compound in rat lung after 2 hr activity expressed as %ID/Organ,A,In vivo,,Rattus norvegicus,10116.0,
10692,1,,BAO_0000218,Intermediate,2048.0,17738,Biodistribution of radiolabeled compound in rat lung after 30 min activity expressed as %ID/Organ,A,In vivo,,Rattus norvegicus,10116.0,
10693,1,,BAO_0000218,Intermediate,2048.0,17738,Biodistribution of radiolabeled compound in rat lung after 5 min activity expressed as %ID/Organ,A,In vivo,,Rattus norvegicus,10116.0,
10694,1,,BAO_0000218,Intermediate,2385.0,17738,Biodistribution of radiolabeled compound in rat muscle after 24 hr activity expressed as %ID/Organ,A,In vivo,,Rattus norvegicus,10116.0,
10695,1,,BAO_0000218,Intermediate,2385.0,17738,Biodistribution of radiolabeled compound in rat muscle after 2 hr activity expressed as %ID/Organ,A,In vivo,,Rattus norvegicus,10116.0,
10696,1,,BAO_0000218,Intermediate,2385.0,17738,Biodistribution of radiolabeled compound in rat muscle after 30 min activity expressed as %ID/Organ,A,In vivo,,Rattus norvegicus,10116.0,
10697,1,,BAO_0000218,Intermediate,2385.0,17738,Biodistribution of radiolabeled compound in rat muscle after 5 min activity expressed as %ID/Organ,A,In vivo,,Rattus norvegicus,10116.0,
10698,1,,BAO_0000218,Intermediate,178.0,11195,Biodistribution of the radiolabeled compound (2-5 uCi) in rat blood 15 mins after i.v. administration,A,In vivo,,Rattus norvegicus,10116.0,
10699,1,,BAO_0000218,Intermediate,178.0,11195,Biodistribution of the radiolabeled compound (2-5 uCi) in rat blood 2 mins after i.v. administration,A,In vivo,,Rattus norvegicus,10116.0,
10700,1,,BAO_0000218,Intermediate,178.0,11195,Biodistribution of the radiolabeled compound (2-5 uCi) in rat blood 65 mins after i.v. administration,A,In vivo,,Rattus norvegicus,10116.0,
10701,1,,BAO_0000218,Intermediate,955.0,11195,Biodistribution of the radiolabeled compound (2-5 uCi) in rat brain 15 mins after i.v. administration,A,In vivo,,Rattus norvegicus,10116.0,
10702,1,,BAO_0000218,Intermediate,955.0,11195,Biodistribution of the radiolabeled compound (2-5 uCi) in rat brain 2 mins after i.v. administration,A,In vivo,,Rattus norvegicus,10116.0,
10703,1,,BAO_0000218,Intermediate,955.0,11195,Biodistribution of the radiolabeled compound (2-5 uCi) in rat brain 65 mins after i.v. administration,A,In vivo,,Rattus norvegicus,10116.0,
10704,1,,BAO_0000218,Intermediate,948.0,11195,Biodistribution of the radiolabeled compound (2-5 uCi) in rat heart 15 mins after i.v. administration,A,In vivo,,Rattus norvegicus,10116.0,
10705,1,,BAO_0000218,Intermediate,948.0,11195,Biodistribution of the radiolabeled compound (2-5 uCi) in rat heart 2 mins after i.v. administration,A,In vivo,,Rattus norvegicus,10116.0,
10706,1,,BAO_0000218,Intermediate,948.0,11195,Biodistribution of the radiolabeled compound (2-5 uCi) in rat heart 65 mins after i.v. administration,A,In vivo,,Rattus norvegicus,10116.0,
10707,1,,BAO_0000218,Intermediate,2113.0,11195,Biodistribution of the radiolabeled compound (2-5 uCi) in rat kidney 15 mins after i.v. administration,A,In vivo,,Rattus norvegicus,10116.0,
10708,1,,BAO_0000218,Intermediate,2113.0,11195,Biodistribution of the radiolabeled compound (2-5 uCi) in rat kidney 2 mins after i.v. administration,A,In vivo,,Rattus norvegicus,10116.0,
10709,1,,BAO_0000218,Intermediate,2113.0,11195,Biodistribution of the radiolabeled compound (2-5 uCi) in rat kidney 65 mins after i.v. administration,A,In vivo,,Rattus norvegicus,10116.0,
10710,1,,BAO_0000218,Intermediate,2107.0,11195,Biodistribution of the radiolabeled compound (2-5 uCi) in rat liver 15 mins after i.v. administration,A,In vivo,,Rattus norvegicus,10116.0,
10711,1,,BAO_0000218,Intermediate,2107.0,11195,Biodistribution of the radiolabeled compound (2-5 uCi) in rat liver 2 mins after i.v. administration,A,In vivo,,Rattus norvegicus,10116.0,
10712,1,,BAO_0000218,Intermediate,2107.0,11195,Biodistribution of the radiolabeled compound (2-5 uCi) in rat liver 65 mins after i.v. administration,A,In vivo,,Rattus norvegicus,10116.0,
10713,1,,BAO_0000218,Intermediate,2048.0,11195,Biodistribution of the radiolabeled compound (2-5 uCi) in rat lung 15 mins after i.v. administration,A,In vivo,,Rattus norvegicus,10116.0,
10714,1,,BAO_0000218,Intermediate,2048.0,11195,Biodistribution of the radiolabeled compound (2-5 uCi) in rat lung 2 mins after i.v. administration,A,In vivo,,Rattus norvegicus,10116.0,
10715,1,,BAO_0000218,Intermediate,2048.0,11195,Biodistribution of the radiolabeled compound (2-5 uCi) in rat lung 65 mins after i.v. administration,A,In vivo,,Rattus norvegicus,10116.0,
10716,1,,BAO_0000218,Intermediate,2385.0,11195,Biodistribution of the radiolabeled compound (2-5 uCi) in rat muscle 15 mins after i.v. administration,A,In vivo,,Rattus norvegicus,10116.0,
10717,1,,BAO_0000218,Intermediate,2385.0,11195,Biodistribution of the radiolabeled compound (2-5 uCi) in rat muscle 2 mins after i.v. administration,A,In vivo,,Rattus norvegicus,10116.0,
10718,1,,BAO_0000218,Intermediate,2385.0,11195,Biodistribution of the radiolabeled compound (2-5 uCi) in rat muscle 65 mins after i.v. administration,A,In vivo,,Rattus norvegicus,10116.0,
10719,1,,BAO_0000218,Intermediate,14.0,11195,Biodistribution of the radiolabeled compound (2-5 uCi) in rat skin 15 mins after i.v. administration,A,In vivo,,Rattus norvegicus,10116.0,
10720,1,,BAO_0000218,Intermediate,14.0,11195,Biodistribution of the radiolabeled compound (2-5 uCi) in rat skin 2 mins after i.v. administration,A,In vivo,,Rattus norvegicus,10116.0,
10721,1,,BAO_0000218,Intermediate,14.0,11195,Biodistribution of the radiolabeled compound (2-5 uCi) in rat skin 65 mins after i.v. administration,A,In vivo,,Rattus norvegicus,10116.0,
10722,1,,BAO_0000218,Intermediate,2106.0,11195,Biodistribution of the radiolabeled compound (2-5 uCi) in rat spleen 15 mins after i.v. administration,A,In vivo,,Rattus norvegicus,10116.0,
10723,1,,BAO_0000218,Intermediate,2106.0,11195,Biodistribution of the radiolabeled compound (2-5 uCi) in rat spleen 2 mins after i.v. administration,A,In vivo,,Rattus norvegicus,10116.0,
10724,1,,BAO_0000218,Intermediate,,6193,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,
10725,1,,BAO_0000218,Intermediate,,6803,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,
10726,1,,BAO_0000218,Intermediate,,6647,Oral bioavailability in rats at 6 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,
10727,1,,BAO_0000218,Intermediate,,6647,Oral bioavailability in rat (dose 6 mg/kg),A,In vivo,,Rattus norvegicus,10116.0,
10728,1,,BAO_0000218,Intermediate,,6647,Oral bioavailability in rats at 6 mg/kg dose; Not tested,A,In vivo,,Rattus norvegicus,10116.0,
10729,1,,BAO_0000218,Intermediate,,6640,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,
10730,1,,BAO_0000218,Intermediate,,6641,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,
10731,1,,BAO_0000218,Intermediate,,6641,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,
10732,1,,BAO_0000218,Intermediate,,6642,Bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,
10733,1,,BAO_0000218,Intermediate,,5472,Oral bioavailability,A,In vivo,,Rattus norvegicus,10116.0,
10734,1,,BAO_0000218,Intermediate,,6141,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg),A,In vivo,,Rattus norvegicus,10116.0,
10735,1,,BAO_0000218,Intermediate,,4390,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,
10736,1,,BAO_0000218,Intermediate,,5472,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,
10737,1,,BAO_0000218,Intermediate,,5472,Oral bioavailability was evaluated; Not tested,A,In vivo,,Rattus norvegicus,10116.0,
10738,1,,BAO_0000218,Intermediate,,5438,Oral bioavailability,A,In vivo,,Rattus norvegicus,10116.0,
10739,1,,BAO_0000218,Intermediate,,4883,Oral bioavailability in rat by oral dosing,A,In vivo,,Rattus norvegicus,10116.0,
10740,1,,BAO_0000218,Intermediate,,1908,Oral bioavailability in rat (dose 10 mg/kg p.o.),A,In vivo,,Rattus norvegicus,10116.0,
10741,1,,BAO_0000218,Intermediate,,4853,Oral bioavailability in rat (Sprague-Dawley),A,In vivo,,Rattus norvegicus,10116.0,
10742,1,,BAO_0000218,Intermediate,,4853,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),A,In vivo,,Rattus norvegicus,10116.0,
10743,1,,BAO_0000218,Intermediate,,4853,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),A,In vivo,,Rattus norvegicus,10116.0,
10744,1,,BAO_0000218,Intermediate,,4853,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg),A,In vivo,,Rattus norvegicus,10116.0,
10745,1,,BAO_0000218,Intermediate,,4853,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg p.o.),A,In vivo,,Rattus norvegicus,10116.0,
10746,1,,BAO_0000218,Intermediate,,4853,Oral bioavailability was calculated in Spragun Dawley rat at oral dosage of 1 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,
10747,1,,BAO_0000218,Intermediate,,4853,Oral bioavailability was calculated in Spragun Dawley rat at oral dosage of 2 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,
10748,1,,BAO_0000218,Intermediate,,12873,Oral bioavailability was calculated in rats using an average of the intravenous AUC at peroral dose of 5 mgkg in solution form,A,In vivo,,Rattus norvegicus,10116.0,
10749,1,,BAO_0000218,Intermediate,,12873,Oral bioavailability was calculated in rats using an average of the intravenous AUC at peroral dose of 5 mgkg in suspension form,A,In vivo,,Rattus norvegicus,10116.0,
10750,1,,BAO_0000218,Intermediate,,3169,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,
10751,1,,BAO_0000218,Intermediate,,6305,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,
10752,1,,BAO_0000218,Intermediate,,4762,Oral bioavailability of compound at 5 mg/kg after po administration was determined in rat,A,In vivo,,Rattus norvegicus,10116.0,
10753,1,,BAO_0000218,Intermediate,,17847,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,
10754,1,,BAO_0000218,Intermediate,,6211,Oral bioavailability in rat (Sprague-Dawley) (fasted male) (dose 10 mg/kg),A,In vivo,,Rattus norvegicus,10116.0,
10755,1,,BAO_0000218,Intermediate,,6011,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,
10756,1,,BAO_0000218,Intermediate,,6317,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,
10757,1,,BAO_0000218,Intermediate,,6644,Oral bioavailability in rat after oral administration at 10.5 mg/kg dose,A,In vivo,,Rattus norvegicus,10116.0,
10758,1,,BAO_0000218,Intermediate,,6644,Oral bioavailability in rat after oral administration at 11.2 mg/kg dose,A,In vivo,,Rattus norvegicus,10116.0,
10759,1,,BAO_0000218,Intermediate,,6644,Oral bioavailability in rat after oral administration at 13 mg/kg dose,A,In vivo,,Rattus norvegicus,10116.0,
10760,1,,BAO_0000218,Intermediate,,6644,Oral bioavailability in rat after oral administration at 9.7 mg/kg dose,A,In vivo,,Rattus norvegicus,10116.0,
10761,1,,BAO_0000218,Intermediate,,6113,Oral bioavailability (dose 20 mg/kg p.o.),A,In vivo,,Rattus norvegicus,10116.0,
10762,1,,BAO_0000218,Intermediate,,5937,Oral bioavailability was determined in rat after oral administration at a concentration 1 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,
10763,1,,BAO_0000218,Intermediate,,5711,Oral bioavailability in rat at 10 mg/kg of the compound,A,In vivo,,Rattus norvegicus,10116.0,
10764,1,,BAO_0000218,Intermediate,,17717,Bioavailability in rat at a concentration of 15 mg/kg perorally in rat along with 100 mg/kg 11,A,In vivo,,Rattus norvegicus,10116.0,
10765,1,,BAO_0000218,Intermediate,,17717,Bioavailability in rat (dose 3 mg/kg i.v.),A,In vivo,,Rattus norvegicus,10116.0,
10766,1,,BAO_0000218,Intermediate,,17717,Bioavailability in rat at a concentration of 60 mg/kg perorally in rat along with 100 mg/kg 11,A,In vivo,,Rattus norvegicus,10116.0,
10767,1,,BAO_0000218,Intermediate,,17717,Oral bioavailability in rat (dose 60 mg/kg p.o.),A,In vivo,,Rattus norvegicus,10116.0,
10768,1,,BAO_0000218,Intermediate,,4722,Percent bioavailability (F) in rats after iv administration,A,In vivo,,Rattus norvegicus,10116.0,
10769,1,,BAO_0000218,Intermediate,,4722,Percent bioavailability (F) in rats after oral dose of 10 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,
10770,1,,BAO_0000218,Intermediate,,4353,Bioavailability in rat (dose 5 uM/kg p.o.),A,In vivo,,Rattus norvegicus,10116.0,
10771,1,,BAO_0000218,Intermediate,,15662,Oral bioavailability,A,In vivo,,Rattus norvegicus,10116.0,
10772,1,,BAO_0000218,Intermediate,,4756,Bioavailability in rat (dose 2 mg/kg p.o.),A,In vivo,,Rattus norvegicus,10116.0,
10773,1,,BAO_0000218,Intermediate,,4756,Percent bioavailability at the dose of 5 mg/Kg administered perorally in rats,A,In vivo,,Rattus norvegicus,10116.0,
10774,1,,BAO_0000218,Intermediate,,3436,Oral bioavailability in rat (dose 20 mg/kg),A,In vivo,,Rattus norvegicus,10116.0,
10775,1,,BAO_0000218,Intermediate,,17800,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,
10776,1,,BAO_0000218,Intermediate,,15762,Percent oral bioavailability evaluated in rat,A,In vivo,,Rattus norvegicus,10116.0,
10777,1,,BAO_0000218,Intermediate,,5089,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,
10778,1,,BAO_0000218,Intermediate,,5089,Percent oral bioavailability in rat; Not determined,A,In vivo,,Rattus norvegicus,10116.0,
10779,1,,BAO_0000218,Intermediate,,3185,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,
10780,1,,BAO_0000218,Intermediate,,5145,Bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,
10781,1,,BAO_0000218,Intermediate,,3457,Pharmacokinetic property (oral bioavailability) in rat (dose given as a solution),A,In vivo,,Rattus norvegicus,10116.0,
10782,1,,BAO_0000218,Intermediate,,3457,Pharmacokinetic property (oral bioavailability) in rat (dose given as a suspension),A,In vivo,,Rattus norvegicus,10116.0,
10783,1,,BAO_0000218,Intermediate,,5983,Pharmacokinetic property (F) was measured in rat at the dose of 0.32 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,
10784,1,,BAO_0000218,Intermediate,,5739,Oral bioavailability in rat (dose 20 mg/kg p.o.),A,In vivo,,Rattus norvegicus,10116.0,
10785,1,,BAO_0000218,Intermediate,,3579,Cmax at a dose of 30 mg/kg in rat,A,In vivo,,Rattus norvegicus,10116.0,
10786,0,,BAO_0000218,Autocuration,,17788,Cmax in monkeys at a dose of 1 mg/kg,A,In vivo,,Simiiformes,314293.0,
10787,1,,BAO_0000218,Intermediate,,14956,Cmax in rat,A,In vivo,,Rattus norvegicus,10116.0,
10788,1,,BAO_0000218,Intermediate,,17788,Cmax in rats at a dose of 1 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,
10789,1,,BAO_0000218,Intermediate,,9750,Cmax was measured in mice after an oral dose of 50 mg/kg.,A,In vivo,,Mus musculus,10090.0,
10790,0,,BAO_0000218,Autocuration,,12767,"Cmax value at a dose of 12.7 uM/kg, po",A,In vivo,,,,
10791,0,,BAO_0000218,Autocuration,,12767,"Cmax value at a dose of 6.3 uM/kg, iv",A,In vivo,,,,
10792,0,,BAO_0000218,Autocuration,,12767,"Cmax value at a dose of 7.1 uM/kg, iv",A,In vivo,,,,
10793,0,,BAO_0000218,Autocuration,,12703,Cmax value of compound was determined after 1 hr,A,In vivo,,,,
10794,0,,BAO_0000218,Autocuration,,15778,Cmax value of the compound,A,In vivo,,,,
10795,1,,BAO_0000218,Intermediate,,12818,Cmax value administered intraintestinal in rats.,A,In vivo,,Rattus norvegicus,10116.0,
10796,1,,BAO_0000218,Intermediate,,14964,Cmax value administered perorally was determined in rat; Not determined,A,In vivo,,Rattus norvegicus,10116.0,
10797,0,,BAO_0000218,Autocuration,,15808,Cmax value at the dose of 2.3 mg/kg,A,In vivo,,,,
10798,0,,BAO_0000218,Autocuration,,15808,Cmax value at the dose of 5 mg/kg,A,In vivo,,,,
10799,0,,BAO_0000218,Autocuration,,15778,Cmax value in the period of 8 hr after dosing. ,A,In vivo,,,,
10800,0,,BAO_0000218,Autocuration,,3715,Cmax value at a oral dose of 20 mg/kg; Not tested,A,In vivo,,,,
10801,0,,BAO_0000218,Autocuration,,3715,Cmax value at a oral dose of 20 mg/kg,A,In vivo,,,,
10802,1,,BAO_0000218,Intermediate,,1446,Cmax value was determined between 15 and 30 minutes post administration in fisher rats; value ranges from 200-500,A,In vivo,,Rattus norvegicus,10116.0,
10803,1,,BAO_0000218,Intermediate,,15240,Cmax(ng /mL)values after oral administration of 10 mg/kg in guinea pig.,A,In vivo,,Cavia porcellus,10141.0,
10804,1,,BAO_0000218,Intermediate,,15240,Cmax(ng /mL)values after oral administration of 10 mg/kg in rat.,A,In vivo,,Rattus norvegicus,10116.0,
10805,1,,BAO_0000218,Intermediate,1969.0,14810,Compound at a dose of 10 mg/kg was orally administered to rats and maximum plasma concentration was reported,A,In vivo,,Rattus norvegicus,10116.0,
10806,1,,BAO_0000218,Intermediate,1969.0,14239,Compound was evaluated for maximum plasma concentration by administering orally at 25 mg/kg in mice,A,In vivo,,Mus musculus,10090.0,
10807,1,,BAO_0000218,Intermediate,2107.0,12555,Compound was evaluated for maximum plasma concentration levels in dogs for the orally delivered compound in 0.05 M citric acid,A,In vivo,,Canis lupus familiaris,9615.0,
10808,1,,BAO_0000218,Intermediate,,10754,Compound was evaluated in vivo for its concentration after a peroral administration 40 mg/kg in dogs.,A,In vivo,,Canis lupus familiaris,9615.0,
10809,1,,BAO_0000218,Intermediate,178.0,10754,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after a intramuscular administration 40 mg/kg in mice,A,In vivo,,Mus musculus,10090.0,
10810,1,,BAO_0000218,Intermediate,178.0,10754,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after a peroral administration 40 mg/kg in mice,A,In vivo,,Mus musculus,10090.0,
10811,1,,BAO_0000218,Intermediate,178.0,10754,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after a peroral administration of 40 mg/kg in mice,A,In vivo,,Mus musculus,10090.0,
10812,1,,BAO_0000218,Intermediate,178.0,10754,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after an intramuscular administration of 40 mg/kg in mice,A,In vivo,,Mus musculus,10090.0,
10813,1,,BAO_0000218,Intermediate,178.0,10754,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after an intramuscular administration of 40 mg/kg in mice.,A,In vivo,,Mus musculus,10090.0,
10814,1,,BAO_0000218,Intermediate,,14600,Compound was tested Growth Hormone(GH) release after 0.5 mg/kg administration (Po) in Beagle dogs,F,In vivo,,Canis lupus familiaris,9615.0,
10815,1,,BAO_0000218,Intermediate,,14600,Compound was tested Growth Hormone(GH) release after 10 mg/kg administration (Po) in Beagle dogs,F,In vivo,,Canis lupus familiaris,9615.0,
10816,1,,BAO_0000218,Intermediate,,14600,Compound was tested Growth Hormone(GH) release after 2.5 mg/kg administration (Po) in Beagle dogs,F,In vivo,,Canis lupus familiaris,9615.0,
10817,1,,BAO_0000218,Intermediate,1969.0,13543,Bioavailability as maximal plasma concentration in dogs,A,In vivo,,Canis lupus familiaris,9615.0,
10818,1,,BAO_0000218,Intermediate,1969.0,13543,Bioavailability as maximal plasma concentration in dogs,A,In vivo,,Canis lupus familiaris,9615.0,
10819,1,,BAO_0000218,Intermediate,1969.0,13543,Bioavailability as maximal plasma concentration in rats,A,In vivo,,Rattus norvegicus,10116.0,
10820,0,,BAO_0000218,Autocuration,1969.0,13543,Bioavailability as maximal plasma concentration in rats,A,In vivo,,Rattus norvegicus,10116.0,
10821,1,,BAO_0000218,Intermediate,178.0,14600,Compound was tested for maximum blood concentration after 0.5 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,A,In vivo,,Canis lupus familiaris,9615.0,
10822,1,,BAO_0000218,Intermediate,178.0,14600,Compound was tested for maximum blood concentration after 10 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,A,In vivo,,Canis lupus familiaris,9615.0,
10823,1,,BAO_0000218,Intermediate,178.0,14600,Compound was tested for maximum blood concentration after 2.5 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,A,In vivo,,Canis lupus familiaris,9615.0,
10824,1,,BAO_0000218,Intermediate,178.0,14600,Compound was tested for maximum concentration in blood after 0.5 mg/kg administration (Po) in Beagle dogs; nd = Not Detectable,A,In vivo,,Canis lupus familiaris,9615.0,
10825,1,,BAO_0000218,Intermediate,178.0,14600,Compound was tested for maximum concentration in blood after 10 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,A,In vivo,,Canis lupus familiaris,9615.0,
10826,1,,BAO_0000218,Intermediate,178.0,14600,Compound was tested for maximum concentration in blood after 2.5 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,A,In vivo,,Canis lupus familiaris,9615.0,
10827,1,,BAO_0000218,Intermediate,,14681,Compound was tested for maximum observed concentration in three male Wistar rats at a single 5 mg/kg oral gavage dose,A,In vivo,,Rattus norvegicus,10116.0,
10828,0,,BAO_0000218,Autocuration,,15905,Compound was tested for the max. conc. when administered perorally(po) 30 mg/kg,A,In vivo,,,,
10829,0,,BAO_0000218,Autocuration,1969.0,15905,Compound was tested for the max. plasma conc. when administered intraperitoneally (ip) 30 mg/kg.,A,In vivo,,,,
10830,1,,BAO_0000218,Intermediate,1969.0,13304,"Drug plasma level in rat was determined on the last day of dosing at 1,2,4.8 and 24 hr and ED50 was evaluated",A,In vivo,,Rattus norvegicus,10116.0,
10831,1,,BAO_0000218,Intermediate,1969.0,15137,Effect of ip administration of compound on plasma concentration of allo-pregnanolone (AP) in rats after 30 min.,A,In vivo,,Rattus norvegicus,10116.0,
10832,1,,BAO_0000218,Intermediate,1969.0,15137,Effect of ip administration of compound on plasma concentration of allotetrahydrodeoxy corticosterone(THDOC) in rats after 30 min.,A,In vivo,,Rattus norvegicus,10116.0,
10833,1,,BAO_0000218,Intermediate,1969.0,15137,Effect of ip administration of compound on plasma concentration of corticosterone (CTS) in rats after 30 min.,A,In vivo,,Rattus norvegicus,10116.0,
10834,1,,BAO_0000218,Intermediate,1969.0,15137,Effect of ip administration of compound on plasma concentration of pregnenolone (PRE) in rats after 30 min.,A,In vivo,,Rattus norvegicus,10116.0,
10835,1,,BAO_0000218,Intermediate,1969.0,15137,Effect of ip administration of compound on plasma concentration of progesterone (PRO) in rats after 30 min.,A,In vivo,,Rattus norvegicus,10116.0,
10836,1,,BAO_0000218,Intermediate,1969.0,14839,In vivo antitumor efficacy expressed as maximum plasma concentration 0.4 hr after a peroral dose of 25 mg/kg in cynomolgus monkeys,A,In vivo,,Macaca fascicularis,9541.0,
10837,1,,BAO_0000218,Intermediate,1969.0,14839,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,A,In vivo,,Mus musculus,10090.0,
10838,1,,BAO_0000218,Intermediate,1969.0,14839,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,A,In vivo,,Mus musculus,10090.0,
10839,1,,BAO_0000218,Intermediate,1969.0,14839,In vivo antitumor efficacy expressed as maximum plasma concentration after a peroral dose of 10 mg/kg in cynomolgus monkeys,A,In vivo,,Macaca fascicularis,9541.0,
10840,1,,BAO_0000218,Intermediate,948.0,8418,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 0.89-1.24,A,,,Rattus norvegicus,10116.0,
10841,1,,BAO_0000218,Intermediate,948.0,8418,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 2.24-2.58,A,,,Rattus norvegicus,10116.0,
10842,1,,BAO_0000218,Intermediate,948.0,8418,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.24-0.28,A,,,Rattus norvegicus,10116.0,
10843,1,,BAO_0000218,Intermediate,948.0,8418,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.52-0.62,A,,,Rattus norvegicus,10116.0,
10844,1,,BAO_0000218,Intermediate,948.0,8418,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.68-0.84,A,,,Rattus norvegicus,10116.0,
10845,1,,BAO_0000218,Intermediate,948.0,8418,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.75-1.03,A,,,Rattus norvegicus,10116.0,
10846,1,,BAO_0000218,Intermediate,948.0,8418,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.96-2.46,A,,,Rattus norvegicus,10116.0,
10847,1,,BAO_0000218,Intermediate,948.0,8418,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.36-0.42,A,,,Rattus norvegicus,10116.0,
10848,1,,BAO_0000218,Intermediate,948.0,8418,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.58-0.82,A,,,Rattus norvegicus,10116.0,
10849,1,,BAO_0000218,Intermediate,948.0,8418,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.24-1.46,A,,,Rattus norvegicus,10116.0,
10850,1,,BAO_0000218,Intermediate,948.0,8418,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 2.36-3.96,A,,,Rattus norvegicus,10116.0,
10851,1,,BAO_0000218,Intermediate,948.0,8418,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.24-0.29,A,,,Rattus norvegicus,10116.0,
10852,1,,BAO_0000218,Intermediate,948.0,8418,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.39-0.74,A,,,Rattus norvegicus,10116.0,
10853,1,,BAO_0000218,Intermediate,948.0,8418,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.79-0.85,A,,,Rattus norvegicus,10116.0,
10854,1,,BAO_0000218,Intermediate,948.0,8418,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.64-0.86,A,,,Rattus norvegicus,10116.0,
10855,1,,BAO_0000218,Intermediate,948.0,8418,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 1.68-2.23,A,,,Rattus norvegicus,10116.0,
10856,1,,BAO_0000218,Intermediate,948.0,8418,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.19-0.23,A,,,Rattus norvegicus,10116.0,
10857,1,,BAO_0000218,Intermediate,948.0,8418,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.22-0.29,A,,,Rattus norvegicus,10116.0,
10858,1,,BAO_0000218,Intermediate,948.0,8418,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.58-0.75,A,,,Rattus norvegicus,10116.0,
10859,1,,BAO_0000218,Intermediate,2113.0,8418,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 1.42-1.82,A,,,Rattus norvegicus,10116.0,
10860,1,,BAO_0000218,Intermediate,2113.0,8418,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 2.24-3.12,A,,,Rattus norvegicus,10116.0,
10861,1,,BAO_0000218,Intermediate,2113.0,8418,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.62-0.92,A,,,Rattus norvegicus,10116.0,
10862,1,,BAO_0000218,Intermediate,2113.0,8418,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 1.12-2.04,A,,,Rattus norvegicus,10116.0,
10863,1,,BAO_0000218,Intermediate,2113.0,8418,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 1.59-2.03,A,,,Rattus norvegicus,10116.0,
10864,1,,BAO_0000218,Intermediate,2113.0,8418,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.14-1.4,A,,,Rattus norvegicus,10116.0,
10865,1,,BAO_0000218,Intermediate,2113.0,8418,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.56-1.83,A,,,Rattus norvegicus,10116.0,
10866,1,,BAO_0000218,Intermediate,2113.0,8418,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.58-0.73,A,,,Rattus norvegicus,10116.0,
10867,1,,BAO_0000218,Intermediate,2113.0,8418,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 1.67-2.11,A,,,Rattus norvegicus,10116.0,
10868,1,,BAO_0000218,Intermediate,2113.0,8418,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.64-3.43,A,,,Rattus norvegicus,10116.0,
10869,1,,BAO_0000218,Intermediate,2113.0,8418,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 3.18-4.74,A,,,Rattus norvegicus,10116.0,
10870,1,,BAO_0000218,Intermediate,2113.0,8418,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.62-1.13,A,,,Rattus norvegicus,10116.0,
10871,1,,BAO_0000218,Intermediate,2113.0,8418,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 1.73-2.64,A,,,Rattus norvegicus,10116.0,
10872,1,,BAO_0000218,Intermediate,2113.0,8418,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 13.02-19.07,A,,,Rattus norvegicus,10116.0,
10873,1,,BAO_0000218,Intermediate,2113.0,8418,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.89-1.19,A,,,Rattus norvegicus,10116.0,
10874,1,,BAO_0000218,Intermediate,2113.0,8418,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 1.17-1.48,A,,,Rattus norvegicus,10116.0,
10875,1,,BAO_0000218,Intermediate,2113.0,8418,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.48-0.72,A,,,Rattus norvegicus,10116.0,
10876,1,,BAO_0000218,Intermediate,2113.0,8418,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.49-0.57,A,,,Rattus norvegicus,10116.0,
10877,1,,BAO_0000218,Intermediate,2113.0,8418,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.99-1.24,A,,,Rattus norvegicus,10116.0,
10878,1,,BAO_0000218,Intermediate,2107.0,8418,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 1.23-1.78,A,,,Rattus norvegicus,10116.0,
10879,1,,BAO_0000218,Intermediate,2107.0,8418,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 2.43-2.92,A,,,Rattus norvegicus,10116.0,
10880,1,,BAO_0000218,Intermediate,2107.0,8418,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.81-1.18,A,,,Rattus norvegicus,10116.0,
10881,1,,BAO_0000218,Intermediate,2107.0,8418,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 1.37-1.74,A,,,Rattus norvegicus,10116.0,
10882,1,,BAO_0000218,Intermediate,2107.0,8418,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 4.01-4.81,A,,,Rattus norvegicus,10116.0,
10883,1,,BAO_0000218,Intermediate,,6996,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5.4 mg/kg after ip administration ( 0-6 hr),A,,,Canis lupus familiaris,9615.0,
10884,1,,BAO_0000218,Intermediate,,6996,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration,A,,,Canis lupus familiaris,9615.0,
10885,1,,BAO_0000218,Intermediate,,6996,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration (0-6 hr),A,,,Canis lupus familiaris,9615.0,
10886,1,,BAO_0000218,Intermediate,,6996,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration ( 0 - 6 hr),A,,,Canis lupus familiaris,9615.0,
10887,1,,BAO_0000218,Intermediate,,6996,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration ( 0-6 hr ),A,,,Canis lupus familiaris,9615.0,
10888,1,,BAO_0000218,Intermediate,,6996,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration ( 0-6 hr),A,,,Canis lupus familiaris,9615.0,
10889,1,,BAO_0000218,Intermediate,,6996,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration,A,,,Rattus norvegicus,10116.0,
10890,1,,BAO_0000218,Intermediate,,6996,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),A,,,Rattus norvegicus,10116.0,
10891,1,,BAO_0000218,Intermediate,,6996,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration (0-5 hr),A,,,Rattus norvegicus,10116.0,
10892,1,,BAO_0000218,Intermediate,,6996,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration ( 0 - 5 hr),A,,,Rattus norvegicus,10116.0,
10893,1,,BAO_0000218,Intermediate,,6996,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr ),A,,,Rattus norvegicus,10116.0,
10894,1,,BAO_0000218,Intermediate,,6996,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),A,,,Rattus norvegicus,10116.0,
10895,1,,BAO_0000218,Intermediate,,6996,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration,A,,,Rattus norvegicus,10116.0,
10896,1,,BAO_0000218,Intermediate,,6996,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),A,,,Rattus norvegicus,10116.0,
10897,1,,BAO_0000218,Intermediate,,6996,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration (0-5 hr),A,,,Rattus norvegicus,10116.0,
10898,1,,BAO_0000218,Intermediate,,6996,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration ( 0 - 5 hr),A,,,Rattus norvegicus,10116.0,
10899,1,,BAO_0000218,Intermediate,,6996,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr ),A,,,Rattus norvegicus,10116.0,
10900,1,,BAO_0000218,Intermediate,,6996,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),A,,,Rattus norvegicus,10116.0,
10901,1,,BAO_0000218,Intermediate,,6996,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration,A,,,Rattus norvegicus,10116.0,
10902,1,,BAO_0000218,Intermediate,,6996,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),A,,,Rattus norvegicus,10116.0,
10903,1,,BAO_0000218,Intermediate,,6996,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration (0-5 hr),A,,,Rattus norvegicus,10116.0,
10904,1,,BAO_0000218,Intermediate,,6996,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration ( 0 - 5 hr),A,,,Rattus norvegicus,10116.0,
10905,1,,BAO_0000218,Intermediate,,6996,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr ),A,,,Rattus norvegicus,10116.0,
10906,1,,BAO_0000218,Intermediate,,6996,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),A,,,Rattus norvegicus,10116.0,
10907,1,,BAO_0000218,Intermediate,,6996,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration,A,,,Rattus norvegicus,10116.0,
10908,1,,BAO_0000218,Intermediate,,6996,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),A,,,Rattus norvegicus,10116.0,
10909,1,,BAO_0000218,Intermediate,,6996,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration (0-5 hr),A,,,Rattus norvegicus,10116.0,
10910,1,,BAO_0000218,Intermediate,,6996,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration ( 0 - 5 hr),A,,,Rattus norvegicus,10116.0,
10911,1,,BAO_0000218,Intermediate,,6996,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr ),A,,,Rattus norvegicus,10116.0,
10912,1,,BAO_0000218,Intermediate,,6996,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),A,,,Rattus norvegicus,10116.0,
10913,1,,BAO_0000218,Intermediate,,6996,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 0.312 mg/kg after ip administration,A,,,Canis lupus familiaris,9615.0,
10914,1,,BAO_0000218,Intermediate,,6996,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 0.3 mg/kg after ip administration (0-6 hr),A,,,Canis lupus familiaris,9615.0,
10915,1,,BAO_0000218,Intermediate,,6996,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 0.625 mg/kg after ip administration,A,,,Canis lupus familiaris,9615.0,
10916,1,,BAO_0000218,Intermediate,,6996,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 0.6 mg/kg after ip administration ( 0-6 hr),A,,,Canis lupus familiaris,9615.0,
10917,1,,BAO_0000218,Intermediate,,6996,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1.8 mg/kg after ip administration ( 0-6 hr),A,,,Canis lupus familiaris,9615.0,
10918,1,,BAO_0000218,Intermediate,,6996,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 10 mg/kg after ip administration (0-6 hr),A,,,Canis lupus familiaris,9615.0,
10919,1,,BAO_0000218,Intermediate,,6996,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 10 mg/kg after ip administration ( 0-6 hr),A,,,Canis lupus familiaris,9615.0,
10920,1,,BAO_0000218,Intermediate,,6996,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 16.2 mg/kg after ip administration ( 0-6 hr),A,,,Canis lupus familiaris,9615.0,
10921,1,,BAO_0000218,Intermediate,,6996,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1 mg/kg after ip administration ( 0-6 hr),A,,,Canis lupus familiaris,9615.0,
10922,1,,BAO_0000218,Intermediate,,6996,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1 mg/kg after ip administration (0-6 hr),A,,,Canis lupus familiaris,9615.0,
10923,1,,BAO_0000218,Intermediate,,6996,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1 mg/kg after ip administration ( 0 - 6 hr),A,,,Canis lupus familiaris,9615.0,
10924,1,,BAO_0000218,Intermediate,,6996,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1 mg/kg after ip administration ( 0-6 hr ),A,,,Canis lupus familiaris,9615.0,
10925,1,,BAO_0000218,Intermediate,,6996,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 20 mg/kg after ip administration ( 0-6 hr),A,,,Canis lupus familiaris,9615.0,
10926,1,,BAO_0000218,Intermediate,,6996,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 2 mg/kg after ip administration,A,,,Canis lupus familiaris,9615.0,
10927,1,,BAO_0000218,Intermediate,,6996,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 2 mg/kg after ip administration (0-6 hr),A,,,Canis lupus familiaris,9615.0,
10928,1,,BAO_0000218,Intermediate,,6996,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 2 mg/kg after ip administration ( 0 - 6 hr),A,,,Canis lupus familiaris,9615.0,
10929,1,,BAO_0000218,Intermediate,1637.0,9025,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 1/3 range; -2/-14,A,In vivo,,Canis lupus familiaris,9615.0,
10930,1,,BAO_0000218,Intermediate,1637.0,9025,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 1/3 range; -4/-4,A,In vivo,,Canis lupus familiaris,9615.0,
10931,1,,BAO_0000218,Intermediate,1637.0,9025,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 1/3 range; 4/7,A,In vivo,,Canis lupus familiaris,9615.0,
10932,1,,BAO_0000218,Intermediate,1637.0,9025,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 1/3/10 range; -3/0/4,A,In vivo,,Canis lupus familiaris,9615.0,
10933,1,,BAO_0000218,Intermediate,1637.0,9025,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; -6/0,A,In vivo,,Canis lupus familiaris,9615.0,
10934,1,,BAO_0000218,Intermediate,1637.0,9025,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 10/31,A,In vivo,,Canis lupus familiaris,9615.0,
10935,1,,BAO_0000218,Intermediate,1637.0,9025,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 11/-19,A,In vivo,,Canis lupus familiaris,9615.0,
10936,1,,BAO_0000218,Intermediate,1637.0,9025,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 14/6,A,In vivo,,Canis lupus familiaris,9615.0,
10937,1,,BAO_0000218,Intermediate,1637.0,9025,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 19/25,A,In vivo,,Canis lupus familiaris,9615.0,
10938,1,,BAO_0000218,Intermediate,1637.0,9025,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 19/3,A,In vivo,,Canis lupus familiaris,9615.0,
10939,1,,BAO_0000218,Intermediate,1637.0,9025,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 2/16,A,In vivo,,Canis lupus familiaris,9615.0,
10940,1,,BAO_0000218,Intermediate,1637.0,9025,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 6/2,A,In vivo,,Canis lupus familiaris,9615.0,
10941,1,,BAO_0000218,Intermediate,1637.0,9025,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 7/26,A,In vivo,,Canis lupus familiaris,9615.0,
10942,1,,BAO_0000218,Intermediate,1637.0,9025,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 8/49,A,In vivo,,Canis lupus familiaris,9615.0,
10943,1,,BAO_0000218,Intermediate,1637.0,9025,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 8/8,A,In vivo,,Canis lupus familiaris,9615.0,
10944,1,,BAO_0000218,Intermediate,1637.0,9025,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 9/-18,A,In vivo,,Canis lupus familiaris,9615.0,
10945,1,,BAO_0000218,Intermediate,1637.0,9025,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/60 range; 13/23,A,In vivo,,Canis lupus familiaris,9615.0,
10946,1,,BAO_0000218,Intermediate,1637.0,9025,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 3 range,A,In vivo,,Canis lupus familiaris,9615.0,
10947,1,,BAO_0000218,Intermediate,1637.0,9025,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 3/10 range; -7/-11,A,In vivo,,Canis lupus familiaris,9615.0,
10948,1,,BAO_0000218,Intermediate,1637.0,9025,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a of 1/3 dose range; 6/-7,A,In vivo,,Canis lupus familiaris,9615.0,
10949,1,,BAO_0000218,Intermediate,1637.0,9025,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a of 10/30 dose range; -13/19,A,In vivo,,Canis lupus familiaris,9615.0,
10950,1,,BAO_0000218,Intermediate,1637.0,9025,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a of 3/10 dose range; 30/47,A,In vivo,,Canis lupus familiaris,9615.0,
10951,1,,BAO_0000218,Intermediate,,2249,Compound was evaluated for its bioavailability in the dogs,A,In vivo,,Canis lupus familiaris,9615.0,
10952,1,,BAO_0000218,Intermediate,,2249,Compound was evaluated for its bioavailability in the rats,A,In vivo,,Rattus norvegicus,10116.0,
10953,0,,BAO_0000218,Autocuration,,17515,Compound was evaluated for oral bioavailability,A,In vivo,,,,
10954,1,,BAO_0000218,Intermediate,,14541,Compound was evaluated for percentage of Oral bioavailability in rats,A,In vivo,,Rattus norvegicus,10116.0,
10955,0,,BAO_0000218,Autocuration,,12797,Bioavailability in guinea pig,A,In vivo,,Cavia porcellus,10141.0,
10956,1,,BAO_0000218,Intermediate,,12797,Compound was evaluated for the oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,
10957,1,,BAO_0000218,Intermediate,,12797,Compound was evaluated for the oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,
10958,1,,BAO_0000218,Intermediate,,12797,Compound was evaluated for the oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,
10959,0,,BAO_0000218,Autocuration,,11727,Bioavailability in dog (dosed i.v.),F,In vivo,,Canis lupus familiaris,9615.0,
10960,1,,BAO_0000218,Intermediate,,13249,Compound was tested for in vivo bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,
10961,1,,BAO_0000218,Intermediate,,13249,Compound was tested for in vivo bioavailability in hamsters,A,In vivo,,Cricetinae,10026.0,
10962,0,,BAO_0000218,Autocuration,,13249,Compound was tested for in vivo bioavailability in monkey,A,In vivo,,Simiiformes,314293.0,
10963,1,,BAO_0000218,Intermediate,,13249,Compound was tested for in vivo bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,
10964,0,,BAO_0000218,Autocuration,,9552,Oral bioavailability in mouse,A,In vivo,,Mus musculus,10090.0,
10965,1,,BAO_0000218,Intermediate,,9552,Compound was tested for percent of oral bioavailability in mice; 56-74,A,In vivo,,Mus musculus,10090.0,
10966,0,,BAO_0000218,Autocuration,,14839,Oral bioavailability in mouse (nude) (dose of 25 mg/kg),A,In vivo,,Mus musculus,10090.0,
10967,0,,BAO_0000218,Autocuration,,14839,Bioavailability in cynomolgus monkey (dose 25 mg/kg i.v.),A,In vivo,,Macaca fascicularis,9541.0,
10968,0,,BAO_0000218,Autocuration,,14839,Bioavailability in cynomolgus monkey (dose 5 mg/kg i.v.),A,In vivo,,Macaca fascicularis,9541.0,
10969,1,,BAO_0000218,Intermediate,,14839,Oral bioavailability in mouse (nude) (dose 25 mg/kg i.v.),A,In vivo,,Mus musculus,10090.0,
10970,1,,BAO_0000218,Intermediate,,14839,Oral bioavailability in nude mice,A,In vivo,,Mus musculus,10090.0,
10971,0,,BAO_0000218,Autocuration,,11219,Bioavailability in monkey (i.d. dosing),A,In vivo,,Primates,9443.0,
10972,0,,BAO_0000218,Autocuration,,9552,Bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,
10973,0,,BAO_0000218,Autocuration,,11732,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 10%,A,In vivo,,,,
10974,0,,BAO_0000218,Autocuration,,11732,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 20%,A,In vivo,,,,
10975,1,,BAO_0000218,Intermediate,,14839,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 10 mg/kg, as HCl salt in saline solution, perorally and the maximum drug concentration was determined",A,In vivo,,Macaca fascicularis,9541.0,
10976,1,,BAO_0000218,Intermediate,,14839,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the maximum drug concentration was determined",A,In vivo,,Macaca fascicularis,9541.0,
10977,1,,BAO_0000218,Intermediate,,14839,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 5 mg/kg, as HCl salt in saline solution, perorally and the maximum drug concentration was determined",A,In vivo,,Macaca fascicularis,9541.0,
10978,1,,BAO_0000218,Intermediate,1969.0,14839,Maximal plasma concentration in cynomolgus monkeys after 10 mg/kg oral dose,A,In vivo,,Macaca fascicularis,9541.0,
10979,1,,BAO_0000218,Intermediate,1969.0,14839,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,A,In vivo,,Mus musculus,10090.0,
10980,1,,BAO_0000218,Intermediate,1969.0,14839,Maximal plasma concentration in cynomolgus monkeys after 5 mg/kg oral dose,A,In vivo,,Macaca fascicularis,9541.0,
10981,1,,BAO_0000218,Intermediate,1969.0,14839,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,A,In vivo,,Mus musculus,10090.0,
10982,1,,BAO_0000218,Intermediate,1969.0,14839,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,A,In vivo,,Mus musculus,10090.0,
10983,1,,BAO_0000218,Intermediate,1969.0,14839,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,A,In vivo,,Mus musculus,10090.0,
10984,0,,BAO_0000218,Autocuration,1969.0,13932,In vivo evaluation of maximum plasma concentration at a dose of 10 mg/kg,A,In vivo,,,,
10985,1,,BAO_0000218,Intermediate,1969.0,11637,Cmax in mouse plasma,A,In vivo,,Mus musculus,10090.0,
10986,0,,BAO_0000218,Autocuration,1969.0,11637,Max plasma concentration was measured by 40 mg/kg dose of peroral administration.,A,In vivo,,,,
10987,1,,BAO_0000218,Intermediate,1969.0,13960,Maximal plasma concentration in rat,A,In vivo,,Rattus norvegicus,10116.0,
10988,1,,BAO_0000218,Intermediate,1969.0,15905,Maximal plasma level when administered 1 mg/kg perorally (po) in rat,A,In vivo,,Rattus norvegicus,10116.0,
10989,1,,BAO_0000218,Intermediate,,14062,Maximum concentration at an intraduodenal dose of 5.2 mg/kg in rat,A,In vivo,,Rattus norvegicus,10116.0,
10990,1,,BAO_0000218,Intermediate,,14062,Maximum concentration at an intraduodenal dose of 6.6 mg/kg in rat,A,In vivo,,Rattus norvegicus,10116.0,
10991,1,,BAO_0000218,Intermediate,,14062,Maximum concentration at an intravenous dose of 5.5 mg/kg in rat,A,In vivo,,Rattus norvegicus,10116.0,
10992,1,,BAO_0000218,Intermediate,,14062,Maximum concentration at an intravenous dose of 6.5 mg/kg in rat,A,In vivo,,Rattus norvegicus,10116.0,
10993,1,,BAO_0000218,Intermediate,,14062,Maximum concentration at an peroral dose of 6.2 mg/kg in rat,A,In vivo,,Rattus norvegicus,10116.0,
10994,1,,BAO_0000218,Intermediate,,14062,Maximum concentration at an peroral dose of 6.3 mg/kg in rat,A,In vivo,,Rattus norvegicus,10116.0,
10995,1,,BAO_0000218,Intermediate,,15011,Maximum concentration (Cmax) using 0.4% Methyl cellulose (MC) as vehicle. compound was administered intravenously to nude mice at a dose of 25 mg/kg,A,In vivo,,Mus musculus,10090.0,
10996,1,,BAO_0000218,Intermediate,,15011,Maximum concentration (Cmax) using 0.4% Methyl cellulose (MC) as vehicle. compound was administered orally to nude mice at a dose of 25 mg/kg,A,In vivo,,Mus musculus,10090.0,
10997,1,,BAO_0000218,Intermediate,,15011,Maximum concentration (Cmax) using 0.4% Methyl cellulose (MC) as vehicle. compound was administered orally to nude mice at a dose of 25 mg/kg (micronized sample),A,In vivo,,Mus musculus,10090.0,
10998,1,,BAO_0000218,Intermediate,,15011,Maximum concentration (Cmax) using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. compound was administered intravenously to nude mice at a dose of 25 mg/kg,A,In vivo,,Mus musculus,10090.0,
10999,1,,BAO_0000218,Intermediate,,15011,Maximum concentration (Cmax) using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. compound was administered orally to nude mice at a dose of 25 mg/kg,A,In vivo,,Mus musculus,10090.0,
11000,0,,BAO_0000218,Autocuration,,10291,Maximum Concentration of the compound.,A,In vivo,,,,
11001,1,,BAO_0000218,Intermediate,,14599,Maximum Concentration was measured after iv administration into Beagle dog,A,In vivo,,Canis lupus familiaris,9615.0,
11002,1,,BAO_0000218,Intermediate,,14599,Maximum Concentration was measured after iv administration into Beagle dog.,A,In vivo,,Canis lupus familiaris,9615.0,
11003,1,,BAO_0000218,Intermediate,,14599,Maximum Concentration was measured after po administration into Beagle dog,A,In vivo,,Canis lupus familiaris,9615.0,
11004,1,,BAO_0000218,Intermediate,,14599,Maximum Concentration was measured after po administration into Beagle dog.,A,In vivo,,Canis lupus familiaris,9615.0,
11005,0,,BAO_0000218,Autocuration,178.0,12767,Maximum blood level reached after an dose of 10.6 uM/kg intravenously,A,In vivo,,,,
11006,0,,BAO_0000218,Autocuration,178.0,12767,Maximum blood level reached after an iv dose of 12.2 uM/kg,A,In vivo,,,,
11007,0,,BAO_0000218,Autocuration,178.0,12767,Maximum blood level reached after an oral dose 14.7 uM/kg oral route,A,In vivo,,,,
11008,0,,BAO_0000218,Autocuration,178.0,12767,Maximum blood level reached after an oral dose of 14.7 uM/kg intravenous route,A,In vivo,,,,
11009,0,,BAO_0000218,Autocuration,178.0,12767,Maximum blood level reached after an oral dose of 5.0 mg/kg,A,In vivo,,,,
11010,0,,BAO_0000218,Autocuration,178.0,12767,Maximum blood level reached at dose of 10.6 uM/kg orally,A,In vivo,,,,
11011,1,,BAO_0000218,Intermediate,,14706,Maximum concentration (Cmax) in guinea pigs at 2 mg/kg after oral administration,A,In vivo,,Cavia porcellus,10141.0,
11012,1,,BAO_0000218,Intermediate,,14706,Maximum concentration (Cmax) in guinea pigs at 3 mg/kg after oral administration,A,In vivo,,Cavia porcellus,10141.0,
11013,1,,BAO_0000218,Intermediate,955.0,14793,Maximum concentration achieved in rat brain when administered intraperitoneally at a dose of 10 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,
11014,1,,BAO_0000218,Intermediate,955.0,14793,Maximum concentration achieved in rat brain when administered intravenously at a dose of 10 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,
11015,1,,BAO_0000218,Intermediate,955.0,14793,Maximum concentration achieved in rat brain when administered perorally at a dose of 100 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,
11016,1,,BAO_0000218,Intermediate,955.0,14793,Maximum concentration achieved in rat brain when administered perorally at a dose of 10 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,
11017,1,,BAO_0000218,Intermediate,,14793,Maximum concentration achieved in rat plasma when administered intraperitoneally at a dose of 10 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,
11018,1,,BAO_0000218,Intermediate,,14793,Maximum concentration achieved in rat plasma when administered intravenously at a dose of 10 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,
11019,1,,BAO_0000218,Intermediate,,14793,Maximum concentration achieved in rat plasma when administered perorally at a dose of 100 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,
11020,1,,BAO_0000218,Intermediate,,14793,Maximum concentration achieved in rat plasma when administered perorally at a dose of 10 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,
11021,1,,BAO_0000218,Intermediate,,10524,Maximum concentration determined against Bacillus subtilis ATCC 6633 after oral administration in dog(25 mg/kg),A,In vivo,,Bacillus subtilis,1423.0,
11022,0,,BAO_0000218,Autocuration,,11871,Maximum concentration determined in monkeys dosed intravenously with 30 mg/kg,A,In vivo,,Simiiformes,314293.0,
11023,1,,BAO_0000218,Intermediate,,11871,Maximum concentration determined in rats dosed intravenously with 20 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,
11024,0,,BAO_0000218,Autocuration,,3437,Maximum concentration for the bioavailability at a dose of 20 mg/kg administered orally,A,In vivo,,,,
11025,1,,BAO_0000218,Intermediate,,12038,Maximum concentration in male CD-1 mice after sc administration of 20 mg/kg,A,In vivo,,Mus musculus,10090.0,
11026,1,,BAO_0000218,Intermediate,,12038,Maximum concentration in male rats after iv administration of 20 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,
11027,1,,BAO_0000218,Intermediate,2107.0,8418,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.06-1.29,A,,,Rattus norvegicus,10116.0,
11028,1,,BAO_0000218,Intermediate,2107.0,8418,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.77-2.08,A,,,Rattus norvegicus,10116.0,
11029,1,,BAO_0000218,Intermediate,2107.0,8418,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.54-0.89,A,,,Rattus norvegicus,10116.0,
11030,1,,BAO_0000218,Intermediate,2107.0,8418,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 1.57-1.66,A,,,Rattus norvegicus,10116.0,
11031,1,,BAO_0000218,Intermediate,2107.0,8418,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.06-2.71,A,,,Rattus norvegicus,10116.0,
11032,1,,BAO_0000218,Intermediate,2107.0,8418,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 2.98-3.22,A,,,Rattus norvegicus,10116.0,
11033,1,,BAO_0000218,Intermediate,2107.0,8418,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.73-1.45,A,,,Rattus norvegicus,10116.0,
11034,1,,BAO_0000218,Intermediate,2107.0,8418,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 1.03-1.31,A,,,Rattus norvegicus,10116.0,
11035,1,,BAO_0000218,Intermediate,2107.0,8418,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 6.76-10.44,A,,,Rattus norvegicus,10116.0,
11036,1,,BAO_0000218,Intermediate,2107.0,8418,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.47-1.17,A,,,Rattus norvegicus,10116.0,
11037,1,,BAO_0000218,Intermediate,2107.0,8418,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 1.12-1.44,A,,,Rattus norvegicus,10116.0,
11038,1,,BAO_0000218,Intermediate,2107.0,8418,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.38-0.57,A,,,Rattus norvegicus,10116.0,
11039,1,,BAO_0000218,Intermediate,2107.0,8418,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.75-1.14,A,,,Rattus norvegicus,10116.0,
11040,1,,BAO_0000218,Intermediate,2107.0,8418,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 1.36-1.74,A,,,Rattus norvegicus,10116.0,
11041,1,,BAO_0000218,Intermediate,2048.0,8418,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 1.05-1.5,A,,,Rattus norvegicus,10116.0,
11042,1,,BAO_0000218,Intermediate,2048.0,8418,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 3.10-3.77,A,,,Rattus norvegicus,10116.0,
11043,1,,BAO_0000218,Intermediate,2048.0,8418,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.4-0.54,A,,,Rattus norvegicus,10116.0,
11044,1,,BAO_0000218,Intermediate,2048.0,8418,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.58-0.86,A,,,Rattus norvegicus,10116.0,
11045,1,,BAO_0000218,Intermediate,2048.0,8418,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.77-0.86,A,,,Rattus norvegicus,10116.0,
11046,1,,BAO_0000218,Intermediate,2048.0,8418,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.86-1.13,A,,,Rattus norvegicus,10116.0,
11047,1,,BAO_0000218,Intermediate,2048.0,8418,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 2.26-2.89,A,,,Rattus norvegicus,10116.0,
11048,1,,BAO_0000218,Intermediate,2048.0,8418,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.54-0.7,A,,,Rattus norvegicus,10116.0,
11049,1,,BAO_0000218,Intermediate,2048.0,8418,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.6-0.66,A,,,Rattus norvegicus,10116.0,
11050,1,,BAO_0000218,Intermediate,2048.0,8418,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.35-1.74,A,,,Rattus norvegicus,10116.0,
11051,1,,BAO_0000218,Intermediate,2048.0,8418,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 3.62-7.08,A,,,Rattus norvegicus,10116.0,
11052,1,,BAO_0000218,Intermediate,2048.0,8418,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.47-0.56,A,,,Rattus norvegicus,10116.0,
11053,1,,BAO_0000218,Intermediate,2048.0,8418,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.54-1.07,A,,,Rattus norvegicus,10116.0,
11054,1,,BAO_0000218,Intermediate,2048.0,8418,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.76-0.91,A,,,Rattus norvegicus,10116.0,
11055,1,,BAO_0000218,Intermediate,2048.0,8418,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.61-0.86,A,,,Rattus norvegicus,10116.0,
11056,1,,BAO_0000218,Intermediate,2048.0,8418,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 2.11-3.79,A,,,Rattus norvegicus,10116.0,
11057,1,,BAO_0000218,Intermediate,2048.0,8418,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.3-0.36,A,,,Rattus norvegicus,10116.0,
11058,1,,BAO_0000218,Intermediate,2048.0,8418,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.36-0.44,A,,,Rattus norvegicus,10116.0,
11059,1,,BAO_0000218,Intermediate,2048.0,8418,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.5-0.65,A,,,Rattus norvegicus,10116.0,
11060,1,,BAO_0000218,Intermediate,,9796,Distribution of radiolabeled compound in intestinal contents of rat 1 hr after ip administration of dose and excess 8 microg of estradiol; fmol equivalents per 100 mg,A,,,Rattus norvegicus,10116.0,
11061,1,,BAO_0000218,Intermediate,,9796,Distribution of radiolabeled compound in intestinal contents of rat 1 hr after ip administration of dose; fmol equivalents per 100 mg,A,,,Rattus norvegicus,10116.0,
11062,1,,BAO_0000218,Intermediate,,9796,Distribution of radiolabeled compound in intestinal contents of rat 1 hr after iv administration of dose; fmol equivalents per 100 mg,A,,,Rattus norvegicus,10116.0,
11063,1,,BAO_0000218,Intermediate,,9796,Distribution of radiolabeled compound in intestinal contents of rat 4 hr after ip administration of dose; fmol equivalents per 100 mg,A,,,Rattus norvegicus,10116.0,
11064,1,,BAO_0000218,Intermediate,,9796,Distribution of radiolabeled compound in intestinal contents of rat 8 hr after ip administration of dose; fmol equivalents per 100 mg,A,,,Rattus norvegicus,10116.0,
11065,1,,BAO_0000218,Intermediate,2107.0,9796,Distribution of radiolabeled compound in liver of rat 1 hr after ip administration of dose and excess 8 microg of estradiol; fmol equivalents per 100 mg,A,,,Rattus norvegicus,10116.0,
11066,1,,BAO_0000218,Intermediate,2107.0,9796,Distribution of radiolabeled compound in liver of rat 1 hr after ip administration of dose; fmol equivalents per 100 mg,A,,,Rattus norvegicus,10116.0,
11067,1,,BAO_0000218,Intermediate,2107.0,9796,Distribution of radiolabeled compound in liver of rat 1 hr after iv administration of dose; fmol equivalents per 100 mg,A,,,Rattus norvegicus,10116.0,
11068,1,,BAO_0000218,Intermediate,2107.0,9796,Distribution of radiolabeled compound in liver of rat 4 hr after ip administration of dose; fmol equivalents per 100 mg,A,,,Rattus norvegicus,10116.0,
11069,1,,BAO_0000218,Intermediate,2107.0,9796,Distribution of radiolabeled compound in liver of rat 8 hr after ip administration of dose; fmol equivalents per 100 mg,A,,,Rattus norvegicus,10116.0,
11070,1,,BAO_0000218,Intermediate,,6996,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5.4 mg/kg after ip administration ( 0-6 hr),A,,,Canis lupus familiaris,9615.0,
11071,1,,BAO_0000218,Intermediate,,6996,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration,A,,,Canis lupus familiaris,9615.0,
11072,1,,BAO_0000218,Intermediate,,6996,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration (0-6 hr),A,,,Canis lupus familiaris,9615.0,
11073,1,,BAO_0000218,Intermediate,,6996,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration ( 0 - 6 hr),A,,,Canis lupus familiaris,9615.0,
11074,1,,BAO_0000218,Intermediate,,6996,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration ( 0-6 hr ),A,,,Canis lupus familiaris,9615.0,
11075,1,,BAO_0000218,Intermediate,,6996,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration ( 0-6 hr),A,,,Canis lupus familiaris,9615.0,
11076,1,,BAO_0000218,Intermediate,,6996,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration,A,,,Rattus norvegicus,10116.0,
11077,1,,BAO_0000218,Intermediate,,6996,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),A,,,Rattus norvegicus,10116.0,
11078,1,,BAO_0000218,Intermediate,,6996,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration (0-5 hr),A,,,Rattus norvegicus,10116.0,
11079,1,,BAO_0000218,Intermediate,,6996,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration ( 0 - 5 hr),A,,,Rattus norvegicus,10116.0,
11080,1,,BAO_0000218,Intermediate,,6996,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr ),A,,,Rattus norvegicus,10116.0,
11081,1,,BAO_0000218,Intermediate,,6996,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),A,,,Rattus norvegicus,10116.0,
11082,1,,BAO_0000218,Intermediate,,6996,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration,A,,,Rattus norvegicus,10116.0,
11083,1,,BAO_0000218,Intermediate,,6996,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration ( 0 - 5 hr),A,,,Rattus norvegicus,10116.0,
11084,1,,BAO_0000218,Intermediate,,6996,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr ),A,,,Rattus norvegicus,10116.0,
11085,1,,BAO_0000218,Intermediate,,6996,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),A,,,Rattus norvegicus,10116.0,
11086,1,,BAO_0000218,Intermediate,,6996,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration (0-5 hr),A,,,Rattus norvegicus,10116.0,
11087,1,,BAO_0000218,Intermediate,,6996,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),A,,,Rattus norvegicus,10116.0,
11088,1,,BAO_0000218,Intermediate,,6996,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration,A,,,Rattus norvegicus,10116.0,
11089,1,,BAO_0000218,Intermediate,,6996,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),A,,,Rattus norvegicus,10116.0,
11090,1,,BAO_0000218,Intermediate,,6996,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration (0-5 hr),A,,,Rattus norvegicus,10116.0,
11091,1,,BAO_0000218,Intermediate,,6996,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr ),A,,,Rattus norvegicus,10116.0,
11092,1,,BAO_0000218,Intermediate,,6996,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),A,,,Rattus norvegicus,10116.0,
11093,1,,BAO_0000218,Intermediate,,6996,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration,A,,,Rattus norvegicus,10116.0,
11094,1,,BAO_0000218,Intermediate,,6996,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),A,,,Rattus norvegicus,10116.0,
11095,1,,BAO_0000218,Intermediate,,6996,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration (0-5 hr),A,,,Rattus norvegicus,10116.0,
11096,1,,BAO_0000218,Intermediate,,6996,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration ( 0 - 5 hr),A,,,Rattus norvegicus,10116.0,
11097,1,,BAO_0000218,Intermediate,,6996,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr ),A,,,Rattus norvegicus,10116.0,
11098,1,,BAO_0000218,Intermediate,,6996,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),A,,,Rattus norvegicus,10116.0,
11099,1,,BAO_0000218,Intermediate,,6996,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 0.312 mg/kg after ip administration,A,,,Canis lupus familiaris,9615.0,
11100,1,,BAO_0000218,Intermediate,,6996,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 0.3 mg/kg after ip administration (0-6 hr),A,,,Canis lupus familiaris,9615.0,
11101,1,,BAO_0000218,Intermediate,,6996,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 0.625 mg/kg after ip administration,A,,,Canis lupus familiaris,9615.0,
11102,1,,BAO_0000218,Intermediate,,6996,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 0.6 mg/kg after ip administration ( 0-6 hr),A,,,Canis lupus familiaris,9615.0,
11103,1,,BAO_0000218,Intermediate,,6996,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1.8 mg/kg after ip administration ( 0-6 hr),A,,,Canis lupus familiaris,9615.0,
11104,1,,BAO_0000218,Intermediate,,6996,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 10 mg/kg after ip administration (0-6 hr),A,,,Canis lupus familiaris,9615.0,
11105,1,,BAO_0000218,Intermediate,,6996,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 10 mg/kg after ip administration ( 0-6 hr),A,,,Canis lupus familiaris,9615.0,
11106,1,,BAO_0000218,Intermediate,,6996,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 16.2 mg/kg after ip administration ( 0-6 hr),A,,,Canis lupus familiaris,9615.0,
11107,1,,BAO_0000218,Intermediate,,6996,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1 mg/kg after ip administration ( 0-6 hr),A,,,Canis lupus familiaris,9615.0,
11108,1,,BAO_0000218,Intermediate,,6996,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1 mg/kg after ip administration (0-6 hr),A,,,Canis lupus familiaris,9615.0,
11109,1,,BAO_0000218,Intermediate,,6996,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1 mg/kg after ip administration ( 0 - 6 hr),A,,,Canis lupus familiaris,9615.0,
11110,1,,BAO_0000218,Intermediate,,6996,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1 mg/kg after ip administration ( 0-6 hr ),A,,,Canis lupus familiaris,9615.0,
11111,1,,BAO_0000218,Intermediate,,6996,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 20 mg/kg after ip administration ( 0-6 hr),A,,,Canis lupus familiaris,9615.0,
11112,1,,BAO_0000218,Intermediate,,6996,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 2 mg/kg after ip administration,A,,,Canis lupus familiaris,9615.0,
11113,1,,BAO_0000218,Intermediate,,6996,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 2 mg/kg after ip administration (0-6 hr),A,,,Canis lupus familiaris,9615.0,
11114,1,,BAO_0000218,Intermediate,,6996,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 2 mg/kg after ip administration ( 0 - 6 hr),A,,,Canis lupus familiaris,9615.0,
11115,0,,BAO_0000218,Autocuration,,11732,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 27%,A,In vivo,,,,
11116,0,,BAO_0000218,Autocuration,,11732,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 4%,A,In vivo,,,,
11117,0,,BAO_0000218,Autocuration,,11732,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 54%,A,In vivo,,,,
11118,0,,BAO_0000218,Autocuration,,11732,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 72%,A,In vivo,,,,
11119,0,,BAO_0000218,Autocuration,,11732,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 76%,A,In vivo,,,,
11120,0,,BAO_0000218,Autocuration,,13359,Oral bioavailability in rat (dose 10 mg/kg),A,In vivo,,Rattus norvegicus,10116.0,
11121,0,,BAO_0000218,Autocuration,,16618,Oral bioavailability in rat (Sprague-Dawley),A,In vivo,,Rattus norvegicus,10116.0,
11122,0,,BAO_0000218,Autocuration,,13960,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,
11123,0,,BAO_0000218,Autocuration,,13917,Oral bioavailability in rats was determined in vivo,A,In vivo,,Rattus norvegicus,10116.0,
11124,0,,BAO_0000218,Autocuration,,14266,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,
11125,0,,BAO_0000218,Autocuration,,12359,Oral bioavailability of compound in monkey,A,In vivo,,Simiiformes,314293.0,
11126,1,,BAO_0000218,Intermediate,,12359,Oral bioavailability of compound in rat,A,In vivo,,Rattus norvegicus,10116.0,
11127,0,,BAO_0000218,Autocuration,,12359,Bioavailability in rat of PMEA prodrug,A,In vivo,,Rattus norvegicus,10116.0,
11128,1,,BAO_0000218,Intermediate,,12359,Oral bioavailability of compound was evaluated relative to that of PMEA in rat; Not determined due to lack of solubility,A,In vivo,,Rattus norvegicus,10116.0,
11129,0,,BAO_0000218,Autocuration,,10791,Serum conc at 3 hours following 25 mg/kg dose,A,In vivo,,Macaca mulatta,9544.0,
11130,0,,BAO_0000218,Autocuration,1088.0,10791,Urine conc 0-5 hours following 25 mg/kg dose,A,In vivo,,Macaca mulatta,9544.0,
11131,0,,BAO_0000218,Autocuration,1088.0,10791,Urine conc 0-24 hours following 25 mg/kg dose,A,In vivo,,Macaca mulatta,9544.0,
11132,0,,BAO_0000218,Autocuration,,138,Oral bioavailability in African green monkeys; 20-25,A,In vivo,,Chlorocebus aethiops,9534.0,
11133,1,,BAO_0000218,Intermediate,,14521,Oral bioavailability in cynomolgus monkey.,A,In vivo,,Macaca fascicularis,9541.0,
11134,0,,BAO_0000218,Autocuration,,13953,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,
11135,1,,BAO_0000218,Intermediate,,12836,Oral bioavailability in dog at 10 mg/kg oral dose,A,In vivo,,Canis lupus familiaris,9615.0,
11136,1,,BAO_0000218,Intermediate,,12836,Oral bioavailability in hamster at 10 mg/kg oral dose,A,In vivo,,Cricetinae,10026.0,
11137,1,,BAO_0000218,Intermediate,,12836,Oral bioavailability in rat at 10 mg/kg oral dose,A,In vivo,,Rattus norvegicus,10116.0,
11138,0,,BAO_0000218,Autocuration,,14521,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,
11139,0,,BAO_0000218,Autocuration,,13953,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,
11140,0,,BAO_0000218,Autocuration,,6799,Oral bioavailability,A,In vivo,,Eutheria,9347.0,
11141,0,,BAO_0000218,Autocuration,,11311,Oral bioavailability was determined; range 49-102%,A,In vivo,,,,
11142,1,,BAO_0000218,Intermediate,,4013,Oral bioavailability was determined in dogs,A,In vivo,,Canis lupus familiaris,9615.0,
11143,0,,BAO_0000218,Autocuration,,4013,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,
11144,0,,BAO_0000218,Autocuration,,17591,Oral bioavailability,A,In vivo,,Eutheria,9347.0,
11145,0,,BAO_0000218,Autocuration,,17591,Oral bioavailability was determined; Not orally available,A,In vivo,,,,
11146,1,,BAO_0000218,Intermediate,,15011,Percent bioavailability was administered by using 0.4% Methyl cellulose (MC) as vehicle to nude mice at a dose of 25 mg/kg (micronized sample),A,In vivo,,Mus musculus,10090.0,
11147,0,,BAO_0000218,Autocuration,,15011,Bioavailability in mouse (nude) (dose 0.4% Methylcellulose (MC) as vehicle 25 mg/kg),A,In vivo,,Mus musculus,10090.0,
11148,0,,BAO_0000218,Autocuration,,15011,Bioavailability in mouse (nude) using 20% aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle 25 mg/kg,A,In vivo,,Mus musculus,10090.0,
11149,0,,BAO_0000218,Autocuration,,9552,Oral bioavailability in Rhesus monkey,A,In vivo,,Macaca mulatta,9544.0,
11150,0,,BAO_0000218,Autocuration,,9552,Oral bioavailability in dog (female mongrel),A,In vivo,,Canis lupus familiaris,9615.0,
11151,0,,BAO_0000218,Autocuration,,3639,Percent oral bioavailability of perorally administered compound (30 mg/kg) was tested,A,In vivo,,,,
11152,0,,BAO_0000218,Autocuration,,13397,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,
11153,0,,BAO_0000218,Autocuration,,3031,Percentage Bioavailability was evaluated.,A,In vivo,,,,
11154,0,,BAO_0000218,Autocuration,,12818,Bioavailability in rat administered i.d.,A,In vivo,,Rattus norvegicus,10116.0,
11155,0,,BAO_0000218,Autocuration,,4847,Bioavailability,A,In vivo,,Eutheria,9347.0,
11156,0,,BAO_0000218,Autocuration,,12421,Bioavailability in dog (male Beagle) i.v. administration,A,In vivo,,Canis lupus familiaris,9615.0,
11157,0,,BAO_0000218,Autocuration,,11966,"Bioavailability in rat (dose 20 mg/kg p.o. in 1% methocel, and 5 mg/kg i.v. in PEG400)",A,In vivo,,Rattus norvegicus,10116.0,
11158,0,,BAO_0000218,Autocuration,,11218,Bioavailability in monkey (dose 10 mg/kg i.d. or 0.3 mg/kg i.v.),A,In vivo,,Primates,9443.0,
11159,0,,BAO_0000218,Autocuration,,13129,Oral bioavailability in rat (Sprague-Dawley) (male),A,In vivo,,Rattus norvegicus,10116.0,
11160,1,,BAO_0000218,Intermediate,,12350,The oral bioavailability was measured on rats after oral administration,A,In vivo,,Rattus norvegicus,10116.0,
11161,1,,BAO_0000218,Intermediate,,2231,Bioavailability was evaluated in rat at an intravenous dose of 3 mg/kg and peroral dose of 5 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,
11162,1,,BAO_0000218,Intermediate,,2231,Bioavailability was evaluated in rhesus monkey at an intravenous dose of 1 mg/kg and peroral dose of 1 mg/kg,A,In vivo,,Macaca mulatta,9544.0,
11163,0,,BAO_0000218,Autocuration,,12187,Bioavailability in rat (dose 10 mg/kg i.d.),A,In vivo,,Rattus norvegicus,10116.0,
11164,0,,BAO_0000218,Autocuration,,12421,Bioavailability in dog (male Beagle) i.v. administration,A,In vivo,,Canis lupus familiaris,9615.0,
11165,1,,BAO_0000218,Intermediate,,13256,Biodistribution in CD-1 mice was determined after 1 minute in Striatum(expressed as percent injected dose per gram normalized to a 25 g mouse),A,In vivo,,Mus musculus,10090.0,
11166,1,,BAO_0000218,Intermediate,178.0,13256,Biodistribution in CD-1 mice was determined after 1 minute in blood(expressed as percent injected dose per gram normalized to a 25 g mouse),A,In vivo,,Mus musculus,10090.0,
11167,1,,BAO_0000218,Intermediate,2037.0,13256,Biodistribution in CD-1 mice was determined after 1 minute in cerebellum(expressed as percent injected dose per gram normalized to a 25 g mouse),A,In vivo,,Mus musculus,10090.0,
11168,1,,BAO_0000218,Intermediate,,13256,Biodistribution in CD-1 mice was determined after 1 minute in cortex(expressed as percent injected dose per gram normalized to a 25 g mouse),A,In vivo,,Mus musculus,10090.0,
11169,1,,BAO_0000218,Intermediate,1969.0,2231,Maximum concentration in plasma (Cmax) was evaluated in rat at an intravenous dose of 3 mg/kg and peroral dose of 5 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,
11170,1,,BAO_0000218,Intermediate,1969.0,2231,Maximum concentration in plasma (Cmax) was evaluated in rhesus monkey at an intravenous dose of 1 mg/kg and peroral dose of 1 mg/kg,A,In vivo,,Macaca mulatta,9544.0,
11171,1,,BAO_0000218,Intermediate,178.0,12178,Maximum concentration in whole blood recorded in the period 0-24 hr postdose of 1 mg/kg in rat (normalized to a 1 mg/kg dose),A,In vivo,,Rattus norvegicus,10116.0,
11172,0,,BAO_0000218,Autocuration,178.0,12178,Maximum concentration in whole blood recorded in the period 0-24 hr postdose of 2.5 mg/kg in rat (normalized to a 1 mg/kg dose),A,In vivo,,,,
11173,0,,BAO_0000218,Autocuration,178.0,12178,Maximum concentration in whole blood recorded in the period 0-24 hr postdose of 5.0 mg/kg GP (normalized to a 1 mg/kg dose),A,In vivo,,,,
11174,1,,BAO_0000218,Expert,,15633,Maximum concentration observed in rats at an oral dose of 50 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,
11175,1,,BAO_0000218,Intermediate,1969.0,14258,Maximum concentration of compound in plasma administered orally to rats,A,In vivo,,Rattus norvegicus,10116.0,
11176,1,,BAO_0000218,Intermediate,1969.0,14224,"Maximum concentration (10 mg/kg, orally) in plasma of dogs",A,In vivo,,Canis lupus familiaris,9615.0,
11177,1,,BAO_0000218,Intermediate,1969.0,14224,"Maximum concentration (10 mg/kg, perorally) in plasma of dogs",A,In vivo,,Canis lupus familiaris,9615.0,
11178,1,,BAO_0000218,Intermediate,1969.0,14224,"Maximum concentration (5 mg/kg, intravenously) in plasma of dogs",A,In vivo,,Canis lupus familiaris,9615.0,
11179,0,,BAO_0000218,Autocuration,,5566,Maximum concentration after 10 mg/kg by oral administration,A,In vivo,,,,
11180,0,,BAO_0000218,Autocuration,,16935,Maximum concentration at a dose of 1.5 mg/kg,A,In vivo,,,,
11181,0,,BAO_0000218,Autocuration,,16935,Maximum concentration at a dose of 2.0 mg/kg,A,In vivo,,,,
11182,1,,BAO_0000218,Intermediate,1969.0,14224,Maximum concentration in dog plasma,A,In vivo,,Canis lupus familiaris,9615.0,
11183,0,,BAO_0000218,Autocuration,1969.0,12536,Maximum concentration in plasma after administration of 10 umol/kg dose perorally,A,In vivo,,,,
11184,0,,BAO_0000218,Autocuration,1969.0,12536,Maximum concentration in plasma after administration of 2 umol/kg dose intravenously,A,In vivo,,,,
11185,0,,BAO_0000218,Autocuration,1969.0,12536,Maximum concentration in plasma after administration of 4 umol/kg dose intravenously,A,In vivo,,,,
11186,0,,BAO_0000218,Autocuration,1969.0,12536,Maximum concentration in plasma after administration of 40 umol/kg dose perorally,A,In vivo,,,,
11187,0,,BAO_0000218,Autocuration,1969.0,12536,Maximum concentration in plasma after administration of 5 umol/kg dose intravenously,A,In vivo,,,,
11188,1,,BAO_0000218,Intermediate,1969.0,9994,Maximum concentration in plasma after oral administration in dog (25 mg/kg),A,In vivo,,Canis lupus familiaris,9615.0,
11189,0,,BAO_0000218,Autocuration,1969.0,1434,Maximum concentration in plasma at Tmax,A,In vivo,,,,
11190,1,,BAO_0000218,Expert,1969.0,12836,Maximum concentration in plasma recorded 0-6 hr post dose in dog at 10 mg/kg oral dose,A,In vivo,,Canis lupus familiaris,9615.0,
11191,1,,BAO_0000218,Intermediate,1969.0,12836,Maximum concentration in plasma recorded in the period 0-6 hr post dose in hamster at 10 mg/kg oral dose,A,In vivo,,Cricetinae,10026.0,
11192,1,,BAO_0000218,Intermediate,1969.0,12836,Maximum concentration in plasma recorded in the period 0-6 hr post dose in rat at 10 mg/kg oral dose,A,In vivo,,Rattus norvegicus,10116.0,
11193,1,,BAO_0000218,Intermediate,1969.0,12545,Maximum concentration in plasma was determined by oral administration to rats at 20 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,
11194,1,,BAO_0000218,Intermediate,1969.0,13856,Maximum concentration present in the rabbit plasma following peroral administration of 10 mg/kg,A,In vivo,,Oryctolagus cuniculus,9986.0,
11195,0,,BAO_0000218,Autocuration,,3550,Maximum concentration was calculated,A,In vivo,,,,
11196,0,,BAO_0000218,Autocuration,,2632,Maximum concentration was calculated.,A,In vivo,,,,
11197,0,,BAO_0000218,Autocuration,,5566,Maximum concentration at a peroral dose of 10 mg/kg,A,In vivo,,,,
11198,0,,BAO_0000218,Autocuration,,11883,Maximum concentration of the drug at 10 uM/dg administered perorally,A,In vivo,,,,
11199,0,,BAO_0000218,Autocuration,,11883,Maximum concentration of the drug at 2 uM/dg administered intravenously,A,In vivo,,,,
11200,1,,BAO_0000218,Intermediate,1969.0,14122,"Maximum concentration of the unchanged compound in dog plasma, recorded in the period 0-6 hr post dose.",A,In vivo,,Canis lupus familiaris,9615.0,
11201,1,,BAO_0000218,Intermediate,1969.0,14122,"Maximum concentration of the unchanged compound in hamster plasma, recorded in the period 0-6 hr post dose.",A,In vivo,,Cricetinae,10026.0,
11202,1,,BAO_0000218,Intermediate,1969.0,14122,"Maximum concentration of the unchanged compound in rat plasma, recorded in the period 0-6 hr post dose.",A,In vivo,,Rattus norvegicus,10116.0,
11203,1,,BAO_0000218,Intermediate,1969.0,12542,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose in anesthetized rat at 60 mg/kg oral dose,A,In vivo,,Rattus norvegicus,10116.0,
11204,1,,BAO_0000218,Intermediate,1969.0,12542,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose in dog at 5 mg/kg oral dose,A,In vivo,,Canis lupus familiaris,9615.0,
11205,1,,BAO_0000218,Intermediate,1969.0,12542,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose in hamster at 40 mg/kg oral dose,A,In vivo,,Cricetinae,10026.0,
11206,1,,BAO_0000218,Intermediate,1969.0,12542,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose to hamster at 40 mg/kg oral dose,A,In vivo,,Cricetinae,10026.0,
11207,1,,BAO_0000218,Intermediate,1969.0,12542,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose in anesthetized rat at 25 mg/kg oral dose,A,In vivo,,Rattus norvegicus,10116.0,
11208,1,,BAO_0000218,Intermediate,1969.0,14080,Maximum concentration of unchanged drug in rat plasma in the period 0-24 hr after dosing,A,In vivo,,Rattus norvegicus,10116.0,
11209,1,,BAO_0000218,Intermediate,,11911,Maximum concentration reached following intravenous administration in male rat,A,In vivo,,Rattus norvegicus,10116.0,
11210,1,,BAO_0000218,Intermediate,,13204,Maximum concentration was determined in an aqueous sodium hydroxide solution adjusted to pH 10 at 10 mg/kg dosage administered perorally in dog,A,In vivo,,Canis lupus familiaris,9615.0,
11211,1,,BAO_0000218,Intermediate,,13204,Maximum concentration was determined in an aqueous sodium hydroxide solution adjusted to pH 10 at 5 mg/kg dosage administered perorally in rats,A,In vivo,,Rattus norvegicus,10116.0,
11212,1,,BAO_0000218,Intermediate,,14346,Maximum concentration was measured after peroral administration of 10 mg/kg of drug in male Beagle dogs,A,In vivo,,Canis lupus familiaris,9615.0,
11213,1,,BAO_0000218,Intermediate,,14346,Maximum concentration was measured after peroral administration of 5.0 mg/kg of drug in male Dawley rats,A,In vivo,,Rattus norvegicus,10116.0,
11214,1,,BAO_0000218,Intermediate,,14346,Maximum concentration was measured after peroral administration of 5.1 mg/kg of drug in male Dawley rats,A,In vivo,,Rattus norvegicus,10116.0,
11215,1,,BAO_0000218,Intermediate,,14346,Maximum concentration was measured after peroral administration of 5.2 mg/kg of drug in male Dawley rats,A,In vivo,,Rattus norvegicus,10116.0,
11216,1,,BAO_0000218,Intermediate,,14127,Maximum drug concentration is determined after oral dosing in rats.,A,In vivo,,Rattus norvegicus,10116.0,
11217,1,,BAO_0000218,Intermediate,,14339,Maximum observed concentration in oral (5 mg/kg) fasted dogs,A,In vivo,,Canis lupus familiaris,9615.0,
11218,1,,BAO_0000218,Intermediate,,14339,Maximum observed concentration in oral (5 mg/kg) fed dogs,A,In vivo,,Canis lupus familiaris,9615.0,
11219,0,,BAO_0000218,Autocuration,1969.0,13494,Maximum plasma concentration,A,In vivo,,,,
11220,1,,BAO_0000218,Intermediate,1969.0,14925,Maximum plasma concentration (Cmax) was determined in rats after intraduodenal administration of the drug,A,In vivo,,Rattus norvegicus,10116.0,
11221,1,,BAO_0000218,Intermediate,1969.0,14474,Maximum plasma concentration following oral administration of 26.3 mg/kg in rats,A,In vivo,,Rattus norvegicus,10116.0,
11222,1,,BAO_0000218,Intermediate,1969.0,14474,Maximum plasma concentration following oral administration of 3.8 mg/kg in Beagle dog,A,In vivo,,Canis lupus familiaris,9615.0,
11223,0,,BAO_0000218,Autocuration,1969.0,13917,Maximum plasma concentration following oral administration of 30 umol/kg,A,In vivo,,,,
11224,1,,BAO_0000218,Intermediate,1969.0,9796,Distribution of radiolabeled compound in plasma of rat 1 hr after ip administration of dose,A,,,Rattus norvegicus,10116.0,
11225,1,,BAO_0000218,Intermediate,1969.0,9796,Distribution of radiolabeled compound in plasma of rat 1 hr after ip administration of dose and excess 8 microg of estradiol; fmol equivalents per 100 mg,A,,,Rattus norvegicus,10116.0,
11226,1,,BAO_0000218,Intermediate,1969.0,9796,Distribution of radiolabeled compound in plasma of rat 1 hr after iv administration of dose; fmol equivalents per 100 mg,A,,,Rattus norvegicus,10116.0,
11227,1,,BAO_0000218,Intermediate,1969.0,9796,Distribution of radiolabeled compound in plasma of rat 4 hr after ip administration of dose; fmol equivalents per 100 mg,A,,,Rattus norvegicus,10116.0,
11228,1,,BAO_0000218,Intermediate,1969.0,9796,Distribution of radiolabeled compound in plasma of rat 8 hr after ip administration of dose; fmol equivalents per 100 mg,A,,,Rattus norvegicus,10116.0,
11229,1,,BAO_0000218,Intermediate,995.0,9796,Distribution of radiolabeled compound in uterus of rat 1 hr after ip administration of dose; fmol equivalents per 100 mg,A,,,Rattus norvegicus,10116.0,
11230,1,,BAO_0000218,Intermediate,995.0,9796,Distribution of radiolabeled compound in uterus of rat 1 hr after ip administration of dose and excess 8 microg of estradiol; fmol equivalents per 100 mg,A,,,Rattus norvegicus,10116.0,
11231,1,,BAO_0000218,Intermediate,995.0,9796,Distribution of radiolabeled compound in uterus of rat 1 hr after iv administration of dose; fmol equivalents per 100 mg,A,,,Rattus norvegicus,10116.0,
11232,1,,BAO_0000218,Intermediate,995.0,9796,Distribution of radiolabeled compound in uterus of rat 4 hr after ip administration of dose; fmol equivalents per 100 mg,A,,,Rattus norvegicus,10116.0,
11233,1,,BAO_0000218,Intermediate,995.0,9796,Distribution of radiolabeled compound in uterus of rat 8 hr after ip administration of dose; fmol equivalents per 100 mg,A,,,Rattus norvegicus,10116.0,
11234,1,,BAO_0000218,Intermediate,,8363,Distribution of rat erythrocytes for tube 2 on rate of aging in 2 mL of cell suspension; Minus (-),A,,,Rattus norvegicus,10116.0,
11235,1,,BAO_0000218,Intermediate,,8363,Distribution of rat erythrocytes for tube 2 on rate of aging in 2 mL of cell suspension; Plus (+),A,,,Rattus norvegicus,10116.0,
11236,1,,BAO_0000218,Intermediate,,8363,Distribution of rat erythrocytes for tube 3 on rate of aging in 2 mL of cell suspension; Minus (-),A,,,Rattus norvegicus,10116.0,
11237,1,,BAO_0000218,Intermediate,,8363,Distribution of rat erythrocytes for tube 3 on rate of aging in 2 mL of cell suspension; Plus (+),A,,,Rattus norvegicus,10116.0,
11238,1,,BAO_0000218,Intermediate,,8363,Distribution of rat erythrocytes for tube 4 on rate of aging in 2 mL of cell suspension; Minus (-),A,,,Rattus norvegicus,10116.0,
11239,1,,BAO_0000218,Intermediate,,8363,Distribution of rat erythrocytes for tube 4 on rate of aging in 2 mL of cell suspension; Plus (+),A,,,Rattus norvegicus,10116.0,
11240,1,,BAO_0000218,Intermediate,,8363,Distribution of rat erythrocytes for tube 5 on rate of aging in 2 mL of cell suspension; Minus (-),A,,,Rattus norvegicus,10116.0,
11241,1,,BAO_0000218,Intermediate,,8363,Distribution of rat erythrocytes for tube 5 on rate of aging in 2 mL of cell suspension; Plus (+),A,,,Rattus norvegicus,10116.0,
11242,1,,BAO_0000218,Intermediate,,8363,Distribution of rat erythrocytes for tube 6 on rate of aging in 2 mL of cell suspension; Minus (-),A,,,Rattus norvegicus,10116.0,
11243,1,,BAO_0000218,Intermediate,,8363,Distribution of rat erythrocytes for tube 6 on rate of aging in 2 mL of cell suspension; Plus (+),A,,,Rattus norvegicus,10116.0,
11244,1,,BAO_0000218,Intermediate,,8363,Distribution of rat erythrocytes for tube 7 on rate of aging in 2 mL of cell suspension; Plus (+),A,,,Rattus norvegicus,10116.0,
11245,1,,BAO_0000218,Intermediate,,8363,Distribution of rat erythrocytes for tube 1 on rate of aging in 2 mL of cell suspension; Minus (-),A,,,Rattus norvegicus,10116.0,
11246,1,,BAO_0000218,Intermediate,178.0,8684,"Distribution in blood of rat 5 min after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0,
11247,1,,BAO_0000218,Intermediate,178.0,8684,"Distribution in blood of rat, 15 min after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0,
11248,1,,BAO_0000218,Intermediate,178.0,8684,"Distribution in blood of rat, 1 hr after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0,
11249,1,,BAO_0000218,Intermediate,178.0,8684,"Distribution in blood of rat, 2 hr after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0,
11250,1,,BAO_0000218,Intermediate,178.0,8684,"Distribution in blood of rat, 30 min after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0,
11251,1,,BAO_0000218,Intermediate,178.0,8684,"Distribution in blood of rat, 4 hr after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0,
11252,1,,BAO_0000218,Intermediate,178.0,8684,"Distribution in blood of rat, 6 hr after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0,
11253,1,,BAO_0000218,Intermediate,178.0,8684,"Distribution in blood of rat, 8 hr after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0,
11254,1,,BAO_0000218,Intermediate,955.0,8684,"Distribution in brain of rat, 15 min after intravenous administered, injected dose/gm",A,,,Rattus norvegicus,10116.0,
11255,1,,BAO_0000218,Intermediate,955.0,8684,"Distribution in brain of rat, 1 hr after intravenous administered, injected dose/gm",A,,,Rattus norvegicus,10116.0,
11256,1,,BAO_0000218,Intermediate,955.0,8684,"Distribution in brain of rat, 2 hr after intravenous administered, injected dose/gm",A,,,Rattus norvegicus,10116.0,
11257,1,,BAO_0000218,Intermediate,955.0,8684,"Distribution in brain of rat, 30 min after intravenous administered, injected dose/gm",A,,,Rattus norvegicus,10116.0,
11258,1,,BAO_0000218,Intermediate,955.0,8684,"Distribution in brain of rat, 4 hr after intravenous administered, injected dose/gm",A,,,Rattus norvegicus,10116.0,
11259,1,,BAO_0000218,Intermediate,955.0,8684,"Distribution in brain of rat, 5 min after intravenous administered, injected dose/gm",A,,,Rattus norvegicus,10116.0,
11260,1,,BAO_0000218,Intermediate,955.0,8684,"Distribution in brain of rat, 6 hr after intravenous administered, injected dose/gm",A,,,Rattus norvegicus,10116.0,
11261,1,,BAO_0000218,Intermediate,955.0,8684,"Distribution in brain of rat, 8 hr after intravenous administered, injected dose/gm",A,,,Rattus norvegicus,10116.0,
11262,1,,BAO_0000218,Intermediate,,8684,"Distribution in rat fat 15 min after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0,
11263,1,,BAO_0000218,Intermediate,,8684,"Distribution in rat fat 1 hr after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0,
11264,1,,BAO_0000218,Intermediate,,8684,"Distribution in rat fat 2 hr after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0,
11265,1,,BAO_0000218,Intermediate,,8684,"Distribution in rat fat 30 min after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0,
11266,1,,BAO_0000218,Intermediate,,8684,"Distribution in rat fat 4 hr after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0,
11267,1,,BAO_0000218,Intermediate,,8684,"Distribution in rat fat 5 min after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0,
11268,1,,BAO_0000218,Intermediate,,8684,"Distribution in rat fat 6 hr after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0,
11269,1,,BAO_0000218,Intermediate,,8684,"Distribution in rat fat 8 hr after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0,
11270,1,,BAO_0000218,Intermediate,,8684,"Distribution in rat heart 15 min after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0,
11271,1,,BAO_0000218,Intermediate,,8684,"Distribution in rat heart 1 hr after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0,
11272,1,,BAO_0000218,Intermediate,,8684,"Distribution in rat heart 2 hr after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0,
11273,1,,BAO_0000218,Intermediate,,8684,"Distribution in rat heart 30 min after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0,
11274,1,,BAO_0000218,Intermediate,,6996,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5.4 mg/kg after ip administration ( 0-6 hr),A,,,Canis lupus familiaris,9615.0,
11275,1,,BAO_0000218,Intermediate,,6996,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5 mg/kg after ip administration,A,,,Canis lupus familiaris,9615.0,
11276,1,,BAO_0000218,Intermediate,,6996,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5 mg/kg after ip administration (0-6 hr),A,,,Canis lupus familiaris,9615.0,
11277,1,,BAO_0000218,Intermediate,,6996,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5 mg/kg after ip administration ( 0 - 6 hr),A,,,Canis lupus familiaris,9615.0,
11278,1,,BAO_0000218,Intermediate,,6996,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5 mg/kg after ip administration ( 0-6 hr ),A,,,Canis lupus familiaris,9615.0,
11279,1,,BAO_0000218,Intermediate,,6996,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5 mg/kg after ip administration ( 0-6 hr),A,,,Canis lupus familiaris,9615.0,
11280,1,,BAO_0000218,Intermediate,,15599,Observed diffusion coefficient in organic solvent for Escherichia coli,A,,,Escherichia coli,562.0,
11281,1,,BAO_0000218,Intermediate,178.0,9614,"Concentration of compound in blood of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",A,,,Rattus norvegicus,10116.0,
11282,1,,BAO_0000218,Intermediate,178.0,9614,"Concentration of compound in blood of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",A,,,Rattus norvegicus,10116.0,
11283,1,,BAO_0000218,Intermediate,2081.0,9614,"Concentration of compound in left atrium of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",A,,,Rattus norvegicus,10116.0,
11284,1,,BAO_0000218,Intermediate,2081.0,9614,"Concentration of compound in left atrium of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",A,,,Rattus norvegicus,10116.0,
11285,1,,BAO_0000218,Intermediate,,9614,"Concentration of compound in left ventricle of of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",A,,,Rattus norvegicus,10116.0,
11286,1,,BAO_0000218,Intermediate,,9614,"Concentration of compound in left ventricle of of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",A,,,Rattus norvegicus,10116.0,
11287,1,,BAO_0000218,Intermediate,2107.0,9614,"Concentration of compound in liver of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",A,,,Rattus norvegicus,10116.0,
11288,1,,BAO_0000218,Intermediate,2107.0,9614,"Concentration of compound in liver of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",A,,,Rattus norvegicus,10116.0,
11289,1,,BAO_0000218,Intermediate,2081.0,9614,"Concentration of compound in right atrium of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",A,,,Rattus norvegicus,10116.0,
11290,1,,BAO_0000218,Intermediate,2081.0,9614,"Concentration of compound in right atrium of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",A,,,Rattus norvegicus,10116.0,
11291,1,,BAO_0000218,Intermediate,,9614,"Concentration of compound in right ventricle of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",A,,,Rattus norvegicus,10116.0,
11292,1,,BAO_0000218,Intermediate,,9614,"Concentration of compound in right ventricle of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",A,,,Rattus norvegicus,10116.0,
11293,1,,BAO_0000218,Intermediate,2106.0,9614,"Concentration of compound in spleen of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",A,,,Rattus norvegicus,10116.0,
11294,1,,BAO_0000218,Intermediate,2106.0,9614,"Concentration of compound in spleen of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",A,,,Rattus norvegicus,10116.0,
11295,1,,BAO_0000218,Intermediate,178.0,9071,Distribution of radioactivity of radiolabeled compound in blood of female rats 30 minutes after intravenous administration,A,,,Rattus norvegicus,10116.0,
11296,1,,BAO_0000218,Intermediate,178.0,9071,Distribution of radioactivity of radiolabeled compound in blood of female rats 5 minutes after intravenous administration,A,,,Rattus norvegicus,10116.0,
11297,1,,BAO_0000218,Intermediate,948.0,9071,Distribution of radioactivity of radiolabeled compound in heart of female rats 30 minutes after intravenous administration,A,,,Rattus norvegicus,10116.0,
11298,1,,BAO_0000218,Intermediate,948.0,9071,Distribution of radioactivity of radiolabeled compound in heart of female rats 30 minutes after intravenous administration at,A,,,Rattus norvegicus,10116.0,
11299,1,,BAO_0000218,Intermediate,948.0,9071,Distribution of radioactivity of radiolabeled compound in heart of female rats 5 minutes after intravenous administration,A,,,Rattus norvegicus,10116.0,
11300,1,,BAO_0000218,Intermediate,2113.0,9071,Distribution of radioactivity of radiolabeled compound in kidney of female rats 30 minutes after intravenous administration,A,,,Rattus norvegicus,10116.0,
11301,1,,BAO_0000218,Intermediate,2113.0,9071,Distribution of radioactivity of radiolabeled compound in kidney of female rats 30 minutes after intravenous administration,A,,,Rattus norvegicus,10116.0,
11302,1,,BAO_0000218,Intermediate,2113.0,9071,Distribution of radioactivity of radiolabeled compound in kidney of female rats 5 minutes after intravenous administration,A,,,Rattus norvegicus,10116.0,
11303,1,,BAO_0000218,Intermediate,2107.0,9071,Distribution of radioactivity of radiolabeled compound in liver of female rats 30 minutes after intravenous administration,A,,,Rattus norvegicus,10116.0,
11304,1,,BAO_0000218,Intermediate,2107.0,9071,Distribution of radioactivity of radiolabeled compound in liver of female rats 5 minutes after intravenous administration,A,,,Rattus norvegicus,10116.0,
11305,1,,BAO_0000218,Intermediate,2107.0,9071,Distribution of radioactivity of radiolabeled compound in liver of female rats 5 minutes after intravenous administration at,A,,,Rattus norvegicus,10116.0,
11306,1,,BAO_0000218,Intermediate,2048.0,9071,Distribution of radioactivity of radiolabeled compound in lung of female rats 30 minutes after intravenous administration,A,,,Rattus norvegicus,10116.0,
11307,1,,BAO_0000218,Intermediate,2048.0,9071,Distribution of radioactivity of radiolabeled compound in lung of female rats 5 minutes after intravenous administration,A,,,Rattus norvegicus,10116.0,
11308,1,,BAO_0000218,Intermediate,2048.0,9071,Distribution of radioactivity of radiolabeled compound in lung of female rats 5 minutes after intravenous administration at,A,,,Rattus norvegicus,10116.0,
11309,1,,BAO_0000218,Intermediate,2048.0,9071,Distribution of radioactivity of radiolabeled compound in lung of female rats 30 minutes after intravenous administration,A,,,Rattus norvegicus,10116.0,
11310,0,,BAO_0000218,Autocuration,,10677,"Original dose appeared in the bile as unchanged compound, which was eliminated at a fairly constant rate over the first 4 hr following the iv administration",A,,,,,
11311,1,,BAO_0000218,Intermediate,1088.0,9750,Percentage of dose recovered after 0-6 hr in the urine of mice was measured.,A,,,Mus musculus,10090.0,
11312,1,,BAO_0000218,Intermediate,,8319,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat blood as Percent of injected dose per gram in the organ,A,,,Rattus norvegicus,10116.0,
11313,1,,BAO_0000218,Intermediate,,8319,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat brain as Percent of injected dose in the total organ,A,,,Rattus norvegicus,10116.0,
11314,1,,BAO_0000218,Intermediate,,8319,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat brain as Percent of injected dose per gram in the organ,A,,,Rattus norvegicus,10116.0,
11315,1,,BAO_0000218,Intermediate,,8319,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat heart as Percent of injected dose in the total organ,A,,,Rattus norvegicus,10116.0,
11316,1,,BAO_0000218,Intermediate,,8319,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat heart as Percent of injected dose per gram in the organ,A,,,Rattus norvegicus,10116.0,
11317,1,,BAO_0000218,Intermediate,2113.0,8319,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat kidney as Percent of injected dose in the total organ,A,,,Rattus norvegicus,10116.0,
11318,1,,BAO_0000218,Intermediate,2113.0,8319,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat kidney as Percent of injected dose per gram in the organ,A,,,Rattus norvegicus,10116.0,
11319,1,,BAO_0000218,Intermediate,2107.0,8319,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat liver as Percent of injected dose in the total organ,A,,,Rattus norvegicus,10116.0,
11320,1,,BAO_0000218,Intermediate,,13256,Biodistribution in CD-1 mice was determined after 1 minute in femur(expressed as percent injected dose per gram normalized to a 25 g mouse),A,In vivo,,Mus musculus,10090.0,
11321,1,,BAO_0000218,Intermediate,2107.0,13256,Biodistribution in CD-1 mice was determined after 1 minute in liver(expressed as percent injected dose per gram normalized to a 25 g mouse),A,In vivo,,Mus musculus,10090.0,
11322,1,,BAO_0000218,Intermediate,,13256,Biodistribution in CD-1 mice was determined after 1 minute in lung(expressed as percent injected dose per gram normalized to a 25 g mouse),A,In vivo,,Mus musculus,10090.0,
11323,1,,BAO_0000218,Intermediate,,13256,Biodistribution in CD-1 mice was determined after 120 minutes in Striatum(expressed as percent injected dose per gram normalized to a 25 g mouse),A,In vivo,,Mus musculus,10090.0,
11324,1,,BAO_0000218,Intermediate,178.0,13256,Biodistribution in CD-1 mice was determined after 120 minutes in blood(expressed as percent injected dose per gram normalized to a 25 g mouse),A,In vivo,,Mus musculus,10090.0,
11325,1,,BAO_0000218,Intermediate,2037.0,13256,Biodistribution in CD-1 mice was determined after 120 minutes in cerebellum(expressed as percent injected dose per gram normalized to a 25 g mouse),A,In vivo,,Mus musculus,10090.0,
11326,1,,BAO_0000218,Intermediate,,13256,Biodistribution in CD-1 mice was determined after 120 minutes in cortex(expressed as percent injected dose per gram normalized to a 25 g mouse),A,In vivo,,Mus musculus,10090.0,
11327,1,,BAO_0000218,Intermediate,,13256,Biodistribution in CD-1 mice was determined after 120 minutes in femur(expressed as percent injected dose per gram normalized to a 25 g mouse),A,In vivo,,Mus musculus,10090.0,
11328,1,,BAO_0000218,Intermediate,2107.0,13256,Biodistribution in CD-1 mice was determined after 120 minutes in liver(expressed as percent injected dose per gram normalized to a 25 g mouse),A,In vivo,,Mus musculus,10090.0,
11329,1,,BAO_0000218,Intermediate,,13256,Biodistribution in CD-1 mice was determined after 120 minutes in lung(expressed as percent injected dose per gram normalized to a 25 g mouse),A,In vivo,,Mus musculus,10090.0,
11330,1,,BAO_0000218,Intermediate,,13256,Biodistribution in CD-1 mice was determined after 30 minutes in Striatum (expressed as percent injected dose per gram normalized to a 25 g mouse),A,In vivo,,Mus musculus,10090.0,
11331,1,,BAO_0000218,Intermediate,178.0,13256,Biodistribution in CD-1 mice was determined after 30 minutes in blood (expressed as percent injected dose per gram normalized to a 25 g mouse),A,In vivo,,Mus musculus,10090.0,
11332,1,,BAO_0000218,Intermediate,2037.0,13256,Biodistribution in CD-1 mice was determined after 30 minutes in cerebellum (expressed as percent injected dose per gram normalized to a 25 g mouse),A,In vivo,,Mus musculus,10090.0,
11333,1,,BAO_0000218,Intermediate,,13256,Biodistribution in CD-1 mice was determined after 30 minutes in cortex (expressed as percent injected dose per gram normalized to a 25 g mouse),A,In vivo,,Mus musculus,10090.0,
11334,1,,BAO_0000218,Intermediate,,13256,Biodistribution in CD-1 mice was determined after 30 minutes in femur (expressed as percent injected dose per gram normalized to a 25 g mouse),A,In vivo,,Mus musculus,10090.0,
11335,1,,BAO_0000218,Intermediate,2107.0,13256,Biodistribution in CD-1 mice was determined after 30 minutes in liver (expressed as percent injected dose per gram normalized to a 25 g mouse),A,In vivo,,Mus musculus,10090.0,
11336,1,,BAO_0000218,Intermediate,,13256,Biodistribution in CD-1 mice was determined after 30 minutes in lung (expressed as percent injected dose per gram normalized to a 25 g mouse),A,In vivo,,Mus musculus,10090.0,
11337,1,,BAO_0000218,Intermediate,,13256,Biodistribution in CD-1 mice was determined after 5 minute in Striatum(expressed as percent injected dose per gram normalized to a 25 g mouse),A,In vivo,,Mus musculus,10090.0,
11338,1,,BAO_0000218,Intermediate,178.0,13256,Biodistribution in CD-1 mice was determined after 5 minute in blood(expressed as percent injected dose per gram normalized to a 25 g mouse),A,In vivo,,Mus musculus,10090.0,
11339,1,,BAO_0000218,Intermediate,2037.0,13256,Biodistribution in CD-1 mice was determined after 5 minute in cerebellum(expressed as percent injected dose per gram normalized to a 25 g mouse),A,In vivo,,Mus musculus,10090.0,
11340,1,,BAO_0000218,Intermediate,,13256,Biodistribution in CD-1 mice was determined after 5 minute in cortex(expressed as percent injected dose per gram normalized to a 25 g mouse),A,In vivo,,Mus musculus,10090.0,
11341,1,,BAO_0000218,Intermediate,,13256,Biodistribution in CD-1 mice was determined after 5 minute in femur(expressed as percent injected dose per gram normalized to a 25 g mouse),A,In vivo,,Mus musculus,10090.0,
11342,1,,BAO_0000218,Intermediate,2107.0,13256,Biodistribution in CD-1 mice was determined after 5 minute in liver(expressed as percent injected dose per gram normalized to a 25 g mouse),A,In vivo,,Mus musculus,10090.0,
11343,1,,BAO_0000218,Intermediate,,13256,Biodistribution in CD-1 mice was determined after 5 minute in lung(expressed as percent injected dose per gram normalized to a 25 g mouse),A,In vivo,,Mus musculus,10090.0,
11344,1,,BAO_0000218,Intermediate,178.0,8829,Biodistribution in Rat blood after 24 hours of iv administration,A,In vivo,,Rattus norvegicus,10116.0,
11345,1,,BAO_0000218,Intermediate,178.0,8829,Biodistribution in Rat blood after 24 hours of iv administration; per g of tissue,A,In vivo,,Rattus norvegicus,10116.0,
11346,1,,BAO_0000218,Intermediate,178.0,8829,Biodistribution in Rat blood after 30 minutes of iv administration,A,In vivo,,Rattus norvegicus,10116.0,
11347,1,,BAO_0000218,Intermediate,178.0,8829,Biodistribution in Rat blood after 30 minutes of iv administration; per g of tissue,A,In vivo,,Rattus norvegicus,10116.0,
11348,1,,BAO_0000218,Intermediate,178.0,8829,Biodistribution in Rat blood after 5 minutes of iv administration,A,In vivo,,Rattus norvegicus,10116.0,
11349,1,,BAO_0000218,Intermediate,178.0,8829,Biodistribution in Rat blood after 5 minutes of iv administration; per g of tissue,A,In vivo,,Rattus norvegicus,10116.0,
11350,1,,BAO_0000218,Intermediate,948.0,8829,Biodistribution in Rat heart after 24 hours of iv administration,A,In vivo,,Rattus norvegicus,10116.0,
11351,1,,BAO_0000218,Intermediate,948.0,8829,Biodistribution in Rat heart after 24 hours of iv administration; per g of tissue,A,In vivo,,Rattus norvegicus,10116.0,
11352,1,,BAO_0000218,Intermediate,948.0,8829,Biodistribution in Rat heart after 30 minutes of iv administration,A,In vivo,,Rattus norvegicus,10116.0,
11353,1,,BAO_0000218,Intermediate,948.0,8829,Biodistribution in Rat heart after 30 minutes of iv administration; per g of tissue,A,In vivo,,Rattus norvegicus,10116.0,
11354,1,,BAO_0000218,Intermediate,948.0,8829,Biodistribution in Rat heart after 5 minutes of iv administration,A,In vivo,,Rattus norvegicus,10116.0,
11355,1,,BAO_0000218,Intermediate,948.0,8829,Biodistribution in Rat heart after 5 minutes of iv administration; per g of tissue,A,In vivo,,Rattus norvegicus,10116.0,
11356,1,,BAO_0000218,Intermediate,2107.0,8829,Biodistribution in Rat liver after 24 hours of iv administration,A,In vivo,,Rattus norvegicus,10116.0,
11357,1,,BAO_0000218,Intermediate,2107.0,8829,Biodistribution in Rat liver after 24 hours of iv administration; per g of tissue,A,In vivo,,Rattus norvegicus,10116.0,
11358,1,,BAO_0000218,Intermediate,2107.0,8829,Biodistribution in Rat liver after 30 minutes of iv administration,A,In vivo,,Rattus norvegicus,10116.0,
11359,1,,BAO_0000218,Intermediate,2107.0,8829,Biodistribution in Rat liver after 30 minutes of iv administration; per g of tissue,A,In vivo,,Rattus norvegicus,10116.0,
11360,1,,BAO_0000218,Intermediate,2107.0,8829,Biodistribution in Rat liver after 30 minutes of iv administration,A,In vivo,,Rattus norvegicus,10116.0,
11361,1,,BAO_0000218,Intermediate,1969.0,13249,Maximum plasma concentration in Beagle dogs at oral dose of 20 mg/kg and an intravenous dose of 5 mg/kg was administered,A,In vivo,,Canis lupus familiaris,9615.0,
11362,1,,BAO_0000218,Intermediate,,13622,Cmax in cynomolgus monkey (PO dose),A,In vivo,,Macaca fascicularis,9541.0,
11363,1,,BAO_0000218,Intermediate,,13622,Cmax in rat (PO dose),A,In vivo,,Rattus norvegicus,10116.0,
11364,1,,BAO_0000218,Intermediate,,13622,Cmax in rat (PO dose),A,In vivo,,Rattus norvegicus,10116.0,
11365,1,,BAO_0000218,Intermediate,1969.0,13494,Maximum plasma concentration in rats after an oral dose of 5 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,
11366,1,,BAO_0000218,Intermediate,1969.0,12170,Cmax in rat plasma after oral dose (10 mg/kg),A,In vivo,,Rattus norvegicus,10116.0,
11367,0,,BAO_0000218,Autocuration,1969.0,12170,Cmax in plasma after oral dose (10 mg/kg),A,In vivo,,,,
11368,1,,BAO_0000218,Intermediate,1969.0,17025,Maximum plasma concentration of compound was determined in dog at 25 mg/kg orally,A,In vivo,,Canis lupus familiaris,9615.0,
11369,0,,BAO_0000218,Autocuration,1969.0,17025,Maximum plasma concentration of compound was determined in monkey at 25 mg/kg orally,A,In vivo,,Simiiformes,314293.0,
11370,1,,BAO_0000218,Intermediate,1969.0,17025,Maximum plasma concentration of compound was determined in rabbit at 25 mg/kg orally,A,In vivo,,Oryctolagus cuniculus,9986.0,
11371,1,,BAO_0000218,Intermediate,1969.0,17025,Maximum plasma concentration of compound was determined in rat at 25 mg/kg orally,A,In vivo,,Rattus norvegicus,10116.0,
11372,1,,BAO_0000218,Intermediate,1969.0,14187,Maximum plasma concentration after p.o. (10 mpk) administration in rats.,A,In vivo,,Rattus norvegicus,10116.0,
11373,1,,BAO_0000218,Intermediate,1969.0,14816,Maximum plasma concentration (Cmax) after p.o. administration of 200 mg/kg in mice,A,In vivo,,Mus musculus,10090.0,
11374,1,,BAO_0000218,Intermediate,1969.0,17820,Maximum plasma concentration after oral dosing in rat,A,In vivo,,Rattus norvegicus,10116.0,
11375,0,,BAO_0000218,Autocuration,1969.0,14380,Maximum plasma concentration evaluated in 100% PEG solution at a dose of 20 mg/kg orally,A,In vivo,,,,
11376,0,,BAO_0000218,Autocuration,1969.0,14380,Maximum plasma concentration evaluated in HP-beta-CD solution at a dose of 20 mg/kg orally,A,In vivo,,,,
11377,1,,BAO_0000218,Intermediate,1969.0,14691,Maximum plasma concentration in dogs at 0.5 mg/kg dose upon oral administration,A,In vivo,,Canis lupus familiaris,9615.0,
11378,1,,BAO_0000218,Intermediate,1969.0,14691,Maximum plasma concentration in dogs at 1 mg/kg dose upon oral administration,A,In vivo,,Canis lupus familiaris,9615.0,
11379,1,,BAO_0000218,Intermediate,1969.0,13375,Maximum plasma concentration in rat upon oral administration of 40 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,
11380,0,,BAO_0000218,Autocuration,1969.0,6236,Maximum plasma concentration was determined,A,In vivo,,,,
11381,0,,BAO_0000218,Autocuration,1969.0,14380,Maximum plasma concentration was evaluated in 0.5% methylcellulose suspension at a dose of 20 mg/kg orally,A,In vivo,,,,
11382,0,,BAO_0000218,Autocuration,1969.0,14380,Maximum plasma concentration was evaluated in 0.5% methylcellulose suspension at a dose of 20 mg/kg orally,A,In vivo,,,,
11383,0,,BAO_0000218,Autocuration,1969.0,14380,Maximum plasma concentration was evaluated in 10% of PEG suspension at a dose of 20 mg/kg orally,A,In vivo,,,,
11384,0,,BAO_0000218,Autocuration,1969.0,14380,Maximum plasma concentration was evaluated in 100% of PEG solution at a dose of 20 mg/kg orally,A,In vivo,,,,
11385,0,,BAO_0000218,Autocuration,1969.0,14380,Maximum plasma concentration was evaluated in DMA:H2O solution at a dose of 20 mg/kg orally,A,In vivo,,,,
11386,0,,BAO_0000218,Autocuration,1969.0,14380,Maximum plasma concentration was evaluated in HP-beta-CD solution at a dose of 20 mg/kg orally,A,In vivo,,,,
11387,0,,BAO_0000218,Autocuration,1969.0,14380,Maximum plasma concentration was evaluated in Hp-beta-CD solution at a dose of 20 mg/kg orally,A,In vivo,,,,
11388,0,,BAO_0000218,Autocuration,1969.0,14380,Maximum plasma concentration was evaluated in saline solution at a dose of 20 mg/kg orally,A,In vivo,,,,
11389,1,,BAO_0000218,Intermediate,1969.0,13622,Plasma Cmax in rat (PO dose),A,In vivo,,Rattus norvegicus,10116.0,
11390,1,,BAO_0000218,Intermediate,,15372,Maximum serum concentration after po dose of 5.22 mg/kg in rats,A,In vivo,,Rattus norvegicus,10116.0,
11391,1,,BAO_0000218,Intermediate,,15372,Maximum serum concentration after po dose of 5.46 mg/kg in rats,A,In vivo,,Rattus norvegicus,10116.0,
11392,1,,BAO_0000218,Intermediate,,15372,Maximum serum concentration was determined for the compound after po dose of 5.01 mg/kg in rats,A,In vivo,,Rattus norvegicus,10116.0,
11393,1,,BAO_0000218,Intermediate,,15372,Maximum serum concentration was determined for the compound after po dose of 5.03 mg/kg in rats,A,In vivo,,Rattus norvegicus,10116.0,
11394,1,,BAO_0000218,Intermediate,1969.0,14925,Maximum plasma concentration (Cmax) was determined in dogs fed after oral administration of 25 mg/kg of the compound.,A,In vivo,,Canis lupus familiaris,9615.0,
11395,1,,BAO_0000218,Intermediate,1969.0,14925,Maximum plasma concentration (Cmax) was determined in fasted dogs after oral administration of 25 mg/kg of the compound.,A,In vivo,,Canis lupus familiaris,9615.0,
11396,0,,BAO_0000218,Autocuration,,11883,Maximum concentration of the drug at 1 uM/dg administered intravenously,A,In vivo,,,,
11397,0,,BAO_0000218,Autocuration,,11883,Maximum concentration of the drug at 20 uM/dg administered perorally,A,In vivo,,,,
11398,0,,BAO_0000218,Autocuration,,13391,Oral Bioavailability was measured as Maximal observed concentration (Cmax) value at dose 125 mg/kg,A,In vivo,,,,
11399,0,,BAO_0000218,Autocuration,178.0,13391,Oral Bioavailability was measured as Maximal observed concentration (Cmax) value at dose 125 mg/kg; b = No compound detectable in blood above the detection limit of 0.1 uM,A,In vivo,,,,
11400,0,,BAO_0000218,Autocuration,178.0,13391,Oral Bioavailability was measured as Maximal observed concentration (Cmax) value at dose 125 mg/kg; b denotes No compound detectable in blood above the detection limit of 0.1 uM,A,In vivo,,,,
11401,0,,BAO_0000218,Autocuration,178.0,13391,Oral Bioavailability was measured as Maximal observed concentration (Cmax) value at dose 125 mg/kg;b = No compound detectable in blood above the detection limit of 0.1 uM,A,In vivo,,,,
11402,1,,BAO_0000218,Intermediate,1969.0,16360,Oral absorption expressed as peak plasma conc (Cmax) after oral dosing of 50 mg/kg in rat,A,In vivo,,Rattus norvegicus,10116.0,
11403,1,,BAO_0000218,Intermediate,1969.0,3673,Cmax in dog plasma after 1mg/kg oral dose,A,In vivo,,Canis lupus familiaris,9615.0,
11404,1,,BAO_0000218,Intermediate,1969.0,14431,Bioavailability as maximal plasma concentration in dogs after 2.5 mg/kg oral dose,A,In vivo,,Canis lupus familiaris,9615.0,
11405,1,,BAO_0000218,Intermediate,1969.0,14431,Bioavailability as maximal plasma concentration in rats after 10 mg/kg oral dose,A,In vivo,,Rattus norvegicus,10116.0,
11406,1,,BAO_0000218,Intermediate,,14964,Oral maximum concentration in rat,A,In vivo,,Rattus norvegicus,10116.0,
11407,1,,BAO_0000218,Intermediate,,14964,Oral maximum concentration in rat,A,In vivo,,Rattus norvegicus,10116.0,
11408,1,,BAO_0000218,Intermediate,1969.0,14209,Oral plasma concentration in mice at 100 mg/kg dosage within 4-hr time frame.,A,In vivo,,Mus musculus,10090.0,
11409,1,,BAO_0000218,Intermediate,178.0,11355,Peak concentration in blood after intravenous administration to mice,A,In vivo,,Mus musculus,10090.0,
11410,1,,BAO_0000218,Intermediate,178.0,11355,Peak concentration in blood after peroral administration to mice,A,In vivo,,Mus musculus,10090.0,
11411,1,,BAO_0000218,Intermediate,1969.0,11966,Peak concentration in rat plasma was determined,A,In vivo,,Rattus norvegicus,10116.0,
11412,0,,BAO_0000218,Autocuration,1969.0,8918,Peak plasma concentration expresses the ability of compound for the release of L-Dopa in the plasma of monkey after oral administration of 0.05 mmol/kg,A,In vivo,,Simiiformes,314293.0,
11413,1,,BAO_0000218,Intermediate,1969.0,8918,Peak plasma concentration expresses the ability of compound for the release of L-Dopa in the plasma of mouse after oral administration of 0.05 mmol/kg,A,In vivo,,Mus musculus,10090.0,
11414,1,,BAO_0000218,Intermediate,1969.0,8918,Peak plasma concentration expresses the ability of compound for the release of L-Dopa in the plasma of rat after oral administration of 0.05 mmol/kg,A,In vivo,,Rattus norvegicus,10116.0,
11415,1,,BAO_0000218,Intermediate,,8684,"Distribution in rat heart 4 hr after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0,
11416,1,,BAO_0000218,Intermediate,,8684,"Distribution in rat heart 5 min after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0,
11417,1,,BAO_0000218,Intermediate,,8684,"Distribution in rat heart 6 hr after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0,
11418,1,,BAO_0000218,Intermediate,,8684,"Distribution in rat heart 8 hr after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0,
11419,1,,BAO_0000218,Intermediate,160.0,8684,"Distribution in rat intestine 15 min after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0,
11420,1,,BAO_0000218,Intermediate,160.0,8684,"Distribution in rat intestine 1 hr after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0,
11421,1,,BAO_0000218,Intermediate,160.0,8684,"Distribution in rat intestine 2 hr after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0,
11422,1,,BAO_0000218,Intermediate,160.0,8684,"Distribution in rat intestine 30 min after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0,
11423,1,,BAO_0000218,Intermediate,160.0,8684,"Distribution in rat intestine 4 hr after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0,
11424,1,,BAO_0000218,Intermediate,160.0,8684,"Distribution in rat intestine 5 min after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0,
11425,1,,BAO_0000218,Intermediate,160.0,8684,"Distribution in rat intestine 6 hr after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0,
11426,1,,BAO_0000218,Intermediate,160.0,8684,"Distribution in rat intestine 8 hr after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0,
11427,1,,BAO_0000218,Intermediate,,8684,"Distribution in rat kidney, 15 min after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0,
11428,1,,BAO_0000218,Intermediate,,8684,"Distribution in rat kidney, 1 hr after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0,
11429,1,,BAO_0000218,Intermediate,,8684,"Distribution in rat kidney, 2 hr after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0,
11430,1,,BAO_0000218,Intermediate,,8684,"Distribution in rat kidney, 30 min after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0,
11431,1,,BAO_0000218,Intermediate,,8684,"Distribution in rat kidney, 4 hr after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0,
11432,1,,BAO_0000218,Intermediate,,8684,"Distribution in rat kidney, 5 min after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0,
11433,1,,BAO_0000218,Intermediate,,8684,"Distribution in rat kidney, 6 hr after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0,
11434,1,,BAO_0000218,Intermediate,,8684,"Distribution in rat kidney, 8 hr after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0,
11435,1,,BAO_0000218,Intermediate,,8684,"Distribution in rat liver 15 min after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0,
11436,1,,BAO_0000218,Intermediate,,8684,"Distribution in rat liver 1 hr after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0,
11437,1,,BAO_0000218,Intermediate,,8684,"Distribution in rat liver 2 hr after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0,
11438,1,,BAO_0000218,Intermediate,,8684,"Distribution in rat liver 30 min after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0,
11439,1,,BAO_0000218,Intermediate,,8684,"Distribution in rat liver 4 hr after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0,
11440,1,,BAO_0000218,Intermediate,,8684,"Distribution in rat liver 5 min after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0,
11441,1,,BAO_0000218,Intermediate,,8684,"Distribution in rat liver 6 hr after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0,
11442,1,,BAO_0000218,Intermediate,,8684,"Distribution in rat liver 8 hr after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0,
11443,1,,BAO_0000218,Intermediate,,8684,"Distribution in rat lungs 15 min after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0,
11444,1,,BAO_0000218,Intermediate,,8684,"Distribution in rat lungs 1 hr after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0,
11445,1,,BAO_0000218,Intermediate,,8684,"Distribution in rat lungs 2 hr after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0,
11446,1,,BAO_0000218,Intermediate,,8684,"Distribution in rat lungs 30 min after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0,
11447,1,,BAO_0000218,Intermediate,,8684,"Distribution in rat lungs 4 hr after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0,
11448,1,,BAO_0000218,Intermediate,,8684,"Distribution in rat lungs 5 min after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0,
11449,1,,BAO_0000218,Intermediate,,8684,"Distribution in rat lungs 6 hr after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0,
11450,1,,BAO_0000218,Intermediate,,8684,"Distribution in rat lungs 8 hr after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0,
11451,1,,BAO_0000218,Intermediate,2385.0,8684,"Distribution in rat muscle 15 min after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0,
11452,1,,BAO_0000218,Intermediate,2385.0,8684,"Distribution in rat muscle 1 hr after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0,
11453,1,,BAO_0000218,Intermediate,2385.0,8684,"Distribution in rat muscle 2 hr after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0,
11454,1,,BAO_0000218,Intermediate,2385.0,8684,"Distribution in rat muscle 30 min after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0,
11455,1,,BAO_0000218,Intermediate,2385.0,8684,"Distribution in rat muscle 4 hr after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0,
11456,1,,BAO_0000218,Intermediate,2385.0,8684,"Distribution in rat muscle 5 min after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0,
11457,1,,BAO_0000218,Intermediate,2385.0,8684,"Distribution in rat muscle 6 hr after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0,
11458,1,,BAO_0000218,Intermediate,2385.0,8684,"Distribution in rat muscle 8 hr after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0,
11459,1,,BAO_0000218,Intermediate,,8684,"Distribution in rat pancreas 15 min after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0,
11460,1,,BAO_0000218,Intermediate,,8684,"Distribution in rat pancreas 1 hr after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0,
11461,1,,BAO_0000218,Intermediate,,8684,"Distribution in rat pancreas 2 hr after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0,
11462,1,,BAO_0000218,Intermediate,,8684,"Distribution in rat pancreas 30 min after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0,
11463,1,,BAO_0000218,Intermediate,,8684,"Distribution in rat pancreas 4 hr after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0,
11464,1,,BAO_0000218,Intermediate,,8684,"Distribution in rat pancreas 5 min after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0,
11465,1,,BAO_0000218,Intermediate,,8684,"Distribution in rat pancreas 6 hr after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0,
11466,1,,BAO_0000218,Intermediate,,8684,"Distribution in rat pancreas 8 hr after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0,
11467,1,,BAO_0000218,Intermediate,2107.0,8319,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat liver as Percent of injected dose per gram in the organ,A,,,Rattus norvegicus,10116.0,
11468,1,,BAO_0000218,Intermediate,,8319,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat lung as Percent of injected dose per gram in the organ,A,,,Rattus norvegicus,10116.0,
11469,1,,BAO_0000218,Intermediate,,8319,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat blood as Percent of injected dose per gram in the organ,A,,,Rattus norvegicus,10116.0,
11470,1,,BAO_0000218,Intermediate,,8319,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat brain as Percent of injected dose in the total organ,A,,,Rattus norvegicus,10116.0,
11471,1,,BAO_0000218,Intermediate,,8319,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat brain as Percent of injected dose per gram in the organ,A,,,Rattus norvegicus,10116.0,
11472,1,,BAO_0000218,Intermediate,,8319,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat heart as Percent of injected dose in the total organ,A,,,Rattus norvegicus,10116.0,
11473,1,,BAO_0000218,Intermediate,,8319,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat heart as Percent of injected dose per gram in the organ,A,,,Rattus norvegicus,10116.0,
11474,1,,BAO_0000218,Intermediate,2113.0,8319,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat kidney as Percent of injected dose in the total organ,A,,,Rattus norvegicus,10116.0,
11475,1,,BAO_0000218,Intermediate,2113.0,8319,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat kidney as Percent of injected dose per gram in the organ,A,,,Rattus norvegicus,10116.0,
11476,1,,BAO_0000218,Intermediate,2107.0,8319,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat liver as Percent of injected dose in the total organ,A,,,Rattus norvegicus,10116.0,
11477,1,,BAO_0000218,Intermediate,2107.0,8319,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat liver as Percent of injected dose per gram in the organ,A,,,Rattus norvegicus,10116.0,
11478,1,,BAO_0000218,Intermediate,,8319,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat lung as Percent of injected dose per gram in the organ,A,,,Rattus norvegicus,10116.0,
11479,1,,BAO_0000218,Intermediate,1088.0,14571,The total amount of penciclovir recovered in the urine over a 48-h period was determined by HPLC using a C18 reversed-phase column in mouse.,A,,,Mus musculus,10090.0,
11480,1,,BAO_0000218,Intermediate,1088.0,14571,The total amount of penciclovir recovered in the urine over a 48-h period was determined by HPLC using a C18 reversed-phase column in rat.,A,,,Rattus norvegicus,10116.0,
11481,1,,BAO_0000218,Intermediate,,8319,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat blood as Percent of injected dose per gram in the organ,A,,,Rattus norvegicus,10116.0,
11482,1,,BAO_0000218,Intermediate,,8319,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat brain as Percent of injected dose in the total organ,A,,,Rattus norvegicus,10116.0,
11483,1,,BAO_0000218,Intermediate,,8319,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat brain as Percent of injected dose per gram in the organ,A,,,Rattus norvegicus,10116.0,
11484,1,,BAO_0000218,Intermediate,,8319,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat heart as Percent of injected dose in the total organ,A,,,Rattus norvegicus,10116.0,
11485,1,,BAO_0000218,Intermediate,,8319,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat heart as Percent of injected dose per gram in the organ,A,,,Rattus norvegicus,10116.0,
11486,1,,BAO_0000218,Intermediate,2113.0,8319,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat kidney as Percent of injected dose in the total organ,A,,,Rattus norvegicus,10116.0,
11487,1,,BAO_0000218,Intermediate,2113.0,8319,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat kidney as Percent of injected dose per gram in the organ,A,,,Rattus norvegicus,10116.0,
11488,1,,BAO_0000218,Intermediate,,8319,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat liver as Percent of injected dose in the total organ,A,,,Rattus norvegicus,10116.0,
11489,1,,BAO_0000218,Intermediate,,8319,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat liver as Percent of injected dose per gram in the organ,A,,,Rattus norvegicus,10116.0,
11490,1,,BAO_0000218,Intermediate,,8319,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat lung as Percent of injected dose per gram in the organ,A,,,Rattus norvegicus,10116.0,
11491,1,,BAO_0000218,Intermediate,,8319,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat blood as Percent of injected dose per gram in the organ,A,,,Rattus norvegicus,10116.0,
11492,1,,BAO_0000218,Intermediate,,8319,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat brain as Percent of injected dose in the total organ,A,,,Rattus norvegicus,10116.0,
11493,1,,BAO_0000218,Intermediate,,8319,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat brain as Percent of injected dose per gram in the organ,A,,,Rattus norvegicus,10116.0,
11494,1,,BAO_0000218,Intermediate,,8319,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat heart as Percent of injected dose in the total organ,A,,,Rattus norvegicus,10116.0,
11495,1,,BAO_0000218,Intermediate,,8319,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat heart as Percent of injected dose per gram in the organ,A,,,Rattus norvegicus,10116.0,
11496,1,,BAO_0000218,Intermediate,2113.0,8319,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat kidney as Percent of injected dose in the total organ,A,,,Rattus norvegicus,10116.0,
11497,1,,BAO_0000218,Intermediate,2113.0,8319,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat kidney as Percent of injected dose per gram in the organ,A,,,Rattus norvegicus,10116.0,
11498,1,,BAO_0000218,Intermediate,,8319,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat liver as Percent of injected dose in the total organ,A,,,Rattus norvegicus,10116.0,
11499,1,,BAO_0000218,Intermediate,,8319,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat liver as Percent of injected dose per gram in the organ,A,,,Rattus norvegicus,10116.0,
11500,1,,BAO_0000218,Intermediate,,8319,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat lung as Percent of injected dose per gram in the organ,A,,,Rattus norvegicus,10116.0,
11501,1,,BAO_0000218,Intermediate,1088.0,12064,Urinary excretion in rat after 0-4 hours of oral administration at 50 mg/kg,A,,,Rattus norvegicus,10116.0,
11502,1,,BAO_0000218,Intermediate,1088.0,12064,Urinary excretion in rat after 4-8 hours of oral administration at 50 mg/kg,A,,,Rattus norvegicus,10116.0,
11503,1,,BAO_0000218,Intermediate,1088.0,12064,Urinary excretion in rat after 8-24 hours of oral administration at 50 mg/kg,A,,,Rattus norvegicus,10116.0,
11504,1,,BAO_0000218,Intermediate,1088.0,12038,Urinary recovery expressed as percentage dose in male rats after iv administration of 20 mg/kg,A,,,Rattus norvegicus,10116.0,
11505,0,,BAO_0000019,Autocuration,,14314,% dose converted to 2-amino-5-chlorophenyl sulfate,A,,,,,
11506,0,,BAO_0000019,Autocuration,,14314,% dose converted to 4-(S-amino-N-{[(4-chlorophenyl)amino]carbonyl}sulfonimidoyl)benzoic acid (compound 41),A,,,,,
11507,1,,BAO_0000218,Intermediate,1988.0,11488,"Compound was evaluated for the percentage of feces excretion of radioactivity, by male Sprague-Dawley rats after intravenous administration of compound dose (1 mg/kg) at 0-24 hr",A,,,Rattus norvegicus,10116.0,
11508,1,,BAO_0000218,Intermediate,1988.0,11488,"Compound was evaluated for the percentage of feces excretion of radioactivity, by male Sprague-Dawley rats after intravenous administration of compound dose (1 mg/kg) at 24-48 hr",A,,,Rattus norvegicus,10116.0,
11509,1,,BAO_0000218,Intermediate,1988.0,11488,"Compound was evaluated for the percentage of feces excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 0-24 hr",A,,,Rattus norvegicus,10116.0,
11510,1,,BAO_0000218,Intermediate,1988.0,11488,"Compound was evaluated for the percentage of feces excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 24-48 hr",A,,,Rattus norvegicus,10116.0,
11511,1,,BAO_0000218,Intermediate,2107.0,8829,Biodistribution in Rat liver after 30 minutes of iv administration; per g of tissue,A,In vivo,,Rattus norvegicus,10116.0,
11512,1,,BAO_0000218,Intermediate,2107.0,8829,Biodistribution in Rat liver after 5 minutes of iv administration,A,In vivo,,Rattus norvegicus,10116.0,
11513,1,,BAO_0000218,Intermediate,2107.0,8829,Biodistribution in Rat liver after 5 minutes of iv administration; per g of tissue,A,In vivo,,Rattus norvegicus,10116.0,
11514,1,,BAO_0000218,Intermediate,2048.0,8829,Biodistribution in Rat lung after 24 hours of iv administration,A,In vivo,,Rattus norvegicus,10116.0,
11515,1,,BAO_0000218,Intermediate,2048.0,8829,Biodistribution in Rat lung after 24 hours of iv administration; per g of tissue,A,In vivo,,Rattus norvegicus,10116.0,
11516,1,,BAO_0000218,Intermediate,2048.0,8829,Biodistribution in Rat lung after 30 minutes of iv administration,A,In vivo,,Rattus norvegicus,10116.0,
11517,1,,BAO_0000218,Intermediate,2048.0,8829,Biodistribution in Rat lung after 30 minutes of iv administration; per g of tissue,A,In vivo,,Rattus norvegicus,10116.0,
11518,1,,BAO_0000218,Intermediate,2048.0,8829,Biodistribution in Rat lung after 5 minutes of iv administration,A,In vivo,,Rattus norvegicus,10116.0,
11519,1,,BAO_0000218,Intermediate,2048.0,8829,Biodistribution in Rat lung after 5 minutes of iv administration; per g of tissue,A,In vivo,,Rattus norvegicus,10116.0,
11520,1,,BAO_0000218,Intermediate,2037.0,14972,"Biodistribution in rat cerebellum, expressed as percent I.D./g tissue",A,In vivo,,Rattus norvegicus,10116.0,
11521,1,,BAO_0000218,Intermediate,,14972,"Biodistribution in rat superior coliculus, expressed as percent I.D./g tissue",A,In vivo,,Rattus norvegicus,10116.0,
11522,1,,BAO_0000218,Intermediate,10000006.0,14972,"Biodistribution in rat thalamus, expressed as percent I.D./g tissue",A,In vivo,,Rattus norvegicus,10116.0,
11523,1,,BAO_0000218,Intermediate,178.0,14608,Biodistribution was measured in blood of rat by injecting the radiolabeled compound intravenously and the value measured after 2 min,A,In vivo,,Rattus norvegicus,10116.0,
11524,1,,BAO_0000218,Intermediate,178.0,14608,Biodistribution was measured in blood of rat by injecting the radiolabeled compound intravenously and the value measured after 30 min,A,In vivo,,Rattus norvegicus,10116.0,
11525,1,,BAO_0000218,Intermediate,178.0,14608,Biodistribution was measured in blood of rat by injecting the radiolabeled compound intravenously and the value measured after 60 min,A,In vivo,,Rattus norvegicus,10116.0,
11526,0,,BAO_0000218,Autocuration,10000000.0,14608,Biodistribution was measured in hippocampus region(HP/CB) by injecting the radiolabeled compound intravenously and the value measured after 2 min,A,In vivo,,,,
11527,0,,BAO_0000218,Autocuration,10000000.0,14608,Biodistribution was measured in hippocampus region(HP/CB) by injecting the radiolabeled compound intravenously and the value measured after 30 min,A,In vivo,,,,
11528,0,,BAO_0000218,Autocuration,10000000.0,14608,Biodistribution was measured in hippocampus region(HP/CB) by injecting the radiolabeled compound intravenously and the value measured after 60 min,A,In vivo,,,,
11529,1,,BAO_0000218,Intermediate,955.0,14608,Biodistribution was measured in rat brain by injecting the radiolabeled compound intravenously and the value measured after 2 min,A,In vivo,,Rattus norvegicus,10116.0,
11530,1,,BAO_0000218,Intermediate,955.0,14608,Biodistribution was measured in rat brain by injecting the radiolabeled compound intravenously and the value measured after 30 min,A,In vivo,,Rattus norvegicus,10116.0,
11531,1,,BAO_0000218,Intermediate,955.0,14608,Biodistribution was measured in rat brain by injecting the radiolabeled compound intravenously and the value measured after 60 min,A,In vivo,,Rattus norvegicus,10116.0,
11532,1,,BAO_0000218,Intermediate,2037.0,14608,Biodistribution was measured in rat cerebellum by injecting the radiolabeled compound intravenously and the value measured after 2 min,A,In vivo,,Rattus norvegicus,10116.0,
11533,1,,BAO_0000218,Intermediate,2037.0,14608,Biodistribution was measured in rat cerebellum by injecting the radiolabeled compound intravenously and the value measured after 30 min,A,In vivo,,Rattus norvegicus,10116.0,
11534,1,,BAO_0000218,Intermediate,2037.0,14608,Biodistribution was measured in rat cerebellum by injecting the radiolabeled compound intravenously and the value measured after 60 min,A,In vivo,,Rattus norvegicus,10116.0,
11535,1,,BAO_0000218,Intermediate,,14608,Biodistribution was measured in rat cortex by injecting the radiolabeled compound intravenously and the value measured after 2 min,A,In vivo,,Rattus norvegicus,10116.0,
11536,1,,BAO_0000218,Intermediate,,14608,Biodistribution was measured in rat cortex by injecting the radiolabeled compound intravenously and the value measured after 30 min,A,In vivo,,Rattus norvegicus,10116.0,
11537,1,,BAO_0000218,Intermediate,,14608,Biodistribution was measured in rat cortex by injecting the radiolabeled compound intravenously and the value measured after 60 min,A,In vivo,,Rattus norvegicus,10116.0,
11538,1,,BAO_0000218,Intermediate,948.0,14608,Biodistribution was measured in rat heart by injecting the radiolabeled compound intravenously and the value measured after 2 min,A,In vivo,,Rattus norvegicus,10116.0,
11539,1,,BAO_0000218,Intermediate,948.0,14608,Biodistribution was measured in rat heart by injecting the radiolabeled compound intravenously and the value measured after 30 min,A,In vivo,,Rattus norvegicus,10116.0,
11540,1,,BAO_0000218,Intermediate,948.0,14608,Biodistribution was measured in rat heart by injecting the radiolabeled compound intravenously and the value measured after 60 min,A,In vivo,,Rattus norvegicus,10116.0,
11541,1,,BAO_0000218,Intermediate,10000000.0,14608,Biodistribution was measured in rat hippocampus by injecting the radiolabeled compound intravenously and the value measured after 2 min,A,In vivo,,Rattus norvegicus,10116.0,
11542,1,,BAO_0000218,Intermediate,10000000.0,14608,Biodistribution was measured in rat hippocampus by injecting the radiolabeled compound intravenously and the value measured after 30 min,A,In vivo,,Rattus norvegicus,10116.0,
11543,1,,BAO_0000218,Intermediate,10000000.0,14608,Biodistribution was measured in rat hippocampus by injecting the radiolabeled compound intravenously and the value measured after 60 min,A,In vivo,,Rattus norvegicus,10116.0,
11544,1,,BAO_0000218,Intermediate,2113.0,14608,Biodistribution was measured in rat kidney by injecting the radiolabeled compound intravenously and the value measured after 2 min,A,In vivo,,Rattus norvegicus,10116.0,
11545,1,,BAO_0000218,Intermediate,2113.0,14608,Biodistribution was measured in rat kidney by injecting the radiolabeled compound intravenously and the value measured after 30 min,A,In vivo,,Rattus norvegicus,10116.0,
11546,1,,BAO_0000218,Intermediate,2113.0,14608,Biodistribution was measured in rat kidney by injecting the radiolabeled compound intravenously and the value measured after 60 min,A,In vivo,,Rattus norvegicus,10116.0,
11547,1,,BAO_0000218,Intermediate,2107.0,14608,Biodistribution was measured in rat liver by injecting the radiolabeled compound intravenously and the value measured after 2 min,A,In vivo,,Rattus norvegicus,10116.0,
11548,1,,BAO_0000218,Intermediate,2107.0,14608,Biodistribution was measured in rat liver by injecting the radiolabeled compound intravenously and the value measured after 30 min,A,In vivo,,Rattus norvegicus,10116.0,
11549,1,,BAO_0000218,Intermediate,2107.0,14608,Biodistribution was measured in rat liver by injecting the radiolabeled compound intravenously and the value measured after 60 min,A,In vivo,,Rattus norvegicus,10116.0,
11550,1,,BAO_0000218,Intermediate,2048.0,14608,Biodistribution was measured in rat lung by injecting the radiolabeled compound intravenously and the value measured after 2 min,A,In vivo,,Rattus norvegicus,10116.0,
11551,1,,BAO_0000218,Intermediate,2048.0,14608,Biodistribution was measured in rat lung by injecting the radiolabeled compound intravenously and the value measured after 30 min,A,In vivo,,Rattus norvegicus,10116.0,
11552,1,,BAO_0000218,Intermediate,2048.0,14608,Biodistribution was measured in rat lung by injecting the radiolabeled compound intravenously and the value measured after 60 min,A,In vivo,,Rattus norvegicus,10116.0,
11553,1,,BAO_0000218,Intermediate,2385.0,14608,Biodistribution was measured in rat muscle by injecting the radiolabeled compound intravenously and the value measured after 2 min,A,In vivo,,Rattus norvegicus,10116.0,
11554,0,,BAO_0000218,Autocuration,1969.0,8918,Peak plasma concentration expresses the ability of compound for the release of dopamine in the plasma of monkey after oral administration of 0.05 mmol/kg,A,In vivo,,Simiiformes,314293.0,
11555,1,,BAO_0000218,Intermediate,1969.0,8918,Peak plasma concentration expresses the ability of compound for the release of dopamine in the plasma of mouse after oral administration of 0.05 mmol/kg,A,In vivo,,Mus musculus,10090.0,
11556,1,,BAO_0000218,Intermediate,1969.0,8918,Peak plasma concentration expresses the ability of compound for the release of dopamine in the plasma of rat after oral administration of 0.05 mmol/kg,A,In vivo,,Rattus norvegicus,10116.0,
11557,1,,BAO_0000218,Intermediate,1969.0,14470,Peak plasma concentration was measured in dogs,A,In vivo,,Canis lupus familiaris,9615.0,
11558,1,,BAO_0000218,Intermediate,,14393,Pharmacokinetic Parameter (Cmax) was evaluated at 10 mg/kg (p.o.) in Wistar rats,A,In vivo,,Rattus norvegicus,10116.0,
11559,1,,BAO_0000218,Intermediate,,14886,Pharmacokinetic parameter (Cmax ) was evaluated in Spargue-Dawley rat when given intravenously at dose 15 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,
11560,1,,BAO_0000218,Intermediate,,14886,Pharmacokinetic parameter (Cmax ) was evaluated in Spargue-Dawley rat when given peroral at dose 30 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,
11561,1,,BAO_0000218,Intermediate,,14886,Pharmacokinetic parameter (Cmax ) was evaluated in Spargue-Dawley rat when given peroral at dose 80 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,
11562,1,,BAO_0000218,Intermediate,,14393,Pharmacokinetic parameter (Cmax) was evaluated at 10 mg/kg (p.o.) in Wistar rats,A,In vivo,,Rattus norvegicus,10116.0,
11563,1,,BAO_0000218,Intermediate,,13465,Pharmacokinetic parameter Cmax determined after intravenous administration of 15 mg/kg to dog,A,In vivo,,Canis lupus familiaris,9615.0,
11564,0,,BAO_0000218,Autocuration,,13465,Pharmacokinetic parameter Cmax determined after intravenous administration of 25 mg/kg to monkey,A,In vivo,,Simiiformes,314293.0,
11565,1,,BAO_0000218,Intermediate,,13465,Pharmacokinetic parameter Cmax determined after intravenous administration of 30 mg/kg abd antacid (CaCO3 dosed orally 10 min prior to and 60 min postdosing) to dog,A,In vivo,,Canis lupus familiaris,9615.0,
11566,1,,BAO_0000218,Intermediate,,13465,Pharmacokinetic parameter Cmax determined after intravenous administration of 30 mg/kg to dog,A,In vivo,,Canis lupus familiaris,9615.0,
11567,1,,BAO_0000218,Intermediate,,13465,Pharmacokinetic parameter Cmax determined after intravenous administration of 50 mg/kg to rat,A,In vivo,,Rattus norvegicus,10116.0,
11568,1,,BAO_0000218,Intermediate,,13465,Pharmacokinetic parameter Cmax determined after intravenous administration of 60 mg/kg to rat,A,In vivo,,Rattus norvegicus,10116.0,
11569,1,,BAO_0000218,Intermediate,,13465,Pharmacokinetic parameter Cmax determined after oral administration of 50 mg/kg to dog,A,In vivo,,Canis lupus familiaris,9615.0,
11570,1,,BAO_0000218,Intermediate,,13465,Pharmacokinetic parameter Cmax determined after oral administration of 50 mg/kg to rat,A,In vivo,,Rattus norvegicus,10116.0,
11571,1,,BAO_0000218,Intermediate,,13465,Pharmacokinetic parameter Cmax determined after oral administration of 50 mg/kg to rat; No levels,A,In vivo,,Rattus norvegicus,10116.0,
11572,1,,BAO_0000218,Intermediate,,13465,Pharmacokinetic parameter Cmax determined after peroral administration of 15 mg/kg to dog,A,In vivo,,Canis lupus familiaris,9615.0,
11573,1,,BAO_0000218,Intermediate,,13465,Pharmacokinetic parameter Cmax determined after peroral administration of 25 mg/kg to dog,A,In vivo,,Canis lupus familiaris,9615.0,
11574,0,,BAO_0000218,Autocuration,,13465,Pharmacokinetic parameter Cmax determined after peroral administration of 25 mg/kg to monkey,A,In vivo,,Simiiformes,314293.0,
11575,0,,BAO_0000218,Autocuration,,13465,Pharmacokinetic parameter Cmax determined after peroral administration of 25 mg/kg to monkey; No levels,A,In vivo,,Simiiformes,314293.0,
11576,1,,BAO_0000218,Intermediate,,13465,Pharmacokinetic parameter Cmax determined after peroral administration of 50 mg/kg to rat,A,In vivo,,Rattus norvegicus,10116.0,
11577,1,,BAO_0000218,Intermediate,,14731,Pharmacokinetic parameter Cmax for the compound was evaluated in nude cynomolgus monkeys after oral administration. ,A,In vivo,,Macaca fascicularis,9541.0,
11578,1,,BAO_0000218,Intermediate,,14731,Pharmacokinetic parameter Cmax for the compound was evaluated in nude mice after oral administration. ,A,In vivo,,Mus musculus,10090.0,
11579,1,,BAO_0000218,Intermediate,,13376,Pharmacokinetic parameter Cmax has been determined in fed Beagle dogs at a dose of 375 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,
11580,1,,BAO_0000218,Intermediate,,13376,Pharmacokinetic parameter Cmax has been determined in fed Beagle dogs at a dose of 500 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,
11581,1,,BAO_0000218,Intermediate,,14443,Maximum concentration (Cmax) in rat when administered orally,A,In vivo,,Rattus norvegicus,10116.0,
11582,0,,BAO_0000218,Autocuration,1969.0,13465,Maximal concentration in monkey plasma after 25 mg/kg oral dose,A,In vivo,,Simiiformes,314293.0,
11583,0,,BAO_0000218,Autocuration,,16359,"Mean Cmax in rats after 5 mg/kg oral dose, range (0.17-0.20)",A,In vivo,,Rattus norvegicus,10116.0,
11584,0,,BAO_0000218,Autocuration,,16359,"Mean Cmax in rats after 5 mg/kg oral dose, range (0.4-0.8)",A,In vivo,,Rattus norvegicus,10116.0,
11585,0,,BAO_0000218,Autocuration,1969.0,15618,Cmax in rat plasma after single 5 mg/kg oral cassette gavage dose,A,In vivo,,,,
11586,1,,BAO_0000218,Intermediate,,14554,Pharmacokinetic profile Cmax was evaluated in rats,A,In vivo,,Rattus norvegicus,10116.0,
11587,1,,BAO_0000218,Intermediate,,11537,Pharmacokinetic property(Cmax- maximum concentration) after oral administration in dog (25 mg/kg),A,In vivo,,Canis lupus familiaris,9615.0,
11588,1,,BAO_0000218,Intermediate,,11537,Pharmacokinetic property(Cmax- maximum concentration) after oral administration in mice (50 mg/kg),A,In vivo,,Mus musculus,10090.0,
11589,1,,BAO_0000218,Intermediate,,11537,Pharmacokinetic property(Cmax- maximum concentration) after oral administration to dog (25 mg/kg),A,In vivo,,Canis lupus familiaris,9615.0,
11590,1,,BAO_0000218,Intermediate,,11537,Pharmacokinetic property(Cmax- maximum concentration) after oral administration to mice (50 mg/kg),A,In vivo,,Mus musculus,10090.0,
11591,0,,BAO_0000218,Autocuration,1969.0,2021,Cmax in rat plasma,A,In vivo,,Rattus norvegicus,10116.0,
11592,1,,BAO_0000218,Intermediate,1969.0,5932,Cmax in dog plasma after 30mg/kg oral dose,A,In vivo,,Canis lupus familiaris,9615.0,
11593,1,,BAO_0000218,Intermediate,1969.0,5932,Cmax in rat plasma after 30mg/kg oral dose,A,In vivo,,Rattus norvegicus,10116.0,
11594,1,,BAO_0000218,Intermediate,1969.0,17320,Plasma level in rats at 30 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,
11595,1,,BAO_0000218,Intermediate,1969.0,15831,Tested for maximum plasma concentration in mice,A,In vivo,,Mus musculus,10090.0,
11596,1,,BAO_0000218,Intermediate,,15078,"The Cmax value in female wistar rat at 100 mg/kg, p.o. dose",A,In vivo,,Rattus norvegicus,10116.0,
11597,1,,BAO_0000218,Intermediate,,14941,The Cmax values in female wistar rats.,A,In vivo,,Rattus norvegicus,10116.0,
11598,1,,BAO_0000218,Intermediate,1969.0,15343,The Peak plasma concentration was measured in dogs after oral administration of 1 mg/kg dose,A,In vivo,,Canis lupus familiaris,9615.0,
11599,1,,BAO_0000218,Intermediate,1969.0,15343,The Peak plasma concentration was measured in rats after oral administration of 1 mg/kg dose,A,In vivo,,Rattus norvegicus,10116.0,
11600,1,,BAO_0000218,Intermediate,1969.0,14856,The compound tested for maximum observed plasma concentration in rats and is expressed in microgram/mL.,A,In vivo,,Rattus norvegicus,10116.0,
11601,1,,BAO_0000218,Intermediate,,13129,The compound was tested for Cmax value pharmacokinetic parameter in the male Sprague-Dawley rat.,A,In vivo,,Rattus norvegicus,10116.0,
11602,1,,BAO_0000218,Intermediate,178.0,13098,The compound was tested for maximum blood level reached in rats at 15.9 uM/kg after peroral administration.,A,In vivo,,Rattus norvegicus,10116.0,
11603,1,,BAO_0000218,Intermediate,178.0,13098,The compound was tested for maximum blood level reached in rats at 15.9 uM/Kg after intravenous administration.,A,In vivo,,Rattus norvegicus,10116.0,
11604,1,,BAO_0000218,Intermediate,178.0,13098,The compound was tested for maximum blood level reached in rats at 15.9 uM/Kg after peroral administration.,A,In vivo,,Rattus norvegicus,10116.0,
11605,0,,BAO_0000218,Autocuration,178.0,15478,The maximum concentration observed (Cmax) in the blood sample at indicated time point (tmax) at a dose 50 mg/Kg administered orally in mice.,A,In vivo,,Mus musculus,10090.0,
11606,1,,BAO_0000218,Intermediate,,15341,The maximum concentration of the compound was measured in dog at dose 5 mg/kg after peroral administration.,A,In vivo,,Canis lupus familiaris,9615.0,
11607,1,,BAO_0000218,Intermediate,,15341,The maximum concentration of the compound was measured in rat at dose 1 mg/kg after peroral administration.,A,In vivo,,Rattus norvegicus,10116.0,
11608,1,,BAO_0000218,Intermediate,,8684,"Distribution in rat skin 15 min after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0,
11609,1,,BAO_0000218,Intermediate,,8684,"Distribution in rat skin 1 hr after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0,
11610,1,,BAO_0000218,Intermediate,,8684,"Distribution in rat skin 2 hr after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0,
11611,1,,BAO_0000218,Intermediate,,8684,"Distribution in rat skin 30 min after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0,
11612,1,,BAO_0000218,Intermediate,,8684,"Distribution in rat skin 4 hr after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0,
11613,1,,BAO_0000218,Intermediate,,8684,"Distribution in rat skin 5 min after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0,
11614,1,,BAO_0000218,Intermediate,,8684,"Distribution in rat skin 6 hr after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0,
11615,1,,BAO_0000218,Intermediate,,8684,"Distribution in rat skin 8 hr after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0,
11616,1,,BAO_0000218,Intermediate,2106.0,8684,"Distribution in rat spleen 15 min after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0,
11617,1,,BAO_0000218,Intermediate,2106.0,8684,"Distribution in rat spleen 1 hr after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0,
11618,1,,BAO_0000218,Intermediate,2106.0,8684,"Distribution in rat spleen 2 hr after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0,
11619,1,,BAO_0000218,Intermediate,2106.0,8684,"Distribution in rat spleen 30 min after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0,
11620,1,,BAO_0000218,Intermediate,2106.0,8684,"Distribution in rat spleen 4 hr after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0,
11621,1,,BAO_0000218,Intermediate,2106.0,8684,"Distribution in rat spleen 5 min after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0,
11622,1,,BAO_0000218,Intermediate,2106.0,8684,"Distribution in rat spleen 6 hr after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0,
11623,1,,BAO_0000218,Intermediate,2106.0,8684,"Distribution in rat spleen 8 hr after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0,
11624,1,,BAO_0000218,Intermediate,995.0,8684,"Distribution in rat uterus 15 min after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0,
11625,1,,BAO_0000218,Intermediate,995.0,8684,"Distribution in rat uterus 1 hr after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0,
11626,1,,BAO_0000218,Intermediate,995.0,8684,"Distribution in rat uterus 2 hr after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0,
11627,1,,BAO_0000218,Intermediate,995.0,8684,"Distribution in rat uterus 30 min after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0,
11628,1,,BAO_0000218,Intermediate,995.0,8684,"Distribution in rat uterus 4 hr after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0,
11629,1,,BAO_0000218,Intermediate,995.0,8684,"Distribution in rat uterus 5 min after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0,
11630,1,,BAO_0000218,Intermediate,995.0,8684,"Distribution in rat uterus 6 hr after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0,
11631,1,,BAO_0000218,Intermediate,995.0,8684,"Distribution in rat uterus 8 hr after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0,
11632,0,,BAO_0000019,Autocuration,,8926,Distribution in the blood after 120 min of intravenous administration,A,,,,,
11633,0,,BAO_0000019,Autocuration,,8926,Distribution in the blood after 15 min of intravenous administration,A,,,,,
11634,0,,BAO_0000019,Autocuration,,8926,Distribution in the blood after 30 min of intravenous administration,A,,,,,
11635,0,,BAO_0000019,Autocuration,,8926,Distribution in the blood after 5 min of intravenous administration,A,,,,,
11636,0,,BAO_0000019,Autocuration,,8926,Distribution in the blood after 60 min of intravenous administration,A,,,,,
11637,0,,BAO_0000019,Autocuration,,8926,Distribution in the blood after 90 min of intravenous administration,A,,,,,
11638,0,,BAO_0000019,Autocuration,,8926,Distribution in the bone after 120 min of intravenous administration,A,,,,,
11639,0,,BAO_0000019,Autocuration,,8926,Distribution in the bone after 15 min of intravenous administration,A,,,,,
11640,0,,BAO_0000019,Autocuration,,8926,Distribution in the bone after 30 min of intravenous administration,A,,,,,
11641,0,,BAO_0000019,Autocuration,,8926,Distribution in the bone after 5 min of intravenous administration,A,,,,,
11642,0,,BAO_0000019,Autocuration,,8926,Distribution in the bone after 60 min of intravenous administration,A,,,,,
11643,0,,BAO_0000019,Autocuration,,8926,Distribution in the bone after 90 min of intravenous administration,A,,,,,
11644,0,,BAO_0000019,Autocuration,,8926,Distribution in the heart after 120 min of intravenous administration,A,,,,,
11645,0,,BAO_0000019,Autocuration,,8926,Distribution in the heart after 15 min of intravenous administration,A,,,,,
11646,0,,BAO_0000019,Autocuration,,8926,Distribution in the heart after 30 min of intravenous administration,A,,,,,
11647,0,,BAO_0000019,Autocuration,,8926,Distribution in the heart after 5 min of intravenous administration,A,,,,,
11648,0,,BAO_0000019,Autocuration,,8926,Distribution in the heart after 60 min of intravenous administration,A,,,,,
11649,0,,BAO_0000019,Autocuration,,8926,Distribution in the heart after 90 min of intravenous administration,A,,,,,
11650,0,,BAO_0000019,Autocuration,,8926,Distribution in the kidneys after 120 min of intravenous administration,A,,,,,
11651,0,,BAO_0000019,Autocuration,,8926,Distribution in the kidneys after 15 min of intravenous administration,A,,,,,
11652,0,,BAO_0000019,Autocuration,,8926,Distribution in the kidneys after 30 min of intravenous administration,A,,,,,
11653,0,,BAO_0000019,Autocuration,,8926,Distribution in the kidneys after 5 min of intravenous administration,A,,,,,
11654,0,,BAO_0000019,Autocuration,,8926,Distribution in the kidneys after 60 min of intravenous administration,A,,,,,
11655,0,,BAO_0000019,Autocuration,,8926,Distribution in the kidneys after 90 min of intravenous administration,A,,,,,
11656,0,,BAO_0000019,Autocuration,,8926,Distribution in the liver after 120 min of intravenous administration,A,,,,,
11657,0,,BAO_0000019,Autocuration,,8926,Distribution in the liver after 15 min of intravenous administration,A,,,,,
11658,0,,BAO_0000019,Autocuration,,8926,Distribution in the liver after 30 min of intravenous administration,A,,,,,
11659,0,,BAO_0000019,Autocuration,,8926,Distribution in the liver after 5 min of intravenous administration,A,,,,,
11660,0,,BAO_0000019,Autocuration,,8926,Distribution in the liver after 60 min of intravenous administration,A,,,,,
11661,0,,BAO_0000019,Autocuration,,8926,Distribution in the liver after 90 min of intravenous administration,A,,,,,
11662,0,,BAO_0000019,Autocuration,,8926,Distribution in the lung after 120 min of intravenous administration,A,,,,,
11663,1,,BAO_0000218,Intermediate,,14839,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in solution, iv and the total drug exposure was determined. (0-24hr)",A,,,Mus musculus,10090.0,
11664,1,,BAO_0000218,Intermediate,,14839,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in solution, perorally and the total drug exposure was determined (0-24hr)",A,,,Mus musculus,10090.0,
11665,1,,BAO_0000218,Intermediate,,14839,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, micronized free base in 20% HPbetaCD, iv and the total drug exposure was determined. (0-24hr)",A,,,Mus musculus,10090.0,
11666,1,,BAO_0000218,Intermediate,,14839,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, micronized free base in 20% HPbetaCD, perorally and the total drug exposure was determined (0-24hr)",A,,,Mus musculus,10090.0,
11667,1,,BAO_0000218,Intermediate,,12178,Integrated area under the blood concentration vs time curve for the period 0-24 hr postdose of 1 mg/kg (normalized to a 1 mg/kg dose) in rat,A,,,Rattus norvegicus,10116.0,
11668,1,,BAO_0000218,Intermediate,,12178,Integrated area under the blood concentration vs time curve for the period 0-24 hr postdose of 2.5 mg/kg (normalized to a 1 mg/kg dose) in rat,A,,,Rattus norvegicus,10116.0,
11669,0,,BAO_0000218,Autocuration,,12178,Integrated area under the blood concentration vs time curve for the period 0-24 hr postdose of 5.0 mg/kg (normalized to a 1 mg/kg dose) GP,A,,,,,
11670,1,,BAO_0000218,Intermediate,,12186,Integrated area under the plasma drug level-time curve after intraduodenal administration at a dose 10 mg/kg from portal circulation in salt-depleted cynomolgus monkeys using HPLC assay,A,,,Macaca fascicularis,9541.0,
11671,1,,BAO_0000218,Intermediate,,12186,Integrated area under the plasma drug level-time curve after intraduodenal administration at a dose 10 mg/kg from portal circulation in salt-depleted cynomolgus monkeys using renin inhibition assay,A,,,Macaca fascicularis,9541.0,
11672,1,,BAO_0000218,Intermediate,,12186,Integrated area under the plasma drug level-time curve after intraduodenal administration at a dose 10 mg/kg from systemic circulation in salt-depleted cynomolgus monkeys using HPLC assay,A,,,Macaca fascicularis,9541.0,
11673,1,,BAO_0000218,Intermediate,,12186,Integrated area under the plasma drug level-time curve after intraduodenal administration at a dose 10 mg/kg from systemic circulation in salt-depleted cynomolgus monkeys using renin inhibition assay,A,,,Macaca fascicularis,9541.0,
11674,0,,BAO_0000218,Autocuration,,12187,Integrated area under the plasma drug level-time curve was determined in portal circulation after intraduodenal dose of 10 mg/kg in monkey,A,,,Simiiformes,314293.0,
11675,1,,BAO_0000218,Intermediate,,12187,Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in ferret,A,,,Mustela putorius furo,9669.0,
11676,1,,BAO_0000218,Intermediate,,12187,"Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in ferret, determined by renin inhibition assay",A,,,Mustela putorius furo,9669.0,
11677,0,,BAO_0000218,Autocuration,,12187,Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in monkey,A,,,Simiiformes,314293.0,
11678,0,,BAO_0000218,Autocuration,,12187,Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in monkey determined by renin inhibition assay,A,,,Simiiformes,314293.0,
11679,1,,BAO_0000218,Intermediate,,12187,Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in rat,A,,,Rattus norvegicus,10116.0,
11680,1,,BAO_0000218,Intermediate,,12187,"Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in rat, determined by renin inhibition assay",A,,,Rattus norvegicus,10116.0,
11681,1,,BAO_0000218,Intermediate,,14122,"Intravenous integrated area under the concentration vs time curve, for compound in dog plasma",A,,,Canis lupus familiaris,9615.0,
11682,1,,BAO_0000218,Intermediate,,14122,"Intravenous integrated area under the concentration vs time curve, for compound in hamster plasma",A,,,Cricetinae,10026.0,
11683,1,,BAO_0000218,Intermediate,,14122,"Intravenous integrated area under the concentration vs time curve, for compound in rat plasma",A,,,Rattus norvegicus,10116.0,
11684,0,,BAO_0000218,Autocuration,,13391,Oral Bioavailability was measured as area-under-curve(AUC) value at dose 125 mg/kg,A,,,,,
11685,0,,BAO_0000218,Autocuration,178.0,13391,Oral Bioavailability was measured as area-under-curve(AUC) value at dose 125 mg/kg; b = No compound detectable in blood above the detection limit of 0.1 uM,A,,,,,
11686,0,,BAO_0000218,Autocuration,178.0,13391,Oral Bioavailability was measured as area-under-curve(AUC) value at dose 125 mg/kg; b denotes No compound detectable in blood above the detection limit of 0.1 uM,A,,,,,
11687,0,,BAO_0000218,Autocuration,178.0,13391,Oral Bioavailability was measured as area-under-curve(AUC) value at dose 125 mg/kg;b = No compound detectable in blood above the detection limit of 0.1 uM,A,,,,,
11688,0,,BAO_0000019,Autocuration,,16360,Oral absorption expressed as Area under curve was determined,A,,,,,
11689,1,,BAO_0000218,Intermediate,,3673,Oral absorption kinetics (AUC) was determined after administration of compound orally at 1 mg/kg in dogs,A,,,Canis lupus familiaris,9615.0,
11690,1,,BAO_0000218,Intermediate,,14122,"Oral integrated area under the concentration vs time curve, for compound in dog plasma",A,,,Canis lupus familiaris,9615.0,
11691,1,,BAO_0000218,Intermediate,,14122,"Oral integrated area under the concentration vs time curve, for compound in hamster plasma",A,,,Cricetinae,10026.0,
11692,1,,BAO_0000218,Intermediate,,14122,"Oral integrated area under the concentration vs time curve, for compound in hamster plasma",A,,,Cricetinae,10026.0,
11693,1,,BAO_0000218,Intermediate,,14122,"Oral integrated area under the concentration vs time curve, for compound in rat plasma",A,,,Rattus norvegicus,10116.0,
11694,0,,BAO_0000019,Autocuration,,13889,Pharmacokinetic parameter AUC in mice following a single dose intravenous administration of the compound,A,,,,,
11695,1,,BAO_0000218,Intermediate,,14393,Pharmacokinetic Parameter [Area under curve (AUC)] was evaluated at 10 mg/kg (p.o.) in Wistar rats,A,,,Rattus norvegicus,10116.0,
11696,1,,BAO_0000218,Intermediate,,17279,Pharmacokinetic parameter (AUC) was determined after administering 1 mg/kg of compound intravenously in rat no.3 belonging to phenotype EM (extensive metabolizer),A,,,Rattus norvegicus,10116.0,
11697,1,,BAO_0000218,Intermediate,,14548,Pharmacokinetic parameter AUC calculated in cynomolgus monkey when the compound was administered intravenously at 0.5 mg/kg concentration,A,,,Macaca fascicularis,9541.0,
11698,1,,BAO_0000218,Intermediate,,14548,Pharmacokinetic parameter AUC calculated in cynomolgus monkey when the compound was administered intravenously at 1 mg/kg concentration,A,,,Macaca fascicularis,9541.0,
11699,1,,BAO_0000218,Intermediate,,14548,Pharmacokinetic parameter AUC calculated in cynomolgus monkey when the compound was administered po at 5 mg/kg concentration,A,,,Macaca fascicularis,9541.0,
11700,1,,BAO_0000218,Intermediate,,14548,Pharmacokinetic parameter AUC calculated in dog when the compound was administered intravenously at 2 mg/kg concentration,A,,,Canis lupus familiaris,9615.0,
11701,1,,BAO_0000218,Intermediate,,14548,Pharmacokinetic parameter AUC calculated in dog when the compound was administered po at 5 mg/kg concentration,A,,,Canis lupus familiaris,9615.0,
11702,1,,BAO_0000218,Intermediate,,14548,Pharmacokinetic parameter AUC calculated in rat when the compound was administered intravenously at 5 mg/kg concentration,A,,,Rattus norvegicus,10116.0,
11703,1,,BAO_0000218,Intermediate,,14548,Pharmacokinetic parameter AUC calculated in rat when the compound was administered po at 12 mg/kg concentration,A,,,Rattus norvegicus,10116.0,
11704,1,,BAO_0000218,Intermediate,,14548,Pharmacokinetic parameter AUC calculated in rat when the compound was administered po at 20 mg/kg concentration,A,,,Rattus norvegicus,10116.0,
11705,1,,BAO_0000218,Intermediate,2385.0,14608,Biodistribution was measured in rat muscle by injecting the radiolabeled compound intravenously and the value measured after 30 min,A,In vivo,,Rattus norvegicus,10116.0,
11706,1,,BAO_0000218,Intermediate,2385.0,14608,Biodistribution was measured in rat muscle by injecting the radiolabeled compound intravenously and the value measured after 60 min,A,In vivo,,Rattus norvegicus,10116.0,
11707,1,,BAO_0000218,Intermediate,14.0,14608,Biodistribution was measured in rat skin by injecting the radiolabeled compound intravenously and the value measured after 2 min,A,In vivo,,Mus musculus,10090.0,
11708,1,,BAO_0000218,Intermediate,14.0,14608,Biodistribution was measured in rat skin by injecting the radiolabeled compound intravenously and the value measured after 30 min,A,In vivo,,Rattus norvegicus,10116.0,
11709,1,,BAO_0000218,Intermediate,14.0,14608,Biodistribution was measured in rat skin by injecting the radiolabeled compound intravenously and the value measured after 60 min,A,In vivo,,Rattus norvegicus,10116.0,
11710,1,,BAO_0000218,Intermediate,2106.0,14608,Biodistribution was measured in rat spleen by injecting the radiolabeled compound intravenously and the value measured after 2 min,A,In vivo,,Rattus norvegicus,10116.0,
11711,1,,BAO_0000218,Intermediate,2106.0,14608,Biodistribution was measured in rat spleen by injecting the radiolabeled compound intravenously and the value measured after 30 min,A,In vivo,,Rattus norvegicus,10116.0,
11712,1,,BAO_0000218,Intermediate,2106.0,14608,Biodistribution was measured in rat spleen by injecting the radiolabeled compound intravenously and the value measured after 60 min,A,In vivo,,Rattus norvegicus,10116.0,
11713,1,,BAO_0000218,Intermediate,2435.0,14608,Biodistribution was measured in rat striatum by injecting the radiolabeled compound intravenously and the value measured after 2 min,A,In vivo,,Rattus norvegicus,10116.0,
11714,1,,BAO_0000218,Intermediate,2435.0,14608,Biodistribution was measured in rat striatum by injecting the radiolabeled compound intravenously and the value measured after 30 min,A,In vivo,,Rattus norvegicus,10116.0,
11715,1,,BAO_0000218,Intermediate,2435.0,14608,Biodistribution was measured in rat striatum by injecting the radiolabeled compound intravenously and the value measured after 60 min,A,In vivo,,Rattus norvegicus,10116.0,
11716,1,,BAO_0000218,Intermediate,2046.0,14608,Biodistribution was measured in rat thyroid by injecting the radiolabeled compound intravenously and the value measured after 2 min,A,In vivo,,Rattus norvegicus,10116.0,
11717,1,,BAO_0000218,Intermediate,2046.0,14608,Biodistribution was measured in rat thyroid by injecting the radiolabeled compound intravenously and the value measured after 30 min,A,In vivo,,Rattus norvegicus,10116.0,
11718,1,,BAO_0000218,Intermediate,2046.0,14608,Biodistribution was measured in rat thyroid by injecting the radiolabeled compound intravenously and the value measured after 60 min,A,In vivo,,Rattus norvegicus,10116.0,
11719,1,,BAO_0000218,Intermediate,,15383,In vivo biodistribution in mice blood bearing intracerebral GL261 gliomas at the dose of 30 ug/day,A,,,Mus musculus,10090.0,
11720,1,,BAO_0000218,Intermediate,,15383,In vivo biodistribution in mice blood bearing subcutaneous B16 melanomas at the dose of 10 ug/g,A,,,Mus musculus,10090.0,
11721,1,,BAO_0000218,Intermediate,,15383,In vivo biodistribution in mice blood bearing subcutaneous B16 melanomas at the dose of 20 ug/g,A,,,Mus musculus,10090.0,
11722,1,,BAO_0000218,Intermediate,,15383,In vivo biodistribution in mice blood bearing subcutaneous B16 melanomas at the dose of 30 ug/g,A,,,Mus musculus,10090.0,
11723,1,,BAO_0000218,Intermediate,,15383,In vivo biodistribution in mice blood bearing subcutaneous B16 melanomas at the dose of 40 ug/g,A,,,Mus musculus,10090.0,
11724,1,,BAO_0000218,Intermediate,955.0,15383,In vivo biodistribution in mice brain bearing intracerebral GL261 gliomas at the dose of 30 ug/day,A,,,Mus musculus,10090.0,
11725,1,,BAO_0000218,Intermediate,955.0,15383,In vivo biodistribution in mice brain bearing subcutaneous B16 melanomas at the dose of 30 ug/g,A,,,Mus musculus,10090.0,
11726,1,,BAO_0000218,Intermediate,955.0,15383,In vivo biodistribution in mice brain bearing subcutaneous B16 melanomas at the dose of 40 ug/g,A,,,Mus musculus,10090.0,
11727,1,,BAO_0000218,Intermediate,,15383,In vivo biodistribution in mice eyes bearing subcutaneous B16 melanomas at the dose of 30 ug/g,A,,,Mus musculus,10090.0,
11728,1,,BAO_0000218,Intermediate,,15383,In vivo biodistribution in mice eyes bearing subcutaneous B16 melanomas at the dose of 40 ug/g,A,,,Mus musculus,10090.0,
11729,1,,BAO_0000218,Intermediate,2113.0,15383,In vivo biodistribution in mice kidney bearing intracerebral GL261 gliomas at the dose of 10 microg of boron/g/day,A,,,Mus musculus,10090.0,
11730,1,,BAO_0000218,Intermediate,2113.0,15383,In vivo biodistribution in mice kidney bearing intracerebral GL261 gliomas at the dose of 30 ug/day,A,,,Mus musculus,10090.0,
11731,1,,BAO_0000218,Intermediate,2113.0,15383,In vivo biodistribution in mice kidney bearing subcutaneous B16 melanomas at the dose of 10 ug/g,A,,,Mus musculus,10090.0,
11732,1,,BAO_0000218,Intermediate,2113.0,15383,In vivo biodistribution in mice kidney bearing subcutaneous B16 melanomas at the dose of 20 ug/g,A,,,Mus musculus,10090.0,
11733,1,,BAO_0000218,Intermediate,2113.0,15383,In vivo biodistribution in mice kidney bearing subcutaneous B16 melanomas at the dose of 30 ug/g,A,,,Mus musculus,10090.0,
11734,1,,BAO_0000218,Intermediate,2113.0,15383,In vivo biodistribution in mice kidney bearing subcutaneous B16 melanomas at the dose of 40 ug/g,A,,,Mus musculus,10090.0,
11735,1,,BAO_0000218,Intermediate,2107.0,15383,In vivo biodistribution in mice liver bearing intracerebral GL261 gliomas at the dose of 10 microg of boron/g/day,A,,,Mus musculus,10090.0,
11736,1,,BAO_0000218,Intermediate,2107.0,15383,In vivo biodistribution in mice liver bearing intracerebral GL261 gliomas at the dose of 30 ug/day,A,,,Mus musculus,10090.0,
11737,1,,BAO_0000218,Intermediate,2107.0,15383,In vivo biodistribution in mice liver bearing subcutaneous B16 melanomas at the dose of 10 ug/g,A,,,Mus musculus,10090.0,
11738,1,,BAO_0000218,Intermediate,2107.0,15383,In vivo biodistribution in mice liver bearing subcutaneous B16 melanomas at the dose of 20 ug/g,A,,,Mus musculus,10090.0,
11739,1,,BAO_0000218,Intermediate,2107.0,15383,In vivo biodistribution in mice liver bearing subcutaneous B16 melanomas at the dose of 30 ug/g,A,,,Mus musculus,10090.0,
11740,1,,BAO_0000218,Intermediate,2107.0,15383,In vivo biodistribution in mice liver bearing subcutaneous B16 melanomas at the dose of 40 ug/g,A,,,Mus musculus,10090.0,
11741,1,,BAO_0000218,Intermediate,2385.0,15383,In vivo biodistribution in mice muscle bearing intracerebral GL261 gliomas at the dose of 30 ug/day,A,,,Mus musculus,10090.0,
11742,1,,BAO_0000218,Intermediate,2385.0,15383,In vivo biodistribution in mice muscle bearing subcutaneous B16 melanomas at the dose of 10 ug/g,A,,,Mus musculus,10090.0,
11743,1,,BAO_0000218,Intermediate,2385.0,15383,In vivo biodistribution in mice muscle bearing subcutaneous B16 melanomas at the dose of 20 ug/g,A,,,Mus musculus,10090.0,
11744,1,,BAO_0000218,Intermediate,2385.0,15383,In vivo biodistribution in mice muscle bearing subcutaneous B16 melanomas at the dose of 30 ug/g,A,,,Mus musculus,10090.0,
11745,1,,BAO_0000218,Intermediate,2385.0,15383,In vivo biodistribution in mice muscle bearing subcutaneous B16 melanomas at the dose of 40 ug/g,A,,,Mus musculus,10090.0,
11746,1,,BAO_0000218,Intermediate,,15383,In vivo biodistribution in mice skin bearing intracerebral GL261 gliomas at the dose of 30 ug/day,A,,,Mus musculus,10090.0,
11747,1,,BAO_0000218,Intermediate,,15383,In vivo biodistribution in mice skin bearing subcutaneous B16 melanomas at the dose of 30 ug/g,A,,,Mus musculus,10090.0,
11748,1,,BAO_0000218,Intermediate,,15383,In vivo biodistribution in mice skin bearing subcutaneous B16 melanomas at the dose of 40 ug/g,A,,,Mus musculus,10090.0,
11749,1,,BAO_0000218,Intermediate,,15383,In vivo biodistribution in mice skin by pump bearing subcutaneous B16 melanomas at the dose of 30 ug/g,A,,,Mus musculus,10090.0,
11750,1,,BAO_0000218,Intermediate,,15383,In vivo biodistribution in mice skin by pump bearing subcutaneous B16 melanomas at the dose of 40 ug/g,A,,,Mus musculus,10090.0,
11751,1,,BAO_0000218,Intermediate,,15341,The maximum concentration of the compound was measured in rat at dose 30 mg/kg after intraperitoneal administration.,A,In vivo,,Rattus norvegicus,10116.0,
11752,1,,BAO_0000218,Intermediate,,15341,The maximum concentration of the compound was measured in rat at dose 30 mg/kg after intravenous administration.,A,In vivo,,Rattus norvegicus,10116.0,
11753,1,,BAO_0000218,Intermediate,,15341,The maximum concentration of the compound was measured in rat at dose 30 mg/kg after peroral administration.,A,In vivo,,Rattus norvegicus,10116.0,
11754,1,,BAO_0000218,Intermediate,1969.0,14906,The maximum plasma concentration (Cmax) is the observed peak plasma concentration after an oral dose on dog.,A,In vivo,,Canis lupus familiaris,9615.0,
11755,1,,BAO_0000218,Intermediate,1969.0,14906,The maximum plasma concentration (Cmax) is the observed peak plasma concentration after an oral dose on rat,A,In vivo,,Rattus norvegicus,10116.0,
11756,1,,BAO_0000218,Intermediate,1969.0,14906,The maximum plasma concentration (Cmax) is the observed peak plasma concentration after an oral dose on rat.,A,In vivo,,Rattus norvegicus,10116.0,
11757,1,,BAO_0000218,Intermediate,1969.0,14215,The maximum plasma concentration (100 mg/kg) administered orally in human,A,In vivo,,Homo sapiens,9606.0,
11758,0,,BAO_0000218,Autocuration,1969.0,14215,The maximum plasma concentration (12.5 mg/kg) administered intravenously in marmoset,A,In vivo,,Callithrix,9481.0,
11759,0,,BAO_0000218,Autocuration,1969.0,14215,The maximum plasma concentration (12.5 mg/kg) administered intravenously in monkey,A,In vivo,,Simiiformes,314293.0,
11760,1,,BAO_0000218,Intermediate,1969.0,14215,The maximum plasma concentration (15 mg/kg) administered intravenously in dog,A,In vivo,,Canis lupus familiaris,9615.0,
11761,1,,BAO_0000218,Intermediate,1969.0,14215,The maximum plasma concentration (200 mg/kg) administered orally in human,A,In vivo,,Homo sapiens,9606.0,
11762,1,,BAO_0000218,Intermediate,1969.0,14215,The maximum plasma concentration (25 mg/kg) administered intravenously in rat,A,In vivo,,Rattus norvegicus,10116.0,
11763,0,,BAO_0000218,Autocuration,1969.0,14215,The maximum plasma concentration (25 mg/kg) administered orally in marmoset,A,In vivo,,Callithrix,9481.0,
11764,0,,BAO_0000218,Autocuration,1969.0,14215,The maximum plasma concentration (25 mg/kg) administered orally in monkey,A,In vivo,,Simiiformes,314293.0,
11765,0,,BAO_0000218,Autocuration,1969.0,14215,The maximum plasma concentration (30 mg/kg) administered orally in dog,A,In vivo,,Canis lupus familiaris,9615.0,
11766,1,,BAO_0000218,Intermediate,1969.0,14215,The maximum plasma concentration (400 mg/kg) administered orally in human,A,In vivo,,Homo sapiens,9606.0,
11767,1,,BAO_0000218,Intermediate,1969.0,14215,The maximum plasma concentration (50 mg/kg) administered orally in fasted rat,A,In vivo,,Rattus norvegicus,10116.0,
11768,1,,BAO_0000218,Intermediate,1969.0,14215,The maximum plasma concentration (50 mg/kg) administered orally in rat,A,In vivo,,Rattus norvegicus,10116.0,
11769,1,,BAO_0000218,Intermediate,1969.0,14215,The maximum plasma concentration (800 mg/kg) administered orally in human,A,In vivo,,Homo sapiens,9606.0,
11770,1,,BAO_0000218,Intermediate,1969.0,14067,The maximum plasma concentration was measured on rats,A,In vivo,,Rattus norvegicus,10116.0,
11771,1,,BAO_0000218,Intermediate,1969.0,12350,The maximum plasma concentration was measured on rats after oral administration,A,In vivo,,Rattus norvegicus,10116.0,
11772,1,,BAO_0000218,Intermediate,1969.0,14813,Plasma drug Cmax in rat (PO dose),A,In vivo,,Rattus norvegicus,10116.0,
11773,0,,BAO_0000218,Autocuration,,12536,Time taken to reach maximum concentration after administration of 2 umol/kg dose intravenously,A,In vivo,,,,
11774,1,,BAO_0000218,Intermediate,1969.0,14169,maximum Plasma concentration in Dog was determined after Peroral administration,A,In vivo,,Canis lupus familiaris,9615.0,
11775,1,,BAO_0000218,Intermediate,1969.0,14169,maximum Plasma concentration in Rats was determined after Peroral administration,A,In vivo,,Rattus norvegicus,10116.0,
11776,1,,BAO_0000218,Intermediate,1969.0,15604,maximum concentration in plasma in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in dog,A,In vivo,,Canis lupus familiaris,9615.0,
11777,0,,BAO_0000218,Autocuration,1969.0,15604,maximum concentration in plasma in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in monkey,A,In vivo,,Simiiformes,314293.0,
11778,1,,BAO_0000218,Intermediate,1969.0,15604,maximum concentration in plasma in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in rat,A,In vivo,,Rattus norvegicus,10116.0,
11779,1,,BAO_0000218,Intermediate,,14387,maximum concentration was measured when administered through oral route in mice,A,In vivo,,Mus musculus,10090.0,
11780,1,,BAO_0000218,Intermediate,,15115,Compound was evaluated for Cmax/Tmax when administered through oral route in mouse; Value is 0.93/1,A,,,Mus musculus,10090.0,
11781,0,,BAO_0000019,Autocuration,,15115,Compound was evaluated for Cmax/Tmax when administered through oral route to mouse; Value is 0.34/1,A,,,Simiiformes,314293.0,
11782,0,,BAO_0000019,Autocuration,,15115,Compound was evaluated for Cmax/Tmax when administered through oral route to mouse; Value is 0.81/1.6,A,,,Simiiformes,314293.0,
11783,0,,BAO_0000019,Autocuration,,15115,Compound was evaluated for Cmax/Tmax when administered through oral route to mouse; Value is 1.1/1.3,A,,,Simiiformes,314293.0,
11784,1,,BAO_0000218,Intermediate,,16359,Pharmacokinetic parameter was evaluated in rats,A,,,Rattus norvegicus,10116.0,
11785,1,,BAO_0000218,Intermediate,,12829,Plasma concentration at time-0 was measured in mice at 100 mg/kg after intraperitoneal administration with 90% DMSO as vehicle,A,,,Mus musculus,10090.0,
11786,1,,BAO_0000218,Intermediate,,12829,Plasma concentration at time-0 was measured in mice at 100 mg/kg after intraperitoneal administration with saline(pH=11.4) as vehicle,A,,,Mus musculus,10090.0,
11787,1,,BAO_0000218,Intermediate,,12829,Plasma concentration at time-0 was measured in mice at 120 mg/kg after intraperitoneal administration with 90% DMSO as vehicle,A,,,Mus musculus,10090.0,
11788,1,,BAO_0000218,Intermediate,,12829,Plasma concentration at time-0 was measured in mice at 40 mg/kg after intravenous administration with saline(pH=11.4) as vehicle,A,,,Mus musculus,10090.0,
11789,1,,BAO_0000218,Intermediate,,12829,Plasma concentration at time-0 was measured in mice at 40 mg/kg after intravenous administration with 90% DMSO as vehicle,A,,,Mus musculus,10090.0,
11790,1,,BAO_0000218,Intermediate,1969.0,15137,Effect of ip administration of compound on plasma concentration of allo-pregnanolone (AP) in rats(Cerebral Cortex) after 30 min.,A,,,Rattus norvegicus,10116.0,
11791,1,,BAO_0000218,Intermediate,1969.0,15137,Effect of ip administration of compound on plasma concentration of allotetrahydrodeoxy corticosterone(THDOC) in rats(Cerebral Cortex) after 30 min.,A,,,Rattus norvegicus,10116.0,
11792,1,,BAO_0000218,Intermediate,1969.0,15137,Effect of ip administration of compound on plasma concentration of pregnenolone (PRE) in rats(Cerebral Cortex) after 30 min.,A,,,Rattus norvegicus,10116.0,
11793,1,,BAO_0000218,Intermediate,1969.0,15137,Effect of ip administration of compound on plasma concentration of progesterone (PRO) in rats(Cerebral Cortex) after 30 min.,A,,,Mus musculus,10090.0,
11794,1,,BAO_0000218,Intermediate,,13509,Plasma Concentration after 120 min of oral administration to mice,A,,,Mus musculus,10090.0,
11795,1,,BAO_0000218,Intermediate,,13509,Plasma Concentration after 30 min of oral administration to mice,A,,,Mus musculus,10090.0,
11796,1,,BAO_0000218,Intermediate,,13509,Plasma Concentration after 60 min of oral administration to mice,A,,,Macaca fascicularis,9541.0,
11797,1,,BAO_0000218,Intermediate,,13509,Plasma Concentration after 60 min of oral administration to mice; Not determined,A,,,Mus musculus,10090.0,
11798,1,,BAO_0000218,Intermediate,,13509,Plasma Concentration after 90 min of oral administration to mice,A,,,Mus musculus,10090.0,
11799,1,,BAO_0000218,Intermediate,,12064,Plasma concentration level in rat after 1 hour of oral administration at 50 mg/kg,A,,,Rattus norvegicus,10116.0,
11800,1,,BAO_0000218,Intermediate,,12064,Plasma concentration level in rat after 15 hours of oral administration at 50 mg/kg,A,,,Rattus norvegicus,10116.0,
11801,1,,BAO_0000218,Intermediate,,12064,Plasma concentration level in rat after 4 hours of oral administration at 50 mg/kg,A,,,Rattus norvegicus,10116.0,
11802,1,,BAO_0000218,Intermediate,,10677,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 0-1 hr time,A,,,Rattus norvegicus,10116.0,
11803,1,,BAO_0000218,Intermediate,,10677,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 1-2 hr time,A,,,Rattus norvegicus,10116.0,
11804,0,,BAO_0000019,Autocuration,,8926,Distribution in the lung after 15 min of intravenous administration,A,,,,,
11805,0,,BAO_0000019,Autocuration,,8926,Distribution in the lung after 30 min of intravenous administration,A,,,,,
11806,0,,BAO_0000019,Autocuration,,8926,Distribution in the lung after 5 min of intravenous administration,A,,,,,
11807,0,,BAO_0000019,Autocuration,,8926,Distribution in the lung after 60 min of intravenous administration,A,,,,,
11808,0,,BAO_0000019,Autocuration,,8926,Distribution in the lung after 90 min of intravenous administration,A,,,,,
11809,0,,BAO_0000019,Autocuration,2385.0,8926,Distribution in the muscle after 120 min of intravenous administration,A,,,,,
11810,0,,BAO_0000019,Autocuration,2385.0,8926,Distribution in the muscle after 15 min of intravenous administration,A,,,,,
11811,1,,BAO_0000218,Intermediate,2385.0,8926,Distribution in the muscle after 30 min of intravenous administration,A,,,Mus musculus,10090.0,
11812,0,,BAO_0000019,Autocuration,2385.0,8926,Distribution in the muscle after 5 min of intravenous administration,A,,,,,
11813,0,,BAO_0000019,Autocuration,2385.0,8926,Distribution in the muscle after 60 min of intravenous administration,A,,,,,
11814,0,,BAO_0000019,Autocuration,2385.0,8926,Distribution in the muscle after 90 min of intravenous administration,A,,,,,
11815,0,,BAO_0000019,Autocuration,2106.0,8926,Distribution in the spleen after 120 min of intravenous administration,A,,,,,
11816,0,,BAO_0000019,Autocuration,2106.0,8926,Distribution in the spleen after 15 min of intravenous administration,A,,,,,
11817,0,,BAO_0000019,Autocuration,2106.0,8926,Distribution in the spleen after 30 min of intravenous administration,A,,,,,
11818,0,,BAO_0000019,Autocuration,2106.0,8926,Distribution in the spleen after 5 min of intravenous administration,A,,,,,
11819,0,,BAO_0000019,Autocuration,2106.0,8926,Distribution in the spleen after 60 min of intravenous administration,A,,,,,
11820,0,,BAO_0000019,Autocuration,2106.0,8926,Distribution in the spleen after 90 min of intravenous administration,A,,,,,
11821,1,,BAO_0000218,Intermediate,1235.0,7570,Evaluated for distribution at 0.5 hr after intravenous administration in adrenal cortex of female Sprague Dawley rats,A,,,Rattus norvegicus,10116.0,
11822,1,,BAO_0000218,Intermediate,178.0,7570,Evaluated for distribution at 0.5 hr after intravenous administration in blood of female Sprague Dawley rats,A,,,Rattus norvegicus,10116.0,
11823,1,,BAO_0000218,Intermediate,2107.0,7570,Evaluated for distribution at 0.5 hr after intravenous administration in liver of female Sprague Dawley rats,A,,,Rattus norvegicus,10116.0,
11824,1,,BAO_0000218,Intermediate,992.0,7570,Evaluated for distribution at 0.5 hr after intravenous administration in ovary of female Sprague Dawley rats,A,,,Rattus norvegicus,10116.0,
11825,1,,BAO_0000218,Intermediate,2046.0,7570,Evaluated for distribution at 0.5 hr after intravenous administration in thyroid of female Sprague Dawley rats,A,,,Rattus norvegicus,10116.0,
11826,1,,BAO_0000218,Intermediate,1235.0,7570,Evaluated for distribution at 24 hours after intravenous administration in adrenal cortex of female Sprague Dawley rats,A,,,Rattus norvegicus,10116.0,
11827,1,,BAO_0000218,Intermediate,178.0,7570,Evaluated for distribution at 24 hours after intravenous administration in blood of female Sprague Dawley rats,A,,,Rattus norvegicus,10116.0,
11828,1,,BAO_0000218,Intermediate,2107.0,7570,Evaluated for distribution at 24 hours after intravenous administration in liver of female Sprague Dawley rats,A,,,Rattus norvegicus,10116.0,
11829,1,,BAO_0000218,Intermediate,992.0,7570,Evaluated for distribution at 24 hours after intravenous administration in ovary of female Sprague Dawley rats,A,,,Rattus norvegicus,10116.0,
11830,1,,BAO_0000218,Intermediate,2046.0,7570,Evaluated for distribution at 24 hours after intravenous administration in thyroid of female Sprague Dawley rats,A,,,Rattus norvegicus,10116.0,
11831,1,,BAO_0000218,Intermediate,178.0,8608,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.07-0.09",A,,,Rattus norvegicus,10116.0,
11832,1,,BAO_0000218,Intermediate,178.0,8608,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.10-0.13",A,,,Rattus norvegicus,10116.0,
11833,1,,BAO_0000218,Intermediate,178.0,8608,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.18-0.24",A,,,Rattus norvegicus,10116.0,
11834,1,,BAO_0000218,Intermediate,178.0,8608,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.19-0.24",A,,,Rattus norvegicus,10116.0,
11835,1,,BAO_0000218,Intermediate,178.0,8608,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.22-0.32",A,,,Rattus norvegicus,10116.0,
11836,1,,BAO_0000218,Intermediate,178.0,8608,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.25-0.32",A,,,Rattus norvegicus,10116.0,
11837,1,,BAO_0000218,Intermediate,178.0,8608,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.10-0.14",A,,,Rattus norvegicus,10116.0,
11838,1,,BAO_0000218,Intermediate,178.0,8608,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.25-0.34",A,,,Rattus norvegicus,10116.0,
11839,1,,BAO_0000218,Intermediate,178.0,8608,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.27-0.33",A,,,Rattus norvegicus,10116.0,
11840,1,,BAO_0000218,Intermediate,178.0,8608,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.32-0.46",A,,,Rattus norvegicus,10116.0,
11841,1,,BAO_0000218,Intermediate,178.0,8608,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.40-0.45",A,,,Rattus norvegicus,10116.0,
11842,1,,BAO_0000218,Intermediate,178.0,8608,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.44-0.52",A,,,Rattus norvegicus,10116.0,
11843,1,,BAO_0000218,Intermediate,178.0,8608,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.08-0.09",A,,,Rattus norvegicus,10116.0,
11844,1,,BAO_0000218,Intermediate,178.0,8608,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.12-0.14",A,,,Rattus norvegicus,10116.0,
11845,1,,BAO_0000218,Intermediate,178.0,8608,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.13-0.15",A,,,Rattus norvegicus,10116.0,
11846,1,,BAO_0000218,Intermediate,178.0,8608,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.15-0.20",A,,,Rattus norvegicus,10116.0,
11847,1,,BAO_0000218,Intermediate,178.0,8608,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.15-0.23",A,,,Rattus norvegicus,10116.0,
11848,1,,BAO_0000218,Intermediate,178.0,8608,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.16-0.21",A,,,Rattus norvegicus,10116.0,
11849,1,,BAO_0000218,Intermediate,,13792,Pharmacokinetic parameter AUC for the compound after intravenous administration into BALB/c Mice in plasma samples.,A,,,Mus musculus,10090.0,
11850,1,,BAO_0000218,Intermediate,,13376,Pharmacokinetic parameter AUC has been determined in fed Beagle dogs at a dose of 375 mg/kg,A,,,Canis lupus familiaris,9615.0,
11851,1,,BAO_0000218,Intermediate,,13376,Pharmacokinetic parameter AUC has been determined in fed Beagle dogs at a dose of 500 mg/kg,A,,,Canis lupus familiaris,9615.0,
11852,0,,BAO_0000218,Autocuration,,14380,Pharmacokinetic parameter AUC evaluated in 0.5% methylcellulose suspension at a dose of 20 mg/kg orally,A,,,,,
11853,0,,BAO_0000218,Autocuration,,14380,Pharmacokinetic parameter AUC was evaluated in 0.5% methylcellulose suspension at a dose of 20 mg/kg orally,A,,,,,
11854,0,,BAO_0000218,Autocuration,,14380,Pharmacokinetic parameter AUC was evaluated in 10% PEG suspension at a dose of 20 mg/kg orally,A,,,,,
11855,0,,BAO_0000218,Autocuration,,14380,Pharmacokinetic parameter AUC was evaluated in 100% PEG solution at a dose of 20 mg/kg orally,A,,,,,
11856,0,,BAO_0000218,Autocuration,,14380,Pharmacokinetic parameter AUC was evaluated in DMA:H2O solution at a dose of 20 mg/kg orally,A,,,,,
11857,0,,BAO_0000218,Autocuration,,14380,Pharmacokinetic parameter AUC was evaluated in HP-beta-CD solution at a dose of 20 mg/kg orally,A,,,,,
11858,0,,BAO_0000019,Autocuration,,14380,Pharmacokinetic parameter AUC was evaluated in Hp-beta-CD solution,A,,,,,
11859,0,,BAO_0000218,Autocuration,,14380,Pharmacokinetic parameter AUC was evaluated in saline solution at a dose of 20 mg/kg orally,A,,,,,
11860,1,,BAO_0000218,Intermediate,,13701,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration in mice brain; AUC (mM.h); not detected,A,,,Mus musculus,10090.0,
11861,1,,BAO_0000218,Intermediate,,13701,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration in mice serum; AUC (mM.h),A,,,Mus musculus,10090.0,
11862,1,,BAO_0000218,Intermediate,,13701,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration in mice serum; AUC 0-r (mM.h),A,,,Mus musculus,10090.0,
11863,1,,BAO_0000218,Intermediate,,13701,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration in mice brain; AUC (mM.h),A,,,Mus musculus,10090.0,
11864,1,,BAO_0000218,Intermediate,,13701,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration in mice serum; AUC (mM.h),A,,,Mus musculus,10090.0,
11865,1,,BAO_0000218,Intermediate,,13701,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration using FMAddA as substrate in mice brain; AUC 0-r (mM.h); not detected,A,,,Mus musculus,10090.0,
11866,1,,BAO_0000218,Intermediate,,13701,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by intravenous administration in mice brain; AUC (mM.h),A,,,Mus musculus,10090.0,
11867,1,,BAO_0000218,Intermediate,,13701,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by intravenous administration in mice brain; AUC 0-r (mM.h),A,,,Mus musculus,10090.0,
11868,1,,BAO_0000218,Intermediate,,13701,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by intravenous administration in mice serum; AUC 0-r (mM.h),A,,,Mus musculus,10090.0,
11869,1,,BAO_0000218,Intermediate,,13701,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by intravenous administration using 2`-F-ara-ddI as substrate in mice serum; AUC (mM.h),A,,,Mus musculus,10090.0,
11870,1,,BAO_0000218,Intermediate,,13701,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by oral administration in mice serum; AUC 0-r (mM.h),A,,,Mus musculus,10090.0,
11871,1,,BAO_0000218,Intermediate,,13701,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by intravenous administration in mice serum; AUC 0-r (mM.h).,A,,,Mus musculus,10090.0,
11872,1,,BAO_0000218,Intermediate,,13701,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by oral administration in mice serum.; AUC 0-r (mM.h),A,,,Mus musculus,10090.0,
11873,1,,BAO_0000218,Intermediate,,13701,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by intravenous administration in mice brain; AUC 0-r (mM.h),A,,,Mus musculus,10090.0,
11874,1,,BAO_0000218,Intermediate,,13701,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by intravenous administration in mice serum; AUC (mM.h),A,,,Mus musculus,10090.0,
11875,1,,BAO_0000218,Intermediate,,13701,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by intravenous administration in mice serum; AUC 0-r (mM.h),A,,,Mus musculus,10090.0,
11876,1,,BAO_0000218,Intermediate,,13701,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral administration in mice brain; AUC 0-r (mM.h); not detected,A,,,Mus musculus,10090.0,
11877,1,,BAO_0000218,Intermediate,,13701,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral administration in mice serum; AUC (mM.h),A,,,Mus musculus,10090.0,
11878,1,,BAO_0000218,Intermediate,,13701,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral administration in mice serum; AUC 0-r (mM.h),A,,,Mus musculus,10090.0,
11879,1,,BAO_0000218,Intermediate,,13701,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral in mice brain; AUC (mM.h); not detected,A,,,Mus musculus,10090.0,
11880,1,,BAO_0000218,Intermediate,,13701,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by intravenous administration in mice brain; AUC 0-r (mM.h),A,,,Mus musculus,10090.0,
11881,1,,BAO_0000218,Intermediate,,13701,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by intravenous administration mice serum.; AUC 0-r (mM.h),A,,,Mus musculus,10090.0,
11882,1,,BAO_0000218,Intermediate,,13701,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral administration in mice brain.; AUC 0-r (mM.h),A,,,Mus musculus,10090.0,
11883,1,,BAO_0000218,Intermediate,,13701,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral administration in mice serum.,A,,,Mus musculus,10090.0,
11884,1,,BAO_0000218,Intermediate,,14393,Pharmacokinetic parameter [area under curve (AUC)] was evaluated at 10 mg/kg (p.o.) in Wistar rats,A,,,Rattus norvegicus,10116.0,
11885,1,,BAO_0000218,Intermediate,,14731,Pharmacokinetic parameter area under the curve (0-24 hr) for the compound was evaluated in nude mice after oral administration. ,A,,,Mus musculus,10090.0,
11886,1,,BAO_0000218,Intermediate,,14731,Pharmacokinetic parameter area under the curve (0-48 h) for the compound was evaluated in nude cynomolgus monkeys after oral administration,A,,,Macaca fascicularis,9541.0,
11887,1,,BAO_0000218,Intermediate,,14731,Pharmacokinetic parameter area under the curve (0-48 h) for the compound was evaluated in nude cynomolgus monkeys after oral administration. ,A,,,Macaca fascicularis,9541.0,
11888,0,,BAO_0000218,Autocuration,955.0,13758,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered intravenously in brain,A,,,,,
11889,0,,BAO_0000218,Autocuration,1977.0,13758,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered intravenously in serum,A,,,,,
11890,0,,BAO_0000218,Autocuration,955.0,13758,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered orally in brain,A,,,,,
11891,0,,BAO_0000218,Autocuration,1977.0,13758,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered orally in serum,A,,,,,
11892,0,,BAO_0000019,Autocuration,,16359,Pharmacokinetic parameter was evaluated which is represented as AUC when administered 5 mg/Kg orally; range (0.19-0.35),A,,,,,
11893,0,,BAO_0000218,Autocuration,,16359,Pharmacokinetic parameter was evaluated which is represented as AUC when administered 5 mg/kg intravenously; range (2.1-2.3),A,,,,,
11894,1,,BAO_0000218,Intermediate,2106.0,15383,In vivo biodistribution in mice spleen bearing intracerebral GL261 gliomas at the dose of 30 ug/day,A,,,Mus musculus,10090.0,
11895,1,,BAO_0000218,Intermediate,2106.0,15383,In vivo biodistribution in mice spleen bearing subcutaneous B16 melanomas at the dose of 30 ug/g,A,,,Mus musculus,10090.0,
11896,1,,BAO_0000218,Intermediate,2106.0,15383,In vivo biodistribution in mice spleen bearing subcutaneous B16 melanomas at the dose of 40 ug/g,A,,,Mus musculus,10090.0,
11897,1,,BAO_0000218,Intermediate,,15383,In vivo biodistribution in mice tumor bearing intracerebral GL261 gliomas at the dose of 30 ug/day,A,,,Mus musculus,10090.0,
11898,1,,BAO_0000218,Intermediate,,15383,In vivo biodistribution in mice tumor bearing subcutaneous B16 melanomas at the dose of 20 ug/g,A,,,Mus musculus,10090.0,
11899,1,,BAO_0000218,Intermediate,,15383,In vivo biodistribution in mice tumor bearing subcutaneous B16 melanomas at the dose of 30 ug/g,A,,,Mus musculus,10090.0,
11900,1,,BAO_0000218,Intermediate,,15383,In vivo biodistribution in mice tumor bearing subcutaneous B16 melanomas at the dose of 40 ug/g,A,,,Mus musculus,10090.0,
11901,1,,BAO_0000218,Intermediate,,14439,Ratio of biodistributions in Athymic mice bearing human Tumor (KB) xenografts in Heart (H) and Blood (B),A,,,Mus musculus,10090.0,
11902,1,,BAO_0000218,Intermediate,,14439,Ratio of biodistributions in Athymic mice bearing human Tumor (KB) xenografts in Heart (H) and Lung (L),A,,,Mus musculus,10090.0,
11903,1,,BAO_0000218,Intermediate,,14439,Ratio of biodistributions in Athymic mice bearing human Tumor (KB) xenografts in Tumor (T) and Muscle (M),A,,,Mus musculus,10090.0,
11904,1,,BAO_0000218,Intermediate,,14439,Ratio of biodistributions in Athymic mice bearing human Tumor (KB) xenografts in Tumor (T) and blood (B),A,,,Mus musculus,10090.0,
11905,1,,BAO_0000218,Intermediate,,14439,Ratio of biodistributions in Athymic mice bearing human Tumor (LS174T) xenografts in Heart (H) and Blood (B),A,,,Mus musculus,10090.0,
11906,1,,BAO_0000218,Intermediate,,14439,Ratio of biodistributions in Athymic mice bearing human Tumor (LS174T) xenografts in Heart (H) and Lung (L),A,,,Mus musculus,10090.0,
11907,1,,BAO_0000218,Intermediate,,14439,Ratio of biodistributions in Athymic mice bearing human Tumor (LS174T) xenografts in Tumor (T) and Muscle (M),A,,,Mus musculus,10090.0,
11908,1,,BAO_0000218,Intermediate,,14439,Ratio of biodistributions in Athymic mice bearing human Tumor (LS174T) xenografts in Tumor (T) and blood (B),A,,,Mus musculus,10090.0,
11909,1,,BAO_0000218,Intermediate,,14439,Ratio of biodistributions in Athymic mice bearing human Tumor (TE671) xenografts in Heart (H) and Blood (B),A,,,Mus musculus,10090.0,
11910,1,,BAO_0000218,Intermediate,,14439,Ratio of biodistributions in Athymic mice bearing human Tumor (TE671) xenografts in Heart (H) and Lung (L),A,,,Mus musculus,10090.0,
11911,1,,BAO_0000218,Intermediate,,14439,Ratio of biodistributions in Athymic mice bearing human Tumor (TE671) xenografts in Tumor (T) and Muscle (M),A,,,Mus musculus,10090.0,
11912,1,,BAO_0000218,Intermediate,,14439,Ratio of biodistributions in Athymic mice bearing human Tumor (TE671) xenografts in Tumor (T) and blood (B),A,,,Mus musculus,10090.0,
11913,1,,BAO_0000218,Intermediate,,13751,"Biodistribution in abdominal Dawley rat after 30min, expressed as percent injected dose/g",A,In vivo,,Rattus norvegicus,10116.0,
11914,1,,BAO_0000218,Intermediate,,13751,"Biodistribution in abdominal of mature female Dawley rat after 10min, expressed as percent injected dose/g",A,In vivo,,Rattus norvegicus,10116.0,
11915,1,,BAO_0000218,Intermediate,,13751,"Biodistribution in abdominal of mature female Dawley rat after 15min, expressed as percent injected dose/g",A,In vivo,,Rattus norvegicus,10116.0,
11916,1,,BAO_0000218,Intermediate,,13751,"Biodistribution in abdominal of mature female Dawley rat after 1h, expressed as percent injected dose/g",A,In vivo,,Rattus norvegicus,10116.0,
11917,1,,BAO_0000218,Intermediate,,13751,"Biodistribution in abdominal of mature female Dawley rat after 3 h, expressed as percent injected dose/g",A,In vivo,,Rattus norvegicus,10116.0,
11918,1,,BAO_0000218,Intermediate,,13751,"Biodistribution in abdominal of mature female Dawley rat after 30min, expressed as percent injected dose/g",A,In vivo,,Rattus norvegicus,10116.0,
11919,1,,BAO_0000218,Intermediate,,13751,"Biodistribution in abdominal of mature female Dawley rat after 45min, expressed as percent injected dose/g",A,In vivo,,Rattus norvegicus,10116.0,
11920,1,,BAO_0000218,Intermediate,,13751,"Biodistribution in abdominal of mature female Dawley rat after 5min, expressed as percent injected dose/g",A,In vivo,,Rattus norvegicus,10116.0,
11921,1,,BAO_0000218,Intermediate,178.0,13751,"Biodistribution in blood of mature female Dawley rat after 10min, expressed as percent injected dose/g",A,In vivo,,Rattus norvegicus,10116.0,
11922,1,,BAO_0000218,Intermediate,178.0,13751,"Biodistribution in blood of mature female Dawley rat after 15min, expressed as percent injected dose/g",A,In vivo,,Rattus norvegicus,10116.0,
11923,1,,BAO_0000218,Intermediate,178.0,13751,"Biodistribution in blood of mature female Dawley rat after 1h, expressed as percent injected dose/g",A,In vivo,,Rattus norvegicus,10116.0,
11924,1,,BAO_0000218,Intermediate,178.0,13751,"Biodistribution in blood of mature female Dawley rat after 3 h, expressed as percent injected dose/g",A,In vivo,,Rattus norvegicus,10116.0,
11925,1,,BAO_0000218,Intermediate,178.0,13751,"Biodistribution in blood of mature female Dawley rat after 30min, expressed as percent injected dose/g",A,In vivo,,Rattus norvegicus,10116.0,
11926,1,,BAO_0000218,Intermediate,178.0,13751,"Biodistribution in blood of mature female Dawley rat after 45min, expressed as percent injected dose/g",A,In vivo,,Rattus norvegicus,10116.0,
11927,1,,BAO_0000218,Intermediate,178.0,13751,"Biodistribution in blood of mature female Dawley rat after 5min, expressed as percent injected dose/g",A,In vivo,,Rattus norvegicus,10116.0,
11928,1,,BAO_0000218,Intermediate,10000001.0,13751,"Biodistribution in bone of mature female Dawley rat after 10min, expressed as percent injected dose/g",A,In vivo,,Rattus norvegicus,10116.0,
11929,1,,BAO_0000218,Intermediate,10000001.0,13751,"Biodistribution in bone of mature female Dawley rat after 1h, expressed as percent injected dose/g",A,In vivo,,Rattus norvegicus,10116.0,
11930,1,,BAO_0000218,Intermediate,10000001.0,13751,"Biodistribution in bone of mature female Dawley rat after 3 h, expressed as percent injected dose/g",A,In vivo,,Rattus norvegicus,10116.0,
11931,1,,BAO_0000218,Intermediate,10000001.0,13751,"Biodistribution in bone of mature female Dawley rat after 30min, expressed as percent injected dose/g",A,In vivo,,Rattus norvegicus,10116.0,
11932,1,,BAO_0000218,Intermediate,955.0,13751,"Biodistribution in brain of mature female Dawley rat after 10min, expressed as percent injected dose/g",A,In vivo,,Rattus norvegicus,10116.0,
11933,1,,BAO_0000218,Intermediate,955.0,13751,"Biodistribution in brain of mature female Dawley rat after 15min, expressed as percent injected dose/g",A,In vivo,,Rattus norvegicus,10116.0,
11934,1,,BAO_0000218,Intermediate,955.0,13751,"Biodistribution in brain of mature female Dawley rat after 1h, expressed as percent injected dose/g",A,In vivo,,Rattus norvegicus,10116.0,
11935,1,,BAO_0000218,Intermediate,955.0,13751,"Biodistribution in brain of mature female Dawley rat after 3 h, expressed as percent injected dose/g",A,In vivo,,Rattus norvegicus,10116.0,
11936,1,,BAO_0000218,Intermediate,955.0,13751,"Biodistribution in brain of mature female Dawley rat after 30min, expressed as percent injected dose/g",A,In vivo,,Rattus norvegicus,10116.0,
11937,1,,BAO_0000218,Intermediate,955.0,13751,"Biodistribution in brain of mature female Dawley rat after 45min, expressed as percent injected dose/g",A,In vivo,,Rattus norvegicus,10116.0,
11938,1,,BAO_0000218,Intermediate,,10677,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 2-3 hr time,A,,,Rattus norvegicus,10116.0,
11939,1,,BAO_0000218,Intermediate,,10677,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 3-4 hr time,A,,,Rattus norvegicus,10116.0,
11940,1,,BAO_0000218,Intermediate,,10677,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 4-5 hr time,A,,,Rattus norvegicus,10116.0,
11941,1,,BAO_0000218,Intermediate,,10677,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 5-6 hr time,A,,,Rattus norvegicus,10116.0,
11942,1,,BAO_0000218,Intermediate,,10677,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 6-24 h time,A,,,Rattus norvegicus,10116.0,
11943,1,,BAO_0000218,Intermediate,2369.0,10911,Biodistribution studied in the adrenals of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,A,In vivo,,Rattus norvegicus,10116.0,
11944,1,,BAO_0000218,Intermediate,2369.0,10911,Biodistribution studied in the adrenals of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,A,In vivo,,Rattus norvegicus,10116.0,
11945,1,,BAO_0000218,Intermediate,2369.0,10911,Biodistribution studied in the adrenals of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,A,In vivo,,Rattus norvegicus,10116.0,
11946,1,,BAO_0000218,Intermediate,2369.0,10911,Biodistribution studied in the adrenals of immature Fischer female rats at 5 hour,A,In vivo,,Rattus norvegicus,10116.0,
11947,1,,BAO_0000218,Intermediate,2369.0,10911,Biodistribution studied in the adrenals of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,A,In vivo,,Rattus norvegicus,10116.0,
11948,1,,BAO_0000218,Intermediate,178.0,10911,Biodistribution studied in the blood of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,A,In vivo,,Rattus norvegicus,10116.0,
11949,1,,BAO_0000218,Intermediate,178.0,10911,Biodistribution studied in the blood of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,A,In vivo,,Rattus norvegicus,10116.0,
11950,1,,BAO_0000218,Intermediate,178.0,10911,Biodistribution studied in the blood of immature Fischer female rats at 2 hou; activity is expressed as inductive dose / gram,A,In vivo,,Rattus norvegicus,10116.0,
11951,1,,BAO_0000218,Intermediate,178.0,10911,Biodistribution studied in the blood of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,A,In vivo,,Rattus norvegicus,10116.0,
11952,1,,BAO_0000218,Intermediate,178.0,10911,Biodistribution studied in the blood of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,A,In vivo,,Rattus norvegicus,10116.0,
11953,1,,BAO_0000218,Intermediate,955.0,10911,Biodistribution studied in the brain of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,A,In vivo,,Rattus norvegicus,10116.0,
11954,1,,BAO_0000218,Intermediate,955.0,10911,Biodistribution studied in the brain of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,A,In vivo,,Rattus norvegicus,10116.0,
11955,1,,BAO_0000218,Intermediate,955.0,10911,Biodistribution studied in the brain of immature Fischer female rats at 2 hou; activity is expressed as inductive dose / gram,A,In vivo,,Rattus norvegicus,10116.0,
11956,1,,BAO_0000218,Intermediate,955.0,10911,Biodistribution studied in the brain of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,A,In vivo,,Rattus norvegicus,10116.0,
11957,1,,BAO_0000218,Intermediate,955.0,10911,Biodistribution studied in the brain of immature Fischer female rats at 5 hou; activity is expressed as inductive dose / gram,A,In vivo,,Rattus norvegicus,10116.0,
11958,1,,BAO_0000218,Intermediate,955.0,10911,Biodistribution studied in the brain of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,A,In vivo,,Rattus norvegicus,10116.0,
11959,1,,BAO_0000218,Intermediate,,10911,Biodistribution studied in the fat of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,A,In vivo,,Rattus norvegicus,10116.0,
11960,1,,BAO_0000218,Intermediate,,10911,Biodistribution studied in the fat of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,A,In vivo,,Rattus norvegicus,10116.0,
11961,1,,BAO_0000218,Intermediate,,10911,Biodistribution studied in the fat of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,A,In vivo,,Rattus norvegicus,10116.0,
11962,1,,BAO_0000218,Intermediate,,10911,Biodistribution studied in the fat of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,A,In vivo,,Rattus norvegicus,10116.0,
11963,1,,BAO_0000218,Intermediate,2113.0,10911,Biodistribution studied in the kidneys of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,A,In vivo,,Rattus norvegicus,10116.0,
11964,1,,BAO_0000218,Intermediate,2113.0,10911,Biodistribution studied in the kidneys of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,A,In vivo,,Rattus norvegicus,10116.0,
11965,1,,BAO_0000218,Intermediate,2113.0,10911,Biodistribution studied in the kidneys of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,A,In vivo,,Rattus norvegicus,10116.0,
11966,1,,BAO_0000218,Intermediate,2113.0,10911,Biodistribution studied in the kidneys of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,A,In vivo,,Rattus norvegicus,10116.0,
11967,1,,BAO_0000218,Intermediate,2107.0,10911,Biodistribution studied in the liver of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,A,In vivo,,Rattus norvegicus,10116.0,
11968,1,,BAO_0000218,Intermediate,2107.0,10911,Biodistribution studied in the liver of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,A,In vivo,,Rattus norvegicus,10116.0,
11969,1,,BAO_0000218,Intermediate,2107.0,10911,Biodistribution studied in the liver of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,A,In vivo,,Rattus norvegicus,10116.0,
11970,1,,BAO_0000218,Intermediate,2107.0,10911,Biodistribution studied in the liver of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,A,In vivo,,Rattus norvegicus,10116.0,
11971,1,,BAO_0000218,Intermediate,2048.0,10911,Biodistribution studied in the lungs of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,A,In vivo,,Rattus norvegicus,10116.0,
11972,1,,BAO_0000218,Intermediate,2048.0,10911,Biodistribution studied in the lungs of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,A,In vivo,,Rattus norvegicus,10116.0,
11973,1,,BAO_0000218,Intermediate,2048.0,10911,Biodistribution studied in the lungs of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,A,In vivo,,Rattus norvegicus,10116.0,
11974,1,,BAO_0000218,Intermediate,2048.0,10911,Biodistribution studied in the lungs of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,A,In vivo,,Rattus norvegicus,10116.0,
11975,1,,BAO_0000218,Intermediate,2385.0,10911,Biodistribution studied in the muscle of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,A,In vivo,,Rattus norvegicus,10116.0,
11976,1,,BAO_0000218,Intermediate,2385.0,10911,Biodistribution studied in the muscle of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,A,In vivo,,Rattus norvegicus,10116.0,
11977,1,,BAO_0000218,Intermediate,,8608,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 0.95-1.44",A,,,Rattus norvegicus,10116.0,
11978,1,,BAO_0000218,Intermediate,,8608,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 1.39-2.43",A,,,Rattus norvegicus,10116.0,
11979,1,,BAO_0000218,Intermediate,,8608,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 2.47-2.96",A,,,Rattus norvegicus,10116.0,
11980,1,,BAO_0000218,Intermediate,,8608,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 2.67-3.69",A,,,Rattus norvegicus,10116.0,
11981,1,,BAO_0000218,Intermediate,,8608,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 2.67-4.31",A,,,Rattus norvegicus,10116.0,
11982,1,,BAO_0000218,Intermediate,,8608,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 3.17-4.70",A,,,Rattus norvegicus,10116.0,
11983,1,,BAO_0000218,Intermediate,,8608,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration.; dose/g, range 2.20-2.97",A,,,Rattus norvegicus,10116.0,
11984,1,,BAO_0000218,Intermediate,,8608,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration; dose/g, range 0.90-1.46",A,,,Rattus norvegicus,10116.0,
11985,1,,BAO_0000218,Intermediate,,8608,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration; dose/g, range 2.72-3.52",A,,,Rattus norvegicus,10116.0,
11986,1,,BAO_0000218,Intermediate,,8608,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration; dose/g, range 2.78-3.62",A,,,Rattus norvegicus,10116.0,
11987,1,,BAO_0000218,Intermediate,,8608,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration; dose/g, range 2.82-3.86",A,,,Rattus norvegicus,10116.0,
11988,1,,BAO_0000218,Intermediate,,8608,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration; dose/g, range 3.80-5.74",A,,,Rattus norvegicus,10116.0,
11989,1,,BAO_0000218,Intermediate,,8608,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 1.05-1.57",A,,,Rattus norvegicus,10116.0,
11990,1,,BAO_0000218,Intermediate,,8608,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 1.93-3.58",A,,,Rattus norvegicus,10116.0,
11991,1,,BAO_0000218,Intermediate,,8608,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 2.88-4.32",A,,,Rattus norvegicus,10116.0,
11992,1,,BAO_0000218,Intermediate,,8608,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 3-3.70",A,,,Rattus norvegicus,10116.0,
11993,1,,BAO_0000218,Intermediate,,8608,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 3.21-3.92",A,,,Rattus norvegicus,10116.0,
11994,1,,BAO_0000218,Intermediate,,8608,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 3.51-5.44",A,,,Rattus norvegicus,10116.0,
11995,1,,BAO_0000218,Intermediate,,8608,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 0.24-0.31",A,,,Rattus norvegicus,10116.0,
11996,1,,BAO_0000218,Intermediate,,8608,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 10.5-14.4",A,,,Rattus norvegicus,10116.0,
11997,1,,BAO_0000218,Intermediate,,8608,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 6.28-7.41",A,,,Rattus norvegicus,10116.0,
11998,1,,BAO_0000218,Intermediate,,8608,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 6.47-10.2",A,,,Rattus norvegicus,10116.0,
11999,1,,BAO_0000218,Intermediate,,8608,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 7.21-7.95",A,,,Rattus norvegicus,10116.0,
12000,1,,BAO_0000218,Intermediate,,8608,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 8.28-10.72",A,,,Rattus norvegicus,10116.0,
12001,1,,BAO_0000218,Intermediate,,8608,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 1.04-2.56",A,,,Rattus norvegicus,10116.0,
12002,1,,BAO_0000218,Intermediate,,8608,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 10.7-16.9",A,,,Rattus norvegicus,10116.0,
12003,1,,BAO_0000218,Intermediate,,8608,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 11.7-14.6",A,,,Rattus norvegicus,10116.0,
12004,1,,BAO_0000218,Intermediate,,8608,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 14.4-20.1",A,,,Rattus norvegicus,10116.0,
12005,1,,BAO_0000218,Intermediate,,8608,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 4.78-9.72",A,,,Rattus norvegicus,10116.0,
12006,1,,BAO_0000218,Intermediate,,8608,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 9.87-11.9",A,,,Rattus norvegicus,10116.0,
12007,1,,BAO_0000218,Intermediate,,8608,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 0.17-0.25",A,,,Rattus norvegicus,10116.0,
12008,1,,BAO_0000218,Intermediate,,8608,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 3.33-4.68",A,,,Rattus norvegicus,10116.0,
12009,1,,BAO_0000218,Intermediate,,8608,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 4.59-8.81",A,,,Rattus norvegicus,10116.0,
12010,1,,BAO_0000218,Intermediate,,8608,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 4.62-5.60",A,,,Rattus norvegicus,10116.0,
12011,1,,BAO_0000218,Intermediate,,8608,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 5.02-6.57",A,,,Rattus norvegicus,10116.0,
12012,1,,BAO_0000218,Intermediate,,8608,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 5.67-8.41",A,,,Rattus norvegicus,10116.0,
12013,0,,BAO_0000218,Autocuration,,16359,Pharmacokinetic parameter was evaluated which is represented as AUC when administered orally a dose of 5 mg/kg; range (4.2-8.8),A,,,,,
12014,1,,BAO_0000218,Intermediate,,13701,Pharmacokinetic parameters was measured at 55 mg/kg dose by oral administration in mice serum.; AUC 0-r (mM.h),A,,,Mus musculus,10090.0,
12015,1,,BAO_0000218,Intermediate,,14554,Pharmacokinetic profile AUC was evaluated in rats,A,,,Rattus norvegicus,10116.0,
12016,0,,BAO_0000019,Autocuration,,6241,Pharmacokinetic property (Area under curve),A,,,,,
12017,1,,BAO_0000218,Intermediate,,11537,"Pharmacokinetic property(AUC- area under curve, (micro g/mL/h)) after oral administration in dog (25 mg/kg).",A,,,Canis lupus familiaris,9615.0,
12018,1,,BAO_0000218,Intermediate,,11537,"Pharmacokinetic property(AUC- area under curve, (micro g/mL/h)) after oral administration in mice (50 mg/kg).",A,,,Mus musculus,10090.0,
12019,1,,BAO_0000218,Intermediate,,11537,"Pharmacokinetic property(AUC- area under curve, (micro g/mL/h)) after oral administration to dog (25 mg/kg).",A,,,Canis lupus familiaris,9615.0,
12020,1,,BAO_0000218,Intermediate,,11537,"Pharmacokinetic property(AUC- area under curve, (micro g/mL/h)) after oral administration to mice (50 mg/kg).",A,,,Mus musculus,10090.0,
12021,0,,BAO_0000019,Autocuration,,13118,Plasma concentration (AUC) was determined,A,,,,,
12022,0,,BAO_0000019,Autocuration,,13118,Plasma concentration (AUC) was determined; Not detectable,A,,,,,
12023,1,,BAO_0000218,Intermediate,,9562,Prolongation of time to collapse in guinea pig treated with aerosolized histamine was measured in vivo as area under curve (AUC),A,,,Cavia porcellus,10141.0,
12024,1,,BAO_0000218,Intermediate,,10363,Suppressor cell activity was measured as area under curve(AUC) in normal rats by a splenic cell coculture assay at a dose of 30 mg/kg,A,,,Rattus norvegicus,10116.0,
12025,1,,BAO_0000218,Intermediate,,10363,Suppressor cell activity was measured as area under curve(AUC) in normal rats by a splenic cell coculture assay at a dose of 30 mg/kg; Not significant,A,,,Rattus norvegicus,10116.0,
12026,1,,BAO_0000218,Intermediate,,10363,Suppressor cell activity was measured as area under curve(AUC) in normal rats by a splenic cell coculture assay at a dose of 60 mg/kg,A,,,Rattus norvegicus,10116.0,
12027,1,,BAO_0000218,Intermediate,,10363,Suppressor cell activity was measured as area under curve(AUC) in normal rats by a splenic cell coculture assay at a dose of 7.5 mg/kg,A,,,Rattus norvegicus,10116.0,
12028,1,,BAO_0000218,Intermediate,,12504,Tested for area under the curve (AUC) after intravenous bolus administration of 100 mg/kg in rat 1,A,,,Rattus norvegicus,10116.0,
12029,1,,BAO_0000218,Intermediate,,12504,Tested for area under the curve (AUC) after intravenous bolus administration of 100 mg/kg in rat 2,A,,,Rattus norvegicus,10116.0,
12030,1,,BAO_0000218,Intermediate,,12504,Tested for area under the curve (AUC) after intravenous bolus administration of 100 mg/kg in rat 3,A,,,Rattus norvegicus,10116.0,
12031,1,,BAO_0000218,Intermediate,,12504,Tested for area under the curve (AUC) after intravenous bolus administration of 100 mg/kg in rat 4,A,,,Rattus norvegicus,10116.0,
12032,1,,BAO_0000218,Intermediate,,13317,Tested for pharmacokinetic parameter in fasted Beagle dogs (Area Under Curve value) iv administration.,A,,,Canis lupus familiaris,9615.0,
12033,1,,BAO_0000218,Intermediate,,15078,"The AUC(0-infinitive) value in female wistar rat at 100 mg/kg, p.o. dose",A,,,Rattus norvegicus,10116.0,
12034,1,,BAO_0000218,Intermediate,,14941,The AUC(0-infinity) values in female wistar rats.,A,,,Rattus norvegicus,10116.0,
12035,1,,BAO_0000218,Intermediate,,15078,"The AUC(0-t)value in female wistar rat at 100 mg/kg, p.o. dose",A,,,Rattus norvegicus,10116.0,
12036,1,,BAO_0000218,Intermediate,,15078,"The AUC(0-t)value in female wistar rat at 100 mg/kg, p.o. dose in mice",A,,,Rattus norvegicus,10116.0,
12037,1,,BAO_0000218,Intermediate,,14941,The AUC(0-t)values in female wistar rats.,A,,,Rattus norvegicus,10116.0,
12038,1,,BAO_0000218,Intermediate,,14067,The Area under the concentration time curve of compound was measured on rats,A,,,Rattus norvegicus,10116.0,
12039,1,,BAO_0000218,Intermediate,,14215,The area under curve (100 mg/kg) administered orally in humans,A,,,Homo sapiens,9606.0,
12040,0,,BAO_0000218,Autocuration,,14215,The area under curve (12.5 mg/kg) administered intravenously in marmoset,A,,,Callithrix,9481.0,
12041,0,,BAO_0000218,Autocuration,,14215,The area under curve (12.5 mg/kg) administered intravenously in monkey,A,,,Simiiformes,314293.0,
12042,1,,BAO_0000218,Intermediate,,14215,The area under curve (15 mg/kg) administered intravenously in dog,A,,,Canis lupus familiaris,9615.0,
12043,1,,BAO_0000218,Intermediate,,14215,The area under curve (200 mg/kg) administered orally in humans,A,,,Homo sapiens,9606.0,
12044,1,,BAO_0000218,Intermediate,,14215,The area under curve (25 mg/kg) administered intravenously in rat,A,,,Rattus norvegicus,10116.0,
12045,0,,BAO_0000218,Autocuration,,14215,The area under curve (25 mg/kg) administered orally in marmoset,A,,,Callithrix,9481.0,
12046,0,,BAO_0000218,Autocuration,,14215,The area under curve (25 mg/kg) administered orally in monkey,A,,,Simiiformes,314293.0,
12047,1,,BAO_0000218,Intermediate,,14215,The area under curve (30 mg/kg) administered orally in dog,A,,,Canis lupus familiaris,9615.0,
12048,1,,BAO_0000218,Intermediate,,14215,The area under curve (400 mg/kg) administered orally in humans,A,,,Homo sapiens,9606.0,
12049,1,,BAO_0000218,Intermediate,,14215,The area under curve (50 mg/kg) administered orally in fasted rat,A,,,Rattus norvegicus,10116.0,
12050,1,,BAO_0000218,Intermediate,,14215,The area under curve (50 mg/kg) administered orally in rat,A,,,Rattus norvegicus,10116.0,
12051,1,,BAO_0000218,Intermediate,,14215,The area under curve (800 mg/kg) administered orally in humans,A,,,Homo sapiens,9606.0,
12052,0,,BAO_0000019,Autocuration,,11324,The compound was evaluated for area under the curve,A,,,,,
12053,0,,BAO_0000019,Autocuration,,11324,The compound was evaluated for area under the curve in marmosets,A,,,Callithrix,9481.0,
12054,0,,BAO_0000019,Autocuration,,11324,The compound was evaluated for area under the curve in marmosets,A,,,Callithrix,9481.0,
12055,1,,BAO_0000218,Intermediate,,13875,The compound was tested for the area of the change in MABP versus time curve at dose 30 mg/kg (po) in conscious spontaneously hypertensive rat,A,,,Rattus norvegicus,10116.0,
12056,1,,BAO_0000218,Intermediate,,13875,The compound was tested for the area of the change in MABP versus time curve at dose 10 mg/kg (po) in conscious spontaneously hypertensive rat,A,,,Rattus norvegicus,10116.0,
12057,0,,BAO_0000218,Autocuration,,13875,The compound was tested for the area of the change in MABP versus time curve at dose 10 mg/kg (po),A,,,,,
12058,1,,BAO_0000218,Intermediate,,13875,The compound was tested for the area of the change in MABP versus time curve at dose 30 mg/kg (po) in conscious spontaneously hypertensive rat,A,,,Rattus norvegicus,10116.0,
12059,1,,BAO_0000218,Intermediate,,13875,The compound was tested for the area of the change in MABP versus time curve at dose 30 mg/kg (po) in conscious spontaneously hypertensive rat,A,,,Rattus norvegicus,10116.0,
12060,1,,BAO_0000218,Intermediate,,13875,The compound was tested for the area of the change in MABP versus time curve at dose 5 mg/kg (po) in conscious spontaneously hypertensive rat,A,,,Rattus norvegicus,10116.0,
12061,1,,BAO_0000218,Intermediate,,13807,Total absorption was estimated by area under curve (AUC) after intravenous administration in rat,A,,,Rattus norvegicus,10116.0,
12062,1,,BAO_0000218,Intermediate,,14127,Total drug exposure is determined after oral dosing in rats.,A,,,Rattus norvegicus,10116.0,
12063,0,,BAO_0000218,Autocuration,,15116,Total drug exposure (5 mg/kg) when administered intravenously,A,,,,,
12064,0,,BAO_0000218,Autocuration,,15116,Total drug exposure (5 mg/kg) when administered orally,A,,,,,
12065,0,,BAO_0000218,Autocuration,,15604,area under curve in preclinical species was measured after Intravenous administration at the given dose (0.01 mg/kg) in monkey,A,,,Simiiformes,314293.0,
12066,1,,BAO_0000218,Intermediate,,15604,area under curve in preclinical species was measured after Intravenous administration at the given dose (0.05 mg/kg) in rat,A,,,Rattus norvegicus,10116.0,
12067,1,,BAO_0000218,Intermediate,,15604,area under curve in preclinical species was measured after Intravenous administration at the given dose (0.1 mg/kg) in dog,A,,,Canis lupus familiaris,9615.0,
12068,1,,BAO_0000218,Intermediate,,15604,area under curve in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in dog,A,,,Canis lupus familiaris,9615.0,
12069,1,,BAO_0000218,Intermediate,955.0,13751,"Biodistribution in brain of mature female Dawley rat after 5min, expressed as percent injected dose/g",A,In vivo,,Rattus norvegicus,10116.0,
12070,1,,BAO_0000218,Intermediate,955.0,13751,"Biodistribution in brain of mature female Dawley rat after 30min, expressed as percent injected dose/g",A,In vivo,,Rattus norvegicus,10116.0,
12071,1,,BAO_0000218,Intermediate,,13751,"Biodistribution in fat of mature female Dawley rat after 10min, expressed as percent injected dose/g",A,In vivo,,Rattus norvegicus,10116.0,
12072,1,,BAO_0000218,Intermediate,,13751,"Biodistribution in fat of mature female Dawley rat after 15min, expressed as percent injected dose/g",A,In vivo,,Rattus norvegicus,10116.0,
12073,1,,BAO_0000218,Intermediate,,13751,"Biodistribution in fat of mature female Dawley rat after 1h, expressed as percent injected dose/g",A,In vivo,,Rattus norvegicus,10116.0,
12074,1,,BAO_0000218,Intermediate,,13751,"Biodistribution in fat of mature female Dawley rat after 3 h, expressed as percent injected dose/g",A,In vivo,,Rattus norvegicus,10116.0,
12075,1,,BAO_0000218,Intermediate,,13751,"Biodistribution in fat of mature female Dawley rat after 30min, expressed as percent injected dose/g",A,In vivo,,Rattus norvegicus,10116.0,
12076,1,,BAO_0000218,Intermediate,,13751,"Biodistribution in fat of mature female Dawley rat after 45min, expressed as percent injected dose/g",A,In vivo,,Rattus norvegicus,10116.0,
12077,1,,BAO_0000218,Intermediate,,13751,"Biodistribution in fat of mature female Dawley rat after 5min, expressed as percent injected dose/g",A,In vivo,,Rattus norvegicus,10116.0,
12078,1,,BAO_0000218,Intermediate,948.0,13751,"Biodistribution in heart of mature female Dawley rat after 10min, expressed as percent injected dose/g",A,In vivo,,Rattus norvegicus,10116.0,
12079,1,,BAO_0000218,Intermediate,948.0,13751,"Biodistribution in heart of mature female Dawley rat after 15min, expressed as percent injected dose/g",A,In vivo,,Rattus norvegicus,10116.0,
12080,1,,BAO_0000218,Intermediate,948.0,13751,"Biodistribution in heart of mature female Dawley rat after 1h, expressed as percent injected dose/g",A,In vivo,,Rattus norvegicus,10116.0,
12081,1,,BAO_0000218,Intermediate,948.0,13751,"Biodistribution in heart of mature female Dawley rat after 3 h, expressed as percent injected dose/g",A,In vivo,,Rattus norvegicus,10116.0,
12082,1,,BAO_0000218,Intermediate,948.0,13751,"Biodistribution in heart of mature female Dawley rat after 30min, expressed as percent injected dose/g",A,In vivo,,Rattus norvegicus,10116.0,
12083,1,,BAO_0000218,Intermediate,948.0,13751,"Biodistribution in heart of mature female Dawley rat after 45min, expressed as percent injected dose/g",A,In vivo,,Rattus norvegicus,10116.0,
12084,1,,BAO_0000218,Intermediate,948.0,13751,"Biodistribution in heart of mature female Dawley rat after 5min, expressed as percent injected dose/g",A,In vivo,,Rattus norvegicus,10116.0,
12085,1,,BAO_0000218,Intermediate,2113.0,13751,"Biodistribution in kidney of mature female Dawley rat after 10min, expressed as percent injected dose/g",A,In vivo,,Rattus norvegicus,10116.0,
12086,1,,BAO_0000218,Intermediate,2113.0,13751,"Biodistribution in kidney of mature female Dawley rat after 15min, expressed as percent injected dose/g",A,In vivo,,Rattus norvegicus,10116.0,
12087,1,,BAO_0000218,Intermediate,2113.0,13751,"Biodistribution in kidney of mature female Dawley rat after 1h, expressed as percent injected dose/g",A,In vivo,,Rattus norvegicus,10116.0,
12088,1,,BAO_0000218,Intermediate,2113.0,13751,"Biodistribution in kidney of mature female Dawley rat after 3 h, expressed as percent injected dose/g",A,In vivo,,Rattus norvegicus,10116.0,
12089,1,,BAO_0000218,Intermediate,2113.0,13751,"Biodistribution in kidney of mature female Dawley rat after 30min, expressed as percent injected dose/g",A,In vivo,,Rattus norvegicus,10116.0,
12090,1,,BAO_0000218,Intermediate,2113.0,13751,"Biodistribution in kidney of mature female Dawley rat after 45min, expressed as percent injected dose/g",A,In vivo,,Rattus norvegicus,10116.0,
12091,1,,BAO_0000218,Intermediate,2113.0,13751,"Biodistribution in kidney of mature female Dawley rat after 5min, expressed as percent injected dose/g",A,In vivo,,Rattus norvegicus,10116.0,
12092,1,,BAO_0000218,Intermediate,2107.0,13751,"Biodistribution in liver of mature female Dawley rat after 10min, expressed as percent injected dose/g",A,In vivo,,Rattus norvegicus,10116.0,
12093,1,,BAO_0000218,Intermediate,2048.0,13751,"Biodistribution in lung of mature female Dawley rat after 10min, expressed as percent injected dose/g",A,In vivo,,Rattus norvegicus,10116.0,
12094,1,,BAO_0000218,Intermediate,2048.0,13751,"Biodistribution in lung of mature female Dawley rat after 15min, expressed as percent injected dose/g",A,In vivo,,Rattus norvegicus,10116.0,
12095,1,,BAO_0000218,Intermediate,2048.0,13751,"Biodistribution in lung of mature female Dawley rat after 1h, expressed as percent injected dose/g",A,In vivo,,Rattus norvegicus,10116.0,
12096,1,,BAO_0000218,Intermediate,2048.0,13751,"Biodistribution in lung of mature female Dawley rat after 3 h, expressed as percent injected dose/g",A,In vivo,,Rattus norvegicus,10116.0,
12097,1,,BAO_0000218,Intermediate,2048.0,13751,"Biodistribution in lung of mature female Dawley rat after 30min, expressed as percent injected dose/g",A,In vivo,,Rattus norvegicus,10116.0,
12098,1,,BAO_0000218,Intermediate,2048.0,13751,"Biodistribution in lung of mature female Dawley rat after 45min, expressed as percent injected dose/g",A,In vivo,,Rattus norvegicus,10116.0,
12099,1,,BAO_0000218,Intermediate,2048.0,13751,"Biodistribution in lung of mature female Dawley rat after 5min, expressed as percent injected dose/g",A,In vivo,,Rattus norvegicus,10116.0,
12100,1,,BAO_0000218,Intermediate,2385.0,13751,"Biodistribution in muscle of mature female Dawley rat after 10min, expressed as percent injected dose/g",A,In vivo,,Rattus norvegicus,10116.0,
12101,1,,BAO_0000218,Intermediate,2385.0,13751,"Biodistribution in muscle of mature female Dawley rat after 15min, expressed as percent injected dose/g",A,In vivo,,Rattus norvegicus,10116.0,
12102,1,,BAO_0000218,Intermediate,2385.0,13751,"Biodistribution in muscle of mature female Dawley rat after 1h, expressed as percent injected dose/g",A,In vivo,,Rattus norvegicus,10116.0,
12103,1,,BAO_0000218,Intermediate,2385.0,13751,"Biodistribution in muscle of mature female Dawley rat after 3 h, expressed as percent injected dose/g",A,In vivo,,Rattus norvegicus,10116.0,
12104,1,,BAO_0000218,Intermediate,2385.0,13751,"Biodistribution in muscle of mature female Dawley rat after 30min, expressed as percent injected dose/g",A,In vivo,,Rattus norvegicus,10116.0,
12105,1,,BAO_0000218,Intermediate,2385.0,13751,"Biodistribution in muscle of mature female Dawley rat after 45min, expressed as percent injected dose/g",A,In vivo,,Rattus norvegicus,10116.0,
12106,1,,BAO_0000218,Intermediate,2385.0,13751,"Biodistribution in muscle of mature female Dawley rat after 5min, expressed as percent injected dose/g",A,In vivo,,Rattus norvegicus,10116.0,
12107,1,,BAO_0000218,Intermediate,,13751,"Biodistribution inl ilver of mature female Dawley rat after 30min, expressed as percent injected dose/g",A,In vivo,,Rattus norvegicus,10116.0,
12108,1,,BAO_0000218,Intermediate,2107.0,13751,"Biodistribution inl iver of mature female Dawley rat after 15min, expressed as percent injected dose/g",A,In vivo,,Rattus norvegicus,10116.0,
12109,1,,BAO_0000218,Intermediate,2107.0,13751,"Biodistribution inl iver of mature female Dawley rat after 3 h, expressed as percent injected dose/g",A,In vivo,,Rattus norvegicus,10116.0,
12110,1,,BAO_0000218,Intermediate,2107.0,13751,"Biodistribution inl iver of mature female Dawley rat after 5min, expressed as percent injected dose/g",A,In vivo,,Rattus norvegicus,10116.0,
12111,1,,BAO_0000218,Intermediate,2385.0,10911,Biodistribution studied in the muscle of immature Fischer female rats at 2 hou; activity is expressed as inductive dose / gram,A,In vivo,,Rattus norvegicus,10116.0,
12112,1,,BAO_0000218,Intermediate,2385.0,10911,Biodistribution studied in the muscle of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,A,In vivo,,Rattus norvegicus,10116.0,
12113,1,,BAO_0000218,Intermediate,2385.0,10911,Biodistribution studied in the muscle of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,A,In vivo,,Rattus norvegicus,10116.0,
12114,1,,BAO_0000218,Intermediate,992.0,10911,Biodistribution studied in the ovaries of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,A,In vivo,,Rattus norvegicus,10116.0,
12115,1,,BAO_0000218,Intermediate,992.0,10911,Biodistribution studied in the ovaries of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,A,In vivo,,Rattus norvegicus,10116.0,
12116,1,,BAO_0000218,Intermediate,992.0,10911,Biodistribution studied in the ovaries of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,A,In vivo,,Rattus norvegicus,10116.0,
12117,1,,BAO_0000218,Intermediate,992.0,10911,Biodistribution studied in the ovaries of immature Fischer female rats at 5 hour,A,In vivo,,Rattus norvegicus,10116.0,
12118,1,,BAO_0000218,Intermediate,992.0,10911,Biodistribution studied in the ovaries of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,A,In vivo,,Rattus norvegicus,10116.0,
12119,1,,BAO_0000218,Intermediate,1969.0,10911,Biodistribution studied in the plasma of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,A,In vivo,,Rattus norvegicus,10116.0,
12120,1,,BAO_0000218,Intermediate,1969.0,10911,Biodistribution studied in the plasma of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,A,In vivo,,Rattus norvegicus,10116.0,
12121,1,,BAO_0000218,Intermediate,1969.0,10911,Biodistribution studied in the plasma of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,A,In vivo,,Rattus norvegicus,10116.0,
12122,1,,BAO_0000218,Intermediate,1969.0,10911,Biodistribution studied in the plasma of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,A,In vivo,,Rattus norvegicus,10116.0,
12123,1,,BAO_0000218,Intermediate,2106.0,10911,Biodistribution studied in the spleen of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,A,In vivo,,Rattus norvegicus,10116.0,
12124,1,,BAO_0000218,Intermediate,2106.0,10911,Biodistribution studied in the spleen of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,A,In vivo,,Rattus norvegicus,10116.0,
12125,1,,BAO_0000218,Intermediate,2106.0,10911,Biodistribution studied in the spleen of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,A,In vivo,,Rattus norvegicus,10116.0,
12126,1,,BAO_0000218,Intermediate,2106.0,10911,Biodistribution studied in the spleen of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,A,In vivo,,Rattus norvegicus,10116.0,
12127,1,,BAO_0000218,Intermediate,2046.0,10911,Biodistribution studied in the thyroid of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,A,In vivo,,Rattus norvegicus,10116.0,
12128,1,,BAO_0000218,Intermediate,2046.0,10911,Biodistribution studied in the thyroid of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,A,In vivo,,Rattus norvegicus,10116.0,
12129,1,,BAO_0000218,Intermediate,2046.0,10911,Biodistribution studied in the thyroid of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,A,In vivo,,Rattus norvegicus,10116.0,
12130,1,,BAO_0000218,Intermediate,2046.0,10911,Biodistribution studied in the thyroid of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,A,In vivo,,Rattus norvegicus,10116.0,
12131,1,,BAO_0000218,Intermediate,995.0,10911,Biodistribution studied in the uterus of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,A,In vivo,,Rattus norvegicus,10116.0,
12132,1,,BAO_0000218,Intermediate,995.0,10911,Biodistribution studied in the uterus of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,A,In vivo,,Rattus norvegicus,10116.0,
12133,1,,BAO_0000218,Intermediate,995.0,10911,Biodistribution studied in the uterus of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,A,In vivo,,Rattus norvegicus,10116.0,
12134,1,,BAO_0000218,Intermediate,995.0,10911,Biodistribution studied in the uterus of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,A,In vivo,,Rattus norvegicus,10116.0,
12135,0,,BAO_0000019,Autocuration,,8081,C(f=2) is the concentration at which the half life (t1/2) in the time course of inhibition of BChE by DFP increased by twofold in the presence of compound,A,,,,,
12136,1,,BAO_0000218,Intermediate,1969.0,17248,Compound was tested for plasma concentration in CM-monkeys 7 hours after oral administration (50 mg/kg),A,,,Macaca fascicularis,9541.0,
12137,1,,BAO_0000218,Intermediate,1969.0,17248,Compound was tested for plasma concentration in CM-monkeys 7 hours after oral administration (50 mg/kg); Not applicable,A,,,Macaca fascicularis,9541.0,
12138,1,,BAO_0000218,Intermediate,1969.0,17248,Compound was tested for plasma concentration in CM-monkeys 7 hours after oral administration (50 mg/kg); Not determined,A,,,Macaca fascicularis,9541.0,
12139,1,,BAO_0000218,Intermediate,1969.0,17248,Compound was tested for plasma concentration in dogs 7 hours after oral administration (30 mg/kg),A,,,Canis lupus familiaris,9615.0,
12140,1,,BAO_0000218,Intermediate,1969.0,17248,Compound was tested for plasma concentration in dogs 7 hours after oral administration (30 mg/kg) in experiment 1,A,,,Canis lupus familiaris,9615.0,
12141,1,,BAO_0000218,Intermediate,1969.0,17248,Compound was tested for plasma concentration in dogs 7 hours after oral administration (30 mg/kg) in experiment 2,A,,,Canis lupus familiaris,9615.0,
12142,1,,BAO_0000218,Intermediate,1969.0,17248,Compound was tested for plasma concentration in dogs 7 hours after oral administration (30 mg/kg); Not applicable,A,,,Canis lupus familiaris,9615.0,
12143,1,,BAO_0000218,Intermediate,,15592,"Concentration after 8 hour (bioavailability in dog, compound was delivered orally in 0.05 M citric acid at 10 mg/Kg. n=2 )",A,,,Canis lupus familiaris,9615.0,
12144,0,,BAO_0000019,Autocuration,,7040,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 10,A,,,,,
12145,0,,BAO_0000019,Autocuration,,7040,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 10.5,A,,,,,
12146,0,,BAO_0000019,Autocuration,,7040,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 6.8,A,,,,,
12147,0,,BAO_0000019,Autocuration,,7040,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 7.2,A,,,,,
12148,0,,BAO_0000019,Autocuration,,7040,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 7.6,A,,,,,
12149,0,,BAO_0000019,Autocuration,,7040,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 8.2,A,,,,,
12150,0,,BAO_0000019,Autocuration,,7040,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 9.6,A,,,,,
12151,1,,BAO_0000218,Intermediate,1236.0,9614,"Concentration of compound in adrenal medulla of dog 2, after administering intravenously",A,,,Canis lupus familiaris,9615.0,
12152,1,,BAO_0000218,Intermediate,1236.0,9614,"Concentration of compound in adrenal medulla of dog1, after administering intravenously",A,,,Canis lupus familiaris,9615.0,
12153,1,,BAO_0000218,Intermediate,178.0,9614,"Concentration of compound in blood of dog 1, after administering intravenously",A,,,Canis lupus familiaris,9615.0,
12154,1,,BAO_0000218,Intermediate,2107.0,8608,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration.; dose/g, range 0.23-0.29",A,,,Rattus norvegicus,10116.0,
12155,1,,BAO_0000218,Intermediate,2107.0,8608,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration; dose/g, range 0.22-0.30",A,,,Rattus norvegicus,10116.0,
12156,1,,BAO_0000218,Intermediate,2107.0,8608,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration; dose/g, range 0.55-0.71",A,,,Rattus norvegicus,10116.0,
12157,1,,BAO_0000218,Intermediate,2107.0,8608,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration; dose/g, range 0.57-0.72",A,,,Rattus norvegicus,10116.0,
12158,1,,BAO_0000218,Intermediate,2107.0,8608,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration; dose/g, range 1.51-2.23",A,,,Rattus norvegicus,10116.0,
12159,1,,BAO_0000218,Intermediate,2107.0,8608,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration; dose/g, range 2.30-3.12",A,,,Rattus norvegicus,10116.0,
12160,1,,BAO_0000218,Intermediate,2107.0,8608,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 0.93-1.20",A,,,Rattus norvegicus,10116.0,
12161,1,,BAO_0000218,Intermediate,2107.0,8608,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 1.04-2.56",A,,,Rattus norvegicus,10116.0,
12162,1,,BAO_0000218,Intermediate,2107.0,8608,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 1.06-1.70",A,,,Rattus norvegicus,10116.0,
12163,1,,BAO_0000218,Intermediate,2107.0,8608,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 1.26-2.45",A,,,Rattus norvegicus,10116.0,
12164,1,,BAO_0000218,Intermediate,2107.0,8608,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 3.12-4.56",A,,,Rattus norvegicus,10116.0,
12165,1,,BAO_0000218,Intermediate,2107.0,8608,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 4.12-6.30",A,,,Rattus norvegicus,10116.0,
12166,1,,BAO_0000218,Intermediate,2107.0,8608,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 0.14-0.19",A,,,Rattus norvegicus,10116.0,
12167,1,,BAO_0000218,Intermediate,2107.0,8608,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 0.15-0.19",A,,,Rattus norvegicus,10116.0,
12168,1,,BAO_0000218,Intermediate,2107.0,8608,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 0.24-0.30",A,,,Rattus norvegicus,10116.0,
12169,1,,BAO_0000218,Intermediate,2107.0,8608,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 0.44-0.54",A,,,Rattus norvegicus,10116.0,
12170,1,,BAO_0000218,Intermediate,2107.0,8608,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 0.73-1.19",A,,,Rattus norvegicus,10116.0,
12171,1,,BAO_0000218,Intermediate,2107.0,8608,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 1.08-2.31",A,,,Rattus norvegicus,10116.0,
12172,1,,BAO_0000218,Intermediate,2048.0,8608,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration.; dose/g, range 0.34-0.47",A,,,Rattus norvegicus,10116.0,
12173,1,,BAO_0000218,Intermediate,2048.0,8608,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration; dose/g, range 0.83-1.21",A,,,Rattus norvegicus,10116.0,
12174,1,,BAO_0000218,Intermediate,2048.0,8608,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration; dose/g, range 0.91-1.74",A,,,Rattus norvegicus,10116.0,
12175,1,,BAO_0000218,Intermediate,2048.0,8608,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration; dose/g, range 0.99-1.23",A,,,Rattus norvegicus,10116.0,
12176,1,,BAO_0000218,Intermediate,2048.0,8608,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration; dose/g, range 1.07-1.30",A,,,Rattus norvegicus,10116.0,
12177,1,,BAO_0000218,Intermediate,2048.0,8608,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration; dose/g, range 1.12-1.39",A,,,Rattus norvegicus,10116.0,
12178,1,,BAO_0000218,Intermediate,2048.0,8608,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 0.51-0.66",A,,,Rattus norvegicus,10116.0,
12179,1,,BAO_0000218,Intermediate,2048.0,8608,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 0.95-1.49",A,,,Rattus norvegicus,10116.0,
12180,1,,BAO_0000218,Intermediate,2048.0,8608,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 0.96-1.35",A,,,Rattus norvegicus,10116.0,
12181,1,,BAO_0000218,Intermediate,2048.0,8608,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 1.18-1.44",A,,,Rattus norvegicus,10116.0,
12182,1,,BAO_0000218,Intermediate,2048.0,8608,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 1.20-1.52",A,,,Rattus norvegicus,10116.0,
12183,1,,BAO_0000218,Intermediate,2048.0,8608,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 1.41-2.17",A,,,Rattus norvegicus,10116.0,
12184,1,,BAO_0000218,Intermediate,2048.0,8608,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 0.28-0.33",A,,,Rattus norvegicus,10116.0,
12185,1,,BAO_0000218,Intermediate,2048.0,8608,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 0.81-1.13",A,,,Rattus norvegicus,10116.0,
12186,1,,BAO_0000218,Intermediate,2048.0,8608,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 0.83-2.11",A,,,Rattus norvegicus,10116.0,
12187,1,,BAO_0000218,Intermediate,2048.0,8608,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 0.94-1.36",A,,,Rattus norvegicus,10116.0,
12188,1,,BAO_0000218,Intermediate,2048.0,8608,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 0.97-1.54",A,,,Rattus norvegicus,10116.0,
12189,1,,BAO_0000218,Intermediate,2048.0,8608,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 1.07-1.26",A,,,Rattus norvegicus,10116.0,
12190,0,,BAO_0000218,Autocuration,,15604,area under curve in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in monkey,A,,,Simiiformes,314293.0,
12191,1,,BAO_0000218,Intermediate,,15604,area under curve in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in rat,A,,,Rattus norvegicus,10116.0,
12192,0,,BAO_0000218,Autocuration,1969.0,1806,compound was evaluated for area under the plasma concentration vs. time curve at different dose 27.5 mg/kg DMP323 equiv,A,,,,,
12193,0,,BAO_0000218,Autocuration,1969.0,1806,compound was evaluated for area under the plasma concentration vs. time curve at different dose 7.7 mg/kg DMP323 equiv,A,,,,,
12194,1,,BAO_0000218,Intermediate,1969.0,17237,AUC 0-inf in dog,A,,,Canis lupus familiaris,9615.0,
12195,1,,BAO_0000218,Intermediate,1969.0,17237,AUC 0-inf in guinea pig,A,,,Cavia porcellus,10141.0,
12196,1,,BAO_0000218,Intermediate,1969.0,17237,AUC 0-t in dog,A,,,Canis lupus familiaris,9615.0,
12197,1,,BAO_0000218,Intermediate,1969.0,17237,AUC 0-t in guinea pig,A,,,Cavia porcellus,10141.0,
12198,1,,BAO_0000218,Intermediate,,15194,The compound was tested for brain to plasma partition in rat,A,,,Rattus norvegicus,10116.0,
12199,1,,BAO_0000218,Intermediate,,15194,The compound was tested for brain to plasma partition in rat.,A,,,Rattus norvegicus,10116.0,
12200,0,,BAO_0000019,Autocuration,178.0,8787,Area under curve was determined for 0-6 hr duration using dihydralazine as reference drug for the peak blood pressure,A,,,,,
12201,1,,BAO_0000218,Intermediate,,17025,Area under concentration-time curve of compound was determined in dog at 5 mg/kg intravenously admn.,A,,,Canis lupus familiaris,9615.0,
12202,0,,BAO_0000218,Autocuration,,17025,Area under concentration-time curve of compound was determined in monkey at 5 mg/kg intravenously admn.,A,,,Simiiformes,314293.0,
12203,1,,BAO_0000218,Intermediate,,17025,Area under concentration-time curve of compound was determined in rabbit at 5 mg/kg intravenously admn.,A,,,Oryctolagus cuniculus,9986.0,
12204,1,,BAO_0000218,Intermediate,,17025,Area under concentration-time curve of compound was determined in rat at 5 mg/kg intravenously admn.,A,,,Rattus norvegicus,10116.0,
12205,1,,BAO_0000218,Intermediate,,4236,Area under curve obtained at a dose of 10 mg/kg when administered orally to rhesus monkey,A,,,Macaca mulatta,9544.0,
12206,1,,BAO_0000218,Intermediate,,15343,The Plasma area under the compound concentration -time curve was measured in dogs after oral administration of 1 mg/kg dose,A,,,Canis lupus familiaris,9615.0,
12207,1,,BAO_0000218,Intermediate,,15343,The Plasma area under the compound concentration -time curve was measured in rats after oral administration of 1 mg/kg dose,A,,,Rattus norvegicus,10116.0,
12208,0,,BAO_0000019,Autocuration,,17720,Area under curve of the compound was determined,A,,,,,
12209,0,,BAO_0000218,Autocuration,1969.0,17788,AUC in monkeys at a dose of 1 mg/kg,A,,,Simiiformes,314293.0,
12210,1,,BAO_0000218,Intermediate,1969.0,17788,AUC in rats at a dose of 1 mg/kg,A,,,Rattus norvegicus,10116.0,
12211,0,,BAO_0000019,Autocuration,,8778,Compound was evaluated for the overall absorbance loss at pH of 2,A,,,,,
12212,0,,BAO_0000019,Autocuration,,8778,Compound was evaluated for the overall absorbance loss at pH of 4,A,,,,,
12213,0,,BAO_0000019,Autocuration,,8778,Compound was evaluated for the overall absorbance loss at pH of 7,A,,,,,
12214,1,,BAO_0000218,Intermediate,,2249,Compound was evaluated for its absorption in the rats,A,,,Rattus norvegicus,10116.0,
12215,1,,BAO_0000218,Intermediate,1088.0,8881,Compound was evaluated for percent tranexamic acid recovered in rat urine within 24 hr after oral administration of 0.1 mmol/kg of body weight per mole of pro drug,A,,,Rattus norvegicus,10116.0,
12216,1,,BAO_0000218,Intermediate,1088.0,8881,Compound was evaluated for percent tranexamic acid recovered in rat urine within 24 hr after oral administration of 0.1 mmol/kg of body weight.,A,,,Rattus norvegicus,10116.0,
12217,1,,BAO_0000218,Intermediate,1088.0,8881,Compound was evaluated for percent tranexamic acid recovered in rat urine within 24 hr after oral administration of 0.1 mmol/kg of body weight per mole of pro drug,A,,,Rattus norvegicus,10116.0,
12218,1,,BAO_0000218,Intermediate,1088.0,8881,Compound was evaluated for percent tranexamic acid recovered in rat urine within 24 hr after oral administration of per moiety tranexamic acid,A,,,Rattus norvegicus,10116.0,
12219,1,,BAO_0000218,Intermediate,,15286,In vitro percent permeability into rat ileum,A,,,Rattus norvegicus,10116.0,
12220,1,,BAO_0000218,Intermediate,,15286,In vitro percent permeability into rat ileum; Range is 10-17,A,,,Rattus norvegicus,10116.0,
12221,1,,BAO_0000218,Intermediate,,15286,In vitro percent permeability into rat ileum; Range is 10-18,A,,,Rattus norvegicus,10116.0,
12222,1,,BAO_0000218,Intermediate,,15286,In vitro percent permeability into rat ileum; Range is 10-19,A,,,Rattus norvegicus,10116.0,
12223,1,,BAO_0000218,Intermediate,,15286,In vitro percent permeability into rat ileum; Range is 12-15,A,,,Rattus norvegicus,10116.0,
12224,1,,BAO_0000218,Intermediate,,15286,In vitro percent permeability into rat ileum; Range is 13-19,A,,,Rattus norvegicus,10116.0,
12225,1,,BAO_0000218,Intermediate,,15286,In vitro percent permeability into rat ileum; Range is 14-17,A,,,Rattus norvegicus,10116.0,
12226,1,,BAO_0000218,Intermediate,,15286,In vitro percent permeability into rat ileum; Range is 15-18,A,,,Rattus norvegicus,10116.0,
12227,1,,BAO_0000218,Intermediate,,15286,In vitro percent permeability into rat ileum; Range is 2-5,A,,,Rattus norvegicus,10116.0,
12228,0,,BAO_0000221,Autocuration,2116.0,15286,In vitro percent permeability into rat ileum; Range is 23-42,A,,,,,
12229,1,,BAO_0000218,Intermediate,,15286,In vitro percent permeability into rat ileum; Range is 28-36,A,,,Rattus norvegicus,10116.0,
12230,1,,BAO_0000218,Intermediate,,15286,In vitro percent permeability into rat ileum; Range is 29-35,A,,,Rattus norvegicus,10116.0,
12231,1,,BAO_0000218,Intermediate,,15286,In vitro percent permeability into rat ileum; Range is 46-66,A,,,Rattus norvegicus,10116.0,
12232,1,,BAO_0000218,Intermediate,,15286,In vitro percent permeability into rat ileum; Range is 50-68,A,,,Rattus norvegicus,10116.0,
12233,1,,BAO_0000218,Intermediate,,15286,In vitro percent permeability into rat ileum; Range is 78-81,A,,,Rattus norvegicus,10116.0,
12234,1,,BAO_0000218,Intermediate,,15286,In vitro percent permeability into rat ileum; insol indicates not soluble in aqueous buffer,A,,,Rattus norvegicus,10116.0,
12235,1,,BAO_0000218,Intermediate,,15286,In vitro percent permeability into rat ileum; nd indicates not detected,A,,,Rattus norvegicus,10116.0,
12236,1,,BAO_0000218,Intermediate,,15286,In vitro percent permeability into rat ileum; nt indicates not detected,A,,,Rattus norvegicus,10116.0,
12237,1,,BAO_0000218,Intermediate,,15286,In vitro percent permeability into rat ileum; nt indicates not tested,A,,,Rattus norvegicus,10116.0,
12238,1,,BAO_0000218,Intermediate,,13770,Compound was tested for oral absorption in bile-duct cannulated rats,A,,,Rattus norvegicus,10116.0,
12239,1,,BAO_0000218,Intermediate,,13770,Compound was tested for oral absorption in bile-duct cannulated rats.,A,,,Rattus norvegicus,10116.0,
12240,1,,BAO_0000218,Intermediate,,5202,Oral absorption using Caco-2 cell monolayers.,A,,,Homo sapiens,9606.0,
12241,1,,BAO_0000218,Intermediate,,14920,Percent of the drug absorbed after administration to humans was determined,A,,,Homo sapiens,9606.0,
12242,1,,BAO_0000218,Intermediate,1969.0,14103,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 120 minutes.,A,,,Rattus norvegicus,10116.0,
12243,1,,BAO_0000218,Intermediate,1969.0,14103,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 15 minutes.,A,,,Rattus norvegicus,10116.0,
12244,1,,BAO_0000218,Intermediate,1969.0,14103,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 180 minutes.,A,,,Rattus norvegicus,10116.0,
12245,1,,BAO_0000218,Intermediate,2107.0,13751,"Biodistribution inl liver of mature female Dawley rat after 1h, expressed as percent injected dose/g",A,In vivo,,Rattus norvegicus,10116.0,
12246,1,,BAO_0000218,Intermediate,2107.0,13751,"Biodistribution inl liver of mature female Dawley rat after 30min, expressed as percent injected dose/g",A,In vivo,,Rattus norvegicus,10116.0,
12247,1,,BAO_0000218,Intermediate,2107.0,13751,"Biodistribution inl liver of mature female Dawley rat after 45min, expressed as percent injected dose/g",A,In vivo,,Rattus norvegicus,10116.0,
12248,1,,BAO_0000218,Intermediate,,15807,"Distribution of radioactivity in rat blood after 2 minutes of iv administration at the dose of 10.05-0.07 gram of tissue, expressed as percent injected dose per gram of tissue",A,,,Rattus norvegicus,10116.0,
12249,1,,BAO_0000218,Intermediate,2435.0,15807,"Distribution of radioactivity in rat striatum after 5 minutes of iv administration at the dose of 1.89-3.73 g of tissue, expressed as percent injected dose per gram of tissue",A,,,Rattus norvegicus,10116.0,
12250,1,,BAO_0000218,Intermediate,2435.0,15807,"Distribution of radioactivity in rat striatum after 5 minutes of iv administration at the dose of 3.44-4.80 g of tissue, expressed as percent injected dose per gram of tissue",A,,,Rattus norvegicus,10116.0,
12251,1,,BAO_0000218,Intermediate,,14950,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat and 5-alpha-DHT was reported,A,,,Rattus norvegicus,10116.0,
12252,1,,BAO_0000218,Intermediate,,14950,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat blood at 1 hour time,A,,,Rattus norvegicus,10116.0,
12253,1,,BAO_0000218,Intermediate,,14950,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat blood at 2 hours time,A,,,Rattus norvegicus,10116.0,
12254,1,,BAO_0000218,Intermediate,,14950,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat fat at 0.5 hours time,A,,,Rattus norvegicus,10116.0,
12255,1,,BAO_0000218,Intermediate,,14950,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat fat at 4 hours time,A,,,Rattus norvegicus,10116.0,
12256,1,,BAO_0000218,Intermediate,2113.0,14950,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat kidney at 0.5 hours time,A,,,Rattus norvegicus,10116.0,
12257,1,,BAO_0000218,Intermediate,2113.0,14950,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat kidney at 4 hours time,A,,,Rattus norvegicus,10116.0,
12258,1,,BAO_0000218,Intermediate,,14950,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat liver at 1 hour time,A,,,Rattus norvegicus,10116.0,
12259,1,,BAO_0000218,Intermediate,,14950,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat liver at 2 hours time,A,,,Rattus norvegicus,10116.0,
12260,1,,BAO_0000218,Intermediate,2048.0,14950,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat lung at 1 hour time,A,,,Rattus norvegicus,10116.0,
12261,1,,BAO_0000218,Intermediate,2048.0,14950,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat lung at 2 hours time,A,,,Rattus norvegicus,10116.0,
12262,1,,BAO_0000218,Intermediate,2385.0,14950,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat muscle at 0.5 hours time,A,,,Rattus norvegicus,10116.0,
12263,1,,BAO_0000218,Intermediate,2385.0,14950,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat muscle at 4 hours time,A,,,Rattus norvegicus,10116.0,
12264,1,,BAO_0000218,Intermediate,2367.0,14950,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat prostate at 0.5 hours time,A,,,Rattus norvegicus,10116.0,
12265,1,,BAO_0000218,Intermediate,2367.0,14950,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat prostate at 4 hours time,A,,,Rattus norvegicus,10116.0,
12266,1,,BAO_0000218,Intermediate,,14950,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat prostate/blood,A,,,Rattus norvegicus,10116.0,
12267,1,,BAO_0000218,Intermediate,,14950,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat prostate/blood at 1 hours time,A,,,Rattus norvegicus,10116.0,
12268,1,,BAO_0000218,Intermediate,,14950,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat prostate/blood at 2 hours time,A,,,Rattus norvegicus,10116.0,
12269,1,,BAO_0000218,Intermediate,2106.0,14950,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat spleen at 1 hour time,A,,,Rattus norvegicus,10116.0,
12270,1,,BAO_0000218,Intermediate,2106.0,14950,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat spleen at 2 hours time,A,,,Rattus norvegicus,10116.0,
12271,1,,BAO_0000218,Intermediate,2046.0,14950,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat thyroid at 0.5 hours time,A,,,Rattus norvegicus,10116.0,
12272,1,,BAO_0000218,Intermediate,2046.0,14950,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat thyroid at 4 hours time,A,,,Rattus norvegicus,10116.0,
12273,1,,BAO_0000218,Intermediate,,14950,Distribution of tissue Radioactivity following subcutaneous injection of 500 mg of 5-alpha-DHT 15 min before the administration of the [125I]- tracer castarted male rat fat at 1 hour time,A,,,Rattus norvegicus,10116.0,
12274,1,,BAO_0000218,Intermediate,,14950,Distribution of tissue Radioactivity following subcutaneous injection of 500 mg of 5-alpha-DHT 15 min before the administration of the [125I]- tracer castarted male rat kidney at 1 hour time,A,,,Rattus norvegicus,10116.0,
12275,1,,BAO_0000218,Intermediate,2385.0,14950,Distribution of tissue Radioactivity following subcutaneous injection of 500 mg of 5-alpha-DHT 15 min before the administration of the [125I]- tracer castarted male rat muscle at 1 hour time,A,,,Rattus norvegicus,10116.0,
12276,1,,BAO_0000218,Intermediate,,14950,Distribution of tissue Radioactivity following subcutaneous injection of 500 mg of 5-alpha-DHT 15 min before the administration of the [125I]- tracer castarted male rat prostrateat 1 hour time,A,,,Rattus norvegicus,10116.0,
12277,1,,BAO_0000218,Intermediate,2046.0,14950,Distribution of tissue Radioactivity following subcutaneous injection of 500 mg of 5-alpha-DHT 15 min before the administration of the [125I]- tracer castarted male rat thyroid at 1 hour time,A,,,Rattus norvegicus,10116.0,
12278,1,,BAO_0000218,Intermediate,178.0,8631,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 10 minutes,A,,,Rattus norvegicus,10116.0,
12279,1,,BAO_0000218,Intermediate,178.0,8631,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 15 minutes,A,,,Rattus norvegicus,10116.0,
12280,1,,BAO_0000218,Intermediate,178.0,8631,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 20 minutes,A,,,Rattus norvegicus,10116.0,
12281,1,,BAO_0000218,Intermediate,178.0,8631,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 30 minutes,A,,,Rattus norvegicus,10116.0,
12282,1,,BAO_0000218,Intermediate,178.0,9614,"Concentration of compound in blood of dog 2, after administering intravenously",A,,,Canis lupus familiaris,9615.0,
12283,1,,BAO_0000218,Intermediate,,9614,"Concentration of compound in left ventricle of dog 1, after administering intravenously",A,,,Canis lupus familiaris,9615.0,
12284,1,,BAO_0000218,Intermediate,,9614,"Concentration of compound in left ventricle of dog 2, after administering intravenously",A,,,Canis lupus familiaris,9615.0,
12285,1,,BAO_0000218,Intermediate,2107.0,9614,"Concentration of compound in liver of dog 1, after administering intravenously",A,,,Canis lupus familiaris,9615.0,
12286,1,,BAO_0000218,Intermediate,2107.0,9614,"Concentration of compound in liver of dog 2, after administering intravenously",A,,,Canis lupus familiaris,9615.0,
12287,1,,BAO_0000218,Intermediate,2048.0,9614,"Concentration of compound in lung of dog 1, after administering intravenously",A,,,Canis lupus familiaris,9615.0,
12288,1,,BAO_0000218,Intermediate,2048.0,9614,"Concentration of compound in lung of dog 2, after administering intravenously",A,,,Canis lupus familiaris,9615.0,
12289,1,,BAO_0000218,Intermediate,2385.0,9614,"Concentration of compound in muscle of dog 1, after administering intravenously",A,,,Canis lupus familiaris,9615.0,
12290,1,,BAO_0000218,Intermediate,2385.0,9614,"Concentration of compound in muscle of dog 2, after administering intravenously",A,,,Canis lupus familiaris,9615.0,
12291,1,,BAO_0000218,Intermediate,2106.0,9614,"Concentration of compound in spleen of dog 1,after administering intravenously",A,,,Canis lupus familiaris,9615.0,
12292,1,,BAO_0000218,Intermediate,2106.0,9614,"Concentration of compound in spleen of dog 2, after administering intravenously",A,,,Canis lupus familiaris,9615.0,
12293,0,,BAO_0000218,Autocuration,,10353,Concentration of liberated compound in serum after 120 min at the dose of 50 mg/kg (po).,F,,,,,
12294,0,,BAO_0000218,Autocuration,,10353,Concentration of liberated compound in serum after 240 min at the dose of 50 mg/kg (po).,F,,,,,
12295,0,,BAO_0000218,Autocuration,,10353,Concentration of liberated compound in serum after 30 min at the dose of 50 mg/kg (po).,A,,,,,
12296,0,,BAO_0000218,Autocuration,,10353,Concentration of liberated compound in serum after 30 min at the dose of 50 mg/kg (po).,F,,,,,
12297,0,,BAO_0000218,Autocuration,,10353,Concentration of liberated compound in serum after 60 min at the dose of 50 mg/kg (po).,F,,,,,
12298,0,,BAO_0000218,Autocuration,,9196,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous after 1.5 hr,A,,,,,
12299,0,,BAO_0000218,Autocuration,,9196,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.5 hr,A,,,,,
12300,0,,BAO_0000218,Autocuration,,9196,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 4.0 hr,A,,,,,
12301,0,,BAO_0000218,Autocuration,,9196,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 0.5 hr,A,,,,,
12302,0,,BAO_0000218,Autocuration,,9196,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.0 hr,A,,,,,
12303,0,,BAO_0000218,Autocuration,,9196,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.0 hr,A,,,,,
12304,0,,BAO_0000218,Autocuration,,9196,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.0 hr,A,,,,,
12305,0,,BAO_0000218,Autocuration,,9196,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.5 hr,A,,,,,
12306,0,,BAO_0000218,Autocuration,,9196,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous after 1.5 hr,A,,,,,
12307,0,,BAO_0000218,Autocuration,,9196,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage a after 4.0 hr,A,,,,,
12308,0,,BAO_0000218,Autocuration,,9196,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 0.5 hr,A,,,,,
12309,0,,BAO_0000218,Autocuration,,9196,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.0 hr,A,,,,,
12310,0,,BAO_0000218,Autocuration,,9196,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.0 hr,A,,,,,
12311,0,,BAO_0000218,Autocuration,,9196,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.5 hr,A,,,,,
12312,0,,BAO_0000218,Autocuration,,9196,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg i intravenous dosage after 1.0 hr; insufficient gastric juice produced,A,,,,,
12313,0,,BAO_0000218,Autocuration,,9196,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage a after 2.5 hr,A,,,,,
12314,0,,BAO_0000218,Autocuration,,9196,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 0.5 hr,A,,,,,
12315,0,,BAO_0000218,Autocuration,,9196,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.0 hr,A,,,,,
12316,0,,BAO_0000218,Autocuration,,9196,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.0 hr; ND means not determined,A,,,,,
12317,0,,BAO_0000218,Autocuration,,9196,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.0 hr,A,,,,,
12318,0,,BAO_0000218,Autocuration,,9196,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.0 hr,A,,,,,
12319,0,,BAO_0000218,Autocuration,,9196,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.5 hr; ND means not determined,A,,,,,
12320,0,,BAO_0000218,Autocuration,,9196,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 4.0 hr,A,,,,,
12321,0,,BAO_0000218,Autocuration,,9196,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 0.5 hr,A,,,,,
12322,0,,BAO_0000218,Autocuration,,9196,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.0 hr,A,,,,,
12323,0,,BAO_0000218,Autocuration,,9196,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.5 hr; ND means not determined,A,,,,,
12324,0,,BAO_0000218,Autocuration,,9196,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.0 hr,A,,,,,
12325,0,,BAO_0000218,Autocuration,,9196,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.5 hr; ND means not determined,A,,,,,
12326,1,,BAO_0000218,Intermediate,2046.0,8608,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 19-24",A,,,Rattus norvegicus,10116.0,
12327,1,,BAO_0000218,Intermediate,2046.0,8608,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 26-40",A,,,Rattus norvegicus,10116.0,
12328,1,,BAO_0000218,Intermediate,2046.0,8608,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 29-44",A,,,Rattus norvegicus,10116.0,
12329,1,,BAO_0000218,Intermediate,2046.0,8608,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 32-42",A,,,Rattus norvegicus,10116.0,
12330,1,,BAO_0000218,Intermediate,2046.0,8608,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 33-60",A,,,Rattus norvegicus,10116.0,
12331,1,,BAO_0000218,Intermediate,2046.0,8608,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 4-7",A,,,Rattus norvegicus,10116.0,
12332,1,,BAO_0000218,Intermediate,2046.0,8608,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 13-18",A,,,Rattus norvegicus,10116.0,
12333,1,,BAO_0000218,Intermediate,2046.0,8608,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 16-32",A,,,Rattus norvegicus,10116.0,
12334,1,,BAO_0000218,Intermediate,2046.0,8608,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 22-25",A,,,Rattus norvegicus,10116.0,
12335,1,,BAO_0000218,Intermediate,2046.0,8608,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 26-49",A,,,Rattus norvegicus,10116.0,
12336,1,,BAO_0000218,Intermediate,2046.0,8608,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 29-36",A,,,Rattus norvegicus,10116.0,
12337,1,,BAO_0000218,Intermediate,2046.0,8608,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 5-8",A,,,Rattus norvegicus,10116.0,
12338,1,,BAO_0000218,Intermediate,2046.0,8608,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 26-42",A,,,Rattus norvegicus,10116.0,
12339,1,,BAO_0000218,Intermediate,2046.0,8608,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 30-53",A,,,Rattus norvegicus,10116.0,
12340,1,,BAO_0000218,Intermediate,2046.0,8608,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 32-43",A,,,Rattus norvegicus,10116.0,
12341,1,,BAO_0000218,Intermediate,2046.0,8608,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 35-53",A,,,Rattus norvegicus,10116.0,
12342,1,,BAO_0000218,Intermediate,2046.0,8608,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 5-12",A,,,Rattus norvegicus,10116.0,
12343,1,,BAO_0000218,Intermediate,2046.0,8608,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 55-102",A,,,Rattus norvegicus,10116.0,
12344,1,,BAO_0000218,Intermediate,,8085,In vivo distribution of the drug in plasma was determined at 1 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,A,,,Rattus norvegicus,10116.0,
12345,1,,BAO_0000218,Intermediate,,8085,In vivo distribution of the drug in plasma was determined at 2 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,A,,,Rattus norvegicus,10116.0,
12346,1,,BAO_0000218,Intermediate,,8085,In vivo distribution of the drug in plasma was determined at 3h following injection of five microcurics of the radiolabeled [125 I] compound in rats,A,,,Rattus norvegicus,10116.0,
12347,1,,BAO_0000218,Intermediate,995.0,8085,In vivo distribution of the drug in uterus was determined at 1 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,A,,,Rattus norvegicus,10116.0,
12348,1,,BAO_0000218,Intermediate,995.0,8085,In vivo distribution of the drug in uterus was determined at 2 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,A,,,Rattus norvegicus,10116.0,
12349,1,,BAO_0000218,Intermediate,995.0,8085,In vivo distribution of the drug in uterus was determined at 3h following injection of five microcurics of the radiolabeled [125 I] compound in rats,A,,,Rattus norvegicus,10116.0,
12350,1,,BAO_0000218,Intermediate,995.0,8085,In vivo distribution of the drug in uterus/plasma was determined at 1 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,A,,,Rattus norvegicus,10116.0,
12351,1,,BAO_0000218,Intermediate,995.0,8085,In vivo distribution of the drug in uterus/plasma was determined at 2 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,A,,,Rattus norvegicus,10116.0,
12352,1,,BAO_0000218,Intermediate,995.0,8085,In vivo distribution of the drug in uterus/plasma was determined at 3h following injection of five microcurics of the radiolabeled [125 I] compound in rats,A,,,Rattus norvegicus,10116.0,
12353,1,,BAO_0000218,Intermediate,995.0,8085,In vivo distribution of the drug in uterus/plasma was determined at 3h following injection of five microcurics of the radiolabeled [125 I] compound in rats,A,,,Rattus norvegicus,10116.0,
12354,0,,BAO_0000100,Autocuration,,7657,Distribution coefficient (D %) between octanol and buffer of pH 7.4,P,,,,,
12355,1,,BAO_0000218,Intermediate,,8935,Partition coefficient (logD7.4),A,,,Mus musculus,10090.0,
12356,1,,BAO_0000218,Intermediate,,13792,"Percentage of radioactivity in P1 subregion in mouse brain that contains nuclei and cell debris, after Jugular Vein Injection",A,,,Mus musculus,10090.0,
12357,1,,BAO_0000218,Intermediate,955.0,13792,"Percentage of radioactivity in P2 subregion in mouse brain that contains myelin fragments, synaptosomes (pinched-nerve endings), and mitochondria after Jugular Vein Injection",A,,,Mus musculus,10090.0,
12358,1,,BAO_0000218,Intermediate,,13792,Percentage of radioactivity in P3 subregion in mouse brain that contains microsomal fraction after Jugular Vein Injection,A,,,Mus musculus,10090.0,
12359,1,,BAO_0000218,Intermediate,955.0,13792,Percentage of radioactivity in S3 which is the soluble fraction in mouse brain after Jugular Vein Injection,A,,,Mus musculus,10090.0,
12360,1,,BAO_0000218,Intermediate,,13792,"Percentage of total protein recovered in P1 subregion in mouse brain that contains nuclei and cell debris, after Jugular Vein Injection",A,,,Mus musculus,10090.0,
12361,1,,BAO_0000218,Intermediate,955.0,13792,"Percentage of total protein recovered in P2 subregion in mouse brain that contains myelin fragments, synaptosomes (pinched-nerve endings), and mitochondria after Jugular Vein Injection",A,,,Mus musculus,10090.0,
12362,1,,BAO_0000218,Intermediate,,13792,Percentage of total protein recovered in P3 subregion in mouse brain that contains microsomal fraction after Jugular Vein Injection,A,,,Mus musculus,10090.0,
12363,1,,BAO_0000218,Intermediate,955.0,13792,Percentage of total protein recovered in S3 which is the soluble fraction in mouse brain after Jugular Vein Injection,A,,,Rattus norvegicus,10116.0,
12364,1,,BAO_0000218,Intermediate,1969.0,14103,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 2 minutes.,A,,,Rattus norvegicus,10116.0,
12365,1,,BAO_0000218,Intermediate,1969.0,14103,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 240 minutes.,A,,,Rattus norvegicus,10116.0,
12366,1,,BAO_0000218,Intermediate,1969.0,14103,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 30 minutes.,A,,,Rattus norvegicus,10116.0,
12367,1,,BAO_0000218,Intermediate,1969.0,14103,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 45 minutes.,A,,,Rattus norvegicus,10116.0,
12368,1,,BAO_0000218,Intermediate,1969.0,14103,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 5 minutes.,A,,,Rattus norvegicus,10116.0,
12369,1,,BAO_0000218,Intermediate,1969.0,14103,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 60 minutes.,A,,,Rattus norvegicus,10116.0,
12370,1,,BAO_0000218,Intermediate,1969.0,14103,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 90 minutes.,A,,,Rattus norvegicus,10116.0,
12371,1,,BAO_0000218,Intermediate,1969.0,14103,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 120 minutes.,A,,,Rattus norvegicus,10116.0,
12372,1,,BAO_0000218,Intermediate,1969.0,14103,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 15 minutes.,A,,,Rattus norvegicus,10116.0,
12373,1,,BAO_0000218,Intermediate,1969.0,14103,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 15 minutes;nd=not determined,A,,,Rattus norvegicus,10116.0,
12374,1,,BAO_0000218,Intermediate,1969.0,14103,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 180 minutes.,A,,,Rattus norvegicus,10116.0,
12375,1,,BAO_0000218,Intermediate,1969.0,14103,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 2 minutes;nd=not determined,A,,,Rattus norvegicus,10116.0,
12376,1,,BAO_0000218,Intermediate,1969.0,14103,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 240 minutes.,A,,,Rattus norvegicus,10116.0,
12377,1,,BAO_0000218,Intermediate,1969.0,14103,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 240 minutes;nd=not determined,A,,,Rattus norvegicus,10116.0,
12378,1,,BAO_0000218,Intermediate,1969.0,14103,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 30 minutes.,A,,,Rattus norvegicus,10116.0,
12379,1,,BAO_0000218,Intermediate,1969.0,14103,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 45 minutes.,A,,,Rattus norvegicus,10116.0,
12380,1,,BAO_0000218,Intermediate,1969.0,14103,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 45 minutes;nd=not determined,A,,,Rattus norvegicus,10116.0,
12381,1,,BAO_0000218,Intermediate,1969.0,14103,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 5 minutes.,A,,,Rattus norvegicus,10116.0,
12382,1,,BAO_0000218,Intermediate,1969.0,14103,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 5 minutes;nd=not determined,A,,,Rattus norvegicus,10116.0,
12383,1,,BAO_0000218,Intermediate,1969.0,14103,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 60 minutes.,A,,,Rattus norvegicus,10116.0,
12384,1,,BAO_0000218,Intermediate,1969.0,14103,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 90 minutes.,A,,,Rattus norvegicus,10116.0,
12385,1,,BAO_0000218,Intermediate,1969.0,14103,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 90 minutes;nd=not determined,A,,,Rattus norvegicus,10116.0,
12386,0,,BAO_0000019,Autocuration,,12904,Amount of acetic acid produced by the compound,A,,,,,
12387,0,,BAO_0000019,Autocuration,,12904,Apparent first-order rate of solvolysis for the bipinnatin-A(A4) was determined,A,,,,,
12388,1,,BAO_0000218,Intermediate,,9663,Log of (Cbrain/Cblood) in rats,A,,,Rattus norvegicus,10116.0,
12389,0,,BAO_0000221,Autocuration,,7652,Compound in absence of MPM cell homogenate at pH 3 to isolate compound 4 (ng),A,,,,,
12390,0,,BAO_0000221,Autocuration,,7652,Compound in absence of MPM cell homogenate at pH 4.5 to isolate compound 4 (ng),A,,,,,
12391,0,,BAO_0000221,Autocuration,,7652,Compound in absence of MPM cell homogenate at pH 7 to isolate compound 4 (ng),A,,,,,
12392,0,,BAO_0000219,Autocuration,,7652,Compound in presence of MPM cells and in absence of inactivator at pH 8 to isolate compound 4 (ng),B,,,,,
12393,0,,BAO_0000221,Autocuration,,7652,Compound treated in absence of MPM cell homogenate at pH 4.5 to isolate compound 4 (ng),A,,,,,
12394,0,,BAO_0000019,Autocuration,,7652,Compound treated with MPM cell homogenate at pH 3 to isolate compound 4 (ng),A,,,,,
12395,0,,BAO_0000019,Autocuration,,7652,Compound treated with MPM cell homogenate at pH 3.5 to isolate compound 4 (ng),A,,,,,
12396,0,,BAO_0000019,Autocuration,,7652,Compound treated with MPM cell homogenate at pH 4 to isolate compound 4 (ng),A,,,,,
12397,0,,BAO_0000019,Autocuration,,7652,Compound treated with MPM cell homogenate at pH 4.5 to isolate compound 4 (ng),A,,,,,
12398,0,,BAO_0000019,Autocuration,,7652,Compound treated with MPM cell homogenate at pH 5 to isolate compound 4 (ng),A,,,,,
12399,0,,BAO_0000019,Autocuration,,7652,Compound treated with MPM cell homogenate at pH 5.5 to isolate compound 4 (ng),A,,,,,
12400,0,,BAO_0000019,Autocuration,,7652,Compound treated with MPM cell homogenate at pH 6 to isolate compound 4 (ng),A,,,,,
12401,0,,BAO_0000019,Autocuration,,7652,Compound treated with MPM cell homogenate at pH 6.5 to isolate compound 4 (ng),A,,,,,
12402,0,,BAO_0000019,Autocuration,,7652,Compound treated with MPM cell homogenate at pH 7 to isolate compound 4 (ng),A,,,,,
12403,0,,BAO_0000019,Autocuration,,7652,Compound treated with MPM cell homogenate at pH 7.5 to isolate compound 4 (ng),A,,,,,
12404,0,,BAO_0000019,Autocuration,,7652,Compound treated with MPM cell homogenate at pH 8 to isolate compound 4 (ng),A,,,,,
12405,0,,BAO_0000218,Autocuration,,8267,Compound was evaluated for its urinary recovery after oral administration (100 mg) to Beagle dogs,F,In vivo,,,,
12406,1,,BAO_0000218,Intermediate,,8267,Compound was evaluated for its urinary recovery after oral administration (200 mg) to Beagle dogs,A,,,Canis lupus familiaris,9615.0,
12407,0,,BAO_0000019,Autocuration,,14479,Compound was evaluated for the rate of degradation by Carboxypeptidase A.,A,,,,,
12408,0,,BAO_0000019,Autocuration,,17515,Compound was evaluated for total body clearance,A,,,,,
12409,0,,BAO_0000019,Autocuration,,17515,Compound was evaluated for volume of distribution at steady state,A,,,,,
12410,0,,BAO_0000019,Autocuration,,8142,Compound was tested for hydrolysis by acetylcholinesterase and the kinetic constant KOH- was reported.,A,,,,,
12411,0,,BAO_0000019,Autocuration,,14849,Percentage of the diamine which is monoprotonated at pH 7.4,A,,,,,
12412,0,,BAO_0000019,Autocuration,,7653,Distribution of radioactivity derived form [C14]-labeled compound taken up by 7800C1 cells,A,,,,,
12413,1,,BAO_0000218,Intermediate,178.0,8631,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 5 minutes,A,,,Rattus norvegicus,10116.0,
12414,1,,BAO_0000218,Intermediate,178.0,8631,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 10 minutes,A,,,Rattus norvegicus,10116.0,
12415,1,,BAO_0000218,Intermediate,178.0,8631,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 15 minutes,A,,,Rattus norvegicus,10116.0,
12416,1,,BAO_0000218,Intermediate,178.0,8631,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 20 minutes,A,,,Rattus norvegicus,10116.0,
12417,1,,BAO_0000218,Intermediate,178.0,8631,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 30 minutes,A,,,Rattus norvegicus,10116.0,
12418,1,,BAO_0000218,Intermediate,178.0,8631,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 5 minutes,A,,,Rattus norvegicus,10116.0,
12419,1,,BAO_0000218,Intermediate,178.0,8631,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 10 minutes,A,,,Rattus norvegicus,10116.0,
12420,1,,BAO_0000218,Intermediate,178.0,8631,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 15 minutes,A,,,Rattus norvegicus,10116.0,
12421,1,,BAO_0000218,Intermediate,178.0,8631,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 20 minutes,A,,,Rattus norvegicus,10116.0,
12422,1,,BAO_0000218,Intermediate,178.0,8631,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 30 minutes,A,,,Rattus norvegicus,10116.0,
12423,1,,BAO_0000218,Intermediate,178.0,8631,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 5 minutes,A,,,Rattus norvegicus,10116.0,
12424,1,,BAO_0000218,Intermediate,178.0,8631,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 10 min,A,,,Rattus norvegicus,10116.0,
12425,1,,BAO_0000218,Intermediate,178.0,8631,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 15 minutes,A,,,Rattus norvegicus,10116.0,
12426,1,,BAO_0000218,Intermediate,178.0,8631,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 20 minutes,A,,,Rattus norvegicus,10116.0,
12427,1,,BAO_0000218,Intermediate,178.0,8631,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 5 minutes,A,,,Rattus norvegicus,10116.0,
12428,1,,BAO_0000218,Intermediate,178.0,8631,Amount of compound present in blood of rat 3 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 10 minutes,A,,,Rattus norvegicus,10116.0,
12429,1,,BAO_0000218,Intermediate,178.0,8631,Amount of compound present in blood of rat 3 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 15 minutes,A,,,Rattus norvegicus,10116.0,
12430,1,,BAO_0000218,Intermediate,178.0,8631,Amount of compound present in blood of rat 3 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 20 minutes,A,,,Rattus norvegicus,10116.0,
12431,1,,BAO_0000218,Intermediate,178.0,8631,Amount of compound present in blood of rat 3 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 5 minutes,A,,,Rattus norvegicus,10116.0,
12432,1,,BAO_0000218,Intermediate,178.0,8631,Amount of compound present in blood of rat 4 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 10 minutes,A,,,Rattus norvegicus,10116.0,
12433,1,,BAO_0000218,Intermediate,178.0,8631,Amount of compound present in blood of rat 4 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 15 minutes,A,,,Rattus norvegicus,10116.0,
12434,1,,BAO_0000218,Intermediate,178.0,8631,Amount of compound present in blood of rat 4 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 20 minutes,A,,,Rattus norvegicus,10116.0,
12435,1,,BAO_0000218,Intermediate,178.0,8631,Amount of compound present in blood of rat 4 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 30 minutes,A,,,Rattus norvegicus,10116.0,
12436,1,,BAO_0000218,Intermediate,178.0,8631,Amount of compound present in blood of rat 4 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 5 minutes,A,,,Rattus norvegicus,10116.0,
12437,0,,BAO_0000218,Autocuration,,10263,Maximum biodistribution (Bmax) was determined.,A,,,,,
12438,1,,BAO_0000218,Intermediate,,12364,Mean difference between rectal temperature measured at time zero and rectal temperature measured at 10 min at 1.5625 (mg/kg) intravenous dose in 6 mice,A,,,Mus musculus,10090.0,
12439,1,,BAO_0000218,Intermediate,,12364,Mean difference between rectal temperature measured at time zero and rectal temperature measured at 10 min at 10 (mg/kg) intravenous dose in 6 mice,A,,,Mus musculus,10090.0,
12440,1,,BAO_0000218,Intermediate,,12364,Mean difference between rectal temperature measured at time zero and rectal temperature measured at 10 min at 3.125 (mg/kg) intravenous dose in 6 mice,A,,,Mus musculus,10090.0,
12441,1,,BAO_0000218,Intermediate,,12364,Mean difference between rectal temperature measured at time zero and rectal temperature measured at 10 min at 6.25 (mg/kg) intravenous dose in 6 mice,A,,,Mus musculus,10090.0,
12442,0,,BAO_0000218,Autocuration,,14793,Brain concentration after 0.25 hr at a dose of 10 mg/kg when administered intraperitoneally,A,,,,,
12443,0,,BAO_0000218,Autocuration,,14793,Brain concentration after 0.25 h at a dose of 10 mg/kg when administered intravenously,A,,,,,
12444,0,,BAO_0000218,Autocuration,,14793,Brain concentration after 0.5 h at a dose of 100 mg/kg when administered perorally,A,,,,,
12445,0,,BAO_0000218,Autocuration,,14793,Brain concentration after 0.5 h at a dose of 10 mg/kg when administered intraperitoneally,A,,,,,
12446,0,,BAO_0000218,Autocuration,,14793,Brain concentration after 0.5 hr at a dose of 10 mg/kg when administered intravenously,A,,,,,
12447,0,,BAO_0000218,Autocuration,,14793,Brain concentration after 0.5 hr at a dose of 10 mg/kg when administered perorally,A,,,,,
12448,0,,BAO_0000218,Autocuration,,14793,Brain concentration after 1 hr at a dose of 100 mg/kg when administered perorally,A,,,,,
12449,0,,BAO_0000218,Autocuration,,14793,Brain concentration after 1 hr at a dose of 10 mg/kg when administered intraperitoneally,A,,,,,
12450,0,,BAO_0000218,Autocuration,,14793,Brain concentration after 1 hr at a dose of 10 mg/kg when administered intravenously,A,,,,,
12451,0,,BAO_0000218,Autocuration,,14793,Brain concentration after 1 hr at a dose of 10 mg/kg when administered perorally,A,,,,,
12452,0,,BAO_0000218,Autocuration,,9196,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.0 hr,A,,,,,
12453,0,,BAO_0000218,Autocuration,,9196,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.5 hr; ND means not determined,A,,,,,
12454,0,,BAO_0000218,Autocuration,,9196,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 4.0 hr,A,,,,,
12455,1,,BAO_0000218,Intermediate,178.0,8374,Concentration 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,A,,,Rattus norvegicus,10116.0,
12456,1,,BAO_0000218,Intermediate,178.0,8374,Concentration 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg; ND is Not Detected,A,,,Rattus norvegicus,10116.0,
12457,1,,BAO_0000218,Intermediate,178.0,8374,Concentration 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg; ND is Not Detected.,A,,,Rattus norvegicus,10116.0,
12458,1,,BAO_0000218,Intermediate,178.0,8374,"Concentration 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound, Compound was found to be in trace amount.",A,,,Rattus norvegicus,10116.0,
12459,1,,BAO_0000218,Intermediate,178.0,8374,Concentration 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound; ND is Not Detected.,A,,,Rattus norvegicus,10116.0,
12460,1,,BAO_0000218,Intermediate,178.0,8374,Concentration 1 detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,A,,,Rattus norvegicus,10116.0,
12461,1,,BAO_0000218,Intermediate,178.0,8374,Concentration 1 detected in blood of rat 3 hr after an oral dose of 200 mg/kg; ND is Not Detected,A,,,Rattus norvegicus,10116.0,
12462,1,,BAO_0000218,Intermediate,178.0,8374,Concentration 1 detected in blood of rat 3 hr after an oral dose of 200 mg/kg; ND is Not Detected.,A,,,Rattus norvegicus,10116.0,
12463,1,,BAO_0000218,Intermediate,178.0,8374,Concentration 5a detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,A,,,Rattus norvegicus,10116.0,
12464,1,,BAO_0000218,Intermediate,178.0,8374,Concentration 5a detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,A,,,Rattus norvegicus,10116.0,
12465,1,,BAO_0000218,Intermediate,178.0,8374,Concentration 5b detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,A,,,Rattus norvegicus,10116.0,
12466,1,,BAO_0000218,Intermediate,178.0,8374,Concentration 5b detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,A,,,Rattus norvegicus,10116.0,
12467,1,,BAO_0000218,Intermediate,178.0,8374,Concentration 5c detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,A,,,Rattus norvegicus,10116.0,
12468,1,,BAO_0000218,Intermediate,178.0,8374,Concentration 5c detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,A,,,Rattus norvegicus,10116.0,
12469,1,,BAO_0000218,Intermediate,178.0,8374,Concentration 5d detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,A,,,Rattus norvegicus,10116.0,
12470,1,,BAO_0000218,Intermediate,178.0,8374,Concentration 5d detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,A,,,Rattus norvegicus,10116.0,
12471,1,,BAO_0000218,Intermediate,178.0,8374,Concentration 5e detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,A,,,Rattus norvegicus,10116.0,
12472,1,,BAO_0000218,Intermediate,178.0,8374,Concentration 5e detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,A,,,Rattus norvegicus,10116.0,
12473,1,,BAO_0000218,Intermediate,178.0,8374,Concentration 5f detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound; ND is Not Detected,A,,,Rattus norvegicus,10116.0,
12474,1,,BAO_0000218,Intermediate,178.0,8374,Concentration 5f detected in blood of rat 3 hr after an oral dose of 200 mg/kg; ND is Not Detected,A,,,Rattus norvegicus,10116.0,
12475,1,,BAO_0000218,Intermediate,178.0,8374,Concentration 6a detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,A,,,Rattus norvegicus,10116.0,
12476,1,,BAO_0000218,Intermediate,178.0,8374,Concentration 6a detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,A,,,Rattus norvegicus,10116.0,
12477,1,,BAO_0000218,Intermediate,178.0,8374,Concentration 6c detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,A,,,Rattus norvegicus,10116.0,
12478,1,,BAO_0000218,Intermediate,178.0,8374,Concentration 6c detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,A,,,Rattus norvegicus,10116.0,
12479,1,,BAO_0000218,Intermediate,178.0,8374,Concentration 6d detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,A,,,Rattus norvegicus,10116.0,
12480,1,,BAO_0000218,Intermediate,178.0,8374,Concentration 6d detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,A,,,Rattus norvegicus,10116.0,
12481,1,,BAO_0000218,Intermediate,178.0,8374,Concentration 6e detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,A,,,Rattus norvegicus,10116.0,
12482,1,,BAO_0000218,Intermediate,178.0,8374,Concentration 6e detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,A,,,Rattus norvegicus,10116.0,
12483,1,,BAO_0000218,Intermediate,178.0,8374,Concentration 6f detected in blood of rat 1 hr after an oral dose of 200 mg/kg; ND is Not Detected,A,,,Rattus norvegicus,10116.0,
12484,1,,BAO_0000218,Intermediate,178.0,8374,Concentration 6f detected in blood of rat 3 hr after an oral dose of 200 mg/kg; ND is Not Detected,A,,,Rattus norvegicus,10116.0,
12485,1,,BAO_0000218,Intermediate,178.0,8374,Concentration detected in blood of rat 1 hr after an oral dose of 200 mg/kg,A,,,Rattus norvegicus,10116.0,
12486,1,,BAO_0000218,Intermediate,178.0,8374,Concentration detected in blood of rat 3 hr after an oral dose of 200 mg/kg; ND is Not Detected,A,,,Rattus norvegicus,10116.0,
12487,1,,BAO_0000218,Intermediate,178.0,8374,Concentration detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,A,,,Rattus norvegicus,10116.0,
12488,0,,BAO_0000218,Autocuration,,9196,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 0.5 hr,A,,,,,
12489,0,,BAO_0000218,Autocuration,,9196,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.0 hr,A,,,,,
12490,0,,BAO_0000218,Autocuration,,9196,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.5 hr,A,,,,,
12491,0,,BAO_0000218,Autocuration,,9196,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.0 hr,A,,,,,
12492,0,,BAO_0000218,Autocuration,,9196,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.5 hr,A,,,,,
12493,0,,BAO_0000218,Autocuration,,9196,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.5 hr,A,,,,,
12494,0,,BAO_0000218,Autocuration,,9196,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 4.0 hr,A,,,,,
12495,0,,BAO_0000218,Autocuration,,9196,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.0 hr,A,,,,,
12496,1,,BAO_0000218,Intermediate,,12023,Volume of distribution in Beagles dog at a dose of 1 mg/kg given intravenously,A,,,Canis lupus familiaris,9615.0,
12497,1,,BAO_0000218,Intermediate,,12023,Volume of distribution in CD rat at a dose of 5 mg/kg given intravenously,A,,,Rattus norvegicus,10116.0,
12498,1,,BAO_0000218,Intermediate,,12023,Volume of distribution in Cynomolgus monkey at a dose of 5 mg/kg given intravenously,A,,,Macaca fascicularis,9541.0,
12499,0,,BAO_0000100,Autocuration,,10580,Distribution coefficient and iron(III) complex was measured at an aqueous phase buffered at pH 7.4 and octanol,P,,,,,
12500,0,,BAO_0000100,Autocuration,,10580,Distribution coefficient was measured at an aqueous phase buffered at pH 7.4 and octanol,P,,,,,
12501,0,,BAO_0000019,Autocuration,,16032,Iron clearance was stimulated by the compound was expressed as % distribution of excreted Fe in bile by subcutaneous dose of 150 umol/kg,A,,,,,
12502,0,,BAO_0000019,Autocuration,1088.0,16032,Iron clearance was stimulated by the compound was expressed as % distribution of excreted Fe in urine by subcutaneous dose of 150 umol/kg,A,,,,,
12503,1,,BAO_0000218,Intermediate,178.0,8594,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0,
12504,1,,BAO_0000218,Intermediate,178.0,8594,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,A,,,Rattus norvegicus,10116.0,
12505,1,,BAO_0000218,Intermediate,178.0,8594,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0,
12506,1,,BAO_0000218,Intermediate,178.0,8594,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,A,,,Rattus norvegicus,10116.0,
12507,1,,BAO_0000218,Intermediate,178.0,8594,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0,
12508,1,,BAO_0000218,Intermediate,178.0,8594,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,A,,,Rattus norvegicus,10116.0,
12509,1,,BAO_0000218,Intermediate,178.0,8594,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0,
12510,1,,BAO_0000218,Intermediate,178.0,8594,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0,
12511,1,,BAO_0000218,Intermediate,178.0,8594,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,A,,,Rattus norvegicus,10116.0,
12512,1,,BAO_0000218,Intermediate,178.0,8594,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0,
12513,1,,BAO_0000218,Intermediate,948.0,8594,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0,
12514,1,,BAO_0000218,Intermediate,948.0,8594,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0,
12515,1,,BAO_0000218,Intermediate,948.0,8594,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,A,,,Rattus norvegicus,10116.0,
12516,1,,BAO_0000218,Intermediate,948.0,8594,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,A,,,Rattus norvegicus,10116.0,
12517,1,,BAO_0000218,Intermediate,948.0,8594,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0,
12518,1,,BAO_0000218,Intermediate,948.0,8594,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,A,,,Rattus norvegicus,10116.0,
12519,1,,BAO_0000218,Intermediate,948.0,8594,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0,
12520,1,,BAO_0000218,Intermediate,948.0,8594,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,A,,,Rattus norvegicus,10116.0,
12521,1,,BAO_0000218,Intermediate,948.0,8594,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0,
12522,1,,BAO_0000218,Intermediate,948.0,8594,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 10 min (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0,
12523,1,,BAO_0000218,Intermediate,948.0,8594,"Concentration was measured in heart tissue of unfasted Fischer 344 rats, administered intravenous, after 5 minute (radiolabeled with [125I]-",A,,,Rattus norvegicus,10116.0,
12524,1,,BAO_0000218,Intermediate,2113.0,8594,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0,
12525,1,,BAO_0000218,Intermediate,2113.0,8594,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,A,,,Rattus norvegicus,10116.0,
12526,1,,BAO_0000218,Intermediate,2113.0,8594,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0,
12527,1,,BAO_0000218,Intermediate,2113.0,8594,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,A,,,Rattus norvegicus,10116.0,
12528,1,,BAO_0000218,Intermediate,2113.0,8594,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0,
12529,1,,BAO_0000218,Intermediate,2113.0,8594,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,A,,,Rattus norvegicus,10116.0,
12530,1,,BAO_0000218,Intermediate,2113.0,8594,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0,
12531,1,,BAO_0000218,Intermediate,2113.0,8594,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,A,,,Rattus norvegicus,10116.0,
12532,1,,BAO_0000218,Intermediate,2113.0,8594,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0,
12533,1,,BAO_0000218,Intermediate,2113.0,8594,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0,
12534,1,,BAO_0000218,Intermediate,2107.0,8594,Concentration was measured in liver tissue f unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0,
12535,1,,BAO_0000218,Intermediate,2107.0,8594,Concentration was measured in liver tissue f unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,A,,,Rattus norvegicus,10116.0,
12536,1,,BAO_0000218,Intermediate,2107.0,8594,Concentration was measured in liver tissue f unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0,
12537,0,,BAO_0000019,Autocuration,,7653,Distribution of radioactivity derived form [C14]-labeled compound taken up by 7800C1 cells; acid insoluble (nucleic acids),A,,,,,
12538,0,,BAO_0000019,Autocuration,,7653,Distribution of radioactivity derived form [C14]-labeled compound taken up by 7800C1 cells; acid insoluble (protein),A,,,,,
12539,0,,BAO_0000019,Autocuration,,7653,Distribution of radioactivity derived form [C14]-labeled compound taken up by 7800C1 cells; acid soluble,A,,,,,
12540,0,,BAO_0000019,Autocuration,,7653,Distribution of radioactivity derived form [C14]-labeled compound taken up by 7800C1 cells; total uptake,A,,,,,
12541,1,,BAO_0000218,Intermediate,,9104,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated Number of new tumors observed",A,,,Rattus norvegicus,10116.0,
12542,1,,BAO_0000218,Intermediate,,9104,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated complete percent remission indicates tumor not palpable.",A,,,Rattus norvegicus,10116.0,
12543,1,,BAO_0000218,Intermediate,,9104,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated number of tumors at the beginning of the test.",A,,,Rattus norvegicus,10116.0,
12544,1,,BAO_0000218,Intermediate,,9104,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated of percent static tumors indicates size of tumor 51-150% of the initial size",A,,,Rattus norvegicus,10116.0,
12545,1,,BAO_0000218,Intermediate,,9104,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated partial percent remission indicates reduction of initial tumor size <=50%.",A,,,Rattus norvegicus,10116.0,
12546,1,,BAO_0000218,Intermediate,,9104,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated percent progress in tumor size indicates >150% of the initial size",A,,,Rattus norvegicus,10116.0,
12547,1,,BAO_0000218,Intermediate,,9104,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated percent static tumors indicates size of tumor 51-150% of the initial size",A,,,Rattus norvegicus,10116.0,
12548,1,,BAO_0000218,Intermediate,,9104,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated percent tumor area measured as the average on the 28th day of therapy.",A,,,Rattus norvegicus,10116.0,
12549,1,,BAO_0000218,Intermediate,,12902,Free level in rat plasma,A,,,Rattus norvegicus,10116.0,
12550,0,,BAO_0000019,Autocuration,,6614,Level reaching in blood plasma of rat or human was determined,A,,,,,
12551,1,,BAO_0000218,Intermediate,,9663,Log (Cbrain/Cblood) in rats,A,,,Rattus norvegicus,10116.0,
12552,0,,BAO_0000019,Autocuration,,17658,Mean percentage of compound transport through P-glycoprotein; expressed as p-glycoprotein affinity,A,,,,,
12553,0,,BAO_0000019,Autocuration,,17658,Mean percentage of compound transport through membrane; expressed as membrane transport,A,,,,,
12554,0,,BAO_0000218,Autocuration,,14314,Metabolic breakdown to the o-sulfate of p-chloroaniline (2-amino-5-chlorophenyl sulfate) by giving 100 mg/kg oral doses of the compound,A,,,,,
12555,0,,BAO_0000019,Autocuration,,7385,Michaelis-Menten constant was measured in the inactivation of HPK; Km x 10 e5,A,,,,,
12556,0,,BAO_0000019,Autocuration,,7385,"Michaelis-Menten constant was measured in the inactivation of HPK; Km x 10 e5, ND=Not determined",A,,,,,
12557,0,,BAO_0000019,Autocuration,,7385,Michaelis-Menten constant was measured in the inactivation of trypsin; Km x 10 e5,A,,,,,
12558,0,,BAO_0000019,Autocuration,,1329,Net water uptake by a carrier mediated transport (%cm) mechanism,A,,,,,
12559,0,,BAO_0000218,Autocuration,,12187,Peak concentration was determined in portal circulation after intraduodenal dose of 10 mg/kg in monkey,A,,,Simiiformes,314293.0,
12560,1,,BAO_0000218,Intermediate,,12187,Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in ferret,A,,,Mustela putorius furo,9669.0,
12561,1,,BAO_0000218,Intermediate,,12187,"Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in ferret, determined by renin inhibition assay",A,,,Mustela putorius furo,9669.0,
12562,0,,BAO_0000218,Autocuration,,12187,Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in monkey,A,,,Simiiformes,314293.0,
12563,0,,BAO_0000218,Autocuration,,12187,"Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in monkey, determined by renin inhibition assay",A,,,Simiiformes,314293.0,
12564,1,,BAO_0000218,Intermediate,,12187,Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in rat,A,,,Rattus norvegicus,10116.0,
12565,1,,BAO_0000218,Intermediate,,12187,"Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in rat, determined by renin inhibition assay",A,,,Rattus norvegicus,10116.0,
12566,1,,BAO_0000218,Intermediate,1969.0,9278,"Peak plasma concentration at a dose of 10 mg/kg, ip route in rat suspended in carboxymethyl cellulose (CMC);ND is defined as no-data.",A,,,Rattus norvegicus,10116.0,
12567,1,,BAO_0000218,Intermediate,1969.0,9278,"Peak plasma concentration at a dose of 100 mg/kg, os route in rat suspended in carboxymethyl cellulose (CMC)",A,,,Rattus norvegicus,10116.0,
12568,1,,BAO_0000218,Intermediate,1969.0,9278,"Peak plasma concentration at a dose of 20 mg/kg, oral route in monkey (Macaca fascicularis) suspended in carboxymethyl cellulose (CMC);Range is between (5.5-6)",A,,,Macaca fascicularis,9541.0,
12569,1,,BAO_0000218,Intermediate,1969.0,9278,"Peak plasma concentration at a dose of 200 mg/kg, oral route in human",A,,,Homo sapiens,9606.0,
12570,1,,BAO_0000218,Intermediate,1969.0,9278,"Peak plasma concentration at a dose of 25 mg/kg, ip route in rat suspended in carboxymethyl cellulose (CMC);ND is defined as no-data.",A,,,Rattus norvegicus,10116.0,
12571,1,,BAO_0000218,Intermediate,1969.0,9278,"Peak plasma concentration at a dose of 25 mg/kg, os route in rat suspended in carboxymethyl cellulose (CMC)",A,,,Rattus norvegicus,10116.0,
12572,1,,BAO_0000218,Intermediate,1969.0,9278,"Peak plasma concentration at a dose of 50 mg/kg, os route in rat suspended in carboxymethyl cellulose (CMC)",A,,,Rattus norvegicus,10116.0,
12573,1,,BAO_0000218,Intermediate,,12186,Peak plasma drug level after intraduodenal administration at a dose 10 mg/kg from portal circulation in salt-depleted cynomolgus monkeys using HPLC assay,A,,,Macaca fascicularis,9541.0,
12574,1,,BAO_0000218,Intermediate,,12186,Peak plasma drug level after intraduodenal administration at a dose 10 mg/kg from systemic circulation in salt-depleted cynomolgus monkeys using HPLC assay,A,,,Macaca fascicularis,9541.0,
12575,0,,BAO_0000218,Autocuration,,12186,Peak plasma drug level after intraduodenal administration at a dose 10 mg/kg from systemic circulation in salt-depleted cynomolgus monkeys using renin inhibition assay,A,,,,,
12576,0,,BAO_0000019,Autocuration,,12041,% metabolized in monkey S-9 after 2 hours (10 ug/mL),A,,,Simiiformes,314293.0,
12577,0,,BAO_0000019,Autocuration,,12041,% metabolized in monkey S-9 after 2 hours (1 ug/ml),A,,,Simiiformes,314293.0,
12578,0,,BAO_0000019,Autocuration,,12041,% metabolized in monkey S-9 after 2 hours (10 ug/ml),A,,,Simiiformes,314293.0,
12579,1,,BAO_0000218,Intermediate,,6737,Permeability in Caco-2 assay at 10E-6,A,,,Homo sapiens,9606.0,
12580,0,,BAO_0000218,Autocuration,955.0,13758,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered intravenously in brain,A,,,,,
12581,0,,BAO_0000218,Autocuration,955.0,13758,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered orally in brain,A,,,,,
12582,0,,BAO_0000019,Autocuration,,5676,Plasma protein binding was determined,A,,,,,
12583,0,,BAO_0000218,Autocuration,,14793,Brain concentration after 2 hr at a dose of 100 mg/kg when administered perorally,A,,,,,
12584,0,,BAO_0000218,Autocuration,,14793,Brain concentration after 2 hr at a dose of 10 mg/kg when administered intraperitoneally,A,,,,,
12585,0,,BAO_0000218,Autocuration,,14793,Brain concentration after 2 hr at a dose of 10 mg/kg when administered intravenously,A,,,,,
12586,0,,BAO_0000218,Autocuration,,14793,Brain concentration after 2 hr at a dose of 10 mg/kg when administered perorally,A,,,,,
12587,0,,BAO_0000218,Autocuration,,14793,Brain concentration after 4 hr at a dose of 100 mg/kg when administered perorally,A,,,,,
12588,0,,BAO_0000218,Autocuration,,14793,Brain concentration after 4 hr at a dose of 10 mg/kg when administered intraperitoneally,A,,,,,
12589,0,,BAO_0000218,Autocuration,,14793,Brain concentration after 4 hr at a dose of 10 mg/kg when administered intravenously,A,,,,,
12590,0,,BAO_0000218,Autocuration,,14793,Brain concentration after 4 hr at a dose of 10 mg/kg when administered perorally,A,,,,,
12591,0,,BAO_0000218,Autocuration,,14793,Brain concentration after 6 hr at a dose of 100 mg/kg when administered perorally,A,,,,,
12592,0,,BAO_0000218,Autocuration,,14793,Brain concentration after 6 hr at a dose of 10 mg/kg when administered perorally,A,,,,,
12593,0,,BAO_0000019,Autocuration,,14000,Bullaticin index relates the IC50 values by normalizing to the value of bullatacin for easy comparison.,A,,,,,
12594,0,,BAO_0000019,Autocuration,,5948,Partition coefficient (logP),A,,,,,
12595,0,,BAO_0000100,Autocuration,,13824,Calculated partition coefficient (clogP) (CLOGP3 V3.4),P,,,,,
12596,0,,BAO_0000100,Autocuration,,10778,Calculated partition coefficient (clogP),P,,,,,
12597,1,,BAO_0000218,Intermediate,,17237,C max in dog,A,In vivo,,Canis lupus familiaris,9615.0,
12598,1,,BAO_0000218,Intermediate,,17237,C max in guinea pig,A,In vivo,,Cavia porcellus,10141.0,
12599,0,,BAO_0000218,Autocuration,,2809,C max value was evaluated,A,In vivo,,,,
12600,0,,BAO_0000218,Autocuration,,11954,Cmax value after oral dose of 0.1 mg//kg,A,In vivo,,,,
12601,0,,BAO_0000218,Autocuration,,11954,Cmax value after oral dose of 0.3 mg/kg,A,In vivo,,,,
12602,0,,BAO_0000218,Autocuration,,11954,Cmax value after oral dose of 1 mg/kg,A,In vivo,,,,
12603,0,,BAO_0000218,Autocuration,,11954,Cmax value after oral dose of 10 mg/kg,A,In vivo,,,,
12604,0,,BAO_0000218,Autocuration,,11954,Cmax value after oral dose of 23.4 mg/kg,A,In vivo,,,,
12605,0,,BAO_0000218,Autocuration,,11954,Cmax value after oral dose of 3 mg/kg,A,In vivo,,,,
12606,0,,BAO_0000218,Autocuration,,11954,Cmax value after oral dose of 3.87 mg/kg,A,In vivo,,,,
12607,1,,BAO_0000218,Intermediate,,12768,Cmax value in female Beagle dogs,A,In vivo,,Canis lupus familiaris,9615.0,
12608,1,,BAO_0000218,Intermediate,,12768,Cmax value in male rats,A,In vivo,,Rattus norvegicus,10116.0,
12609,1,,BAO_0000218,Intermediate,1969.0,12780,Cmax value in rat plasma when administered 20 mg/kg perorally,A,In vivo,,Rattus norvegicus,10116.0,
12610,1,,BAO_0000218,Intermediate,1969.0,15592,Maximal plasma concentration in dogs at 10mg/kg oral dose 0.05M citric acid,A,In vivo,,Canis lupus familiaris,9615.0,
12611,1,,BAO_0000218,Intermediate,1969.0,15592,Maximal plasma concentration in dogs at 10mg/kg oral dose 0.05M citric acid,A,In vivo,,Canis lupus familiaris,9615.0,
12612,1,,BAO_0000218,Intermediate,,17025,Peak concentration of compound at Time = 0 was determined in dog at 5 mg/kg intravenously admn.,A,,,Canis lupus familiaris,9615.0,
12613,0,,BAO_0000218,Autocuration,,17025,Peak concentration of compound at Time = 0 was determined in monkey at 5 mg/kg intravenously admn.,A,,,Simiiformes,314293.0,
12614,1,,BAO_0000218,Intermediate,,17025,Peak concentration of compound at Time = 0 was determined in rabbit at 5 mg/kg intravenously admn.,A,,,Oryctolagus cuniculus,9986.0,
12615,1,,BAO_0000218,Intermediate,,17025,Peak concentration of compound at Time = 0 was determined in rat at 5 mg/kg intravenously admn.,A,,,Rattus norvegicus,10116.0,
12616,1,,BAO_0000218,Intermediate,1969.0,4236,Total plasma concentration at 24 hr at a dose of 10 mg/kg when administered orally to rhesus monkey,A,,,Macaca mulatta,9544.0,
12617,1,,BAO_0000218,Intermediate,,15791,C5min (nM) value was determined in rats after intravenous dose of 5 mg/kg,A,,,Rattus norvegicus,10116.0,
12618,0,,BAO_0000019,Autocuration,,11149,C6h was measured as concentration obtained after 6 hr of oral administration in air pouch exudate,A,,,,,
12619,1,,BAO_0000218,Intermediate,,15592,"Concentration after 8 hour (bioavailability in dog, compound was delivered orally in 0.05 M citric acid at 10 mg/Kg. n=2 )",A,,,Canis lupus familiaris,9615.0,
12620,1,,BAO_0000218,Intermediate,,15778,cytotoxicity against HIV protease enzyme.,A,,,Human immunodeficiency virus,12721.0,
12621,1,,BAO_0000218,Intermediate,,12745,Apparent clearance in mice after intravenous administration of 105.1 mg/kg of dose,A,,,Mus musculus,10090.0,
12622,1,,BAO_0000218,Intermediate,,12745,Apparent clearance in mice after oral administration of 100 mg/kg of dose,A,,,Mus musculus,10090.0,
12623,1,,BAO_0000218,Intermediate,1969.0,13941,The plasma clearance in dog.,A,In vivo,,Canis lupus familiaris,9615.0,
12624,1,,BAO_0000218,Intermediate,1969.0,13941,The plasma clearance in rat.,A,In vivo,,Rattus norvegicus,10116.0,
12625,1,,BAO_0000218,Intermediate,1969.0,16449,Clearance from plasma in male Sprague-Dawley rats,A,In vivo,,Rattus norvegicus,10116.0,
12626,1,,BAO_0000218,Intermediate,1969.0,16449,Clearance from plasma in male cynomolgus monkeys,A,In vivo,,Macaca fascicularis,9541.0,
12627,1,,BAO_0000218,Intermediate,1969.0,14224,"Clearance of compound (5 mg/kg, intravenously), in dog plasma",A,In vivo,,Canis lupus familiaris,9615.0,
12628,1,,BAO_0000218,Intermediate,1969.0,14224,Clearance of compound in dog plasma,A,In vivo,,Canis lupus familiaris,9615.0,
12629,1,,BAO_0000218,Intermediate,1969.0,14224,Clearance of compound in human plasma,A,In vivo,,Homo sapiens,9606.0,
12630,1,,BAO_0000218,Intermediate,,14317,Clearance of compound when administered intravenously as a mixture (five-in-one dose) to a single dog.,A,In vivo,,Canis lupus familiaris,9615.0,
12631,1,,BAO_0000218,Intermediate,,14317,Clearance of compound when administered intravenously as an individual dose to a single dog.,A,In vivo,,Canis lupus familiaris,9615.0,
12632,1,,BAO_0000218,Intermediate,1969.0,14224,"Clearance (10 mg/kg, intravenously) in dog plasma",A,In vivo,,Canis lupus familiaris,9615.0,
12633,1,,BAO_0000218,Intermediate,,17237,Clearance value in dog,A,In vivo,,Canis lupus familiaris,9615.0,
12634,1,,BAO_0000218,Intermediate,,17237,Clearance value in guinea pig,A,In vivo,,Cavia porcellus,10141.0,
12635,1,,BAO_0000218,Intermediate,,14187,Clearance values in rats after iv administration.,A,In vivo,,Rattus norvegicus,10116.0,
12636,0,,BAO_0000218,Autocuration,1969.0,4806,Compound was tested for plasma clearance on administered orally as aqueous solutions at 1 mpk and by iv at 0.2 mpk,A,In vivo,,,,
12637,1,,BAO_0000218,Intermediate,,15025,In vivo clearance (5 mg/kg) was determined in rabbits,A,In vivo,,Oryctolagus cuniculus,9986.0,
12638,1,,BAO_0000218,Intermediate,,13197,Plasma Clearance rate was determined for the compound in rats,A,In vivo,,Rattus norvegicus,10116.0,
12639,0,,BAO_0000218,Autocuration,,13197,Plasma Clearance rate was determined for the compound in squirrel monkeys,A,In vivo,,Saimiri,9520.0,
12640,1,,BAO_0000218,Intermediate,,13960,Plasma clearance in rat,A,In vivo,,Rattus norvegicus,10116.0,
12641,0,,BAO_0000218,Autocuration,,17820,Plasma clearance of the compound,A,In vivo,,,,
12642,1,,BAO_0000218,Intermediate,,14706,Plasma clearance in guinea pigs at 2 mg/kg after iv administration,A,In vivo,,Cavia porcellus,10141.0,
12643,1,,BAO_0000218,Intermediate,,14706,Plasma clearance in guinea pigs at 3 mg/kg after iv administration,A,In vivo,,Cavia porcellus,10141.0,
12644,0,,BAO_0000218,Autocuration,,6504,Plasma clearance was determined,A,In vivo,,,,
12645,1,,BAO_0000218,Intermediate,,14925,Plasma clearance rate (CL) was determined in dogs after intravenous administration of 25 mg/kg of the compound.,A,In vivo,,Canis lupus familiaris,9615.0,
12646,1,,BAO_0000218,Intermediate,,13197,Plasma clearance rate was determined for the compound in rats,A,In vivo,,Rattus norvegicus,10116.0,
12647,0,,BAO_0000218,Autocuration,,13197,Plasma clearance rate was determined for the compound in squirrel monkeys,A,In vivo,,Saimiri,9520.0,
12648,0,,BAO_0000218,Autocuration,,3437,Slow clearance (CL) was determined,A,In vivo,,,,
12649,0,,BAO_0000218,Autocuration,,9196,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 0.5 hr,A,,,,,
12650,0,,BAO_0000218,Autocuration,,9196,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.0 hr; insufficient gastric juice produced,A,,,,,
12651,0,,BAO_0000218,Autocuration,,9196,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.5 hr,A,,,,,
12652,0,,BAO_0000218,Autocuration,,9196,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.0 hr,A,,,,,
12653,0,,BAO_0000218,Autocuration,,9196,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.5 hr,A,,,,,
12654,0,,BAO_0000218,Autocuration,,9196,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.5 hr,A,,,,,
12655,0,,BAO_0000218,Autocuration,,9196,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 4.0 hr,A,,,,,
12656,0,,BAO_0000218,Autocuration,,9196,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.0 hr,A,,,,,
12657,0,,BAO_0000218,Autocuration,,9196,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 0.5 hr,A,,,,,
12658,0,,BAO_0000218,Autocuration,,9196,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.0 hr,A,,,,,
12659,0,,BAO_0000218,Autocuration,,9196,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.5 hr,A,,,,,
12660,0,,BAO_0000218,Autocuration,,9196,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.0 hr,A,,,,,
12661,0,,BAO_0000218,Autocuration,,9196,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.5 hr,A,,,,,
12662,0,,BAO_0000218,Autocuration,,9196,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.0 hr,A,,,,,
12663,0,,BAO_0000218,Autocuration,,9196,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.5 hr,A,,,,,
12664,0,,BAO_0000218,Autocuration,,9196,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 4.0 hr,A,,,,,
12665,0,,BAO_0000218,Autocuration,,9196,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.0 hr,A,,,,,
12666,0,,BAO_0000218,Autocuration,,9196,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.5 hr,A,,,,,
12667,0,,BAO_0000218,Autocuration,,9196,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.0 hr,A,,,,,
12668,0,,BAO_0000218,Autocuration,,9196,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.5 hr,A,,,,,
12669,0,,BAO_0000218,Autocuration,,9196,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 4.0 hr,A,,,,,
12670,0,,BAO_0000218,Autocuration,,9196,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.5 hr,A,,,,,
12671,1,,BAO_0000218,Intermediate,178.0,8374,Cumulative concentration 6b and compound 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,A,,,Rattus norvegicus,10116.0,
12672,1,,BAO_0000218,Intermediate,178.0,8374,Cumulative concentration 6b and compound 1 detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,A,,,Rattus norvegicus,10116.0,
12673,1,,BAO_0000218,Intermediate,,13477,Degradation of compound in incubations at 25 uM with normal rat liver microsomes after 1 hour relative to initial concentration of 1 uM,A,,,Rattus norvegicus,10116.0,
12674,1,,BAO_0000218,Intermediate,,13477,Degradation of compound in incubations at 25 uM with normal rat liver microsomes after 24 hour relative to initial concentration of 1 uM,A,,,Rattus norvegicus,10116.0,
12675,1,,BAO_0000218,Intermediate,,13477,Degradation of compound in incubations at 25 uM with normal rat liver microsomes after 4 hour relative to initial concentration of 1 uM,A,,,Rattus norvegicus,10116.0,
12676,1,,BAO_0000218,Intermediate,955.0,10009,Distribution of compound in mice brain was measured after 1 hr,A,,,Mus musculus,10090.0,
12677,1,,BAO_0000218,Intermediate,955.0,10009,Distribution of compound in mice brain was measured after 24 hr r,A,,,Mus musculus,10090.0,
12678,1,,BAO_0000218,Intermediate,955.0,10009,Distribution of compound in mice brain was measured after 2 hr,A,,,Mus musculus,10090.0,
12679,1,,BAO_0000218,Intermediate,955.0,10009,Distribution of compound in mice brain was measured after 3 hr,A,,,Mus musculus,10090.0,
12680,1,,BAO_0000218,Intermediate,955.0,10009,Distribution of compound in mice brain was measured after 6 hr,A,,,Mus musculus,10090.0,
12681,1,,BAO_0000218,Intermediate,,10009,Distribution of compound in mice liver was measured after 1 hr,A,,,Mus musculus,10090.0,
12682,1,,BAO_0000218,Intermediate,,10009,Distribution of compound in mice liver was measured after 24 hr; b=Undetected,A,,,Mus musculus,10090.0,
12683,1,,BAO_0000218,Intermediate,,10009,Distribution of compound in mice liver was measured after 2 hr,A,,,Mus musculus,10090.0,
12684,1,,BAO_0000218,Intermediate,,10009,Distribution of compound in mice liver was measured after 3 hr,A,,,Mus musculus,10090.0,
12685,1,,BAO_0000218,Intermediate,,10009,Distribution of compound in mice liver was measured after 6 hr,A,,,Mus musculus,10090.0,
12686,1,,BAO_0000218,Intermediate,1236.0,8170,Distribution in dog adrenal medulla 30 min after administration.,A,,,Canis lupus familiaris,9615.0,
12687,1,,BAO_0000218,Intermediate,1236.0,8170,Distribution in dog adrenal medulla 72 hours after administration.,A,,,Canis lupus familiaris,9615.0,
12688,1,,BAO_0000218,Intermediate,,8170,Distribution in female dog Ovary 24 hours after administration.,A,,,Canis lupus familiaris,9615.0,
12689,1,,BAO_0000218,Intermediate,,8170,Distribution in female dog Ovary 72 hours after administration.,A,,,Canis lupus familiaris,9615.0,
12690,1,,BAO_0000218,Intermediate,,8170,Distribution in female dog adipose 24 hours after administration.,A,,,Canis lupus familiaris,9615.0,
12691,1,,BAO_0000218,Intermediate,,8170,Distribution in female dog adipose 72 hours after administration.,A,,,Canis lupus familiaris,9615.0,
12692,1,,BAO_0000218,Intermediate,1235.0,8170,Distribution in female dog adrenal cortex 72 hours after administration.,A,,,Canis lupus familiaris,9615.0,
12693,1,,BAO_0000218,Intermediate,1235.0,8170,Distribution in female dog adrenal cortex 72 hours after administration.,A,,,Canis lupus familiaris,9615.0,
12694,1,,BAO_0000218,Intermediate,2107.0,8594,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,A,,,Rattus norvegicus,10116.0,
12695,1,,BAO_0000218,Intermediate,2107.0,8594,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0,
12696,1,,BAO_0000218,Intermediate,2107.0,8594,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0,
12697,1,,BAO_0000218,Intermediate,2107.0,8594,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0,
12698,1,,BAO_0000218,Intermediate,2107.0,8594,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,A,,,Rattus norvegicus,10116.0,
12699,1,,BAO_0000218,Intermediate,2107.0,8594,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0,
12700,1,,BAO_0000218,Intermediate,2048.0,8594,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0,
12701,1,,BAO_0000218,Intermediate,2048.0,8594,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0,
12702,1,,BAO_0000218,Intermediate,2048.0,8594,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,A,,,Rattus norvegicus,10116.0,
12703,1,,BAO_0000218,Intermediate,2048.0,8594,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0,
12704,1,,BAO_0000218,Intermediate,2048.0,8594,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,A,,,Rattus norvegicus,10116.0,
12705,1,,BAO_0000218,Intermediate,2048.0,8594,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0,
12706,1,,BAO_0000218,Intermediate,2048.0,8594,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,A,,,Rattus norvegicus,10116.0,
12707,1,,BAO_0000218,Intermediate,2048.0,8594,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0,
12708,1,,BAO_0000218,Intermediate,2048.0,8594,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,A,,,Rattus norvegicus,10116.0,
12709,1,,BAO_0000218,Intermediate,2048.0,8594,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0,
12710,1,,BAO_0000218,Intermediate,,8594,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0,
12711,1,,BAO_0000218,Intermediate,,8594,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0,
12712,1,,BAO_0000218,Intermediate,,8594,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,A,,,Rattus norvegicus,10116.0,
12713,1,,BAO_0000218,Intermediate,,8594,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0,
12714,1,,BAO_0000218,Intermediate,,8594,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,A,,,Rattus norvegicus,10116.0,
12715,1,,BAO_0000218,Intermediate,,8594,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0,
12716,1,,BAO_0000218,Intermediate,,8594,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,A,,,Rattus norvegicus,10116.0,
12717,1,,BAO_0000218,Intermediate,,8594,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0,
12718,1,,BAO_0000218,Intermediate,,8594,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,A,,,Rattus norvegicus,10116.0,
12719,1,,BAO_0000218,Intermediate,,8594,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0,
12720,1,,BAO_0000218,Intermediate,2046.0,8594,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0,
12721,1,,BAO_0000218,Intermediate,2046.0,8594,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0,
12722,1,,BAO_0000218,Intermediate,2046.0,8594,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,A,,,Rattus norvegicus,10116.0,
12723,1,,BAO_0000218,Intermediate,2046.0,8594,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0,
12724,1,,BAO_0000218,Intermediate,2046.0,8594,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,A,,,Rattus norvegicus,10116.0,
12725,1,,BAO_0000218,Intermediate,2046.0,8594,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0,
12726,1,,BAO_0000218,Intermediate,2046.0,8594,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,A,,,Rattus norvegicus,10116.0,
12727,1,,BAO_0000218,Intermediate,2046.0,8594,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0,
12728,1,,BAO_0000218,Intermediate,2046.0,8594,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0,
12729,1,,BAO_0000218,Intermediate,,8594,Concentration was measured in tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,A,,,Rattus norvegicus,10116.0,
12730,1,,BAO_0000218,Intermediate,,8594,Concentration was measured in tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0,
12731,1,,BAO_0000218,Intermediate,,8594,Concentration was measured in tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,A,,,Rattus norvegicus,10116.0,
12732,1,,BAO_0000218,Intermediate,,8594,Concentration was measured in tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0,
12733,0,,BAO_0000019,Autocuration,,12904,Rate of acetate production by the compound was determined,A,,,,,
12734,0,,BAO_0000019,Autocuration,,12904,Rate of acetate production by the compound was determined; Not determined,A,,,,,
12735,0,,BAO_0000019,Autocuration,,3730,Rate of hydrolysis of nitrocefin by compound was evaluated in water,A,,,,,
12736,0,,BAO_0000019,Autocuration,,3627,Reductive elimination of leaving group was determined at pH 7.4; expressed as loss of parent,A,,,,,
12737,1,,BAO_0000218,Intermediate,,13799,Relative concentration of compound (70 mg/Kg) in brain compared to concentration in plasma (160 ug/mL) at the time of tissue collection from rabbit; relative concentration,A,,,Oryctolagus cuniculus,9986.0,
12738,1,,BAO_0000218,Intermediate,1969.0,13799,Relative concentration of compound (70 mg/Kg) in lung compared to concentration in plasma (160 ug/mL) at the time of tissue collection from rabbit; relative concentration,A,,,Oryctolagus cuniculus,9986.0,
12739,1,,BAO_0000218,Intermediate,,13799,Relative concentration of compound in brain compared to concentration in plasma (0.4 ug/mL) at the time of tissue collection from mice; relative concentration,A,,,Mus musculus,10090.0,
12740,1,,BAO_0000218,Intermediate,,13799,Relative concentration of compound in brain compared to concentration in plasma (3.5 ug/mL) at the time of tissue collection from mice; relative concentration,A,,,Rattus norvegicus,10116.0,
12741,1,,BAO_0000218,Intermediate,1969.0,13799,Relative concentration of compound in lung compared to concentration in plasma (0.4 ug/mL) at the time of tissue collection from mice; relative concentration,A,,,Rattus norvegicus,10116.0,
12742,1,,BAO_0000218,Intermediate,1969.0,13799,Relative concentration of compound in lung compared to concentration in plasma (3.5 ug/mL) at the time of tissue collection from mice; relative concentration,A,,,Rattus norvegicus,10116.0,
12743,0,,BAO_0000100,Autocuration,,6629,Solubility after at a pH 1.2,P,,,,,
12744,0,,BAO_0000100,Autocuration,,6629,Solubility after at pH 1.2,P,,,,,
12745,0,,BAO_0000100,Autocuration,,6629,Solubility after injection of water,P,,,,,
12746,0,,BAO_0000019,Autocuration,,14000,Statistical significance of IC 50 values; Expressed as R value,A,,,,,
12747,0,,BAO_0000019,Autocuration,,8267,Systemic availability with respect to methyldopa was determined,A,,,,,
12748,1,,BAO_0000218,Intermediate,,13799,Tissue distribution of the in rat brain relative to plasma concentration of 1 ug/kg; relative concentration,A,,,Rattus norvegicus,10116.0,
12749,1,,BAO_0000218,Intermediate,1969.0,13799,Tissue distribution of the in rat lung relative to plasma concentration of 1 ug/kg; relative concentration,A,,,Rattus norvegicus,10116.0,
12750,1,,BAO_0000218,Intermediate,1988.0,7132,"100 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit 1 lung, and radioactivity content in feces was estimated",A,,,Oryctolagus cuniculus,9986.0,
12751,1,,BAO_0000218,Intermediate,1988.0,7132,"100 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit 1 liver, and radioactivity content in feces was estimated",A,,,Oryctolagus cuniculus,9986.0,
12752,1,,BAO_0000218,Intermediate,1988.0,7132,"100 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit3, and radioactivity content in feces was estimated at total hours",A,,,Oryctolagus cuniculus,9986.0,
12753,1,,BAO_0000218,Intermediate,1088.0,7132,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit1, and radioactivity content in urine was estimated at 0-2 hr",A,,,Oryctolagus cuniculus,9986.0,
12754,1,,BAO_0000218,Intermediate,1088.0,7132,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit3, and radioactivity content in urine was estimated at 0-24 hr",A,,,Oryctolagus cuniculus,9986.0,
12755,1,,BAO_0000218,Intermediate,1088.0,7132,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit3, and radioactivity content in urine was estimated at 0-48 hr",A,,,Oryctolagus cuniculus,9986.0,
12756,1,,BAO_0000218,Intermediate,1088.0,7132,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit3, and radioactivity content in urine was estimated at 24-48 h",A,,,Oryctolagus cuniculus,9986.0,
12757,1,,BAO_0000218,Intermediate,1088.0,7132,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit3, and radioactivity content in urine was estimated at 48-72 h",A,,,Oryctolagus cuniculus,9986.0,
12758,1,,BAO_0000218,Intermediate,2113.0,7132,"100 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit kidney, and radioactivity content in feces was estimated",A,,,Oryctolagus cuniculus,9986.0,
12759,1,,BAO_0000218,Intermediate,1988.0,7132,"100 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit, and radioactivity content in feces was estimated",A,,,Oryctolagus cuniculus,9986.0,
12760,1,,BAO_0000218,Intermediate,1988.0,7132,"100 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit 1 lung, and radioactivity content in feces was estimated at",A,,,Oryctolagus cuniculus,9986.0,
12761,1,,BAO_0000218,Intermediate,1988.0,7132,"100 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit1plasma, and radioactivity content in feces was estimated",A,,,Oryctolagus cuniculus,9986.0,
12762,1,,BAO_0000218,Intermediate,1088.0,7132,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit3, and radioactivity content in urine was estimated at total hours",A,,,Oryctolagus cuniculus,9986.0,
12763,1,,BAO_0000218,Intermediate,1988.0,7132,"200 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit4, and radioactivity content in feces was estimated at 0-48 hr",A,,,Oryctolagus cuniculus,9986.0,
12764,1,,BAO_0000218,Intermediate,1988.0,7132,"200 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit4, and radioactivity content in feces was estimated at total hours",A,,,Oryctolagus cuniculus,9986.0,
12765,1,,BAO_0000218,Intermediate,1088.0,7132,"200 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit2, and radioactivity content in urine was estimated at 0-4 hr",A,,,Oryctolagus cuniculus,9986.0,
12766,1,,BAO_0000218,Intermediate,1088.0,7132,"200 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit4, and radioactivity content in urine was estimated at",A,,,Oryctolagus cuniculus,9986.0,
12767,1,,BAO_0000218,Intermediate,1088.0,7132,"200 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit4, and radioactivity content in urine was estimated at 24-48 h",A,,,Oryctolagus cuniculus,9986.0,
12768,1,,BAO_0000218,Intermediate,1088.0,7132,"200 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit4, and radioactivity content in urine was estimated at 48-72 h",A,,,Oryctolagus cuniculus,9986.0,
12769,1,,BAO_0000218,Intermediate,1088.0,7132,"200 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit4, and radioactivity content in urine was estimated at total hours",A,,,Oryctolagus cuniculus,9986.0,
12770,1,,BAO_0000218,Intermediate,2113.0,7132,"200 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit 2 kidney, and radioactivity content in feces was estimated",A,,,Oryctolagus cuniculus,9986.0,
12771,1,,BAO_0000218,Intermediate,1988.0,7132,"200 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit 2 liver, and radioactivity content in feces was estimated",A,,,Oryctolagus cuniculus,9986.0,
12772,1,,BAO_0000218,Intermediate,1988.0,7132,"200 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit 2 lung, and radioactivity content in feces was estimated",A,,,Oryctolagus cuniculus,9986.0,
12773,1,,BAO_0000218,Intermediate,1988.0,7132,200 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit 2 plasma and radioactivity content in feces was estimated,A,,,Oryctolagus cuniculus,9986.0,
12774,1,,BAO_0000218,Intermediate,,7132,Percent of 3-Methyl-thiazolidin-2-ylideneamine as administered dose was reported in rabbit 1,A,,,Oryctolagus cuniculus,9986.0,
12775,1,,BAO_0000218,Intermediate,,7132,Percent of 3-Methyl-thiazolidin-2-ylideneamine as administered dose was reported in rabbit 3 by Gas-liquid chromatographic analysis,A,,,Oryctolagus cuniculus,9986.0,
12776,1,,BAO_0000218,Intermediate,,13317,Tested for pharmacokinetic parameter in fasted Beagle dogs (Clearance value of the compound) iv administration.,A,In vivo,,Canis lupus familiaris,9615.0,
12777,1,,BAO_0000218,Intermediate,,15341,The clearance was measured in dog at dose 5 mg/kg after intravenous administration.,A,In vivo,,Canis lupus familiaris,9615.0,
12778,1,,BAO_0000218,Intermediate,,15341,The clearance was measured in rat at dose 12 mg/kg after intravenous administration.,A,In vivo,,Rattus norvegicus,10116.0,
12779,1,,BAO_0000218,Intermediate,,15341,The clearance was measured in rat at dose 1 mg/kg after intravenous administration.,A,In vivo,,Rattus norvegicus,10116.0,
12780,1,,BAO_0000218,Intermediate,,15341,The clearance was measured in rat at dose 30 mg/kg after intravenous administration.,A,In vivo,,Rattus norvegicus,10116.0,
12781,1,,BAO_0000218,Intermediate,,12801,The compound was evaluated for clearance value in rat isolated esophageal tunica muscularis mucose,A,In vitro,,Rattus norvegicus,10116.0,
12782,1,,BAO_0000218,Intermediate,,12801,The compound was evaluated for the value in rat isolated esophageal tunica muscularis mucose,A,In vitro,,Rattus norvegicus,10116.0,
12783,1,,BAO_0000218,Intermediate,1969.0,14856,The compound was tested for systemic plasma clearance(CL) in rats and is expressed in mL/min/kg.,A,In vivo,,Rattus norvegicus,10116.0,
12784,1,,BAO_0000218,Intermediate,,14062,Total body clearance at an intravenous dose of 5.2 mg/kg in rat,A,In vivo,,Rattus norvegicus,10116.0,
12785,1,,BAO_0000218,Intermediate,,14062,Total body clearance at an intravenous dose of 5.5 mg/kg in rat,A,In vivo,,Rattus norvegicus,10116.0,
12786,1,,BAO_0000218,Intermediate,,14062,Total body clearance at an intravenous dose of 6.3 mg/kg in rat,A,In vivo,,Rattus norvegicus,10116.0,
12787,1,,BAO_0000218,Intermediate,,14062,Total body clearance at an intravenous dose of 6.5 mg/kg in rat,A,In vivo,,Rattus norvegicus,10116.0,
12788,1,,BAO_0000218,Intermediate,1969.0,14346,Total plasma clearance value was obtained after intravenous administration of 1.8 mg/kg of drug in male Beagle dogs,A,In vivo,,Canis lupus familiaris,9615.0,
12789,1,,BAO_0000218,Intermediate,1969.0,14346,Total plasma clearance value was obtained after intravenous administration of 2.5 mg/kg of drug in male Dawley rats,A,In vivo,,Rattus norvegicus,10116.0,
12790,1,,BAO_0000218,Intermediate,1969.0,14346,Total plasma clearance value was obtained after intravenous administration of 2.6 mg/kg of drug in male Dawley rats,A,In vivo,,Rattus norvegicus,10116.0,
12791,1,,BAO_0000218,Intermediate,1969.0,14346,Total plasma clearance value was obtained after intravenous administration of 2.7 mg/kg of drug in male Dawley rats,A,In vivo,,Rattus norvegicus,10116.0,
12792,1,,BAO_0000218,Intermediate,1969.0,14346,Total plasma clearance value was obtained after intravenous administration of 2.8 mg/kg of drug in male Dawley rats,A,In vivo,,Rattus norvegicus,10116.0,
12793,1,,BAO_0000218,Intermediate,1969.0,14346,Total plasma clearance value was obtained after intravenous administration of 4.9 mg/kg of drug in male Beagle dogs,A,In vivo,,Canis lupus familiaris,9615.0,
12794,1,,BAO_0000218,Intermediate,1969.0,14346,Total plasma clearance value was obtained after intravenous administration of 5.1 mg/kg of drug in male Dawley rats,A,In vivo,,Rattus norvegicus,10116.0,
12795,1,,BAO_0000218,Intermediate,1969.0,15711,plasma clearance in human,A,In vivo,,Homo sapiens,9606.0,
12796,1,,BAO_0000218,Intermediate,,14886,Pharmacokinetic parameter (CL/F ) was evaluated in Spargue-Dawley rat when given intravenously at dose 15 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,
12797,1,,BAO_0000218,Intermediate,,14886,Pharmacokinetic parameter (CL/F ) was evaluated in Spargue-Dawley rat when given peroral at dose 30 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,
12798,1,,BAO_0000218,Intermediate,,14886,Pharmacokinetic parameter (CL/F) was evaluated in Spargue-Dawley rat when given peroral at dose 80 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,
12799,0,,BAO_0000100,Autocuration,,4115,1-Octanol/water partition coefficient measured at 7.4,P,,,,,
12800,0,,BAO_0000100,Autocuration,,13733,Calculated partition coefficient (clogP),P,,,,,
12801,0,,BAO_0000019,Autocuration,,12102,Partition coefficient (logP),A,,,,,
12802,0,,BAO_0000100,Autocuration,,12676,Calculated partition coefficient (clogP),P,,,,,
12803,0,,BAO_0000100,Autocuration,,13733,Calculated partition coefficient (clogP),P,,,,,
12804,0,,BAO_0000100,Autocuration,,13740,Calculated partition coefficient (clogP),P,,,,,
12805,0,,BAO_0000100,Autocuration,,12766,Calculated partition coefficient (clogP) (relative to BAY K 8644),P,,,,,
12806,0,,BAO_0000100,Autocuration,,2764,Calculated partition coefficient (clogP),P,,,,,
12807,0,,BAO_0000100,Autocuration,,12355,Calculated partition coefficient (clogP),P,,,,,
12808,0,,BAO_0000100,Autocuration,,11314,Calculated partition coefficient of the compound,P,,,,,
12809,0,,BAO_0000019,Autocuration,,12706,Partition coefficient (logP),A,,,,,
12810,0,,BAO_0000100,Autocuration,,12645,Calculated partition coefficient (clogP),P,,,,,
12811,0,,BAO_0000100,Autocuration,,13668,Calculated partition coefficient (clogP),P,,,,,
12812,0,,BAO_0000100,Autocuration,,12819,Calculated partition coefficient (clogP),P,,,,,
12813,0,,BAO_0000100,Autocuration,,13668,Calculated partition coefficient (clogP),P,,,,,
12814,0,,BAO_0000100,Autocuration,,13017,Calculated partition coefficient (clogP),P,,,,,
12815,0,,BAO_0000019,Autocuration,,2448,Partition coefficient of the compound,A,,,,,
12816,0,,BAO_0000019,Autocuration,,11526,Partition coefficient of the compound,A,,,,,
12817,0,,BAO_0000019,Autocuration,,12426,Partition coefficient of compound was determined,A,,,,,
12818,0,,BAO_0000019,Autocuration,,2448,Partition coefficient was determined,A,,,,,
12819,0,,BAO_0000100,Autocuration,,12001,Calculated partition coefficient (clogP),P,,,,,
12820,0,,BAO_0000100,Autocuration,,12426,partition coefficient of compound was determined,P,,,,,
12821,1,,BAO_0000218,Intermediate,,13204,The total body administered intravenously in dog,A,In vivo,,Canis lupus familiaris,9615.0,
12822,1,,BAO_0000218,Intermediate,,13204,The total body administered intravenously in rats,A,In vivo,,Rattus norvegicus,10116.0,
12823,1,,BAO_0000218,Intermediate,,13889,Time taken for the administration to female NIH mice weighing 25-30 g.,A,,,Mus musculus,10090.0,
12824,0,,BAO_0000019,Autocuration,,13889,Time taken for the administration,A,,,,,
12825,1,,BAO_0000218,Intermediate,,17025,Total clearance of compound was determined in dog at 5 mg/kg intravenously admn.,A,In vivo,,Canis lupus familiaris,9615.0,
12826,0,,BAO_0000218,Autocuration,,17025,Total clearance of compound was determined in monkey at 5 mg/kg intravenously admn.,A,In vivo,,Simiiformes,314293.0,
12827,1,,BAO_0000218,Intermediate,,17025,Total clearance of compound was determined in rabbit at 5 mg/kg intravenously admn.,A,In vivo,,Oryctolagus cuniculus,9986.0,
12828,1,,BAO_0000218,Intermediate,,17025,Total clearance of compound was determined in rat at 5 mg/kg intravenously admn.,A,In vivo,,Rattus norvegicus,10116.0,
12829,0,,BAO_0000019,Autocuration,,15067,Plasma clearance for the compound was determined.,A,,,,,
12830,0,,BAO_0000100,Autocuration,,3091,CLog P value of the compound,P,,,,,
12831,0,,BAO_0000100,Autocuration,,15592,Calculated partition coefficient (clogP),P,,,,,
12832,0,,BAO_0000100,Autocuration,,14738,Calculated partition coefficient (clogP),P,,,,,
12833,0,,BAO_0000100,Autocuration,,14738,ClogP value of the compound; nd ='no data',P,,,,,
12834,0,,BAO_0000100,Autocuration,,14738,ClogP value of the compound; nd ='not determined',P,,,,,
12835,0,,BAO_0000100,Autocuration,,6076,CLog P was determined,P,,,,,
12836,0,,BAO_0000100,Autocuration,,17840,Calculated partition coefficient (clogP),P,,,,,
12837,0,,BAO_0000019,Autocuration,,13589,CLogP was calculated,A,,,,,
12838,0,,BAO_0000019,Autocuration,,17655,CLogP value was determined,A,,,,,
12839,0,,BAO_0000019,Autocuration,,5867,CLogP value was evaluated using http://esc.syrres.com/interkow/kowdemo.htm.,A,,,,,
12840,0,,BAO_0000100,Autocuration,,5867,Calculated partition coefficient (clogP),P,,,,,
12841,0,,BAO_0000100,Autocuration,,10783,Calculated partition coefficient (clogP),P,,,,,
12842,0,,BAO_0000100,Autocuration,,14849,Calculated partition coefficient (clogP),P,,,,,
12843,1,,BAO_0000218,Intermediate,1236.0,8170,Distribution in female dog adrenal medulla 24 hours after administration.,A,,,Canis lupus familiaris,9615.0,
12844,1,,BAO_0000218,Intermediate,1236.0,8170,Distribution in female dog adrenal medulla 72 hours after administration.,A,,,Canis lupus familiaris,9615.0,
12845,1,,BAO_0000218,Intermediate,,8170,Distribution in female dog bile 24 hours after administration.,A,,,Canis lupus familiaris,9615.0,
12846,1,,BAO_0000218,Intermediate,,8170,Distribution in female dog bile 72 hr after administration.,A,,,Canis lupus familiaris,9615.0,
12847,1,,BAO_0000218,Intermediate,,8170,Distribution in female dog blood 24 hours after administration.,A,,,Canis lupus familiaris,9615.0,
12848,1,,BAO_0000218,Intermediate,,8170,Distribution in female dog blood 72 hours after administration.,A,,,Canis lupus familiaris,9615.0,
12849,1,,BAO_0000218,Intermediate,,8170,Distribution in female dog heart 24 hours after administration.,A,,,Canis lupus familiaris,9615.0,
12850,1,,BAO_0000218,Intermediate,,8170,Distribution in female dog heart 72 hours after administration.,A,,,Canis lupus familiaris,9615.0,
12851,1,,BAO_0000218,Intermediate,,8170,Distribution in female dog kidney 24 hours after administration.,A,,,Canis lupus familiaris,9615.0,
12852,1,,BAO_0000218,Intermediate,,8170,Distribution in female dog kidney 72 hours after administration.,A,,,Canis lupus familiaris,9615.0,
12853,1,,BAO_0000218,Intermediate,160.0,8170,Distribution in female dog large intestine 24 hours after administration.,A,,,Canis lupus familiaris,9615.0,
12854,1,,BAO_0000218,Intermediate,160.0,8170,Distribution in female dog large intestine 72 hours after administration.,A,,,Canis lupus familiaris,9615.0,
12855,1,,BAO_0000218,Intermediate,,8170,Distribution in female dog liver 24 hours after administration.,A,,,Canis lupus familiaris,9615.0,
12856,1,,BAO_0000218,Intermediate,,8170,Distribution in female dog liver 72 hours after administration.,A,,,Canis lupus familiaris,9615.0,
12857,1,,BAO_0000218,Intermediate,,8170,Distribution in female dog lung 24 hours after administration.,A,,,Canis lupus familiaris,9615.0,
12858,1,,BAO_0000218,Intermediate,,8170,Distribution in female dog lung 72 hours after administration.,A,,,Canis lupus familiaris,9615.0,
12859,1,,BAO_0000218,Intermediate,2385.0,8170,Distribution in female dog muscle 24 hours after administration.,A,,,Canis lupus familiaris,9615.0,
12860,1,,BAO_0000218,Intermediate,2385.0,8170,Distribution in female dog muscle 72 hours after administration.,A,,,Canis lupus familiaris,9615.0,
12861,1,,BAO_0000218,Intermediate,,8170,Distribution in female dog pancreas 24 hours after administration.,A,,,Canis lupus familiaris,9615.0,
12862,1,,BAO_0000218,Intermediate,,8170,Distribution in female dog pancreas 72 hours after administration.,A,,,Canis lupus familiaris,9615.0,
12863,1,,BAO_0000218,Intermediate,160.0,8170,Distribution in female dog small intestine 24 hours after administration.,A,,,Canis lupus familiaris,9615.0,
12864,1,,BAO_0000218,Intermediate,160.0,8170,Distribution in female dog small intestine 72 hours after administration.,A,,,Canis lupus familiaris,9615.0,
12865,1,,BAO_0000218,Intermediate,2106.0,8170,Distribution in female dog spleen 24 hours after administration.,A,,,Canis lupus familiaris,9615.0,
12866,1,,BAO_0000218,Intermediate,2106.0,8170,Distribution in female dog spleen 72 hours after administration.,A,,,Canis lupus familiaris,9615.0,
12867,1,,BAO_0000218,Intermediate,945.0,8170,Distribution in female dog stomach 24 hours after administration.,A,,,Canis lupus familiaris,9615.0,
12868,1,,BAO_0000218,Intermediate,945.0,8170,Distribution in female dog stomach 72 hours after administration.,A,,,Canis lupus familiaris,9615.0,
12869,1,,BAO_0000218,Intermediate,2046.0,8170,Distribution in female dog thyroid 24 hours after administration.,A,,,Canis lupus familiaris,9615.0,
12870,1,,BAO_0000218,Intermediate,2046.0,8170,Distribution in female dog thyroid 72 hours after administration.,A,,,Canis lupus familiaris,9615.0,
12871,1,,BAO_0000218,Intermediate,1088.0,8170,Distribution in female dog urine 24 hours after administration.,A,,,Canis lupus familiaris,9615.0,
12872,1,,BAO_0000218,Intermediate,1088.0,8170,Distribution in female dog urine 72 hr after administration.,A,,,Canis lupus familiaris,9615.0,
12873,0,,BAO_0000218,Autocuration,1969.0,14283,Mean plasma concentration measured 1 h following an oral dose of 30 mg/kg,A,,,,,
12874,0,,BAO_0000019,Autocuration,,5623,Plasma concentration at 7 hr after intravenous dosing,A,,,,,
12875,1,,BAO_0000218,Intermediate,,13477,Plasma concentration of 3 mg/kg iv after 0.25 hr in rats,A,,,Rattus norvegicus,10116.0,
12876,1,,BAO_0000218,Intermediate,,13477,Plasma concentration of 3 mg/kg iv after 0.5 hr in rats,A,,,Rattus norvegicus,10116.0,
12877,1,,BAO_0000218,Intermediate,,13477,Plasma concentration of 3 mg/kg iv after 1 hr in rats,A,,,Rattus norvegicus,10116.0,
12878,1,,BAO_0000218,Intermediate,,13477,Plasma concentration of 3 mg/kg iv after 2 hr in rats,A,,,Rattus norvegicus,10116.0,
12879,1,,BAO_0000218,Intermediate,,13477,Plasma concentration of 3 mg/kg iv after 4 hr in rats,A,,,Rattus norvegicus,10116.0,
12880,1,,BAO_0000218,Intermediate,,13477,Plasma concentration of 3 mg/kg iv after 6 hr in rats,A,,,Rattus norvegicus,10116.0,
12881,1,,BAO_0000218,Intermediate,,13477,Plasma concentration of 3 mg/kg po after 0.083 hr in rats,A,,,Rattus norvegicus,10116.0,
12882,1,,BAO_0000218,Intermediate,,13477,Plasma concentration after 3 mg/kg peroral dosing in rat at 0.083 h,A,,,Rattus norvegicus,10116.0,
12883,1,,BAO_0000218,Intermediate,,13477,Plasma concentration after 3 mg/kg peroral dosing in rat at 0.25 hr,A,,,Rattus norvegicus,10116.0,
12884,1,,BAO_0000218,Intermediate,,13477,Plasma concentration after 3 mg/kg peroral dosing in rat at 0.5 hr,A,,,Rattus norvegicus,10116.0,
12885,1,,BAO_0000218,Intermediate,,13477,Plasma concentration after 3 mg/kg peroral dosing in rat at 1 hr,A,,,Rattus norvegicus,10116.0,
12886,1,,BAO_0000218,Intermediate,,13477,Plasma concentration after 3 mg/kg peroral dosing in rat at 2 hr,A,,,Rattus norvegicus,10116.0,
12887,1,,BAO_0000218,Intermediate,,13477,Plasma concentration after 3 mg/kg peroral dosing in rat at 4 hr,A,,,Rattus norvegicus,10116.0,
12888,1,,BAO_0000218,Intermediate,,13477,Plasma concentration after 3 mg/kg peroral dosing in rat at 6 hr,A,,,Rattus norvegicus,10116.0,
12889,1,,BAO_0000218,Intermediate,,13477,Plasma concentration after 3 mg/kg peroral dosing in rat at 8 hr,A,,,Rattus norvegicus,10116.0,
12890,0,,BAO_0000019,Autocuration,,12553,Tested for the highest concentration at which toxicity was not observed or the concentration which provided the highest number of net grain counts,A,,,,,
12891,0,,BAO_0000019,Autocuration,1969.0,14548,The concentration in plasmat; Not determined,A,,,,,
12892,1,,BAO_0000218,Intermediate,,14393,Tissue level at 10 mg/kg/po in wistar rats in blood,A,,,Rattus norvegicus,10116.0,
12893,1,,BAO_0000218,Intermediate,,14393,Tissue level at 10 mg/kg/po in wistar rats in brown fat,A,,,Rattus norvegicus,10116.0,
12894,1,,BAO_0000218,Intermediate,,14393,Tissue level at 10 mg/kg/po in wistar rats in heart,A,,,Rattus norvegicus,10116.0,
12895,1,,BAO_0000218,Intermediate,2107.0,14393,Tissue level at 10 mg/kg/po in wistar rats in liver,A,,,Rattus norvegicus,10116.0,
12896,1,,BAO_0000218,Intermediate,,14393,Tissue level at 10 mg/kg/po in wistar rats in plasma,A,,,Rattus norvegicus,10116.0,
12897,1,,BAO_0000218,Intermediate,2385.0,14393,Tissue level at 10 mg/kg/po in wistar rats in skeletal muscle,A,,,Rattus norvegicus,10116.0,
12898,1,,BAO_0000218,Intermediate,,14393,Tissue level at 10 mg/kg/po in wistar rats in subcutaneous fat,A,,,Rattus norvegicus,10116.0,
12899,0,,BAO_0000019,Autocuration,,1629,Water solubility at 37 degree C.,A,,,,,
12900,0,,BAO_0000100,Autocuration,,8194,Solubility of 10 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 13.5 hr,P,,,,,
12901,0,,BAO_0000100,Autocuration,,8194,Solubility of 10 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 4.0 hr,P,,,,,
12902,1,,BAO_0000218,Intermediate,178.0,8594,Distribution of radioactivity was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0,
12903,1,,BAO_0000218,Intermediate,178.0,8594,Distribution of radioactivity was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0,
12904,1,,BAO_0000218,Intermediate,178.0,8594,Distribution of radioactivity was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0,
12905,1,,BAO_0000218,Intermediate,178.0,8594,Distribution of radioactivity was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0,
12906,1,,BAO_0000218,Intermediate,178.0,8594,Distribution of radioactivity was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0,
12907,1,,BAO_0000218,Intermediate,948.0,8594,Distribution of radioactivity was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0,
12908,1,,BAO_0000218,Intermediate,948.0,8594,Distribution of radioactivity was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0,
12909,1,,BAO_0000218,Intermediate,948.0,8594,Distribution of radioactivity was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0,
12910,1,,BAO_0000218,Intermediate,948.0,8594,Distribution of radioactivity was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0,
12911,1,,BAO_0000218,Intermediate,948.0,8594,Distribution of radioactivity was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0,
12912,1,,BAO_0000218,Intermediate,2113.0,8594,Distribution of radioactivity was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0,
12913,1,,BAO_0000218,Intermediate,2113.0,8594,Distribution of radioactivity was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0,
12914,1,,BAO_0000218,Intermediate,2113.0,8594,Distribution of radioactivity was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0,
12915,1,,BAO_0000218,Intermediate,2113.0,8594,Distribution of radioactivity was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0,
12916,1,,BAO_0000218,Intermediate,2113.0,8594,Distribution of radioactivity was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0,
12917,1,,BAO_0000218,Intermediate,2107.0,8594,Distribution of radioactivity was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0,
12918,1,,BAO_0000218,Intermediate,2107.0,8594,Distribution of radioactivity was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0,
12919,1,,BAO_0000218,Intermediate,2107.0,8594,Distribution of radioactivity was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0,
12920,1,,BAO_0000218,Intermediate,2107.0,8594,Distribution of radioactivity was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0,
12921,1,,BAO_0000218,Intermediate,2107.0,8594,Distribution of radioactivity was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0,
12922,1,,BAO_0000218,Intermediate,2048.0,8594,Distribution of radioactivity was measured in lung tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0,
12923,1,,BAO_0000218,Intermediate,2048.0,8594,Distribution of radioactivity was measured in lung tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0,
12924,1,,BAO_0000218,Intermediate,2048.0,8594,Distribution of radioactivity was measured in lung tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0,
12925,1,,BAO_0000218,Intermediate,2048.0,8594,Distribution of radioactivity was measured in lung tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0,
12926,1,,BAO_0000218,Intermediate,2048.0,8594,Distribution of radioactivity was measured in lung tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0,
12927,1,,BAO_0000218,Intermediate,2046.0,8594,Distribution of radioactivity was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0,
12928,1,,BAO_0000218,Intermediate,2046.0,8594,Distribution of radioactivity was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0,
12929,1,,BAO_0000218,Intermediate,2046.0,8594,Distribution of radioactivity was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0,
12930,1,,BAO_0000218,Intermediate,2046.0,8594,Distribution of radioactivity was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0,
12931,1,,BAO_0000218,Intermediate,2046.0,8594,Distribution of radioactivity was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0,
12932,1,,BAO_0000218,Intermediate,,8594,Mean heart/blood tissue of unfasted Fischer 344 rats administered intravenous after 15 minutes (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0,
12933,1,,BAO_0000218,Intermediate,,8594,Mean heart/blood tissue of unfasted Fischer 344 rats administered intravenous after 2 minutes (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0,
12934,1,,BAO_0000218,Intermediate,,8594,Mean heart/blood tissue of unfasted Fischer 344 rats administered intravenous after 30 minutes (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0,
12935,1,,BAO_0000218,Intermediate,,8594,Mean heart/blood tissue of unfasted Fischer 344 rats administered intravenous after 5 minutes (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0,
12936,1,,BAO_0000218,Intermediate,,8594,Mean heart/blood tissue of unfasted Fischer 344 rats administered intravenous after 60 minutes (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0,
12937,0,,BAO_0000019,Autocuration,,8151,Antidiuretic activity was determined expressed as Na+(sodium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 10 mg/Kg,A,,,,,
12938,0,,BAO_0000019,Autocuration,,8151,Antidiuretic activity was determined expressed as Na+(sodium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg,A,,,,,
12939,1,,BAO_0000218,Intermediate,,7132,Percent of 3-Methyl-thiazolidin-2-ylideneamine as administered dose was reported in rabbit 4 by Gas-liquid chromatographic analysis,A,,,Oryctolagus cuniculus,9986.0,
12940,1,,BAO_0000218,Intermediate,,7132,Percent of 3-Methyl-thiazolidin-2-ylideneamine as administered dose was reported in rabbit 2,A,,,Oryctolagus cuniculus,9986.0,
12941,0,,BAO_0000019,Autocuration,,5797,Alkylating activity (0.1 mM) was determined at pH 7.4; expressed as OD (540n m)/mM of drug),A,,,,,
12942,0,,BAO_0000019,Autocuration,,7849,Alkylating activity was determined,A,,,,,
12943,0,,BAO_0000251,Autocuration,,14220,Amount of metabolites in the microsomal medium after 90 min incubation of BTCP (500 uM),A,,,,,
12944,1,,BAO_0000218,Intermediate,,8650,"Formation of metabolite by rabbit liver microsomal preparation in absence of NADPH, at 2 hours",A,,,Oryctolagus cuniculus,9986.0,
12945,1,,BAO_0000218,Intermediate,,8650,"Formation of metabolite by rabbit liver microsomal preparation in presence of Co-O2 (90:10),at 2 hour",A,,,Oryctolagus cuniculus,9986.0,
12946,1,,BAO_0000218,Intermediate,,8650,"Formation of metabolite by rabbit liver microsomal preparation in presence of N2,at 2 hour",A,,,Oryctolagus cuniculus,9986.0,
12947,1,,BAO_0000218,Intermediate,,8650,"Formation of metabolite by rabbit liver microsomal preparation in presence of NADPH, at 2 hours",A,,,Oryctolagus cuniculus,9986.0,
12948,1,,BAO_0000218,Intermediate,,8650,"Formation of metabolite by rabbit liver microsomal preparation in presence of SKF525A,at 2 hour",A,,,Oryctolagus cuniculus,9986.0,
12949,1,,BAO_0000218,Intermediate,,7116,Compound was tested for antidiuretic activity in rats,A,,,Rattus norvegicus,10116.0,
12950,0,,BAO_0000019,Autocuration,,14131,Compound was tested for inactivation kinetic values,A,,,,,
12951,0,,BAO_0000218,Autocuration,,7415,Compound was evaluated for the average apparent volume of distribution when administered through intravenous route,A,In vivo,,,,
12952,0,,BAO_0000019,Autocuration,,13178,Dissociation rate calculated from the first-order equation using the t1/2 value,A,,,,,
12953,0,,BAO_0000100,Autocuration,,8815,Compound was evaluated for pKa by titration of the compounds in 1:2 methyl alcohol and water,P,,,,,
12954,0,,BAO_0000100,Autocuration,,1450,Aqueous solubility was measured,P,,,,,
12955,0,,BAO_0000100,Autocuration,,1450,Aqueous solubility was measured at a pH 4,P,,,,,
12956,0,,BAO_0000100,Autocuration,,1450,Aqueous solubility (pH 7),P,,,,,
12957,0,,BAO_0000100,Autocuration,,1450,Aqueous solubility was measured at a pH 9,P,,,,,
12958,0,,BAO_0000019,Autocuration,,12711,"Aqueous solubilities were determined by dissolving an crystalline hemisulfate and dichloride salts, respectively in water and adding acetate to pH 5.0, concentrations are expressed in free base equivalents",A,,,,,
12959,0,,BAO_0000019,Autocuration,,12711,"Aqueous solubilities were determined by dissolving an crystalline hemisulfate and dichloride salts, respectively in water and adding acetate to pH 5.0, concentrations are expressed in free base equivalents.",A,,,,,
12960,0,,BAO_0000019,Autocuration,,12711,"Aqueous solubilities were determined by dissolving an crystalline hemisulfate and dichloride salts, respectively in water and adding acetate to pH 5.0, concentrations are expressed in free base equivalents.",A,,,,,
12961,0,,BAO_0000100,Autocuration,,15032,Aqueous solubility of the compound,P,,,,,
12962,0,,BAO_0000100,Autocuration,,9964,Aqueous solubility at 37 degree Celsius at pH 7.38,P,,,,,
12963,0,,BAO_0000100,Autocuration,,14962,Aqueous solubility in pH 7.4 phosphate buffer,P,,,,,
12964,1,,BAO_0000218,Intermediate,,12487,Mean arterial pressure response following 10 mg/kg intraduodenal administration to salt depleted dog,A,,,Canis lupus familiaris,9615.0,
12965,1,,BAO_0000218,Intermediate,,12487,Mean arterial pressure response following 1 mg/kg intravenous administration to salt depleted dog,A,,,Canis lupus familiaris,9615.0,
12966,1,,BAO_0000218,Intermediate,,10026,Percentage of aspirin formed during hydrolysis in 10% human plasma at pH 7.4 at 37 degrees celsius,A,,,Homo sapiens,9606.0,
12967,1,,BAO_0000218,Intermediate,,10026,Percentage of aspirin formed during hydrolysis in undiluted human plasma at pH 7.4 at 37 degrees celsius,A,,,Homo sapiens,9606.0,
12968,1,,BAO_0000218,Intermediate,,10026,The percentage of aspirin formed during hydrolysis in 100% human plasma at pH 7.4 at 37 degrees celsius,A,,,Homo sapiens,9606.0,
12969,1,,BAO_0000218,Intermediate,,10026,The percentage of aspirin formed during hydrolysis in 20% human plasma at pH 7.4 at 37 degrees celsius,A,,,Homo sapiens,9606.0,
12970,1,,BAO_0000218,Intermediate,,10026,The percentage of aspirin formed during hydrolysis in 60% human plasma at pH 7.4 at 37 degrees celsius,A,,,Homo sapiens,9606.0,
12971,0,,BAO_0000019,Autocuration,,10026,The percentage of aspirin formed during hydrolysis in 80% human plasma at pH 7.4 at 37 degrees celsius,A,,,,,
12972,1,,BAO_0000218,Intermediate,,7415,Compound was evaluated for the average bile flow rat in rats,A,,,Rattus norvegicus,10116.0,
12973,1,,BAO_0000218,Intermediate,,17025,"Effect of compound on cartilage in surgically induced osteoarthritis (OA) model in rabbit at 15 mg/kg, value are relative to activity of RS-130830 (7.9+/-1.5) at 25 mg/kg",A,,,Oryctolagus cuniculus,9986.0,
12974,1,,BAO_0000218,Intermediate,,17025,"Effect of compound on cartilage in surgically induced osteoarthritis (OA) model in rabbit at 25 mg/kg, value are relative to activity of RS-130830 (7.9+/-1.5) at 25 mg/kg",A,,,Oryctolagus cuniculus,9986.0,
12975,0,,BAO_0000019,Autocuration,,10184,Average half life period was determined,A,,,,,
12976,0,,BAO_0000019,Autocuration,,10184,Average half life period was determined,A,,,,,
12977,1,,BAO_0000218,Intermediate,,8613,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 0.8 mg/kg per day.,A,,,Human herpesvirus 1,10298.0,
12978,1,,BAO_0000218,Intermediate,,8613,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 0.8 mg/kg per day.,A,,,Human herpesvirus 1,10298.0,
12979,1,,BAO_0000218,Intermediate,,8613,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 12.5 mg/kg per day.,A,,,Human herpesvirus 1,10298.0,
12980,1,,BAO_0000218,Intermediate,,8613,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 3.1 mg/kg per day.,A,,,Human herpesvirus 1,10298.0,
12981,1,,BAO_0000218,Intermediate,,8613,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 50 mg/kg per day.,A,,,Human herpesvirus 1,10298.0,
12982,1,,BAO_0000218,Intermediate,,8613,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 50 mg/kg per day.,A,,,Human herpesvirus 1,10298.0,
12983,1,,BAO_0000218,Intermediate,,8613,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.02 mg/kg per day.,A,,,Human herpesvirus 1,10298.0,
12984,1,,BAO_0000218,Intermediate,,8613,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.06 mg/kg per day.,A,,,Human herpesvirus 1,10298.0,
12985,1,,BAO_0000218,Intermediate,,8613,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.25 mg/kg per day.,A,,,Human herpesvirus 1,10298.0,
12986,0,,BAO_0000100,Autocuration,,6030,Calculated partition coefficient (clogP),P,,,,,
12987,0,,BAO_0000100,Autocuration,,6147,Calculated partition coefficient (clogP),P,,,,,
12988,0,,BAO_0000100,Autocuration,,14556,Calculated partition coefficient (clogP) (MacLogP),P,,,,,
12989,0,,BAO_0000019,Autocuration,,768,Hydrophilicity was determined,A,,,,,
12990,0,,BAO_0000100,Autocuration,,14452,Calculated partition coefficient (clogP),P,,,,,
12991,0,,BAO_0000019,Autocuration,,5237,Increased absorption was determined,A,,,,,
12992,0,,BAO_0000100,Autocuration,,14378,Lipophilicity value was evaluated,P,,,,,
12993,0,,BAO_0000100,Autocuration,,14418,Log P value of the compound.,P,,,,,
12994,0,,BAO_0000019,Autocuration,,5249,Partition coefficient of compound was determined,A,,,,,
12995,0,,BAO_0000100,Autocuration,,14621,Calculated partition coefficient (clogP),P,,,,,
12996,0,,BAO_0000100,Autocuration,,12542,Calculated partition coefficient (clogP),P,,,,,
12997,0,,BAO_0000019,Autocuration,,12542,Partition coefficient was measured by medchem software; Not calculated,A,,,,,
12998,0,,BAO_0000100,Autocuration,,12542,Partition coefficient was measured by octanol-water using standard shake-flask method,P,,,,,
12999,0,,BAO_0000100,Autocuration,,15462,Calculated partition coefficient (clogP),P,,,,,
13000,0,,BAO_0000019,Autocuration,,14884,Partition coefficient (logP),A,,,,,
13001,0,,BAO_0000100,Autocuration,,16526,Calculated partition coefficient (clogP),P,,,,,
13002,0,,BAO_0000100,Autocuration,,13693,The Octanol/Water partition coefficient CLogP,P,,,,,
13003,0,,BAO_0000019,Autocuration,,13693,The pharmacokinetic parameter C Log p was reported,A,,,,,
13004,0,,BAO_0000100,Autocuration,,13779,Calculated partition coefficient (clogP),P,,,,,
13005,0,,BAO_0000100,Autocuration,,14772,Calculated partition coefficient (clogP),P,,,,,
13006,0,,BAO_0000100,Autocuration,,14393,Calculated partition coefficient (clogP),P,,,,,
13007,1,,BAO_0000218,Intermediate,1969.0,14793,Clearance rate in rat plasma when administered intraperitoneally at a dose of 10 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,
13008,1,,BAO_0000218,Intermediate,1969.0,14793,Clearance rate in rat plasma when administered intravenously at a dose of 10 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,
13009,1,,BAO_0000218,Intermediate,1969.0,13744,Compound was administered intravenously in dog to evaluate plasma clearance values,A,In vivo,,Canis lupus familiaris,9615.0,
13010,0,,BAO_0000218,Autocuration,1969.0,13744,Compound was administered intravenously in monkey to evaluate plasma clearance values,A,In vivo,,Simiiformes,314293.0,
13011,1,,BAO_0000218,Intermediate,1969.0,13744,Compound was administered intravenously in mouse to evaluate plasma clearance values,A,In vivo,,Mus musculus,10090.0,
13012,1,,BAO_0000218,Intermediate,1969.0,13207,Compound was evaluated in vivo for plasma clearance in dog after intravenous dose at 2 mg/Kg,A,In vivo,,Canis lupus familiaris,9615.0,
13013,1,,BAO_0000218,Intermediate,2107.0,5669,Intrinsic clearance in Rhesus liver microsome,A,In vitro,,Macaca mulatta,9544.0,
13014,1,,BAO_0000218,Intermediate,2107.0,5669,Intrinsic clearance in dog liver microsome,A,In vitro,,Canis lupus familiaris,9615.0,
13015,1,,BAO_0000218,Intermediate,2107.0,5669,Intrinsic clearance in rat liver microsome,A,In vitro,,Rattus norvegicus,10116.0,
13016,1,,BAO_0000218,Intermediate,1969.0,4853,Low plasma clearance was calculated in rhesus monkey,A,In vivo,,Macaca mulatta,9544.0,
13017,1,,BAO_0000218,Intermediate,,16452,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,A,In vivo,,Canis lupus familiaris,9615.0,
13018,0,,BAO_0000218,Autocuration,,11954,Plasma clearance after intravenous dose of 0.3 mg/kg,A,In vivo,,,,
13019,0,,BAO_0000218,Autocuration,,11954,Plasma clearance after intravenous dose of 1 mg/kg,A,In vivo,,,,
13020,0,,BAO_0000218,Autocuration,,11954,Plasma clearance after intravenous dose of 3 mg/kg,A,In vivo,,,,
13021,0,,BAO_0000218,Autocuration,,11954,Plasma clearance after intravenous dose of 3.87 mg/kg,A,In vivo,,,,
13022,1,,BAO_0000218,Intermediate,,5669,Plasma clearance after peroral administration at 10 mpk in Rat,A,In vivo,,Rattus norvegicus,10116.0,
13023,1,,BAO_0000218,Intermediate,,5669,Plasma clearance after peroral administration at 10 mpk in Rhesus,A,In vivo,,Macaca mulatta,9544.0,
13024,1,,BAO_0000218,Intermediate,,5669,Plasma clearance after peroral administration at 10 mpk in dog,A,In vivo,,Canis lupus familiaris,9615.0,
13025,1,,BAO_0000218,Intermediate,,13662,Totla clearance of compound reported after 5 mg/kg i.v. dose in rat,A,In vivo,,Rattus norvegicus,10116.0,
13026,0,,BAO_0000019,Autocuration,,8272,Compound was evaluated for physico-chemical property of Critical micellar concentration (CMC),A,,,,,
13027,0,,BAO_0000019,Autocuration,,13410,Critical Micellar concentration was determined,A,,,,,
13028,0,,BAO_0000019,Autocuration,,13410,Critical Micellar concentration of the compound. was determined,A,,,,,
13029,0,,BAO_0000019,Autocuration,,12628,Critical micelle concentration determined from the plots of the fluorescence intensity as a function of compound concentration,A,,,,,
13030,0,,BAO_0000019,Autocuration,,9675,Critical micellar concentration was measured in water by the dye solubilization method,A,,,,,
13031,0,,BAO_0000019,Autocuration,,12628,Hydrolysis turn over determined from the plots of the fluorescence assay quantified by HPLC,B,,,,,
13032,0,,BAO_0000019,Autocuration,,12766,CMR value (relative to BAY K 8644),A,,,,,
13033,0,,BAO_0000019,Autocuration,,7849,Carbamoylating activity was determined,A,,,,,
13034,0,,BAO_0000218,Autocuration,,12187,Hypotension peak is percentage change from predose baseline pressure observed after intraduodenal dose of 10 mg/kg in monkey,A,,,Simiiformes,314293.0,
13035,0,,BAO_0000019,Autocuration,,2040,Compound was evaluated for induced thermal stabilization for compound: DNA ratio of 1:10 at 0.1 to 0.2 degrees Centigrade.,A,,,,,
13036,0,,BAO_0000019,Autocuration,,2040,Compound was evaluated for induced thermal stabilization for compound: DNA ratio of 1:5 at 0.1 to 0.2 degrees Centigrade.,A,,,,,
13037,1,,BAO_0000218,Intermediate,1969.0,14180,Clearance from dog plasma after intravenous injection of 1 mg/kg of compound,A,In vivo,,Canis lupus familiaris,9615.0,
13038,1,,BAO_0000218,Intermediate,1969.0,14180,Clearance from rat plasma after intravenous injection of 1 mg/kg of compound,A,In vivo,,Rattus norvegicus,10116.0,
13039,1,,BAO_0000218,Intermediate,,14474,"Clearance rate at 0.46 mg/kg, iv, in dogs",A,In vivo,,Canis lupus familiaris,9615.0,
13040,1,,BAO_0000218,Intermediate,,14474,"Clearance rate at 5.5 mg/kg, iv, in rat",A,In vivo,,Rattus norvegicus,10116.0,
13041,1,,BAO_0000218,Intermediate,,14548,Pharmacokinetic parameter Cl calculated in cynomolgus monkey when the compound was administered intravenously at 1 mg/kg concentration,A,In vivo,,Macaca fascicularis,9541.0,
13042,1,,BAO_0000218,Intermediate,,14548,Pharmacokinetic parameter Cl calculated in cynomolgus monkey when the compound was administered intravenously at 0.5 mg/kg concentration,A,In vivo,,Macaca fascicularis,9541.0,
13043,1,,BAO_0000218,Intermediate,,14548,Pharmacokinetic parameter Cl calculated in dog when the compound was administered intravenously at 2 mg/kg concentration,A,In vivo,,Canis lupus familiaris,9615.0,
13044,1,,BAO_0000218,Intermediate,,14548,Pharmacokinetic parameter Cl calculated in rat when the compound was administered intravenously at 5 mg/kg concentration,A,In vivo,,Rattus norvegicus,10116.0,
13045,1,,BAO_0000218,Intermediate,2107.0,6125,Clearance rate constant using isolated perfused rat liver (IPRL) assay,A,Ex vivo,,Rattus norvegicus,10116.0,
13046,0,,BAO_0000218,Autocuration,,6874,Tested for the total clearance of the compound,A,In vivo,,,,
13047,1,,BAO_0000218,Intermediate,,15343,The clearance was measured in dogs after intravenous administration of 1 mg/kg dose,A,In vivo,,Canis lupus familiaris,9615.0,
13048,0,,BAO_0000218,Autocuration,,6236,Total body clearance was determined,A,In vivo,,,,
13049,1,,BAO_0000218,Intermediate,,11510,Mean Chlorine excretion in rats when compound administered at 0 mg/kg po and vehicle dosed at 0 umol/kg,A,,,Rattus norvegicus,10116.0,
13050,1,,BAO_0000218,Intermediate,,11510,Mean Chlorine excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 30.23 umol/kg,A,,,Rattus norvegicus,10116.0,
13051,0,,BAO_0000100,Autocuration,,8194,Solubility of 10 mg compound in aqueous buffer at pH 7.3 and 37 degree Centigrade after 8.0 hr,P,,,,,
13052,0,,BAO_0000100,Autocuration,,8194,Solubility of 150 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 4.0 hr,P,,,,,
13053,0,,BAO_0000100,Autocuration,,8194,Solubility of 150 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 8.0 hr,P,,,,,
13054,0,,BAO_0000100,Autocuration,,8194,Solubility of 20 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 13.5 hr,P,,,,,
13055,0,,BAO_0000100,Autocuration,,8194,Solubility of 20 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 4.0 hr,P,,,,,
13056,0,,BAO_0000100,Autocuration,,8194,Solubility of 20 mg compound in aqueous buffer at pH 7.3 and 37 degree Centigrade after 8.0 hr,P,,,,,
13057,1,,BAO_0000218,Intermediate,,13273,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 10.9 uM/Kg/day),A,,,Pneumocystis carinii,4754.0,
13058,1,,BAO_0000218,Intermediate,,13273,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 2.3 uM/Kg/day,A,,,Pneumocystis carinii,4754.0,
13059,1,,BAO_0000218,Intermediate,,13273,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 23.3 uM/Kg/day,A,,,Pneumocystis carinii,4754.0,
13060,1,,BAO_0000218,Intermediate,,13273,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 4.8 uM/Kg/day,A,,,Pneumocystis carinii,4754.0,
13061,1,,BAO_0000218,Intermediate,,13273,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 9.2 uM/Kg/day,A,,,Pneumocystis carinii,4754.0,
13062,1,,BAO_0000218,Intermediate,,13273,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted uM/Kg/day,A,,,Pneumocystis carinii,4754.0,
13063,1,,BAO_0000218,Intermediate,,13273,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 0.027 (uM/kg/day),A,,,Pneumocystis carinii,4754.0,
13064,1,,BAO_0000218,Intermediate,,13273,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 0.27 (uM/kg/day),A,,,Pneumocystis carinii,4754.0,
13065,1,,BAO_0000218,Intermediate,,13273,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 13.3 (uM/kg/day),A,,,Pneumocystis carinii,4754.0,
13066,1,,BAO_0000218,Intermediate,,13273,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 2.7 (uM/kg/day),A,,,Pneumocystis carinii,4754.0,
13067,1,,BAO_0000218,Intermediate,,13273,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 22.1 (uM/kg/day),A,,,Pneumocystis carinii,4754.0,
13068,1,,BAO_0000218,Intermediate,,13273,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 66.3 (uM/kg/day),A,,,Pneumocystis carinii,4754.0,
13069,0,,BAO_0000019,Autocuration,,13118,Conversion rate by hydrolysis of compound in plasma after 2 hr at a pH of 1.0,A,,,,,
13070,0,,BAO_0000019,Autocuration,,13118,Conversion rate by hydrolysis of compound in plasma after 2 hr at a pH of 1.0; Not detectable,A,,,,,
13071,0,,BAO_0000019,Autocuration,,13118,Conversion rate by hydrolysis of compound in plasma after 4 hr at a pH of 7.4,A,,,,,
13072,0,,BAO_0000019,Autocuration,,13118,Conversion rate by hydrolysis of compound in plasma after 4 hr at a pH of 7.4; Not detectable,A,,,,,
13073,0,,BAO_0000019,Autocuration,,13118,Conversion rate by hydrolysis of compound in plasma after 6 hr. ,A,,,,,
13074,0,,BAO_0000019,Autocuration,,13118,Conversion rate by hydrolysis of compound in plasma after 6 h; Not detectable,A,,,,,
13075,1,,BAO_0000218,Intermediate,,10633,"In vitro rate constant, correlation coefficient for the conversion to progesterone in rat liver homogenate",A,,,Rattus norvegicus,10116.0,
13076,1,,BAO_0000218,Intermediate,,10633,"In vitro rate constant, correlation coefficient for the conversion to progesterone in whole rat blood.",A,,,Rattus norvegicus,10116.0,
13077,1,,BAO_0000218,Intermediate,,10633,"In vitro rate constant, correlation coefficient for the disappearance in rat liver homogenate",A,,,Rattus norvegicus,10116.0,
13078,1,,BAO_0000218,Intermediate,,10633,"In vitro rate constant, correlation coefficient for the disappearance in rat brain homogenate",A,,,Rattus norvegicus,10116.0,
13079,0,,BAO_0000218,Autocuration,,5767,Cp max following ip administration at 1 mg/kg,A,,,,,
13080,0,,BAO_0000218,Autocuration,1969.0,3302,Maximum concentration in plasma was reported at 0.5 hour,A,In vivo,,,,
13081,0,,BAO_0000218,Autocuration,1969.0,3302,Maximum concentration in plasma was reported at 2 hour,A,In vivo,,,,
13082,1,,BAO_0000218,Intermediate,,12467,Cellular uptake kinetics of Porphycenes saturation cell level (cs) in SSK3 murine fibrosarcoma cells,A,,,Mus musculus,10090.0,
13083,0,,BAO_0000100,Autocuration,,11778,Aqueous solubility in 25 mM N-glycyl-glycine and 10 mM MgSO4 (pH 7.8),P,,,,,
13084,0,,BAO_0000019,Autocuration,,4321,Steady state concentration was evaluated,A,,,,,
13085,0,,BAO_0000019,Autocuration,,14884,Partition coefficient (logP),A,,,,,
13086,0,,BAO_0000019,Autocuration,,15234,Partition coefficient (logD7.4),A,,,,,
13087,1,,BAO_0000218,Intermediate,2107.0,14198,Biodistribution of {18]Fluoro-CGP 12388 (60 minutes post injection) in liver of male wistar rats,A,In vivo,,Rattus norvegicus,10116.0,
13088,1,,BAO_0000218,Intermediate,10000001.0,14198,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in bone of male wistar rats,A,In vivo,,Rattus norvegicus,10116.0,
13089,1,,BAO_0000218,Intermediate,2037.0,14198,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in cerebellum of male wistar rats,A,In vivo,,Rattus norvegicus,10116.0,
13090,1,,BAO_0000218,Intermediate,,14198,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in cortex of male wistar rats,A,In vivo,,Rattus norvegicus,10116.0,
13091,1,,BAO_0000218,Intermediate,,14198,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in fat of male wistar rats,A,In vivo,,Rattus norvegicus,10116.0,
13092,1,,BAO_0000218,Intermediate,948.0,14198,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in heart of male wistar rats,A,In vivo,,Rattus norvegicus,10116.0,
13093,1,,BAO_0000218,Intermediate,160.0,14198,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in intestine of male wistar rats,A,In vivo,,Rattus norvegicus,10116.0,
13094,0,,BAO_0000019,Autocuration,,8151,Antidiuretic activity was determined expressed as Na+(sodium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 25 mg/Kg,A,,,,,
13095,0,,BAO_0000019,Autocuration,,8151,Antidiuretic activity was determined expressed as Na+(sodium) excreted in milli euivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg,A,,,,,
13096,0,,BAO_0000019,Autocuration,1088.0,8151,Antidiuretic activity was determined expressed as volume of urine excreted in mL was reported at a dose of 10 mg/Kg,A,,,,,
13097,0,,BAO_0000019,Autocuration,1088.0,8151,Antidiuretic activity was determined expressed as volume of urine excreted in mL was reported at a dose of 100 mg/Kg,A,,,,,
13098,0,,BAO_0000019,Autocuration,1088.0,8151,Antidiuretic activity was determined expressed as volume of urine excreted in mL was reported at a dose of 25 mg/Kg,A,,,,,
13099,1,,BAO_0000218,Intermediate,,8151,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 10 mg/Kg.,A,,,Rattus norvegicus,10116.0,
13100,1,,BAO_0000218,Intermediate,,8151,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg,A,,,Rattus norvegicus,10116.0,
13101,1,,BAO_0000218,Intermediate,,8151,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg.,A,,,Rattus norvegicus,10116.0,
13102,1,,BAO_0000218,Intermediate,,8151,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 25 mg/Kg,A,,,Rattus norvegicus,10116.0,
13103,1,,BAO_0000218,Intermediate,,8151,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 25 mg/Kg.,A,,,Rattus norvegicus,10116.0,
13104,1,,BAO_0000218,Intermediate,,8151,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli euivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg.,A,,,Rattus norvegicus,10116.0,
13105,1,,BAO_0000218,Intermediate,,6996,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog,A,,,Canis lupus familiaris,9615.0,
13106,1,,BAO_0000218,Intermediate,,6996,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 0-99,A,,,Canis lupus familiaris,9615.0,
13107,1,,BAO_0000218,Intermediate,,6996,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 100-249,A,,,Canis lupus familiaris,9615.0,
13108,1,,BAO_0000218,Expert,,6996,Salidiuretic activity in dog following i.v. dosing at 5 mg/kg,F,,,Canis lupus familiaris,9615.0,
13109,1,,BAO_0000218,Intermediate,,6996,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 400-599,A,,,Canis lupus familiaris,9615.0,
13110,1,,BAO_0000218,Intermediate,,6996,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 600- 799,A,,,Canis lupus familiaris,9615.0,
13111,1,,BAO_0000218,Intermediate,,6996,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 600-799,A,,,Canis lupus familiaris,9615.0,
13112,1,,BAO_0000218,Intermediate,,6996,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 800-899,A,,,Canis lupus familiaris,9615.0,
13113,1,,BAO_0000218,Intermediate,,6996,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 100-249,A,,,Canis lupus familiaris,9615.0,
13114,1,,BAO_0000218,Intermediate,,6996,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; act above 5 mg/kg,A,,,Canis lupus familiaris,9615.0,
13115,1,,BAO_0000218,Intermediate,,6996,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog,A,,,Canis lupus familiaris,9615.0,
13116,1,,BAO_0000218,Intermediate,,6996,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 0-99,A,,,Canis lupus familiaris,9615.0,
13117,1,,BAO_0000218,Intermediate,,6996,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 100-249,A,,,Canis lupus familiaris,9615.0,
13118,1,,BAO_0000218,Intermediate,,6996,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 100-299,A,,,Canis lupus familiaris,9615.0,
13119,1,,BAO_0000218,Intermediate,,6996,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 250-399,A,,,Canis lupus familiaris,9615.0,
13120,1,,BAO_0000218,Intermediate,,6996,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 400-599,A,,,Canis lupus familiaris,9615.0,
13121,1,,BAO_0000218,Intermediate,,6996,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 600-799,A,,,Canis lupus familiaris,9615.0,
13122,1,,BAO_0000218,Intermediate,,6996,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 800-899,A,,,Canis lupus familiaris,9615.0,
13123,0,,BAO_0000218,Autocuration,,6996,"Evaluated for salidiuretic activity measured as sodium ion excretion in Rat, administered orally at a dose of 16.5 mg/kg",B,,,,,
13124,1,,BAO_0000218,Intermediate,,6996,Compound administered orally at a dose of 1 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Rat,A,,,Canis lupus familiaris,9615.0,
13125,1,,BAO_0000218,Expert,,6996,"Evaluated for salidiuretic activity measured as sodium ion excretion in Rat, administered orally at a dose of 50 mg/kg",F,,,Rattus norvegicus,10116.0,
13126,0,,BAO_0000218,Autocuration,,6996,Compound administered orally at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Rat,B,,,,,
13127,1,,BAO_0000218,Expert,,6996,Compound administered orally at a dose of 81 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Rat,A,,,Rattus norvegicus,10116.0,
13128,1,,BAO_0000218,Intermediate,,6996,Compound administered orally was evaluated for salidiuretic activity measured as sodium ion excretion in Rat,A,,,Rattus norvegicus,10116.0,
13129,0,,BAO_0000019,Autocuration,,7114,Compound was tested for diuretic activity in potassium content of the 3-h sample was measured by flame photometry,A,,,,,
13130,1,,BAO_0000218,Intermediate,,7114,Compound was tested for diuretic activity in potassium content of the 3-h sample was measured by flame photometry in rat,A,,,Rattus norvegicus,10116.0,
13131,1,,BAO_0000218,Intermediate,,8613,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 1 mg/kg per day.,A,,,Human herpesvirus 1,10298.0,
13132,1,,BAO_0000218,Intermediate,,8613,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 0.8 mg/kg administered subcutaneously,A,,,Human herpesvirus 1,10298.0,
13133,1,,BAO_0000218,Intermediate,,8613,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 0.8 mg/kg administered subcutaneously.,A,,,Human herpesvirus 1,10298.0,
13134,1,,BAO_0000218,Intermediate,,8613,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 12.5 mg/kg administered subcutaneously,A,,,Human herpesvirus 1,10298.0,
13135,1,,BAO_0000218,Intermediate,,8613,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 12.5 mg/kg administered subcutaneously.,A,,,Human herpesvirus 1,10298.0,
13136,1,,BAO_0000218,Intermediate,,8613,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 12.5 mg/kg administered orally.,A,,,Human herpesvirus 1,10298.0,
13137,1,,BAO_0000218,Intermediate,,8613,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 3.1 mg/kg administered subcutaneously,A,,,Human herpesvirus 1,10298.0,
13138,1,,BAO_0000218,Intermediate,,8613,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 3.1 mg/kg administered subcutaneously.,A,,,Human herpesvirus 1,10298.0,
13139,1,,BAO_0000218,Intermediate,,8613,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 3.1 mg/kg administered orally.,A,,,Human herpesvirus 1,10298.0,
13140,1,,BAO_0000218,Intermediate,,8613,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 50 mg/kg administered orally.,A,,,Human herpesvirus 1,10298.0,
13141,1,,BAO_0000218,Intermediate,,8613,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 50 mg/kg administered orally.,A,,,Human herpesvirus 1,10298.0,
13142,1,,BAO_0000218,Intermediate,,8613,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 12.5 mg/kg administered subcutaneously.,A,,,Mus musculus,10090.0,
13143,1,,BAO_0000218,Intermediate,,11219,"Average area under curve value dosed at 0.3 mg/kg, iv in ferrets.",A,,,Mustela putorius furo,9669.0,
13144,1,,BAO_0000218,Intermediate,,11219,"Average area under curve value dosed at 10 mg/kg, id in ferrets.",A,,,Mustela putorius furo,9669.0,
13145,1,,BAO_0000218,Intermediate,,11219,"Average area under curve value dosed at 10 mg/kg, id in ferrets.",A,,,Mustela putorius furo,9669.0,
13146,1,,BAO_0000218,Intermediate,,11219,Average peak plasma drug concentration after id dose of 10 mg/kg in ferrets(Plasma samples collected from portal blood).,A,,,Mustela putorius furo,9669.0,
13147,1,,BAO_0000218,Intermediate,,11219,Average peak plasma drug concentration after id dose of 10 mg/kg in ferrets(Plasma samples collected from arterial blood).,A,,,Mustela putorius furo,9669.0,
13148,1,,BAO_0000218,Intermediate,,11219,Average peak plasma drug concentration after id dose of 10 mg/kg in ferrets(Plasma samples collected from portal blood).,A,,,Mustela putorius furo,9669.0,
13149,1,,BAO_0000218,Intermediate,,11219,Average peak plasma drug concentration after iv dose of 0.3 mg/kg in ferrets.,A,,,Mustela putorius furo,9669.0,
13150,0,,BAO_0000019,Autocuration,,14837,Pharmacokinetic parameter :drug bound to plasma was reported,A,,,,,
13151,0,,BAO_0000019,Autocuration,,14837,compound was evaluated for drug bound in plasma,A,,,,,
13152,1,,BAO_0000218,Intermediate,,15343,The Brain concentration compared to plasma concentration in rats after oral administration of 1 mg/kg dose,A,,,Rattus norvegicus,10116.0,
13153,0,,BAO_0000218,Autocuration,,13761,Bioavailability,A,,,Eutheria,9347.0,
13154,1,,BAO_0000218,Intermediate,,14810,Compound at a dose of 10 mg/kg was orally administered to rats and Bioavailability was reported,A,,,Rattus norvegicus,10116.0,
13155,1,,BAO_0000218,Intermediate,,14810,Compound at a dose of 10 mg/kg was orally administered to rats and Bioavailability was reported; Not tested,A,,,Rattus norvegicus,10116.0,
13156,1,,BAO_0000218,Intermediate,,13249,Oral bioavailability in Beagle dogs at oral dose of 20 mg/kg and an intravenous dose of 5 mg/kg was administered,A,,,Canis lupus familiaris,9615.0,
13157,1,,BAO_0000218,Intermediate,1970.0,9267,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-1 hr after the treatment.,A,,,Rattus norvegicus,10116.0,
13158,1,,BAO_0000218,Intermediate,1970.0,9267,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-2 hr after the treatment.,A,,,Rattus norvegicus,10116.0,
13159,1,,BAO_0000218,Intermediate,1970.0,9267,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-3 hr after the treatment.,A,,,Rattus norvegicus,10116.0,
13160,1,,BAO_0000218,Intermediate,1970.0,9267,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-4 hr after the treatment.,A,,,Rattus norvegicus,10116.0,
13161,1,,BAO_0000218,Intermediate,1970.0,9267,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-5 hr after the treatment.,A,,,Rattus norvegicus,10116.0,
13162,1,,BAO_0000218,Intermediate,1970.0,9267,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-6 hr after the treatment.,A,,,Rattus norvegicus,10116.0,
13163,1,,BAO_0000218,Intermediate,1977.0,15549,In vitro protein binding in human serum at 5 ug/ml,A,,,Homo sapiens,9606.0,
13164,0,,BAO_0000019,Autocuration,,10929,Serum protein binding ability was measured,A,,,,,
13165,0,,BAO_0000019,Autocuration,,15444,The ability binding to plasma (Binding classified based on injection of compound at 80 concentration.),A,,,,,
13166,0,,BAO_0000218,Autocuration,,12860,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,
13167,1,,BAO_0000218,Intermediate,,12170,% bioavailability in rat after oral dose (10 mg/kg) 0 - 6 h.,A,In vivo,,Rattus norvegicus,10116.0,
13168,0,,BAO_0000218,Autocuration,,15173,Absolute oral bioavailability at an iv dose of 14 mg/kg,A,In vivo,,,,
13169,0,,BAO_0000218,Autocuration,,15173,Absolute oral bioavailability at an iv dose of 15.2 mg/kg,A,In vivo,,,,
13170,0,,BAO_0000218,Autocuration,,15173,Oral bioavailability (dose 15 mg/kg i.v.),A,In vivo,,Eutheria,9347.0,
13171,0,,BAO_0000218,Autocuration,,15173,Absolute oral bioavailability at an peroral dose of 15 mg/kg orally.,A,In vivo,,,,
13172,0,,BAO_0000218,Autocuration,,15173,Absolute oral bioavailability at an peroral dose of 30 mg/kg orally,A,In vivo,,,,
13173,0,,BAO_0000218,Autocuration,,15173,Absolute oral bioavailability at an peroral dose of 30.2 mg/kg orally.,A,In vivo,,,,
13174,0,,BAO_0000218,Autocuration,,15173,Absolute oral bioavailability at an peroral dose of 30.3 mg/kg orally.,A,In vivo,,,,
13175,1,,BAO_0000218,Intermediate,,11767,Apparent bioavailability in dogs at 15 mg/kg in an iv vs po dosing regimen,A,In vivo,,Canis lupus familiaris,9615.0,
13176,0,,BAO_0000218,Autocuration,,11219,Bioavailability in ferret,A,In vivo,,Mustela putorius furo,9669.0,
13177,1,,BAO_0000218,Intermediate,,12186,Bioavailability after intraduodenal administration at a dose 10 mg/kg in cynomolgus monkeys using renin inhibition assay,A,In vivo,,Macaca fascicularis,9541.0,
13178,1,,BAO_0000218,Intermediate,,11510,Mean Chlorine excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 33.59 umol/kg,A,,,Rattus norvegicus,10116.0,
13179,1,,BAO_0000218,Intermediate,,11510,Mean Chlorine excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 37.13 umol/kg,A,,,Rattus norvegicus,10116.0,
13180,1,,BAO_0000218,Intermediate,,11510,Mean Chlorine excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 39.48 umol/kg,A,,,Rattus norvegicus,10116.0,
13181,1,,BAO_0000218,Intermediate,,11510,Mean Chlorine excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 483.72 umol/kg,A,,,Rattus norvegicus,10116.0,
13182,1,,BAO_0000218,Intermediate,,11510,Mean Chlorine excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg,A,,,Rattus norvegicus,10116.0,
13183,1,,BAO_0000218,Intermediate,,11510,Mean Chlorine excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg; Not determined,A,,,Rattus norvegicus,10116.0,
13184,1,,BAO_0000218,Intermediate,,11510,Mean Chlorine excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 631.76 umol/kg,A,,,Rattus norvegicus,10116.0,
13185,1,,BAO_0000218,Intermediate,,11510,Mean Chlorine excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 7.56 umol/kg,A,,,Rattus norvegicus,10116.0,
13186,1,,BAO_0000218,Intermediate,,11510,Mean Chlorine excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 8.4 umol/kg,A,,,Rattus norvegicus,10116.0,
13187,1,,BAO_0000218,Intermediate,,11510,Mean Chlorine excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.28 umol/kg,A,,,Rattus norvegicus,10116.0,
13188,1,,BAO_0000218,Intermediate,,11510,Mean Chlorine excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.87 umol/kg,A,,,Rattus norvegicus,10116.0,
13189,1,,BAO_0000218,Intermediate,,11510,Mean Chlorine excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 60.46 umol/kg,A,,,Rattus norvegicus,10116.0,
13190,1,,BAO_0000218,Intermediate,,11510,Mean Chlorine excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 67.18 umol/kg,A,,,Rattus norvegicus,10116.0,
13191,1,,BAO_0000218,Intermediate,,11510,Mean Chlorine excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 74.26 umol/kg,A,,,Rattus norvegicus,10116.0,
13192,1,,BAO_0000218,Intermediate,,11510,Mean Chlorine excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 78.97 umol/kg,A,,,Rattus norvegicus,10116.0,
13193,1,,BAO_0000218,Intermediate,,11510,Mean Chlorine excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 120.93 umol/kg,A,,,Rattus norvegicus,10116.0,
13194,1,,BAO_0000218,Intermediate,,11510,Mean Chlorine excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 134.35 umol/kg,A,,,Rattus norvegicus,10116.0,
13195,1,,BAO_0000218,Intermediate,,11510,Mean Chlorine excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 148.52 umol/kg,A,,,Rattus norvegicus,10116.0,
13196,1,,BAO_0000218,Intermediate,,11510,Mean Chlorine excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 157.94 umol/kg,A,,,Rattus norvegicus,10116.0,
13197,1,,BAO_0000218,Intermediate,,11510,Mean Chlorine excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 15.12 umol/kg,A,,,Rattus norvegicus,10116.0,
13198,1,,BAO_0000218,Intermediate,,11510,Mean Chlorine excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 16.79 umol/kg,A,,,Rattus norvegicus,10116.0,
13199,1,,BAO_0000218,Intermediate,,11510,Mean Chlorine excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 18.56 umol/kg,A,,,Rattus norvegicus,10116.0,
13200,1,,BAO_0000218,Intermediate,,11510,Mean Chlorine excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 19.74 umol/kg,A,,,Rattus norvegicus,10116.0,
13201,1,,BAO_0000218,Intermediate,,11510,Mean Chlorine excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 241.86 umol/kg,A,,,Rattus norvegicus,10116.0,
13202,1,,BAO_0000218,Intermediate,,11510,Mean Chlorine excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 268.71 umol/kg,A,,,Rattus norvegicus,10116.0,
13203,1,,BAO_0000218,Intermediate,,11510,Mean Chlorine excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 297.03 umol/kg,A,,,Rattus norvegicus,10116.0,
13204,1,,BAO_0000218,Intermediate,,11510,Mean Chlorine excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 315.88 umol/kg,A,,,Rattus norvegicus,10116.0,
13205,0,,BAO_0000019,Autocuration,,7199,Total body clearance was measured at given dose,A,,,,,
13206,0,,BAO_0000218,Autocuration,,7199,Total body clearance was measured at given dose.,A,,,,,
13207,1,,BAO_0000218,Intermediate,,7095,Metabolic clearance from the body in rat,A,,,Rattus norvegicus,10116.0,
13208,0,,BAO_0000218,Autocuration,,7095,Renal clearance from the body,A,In vivo,,,,
13209,1,,BAO_0000218,Intermediate,,7095,Renal clearance from the body in rat,A,In vivo,,Rattus norvegicus,10116.0,
13210,1,,BAO_0000218,Intermediate,,12528,Tested for pharmacokinetic parameter to calculate the total body clearance at a dosage of 12 mg/kg in rat,A,In vivo,,Rattus norvegicus,10116.0,
13211,1,,BAO_0000218,Intermediate,,12528,Tested for pharmacokinetic parameter to calculate the total body clearance at a dosage of 2.5 mg/kg in dog,A,In vivo,,Canis lupus familiaris,9615.0,
13212,1,,BAO_0000218,Intermediate,,7095,Total clearance from the body in rat,A,,,Rattus norvegicus,10116.0,
13213,1,,BAO_0000218,Intermediate,1969.0,14223,Clearance into cortex from rat plasma or PBS,A,In vivo,,Rattus norvegicus,10116.0,
13214,0,,BAO_0000218,Autocuration,,13569,Clearance at an iv dose of 15 mg/Kg and po dose of 120 mg/Kg,A,In vivo,,,,
13215,0,,BAO_0000218,Autocuration,,13569,Clearance at an iv dose of 15 mg/Kg and po dose of 240 mg/Kg,A,In vivo,,,,
13216,0,,BAO_0000218,Autocuration,,13569,Clearance at an iv dose of 15 mg/Kg and po dose of 29.1 mg/Kg,A,In vivo,,,,
13217,0,,BAO_0000218,Autocuration,,13569,Clearance at an iv dose of 15 mg/Kg and po dose of 30 mg/Kg,A,In vivo,,,,
13218,0,,BAO_0000218,Autocuration,,13569,Clearance at an iv dose of 15 mg/Kg and po dose of 60 mg/Kg,A,In vivo,,,,
13219,0,,BAO_0000218,Autocuration,,13979,Clearance was determined,A,In vivo,,,,
13220,1,,BAO_0000218,Intermediate,,14315,Clearance was measured in mouse after administration of compound 20 mg/kg intravenously,A,In vivo,,Mus musculus,10090.0,
13221,1,,BAO_0000218,Intermediate,,14315,Clearance was measured in rabbit after administration of compound 20 mg/kg intravenously,A,In vivo,,Oryctolagus cuniculus,9986.0,
13222,1,,BAO_0000218,Intermediate,,14315,Clearance was measured in rat after administration of compound 20 mg/kg intravenously,A,In vivo,,Rattus norvegicus,10116.0,
13223,1,,BAO_0000218,Intermediate,,12174,Clearance in rat after iv dose (100 ug/kg),A,In vivo,,Rattus norvegicus,10116.0,
13224,0,,BAO_0000218,Autocuration,,12797,Clearance in guinea pig,A,In vivo,,Cavia porcellus,10141.0,
13225,1,,BAO_0000218,Intermediate,,12797,Compound was evaluated for clearance in rat,A,In vivo,,Rattus norvegicus,10116.0,
13226,1,,BAO_0000218,Intermediate,,12797,Compound was evaluated for the clearance in dog,A,In vivo,,Canis lupus familiaris,9615.0,
13227,1,,BAO_0000218,Intermediate,,12797,Compound was evaluated for the clearance in rat,A,In vivo,,Rattus norvegicus,10116.0,
13228,1,,BAO_0000218,Intermediate,,11500,Compound was tested in vivo for clearance after iv administration in the rat,A,In vivo,,Rattus norvegicus,10116.0,
13229,0,,BAO_0000218,Autocuration,,15173,IV clearance determined at an iv dose of 14 mg/kg,A,In vivo,,,,
13230,0,,BAO_0000218,Autocuration,,15173,IV clearance determined at an iv dose of 15.2 mg/kg,A,In vivo,,,,
13231,0,,BAO_0000218,Autocuration,,15173,IV clearance determined at an iv dose of 15 mg/kg,A,In vivo,,,,
13232,0,,BAO_0000218,Autocuration,,15173,IV clearance determined at an peroral dose of 30 mg/kg.,A,In vivo,,,,
13233,0,,BAO_0000218,Autocuration,,15173,IV clearance determined at an peroral dose of 30.2 mg/kg.,A,In vivo,,,,
13234,0,,BAO_0000218,Autocuration,,15173,IV clearance determined at an peroral dose of 30.3 mg/kg.,A,In vivo,,,,
13235,1,,BAO_0000218,Intermediate,2113.0,14198,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in kidney of male wistar rats,A,In vivo,,Rattus norvegicus,10116.0,
13236,1,,BAO_0000218,Intermediate,2107.0,14198,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in liver of male wistar rats,A,In vivo,,Rattus norvegicus,10116.0,
13237,1,,BAO_0000218,Intermediate,2048.0,14198,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in lung of male wistar rats,A,In vivo,,Rattus norvegicus,10116.0,
13238,1,,BAO_0000218,Intermediate,2385.0,14198,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in muscle of male wistar rats,A,In vivo,,Rattus norvegicus,10116.0,
13239,1,,BAO_0000218,Intermediate,1969.0,14198,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in plasma of male wistar rats,A,In vivo,,Rattus norvegicus,10116.0,
13240,1,,BAO_0000218,Intermediate,,14198,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in red blood cells of male wistar rats,A,In vivo,,Rattus norvegicus,10116.0,
13241,1,,BAO_0000218,Intermediate,2106.0,14198,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in spleen of male wistar rats,A,In vivo,,Rattus norvegicus,10116.0,
13242,1,,BAO_0000218,Intermediate,3126.0,14198,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in trachea of male wistar rats,A,In vivo,,Rattus norvegicus,10116.0,
13243,1,,BAO_0000218,Intermediate,10000001.0,14198,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in bone of male wistar rats,A,In vivo,,Rattus norvegicus,10116.0,
13244,1,,BAO_0000218,Intermediate,2037.0,14198,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in cerebellum of male wistar rats,A,In vivo,,Rattus norvegicus,10116.0,
13245,1,,BAO_0000218,Intermediate,,14198,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in cortex of male wistar rats,A,In vivo,,Rattus norvegicus,10116.0,
13246,1,,BAO_0000218,Intermediate,,14198,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in fat of male wistar rats,A,In vivo,,Rattus norvegicus,10116.0,
13247,1,,BAO_0000218,Intermediate,948.0,14198,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in heart of male wistar rats,A,In vivo,,Rattus norvegicus,10116.0,
13248,1,,BAO_0000218,Intermediate,10000001.0,14198,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in intestine bone of male wistar rats,A,In vivo,,Rattus norvegicus,10116.0,
13249,1,,BAO_0000218,Intermediate,2113.0,14198,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in kidney of male wistar rats,A,In vivo,,Rattus norvegicus,10116.0,
13250,1,,BAO_0000218,Intermediate,2107.0,14198,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in liver of male wistar rats,A,In vivo,,Rattus norvegicus,10116.0,
13251,1,,BAO_0000218,Intermediate,2048.0,14198,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in lung of male wistar rats,A,In vivo,,Rattus norvegicus,10116.0,
13252,1,,BAO_0000218,Intermediate,2385.0,14198,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in muscle of male wistar rats,A,In vivo,,Rattus norvegicus,10116.0,
13253,1,,BAO_0000218,Intermediate,1969.0,14198,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in plasma of male wistar rats,A,In vivo,,Rattus norvegicus,10116.0,
13254,1,,BAO_0000218,Intermediate,,14198,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in red blood cells of male wistar rats,A,In vivo,,Rattus norvegicus,10116.0,
13255,1,,BAO_0000218,Intermediate,2106.0,14198,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in spleen of male wistar rats,A,In vivo,,Rattus norvegicus,10116.0,
13256,1,,BAO_0000218,Intermediate,3126.0,14198,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in trachea of male wistar rats,A,In vivo,,Rattus norvegicus,10116.0,
13257,1,,BAO_0000218,Intermediate,10000001.0,14198,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in bone of male wistar rats,A,In vivo,,Rattus norvegicus,10116.0,
13258,1,,BAO_0000218,Intermediate,2037.0,14198,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in cerebellum of male wistar rats,A,In vivo,,Rattus norvegicus,10116.0,
13259,1,,BAO_0000218,Intermediate,,14198,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in cortex of male wistar rats,A,In vivo,,Rattus norvegicus,10116.0,
13260,1,,BAO_0000218,Intermediate,,14198,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in fat of male wistar rats,A,In vivo,,Rattus norvegicus,10116.0,
13261,1,,BAO_0000218,Intermediate,948.0,14198,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in heart of male wistar rats,A,In vivo,,Rattus norvegicus,10116.0,
13262,1,,BAO_0000218,Intermediate,160.0,14198,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in intestine of male wistar rats,A,In vivo,,Rattus norvegicus,10116.0,
13263,1,,BAO_0000218,Intermediate,2113.0,14198,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in kidney of male wistar rats,A,In vivo,,Rattus norvegicus,10116.0,
13264,1,,BAO_0000218,Intermediate,2107.0,14198,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in liver of male wistar rats,A,In vivo,,Rattus norvegicus,10116.0,
13265,1,,BAO_0000218,Intermediate,2048.0,14198,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in lung of male wistar rats,A,In vivo,,Rattus norvegicus,10116.0,
13266,1,,BAO_0000218,Intermediate,2385.0,14198,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in muscle of male wistar rats,A,In vivo,,Rattus norvegicus,10116.0,
13267,1,,BAO_0000218,Intermediate,1969.0,14198,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in plasma of male wistar rats,A,In vivo,,Rattus norvegicus,10116.0,
13268,1,,BAO_0000218,Intermediate,,14198,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in red blood cells of male wistar rats,A,In vivo,,Rattus norvegicus,10116.0,
13269,1,,BAO_0000218,Intermediate,2106.0,14198,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in spleen of male wistar rats,A,In vivo,,Rattus norvegicus,10116.0,
13270,1,,BAO_0000218,Intermediate,3126.0,14198,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in trachea of male wistar rats,A,In vivo,,Rattus norvegicus,10116.0,
13271,1,,BAO_0000218,Intermediate,10000001.0,14198,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in bone of male wistar rats,A,In vivo,,Rattus norvegicus,10116.0,
13272,1,,BAO_0000218,Intermediate,2037.0,14198,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in cerebellum of male wistar rats,A,In vivo,,Rattus norvegicus,10116.0,
13273,1,,BAO_0000218,Intermediate,,14198,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in cortex of male wistar rats,A,In vivo,,Rattus norvegicus,10116.0,
13274,1,,BAO_0000218,Intermediate,,14198,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in fat of male wistar rats,A,In vivo,,Rattus norvegicus,10116.0,
13275,1,,BAO_0000218,Intermediate,948.0,14198,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in heart of male wistar rats,A,In vivo,,Rattus norvegicus,10116.0,
13276,1,,BAO_0000218,Intermediate,160.0,14198,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in intestine of male wistar rats,A,In vivo,,Rattus norvegicus,10116.0,
13277,1,,BAO_0000218,Intermediate,2113.0,14198,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in kidney of male wistar rats,A,In vivo,,Rattus norvegicus,10116.0,
13278,1,,BAO_0000218,Intermediate,2048.0,14198,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in lung of male wistar rats,A,In vivo,,Rattus norvegicus,10116.0,
13279,1,,BAO_0000218,Intermediate,2385.0,14198,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in muscle of male wistar rats,A,In vivo,,Rattus norvegicus,10116.0,
13280,1,,BAO_0000218,Intermediate,1969.0,14198,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in plasma of male wistar rats,A,In vivo,,Rattus norvegicus,10116.0,
13281,1,,BAO_0000218,Intermediate,,14198,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in red blood cells of male wistar rats,A,In vivo,,Rattus norvegicus,10116.0,
13282,1,,BAO_0000218,Intermediate,2106.0,14198,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in spleen of male wistar rats,A,In vivo,,Rattus norvegicus,10116.0,
13283,1,,BAO_0000218,Intermediate,3126.0,14198,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in trachea of male wistar rats,A,In vivo,,Rattus norvegicus,10116.0,
13284,1,,BAO_0000218,Intermediate,,15599,Normal diffusion coefficient in water for Escherichia coli,A,,,Escherichia coli,562.0,
13285,0,,BAO_0000019,Autocuration,,8204,Average max percent decrease in RVR (renal vascular resistance) was determined,A,,,,,
13286,0,,BAO_0000019,Autocuration,,8204,Average max percent decrease in RVR (renal vascular resistance) was determined.,A,,,,,
13287,0,,BAO_0000019,Autocuration,,6154,In vitro stability to pepsin promoting hydrolysis after 1 hr incubation time,A,,,,,
13288,0,,BAO_0000019,Autocuration,,6154,In vitro stability to pepsin promoting hydrolysis after 2 hr incubation time,A,,,,,
13289,0,,BAO_0000019,Autocuration,,6154,In vitro stability to pepsin promoting hydrolysis after 64h incubation time,A,,,,,
13290,0,,BAO_0000019,Autocuration,,6154,In vitro stability to pepsin promoting hydrolysis after 84 hr incubation time,A,,,,,
13291,0,,BAO_0000019,Autocuration,,7114,Compound was tested for diuretic activity in sodium content of the 3-h sample was measured by flame photometry,A,,,,,
13292,1,,BAO_0000218,Intermediate,,7114,Compound was tested for diuretic activity in sodium content of the 3-h sample was measured by flame photometry in rat,A,,,Rattus norvegicus,10116.0,
13293,1,,BAO_0000218,Intermediate,1088.0,8133,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded dogs at 0.03mg/kg, po",A,,,Canis lupus familiaris,9615.0,
13294,1,,BAO_0000218,Intermediate,1088.0,8133,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 1.0 mg/kg, po",A,,,Canis lupus familiaris,9615.0,
13295,1,,BAO_0000218,Intermediate,1088.0,8133,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 10.0 mg/kg, po",A,,,Canis lupus familiaris,9615.0,
13296,1,,BAO_0000218,Intermediate,1088.0,8133,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded dogs at 1 mg/kg, po",A,,,Canis lupus familiaris,9615.0,
13297,1,,BAO_0000218,Intermediate,1088.0,8133,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 3.0 mg/kg, po",A,,,Canis lupus familiaris,9615.0,
13298,1,,BAO_0000218,Intermediate,1088.0,8133,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 30 mg/kg, po",A,,,Canis lupus familiaris,9615.0,
13299,1,,BAO_0000218,Intermediate,1088.0,8133,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded dogs at 0.1 mg/kg, po",A,,,Canis lupus familiaris,9615.0,
13300,1,,BAO_0000218,Intermediate,1088.0,8133,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 0.3mg/kg, po",A,,,Canis lupus familiaris,9615.0,
13301,1,,BAO_0000218,Intermediate,1088.0,8133,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded dogs at 10mg/kg, po",A,,,Canis lupus familiaris,9615.0,
13302,1,,BAO_0000218,Intermediate,1088.0,8133,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 3 mg/kg, po",A,,,Canis lupus familiaris,9615.0,
13303,0,,BAO_0000218,Autocuration,1088.0,8133,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded monkey at 100 mg/kg, po",A,,,Simiiformes,314293.0,
13304,0,,BAO_0000218,Autocuration,1088.0,8133,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded monkey at 10mg/kg, po",A,,,Simiiformes,314293.0,
13305,0,,BAO_0000218,Autocuration,1088.0,8133,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded monkey at 1 mg/kg, po",A,,,Simiiformes,314293.0,
13306,0,,BAO_0000218,Autocuration,1088.0,8133,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded monkey at 30 mg/kg, po",A,,,Simiiformes,314293.0,
13307,0,,BAO_0000218,Autocuration,1088.0,8133,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded monkey at 3 mg/kg, po",A,,,Simiiformes,314293.0,
13308,1,,BAO_0000218,Intermediate,1088.0,8133,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 0.1 mg/kg, po",A,,,Rattus norvegicus,10116.0,
13309,1,,BAO_0000218,Intermediate,1088.0,8133,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 0.3mg/kg, po",A,,,Rattus norvegicus,10116.0,
13310,1,,BAO_0000218,Intermediate,1088.0,8133,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 1.0mg/kg, po",A,,,Rattus norvegicus,10116.0,
13311,1,,BAO_0000218,Intermediate,1088.0,8133,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 10.0mg/kg, po",A,,,Rattus norvegicus,10116.0,
13312,1,,BAO_0000218,Intermediate,1088.0,8133,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 100.0mg/kg, po",A,,,Rattus norvegicus,10116.0,
13313,1,,BAO_0000218,Intermediate,1088.0,8133,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 2.1 mg/kg, po",A,,,Rattus norvegicus,10116.0,
13314,1,,BAO_0000218,Intermediate,1088.0,8133,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 20.8mg/kg, po",A,,,Rattus norvegicus,10116.0,
13315,1,,BAO_0000218,Intermediate,1088.0,8133,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 207.6mg/kg, po",A,,,Rattus norvegicus,10116.0,
13316,1,,BAO_0000218,Intermediate,1088.0,8133,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 3.0mg/kg, po",A,,,Rattus norvegicus,10116.0,
13317,1,,BAO_0000218,Intermediate,1088.0,8133,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded rats at 30.0 mg/kg, po",A,,,Rattus norvegicus,10116.0,
13318,1,,BAO_0000218,Intermediate,1088.0,8133,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 6.9mg/kg, po",A,,,Rattus norvegicus,10116.0,
13319,1,,BAO_0000218,Intermediate,1088.0,8133,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 69.2mg/kg, po",A,,,Rattus norvegicus,10116.0,
13320,1,,BAO_0000218,Intermediate,1088.0,8133,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 691.9mg/kg, po",A,,,Rattus norvegicus,10116.0,
13321,1,,BAO_0000218,Intermediate,1088.0,8133,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 0.03mg/kg, po",A,,,Canis lupus familiaris,9615.0,
13322,1,,BAO_0000218,Intermediate,1088.0,8133,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 0.1 mg/kg, po",A,,,Canis lupus familiaris,9615.0,
13323,1,,BAO_0000218,Intermediate,1088.0,8133,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 0.3mg/kg, po",A,,,Canis lupus familiaris,9615.0,
13324,1,,BAO_0000218,Intermediate,1088.0,8133,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded dogs at 1.0 mg/kg, po",A,,,Canis lupus familiaris,9615.0,
13325,1,,BAO_0000218,Intermediate,1088.0,8133,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 10.0mg/kg, po",A,,,Canis lupus familiaris,9615.0,
13326,1,,BAO_0000218,Intermediate,1088.0,8133,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 10mg/kg, po",A,,,Canis lupus familiaris,9615.0,
13327,1,,BAO_0000218,Intermediate,1088.0,8133,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded dogs at 1 mg/kg, po",A,,,Canis lupus familiaris,9615.0,
13328,1,,BAO_0000218,Intermediate,1088.0,8133,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 3.0mg/kg, po",A,,,Canis lupus familiaris,9615.0,
13329,1,,BAO_0000218,Intermediate,1088.0,8133,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 30mg/kg, po",A,,,Canis lupus familiaris,9615.0,
13330,1,,BAO_0000218,Intermediate,1088.0,8133,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 3mg/kg, po",A,,,Canis lupus familiaris,9615.0,
13331,0,,BAO_0000218,Autocuration,1088.0,8133,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded monkey at 100 mg/kg, po",A,,,Simiiformes,314293.0,
13332,0,,BAO_0000218,Autocuration,,12170,% bioavailability in rat after oral dose (10 mg/kg) 0 - 6 h.,A,In vivo,,Rattus norvegicus,10116.0,
13333,0,,BAO_0000218,Autocuration,,12170,% bioavailability in rat after oral dose (10 mg/kg) 0 - 6 h.,A,In vivo,,Rattus norvegicus,10116.0,
13334,0,,BAO_0000218,Autocuration,,4985,Bioavailability (dose 20 mg/kg),A,In vivo,,Eutheria,9347.0,
13335,0,,BAO_0000218,Autocuration,,15145,Bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,
13336,0,,BAO_0000218,Autocuration,,14080,Bioavailability in rat (Sprague-Dawley) (male),A,In vivo,,Rattus norvegicus,10116.0,
13337,0,,BAO_0000218,Autocuration,,11219,Bioavailability in monkey (dose 10 mg/kg i.d.),A,In vivo,,Primates,9443.0,
13338,0,,BAO_0000218,Autocuration,,15145,Bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,
13339,0,,BAO_0000218,Autocuration,,15145,Bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,
13340,0,,BAO_0000218,Autocuration,,1202,Bioavailability in dog (dose 3.0 mg/kg p.o.),A,In vivo,,Canis lupus familiaris,9615.0,
13341,0,,BAO_0000218,Autocuration,,1202,Bioavailability in dog (dose of 1.0 mg/kg i.v.) 0.5 hr,A,In vivo,,Canis lupus familiaris,9615.0,
13342,1,,BAO_0000218,Intermediate,,1202,Bioavailability was calculated after peroral dose of 10 mg/Kg in chimp,A,In vivo,,Pan troglodytes,9598.0,
13343,0,,BAO_0000218,Autocuration,,4026,Bioavailability,A,In vivo,,Eutheria,9347.0,
13344,0,,BAO_0000218,Autocuration,,1492,Bioavailability in squirrel monkey,A,In vivo,,Saimiri,9520.0,
13345,1,,BAO_0000218,Intermediate,,12793,Bioavailability was evaluated in dog,A,In vivo,,Canis lupus familiaris,9615.0,
13346,1,,BAO_0000218,Intermediate,,12793,Bioavailability was evaluated in hamster,A,In vivo,,Cricetinae,10026.0,
13347,0,,BAO_0000218,Autocuration,,12793,Bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,
13348,1,,BAO_0000218,Intermediate,1969.0,14793,Bioavailability was evaluated in rat plasma when administered intraperitoneally at a dose of 10 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,
13349,1,,BAO_0000218,Intermediate,1969.0,14793,Bioavailability was evaluated in rat plasma when administered intravenously at a dose of 10 mg/kg; <Tr>,A,In vivo,,Rattus norvegicus,10116.0,
13350,0,,BAO_0000218,Autocuration,,14793,Bioavailability in rat (dose 10 mg/kg p.o.),A,In vivo,,Rattus norvegicus,10116.0,
13351,1,,BAO_0000218,Intermediate,,14731,Bioavailability was measured in cynomolgus monkeys.,A,In vivo,,Macaca fascicularis,9541.0,
13352,1,,BAO_0000218,Intermediate,,14731,Bioavailability was measured in nude mice.,A,In vivo,,Mus musculus,10090.0,
13353,0,,BAO_0000218,Autocuration,,12187,Bioavailability in ferret (dose 10 mg/kg i.d.),A,In vivo,,Mustela putorius furo,9669.0,
13354,0,,BAO_0000218,Autocuration,,12187,Bioavailability was determined after intraduodenal dose of 10 mg/kg in monkey (compared to 0.3 mg/kg intravenous dose),A,In vivo,,Simiiformes,314293.0,
13355,0,,BAO_0000218,Autocuration,,12187,"Bioavailability was determined after intraduodenal dose of 10 mg/kg in monkey (compared to 0.3 mg/kg intravenous dose), determined by renin inhibition assay",A,In vivo,,Simiiformes,314293.0,
13356,0,,BAO_0000218,Autocuration,,12187,Bioavailability was determined after intraduodenal dose of 10 mg/kg in monkey (compared to 1 mg/kg intravenous dose),A,In vivo,,Simiiformes,314293.0,
13357,0,,BAO_0000218,Autocuration,,12187,Bioavailability in rat (dose 10 mg/kg i.d.),A,In vivo,,Rattus norvegicus,10116.0,
13358,1,,BAO_0000218,Intermediate,,12187,"Bioavailability was determined after intraduodenal dose of 10 mg/kg in rat, determined by renin inhibition assay",A,In vivo,,Rattus norvegicus,10116.0,
13359,0,,BAO_0000218,Autocuration,,17431,Bioavailability was determined; extremely poor,A,In vivo,,,,
13360,1,,BAO_0000218,Intermediate,,13318,% bioavailability in mice after oral administration of prodrug,A,In vivo,,Mus musculus,10090.0,
13361,1,,BAO_0000218,Intermediate,,9025,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose 10/30 range (low/high); -21/-5,A,In vivo,,Canis lupus familiaris,9615.0,
13362,1,,BAO_0000218,Intermediate,,9025,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 1/3 range (low/high); -2/6,A,In vivo,,Canis lupus familiaris,9615.0,
13363,1,,BAO_0000218,Intermediate,,9025,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 1/3 range (low/high); -4/-14,A,In vivo,,Canis lupus familiaris,9615.0,
13364,1,,BAO_0000218,Intermediate,,9025,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 1/3 range (low/high); -5/-12,A,In vivo,,Canis lupus familiaris,9615.0,
13365,1,,BAO_0000218,Intermediate,,9025,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 1/3/10 range (low/high); -1/-7/-11,A,In vivo,,Canis lupus familiaris,9615.0,
13366,1,,BAO_0000218,Intermediate,,9025,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high),A,In vivo,,Canis lupus familiaris,9615.0,
13367,1,,BAO_0000218,Intermediate,,9025,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -1/-9,A,In vivo,,Canis lupus familiaris,9615.0,
13368,1,,BAO_0000218,Intermediate,,9025,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -11/-28,A,In vivo,,Canis lupus familiaris,9615.0,
13369,1,,BAO_0000218,Intermediate,,9025,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -13/-29,A,In vivo,,Canis lupus familiaris,9615.0,
13370,1,,BAO_0000218,Intermediate,,9025,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -13/30,A,In vivo,,Canis lupus familiaris,9615.0,
13371,1,,BAO_0000218,Intermediate,,9025,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -16/-18,A,In vivo,,Canis lupus familiaris,9615.0,
13372,1,,BAO_0000218,Intermediate,,9025,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -16/-35,A,In vivo,,Canis lupus familiaris,9615.0,
13373,1,,BAO_0000218,Intermediate,,9025,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -19/-50,A,In vivo,,Canis lupus familiaris,9615.0,
13374,1,,BAO_0000218,Intermediate,,9025,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -21/-29,A,In vivo,,Canis lupus familiaris,9615.0,
13375,1,,BAO_0000218,Intermediate,,9025,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -24/-56,A,In vivo,,Canis lupus familiaris,9615.0,
13376,1,,BAO_0000218,Intermediate,,9025,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -25/-33,A,In vivo,,Canis lupus familiaris,9615.0,
13377,1,,BAO_0000218,Intermediate,,9025,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -3/-13,A,In vivo,,Canis lupus familiaris,9615.0,
13378,1,,BAO_0000218,Intermediate,,9025,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -5/-47,A,In vivo,,Canis lupus familiaris,9615.0,
13379,0,,BAO_0000218,Autocuration,,15173,IV clearance determined at an peroral dose of 15 mg/kg.,A,In vivo,,,,
13380,1,,BAO_0000218,Expert,,7732,Mouse oral clearance was measured against Hymenolepiasis nana.,F,In vivo,,Hymenolepis nana,102285.0,
13381,1,,BAO_0000218,Expert,,7732,Mouse oral clearance was measured against Nematospiroides dubius,F,In vivo,,Heligmosomoides polygyrus,6339.0,
13382,0,,BAO_0000218,Autocuration,,7732,Mouse oral clearance was measured against N. dubius; NT is Not Tested,F,In vivo,,,,
13383,1,,BAO_0000218,Intermediate,,7732,Mouse oral clearance was measured against N. nana; NT is Not Tested,A,In vivo,,Mus musculus,10090.0,
13384,0,,BAO_0000218,Autocuration,,7732,Mouse oral clearance was measured against N. nana; NT is Not Tested,B,In vivo,,,,
13385,0,,BAO_0000218,Autocuration,,8328,Percentage of clearance of psoriatic lesions by 8-methoxypsoralen (8-MOP) for comparison at dose of 10 J/cm e2 ultraviolet-A radiation,A,In vivo,,,,
13386,0,,BAO_0000218,Autocuration,,8328,Percentage of clearance of psoriatic lesions by 8-methoxypsoralen (8-MOP) for comparison at dose of 6 J/cm e2 ultraviolet-A radiation,A,In vivo,,,,
13387,0,,BAO_0000218,Autocuration,,8328,Percentage of clearance of psoriatic lesions by 8-methoxypsoralen (8-MOP) for comparison at dose of 8 J/cm e2 ultraviolet-A radiation,A,In vivo,,,,
13388,0,,BAO_0000218,Autocuration,,8328,Percentage of clearance of psoriatic lesions by 8-methoxypsoralen (8-MOP) for comparison at dose of 9 J/cm e2 ultraviolet-A radiation,A,In vivo,,,,
13389,0,,BAO_0000218,Autocuration,,8328,Percentage of clearance of psoriatic lesions by the compound at dose of 10 J/cm e2 ultraviolet-A radiation,A,In vivo,,,,
13390,0,,BAO_0000218,Autocuration,,8328,Percentage of clearance of psoriatic lesions by the compound at dose of 4 J/cm e2 ultraviolet-A radiation,A,In vivo,,,,
13391,0,,BAO_0000218,Autocuration,,8328,Percentage of clearance of psoriatic lesions by the compound at dose of 6 J/cm e2 ultraviolet-A radiation,A,In vivo,,,,
13392,0,,BAO_0000218,Autocuration,,8328,Percentage of clearance of psoriatic lesions by the compound at dose of 8 J/cm e2 ultraviolet-A radiation,A,In vivo,,,,
13393,0,,BAO_0000218,Autocuration,,8328,Percentage of clearance of psoriatic lesions by the compound at dose of 9 J/cm e2 ultraviolet-A radiation,A,In vivo,,,,
13394,1,,BAO_0000218,Intermediate,,13376,Pharmacokinetic parameter clearance was determined in fed Beagle dogs after iv administration of 1.5 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,
13395,1,,BAO_0000218,Intermediate,,13477,Plasma clearance after intravenous administration dosing (30 mg/kg) in Rhesus monkey,A,In vivo,,Macaca mulatta,9544.0,
13396,1,,BAO_0000218,Intermediate,,13477,Plasma clearance after intravenous administration dosing (30 mg/kg) in rat,A,In vivo,,Rattus norvegicus,10116.0,
13397,1,,BAO_0000218,Intermediate,,13477,Plasma clearance after intravenous administration iv dosing of 3 mg/kg in rat,A,In vivo,,Rattus norvegicus,10116.0,
13398,1,,BAO_0000218,Intermediate,,13313,Plasma clearance was determined for the compound in rats,A,In vivo,,Rattus norvegicus,10116.0,
13399,1,,BAO_0000218,Intermediate,,12504,Tested for total body clearance (CL) after intravenous bolus administration of 100 mg/kg in rat 1,A,In vivo,,Rattus norvegicus,10116.0,
13400,1,,BAO_0000218,Intermediate,,12504,Tested for total body clearance (CL) after intravenous bolus administration of 100 mg/kg in rat 2,A,In vivo,,Rattus norvegicus,10116.0,
13401,1,,BAO_0000218,Intermediate,,12504,Tested for total body clearance (CL) after intravenous bolus administration of 100 mg/kg in rat 3,A,In vivo,,Rattus norvegicus,10116.0,
13402,1,,BAO_0000218,Intermediate,,12504,Tested for total body clearance (CL) after intravenous bolus administration of 100 mg/kg in rat 4,A,In vivo,,Rattus norvegicus,10116.0,
13403,1,,BAO_0000218,Intermediate,,13129,The compound was tested for systemic clearance pharmacokinetic parameter in the male Sprague-Dawley rat.,A,In vivo,,Rattus norvegicus,10116.0,
13404,1,,BAO_0000218,Intermediate,,7732,Titration of anthelmintic activity against Nematospiroides dubius in mice at 0.0125 concentration of diet.,A,In vivo,,Heligmosomoides polygyrus,6339.0,
13405,1,,BAO_0000218,Intermediate,,7732,Titration of anthelmintic activity against Nematospiroides dubius in mice at 0.025 concentration of diet.,A,In vivo,,Heligmosomoides polygyrus,6339.0,
13406,1,,BAO_0000218,Intermediate,,7732,Titration of anthelmintic activity against Nematospiroides dubius in mice at 0.05 concentration of diet.,A,In vivo,,Heligmosomoides polygyrus,6339.0,
13407,1,,BAO_0000218,Intermediate,,7732,Titration of anthelmintic activity against Nematospiroides dubius in mice at 0.1 concentration of diet.,A,In vivo,,Heligmosomoides polygyrus,6339.0,
13408,1,,BAO_0000218,Intermediate,,7732,Titration of anthelmintic activity against Nematospiroides dubius in mice at 0.2 concentration of diet.,A,In vivo,,Heligmosomoides polygyrus,6339.0,
13409,0,,BAO_0000218,Autocuration,1088.0,9278,Urinary clearance was determined in rat at 100 mg/kg os dosage;ND is defined as no-data.,A,In vivo,,Rattus norvegicus,10116.0,
13410,0,,BAO_0000218,Autocuration,,9278,Total clearance was determined in rat at 10 mg/kg intraperitoneal dosage,A,In vivo,,Rattus norvegicus,10116.0,
13411,0,,BAO_0000218,Autocuration,,9278,Total clearance was determined in rat at 25 mg/kg os dosage;ND is defined as no-data.,A,In vivo,,Rattus norvegicus,10116.0,
13412,0,,BAO_0000218,Autocuration,1088.0,9278,Urinary clearance was determined in rat at 10 mg/kg intraperitoneal dosage,A,In vivo,,Rattus norvegicus,10116.0,
13413,0,,BAO_0000218,Autocuration,1088.0,9278,Urinary clearance was determined in rat at 25 mg/kg os dosage,A,In vivo,,Rattus norvegicus,10116.0,
13414,1,,BAO_0000218,Intermediate,1088.0,9278,Urinary clearance was determined at 100 mg/kg oral dosage in human,A,In vivo,,Homo sapiens,9606.0,
13415,1,,BAO_0000218,Intermediate,1088.0,9278,Urinary clearance was determined at 20 mg/kg oral dosage in dog(beagle);ND is defined as no-data.,A,In vivo,,Canis lupus familiaris,9615.0,
13416,1,,BAO_0000218,Intermediate,1969.0,5932,Plasma concentration in dogs after 2 hr at 30mg/kg oral dose,A,In vivo,,Canis lupus familiaris,9615.0,
13417,1,,BAO_0000218,Intermediate,1969.0,5932,Plasma concentration in rats after 7 hr at 30mg/kg oral dose,A,In vivo,,Rattus norvegicus,10116.0,
13418,1,,BAO_0000218,Intermediate,,5182,Clearance was determined by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat,A,In vivo,,Rattus norvegicus,10116.0,
13419,1,,BAO_0000218,Intermediate,,10499,Clearance rate in dogs,A,In vivo,,Canis lupus familiaris,9615.0,
13420,0,,BAO_0000019,Autocuration,,6051,Compound was measured for intrinsic clearance,A,In vitro,,,,
13421,0,,BAO_0000100,Autocuration,,17508,Calculated partition coefficient (clogP),P,,,,,
13422,0,,BAO_0000100,Autocuration,,6228,Calculated partition coefficient (clogP),P,,,,,
13423,0,,BAO_0000100,Autocuration,,6231,Calculated partition coefficient (clogP),P,,,,,
13424,0,,BAO_0000100,Autocuration,,17740,Calculated partition coefficient (clogP),P,,,,,
13425,0,,BAO_0000100,Autocuration,,6495,Calculated partition coefficient (clogP),P,,,,,
13426,0,,BAO_0000100,Autocuration,,2171,Calculated partition coefficient (clogP),P,,,,,
13427,0,,BAO_0000019,Autocuration,,3255,Partition coefficient of the compound,A,,,,,
13428,0,,BAO_0000019,Autocuration,,6821,Permeability,A,,,,,
13429,0,,BAO_0000100,Autocuration,,2685,Calculated partition coefficient (clogP),P,,,,,
13430,0,,BAO_0000019,Autocuration,,17584,Partition coefficient (logD),A,,,,,
13431,0,,BAO_0000100,Autocuration,,13824,Calculated partition coefficient (clogP) (CLOGP3 V3.4),P,,,,,
13432,0,,BAO_0000100,Autocuration,,13824,Calculated partition coefficient (clogP) (CLOGP3 V3.4),P,,,,,
13433,0,,BAO_0000100,Autocuration,,16479,Calculated partition coefficient (clogP),P,,,,,
13434,0,,BAO_0000100,Autocuration,,11997,Calculated partition coefficient (clogP),P,,,,,
13435,0,,BAO_0000100,Autocuration,,2988,Calculated logarithm of partition coefficient (P) was determined,P,,,,,
13436,0,,BAO_0000100,Autocuration,,931,Calculated partition coefficient (clogP),P,,,,,
13437,0,,BAO_0000100,Autocuration,,4381,Calculated partition coefficient (clogP),P,,,,,
13438,0,,BAO_0000100,Autocuration,,4397,Calculated partition coefficient (clogP),P,,,,,
13439,0,,BAO_0000100,Autocuration,,5889,Calculated partition coefficient (clogP),P,,,,,
13440,0,,BAO_0000019,Autocuration,,6154,In vitro stability to pepsin promoting hydrolysis after 8 hr incubation time,A,,,,,
13441,0,,BAO_0000019,Autocuration,,6154,In vitro stability to trypsin promoting hydrolysis after 1 hr incubation time,A,,,,,
13442,0,,BAO_0000019,Autocuration,,6154,In vitro stability to trypsin promoting hydrolysis after 2 hr incubation time,A,,,,,
13443,0,,BAO_0000019,Autocuration,,6154,In vitro stability to trypsin promoting hydrolysis after 64h incubation time,A,,,,,
13444,0,,BAO_0000019,Autocuration,,6154,In vitro stability to trypsin promoting hydrolysis after 84 hr incubation time,A,,,,,
13445,0,,BAO_0000019,Autocuration,,6154,In vitro stability to trypsin promoting hydrolysis after 8 hr incubation time,A,,,,,
13446,0,,BAO_0000019,Autocuration,,6887,Percent degradation of compound at a pH of 1 over a 18 hr period,A,,,,,
13447,0,,BAO_0000019,Autocuration,,6887,Percent degradation of compound at pH of 1 over an 18 hr period,A,,,,,
13448,0,,BAO_0000019,Autocuration,,14116,Delta Logarithm of Partition Coefficient value was determined.,A,,,,,
13449,0,,BAO_0000019,Autocuration,,11137,Delta logPoct-cyc,A,,,,,
13450,0,,BAO_0000100,Autocuration,,7230,Lipophilicity estimated on reversed phase TLC,P,,,,,
13451,0,,BAO_0000019,Autocuration,,15741,Delta Tm value ( Tmdrug-DNA )-TmDNA ) was obtained for the covalently cross-linked compound in the absence of formaldehyde using calf thymus DNA.,A,,,,,
13452,0,,BAO_0000019,Autocuration,,9663,Delta logPoct-cyc,A,,,,,
13453,0,,BAO_0000100,Autocuration,,9663,Change in logarithm of partition coefficient of the compound,P,,,,,
13454,0,,BAO_0000019,Autocuration,,13807,Delta logD (pH 6.5),A,,,,,
13455,0,,BAO_0000100,Autocuration,,13807,"Partition coefficient by standard shake-flask techniquesat 37 C, using octanol and cyclohexane",P,,,,,
13456,0,,BAO_0000019,Autocuration,,17425,Oxygen pressure at which hemoglobin is 50% oxygenated; negative sign indicates that P50 of modified Hb is lower than that of unmodified Hb,A,,,,,
13457,0,,BAO_0000019,Autocuration,,12143,Deoxyribose-damaging property as a measure of hydroxyl-radical formation (uM of malondialdehyde/mmol of deoxyribose released by 75 uM test compound),A,,,,,
13458,0,,BAO_0000219,Autocuration,,12608,Peak depolarizations produced by injections of 100 micro M Ins p3 isomers in nine cells,A,,,,,
13459,0,,BAO_0000219,Autocuration,,12608,Peak depolarizations produced by injections of 100 micro M Ins p3 isomers in six cells,A,,,,,
13460,1,,BAO_0000218,Intermediate,,8649,Amount of deuterium retained was reported after normal workup in beta-naphthoflavone-treated male rats with the substrate rac 7-D,A,,,Rattus norvegicus,10116.0,
13461,1,,BAO_0000218,Intermediate,,8649,Amount of deuterium retained was reported after normal workup in rats,A,,,Rattus norvegicus,10116.0,
13462,1,,BAO_0000218,Intermediate,,8649,Amount of deuterium retained was reported after reincubation followed by normal workup in phenobarbital treated male rats,A,,,Rattus norvegicus,10116.0,
13463,1,,BAO_0000218,Intermediate,,8649,Amount of deuterium retained was reported after reincubation followed by normal workup in phenobarbital treated male rats with rac 8-D,A,,,Rattus norvegicus,10116.0,
13464,1,,BAO_0000218,Intermediate,,8649,Compound incubated with microsomal preparations from beta-naphthoflavone-treated male rats with the substrate rac 7-D and the amount of deuterium retained was reported after reincubation followed by normal workup,A,,,Rattus norvegicus,10116.0,
13465,1,,BAO_0000218,Intermediate,,8649,Compound incubated with microsomal preparations from beta-naphthoflavone-treated male rats with the substrate rac 7-D and the amount of deuterium retained was reported after reincubation followed by normal workup,A,,,Rattus norvegicus,10116.0,
13466,1,,BAO_0000218,Intermediate,,8649,Compound incubated with microsomal preparations from phenobarbital treated male rats with the substrate rac 8-D and the amount of deuterium retained was reported after normal workup,A,,,Rattus norvegicus,10116.0,
13467,0,,BAO_0000019,Autocuration,,9659,Compound was subjected to electrochemical oxidation,A,,,,,
13468,0,,BAO_0000019,Autocuration,,9659,Compound was subjected to photochemical oxidation,A,,,,,
13469,0,,BAO_0000019,Autocuration,,9659,Oxidation of compound by Chloroperoxidase in presence of ethylperoxide,A,,,,,
13470,0,,BAO_0000019,Autocuration,,9659,Oxidation of compound by horseradish peroxidase in presence of hydroperoxide,A,,,,,
13471,0,,BAO_0000019,Autocuration,,9659,Oxidation of compound by methemoglobin in presence of hydroperoxide,A,,,,,
13472,1,,BAO_0000218,Intermediate,,9607,Percent diffusion through fuzzy rat skin after 48 h of incubation,A,,,Rattus norvegicus,10116.0,
13473,0,,BAO_0000100,Autocuration,,7057,Dissociation constant (pKa),P,,,,,
13474,0,,BAO_0000100,Autocuration,,7057,Dissociation constant value of the compound; ND means not determined.,P,,,,,
13475,1,,BAO_0000218,Intermediate,178.0,7911,% distribution of the radioiron in blood of rat followed by intravenous injection of chelating agent,A,,,Rattus norvegicus,10116.0,
13476,1,,BAO_0000218,Intermediate,178.0,7911,% distribution of the radioiron in blood of rats followed by intravenous injection of transferrin pre-incubated with 10 mg of chelating agent,A,,,Rattus norvegicus,10116.0,
13477,1,,BAO_0000218,Intermediate,,7911,% distribution of the radioiron in rat kidney followed by intravenous injection of chelating agent,A,,,Rattus norvegicus,10116.0,
13478,1,,BAO_0000218,Intermediate,,7911,% distribution of the radioiron in rat kidney followed by intravenous injection of transferrin pre-incubated with 10 mg of chelating agent,A,,,Rattus norvegicus,10116.0,
13479,1,,BAO_0000218,Intermediate,2107.0,7911,% distribution of the radioiron in rat liver followed by intravenous injection of chelating agent,A,,,Rattus norvegicus,10116.0,
13480,1,,BAO_0000218,Intermediate,2107.0,7911,% distribution of the radioiron in rat liver followed by intravenous injection of transferrin preincubated with 10 mg of chelating agent,A,,,Rattus norvegicus,10116.0,
13481,1,,BAO_0000218,Intermediate,2106.0,7911,% distribution of the radioiron in rat spleen followed by intravenous injection of chelating agent,A,,,Rattus norvegicus,10116.0,
13482,1,,BAO_0000218,Intermediate,2106.0,7911,% distribution of the radioiron in rat spleen followed by intravenous injection of transferrin pre-incubated with 10 mg of chelating agent,A,,,Rattus norvegicus,10116.0,
13483,1,,BAO_0000218,Intermediate,,7911,% excretion of ferritin determined in faces of rat followed by intravenous injection of chelating agent,A,,,Rattus norvegicus,10116.0,
13484,1,,BAO_0000218,Intermediate,1088.0,7911,% excretion of ferritin determined in urine of rat followed by intravenous injection of chelating agent,A,,,Rattus norvegicus,10116.0,
13485,1,,BAO_0000218,Intermediate,1988.0,7911,% excretion of radioiron determined in feces of rat followed by intravenous injection of transferrin pre-incubated with 10 mg of chelating agent,A,,,Rattus norvegicus,10116.0,
13486,1,,BAO_0000218,Intermediate,1088.0,7911,% excretion of radioiron determined in urine of rat followed by intravenous injection of transferrin preincubated with 10 mg of chelating agent,A,,,Rattus norvegicus,10116.0,
13487,1,,BAO_0000218,Intermediate,2037.0,13792,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into cerebellum,A,,,Mus musculus,10090.0,
13488,1,,BAO_0000218,Intermediate,955.0,13792,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into cortex,A,,,Mus musculus,10090.0,
13489,0,,BAO_0000218,Autocuration,1088.0,8133,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded monkey at 10 mg/kg, po",A,,,Simiiformes,314293.0,
13490,0,,BAO_0000218,Autocuration,1088.0,8133,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded monkey at 1 mg/kg, po",A,,,Simiiformes,314293.0,
13491,0,,BAO_0000218,Autocuration,1088.0,8133,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded monkey at 30mg/kg, po",A,,,Simiiformes,314293.0,
13492,0,,BAO_0000218,Autocuration,1088.0,8133,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded monkey at 3mg/kg, po",A,,,Simiiformes,314293.0,
13493,1,,BAO_0000218,Intermediate,1088.0,8133,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 0.1 mg/kg, po",A,,,Rattus norvegicus,10116.0,
13494,1,,BAO_0000218,Intermediate,1088.0,8133,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 0.3mg/kg, po",A,,,Rattus norvegicus,10116.0,
13495,1,,BAO_0000218,Intermediate,1088.0,8133,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded rats at 1.0 mg/kg, po",A,,,Rattus norvegicus,10116.0,
13496,1,,BAO_0000218,Intermediate,1088.0,8133,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 10.0mg/kg, po",A,,,Rattus norvegicus,10116.0,
13497,1,,BAO_0000218,Intermediate,1088.0,8133,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded rats at 100.0 mg/kg, po",A,,,Rattus norvegicus,10116.0,
13498,1,,BAO_0000218,Intermediate,1088.0,8133,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 2.1 mg/kg, po",A,,,Rattus norvegicus,10116.0,
13499,1,,BAO_0000218,Intermediate,1088.0,8133,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 20.8mg/kg, po",A,,,Rattus norvegicus,10116.0,
13500,1,,BAO_0000218,Intermediate,1088.0,8133,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded rats at 207.6 mg/kg, po",A,,,Rattus norvegicus,10116.0,
13501,1,,BAO_0000218,Intermediate,1088.0,8133,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 3.0mg/kg, po",A,,,Rattus norvegicus,10116.0,
13502,1,,BAO_0000218,Intermediate,1088.0,8133,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 30.0mg/kg, po",A,,,Rattus norvegicus,10116.0,
13503,1,,BAO_0000218,Intermediate,1088.0,8133,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded rats at 6.9 mg/kg, po",A,,,Rattus norvegicus,10116.0,
13504,1,,BAO_0000218,Intermediate,1088.0,8133,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 69.2mg/kg, po",A,,,Rattus norvegicus,10116.0,
13505,1,,BAO_0000218,Intermediate,1088.0,8133,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 691.9mg/kg, po",A,,,Rattus norvegicus,10116.0,
13506,1,,BAO_0000218,Intermediate,1088.0,8133,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded dogs at 0.03 mg/kg, po",A,,,Canis lupus familiaris,9615.0,
13507,1,,BAO_0000218,Intermediate,1088.0,8133,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded dogs at 0.1 mg/kg, po",A,,,Canis lupus familiaris,9615.0,
13508,1,,BAO_0000218,Intermediate,1088.0,8133,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded dogs at 0.3 mg/kg, po",A,,,Canis lupus familiaris,9615.0,
13509,1,,BAO_0000218,Intermediate,1088.0,8133,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded dogs at 1.0 mg/kg, po",A,,,Canis lupus familiaris,9615.0,
13510,1,,BAO_0000218,Intermediate,1088.0,8133,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded dogs at 10.0mg/kg, po",A,,,Canis lupus familiaris,9615.0,
13511,1,,BAO_0000218,Intermediate,1088.0,8133,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded dogs at 10mg/kg, po",A,,,Canis lupus familiaris,9615.0,
13512,1,,BAO_0000218,Intermediate,1088.0,8133,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded dogs at 1 mg/kg, po",A,,,Canis lupus familiaris,9615.0,
13513,1,,BAO_0000218,Intermediate,1088.0,8133,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded dogs at 30 mg/kg, po",A,,,Canis lupus familiaris,9615.0,
13514,1,,BAO_0000218,Intermediate,1088.0,8133,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded dogs at 3mg/kg, po",A,,,Canis lupus familiaris,9615.0,
13515,1,,BAO_0000218,Intermediate,1088.0,8133,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded dogs at 3.0mg/kg, po",A,,,Canis lupus familiaris,9615.0,
13516,0,,BAO_0000218,Autocuration,1088.0,8133,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded monkey at 100 mg/kg, po",A,,,Simiiformes,314293.0,
13517,0,,BAO_0000218,Autocuration,1088.0,8133,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded monkey at 10mg/kg, po",A,,,Simiiformes,314293.0,
13518,0,,BAO_0000218,Autocuration,1088.0,8133,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded monkey at 1 mg/kg, po",A,,,Simiiformes,314293.0,
13519,0,,BAO_0000218,Autocuration,1088.0,8133,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded monkey at 30mg/kg, po",A,,,Simiiformes,314293.0,
13520,0,,BAO_0000218,Autocuration,1088.0,8133,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded monkey at 3mg/kg, po",A,,,Simiiformes,314293.0,
13521,1,,BAO_0000218,Intermediate,1088.0,8133,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded rats at 0.1 mg/kg, po",A,,,Rattus norvegicus,10116.0,
13522,1,,BAO_0000218,Intermediate,1088.0,8133,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 0.3 mg/kg, po",A,,,Rattus norvegicus,10116.0,
13523,1,,BAO_0000218,Intermediate,1088.0,8133,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded rats at 1.0mg/kg, po",A,,,Rattus norvegicus,10116.0,
13524,1,,BAO_0000218,Intermediate,1088.0,8133,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 10.0 mg/kg, po",A,,,Rattus norvegicus,10116.0,
13525,1,,BAO_0000218,Intermediate,1088.0,8133,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 100.0 mg/kg, po",A,,,Rattus norvegicus,10116.0,
13526,1,,BAO_0000218,Intermediate,1088.0,8133,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 2.08 mg/kg, po",A,,,Rattus norvegicus,10116.0,
13527,1,,BAO_0000218,Intermediate,1088.0,8133,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded rats at 207.6mg/kg, po",A,,,Rattus norvegicus,10116.0,
13528,1,,BAO_0000218,Intermediate,1088.0,8133,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 3.0 mg/kg, po",A,,,Rattus norvegicus,10116.0,
13529,1,,BAO_0000218,Intermediate,1088.0,8133,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded rats at 30.0mg/kg, po",A,,,Rattus norvegicus,10116.0,
13530,1,,BAO_0000218,Intermediate,,9025,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -8/-38,A,In vivo,,Canis lupus familiaris,9615.0,
13531,1,,BAO_0000218,Intermediate,,9025,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); 13/-25,A,In vivo,,Canis lupus familiaris,9615.0,
13532,1,,BAO_0000218,Intermediate,,9025,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); 27/-15,A,In vivo,,Canis lupus familiaris,9615.0,
13533,1,,BAO_0000218,Intermediate,,9025,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -2/-19,A,In vivo,,Canis lupus familiaris,9615.0,
13534,1,,BAO_0000218,Intermediate,,9025,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/60 range (low/high); -3/-4,A,In vivo,,Canis lupus familiaris,9615.0,
13535,1,,BAO_0000218,Intermediate,,9025,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 3 range (low/high),A,In vivo,,Canis lupus familiaris,9615.0,
13536,1,,BAO_0000218,Intermediate,,9025,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 3/10 range (low/high); -9/24,A,In vivo,,Canis lupus familiaris,9615.0,
13537,1,,BAO_0000218,Intermediate,,9025,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 3/10 range (low/high); 3/-1,A,In vivo,,Canis lupus familiaris,9615.0,
13538,1,,BAO_0000218,Intermediate,,9025,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 1/030 range (low/high); 12/23,A,In vivo,,Canis lupus familiaris,9615.0,
13539,1,,BAO_0000218,Intermediate,,9025,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 1/3 range (low/high); 1/3,A,In vivo,,Canis lupus familiaris,9615.0,
13540,1,,BAO_0000218,Intermediate,,9025,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 1/3 range (low/high); 6/16,A,In vivo,,Canis lupus familiaris,9615.0,
13541,1,,BAO_0000218,Intermediate,,9025,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 1/3 range (low/high); 7/14,A,In vivo,,Canis lupus familiaris,9615.0,
13542,1,,BAO_0000218,Intermediate,,9025,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 1/3/10 range (low/high); 4/4/23,A,In vivo,,Canis lupus familiaris,9615.0,
13543,1,,BAO_0000218,Intermediate,,9025,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 10/14,A,In vivo,,Canis lupus familiaris,9615.0,
13544,1,,BAO_0000218,Intermediate,,9025,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 11/15,A,In vivo,,Canis lupus familiaris,9615.0,
13545,1,,BAO_0000218,Intermediate,,9025,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 11/44,A,In vivo,,Canis lupus familiaris,9615.0,
13546,1,,BAO_0000218,Intermediate,,9025,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 14/28,A,In vivo,,Canis lupus familiaris,9615.0,
13547,1,,BAO_0000218,Intermediate,,9025,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 15-28,A,In vivo,,Canis lupus familiaris,9615.0,
13548,1,,BAO_0000218,Intermediate,,9025,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 2/3,A,In vivo,,Canis lupus familiaris,9615.0,
13549,1,,BAO_0000218,Intermediate,,9025,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 26/32,A,In vivo,,Canis lupus familiaris,9615.0,
13550,1,,BAO_0000218,Intermediate,,9025,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 5/1,A,In vivo,,Canis lupus familiaris,9615.0,
13551,1,,BAO_0000218,Intermediate,,9025,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 5/12,A,In vivo,,Canis lupus familiaris,9615.0,
13552,1,,BAO_0000218,Intermediate,,9025,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 6/7,A,In vivo,,Canis lupus familiaris,9615.0,
13553,1,,BAO_0000218,Intermediate,,9025,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 7/6,A,In vivo,,Canis lupus familiaris,9615.0,
13554,1,,BAO_0000218,Intermediate,,9025,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 8/12,A,In vivo,,Canis lupus familiaris,9615.0,
13555,1,,BAO_0000218,Intermediate,,9025,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 8/27,A,In vivo,,Canis lupus familiaris,9615.0,
13556,1,,BAO_0000218,Intermediate,,9025,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 9/14,A,In vivo,,Canis lupus familiaris,9615.0,
13557,1,,BAO_0000218,Intermediate,,9025,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 9/16,A,In vivo,,Canis lupus familiaris,9615.0,
13558,1,,BAO_0000218,Intermediate,,9025,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/60 range (low/high); 12/23,A,In vivo,,Canis lupus familiaris,9615.0,
13559,1,,BAO_0000218,Intermediate,,9025,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 3 range (low/high),A,In vivo,,Canis lupus familiaris,9615.0,
13560,1,,BAO_0000218,Intermediate,,9025,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 3/10 range (low/high); 10/22,A,In vivo,,Canis lupus familiaris,9615.0,
13561,1,,BAO_0000218,Intermediate,,9025,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 3/10 range (low/high); 4/12,A,In vivo,,Rattus norvegicus,10116.0,
13562,1,,BAO_0000218,Intermediate,1637.0,9025,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a 10/30 dose range; 11/-11,A,In vivo,,Canis lupus familiaris,9615.0,
13563,0,,BAO_0000100,Autocuration,,6448,Calculated partition coefficient (clogP),P,,,,,
13564,0,,BAO_0000100,Autocuration,,17221,Calculated partition coefficient (clogP),P,,,,,
13565,0,,BAO_0000100,Autocuration,,6545,Calculated partition coefficient (clogP),P,,,,,
13566,0,,BAO_0000100,Autocuration,,577,Calculated partition coefficient (clogP),P,,,,,
13567,0,,BAO_0000100,Autocuration,,6285,Calculated partition coefficient (clogP),P,,,,,
13568,0,,BAO_0000100,Autocuration,,6500,Calculated partition coefficient (clogP),P,,,,,
13569,0,,BAO_0000100,Autocuration,,6716,Calculated partition coefficient (clogP),P,,,,,
13570,0,,BAO_0000100,Autocuration,,13658,Calculated partition coefficient (clogP),P,,,,,
13571,0,,BAO_0000100,Autocuration,,6549,Calculated partition coefficient (clogP),P,,,,,
13572,0,,BAO_0000100,Autocuration,,14685,Calculated partition coefficient (clogP) (MacLogP),P,,,,,
13573,0,,BAO_0000019,Autocuration,,6893,Partition coefficient (logP),A,,,,,
13574,0,,BAO_0000019,Autocuration,,3687,Kinetic parameter was determined,A,,,,,
13575,0,,BAO_0000100,Autocuration,,4207,Calculated partition coefficient (clogP),P,,,,,
13576,0,,BAO_0000100,Autocuration,,4626,Calculated partition coefficient (clogP),P,,,,,
13577,0,,BAO_0000100,Autocuration,,1021,Lipophilicity was determined,P,,,,,
13578,0,,BAO_0000100,Autocuration,,3777,Lipophilicity was determined,P,,,,,
13579,0,,BAO_0000100,Autocuration,,17533,Lipophilicity was determined,P,,,,,
13580,0,,BAO_0000100,Autocuration,,6524,Calculated partition coefficient (clogP),P,,,,,
13581,0,,BAO_0000100,Autocuration,,17533,Lipophilicity was determined,P,,,,,
13582,0,,BAO_0000100,Autocuration,,6480,Lipophilicity in octanol-water,P,,,,,
13583,0,,BAO_0000100,Autocuration,,17606,Calculated partition coefficient (clogP),P,,,,,
13584,0,,BAO_0000100,Autocuration,,6863,Octanol-water partition coefficient was determined,P,,,,,
13585,0,,BAO_0000019,Autocuration,,1356,Partition coefficient (logP),A,,,,,
13586,0,,BAO_0000100,Autocuration,,3326,Calculated partition coefficient (clogP),P,,,,,
13587,0,,BAO_0000019,Autocuration,,1356,Partition coefficient was determined; ND means not determined,A,,,,,
13588,0,,BAO_0000100,Autocuration,,12984,Calculated partition coefficient (clogP),P,,,,,
13589,0,,BAO_0000019,Autocuration,,17363,Partition coefficient of the compound,A,,,,,
13590,0,,BAO_0000019,Autocuration,,6827,Permeability was determined,A,,,,,
13591,0,,BAO_0000100,Autocuration,,261,The compound was evaluated for the partition coefficient,P,,,,,
13592,0,,BAO_0000019,Autocuration,,2685,Partition coefficient (logP),A,,,,,
13593,0,,BAO_0000100,Autocuration,,414,The lipophilicity was reported,P,,,,,
13594,0,,BAO_0000100,Autocuration,,15769,logarithm of the octanol-water partition coefficient for the compound,P,,,,,
13595,0,,BAO_0000019,Autocuration,,17248,Clogp value was determined,A,,,,,
13596,0,,BAO_0000218,Autocuration,,16935,Clp at a dose of 1.5 mg/kg,A,In vivo,,,,
13597,0,,BAO_0000218,Autocuration,,16935,Clp at a dose of 2.0 mg/kg,A,In vivo,,,,
13598,0,,BAO_0000218,Autocuration,1969.0,14832,"Clp, plasma clearance at a dose of 10 mg/kg",A,In vivo,,,,
13599,0,,BAO_0000218,Autocuration,1969.0,14832,"Clp, plasma clearance at a dose of 50 mg/kg",A,In vivo,,,,
13600,1,,BAO_0000218,Intermediate,1969.0,2399,Compound was tested for plasma clearance in rat,A,In vivo,,Rattus norvegicus,10116.0,
13601,1,,BAO_0000218,Intermediate,1969.0,2399,Compound was tested for plasma clearance in rat; Not determined,A,In vivo,,Rattus norvegicus,10116.0,
13602,1,,BAO_0000218,Intermediate,,6227,Plasma clearance (pharmacokinetic parameter) in rat (in vivo) at a dose of 10 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,
13603,1,,BAO_0000218,Intermediate,,6227,Plasma clearance (pharmacokinetic parameter) in rhesus (in vivo) at a dose of 5 mg/kg,A,In vivo,,Macaca mulatta,9544.0,
13604,0,,BAO_0000218,Autocuration,,5623,Plasma clearance by iv administration at a dose 0.003 ug/mL,A,In vivo,,,,
13605,0,,BAO_0000218,Autocuration,,4854,Plasma clearance determined,A,In vivo,,,,
13606,1,,BAO_0000218,Intermediate,,4493,Plasma clearance after iv administration at 3 mg/kg in hamster,A,In vivo,,Cricetinae,10026.0,
13607,1,,BAO_0000218,Intermediate,,4493,Plasma clearance after iv administration at 4 mg/kg in hamster,A,In vivo,,Cricetinae,10026.0,
13608,1,,BAO_0000218,Intermediate,,14956,Rate of clearance in rat was determined,A,In vivo,,Rattus norvegicus,10116.0,
13609,1,,BAO_0000218,Intermediate,1969.0,15372,Total plasma clearance Clp was determined for the compound after iv dose of 5.06 mg/kg in rats,A,In vivo,,Rattus norvegicus,10116.0,
13610,1,,BAO_0000218,Intermediate,1969.0,15372,Total plasma clearance after iv dose of 5.10 mg/kg in rats,A,In vivo,,Rattus norvegicus,10116.0,
13611,1,,BAO_0000218,Intermediate,1969.0,15372,Total plasma clearance was determined for the compound after iv dose of 4.74 mg/kg in rats,A,In vivo,,Rattus norvegicus,10116.0,
13612,1,,BAO_0000218,Intermediate,1969.0,15372,Total plasma clearance was determined for the compound after iv dose of 4.97 mg/kg in rats,A,In vivo,,Rattus norvegicus,10116.0,
13613,0,,BAO_0000218,Autocuration,1969.0,15604,plasma clearance in preclinical species was measured after Intravenous administration at the given dose (0.01 mg/kg) in monkey,A,In vivo,,Simiiformes,314293.0,
13614,1,,BAO_0000218,Intermediate,1969.0,15604,plasma clearance in preclinical species was measured after Intravenous administration at the given dose (0.05 mg/kg) in rat,A,In vivo,,Rattus norvegicus,10116.0,
13615,1,,BAO_0000218,Intermediate,1969.0,15604,plasma clearance in preclinical species was measured after Intravenous administration at the given dose (0.1 mg/kg) in dog,A,In vivo,,Canis lupus familiaris,9615.0,
13616,1,,BAO_0000218,Intermediate,,14964,Clpl value in rat,A,In vivo,,Rattus norvegicus,10116.0,
13617,1,,BAO_0000218,Intermediate,,15240,Cmax (ng /mL) value after oral administration of 10 mg/kg in guinea pig.,A,In vivo,,Cavia porcellus,10141.0,
13618,1,,BAO_0000218,Intermediate,,16449,Cmax after an oral dose of 10 uM/Kg in male Sprague-Dawley rats,A,In vivo,,Rattus norvegicus,10116.0,
13619,1,,BAO_0000218,Intermediate,,16449,Cmax after an oral dose of 10 uM/Kg in male cynomolgus monkeys,A,In vivo,,Macaca fascicularis,9541.0,
13620,0,,BAO_0000218,Autocuration,,12902,Cmax in minutes at a iv dose of 1.0(pmol/g/h).,A,In vivo,,,,
13621,0,,BAO_0000218,Autocuration,,12902,Cmax in minutes at a iv dose of 2.0(pmol/g/h).,A,In vivo,,,,
13622,0,,BAO_0000218,Autocuration,,12902,Cmax in minutes at a iv dose of 4.0(pmol/g/h).,A,In vivo,,,,
13623,0,,BAO_0000218,Autocuration,,12902,Cmax in minutes at a iv dose of 5.0(pmol/g/h).,A,In vivo,,,,
13624,0,,BAO_0000218,Autocuration,,12902,Cmax in minutes at a iv dose of 54.0(pmol/g/h).,A,In vivo,,,,
13625,0,,BAO_0000218,Autocuration,,12902,Cmax in minutes at a po dose of 10.0(pmol/g/h).,A,In vivo,,,,
13626,0,,BAO_0000218,Autocuration,,12902,Cmax in minutes at a po dose of 20.0(pmol/g/h).,A,In vivo,,,,
13627,0,,BAO_0000218,Autocuration,,12902,Cmax in minutes at a po dose of 40.0(pmol/g/h).,A,In vivo,,,,
13628,0,,BAO_0000218,Autocuration,178.0,11149,Cmax was calculated as maximum concentration reached in the blood,A,In vivo,,,,
13629,0,,BAO_0000218,Autocuration,178.0,11149,Cmax was calculated as maximum concentration reached in the blood in air pouch exudate,A,In vivo,,,,
13630,1,,BAO_0000218,Intermediate,,5669,Cmax was determine after peroral administration at 10 mpk in Rat,A,In vivo,,Rattus norvegicus,10116.0,
13631,1,,BAO_0000218,Intermediate,,5669,Cmax was determine after peroral administration at 10 mpk in Rhesus,A,In vivo,,Macaca mulatta,9544.0,
13632,1,,BAO_0000218,Intermediate,,5669,Cmax was determine after peroral administration at 10 mpk in dog,A,In vivo,,Canis lupus familiaris,9615.0,
13633,1,,BAO_0000218,Intermediate,,5669,Cmax was determine after peroral administration at 160 mpk in Rat,A,In vivo,,Rattus norvegicus,10116.0,
13634,1,,BAO_0000218,Intermediate,,5669,Cmax was determine after peroral administration at 20 mpk in Rat,A,In vivo,,Rattus norvegicus,10116.0,
13635,1,,BAO_0000218,Intermediate,,5669,Cmax was determine after peroral administration at 50 mpk in Rat,A,In vivo,,Rattus norvegicus,10116.0,
13636,0,,BAO_0000218,Autocuration,,4236,Cmax was determined,A,In vivo,,,,
13637,1,,BAO_0000218,Intermediate,955.0,13792,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into hippocampus,A,,,Mus musculus,10090.0,
13638,1,,BAO_0000218,Intermediate,955.0,13792,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into hypothalamus,A,,,Mus musculus,10090.0,
13639,1,,BAO_0000218,Intermediate,955.0,13792,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into pons and medulla,A,,,Mus musculus,10090.0,
13640,1,,BAO_0000218,Intermediate,955.0,13792,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into rest of the brain,A,,,Mus musculus,10090.0,
13641,1,,BAO_0000218,Intermediate,2435.0,13792,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into striatum,A,,,Mus musculus,10090.0,
13642,1,,BAO_0000218,Intermediate,178.0,8418,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 0.31-0.4,A,,,Rattus norvegicus,10116.0,
13643,1,,BAO_0000218,Intermediate,178.0,8418,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 0.97-1.12,A,,,Rattus norvegicus,10116.0,
13644,1,,BAO_0000218,Intermediate,178.0,8418,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.35-0.37,A,,,Rattus norvegicus,10116.0,
13645,1,,BAO_0000218,Intermediate,178.0,8418,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.72-1.03,A,,,Rattus norvegicus,10116.0,
13646,1,,BAO_0000218,Intermediate,178.0,8418,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.95-1.06,A,,,Rattus norvegicus,10116.0,
13647,1,,BAO_0000218,Intermediate,178.0,8418,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.35-0.4,A,,,Rattus norvegicus,10116.0,
13648,1,,BAO_0000218,Intermediate,178.0,8418,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.73-0.85,A,,,Rattus norvegicus,10116.0,
13649,1,,BAO_0000218,Intermediate,178.0,8418,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.65-0.83,A,,,Rattus norvegicus,10116.0,
13650,1,,BAO_0000218,Intermediate,178.0,8418,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.69-0.84,A,,,Rattus norvegicus,10116.0,
13651,1,,BAO_0000218,Intermediate,178.0,8418,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 0.28-0.46,A,,,Rattus norvegicus,10116.0,
13652,1,,BAO_0000218,Intermediate,178.0,8418,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.38-1.5,A,,,Rattus norvegicus,10116.0,
13653,1,,BAO_0000218,Intermediate,178.0,8418,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.34-0.48,A,,,Rattus norvegicus,10116.0,
13654,1,,BAO_0000218,Intermediate,178.0,8418,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.58-1.17,A,,,Rattus norvegicus,10116.0,
13655,1,,BAO_0000218,Intermediate,178.0,8418,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 1.0-1.24,A,,,Rattus norvegicus,10116.0,
13656,1,,BAO_0000218,Intermediate,178.0,8418,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.28-0.37,A,,,Rattus norvegicus,10116.0,
13657,1,,BAO_0000218,Intermediate,178.0,8418,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.54-0.63,A,,,Rattus norvegicus,10116.0,
13658,1,,BAO_0000218,Intermediate,178.0,8418,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.25-0.32,A,,,Rattus norvegicus,10116.0,
13659,1,,BAO_0000218,Intermediate,178.0,8418,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.49-0.58,A,,,Rattus norvegicus,10116.0,
13660,1,,BAO_0000218,Intermediate,178.0,8418,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.58-0.77,A,,,Rattus norvegicus,10116.0,
13661,1,,BAO_0000218,Intermediate,,8418,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 0.20-0.25,A,,,Rattus norvegicus,10116.0,
13662,1,,BAO_0000218,Intermediate,,8418,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 1.05-1.25,A,,,Rattus norvegicus,10116.0,
13663,1,,BAO_0000218,Intermediate,,8418,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.03-0.03,A,,,Rattus norvegicus,10116.0,
13664,1,,BAO_0000218,Intermediate,,8418,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.03-0.06,A,,,Rattus norvegicus,10116.0,
13665,1,,BAO_0000218,Intermediate,,8418,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.34-0.5,A,,,Rattus norvegicus,10116.0,
13666,1,,BAO_0000218,Intermediate,,8418,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.17-0.20,A,,,Rattus norvegicus,10116.0,
13667,1,,BAO_0000218,Intermediate,,8418,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.81-1.26,A,,,Rattus norvegicus,10116.0,
13668,1,,BAO_0000218,Intermediate,,8418,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.03-0.06,A,,,Rattus norvegicus,10116.0,
13669,1,,BAO_0000218,Intermediate,,8418,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.18-0.36,A,,,Rattus norvegicus,10116.0,
13670,1,,BAO_0000218,Intermediate,,8418,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 0.28-0.37,A,,,Rattus norvegicus,10116.0,
13671,1,,BAO_0000218,Intermediate,,8418,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 0.97-2.17,A,,,Rattus norvegicus,10116.0,
13672,1,,BAO_0000218,Intermediate,,8418,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.02-0.03,A,,,Rattus norvegicus,10116.0,
13673,1,,BAO_0000218,Intermediate,,8418,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.05-0.07,A,,,Rattus norvegicus,10116.0,
13674,1,,BAO_0000218,Intermediate,,8418,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.35-0.72,A,,,Rattus norvegicus,10116.0,
13675,1,,BAO_0000218,Intermediate,,8418,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.15-0.19,A,,,Rattus norvegicus,10116.0,
13676,1,,BAO_0000218,Intermediate,,8418,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.76-1.42,A,,,Rattus norvegicus,10116.0,
13677,1,,BAO_0000218,Intermediate,,8418,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.02-0.03,A,,,Rattus norvegicus,10116.0,
13678,1,,BAO_0000218,Intermediate,,8418,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.03-0.06,A,,,Rattus norvegicus,10116.0,
13679,1,,BAO_0000218,Intermediate,,8418,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.05-0.06,A,,,Rattus norvegicus,10116.0,
13680,1,,BAO_0000218,Intermediate,1088.0,8133,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded rats at 6.9mg/kg, po",A,,,Rattus norvegicus,10116.0,
13681,1,,BAO_0000218,Intermediate,1088.0,8133,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 69.2 mg/kg, po",A,,,Rattus norvegicus,10116.0,
13682,1,,BAO_0000218,Intermediate,1088.0,8133,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 691.9 mg/kg, po",A,,,Rattus norvegicus,10116.0,
13683,1,,BAO_0000218,Intermediate,,6996,Oral diuretic activity measured by Na+ excretion in Rat at 9 mg/kg after ip administration (0-5 hr),A,,,Rattus norvegicus,10116.0,
13684,1,,BAO_0000218,Intermediate,,6996,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration,A,,,Rattus norvegicus,10116.0,
13685,1,,BAO_0000218,Intermediate,,6996,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),A,,,Rattus norvegicus,10116.0,
13686,1,,BAO_0000218,Intermediate,,6996,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration (0-5 hr),A,,,Rattus norvegicus,10116.0,
13687,1,,BAO_0000218,Intermediate,,6996,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration ( 0 - 5 hr),A,,,Rattus norvegicus,10116.0,
13688,1,,BAO_0000218,Intermediate,,6996,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr ),A,,,Rattus norvegicus,10116.0,
13689,1,,BAO_0000218,Intermediate,,6996,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),A,,,Rattus norvegicus,10116.0,
13690,1,,BAO_0000218,Intermediate,,6996,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration,A,,,Rattus norvegicus,10116.0,
13691,1,,BAO_0000218,Intermediate,,6996,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),A,,,Rattus norvegicus,10116.0,
13692,1,,BAO_0000218,Intermediate,,6996,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration (0-5 hr),A,,,Rattus norvegicus,10116.0,
13693,1,,BAO_0000218,Intermediate,,6996,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration ( 0 - 5 hr),A,,,Rattus norvegicus,10116.0,
13694,1,,BAO_0000218,Intermediate,,6996,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr ),A,,,Rattus norvegicus,10116.0,
13695,1,,BAO_0000218,Intermediate,,6996,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),A,,,Rattus norvegicus,10116.0,
13696,1,,BAO_0000218,Intermediate,,6996,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration,A,,,Rattus norvegicus,10116.0,
13697,1,,BAO_0000218,Intermediate,,6996,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),A,,,Rattus norvegicus,10116.0,
13698,1,,BAO_0000218,Intermediate,,6996,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration (0-5 hr),A,,,Rattus norvegicus,10116.0,
13699,1,,BAO_0000218,Intermediate,,6996,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration ( 0 - 5 hr),A,,,Rattus norvegicus,10116.0,
13700,1,,BAO_0000218,Intermediate,,6996,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr ),A,,,Rattus norvegicus,10116.0,
13701,1,,BAO_0000218,Intermediate,,6996,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),A,,,Rattus norvegicus,10116.0,
13702,1,,BAO_0000218,Intermediate,,6996,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration,A,,,Rattus norvegicus,10116.0,
13703,1,,BAO_0000218,Intermediate,,6996,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),A,,,Rattus norvegicus,10116.0,
13704,1,,BAO_0000218,Intermediate,,6996,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration (0-5 hr),A,,,Rattus norvegicus,10116.0,
13705,1,,BAO_0000218,Intermediate,,6996,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration ( 0 - 5 hr),A,,,Rattus norvegicus,10116.0,
13706,1,,BAO_0000218,Intermediate,,6996,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr ),A,,,Rattus norvegicus,10116.0,
13707,1,,BAO_0000218,Intermediate,,6996,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),A,,,Rattus norvegicus,10116.0,
13708,1,,BAO_0000218,Intermediate,,6996,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 0.312 mg/kg after ip administration,A,,,Canis lupus familiaris,9615.0,
13709,1,,BAO_0000218,Intermediate,,6996,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 0.3 mg/kg after ip administration (0-6 hr),A,,,Canis lupus familiaris,9615.0,
13710,1,,BAO_0000218,Intermediate,,6996,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 0.625 mg/kg after ip administration,A,,,Canis lupus familiaris,9615.0,
13711,1,,BAO_0000218,Intermediate,,6996,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 0.6 mg/kg after ip administration ( 0-6 hr),A,,,Canis lupus familiaris,9615.0,
13712,1,,BAO_0000218,Intermediate,,6996,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1.8 mg/kg after ip administration ( 0-6 hr),A,,,Canis lupus familiaris,9615.0,
13713,1,,BAO_0000218,Intermediate,,6996,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 10 mg/kg after ip administration (0-6 hr),A,,,Canis lupus familiaris,9615.0,
13714,1,,BAO_0000218,Intermediate,,6996,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 10 mg/kg after ip administration ( 0-6 hr),A,,,Canis lupus familiaris,9615.0,
13715,1,,BAO_0000218,Intermediate,,6996,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 16.2 mg/kg after ip administration ( 0-6 hr),A,,,Canis lupus familiaris,9615.0,
13716,1,,BAO_0000218,Intermediate,,6996,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1 mg/kg after ip administration ( 0-6 hr),A,,,Canis lupus familiaris,9615.0,
13717,1,,BAO_0000218,Intermediate,,6996,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1 mg/kg after ip administration (0-6 hr),A,,,Canis lupus familiaris,9615.0,
13718,1,,BAO_0000218,Intermediate,,6996,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1 mg/kg after ip administration ( 0 - 6 hr),A,,,Canis lupus familiaris,9615.0,
13719,1,,BAO_0000218,Intermediate,,6996,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1 mg/kg after ip administration ( 0-6 hr ),A,,,Canis lupus familiaris,9615.0,
13720,1,,BAO_0000218,Intermediate,,6996,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1 mg/kg g after ip administration (0-6 hr),A,,,Canis lupus familiaris,9615.0,
13721,1,,BAO_0000218,Intermediate,,6996,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 20 mg/kg after ip administration ( 0-6 hr),A,,,Canis lupus familiaris,9615.0,
13722,1,,BAO_0000218,Intermediate,,6996,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 2 mg/kg after ip administration,A,,,Canis lupus familiaris,9615.0,
13723,1,,BAO_0000218,Intermediate,,6996,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 2 mg/kg after ip administration (0-6 hr),A,,,Canis lupus familiaris,9615.0,
13724,1,,BAO_0000218,Intermediate,,6996,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 2 mg/kg after ip administration ( 0 - 6 hr),A,,,Canis lupus familiaris,9615.0,
13725,1,,BAO_0000218,Intermediate,14.0,9716,"Biodistribution in mice skin, after 24 hr of intravenous aadministration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",A,In vivo,,Mus musculus,10090.0,
13726,1,,BAO_0000218,Intermediate,14.0,9716,"Biodistribution in mice skin, after 48 hr of intravenous administration of 1-2 ug ofcompound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",A,In vivo,,Mus musculus,10090.0,
13727,1,,BAO_0000218,Intermediate,2106.0,9716,"Biodistribution in mice spleen, after 12 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",A,In vivo,,Mus musculus,10090.0,
13728,1,,BAO_0000218,Intermediate,2106.0,9716,"Biodistribution in mice spleen, after 1 hr of intravenous aadministration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",A,In vivo,,Mus musculus,10090.0,
13729,1,,BAO_0000218,Intermediate,2106.0,9716,"Biodistribution in mice spleen, after 24 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",A,In vivo,,Mus musculus,10090.0,
13730,1,,BAO_0000218,Intermediate,2106.0,9716,"Biodistribution in mice spleen, after 48 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",A,In vivo,,Mus musculus,10090.0,
13731,1,,BAO_0000218,Intermediate,945.0,9716,"Biodistribution in mice stomach, after 12 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",A,In vivo,,Mus musculus,10090.0,
13732,1,,BAO_0000218,Intermediate,945.0,9716,"Biodistribution in mice stomach, after 1 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",A,In vivo,,Mus musculus,10090.0,
13733,1,,BAO_0000218,Intermediate,945.0,9716,"Biodistribution in mice stomach, after 24 hr of intravenous administration of 1-2 ug of ofcompound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",A,In vivo,,Mus musculus,10090.0,
13734,1,,BAO_0000218,Intermediate,945.0,9716,"Biodistribution in mice stomach, after 48 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",A,In vivo,,Mus musculus,10090.0,
13735,1,,BAO_0000218,Intermediate,,9716,"Biodistribution in mice tail, after 12 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",A,In vivo,,Mus musculus,10090.0,
13736,1,,BAO_0000218,Intermediate,,9716,"Biodistribution in mice tail, after 1 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",A,In vivo,,Mus musculus,10090.0,
13737,1,,BAO_0000218,Intermediate,,9716,"Biodistribution in mice tail, after 24 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",A,In vivo,,Mus musculus,10090.0,
13738,1,,BAO_0000218,Intermediate,,9716,"Biodistribution in mice tail, after 48 hr of intravenous administration of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",A,In vivo,,Mus musculus,10090.0,
13739,1,,BAO_0000218,Intermediate,2113.0,12192,Percent of injected 238-Plutonium(IV) in mice kidney at 24 hr (orally administered),A,,,Mus musculus,10090.0,
13740,1,,BAO_0000218,Intermediate,2113.0,12192,Percent of injected 238-Plutonium(IV) in mice kidneys at 24 h,A,,,Mus musculus,10090.0,
13741,1,,BAO_0000218,Intermediate,2113.0,12192,Percent of injected 238-Plutonium(IV) in mice kidneys at 24 hr (orally administered),A,,,Mus musculus,10090.0,
13742,1,,BAO_0000218,Intermediate,,12192,Percent of injected 238-Plutonium(IV) in mice liver at 24 h,A,,,Mus musculus,10090.0,
13743,1,,BAO_0000218,Intermediate,,12192,Percent of injected 238-Plutonium(IV) in mice liver at 24 hr (orally administered),A,,,Mus musculus,10090.0,
13744,1,,BAO_0000218,Intermediate,,12192,Percent of injected 238-Plutonium(IV) in mice skeleton at 24 h,A,,,Mus musculus,10090.0,
13745,1,,BAO_0000218,Intermediate,,12192,Percent of injected 238-Plutonium(IV) in mice skeleton at 24 hr (orally administered),A,,,Mus musculus,10090.0,
13746,1,,BAO_0000218,Intermediate,,12192,Percent of injected 238-Plutonium(IV) in mice soft tissue at 24 h,A,,,Mus musculus,10090.0,
13747,1,,BAO_0000218,Intermediate,,12192,Percent of injected 238-Plutonium(IV) in mice soft tissue at 24 hr (orally administered),A,,,Mus musculus,10090.0,
13748,1,,BAO_0000218,Intermediate,,12192,Percent of injected 238-Plutonium(IV) in mice whole body at 24 h,A,,,Mus musculus,10090.0,
13749,1,,BAO_0000218,Intermediate,,12192,Percent of injected 238-Plutonium(IV) in mice whole body at 24 hr (orally administered),A,,,Mus musculus,10090.0,
13750,0,,BAO_0000019,Autocuration,1988.0,12192,Removal of 238-Plutonium(IV) in feces at 24 h,A,,,,,
13751,0,,BAO_0000019,Autocuration,1988.0,12192,Removal of 238-Plutonium(IV) in feces at 24 hr (orally administered),A,,,,,
13752,0,,BAO_0000019,Autocuration,,12192,Removal of 238-Plutonium(IV) in gastrointestinal (GI) contents at 24 h,A,,,,,
13753,0,,BAO_0000019,Autocuration,,12192,Removal of 238-Plutonium(IV) in gastrointestinal (GI) contents at 24 hr (orally administered),A,,,,,
13754,0,,BAO_0000019,Autocuration,1088.0,12192,Removal of 238-Plutonium(IV) in urine 0-4 h (orally administered),A,,,,,
13755,0,,BAO_0000019,Autocuration,1088.0,12192,Removal of 238-Plutonium(IV) in urine 4-24 hr (orally administered),A,,,,,
13756,0,,BAO_0000019,Autocuration,1088.0,12192,Removal of 238-Plutonium(IV) in urine after 0-24 h,A,,,,,
13757,0,,BAO_0000019,Autocuration,1088.0,12192,Removal of 238-Plutonium(IV) in urine after 0-24 hr (orally administered),A,,,,,
13758,0,,BAO_0000019,Autocuration,1088.0,12192,Removal of 238-Plutonium(IV) in urine after 0-4 h,A,,,,,
13759,0,,BAO_0000019,Autocuration,1088.0,12192,Removal of 238-Plutonium(IV) in urine after 0-4 hr (orally administered),A,,,,,
13760,0,,BAO_0000019,Autocuration,1088.0,12192,Removal of 238-Plutonium(IV) in urine after 4-24 h,A,,,,,
13761,0,,BAO_0000019,Autocuration,1088.0,12192,Removal of 238-Plutonium(IV) in urine after 4-24 hr (orally administered),A,,,,,
13762,0,,BAO_0000019,Autocuration,1088.0,12192,Removal of 238-Plutonium(IV) in urine at 0-4 hr (orally administered),A,,,,,
13763,0,,BAO_0000019,Autocuration,1088.0,12192,Removal of 238-Plutonium(IV) in urine at 4-24 hr (orally administered),A,,,,,
13764,1,,BAO_0000218,Intermediate,178.0,12017,Biodistribution in blood of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0,
13765,1,,BAO_0000218,Intermediate,178.0,12017,Biodistribution in blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0,
13766,1,,BAO_0000218,Intermediate,178.0,12017,Biodistribution in blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),A,In vivo,,Rattus norvegicus,10116.0,
13767,1,,BAO_0000218,Intermediate,178.0,12017,Biodistribution in blood of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0,
13768,1,,BAO_0000218,Intermediate,178.0,12017,Biodistribution in blood of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0,
13769,1,,BAO_0000218,Intermediate,,12017,Biodistribution in fat of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0,
13770,1,,BAO_0000218,Intermediate,,12017,Biodistribution in fat of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0,
13771,1,,BAO_0000218,Intermediate,,12017,Biodistribution in fat of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),A,In vivo,,Rattus norvegicus,10116.0,
13772,1,,BAO_0000218,Intermediate,,12017,Biodistribution in fat of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0,
13773,1,,BAO_0000218,Intermediate,,12017,Biodistribution in fat of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0,
13774,1,,BAO_0000218,Intermediate,,11836,Tested in vivo for the biodistribution in rat uterus/blood at 1 hour after intravenous dose of 15 microCi of the drug and 15 micro g of estradiol,A,,,Rattus norvegicus,10116.0,
13775,1,,BAO_0000218,Intermediate,,11836,Tested in vivo for the biodistribution in rat uterus/blood at 1 hour after intravenous dose of 50 microCi of drug in 10%ethanol saline,A,,,Rattus norvegicus,10116.0,
13776,1,,BAO_0000218,Intermediate,,11836,Tested in vivo for the biodistribution in rat uterus/blood at 1 hour after intravenous dose of 50 microCi of the drug and 15 ug of estradiol,A,,,Rattus norvegicus,10116.0,
13777,1,,BAO_0000218,Intermediate,2385.0,11836,Tested in vivo for the biodistribution in rat uterus/muscle after 3 hours following an intravenous dose of 100 microCi of drug in 10%ethanol saline,A,,,Rattus norvegicus,10116.0,
13778,1,,BAO_0000218,Intermediate,2385.0,11836,Tested in vivo for the biodistribution in rat uterus/muscle after 3 hours following an intravenous dose of 120 microCi of drug in 10%ethanol saline,A,,,Rattus norvegicus,10116.0,
13779,1,,BAO_0000218,Intermediate,2385.0,11836,Tested in vivo for the biodistribution in rat uterus/muscle after 3 hours following an intravenous dose of 15 microCi of drug in 10%ethanol saline,A,,,Rattus norvegicus,10116.0,
13780,1,,BAO_0000218,Intermediate,2385.0,11836,Tested in vivo for the biodistribution in rat uterus/muscle after 3 hours following an intravenous dose of 50 microCi of drug in 10%ethanol saline,A,,,Rattus norvegicus,10116.0,
13781,1,,BAO_0000218,Intermediate,2385.0,11836,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 100 microCi of drug in 10%ethanol saline,A,,,Rattus norvegicus,10116.0,
13782,1,,BAO_0000218,Intermediate,2385.0,11836,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 100 microCi of the drug and 15 ug of estradiol,A,,,Rattus norvegicus,10116.0,
13783,1,,BAO_0000218,Intermediate,2385.0,11836,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 120 microCi of drug in 10%ethanol saline,A,,,Rattus norvegicus,10116.0,
13784,1,,BAO_0000218,Intermediate,2385.0,11836,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 120 microCi of the drug and 15 micro g of estradiol,A,,,Rattus norvegicus,10116.0,
13785,1,,BAO_0000218,Intermediate,2385.0,11836,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 15 microCi of the drug and 15 ug of estradiol,A,,,Rattus norvegicus,10116.0,
13786,1,,BAO_0000218,Intermediate,2385.0,11836,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 50 microCi of drug in 10%ethanol saline,A,,,Rattus norvegicus,10116.0,
13787,1,,BAO_0000218,Intermediate,2385.0,11836,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 50 microCi of the drug and 15 ug of estradiol,A,,,Rattus norvegicus,10116.0,
13788,1,,BAO_0000218,Intermediate,,11836,Tested in vivo for the biodistribution in rat fat at 1 hour after intravenous dose of 50 microCi of drug in 10%ethanol saline,A,,,Rattus norvegicus,10116.0,
13789,1,,BAO_0000218,Intermediate,995.0,11836,Tested in vivo for the biodistribution in rat uterus at 1 hour after intravenous dose of 120 microCi of drug in 10%ethanol saline,A,,,Rattus norvegicus,10116.0,
13790,0,,BAO_0000019,Autocuration,,12640,Tested in vitro for intrinsic activity relative to quinpirole,A,,,,,
13791,0,,BAO_0000019,Autocuration,,14218,"Relative ion enhancement, determined in pulsed ultrafiltration",A,,,,,
13792,0,,BAO_0000019,Autocuration,,11296,% ionization at the pH 7.4 at 37 degree Centigrade,A,,,,,
13793,0,,BAO_0000019,Autocuration,,10929,Percentage ionization was measured,A,,,,,
13794,1,,BAO_0000218,Intermediate,,13841,Association constant of binding of compound with calf thymus DNA was determined by using equilibrium dialysis.,A,,,Bos taurus,9913.0,
13795,0,,BAO_0000019,Autocuration,,10431,Compound was autooxidized for 2 hour at 37 degree Celsius in pH 7.4 Pseudo-first-order rate constant,A,,,,,
13796,0,,BAO_0000019,Autocuration,,10431,Compound was autooxidized for 2 hour at 37 degree Celsius in pH 7.4 phosphate buffer Pseudo-first-order rate constant,A,,,,,
13797,0,,BAO_0000019,Autocuration,,10431,Compound was autooxidized for 2 hour at 37 degree Celsius in pH 7.4 phosphate buffer pseudo-first-order rate constant 0.1 mM EDTA,A,,,,,
13798,0,,BAO_0000100,Autocuration,,8826,Compound was evaluated for the partition coefficient in octanol/water,P,,,,,
13799,0,,BAO_0000100,Autocuration,,8826,Compound was evaluated for the partition coefficient in octanol/water (1-octanol / 10 mM phosphate buffer at pH 7.4),P,,,,,
13800,0,,BAO_0000019,Autocuration,,9884,Equilibrium constant measured by the pulse radiolysis at pH 7,A,,,,,
13801,1,,BAO_0000218,Intermediate,,9827,In vitro hydrolytic rate constant determined in human blood,A,,,Homo sapiens,9606.0,
13802,1,,BAO_0000218,Intermediate,,10009,In vitro oxidation of compound to its pyridinium salt (3) in presence of human plasma,A,,,Homo sapiens,9606.0,
13803,0,,BAO_0000019,Autocuration,,10009,In vitro oxidation of compound to its pyridinium salt (3) in presence of hydrogen peroxide,A,,,,,
13804,1,,BAO_0000218,Intermediate,,10009,In vitro oxidation of compound to its pyridinium salt (3) in presence of mouse brain homogenate,A,,,Mus musculus,10090.0,
13805,1,,BAO_0000218,Intermediate,,10009,In vitro oxidation of compound to its pyridinium salt (3) in presence of mouse liver homogenate,A,,,Mus musculus,10090.0,
13806,1,,BAO_0000218,Intermediate,,10009,In vitro oxidation of compound in presence of human plasma,A,,,Homo sapiens,9606.0,
13807,0,,BAO_0000019,Autocuration,,10009,In vitro oxidation of compound in presence of hydrogen peroxide,A,,,,,
13808,1,,BAO_0000218,Intermediate,,10009,In vitro oxidation of compound in presence of mouse brain homogenate,A,,,Mus musculus,10090.0,
13809,1,,BAO_0000218,Intermediate,,10009,In vitro oxidation of compound in presence of mouse liver homogenate,A,,,Mus musculus,10090.0,
13810,1,,BAO_0000218,Intermediate,,11510,Mean potassium excretion in rats when compound administered at 0 mg/kg po and vehicle dosed at 0 umol/kg,A,,,Rattus norvegicus,10116.0,
13811,1,,BAO_0000218,Intermediate,,11510,Mean potassium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 30.23 umol/kg,A,,,Rattus norvegicus,10116.0,
13812,1,,BAO_0000218,Intermediate,,11510,Mean potassium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 33.59 umol/kg,A,,,Rattus norvegicus,10116.0,
13813,1,,BAO_0000218,Intermediate,,11510,Mean potassium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 37.13 umol/kg,A,,,Rattus norvegicus,10116.0,
13814,1,,BAO_0000218,Intermediate,,11510,Mean potassium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 39.48 umol/kg,A,,,Rattus norvegicus,10116.0,
13815,1,,BAO_0000218,Intermediate,,11510,Mean potassium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 483.72 umol/kg,A,,,Rattus norvegicus,10116.0,
13816,1,,BAO_0000218,Intermediate,,11510,Mean potassium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg,A,,,Rattus norvegicus,10116.0,
13817,1,,BAO_0000218,Intermediate,,11510,Mean potassium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg; Not determined,A,,,Rattus norvegicus,10116.0,
13818,1,,BAO_0000218,Intermediate,,11510,Mean potassium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 631.76 umol/kg,A,,,Rattus norvegicus,10116.0,
13819,1,,BAO_0000218,Intermediate,,11510,Mean potassium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 7.56 umol/kg,A,,,Rattus norvegicus,10116.0,
13820,1,,BAO_0000218,Intermediate,,11510,Mean potassium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 8.4 umol/kg,A,,,Rattus norvegicus,10116.0,
13821,1,,BAO_0000218,Intermediate,,11510,Mean potassium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.28 umol/kg,A,,,Rattus norvegicus,10116.0,
13822,1,,BAO_0000218,Intermediate,,11510,Mean potassium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.87 umol/kg,A,,,Rattus norvegicus,10116.0,
13823,1,,BAO_0000218,Intermediate,178.0,13100,Biodistribution in rat blood at 240 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0,
13824,1,,BAO_0000218,Intermediate,178.0,13100,Biodistribution in rat blood at 30 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0,
13825,1,,BAO_0000218,Intermediate,178.0,13100,Biodistribution in rat blood at 360 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0,
13826,1,,BAO_0000218,Intermediate,178.0,13100,Biodistribution in rat blood at 3 hr after dose administration.,A,In vivo,,Rattus norvegicus,10116.0,
13827,1,,BAO_0000218,Intermediate,178.0,13100,Biodistribution in rat blood at 60 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0,
13828,1,,BAO_0000218,Intermediate,2037.0,13100,Biodistribution in rat cerebellum at 120 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0,
13829,1,,BAO_0000218,Intermediate,2037.0,13100,Biodistribution in rat cerebellum at 1440 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0,
13830,1,,BAO_0000218,Intermediate,2037.0,13100,Biodistribution in rat cerebellum at 15 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0,
13831,1,,BAO_0000218,Intermediate,2037.0,13100,Biodistribution in rat cerebellum at 240 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0,
13832,1,,BAO_0000218,Intermediate,2037.0,13100,Biodistribution in rat cerebellum at 30 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0,
13833,1,,BAO_0000218,Intermediate,2037.0,13100,Biodistribution in rat cerebellum at 360 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0,
13834,1,,BAO_0000218,Intermediate,2037.0,13100,Biodistribution in rat cerebellum at 3 hr after dose administration.,A,In vivo,,Rattus norvegicus,10116.0,
13835,1,,BAO_0000218,Intermediate,2037.0,13100,Biodistribution in rat cerebellum at 60 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0,
13836,1,,BAO_0000218,Intermediate,,13100,Biodistribution in rat cortex at 120 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0,
13837,1,,BAO_0000218,Intermediate,,13100,Biodistribution in rat cortex at 1440 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0,
13838,1,,BAO_0000218,Intermediate,,13100,Biodistribution in rat cortex at 15 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0,
13839,1,,BAO_0000218,Intermediate,,13100,Biodistribution in rat cortex at 240 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0,
13840,1,,BAO_0000218,Intermediate,,13100,Biodistribution in rat cortex at 30 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0,
13841,1,,BAO_0000218,Intermediate,,13100,Biodistribution in rat cortex at 360 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0,
13842,1,,BAO_0000218,Intermediate,,13100,Biodistribution in rat cortex at 3 hr after dose administration.,A,In vivo,,Rattus norvegicus,10116.0,
13843,1,,BAO_0000218,Intermediate,,13100,Biodistribution in rat cortex at 60 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0,
13844,1,,BAO_0000218,Intermediate,948.0,13100,Biodistribution in rat heart at 120 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0,
13845,1,,BAO_0000218,Intermediate,948.0,13100,Biodistribution in rat heart at 15 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0,
13846,1,,BAO_0000218,Intermediate,948.0,13100,Biodistribution in rat heart at 240 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0,
13847,1,,BAO_0000218,Intermediate,948.0,13100,Biodistribution in rat heart at 30 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0,
13848,1,,BAO_0000218,Intermediate,948.0,13100,Biodistribution in rat heart at 360 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0,
13849,1,,BAO_0000218,Intermediate,948.0,13100,Biodistribution in rat heart at 3 hr after dose administration.,A,In vivo,,Rattus norvegicus,10116.0,
13850,1,,BAO_0000218,Intermediate,948.0,13100,Biodistribution in rat heart at 60 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0,
13851,1,,BAO_0000218,Intermediate,10000000.0,13100,Biodistribution in rat hippocampus at 1440 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0,
13852,1,,BAO_0000218,Intermediate,10000000.0,13100,Biodistribution in rat hippocampus at 240 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0,
13853,1,,BAO_0000218,Intermediate,10000000.0,13100,Biodistribution in rat hippocampus at 30 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0,
13854,1,,BAO_0000218,Intermediate,10000000.0,13100,Biodistribution in rat hippocampus at 360 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0,
13855,1,,BAO_0000218,Intermediate,10000000.0,13100,Biodistribution in rat hippocampus at 15 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0,
13856,1,,BAO_0000218,Intermediate,2113.0,13100,Biodistribution in rat kidney at 120 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0,
13857,1,,BAO_0000218,Intermediate,2113.0,13100,Biodistribution in rat kidney at 1440 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0,
13858,1,,BAO_0000218,Intermediate,2113.0,13100,Biodistribution in rat kidney at 15 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0,
13859,1,,BAO_0000218,Intermediate,2113.0,13100,Biodistribution in rat kidney at 240 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0,
13860,1,,BAO_0000218,Intermediate,2113.0,13100,Biodistribution in rat kidney at 30 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0,
13861,1,,BAO_0000218,Intermediate,2113.0,13100,Biodistribution in rat kidney at 360 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0,
13862,1,,BAO_0000218,Intermediate,2113.0,13100,Biodistribution in rat kidney at 60 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0,
13863,1,,BAO_0000218,Intermediate,2107.0,13100,Biodistribution in rat liver at 120 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0,
13864,1,,BAO_0000218,Intermediate,2107.0,13100,Biodistribution in rat liver at 1440 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0,
13865,1,,BAO_0000218,Intermediate,2107.0,13100,Biodistribution in rat liver at 15 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0,
13866,1,,BAO_0000218,Intermediate,2107.0,13100,Biodistribution in rat liver at 240 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0,
13867,1,,BAO_0000218,Intermediate,2107.0,13100,Biodistribution in rat liver at 30 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0,
13868,1,,BAO_0000218,Intermediate,2107.0,13100,Biodistribution in rat liver at 360 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0,
13869,1,,BAO_0000218,Intermediate,2107.0,13100,Biodistribution in rat liver at 60 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0,
13870,1,,BAO_0000218,Intermediate,2048.0,13100,Biodistribution in rat lung at 120 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0,
13871,1,,BAO_0000218,Intermediate,2048.0,13100,Biodistribution in rat lung at 1440 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0,
13872,1,,BAO_0000218,Intermediate,2048.0,13100,Biodistribution in rat lung at 15 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0,
13873,1,,BAO_0000218,Intermediate,2048.0,13100,Biodistribution in rat lung at 240 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0,
13874,1,,BAO_0000218,Intermediate,2048.0,13100,Biodistribution in rat lung at 30 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0,
13875,1,,BAO_0000218,Intermediate,2048.0,13100,Biodistribution in rat lung at 360 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0,
13876,1,,BAO_0000218,Intermediate,1515.0,12361,Percent of maximal contractile response to compound in rat thoracic aorta strips in the presence of calcium deficient buffer,A,,,Rattus norvegicus,10116.0,
13877,1,,BAO_0000218,Intermediate,1515.0,12361,Percent of maximal contractile response to compound in rat thoracic aorta strips in the presence of nifedipine,A,,,Rattus norvegicus,10116.0,
13878,1,,BAO_0000218,Intermediate,1515.0,12361,Percent of maximal contractile response to compound in rat thoracic aorta strips in the presence of verapamil,A,,,Rattus norvegicus,10116.0,
13879,1,,BAO_0000218,Intermediate,1515.0,12361,Percent of maximal contractile response to compound in rat thoracic aorta strips presence of PBZ and CIR,A,,,Rattus norvegicus,10116.0,
13880,1,,BAO_0000218,Intermediate,1515.0,12361,Percent of maximal contractile response to compound in rat thoracic aorta strips v,A,,,Rattus norvegicus,10116.0,
13881,1,,BAO_0000218,Intermediate,1515.0,12361,Percent of maximal contractile response to compound with phenoxybenzamine pretreatment on rat thoracic aorta strips,A,,,Rattus norvegicus,10116.0,
13882,1,,BAO_0000218,Intermediate,1515.0,12361,Percent of maximal contractile response to compound without phenoxybenzamine pretreatment on rat thoracic aorta strips,A,,,Rattus norvegicus,10116.0,
13883,1,,BAO_0000218,Intermediate,1088.0,12712,% of the total radioactive dose of compound present in the 0-24 hour urine after a single 5 mg/kg dose administered intravenously in rats,A,,,Rattus norvegicus,10116.0,
13884,1,,BAO_0000218,Intermediate,1988.0,7415,Compound at the dose 10 mg/kg administered intraperitoneally was evaluated for the excretion rate in rats in 7 days through feces,A,,,Rattus norvegicus,10116.0,
13885,1,,BAO_0000218,Intermediate,1088.0,7415,Compound at the dose 10 mg/kg administered intraperitoneally was evaluated for the excretion rate in rats in 7 days through urine,A,,,Rattus norvegicus,10116.0,
13886,1,,BAO_0000218,Intermediate,,7415,Compound was evaluated for the biliary excretion in the anesthetized rats in 6 hours after intravenous doses 1 mg/kg,A,,,Rattus norvegicus,10116.0,
13887,1,,BAO_0000218,Intermediate,,7415,Compound was evaluated for the biliary excretion in the anesthetized rats in 6 hours after intravenous doses 10 mg/kg,A,,,Rattus norvegicus,10116.0,
13888,1,,BAO_0000218,Intermediate,1988.0,7415,"Compound was evaluated for the cumulative excretion rate in rats at the dose 10 mg/kg, intraperitoneally for 18 days through feces",A,,,Rattus norvegicus,10116.0,
13889,1,,BAO_0000218,Intermediate,1088.0,7415,"Compound was evaluated for the cumulative excretion rate in rats at the dose 10 mg/kg, intraperitoneally for 18 days through urine",A,,,Rattus norvegicus,10116.0,
13890,1,,BAO_0000218,Intermediate,,7415,"Compound was evaluated for the in rats after the dose of 5 mg/kg intravenously, at the dose 4 hour biliary excretion",A,,,Rattus norvegicus,10116.0,
13891,1,,BAO_0000218,Intermediate,,8050,faecal levels excreted after administration of cysteamine (175 mg/kg) to mice measured at 0-30h,A,,,Mus musculus,10090.0,
13892,1,,BAO_0000218,Intermediate,,8050,fecal levels excreted after administration of 2-(3-bromophenyl)thiazolidine(500 mg/kg) to mice measured at 0-30h,A,,,Mus musculus,10090.0,
13893,1,,BAO_0000218,Intermediate,,8050,fecal levels excreted after administration of 2-phenylthiazolidine (500 mg/kg) to mice measured at 0-30h,A,,,Mus musculus,10090.0,
13894,1,,BAO_0000218,Intermediate,,8050,fecal levels excreted after administration of benzaldehyde (250 mg/kg) to mice measured at 0-30h,A,,,Mus musculus,10090.0,
13895,1,,BAO_0000218,Intermediate,1088.0,8050,urine levels excreted after administration of 2-(3-bromophenyl)thiazolidine(500 mg/kg) to mice measured at 0-24 hr,A,,,Mus musculus,10090.0,
13896,1,,BAO_0000218,Intermediate,1088.0,8050,urine levels excreted after administration of 2-(3-bromophenyl)thiazolidine(500 mg/kg) to mice measured at 0-6 hr,A,,,Mus musculus,10090.0,
13897,1,,BAO_0000218,Intermediate,1088.0,8050,urine levels excreted after administration of 2-(3-bromophenyl)thiazolidine(500 mg/kg) to mice measured at 24-30 hr,A,,,Mus musculus,10090.0,
13898,1,,BAO_0000218,Intermediate,1088.0,8050,urine levels excreted after administration of 2-phenylthiazolidine (500 mg/kg) to mice measured at 0-24 hr,A,,,Mus musculus,10090.0,
13899,1,,BAO_0000218,Intermediate,1088.0,8050,urine levels excreted after administration of 2-phenylthiazolidine (500 mg/kg) to mice measured at 0-6 hr,A,,,Mus musculus,10090.0,
13900,1,,BAO_0000218,Intermediate,1088.0,8050,urine levels excreted after administration of 2-phenylthiazolidine (500 mg/kg) to mice measured at 24-30 hr,A,,,Mus musculus,10090.0,
13901,1,,BAO_0000218,Intermediate,1088.0,8050,urine levels excreted after administration of benzaldehyde (250 mg/kg) to mice measured at 0-24 hr,A,,,Mus musculus,10090.0,
13902,1,,BAO_0000218,Intermediate,1088.0,8050,urine levels excreted after administration of benzaldehyde (250 mg/kg) to mice measured at 0-6 hr,A,,,Mus musculus,10090.0,
13903,1,,BAO_0000218,Intermediate,1088.0,8050,urine levels excreted after administration of benzaldehyde (250 mg/kg) to mice measured at 24-30 hr,A,,,Mus musculus,10090.0,
13904,1,,BAO_0000218,Intermediate,1088.0,8050,urine levels excreted after administration of cysteamine (175 mg/kg) to mice measured at 0-24 hr,A,,,Mus musculus,10090.0,
13905,1,,BAO_0000218,Intermediate,1088.0,8050,urine levels excreted after administration of cysteamine (175 mg/kg) to mice measured at 0-6 hr,A,,,Mus musculus,10090.0,
13906,1,,BAO_0000218,Intermediate,1088.0,8050,urine levels excreted after administration of cysteamine (175 mg/kg) to mice measured at 24-30 hr,A,,,Mus musculus,10090.0,
13907,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 11.9 uM/Kg of drug,A,,,Canis lupus familiaris,9615.0,
13908,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 2.49 uM/Kg of drug,A,,,Canis lupus familiaris,9615.0,
13909,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 26.2 uM/Kg of drug,A,,,Canis lupus familiaris,9615.0,
13910,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 3.03 uM/Kg of drug,A,,,Canis lupus familiaris,9615.0,
13911,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 30.3 uM/Kg of drug,A,,,Canis lupus familiaris,9615.0,
13912,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 34.1 uM/Kg of drug,A,,,Canis lupus familiaris,9615.0,
13913,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 52.4 uM/Kg of drug,A,,,Canis lupus familiaris,9615.0,
13914,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 7.85 uM/Kg of drug,A,,,Canis lupus familiaris,9615.0,
13915,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 8.47 uM/Kg of drug,A,,,Canis lupus familiaris,9615.0,
13916,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 9.09 uM/Kg of drug,A,,,Canis lupus familiaris,9615.0,
13917,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 10.1 uM/Kg of drug,A,,,Canis lupus familiaris,9615.0,
13918,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 102 uM/Kg of drug,A,,,Canis lupus familiaris,9615.0,
13919,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 3.40 uM/Kg of drug,A,,,Canis lupus familiaris,9615.0,
13920,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 3.76 uM/Kg of drug,A,,,Canis lupus familiaris,9615.0,
13921,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 34.1 uM/Kg of drug,A,,,Canis lupus familiaris,9615.0,
13922,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 50.8 uM/Kg of drug,A,,,Canis lupus familiaris,9615.0,
13923,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 68.1 uM/Kg of drug,A,,,Canis lupus familiaris,9615.0,
13924,1,,BAO_0000218,Intermediate,2113.0,12017,Biodistribution in kidney of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0,
13925,1,,BAO_0000218,Intermediate,2113.0,12017,Biodistribution in kidney of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0,
13926,1,,BAO_0000218,Intermediate,2113.0,12017,Biodistribution in kidney of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),A,In vivo,,Rattus norvegicus,10116.0,
13927,1,,BAO_0000218,Intermediate,2113.0,12017,Biodistribution in kidney of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0,
13928,1,,BAO_0000218,Intermediate,2113.0,12017,Biodistribution in kidney of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0,
13929,1,,BAO_0000218,Intermediate,2107.0,12017,Biodistribution in liver of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0,
13930,1,,BAO_0000218,Intermediate,2107.0,12017,Biodistribution in liver of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0,
13931,1,,BAO_0000218,Intermediate,2107.0,12017,Biodistribution in liver of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),A,In vivo,,Rattus norvegicus,10116.0,
13932,1,,BAO_0000218,Intermediate,2107.0,12017,Biodistribution in liver of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0,
13933,1,,BAO_0000218,Intermediate,2107.0,12017,Biodistribution in liver of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0,
13934,1,,BAO_0000218,Intermediate,2048.0,12017,Biodistribution in lungs of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0,
13935,1,,BAO_0000218,Intermediate,2048.0,12017,Biodistribution in lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0,
13936,1,,BAO_0000218,Intermediate,2048.0,12017,Biodistribution in lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),A,In vivo,,Rattus norvegicus,10116.0,
13937,1,,BAO_0000218,Intermediate,2048.0,12017,Biodistribution in lungs of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0,
13938,1,,BAO_0000218,Intermediate,2048.0,12017,Biodistribution in lungs of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0,
13939,1,,BAO_0000218,Intermediate,2385.0,12017,Biodistribution in muscle of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0,
13940,1,,BAO_0000218,Intermediate,2385.0,12017,Biodistribution in muscle of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0,
13941,1,,BAO_0000218,Intermediate,2385.0,12017,Biodistribution in muscle of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),A,In vivo,,Rattus norvegicus,10116.0,
13942,1,,BAO_0000218,Intermediate,2385.0,12017,Biodistribution in muscle of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0,
13943,1,,BAO_0000218,Intermediate,2385.0,12017,Biodistribution in muscle of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0,
13944,1,,BAO_0000218,Intermediate,2106.0,12017,Biodistribution in spleen of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0,
13945,1,,BAO_0000218,Intermediate,2106.0,12017,Biodistribution in spleen of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0,
13946,1,,BAO_0000218,Intermediate,2106.0,12017,Biodistribution in spleen of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),A,In vivo,,Rattus norvegicus,10116.0,
13947,1,,BAO_0000218,Intermediate,2106.0,12017,Biodistribution in spleen of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0,
13948,1,,BAO_0000218,Intermediate,2106.0,12017,Biodistribution in spleen of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0,
13949,1,,BAO_0000218,Intermediate,2046.0,12017,Biodistribution in thyroid of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0,
13950,1,,BAO_0000218,Intermediate,2046.0,12017,Biodistribution in thyroid of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0,
13951,1,,BAO_0000218,Intermediate,2046.0,12017,Biodistribution in thyroid of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),A,In vivo,,Rattus norvegicus,10116.0,
13952,1,,BAO_0000218,Intermediate,2046.0,12017,Biodistribution in thyroid of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0,
13953,1,,BAO_0000218,Intermediate,2046.0,12017,Biodistribution in thyroid of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0,
13954,1,,BAO_0000218,Intermediate,,12017,Biodistribution in uterus / blood of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0,
13955,1,,BAO_0000218,Intermediate,,12017,Biodistribution in uterus / blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0,
13956,1,,BAO_0000218,Intermediate,,12017,Biodistribution in uterus / blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),A,In vivo,,Rattus norvegicus,10116.0,
13957,1,,BAO_0000218,Intermediate,,12017,Biodistribution in uterus / blood of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0,
13958,1,,BAO_0000218,Intermediate,,12017,Biodistribution in uterus / blood of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0,
13959,1,,BAO_0000218,Intermediate,2106.0,12017,"Biodistribution in uterus / spleen, muscle, lungs of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",A,In vivo,,Rattus norvegicus,10116.0,
13960,1,,BAO_0000218,Intermediate,2106.0,12017,"Biodistribution in uterus / spleen, muscle, lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",A,In vivo,,Rattus norvegicus,10116.0,
13961,1,,BAO_0000218,Intermediate,2106.0,12017,"Biodistribution in uterus / spleen, muscle, lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2)",A,In vivo,,Rattus norvegicus,10116.0,
13962,1,,BAO_0000218,Intermediate,2106.0,12017,"Biodistribution in uterus / spleen, muscle, lungs of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",A,In vivo,,Rattus norvegicus,10116.0,
13963,1,,BAO_0000218,Intermediate,2106.0,12017,"Biodistribution in uterus / spleen, muscle, lungs of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",A,In vivo,,Rattus norvegicus,10116.0,
13964,1,,BAO_0000218,Intermediate,2106.0,12017,"Biodistribution in uterus / spleen, muscle, lungs of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",A,In vivo,,Rattus norvegicus,10116.0,
13965,1,,BAO_0000218,Intermediate,,11510,Mean potassium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 60.46 umol/kg,A,,,Rattus norvegicus,10116.0,
13966,1,,BAO_0000218,Intermediate,,11510,Mean potassium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 67.18 umol/kg,A,,,Rattus norvegicus,10116.0,
13967,1,,BAO_0000218,Intermediate,,11510,Mean potassium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 74.26 umol/kg,A,,,Rattus norvegicus,10116.0,
13968,1,,BAO_0000218,Intermediate,,11510,Mean potassium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 78.97 umol/kg,A,,,Rattus norvegicus,10116.0,
13969,1,,BAO_0000218,Intermediate,,11510,Mean potassium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 120.93 umol/kg,A,,,Rattus norvegicus,10116.0,
13970,1,,BAO_0000218,Intermediate,,11510,Mean potassium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 134.35 umol/kg,A,,,Rattus norvegicus,10116.0,
13971,1,,BAO_0000218,Intermediate,,11510,Mean potassium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 148.52 umol/kg,A,,,Rattus norvegicus,10116.0,
13972,1,,BAO_0000218,Intermediate,,11510,Mean potassium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 157.94 umol/kg,A,,,Rattus norvegicus,10116.0,
13973,1,,BAO_0000218,Intermediate,,11510,Mean potassium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 15.12 umol/kg,A,,,Rattus norvegicus,10116.0,
13974,1,,BAO_0000218,Intermediate,,11510,Mean potassium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 16.79 umol/kg,A,,,Rattus norvegicus,10116.0,
13975,1,,BAO_0000218,Intermediate,,11510,Mean potassium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 18.56 umol/kg,A,,,Rattus norvegicus,10116.0,
13976,1,,BAO_0000218,Intermediate,,11510,Mean potassium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 19.74 umol/kg,A,,,Rattus norvegicus,10116.0,
13977,1,,BAO_0000218,Intermediate,,11510,Mean potassium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 241.86 umol/kg,A,,,Rattus norvegicus,10116.0,
13978,1,,BAO_0000218,Intermediate,,11510,Mean potassium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 268.71 umol/kg,A,,,Rattus norvegicus,10116.0,
13979,1,,BAO_0000218,Intermediate,,11510,Mean potassium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 297.03 umol/kg,A,,,Rattus norvegicus,10116.0,
13980,1,,BAO_0000218,Intermediate,,11510,Mean potassium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 315.88 umol/kg,A,,,Rattus norvegicus,10116.0,
13981,0,,BAO_0000100,Autocuration,,8362,Octanol:water partition coefficient is evaluated,P,,,,,
13982,0,,BAO_0000100,Autocuration,,8257,Partition coefficient in 1-octanol/water system,P,,,,,
13983,0,,BAO_0000100,Autocuration,,8257,Partition coefficient in 1-octanol/water system measured using radio active compounds,P,,,,,
13984,0,,BAO_0000100,Autocuration,,9468,Partition coefficient in octanol/water system was determined,P,,,,,
13985,0,,BAO_0000100,Autocuration,,9468,Partition coefficient in octanol/water system was determined using [14C]-labeled compounds.,P,,,,,
13986,0,,BAO_0000019,Autocuration,,10568,Pseudo-first-order rate constant at pH 10 and 35 degrees Centigrade,A,,,,,
13987,0,,BAO_0000019,Autocuration,,10568,"Pseudo-first-order rate constant at pH 10, micro=0.5, 35 degrees Centigrade",A,,,,,
13988,0,,BAO_0000019,Autocuration,,15359,Pseudo-first-order rate constant of the compound,A,,,,,
13989,0,,BAO_0000019,Autocuration,,15359,Pseudo-first-order rate constant with 1-min time point,A,,,,,
13990,0,,BAO_0000019,Autocuration,,15359,Pseudo-first-order rate constant without 1-min time point,A,,,,,
13991,0,,BAO_0000019,Autocuration,,10431,Pseudo-first-order rate constant was determined in pH 7.4 phosphate buffer in presence 0.5 mM EDTA,A,,,,,
13992,0,,BAO_0000019,Autocuration,,10431,Pseudo-first-order rate constant was determined in pH 7.4 phosphate buffer in presence 50 mM EDTA,A,,,,,
13993,0,,BAO_0000019,Autocuration,,10431,Pseudo-first-order rate constant was determined in pH 7.4 phosphate buffer in presence 70 mM EDTA,A,,,,,
13994,0,,BAO_0000019,Autocuration,,15704,Rate constants determined using 31P NMR Kinetics experiments at 37 degrees Centigrade,A,,,,,
13995,0,,BAO_0000019,Autocuration,,15287,The alkaline hydrolysis second order rate constant(K OH) of the compound,A,,,,,
13996,0,,BAO_0000019,Autocuration,,7516,The efflux rate constant of the compound,A,,,,,
13997,0,,BAO_0000019,Autocuration,,12973,The reaction rate constant (K) by measuring competition with nitroblue tetrazolium of the superoxide radicals formed by xanthine oxidase/xanthine,A,,,,,
13998,0,,BAO_0000019,Autocuration,,12973,The reaction rate constant(K) by measuring competition with nitroblue tetrazolium of the superoxide radicals formed by xanthine oxidase/xanthine,A,,,,,
13999,0,,BAO_0000019,Autocuration,,12973,The reaction rate constant(K) by measuring competition with nitroblue tetrazolium of the superoxide radicals formed by xanthine oxidase/xanthine,F,,,,,
14000,0,,BAO_0000019,Autocuration,,12973,The reaction rate constant(K) by measuring competition with nitroblue tetrazolium of the superoxide radicals formed by xanthine oxidase/xanthine; ND= not determined,A,,,,,
14001,0,,BAO_0000019,Autocuration,,8696,Association constant was evaluated towards synthetic peptidoglycan analogue Ac2-Lys-D-Ala-D-Ala,A,,,,,
14002,0,,BAO_0000019,Autocuration,,15052,Equilibrium association (binding) constant interacting with Unilamellar Vesicles of electroneutral DMPC in PBSbuffer at pH 7.4 and 37 C,A,,,,,
14003,0,,BAO_0000019,Autocuration,,15052,Equilibrium association (binding) constant interacting with Unilamellar Vesicles of negatively charged DMPG in PBS buffer at pH 7.4 and 37 C,A,,,,,
14004,0,,BAO_0000019,Autocuration,,10503,Evaluated for the mustard reactivity by determining rate constant for hydrolysis of mustard in aqueous acetone (K H),A,,,,,
14005,0,,BAO_0000019,Autocuration,,8354,"Effective biomolecular rate constant at the concentration 0.500 mM [HOX] in the conditions of 25degreeC,pH 7.6",A,,,,,
14006,0,,BAO_0000019,Autocuration,,8354,"Effective biomolecular rate constant at the concentration 0.767 mM [HOX] in the conditions of 25degreeC,pH 7.6",A,,,,,
14007,0,,BAO_0000019,Autocuration,,8354,"Effective biomolecular rate constant at the concentration 0.790 mM [HOX] in the conditions of 25degreeC,pH 7.6",A,,,,,
14008,0,,BAO_0000019,Autocuration,,8354,"Effective biomolecular rate constant at the concentration 1.00 mM [HOX] in the conditions of 25degreeC,pH 7.6",A,,,,,
14009,0,,BAO_0000019,Autocuration,,8354,"Effective biomolecular rate constant in the conditions of 25degreeC,pH 7.6",A,,,,,
14010,0,,BAO_0000019,Autocuration,,10503,Evaluated for the mustard reactivity by determining rate constant for alkylation of 4-(4-nitrobenzyl)pyridine using NBP alkylation assay,A,,,,,
14011,0,,BAO_0000019,Autocuration,,8354,"Biomolecular rate constant for reactivation and measure of the inherent reactivity of the oximate form of the reactivator at the concentration 0.500 mM [HOX] in the conditions of 25degreeC,pH 7.6",A,,,,,
14012,0,,BAO_0000019,Autocuration,,8354,"Biomolecular rate constant for reactivation and measure of the inherent reactivity of the oximate form of the reactivator at the concentration 0.767 mM [HOX] in the conditions of 25degreeC,pH 7.6",A,,,,,
14013,0,,BAO_0000019,Autocuration,,8354,"Biomolecular rate constant for reactivation and measure of the inherent reactivity of the oximate form of the reactivator at the concentration 0.790 mM [HOX] in the conditions of 25degreeC,pH 7.6",A,,,,,
14014,0,,BAO_0000019,Autocuration,,8354,"Biomolecular rate constant for reactivation and measure of the inherent reactivity of the oximate form of the reactivator at the concentration 1.00 mM [HOX] in the conditions of 25degreeC,pH 7.6",A,,,,,
14015,1,,BAO_0000218,Intermediate,2048.0,13100,Biodistribution in rat lung at 60 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0,
14016,1,,BAO_0000218,Intermediate,,13100,Biodistribution in rat pons/medulla at 120 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0,
14017,1,,BAO_0000218,Intermediate,,13100,Biodistribution in rat pons/medulla at 15 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0,
14018,1,,BAO_0000218,Intermediate,,13100,Biodistribution in rat pons/medulla at 240 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0,
14019,1,,BAO_0000218,Intermediate,,13100,Biodistribution in rat pons/medulla at 30 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0,
14020,1,,BAO_0000218,Intermediate,,13100,Biodistribution in rat pons/medulla at 360 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0,
14021,1,,BAO_0000218,Intermediate,,13100,Biodistribution in rat pons/medulla at 60 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0,
14022,1,,BAO_0000218,Intermediate,2435.0,13100,Biodistribution in rat striatum at 120 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0,
14023,1,,BAO_0000218,Intermediate,2435.0,13100,Biodistribution in rat striatum at 1440 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0,
14024,1,,BAO_0000218,Intermediate,2435.0,13100,Biodistribution in rat striatum at 15 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0,
14025,1,,BAO_0000218,Intermediate,2435.0,13100,Biodistribution in rat striatum at 240 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0,
14026,1,,BAO_0000218,Intermediate,2435.0,13100,Biodistribution in rat striatum at 30 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0,
14027,1,,BAO_0000218,Intermediate,2435.0,13100,Biodistribution in rat striatum at 360 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0,
14028,1,,BAO_0000218,Intermediate,2435.0,13100,Biodistribution in rat striatum at 3 hr after dose administration.,A,In vivo,,Rattus norvegicus,10116.0,
14029,1,,BAO_0000218,Intermediate,2435.0,13100,Biodistribution in rat striatum at 60 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0,
14030,1,,BAO_0000218,Intermediate,2046.0,13100,Biodistribution in rat thyroid at 120 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0,
14031,1,,BAO_0000218,Intermediate,2046.0,13100,Biodistribution in rat thyroid at 1440 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0,
14032,1,,BAO_0000218,Intermediate,2046.0,13100,Biodistribution in rat thyroid at 15 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0,
14033,1,,BAO_0000218,Intermediate,2046.0,13100,Biodistribution in rat thyroid at 240 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0,
14034,1,,BAO_0000218,Intermediate,2046.0,13100,Biodistribution in rat thyroid at 30 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0,
14035,1,,BAO_0000218,Intermediate,2046.0,13100,Biodistribution in rat thyroid at 360 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0,
14036,1,,BAO_0000218,Intermediate,2046.0,13100,Biodistribution in rat thyroid at 60 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0,
14037,1,,BAO_0000218,Intermediate,955.0,13100,Biodistribution in rest of brain of rat 120 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0,
14038,1,,BAO_0000218,Intermediate,955.0,13100,Biodistribution in rest of brain of rat at 1440 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0,
14039,1,,BAO_0000218,Intermediate,955.0,13100,Biodistribution in rest of brain of rat at 15 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0,
14040,1,,BAO_0000218,Intermediate,955.0,13100,Biodistribution in rest of brain of rat at 240 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0,
14041,1,,BAO_0000218,Intermediate,955.0,13100,Biodistribution in rest of brain of rat at 30 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0,
14042,1,,BAO_0000218,Intermediate,955.0,13100,Biodistribution in rest of brain of rat at 360 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0,
14043,1,,BAO_0000218,Intermediate,955.0,13100,Biodistribution in rest of brain of rat at 60 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0,
14044,0,,BAO_0000019,Autocuration,,13331,"Mean rate constant for the hydrolysis of compound in buffers at pH 6.5, at 37 degrees Celsius in incubation mixture - d(A)-d(T) (10:1)",A,,,,,
14045,0,,BAO_0000019,Autocuration,,13331,"Mean rate constant for the hydrolysis of compound in buffers at pH 6.5, at 37 degrees Celsius in incubation mixture - d(G)-d(C) (10:1)",A,,,,,
14046,0,,BAO_0000019,Autocuration,,13331,Mean rate constant for the hydrolysis of compound in buffers at pH 7.4 at 37 degrees Centigrade in incubation mixture - d(A)-d(T) (10:!),A,,,,,
14047,0,,BAO_0000019,Autocuration,,13331,"Mean rate constant for the hydrolysis of compound in buffers at pH 7.4, at 37 degrees Celsius in incubation mixture - 5'-GMP/5'-CMP (1:1)",A,,,,,
14048,0,,BAO_0000019,Autocuration,,13331,"Mean rate constant for the hydrolysis of compound in buffers at pH 7.4, at 37 degrees Celsius in incubation mixture - d(A)-d(T) (1:1)",A,,,,,
14049,0,,BAO_0000019,Autocuration,,13331,"Mean rate constant for the hydrolysis of compound in buffers at pH 7.4, at 37 degrees Celsius in incubation mixture - d(G)-d(C) (10:1)",A,,,,,
14050,0,,BAO_0000019,Autocuration,,13331,"Mean rate constant for the hydrolysis of compound in buffers at pH 7.4, at 37 degrees Celsius in incubation mixture - d(G)-d(C) (1:1)",A,,,,,
14051,0,,BAO_0000019,Autocuration,,13331,"Mean rate constant for the hydrolysis of compound in buffers at pH 7.4, at 37 degrees Celsius in incubation mixture - d(G)-d(T) (10:1)",A,,,,,
14052,1,,BAO_0000218,Intermediate,1088.0,10086,Mean urine volume excretion in conscious rats at a dose of 0.3 mg/kg given orally,A,,,Rattus norvegicus,10116.0,
14053,0,,BAO_0000218,Autocuration,1088.0,10086,Mean urine volume excretion in conscious rats at a dose of 0.3 mg/kg given orally,F,,,,,
14054,1,,BAO_0000218,Intermediate,1088.0,10086,Mean urine volume excretion in conscious rats at a dose of 1.0 mg/kg given orally,A,,,Rattus norvegicus,10116.0,
14055,0,,BAO_0000218,Autocuration,1088.0,10086,Mean urine volume excretion in conscious rats at a dose of 1.0 mg/kg given orally,F,,,,,
14056,1,,BAO_0000218,Intermediate,1088.0,10086,Mean urine volume excretion in conscious rats at a dose of 10 mg/kg given orally,A,,,Rattus norvegicus,10116.0,
14057,1,,BAO_0000218,Intermediate,1088.0,10086,Mean urine volume excretion in conscious rats at a dose of 100 mg/kg given orally,A,,,Rattus norvegicus,10116.0,
14058,1,,BAO_0000218,Intermediate,1088.0,10086,Mean urine volume excretion in conscious rats at a dose of 3.0 mg/kg given orally,A,,,Rattus norvegicus,10116.0,
14059,1,,BAO_0000218,Intermediate,1088.0,10086,Mean urine volume excretion in conscious rats at a dose of 30 mg/kg given orally,A,,,Rattus norvegicus,10116.0,
14060,1,,BAO_0000218,Intermediate,,13248,In vitro metabolic stability of the test compound was evaluated after incubation in the presence of freshly isolated rat hepatocytes,A,,,Rattus norvegicus,10116.0,
14061,1,,BAO_0000218,Intermediate,,13248,In vitro metabolic stability of the test compound was evaluated after incubation in the presence of freshly isolated rat hepatocytes; NA= Not tested,A,,,Rattus norvegicus,10116.0,
14062,1,,BAO_0000218,Intermediate,2107.0,14527,In vitro metabolism in human liver microsomes,A,,,Homo sapiens,9606.0,
14063,1,,BAO_0000218,Intermediate,,3008,Metabolism (NADH oxidation) by recombinant human NAD(P)H: quinone oxidoreductase (NQO1) is evaluated.,A,,,Homo sapiens,9606.0,
14064,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 9.06 uM/Kg of drug,A,,,Canis lupus familiaris,9615.0,
14065,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 9.6 uM/Kg of drug,A,,,Canis lupus familiaris,9615.0,
14066,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of chlorine in urine of rats after intravenous administration of 7.94 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,
14067,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 0 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,
14068,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 1.01 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,
14069,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 1.13 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,
14070,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 10.1 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,
14071,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 102 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,
14072,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 105 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,
14073,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 11.3 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,
14074,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 113 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,
14075,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 19.5 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,
14076,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 195 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,
14077,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 21.7 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,
14078,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 217 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,
14079,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 23.9 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,
14080,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 239 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,
14081,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 24.9 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,
14082,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 249 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,
14083,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 25.9 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,
14084,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 259 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,
14085,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 26.5 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,
14086,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 265 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,
14087,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 27 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,
14088,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 27.9 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,
14089,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 270 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,
14090,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 279 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,
14091,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 28.2 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,
14092,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 28.22 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,
14093,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 28.9 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,
14094,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 282 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,
14095,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 289 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,
14096,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 3.40 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,
14097,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 3.76 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,
14098,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 30.2 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,
14099,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 302 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,
14100,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 31.6 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,
14101,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 316 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,
14102,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 32.4 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,
14103,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 324 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,
14104,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 34.0 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,
14105,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 34.1 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,
14106,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 34.8 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,
14107,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 341 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,
14108,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 348 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,
14109,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 37.6 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,
14110,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 58.4 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,
14111,1,,BAO_0000218,Intermediate,2106.0,12017,"Biodistribution in uterus / spleen, muscle, lungs of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",A,In vivo,,Rattus norvegicus,10116.0,
14112,1,,BAO_0000218,Intermediate,995.0,12017,Biodistribution in uterus of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0,
14113,1,,BAO_0000218,Intermediate,995.0,12017,Biodistribution in uterus of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0,
14114,1,,BAO_0000218,Intermediate,995.0,12017,Biodistribution in uterus of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0,
14115,1,,BAO_0000218,Intermediate,178.0,14045,Biodistribution of 99m Tc complexes in rat and radio activity in blood at 10 min post injection (Average of three to five animals),A,In vivo,,Rattus norvegicus,10116.0,
14116,1,,BAO_0000218,Intermediate,178.0,14045,Biodistribution of 99m Tc complexes in rat and radio activity in blood at 30 min post injection (Average of three to five animals),A,In vivo,,Rattus norvegicus,10116.0,
14117,1,,BAO_0000218,Intermediate,178.0,14045,Biodistribution of 99m Tc complexes in rat and radio activity in blood at 5 min post injection (Average of three to five animals),A,In vivo,,Rattus norvegicus,10116.0,
14118,1,,BAO_0000218,Intermediate,178.0,14045,Biodistribution of 99m Tc complexes in rat and radio activity in blood at 60 min post injection (Average of three to five animals),A,In vivo,,Rattus norvegicus,10116.0,
14119,1,,BAO_0000218,Intermediate,955.0,14045,Biodistribution of 99m Tc complexes in rat and radio activity in brain at 10 min post injection (Average of three to five animals),A,In vivo,,Rattus norvegicus,10116.0,
14120,1,,BAO_0000218,Intermediate,955.0,14045,Biodistribution of 99m Tc complexes in rat and radio activity in brain at 30 min post injection (Average of three to five animals),A,In vivo,,Rattus norvegicus,10116.0,
14121,1,,BAO_0000218,Intermediate,955.0,14045,Biodistribution of 99m Tc complexes in rat and radio activity in brain at 5 min post injection (Average of three to five animals),A,In vivo,,Rattus norvegicus,10116.0,
14122,1,,BAO_0000218,Intermediate,955.0,14045,Biodistribution of 99m Tc complexes in rat and radio activity in brain at 60 min post injection (Average of three to five animals),A,In vivo,,Rattus norvegicus,10116.0,
14123,1,,BAO_0000218,Intermediate,,14045,Biodistribution of 99m Tc complexes in rat and radio activity in brain/blood at 10 min post injection (Average of three to five animals),A,In vivo,,Rattus norvegicus,10116.0,
14124,1,,BAO_0000218,Intermediate,,14045,Biodistribution of 99m Tc complexes in rat and radio activity in brain/blood at 30 min post injection (Average of three to five animals),A,In vivo,,Rattus norvegicus,10116.0,
14125,1,,BAO_0000218,Intermediate,,14045,Biodistribution of 99m Tc complexes in rat and radio activity in brain/blood at 5 min post injection (Average of three to five animals),A,In vivo,,Rattus norvegicus,10116.0,
14126,1,,BAO_0000218,Intermediate,,14045,Biodistribution of 99m Tc complexes in rat and radio activity in brain/blood at 60 min post injection (Average of three to five animals),A,In vivo,,Rattus norvegicus,10116.0,
14127,1,,BAO_0000218,Intermediate,,14045,Biodistribution in mice bladder plus excreted urine was determined,A,In vivo,,Mus musculus,10090.0,
14128,1,,BAO_0000218,Intermediate,,14045,"Percentage biodistribution in mouse blood, 10 minutes post injection",A,,,Mus musculus,10090.0,
14129,1,,BAO_0000218,Intermediate,,14045,"Percentage biodistribution in mouse blood, 30 minutes post injection",A,,,Mus musculus,10090.0,
14130,1,,BAO_0000218,Intermediate,,14045,"Percentage biodistribution in mouse blood, 5 minutes post injection",A,,,Mus musculus,10090.0,
14131,1,,BAO_0000218,Intermediate,,14045,"Percentage biodistribution in mouse blood, 60 minutes post injection",A,,,Mus musculus,10090.0,
14132,1,,BAO_0000218,Intermediate,955.0,14045,"Percentage biodistribution in mouse brain, 10 minutes post injection",A,,,Mus musculus,10090.0,
14133,1,,BAO_0000218,Intermediate,955.0,14045,"Percentage biodistribution in mouse brain, 30 minutes post injection",A,,,Mus musculus,10090.0,
14134,1,,BAO_0000218,Intermediate,955.0,14045,"Percentage biodistribution in mouse brain, 5 minutes post injection",A,,,Mus musculus,10090.0,
14135,1,,BAO_0000218,Intermediate,955.0,14045,"Percentage biodistribution in mouse brain, 60 minutes post injection",A,,,Mus musculus,10090.0,
14136,1,,BAO_0000218,Intermediate,,14045,"Percentage biodistribution in mouse heart, 10 minutes post injection",A,,,Mus musculus,10090.0,
14137,1,,BAO_0000218,Intermediate,,14045,"Percentage biodistribution in mouse heart, 30 minutes post injection",A,,,Mus musculus,10090.0,
14138,1,,BAO_0000218,Intermediate,,14045,"Percentage biodistribution in mouse heart, 5 minutes post injection",A,,,Mus musculus,10090.0,
14139,1,,BAO_0000218,Intermediate,,14045,"Percentage biodistribution in mouse heart, 60 minutes post injection",A,,,Mus musculus,10090.0,
14140,1,,BAO_0000218,Intermediate,160.0,14045,"Percentage biodistribution in mouse intestine, 10 minutes post injection",A,,,Mus musculus,10090.0,
14141,1,,BAO_0000218,Intermediate,160.0,14045,"Percentage biodistribution in mouse intestine, 30 minutes post injection",A,,,Mus musculus,10090.0,
14142,1,,BAO_0000218,Intermediate,160.0,14045,"Percentage biodistribution in mouse intestine, 5 minutes post injection",A,,,Mus musculus,10090.0,
14143,1,,BAO_0000218,Intermediate,160.0,14045,"Percentage biodistribution in mouse intestine, 60 minutes post injection",A,,,Mus musculus,10090.0,
14144,1,,BAO_0000218,Intermediate,2107.0,14045,"Percentage biodistribution in mouse liver, 10 minutes post injection",A,,,Mus musculus,10090.0,
14145,1,,BAO_0000218,Intermediate,2107.0,14045,"Percentage biodistribution in mouse liver, 30 minutes of post injection",A,,,Mus musculus,10090.0,
14146,1,,BAO_0000218,Intermediate,2107.0,14045,"Percentage biodistribution in mouse liver, 5 minutes post injection",A,,,Mus musculus,10090.0,
14147,1,,BAO_0000218,Intermediate,2107.0,14045,Biodistribution in mice liver at 60 minutes of post injection,A,In vivo,,Mus musculus,10090.0,
14148,1,,BAO_0000218,Intermediate,2048.0,14045,Biodistribution in mice lungs at 10 min of post injection,A,In vivo,,Mus musculus,10090.0,
14149,1,,BAO_0000218,Intermediate,,14045,"Percentage biodistribution in mouse lung, 30 minutes post injection",A,,,Mus musculus,10090.0,
14150,1,,BAO_0000218,Intermediate,,14045,"Percentage biodistribution in mousee lung, 5 minutes post injection",A,,,Mus musculus,10090.0,
14151,1,,BAO_0000218,Intermediate,2048.0,14045,Biodistribution in mice lungs at 60 min of post injection,A,In vivo,,Mus musculus,10090.0,
14152,1,,BAO_0000218,Intermediate,2106.0,14045,Percentage biodistribution in mouse spleen,A,,,Mus musculus,10090.0,
14153,1,,BAO_0000218,Intermediate,945.0,14045,Percentage biodistribution in mouse stomach,A,,,Mus musculus,10090.0,
14154,1,,BAO_0000218,Intermediate,1088.0,11745,Mean biodistribution and elimination data in urine was reported 24 h after administering compound intravenously in tumor-bearing female BALB-C mice.,A,,,Mus musculus,10090.0,
14155,0,,BAO_0000218,Autocuration,1255.0,13257,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in bladder,A,In vivo,,,,
14156,0,,BAO_0000218,Autocuration,178.0,13257,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in blood,A,In vivo,,,,
14157,0,,BAO_0000218,Autocuration,1474.0,13257,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in bone,A,In vivo,,,,
14158,0,,BAO_0000218,Autocuration,,13257,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in fat,A,In vivo,,,,
14159,0,,BAO_0000218,Autocuration,2113.0,13257,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in kidney,A,In vivo,,,,
14160,0,,BAO_0000218,Autocuration,2107.0,13257,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in liver,A,In vivo,,,,
14161,0,,BAO_0000218,Autocuration,2048.0,13257,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in lung,A,In vivo,,,,
14162,0,,BAO_0000218,Autocuration,2385.0,13257,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in muscle,A,In vivo,,,,
14163,0,,BAO_0000019,Autocuration,,8354,"Biomolecular rate constant for reactivation and measure of the inherent reactivity of the oximate form of the reactivator in the conditions of 25degreeC,pH 7.6",A,,,,,
14164,1,,BAO_0000218,Intermediate,1977.0,7095,Affinity for protein binding expressed as association constant in fresh rat serum,A,,,Rattus norvegicus,10116.0,
14165,0,,BAO_0000019,Autocuration,,12185,Kinetic constant (Kcat) was calculated by inhibition of monoamino oxidase B (MAO B) at saturation,A,,,,,
14166,0,,BAO_0000019,Autocuration,,12185,Kinetic constant (Kcat) was calculated by inhibition of monoamino oxidase B (MAO B) at saturation; Inactive,A,,,,,
14167,0,,BAO_0000019,Autocuration,,12185,Inactivation constant (Kinact) was calculated by inhibition of monoamino oxidase B (MAO B) at saturation,A,,,,,
14168,0,,BAO_0000019,Autocuration,,12185,Inactivation constant (Kinact) was calculated by inhibition of monoamino oxidase B (MAO B) at saturation; Inactive,A,,,,,
14169,0,,BAO_0000019,Autocuration,,12686,The observed pseudo-first-order rate constants of compound for cyclization reaction at pH 2.4,A,,,,,
14170,0,,BAO_0000019,Autocuration,,12686,"The observed pseudo-first-order rate constants of compound for cyclization reaction at pH 2.4; Significant cyclization occurred during nitro reduction, precluding isolation of the pure amine and determination of rate constants",A,,,,,
14171,0,,BAO_0000019,Autocuration,,12686,The observed pseudo-first-order rate constants of compound for cyclization reaction at pH 6.8; No cyclization detected over 4 h,A,,,,,
14172,0,,BAO_0000019,Autocuration,,12686,"The observed pseudo-first-order rate constants of compound for cyclization reaction at pH 6.8; Significant cyclization occurred during nitro reduction, precluding isolation of the pure amine and determination of rate constants",A,,,,,
14173,0,,BAO_0000019,Autocuration,,8057,Apparent rate constant Koff for inactivation of dTMP synthase.,A,,,,,
14174,0,,BAO_0000019,Autocuration,,15778,The irreversible inhibitor activity by second order rate equation.,A,,,,,
14175,1,,BAO_0000218,Intermediate,,12375,Compound was tested for oral diuretic effect on spontaneously hypertensive rats by measuring the potassium excretion at 1 mg/kg concentration,A,,,Rattus norvegicus,10116.0,
14176,1,,BAO_0000218,Intermediate,,12375,Compound was tested for oral diuretic effect on spontaneously hypertensive rats by measuring the potassium excretion at 5 mg/kg concentration,A,,,Rattus norvegicus,10116.0,
14177,1,,BAO_0000218,Intermediate,,12375,Compound was tested for oral diuretic effect on spontaneously hypertensive rats by measuring the potassium excretion at vehicle concentration,A,,,Rattus norvegicus,10116.0,
14178,0,,BAO_0000019,Autocuration,,13588,Dissociation rate calculated from the first-order equation using t1/2 value,A,,,,,
14179,0,,BAO_0000019,Autocuration,,15039,The compound was tested for Binding constant against DNA,A,,,,,
14180,0,,BAO_0000019,Autocuration,,9500,First order rate constant for cyclization of the compound,A,,,,,
14181,0,,BAO_0000019,Autocuration,,10014,First order rate constant of compound was determined in 50 mM phosphate buffer (pH 7.4) at 24 degree celsius,A,,,,,
14182,0,,BAO_0000019,Autocuration,,10014,First order rate constant of compound was determined in 50 mM phosphate buffer (pH 7.4) at 37 degree celsius,A,,,,,
14183,0,,BAO_0000019,Autocuration,,568,Hydrolysis rate constant was determined,A,,,,,
14184,0,,BAO_0000019,Autocuration,,10026,Observed first order rate constant,A,,,,,
14185,0,,BAO_0000019,Autocuration,,10281,Rate constant (cyclization rate) in CD3CN-deuterated phosphate buffer at pH 7.4,A,,,,,
14186,0,,BAO_0000019,Autocuration,,10281,Rate constant (cyclization rate) in CD3CN-deuterated phosphate buffer at pH 7.4,A,,,,,
14187,0,,BAO_0000019,Autocuration,,9680,Second-order rate constant for attack on PNPA at 25 degree Centigrade,A,,,,,
14188,0,,BAO_0000019,Autocuration,,13028,Kinetic parameter of epimerization at a salt concentration (0.01 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,A,,,,,
14189,0,,BAO_0000019,Autocuration,,13028,Kinetic parameter of epimerization at a salt concentration (0.1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,A,,,,,
14190,0,,BAO_0000019,Autocuration,,13028,Kinetic parameter of epimerization at a salt concentration (1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,A,,,,,
14191,0,,BAO_0000019,Autocuration,,13028,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,A,,,,,
14192,0,,BAO_0000019,Autocuration,,13028,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,A,,,,,
14193,0,,BAO_0000019,Autocuration,,13028,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 11.3 (or )in RMPI 1640 cell culture medium containing 10%FCS,A,,,,,
14194,0,,BAO_0000019,Autocuration,,13028,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 7.5 (or )in RMPI 1640 cell culture medium containing 10%FCS,A,,,,,
14195,0,,BAO_0000019,Autocuration,,13028,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 8.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,A,,,,,
14196,0,,BAO_0000019,Autocuration,,13028,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,A,,,,,
14197,0,,BAO_0000019,Autocuration,,13028,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,A,,,,,
14198,0,,BAO_0000019,Autocuration,,13028,Kinetic parameter of epimerization at a salt concentration (0.01 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,A,,,,,
14199,0,,BAO_0000019,Autocuration,,13028,Kinetic parameter of epimerization at a salt concentration (0.1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,A,,,,,
14200,0,,BAO_0000019,Autocuration,,13028,Kinetic parameter of epimerization at a salt concentration (1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,A,,,,,
14201,0,,BAO_0000019,Autocuration,,13028,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,A,,,,,
14202,0,,BAO_0000019,Autocuration,,13028,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,A,,,,,
14203,0,,BAO_0000019,Autocuration,,13028,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 11.3 (or )in RMPI 1640 cell culture medium containing 10%FCS,A,,,,,
14204,0,,BAO_0000019,Autocuration,,13028,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 7.5 (or )in RMPI 1640 cell culture medium containing 10%FCS,A,,,,,
14205,0,,BAO_0000019,Autocuration,,13028,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 8.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,A,,,,,
14206,0,,BAO_0000019,Autocuration,,13028,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,A,,,,,
14207,0,,BAO_0000019,Autocuration,,13028,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,A,,,,,
14208,1,,BAO_0000218,Intermediate,,3008,Metabolism (NADH oxidation) by recombinant human NAD(P)H: quinone oxidoreductase (NQO1) is evaluated; not detected,A,,,Homo sapiens,9606.0,
14209,1,,BAO_0000218,Intermediate,,4509,Metabolism after 30 min of incubation with human liver microsomes in the absence of cofactor NADH (2.0 mM) at a concentration of 25 uM,A,,,Homo sapiens,9606.0,
14210,1,,BAO_0000218,Intermediate,,4509,Metabolism after 30 min of incubation with human liver microsomes in the presence of cofactor NADH (2.0 mM) at a concentration of 25 uM,A,,,Homo sapiens,9606.0,
14211,1,,BAO_0000218,Intermediate,,8613,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 12.5 mg/kg per day; Tested mice 10,A,,,Human herpesvirus 1,10298.0,
14212,1,,BAO_0000218,Intermediate,,8613,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 12.5 mg/kg per day; Total mice tested 10,A,,,Human herpesvirus 1,10298.0,
14213,1,,BAO_0000218,Intermediate,,8613,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 3.1 mg/kg per day; Tested mice 10,A,,,Human herpesvirus 1,10298.0,
14214,1,,BAO_0000218,Intermediate,,8613,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 50 mg/kg per day; Tested mice 10,A,,,Human herpesvirus 1,10298.0,
14215,1,,BAO_0000218,Intermediate,,8613,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 50 mg/kg per day; Total mice tested 10,A,,,Human herpesvirus 1,10298.0,
14216,1,,BAO_0000218,Intermediate,,8613,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at dose 0.8 mg/kg per day; Tested mice 10,A,,,Human herpesvirus 1,10298.0,
14217,1,,BAO_0000218,Intermediate,,8613,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at dose 3.1 mg/kg per day; Total mice tested 10,A,,,Human herpesvirus 1,10298.0,
14218,1,,BAO_0000218,Intermediate,,8613,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.02 mg/kg per day; Tested mice 10,A,,,Human herpesvirus 1,10298.0,
14219,1,,BAO_0000218,Intermediate,,8613,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.06 mg/kg per day; Tested mice 10,A,,,Human herpesvirus 1,10298.0,
14220,1,,BAO_0000218,Intermediate,,8613,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.25 mg/kg per day; Tested mice 10,A,,,Human herpesvirus 1,10298.0,
14221,1,,BAO_0000218,Intermediate,,8613,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 1 mg/kg per day; Tested mice 10,A,,,Human herpesvirus 1,10298.0,
14222,0,,BAO_0000100,Autocuration,,6021,Calculated partition coefficient (clogP) (MlogP),P,,,,,
14223,0,,BAO_0000019,Autocuration,,9348,Equipotent potent ratio relative to carbachol (nicotinic activity),A,,,,,
14224,1,,BAO_0000218,Intermediate,,15592,"Concentration after 8 hour (bioavailability in dog, compound was delivered orally in 0.05 M citric acid at 10 mg/Kg. n=2 ); NA denotes not available",A,,,Canis lupus familiaris,9615.0,
14225,1,,BAO_0000218,Intermediate,,15592,"Concentration after 8 hour (bioavailability in dog, compound was delivered orally in 0.05 M citric acid at 10 mg/Kg. n=2 );NA denotes not available",A,,,Canis lupus familiaris,9615.0,
14226,0,,BAO_0000100,Autocuration,,15592,Solubility at pH 7.4 in micro g/mL;NA denotes available,P,,,,,
14227,0,,BAO_0000100,Autocuration,,15592,Solubility at pH 7.4 in micro g/mL;NA denotes not available,P,,,,,
14228,0,,BAO_0000100,Autocuration,,15592,Solubility at pH 7.4 in ug/mL;NA denotes not available,P,,,,,
14229,1,,BAO_0000218,Intermediate,1969.0,15592,Maximal plasma concentration in dogs at 10mg/kg oral dose 0.05M citric acid,A,In vivo,,Canis lupus familiaris,9615.0,
14230,1,,BAO_0000218,Intermediate,1977.0,7095,Affinity for protein binding expressed as association constant in fresh rat serum; ND is Not Determined.,A,,,Rattus norvegicus,10116.0,
14231,0,,BAO_0000019,Autocuration,,16618,Area under the MAP curve measured over 5 min; ND means Not determined,A,,,,,
14232,0,,BAO_0000100,Autocuration,,16835,Lipophilicity expressed as the negative logarithm of the equilibrium constant; ND denotes no data.,P,,,,,
14233,0,,BAO_0000100,Autocuration,,15284,The apparent partition coefficient(D) in cyclohexane-0.05 M phosphate buffer (pH 7.4) at 21 degree celsius; not determined,P,,,,,
14234,0,,BAO_0000019,Autocuration,,15750,Half-life was measured in the presence of NADPH at 20 uM; No inhibition,A,,,,,
14235,1,,BAO_0000218,Intermediate,,16618,Half life after oral administration to Sprague-Dawley rats; NT is Not tested,A,In vivo,,Rattus norvegicus,10116.0,
14236,0,,BAO_0000218,Autocuration,,16618,Half life after oral tested,A,In vivo,,,,
14237,1,,BAO_0000218,Intermediate,1969.0,15812,Half life was determined in plasma of rat; NT indicates not tested,A,,,Rattus norvegicus,10116.0,
14238,1,,BAO_0000218,Intermediate,,16618,Oral bioavailability after oral administration to Sprague-Dawley rats; NT is Not tested,A,In vivo,,Rattus norvegicus,10116.0,
14239,0,,BAO_0000218,Autocuration,,16618,Oral bioavailability after oral tested,A,In vivo,,,,
14240,1,,BAO_0000218,Intermediate,,13098,The bioavailability in rats at 15.9 uM/Kg after intravenous administration; NT=Not tested (F),A,,,Rattus norvegicus,10116.0,
14241,1,,BAO_0000218,Intermediate,,13098,The compound was tested for volume of distribution in rat at 15.9 uM/Kg after peroral administration; NT=Not tested (Vd L/Kg),A,,,Rattus norvegicus,10116.0,
14242,1,,BAO_0000218,Intermediate,1969.0,15812,half life was determined in plasma of rat; NT indicates not tested,A,,,Rattus norvegicus,10116.0,
14243,1,,BAO_0000218,Intermediate,1969.0,15812,half life was determined in plasma of rat; NT means not tested,A,,,Rattus norvegicus,10116.0,
14244,1,,BAO_0000218,Intermediate,,11510,Mean sodium excretion in rats (Control/Drug treatment value); Value 0.41/2.32,A,,,Rattus norvegicus,10116.0,
14245,1,,BAO_0000218,Intermediate,,11510,Mean sodium excretion in rats (Control/Drug treatment value); inactive,A,,,Rattus norvegicus,10116.0,
14246,1,,BAO_0000218,Intermediate,,11510,Mean sodium excretion in rats (Control/Drug treatment value); value 0.17/0.43,A,,,Rattus norvegicus,10116.0,
14247,1,,BAO_0000218,Intermediate,,11510,Mean sodium excretion in rats (Control/Drug treatment value); value 0.2/0.38,A,,,Rattus norvegicus,10116.0,
14248,1,,BAO_0000218,Intermediate,,11510,Mean sodium excretion in rats (Control/Drug treatment value); value 0.26/0.23,A,,,Rattus norvegicus,10116.0,
14249,1,,BAO_0000218,Intermediate,,11510,Mean sodium excretion in rats (Control/Drug treatment value); value 0.28/0.26,A,,,Rattus norvegicus,10116.0,
14250,1,,BAO_0000218,Intermediate,,11510,Mean sodium excretion in rats (Control/Drug treatment value); value 0.31/0.35,A,,,Rattus norvegicus,10116.0,
14251,1,,BAO_0000218,Intermediate,,11510,Mean sodium excretion in rats (Control/Drug treatment value); value 0.35/2.88,A,,,Rattus norvegicus,10116.0,
14252,1,,BAO_0000218,Intermediate,,11510,Mean sodium excretion in rats (Control/Drug treatment value); value 0.36/0.29,A,,,Rattus norvegicus,10116.0,
14253,1,,BAO_0000218,Intermediate,,11510,Mean sodium excretion in rats (Control/Drug treatment value); value 0.36/0.47,A,,,Rattus norvegicus,10116.0,
14254,1,,BAO_0000218,Intermediate,,11510,Mean sodium excretion in rats (Control/Drug treatment value); value 0.36/0.49,A,,,Rattus norvegicus,10116.0,
14255,1,,BAO_0000218,Intermediate,,11510,Mean sodium excretion in rats (Control/Drug treatment value); value 0.38/0.23,A,,,Rattus norvegicus,10116.0,
14256,1,,BAO_0000218,Intermediate,,11510,Mean sodium excretion in rats (Control/Drug treatment value); value 0.39/0.22,A,,,Rattus norvegicus,10116.0,
14257,1,,BAO_0000218,Intermediate,,11510,Mean sodium excretion in rats (Control/Drug treatment value); value 0.41/0.48,A,,,Rattus norvegicus,10116.0,
14258,1,,BAO_0000218,Intermediate,,11510,Mean sodium excretion in rats (Control/Drug treatment value); value 0.41/1.49,A,,,Rattus norvegicus,10116.0,
14259,1,,BAO_0000218,Intermediate,,11510,Mean sodium excretion in rats (Control/Drug treatment value); value 0.41/2.06,A,,,Rattus norvegicus,10116.0,
14260,1,,BAO_0000218,Intermediate,,11510,Mean sodium excretion in rats (Control/Drug treatment value); value 0.42/0.65,A,,,Rattus norvegicus,10116.0,
14261,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 65.2 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,
14262,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 71.6 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,
14263,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 71.8 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,
14264,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 74.8 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,
14265,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 77.5 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,
14266,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 79.4 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,
14267,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 80.9 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,
14268,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 83.8 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,
14269,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 84.5 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,
14270,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 84.7 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,
14271,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 86.7 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,
14272,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 86.9 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,
14273,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 9.06 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,
14274,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 90.6 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,
14275,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 94.9 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,
14276,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 97.1 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,
14277,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 11.9 uM/Kg of drug,A,,,Canis lupus familiaris,9615.0,
14278,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 2.49 uM/Kg of drug,A,,,Canis lupus familiaris,9615.0,
14279,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 26.2 uM/Kg of drug,A,,,Canis lupus familiaris,9615.0,
14280,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 3.03 uM/Kg of drug,A,,,Canis lupus familiaris,9615.0,
14281,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 30.3 uM/Kg of drug,A,,,Canis lupus familiaris,9615.0,
14282,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 34.1 uM/Kg of drug,A,,,Canis lupus familiaris,9615.0,
14283,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 52.4 uM/Kg of drug,A,,,Canis lupus familiaris,9615.0,
14284,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 7.85 uM/Kg of drug,A,,,Canis lupus familiaris,9615.0,
14285,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 8.47 uM/Kg of drug,A,,,Canis lupus familiaris,9615.0,
14286,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 9.09 uM/Kg of drug,A,,,Canis lupus familiaris,9615.0,
14287,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of potassium in urine of dogs after peroral administration of 10.1 uM/Kg of drug,A,,,Canis lupus familiaris,9615.0,
14288,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of potassium in urine of dogs after peroral administration of 3.40 uM/Kg of drug,A,,,Canis lupus familiaris,9615.0,
14289,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of potassium in urine of dogs after peroral administration of 3.76 uM/Kg of drug,A,,,Canis lupus familiaris,9615.0,
14290,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of potassium in urine of dogs after peroral administration of 9.06 uM/Kg of drug,A,,,Canis lupus familiaris,9615.0,
14291,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of potassium in urine of dogs after peroral administration of 9.6 uM/Kg of drug,A,,,Canis lupus familiaris,9615.0,
14292,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of potassium in urine of rats after peroral administration of 0 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,
14293,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of potassium in urine of rats after peroral administration of 1.01 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,
14294,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of potassium in urine of rats after peroral administration of 1.13 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,
14295,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of potassium in urine of rats after peroral administration of 10.1 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,
14296,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of potassium in urine of rats after peroral administration of 102 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,
14297,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of potassium in urine of rats after peroral administration of 105 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,
14298,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of potassium in urine of rats after peroral administration of 11.3 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,
14299,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of potassium in urine of rats after peroral administration of 113 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,
14300,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of potassium in urine of rats after peroral administration of 19.5 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,
14301,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of potassium in urine of rats after peroral administration of 195 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,
14302,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of potassium in urine of rats after peroral administration of 21.7 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,
14303,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of potassium in urine of rats after peroral administration of 217 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,
14304,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of potassium in urine of rats after peroral administration of 23.9 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,
14305,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of potassium in urine of rats after peroral administration of 239 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,
14306,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of potassium in urine of rats after peroral administration of 24.9 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,
14307,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of potassium in urine of rats after peroral administration of 249 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,
14308,0,,BAO_0000218,Autocuration,2367.0,13257,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (d),A,In vivo,,,,
14309,0,,BAO_0000218,Autocuration,2367.0,13257,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (d)/biood,A,In vivo,,,,
14310,0,,BAO_0000218,Autocuration,2385.0,13257,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (d)/muscle,A,In vivo,,,,
14311,0,,BAO_0000218,Autocuration,2367.0,13257,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (v),A,In vivo,,,,
14312,0,,BAO_0000218,Autocuration,,13257,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (v)/blood,A,In vivo,,,,
14313,0,,BAO_0000218,Autocuration,2385.0,13257,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (v)/muscle,A,In vivo,,,,
14314,0,,BAO_0000218,Autocuration,2106.0,13257,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in spleen,A,In vivo,,,,
14315,0,,BAO_0000218,Autocuration,1255.0,13257,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in bladder,A,In vivo,,,,
14316,0,,BAO_0000218,Autocuration,178.0,13257,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in blood,A,In vivo,,,,
14317,0,,BAO_0000218,Autocuration,1474.0,13257,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in bone,A,In vivo,,,,
14318,0,,BAO_0000218,Autocuration,,13257,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in fat,A,In vivo,,,,
14319,0,,BAO_0000218,Autocuration,2113.0,13257,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in kidney,A,In vivo,,,,
14320,0,,BAO_0000218,Autocuration,2107.0,13257,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in liver,A,In vivo,,,,
14321,0,,BAO_0000218,Autocuration,2048.0,13257,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in lung,A,In vivo,,,,
14322,0,,BAO_0000218,Autocuration,2385.0,13257,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in muscle,A,In vivo,,,,
14323,0,,BAO_0000218,Autocuration,2367.0,13257,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in prostate (d),A,In vivo,,,,
14324,0,,BAO_0000218,Autocuration,2385.0,13257,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in prostate (d)/muscle,A,In vivo,,,,
14325,0,,BAO_0000218,Autocuration,2367.0,13257,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in prostate (v),A,In vivo,,,,
14326,0,,BAO_0000218,Autocuration,,13257,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in prostate (v)/blood,A,In vivo,,,,
14327,0,,BAO_0000218,Autocuration,2385.0,13257,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in prostate (v)/muscle,A,In vivo,,,,
14328,0,,BAO_0000218,Autocuration,2106.0,13257,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in spleen,A,In vivo,,,,
14329,0,,BAO_0000218,Autocuration,2367.0,13257,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked)i n prostate (d)/biood,A,In vivo,,,,
14330,0,,BAO_0000218,Autocuration,1255.0,13257,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in bladder,A,In vivo,,,,
14331,0,,BAO_0000218,Autocuration,178.0,13257,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in blood,A,In vivo,,,,
14332,0,,BAO_0000218,Autocuration,1474.0,13257,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in bone,A,In vivo,,,,
14333,0,,BAO_0000218,Autocuration,,13257,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in fat,A,In vivo,,,,
14334,0,,BAO_0000218,Autocuration,2113.0,13257,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in kidney,A,In vivo,,,,
14335,0,,BAO_0000218,Autocuration,2107.0,13257,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in liver,A,In vivo,,,,
14336,0,,BAO_0000218,Autocuration,2048.0,13257,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in lung,A,In vivo,,,,
14337,0,,BAO_0000218,Autocuration,2385.0,13257,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in muscle,A,In vivo,,,,
14338,0,,BAO_0000218,Autocuration,2367.0,13257,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (d),A,In vivo,,,,
14339,0,,BAO_0000218,Autocuration,2367.0,13257,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (d)/biood,A,In vivo,,,,
14340,0,,BAO_0000218,Autocuration,2385.0,13257,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (d)/muscle,A,In vivo,,,,
14341,0,,BAO_0000218,Autocuration,2367.0,13257,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (v),A,In vivo,,,,
14342,0,,BAO_0000218,Autocuration,,13257,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (v)/blood,A,In vivo,,,,
14343,0,,BAO_0000218,Autocuration,2385.0,13257,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (v)/muscle,A,In vivo,,,,
14344,0,,BAO_0000218,Autocuration,2106.0,13257,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in spleen,A,In vivo,,,,
14345,0,,BAO_0000218,Autocuration,1255.0,13257,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in bladder,A,In vivo,,,,
14346,0,,BAO_0000218,Autocuration,178.0,13257,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in blood,A,In vivo,,,,
14347,0,,BAO_0000218,Autocuration,1474.0,13257,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in bone,A,In vivo,,,,
14348,0,,BAO_0000218,Autocuration,,13257,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in fat,A,In vivo,,,,
14349,0,,BAO_0000218,Autocuration,2107.0,13257,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in liver,A,In vivo,,,,
14350,0,,BAO_0000218,Autocuration,2048.0,13257,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in lung,A,In vivo,,,,
14351,0,,BAO_0000218,Autocuration,2385.0,13257,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in muscle,A,In vivo,,,,
14352,0,,BAO_0000019,Autocuration,,2193,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 100 uM,A,,,,,
14353,0,,BAO_0000019,Autocuration,,2193,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 100 uM; no inhibition is observed at this concentration,A,,,,,
14354,0,,BAO_0000019,Autocuration,,2193,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 10 uM,A,,,,,
14355,0,,BAO_0000019,Autocuration,,2193,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 10 uM; too active and complete inhibition is observed,A,,,,,
14356,0,,BAO_0000019,Autocuration,,2193,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 1 uM,A,,,,,
14357,0,,BAO_0000019,Autocuration,,2193,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 1 uM; too active and complete inhibition is observed,A,,,,,
14358,0,,BAO_0000019,Autocuration,,568,Hydrolysis rate constant was determined,A,,,,,
14359,0,,BAO_0000019,Autocuration,,9680,"K2, The intrinsic biomolecular reactivation rate constant on VX at 25 degree Centigrade",A,,,,,
14360,0,,BAO_0000019,Autocuration,,9680,"K2, The intrinsic biomolecular reactivation rate constant on paraxon at 25 degree Centigrade",A,,,,,
14361,0,,BAO_0000019,Autocuration,,9680,"K2, The intrinsic biomolecular reactivation rate constant on sarin at 25 degree Centigrade",A,,,,,
14362,0,,BAO_0000019,Autocuration,,10026,Observed second order rate constant,A,,,,,
14363,0,,BAO_0000019,Autocuration,,10281,Rate constant (cyclization rate) in CD3CN-deuterated phosphate buffer at pH 7.4,A,,,,,
14364,0,,BAO_0000019,Autocuration,,10014,Rate constant for decay of compound was determined in 50 mM phosphate buffer (pH 7.4) at 24 degree celsius,A,,,,,
14365,0,,BAO_0000019,Autocuration,,10014,Rate constant for decay of compound was determined in 50 mM phosphate buffer (pH 7.4) at 37 degree celsius,A,,,,,
14366,0,,BAO_0000019,Autocuration,,9680,"k2, The intrinsic biomolecular reactivation rate constant on paraxon at 25 degree Centigrade",A,,,,,
14367,0,,BAO_0000019,Autocuration,,9680,"k2, The intrinsic biomolecular reactivation rate constant on sarin at 25 degree Centigrade",A,,,,,
14368,0,,BAO_0000019,Autocuration,,13028,Kinetic parameter of epimerization at a salt concentration (0.01 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,A,,,,,
14369,0,,BAO_0000019,Autocuration,,13028,Kinetic parameter of epimerization at a salt concentration (0.1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,A,,,,,
14370,0,,BAO_0000019,Autocuration,,13028,Kinetic parameter of epimerization at a salt concentration (1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,A,,,,,
14371,0,,BAO_0000019,Autocuration,,13028,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.0(or )in RMPI 1640 cell culture medium containing 10%FCS,A,,,,,
14372,0,,BAO_0000019,Autocuration,,13028,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,A,,,,,
14373,0,,BAO_0000019,Autocuration,,13028,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 11.3 (or )in RMPI 1640 cell culture medium containing 10%FCS,A,,,,,
14374,0,,BAO_0000019,Autocuration,,13028,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 7.5 (or )in RMPI 1640 cell culture medium containing 10%FCS,A,,,,,
14375,0,,BAO_0000019,Autocuration,,13028,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 8.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,A,,,,,
14376,0,,BAO_0000019,Autocuration,,13028,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,A,,,,,
14377,0,,BAO_0000019,Autocuration,,13028,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,A,,,,,
14378,1,,BAO_0000218,Intermediate,,10014,Rate constants of compound was determined at muscarinic receptor in the rat cerebral cortex,A,,,Rattus norvegicus,10116.0,
14379,0,,BAO_0000019,Autocuration,,9962,Association constant for compound at 31 degree C was determined,A,,,,,
14380,0,,BAO_0000019,Autocuration,,12029,Calculated antagonist equilibrium dissociation constant of the compound,A,,,,,
14381,0,,BAO_0000019,Autocuration,,12029,Calculated antagonist equilibrium dissociation constant of the compound; No statistically significant antagonism observed,A,,,,,
14382,1,,BAO_0000218,Intermediate,3126.0,10583,Dissociation constants vs LTE4 on guinea pig trachea,A,,,Cavia porcellus,10141.0,
14383,0,,BAO_0000019,Autocuration,,568,"Tested for hydrolysis in presence of boric acid by UV spectrophotometry, dissociation constant was evaluated at the pH < 8",A,,,,,
14384,0,,BAO_0000019,Autocuration,,568,"Tested for hydrolysis in presence of boric acid, rate constant was evaluated at the pH 8.5",A,,,,,
14385,0,,BAO_0000019,Autocuration,,568,"Tested for hydrolysis in presence of boric acid, rate constant was evaluated at the pH 9.5",A,,,,,
14386,0,,BAO_0000019,Autocuration,,568,"Tested for hydrolysis in presence of phenylboronic acid, rate constant was evaluated at the pH 9.5",A,,,,,
14387,0,,BAO_0000019,Autocuration,,7493,Affinity constant KD value was derived from TMP,A,,,,,
14388,0,,BAO_0000019,Autocuration,,8371,Apparent dissociation (binding) rate constant was evaluated,A,,,,,
14389,0,,BAO_0000100,Autocuration,,13114,Dissociation constant (KD) of the compound,P,,,,,
14390,0,,BAO_0000100,Autocuration,,15515,Dissociation constant determined by heteronuclear 1H/15N correlation NMR spectroscopy,P,,,,,
14391,0,,BAO_0000100,Autocuration,,522,Dissociation constant from ESR titration experiments,P,,,,,
14392,0,,BAO_0000019,Autocuration,,13888,Dissociation constant was evaluated which is similar to Ki (inhibitory constant),,,,,,
14393,0,,BAO_0000100,Autocuration,,2616,Dissociation constant was evaluated.,P,,,,,
14394,0,,BAO_0000100,Autocuration,,3798,Dissociation constant was reported,P,,,,,
14395,1,,BAO_0000218,Intermediate,,8731,Dissociation constant was determined in rat pituitary cells.,A,,,Rattus norvegicus,10116.0,
14396,0,,BAO_0000019,Autocuration,,11892,Equilibrium dissociation constant of CA complex for enantiomer 1 of compound,A,,,,,
14397,0,,BAO_0000019,Autocuration,,11892,Equilibrium dissociation constant of CA complex for enantiomer 2 of compound,A,,,,,
14398,0,,BAO_0000019,Autocuration,,2582,Equilibrium dissociation constant of the compound,A,,,,,
14399,0,,BAO_0000019,Autocuration,,11892,Equilibrium dissociation constant was determined,A,,,,,
14400,0,,BAO_0000019,Autocuration,,13396,Kinetic constant KD was evaluated,A,,,,,
14401,0,,BAO_0000019,Autocuration,,603,Tested for dissociation constant of the compound; Value ranges from 0.1-0.3,A,,,,,
14402,0,,BAO_0000019,Autocuration,,15673,Equilibrium association constant interacting with unilamellar vesicles of electroneutral in PBS buffer at pH 7.4,A,,,,,
14403,0,,BAO_0000019,Autocuration,,10368,Rate constant for hydrolysis in aqueous acetone.,A,,,,,
14404,0,,BAO_0000019,Autocuration,,14228,Disassociation constant (KI) was obtained from Cheng and Prusoff equation for quercetin trypsin complex,A,,,,,
14405,1,,BAO_0000218,Intermediate,,11510,Mean sodium excretion in rats (Control/Drug treatment value); value 0.43/2.86,A,,,Rattus norvegicus,10116.0,
14406,1,,BAO_0000218,Intermediate,,11510,Mean sodium excretion in rats (Control/Drug treatment value); value 0.44/2.68,A,,,Rattus norvegicus,10116.0,
14407,1,,BAO_0000218,Intermediate,,11510,Mean sodium excretion in rats (Control/Drug treatment value); value 0.45/1.55,A,,,Rattus norvegicus,10116.0,
14408,1,,BAO_0000218,Intermediate,,11510,Mean sodium excretion in rats (Control/Drug treatment value); value 0.48/0.95,A,,,Rattus norvegicus,10116.0,
14409,1,,BAO_0000218,Intermediate,,11510,Mean sodium excretion in rats (Control/Drug treatment value); value 0.5/1.79,A,,,Rattus norvegicus,10116.0,
14410,1,,BAO_0000218,Intermediate,,11510,Mean sodium excretion in rats (Control/Drug treatment value); value 0.51/0.66,A,,,Rattus norvegicus,10116.0,
14411,1,,BAO_0000218,Intermediate,,11510,Mean sodium excretion in rats (Control/Drug treatment value); value 0.52/2.02,A,,,Rattus norvegicus,10116.0,
14412,1,,BAO_0000218,Intermediate,,11510,Mean sodium excretion in rats (Control/Drug treatment value); value 0.61//0.37,A,,,Rattus norvegicus,10116.0,
14413,1,,BAO_0000218,Intermediate,,11510,Mean sodium excretion in rats (Control/Drug treatment value); value 0.71/0.36,A,,,Rattus norvegicus,10116.0,
14414,1,,BAO_0000218,Intermediate,,11510,Mean sodium excretion in rats when compound administered at 0 mg/kg po and vehicle dosed at 0 umol/kg,A,,,Rattus norvegicus,10116.0,
14415,1,,BAO_0000218,Intermediate,,11510,Mean sodium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 30.23 umol/kg,A,,,Rattus norvegicus,10116.0,
14416,1,,BAO_0000218,Intermediate,,11510,Mean sodium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 33.59 umol/kg,A,,,Rattus norvegicus,10116.0,
14417,1,,BAO_0000218,Intermediate,,11510,Mean sodium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 37.13 umol/kg,A,,,Rattus norvegicus,10116.0,
14418,1,,BAO_0000218,Intermediate,,11510,Mean sodium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 39.48 umol/kg,A,,,Rattus norvegicus,10116.0,
14419,1,,BAO_0000218,Intermediate,,11510,Mean sodium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 483.72 umol/kg,A,,,Rattus norvegicus,10116.0,
14420,1,,BAO_0000218,Intermediate,,11510,Mean sodium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg,A,,,Rattus norvegicus,10116.0,
14421,1,,BAO_0000218,Intermediate,,11510,Mean sodium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg; Not determined,A,,,Rattus norvegicus,10116.0,
14422,1,,BAO_0000218,Intermediate,,11510,Mean sodium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 631.76 umol/kg,A,,,Rattus norvegicus,10116.0,
14423,1,,BAO_0000218,Intermediate,,11510,Mean sodium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 7.56 umol/kg,A,,,Rattus norvegicus,10116.0,
14424,1,,BAO_0000218,Intermediate,,11510,Mean sodium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 8.4 umol/kg,A,,,Rattus norvegicus,10116.0,
14425,1,,BAO_0000218,Intermediate,,11510,Mean sodium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.28 umol/kg,A,,,Rattus norvegicus,10116.0,
14426,1,,BAO_0000218,Intermediate,,11510,Mean sodium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.87 umol/kg,A,,,Rattus norvegicus,10116.0,
14427,1,,BAO_0000218,Intermediate,,11510,Mean sodium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 60.46 umol/kg,A,,,Rattus norvegicus,10116.0,
14428,1,,BAO_0000218,Intermediate,,11510,Mean sodium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 67.18 umol/kg,A,,,Rattus norvegicus,10116.0,
14429,1,,BAO_0000218,Intermediate,,11510,Mean sodium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 74.26 umol/kg,A,,,Rattus norvegicus,10116.0,
14430,1,,BAO_0000218,Intermediate,,11510,Mean sodium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 78.97 umol/kg,A,,,Rattus norvegicus,10116.0,
14431,1,,BAO_0000218,Intermediate,,11510,Mean sodium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 120.93 umol/kg,A,,,Rattus norvegicus,10116.0,
14432,1,,BAO_0000218,Intermediate,,11510,Mean sodium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 134.35 umol/kg,A,,,Rattus norvegicus,10116.0,
14433,1,,BAO_0000218,Intermediate,,11510,Mean sodium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 148.52 umol/kg,A,,,Rattus norvegicus,10116.0,
14434,1,,BAO_0000218,Intermediate,,11510,Mean sodium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 157.94 umol/kg,A,,,Rattus norvegicus,10116.0,
14435,1,,BAO_0000218,Intermediate,,11510,Mean sodium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 15.12 umol/kg,A,,,Rattus norvegicus,10116.0,
14436,1,,BAO_0000218,Intermediate,,11510,Mean sodium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 16.79 umol/kg,A,,,Rattus norvegicus,10116.0,
14437,1,,BAO_0000218,Intermediate,,11510,Mean sodium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 18.56 umol/kg,A,,,Rattus norvegicus,10116.0,
14438,1,,BAO_0000218,Intermediate,,11510,Mean sodium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 19.74 umol/kg,A,,,Rattus norvegicus,10116.0,
14439,1,,BAO_0000218,Intermediate,,11510,Mean sodium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 241.86 umol/kg,A,,,Rattus norvegicus,10116.0,
14440,1,,BAO_0000218,Intermediate,,11510,Mean sodium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 268.71 umol/kg,A,,,Rattus norvegicus,10116.0,
14441,1,,BAO_0000218,Intermediate,,11510,Mean sodium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 297.03 umol/kg,A,,,Rattus norvegicus,10116.0,
14442,1,,BAO_0000218,Intermediate,,11510,Mean sodium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 315.88 umol/kg,A,,,Rattus norvegicus,10116.0,
14443,1,,BAO_0000218,Intermediate,,8310,Na+ excretion mequiv /kg in 6 conscious female dogs administered perorally during 0-6 hr,A,,,Canis lupus familiaris,9615.0,
14444,1,,BAO_0000218,Intermediate,,8310,Na+ excretion mequiv /kg in conscious female dogs administered perorally during 0-6 hr,A,,,Canis lupus familiaris,9615.0,
14445,1,,BAO_0000218,Intermediate,,8310,Na+ excretion mequiv /kg in saline-loaded mice administered at a dose 10 ml/kg perorally,A,,,Mus musculus,10090.0,
14446,1,,BAO_0000218,Intermediate,,8310,Na+ excretion mequiv /kg in saline-loaded mice administered at a dose 2 ml/kg perorally,A,,,Mus musculus,10090.0,
14447,1,,BAO_0000218,Intermediate,,8310,Na+ excretion mequiv /kg in saline-loaded mice administered at a dose 2 ml/kg perorally,A,,,Mus musculus,10090.0,
14448,1,,BAO_0000218,Intermediate,,8310,Na+ excretion mequiv /kg in saline-loaded mice administered at a dose 50 ml/kg perorally,A,,,Mus musculus,10090.0,
14449,1,,BAO_0000218,Intermediate,,8310,Na+ excretion mequiv /kg in saline-loaded mice administered at a dose 10 ml/kg perorally,A,,,Mus musculus,10090.0,
14450,1,,BAO_0000218,Intermediate,,8310,Na+ excretion mequiv/kg in 4 conscious female dogs administered perorally during 0-6 hr,A,,,Canis lupus familiaris,9615.0,
14451,1,,BAO_0000218,Intermediate,,8310,Na+ excretion mequiv/kg in 4 saline-loaded mice administered at a dose 50 ml/kg perorally,A,,,Mus musculus,10090.0,
14452,1,,BAO_0000218,Intermediate,,8310,Na+ excretion mequiv/kg in 6 conscious female dogs administered perorally during 0-6 hr,A,,,Canis lupus familiaris,9615.0,
14453,1,,BAO_0000218,Intermediate,,8310,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 0.3 ml/kg perorally,A,,,Canis lupus familiaris,9615.0,
14454,1,,BAO_0000218,Intermediate,,8310,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 10 ml/kg perorally,A,,,Mus musculus,10090.0,
14455,1,,BAO_0000218,Intermediate,,8310,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 10 ml/kg perorally,A,,,Mus musculus,10090.0,
14456,1,,BAO_0000218,Intermediate,,8310,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 2 ml/kg perorally,A,,,Mus musculus,10090.0,
14457,1,,BAO_0000218,Intermediate,,8310,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 250 ml/kg perorally,A,,,Mus musculus,10090.0,
14458,1,,BAO_0000218,Intermediate,,8310,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 3 ml/kg perorally,A,,,Mus musculus,10090.0,
14459,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of potassium in urine of rats after peroral administration of 25.9 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,
14460,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of potassium in urine of rats after peroral administration of 259 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,
14461,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of potassium in urine of rats after peroral administration of 26.5 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,
14462,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of potassium in urine of rats after peroral administration of 265 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,
14463,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of potassium in urine of rats after peroral administration of 27 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,
14464,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of potassium in urine of rats after peroral administration of 27.9 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,
14465,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of potassium in urine of rats after peroral administration of 270 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,
14466,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of potassium in urine of rats after peroral administration of 279 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,
14467,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of potassium in urine of rats after peroral administration of 28.2 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,
14468,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of potassium in urine of rats after peroral administration of 28.22 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,
14469,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of potassium in urine of rats after peroral administration of 28.9 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,
14470,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of potassium in urine of rats after peroral administration of 282 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,
14471,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of potassium in urine of rats after peroral administration of 289 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,
14472,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of potassium in urine of rats after peroral administration of 3.40 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,
14473,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of potassium in urine of rats after peroral administration of 3.76 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,
14474,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of potassium in urine of rats after peroral administration of 30.2 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,
14475,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of potassium in urine of rats after peroral administration of 302 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,
14476,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of potassium in urine of rats after peroral administration of 31.6 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,
14477,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of potassium in urine of rats after peroral administration of 316 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,
14478,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of potassium in urine of rats after peroral administration of 32.4 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,
14479,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of potassium in urine of rats after peroral administration of 324 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,
14480,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of potassium in urine of rats after peroral administration of 34.0 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,
14481,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of potassium in urine of rats after peroral administration of 34.1 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,
14482,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of potassium in urine of rats after peroral administration of 34.8 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,
14483,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of potassium in urine of rats after peroral administration of 341 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,
14484,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of potassium in urine of rats after peroral administration of 348 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,
14485,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of potassium in urine of rats after peroral administration of 37.6 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,
14486,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of potassium in urine of rats after peroral administration of 50.8 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,
14487,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of potassium in urine of rats after peroral administration of 58.4 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,
14488,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of potassium in urine of rats after peroral administration of 65.2 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,
14489,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of potassium in urine of rats after peroral administration of 68.1 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,
14490,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of potassium in urine of rats after peroral administration of 7.94 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,
14491,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of potassium in urine of rats after peroral administration of 71.6 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,
14492,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of potassium in urine of rats after peroral administration of 71.8 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,
14493,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of potassium in urine of rats after peroral administration of 74.8 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,
14494,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of potassium in urine of rats after peroral administration of 77.5 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,
14495,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of potassium in urine of rats after peroral administration of 79.4 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,
14496,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of potassium in urine of rats after peroral administration of 80.9 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,
14497,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of potassium in urine of rats after peroral administration of 83.8 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,
14498,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of potassium in urine of rats after peroral administration of 84.5 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,
14499,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of potassium in urine of rats after peroral administration of 84.7 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,
14500,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of potassium in urine of rats after peroral administration of 86.7 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,
14501,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of potassium in urine of rats after peroral administration of 86.9 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,
14502,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of potassium in urine of rats after peroral administration of 9.06 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,
14503,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of potassium in urine of rats after peroral administration of 90.6 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,
14504,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of potassium in urine of rats after peroral administration of 94.9 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,
14505,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of potassium in urine of rats after peroral administration of 97.1 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,
14506,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 52.4 uM/Kg of drug,A,,,Canis lupus familiaris,9615.0,
14507,0,,BAO_0000218,Autocuration,2367.0,13257,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (d),A,In vivo,,,,
14508,0,,BAO_0000218,Autocuration,2367.0,13257,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (v),A,In vivo,,,,
14509,0,,BAO_0000218,Autocuration,,13257,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (v)/blood,A,In vivo,,,,
14510,0,,BAO_0000218,Autocuration,2385.0,13257,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (v)/muscle,A,In vivo,,,,
14511,0,,BAO_0000218,Autocuration,2106.0,13257,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in spleen,A,In vivo,,,,
14512,0,,BAO_0000218,Autocuration,2113.0,13257,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hr in kidney,A,In vivo,,,,
14513,0,,BAO_0000218,Autocuration,1255.0,13257,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in bladder,A,In vivo,,,,
14514,0,,BAO_0000218,Autocuration,178.0,13257,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in blood,A,In vivo,,,,
14515,0,,BAO_0000218,Autocuration,1474.0,13257,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in bone,A,In vivo,,,,
14516,0,,BAO_0000218,Autocuration,,13257,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in fat,A,In vivo,,,,
14517,0,,BAO_0000218,Autocuration,2113.0,13257,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in kidney,A,In vivo,,,,
14518,0,,BAO_0000218,Autocuration,2107.0,13257,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in liver,A,In vivo,,,,
14519,0,,BAO_0000218,Autocuration,2048.0,13257,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in lung,A,In vivo,,,,
14520,0,,BAO_0000218,Autocuration,2385.0,13257,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in muscle,A,In vivo,,,,
14521,0,,BAO_0000218,Autocuration,2367.0,13257,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (d),A,In vivo,,,,
14522,0,,BAO_0000218,Autocuration,2367.0,13257,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (d)/biood,A,In vivo,,,,
14523,0,,BAO_0000218,Autocuration,2385.0,13257,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (d)/muscle,A,In vivo,,,,
14524,0,,BAO_0000218,Autocuration,2367.0,13257,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (v),A,In vivo,,,,
14525,0,,BAO_0000218,Autocuration,,13257,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (v)/blood,A,In vivo,,,,
14526,0,,BAO_0000218,Autocuration,2385.0,13257,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (v)/muscle,A,In vivo,,,,
14527,0,,BAO_0000218,Autocuration,2106.0,13257,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in spleen,A,In vivo,,,,
14528,0,,BAO_0000218,Autocuration,2367.0,13257,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (d)/biood,A,In vivo,,,,
14529,0,,BAO_0000218,Autocuration,2385.0,13257,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (d)/muscle,A,In vivo,,,,
14530,1,,BAO_0000218,Intermediate,,15413,Biodistribution of the Radiolabeled FBWAY compound in rat Cerebellum at 30 min co-injected with 200 nmol of WAY 100635,A,In vivo,,Rattus norvegicus,10116.0,
14531,1,,BAO_0000218,Intermediate,,15413,Biodistribution of the Radiolabeled FBWAY compound in rat Cerebellum at 30 min co-injected with 50 nmol of WAY 100635,A,In vivo,,Rattus norvegicus,10116.0,
14532,1,,BAO_0000218,Intermediate,,15413,Biodistribution of the Radiolabeled FBWAY compound in rat cortex at 30 min co-injected with 200 nmol of WAY 100635,A,In vivo,,Rattus norvegicus,10116.0,
14533,1,,BAO_0000218,Intermediate,,15413,Biodistribution of the Radiolabeled FBWAY compound in rat cortex at 30 min co-injected with 50 nmol of WAY 100635,A,In vivo,,Rattus norvegicus,10116.0,
14534,1,,BAO_0000218,Intermediate,10000000.0,15413,Biodistribution of the Radiolabeled FBWAY compound in rat hippocampus at 30 min co-injected with 200 nmol of WAY 100635,A,In vivo,,Rattus norvegicus,10116.0,
14535,1,,BAO_0000218,Intermediate,10000000.0,15413,Biodistribution of the Radiolabeled FBWAY compound in rat hippocampus at 30 min co-injected with 50 nmol of WAY 100635,A,In vivo,,Rattus norvegicus,10116.0,
14536,1,,BAO_0000218,Intermediate,1898.0,15413,Biodistribution of the Radiolabeled FBWAY compound in rat hypothalamus at 30 min co-injected with 200 nmol of WAY 100635,A,In vivo,,Rattus norvegicus,10116.0,
14537,1,,BAO_0000218,Intermediate,1898.0,15413,Biodistribution of the Radiolabeled FBWAY compound in rat hypothalamus at 30 min co-injected with 50 nmol of WAY 100635,A,In vivo,,Rattus norvegicus,10116.0,
14538,1,,BAO_0000218,Intermediate,,15413,Biodistribution of the Radiolabeled FCWAY compound in rat Cerebellum at 30 min co-injected with 50 nmol of WAY 100635,A,In vivo,,Rattus norvegicus,10116.0,
14539,1,,BAO_0000218,Intermediate,,15413,Biodistribution of the Radiolabeled FCWAY compound in rat cortex at 30 min co-injected with 50 nmol of WAY 100635,A,In vivo,,Rattus norvegicus,10116.0,
14540,1,,BAO_0000218,Intermediate,10000000.0,15413,Biodistribution of the Radiolabeled FCWAY compound in rat hippocampus at 30 min co-injected with 50 nmol of WAY 100635,A,In vivo,,Rattus norvegicus,10116.0,
14541,1,,BAO_0000218,Intermediate,1898.0,15413,Biodistribution of the Radiolabeled FCWAY compound in rat hypothalamus at 30 min co-injected with 50 nmol of WAY 100635,A,In vivo,,Rattus norvegicus,10116.0,
14542,1,,BAO_0000218,Intermediate,,15413,Biodistribution of the Radiolabeled MeFBWAY compound in rat Cerebellum at 30 min co-injected with 50 nmol of WAY 100635,A,In vivo,,Rattus norvegicus,10116.0,
14543,1,,BAO_0000218,Intermediate,,15413,Biodistribution of the Radiolabeled MeFBWAY compound in rat cortex at 30 min co-injected with 50 nmol of WAY 100635,A,In vivo,,Rattus norvegicus,10116.0,
14544,1,,BAO_0000218,Intermediate,10000000.0,15413,Biodistribution of the Radiolabeled MeFBWAY compound in rat hippocampus at 30 min co-injected with 50 nmol of WAY 100635,A,In vivo,,Rattus norvegicus,10116.0,
14545,1,,BAO_0000218,Intermediate,1898.0,15413,Biodistribution of the Radiolabeled MeFBWAY compound in rat hypothalamus at 30 min co-injected with 50 nmol of WAY 100635; Not determined,A,In vivo,,Rattus norvegicus,10116.0,
14546,1,,BAO_0000218,Intermediate,2037.0,15413,Biodistribution of the [11C]-radiolabeled compound in rat cerebellum,A,In vivo,,Rattus norvegicus,10116.0,
14547,1,,BAO_0000218,Intermediate,2037.0,15413,Biodistribution of the [11C]-radiolabeled compound in rat cerebellum co-injected with 50 nM of WAY 100635.,A,In vivo,,Rattus norvegicus,10116.0,
14548,1,,BAO_0000218,Intermediate,,15413,Biodistribution of the [11C]-radiolabeled compound in rat cortex,A,In vivo,,Rattus norvegicus,10116.0,
14549,1,,BAO_0000218,Intermediate,,15413,Biodistribution of the [11C]-radiolabeled compound in rat cortex co-injected with 50 nM of WAY 100635.,A,In vivo,,Rattus norvegicus,10116.0,
14550,1,,BAO_0000218,Intermediate,10000000.0,15413,Biodistribution of the [11C]-radiolabeled compound in rat hippocampus,A,In vivo,,Rattus norvegicus,10116.0,
14551,1,,BAO_0000218,Intermediate,10000000.0,15413,Biodistribution of the [11C]-radiolabeled compound in rat hippocampus co-injected with 50 nM of WAY 100635.,A,In vivo,,Rattus norvegicus,10116.0,
14552,1,,BAO_0000218,Intermediate,1898.0,15413,Biodistribution of the [11C]-radiolabeled compound in rat hypothalamus,A,In vivo,,Rattus norvegicus,10116.0,
14553,1,,BAO_0000218,Intermediate,1898.0,15413,Biodistribution of the [11C]-radiolabeled compound in rat hypothalamus co-injected with 50 nM of WAY 100635.,A,In vivo,,Rattus norvegicus,10116.0,
14554,1,,BAO_0000218,Intermediate,2037.0,15413,Biodistribution of the [18F]-radiolabeled compound in rat cerebellum,A,In vivo,,Rattus norvegicus,10116.0,
14555,1,,BAO_0000218,Intermediate,,15413,Biodistribution of the [18F]-radiolabeled compound in rat cortex,A,In vivo,,Rattus norvegicus,10116.0,
14556,0,,BAO_0000019,Autocuration,,12404,Reaction rate parameter value for phosphate with transfer with respect to ATP,A,,,,,
14557,0,,BAO_0000019,Autocuration,,568,"Tested for hydrolysis in presence of boric acid, dissociation constant was evaluated at the pH 8.5(Apparent inhibition constant)",A,,,,,
14558,0,,BAO_0000019,Autocuration,,568,"Tested for hydrolysis in presence of boric acid, dissociation constant was evaluated at the pH 9.5(Apparent inhibition constant)",A,,,,,
14559,0,,BAO_0000019,Autocuration,,568,"Tested for hydrolysis in presence of phenylboronic acid, dissociation constant was evaluated at the pH 9.5(Apparent inhibition constant)",A,,,,,
14560,0,,BAO_0000019,Autocuration,,12404,Reaction rate parameter value for phosphate with transfer with respect to ATP,A,,,,,
14561,1,,BAO_0000218,Intermediate,,7624,Ability to inhibit Escherichia coli adenylate kinase II activity expressed as half maximal velocity,A,,,Escherichia coli,562.0,
14562,1,,BAO_0000218,Intermediate,,7624,"Ability to inhibit rat adenylate kinase II, activity expressed as half-maximal velocity",A,,,Rattus norvegicus,10116.0,
14563,1,,BAO_0000218,Intermediate,,7624,"Ability to inhibit rat adenylate kinase III, activity expressed as half-maximal velocity",A,,,Rattus norvegicus,10116.0,
14564,0,,BAO_0000019,Autocuration,,4643,"Compound was evaluated for the Michaelis-Menten constant, Km in a generic protein phosphatase stopped assay system",A,,,,,
14565,0,,BAO_0000019,Autocuration,,11532,Kinetic parameter KM (nM) for the MAO-B catalyzed oxidation of the compound.,A,,,,,
14566,0,,BAO_0000019,Autocuration,,11018,Kinetic parameter KM at pH 7.4 and 37 degree Centigrade,A,,,,,
14567,0,,BAO_0000019,Autocuration,,2276,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 0.25% acetonitrile and 4B2 as catalyst was expressed as KM; Not determined",A,,,,,
14568,0,,BAO_0000019,Autocuration,,2276,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 4B2 as catalyst was expressed as KM",A,,,,,
14569,0,,BAO_0000019,Autocuration,,2276,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 6C2 as catalyst was expressed as KM; Not determined",A,,,,,
14570,0,,BAO_0000019,Autocuration,,2276,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 10% acetonitrile and 4B2 as catalyst was expressed as KM; Not determined",A,,,,,
14571,0,,BAO_0000019,Autocuration,,2276,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 5% acetonitrile and 4B2 as catalyst was expressed as KM",A,,,,,
14572,0,,BAO_0000019,Autocuration,,8949,Michaelis constant (KM) was evaluated,A,,,,,
14573,0,,BAO_0000019,Autocuration,,12404,Reaction rate parameter value for phosphate with transfer with respect to ATP,A,,,,,
14574,0,,BAO_0000019,Autocuration,,7625,Substrate concentration for half maximal velocity was reported for rat hexokinase I,B,,,,,
14575,0,,BAO_0000019,Autocuration,,7625,Substrate concentration for half maximal velocity was reported for rat hexokinase II,B,,,,,
14576,0,,BAO_0000019,Autocuration,,7625,Substrate concentration for half maximal velocity was reported for rat hexokinase III,B,,,,,
14577,0,,BAO_0000019,Autocuration,,7625,Substrate concentration for half maximal velocity was reported for yeast hexokinase,B,,,,,
14578,0,,BAO_0000019,Autocuration,,12908,Pseudo-first-order rate constant for alkylation of NBP in 50% aqueous acetone at 66 degrees celsius with 50 uM and 25 uM of NBP.,A,,,,,
14579,0,,BAO_0000019,Autocuration,,10368,Rate constant for alkylation of 4-(4-nitrobenzyl)pyridine,A,,,,,
14580,0,,BAO_0000019,Autocuration,,13108,Bimolecular rate constant (KOH) at 25 degree C (m = 0.5),A,,,,,
14581,0,,BAO_0000019,Autocuration,,13108,its bimolecular rate constant (KOH) at 25 degree C (m = 0.5),A,,,,,
14582,0,,BAO_0000019,Autocuration,,15217,Acid dissociation constant evaluated towards Hematin mu-oxo dimer,A,,,,,
14583,0,,BAO_0000019,Autocuration,,15217,Acid dissociation constant evaluated towards Hematin mu-oxo dimer; Not available,A,,,,,
14584,0,,BAO_0000019,Autocuration,,10933,Binding constant was determined,A,,,,,
14585,0,,BAO_0000019,Autocuration,,2363,Alkylation of 4-(4-nitrobenzyl)pyridine (NBP) by the compound at a temperature of 66 degree Centigrade,A,,,,,
14586,0,,BAO_0000019,Autocuration,,2363,Alkylation of 4-(4-nitrobenzyl)pyridine (NBP) by the compound at a temperature of 66 degree centigrade; Not determined,A,,,,,
14587,0,,BAO_0000019,Autocuration,,2276,Rate constant with triethylamine at 30 degree C in 0.1 M potassium chloride was expressed as Kamine,A,,,,,
14588,0,,BAO_0000100,Autocuration,,14915,Octanol-water apparent distribution coefficient measured in TRIS buffer at a pH 7.4.,P,,,,,
14589,0,,BAO_0000019,Autocuration,,8847,Catalytic rate constant of the compound,A,,,,,
14590,0,,BAO_0000019,Autocuration,,15357,inactivation rate constant calculated from experimental IC50 value for dipeptidyl peptidase IV inhibition,B,,,,,
14591,0,,BAO_0000019,Autocuration,,2869,Catalytic constant expressed as Kinetic behavior of enzyme (PicK/6-His),A,,,,,
14592,0,,BAO_0000019,Autocuration,,3484,Catalytic rate constant against phospholipase A2 was determined,A,,,,,
14593,0,,BAO_0000019,Autocuration,,1373,"Compound was evaluated for catalytic constant, Kcat",A,,,,,
14594,0,,BAO_0000019,Autocuration,,8142,Compound was tested for hydrolysis by acetylcholinesterase and the kinetic constant (kcat) which is a first-order rate constant was determined,A,,,,,
14595,0,,BAO_0000019,Autocuration,,14131,Kcat calculated from 0.693/T1/2,A,,,,,
14596,0,,BAO_0000019,Autocuration,,17269,Kcat was determined,A,,,,,
14597,0,,BAO_0000019,Autocuration,,3485,Kcat against class A PCI beta-lactamase catalyzed lactone hydrolysis,A,,,,,
14598,0,,BAO_0000019,Autocuration,,3485,Kcat against class A TEM beta-lactamase catalyzed lactone hydrolysis,A,,,,,
14599,0,,BAO_0000019,Autocuration,,3485,Kcat against class C P99 beta-lactamase catalyzed lactone hydrolysis,A,,,,,
14600,0,,BAO_0000019,Autocuration,,5962,Kcat value was determined,A,,,,,
14601,0,,BAO_0000019,Autocuration,,3133,Kinetic constant for the hydrolysis by the catalyst CPA was evaluated,A,,,,,
14602,0,,BAO_0000019,Autocuration,,3133,Kinetic constant for the hydrolysis by the catalyst McAbIIF9D8 was evaluated,A,,,,,
14603,0,,BAO_0000019,Autocuration,,2276,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 0.25% acetonitrile and 4B2 as catalyst was expressed as Kcat; Not determined",A,,,,,
14604,0,,BAO_0000019,Autocuration,,2276,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 4B2 as catalyst was expressed as Kcat",A,,,,,
14605,0,,BAO_0000019,Autocuration,,2276,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 6C2 as catalyst was expressed as Kcat; Not determined",A,,,,,
14606,0,,BAO_0000019,Autocuration,,2276,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 10% acetonitrile and 4B2 as catalyst was expressed as Kcat; Not determined",A,,,,,
14607,0,,BAO_0000019,Autocuration,,2276,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 5% acetonitrile and 4B2 as catalyst was expressed as Kcat",A,,,,,
14608,0,,BAO_0000019,Autocuration,,4892,Kinetic parameter for rate of conversion to PABA was determined,A,,,,,
14609,0,,BAO_0000019,Autocuration,,3133,Rate acceleration expressed as ratio of Kcat to Kuncat was evaluated,A,,,,,
14610,1,,BAO_0000218,Intermediate,1988.0,11488,"Compound was evaluated for the percentage of feces excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 48-72 hr",A,,,Rattus norvegicus,10116.0,
14611,1,,BAO_0000218,Intermediate,1088.0,11488,"Compound was evaluated for the percentage of urine excretion of radioactivity, by male Sprague-Dawley rats after intravenous administration of compound dose (1 mg/kg) at 0-24 hr",A,,,Rattus norvegicus,10116.0,
14612,1,,BAO_0000218,Intermediate,1088.0,11488,"Compound was evaluated for the percentage of urine excretion of radioactivity, by male Sprague-Dawley rats after intravenous administration of compound dose (1 mg/kg) at 24-48 hr",A,,,Rattus norvegicus,10116.0,
14613,1,,BAO_0000218,Intermediate,1088.0,11488,"Compound was evaluated for the percentage of urine excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 0-24 hr",A,,,Rattus norvegicus,10116.0,
14614,1,,BAO_0000218,Intermediate,1088.0,11488,"Compound was evaluated for the percentage of urine excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 24-48 hr",A,,,Rattus norvegicus,10116.0,
14615,1,,BAO_0000218,Intermediate,1088.0,11488,"Compound was evaluated for the percentage of urine excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 48-72 hr",A,,,Rattus norvegicus,10116.0,
14616,1,,BAO_0000218,Intermediate,,11488,Cumulative dose excreted after intraduodenal administration at 0-0.5 hours in rats,A,,,Rattus norvegicus,10116.0,
14617,1,,BAO_0000218,Intermediate,,11488,Cumulative dose excreted after intraduodenal administration at 0.5-1.0 hours in rats,A,,,Rattus norvegicus,10116.0,
14618,1,,BAO_0000218,Intermediate,,11488,Cumulative dose excreted after intraduodenal administration at 1.0-1.5 hours in rats,A,,,Rattus norvegicus,10116.0,
14619,1,,BAO_0000218,Intermediate,,11488,Cumulative dose excreted after intraduodenal administration at 1.5-2.0 hours in rats,A,,,Rattus norvegicus,10116.0,
14620,1,,BAO_0000218,Intermediate,,11488,Cumulative dose excreted after intraduodenal administration at 2-3 hours in rats,A,,,Rattus norvegicus,10116.0,
14621,1,,BAO_0000218,Intermediate,,11488,Cumulative dose excreted after intraduodenal administration at 3-4 hours in rats,A,,,Rattus norvegicus,10116.0,
14622,1,,BAO_0000218,Intermediate,,11488,Cumulative dose excreted after intraduodenal administration at 4-6 hours in rats,A,,,Rattus norvegicus,10116.0,
14623,1,,BAO_0000218,Intermediate,,11488,Cumulative dose excreted after intraduodenal administration at 6-8 hours in rats,A,,,Rattus norvegicus,10116.0,
14624,1,,BAO_0000218,Intermediate,,11488,Cumulative dose excreted after intraduodenal administration at 8-24 hours in rats,A,,,Rattus norvegicus,10116.0,
14625,1,,BAO_0000218,Intermediate,,11488,Cumulative dose excreted after intravenous administration at 0-0.5 hours in rats,A,,,Rattus norvegicus,10116.0,
14626,1,,BAO_0000218,Intermediate,,11488,Cumulative dose excreted after intravenous administration at 0.5-1 hours in rats,A,,,Rattus norvegicus,10116.0,
14627,1,,BAO_0000218,Intermediate,,11488,Cumulative dose excreted after intravenous administration at 1.0-1.5 hours in rats,A,,,Rattus norvegicus,10116.0,
14628,1,,BAO_0000218,Intermediate,,11488,Cumulative dose excreted after intravenous administration at 1.5-2 hours in rats,A,,,Rattus norvegicus,10116.0,
14629,1,,BAO_0000218,Intermediate,,11488,Cumulative dose excreted after intravenous administration at 2-3 hours in rats,A,,,Rattus norvegicus,10116.0,
14630,1,,BAO_0000218,Intermediate,,11488,Cumulative dose excreted after intravenous administration at 3-4 hours in rats,A,,,Rattus norvegicus,10116.0,
14631,1,,BAO_0000218,Intermediate,,11488,Cumulative dose excreted after intravenous administration at 4-6 hours in rats,A,,,Rattus norvegicus,10116.0,
14632,1,,BAO_0000218,Intermediate,,11488,Cumulative dose excreted after intravenous administration at 6-8 hours in rats,A,,,Rattus norvegicus,10116.0,
14633,1,,BAO_0000218,Intermediate,,11488,Cumulative dose excreted after intravenous administration at 8-24 hours in rats,A,,,Rattus norvegicus,10116.0,
14634,1,,BAO_0000218,Intermediate,1988.0,7132,"10 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit, and radioactivity content in feces was estimated (total)",A,,,Oryctolagus cuniculus,9986.0,
14635,1,,BAO_0000218,Intermediate,1988.0,7132,"10 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit, and radioactivity content in feces was estimated at 0-24 h",A,,,Oryctolagus cuniculus,9986.0,
14636,1,,BAO_0000218,Intermediate,1988.0,7132,"10 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit, and radioactivity content in feces was estimated at 24-48 h",A,,,Oryctolagus cuniculus,9986.0,
14637,1,,BAO_0000218,Intermediate,1988.0,7132,"10 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit, and radioactivity content in feces was estimated at 48-72 h",A,,,Oryctolagus cuniculus,9986.0,
14638,1,,BAO_0000218,Intermediate,1088.0,7132,"10 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit, and radioactivity content in urine was estimated (total)",A,,,Oryctolagus cuniculus,9986.0,
14639,1,,BAO_0000218,Intermediate,1088.0,7132,"10 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit, and radioactivity content in urine was estimated at 0-6 h",A,,,Oryctolagus cuniculus,9986.0,
14640,1,,BAO_0000218,Intermediate,1088.0,7132,"10 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit, and radioactivity content in urine was estimated at 24-48 h",A,,,Oryctolagus cuniculus,9986.0,
14641,1,,BAO_0000218,Intermediate,1088.0,7132,"10 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit, and radioactivity content in urine was estimated at 48-72 h",A,,,Oryctolagus cuniculus,9986.0,
14642,1,,BAO_0000218,Intermediate,1088.0,7132,"10 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit, and radioactivity content in urine was estimated at 6-24 h",A,,,Oryctolagus cuniculus,9986.0,
14643,1,,BAO_0000218,Intermediate,1988.0,7132,"25 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit, and radioactivity content in feces was estimated (total)",A,,,Oryctolagus cuniculus,9986.0,
14644,1,,BAO_0000218,Intermediate,1988.0,7132,"25 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit, and radioactivity content in feces was estimated at 0-24 h",A,,,Oryctolagus cuniculus,9986.0,
14645,1,,BAO_0000218,Intermediate,1988.0,7132,"25 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit, and radioactivity content in feces was estimated at 24-48 h",A,,,Oryctolagus cuniculus,9986.0,
14646,1,,BAO_0000218,Intermediate,1988.0,7132,"25 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit, and radioactivity content in feces was estimated at 48-72 h",A,,,Oryctolagus cuniculus,9986.0,
14647,1,,BAO_0000218,Intermediate,1088.0,7132,"25 mg/kg of [14C]- radiolabeled compound was perorally injected in rabbit, and radioactivity content in urine was estimated (total)",A,,,Oryctolagus cuniculus,9986.0,
14648,1,,BAO_0000218,Intermediate,1088.0,7132,"25 mg/kg of [14C]- radiolabeled compound was perorally injected in rabbit, and radioactivity content in urine was estimated at 0-6 h",A,,,Oryctolagus cuniculus,9986.0,
14649,1,,BAO_0000218,Intermediate,1088.0,7132,"25 mg/kg of [14C]- radiolabeled compound was perorally injected in rabbit, and radioactivity content in urine was estimated at 24-48 h",A,,,Oryctolagus cuniculus,9986.0,
14650,1,,BAO_0000218,Intermediate,1088.0,7132,"25 mg/kg of [14C]- radiolabeled compound was perorally injected in rabbit, and radioactivity content in urine was estimated at 48-72 h",A,,,Oryctolagus cuniculus,9986.0,
14651,1,,BAO_0000218,Intermediate,1088.0,7132,"25 mg/kg of [14C]- radiolabeled compound was perorally injected in rabbit, and radioactivity content in urine was estimated at 6-24 h",A,,,Oryctolagus cuniculus,9986.0,
14652,1,,BAO_0000218,Intermediate,178.0,13925,Biodistribution in rat blood post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,A,In vivo,,Rattus norvegicus,10116.0,
14653,1,,BAO_0000218,Intermediate,178.0,13925,Biodistribution in rat blood post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,A,In vivo,,Rattus norvegicus,10116.0,
14654,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 11.9 uM/Kg of drug,A,,,Canis lupus familiaris,9615.0,
14655,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 2.49 uM/Kg of drug,A,,,Canis lupus familiaris,9615.0,
14656,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 26.2 uM/Kg of drug,A,,,Canis lupus familiaris,9615.0,
14657,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 3.03 uM/Kg of drug,A,,,Canis lupus familiaris,9615.0,
14658,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 30.3 uM/Kg of drug,A,,,Canis lupus familiaris,9615.0,
14659,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 34.1 uM/Kg of drug,A,,,Canis lupus familiaris,9615.0,
14660,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 7.85 uM/Kg of drug,A,,,Canis lupus familiaris,9615.0,
14661,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 8.47 uM/Kg of drug,A,,,Canis lupus familiaris,9615.0,
14662,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 9.09 uM/Kg of drug,A,,,Canis lupus familiaris,9615.0,
14663,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 10.1 uM/Kg of drug,A,,,Canis lupus familiaris,9615.0,
14664,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 102 uM/Kg of drug,A,,,Canis lupus familiaris,9615.0,
14665,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 3.40 uM/Kg of drug,A,,,Canis lupus familiaris,9615.0,
14666,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 3.76 uM/Kg of drug,A,,,Canis lupus familiaris,9615.0,
14667,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 34.1 uM/Kg of drug,A,,,Canis lupus familiaris,9615.0,
14668,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 50.8 uM/Kg of drug,A,,,Canis lupus familiaris,9615.0,
14669,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 68.1 uM/Kg of drug,A,,,Canis lupus familiaris,9615.0,
14670,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 9.060 uM/Kg of drug,A,,,Canis lupus familiaris,9615.0,
14671,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 9.6 uM/Kg of drug,A,,,Canis lupus familiaris,9615.0,
14672,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of sodium in urine of rats after intravenous administration of 7.94 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,
14673,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of sodium in urine of rats after peroral administration of 0 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,
14674,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of sodium in urine of rats after peroral administration of 1.01 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,
14675,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of sodium in urine of rats after peroral administration of 1.13 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,
14676,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of sodium in urine of rats after peroral administration of 10.1 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,
14677,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of sodium in urine of rats after peroral administration of 102 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,
14678,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of sodium in urine of rats after peroral administration of 105 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,
14679,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of sodium in urine of rats after peroral administration of 11.3 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,
14680,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of sodium in urine of rats after peroral administration of 113 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,
14681,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of sodium in urine of rats after peroral administration of 19.5 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,
14682,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of sodium in urine of rats after peroral administration of 195 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,
14683,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of sodium in urine of rats after peroral administration of 21.7 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,
14684,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of sodium in urine of rats after peroral administration of 217 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,
14685,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of sodium in urine of rats after peroral administration of 23.9 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,
14686,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of sodium in urine of rats after peroral administration of 239 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,
14687,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of sodium in urine of rats after peroral administration of 24.9 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,
14688,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of sodium in urine of rats after peroral administration of 249 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,
14689,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of sodium in urine of rats after peroral administration of 25.9 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,
14690,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of sodium in urine of rats after peroral administration of 259 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,
14691,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of sodium in urine of rats after peroral administration of 26.5 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,
14692,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of sodium in urine of rats after peroral administration of 265 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,
14693,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of sodium in urine of rats after peroral administration of 27 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,
14694,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of sodium in urine of rats after peroral administration of 27.9 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,
14695,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of sodium in urine of rats after peroral administration of 270 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,
14696,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of sodium in urine of rats after peroral administration of 279 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,
14697,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of sodium in urine of rats after peroral administration of 28.2 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,
14698,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of sodium in urine of rats after peroral administration of 28.9 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,
14699,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of sodium in urine of rats after peroral administration of 282 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,
14700,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of sodium in urine of rats after peroral administration of 289 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,
14701,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of sodium in urine of rats after peroral administration of 3.40 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,
14702,1,,BAO_0000218,Intermediate,10000000.0,15413,Biodistribution of the [18F]-radiolabeled compound in rat hippocampus,A,In vivo,,Rattus norvegicus,10116.0,
14703,1,,BAO_0000218,Intermediate,1898.0,15413,Biodistribution of the [18F]-radiolabeled compound in rat hypothalamus,A,In vivo,,Rattus norvegicus,10116.0,
14704,1,,BAO_0000218,Intermediate,1898.0,15413,Biodistribution of the [18F]-radiolabeled compound in rat hypothalamus; Not determined,A,In vivo,,Rattus norvegicus,10116.0,
14705,1,,BAO_0000218,Intermediate,178.0,12017,Biodistribution in blood of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0,
14706,1,,BAO_0000218,Intermediate,178.0,12017,Biodistribution in blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0,
14707,1,,BAO_0000218,Intermediate,178.0,12017,Biodistribution in blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),A,In vivo,,Rattus norvegicus,10116.0,
14708,1,,BAO_0000218,Intermediate,178.0,12017,Biodistribution in blood of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0,
14709,1,,BAO_0000218,Intermediate,178.0,12017,Biodistribution in blood of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0,
14710,1,,BAO_0000218,Intermediate,178.0,12017,Biodistribution in blood of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0,
14711,1,,BAO_0000218,Intermediate,178.0,12017,Biodistribution in blood of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0,
14712,1,,BAO_0000218,Intermediate,178.0,12017,Biodistribution in blood of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),A,In vivo,,Rattus norvegicus,10116.0,
14713,1,,BAO_0000218,Intermediate,178.0,12017,Biodistribution in blood of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0,
14714,1,,BAO_0000218,Intermediate,178.0,12017,Biodistribution in blood of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0,
14715,1,,BAO_0000218,Intermediate,178.0,12017,Biodistribution in blood of immature femalee rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),A,In vivo,,Rattus norvegicus,10116.0,
14716,1,,BAO_0000218,Intermediate,,12017,Biodistribution in fat of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0,
14717,1,,BAO_0000218,Intermediate,,12017,Biodistribution in fat of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0,
14718,1,,BAO_0000218,Intermediate,,12017,Biodistribution in fat of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),A,In vivo,,Rattus norvegicus,10116.0,
14719,1,,BAO_0000218,Intermediate,,12017,Biodistribution in fat of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0,
14720,1,,BAO_0000218,Intermediate,,12017,Biodistribution in fat of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0,
14721,1,,BAO_0000218,Intermediate,,12017,Biodistribution in fat of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0,
14722,1,,BAO_0000218,Intermediate,,12017,Biodistribution in fat of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0,
14723,1,,BAO_0000218,Intermediate,,12017,Biodistribution in fat of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),A,In vivo,,Rattus norvegicus,10116.0,
14724,1,,BAO_0000218,Intermediate,,12017,Biodistribution in fat of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0,
14725,1,,BAO_0000218,Intermediate,,12017,Biodistribution in fat of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0,
14726,1,,BAO_0000218,Intermediate,2113.0,12017,Biodistribution in kidney of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0,
14727,1,,BAO_0000218,Intermediate,2113.0,12017,Biodistribution in kidney of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0,
14728,1,,BAO_0000218,Intermediate,2113.0,12017,Biodistribution in kidney of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),A,In vivo,,Rattus norvegicus,10116.0,
14729,1,,BAO_0000218,Intermediate,2113.0,12017,Biodistribution in kidney of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0,
14730,1,,BAO_0000218,Intermediate,2113.0,12017,Biodistribution in kidney of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0,
14731,1,,BAO_0000218,Intermediate,2113.0,12017,Biodistribution in kidney of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0,
14732,1,,BAO_0000218,Intermediate,2113.0,12017,Biodistribution in kidney of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0,
14733,1,,BAO_0000218,Intermediate,2113.0,12017,Biodistribution in kidney of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),A,In vivo,,Rattus norvegicus,10116.0,
14734,1,,BAO_0000218,Intermediate,2113.0,12017,Biodistribution in kidney of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0,
14735,1,,BAO_0000218,Intermediate,2113.0,12017,Biodistribution in kidney of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0,
14736,1,,BAO_0000218,Intermediate,2113.0,12017,Biodistribution in kidney of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0,
14737,1,,BAO_0000218,Intermediate,2107.0,12017,Biodistribution in liver of Iimmature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),A,In vivo,,Rattus norvegicus,10116.0,
14738,1,,BAO_0000218,Intermediate,2107.0,12017,Biodistribution in liver of Iimmature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0,
14739,1,,BAO_0000218,Intermediate,2107.0,12017,Biodistribution in liver of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0,
14740,1,,BAO_0000218,Intermediate,2107.0,12017,Biodistribution in liver of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0,
14741,1,,BAO_0000218,Intermediate,2107.0,12017,Biodistribution in liver of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),A,In vivo,,Rattus norvegicus,10116.0,
14742,1,,BAO_0000218,Intermediate,2107.0,12017,Biodistribution in liver of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0,
14743,1,,BAO_0000218,Intermediate,2107.0,12017,Biodistribution in liver of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0,
14744,1,,BAO_0000218,Intermediate,2107.0,12017,Biodistribution in liver of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0,
14745,1,,BAO_0000218,Intermediate,2107.0,12017,Biodistribution in liver of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0,
14746,0,,BAO_0000019,Autocuration,,3133,Rate acceleration expressed as ratio of Kcat to Kuncat was evaluated,A,,,,,
14747,0,,BAO_0000019,Autocuration,,2742,Compound was tested for amidase rate in the presence of N62C fully characterised enzyme,A,,,,,
14748,0,,BAO_0000019,Autocuration,,2742,Compound was tested for amidase rate in the presence of N62C screen enzyme,A,,,,,
14749,0,,BAO_0000019,Autocuration,,2742,Compound was tested for amidase rate in the presence of S166C fully characterised enzyme,A,,,,,
14750,0,,BAO_0000019,Autocuration,,2742,Compound was tested for amidase rate in the presence of S166C screen enzyme,A,,,,,
14751,0,,BAO_0000019,Autocuration,,2742,Compound was tested for esterase rate in the presence of N62C fully characterised enzyme,A,,,,,
14752,0,,BAO_0000019,Autocuration,,2742,Compound was tested for esterase rate in the presence of N62C screen enzyme,A,,,,,
14753,0,,BAO_0000019,Autocuration,,2742,Compound was tested for esterase rate in the presence of S166C fully characterised enzyme,A,,,,,
14754,0,,BAO_0000019,Autocuration,,2742,Compound was tested for esterase rate in the presence of S166C screen enzyme,A,,,,,
14755,0,,BAO_0000019,Autocuration,,2276,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 0.25% acetonitrile and 4B2 as catalyst was expressed as Kcat/KM",A,,,,,
14756,0,,BAO_0000019,Autocuration,,2276,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 4B2 as catalyst was expressed as Kcat/KM",A,,,,,
14757,0,,BAO_0000019,Autocuration,,2276,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 6C2 as catalyst was expressed as Kcat/KM",A,,,,,
14758,0,,BAO_0000019,Autocuration,,2276,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 10% acetonitrile and 4B2 as catalyst was expressed as Kcat/KM",A,,,,,
14759,0,,BAO_0000019,Autocuration,,2276,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 5% acetonitrile and 4B2 as catalyst was expressed as Kcat/KM",A,,,,,
14760,0,,BAO_0000019,Autocuration,,2276,"Rate constant at 30 degree C in phosphate buffer pH 7.1, 0.5 % acetonitrile was expressed as Kcat/KM",A,,,,,
14761,0,,BAO_0000019,Autocuration,,17269,Ratio of Kcat to that of Km was determined,A,,,,,
14762,0,,BAO_0000019,Autocuration,,2276,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 4B2 as catalyst was expressed as Kcat/Kuncat",A,,,,,
14763,0,,BAO_0000019,Autocuration,,2276,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 5% acetonitrile and 4B2 as catalyst was expressed as Kcat/Kuncat",A,,,,,
14764,0,,BAO_0000019,Autocuration,,15917,"Compound was evaluated for constant, Kd",A,,,,,
14765,0,,BAO_0000019,Autocuration,,10933,Deacylation rate constant(Kd fast) was determined by proflavin displacement assay,A,,,,,
14766,0,,BAO_0000019,Autocuration,,10933,Deacylation rate constant(Kd slow) was determined by proflavin displacement assay,A,,,,,
14767,0,,BAO_0000019,Autocuration,,14293,Dissociation Constant of compound determined,A,,,,,
14768,0,,BAO_0000019,Autocuration,,6698,Dissociation constant for the binding of compound to PDZ3 from PSD-95 was determined,B,,,,,
14769,0,,BAO_0000019,Autocuration,,6698,Dissociation constant for the binding of compound to PDZ3 from PSD-95 was determined; No data,B,,,,,
14770,0,,BAO_0000100,Autocuration,,4318,Dissociation constant of compound with Fructose was determined,P,,,,,
14771,0,,BAO_0000100,Autocuration,,4318,Dissociation constant of compound with Fructose was determined; Not determined,P,,,,,
14772,0,,BAO_0000100,Autocuration,,4318,Dissociation constant of compound with Lactulose was determined,P,,,,,
14773,0,,BAO_0000100,Autocuration,,4318,Dissociation constant of compound with Lactulose was determined; Not determined,P,,,,,
14774,0,,BAO_0000100,Autocuration,,14959,Dissociation constant of the Compound,P,,,,,
14775,0,,BAO_0000100,Autocuration,,5913,Dissociation constant by non-linear regression analysis,P,,,,,
14776,0,,BAO_0000100,Autocuration,,14218,Dissociation constant was determined,P,,,,,
14777,0,,BAO_0000100,Autocuration,,10689,Dissociation constant of the compound; value ranges from 0.81-1.2 nM,P,,,,,
14778,0,,BAO_0000100,Autocuration,,13925,Dissociation constant was determined,P,,,,,
14779,0,,BAO_0000100,Autocuration,,16359,Dissociation constant was determined,P,,,,,
14780,1,,BAO_0000218,Intermediate,2385.0,10944,Equilibrium dissociation constant based on membrane concentration in rat smooth muscle,A,,,Rattus norvegicus,10116.0,
14781,0,,BAO_0000019,Autocuration,,11080,The dissociation constant determined by fluorescence displacement assay,A,,,,,
14782,0,,BAO_0000019,Autocuration,,17805,kd value surface plasmon resonance (SPR) method,A,,,,,
14783,1,,BAO_0000218,Intermediate,2385.0,10944,Equilibrium dissociation constant based on aqueous concentration in rat smooth muscle,A,,,Rattus norvegicus,10116.0,
14784,0,,BAO_0000019,Autocuration,,16645,First dissociation constant of the binding of compound to V30M TTR,F,,,,,
14785,0,,BAO_0000019,Autocuration,,16645,Second dissociation constant of the binding of compound to V30M TTR,F,,,,,
14786,0,,BAO_0000019,Autocuration,,7793,"Compound was evaluated for equilibrium constant, Ke",A,,,,,
14787,0,,BAO_0000019,Autocuration,1898.0,12199,Equilibrium constant from the dorsal raphe and the ventromedial hypothalamus,A,,,,,
14788,0,,BAO_0000019,Autocuration,1898.0,12199,Equilibrium constant from the dorsal raphe and the ventromedial hypothalamus; inactive,A,,,,,
14789,0,,BAO_0000019,Autocuration,,9680,Keff is the effective biomolecular rate constant on VX for reactivation at pH 7.8 at 25 degree Centigrade,A,,,,,
14790,0,,BAO_0000019,Autocuration,,9680,Keff is the effective biomolecular rate constant on paraxon for reactivation at pH 7.8 at 25 degree Centigrade,A,,,,,
14791,0,,BAO_0000019,Autocuration,,9680,Keff is the effective biomolecular rate constant on sarin for reactivation at pH 7.8 at 25 degree Centigrade,A,,,,,
14792,1,,BAO_0000218,Intermediate,,13758,In vitro biotransformation of compound along with coformycin in mice liver homogenate 9-(beta-D-arabinifuranosyl)-6-azidopurine(6-AAP) analyte,A,,,Mus musculus,10090.0,
14793,1,,BAO_0000218,Intermediate,,13758,In vitro biotransformation of compound along with coformycin in mice liver homogenate 9-(beta-D-arabinifuranosyl)adenine(ara-A) analyte,A,,,Mus musculus,10090.0,
14794,1,,BAO_0000218,Intermediate,,13758,In vitro biotransformation of compound in mice brain homogenate 9-(beta-D-arabinifuranosyl)-6-azidopurine(6-AAP) analyte,A,,,Mus musculus,10090.0,
14795,1,,BAO_0000218,Intermediate,,13758,In vitro biotransformation of compound in mice liver homogenate 9-(beta-D-arabinifuranosyl)-6-azidopurine(6-AAP) analyte,A,,,Mus musculus,10090.0,
14796,1,,BAO_0000218,Intermediate,,13758,In vitro biotransformation of compound in mice liver homogenate 9-(beta-D-arabinifuranosyl)-6-hypoxanthine(ara-H) analyte,A,,,Mus musculus,10090.0,
14797,1,,BAO_0000218,Intermediate,,13758,In vitro biotransformation of compound in mice liver homogenate 9-(beta-D-arabinifuranosyl)adenine(ara-A) analyte,A,,,Mus musculus,10090.0,
14798,1,,BAO_0000218,Intermediate,,13758,In vitro biotransformation of compound in mice liver homogenate 9-(beta-D-arabinifuranosyl)adenine(ara-H) analyte,A,,,Mus musculus,10090.0,
14799,1,,BAO_0000218,Intermediate,,13758,In vitro biotransformation of compound in mice serum 9-(beta-D-arabinifuranosyl)-6-azidopurine(6-AAP) analyte,A,,,Mus musculus,10090.0,
14800,1,,BAO_0000218,Intermediate,,14393,Pharmacokinetic Parameter [Kel(1/h)] was evaluated at 10 mg/kg (p.o.) in Wistar rats,A,,,Rattus norvegicus,10116.0,
14801,1,,BAO_0000218,Intermediate,,14393,Pharmacokinetic parameter [Kel(1/h)] was evaluated at 10 mg/kg (p.o.) in Wistar rats,A,,,Rattus norvegicus,10116.0,
14802,1,,BAO_0000218,Intermediate,,15078,"The Kel value in female wistar rat at 100 mg/kg, p.o. dose",A,,,Rattus norvegicus,10116.0,
14803,1,,BAO_0000218,Intermediate,955.0,13925,Biodistribution in rat brain post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,A,In vivo,,Rattus norvegicus,10116.0,
14804,1,,BAO_0000218,Intermediate,955.0,13925,Biodistribution in rat brain post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,A,In vivo,,Rattus norvegicus,10116.0,
14805,1,,BAO_0000218,Intermediate,948.0,13925,Biodistribution in rat heart post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,A,In vivo,,Rattus norvegicus,10116.0,
14806,1,,BAO_0000218,Intermediate,948.0,13925,Biodistribution in rat heart post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,A,In vivo,,Rattus norvegicus,10116.0,
14807,1,,BAO_0000218,Intermediate,2113.0,13925,Biodistribution in rat kidney post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,A,In vivo,,Rattus norvegicus,10116.0,
14808,1,,BAO_0000218,Intermediate,2113.0,13925,Biodistribution in rat kidney post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,A,In vivo,,Rattus norvegicus,10116.0,
14809,1,,BAO_0000218,Intermediate,2107.0,13925,Biodistribution in rat liver post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,A,In vivo,,Rattus norvegicus,10116.0,
14810,1,,BAO_0000218,Intermediate,2107.0,13925,Biodistribution in rat liver post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,A,In vivo,,Rattus norvegicus,10116.0,
14811,1,,BAO_0000218,Intermediate,2048.0,13925,Biodistribution in rat lung post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,A,In vivo,,Rattus norvegicus,10116.0,
14812,1,,BAO_0000218,Intermediate,2048.0,13925,Biodistribution in rat lung post intravenous injection for 60 min of [99mTc]-TRODAT ligand expressed as percent dose per organ,A,In vivo,,Rattus norvegicus,10116.0,
14813,1,,BAO_0000218,Intermediate,2385.0,13925,Biodistribution in rat muscle post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,A,In vivo,,Rattus norvegicus,10116.0,
14814,1,,BAO_0000218,Intermediate,2385.0,13925,Biodistribution in rat muscle post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,A,In vivo,,Rattus norvegicus,10116.0,
14815,1,,BAO_0000218,Intermediate,14.0,13925,Biodistribution in rat skin post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,A,In vivo,,Rattus norvegicus,10116.0,
14816,1,,BAO_0000218,Intermediate,14.0,13925,Biodistribution in rat skin post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,A,In vivo,,Rattus norvegicus,10116.0,
14817,1,,BAO_0000218,Intermediate,2106.0,13925,Biodistribution in rat spleen post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,A,In vivo,,Rattus norvegicus,10116.0,
14818,1,,BAO_0000218,Intermediate,2106.0,13925,Biodistribution in rat spleen post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,A,In vivo,,Rattus norvegicus,10116.0,
14819,1,,BAO_0000218,Intermediate,178.0,9712,Biodistribution of Compound in rat blood after 15 minutes of administration,A,In vivo,,Rattus norvegicus,10116.0,
14820,1,,BAO_0000218,Intermediate,178.0,9712,Biodistribution of Compound in rat blood after 2 minutes of administration,A,In vivo,,Rattus norvegicus,10116.0,
14821,1,,BAO_0000218,Intermediate,955.0,9712,Biodistribution of Compound in rat brain after 15 minutes of administration,A,In vivo,,Rattus norvegicus,10116.0,
14822,1,,BAO_0000218,Intermediate,955.0,9712,Biodistribution of Compound in rat brain after 2 minutes of administration,A,In vivo,,Rattus norvegicus,10116.0,
14823,1,,BAO_0000218,Intermediate,948.0,9712,Biodistribution of Compound in rat heart after 15 minutes of administration,A,In vivo,,Rattus norvegicus,10116.0,
14824,1,,BAO_0000218,Intermediate,948.0,9712,Biodistribution of Compound in rat heart after 2 minutes of administration,A,In vivo,,Rattus norvegicus,10116.0,
14825,1,,BAO_0000218,Intermediate,2107.0,9712,Biodistribution of Compound in rat liver after 15 minutes of administration,A,In vivo,,Rattus norvegicus,10116.0,
14826,1,,BAO_0000218,Intermediate,2107.0,9712,Biodistribution of Compound in rat liver after 2 minutes of administration,A,In vivo,,Rattus norvegicus,10116.0,
14827,1,,BAO_0000218,Intermediate,2048.0,9712,Biodistribution of Compound in rat lung after 15 minutes of administration,A,In vivo,,Rattus norvegicus,10116.0,
14828,1,,BAO_0000218,Intermediate,2048.0,9712,Biodistribution of Compound in rat lung after 2 minutes of administration,A,In vivo,,Rattus norvegicus,10116.0,
14829,1,,BAO_0000218,Intermediate,2385.0,9712,Biodistribution of Compound in rat muscle after 15 minutes of administration,A,In vivo,,Rattus norvegicus,10116.0,
14830,1,,BAO_0000218,Intermediate,2385.0,9712,Biodistribution of Compound in rat muscle after 2 minutes of administration,A,In vivo,,Rattus norvegicus,10116.0,
14831,1,,BAO_0000218,Intermediate,,13925,Brain uptake of [99mTc]TRODAT in rat expressed as percent dose per organ at time of 2 mins,A,,,Rattus norvegicus,10116.0,
14832,1,,BAO_0000218,Intermediate,,13925,Brain uptake of [99mTc]TRODAT in rat expressed as percent dose per organ at time of 30 mins,A,,,Rattus norvegicus,10116.0,
14833,1,,BAO_0000218,Intermediate,,13925,Brain uptake of [99mTc]TRODAT in rat expressed as percent dose per organ at time of 60 mins,A,,,Rattus norvegicus,10116.0,
14834,1,,BAO_0000218,Intermediate,,6941,Organ distribution in rat blood 2 minutes after intravenous injection,A,,,Rattus norvegicus,10116.0,
14835,1,,BAO_0000218,Intermediate,,6941,Organ distribution in rat blood 2 hr after intravenous injection,A,,,Rattus norvegicus,10116.0,
14836,1,,BAO_0000218,Intermediate,,6941,Organ distribution in rat blood 30 minutes after intravenous injection,A,,,Rattus norvegicus,10116.0,
14837,1,,BAO_0000218,Intermediate,,6941,Organ distribution in rat blood 30 min after intravenous injection,A,,,Rattus norvegicus,10116.0,
14838,1,,BAO_0000218,Intermediate,,6941,Organ distribution in rat brain 2 minutes after intravenous injection,A,,,Rattus norvegicus,10116.0,
14839,1,,BAO_0000218,Intermediate,,6941,Organ distribution in rat brain 2 hr after intravenous injection,A,,,Rattus norvegicus,10116.0,
14840,1,,BAO_0000218,Intermediate,,6941,Organ distribution in rat brain 30 minutes after intravenous injection,A,,,Rattus norvegicus,10116.0,
14841,1,,BAO_0000218,Intermediate,,6941,Organ distribution in rat heart 2 minutes after intravenous injection,A,,,Rattus norvegicus,10116.0,
14842,1,,BAO_0000218,Intermediate,,6941,Organ distribution in rat heart 2 hr after intravenous injection,A,,,Rattus norvegicus,10116.0,
14843,1,,BAO_0000218,Intermediate,,6941,Organ distribution in rat heart 30 minutes after intravenous injection,A,,,Rattus norvegicus,10116.0,
14844,1,,BAO_0000218,Intermediate,,6941,Organ distribution in rat kidney 2 minutes after intravenous injection,A,,,Rattus norvegicus,10116.0,
14845,1,,BAO_0000218,Intermediate,,6941,Organ distribution in rat kidney 2 hr after intravenous injection,A,,,Rattus norvegicus,10116.0,
14846,1,,BAO_0000218,Intermediate,,6941,Organ distribution in rat kidney 30 minutes after intravenous injection,A,,,Rattus norvegicus,10116.0,
14847,1,,BAO_0000218,Intermediate,2107.0,6941,Organ distribution in rat liver 2 minutes after intravenous injection,A,,,Rattus norvegicus,10116.0,
14848,1,,BAO_0000218,Intermediate,2107.0,6941,Organ distribution in rat liver 2 hr after intravenous injection,A,,,Rattus norvegicus,10116.0,
14849,1,,BAO_0000218,Intermediate,2107.0,6941,Organ distribution in rat liver 30 minutes after intravenous injection,A,,,Rattus norvegicus,10116.0,
14850,1,,BAO_0000218,Intermediate,,6941,Organ distribution in rat lung 2 minutes after intravenous injection,A,,,Rattus norvegicus,10116.0,
14851,1,,BAO_0000218,Intermediate,,6941,Organ distribution in rat lung 2 hr after intravenous injection,A,,,Rattus norvegicus,10116.0,
14852,1,,BAO_0000218,Intermediate,,6941,Organ distribution in rat lung 30 minutes after intravenous injection,A,,,Rattus norvegicus,10116.0,
14853,1,,BAO_0000218,Intermediate,2385.0,6941,Organ distribution in rat muscle 2 minutes after intravenous injection,A,,,Rattus norvegicus,10116.0,
14854,1,,BAO_0000218,Intermediate,2385.0,6941,Organ distribution in rat muscle 2 hr after intravenous injection,A,,,Rattus norvegicus,10116.0,
14855,1,,BAO_0000218,Intermediate,2385.0,6941,Organ distribution in rat muscle 30 minutes after intravenous injection,A,,,Rattus norvegicus,10116.0,
14856,1,,BAO_0000218,Intermediate,,14439,Biodistribution in athymic mice bearing Human Tumor (KB) Xenografts 1 hour after injection in Blood (B),A,In vivo,,Mus musculus,10090.0,
14857,1,,BAO_0000218,Intermediate,,14439,Biodistribution in athymic mice bearing Human Tumor (KB) Xenografts 1 hour after injection in Heart (H),A,In vivo,,Mus musculus,10090.0,
14858,1,,BAO_0000218,Intermediate,,14439,Biodistribution in athymic mice bearing Human Tumor (KB) Xenografts 1 hour after injection in Lung (L),A,In vivo,,Mus musculus,10090.0,
14859,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of sodium in urine of rats after peroral administration of 3.76 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,
14860,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of sodium in urine of rats after peroral administration of 30.20 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,
14861,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of sodium in urine of rats after peroral administration of 302 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,
14862,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of sodium in urine of rats after peroral administration of 31.6 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,
14863,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of sodium in urine of rats after peroral administration of 316 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,
14864,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of sodium in urine of rats after peroral administration of 32.4 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,
14865,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of sodium in urine of rats after peroral administration of 324 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,
14866,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of sodium in urine of rats after peroral administration of 34.0 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,
14867,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of sodium in urine of rats after peroral administration of 34.1 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,
14868,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of sodium in urine of rats after peroral administration of 34.8 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,
14869,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of sodium in urine of rats after peroral administration of 341 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,
14870,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of sodium in urine of rats after peroral administration of 348 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,
14871,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of sodium in urine of rats after peroral administration of 37.6 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,
14872,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of sodium in urine of rats after peroral administration of 58.4 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,
14873,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of sodium in urine of rats after peroral administration of 65.2 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,
14874,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of sodium in urine of rats after peroral administration of 71.6 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,
14875,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of sodium in urine of rats after peroral administration of 71.8 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,
14876,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of sodium in urine of rats after peroral administration of 74.8 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,
14877,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of sodium in urine of rats after peroral administration of 77.5 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,
14878,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of sodium in urine of rats after peroral administration of 79.4 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,
14879,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of sodium in urine of rats after peroral administration of 80.9 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,
14880,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of sodium in urine of rats after peroral administration of 83.8 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,
14881,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of sodium in urine of rats after peroral administration of 84.5 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,
14882,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of sodium in urine of rats after peroral administration of 84.7 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,
14883,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of sodium in urine of rats after peroral administration of 86.7 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,
14884,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of sodium in urine of rats after peroral administration of 86.9 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,
14885,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of sodium in urine of rats after peroral administration of 9.06 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,
14886,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of sodium in urine of rats after peroral administration of 90.6 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,
14887,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of sodium in urine of rats after peroral administration of 94.9 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,
14888,1,,BAO_0000218,Intermediate,1088.0,12582,Total electrolytic excretion of sodium in urine of rats after peroral administration of 97.1 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,
14889,1,,BAO_0000218,Intermediate,,7415,"excretion rate in rats after the dose of 5 mg/kg intravenously, at the dose 4 hour Rate of biliary excretion; 0.06-0.15%/h",A,,,Rattus norvegicus,10116.0,
14890,0,,BAO_0000019,Autocuration,,7313,Extent rates of formation of metabolic intermediate Cytochrome P-450 at compound concentration of 3.75-120 uM,A,,,,,
14891,0,,BAO_0000019,Autocuration,,7313,Extent rates of formation of metabolic intermediate Cytochrome P-450 at compound concentration of 30 uM,A,,,,,
14892,0,,BAO_0000019,Autocuration,,7313,Extent rates of formation of metabolic intermediate Cytochrome P-450 at compound concentration of 7.5-120 uM,A,,,,,
14893,0,,BAO_0000019,Autocuration,1235.0,7570,Percent lipid extracted at 0.5 hr from adrenal cortex liver using CHCl3/CH3OH.,A,,,,,
14894,0,,BAO_0000019,Autocuration,1235.0,7570,Percent lipid extracted at 0.5 hr from adrenal cortex liver using CHCl3/CH3OH.,A,,,,,
14895,0,,BAO_0000019,Autocuration,,7570,Percent lipid extracted at 0.5 hr from liver plasma using CHCl3/CH3OH.,A,,,,,
14896,0,,BAO_0000019,Autocuration,,7570,Percent lipid extracted at 0.5 hr from liver using CHCl3/CH3OH.,A,,,,,
14897,0,,BAO_0000019,Autocuration,1235.0,7570,Percent lipid extracted at 24 hours from adrenal cortex using CHCl3/CH3OH.,A,,,,,
14898,0,,BAO_0000019,Autocuration,1235.0,7570,Percent lipid extracted at 24 hours from adrenal cortex liver using CHCl3/CH3OH.,A,,,,,
14899,0,,BAO_0000019,Autocuration,,7570,Percent lipid extracted at 24 hours from liverliver using CHCl3/CH3OH.,A,,,,,
14900,0,,BAO_0000019,Autocuration,,7570,Percent lipid extracted at 24 hours from plasma using CHCl3/CH3OH.,A,,,,,
14901,0,,BAO_0000019,Autocuration,,7570,Percent lipid extracted at 24 hours from plasmaliver using CHCl3/CH3OH.,A,,,,,
14902,0,,BAO_0000019,Autocuration,,7570,Percent lipid extracted at 24 hr from liver using CHCl3/CH3OH.,A,,,,,
14903,0,,BAO_0000019,Autocuration,1235.0,7570,Percent parent compound extracted at 0.5 hr from adrenal cortex using CHCl3/CH3OH.,A,,,,,
14904,0,,BAO_0000019,Autocuration,,7570,Percent parent compound extracted at 0.5 hr from liver using CHCl3/CH3OH.,A,,,,,
14905,0,,BAO_0000019,Autocuration,,7570,Percent parent compound extracted at 0.5 hr from plasma using CHCl3/CH3OH.,A,,,,,
14906,0,,BAO_0000019,Autocuration,1235.0,7570,Percent parent compound extracted at 24 hours from adrenal cortex using CHCl3/CH3OH.,A,,,,,
14907,0,,BAO_0000019,Autocuration,,7570,Percent parent compound extracted at 24 hours from liver using CHCl3/CH3OH.,A,,,,,
14908,0,,BAO_0000019,Autocuration,,7570,Percent parent compound extracted at 24 hours from plasma using CHCl3/CH3OH.,A,,,,,
14909,0,,BAO_0000218,Autocuration,,14122,"+Ratio of intravenous to oral integrated area under the concentration vs time curve, for compound in dog plasma",A,In vivo,,Canis lupus familiaris,9615.0,
14910,0,,BAO_0000218,Autocuration,,16449,Absolute bioavailability in male cynomolgus monkeys,A,In vivo,,Macaca fascicularis,9541.0,
14911,0,,BAO_0000218,Autocuration,,16449,Absolute bioavailability in maleSprague-Dawley rats,A,In vivo,,Rattus norvegicus,10116.0,
14912,1,,BAO_0000218,Intermediate,2107.0,12017,Biodistribution in liver of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),A,In vivo,,Rattus norvegicus,10116.0,
14913,1,,BAO_0000218,Intermediate,2107.0,12017,Biodistribution in liver of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0,
14914,1,,BAO_0000218,Intermediate,2107.0,12017,Biodistribution in liver of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0,
14915,1,,BAO_0000218,Intermediate,2048.0,12017,Biodistribution in lungs of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0,
14916,1,,BAO_0000218,Intermediate,2048.0,12017,Biodistribution in lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0,
14917,1,,BAO_0000218,Intermediate,2048.0,12017,Biodistribution in lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),A,In vivo,,Rattus norvegicus,10116.0,
14918,1,,BAO_0000218,Intermediate,2048.0,12017,Biodistribution in lungs of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0,
14919,1,,BAO_0000218,Intermediate,2048.0,12017,Biodistribution in lungs of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0,
14920,1,,BAO_0000218,Intermediate,2048.0,12017,Biodistribution in lungs of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0,
14921,1,,BAO_0000218,Intermediate,2048.0,12017,Biodistribution in lungs of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0,
14922,1,,BAO_0000218,Intermediate,2048.0,12017,Biodistribution in lungs of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),A,In vivo,,Rattus norvegicus,10116.0,
14923,1,,BAO_0000218,Intermediate,2048.0,12017,Biodistribution in lungs of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0,
14924,1,,BAO_0000218,Intermediate,2048.0,12017,Biodistribution in lungs of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0,
14925,1,,BAO_0000218,Intermediate,2385.0,12017,Biodistribution in muscle of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0,
14926,1,,BAO_0000218,Intermediate,2385.0,12017,Biodistribution in muscle of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0,
14927,1,,BAO_0000218,Intermediate,2385.0,12017,Biodistribution in muscle of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),A,In vivo,,Rattus norvegicus,10116.0,
14928,1,,BAO_0000218,Intermediate,2385.0,12017,Biodistribution in muscle of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0,
14929,1,,BAO_0000218,Intermediate,2385.0,12017,Biodistribution in muscle of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0,
14930,1,,BAO_0000218,Intermediate,2385.0,12017,Biodistribution in muscle of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0,
14931,1,,BAO_0000218,Intermediate,2385.0,12017,Biodistribution in muscle of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0,
14932,1,,BAO_0000218,Intermediate,2385.0,12017,Biodistribution in muscle of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),A,In vivo,,Rattus norvegicus,10116.0,
14933,1,,BAO_0000218,Intermediate,2385.0,12017,Biodistribution in muscle of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0,
14934,1,,BAO_0000218,Intermediate,2385.0,12017,Biodistribution in muscle of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0,
14935,1,,BAO_0000218,Intermediate,178.0,15045,Biodistribution in normal mice blood after 120 hr,A,In vivo,,Mus musculus,10090.0,
14936,1,,BAO_0000218,Intermediate,178.0,15045,Biodistribution in normal mice blood after 24 hr,A,In vivo,,Mus musculus,10090.0,
14937,1,,BAO_0000218,Intermediate,178.0,15045,Biodistribution in normal mice blood after 4 hr,A,In vivo,,Mus musculus,10090.0,
14938,1,,BAO_0000218,Intermediate,10000001.0,15045,Biodistribution in normal mice bone after 120 hr,A,In vivo,,Mus musculus,10090.0,
14939,1,,BAO_0000218,Intermediate,10000001.0,15045,Biodistribution in normal mice bone after 24 hr,A,In vivo,,Mus musculus,10090.0,
14940,1,,BAO_0000218,Intermediate,10000001.0,15045,Biodistribution in normal mice bone after 4 hr,A,In vivo,,Mus musculus,10090.0,
14941,1,,BAO_0000218,Intermediate,948.0,15045,Biodistribution in normal mice heart after 120 hr,A,In vivo,,Mus musculus,10090.0,
14942,1,,BAO_0000218,Intermediate,948.0,15045,Biodistribution in normal mice heart after 24 hr,A,In vivo,,Mus musculus,10090.0,
14943,1,,BAO_0000218,Intermediate,948.0,15045,Biodistribution in normal mice heart after 4 hr,A,In vivo,,Mus musculus,10090.0,
14944,1,,BAO_0000218,Intermediate,2113.0,15045,Biodistribution in normal mice kidney after 120 hr,A,In vivo,,Mus musculus,10090.0,
14945,1,,BAO_0000218,Intermediate,2113.0,15045,Biodistribution in normal mice kidney after 24 hr,A,In vivo,,Mus musculus,10090.0,
14946,1,,BAO_0000218,Intermediate,2113.0,15045,Biodistribution in normal mice kidney after 4 hr,A,In vivo,,Mus musculus,10090.0,
14947,1,,BAO_0000218,Intermediate,2107.0,15045,Biodistribution in normal mice liver after 120 hr,A,In vivo,,Mus musculus,10090.0,
14948,1,,BAO_0000218,Intermediate,2107.0,15045,Biodistribution in normal mice liver after 24 hr,A,In vivo,,Mus musculus,10090.0,
14949,1,,BAO_0000218,Intermediate,2107.0,15045,Biodistribution in normal mice liver after 4 hr,A,In vivo,,Mus musculus,10090.0,
14950,1,,BAO_0000218,Intermediate,2106.0,15045,Biodistribution in normal mice spleen after 120 hr,A,In vivo,,Mus musculus,10090.0,
14951,1,,BAO_0000218,Intermediate,2106.0,15045,Biodistribution in normal mice spleen after 24 hr,A,In vivo,,Mus musculus,10090.0,
14952,1,,BAO_0000218,Intermediate,2106.0,15045,Biodistribution in normal mice spleen after 4 hr,A,In vivo,,Mus musculus,10090.0,
14953,1,,BAO_0000218,Intermediate,2106.0,12017,Biodistribution in spleen of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0,
14954,1,,BAO_0000218,Intermediate,2106.0,12017,Biodistribution in spleen of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0,
14955,1,,BAO_0000218,Intermediate,2106.0,12017,Biodistribution in spleen of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),A,In vivo,,Rattus norvegicus,10116.0,
14956,1,,BAO_0000218,Intermediate,2106.0,12017,Biodistribution in spleen of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0,
14957,1,,BAO_0000218,Intermediate,2106.0,12017,Biodistribution in spleen of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0,
14958,1,,BAO_0000218,Intermediate,2106.0,12017,Biodistribution in spleen of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0,
14959,1,,BAO_0000218,Intermediate,2106.0,12017,Biodistribution in spleen of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0,
14960,1,,BAO_0000218,Intermediate,2106.0,12017,Biodistribution in spleen of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),A,In vivo,,Rattus norvegicus,10116.0,
14961,1,,BAO_0000218,Intermediate,2106.0,12017,Biodistribution in spleen of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0,
14962,1,,BAO_0000218,Intermediate,2106.0,12017,Biodistribution in spleen of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0,
14963,1,,BAO_0000218,Intermediate,2046.0,12017,Biodistribution in thyroid of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0,
14964,1,,BAO_0000218,Intermediate,,14941,The Kel values in female wistar rats.,A,,,Rattus norvegicus,10116.0,
14965,0,,BAO_0000019,Autocuration,,4646,The equilibrium constant pair at a pH of 7.0 and temperature of 25 degree Centigrade,A,,,,,
14966,0,,BAO_0000019,Autocuration,,8847,Hydrolysis rate constant of the compound,A,,,,,
14967,0,,BAO_0000100,Autocuration,,11778,Headecane/water partition coefficient expressed as the equilibrium ratio of the molar concentration in n-hexadecane to that in the buffer,P,,,,,
14968,0,,BAO_0000019,Autocuration,,2363,"Hydrolysis in acetone/water (50:50) at a pH of 8.0, T=66 degree Centigrade",A,,,,,
14969,0,,BAO_0000019,Autocuration,,2363,"Hydrolysis in acetone/water (50:50) at a pH of 8.0,T =66 degree Centigrade",A,,,,,
14970,0,,BAO_0000019,Autocuration,,2363,"Hydrolysis in acetone/water (50:50) at a pH of 8.0,T =66 degree centigrade; No data",A,,,,,
14971,0,,BAO_0000019,Autocuration,,2363,"Hydrolysis in acetone/water (50:50) at a pH of 8.0,T =66 degree centigrade; Not determined",A,,,,,
14972,0,,BAO_0000019,Autocuration,,8371,Apparent inactivation rate constant was evaluated,A,,,,,
14973,0,,BAO_0000019,Autocuration,,14883,Compound was evaluated for equilibrium constant K obtained from the ratio of reverse rate constants at 25 degree Centigrade.,A,,,,,
14974,0,,BAO_0000019,Autocuration,,14883,Compound was evaluated for equilibrium constant K obtained from the ratio of reverse rate constants at 37 degree Centigrade,A,,,,,
14975,0,,BAO_0000019,Autocuration,,4643,Compound was evaluated for the Ki value for peptide alcohol for competitive inhibition in the presence of Mn2+ ions at pH 7.5,A,,,,,
14976,0,,BAO_0000019,Autocuration,,3519,Compound was tested for the inhibition of antibody-catalyzed hydrolysis.,A,,,,,
14977,0,,BAO_0000019,Autocuration,,10600,DBH (dopamine beta-hydroxylase) activity expressed as Ki value determined by degree to which compound inhibited conversion of tyramine to octopamine,A,,,,,
14978,0,,BAO_0000019,Autocuration,,8501,Dissociation constant against constrictor response to the compound blocked competitively by phentolamine for alpha-mediated events,F,,,,,
14979,0,,BAO_0000100,Autocuration,,8505,Dissociation constant was determined,P,,,,,
14980,0,,BAO_0000100,Autocuration,,9778,Dissociation constant was determined,P,,,,,
14981,0,,BAO_0000100,Autocuration,,9778,Dissociation constant at pH 7.4,P,,,,,
14982,0,,BAO_0000100,Autocuration,,9778,Dissociation constant in presence of 1 mM dithiothreitol,P,,,,,
14983,0,,BAO_0000019,Autocuration,,13007,Kinetic Parameter Ki for Inhibition of Type 1 5-alpha-reductase,A,,,,,
14984,0,,BAO_0000019,Autocuration,,13007,Kinetic Parameter Ki for Inhibition of Type 1 5-alpha-reductase,A,,,,,
14985,0,,BAO_0000019,Autocuration,,13007,Kinetic Parameter Ki for Inhibition of Type-2 5-alpha-reductase,A,,,,,
14986,0,,BAO_0000019,Autocuration,,13007,Kinetic Parameter Ki for Inhibition of Type-2 5-alpha-reductase,A,,,,,
14987,0,,BAO_0000019,Autocuration,,11482,Kinetic constant for aromatization of androstenedione,A,,,,,
14988,0,,BAO_0000019,Autocuration,,11482,Kinetic constant for aromatization of testosterone,A,,,,,
14989,0,,BAO_0000019,Autocuration,,2303,Kinetic parameter for hydrolysis of 1 by Antibody 2D10 after addition of compound 12,A,,,,,
14990,0,,BAO_0000019,Autocuration,,11964,Local inhibition constant was determined,A,,,,,
14991,1,,BAO_0000218,Intermediate,,3140,Rate of inactivation of sterol methyl transferase from Saccharomyces cerevisiae using mechanism based inhibitor,A,,,Saccharomyces cerevisiae,4932.0,
14992,0,,BAO_0000100,Autocuration,,10650,Dissociation constant value of the compound,P,,,,,
14993,0,,BAO_0000019,Autocuration,964.0,4667,In vitro permeability through cornea without epithelium,A,,,,,
14994,0,,BAO_0000019,Autocuration,964.0,4667,In vitro permeability through intact cornea,A,,,,,
14995,1,,BAO_0000218,Intermediate,964.0,9199,Evaluated for first order rate constant (Kin) for transcorneal penetration in anesthetized rabbits,A,,,Oryctolagus cuniculus,9986.0,
14996,0,,BAO_0000019,Autocuration,,11966,Rate of enzyme inactivation for the compound was determined,A,,,,,
14997,0,,BAO_0000019,Autocuration,964.0,4667,In vitro permeability through cornea without epithelium,A,,,,,
14998,0,,BAO_0000019,Autocuration,964.0,4667,In vitro permeability through intact cornea,A,,,,,
14999,0,,BAO_0000019,Autocuration,,8354,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0300 mM [HOX] in the conditions of 25degreeC,pH 7.6",A,,,,,
15000,0,,BAO_0000019,Autocuration,,8354,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0384 mM [HOX] in the conditions of 25degreeC,pH 7.6",A,,,,,
15001,0,,BAO_0000019,Autocuration,,8354,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0395 mM [HOX] in the conditions of 25degreeC,pH 7.6",A,,,,,
15002,0,,BAO_0000019,Autocuration,,8354,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0500 mM [HOX] in the conditions of 25degreeC,pH 7.6",A,,,,,
15003,0,,BAO_0000019,Autocuration,,8354,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.050 mM [HOX] in the conditions of 25degreeC,pH 7.6",A,,,,,
15004,0,,BAO_0000019,Autocuration,,8354,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0767 mM [HOX] in the conditions of 25degreeC,pH 7.6",A,,,,,
15005,0,,BAO_0000019,Autocuration,,8354,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0790 mM [HOX] in the conditions of 25degreeC,pH 7.6",A,,,,,
15006,0,,BAO_0000019,Autocuration,,8354,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0800 mM [HOX] in the conditions of 25degreeC,pH 7.6",A,,,,,
15007,0,,BAO_0000019,Autocuration,,8354,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.100 mM [HOX] in the conditions of 25degreeC,pH 7.6",A,,,,,
15008,0,,BAO_0000019,Autocuration,,8354,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.200 mM [HOX] in the conditions of 25degreeC,pH 7.6",A,,,,,
15009,0,,BAO_0000019,Autocuration,,8354,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.300 mM [HOX] in the conditions of 25degreeC,pH 7.6",A,,,,,
15010,0,,BAO_0000019,Autocuration,,8354,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.384 mM [HOX] in the conditions of 25degreeC,pH 7.6",A,,,,,
15011,0,,BAO_0000019,Autocuration,,8354,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.395 mM [HOX] in the conditions of 25degreeC,pH 7.6",A,,,,,
15012,0,,BAO_0000019,Autocuration,,8354,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.500 mM [HOX] in the conditions of 25degreeC,pH 7.6",A,,,,,
15013,0,,BAO_0000019,Autocuration,,8354,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.767 mM [HOX] in the conditions of 25degreeC,pH 7.6",A,,,,,
15014,1,,BAO_0000218,Intermediate,,14439,Biodistribution in athymic mice bearing Human Tumor (KB) Xenografts 1 hour after injection in Muscle (M),A,In vivo,,Mus musculus,10090.0,
15015,1,,BAO_0000218,Intermediate,,14439,Biodistribution in athymic mice bearing Human Tumor (KB) Xenografts 1 hour after injection in Tumor (T) cells,A,In vivo,,Homo sapiens,9606.0,
15016,1,,BAO_0000218,Intermediate,,14439,Biodistribution in athymic mice bearing Human Tumor (LS174T) Xenografts 1 hour after injection in Blood (B),A,In vivo,,Mus musculus,10090.0,
15017,1,,BAO_0000218,Intermediate,,14439,Biodistribution in athymic mice bearing Human Tumor (LS174T) Xenografts 1 hour after injection in Heart (H),A,In vivo,,Mus musculus,10090.0,
15018,1,,BAO_0000218,Intermediate,,14439,Biodistribution in athymic mice bearing Human Tumor (LS174T) Xenografts 1 hour after injection in Lung (L),A,In vivo,,Mus musculus,10090.0,
15019,1,,BAO_0000218,Intermediate,,14439,Biodistribution in athymic mice bearing Human Tumor (LS174T) Xenografts 1 hour after injection in Muscle (M),A,In vivo,,Mus musculus,10090.0,
15020,1,,BAO_0000218,Intermediate,,14439,Biodistribution in athymic mice bearing Human Tumor (LS174T) Xenografts 1 hour after injection in Tumor (T) cells,A,In vivo,,Mus musculus,10090.0,
15021,1,,BAO_0000218,Intermediate,,14439,Biodistribution in athymic mice bearing Human Tumor (TE671) Xenografts 1 hour after injection in Blood (B),A,In vivo,,Mus musculus,10090.0,
15022,1,,BAO_0000218,Intermediate,,14439,Biodistribution in athymic mice bearing Human Tumor (TE671) Xenografts 1 hour after injection in Heart (H),A,In vivo,,Mus musculus,10090.0,
15023,1,,BAO_0000218,Intermediate,,14439,Biodistribution in athymic mice bearing Human Tumor (TE671) Xenografts 1 hour after injection in Lung (L),A,In vivo,,Mus musculus,10090.0,
15024,1,,BAO_0000218,Intermediate,,14439,Biodistribution in athymic mice bearing Human Tumor (TE671) Xenografts 1 hour after injection in Muscle (M),A,In vivo,,Mus musculus,10090.0,
